FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Evans, MV
   Garchitorena, A
   Rakotonanahary, RJL
   Drake, JM
   Andriamihaja, B
   Rajaonarifara, E
   Ngonghala, CN
   Roche, B
   Bonds, MH
   Rakotonirina, J
AF Evans, Michelle V.
   Garchitorena, Andres
   Rakotonanahary, Rado J. L.
   Drake, John M.
   Andriamihaja, Benjamin
   Rajaonarifara, Elinambinina
   Ngonghala, Calistus N.
   Roche, Benjamin
   Bonds, Matthew H.
   Rakotonirina, Julio
TI Reconciling model predictions with low reported cases of COVID-19 in
   Sub-Saharan Africa: insights from Madagascar
SO GLOBAL HEALTH ACTION
LA English
DT Article
DE COVID-19; Madagascar; infectious disease modelling; non-pharmaceutical
   interventions; age-structured contacts; outbreak response
AB COVID-19 has wreaked havoc globally with particular concerns for sub-Saharan Africa (SSA), where models suggest that the majority of the population will become infected. Conventional wisdom suggests that the continent will bear a higher burden of COVID-19 for the same reasons it suffers from other infectious diseases: ecology, socio-economic conditions, lack of water and sanitation infrastructure, and weak health systems. However, so far SSA has reported lower incidence and fatalities compared to the predictions of standard models and the experience of other regions of the world. There are three leading explanations, each with different implications for the final epidemic burden: (1) low case detection, (2) differences in epidemiology (e.g. lowR(0)), and (3) policy interventions. The low number of cases have led some SSA governments to relaxing these policy interventions. Will this result in a resurgence of cases? To understand how to interpret the lower-than-expected COVID-19 case data in Madagascar, we use a simple age-structured model to explore each of these explanations and predict the epidemic impact associated with them. We show that the incidence of COVID-19 cases as of July 2020 can be explained by any combination of the late introduction of first imported cases, early implementation of non-pharmaceutical interventions (NPIs), and low case detection rates. We then re-evaluate these findings in the context of the COVID-19 epidemic in Madagascar through August 2020. This analysis reinforces that Madagascar, along with other countries in SSA, remains at risk of a growing health crisis. If NPIs remain enforced, up to 50,000 lives may be saved. Even with NPIs, without vaccines and new therapies, COVID-19 could infect up to 30% of the population, making it the largest public health threat in Madagascar for the coming year, hence the importance of clinical trials and continually improving access to healthcare.
C1 [Evans, Michelle V.; Drake, John M.] Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA.
   [Evans, Michelle V.; Drake, John M.] Univ Georgia, Ctr Ecol Infect Dis, Athens, GA 30602 USA.
   [Garchitorena, Andres; Rajaonarifara, Elinambinina; Roche, Benjamin] Univ Montpellier, Ecole Pierre Louis Sante Publ, MIVEGEC, CNRS,IRD, Montpellier, France.
   [Garchitorena, Andres; Rakotonanahary, Rado J. L.; Andriamihaja, Benjamin; Rajaonarifara, Elinambinina; Bonds, Matthew H.] PIVOT, Ranomafana, Madagascar.
   [Andriamihaja, Benjamin] Madagascar Inst Conservat Ecosyst Trop, Antananarivo, Madagascar.
   [Rajaonarifara, Elinambinina] Sorbonne Univ, Paris, France.
   [Ngonghala, Calistus N.] Univ Florida, Dept Math, Gainesville, FL 32611 USA.
   [Ngonghala, Calistus N.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA.
   [Roche, Benjamin] Sorbonne Univ, UMMISCO, IRD, Bondy, France.
   [Roche, Benjamin] Univ Nacl Autonoma Mexico, Mexico City, DF, Mexico.
   [Bonds, Matthew H.] Harvard Med Sch, Boston, MA 02115 USA.
   [Rakotonirina, Julio] Univ Antananarivo, Fac Med, Antananarivo, Madagascar.
RP Bonds, MH (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.
EM mhb9@hms.harvard.edu
OI Rakotonanahary, Rado Jean Luc/0000-0002-1819-1824; Garchitorena,
   Andres/0000-0001-6225-5226
FU Graduate Research Fellowship (National Science Foundation)National
   Science Foundation (NSF)
FX MVE was supported by a Graduate Research Fellowship (National Science
   Foundation).
CR Africa Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   [Anonymous], 2018, LANCET, V392, P1736, DOI [DOI 10.1016/S0140-6736(18)32203-7, 10.1016/S0140-6736(18)32203-7]
   Baker RE, 2020, SCIENCE, V369, P315, DOI 10.1126/science.abc2535
   Bonds MH, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006131
   Cabore JW, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002647
   Clark A, 2020, LANCET GLOB HEALTH, V8, P1003, DOI 10.1016/S2214-109X(20)30264-3
   Diop BZ, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002699corr1
   El-Sadr WM, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2008193
   Google, 2020, COVID 19 COMM MOB RE
   Havers FP, 2020, JAMA INTERN MED, V180, P1576, DOI 10.1001/jamainternmed.2020.4130
   Ihantamalala FA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06290-2
   Ihekweazu C, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01622-w
   John Hopkins University, 2020, J HOPK COVID 19 TEST
   Katz MA, 2012, J INFECT DIS, V206, pS1, DOI 10.1093/infdis/jis548
   Kavanagh MM, 2020, LANCET, V395, P1735, DOI 10.1016/S0140-6736(20)31093-X
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Kucirka LM, 2020, ANN INTERN MED, V173, P262, DOI 10.7326/M20-1495
   Logie CH, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25504
   Madagascar Ministry of Health, 2020, COVID 19 MAD
   Mahase E, 2019, BMJ-BRIT MED J, V366, pl4510, DOI 10.1136/bmj.l451031270074
   Loembe MM, 2020, NAT MED, V26, P999, DOI 10.1038/s41591-020-0961-x
   Moore Jina, 2020, NEW YORKER
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   Nkengasong JN, 2020, LANCET, V395, P841, DOI 10.1016/S0140-6736(20)30464-5
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012
   Pearson CAB, 2020, EUROSURVEILLANCE, V25, P19, DOI 10.2807/1560-7917.ES.2020.25.18.2000543
   Prem K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005697
   Rasambainarivo F, 2020, COVID 19 MADAGASCAR
   Requejo J, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6915
   Rice BD, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25513
   Roche B, 2020, 20073932 MEDRXIV, P20073932
   Rosenthal PJ, 2020, AM J TROP MED HYG, V102, P1145, DOI 10.4269/ajtmh.20-0380
   Senghore M, 2020, LANCET GLOB HEALTH, V8, pE884, DOI 10.1016/S2214-109X(20)30234-5
   Taboe HB, 2020, MATH BIOSCI, V328, DOI 10.1016/j.mbs.2020.108431
   UNICEF, 2018, MAD MULT IND CLUST S
   Walker PGT, 2020, SCIENCE, V369, P413, DOI 10.1126/science.abc0035
   Weiss DJ, 2018, NATURE, V553, P333, DOI 10.1038/nature25181
   (WHO) W.H.O, 2020, ADV US MASKS CONT CO, DOI [10.1093/jiaa077, DOI 10.1093/JIAA077]
   World Health Organization Africa, 2020, WHO URG CAUT COUNTR
NR 40
TC 0
Z9 0
U1 77
U2 77
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PD DEC 31
PY 2020
VL 13
IS 1
AR 1816044
DI 10.1080/16549716.2020.1816044
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NW3YP
UT WOS:000574946400001
PM 33012269
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Astori, G
   Bernardi, M
   Bozza, A
   Catanzaro, D
   Chieregato, K
   Merlo, A
   Santimaria, M
   Barbazza, R
   Amodeo, G
   Ciccocioppo, R
   Elice, F
   Ruggeri, M
AF Astori, Giuseppe
   Bernardi, Martina
   Bozza, Angela
   Catanzaro, Daniela
   Chieregato, Katia
   Merlo, Anna
   Santimaria, Monica
   Barbazza, Roberto
   Amodeo, Giuseppe
   Ciccocioppo, Rachele
   Elice, Francesca
   Ruggeri, Marco
TI Logistics of an advanced therapy medicinal product during COVID-19
   pandemic in Italy: successful delivery of mesenchymal stromal cells in
   dry ice
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE COVID-19; GvHD; Mesenchymal stromal cells; Supply chain
ID STEM-CELLS; STORAGE; CRYOPRESERVATION; ADULT
AB Background During the coronavirus disease-2019 (COVID-19) pandemic, Italian hospitals faced the most daunting challenges of their recent history, and only essential therapeutic interventions were feasible. From March to April 2020, the Laboratory of Advanced Cellular Therapies (Vicenza, Italy) received requests to treat a patient with severe COVID-19 and a patient with acute graft-versus-host disease with umbilical cord-derived mesenchymal stromal cells (UC-MSCs). Access to clinics was restricted due to the risk of contagion. Transport of UC-MSCs in liquid nitrogen was unmanageable, leaving shipment in dry ice as the only option. Methods We assessed effects of the transition from liquid nitrogen to dry ice on cell viability; apoptosis; phenotype; proliferation; immunomodulation; and clonogenesis; and validated dry ice-based transport of UC-MSCs to clinics. Results Our results showed no differences in cell functionality related to the two storage conditions, and demonstrated the preservation of immunomodulatory and clonogenic potentials in dry ice. UC-MSCs were successfully delivered to points-of-care, enabling favourable clinical outcomes. Conclusions This experience underscores the flexibility of a public cell factory in its adaptation of the logistics of an advanced therapy medicinal product during a public health crisis. Alternative supply chains should be evaluated for other cell products to guarantee delivery during catastrophes.
C1 [Astori, Giuseppe; Bernardi, Martina; Bozza, Angela; Catanzaro, Daniela; Chieregato, Katia; Merlo, Anna] Vicenza Hosp, Haematol Unit, Adv Cellular Therapy Lab, Contra S Francesco 41, I-36100 Vicenza I, Italy.
   [Bernardi, Martina; Bozza, Angela; Catanzaro, Daniela; Chieregato, Katia] Consorzio Ric Sanit CORIS Veneto Reg, Padua, Italy.
   [Santimaria, Monica] Vicenza Hosp, Dept Diagnost, Nucl Med Serv, Vicenza, Italy.
   [Barbazza, Roberto] AOUI Osped Maggiore, Dept Med Management, Pharm Serv, Verona, Italy.
   [Amodeo, Giuseppe; Ciccocioppo, Rachele] AOUI Policlin GB Rossi, Dept Med, Gastroenterol Unit, Verona, Italy.
   [Amodeo, Giuseppe; Ciccocioppo, Rachele] Univ Verona, Verona, Italy.
   [Elice, Francesca; Ruggeri, Marco] Vicenza Hosp, Haematol Unit, Vicenza, Italy.
RP Astori, G (corresponding author), Vicenza Hosp, Haematol Unit, Adv Cellular Therapy Lab, Contra S Francesco 41, I-36100 Vicenza I, Italy.
EM giuseppe.astori@aulss8.veneto.it
FU Associazione Vicentina Leucemie e Linfomi (AViLL); Associazione Italiana
   Leucemie (AIL)
FX This work was partially supported by Associazione Vicentina Leucemie e
   Linfomi (AViLL), Associazione Italiana Leucemie (AIL).
CR Amati E, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-017-0755-3
   Angel S, 2016, BIOPRESERV BIOBANK, V14, P539, DOI 10.1089/bio.2016.0046
   Bachanova V, 2020, BIOL BLOOD MARROW TR, V26, P1239, DOI 10.1016/j.bbmt.2020.04.008
   Barilani M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27587-8
   Baust JM, 2001, CELL TRANSPLANT, V10, P561
   Baust JM, 2017, IN VITRO CELL DEV-AN, V53, P855, DOI 10.1007/s11626-017-0201-y
   Chabot D, 2017, CYTOTHERAPY, V19, P978, DOI 10.1016/j.jcyt.2017.04.005
   Ciccocioppo R, 2016, LANCET, V388, P1251, DOI 10.1016/S0140-6736(16)31209-0
   Ciccocioppo R, 2011, GUT, V60, P788, DOI 10.1136/gut.2010.214841
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fisher SA, 2019, COCHRANE DB SYST REV, V1, P9768
   Galleu A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7828
   Glennie S, 2005, BLOOD, V105, P2821, DOI 10.1182/blood-2004-09-3696
   Hunt CJ, 2019, TRANSFUS MED HEMOTH, V46, P134, DOI 10.1159/000497289
   Huppert LA, 2019, TRANSFUSION, V59, P869, DOI 10.1111/trf.14835
   Introna Martino, 2015, Curr Opin Organ Transplant, V20, P72, DOI 10.1097/MOT.0000000000000158
   Kim DH, 2008, J KOREAN MED SCI, V23, P163, DOI 10.3346/jkms.2008.23.1.163
   Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood-2002-07-2104
   LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X
   Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Mareschi K, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13050093
   Massie I, 2013, TISSUE ENG PART C-ME, V19, P189, DOI [10.1089/ten.tec.2012.0307, 10.1089/ten.TEC.2012.0307]
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pogozhykh D, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0512-7
NR 28
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD DEC 30
PY 2020
VL 18
IS 1
AR 451
DI 10.1186/s12967-020-02625-0
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PB4LW
UT WOS:000596295200002
PM 33256746
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Thomas, G
   Frederick, E
   Thompson, L
   Bar-Or, R
   Mulugeta, Y
   Hausburg, M
   Roshon, M
   Mains, C
   Bar-Or, D
AF Thomas, Gregory
   Frederick, Elizabeth
   Thompson, Lisa
   Bar-Or, Raphael
   Mulugeta, Yetti
   Hausburg, Melissa
   Roshon, Michael
   Mains, Charles
   Bar-Or, David
TI LMWF5A suppresses cytokine release by modulating select inflammatory
   transcription factor activity in stimulated PBMC
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE LMWF5A; PPAR&#947; AhR; NF-&#954; b; STAT; Transcription; Cytokines;
   Chemokines
ID ARYL-HYDROCARBON RECEPTOR; HUMAN SERUM-ALBUMIN; MOLECULAR-WEIGHT
   FRACTION; ACTIVATOR PROTEIN-1; GAMMA LIGANDS; KAPPA-B; MECHANISMS;
   AGONISTS; CELLS; DIFFERENTIATION
AB Background Dysregulation of transcription and cytokine expression has been implicated in the pathogenesis of a variety inflammatory diseases. The resulting imbalance between inflammatory and resolving transcriptional programs can cause an overabundance of pro-inflammatory, classically activated macrophage type 1 (M1) and/or helper T cell type 1 (Th1) products, such as IFN gamma, TNF alpha, IL1-beta, and IL12, that prevent immune switching to resolution and healing. The low molecular weight fraction of human serum albumin (LMWF5A) is a novel biologic drug that is currently under clinical investigation for the treatment of osteoarthritis and the hyper-inflammatory response associated with COVID-19. This study aims to elucidate transcriptional mechanisms of action involved with the ability of LMWF5A to reduce pro-inflammatory cytokine release. Methods ELISA arrays were used to identify cytokines and chemokines influenced by LMWF5A treatment of LPS-stimulated peripheral blood mononuclear cells (PBMC). The resulting profiles were analyzed by gene enrichment to gain mechanistic insight into the biologic processes and transcription factors (TFs) underlying the identified differentially expressed cytokines. DNA-binding ELISAs, luciferase reporter assays, and TNF alpha or IL-1 beta relative potency were then employed to confirm the involvement of enriched pathways and TFs. Results LMWF5A was found to significantly inhibit a distinct set of pro-inflammatory cytokines (TNF alpha, IL-1 beta, IL-12, CXCL9, CXCL10, and CXCL11) associated with pro-inflammatory M1/Th1 immune profiles. Gene enrichment analysis also suggests these cytokines are, in part, regulated by NF-kappa B and STAT transcription factors. Data from DNA-binding and reporter assays support this with LMWF5A inhibition of STAT1 alpha DNA-binding activity as well as a reduction in overall NF-kappa B-driven luciferase expression. Experiments using antagonists specific for the immunomodulatory and NF-kappa B/STAT-repressing transcription factors, peroxisome proliferator-activated receptor (PPAR)gamma and aryl hydrocarbon receptor (AhR), indicate these pathways are involved in the LMWF5A mechanisms of action by reducing LMWF5A drug potency as measured by TNF alpha and IL-1 beta release. Conclusion In this report, we provide evidence that LMWF5A reduces pro-inflammatory cytokine release by activating the immunoregulatory transcription factors PPAR gamma and AhR. In addition, our data indicate that LMWF5A suppresses NF-kappa B and STAT1 alpha pro-inflammatory pathways. This suggests that LMWF5A acts through these mechanisms to decrease pro-inflammatory transcription factor activity and subsequent inflammatory cytokine production.
C1 [Thomas, Gregory; Frederick, Elizabeth; Thompson, Lisa; Bar-Or, Raphael; Mulugeta, Yetti] Ampio Pharmaceut Inc, 373 Inverness Pkwy Suite 200, Englewood, CO 80122 USA.
   [Bar-Or, Raphael; Hausburg, Melissa; Bar-Or, David] Swedish Med Ctr, Trauma Res Dept, 501 E Hampden Ave Rm 4-454, Englewood, CO 80113 USA.
   [Bar-Or, Raphael; Hausburg, Melissa; Bar-Or, David] St Anthony Hosp, Trauma Res Dept, 11600 W 2nd Pl, Lakewood, CO 80228 USA.
   [Bar-Or, Raphael; Hausburg, Melissa; Roshon, Michael; Bar-Or, David] Penrose Community Hosp, Trauma Res Dept, 2222 N Nevada Ave, Colorado Springs, CO 80907 USA.
   [Bar-Or, Raphael; Hausburg, Melissa; Mains, Charles; Bar-Or, David] Centura Hlth Syst, 9100 E Mineral Cir, Centennial, CO 80112 USA.
   [Bar-Or, David] Rocky Vista Univ, Dept Mol Biol, 8401 S Chambers Rd, Parker, CO 80134 USA.
RP Bar-Or, D (corresponding author), Swedish Med Ctr, Trauma Res Dept, 501 E Hampden Ave Rm 4-454, Englewood, CO 80113 USA.; Bar-Or, D (corresponding author), St Anthony Hosp, Trauma Res Dept, 11600 W 2nd Pl, Lakewood, CO 80228 USA.; Bar-Or, D (corresponding author), Penrose Community Hosp, Trauma Res Dept, 2222 N Nevada Ave, Colorado Springs, CO 80907 USA.; Bar-Or, D (corresponding author), Centura Hlth Syst, 9100 E Mineral Cir, Centennial, CO 80112 USA.; Bar-Or, D (corresponding author), Rocky Vista Univ, Dept Mol Biol, 8401 S Chambers Rd, Parker, CO 80134 USA.
EM davidbme49@gmail.com
CR Ahmed AU, 2015, BIOMOLECULES, V5, P3087, DOI 10.3390/biom5043087
   Anraku M, 2004, BBA-PROTEINS PROTEOM, V1702, P9, DOI 10.1016/j.bbapap.2004.07.002
   Atri C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061801
   Bar-Or D, 2015, STEM CELL TRANSL MED, V4, P945, DOI 10.5966/sctm.2014-0293
   Bar-Or D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087910
   Barish GD, 2005, MOL ENDOCRINOL, V19, P2466, DOI 10.1210/me.2004-0529
   Bessede A, 2014, NATURE, V511, P184, DOI 10.1038/nature13323
   Bright JJ, 2008, PPAR RES, V2008, DOI 10.1155/2008/658520
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Christian F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5010012
   Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200
   Croasdell A, 2015, PPAR RES, V2015, DOI 10.1155/2015/549691
   Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394
   Fang P, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0637-x
   Ferreira AE, 2014, J IMMUNOL, V192, P2357, DOI 10.4049/jimmunol.1302375
   Gutierrez-Vazquez C, 2018, IMMUNITY, V48, P19, DOI 10.1016/j.immuni.2017.12.012
   Hanieh H, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/520763
   Hasegawa-Moriyama M, 2013, PAIN, V154, P1402, DOI 10.1016/j.pain.2013.04.039
   Hausburg MA, 2018, CLIN EXP RHEUMATOL, V36, P891
   Horhold F, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007657
   Huang JT, 1999, NATURE, V400, P378
   Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895
   Keenan AB, 2019, NUCLEIC ACIDS RES, V47, pW212, DOI 10.1093/nar/gkz446
   Kimura A, 2009, J EXP MED, V206, P2027, DOI 10.1084/jem.20090560
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Larigot Lucie, 2018, Biochim Open, V7, P1, DOI 10.1016/j.biopen.2018.05.001
   Lee W, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.157
   Libby P, 2007, NUTR REV, V65, pS140, DOI 10.1301/nr.2007.dec.S140-S146
   Liberato MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036297
   Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Ma JJ, 2012, J PHARM PHARMACOL, V64, P719, DOI 10.1111/j.2042-7158.2012.01462.x
   Ma YH, 2020, INT J NEPHROL, V2020, DOI 10.1155/2020/2917474
   Matthews Jason, 2006, Nucl Recept Signal, V4, pe016
   Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339
   Nguyen NT, 2013, INT IMMUNOL, V25, P335, DOI 10.1093/intimm/dxt011
   Natarajan C, 2002, GENES IMMUN, V3, P59, DOI 10.1038/sj.gene.6363832
   Puga A, 2000, BIOCHEM PHARMACOL, V59, P997, DOI 10.1016/S0006-2952(99)00406-2
   Quintana FJ, 2013, IMMUNOLOGY, V138, P183, DOI 10.1111/imm.12046
   Rael Leonard T, 2018, Biochem Biophys Rep, V15, P61, DOI 10.1016/j.bbrep.2018.06.006
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013
   Rothhammer V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23323-4
   Ruby CE, 2002, MOL PHARMACOL, V62, P722, DOI 10.1124/mol.62.3.722
   Safe Stephen, 2017, Current Opinion in Toxicology, V2, P24, DOI 10.1016/j.cotox.2017.01.012
   Salottolo K, 2018, PATIENT SAF SURG, V12, DOI 10.1186/s13037-018-0158-0
   Schwappach J, 2018, PATIENT SAF SURG, V12, DOI 10.1186/s13037-018-0162-4
   Schwappach J, 2017, ORTHOPEDICS, V40, pE49, DOI 10.3928/01477447-20160926-02
   Shimonkevitz R, 2008, J TRAUMA, V64, P35, DOI 10.1097/TA.0b013e3181589ff9
   Smale ST, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016261
   Sugimoto MA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00160
   Thomas GW, 2016, BIOCHEM BIOPH RES CO, V478, P1780, DOI 10.1016/j.bbrc.2016.09.026
   Thomas GW, 2016, BIOCHEM BIOPH RES CO, V473, P1328, DOI 10.1016/j.bbrc.2016.04.072
   Thomas Gregory W, 2016, J Immunoassay Immunochem, V37, P55, DOI 10.1080/15321819.2015.1047516
   Tugal D, 2013, ARTERIOSCL THROM VAS, V33, P1135, DOI 10.1161/ATVBAHA.113.301453
   Uchiyama M, 2013, MOL VIS, V19, P2135
   Varga T, 2011, BBA-MOL BASIS DIS, V1812, P1007, DOI 10.1016/j.bbadis.2011.02.014
   Villarino AV, 2015, J IMMUNOL, V194, P21, DOI 10.4049/jimmunol.1401867
   Vogel CFA, 2007, MOL ENDOCRINOL, V21, P2941, DOI 10.1210/me.2007-0211
   Vogel CFA, 2014, J BIOL CHEM, V289, P1866, DOI 10.1074/jbc.M113.505578
   Zingarelli B, 2003, J IMMUNOL, V171, P6827, DOI 10.4049/jimmunol.171.12.6827
NR 61
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD DEC 30
PY 2020
VL 18
IS 1
AR 452
DI 10.1186/s12967-020-02626-z
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PB4LW
UT WOS:000596295200001
PM 33256749
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fahlberg, MD
   Blair, RV
   Doyle-Meyers, LA
   Midkiff, CC
   Zenere, G
   Russell-Lodrigue, KE
   Monjure, CJ
   Haupt, EH
   Penney, TP
   Lehmicke, G
   Threeton, BM
   Golden, N
   Datta, PK
   Roy, CJ
   Bohm, RP
   Maness, NJ
   Fischer, T
   Rappaport, J
   Vaccari, M
AF Fahlberg, M. D.
   Blair, R. V.
   Doyle-Meyers, L. A.
   Midkiff, C. C.
   Zenere, G.
   Russell-Lodrigue, K. E.
   Monjure, C. J.
   Haupt, E. H.
   Penney, T. P.
   Lehmicke, G.
   Threeton, B. M.
   Golden, N.
   Datta, P. K.
   Roy, C. J.
   Bohm, R. P.
   Maness, N. J.
   Fischer, T.
   Rappaport, J.
   Vaccari, M.
TI Cellular events of acute, resolving or progressive COVID-19 in
   SARS-CoV-2 infected non-human primates
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MYELOID CELLS; LUNG INFLAMMATION; SARS CORONAVIRUS; IN-VIVO; RHESUS;
   RECEPTOR; REPLICATION; NEUTROPHILS; ACTIVATION; EXPRESSION
AB Understanding SARS-CoV-2 associated immune pathology is crucial to develop pan-effective vaccines and treatments. Here we investigate the immune events from the acute state up to four weeks post SARS-CoV-2 infection, in non-human primates (NHP) with heterogeneous pulmonary pathology. We show a robust migration of CD16 expressing monocytes to the lungs occurring during the acute phase, and we describe two subsets of interstitial macrophages (HLA-DR(+)CD206(-)): a transitional CD11c(+)CD16(+) cell population directly associated with IL-6 levels in plasma, and a long-lasting CD11b(+)CD16(+) cell population. Trafficking of monocytes is mediated by TARC (CCL17) and associates with viral load measured in bronchial brushes. We also describe associations between disease outcomes and high levels of cell infiltration in lungs including CD11b(+)CD16(hi) macrophages and CD11b(+) neutrophils. Accumulation of macrophages is long-lasting and detectable even in animals with mild or no signs of disease. Interestingly, animals with anti-inflammatory responses including high IL-10:IL-6 and kynurenine to tryptophan ratios show less severe illness. Our results unravel cellular mechanisms of COVID-19 and suggest that NHP may be appropriate models to test immune therapies.
C1 [Fahlberg, M. D.; Blair, R. V.; Doyle-Meyers, L. A.; Midkiff, C. C.; Zenere, G.; Russell-Lodrigue, K. E.; Monjure, C. J.; Haupt, E. H.; Penney, T. P.; Lehmicke, G.; Threeton, B. M.; Golden, N.; Datta, P. K.; Roy, C. J.; Bohm, R. P.; Maness, N. J.; Fischer, T.; Rappaport, J.; Vaccari, M.] Tulane Natl Primate Res Ctr, Covington, LA 70433 USA.
   [Blair, R. V.; Datta, P. K.] Tulane Univ, Sch Med, Dept Pathol & Lab Anim Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Doyle-Meyers, L. A.; Russell-Lodrigue, K. E.; Bohm, R. P.] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA.
   [Roy, C. J.; Maness, N. J.; Fischer, T.; Rappaport, J.; Vaccari, M.] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA.
RP Vaccari, M (corresponding author), Tulane Natl Primate Res Ctr, Covington, LA 70433 USA.; Vaccari, M (corresponding author), Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA.
EM mvaccari@tulane.edu
RI ; Russell-Lodrigue, Kasi/G-7084-2016
OI Fahlberg, Marissa/0000-0002-2597-7147; Russell-Lodrigue,
   Kasi/0000-0003-3719-0779
FU Fast Grant Funding for COVID-19 Science; NIH through the TNPRC base
   grantUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P51 OD011104 59]
FX We would like to thank Dr. Joseph (JC) Mudd and Dr. Cariappa Annaiah for
   critical reading of the manuscript and Dr. Amitinder (Miti) Kaur, Megan
   Varnado, and Kaitlin Didier from the TNPRC Flow Cytometry Core for their
   help. We thank Angela Birnbaum for reviewing and optimizing all
   technical SOPs and overseeing the safety of this study. We would also
   like to thank Fast Grant Funding for COVID-19 Science for partially
   funding this work and the NIH for supporting this work through the TNPRC
   base grant (P51 OD011104 59).
CR Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013
   Agostini C, 2001, AM J PATHOL, V158, P1703, DOI 10.1016/S0002-9440(10)64126-0
   Alferink J, 2003, J EXP MED, V197, P585, DOI 10.1084/jem.20021859
   Anderson CA, 2020, J LEUKOCYTE BIOL, V107, P455, DOI 10.1002/JLB.2A0120-089RR
   Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bronte V, 2003, TRENDS IMMUNOL, V24, P302, DOI 10.1016/S1471-4906(03)00132-7
   Cai YH, 2014, J IMMUNOL, V192, P2821, DOI 10.4049/jimmunol.1302269
   Carlin LE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00781
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Clay C, 2012, J VIROL, V86, P4234, DOI 10.1128/JVI.06791-11
   Cong JJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01416
   Creelan BC, 2019, NAT REV CLIN ONCOL, V16, P277, DOI 10.1038/s41571-019-0182-8
   Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9
   Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gretebeck LM, 2015, CURR OPIN VIROL, V13, P123, DOI 10.1016/j.coviro.2015.06.009
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129
   Irjala H, 2001, J EXP MED, V194, P1033, DOI 10.1084/jem.194.8.1033
   Jiang DH, 2004, J CLIN INVEST, V114, P291, DOI 10.1172/JCI200416861
   Johnston LK, 2012, AM J RESP CELL MOL, V47, P417, DOI 10.1165/rcmb.2012-0090OC
   Kolde R, 2018, PHEATMAP PRETTY HEAT
   Kuhn M., 2020, CORRR CORRELATIONS R
   Kwok I, 2020, IMMUNITY, V53, P303, DOI 10.1016/j.immuni.2020.06.005
   Ng LG, 2019, NAT REV IMMUNOL, V19, P255, DOI 10.1038/s41577-019-0141-8
   Landsman L, 2009, BLOOD, V113, P963, DOI 10.1182/blood-2008-07-170787
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Lin A, 2018, J IMMUNOL, V200, P286, DOI 10.4049/jimmunol.1701005
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   Medoff BD, 2009, J IMMUNOL, V182, P623, DOI 10.4049/jimmunol.182.1.623
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Panganiban AT, 2020, BRAIN PATHOL, DOI 10.1111/bpa.12873
   Pence BD, 2020, GEROSCIENCE, V42, P1051, DOI 10.1007/s11357-020-00213-0
   Peterson B. G., 2020, PERFORMANCEANALYTICS
   PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164
   R Development Core Team, 2019, R LANG ENV STAT COMP
   Reumaux D, 2003, J LEUKOCYTE BIOL, V73, P841, DOI 10.1189/jlb.1102567
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Scapini P, 2016, IMMUNOL REV, V273, P48, DOI 10.1111/imr.12448
   Schulte-Schrepping J, 2020, CELL, V182
   Schyns J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11843-0
   Silvin A, 2020, CELL, V182, P1401, DOI 10.1016/j.cell.2020.08.002
   Simmons HA, 2016, VET PATHOL, V53, P399, DOI 10.1177/0300985815620628
   Singh D. K, 2020, PREPRINT, DOI DOI 10.1101/2020.06.05.136481V1
   Steinmuller C, 2000, AM J RESP CELL MOL, V22, P481, DOI 10.1165/ajrcmb.22.4.3336
   Sun PF, 2020, J MED VIROL, V92, P612, DOI 10.1002/jmv.25735
   Tam JW, 2014, INFECT IMMUN, V82, P2606, DOI 10.1128/IAI.01590-13
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Vaccari M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01072
   Vaccari M, 2018, NAT MED, V24, P847, DOI 10.1038/s41591-018-0025-7
   Weiss SR, 2020, J EXP MED, V217, DOI 10.1084/jem.20200537
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   Wickham H, 2016, GGPLOT2 ELEGANT GRAP, DOI [10.1007/978-3-319-24277-4, DOI 10.1007/978-3-319-24277-4]
   Wilk AJ, 2020, NAT MED, V26, P1070, DOI 10.1038/s41591-020-0944-y
   Woolsey C, 2020, PLOS PATHOG, DOI [10.1371/journal.ppat.1008903, DOI 10.1371/JOURNAL.PPAT.1008903]
   Wu VH, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139783
   Xia CQ, 2004, AM J CLIN PATHOL, V121, P507, DOI 10.1309/WPK7Y2XKNF4CBF3R
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 63
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC 27
PY 2020
VL 11
IS 1
AR 6078
DI 10.1038/s41467-020-19967-4
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB7DR
UT WOS:000596477900001
PM 33247138
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, KN
   Huang, B
   Wu, M
   Zhong, AF
   Li, L
   Cai, Y
   Wang, ZH
   Wu, LX
   Zhu, MY
   Li, J
   Wang, ZY
   Wu, W
   Li, WL
   Bosco, B
   Gan, ZH
   Qiao, QH
   Wu, J
   Wang, QH
   Wang, SK
   Xia, XY
AF Li, Kening
   Huang, Bin
   Wu, Min
   Zhong, Aifang
   Li, Lu
   Cai, Yun
   Wang, Zhihua
   Wu, Lingxiang
   Zhu, Mengyan
   Li, Jie
   Wang, Ziyu
   Wu, Wei
   Li, Wanlin
   Bosco, Bakwatanisa
   Gan, Zhenhua
   Qiao, Qinghua
   Wu, Jian
   Wang, Qianghu
   Wang, Shukui
   Xia, Xinyi
TI Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2
   infection and recovery from COVID-19
SO NATURE COMMUNICATIONS
LA English
DT Article
AB Deciphering the dynamic changes in antibodies against SARS-CoV-2 is essential for understanding the immune response in COVID-19 patients. Here we analyze the laboratory findings of 1,850 patients to describe the dynamic changes of the total antibody, spike protein (S)-, receptor-binding domain (RBD)-, and nucleoprotein (N)-specific immunoglobulin M (IgM) and G (IgG) levels during SARS-CoV-2 infection and recovery. The generation of S-, RBD-, and N-specific IgG occurs one week later in patients with severe/critical COVID-19 compared to patients with mild/moderate disease, while S- and RBD-specific IgG levels are 1.5-fold higher in severe/critical patients during hospitalization. The RBD-specific IgG levels are 4-fold higher in older patients than in younger patients during hospitalization. In addition, the S- and RBD-specific IgG levels are 2-fold higher in the recovered patients who are SARS-CoV-2 RNA negative than those who are RNA positive. Lower S-, RBD-, and N-specific IgG levels are associated with a lower lymphocyte percentage, higher neutrophil percentage, and a longer duration of viral shedding. Patients with low antibody levels on discharge might thereby have a high chance of being tested positive for SARS-CoV-2 RNA after recovery. Our study provides important information for COVID-19 diagnosis, treatment, and vaccine development.
C1 [Li, Kening; Wang, Qianghu] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Nanjing, Peoples R China.
   [Li, Kening; Huang, Bin; Wu, Min; Li, Lu; Cai, Yun; Wu, Lingxiang; Zhu, Mengyan; Li, Jie; Wang, Ziyu; Wu, Wei; Li, Wanlin; Bosco, Bakwatanisa; Wang, Qianghu] Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, Nanjing 211166, Jiangsu, Peoples R China.
   [Li, Kening; Huang, Bin; Wu, Min; Li, Lu; Cai, Yun; Wu, Lingxiang; Zhu, Mengyan; Li, Jie; Wang, Ziyu; Wu, Wei; Li, Wanlin; Bosco, Bakwatanisa; Wang, Qianghu] Nanjing Med Univ, Dept Bioinformat, Nanjing 211166, Jiangsu, Peoples R China.
   [Zhong, Aifang] 904th Hosp, Med Tech Support Div, Changzhou 213003, Jiangsu, Peoples R China.
   [Zhong, Aifang; Wang, Zhihua; Qiao, Qinghua; Xia, Xinyi] Wuhan Huoshenshan Hosp, Dept Lab Med & Blood Transfus, Wuhan 430100, Hubei, Peoples R China.
   [Wang, Zhihua] 907th Hosp, Dept Lab Med & Blood Transfus, Nanping 350702, Fujian, Peoples R China.
   [Gan, Zhenhua] Nanjing Univ, Jinling Hosp, Dept Med Adm, Sch Med, Nanjing 210002, Jiangsu, Peoples R China.
   [Gan, Zhenhua; Xia, Xinyi] Wuhan Huoshenshan Hosp, Joint Expert Grp COVID 19, Wuhan 430100, Hubei, Peoples R China.
   [Qiao, Qinghua] 989th Hosp Joint Logist Support Force, Pingdingshan Med Dist, Med & Tech Support Dept, Pingdingshan 467000, Henan, Peoples R China.
   [Wu, Jian; Xia, Xinyi] Nanjing Univ, Sch Med, COVID 19 Res Ctr, Inst Lab Med,Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China.
   [Wang, Qianghu] Nanjing Med Univ, Collaborat Innovat Ctr Cardiovasc Dis, Nanjing 211166, Peoples R China.
   [Wang, Shukui] Nanjing Med Univ, Nanjing First Hosp, Dept Lab Med, Nanjing 210006, Jiangsu, Peoples R China.
RP Wang, QH (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Nanjing, Peoples R China.; Wang, QH (corresponding author), Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, Nanjing 211166, Jiangsu, Peoples R China.; Wang, QH (corresponding author), Nanjing Med Univ, Dept Bioinformat, Nanjing 211166, Jiangsu, Peoples R China.; Xia, XY (corresponding author), Wuhan Huoshenshan Hosp, Dept Lab Med & Blood Transfus, Wuhan 430100, Hubei, Peoples R China.; Xia, XY (corresponding author), Wuhan Huoshenshan Hosp, Joint Expert Grp COVID 19, Wuhan 430100, Hubei, Peoples R China.; Xia, XY (corresponding author), Nanjing Univ, Sch Med, COVID 19 Res Ctr, Inst Lab Med,Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China.; Wang, QH (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Cardiovasc Dis, Nanjing 211166, Peoples R China.; Wang, SK (corresponding author), Nanjing Med Univ, Nanjing First Hosp, Dept Lab Med, Nanjing 210006, Jiangsu, Peoples R China.
EM wangqh@njmu.edu.cn; sk_wang@njmu.edu.cn; xiaxynju@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572893, 81972358, 91959113]; Key
   Foundation of Wuhan Huoshenshan Hospital [2020[18]]; Key Research &
   Development Program of Jiangsu Province [BE2017733, BE2018713]; Medical
   Innovation Project of Logistics Service [18JS005]; Basic Research
   Program of Jiangsu Province [BK20180036]
FX This study was supported by the National Natural Science Foundation of
   China (Grant Nos. 81572893, 81972358, and 91959113), Key Foundation of
   Wuhan Huoshenshan Hospital (Grant No. 2020[18]), Key Research &
   Development Program of Jiangsu Province (Grant Nos. BE2017733 and
   BE2018713), Medical Innovation Project of Logistics Service (Grant No.
   18JS005), Basic Research Program of Jiangsu Province (Grant No.
   BK20180036). We thank Jinli Li for her advice for the validation of the
   assay.
CR Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen Y, 2020, J MED VIROL, V92, P731, DOI 10.1002/jmv.25787
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Gabriella D, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106519
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang L, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.006
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Mei Q, 2020, LANCET INFECT DIS, V20, P1004, DOI 10.1016/S1473-3099(20)30433-3
   Mercado NB, 2020, NATURE, DOI 10.1038/s41586-020-2607-z
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Sun BQ, 2020, EMERG MICROBES INFEC, V9, P940, DOI 10.1080/22221751.2020.1762515
   Suthar Mehul S, 2020, Cell Rep Med, V1, P100040, DOI 10.1016/j.xcrm.2020.100040
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu X, 2020, NAT MED, V26, P1193, DOI 10.1038/s41591-020-0949-6
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 31
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC 27
PY 2020
VL 11
IS 1
AR 6044
DI 10.1038/s41467-020-19943-y
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB7DH
UT WOS:000596476900021
PM 33247152
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Devos, T
   Geukens, T
   Schauvlieghe, A
   Arien, KK
   Barbezange, C
   Cleeren, M
   Compernolle, V
   Dauby, N
   Desmecht, D
   Grimaldi, D
   Lambrecht, BN
   Luyten, A
   Maes, P
   Moutschen, M
   Romano, M
   Seyler, L
   Nevessignsky, MT
   Vandenberghe, K
   van Griensven, J
   Verbeke, G
   Vlieghe, E
   Yombi, JC
   Liesenborghs, L
   Verhamme, P
   Meyfroidt, G
AF Devos, Timothy
   Geukens, Tatjana
   Schauvlieghe, Alexander
   Arien, Kevin K.
   Barbezange, Cyril
   Cleeren, Myriam
   Compernolle, Veerle
   Dauby, Nicolas
   Desmecht, Daniel
   Grimaldi, David
   Lambrecht, Bart N.
   Luyten, Anne
   Maes, Piet
   Moutschen, Michel
   Romano, Marta
   Seyler, Lucie
   Nevessignsky, Michel Toungouz
   Vandenberghe, Katleen
   van Griensven, Johan
   Verbeke, Geert
   Vlieghe, Erika
   Yombi, Jean Cyr
   Liesenborghs, Laurens
   Verhamme, Peter
   Meyfroidt, Geert
TI A randomized, multicentre, open-label phase II proof-of-concept trial
   investigating the clinical efficacy and safety of the addition of
   convalescent plasma to the standard of care in patients hospitalized
   with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma)
   trial
SO TRIALS
LA English
DT Article
DE SARS-CoV-2; COVID-19; Convalescent plasma; Antibodies; Immunity
AB BackgroundThe COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe influenza to patients actively having the disease showed promising effects on mortality and appeared safe. Whether or not this also holds true for the novel SARS-CoV-2 virus is currently unknown.MethodsDAWn-Plasma is a multicentre nation-wide, randomized, open-label, phase II proof-of-concept clinical trial, evaluating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 in Belgium. Patients hospitalized with a confirmed diagnosis of COVID-19 are eligible when they are symptomatic (i.e. clinical or radiological signs) and have been diagnosed with COVID-19 in the 72h before study inclusion through a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-CT scan showing features compatible with COVID-19 in the absence of an alternative diagnosis. Patients are randomized in a 2:1 ratio to either standard of care and convalescent plasma (active treatment group) or standard of care only. The active treatment group receives 2units of 200 to 250mL of convalescent plasma within 12h after randomization, with a second administration of 2units 24 to 36h after ending the first administration. The trial aims to include 483 patients and will recruit from 25 centres across Belgium. The primary endpoint is the proportion of patients that require mechanical ventilation or have died at day 15. The main secondary endpoints are clinical status on day 15 and day 30 after randomization, as defined by the WHO Progression 10-point ordinal scale, and safety of the administration of convalescent plasma.DiscussionThis trial will either provide support or discourage the use of convalescent plasma as an early intervention for the treatment of hospitalized patients with COVID-19 infection.Trial registrationClinicalTrials.govNCT04429854. Registered on 12 June 2020 - Retrospectively registered.
C1 [Devos, Timothy; Geukens, Tatjana; Cleeren, Myriam; Verhamme, Peter; Meyfroidt, Geert] Univ Hosp Leuven UZ Leuven, Leuven, Belgium.
   [Devos, Timothy; Geukens, Tatjana] Catholic Univ Leuven KU Leuven, Leuven, Belgium.
   [Schauvlieghe, Alexander; Lambrecht, Bart N.] Univ Ziekenhuis Gent, Ghent, Belgium.
   [Arien, Kevin K.; van Griensven, Johan] Inst Trop Geneeskunde, Antwerp, Belgium.
   [Barbezange, Cyril; Romano, Marta] Sciensano, Elsene, Belgium.
   [Compernolle, Veerle] Rode Kruis Vlaanderen, Mechelen, Belgium.
   [Dauby, Nicolas] Univ Libre Bruxelles, Inst Immunol Med, Brussels, Belgium.
   [Desmecht, Daniel; Moutschen, Michel] Univ Liege, Liege, Belgium.
   [Grimaldi, David] Univ Libre Bruxelles, Brussels, Belgium.
   [Luyten, Anne; Vandenberghe, Katleen] Leuven Coordinating Ctr, Leuven, Belgium.
   [Maes, Piet; Liesenborghs, Laurens] Katholieke Univ Leuven, Rega Inst Med Res, Leuven, Belgium.
   [Seyler, Lucie] Univ Ziekenhuis Brussel, Brussels, Belgium.
   [Nevessignsky, Michel Toungouz] Croix Rouge Belgique, Brussels, Belgium.
   [Verbeke, Geert] Interuniv Inst Biostat & Stat Bioinformat, Leuven, Belgium.
   [Vlieghe, Erika] Univ Ziekenhuis Antwerpen, Antwerp, Belgium.
   [Yombi, Jean Cyr] Clin Univ St Luc, St Lambrechts Woluwe, Belgium.
RP Devos, T (corresponding author), Univ Hosp Leuven UZ Leuven, Leuven, Belgium.; Devos, T (corresponding author), Catholic Univ Leuven KU Leuven, Leuven, Belgium.
EM timothy.devos@uzleuven.be
OI Devos, Timothy/0000-0002-6881-417X
FU KCE (Belgian Health Care Knowledge Centre) under the KCE Trials
   Programme
FX This published protocol is independent research funded by KCE (Belgian
   Health Care Knowledge Centre) under the KCE Trials Programme. KCE
   approved the trial design and protocol but was not involved in the
   design of the study. KCE will not be involved in data collection, data
   analysis, data interpretation or writing of manuscripts related to this
   study.
CR Bastos ML, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2516
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Enria DA, 2007, TREATMENT ARGENTINE, DOI [10.1016/j.antiviral.2007.10.010, DOI 10.1016/J.ANTIVIRAL.2007.10.010]
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Mair-Jenkins J, 2014, EFFECTIVENESS CONVAL, DOI [10.1093/infdis/jiu396, DOI 10.1093/INFDIS/JIU396]
   Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 1
Z9 1
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 27
PY 2020
VL 21
IS 1
AR 981
DI 10.1186/s13063-020-04876-0
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA9SP
UT WOS:000595968400003
PM 33246499
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Garcia-Salido, A
   Vicente, JCD
   Hofheinz, SB
   Ramirez, JB
   Barrio, MS
   Gordillo, IL
   Yuste, AH
   Pardellans, CG
   Tejedor, MCM
   Labarga, BH
   Martinez, JLV
   Jimeno, MG
   Oulego-Erroz, I
   Quintela, JT
   Monzon, CM
   Ramos, LM
   Pena, MSH
   Gil-Anton, J
   Orti, CS
   Gonzalez, JCF
   Palomo, RMH
   Ganfornina, IS
   Romero, EF
   Garcia-Besteiro, M
   Cid, JLH
   Cortes, RG
AF Garcia-Salido, Alberto
   de Carlos Vicente, Juan Carlos
   Belda Hofheinz, Sylvia
   Balcells Ramirez, Joan
   Slocker Barrio, Maria
   Leoz Gordillo, Ines
   Hernandez Yuste, Alexandra
   Guitart Pardellans, Carmina
   Cuervas-Mons Tejedor, Maite
   Huidobro Labarga, Beatriz
   Vazquez Martinez, Jose Luis
   Gutierrez Jimeno, Miriam
   Oulego-Erroz, Ignacio
   Trastoy Quintela, Javier
   Medina Monzon, Carmen
   Medina Ramos, Laura
   Holanda Pena, Maria Soledad
   Gil-Anton, Javier
   Sorribes Orti, Clara
   Flores Gonzalez, Jose Carlos
   Hernandez Palomo, Rosa Maria
   Sanchez Ganfornina, Inma
   Fernandez Romero, Emilia
   Garcia-Besteiro, Maria
   Lopez-Herce Cid, Jesus
   Gonzalez Cortes, Rafael
CA Spanish Pediat Intensive Care Soc
TI Severe manifestations of SARS-CoV-2 in children and adolescents: from
   COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre
   study in pediatric intensive care units in Spain
SO CRITICAL CARE
LA English
DT Article
DE SARS-CoV-2; Pediatric multisystem inflammatory syndrome temporally
   associated with COVID-19; Kawasaki disease; Toxic shock syndrome;
   Children; Critical care; Shock
ID DISEASE; SHOCK
AB Background Multisystem inflammatory syndrome temporally associated with COVID-19 (MIS-C) has been described as a novel and often severe presentation of SARS-CoV-2 infection in children. We aimed to describe the characteristics of children admitted to Pediatric Intensive Care Units (PICUs) presenting with MIS-C in comparison with those admitted with SARS-CoV-2 infection with other features such as COVID-19 pneumonia. Methods A multicentric prospective national registry including 47 PICUs was carried out. Data from children admitted with confirmed SARS-CoV-2 infection or fulfilling MIS-C criteria (with or without SARS-CoV-2 PCR confirmation) were collected. Clinical, laboratory and therapeutic features between MIS-C and non-MIS-C patients were compared. Results Seventy-four children were recruited. Sixty-one percent met MIS-C definition. MIS-C patients were older than non-MIS-C patients (p = 0.002): 9.4 years (IQR 5.5-11.8) vs 3.4 years (IQR 0.4-9.4). A higher proportion of them had no previous medical history of interest (88.2% vs 51.7%, p = 0.005). Non-MIS-C patients presented more frequently with respiratory distress (60.7% vs 13.3%, p < 0.001). MIS-C patients showed higher prevalence of fever (95.6% vs 64.3%, p < 0.001), diarrhea (66.7% vs 11.5%, p < 0.001), vomits (71.1% vs 23.1%, p = 0.001), fatigue (65.9% vs 36%, p = 0.016), shock (84.4% vs 13.8%, p < 0.001) and cardiac dysfunction (53.3% vs 10.3%, p = 0.001). MIS-C group had a lower lymphocyte count (p < 0.001) and LDH (p = 0.001) but higher neutrophil count (p = 0.045), neutrophil/lymphocyte ratio (p < 0.001), C-reactive protein (p < 0.001) and procalcitonin (p < 0.001). Patients in the MIS-C group were less likely to receive invasive ventilation (13.3% vs 41.4%, p = 0.005) but were more often treated with vasoactive drugs (66.7% vs 24.1%, p < 0.001), corticosteroids (80% vs 44.8%, p = 0.003) and immunoglobulins (51.1% vs 6.9%, p < 0.001). Most patients were discharged from PICU by the end of data collection with a median length of stay of 5 days (IQR 2.5-8 days) in the MIS-C group. Three patients died, none of them belonged to the MIS-C group. Conclusions MIS-C seems to be the most frequent presentation among critically ill children with SARS-CoV-2 infection. MIS-C patients are older and usually healthy. They show a higher prevalence of gastrointestinal symptoms and shock and are more likely to receive vasoactive drugs and immunomodulators and less likely to need mechanical ventilation than non-MIS-C patients.
C1 [Garcia-Salido, Alberto; Leoz Gordillo, Ines] Hosp Infantil Univ Nino Jesus, Madrid, Spain.
   [de Carlos Vicente, Juan Carlos] Hosp Univ Son Espases, Palma De Mallorca, Spain.
   [Belda Hofheinz, Sylvia] Hosp Univ 12 Octubre, Madrid, Spain.
   [Balcells Ramirez, Joan] Hosp Univ Vall DHebron, Barcelona, Spain.
   [Slocker Barrio, Maria; Lopez-Herce Cid, Jesus; Gonzalez Cortes, Rafael] Hosp Gen Univ Gregorio Maranon, Paediat Intens Care Unit, Calle Doctor Castelo 47, Madrid 28007, Spain.
   [Hernandez Yuste, Alexandra] Hosp Reg Univ Malaga, Malaga, Spain.
   [Guitart Pardellans, Carmina] Hosp Univ St Joan de Deu, Esplugas de Llobregat, Spain.
   [Cuervas-Mons Tejedor, Maite] Hosp Univ Burgos, Burgos, Spain.
   [Huidobro Labarga, Beatriz] Hosp Univ Virgen Salud, Toledo, Spain.
   [Vazquez Martinez, Jose Luis] Hosp Univ Ramon Y Cajal, Madrid, Spain.
   [Gutierrez Jimeno, Miriam] Clin Univ Navarra, Pamplona, Spain.
   [Oulego-Erroz, Ignacio] Complejo Asistencial Univ Leon, Leon, Spain.
   [Trastoy Quintela, Javier] Complejo Hosp Univ Santiago, Santiago De Compostela, Spain.
   [Medina Monzon, Carmen] Hosp Gen Univ Albacete, Albacete, Spain.
   [Medina Ramos, Laura] Hosp Gen Univ Alicante, Alicante, Spain.
   [Holanda Pena, Maria Soledad] Hosp Univ Marques Valdecilla, Santander, Spain.
   [Gil-Anton, Javier] Hosp Univ Cruces, Baracaldo, Spain.
   [Sorribes Orti, Clara] Hosp Univ Joan XXIII, Tarragona, Spain.
   [Flores Gonzalez, Jose Carlos] Hosp Univ Puerta del Mar, Cadiz, Spain.
   [Hernandez Palomo, Rosa Maria] Hosp Univ Quironsalud Madrid, Pozuelo De Alarcon, Spain.
   [Sanchez Ganfornina, Inma] Hosp Univ Virgen Rocio, Seville, Spain.
   [Fernandez Romero, Emilia] Hosp Univ Virgen Macarena, Seville, Spain.
   [Garcia-Besteiro, Maria] Parc Tauli Hosp Univ, Sabadell, Spain.
RP Cortes, RG (corresponding author), Hosp Gen Univ Gregorio Maranon, Paediat Intens Care Unit, Calle Doctor Castelo 47, Madrid 28007, Spain.
EM rafa_gonzalez_cortes@hotmail.com
RI ; Garcia-Salido, Alberto/D-2294-2019
OI Guitart Pardellans, Carmina/0000-0001-9127-5939; Garcia-Salido,
   Alberto/0000-0002-8038-7430
FU Carlos III Health Institute (ISCIII) through the COVID-19 found
   [COV20-00944]
FX This study has been founded by the Carlos III Health Institute (ISCIII)
   through the COVID-19 found. Ref. COV20-00944. The founder had no role in
   study design, data collection, analysis and interpretation.
CR [Anonymous], KIDS KAW DIS SYMPT P
   Belhadjer Z, 2020, CIRCULATION, DOI 10.1161/CIRCULATIONAHA.120.048360
   BUCHDAHL R, 1985, ARCH DIS CHILD, V60, P563, DOI 10.1136/adc.60.6.563
   Cabrero-Hernandez M, 2020, PEDIAT INFECT DIS J
   Carter MJ, 2020, NAT MED, V26, P1701, DOI 10.1038/s41591-020-1054-6
   Cheung EW, 2020, JAMA
   Cruz AT, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0834
   Davies P, 2020, LANCET CHILD ADOLESC
   Del Valle DM, 2020, NAT MED, V26, P1636, DOI 10.1038/s41591-020-1051-9
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dufort EM, 2020, N ENGL J MED
   Esper F, 2005, J INFECT DIS, V191, P499, DOI 10.1086/428291
   Feldstein LR, 2020, N ENGL J MED
   Garazzino S, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.18.2000600
   Cortes RG, 2020, INTENS CARE MED, V46, P1774, DOI 10.1007/s00134-020-06146-8
   Grimaud M, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00690-8
   Guidance- Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS), GUID PAED MULT INFL
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   Hildebrandt P, 2010, EUR HEART J, V31, P1881, DOI 10.1093/eurheartj/ehq163
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Khemani RG, 2015, PEDIATR CRIT CARE ME, V16, pS23, DOI 10.1097/PCC.0000000000000432
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P371, DOI 10.1016/j.jmii.2020.02.011
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Ministerio de Sanidad, CONS BIEN SOC PROF S
   Parri N, 2020, NEW ENGL J MED, V383, P187, DOI 10.1056/NEJMc2007617
   Pathak EB, 2020, J PUBLIC HEALTH MAN, V26, P325, DOI 10.1097/PHH.0000000000001190
   Peacock WF, 2018, JAMA CARDIOL, V3, P104, DOI 10.1001/jamacardio.2017.4625
   Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Rostad CA, 2020, PEDIATRICS
   Sachdeva R, 2020, PEDIAT CRIT CARE MED
   Shekerdemian LS, 2020, JAMA PEDIAT
   Swann OV, 2020, BMJ
   Tagarro A, 2020, JAMA PEDIAT
   Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094
   Turnier JL, 2015, PEDIATRICS, V136, pE609, DOI 10.1542/peds.2015-0950
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Whittaker E, 2020, JAMA
   Wood LE, 2009, HEART, V95, P787, DOI 10.1136/hrt.2008.143669
   Wu VH, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139783
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 42
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1364-8535
EI 1466-609X
J9 CRIT CARE
JI Crit. Care
PD DEC 26
PY 2020
VL 24
IS 1
AR 666
DI 10.1186/s13054-020-03332-4
PG 13
WC Critical Care Medicine
SC General & Internal Medicine
GA PA7AA
UT WOS:000595782400002
PM 33243303
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Azimi, M
   Hasheminasab, FS
AF Azimi, Maryam
   Hasheminasab, Fatemeh Sadat
TI Evaluating the efficacy and safety of the myrtle (Myrtus communis) in
   treatment and prognosis of patients suspected to novel coronavirus
   disease (COVID-19): study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Myrtle; Herb; Persian medicine; M; communis
ID DOUBLE-BLIND
AB BackgroundSince December 2019, the outbreak of coronavirus pneumonia was observed in China and quickly propagate in all of the world. Nowadays, many trials are underway on this disease in which the efficacy of various therapeutic remedies including chemical or natural agents as well as different non-pharmacological methods such as acupuncture are evaluated. This study aims at investigating the effect of M. communis fruit for treatment of COVID-19 disease.MethodsWe are performing an open-label randomized controlled trial on outpatients clinically suspected to COVID-19 disease in the age range of 18-65years old with mild to moderate symptoms and without respiratory distress. Patients in both groups (M. communis and control) receive conventional therapy, but those in M. communis group get M. communis preparation in addition to conventional therapy. Intervention will continue for 5days and the study outcomes including clinical status as well as mortality rate and adverse effects will be measured up to 14days.DiscussionThe protocol describes the design of an ongoing randomized controlled trial to establish the evidence for the usage of water extract of M. communis fruit in clinically suspected COVID-19 disease and identify any safety concerns.Trial registrationThe trial has been registered at the Iranian Registry of Clinical Trials website under the code IRCT20180923041093N3 on March 28th, 2020 (https://www.irct.ir/trial/46721). The results will be disseminated through manuscript publications and presentations to scientific meetings.
C1 [Azimi, Maryam] Kerman Univ Med Sci, Gastroenterol & Hepatol Res Ctr, Kerman, Iran.
   [Azimi, Maryam] Kerman Univ Med Sci, Sch Persian Med, Dept Tradit Med, Kerman, Iran.
   [Hasheminasab, Fatemeh Sadat] Zahedan Univ Med Sci ZaUMS, Pharmacol Res Ctr, Zahedan, Iran.
RP Hasheminasab, FS (corresponding author), Zahedan Univ Med Sci ZaUMS, Pharmacol Res Ctr, Zahedan, Iran.
EM hashemifa67@gmail.com
OI Hasheminasab, Fatemeh Sadat/0000-0002-5709-7670
CR al-Nafis I, 2008, AL SHAMEL FI SANAAT
   Avicenna H, 2005, CANON MED AL QANON F
   Cui HT, 2020, TRADIT MED RES, V5, P65, DOI 10.12032/TMR20200222165
   Fisman Enrique Z., 2001, Journal of Medicine (Westbury), V32, P181
   Gautier JF, 2020, OBESITY, V28, P848, DOI 10.1002/oby.22809
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hasheminasab FS, 2020, J INTEGR MED-JIM, V18, P214, DOI 10.1016/j.joim.2020.02.008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jabri MA, 2016, BIOMED PHARMACOTHER, V84, P1937, DOI 10.1016/j.biopha.2016.11.008
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Maxia A, 2011, NAT PROD COMMUN, V6, p1934578X1100601034
   Moradi MT, 2011, J SHAHREKORD U MED S, V12, P54
   Qiu R, 2020, OUTCOME REPORTING PR, DOI [10.1101/2020.03.04.20031401, DOI 10.1101/2020.03.04.20031401]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Whitehead AL, 2016, STAT METHODS MED RES, V25, P1057, DOI 10.1177/0962280215588241
   Zohalinezhad ME, 2016, J EVID-BASED INTEGR, V21, P23, DOI 10.1177/2156587215589403
NR 18
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 26
PY 2020
VL 21
IS 1
AR 978
DI 10.1186/s13063-020-04915-w
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA6EA
UT WOS:000595725200004
PM 33243284
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mahdi, M
   Motyan, JA
   Szojka, ZI
   Golda, M
   Miczi, M
   Tozser, J
AF Mahdi, Mohamed
   Motyan, Janos Andras
   Szojka, Zsofia Ilona
   Golda, Maria
   Miczi, Mario
   Tozser, Jozsef
TI Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2 '
   s main protease
SO VIROLOGY JOURNAL
LA English
DT Article
DE SARS-CoV-2; Protease; HIV protease inhibitors; In vitro assay;
   Inhibition profiling
ID PLASMA-CONCENTRATIONS; CORONAVIRUS; RITONAVIR; SARS; MONOTHERAPY;
   PNEUMONIA; LOPINAVIR
AB Background The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in millions of infections worldwide. While the search for an effective antiviral is still ongoing, experimental therapies based on repurposing of available antivirals is being attempted, of which HIV protease inhibitors (PIs) have gained considerable interest. Inhibition profiling of the PIs directly against the viral protease has never been attempted in vitro, and while few studies reported an efficacy of lopinavir and ritonavir in SARS-CoV-2 context, the mechanism of action of the drugs remains to be validated. Methods We carried out an in-depth analysis of the efficacy of HIV PIs against the main protease of SARS-CoV-2 (M-pro) in cell culture and in vitro enzymatic assays, using a methodology that enabled us to focus solely on any potential inhibitory effects of the inhibitors against the viral protease. For cell culture experiments a dark-to-bright GFP reporter substrate system was designed. Results Lopinavir, ritonavir, darunavir, saquinavir, and atazanavir were able to inhibit the viral protease in cell culture, albeit in concentrations much higher than their achievable plasma levels, given their current drug formulations. While inhibition by lopinavir was attributed to its cytotoxicity, ritonavir was the most effective of the panel, with IC50 of 13.7 mu M. None of the inhibitors showed significant inhibition of SARS-CoV-2 M-pro in our in vitro enzymatic assays up to 100 mu M concentration. Conclusion Targeting of SARS-CoV-2 M-pro by some of the HIV PIs might be of limited clinical potential, given the high concentration of the drugs required to achieve significant inhibition. Therefore, given their weak inhibition of the viral protease, any potential beneficial effect of the PIs in COVID-19 context might perhaps be attributed to acting on other molecular target(s), rather than SARS-CoV-2 M-pro.
C1 [Mahdi, Mohamed; Motyan, Janos Andras; Szojka, Zsofia Ilona; Golda, Maria; Miczi, Mario; Tozser, Jozsef] Univ Debrecen, Fac Med, Dept Biochem & Mol Biol, Lab Retroviral Biochem, Egyet Ter 1 Life Sci Bldg, H-4032 Debrecen, Hungary.
   [Szojka, Zsofia Ilona; Golda, Maria; Miczi, Mario] Univ Debrecen, Doctoral Sch Mol Cell & Immune Biol, Debrecen, Hungary.
RP Mahdi, M (corresponding author), Univ Debrecen, Fac Med, Dept Biochem & Mol Biol, Lab Retroviral Biochem, Egyet Ter 1 Life Sci Bldg, H-4032 Debrecen, Hungary.
EM mohamed@med.unideb.hu
FU Higher Education Institutional Excellence Programme of the Ministry of
   Innovation and Technology in Hungary [NKFIH-1150-6/2019]; Hungarian
   Scientific Research FundOrszagos Tudomanyos Kutatasi Alapprogramok
   (OTKA) [NKFI 125,238]
FX This work was supported in part by the Higher Education Institutional
   Excellence Programme (NKFIH-1150-6/2019) of the Ministry of Innovation
   and Technology in Hungary, within the framework of the Biotechnology
   thematic programme of the University of Debrecen, and in part, by the
   Hungarian Scientific Research Fund (NKFI 125,238) to J.T. The funders
   had no role in the design of the study; in the collection, analyses, or
   interpretation of data; in the writing of the manuscript, or in the
   decision to publish the results.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Baker A, 1997, GENE THER, V4, P773, DOI 10.1038/sj.gt.3300471
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Calligari P, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040445
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fischer A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103626
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Gutierrez-Valencia A, 2014, ANTIVIR THER, V19, P443, DOI 10.3851/IMP2722
   Hull MW, 2011, ANN MED, V43, P375, DOI 10.3109/07853890.2011.572905
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lotsch J, 2007, ANTIMICROB AGENTS CH, V51, P3264, DOI 10.1128/AAC.00036-07
   Lopez-Cortes LF, 2013, ANTIMICROB AGENTS CH, V57, P3746, DOI 10.1128/AAC.00315-13
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Musarrat F, 2020, J MED VIROL, V92, P2087, DOI 10.1002/jmv.25985
   Nicholls SB, 2011, J BIOL CHEM, V286, P24977, DOI 10.1074/jbc.M111.221648
   Nutho B, 2020, BIOCHEMISTRY-US, V59, P1769, DOI 10.1021/acs.biochem.0c00160
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Sang P, 2020, RSC ADV, V10, P15775, DOI 10.1039/d0ra01899f
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Smith DE, 2006, HIV CLIN TRIALS, V7, P34, DOI 10.1310/0KX0-H9VH-99EE-5D0L
   van der Lugt J, 2009, ANTIVIR THER, V14, P1001, DOI 10.3851/IMP1410
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 33
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD DEC 26
PY 2020
VL 17
IS 1
AR 190
DI 10.1186/s12985-020-01457-0
PG 8
WC Virology
SC Virology
GA PA6FG
UT WOS:000595728400003
PM 33243253
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Puttaswamy, H
   Gowtham, HG
   Ojha, MD
   Yadav, A
   Choudhir, G
   Raguraman, V
   Kongkham, B
   Selvaraju, K
   Shareef, S
   Gehlot, P
   Ahamed, F
   Chauhan, L
AF Puttaswamy, Hariprasad
   Gowtham, Hittanahallikoppal Gajendramurthy
   Ojha, Monu Dinesh
   Yadav, Ajay
   Choudhir, Gourav
   Raguraman, Vasantharaja
   Kongkham, Bhani
   Selvaraju, Koushalya
   Shareef, Shazia
   Gehlot, Priyanka
   Ahamed, Faiz
   Chauhan, Leena
TI In silico studies evidenced the role of structurally diverse plant
   secondary metabolites in reducing SARS-CoV-2 pathogenesis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ELLAGITANNIN METABOLITES; ANTIVIRAL ACTIVITY; POMEGRANATE JUICE;
   GLYCYRRHIZIC ACID; VIRUS-REPLICATION; HUMAN PLASMA; BIOAVAILABILITY;
   CORONAVIRUS; SAPONINS; VIVO
AB Plants are endowed with a large pool of structurally diverse small molecules known as secondary metabolites. The present study aims to virtually screen these plant secondary metabolites (PSM) for their possible anti-SARS-CoV-2 properties targeting four proteins/ enzymes which govern viral pathogenesis. Results of molecular docking with 4,704 ligands against four target proteins, and data analysis revealed a unique pattern of structurally similar PSM interacting with the target proteins. Among the top-ranked PSM which recorded lower binding energy (BE),>50% were triterpenoids which interacted strongly with viral spike protein-receptor binding domain,>32% molecules which showed better interaction with the active site of human transmembrane serine protease were belongs to flavonoids and their glycosides,>16% of flavonol glycosides and>16% anthocyanidins recorded lower BE against active site of viral main protease and>13% flavonol glycoside strongly interacted with active site of viral RNA-dependent RNA polymerase. The primary concern about these PSM is their bioavailability. However, several PSM recorded higher bioavailability score and found fulfilling most of the drug-likeness characters as per Lipinski's rule (Coagulin K, Kamalachalcone C, Ginkgetin, Isoginkgetin, 3,3 ' -Biplumbagin, Chrysophanein, Aromoline, etc.). Natural occurrence, bio-transformation, bioavailability of selected PSM and their interaction with the target site of selected proteins were discussed in detail. Present study provides a platform for researchers to explore the possible use of selected PSM to prevent/ cure the COVID-19 by subjecting them for thorough in vitro and in vivo evaluation for the capabilities to interfering with the process of viral host cell recognition, entry and replication.
C1 [Puttaswamy, Hariprasad; Gowtham, Hittanahallikoppal Gajendramurthy; Ojha, Monu Dinesh; Yadav, Ajay; Choudhir, Gourav; Raguraman, Vasantharaja; Kongkham, Bhani; Selvaraju, Koushalya; Shareef, Shazia; Gehlot, Priyanka; Ahamed, Faiz; Chauhan, Leena] Indian Inst Technol Delhi, Ctr Rural Dev & Technol, Delhi 110016, India.
RP Puttaswamy, H (corresponding author), Indian Inst Technol Delhi, Ctr Rural Dev & Technol, Delhi 110016, India.
EM phari@iitd.ac.in
CR Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1
   AKAI E, 1985, CHEM PHARM BULL, V33, P3715
   Akinwumi BC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030792
   Baba S, 2001, J NUTR, V131, P2885
   Barbosa Wagner Luiz R., 2006, Rev. bras. farmacogn., V16, P333, DOI 10.1590/S0102-695X2006000300009
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Boucaud-Maitre D, 2019, TOXICON, V161, P28, DOI 10.1016/j.toxicon.2019.02.014
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chakraborty D P, 1991, Fortschr Chem Org Naturst, V57, P71
   Chakraborty D.P., 1993, ALKALOIDS, V44, P257, DOI 10.1016/S0099-9598(08)60146-7
   Charlton JL, 1998, J NAT PROD, V61, P1447, DOI 10.1021/np980136z
   Chen HJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01272
   Chen YG, 2005, FITOTERAPIA, V76, P370, DOI 10.1016/j.fitote.2005.03.012
   CHRISTEN P, 1986, PHARM ACTA HELV, V61, P242
   Coulerie P, 2013, PLANTA MED, V79, P1313, DOI 10.1055/s-0033-1350672
   Czank C, 2013, AM J CLIN NUTR, V97, P995, DOI 10.3945/ajcn.112.049247
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   De Maria C. A. B., 1999, Journal of Food Composition and Analysis, V12, P289, DOI 10.1006/jfca.1999.0833
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Federspiel M, 1999, ORG PROCESS RES DEV, V3, P266, DOI 10.1021/op9900176
   Fujioka T, 2003, CHEM PHARM BULL, V51, P365, DOI 10.1248/cpb.51.365
   Furusawa M, 2005, HELV CHIM ACTA, V88, P1048, DOI 10.1002/hlca.200590076
   Gao S, 2012, CURR DRUG TARGETS, V13, P1885, DOI 10.2174/138945012804545498
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gil MI, 2000, J AGR FOOD CHEM, V48, P4581, DOI 10.1021/jf000404a
   GLOTTER E, 1991, NAT PROD REP, V8, P415, DOI 10.1039/np9910800415
   Gonthier MP, 2003, J NUTR, V133, P1853
   Graefe EU, 2001, J CLIN PHARMACOL, V41, P492, DOI 10.1177/00912700122010366
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   HATTORI S, 1952, ARCH BIOCHEM BIOPHYS, V37, P85, DOI 10.1016/0003-9861(52)90164-1
   Hazra B, 2002, PHYTOTHER RES, V16, P133, DOI 10.1002/ptr.867
   He Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24132365
   Heber D, 2011, HERBAL MED BIOMOLECU
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holeski LM, 2012, OECOLOGIA, V170, P695, DOI 10.1007/s00442-012-2344-6
   Holt RR, 2002, AM J CLIN NUTR, V76, P798
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Husson H. P, 1985, ALKALOIDS, V26, P1, DOI 10.1016/S0099-9598(08)60192-3
   Ikeda K, 2011, INT J MOL MED, V28, P595, DOI 10.3892/ijmm.2011.739
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kamng'ona A, 2011, J ENZYM INHIB MED CH, V26, P843, DOI 10.3109/14756366.2011.566220
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kim DE, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110696
   Kim TG, 2001, PHYTOTHER RES, V15, P718, DOI 10.1002/ptr.832
   Knolker HJ, 2008, ALKALOIDS-CHEM BIOL, V65, P181
   Kong R, 2020, COVID 19 DOCKING SER
   Krichel B, 2020, BIOCHEM J, V477, P1009, DOI 10.1042/BCJ20200029
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kubin A, 2005, CURR PHARM DESIGN, V11, P233, DOI 10.2174/1381612053382287
   Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li JH, 2016, MOLECULES, V21, DOI 10.3390/molecules21091133
   Li Z, 2020, FEP BASED SCREENING, DOI [10.1101/2020.03.23.004580, DOI 10.1101/2020.03.23.004580]
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu ZQ, 2006, PHARM RES-DORDR, V23, P2768, DOI 10.1007/s11095-006-9100-8
   Martin YC, 2005, J MED CHEM, V48, P3164, DOI 10.1021/jm0492002
   McDougall B, 1998, ANTIMICROB AGENTS CH, V42, P140, DOI 10.1128/AAC.42.1.140
   Meng T, 2020, INSERT SEQUENCE SARS, DOI [10.1101/2020.02.08.926006, DOI 10.1101/2020.02.08.926006]
   Mirjalili MH, 2009, MOLECULES, V14, P2373, DOI 10.3390/molecules14072373
   Miyake Y, 1997, FOOD SCI TECHNOL INT, V3, P84, DOI DOI 10.3136/FSTI9596T9798.3.84
   Monagas M, 2010, FOOD FUNCT, V1, P233, DOI 10.1039/c0fo00132e
   Nalli Y, 2016, ORG BIOMOL CHEM, V14, P3322, DOI 10.1039/c6ob00267f
   del Hierro JN, 2018, J FUNCT FOODS, V40, P484, DOI 10.1016/j.jff.2017.11.032
   Navarro P, 2001, LIFE SCI, V68, P1199, DOI 10.1016/S0024-3205(00)01019-5
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   PENG S, 1991, PHYTOCHEMISTRY, V30, P775, DOI 10.1016/0031-9422(91)85250-4
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pichersky E, 2000, TRENDS PLANT SCI, V5, P439, DOI 10.1016/S1360-1385(00)01741-6
   POMPEI R, 1979, NATURE, V281, P689, DOI 10.1038/281689a0
   Ramasamy S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126565
   RAO KV, 1974, PLANTA MED, V25, P166, DOI 10.1055/s-0028-1097927
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Refaat J., 2015, INT J PHARMACOGN, V2, P102, DOI DOI 10.13040/IJPSR.0975-8232.IJP.2(3).102-109
   Seeram NP, 2008, J MED FOOD, V11, P390, DOI 10.1089/jmf.2007.650
   Seeram NP, 2004, CLIN CHIM ACTA, V348, P63, DOI 10.1016/j.cccn.2004.04.029
   Serra A, 2010, BRIT J NUTR, V103, P944, DOI 10.1017/S0007114509992741
   Shih CM, 2018, PHYTOMEDICINE, V46, P193, DOI 10.1016/j.phymed.2017.08.009
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   STORMER FC, 1993, FOOD CHEM TOXICOL, V31, P303, DOI 10.1016/0278-6915(93)90080-I
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Sugie S, 1998, CANCER LETT, V127, P177, DOI 10.1016/S0304-3835(98)00035-4
   Takeda S, 1996, J PHARM PHARMACOL, V48, P902, DOI 10.1111/j.2042-7158.1996.tb05998.x
   Takeda S, 1997, J PHARM PHARMACOL, V49, P35, DOI 10.1111/j.2042-7158.1997.tb06748.x
   Tanaka T, 1996, CHEM PHARM BULL, V44, P2236, DOI 10.1248/cpb.44.2236
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Urpi-Sarda M, 2009, ANAL BIOANAL CHEM, V394, P1545, DOI 10.1007/s00216-009-2676-1
   VARSHNEY IP, 1984, J NAT PROD, V47, P44, DOI 10.1021/np50031a002
   Vilhelmova N, 2011, ANTIVIR RES, V89, P174, DOI 10.1016/j.antiviral.2010.11.014
   Vincken JP, 2007, PHYTOCHEMISTRY, V68, P275, DOI 10.1016/j.phytochem.2006.10.008
   Vivas N, 2004, J AGR FOOD CHEM, V52, P2073, DOI 10.1021/jf030460m
   Walle T, 2011, ANN NY ACAD SCI, V1215, P9, DOI 10.1111/j.1749-6632.2010.05842.x
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wright C. R. A., 1879, J CHEM SOC, V35, P405, DOI 10.1039/CT8793500405
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Yu LM, 2020, J BUON, V25, P93
   Zanello PR, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0443-9
   Zheng SJ, 2012, ORG BIOMOL CHEM, V10, P2590, DOI 10.1039/c2ob25065a
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 106
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 25
PY 2020
VL 10
IS 1
AR 20584
DI 10.1038/s41598-020-77602-0
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB4MW
UT WOS:000596297800026
PM 33239694
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Seeland, U
   Coluzzi, F
   Simmaco, M
   Mura, C
   Bourne, PE
   Heiland, M
   Preissner, R
   Preissner, S
AF Seeland, Ute
   Coluzzi, Flaminia
   Simmaco, Maurizio
   Mura, Cameron
   Bourne, Philip E.
   Heiland, Max
   Preissner, Robert
   Preissner, Saskia
TI Evidence for treatment with estradiol for women with SARS-CoV-2
   infection
SO BMC MEDICINE
LA English
DT Article
DE Sex; Women; SARS-CoV-2; COVID-19; Estradiol; Hormone treatment; ACE2
ID GENDER DIFFERENCES; ACE2; 17-BETA-ESTRADIOL; PHYSIOLOGY; HORMONES;
   GENOME
AB BackgroundGiven that an individual's age and gender are strongly predictive of coronavirus disease 2019 (COVID-19) outcomes, do such factors imply anything about preferable therapeutic options?MethodsAn analysis of electronic health records for a large (68,466-case), international COVID-19 cohort, in 5-year age strata, revealed age-dependent sex differences. In particular, we surveyed the effects of systemic hormone administration in women. The primary outcome for estradiol therapy was death. Odds ratios (ORs) and Kaplan-Meier survival curves were analyzed for 37,086 COVID-19 women in two age groups: pre- (15-49years) and peri-/post-menopausal (>50years).ResultsThe incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is higher in women than men (by about +15%) and, in contrast, the fatality rate is higher in men (about +50%). Interestingly, the relationships between these quantities are linked to age: pre-adolescent girls and boys had the same risk of infection and fatality rate, while adult premenopausal women had a significantly higher risk of infection than men in the same 5-year age stratum (about 16,000 vs. 12,000 cases). This ratio changed again in peri- and postmenopausal women, with infection susceptibility converging with men. While fatality rates increased continuously with age for both sexes, at 50years, there was a steeper increase for men. Thus far, these types of intricacies have been largely neglected. Because the hormone 17 ss -estradiol influences expression of the human angiotensin-converting enzyme 2 (ACE2) protein, which plays a role in SARS-CoV-2 cellular entry, propensity score matching was performed for the women's sub-cohort, comparing users vs. non-users of estradiol. This retrospective study of hormone therapy in female COVID-19 patients shows that the fatality risk for women >50years receiving estradiol therapy (user group) is reduced by more than 50%; the OR was 0.33, 95% CI [0.18, 0.62] and the hazard ratio (HR) was 0.29, 95% CI [0.11,0.76]. For younger, pre-menopausal women (15-49years), the risk of COVID-19 fatality is the same irrespective of estradiol treatment, probably because of higher endogenous estradiol levels.ConclusionsAs of this writing, still no effective drug treatment is available for COVID-19; since estradiol shows such a strong improvement regarding fatality in COVID-19, we suggest prospective studies on the potentially more broadly protective roles of this naturally occurring hormone.
C1 [Seeland, Ute; Preissner, Robert] Charite Univ Med Berlin, Inst Physiol & Sci IT, Philippstr 12, D-10115 Berlin, Germany.
   [Seeland, Ute; Preissner, Robert] Free Univ Berlin, Philippstr 12, D-10115 Berlin, Germany.
   [Seeland, Ute; Preissner, Robert] Humboldt Univ, Philippstr 12, D-10115 Berlin, Germany.
   [Seeland, Ute; Preissner, Robert] Berlin Inst Hlth, Philippstr 12, D-10115 Berlin, Germany.
   [Coluzzi, Flaminia] Sapienza Univ Rome, Dept Med & Surg Sci & Biotechnol, I-04100 Latina, Italy.
   [Coluzzi, Flaminia] St Andrea Univ Hosp, Unit Anesthesia & Intens Care Med, I-00189 Rome, Italy.
   [Simmaco, Maurizio] Sapienza Univ Rome, Dept Neurosci Mental Hlth & Sensory Organs, I-00189 Rome, Italy.
   [Simmaco, Maurizio] St Andrea Univ Hosp, Adv Mol Diagnost Unit, I-00189 Rome, Italy.
   [Mura, Cameron; Bourne, Philip E.] Univ Virginia, Sch Data Sci, Charlottesville, VA USA.
   [Mura, Cameron; Bourne, Philip E.] Univ Virginia, Dept Biomed Engn, Charlottesville, VA USA.
   [Heiland, Max; Preissner, Saskia] Charite Univ Med Berlin, Dept Oral & Maxillofacial Surg, Augustenburger Pl 1, D-13353 Berlin, Germany.
   [Heiland, Max; Preissner, Saskia] Free Univ Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany.
   [Heiland, Max; Preissner, Saskia] Humboldt Univ, Augustenburger Pl 1, D-13353 Berlin, Germany.
   [Heiland, Max; Preissner, Saskia] Berlin Inst Hlth, Augustenburger Pl 1, D-13353 Berlin, Germany.
RP Preissner, S (corresponding author), Charite Univ Med Berlin, Dept Oral & Maxillofacial Surg, Augustenburger Pl 1, D-13353 Berlin, Germany.; Preissner, S (corresponding author), Free Univ Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany.; Preissner, S (corresponding author), Humboldt Univ, Augustenburger Pl 1, D-13353 Berlin, Germany.; Preissner, S (corresponding author), Berlin Inst Hlth, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM saskia.preissner@charite.de
FU University of Virginia School of Data Science; NSF CAREER awardNational
   Science Foundation (NSF)NSF - Office of the Director (OD) [MCB-1350957];
   Projekt DEAL
FX Portions of this work were supported by the University of Virginia
   School of Data Science and by NSF CAREER award MCB-1350957. Open Access
   funding enabled and organized by Projekt DEAL.
CR Balaton BP, 2015, BIOL SEX DIFFER, V6, DOI 10.1186/s13293-015-0053-7
   Breithaupt-Faloppa AC, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1980
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Carey MA, 2007, AM J PHYSIOL-LUNG C, V293, pL272, DOI 10.1152/ajplung.00174.2007
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Dorak M. Tevfik, 2012, Frontiers in Genetics, V3, P268, DOI 10.3389/fgene.2012.00268
   Dubey RK, 2001, J APPL PHYSIOL, V91, P1868
   Erfinanda L, 2020, EUR RESP J
   Fischer M, 2002, CARDIOVASC RES, V53, P672, DOI 10.1016/S0008-6363(01)00479-5
   Foresta C, 2020, J ENDOCRINOL INVEST, DOI 10.1007/s40618-020-01383-6
   Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9
   Gemmati D, 2020, INT J MOL SCI, V21
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harrison-Bernard LM, 2003, HYPERTENSION, V42, P1157, DOI 10.1161/01.HYP.0000102180.13341.50
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Klein SL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008570
   La Vignera S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082948
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Robert-Koch-Institut, 2020, COVID 19 DIS GERM PR
   Speyer CL, 2005, AM J PHYSIOL-CELL PH, V288, pC881, DOI 10.1152/ajpcell.00467.2004
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Xie XD, 2006, LIFE SCI, V78, P2166, DOI 10.1016/j.lfs.2005.09.038
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 28
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD DEC 25
PY 2020
VL 18
IS 1
AR 369
DI 10.1186/s12916-020-01851-z
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA PA6EY
UT WOS:000595727600001
PM 33234138
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tuerkova, A
   Zdrazil, B
AF Tuerkova, Alzbeta
   Zdrazil, Barbara
TI A ligand-based computational drug repurposing pipeline using KNIME and
   Programmatic Data Access: case studies for rare diseases and COVID-19
SO JOURNAL OF CHEMINFORMATICS
LA English
DT Article
DE Drug repurposing; Data integration; Data mining; Data access;
   Application programming interface; Substructure search; Rare disease;
   KNIME workflow; COVID-19; SARS-CoV-2; GLUT-1 deficiency syndrome;
   ChEMBL; Open targets platform; DrugBank; PDB; UniProtKB;
   Guide-to-pharmacology; PubChem
ID ANTICONVULSANT
AB Biomedical information mining is increasingly recognized as a promising technique to accelerate drug discovery and development. Especially, integrative approaches which mine data from several (open) data sources have become more attractive with the increasing possibilities to programmatically access data through Application Programming Interfaces (APIs). The use of open data in conjunction with free, platform-independent analytic tools provides the additional advantage of flexibility, re-usability, and transparency. Here, we present a strategy for performing ligand-based in silico drug repurposing with the analytics platform KNIME. We demonstrate the usefulness of the developed workflow on the basis of two different use cases: a rare disease (here: Glucose Transporter Type 1 (GLUT-1) deficiency), and a new disease (here: COVID 19). The workflow includes a targeted download of data through web services, data curation, detection of enriched structural patterns, as well as substructure searches in DrugBank and a recently deposited data set of antiviral drugs provided by Chemical s Service. Developed workflows, tutorials with detailed step-by-step instructions, and the information gained by the analysis of data for GLUT-1 deficiency syndrome and COVID-19 are made freely available to the scientific community. The provided framework can be reused by researchers for other in silico drug repurposing projects, and it should serve as a valuable teaching resource for conveying integrative data mining strategies.
C1 [Tuerkova, Alzbeta; Zdrazil, Barbara] Univ Vienna, Div Drug Design & Med Chem, Dept Pharmaceut Chem, Althanstr 14, A-1090 Vienna, Austria.
RP Tuerkova, A; Zdrazil, B (corresponding author), Univ Vienna, Div Drug Design & Med Chem, Dept Pharmaceut Chem, Althanstr 14, A-1090 Vienna, Austria.
EM alzbeta.tuerkova@univie.ac.at; barbara.zdrazil@univie.ac.at
RI Zdrazil, Barbara/F-1021-2013
OI Zdrazil, Barbara/0000-0001-9395-1515
CR Agatonovic-Kustrin S, 2016, ARTIFICIAL NEURAL NETWORK FOR DRUG DESIGN, DELIVERY AND DISPOSITION, P181, DOI 10.1016/B978-0-12-801559-9.00009-0
   Bajorath J, 2017, METHODS MOL BIOL, V1526, P247, DOI 10.1007/978-1-4939-6613-4_14
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Beisken S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-257
   Bemis GW, 1996, J MED CHEM, V39, P2887, DOI 10.1021/jm9602928
   Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Cao YQ, 2008, BIOINFORMATICS, V24, pI366, DOI 10.1093/bioinformatics/btn186
   Carvalho-Silva D, 2019, NUCLEIC ACIDS RES, V47, pD1056, DOI 10.1093/nar/gky1133
   Chen HM, 2018, DRUG DISCOV TODAY, V23, P1241, DOI 10.1016/j.drudis.2018.01.039
   Cui LJ, 2005, BIOL PHARM BULL, V28, P1216, DOI 10.1248/bpb.28.1216
   Davies M, 2015, NUCLEIC ACIDS RES, V43, pW612, DOI 10.1093/nar/gkv352
   Fang SG, 2008, VIROLOGY, V379, P175, DOI 10.1016/j.virol.2008.06.038
   Fetro C, 2020, THERAPIE, V75, P157, DOI 10.1016/j.therap.2020.02.006
   Gadaleta D, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0315-6
   Gilson MK, 2016, NUCLEIC ACIDS RES, V44, pD1045, DOI 10.1093/nar/gkv1072
   Goodsell DS, 2020, PROTEIN SCI, V29, P52, DOI 10.1002/pro.3730
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Jarada TN, 2020, J CHEMINFORMATICS, V12, DOI 10.1186/s13321-020-00450-7
   Jin HG, 2006, BIOORGAN MED CHEM, V14, P6868, DOI 10.1016/j.bmc.2006.06.044
   Johnson MA, 1990, CONCEPTS APPL MOL SI, P420
   Karaman B, 2019, CURR MED CHEM, V26, P5389, DOI 10.2174/0929867325666180530100332
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Klepper J, 2002, J INHERIT METAB DIS, V25, P449, DOI 10.1023/A:1021238900470
   Landrum G., RDKIT DOCUMENTATION, P159
   Li J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000450
   Littler DR, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101258
   Martin YC, 2002, J MED CHEM, V45, P4350, DOI 10.1021/jm020155c
   Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075
   Orchard S, 2014, NUCLEIC ACIDS RES, V42, pD358, DOI 10.1093/nar/gkt1115
   Oughtred R, 2019, NUCLEIC ACIDS RES, V47, pD529, DOI 10.1093/nar/gky1079
   Pavlov D, 2011, J CHEMINF S1, V3, pP4, DOI [10.1186/1758-2946-3-S1-P4, DOI 10.1186/1758-2946-3-S1-P4]
   Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143
   Pieper U, 2014, NUCLEIC ACIDS RES, V42, pD336, DOI 10.1093/nar/gkt1144
   Pujar S, 2018, NUCLEIC ACIDS RES, V46, pD221, DOI 10.1093/nar/gkx1031
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Qian TQ, 2019, EXPERT REV PRECIS ME, V4, P189, DOI 10.1080/23808993.2019.1617632
   Roughley S, 2018, CURR MED CHEM
   Sayers EW, 2019, NUCLEIC ACIDS RES, V47, pD94, DOI 10.1093/nar/gky989
   Shawe-Taylor J, 2000, INTRO SUPPORT VECTOR, P93
   Sigrist CJA, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104759
   Steinmetz FP, 2015, MOL INFORM, V34, P171, DOI 10.1002/minf.201400188
   Susnow RG, 2003, J CHEM INF COMP SCI, V43, P1308, DOI 10.1021/ci030283p
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tanoli Z, 2020, BRIEF BIOINFORM, V21, P211, DOI 10.1093/bib/bby119
   Ugale VG, 2014, EUR J MED CHEM, V80, P447, DOI 10.1016/j.ejmech.2014.04.072
   Wang F, 2019, J CHEMINFORMATICS, V11, DOI 10.1186/s13321-019-0394-z
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wei CX, 2015, MOLECULES, V20, P20741, DOI 10.3390/molecules201119714
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wood IS, 2003, BRIT J NUTR, V89, P3, DOI 10.1079/BJN2002763
   Wu C, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-S5-S6
   Xie ZF, 2005, BIOORG MED CHEM LETT, V15, P4803, DOI 10.1016/j.bmcl.2005.07.051
   Yang Jinsung, 2020, Nat Commun, V11, P4541, DOI 10.1038/s41467-020-18319-6
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 55
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1758-2946
J9 J CHEMINFORMATICS
JI J. Cheminformatics
PD DEC 25
PY 2020
VL 12
IS 1
AR 71
DI 10.1186/s13321-020-00474-z
PG 20
WC Chemistry, Multidisciplinary; Computer Science, Information Systems;
   Computer Science, Interdisciplinary Applications
SC Chemistry; Computer Science
GA OW0EV
UT WOS:000592572500001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Prachar, M
   Justesen, S
   Steen-Jensen, DB
   Thorgrimsen, S
   Jurgons, E
   Winther, O
   Bagger, FO
AF Prachar, Marek
   Justesen, Sune
   Steen-Jensen, Daniel Bisgaard
   Thorgrimsen, Stephan
   Jurgons, Erik
   Winther, Ole
   Bagger, Frederik Otzen
TI Identification and validation of 174 COVID-19 vaccine candidate epitopes
   reveals low performance of common epitope prediction tools
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MHC CLASS-I; NEURAL-NETWORKS; BINDING; MATRIX; STABILITY; RESPONSES;
   AFFINITY; COMPLEX; TISSUE
AB The outbreak of SARS-CoV-2 (2019-nCoV) virus has highlighted the need for fast and efficacious vaccine development. Stimulation of a proper immune response that leads to protection is highly dependent on presentation of epitopes to circulating T-cells via the HLA complex. SARS-CoV-2 is a large RNA virus and testing of all of its overlapping peptides in vitro to deconvolute an immune response is not feasible. Therefore HLA-binding prediction tools are often used to narrow down the number of peptides to test. We tested NetMHC suite tools' predictions by using an in vitro peptide-MHC stability assay. We assessed 777 peptides that were predicted to be good binders across 11 MHC alleles in a complex-stability assay and tested a selection of 19 epitope-HLA-binding prediction tools against the assay. In this investigation of potential SARS-CoV-2 epitopes we found that current prediction tools vary in performance when assessing binding stability, and they are highly dependent on the MHC allele in question. Designing a COVID-19 vaccine where only a few epitope targets are included is therefore a very challenging task. Here, we present 174 SARS-CoV-2 epitopes with high prediction binding scores, validated to bind stably to 11 HLA alleles. Our findings may contribute to the design of an efficacious vaccine against COVID-19.
C1 [Prachar, Marek; Winther, Ole; Bagger, Frederik Otzen] Copenhagen Univ Hosp, Ctr Genom Med, Rigshosp, Copenhagen, Denmark.
   [Prachar, Marek; Winther, Ole] Univ Copenhagen, Dept Biol, Bioinformat Ctr, Copenhagen, Denmark.
   [Prachar, Marek; Justesen, Sune; Steen-Jensen, Daniel Bisgaard; Thorgrimsen, Stephan] Immunitrack ApS, Copenhagen, Denmark.
   [Jurgons, Erik] INTAVIS Peptide Serv GmbH Co KG, Waldhauser Str 64, D-72076 Tubingen, Germany.
   [Winther, Ole] Tech Univ Denmark, Dept Appl Math & Comp Sci, DK-2800 Lyngby, Denmark.
   [Bagger, Frederik Otzen] UKBB Univ Kinderspital, Dept Biomed, CH-4031 Basel, Switzerland.
   [Bagger, Frederik Otzen] Swiss Inst Bioinformat, CH-4053 Basel, Switzerland.
RP Bagger, FO (corresponding author), Copenhagen Univ Hosp, Ctr Genom Med, Rigshosp, Copenhagen, Denmark.; Bagger, FO (corresponding author), UKBB Univ Kinderspital, Dept Biomed, CH-4031 Basel, Switzerland.; Bagger, FO (corresponding author), Swiss Inst Bioinformat, CH-4053 Basel, Switzerland.
EM frederik.otzen.bagger@regionh.dk
OI Winther, Ole/0000-0002-1966-3205
FU Innovation Foundation Denmark [9065-00225B]
FX We acknowledge support from the Innovation Foundation Denmark [Grant
   Number Ref. No. 9065-00225B]. Special thanks to Savvas Kinalis for
   fruitful inputs on the inner workings of PyTorch.
CR Abdelmageed MI, 2020, DESIGN MULTIEPITOPE, DOI [10.1101/2020.02.04.934232, DOI 10.1101/2020.02.04.934232]
   Andreatta M, 2018, BIOINFORMATICS, V34, P1522, DOI 10.1093/bioinformatics/btx820
   [Anonymous], 2020, COR DIS COVID 19 WEE
   Bassani-Sternberg M, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005725
   Bassani-Sternberg M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13404
   Bhattacharya R, 2017, BIORXIV, DOI [10.1101/154757, DOI 10.1101/154757]
   Blaha DT, 2019, CANCER IMMUNOL RES, V7, P50, DOI 10.1158/2326-6066.CIR-18-0395
   Blicher T, 2005, ACTA CRYSTALLOGR D, V61, P1031, DOI 10.1107/S0907444905013090
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Dines JN, 2020, IMMUNERACE STUDY PRO, DOI [10.1101/2020.08.17.20175158, DOI 10.1101/2020.08.17.20175158]
   Fast E, 2020, POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484]
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Han Y, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1997-x
   Harndahl M, 2006, LARGE SCALE ANAL PEP
   Harndahl M, 2012, EUR J IMMUNOL, V42, P1405, DOI 10.1002/eji.201141774
   Harndahl M, 2009, J BIOMOL SCREEN, V14, P173, DOI 10.1177/1087057108329453
   Ishizuka J, 2009, J IMMUNOL, V183, P4337, DOI 10.4049/jimmunol.0901607
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Jorgensen KW, 2014, IMMUNOLOGY, V141, P18, DOI 10.1111/imm.12160
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Justesen Sune, 2009, Immunome Res, V5, P2, DOI 10.1186/1745-7580-5-2
   Karosiene E, 2012, IMMUNOGENETICS, V64, P177, DOI 10.1007/s00251-011-0579-8
   Kim Y, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-241
   Kim Y, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-394
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Liu G, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix017
   Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871
   Mei ST, 2020, BRIEF BIOINFORM, V21, P1119, DOI 10.1093/bib/bbz051
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   O'Donnell TJ, 2018, CELL SYST, V7, P129, DOI 10.1016/j.cels.2018.05.014
   Paszke A., 2019, ADV NEURAL INFORM PR, P8024
   Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI 10.1038/s41590-020-0782-6
   Peters B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-132
   Peters B, 2019, ANNU REV IMMUNOL, DOI [10.1146/annurev-immunol-082119, DOI 10.1146/ANNUREV-IMMUNOL-082119]
   Qu ZH, 2019, J IMMUNOL, V202, P3493, DOI 10.4049/jimmunol.1900001
   RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6
   Rasmussen M, 2014, LARGE SCALE ANAL PEP
   Saethang T, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-313
   Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Sylvester-Hvid C, 2004, TISSUE ANTIGENS, V63, P395, DOI 10.1111/j.0001-2815.2004.00221.x
   Sylvester-Hvid C, 2002, TISSUE ANTIGENS, V59, P251, DOI 10.1034/j.1399-0039.2002.590402.x
   Trolle T, 2015, BIOINFORMATICS, V31, P2174, DOI 10.1093/bioinformatics/btv123
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048
   Wieczorek M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00292
   World Health Organization, 2020, 1 WHO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02559
   Zhang H, 2009, BIOINFORMATICS, V25, P1293, DOI 10.1093/bioinformatics/btp137
NR 52
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 24
PY 2020
VL 10
IS 1
AR 20465
DI 10.1038/s41598-020-77466-4
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB4HF
UT WOS:000596283100024
PM 33235258
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Huang, Y
   Li, XJ
   Li, YQ
   Dai, W
   Shao, T
   Liu, WY
   Han, M
   Xu, G
   Liu, L
AF Huang, Yi
   Li, Xiao-Juan
   Li, Yue-Qiang
   Dai, Wei
   Shao, Tiffany
   Liu, Wei-Yong
   Han, Min
   Xu, Gang
   Liu, Liu
TI Clinical and pathological findings of SARS-CoV-2 infection and
   concurrent IgA nephropathy: a case report
SO BMC NEPHROLOGY
LA English
DT Article
DE COVID-19; IgA nephropathy; Case report; Macroscopic hematuria; Acute
   kidney injury
ID ACUTE-RENAL-FAILURE
AB Background Since the Coronavirus Disease 2019 (COVID-19) outbreak, there is accumulating data on the clinical characteristics, treatment strategies and prognosis of COVID-19 in patients with concurrent renal disease. Postmortem investigations reveal renal involvement in COVID-19, and most recently, several biopsy researches reveal that acute tubular injury, as well as glomerular nephropathy such as collapsing glomerulopathy were common histological findings. However, to our best knowledge, there is limited data regarding IgA nephropathy in the setting of COVID-19. Case presentation In the present case, we report a 65-year old Chinese woman who presented with dark-colored urine, worsening proteinuria and decreased renal function after COVID-19 infection. She received a renal biopsy during COVID-19 infection. The renal biopsy revealed IgA nephropathy without any evidence for SARS-Cov-2. The findings suggest that the renal abnormalities were a consequence of exacerbation of this patient's underlying glomerular disease after COVID-19 infection. After a regimen of 3-day course of glucocorticoid and angiotensin II receptor blocker therapy, the patient recovered and remained stable upon follow-up. Conclusions It is important to consider the underlying glomerular disease exacerbation as well as virus induced injury when dealing with renal abnormalities in patients with COVID-19. A kidney biopsy may be indicated to exclude a rapidly progressive glomerular disease.
C1 [Huang, Yi; Li, Xiao-Juan; Li, Yue-Qiang; Dai, Wei; Han, Min; Xu, Gang; Liu, Liu] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Nephrol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
   [Shao, Tiffany] Univ Calgary, Dept Pathol & Lab Med, Alberta Precis Labs, Calgary, AB, Canada.
   [Liu, Wei-Yong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Lab Med, Wuhan, Peoples R China.
RP Liu, L (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Nephrol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM liuliu@tjh.tjmu.edu.cn
FU National Science Foundation Committee [81200521]; National Mega Project
   on Major Infectious Disease Prevention [2017ZX10103005-007]; National
   Key Research and Development Program of China [2018YFE0204500]
FX This work was supported by the National Science Foundation Committee
   (No. 81200521), the National Mega Project on Major Infectious Disease
   Prevention (No. 2017ZX10103005-007) and the National Key Research and
   Development Program of China (No. 2018YFE0204500). The funders had no
   role in the design of the study or in the collection analysis or
   interpretation of the data.
CR Akilesh Shreeram, 2021, Am J Kidney Dis, V77, P82, DOI 10.1053/j.ajkd.2020.10.001
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Fu Dian, 2020, Nephron, V144, P245, DOI 10.1159/000507261
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gutieerrez E, 2007, CLIN J AM SOC NEPHRO, V2, P51, DOI 10.2215/CJN.02670706
   Kudose S, 2020, J AM SOC NEPHROL, V31, P1959, DOI 10.1681/ASN.2020060802
   Kupin WL, 2017, CLIN J AM SOC NEPHRO, V12, P1337, DOI 10.2215/CJN.04320416
   Lai KN, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.1
   LEE HS, 1988, AM J KIDNEY DIS, V12, P236, DOI 10.1016/S0272-6386(88)80128-8
   Liu ZH, 2013, NAT REV NEPHROL, V9, P523, DOI 10.1038/nrneph.2013.146
   National Health Commission (NHC) of the PRC and National Administration of Traditional Chinese Medicine of the PRC, 2020, GUID COR VIR DIS 201
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   Sevillano AM, 2019, CLIN J AM SOC NEPHRO, V14, P1183, DOI 10.2215/CJN.13251118
   Sharma P, 2020, J AM SOC NEPHROL, V31, P1948, DOI 10.1681/ASN.2020050699
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Velez JCQ, 2020, NAT REV NEPHROL, V16, P565, DOI 10.1038/s41581-020-0332-3
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang R, 2020, AM J KIDNEY DIS, V76, P141, DOI 10.1053/j.ajkd.2020.03.009
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 22
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD DEC 24
PY 2020
VL 21
IS 1
AR 504
DI 10.1186/s12882-020-02163-3
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA PA6OX
UT WOS:000595753500001
PM 33234164
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vallejos, J
   Zoni, R
   Bangher, M
   Villamandos, S
   Bobadilla, A
   Plano, F
   Campias, C
   Campias, EC
   Achinelli, F
   Guglielmone, HA
   Ojeda, J
   Medina, F
   Salazar, DF
   Andino, G
   Diaz, NRE
   Kawerin, P
   Meza, E
   Dellamea, S
   Aquino, A
   Flores, V
   Martemucci, CN
   Vernengo, MM
   Martinez, SM
   Segovia, JE
   Aguirre, MG
AF Vallejos, Julio
   Zoni, Rodrigo
   Bangher, Maria
   Villamandos, Silvina
   Bobadilla, Angelina
   Plano, Fabian
   Campias, Claudia
   Chaparro Campias, Evangelina
   Achinelli, Fernando
   Guglielmone, Hector A.
   Ojeda, Jorge
   Medina, Fernanda
   Farizano Salazar, Diego
   Andino, Gerardo
   Ruiz Diaz, Natalia E.
   Kawerin, Pablo
   Meza, Elba
   Dellamea, Silvana
   Aquino, Antonia
   Flores, Victor
   Martemucci, Carolina N.
   Vernengo, Maria Mercedes
   Martinez, Silvina Maria
   Segovia, Juan Emanuel
   Aguirre, Maria Gabriela
TI Ivermectin to prevent hospitalizations in patients with COVID-19
   (IVERCOR-COVID19): a structured summary of a study protocol for a
   randomized controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized controlled trial; Protocol; Ivermectin;
   Hospitalization
AB Objectives: To assess the efficacy of ivermectin in addition to standard treatment compared to standard treatment alone in reducing hospitalizations in the COVID-19 patient population.
   Trial design: IVERCOR-COVID19 will be a single-center, prospective, randomized, double-blind, parallel group (1:1 ratio), placebo-controlled study.
   Participants: Patients who meet the following criteria will be invited to participate: Inclusion criteria: (1) Over 18 years of age who reside in the province of Corrientes at the time of diagnosis. (2) Confirmed diagnosis of COVID-19 by polymerase chain reaction (PCR) test for detection of SARS-CoV2 in the last 48 h. (3) In the case of women of childbearing age, they must be using a contraceptive method of proven efficacy and safety (barrier, hormonal, or permanent contraceptives) for at least 3 months prior to inclusion in the present study and for the entire period of time for the duration of the study and until at least 30 days after the end of this study. A woman will be considered to have no reproductive capacity if she is postmenopausal (at least 2 years without her menstrual cycles) or if she has undergone surgical sterilization (at least 1 month before the time of inviting her to participate in this study). (4) Weight at the time of inclusion greater than 48 kg. (5) That they sign the informed consent for participation in the study.
   Exclusion criteria: (1) pregnant or breastfeeding women; (2) known allergy to ivermectin or some of the components of ivermectin tablets or placebo; (3) current use of home oxygen; (4) require hospitalization due to COVID-19 at the time of diagnosis or history of hospitalization for COVID-19; (5) presence of mal-absorptive syndrome; (6) presence of any other concomitant acute infectious disease; (7) known history of severe liver disease, for example liver cirrhosis; (8) need or use of antiviral drugs at the time of admission for another viral pathology other than COVID-19; (9) need or use of hydroxychloroquine or chloroquine; (10) use of ivermectin up to 7 days prior to randomization; (11) patients on dialysis or who have required it in the last 2 months or who plan to do it in the next 2 months; and (12) current participation or in the last 30 days in a research study that has included the administration of a drug (Table 1).
   The study will be carried out by the Ministry of Public Health of the Province of Corrientes (Argentina) in coordination with the Institute of Cardiology of Corrientes in the Province of Corrientes, Argentina.
   Intervention and comparator: Intervention group: patients who are randomized to ivermectin will receive the dose according to their weight (patients up to 80 kg will receive 2 tablets of 6 mg ivermectin; patients with more than 80 kg and up to 110 kg will receive 3 tablets of 6 mg of ivermectin; patients weighing more than 110 kg will receive 4 tablets of 6 mg ivermectin) the day they enter the study and the same dose 24 h after the first dose.
   Control group: patients who are randomized to placebo will receive the dose according to their weight (patients up to 80 kg will receive 2 tablets of 6 mg placebo; patients with more than 80 kg and up to 110 kg will receive 3 tablets of 6 mg of placebo; patients weighing more than 110 kg will receive 4 tablets of 6 mg placebo) on the day they enter the study and the same dose 24 h after the first dose (Table 2). Main outcomes: Primary outcome will be the percentage of hospitalizations in patients with COVID-19 in the intervention and control groups.
   Secondary outcomes: time to hospitalization in each of the arms of the study: number of days elapsed from the inclusion in the study until the hospitalization of the patient; percentage of use of invasive mechanical ventilation in each of the study arms: every patient who is connected to invasive mechanical ventilation after signing the informed consent and before the final study visit; time to invasive mechanical ventilation in each of the arms of the study: number of days elapsed from inclusion in the study to connection to invasive mechanical ventilation of the patient; percentage of patients requiring dialysis in each of the study arms: all patients who require renal replacement therapy of any kind, temporary or permanent, and which begins after signing the informed consent and before the final visit; mortality from all causes in each of the two trial groups: death of the patient, from any cause. Negative PCR swab at 3 +/- 1 and 12 +/- 2 days after entering the study.
   Ivermectin safety: it will be analyzed according to the incidence of adverse events that patients present in the intervention and control groups.
   The end of study (EOS) is recorded as the day the patient is discharged or death. Discharge will be granted according to the current recommendations of the Ministry of Public Health of the Province of Corrientes. A follow-up visit (EOF) will be made by phone 30 days after the EOS when vital status will be verified.
   Randomization: Randomization will be done through a web system with randomly permuted blocks. Randomization will be carried out by one of the investigators who will not participate in the inclusion of patients or in the delivery of medication (Table 3).
   Blinding (masking): The participants, investigators, care providers, and outcome assessors will be blinded.
   Numbers to be randomized (sample size): We will include a total of 500 patients (250 patients in each group).
   Trial status: This is version 1.0, 17 August 2020. The recruitment started on 19 August 2020, and we anticipate the trial will finish recruitment on 31 December 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
C1 [Vallejos, Julio; Zoni, Rodrigo; Bangher, Maria; Villamandos, Silvina; Medina, Fernanda; Aguirre, Maria Gabriela] Inst Cardiol Corrientes Juana F Cabral, Corrientes, Argentina.
   [Bobadilla, Angelina; Plano, Fabian; Campias, Claudia; Chaparro Campias, Evangelina; Achinelli, Fernando; Guglielmone, Hector A.; Ojeda, Jorge; Farizano Salazar, Diego; Andino, Gerardo; Ruiz Diaz, Natalia E.; Kawerin, Pablo; Meza, Elba; Dellamea, Silvana; Aquino, Antonia; Flores, Victor; Martemucci, Carolina N.; Vernengo, Maria Mercedes; Martinez, Silvina Maria; Segovia, Juan Emanuel] Minist Salud Publ Prov Corrientes, Corrientes, Argentina.
RP Zoni, R (corresponding author), Inst Cardiol Corrientes Juana F Cabral, Corrientes, Argentina.
EM rodrizoni@yahoo.com.ar
OI Zoni, Rodrigo/0000-0002-9467-334X
FU Ministry of Health of the Province of Corrientes, Argentina
FX This study is funded by the Ministry of Health of the Province of
   Corrientes, Argentina, which will have no interference in the selection
   of participants, data collection, analysis, interpretation of the
   results, or the final publication of the study.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 24
PY 2020
VL 21
IS 1
AR 965
DI 10.1186/s13063-020-04813-1
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA6DV
UT WOS:000595724700001
PM 33234158
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bosi, E
   Bosi, C
   Querini, PR
   Mancini, N
   Calori, G
   Ruggeri, A
   Canzonieri, C
   Callegaro, L
   Clementi, M
   De Cobelli, F
   Filippi, M
   Bregni, M
AF Bosi, Emanuele
   Bosi, Carlo
   Querini, Patrizia Rovere
   Mancini, Nicasio
   Calori, Giliola
   Ruggeri, Annalisa
   Canzonieri, Cecilia
   Callegaro, Luciano
   Clementi, Massimo
   De Cobelli, Francesco
   Filippi, Massimo
   Bregni, Marco
TI Interferon beta-1a (IFN beta-1a) in COVID-19 patients (INTERCOP): study
   protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE IFN beta-1a; COVID-19; SARS-CoV-2
ID EAST RESPIRATORY SYNDROME; MULTIPLE-SCLEROSIS; COMBINATION; ANTIBODIES;
   RIBAVIRIN; RITONAVIR; LOPINAVIR; EFFICACY
AB BackgroundPharmacological therapies of proven efficacy in coronavirus disease 2019 (COVID-19) are still lacking. We have identified IFN beta -1a as the most promising drug to be repurposed for COVID-19. The rationale relies on the evidence of IFN beta anti-viral activity in vitro against SARS-CoV-2 and animal models resembling SARS-CoV-2 infection and on a recent clinical trial where IFN beta was indicated as the key component of a successful therapeutic combination.MethodsThis is a randomized, controlled, open-label, monocentric, phase II trial (INTERCOP trial). One hundred twenty-six patients with positive swab detection of SARS-CoV-2, radiological signs of pneumonia, and mild-to-moderate disease will be randomized 2:1 to IFN beta -1a in addition to standard of care vs standard of care alone. No other anti-viral drugs will be used as part of the regimens, both in the control and the intervention arms. IFN beta -1a will be administered subcutaneously at the dose of 44 mcg (equivalent to 12 million international units) three times per week, at least 48h apart, for a total of 2 weeks. The primary outcome is the time to negative conversion of SARS-CoV-2 nasopharyngeal swabs. Secondary outcomes include improvement or worsening in a clinical severity score measured on a 7-point ordinal scale (including transfer to intensive care unit and death), oxygen- and ventilator-free days, mortality, changes in pulmonary computed tomography severity score, hospital stay duration, reduction of viral load measured on nasopharyngeal swabs, number of serious adverse events, and changes in biochemical markers of organ dysfunction. Exploratory outcomes include blood cell counts, cytokine and inflammatory profile, peripheral mRNA expression profiles of interferon-stimulated genes, and antibodies to SARS-CoV-2 and to IFN beta -1a. INTERCOP is the first study to specifically investigate the clinical benefits of IFN beta -1a in COVID-19 patients.DiscussionPotential implications of this trial are multifaceted: should the primary outcome be fulfilled and the treatment be safe, one may envisage that IFN beta -1a be used to reduce the infectivity of patients with mild-to moderate disease. In case IFN beta -1a reduced the duration of hospital stay and/or ameliorated the clinical status, it may become a cornerstone of COVID-19 treatment.Trial registrationEudraCT 2020-002458-25. Registered on May 11, 2020ClinicalTrials.gov Identifier: NCT04449380
C1 [Bosi, Emanuele; Querini, Patrizia Rovere] IRCCS Osped San Raffaele, Unit Internal Med, Milan, Italy.
   [Bosi, Emanuele; Querini, Patrizia Rovere; Mancini, Nicasio; Clementi, Massimo; De Cobelli, Francesco; Filippi, Massimo] Univ Vita Salute San Raffaele, Milan, Italy.
   [Bosi, Carlo] Univ Milan, Med Sch, Milan, Italy.
   [Mancini, Nicasio; Clementi, Massimo] IRCCS Osped San Raffaele, Unit Virol, Milan, Italy.
   [Calori, Giliola; Ruggeri, Annalisa; Canzonieri, Cecilia; Callegaro, Luciano; Bregni, Marco] IRCCS Osped San Raffaele, Clin Trial Ctr, Milan, Italy.
   [De Cobelli, Francesco] IRCCS Osped San Raffaele, Unit Radiol, Milan, Italy.
   [Filippi, Massimo] IRCC S Osped San Raffaele, Unit Neurol, Milan, Italy.
RP Bosi, E (corresponding author), IRCCS Osped San Raffaele, Unit Internal Med, Milan, Italy.; Bosi, E (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.
EM bosi.emanuele@hsr.it
FU IRCCS Ospedale San Raffaele; Merck Serono S.p.A.Merck Serono
FX The sponsor of the trial will be the IRCCS Ospedale San Raffaele. A
   contract between IRCCS Ospedale San Raffaele (via Olgettina, 60 -
   Milano) and Merck Serono S.p.A. assigned a grant to cover the costs of
   drug (Rebif (R)) supply and delivery.
CR Beigel J. H., 2020, N ENGL J MED
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bosi C, 2020, J PUBLIC HLTH EMERG, V4, P8, DOI [10.21037/jphe.2020.03.08, DOI 10.21037/JPHE.2020.03.08]
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Ciceri F., 2020, CRIT CARE RESUSC
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Clementi N, 2020, J INFECT DIS, pjiaa350
   Durelli L, 2002, LANCET, V359, P1453, DOI 10.1016/S0140-6736(02)08430-1
   Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0
   Francis G, 2001, NEUROLOGY, V56, P1628
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hippensteel JA, AM J PHYSL LUNG CELL
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Lampasona V, 2003, EUR CYTOKINE NETW, V14, P154
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Polman CH, 2010, LANCET NEUROL, V9, P740, DOI 10.1016/S1474-4422(10)70103-4
   Ranieri VM, 2020, JAMA-J AM MED ASSOC, V323, P725, DOI 10.1001/jama.2019.22525
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Vijay R, 2016, CURR OPIN VIROL, V16, P70, DOI 10.1016/j.coviro.2016.01.011
NR 21
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 23
PY 2020
VL 21
IS 1
AR 939
DI 10.1186/s13063-020-04864-4
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA5ZE
UT WOS:000595712600002
PM 33225960
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ibarra-Estrada, MA
   Marin-Rosales, M
   Garcia-Salcido, R
   Aguirre-Diaz, SA
   Vargas-Obieta, A
   Chavez-Pena, Q
   Lopez-Pulgarin, JA
   Mijangos-Mendez, JC
   Aguirre-Avalos, G
AF Ibarra-Estrada, Miguel A.
   Marin-Rosales, Miguel
   Garcia-Salcido, Roxana
   Aguirre-Diaz, Sara A.
   Vargas-Obieta, Alexandra
   Chavez-Pena, Quetzalcoatl
   Lopez-Pulgarin, Jose A.
   Mijangos-Mendez, Julio C.
   Aguirre-Avalos, Guadalupe
TI Prone positioning in non-intubated patients with COVID-19 associated
   acute respiratory failure, the PRO-CARF trial: A structured summary of a
   study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; randomised controlled trial; protocol; awake
   prone-positioning; acute respiratory failure; high-flow nasal cannula;
   endotracheal intubation
AB Objectives: To assess the effect of prone positioning therapy on intubation rate in awake patients with COVID-19 and acute respiratory failure.
   Trial design: This is a two-center parallel group, superiority, randomized (1:1 allocation ratio) controlled trial.
   Participants: All patients admitted to the Hospital Civil de Guadalajara and Hospital General de Occidente in Mexico for COVID-19 associated acute respiratory failure and in need of supplementary oxygen through high-flow nasal cannula are screened for eligibility.
   Inclusion criteria: all adult patients admitted to the COVID-19 unit who test positive for COVID-19 by PCR-test and in need for oxygen are eligible for inclusion. Randomization starts upon identification of requirement of a fraction of inspired oxygen >= 30% for an oxygen capillary saturation of >= 90%
   Exclusion criteria: less than 18 years-old, pregnancy, patients with immediate need of invasive mechanical ventilation (altered mental status, fatigue), vasopressor requirement to maintain median arterial pressure >65 mmHg, contraindications for prone positioning therapy (recent abdominal or thoracic surgery or trauma, facial, pelvic or spine fracture, untreated pneumothorax, do-not-resuscitate or do-not-intubate order, refusal or inability of the patient to enroll in the study.
   Intervention and comparator: Patients of the intervention group will be asked to remain in a prone position throughout the day as long as possible, with breaks according to tolerance. Pillows will be offered for maximizing comfort at chest, pelvis and knees. Monitoring of vital signs will not be suspended. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of 92%-95%. For patients in the control group, prone positioning will be allowed as a rescue therapy. Staff intensivists will monitor the patient's status in both groups on a 24/7 basis. All other treatment will be unchanged and left to the attending physicians.
   Main outcomes: Endotracheal intubation rate for mechanical ventilation at 28 days.
   Randomisation: Patients will be randomly allocated to either prone positioning or control group at 1:1 ratio. Such randomization will be computer generated and stratified by center with permuted blocks and length of 4.
   Blinding (masking)Due to logistical reasons, only principal investigators and the data analyst will be blinded to group assignment.
   Numbers to be randomised (sample size)With an intubation rate of 60% according to recent reports from some American centers, and assuming a decrease to 40% to be clinically relevant, we calculated a total of 96 patients per group, for a beta error of 0.2, and alpha of 0.5. Therefore, we plan to recruit 200 patients, accounting for minimal losses to follow up, with 100 non-intubated patients in the prone position group and a 100 in the control group.
   Trial StatusThe local registration number is 048-20, with the protocol version number 2.0. The date of approval is 3rd May 2020. Recruitment started on 3(rd) May and is expected to end in December 2020.
   Trial registration: The protocol was retrospectively registered under the title: "Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure. The PRO-CARF trial" in ClinicalTrials.gov with the registration number: NCT04477655. Registered on 20 July 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
   The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
C1 [Ibarra-Estrada, Miguel A.; Vargas-Obieta, Alexandra; Chavez-Pena, Quetzalcoatl; Lopez-Pulgarin, Jose A.; Mijangos-Mendez, Julio C.; Aguirre-Avalos, Guadalupe] Hosp Civil Fray Antonio Alcalde, Intens Care Unit, COVID 19 Unit, Guadalajara, Jalisco, Mexico.
   [Marin-Rosales, Miguel] Hosp Gen Occidente Seguro Social, COVID 19 Unit, Internal Medidine, Zapopan, Jalisco, Mexico.
   [Garcia-Salcido, Roxana] Hosp Civil Fray Antonio Alcalde, COVID 19 Unit, Guadalajara, Jalisco, Mexico.
   [Aguirre-Diaz, Sara A.] Hosp Civil Fray Antonio Alcalde, Infect Dis Dept, Guadalajara, Jalisco, Mexico.
   [Chavez-Pena, Quetzalcoatl; Lopez-Pulgarin, Jose A.; Aguirre-Avalos, Guadalupe] Univ Guadalajara, Ctr Univ Ciencias Salud, Guadalajara, Jalisco, Mexico.
RP Ibarra-Estrada, MA (corresponding author), Hosp Civil Fray Antonio Alcalde, Intens Care Unit, COVID 19 Unit, Guadalajara, Jalisco, Mexico.
EM drmiguelibarra@hotmail.com
OI Ibarra, Miguel/0000-0001-8914-4171
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 23
PY 2020
VL 21
IS 1
AR 940
DI 10.1186/s13063-020-04882-2
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA5ZE
UT WOS:000595712600003
PM 33225990
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lerner, D
   Garvey, K
   Arrighi-Allisan, A
   Filimonov, A
   Filip, P
   Liu, K
   Ninan, S
   Schaberg, M
   Colley, P
   Del Signore, A
   Govindaraj, S
   Iloreta, AM
AF Lerner, David
   Garvey, Katherine
   Arrighi-Allisan, Annie
   Filimonov, Andrey
   Filip, Peter
   Liu, Katherine
   Ninan, Sen
   Schaberg, Madeleine
   Colley, Patrick
   Del Signore, Anthony
   Govindaraj, Satish
   Iloreta, Alfred Marc
TI Letter to the editor: Study Summary - Randomized Control Trial of
   Omega-3 Fatty Acid Supplementation for the Treatment of COVID-19 Related
   Olfactory Dysfunction
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; olfactory dysfunction;
   omega-3 fatty acid; smell loss
AB Objectives: To evaluate a therapeutic role for omega-3 fatty acid supplementation in the treatment of olfactory dysfunction associated with COVID-19 infection
   Trial design: Randomized, double-blinded, placebo-controlled trial
   Participants: Eligible patients are adults with self-reported new-onset olfactory dysfunction of any duration associated with laboratory-confirmed or clinically suspected COVID-19 patients. Exclusion criteria include patients with pre-existing olfactory dysfunction, history of chronic rhinosinusitis or history of sinus surgery, current use of nasal steroid sprays or omega-3 supplementation, fish allergy, or inability to provide informed consent for any reason. The trial is conducted at Mount Sinai Hospital
   Intervention and comparator: The intervention group will receive 2000 mg daily of omega-3 supplementation in the form of two "Fish Oil, Ultra Omega-3" capsules (product of Pharmavite (R)) daily. The comparator group will take 2 placebo capsules of identical size, shape, and odor daily for 6 weeks.
   Main outcomes: Each subject will take a Brief Smell Identification Test at study enrolment and completion after 6 weeks. The primary outcome will be change in Brief Smell Identification Test over the 6-week period.
   Randomisation: Patients will be randomized by the Investigational Drug Pharmacy at the Icahn School of Medicine at Sinai via a computer-generated sequence in a 1:1 allocation to treatment or control arms.
   Blinding (masking)Both participants and researchers will be blinded.
   Numbers to be randomised (sample size)There will be 88 participants randomized to each group. A total of 176 participants will be randomized.
   Trial Status: Protocol Version 1, 8/3/2020Recruitment is ongoing, started 8/5/2020 with estimated completion 11/30/2020.
   Trial registration: The trial is registered on ClinicalTrials.gov with Protocol Identifier: NCT04495816.Trial registration: ClinicalTrials.gov, NCT04495816. Registered 3 August 2020
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
C1 [Lerner, David; Garvey, Katherine; Arrighi-Allisan, Annie; Filimonov, Andrey; Filip, Peter; Liu, Katherine; Ninan, Sen; Schaberg, Madeleine; Colley, Patrick; Del Signore, Anthony; Govindaraj, Satish; Iloreta, Alfred Marc] Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA.
RP Lerner, D (corresponding author), Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA.
EM david.k.lerner.14@gmail.com
OI Lerner, David/0000-0002-0431-2920
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 23
PY 2020
VL 21
IS 1
AR 942
DI 10.1186/s13063-020-04905-y
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA5ZE
UT WOS:000595712600005
PM 33225989
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rangnekar, H
   Patankar, S
   Suryawanshi, K
   Soni, P
AF Rangnekar, Hrishikesh
   Patankar, Suresh
   Suryawanshi, Kishor
   Soni, Pravin
TI Safety and efficacy of herbal extracts to restore respiratory health and
   improve innate immunity in COVID-19 positive patients with mild to
   moderate severity: A structured summary of a study protocol for a
   randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; CAM; Ayurveda; Herbal;
   Herbo-mineral; Viral load
AB Objectives: Primary Objective
   To assess the efficacy of herbal extracts in boosting innate immunity of patients with COVID-19 infection.Secondary Objectives
   To assess the efficacy of herbal extracts in restoring respiratory health
   To assess the efficacy of Cap. IP in early recovery of patients and decline in viral load
   To assess the safety of herbal extracts
   Trial design: This is a single centre, randomized, 2-arm, parallel group, double blind, 1:1 ratio, controlled, exploratory trial with a study period of 30 days from the day of enrolment.
   Participants: Patients attending the COVID treatment centre at Yashwantrao Chavan Memorial Hospital, Nehrunagar, Pimpri, Pune, India were screened for their participation in the study. Patients who were known COVID-19 positive (with positive RT-PCR), eligible and willing were enrolled in the study.
   Intervention and comparator: The intervention in the trial has a background in 'Ayurved'. Intervention Arm: Two capsules, Investigational Product (IP) - 1 - 400mg and Investigational Product - 2 - 450mg, containing herbal extracts (a blend of water and CO2 extracts) of Shunthi (Zingiber officinale (Ginger), Vidanga (Embelia ribes), Yashtimadhu (Glycyrrhiza glabra), Haritaki (Terminalia chebula), Guduchi (Tinospora cordifolia), Shatavari (Asparagus racemosus), Aamalaki (Emblica officinalis), Pippali (Piper longum) and calcined Zinc, Shankha bhasma.Placebo Arm: Edible starch similar to 450 mg. The look and feel of IP and of Placebo boxes were very similar.Patients are to take two capsules (one each of IP-1 and IP-2) twice a day for 15 days, and from the 16th day, one capsule of IP-2 twice a day up-to day 30. Capsules are to be administered orally with plain water.The IP is to be taken with all other concomitant medicines prescribed by the treating physician/doctor.The dose of each component in the IP is very safe to administer. The investigational products are registered products with the Indian Government and have been used for more than 6 months in various health conditions but not for COVID-19.
   Main outcomes: Primary Outcome:
   Efficacy of the herbal extracts in COVID 19 positive patients (in declining viral load: time-point: 4 days and early recovery)Secondary Outcomes: Efficacy of the herbal extracts as an immune-modulator - TH1, TH2, Th17, IL6, NK Cells and CD markers; Immunoglobulin IGG (Serum); Immunoglobulin IGM (Serum) - at 30 days.
   Efficacy of the investigational product in reducing sequela of the disease
   Safety analysis (Liver Function Test and Kidney Function Test) including serious allergic reaction of: rash, itching/swelling, severe dizziness, trouble breathing.
   RandomisationAn alphanumeric coded set of IP/Placebo containers will be used. Participants will be automatically randomized to two groups in the ratio 1:1.
   Blinding (masking)Participants, caregivers and investigators were blinded.
   Numbers to be randomised (sample size)A total of more than 60 and up to 75 patients were to be enrolled in the study into the two groups, considering drop-outs. 72 were enrolled with 37 into the intervention group and 35 into the placebo group.
   Trial Status: Protocol number: CoviQuest-01
   Protocol version number: 1.2
   Protocol Date: 1(st) July 2020
   The recruitment period is completed for the trial. Date of 1(st) patient enrolment was 11(th) Aug 2020 and the last patient was enrolled on 3(rd) of September 2020.
   This is to state that it was a late submission from authors for publication of the protocol to the BMC, after enrolment in the study was over.
   Last Participant's last follow-up is scheduled on 5(th) October 2020
   Trial registrationThe trial was prospectively registered with the CTRI (Clinical Trial Registry of India). Registration number is CTRI/2020/07/026570. Registered on 14 July 2020
   Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Rangnekar, Hrishikesh] Quest Clin & Ayurceut, Pune, Maharashtra, India.
   [Patankar, Suresh] AMAI Charitable Trust, Pune, Maharashtra, India.
   [Suryawanshi, Kishor; Soni, Pravin] YCM Hosp, Pune, Maharashtra, India.
RP Rangnekar, H (corresponding author), Quest Clin & Ayurceut, Pune, Maharashtra, India.
EM h.rangnekar@questclinicalservices.co.in
FU AMAI Charitable Trust, Pune
FX The study was funded by AMAI Charitable Trust, Pune. The same trust
   supplied the intervention IP - 1 and IP - 2 and the placebo. The funding
   body had no role in the design of the study, or in the collection,
   analysis, interpretation of data or in writing the manuscript.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 23
PY 2020
VL 21
IS 1
AR 943
DI 10.1186/s13063-020-04906-x
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA5ZE
UT WOS:000595712600006
PM 33225970
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Akarsu, B
   Ozdemir, DC
   Baser, DA
   Aksoy, H
   Fidanci, I
   Cankurtaran, M
AF Akarsu, Busra
   Canbay ozdemir, Dilara
   Ayhan Baser, Duygu
   Aksoy, Hilal
   Fidanci, Izzet
   Cankurtaran, Mustafa
TI While studies on COVID-19 vaccine is ongoing, the public's thoughts and
   attitudes to the future COVID-19 vaccine
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article; Early Access
ID INFLUENZA-A H1N1; MERCURY; WILLINGNESS
AB Objective In this study, we aim to investigate the thoughts and attitudes of individuals towards the future COVID-19 vaccine.
   Methods This descriptive study was carried out on the web between 10/06/2020 and 10/07/2020. The sample constitutes all individuals above 18 years of age using social media and smartphone. The e-survey form was shared by the researchers via the web for a month, and those who completed the survey were included in the study and formed the sample of the research.
   Results Seven-hundred and fifty-nine people participated. 49.7% of the participants stated to be vaccinated; 38.4% of them stated to be vaccinated their children against COVID-19; if the vaccine for COVID-19 is developed. The request for the COVID-19 vaccine had relationship with gender, occupation, health insurance, anxiety level, having children and willing to get vaccinated for their children. "Afraid of the side effects of vaccine", "don't think it can be reliable as it will be a new vaccine" and "COVID-19 infection is a biological weapon and the vaccine will serve those who produce this virus" were the most common reasons for rejection of vaccine.
   Conclusion In our study, afraid of the side effects of vaccine and not thinking it can be reliable as it will be a new vaccine are the most reasons of indecision and rejection about COVID 19 vaccine. In order for the future COVID 19 vaccination campaign to not fail, media, politicians and healthcare professionals should closely follow the vaccination development processes, inform the public transparently and consider public's concerns.
C1 [Akarsu, Busra; Canbay ozdemir, Dilara; Ayhan Baser, Duygu; Aksoy, Hilal; Fidanci, Izzet] Hacettepe Univ, Family Med, Fac Med, Ankara, Turkey.
   [Cankurtaran, Mustafa] Hacettepe Univ, Div Geriatr, Internal Med Dept, Ankara, Turkey.
RP Baser, DA (corresponding author), Hacettepe Univ, Family Med, Fac Med, Ankara, Turkey.
EM duyguayhan@outlook.com
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Arda B, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-87
   Asmundson GJG, 2020, J ANXIETY DISORD, V71, DOI 10.1016/j.janxdis.2020.102211
   Ball LK, 2001, PEDIATRICS, V107, P1147, DOI 10.1542/peds.107.5.1147
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Bose-O'Reilly S, 2010, CURR PROB PEDIATR AD, V40, P186, DOI 10.1016/j.cppeds.2010.07.002
   Chan EYY, 2015, VACCINE, V33, P4737, DOI 10.1016/j.vaccine.2015.07.046
   Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312
   Drasch G, 1998, J TRACE ELEM MED BIO, V12, P23, DOI 10.1016/S0946-672X(98)80017-5
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Giannattasio A, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1090-x
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   GURBUZ Y, 2013, PAM TIP DERG, V6, P12
   Henley J, 2020, GUARDIAN
   Hessel L, 2003, B ACAD NAT MED PARIS, V187, P1501, DOI 10.1016/S0001-4079(19)33886-5
   Hou ZY, 2014, VACCINE, V32, P4471, DOI 10.1016/j.vaccine.2014.06.047
   Kartal M, 2011, TURKIYE KLIN J FAM M, V2, P5
   Latimer K, 2020, 20 PEOPLE RECENT SUR
   Orbach H, 2010, DISCOV MED, V9, P90
   Ormen B, 2012, MIKROBIYOL BUL, V46, P57
   Sevencan F, 2011, HUM VACCINES, V7, P945, DOI 10.4161/hv.7.9.16368
   Shaw CA, 2013, IMMUNOL RES, V56, P304, DOI 10.1007/s12026-013-8403-1
   Spielmans GI, 2010, J BIOETHIC INQ, V7, P13, DOI 10.1007/s11673-010-9208-8
   T. C. Ministry of Health General Directorate of Public Health, 2020, COVID 19 SARS COV 2
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Wood JM, 2001, PHILOS T R SOC B, V356, P1953, DOI 10.1098/rstb.2001.0981
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49
NR 27
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
AR e13891
DI 10.1111/ijcp.13891
EA DEC 2020
PG 10
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA PG9DR
UT WOS:000600027600001
PM 33278857
OA Bronze
DA 2021-01-01
ER

PT J
AU Erdem, Y
   Ekinci, AP
   Altunay, IK
   Sivaz, O
   Inal, S
   Gokalp, MO
   Pehlivan, G
   Ozkaya, E
AF Erdem, Yasemin
   Polat Ekinci, Algun
   Altunay, Ilknur Kivanc
   Sivaz, Onur
   Inal, Sena
   Gokalp, Mehmet Onur
   Pehlivan, Gizem
   ozkaya, Esen
TI The impact of COVID-19 pandemic on the management of patients with
   chronic urticaria: An observational two-center study from Turkey
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE chronic urticaria; COVID&#8208; 19; management; omalizumab; pandemic;
   UAS7; UCT
ID OMALIZUMAB; DIAGNOSIS
AB The Coronavirus Disease 2019 (COVID-19) outbreak significantly affected the clinical practice in hospitals and the management of many diseases. The aim of this study was to evaluate the effect of pandemic-related factors on the severity and course of chronic urticaria (CU). A total of 194 CU patients who were on regular follow-up, were enrolled in the study. The disease activity was assessed by means of the weekly urticaria activity score (UAS7) and urticaria control test (UCT). Patients were divided into two subgroups according to their disease aggravation as "aggravated" and "non-aggravated". Two groups were compared in terms of demographic, clinical, COVID-19-associated parameters, and parameters related with the effect of COVID-19 pandemic on CU management. The omalizumab use was statistically higher (P = .017), and the systemic corticosteroid use was statistically lower (P = .025) in the "aggravated" group. Adherence to quarantine was significantly lower in the "aggravated" group (P = .027). 173 patients (89.2%) were unable to contact a dermatologist during the pandemic. Among 186 patients who received treatment for CU before the pandemic, 48 (25.8%) did not continue the existing treatment during the pandemic. CU aggravated in one patient with COVID-19 and remained stable in the other. This study showed that CU patients, especially those on omalizumab therapy, had difficulties in attending medical care and even in the maintenance of their existing therapies during the pandemic. Creating novel follow-up and treatment models as well as the increased use of teledermatology might be beneficial in the management of this life-disturbing condition.
C1 [Erdem, Yasemin; Altunay, Ilknur Kivanc; Sivaz, Onur; Inal, Sena] Hlth Sci Univ, Sisli Hamidiye Etfal Training & Res Hosp, Dept Dermatol, Istanbul, Turkey.
   [Polat Ekinci, Algun; Gokalp, Mehmet Onur; Pehlivan, Gizem; ozkaya, Esen] Istanbul Univ, Dept Dermatol & Venereol, Istanbul Fac Med, Istanbul, Turkey.
RP Erdem, Y (corresponding author), Hlth Sci Univ, Sisli Hamidiye Etfal Training & Res Hosp, Halaskargazi Cad,Etfak Sok 34371, Istanbul, Turkey.
EM erdemyasemin1@gmail.com
OI erdem, yasemin/0000-0002-6597-2957; Pehlivan, Gizem/0000-0002-5906-3976
CR Abuelgasim E, 2020, DERMATOL THER, DOI 10.1111/dth.14328
   Bernstein JA, 2014, J ALLERGY CLIN IMMUN, V133, P1270, DOI 10.1016/j.jaci.2014.02.036
   Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705
   Criado PR, 2020, INT J DERMATOL, DOI 10.1111/ijd.15134
   Criado PR, 2020, DERMATOL THER, DOI 10.1111/dth.14068
   Denman S, 2016, BRIT J DERMATOL, V175, P1405, DOI 10.1111/bjd.15074
   Eun SJ, 2019, ALLERGOL INT, V68, P52, DOI 10.1016/j.alit.2018.05.011
   Freeman EE, 2020, J AM ACAD DERMATOL, V83, P1118, DOI 10.1016/j.jaad.2020.06.1016
   Gisondi P, 2020, J EUR ACAD DERMATOL, DOI 10.1111/jdv.16774
   Gisondi P, 2020, J EUR ACAD DERMATOL, V34, P1196, DOI 10.1111/jdv.16515
   Gupta R, 2020, J AM ACAD DERMATOL, V83, P168, DOI 10.1016/j.jaad.2020.04.080
   Henry D, 2020, J EUR ACAD DERMATOL, V34, pE244, DOI 10.1111/jdv.16472
   Hollis K, 2018, AM J CLIN DERMATOL, V19, P267, DOI 10.1007/s40257-017-0331-8
   Kutlu O, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13581
   Lee JH, 2020, ALLERGY ASTHMA IMMUN, V12, P783, DOI 10.4168/aair.2020.12.5.783
   Lommatzsch M, 2020, ALLERGY, V75, P2705, DOI 10.1111/all.14456
   Mahil SK, 2020, BRIT J DERMATOL, V183, P404, DOI 10.1111/bjd.19161
   Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372
   Nazirolu T, 2020, DERMATOL THER, V33, pe13575, DOI 10.1111/dth.13575
   ozkaya E, 2019, DERMATOL THER, V32
   Salman A, 2020, Turkderm-Turk Arch D, V54, P71, DOI 10.4274/turkderm.galenos.2020.80000
   Shaker MS, 2020, J ALLER CL IMM-PRACT, V8, P1477, DOI 10.1016/j.jaip.2020.03.012
   Shakshouk H, 2020, J AM ACAD DERMATOL, V82, pE235, DOI 10.1016/j.jaad.2020.04.005
   Tursen U, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13476
   Vultaggio A, 2020, ALLERGY, V75, P2764, DOI 10.1111/all.14407
   Wedi B, 2004, CURR OPIN ALLERGY CL, V4, P387, DOI 10.1097/00130832-200410000-00010
   Weller K, 2015, J EUR ACAD DERMATOL, V29, P38, DOI 10.1111/jdv.13200
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Zhao ZT, 2016, J ALLERGY CLIN IMMUN, V137, P1742, DOI 10.1016/j.jaci.2015.12.1342
   Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397
NR 30
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14652
DI 10.1111/dth.14652
EA DEC 2020
PG 8
WC Dermatology
SC Dermatology
GA PG9HI
UT WOS:000600037100001
PM 33301190
OA Bronze
DA 2021-01-01
ER

PT J
AU Cherrez-Ojeda, I
   Vanegas, E
   Felix, M
AF Cherrez-Ojeda, Ivan
   Vanegas, Emanuel
   Felix, Miguel
TI The unusual experience of managing a severe COVID-19 case at home: what
   can we do and where do we go?
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Ambulatory care; COVID-19; Developing countries; South America
ID MORTALITY; RISK
AB BackgroundThe speed and reach of the COVID-19 pandemic has created special scenarios to be considered, such as those in where patients who meet criteria for hospitalization due to moderate/severe disease cannot be hospitalized due to economic constraints and saturation of national health systems. The aim of this report is to present an unusual case of a severe COVID-19 patient managed at home in a developing country, and to discuss some of the available guidelines and potential therapeutic options for this type of cases.Case presentationA 60-year-old female seeking medical attention through teleconsultation presents with profound dyspnea, oppressive chest pain, fatigue, episodic hallucinations, and difficulty sleeping, for what she originally sought medical attention at an ER but could not be admitted due to saturation of the health system. A positive PCR test for COVID-19, and a CT scan of the chest showing bilateral consolidations with ground-glass opacities confirmed the diagnosis. The patient was managed at home, with corticosteroids, nitazoxanide and a single dose of 40mg of subcutaneous enoxaparin. Colchicine was added at the third day of treatment. Standard oxygen therapy through nasal cannula was also recommended. Daily follow-ups were established to monitor for signs of clinical improvement. Two weeks later from the initial consultation the patient presents marked improvement in her symptoms, as well as in her CT scan, which prompted in discontinuation of the medications and the oxygen therapy.ConclusionsThere are several limitations in this report regarding the clinical data and the management, but such limitations do also reflect the state of emergency and the chaos that resides in the health care systems of developing nations. For the ambulatory care of COVID-19 patients, several aspects of disease management may differ from current guidelines and basic requirements may represent a huge challenge to cover. Further research is needed to assist physicians in the daily clinical decision making, to optimize patient outcomes, and to reduce the probability of adverse scenarios of patients with COVID-19 managed in the ambulatory setting.
C1 [Cherrez-Ojeda, Ivan; Vanegas, Emanuel; Felix, Miguel] Univ Espiritu Santo, Km 2-5 Via Puntilla, Samborondon 0901952, Ecuador.
   [Cherrez-Ojeda, Ivan; Vanegas, Emanuel; Felix, Miguel] Respiralab Res Grp, Guayaquil, Ecuador.
RP Cherrez-Ojeda, I (corresponding author), Univ Espiritu Santo, Km 2-5 Via Puntilla, Samborondon 0901952, Ecuador.; Cherrez-Ojeda, I (corresponding author), Respiralab Res Grp, Guayaquil, Ecuador.
EM ivancherrez@gmail.com
OI Felix, Miguel/0000-0002-2243-3646; Cherrez Ojeda,
   Ivan/0000-0002-1610-239X
FU Universidad Espiritu Santo
FX This study was supported by an unrestricted grant from the Universidad
   Espiritu Santo. The sponsor had no role in the design of the study or in
   the collection, analysis, and interpretation of data.
CR Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhimraj A, 2020, CLIN INFECT DIS
   Casanova P, 2015, CARDIOL REV, V23, P317, DOI 10.1097/CRD.0000000000000056
   CDC, 2020, OUTP AMB CAR SETT RE
   Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136
   Duca Andrea, 2020, Emerg Med Pract, V22, pCD1
   Fan G, 2020, EUR RESPIR J, V56, P1
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Haimovich AD, 2020, ANN EMERG MED, V76, P442, DOI 10.1016/j.annemergmed.2020.07.022
   Hoffman HM, 2009, J ALLERGY CLIN IMMUN, V124, P1129, DOI 10.1016/j.jaci.2009.11.001
   Horby P, 2020, N ENGL J MED
   Huet T, 2020, LANCET RHEUMATOL, V2, P10
   Karakike E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00055
   Khan NA, 2020, LANCET RHEUMATOL, V2, pE586, DOI 10.1016/S2665-9913(20)30273-3
   Kim AY, 2020, CORONAVIRUS DIS 2019
   Klopfenstein T, 2020, MED MALADIES INFECT, V50, P5
   Koopman RJ, 2008, FAM MED, V40, P412
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu J, 2020, J ALLERGY CLIN IMMUN, V146, P325, DOI 10.1016/j.jaci.2020.05.021
   Lombardia SR, 2020, LINEE GUIDA GESTIONE
   Long Y, 2016, INT J CLIN EXP MED, V9, P8865
   McKibbin W. J., 2020, GLOBAL MACROECONOMIC
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550
   Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X
   Ridker PM, 2014, EUR HEART J, V35, P1782, DOI 10.1093/eurheartj/ehu203
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi SJ, 2017, CLIN RESPIR J, V11, P352, DOI 10.1111/crj.12346
   Slobodnick A, 2015, AM J MED, V128, P461, DOI 10.1016/j.amjmed.2014.12.010
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   United Nations Development Programme, COVID 19 LOOM CRIS D
   World Economic Forum, 2020, COVID 19 WHAT AR BIG
   World Heath Organization, 2020, 72 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wynants L, 2020, BMJ-BRIT MED J, V369, P1
   Zha L, 2020, MED J AUSTRALIA, V212, P9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 44
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 19
PY 2020
VL 20
IS 1
AR 862
DI 10.1186/s12879-020-05608-0
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA PA1JK
UT WOS:000595374900004
PM 33213364
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marinelli, E
   Busardo, FP
   Zaami, S
AF Marinelli, Enrico
   Busardo, Francesco Paolo
   Zaami, Simona
TI Intensive and pharmacological care in times of COVID-19: A "special
   ethics" for emergency?
SO BMC MEDICAL ETHICS
LA English
DT Article
DE COVID-19; Emergency; Ethics
AB Background The Authors have laid out an analysis of Italian COVID-19 confirmed data and fatality rates, pointing out how a dearth of health care resources in northern regions has resulted in hard, ethically challenging decisions in terms of granting patient access to intensive care units (ICU). Main text Having to make such decisions certainly entails substantial difficulties, and that has led many health care professional to seek ethical guidance. The Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) has attempted to meet that growing need by a set of recommendations, applying "clinical soundness" as a beacon standard; that approach tends to prioritize patients with higher life expectancy, which could be characterized as a "moderately utilitarian" approach. Yet, such a selection has engendered daunting ethical quandaries. The authors believe it can only be warranted and acceptable if rooted in a transparent decision-making process and verifiable, reviewed criteria. Moreover, the authors have stressed how clinical experimentation in a pandemic setting is a subtext of great interest from an ethical perspective. In Italy, no drug therapy and trials were undertaken for COVID-19 patients for a rather long period of time. When the epidemic was already circulating, an intervention proved necessary on the system of administrative procedures, aimed at expediting the authorization and validation of protocols, then bogged down by bureaucracy. A new system has since been instituted by a government decree that was signed about one month after the first Covid-19 case was officially recorded in the country. Such a swift implementation, which took just a few weeks, is noteworthy and proves that clinical trials can be initiated in a timely fashion, even with a pandemic unfolding. The concerted, action of supportive care and RCTs is the only way to attain effective forms of treatments for COVID-19 and any other future outbreak. Conclusions The authors have arrived at the conclusion that the most effective and ethically sound response on the part of any national health care system would be to adequately reconfigure its organizational mechanisms, by making clinical trials and all related administrative procedures consistent with the current state of emergency.
C1 [Marinelli, Enrico; Zaami, Simona] Sapienza Univ Rome, Dept Anat Histol Forens & Orthopaed Sci, Rome, Italy.
   [Busardo, Francesco Paolo] Univ Politecn Marche, Dept Excellence Biomed Sci & Publ Hlth, Ancona, Italy.
RP Busardo, FP (corresponding author), Univ Politecn Marche, Dept Excellence Biomed Sci & Publ Hlth, Ancona, Italy.
EM fra.busardo@libero.it
CR [Anonymous], 2020, NICE GUID NG159 COVI
   Biddison ELD, 2019, CHEST, V155, P848, DOI 10.1016/j.chest.2018.09.025
   Comitato Nazionale per la Bioetica, 2020, COVID 19 DEC CLIN CO
   Franchini M, 2020, VOX SANG, DOI 10.1111/vox.12940
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Liddell K, 2020, J MED ETHICS, V46, P421, DOI 10.1136/medethics-2020-106332
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rosenbaum L, 2019, NEW ENGL J MED, V380, P786, DOI 10.1056/NEJMms1813429
   Solnica A, 2020, J MED ETHICS, V46, P441, DOI [10.1136/medethics-2020-106294, 10.1136/medethics-2020-106242]
   Sydney Health Ethics, 2020, ETH FRAM MAK RES ALL
   Unesco International Bioethics Committee UNESCO World Commission on the Ethics of Scientific Knowledge and Technology, 2020, UNESCO WORLD COMM ET
   Vergano M, 2020, SIAARTI
   World Health Organization, NOV COR 2019 NCOV SI
NR 14
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6939
J9 BMC MED ETHICS
JI BMC Med. Ethics
PD DEC 19
PY 2020
VL 21
IS 1
AR 117
DI 10.1186/s12910-020-00562-7
PG 5
WC Ethics; Medical Ethics; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Biomedical Social
   Sciences
GA OU0CW
UT WOS:000591205600001
PM 33213445
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Le, YY
   Rothman, K
   Christensen, A
   Doss, BD
AF Le, Yunying
   Rothman, Karen
   Christensen, Andrew
   Doss, Brian D.
TI Integrating the online OurRelationship program into a stepped-care model
   of couple therapy
SO JOURNAL OF FAMILY THERAPY
LA English
DT Article; Early Access
DE couple therapy; technology; online; OurRelationship; stepped care
ID RANDOMIZED CONTROLLED-TRIAL
AB Due to various barriers, most relationally distressed couples do not seek couple therapy. With the COVID-19 pandemic, many of these barriers are further exacerbated, while the need for relationship services has increased. To increase the reach of couple therapy both during and after the pandemic, we propose a stepped-care model that utilises technology as a precursor to couple therapy and acts as an integral component of it. In this paper, we first introduce the OurRelationship program - an evidence-based online relationship program that improves both relationship and individual functioning in several large-scale, nationwide trials. We then describe how therapists can incorporate this program into an abbreviated, eight-session course of couple therapy. We expect this integration will be useful to couple therapists from a variety of theoretical orientations and will address numerous common barriers to treatment including cost, scheduling difficulties and geographic distance from the therapist.
   Practitioner points
   Couple therapists can leverage technology to increase their reach both during and after the COVID-19 pandemic.
   The online OurRelationship program improves relationship and individual functioning in several nationwide clinical trials.
   The OurRelationship program can be integrated into an eight-session course of couple therapy to serve couples who would otherwise be unable or unwilling to attend therapy.
C1 [Le, Yunying; Rothman, Karen; Doss, Brian D.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
   [Christensen, Andrew] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA.
RP Le, YY (corresponding author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
EM yunyingleannie@gmail.com
CR Benson LA, 2012, BEHAV THER, V43, P25, DOI 10.1016/j.beth.2010.12.009
   Christensen A, 2004, J CONSULT CLIN PSYCH, V72, P176, DOI 10.1037/0022-006X.72.2.176
   Christensen A., 2020, INTEGRATIVE BEHAV CO
   Christensen A, 2010, J CONSULT CLIN PSYCH, V78, P225, DOI 10.1037/a0018132
   Gordon KC, 2020, FAM PROCESS, V59, P956, DOI 10.1111/famp.12576
   Doss BD, 2020, J CONSULT CLIN PSYCH, V88, P283, DOI 10.1037/ccp0000479
   Doss BD, 2019, BEHAV THER, V50, P73, DOI 10.1016/j.beth.2018.03.011
   Doss BD, 2016, J CONSULT CLIN PSYCH, V84, P285, DOI 10.1037/ccp0000063
   Doss BD, 2013, FAM PROCESS, V52, P139, DOI 10.1111/famp.12020
   Doss BD, 2011, J FAM PSYCHOL, V25, P770, DOI 10.1037/a0025239
   Salivar EGJ, 2020, FAM PROCESS, V59, P66, DOI 10.1111/famp.12414
   Gottman J. M., 2015, CLIN HDB COUPLE THER, P129
   Hatch SG, 2020, FAM PROCESS, DOI 10.1111/famp.12548
   Johnson C. A., 2002, MARRIAGE OKLAHOMA 20
   Johnson S. M., 2015, CLIN HDB COUPLE THER, P97
   Kazdin AE, 2011, AM PSYCHOL, V66, P685, DOI 10.1037/a0024975
   Roddy MK, 2020, J CONSULT CLIN PSYCH, V88, P583, DOI 10.1037/ccp0000514
   Roddy MK, 2020, FAM PROCESS, DOI 10.1111/famp.12541
   Roddy MK, 2020, PREV SCI, V21, P861, DOI 10.1007/s11121-020-01100-y
   Roddy MK, 2018, BEHAV RES THER, V110, P47, DOI 10.1016/j.brat.2018.09.002
   Salivar EG, 2020, J CONSULT CLIN PSYCH, V88, P899, DOI 10.1037/ccp0000606
   Simpson LE, 2008, J FAM PSYCHOL, V22, P102, DOI 10.1037/0893-3200.22.1.102
NR 22
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0163-4445
EI 1467-6427
J9 J FAM THER
JI J. Fam. Ther.
DI 10.1111/1467-6427.12321
EA DEC 2020
PG 17
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA PG4ZZ
UT WOS:000599746200001
DA 2021-01-01
ER

PT J
AU Madhusoodhan, PP
   Pierro, J
   Musante, J
   Kothari, P
   Gampel, B
   Appel, B
   Levy, A
   Tal, A
   Hogan, L
   Sharma, A
   Feinberg, S
   Kahn, A
   Pinchinat, A
   Bhatla, T
   Glasser, CL
   Satwani, P
   Raetz, EA
   Onel, K
   Carroll, WL
AF Madhusoodhan, P. Pallavi
   Pierro, Joanna
   Musante, Jordan
   Kothari, Prachi
   Gampel, Bradley
   Appel, Burton
   Levy, Adam
   Tal, Adit
   Hogan, Laura
   Sharma, Archana
   Feinberg, Shari
   Kahn, Alissa
   Pinchinat, Ashley
   Bhatla, Teena
   Glasser, Chana L.
   Satwani, Prakash
   Raetz, Elizabeth A.
   Onel, Kenan
   Carroll, William L.
TI Characterization of COVID-19 disease in pediatric oncology patients: The
   New York-New Jersey regional experience
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article; Early Access
DE chemotherapy; COVID&#8208; 19; immunocompromised; immunotherapy;
   pediatric oncology; SARS&#8208; CoV&#8208; 2
AB Purpose Pediatric oncology patients undergoing active chemotherapy are suspected to be at a high risk for severe disease secondary to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection; however, data to support this are lacking. We aim to describe the characteristics of coronavirus disease 2019 (COVID-19) in this population and also its impact on pediatric cancer care in the New York region during the peak of the pandemic.
   Patients and Methods This multicenter, retrospective study included 13 institutions. Clinical and laboratory information on 98 patients <= 21 years of age receiving active anticancer therapy, who tested positive for SARS-CoV-2 by nasopharyngeal swab polymerase chain reaction (PCR), was collected.
   Results Of the 578 pediatric oncology patients tested for COVID-19, 98 were positive, of whom 73 were symptomatic. Most experienced mild disease, 28 required inpatient management, 25 needed oxygen support, and seven required mechanical ventilation. There is a slightly higher risk of severe disease in males and obese patients, though not statistically significant. Persistent lymphopenia was noted in severe cases. Delays in cancer therapy occurred in 67% of SARS-CoV-2-positive patients. Of four deaths, none were solely attributable to COVID-19. The impact of the pandemic on pediatric oncology care was significant, with 54% of institutions reporting delays in chemotherapy, 46% delays in surgery, and 30% delays in transplant.
   Conclusion In this large multi-institutional cohort, we observed that mortality and morbidity from COVID-19 amongst pediatric oncology patients were low overall, but higher than reported in general pediatrics. Certain subgroups might be at higher risk of severe disease. Delays in cancer care due to SARS-CoV-2 remain a concern.
C1 [Madhusoodhan, P. Pallavi; Musante, Jordan] Icahn Sch Med Mt Sinai, Mt Sinai Kravis Childrens Hosp, Div Pediat Hematol Oncol, Dept Pediat, New York, NY 10029 USA.
   [Pierro, Joanna; Raetz, Elizabeth A.; Carroll, William L.] NYU, Div Pediat Hematol Oncol, Perlmutter Canc Ctr,Hassenfeld Childrens Hosp, Dept Pediat,NYU Langone Hlth,Grossman Sch Med, New York, NY USA.
   [Kothari, Prachi] Mem Sloan Kettering Canc Ctr, Dept Pediat, 1275 York Ave, New York, NY 10021 USA.
   [Gampel, Bradley; Satwani, Prakash] Columbia Univ, Med Ctr, New York Presbyterian Morgan Stanley Childrens Ho, Dept Pediat,Div Pediat Hematol Oncol & Stem Cell, New York, NY USA.
   [Appel, Burton] Hackensack Univ, Med Ctr, Joseph M Sanzari Childrens Hosp, Childrens Canc Inst, Hackensack, NJ USA.
   [Levy, Adam; Tal, Adit] Montefiore Med Ctr, Albert Einstein Coll Med, Div Pediat Hematol Oncol & Cellular Therapy, Dept Pediat, Bronx, NY 10467 USA.
   [Hogan, Laura] Stony Brook Childrens Hosp, Dept Pediat, Stony Brook, NY USA.
   [Sharma, Archana] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
   [Feinberg, Shari] Maimonides Hosp, Div Pediat Hematol Oncol, Dept Pediat, Brooklyn, NY USA.
   [Kahn, Alissa] St Josephs Childrens Hosp, Valerie Fund Ctr, Paterson, NJ USA.
   [Pinchinat, Ashley] New York Med Coll, Westchester Med Ctr, Maria Fareri Childrens Hosp, Dept Pediat,Div Hematol Oncol & Stem Cell Transpl, Valhalla, NY USA.
   [Bhatla, Teena] Newark Beth Israel Med Ctr, Childrens Hosp New Jersey, Dept Pediat, Div Pediat Hematol Oncol, Newark, NJ USA.
   [Glasser, Chana L.] NYU, Long Isl Sch Med, Winthrop Hosp, Dept Pediat,Div Pediat Hematol Oncol, Mineola, NY USA.
   [Onel, Kenan] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Onel, Kenan] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, New York, NY 10029 USA.
   [Onel, Kenan] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pathol, New York, NY 10029 USA.
   [Onel, Kenan] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pediat, New York, NY 10029 USA.
RP Madhusoodhan, PP (corresponding author), Mt Sinai Kravis Childrens Hosp, Jack & Lucy Clark Dept Pediat, Jack Martin Div Pediat Hematol Oncol, 1468 Madison Ave, New York, NY 10029 USA.
EM pallavi.madhusoodhan@mssm.edu
FU NationalCancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01 CA140729-05]; Hyundai Hope on Wheels; Alex's
   Lemonade Stand; Perlmutter Cancer Center Airline and Norman M. Feinberg
   PilotGrant for LymphoidMalignancies and the Perlmutter Cancer Center
   [P30 CA016087]; NCIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [CA98543]
FX NationalCancer Institute, Grant Number: R01 CA140729-05; Hyundai Hope on
   Wheels; Alex's Lemonade Stand; Perlmutter Cancer Center Airline and
   Norman M. Feinberg PilotGrant for LymphoidMalignancies and the
   Perlmutter Cancer Center, Grant Number: P30 CA016087; NCI, Grant Number:
   CA98543
CR Alkhouli M, 2020, MAYO CLIN PROC, V95, P1613, DOI 10.1016/j.mayocp.2020.05.014
   American Society of Hematology Research Collaborative (ASH RC), COVID 19 REG HEM
   Andre N, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28392
   Boulad F, 2020, JAMA ONCOL, V6, P1459, DOI 10.1001/jamaoncol.2020.2028
   CDC, 2020, HLTH WEIGHT NUTR PHY
   Clift Ashley Kieran, 2020, Ann Intern Med, DOI 10.7326/M20-4986
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Fitzmaurice G.M., 2011, APPL LONGITUDINAL AN
   Gampel B, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28420
   Hoang A, 2020, ECLINICALMEDICINE, V24
   Kainth MK, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-003186
   Kim L, 2020, MMWR-MORBID MORTAL W, V69, P1081, DOI 10.15585/mmwr.mm6932e3
   Korea Centers for Disease Control and Prevention, 2020, FIND INV AN RE POS C
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   SAS Institute Inc, 2013, SAS ACCESSR 94 INT A
   St. Jude Global, 2020, GLOB REG COVID 19 PE
   Stokes CL, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28432
   Tagarro Alfredo, 2020, JAMA Pediatr, DOI 10.1001/jamapediatrics.2020.1346
   Tirupathi R, 2020, TRAVEL MED INFECT DI, V38
   UAB, 2020, PED COVID 19 CANC CA
   UK Coronavirus Canc, 2020, LANCET ONCOL, V21, P622, DOI 10.1016/S1470-2045(20)30230-8
   Zhao QW, 2020, INT J INFECT DIS, V96, P131, DOI 10.1016/j.ijid.2020.04.086
NR 24
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
AR e28843
DI 10.1002/pbc.28843
EA DEC 2020
PG 9
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA PG4ZP
UT WOS:000599745200001
PM 33338306
DA 2021-01-01
ER

PT J
AU Zhang, YL
   Wang, SJ
   Wu, YT
   Hou, WH
   Yuan, LZ
   Sheng, CG
   Wang, J
   Ye, JH
   Zheng, QB
   Ma, J
   Xu, JJ
   Wei, M
   Li, ZL
   Nian, S
   Xiong, HL
   Zhang, L
   Shi, Y
   Fu, BR
   Cao, JL
   Yang, CL
   Li, ZY
   Yang, T
   Liu, L
   Yu, H
   Hu, JD
   Ge, SX
   Chen, YX
   Zhang, TY
   Zhang, J
   Cheng, T
   Yuan, Q
   Xia, NS
AF Zhang, Yali
   Wang, Shaojuan
   Wu, Yangtao
   Hou, Wangheng
   Yuan, Lunzhi
   Sheng, Chenguang
   Wang, Juan
   Ye, Jianghui
   Zheng, Qingbing
   Ma, Jian
   Xu, Jingjing
   Wei, Min
   Li, Zonglin
   Nian, Sheng
   Xiong, Hualong
   Zhang, Liang
   Shi, Yang
   Fu, Baorong
   Cao, Jiali
   Yang, Chuanlai
   Li, Zhiyong
   Yang, Ting
   Liu, Lei
   Yu, Hai
   Hu, Jianda
   Ge, Shengxiang
   Chen, Yixin
   Zhang, Tianying
   Zhang, Jun
   Cheng, Tong
   Yuan, Quan
   Xia, Ningshao
TI Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies
   of Neutralizing Antibodies and Compound Inhibitors
SO SMALL METHODS
LA English
DT Article; Early Access
DE entry inhibitor; fluorescent protein; high-content analysis; live-cell
   imaging; SARS-CoV-2; spike glycoprotein; viral entry visualization
ID CRYO-EM STRUCTURE; CORONAVIRUS; MECHANISMS; PNEUMONIA; INFECTION;
   VACCINES; TARGETS; PROTEIN; SPIKE
AB The ongoing corona virus disease 2019 (COVID-19) pandemic, caused by SARS-CoV-2 infection, has resulted in hundreds of thousands of deaths. Cellular entry of SARS-CoV-2, which is mediated by the viral spike protein and ACE2 receptor, is an essential target for the development of vaccines, therapeutic antibodies, and drugs. Using a mammalian cell expression system, a genetically engineered sensor of fluorescent protein (Gamillus)-fused SARS-CoV-2 spike trimer (STG) to probe the viral entry process is developed. In ACE2-expressing cells, it is found that the STG probe has excellent performance in the live-cell visualization of receptor binding, cellular uptake, and intracellular trafficking of SARS-CoV-2 under virus-free conditions. The new system allows quantitative analyses of the inhibition potentials and detailed influence of COVID-19-convalescent human plasmas, neutralizing antibodies and compounds, providing a versatile tool for high-throughput screening and phenotypic characterization of SARS-CoV-2 entry inhibitors. This approach may also be adapted to develop a viral entry visualization system for other viruses.
C1 [Zhang, Yali; Wang, Shaojuan; Wu, Yangtao; Hou, Wangheng; Yuan, Lunzhi; Wang, Juan; Ye, Jianghui; Zheng, Qingbing; Ma, Jian; Wei, Min; Li, Zonglin; Nian, Sheng; Xiong, Hualong; Zhang, Liang; Shi, Yang; Fu, Baorong; Cao, Jiali; Yang, Chuanlai; Yu, Hai; Ge, Shengxiang; Chen, Yixin; Zhang, Tianying; Zhang, Jun; Cheng, Tong; Yuan, Quan; Xia, Ningshao] Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Fujian, Peoples R China.
   [Zhang, Yali; Wang, Shaojuan; Wu, Yangtao; Hou, Wangheng; Yuan, Lunzhi; Wang, Juan; Ye, Jianghui; Zheng, Qingbing; Ma, Jian; Wei, Min; Li, Zonglin; Nian, Sheng; Xiong, Hualong; Zhang, Liang; Shi, Yang; Fu, Baorong; Cao, Jiali; Yang, Chuanlai; Yu, Hai; Ge, Shengxiang; Chen, Yixin; Zhang, Tianying; Zhang, Jun; Cheng, Tong; Yuan, Quan; Xia, Ningshao] Xiamen Univ, Sch Life Sci, Xiamen 361102, Fujian, Peoples R China.
   [Sheng, Chenguang; Liu, Lei] Southern Univ Sci & Technol, Hosp Affiliated 2, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis,Shenzhen Key Lab Pat, Shenzhen 518112, Guangdong, Peoples R China.
   [Xu, Jingjing; Yang, Ting; Hu, Jianda] Fujian Med Univ, Union Hosp, Fujian Prov Key Lab Hematol, Fujian Inst Hematol,Dept Hematol, Fuzhou 350001, Fujian, Peoples R China.
   [Li, Zhiyong] Xiamen Univ, Hosp 1, Xiamen 361003, Peoples R China.
RP Cheng, T; Yuan, Q; Xia, NS (corresponding author), Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Fujian, Peoples R China.; Cheng, T; Yuan, Q; Xia, NS (corresponding author), Xiamen Univ, Sch Life Sci, Xiamen 361102, Fujian, Peoples R China.
EM tcheng@xmu.edu.cn; yuanquan@xmu.edu.cn; nsxia@xmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81993149041, 81902057, 81871316, U1905205];
   National Science and Technology Major Project of Infectious Diseases
   [2017ZX10304402-002-003, 2017ZX10202203-009]; National Science and
   Technology Major Projects for Major New Drugs Innovation and Development
   [2018ZX09711003-005-003]; Science and Technology Major Project of Fujian
   [2020YZ014001]; Science and Technology Major Project of Xiamen
   [3502Z2020YJ01]; Guangdong Basic and Applied Basic Research Foundation
   [2020A1515010368]
FX This study was supported by National Natural Science Foundation of China
   (81993149041 for N.X.; 81902057 for Y.Z.; 81871316 and U1905205 for
   Q.Y.), the National Science and Technology Major Project of Infectious
   Diseases (No. 2017ZX10304402-002-003 for T.C. and No. 2017ZX10202203-009
   for Q.Y.), the National Science and Technology Major Projects for Major
   New Drugs Innovation and Development (No. 2018ZX09711003-005-003 for
   T.C.), the Science and Technology Major Project of Fujian
   (2020YZ014001), the Science and Technology Major Project of Xiamen
   (3502Z2020YJ01), and the Guangdong Basic and Applied Basic Research
   Foundation (2020A1515010368 for C.S.). The authors thank Meng Lai,
   Wenyuan Liu, and Hai Lin from PerkinElmer for technical assistance in
   imaging analysis and equipment maintenance.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bai Y, 2011, P NATL ACAD SCI USA, V108, P18406, DOI 10.1073/pnas.1115348108
   Bajar BT, 2016, SCI REP-UK, V6, DOI 10.1038/srep20889
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chang L., 2020, 20153106 MEDRXIV, DOI [10.1101/2020.07.13.20153106, DOI 10.1101/2020.07.13.20153106]
   Cho NJ, 2020, NAT MATER, V19, P813, DOI 10.1038/s41563-020-0698-4
   Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035
   Deng WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111988
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gayle S, 2017, BLOOD, V129, P1768, DOI 10.1182/blood-2016-09-736892
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Marovich M, 2020, JAMA-J AM MED ASSOC, V324, P131, DOI 10.1001/jama.2020.10245
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Mazzon Michela, 2019, F1000Res, V8, DOI 10.12688/f1000research.19694.1
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pierson Theodore C., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000665
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Sakurai Y, 2015, SCIENCE, V347, P995, DOI 10.1126/science.1258758
   Salazar Eric, 2020, J Clin Invest, V130, P6728, DOI 10.1172/JCI141206
   Shaner NC, 2013, NAT METHODS, V10, P407, DOI [10.1038/NMETH.2413, 10.1038/nmeth.2413]
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shcherbakova DM, 2013, NAT METHODS, V10, P751, DOI 10.1038/nmeth.2521
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shinoda H, 2018, CELL CHEM BIOL, V25, P330, DOI 10.1016/j.chembiol.2017.12.005
   Sun E, 2013, CURR OPIN VIROL, V3, P34, DOI 10.1016/j.coviro.2013.01.005
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xiong HL, 2020, EMERG MICROBES INFEC, V9, P2105, DOI 10.1080/22221751.2020.1815589
   Yamauchi Y, 2013, J CELL SCI, V126, P1289, DOI 10.1242/jcs.119685
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003
   Zhang TY, 2016, GUT, V65, P658, DOI 10.1136/gutjnl-2014-308964
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 50
TC 0
Z9 0
U1 0
U2 0
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2366-9608
J9 SMALL METHODS
JI Small Methods
AR 2001031
DI 10.1002/smtd.202001031
EA DEC 2020
PG 14
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA PG2YM
UT WOS:000599606500001
DA 2021-01-01
ER

PT J
AU Khubber, S
   Hashemifesharaki, R
   Mohammadi, M
   Gharibzahedi, SMT
AF Khubber, Sucheta
   Hashemifesharaki, Reza
   Mohammadi, Mehrdad
   Gharibzahedi, Seyed Mohammad Taghi
TI Garlic (Allium sativum L.): a potential unique therapeutic food rich in
   organosulfur and flavonoid compounds to fight with COVID-19
SO NUTRITION JOURNAL
LA English
DT Letter
DE COVID-19; SARS-CoV-2; Garlic; Allicin; Quercetin; Antiviral
AB Coronavirus disease 2019 (COVID-19) is the current major health crisis in the world. A successful strategy to combat the COVID-19 pandemic is the improvement of nutritional pattern. Garlic is one of the most efficient natural antibiotics against the wide spectrum of viruses and bacteria. Organosulfur (e.g., allicin and alliin) and flavonoid (e.g., quercetin) compounds are responsible for immunomodulatory effects of this healthy spice. The viral replication process is accelerated with the main structural protease of SARS-CoV-2. The formation of hydrogen bonds between this serine-type protease and garlic bioactives in the active site regions inhibits the COVID-19 outbreak. The daily dietary intake of garlic and its derived-products as an adjuvant therapy may improve side effects and toxicity of the main therapeutic drugs with reducing the used dose.
C1 [Khubber, Sucheta] Ctr Innovat & Appl Bioproc, Mohali 140306, India.
   [Khubber, Sucheta] CCS Haryana Agr Univ, Hisar 125004, Haryana, India.
   [Hashemifesharaki, Reza] Nova Harmony LLC, Dept Res & Dev, Santa Monica, CA USA.
   [Mohammadi, Mehrdad] Shahid Beheshti Univ Med Sci, Fac Nutr Sci & Food Technol, Natl Nutr & Food Technol Res Inst, Dept Food Technol Res, Tehran, Iran.
   [Gharibzahedi, Seyed Mohammad Taghi] Islamic Azad Univ, Lahijan Branch, Young Researchers & Elite Club, Lahijan, Iran.
RP Gharibzahedi, SMT (corresponding author), Islamic Azad Univ, Lahijan Branch, Young Researchers & Elite Club, Lahijan, Iran.
EM smt.gharibzahedi@gmail.com
OI Gharibzahedi, Seyed Mohammad Taghi/0000-0001-6280-8361
CR Chakraborty D, 2020, BIOTICA RES TODAY, V2, P755
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   El-Saber Batiha G, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030872
   Hashemifesharaki R, 2020, NUTRIRE, V45, DOI [10.1186/s41110-020-00122-4, DOI 10.1186/S41110-020-00122-4]
   Kalirajan Rajagopal, 2020, International Journal of Health and Allied Sciences, V9, P43, DOI 10.4103/ijhas.IJHAS_55_20
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Pandey P, 2021, BIOINTERFACE RES APP, V11, P7981, DOI 10.33263/BRIAC111.79817993
   Panyod Suraphan, 2020, J Tradit Complement Med, V10, P420, DOI 10.1016/j.jtcme.2020.05.004
   Shojai TM, 2016, AVICENNA J PHYTOMEDI, V6, P458
NR 9
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2891
J9 NUTR J
JI Nutr. J.
PD DEC 18
PY 2020
VL 19
IS 1
AR 124
DI 10.1186/s12937-020-00643-8
PG 3
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA OS9TE
UT WOS:000590498300001
PM 33208167
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kadakia, K
   Patel, B
   Shah, A
AF Kadakia, Kushal
   Patel, Bakul
   Shah, Anand
TI Advancing digital health: FDA innovation during COVID-19
SO NPJ DIGITAL MEDICINE
LA English
DT Article
AB Digital health products have played an important role in the COVID-19 response, from supporting the remote monitoring of patients to enabling continuity in data collection for clinical trials. The U.S. Food and Drug Administration (FDA) has issued a number of temporary policies to support digital health innovation during the pandemic, such as guidance documents to expand the use of digital therapeutics for psychiatric disorders and medical devices for remote patient monitoring. In this article, we contextualize these policies to the agency's existing regulatory framework for digital health, outline key considerations for patients and health care providers, and identify implications for the future of digital health innovation.
C1 [Kadakia, Kushal; Patel, Bakul; Shah, Anand] US FDA, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
RP Shah, A (corresponding author), US FDA, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
EM anand.shah@fda.hhs.gov
CR Andrews JA, 2019, J MED INTERNET RES, V21, DOI 10.2196/11694
   Centers for Medicare & Medicaid Services, 2019, CY2020 REV PAYM POL
   Marra C, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0259-x
   McGinty EE, 2020, JAMA-J AM MED ASSOC, V324, P93, DOI 10.1001/jama.2020.9740
   Shah A, 2020, FDA RESPONSE COVID 1, DOI [10.1377/hblog20200814.704964, DOI 10.1377/HBLOG20200814.704964]
   Shuren J, 2018, JAMA-J AM MED ASSOC, V320, P337, DOI 10.1001/jama.2018.8832
   U.S. Food and Drug Administration, 2020, COVID 19 PAND SOL AP
   U.S. Food and Drug Administration, 2017, DIG HLTH INN ACT PLA
   U.S. Food and Drug Administration, 2020, DIG HLTH POL PUBL SO
   U.S. Food and Drug Administration, 2020, FDA PERM MARK 1 GAM
   U.S. Food and Drug Administration, 2018, PMA APPR
   U.S. Food and Drug Administration, 2020, DEV SOFTW PREC PROGR
   U.S. Food and Drug Administration, 2019, DEV SOFTW PREC MOD W
   U.S. Food and Drug Administration, 2020, GUID DIG HLTH CONT
   U.S. Food and Drug Administration, 2020, FDA GUID COND CLIN T
   U.S. Food and Drug Administration, 2020, FDA LAUNCH DIG HLTH
   U.S. Food and Drug Administration, 2020, ENF POL NON REM MON
   U.S. Food and Drug Administration, 2018, FDA CLEARS MOB MED A
   U.S. Food and Drug Administration, 2020, DIG HLTH SOFTW PREC
   U.S. Food and Drug Administration, 2017, US REAL WORLD EV SUP
   U.S. Food and Drug Administration, 2020, ENF POL DIG HLTH DEV
   Upadhaya S, 2020, NAT REV DRUG DISCOV, V19, P376, DOI 10.1038/d41573-020-00093-1
   Verma S, 2020, EARLY IMPACT CMS EXP, DOI [10.1377/hblog20200715.454789, DOI 10.1377/HBLOG20200715.454789]
   World Health Organization, 2020, COVID 19 SIGN IMP HL
NR 24
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2398-6352
J9 NPJ DIGIT MED
JI npj Digit. Med.
PD DEC 17
PY 2020
VL 3
IS 1
AR 161
DI 10.1038/s41746-020-00371-7
PG 3
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA PG6NO
UT WOS:000599850500001
PM 33335250
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Tang, JY
   Li, WC
   Jiang, FL
   Wang, T
AF Tang, Junyi
   Li, Wencan
   Jiang, Fanli
   Wang, Tao
TI Successfully treatment of application awake extracorporeal membrane
   oxygenation in critical COVID-19 patient: a case report
SO JOURNAL OF CARDIOTHORACIC SURGERY
LA English
DT Article
DE Awake extracorporeal membrane oxygenation; COVID-19; Case report
AB Background A newly infectious diseases named coronavirus disease 2019 (COVID-19) emerged in China and now has spread in many countries, and constituted a public health emergency of international concern. Extracorporeal membrane oxygenation (ECMO) is used as salvage therapies in critical COVID-19 patients with respiratory/cardiac failure. Case presentation A 49-year-old female patient was diagnosed with COVID-19 and progressed to critical cases, she was successfully treated with the application of awake extracorporeal membrane oxygenation. This case is the first reported successfully treatment of application awake ECMO in critical COVID-19 patient in China. Conclusions Here we present the first reported successfully treatment of application awake ECMO in critical COVID-19 patient, however, whether awake ECMO can be widely used in the treatment of critical COVID-19 patients need more practice.
C1 [Tang, Junyi; Li, Wencan; Jiang, Fanli; Wang, Tao] CSU, Dept Thorac & Cardiovasc Surg, Affiliated Zhuzhou Hosp, Xiangya Med Coll, 116 Changjiangnan Rd, Zhuzhou 412007, Hunan, Peoples R China.
RP Wang, T (corresponding author), CSU, Dept Thorac & Cardiovasc Surg, Affiliated Zhuzhou Hosp, Xiangya Med Coll, 116 Changjiangnan Rd, Zhuzhou 412007, Hunan, Peoples R China.
EM 1262673060@qq.com
CR Alshahrani MS, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-017-0350-x
   Langer T, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1329-y
   Liu Q, 2020, Fa Yi Xue Za Zhi, V36, P21, DOI 10.12116/j.issn.1004-5619.2020.01.005
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Xu Q, 2019, QJM-INT J MED, V112, P525, DOI 10.1093/qjmed/hcz087
NR 5
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1749-8090
J9 J CARDIOTHORAC SURG
JI J. Cardiothorac. Surg.
PD DEC 17
PY 2020
VL 15
IS 1
AR 335
DI 10.1186/s13019-020-01376-9
PG 4
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA PG6NU
UT WOS:000599851100001
PM 33334350
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Jirak, P
   Larbig, R
   Shomanova, Z
   Frob, EJ
   Dankl, D
   Torgersen, C
   Frank, N
   Mahringer, M
   Butkiene, D
   Haake, H
   Salzer, HJF
   Tschoellitsch, T
   Lichtenauer, M
   Egle, A
   Lamprecht, B
   Reinecke, H
   Hoppe, UC
   Pistulli, R
   Motloch, LJ
AF Jirak, Peter
   Larbig, Robert
   Shomanova, Zornitsa
   Froeb, Elisabeth J.
   Dankl, Daniel
   Torgersen, Christian
   Frank, Nino
   Mahringer, Magdalena
   Butkiene, Dominyka
   Haake, Hendrik
   Salzer, Helmut J. F.
   Tschoellitsch, Thomas
   Lichtenauer, Michael
   Egle, Alexander
   Lamprecht, Bernd
   Reinecke, Holger
   Hoppe, Uta C.
   Pistulli, Rudin
   Motloch, Lukas J.
TI Myocardial injury in severe COVID-19 is similar to pneumonias of other
   origin: results from a multicentre study
SO ESC HEART FAILURE
LA English
DT Article; Early Access
DE COVID-19; Myocarditis; Thrombosis; Acute respiratory distress syndrome;
   Pneumonia
ID MORTALITY; TROPONIN
AB Aims COVID-19, a respiratory viral disease causing severe pneumonia, also affects the heart and other organs. Whether its cardiac involvement is a specific feature consisting of myocarditis, or simply due to microvascular injury and systemic inflammation, is yet unclear and presently debated. Because myocardial injury is also common in other kinds of pneumonias, we investigated and compared such occurrence in severe pneumonias due to COVID-19 and other causes.
   Methods and results We analysed data from 156 critically ill patients requiring mechanical ventilation in four European tertiary hospitals, including all n = 76 COVID-19 patients with severe disease course requiring at least ventilatory support, matched to n = 76 from a retrospective consecutive patient cohort of severe pneumonias of other origin (matched for age, gender, and type of ventilator therapy). When compared to the non-COVID-19, mortality (COVID-19 = 38.2% vs. non-COVID-19 = 51.3%, P = 0.142) and impairment of systolic function were not significantly different. Surprisingly, myocardial injury was even more frequent in non-COVID-19 (96.4% vs. 78.1% P = 0.004). Although inflammatory activity [C-reactive protein (CRP) and interleukin-6] was indifferent, d-dimer and thromboembolic incidence (COVID-19 = 23.7% vs. non-COVID-19 = 5.3%, P = 0.002) driven by pulmonary embolism rates (COVID-19 = 17.1% vs. non-COVID-19 = 2.6%, P = 0.005) were higher.
   Conclusions Myocardial injury was frequent in severe COVID-19 requiring mechanical ventilation, but still less frequent than in similarly severe pneumonias of other origin, indicating that cardiac involvement may not be a specific feature of COVID-19. While mortality was also similar, COVID-19 is characterized with increased thrombogenicity and high pulmonary embolism rates.
C1 [Jirak, Peter; Mahringer, Magdalena; Lichtenauer, Michael; Hoppe, Uta C.; Motloch, Lukas J.] Paracelsus Med Univ, Univ Hosp Salzburg, Clin Internal Med 2, Salzburg, Austria.
   [Larbig, Robert; Butkiene, Dominyka; Haake, Hendrik] Hosp Maria Hilf Monchengladbach, Div Cardiol, Monchengladbach, Germany.
   [Larbig, Robert] Univ Munster, Div Electrophysiol, Dept Cardiovasc Med, Munster, Germany.
   [Shomanova, Zornitsa; Froeb, Elisabeth J.; Reinecke, Holger; Pistulli, Rudin] Univ Hosp Munster, Heart Failure, Dept Cardiol Coronary & Peripheral Vasc Dis 1, Albert Schweitzer Campus 1,A1, D-48149 Munster, Germany.
   [Dankl, Daniel; Torgersen, Christian; Frank, Nino] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Anesthesiol Perioperat Care & Intens Care Me, Salzburg, Austria.
   [Salzer, Helmut J. F.; Lamprecht, Bernd] Kepler Univ Hosp, Dept Pulmonol, Linz, Austria.
   [Tschoellitsch, Thomas] Johannes Kepler Univ Linz, Kepler Univ Hosp Linz, Dept Anesthesiol & Intens Care Med, Linz, Austria.
   [Egle, Alexander] Paracelsus Med Univ, Med Dept Hematol & Med Oncol 3, Hemostaseol Rheumatol & Infect Dis, Salzburg, Austria.
RP Pistulli, R (corresponding author), Univ Hosp Munster, Heart Failure, Dept Cardiol Coronary & Peripheral Vasc Dis 1, Albert Schweitzer Campus 1,A1, D-48149 Munster, Germany.
EM rpistulli@yahoo.it
FU Projekt DEAL
FX Open access funding enabled and organized by Projekt DEAL.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Ammann P, 2003, J AM COLL CARDIOL, V41, P2004, DOI 10.1016/S0735-1097(03)00421-2
   Bajwa EK, 2007, CRIT CARE MED, V35, P2484, DOI 10.1097/01.CCM.0000281852.36573.22
   Corrales-Medina VF, 2013, LANCET, V381, P496, DOI 10.1016/S0140-6736(12)61266-5
   Deng Q, 2020, INT J CARDIOL, V8
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Frencken JF, 2019, ANN AM THORAC SOC, V16, P606, DOI 10.1513/AnnalsATS.201804-286OC
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566
   Li SSL, 2003, CIRCULATION, V108, P1798, DOI 10.1161/01.CIR.0000094737.21775.32
   Mathew D, 2020, CLIN RADIOL, V75, DOI 10.1016/j.crad.2020.03.017
   Minet C, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1003-9
   Ostermann M, 2017, SHOCK, V47, P702, DOI 10.1097/SHK.0000000000000811
   Papazian L, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0540-9
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492
   Sala S, 2020, EUR HEART J, V41, P1861, DOI 10.1093/eurheartj/ehaa286
   Schaller T, 2020, JAMA-J AM MED ASSOC, V323, P2518, DOI 10.1001/jama.2020.8907
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Takasu O, 2013, AM J RESP CRIT CARE, V187, P509, DOI 10.1164/rccm.201211-1983OC
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Thomas W, 2020, THROMB RES, V191, P76, DOI 10.1016/j.thromres.2020.04.028
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
NR 29
TC 0
Z9 0
U1 0
U2 0
PU WILEY PERIODICALS, INC
PI SAN FRANCISCO
PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA
SN 2055-5822
J9 ESC HEART FAIL
JI ESC Heart Fail.
DI 10.1002/ehf2.13136
EA DEC 2020
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA PF8MN
UT WOS:000599301800001
PM 33350605
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Sayed, AM
   Khalaf, AM
   Abdelrahim, MEA
   Elgendy, MO
AF Sayed, Ahmed M.
   Khalaf, Ahmed M.
   Abdelrahim, Mohamed E. A.
   Elgendy, Marwa O.
TI Repurposing of some anti-infective drugs for COVID-19 treatment: A
   surveillance study supported by an in silico investigation
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article; Early Access
ID SOFTWARE NEWS; NITAZOXANIDE; AZITHROMYCIN; DYNAMICS
AB Objective The repurposing of nitazoxanide, doxycycline and azithromycin may be effective to improve the symptoms in mild and moderate COVID-19 subjects. This study aimed to detect and explain the efficacy of reusing of these drugs in treating COVID-19.
   Methods The study was divided into two parts: clinical and computational parts. In the clinical part, 80 (30 females) subjects with reverse transcription-polymerase chain reaction-confirmed COVID-19 with mild and moderate symptoms were enrolled in the study. Subjects were treated with azithromycin or doxycycline, and nitazoxanide was added to the treatment if the subject had diarrhoea. Subjects were divided into four groups: Group 1: subjects treated with azithromycin (20 subjects); Group 2: subjects treated with doxycycline (20 subjects); Group 3: subjects treated with a combination of nitazoxanide and doxycycline (20 subjects); and Group 4: subjects treated with a combination of nitazoxanide and azithromycin (20 subjects).
   In the computational part, we docked the three drugs against all currently available COVID-19-related protein targets (viral and non-viral). Subsequently, top hits were subjected to molecular dynamic simulations (MDSs) (50 ns) and binding free energy calculations to further validate the docking experiments and to investigate the binding modes of the potential inhibitors.
   Results The symptomatic improvement of mild to moderate subjects was seen on the fifth day after starting treatment in Group 3 and Group 4 and on the seventh day in Group 2. However, for Group 1, the symptomatic improvement of mild to moderate subjects was not seen on the fifth day and required replacement by doxycycline to get the symptomatic improvement. None of the subjects needed intensive care admission and no deaths were reported.
   In silico, results were in good accordance with the clinical outcomes, where both nitazoxanide and doxycycline achieved the best docking scores against the viral ADP-ribose phosphatase (ADPRP) and the human Adaptor-Associated Kinase 1 (AAK1). MDSs revealed that both drugs were stable in their bindings indicating that they can be considered as lead molecules for targeting ADPRP and AAK1.
   Conclusion The clinical and computational studies applied on three FDA-approved antimicrobials together with their recent clinical findings revealed that both nitazoxanide and doxycycline have great therapeutic potential against COVID-19. The future in vitro mechanistic investigation may confirm our primary computational outcomes, and in turn, these classes of compounds provide a promising starting point for further anti-COVID-19 therapeutics.
C1 [Sayed, Ahmed M.] Nahda Univ, Pharmacognosy Dept, Fac Pharm, Bani Suwayf, Egypt.
   [Khalaf, Ahmed M.] Beni Suef Univ, Internal Med Dept, Fac Med, Bani Suwayf, Egypt.
   [Abdelrahim, Mohamed E. A.] Beni Suef Univ, Clin Pharm Dept, Fac Pharm, Bani Suwayf, Egypt.
   [Elgendy, Marwa O.] Beni Suef Univ, Clin Pharm Dept, Teaching Hosp, Fac Med, Bani Suwayf, Egypt.
   [Elgendy, Marwa O.] Nahda Univ NUB, Clin Pharm Dept, Fac Pharm, Bani Suwayf, Egypt.
RP Elgendy, MO (corresponding author), Beni Suef Univ, Clin Pharm Dept, Teaching Hosp, Fac Med, Bani Suwayf, Egypt.
EM marwaosamaelgendy@yahoo.com
OI abdelrahim, mohamed/0000-0003-0227-8404
CR Alam MT, 2020, J BANGLADESH COLL PH, V38, P10, DOI [10.3329/jbcps.v38i0.47512, DOI 10.3329/JBCPS.V38I0.47512]
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Ashiru O, 2014, VIROLOGY, V462, P135, DOI 10.1016/j.virol.2014.05.015
   Ceribelli A, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102442
   Claverie JM, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060646
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13437
   El-Gendy AO, 2020, VACCINE, V38, P5564, DOI 10.1016/j.vaccine.2020.06.083
   Gil C, 2020, J MED CHEM, V63, P12359, DOI 10.1021/acs.jmedchem.0c00606
   Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0
   Hong SK, 2012, INT IMMUNOPHARMACOL, V13, P23, DOI 10.1016/j.intimp.2012.03.002
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jo S, 2013, CHARMM GUI LIGAND BI
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Kelleni M, 2020, NITAZOXANIDE AZITHRO
   Lammers T, 2020, NAT NANOTECHNOL, V15, P622, DOI 10.1038/s41565-020-0752-z
   Lill MA, 2011, J COMPUT AID MOL DES, V25, P13, DOI 10.1007/s10822-010-9395-8
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Malek AE, 2020, DOXYCYCLINE POTENTIA
   Martins PR, 2020, AM J PHYSIOL-LUNG C, V319, pL35, DOI 10.1152/ajplung.00170.2020
   Michalska K, 2020, IUCRJ, V7, P814, DOI 10.1107/S2052252520009653
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Schogler A, 2015, EUR RESPIR J, V45, P428, DOI 10.1183/09031936.00102014
   Sodhi M, 2020, PHARMACOTHERAPY, V40, P487, DOI 10.1002/phar.2395
   Sultana J, 2020, DRUG SAFETY, V43, P691, DOI 10.1007/s40264-020-00976-7
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wasuna A, 2018, REPOSITIONING FUSIDI
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
AR e13877
DI 10.1111/ijcp.13877
EA DEC 2020
PG 9
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA PF7LJ
UT WOS:000599230900001
PM 33300221
OA Bronze
DA 2021-01-01
ER

PT J
AU Ayhan, E
   Ozturk, M
   An, I
   Bekcibasi, M
AF Ayhan, Erhan
   Ozturk, Murat
   An, Isa
   Bekcibasi, Muhammed
TI COVID-19 infection under omalizumab therapy for chronic spontaneous
   urticaria: three cases
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Letter; Early Access
C1 [Ayhan, Erhan] Univ Hlth Sci, Gazi Yasargil Educ & Res Hosp, Dept Dermatol, Diyarbakir, Turkey.
   [Ozturk, Murat] Van Educ & Res Hosp, Dept Dermatol, Van, Turkey.
   [An, Isa] Sanliurfa Educ & Res Hosp, Dept Dermatol, Sanliurfa, Turkey.
   [Bekcibasi, Muhammed] Bismil State Hosp, Dept Infect Dis & Clin Microbiol, Diyarbakir, Turkey.
RP Ayhan, E (corresponding author), Univ Hlth Sci, Gazi Yasargil Educ & Res Hosp, Dept Dermatol, Diyarbakir, Turkey.
EM nanodunya@hotmail.com
OI Ayhan, Erhan/0000-0003-1416-2636
CR Criado PR, 2020, INT J DERMATOL, DOI 10.1111/ijd.15134
   Gill MA, 2018, J ALLERGY CLIN IMMUN, V141, P1735, DOI 10.1016/j.jaci.2017.07.035
   Gimenez-Arnau AM, 2017, EXPERT OPIN BIOL TH, V17, P375, DOI 10.1080/14712598.2017.1285903
   Lommatzsch M, 2020, ALLERGY, V75, P2705, DOI 10.1111/all.14456
   Pinto JM, 2010, RHINOLOGY, V48, P318, DOI 10.4193/Rhin09.144
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
DI 10.1111/ijd.15379
EA DEC 2020
PG 2
WC Dermatology
SC Dermatology
GA PG0LD
UT WOS:000599435500001
PM 33332576
OA Bronze
DA 2021-01-01
ER

PT J
AU Dai, W
   Wu, J
   Li, TF
   Shen, JW
   Pang, RR
   Luo, T
   Guo, YJ
   Yang, Y
   Zhao, J
   Zhang, MC
   Li, N
   Han, Y
   Wu, QY
   Li, WW
   Xia, XY
AF Dai, Wei
   Wu, Jian
   Li, Tianfu
   Shen, Jiawei
   Pang, Rongrong
   Luo, Tao
   Guo, Yanju
   Yang, Yang
   Zhao, Jun
   Zhang, Mingchao
   Li, Na
   Han, Ying
   Wu, Qiuyue
   Li, Weiwei
   Xia, Xinyi
TI Clinical outcomes for COVID-19 patients with diabetes mellitus treated
   with convalescent plasma transfusion in Wuhan, China
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE convalescent plasma transfusion; COVID&#8208; 19; diabetes mellitus;
   SARS&#8208; CoV&#8208; 2
ID EBOLA-VIRUS DISEASE; BLOOD; THERAPY
AB The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is wreaking havoc on public health systems worldwide. The diagnosis of COVID-19 is well defined, but efficacious treatment is lacking. There is a big gap in knowledge regarding COVID-19 patients receiving convalescent plasma transfusion (CPT), especially those also suffering from diabetes mellitus (DM). In this study, among 3059 COVID-19 patients admitted to Wuhan Huoshenshan Hospital of China, we documented the characteristics of 39 COVID-19 patients with DM receiving CPT and compared their baseline information and clinical outcomes to COVID-19 patients with DM receiving conventional treatment. We also performed the propensity-matched comparison of COVID-19 patients with DM between conventional treatment and CPT. The CPT was efficacious and beneficial for COVID-19 patients with DM, including severe or critically ill patients, without obvious adverse effects. Our data demonstrated that CPT significantly improved the clinical outcomes of COVID-19 patients with DM, especially the cure rate and duration of hospitalization compared with that in COVID-19 patients with DM receiving conventional treatment. This study not only provided a deeper understanding of characteristics in COVID-19 patients with DM receiving CPT but also highlighted the efficaciousness of CPT for COVID-19 patients with DM.
C1 [Dai, Wei; Wu, Jian; Li, Tianfu; Shen, Jiawei; Pang, Rongrong; Luo, Tao; Guo, Yanju; Yang, Yang; Zhao, Jun; Zhang, Mingchao; Li, Na; Han, Ying; Wu, Qiuyue; Li, Weiwei; Xia, Xinyi] Southern Med Univ, COVID 19 Res Ctr, Inst Lab Med, Jinling Hosp,Sch Med,Sch Clin Med 1,Nanjing Univ, Nanjing 210002, Jiangsu, Peoples R China.
   [Dai, Wei] Jinling Inst Technol, Dept Anim Sci & Technol, Nanjing, Jiangsu, Peoples R China.
   [Li, Tianfu] Changzhou Maternal & Child Hlth Care Hosp, Changzhou, Jiangsu, Peoples R China.
   [Pang, Rongrong] Nanjing Red Cross Blood Ctr, Dept Lab Med, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Mingchao] Nanjing Univ, Jinling Hosp, Inst Nephrol, Sch Med, Nanjing, Jiangsu, Peoples R China.
   [Li, Na] Nanjing Univ, Jinling Hosp, Dept Blood Transfus, Sch Med, Nanjing, Jiangsu, Peoples R China.
   [Xia, Xinyi] Wuhan Huoshenshan Hosp, Dept Lab Med & Blood Transfus, Joint Expert Grp COVID 19, Wuhan, Hubei, Peoples R China.
RP Xia, XY (corresponding author), Southern Med Univ, COVID 19 Res Ctr, Inst Lab Med, Jinling Hosp,Sch Med,Sch Clin Med 1,Nanjing Univ, Nanjing 210002, Jiangsu, Peoples R China.
EM xinyixia@nju.edu.cn
FU Key Foundation of Wuhan Huoshenshan Hospital [2020[18]]; Key Research &
   Development Program of Jiangsu Province [BE2018713]; Medical Innovation
   Project of Logistics Service [18JS005]; Foundation of Jiangsu Population
   Association [JSPA2019017]; Jiangsu Provincial Association for Maternal
   and Child Health Studies Commissioned Research Project Funding
   [JSFY202005]
FX We thank all COVID-19 patients included in this study. We are grateful
   to the clinical staff who treated COVID-19 patients. This study was
   supported by the Key Foundation of Wuhan Huoshenshan Hospital
   (2020[18]), the Key Research & Development Program of Jiangsu Province
   (BE2018713), the Medical Innovation Project of Logistics Service
   (18JS005), the Foundation of Jiangsu Population Association
   (JSPA2019017), and the Jiangsu Provincial Association for Maternal and
   Child Health Studies Commissioned Research Project Funding (JSFY202005).
CR Al-Riyami AZ, 2020, VOX SANG, DOI 10.1111/vox.12973
   [Anonymous], 2020, CHINESE MED J-PEKING, V133, P1087, DOI 10.1097/CM9.0000000000000819
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Colebunders RL, 2015, J INFECT DIS, V211, P1208, DOI 10.1093/infdis/jiv043
   Delang L, 2020, EUR HEART J-ACUTE CA, V9, P209, DOI 10.1177/2048872620922790
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Kohli P, 2020, CIRCULATION, V142, P98, DOI 10.1161/CIRCULATIONAHA.120.047901
   Li C, 2020, EUR REV MED PHARMACO, V24, P4576, DOI 10.26355/eurrev_202004_21044
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lim WS, 2020, GERIATR GERONTOL INT, V20, P547, DOI 10.1111/ggi.13939
   Lu JDJ, 2020, ADV RADIAT ONCOL, V5, P548, DOI 10.1016/j.adro.2020.04.003
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Mora-Rillo M, 2015, LANCET RESP MED, V3, P554, DOI 10.1016/S2213-2600(15)00180-0
   Rajendran K, 2020, J MED VIROL, V92, P1475, DOI 10.1002/jmv.25961
   Rayman G, 2020, DIABETIC MED, V37, P1087, DOI 10.1111/dme.14316
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Syal K, 2020, J MED VIROL, V92, P1380, DOI 10.1002/jmv.25870
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Wang XY, 2020, EUR REV MED PHARMACO, V24, P4537, DOI 10.26355/eurrev_202004_21037
   Wu HJ, 2020, DIABETOLOGIA, V63, P757, DOI 10.1007/s00125-019-05074-7
   Xia XY, 2020, BLOOD, V136, P755, DOI 10.1182/blood.2020007079
   Xie JF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.5619
   Xu XN, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00251-x
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 33
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26712
EA DEC 2020
PG 11
WC Virology
SC Virology
GA PG0TP
UT WOS:000599457500001
PM 33289151
OA Bronze
DA 2021-01-01
ER

PT J
AU Barrett, JR
   Belij-Rammerstorfer, S
   Dold, C
   Ewer, KJ
   Folegatti, PM
   Gilbride, C
   Halkerston, R
   Hill, J
   Jenkin, D
   Stockdale, L
   Verheul, MK
   Aley, PK
   Angus, B
   Bellamy, D
   Berrie, E
   Bibi, S
   Bittaye, M
   Carroll, MW
   Cavell, B
   Clutterbuck, EA
   Edwards, N
   Flaxman, A
   Fuskova, M
   Gorringe, A
   Hallis, B
   Kerridge, S
   Lawrie, AM
   Linder, A
   Liu, XX
   Madhavan, M
   Makinson, R
   Mellors, J
   Minassian, A
   Moore, M
   Mujadidi, Y
   Plested, E
   Poulton, I
   Ramasamy, MN
   Robinson, H
   Rollier, CS
   Song, R
   Snape, MD
   Tarrant, R
   Taylor, S
   Thomas, KM
   Voysey, M
   Watson, MEE
   Wright, D
   Douglas, AD
   Green, CM
   Hill, AVS
   Lambe, T
   Gilbert, S
   Pollard, AJ
AF Barrett, Jordan R.
   Belij-Rammerstorfer, Sandra
   Dold, Christina
   Ewer, Katie J.
   Folegatti, Pedro M.
   Gilbride, Ciaran
   Halkerston, Rachel
   Hill, Jennifer
   Jenkin, Daniel
   Stockdale, Lisa
   Verheul, Marije K.
   Aley, Parvinder K.
   Angus, Brian
   Bellamy, Duncan
   Berrie, Eleanor
   Bibi, Sagida
   Bittaye, Mustapha
   Carroll, Miles W.
   Cavell, Breeze
   Clutterbuck, Elizabeth A.
   Edwards, Nick
   Flaxman, Amy
   Fuskova, Michelle
   Gorringe, Andrew
   Hallis, Bassam
   Kerridge, Simon
   Lawrie, Alison M.
   Linder, Aline
   Liu, Xinxue
   Madhavan, Meera
   Makinson, Rebecca
   Mellors, Jack
   Minassian, Angela
   Moore, Maria
   Mujadidi, Yama
   Plested, Emma
   Poulton, Ian
   Ramasamy, Maheshi N.
   Robinson, Hannah
   Rollier, Christine S.
   Song, Rinn
   Snape, Matthew D.
   Tarrant, Richard
   Taylor, Stephen
   Thomas, Kelly M.
   Voysey, Merryn
   Watson, Marion E. E.
   Wright, Daniel
   Douglas, Alexander D.
   Green, Catherine M.
   Hill, Adrian V. S.
   Lambe, Teresa
   Gilbert, Sarah
   Pollard, Andrew J.
CA Oxford COVID Vaccine Trial Grp
TI Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster
   dose induces multifunctional antibody responses
SO NATURE MEDICINE
LA English
DT Article; Early Access
ID DOUBLE-BLIND; HIGH-THROUGHPUT; HIV-1 VACCINE; PROTECTION; IMMUNITY;
   ASSAY; DISEASE; ADULTS
AB More than 190 vaccines are currently in development to prevent infection by the novel severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing antibodies against the viral spike protein may correlate with protection, additional antibody functions may also be important in preventing infection. Previously, we reported early immunogenicity and safety outcomes of a viral vector coronavirus vaccine, ChAdOx1 nCoV-19 (AZD1222), in a single-blinded phase 1/2 randomized controlled trial of healthy adults aged 18-55 years (NCT04324606). Now we describe safety and exploratory humoral and cellular immunogenicity of the vaccine, from subgroups of volunteers in that trial, who were subsequently allocated to receive a homologous full-dose (SD/SD D56; n = 20) or half-dose (SD/LD D56; n = 32) ChAdOx1 booster vaccine 56 d following prime vaccination. Previously reported immunogenicity data from the open-label 28-d interval prime-boost group (SD/SD D28; n = 10) are also presented to facilitate comparison. Additionally, we describe volunteers boosted with the comparator vaccine (MenACWY; n = 10). In this interim report, we demonstrate that a booster dose of ChAdOx1 nCoV-19 is safe and better tolerated than priming doses. Using a systems serology approach we also demonstrate that anti-spike neutralizing antibody titers, as well as Fc-mediated functional antibody responses, including antibody-dependent neutrophil/monocyte phagocytosis, complement activation and natural killer cell activation, are substantially enhanced by a booster dose of vaccine. A booster dose of vaccine induced stronger antibody responses than a dose-sparing half-dose boost, although the magnitude of T cell responses did not increase with either boost dose. These data support the two-dose vaccine regime that is now being evaluated in phase 3 clinical trials.
C1 [Barrett, Jordan R.; Belij-Rammerstorfer, Sandra; Ewer, Katie J.; Folegatti, Pedro M.; Gilbride, Ciaran; Jenkin, Daniel; Bellamy, Duncan; Bittaye, Mustapha; Edwards, Nick; Flaxman, Amy; Fuskova, Michelle; Kerridge, Simon; Lawrie, Alison M.; Madhavan, Meera; Makinson, Rebecca; Minassian, Angela; Poulton, Ian; Watson, Marion E. E.; Wright, Daniel; Douglas, Alexander D.; Hill, Adrian V. S.; Lambe, Teresa; Gilbert, Sarah] Univ Oxford, Jenner Inst, Nuffield Dept Med, Oxford, England.
   [Dold, Christina; Hill, Jennifer; Stockdale, Lisa; Verheul, Marije K.; Aley, Parvinder K.; Bibi, Sagida; Clutterbuck, Elizabeth A.; Linder, Aline; Liu, Xinxue; Moore, Maria; Mujadidi, Yama; Plested, Emma; Ramasamy, Maheshi N.; Robinson, Hannah; Rollier, Christine S.; Song, Rinn; Snape, Matthew D.; Voysey, Merryn; Pollard, Andrew J.] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England.
   [Halkerston, Rachel; Cavell, Breeze; Gorringe, Andrew; Hallis, Bassam; Mellors, Jack; Taylor, Stephen; Thomas, Kelly M.] Publ Hlth England, Salisbury, Wilts, England.
   [Angus, Brian] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Berrie, Eleanor; Carroll, Miles W.; Tarrant, Richard; Green, Catherine M.] Univ Oxford, Jenner Inst, Nuffield Dept Med, Clin BioMfg Facil, Oxford, England.
RP Jenkin, D (corresponding author), Univ Oxford, Jenner Inst, Nuffield Dept Med, Oxford, England.; Pollard, AJ (corresponding author), Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England.
EM Daniel.Jenkin@ndm.ox.ac.uk; Andrew.Pollard@paediatrics.ox.ac.uk
OI Folegatti, Pedro/0000-0001-5330-0240; Morter,
   Richard/0000-0002-7005-1546; Phillips, Dan/0000-0003-0686-5091; Baker,
   Philip/0000-0002-4519-1563
FU National Institute for Health Research (NIHR)National Institute for
   Health Research (NIHR); Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior, BrazilCAPES [001]
FX The funder had no role in the design, execution or analysis of this
   study. This report is independent research funded by the National
   Institute for Health Research (NIHR). The views expressed in this
   publication are those of the authors and not necessarily those of the
   NIHR or the UK Department of Health and Social Care (DHSC). Additional
   resources for study delivery were provided by NIHR Southampton Clinical
   Research Facility and NIHR Southampton Biomedical Research Centre;
   University Hospital Southampton NHS Foundation Trust; the NIHR Imperial
   Clinical Research Facility; and NIHR North West London, South London,
   Wessex and West of England Local Clinical Research Networks; and NIHR
   Oxford Health Biomedical Research Centre. P.M.F. received funding from
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil
   (finance code 001). The control vaccine was provided free of charge by
   the UK DHSC. The authors are grateful to the volunteers who participated
   in this study. The investigators express their gratitude for the
   contribution of all the trial participants, the invaluable advice of the
   international DSMB (Supplementary Information) and the independent
   members of the trial steering committee. We are grateful for the advice
   and intellectual support from K.S. Campbell (Institute for Cancer
   Research, Philadelphia) with the NK cell line culture and use. The
   authors are grateful to the senior management at AstraZeneca for
   facilitating and funding the manufacture of the AZD1222 vaccine
   candidate, the pseudovirus neutralization assays and Meso Scale antibody
   assay used in this study. AstraZeneca reviewed the data from the study
   and the final manuscript before submission, but the authors retained
   editorial control. Finally, we acknowledge UKRI, NIHR, CEPI, NIHR Oxford
   Biomedical Research Centre, Thames Valley and South Midland's NIHR
   Clinical Research Network and AstraZeneca.
CR Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Anywaine Z, 2019, J INFECT DIS, V220, P46, DOI 10.1093/infdis/jiz070
   Atyeo C, 2020, IMMUNITY, V53, P524, DOI 10.1016/j.immuni.2020.07.020
   Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/s0140-6736(18)31364-3, 10.1016/S0140-6736(18)31364-3]
   Binyamin L, 2008, J IMMUNOL, V180, P6392, DOI 10.4049/jimmunol.180.9.6392
   Biswas S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107903
   Brown EP, 2012, J IMMUNOL METHODS, V386, P117, DOI 10.1016/j.jim.2012.09.007
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385
   DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443
   Ewer KJ, 2020, NAT MED, DOI 10.1038/s41591-020-01194-5
   Excler JL, 2014, CLIN VACCINE IMMUNOL, V21, P1023, DOI 10.1128/CVI.00230-14
   Fenrich M, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00229
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hodgson SH, 2014, MOL THER, V22, P2142, DOI 10.1038/mt.2014.157
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Karsten CB, 2019, J IMMUNOL METHODS, V471, P46, DOI 10.1016/j.jim.2019.05.006
   Keech C, 2020, NEW ENGL J MED, P1, DOI [10.1056/nejmoa2026920, DOI 10.1056/NEJM0A2026920]
   Koch T, 2020, LANCET INFECT DIS, V20, P827, DOI 10.1016/S1473-3099(20)30248-6
   Ledgerwood JE, 2017, NEW ENGL J MED, V376, P928, DOI [10.1056/NEJMoa1410863, 10.1056/nejmoa1410863]
   Lesne E, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02108
   Levin A. T., 2020, ASSESSING AGE SPECIF, DOI [10.1101/2020.07.23.20160895, DOI 10.1101/2020.07.23.20160895]
   Li JX, 2017, LANCET GLOB HEALTH, V5, pE324, DOI [10.1016/S2214-109X(16)30367-9, 10.1016/s2214-109x(16)30367-9]
   Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3
   MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103
   Mercado NB, 2020, NATURE, DOI 10.1038/s41586-020-2607-z
   Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038
   Payne RO, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96381
   Payne RO, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93683
   Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000
   Reisinger EC, 2018, LANCET, V392, P2718, DOI 10.1016/S0140-6736(18)32488-7
   Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Sadoff J, 2020, SAFETY IMMUNOGENICIT, DOI [10.1101/2020.09.23.20199604, DOI 10.1101/2020.09.23.20199604]
   Sahin U, 2020, NATURE, DOI 10.1038/s41586-020-2814-7
   Sekine T, 2020, CELL, V183, P158, DOI [10.10160.cell.2020.08.017, 10.1016/j.cell.2020.08.017]
   Seo SH, 2000, VIROLOGY, V269, P183, DOI 10.1006/viro.2000.0211
   Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350
   Walsh E. E, 2020, NEW ENGL J MED, P1, DOI [10.1056/nejmoa2027906, DOI 10.1056/NEJM0A2027906]
   Whitcomb JM, 2007, ANTIMICROB AGENTS CH, V51, P566, DOI 10.1128/AAC.00853-06
   WHO, 2020, COVID 19 DRAFT LANDS
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Williams K, 2020, J INFECT DIS, V222, P979, DOI 10.1093/infdis/jiaa193
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wyllie D., 2020, SARS COV 2 RESPONSIV, DOI [10.1101/2020.11.02.20222778, DOI 10.1101/2020.11.02.20222778]
   Xia Shengli, 2021, Lancet Infect Dis, V21, P39, DOI 10.1016/S1473-3099(20)30831-8
   Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
NR 55
TC 1
Z9 1
U1 2
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
DI 10.1038/s41591-020-01179-4
EA DEC 2020
PG 28
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA PG5TH
UT WOS:000599796800002
PM 33335322
OA Bronze
DA 2021-01-01
ER

PT J
AU Ewer, KJ
   Barrett, JR
   Belij-Rammerstorfer, S
   Sharpe, H
   Makinson, R
   Morter, R
   Flaxman, A
   Wright, D
   Bellamy, D
   Bittaye, M
   Dold, C
   Provine, NM
   Aboagye, J
   Fowler, J
   Silk, SE
   Alderson, J
   Aley, PK
   Angus, B
   Berrie, E
   Bibi, S
   Cicconi, P
   Clutterbuck, EA
   Chelysheva, I
   Folegatti, PM
   Fuskova, M
   Green, CM
   Jenkin, D
   Kerridge, S
   Lawrie, A
   Minassian, AM
   Moore, M
   Mujadidi, Y
   Plested, E
   Poulton, I
   Ramasamy, MN
   Robinson, H
   Song, R
   Snape, MD
   Tarrant, R
   Voysey, M
   Watson, MEE
   Douglas, AD
   Hill, AVS
   Gilbert, SC
   Pollard, AJ
   Lambe, T
AF Ewer, Katie J.
   Barrett, Jordan R.
   Belij-Rammerstorfer, Sandra
   Sharpe, Hannah
   Makinson, Rebecca
   Morter, Richard
   Flaxman, Amy
   Wright, Daniel
   Bellamy, Duncan
   Bittaye, Mustapha
   Dold, Christina
   Provine, Nicholas M.
   Aboagye, Jeremy
   Fowler, Jamie
   Silk, Sarah E.
   Alderson, Jennifer
   Aley, Parvinder K.
   Angus, Brian
   Berrie, Eleanor
   Bibi, Sagida
   Cicconi, Paola
   Clutterbuck, Elizabeth A.
   Chelysheva, Irina
   Folegatti, Pedro M.
   Fuskova, Michelle
   Green, Catherine M.
   Jenkin, Daniel
   Kerridge, Simon
   Lawrie, Alison
   Minassian, Angela M.
   Moore, Maria
   Mujadidi, Yama
   Plested, Emma
   Poulton, Ian
   Ramasamy, Maheshi N.
   Robinson, Hannah
   Song, Rinn
   Snape, Matthew D.
   Tarrant, Richard
   Voysey, Merryn
   Watson, Marion E. E.
   Douglas, Alexander D.
   Hill, Adrian V. S.
   Gilbert, Sarah C.
   Pollard, Andrew J.
   Lambe, Teresa
CA Oxford COVID Vaccine Trial Grp
TI T cell and antibody responses induced by a single dose of ChAdOx1
   nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
SO NATURE MEDICINE
LA English
DT Article; Early Access
ID ENHANCEMENT; HIV-1
AB A single dose of the ChAdOx1 nCoV-19 vaccine elicits antibodies and cytokine-producing T cells that might help control or prevent SARS-CoV-2 infection.
   Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed(1). Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses(2) and might reduce the potential for disease enhancement(3). Cytotoxic T cells clear virus-infected host cells and contribute to control of infection(4). Studies of patients infected with SARS-CoV-2 have suggested a protective role for both humoral and cell-mediated immune responses in recovery from COVID-19 (refs. (5,6)). ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838)(7) given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. Here we describe, in detail, exploratory analyses of the immune responses in adults, aged 18-55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 in this trial, demonstrating an induction of a Th1-biased response characterized by interferon-gamma and tumor necrosis factor-alpha cytokine secretion by CD4(+) T cells and antibody production predominantly of IgG1 and IgG3 subclasses. CD8(+) T cells, of monofunctional, polyfunctional and cytotoxic phenotypes, were also induced. Taken together, these results suggest a favorable immune profile induced by ChAdOx1 nCoV-19 vaccine, supporting the progression of this vaccine candidate to ongoing phase 2/3 trials to assess vaccine efficacy.
C1 [Ewer, Katie J.; Barrett, Jordan R.; Belij-Rammerstorfer, Sandra; Sharpe, Hannah; Makinson, Rebecca; Morter, Richard; Flaxman, Amy; Wright, Daniel; Bellamy, Duncan; Bittaye, Mustapha; Aboagye, Jeremy; Fowler, Jamie; Silk, Sarah E.; Folegatti, Pedro M.; Fuskova, Michelle; Jenkin, Daniel; Lawrie, Alison; Minassian, Angela M.; Poulton, Ian; Watson, Marion E. E.; Douglas, Alexander D.; Hill, Adrian V. S.; Gilbert, Sarah C.; Lambe, Teresa] Univ Oxford, Jenner Inst, Oxford, England.
   [Dold, Christina; Aley, Parvinder K.; Bibi, Sagida; Cicconi, Paola; Clutterbuck, Elizabeth A.; Chelysheva, Irina; Kerridge, Simon; Moore, Maria; Mujadidi, Yama; Plested, Emma; Ramasamy, Maheshi N.; Robinson, Hannah; Song, Rinn; Snape, Matthew D.; Voysey, Merryn; Pollard, Andrew J.] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England.
   [Provine, Nicholas M.; Angus, Brian] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Alderson, Jennifer] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England.
   [Berrie, Eleanor; Green, Catherine M.; Tarrant, Richard] Univ Oxford, Nuffield Dept Med, Clin Biomfg Facil, Oxford, England.
RP Ewer, KJ; Lambe, T (corresponding author), Univ Oxford, Jenner Inst, Oxford, England.
EM katie.ewer@ndm.ox.ac.uk; Teresa.lambe@ndm.ox.ac.uk
OI Morter, Richard/0000-0002-7005-1546; Folegatti,
   Pedro/0000-0001-5330-0240; Baker, Philip/0000-0002-4519-1563
FU UK Research and Innovation [MC_PC_19055]; Engineering and Physical
   Sciences Research CouncilEngineering & Physical Sciences Research
   Council (EPSRC) [EP/R013756/1]; Coalition for Epidemic Preparedness
   Innovations (CEPI); National Institute for Health Research
   (NIHR)National Institute for Health Research (NIHR); NIHR Oxford
   Biomedical Research CentreNational Institute for Health Research (NIHR);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, BrazilCAPES
   [001]; U.S. National Institute of Allergy and Infectious Diseases
   Centers of Excellence for Influenza Research and Surveillance
   [HHSN272201400008C]; Huo Family Foundation; Medical Sciences Division;
   Versus ArthritisVersus Arthritis [21509]; Wellcome MSD ISSF [BRD00010];
   Kennedy Trust for Rheumatology Research; Chinese Academy of Medical
   Sciences Innovation Fund for Medical Science, China [2018-I2M-2-002];
   Nuffield Department of Medicine; Department of Paediatrics; Oxford
   Immunology Network COVID Consortium, Clinical Trials Research
   Governance; Public Affairs Directorate; Clinical Biomanufacturing
   Facility; Oxford University Hospitals NHS Foundation Trust; Oxford
   Health NHS Foundation Trust; AstraZenecaAstraZeneca
FX This work was funded by UK Research and Innovation (MC_PC_19055); the
   Engineering and Physical Sciences Research Council (EP/R013756/1); the
   Coalition for Epidemic Preparedness Innovations (CEPI); and the National
   Institute for Health Research (NIHR) and the NIHR Oxford Biomedical
   Research Centre. Additional resources for study delivery were provided
   by the NIHR Southampton Clinical Research Facility and the NIHR
   Southampton Biomedical Research Centre; University Hospital Southampton
   NHS Foundation Trust; the NIHR Imperial Clinical Research Facility; and
   the NIHR North West London, South London, Wessex and West of England
   Local Clinical Research Networks and the NIHR Oxford Health Biomedical
   Research Centre. P.M.F. received funding from the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior, Brazil (finance code 001).
   Development of SARS-CoV-2 reagents was partially supported by the U.S.
   National Institute of Allergy and Infectious Diseases Centers of
   Excellence for Influenza Research and Surveillance contract
   HHSN272201400008C. The research reagent for SARS-CoV-2 RNA (NIBSC
   20/130) was obtained from the National Institute for Biological
   Standards and Control, UK. The control vaccine was provided free of
   charge by the UK Department of Health and Social Care. We received
   invaluable additional financial support through generous philanthropic
   donations to the University of Oxford, including from the Huo Family
   Foundation. The University of Oxford has entered into a partnership with
   AstraZeneca for further development of ChAdOx1 nCov-19 (AZD1222). The
   authors are grateful to the senior management at AstraZeneca for
   facilitating and funding the manufacture of the AZD1222 vaccine
   candidate, the pseudovirus neutralization assays and the Meso Scale
   antibody assay used in this study. AstraZeneca reviewed the data from
   the study and the final manuscript before submission, but the authors
   retained editorial control. The investigators express their gratitude
   for the contribution of all the trial participants, the invaluable
   advice of the international Data Safety Monitoring Board (R. Heyderman,
   M. Sadarangani, S. Black, G. Bouliotis, G. Hussey, B. Ogutu, W.
   Orenstein, S. Ramos, C. Dekker and E. Bukusi) and the independent
   members of the Trial Steering Committee. We additionally acknowledge the
   broader support from the various teams within the University of Oxford,
   including the Medical Sciences Division, the Nuffield Department of
   Medicine (R. Cornall and O. Velicka) and the Department of Paediatrics
   (G. A. Hollander, J. Bagniewska, E. Derow and S. Vanderslott), the
   Oxford Immunology Network COVID Consortium, Clinical Trials Research
   Governance (H. House, C. Riddle, R. Bahadori and A. Brindle), Research
   Services (C. Banner and S. Pelling-Deeves), the Public Affairs
   Directorate (J. Colman, A. Buxton, C. McIntyre and S. Pritchard) and the
   Clinical Biomanufacturing Facility, as well as the Oxford University
   Hospitals NHS Foundation Trust (B. Holthof) and the Oxford Health NHS
   Foundation Trust and the trial sites. We are grateful for the input of
   the protein production team at the Jenner Institute. The MSD Quickplex
   was purchased using joint support from Versus Arthritis (grant reference
   21509), Wellcome MSD ISSF (BRD00010) and the Kennedy Trust for
   Rheumatology Research.; The views expressed in this publication are
   those of the authors and not necessarily those of the NIHR or the UK
   Department of Health and Social Care, UK Research and Innovation,
   Coalition for Epidemic Preparedness Innovations, the National Institute
   for Health Research, the NIHR Oxford Biomedical Research Centre, Thames
   Valley and South Midland's NIHR Clinical Research Network or
   AstraZeneca. A.F.'s post was supported by the Chinese Academy of Medical
   Sciences Innovation Fund for Medical Science, China (grant number
   2018-I2M-2-002).
CR Addetia A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02107-20
   Alharbi NK, 2017, VACCINE, V35, P3780, DOI 10.1016/j.vaccine.2017.05.032
   [Anonymous], 2020, LANCET, V395, P1168, DOI 10.1016/S0140-6736(20)30823-0
   [Anonymous], 2015, BLUEPR R PREP RESP P
   Atyeo C, 2020, IMMUNITY, V53, P524, DOI 10.1016/j.immuni.2020.07.020
   Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/s0140-6736(18)31364-3, 10.1016/S0140-6736(18)31364-3]
   Barrett JR, 2020, NAT MED, DOI 10.1038/s41591-020-01179-4
   Bhopal SS, 2020, LANCET, V396, P532, DOI 10.1016/S0140-6736(20)31748-7
   Bowyer G, 2020, J EXP MED, V217, DOI 10.1084/jem.20200004
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Coughlan L, 2018, EBIOMEDICINE, V29, P146, DOI 10.1016/j.ebiom.2018.02.011
   Darboe A, 2017, EUR J IMMUNOL, V47, P1040, DOI 10.1002/eji.201746974
   de Alwis R, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102768
   Del Valle DM, 2020, NAT MED, V26, P1636, DOI 10.1038/s41591-020-1051-9
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Gilbert SC, 2017, VACCINE, V35, P4461, DOI 10.1016/j.vaccine.2017.04.085
   Gouglas D, 2019, EPIDEMIOL REV, V41, P28, DOI 10.1093/epirev/mxz012
   Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116
   Hammer Q, 2018, NAT IMMUNOL, V19, P453, DOI 10.1038/s41590-018-0082-6
   Hodgson SH, 2014, MOL THER, V22, P2142, DOI 10.1038/mt.2014.157
   Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6
   Jorquera PA, 2016, EXPERT REV VACCINES, V15, P173, DOI 10.1586/14760584.2016.1115353
   Lambert PH, 2020, VACCINE, V38, P4783, DOI 10.1016/j.vaccine.2020.05.064
   Marston HD, 2017, JAMA-J AM MED ASSOC, V318, P1757, DOI 10.1001/jama.2017.15033
   MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Ndiaye BP, 2015, LANCET RESP MED, V3, P190, DOI 10.1016/S2213-2600(15)00037-5
   Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI 10.1038/s41590-020-0782-6
   Sadoff J, 2020, SAFETY IMMUNOGENICIT, DOI DOI 10.1101/2020.09.23.20199604V1
   Sahin U, 2020, CONCURRENT HUMAN ANT, DOI [10.1101/2020.07.17.20140533v1, DOI 10.1101/2020.07.17.20140533V1]
   Sekine T, 2020, CELL, V183, P158, DOI [10.10160.cell.2020.08.017, 10.1016/j.cell.2020.08.017]
   Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wajnberg A, 2020, PREPRINT, DOI [10.1101/2020.07.14.20151126v1, DOI 10.1101/2020.07.14.20151126V1]
   Wolff D, 2020, INFECTION, DOI 10.1007/s15010-020-01509-1
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wyllie D, 2020, SARS COV 2 RESPONSIV, DOI [10.1101/2020.11.02.20222778v1, DOI 10.1101/2020.11.02.20222778V1]
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 41
TC 1
Z9 1
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
DI 10.1038/s41591-020-01194-5
EA DEC 2020
PG 24
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA PG5TH
UT WOS:000599796800001
PM 33335323
OA Bronze
DA 2021-01-01
ER

PT J
AU Bhatia, V
   Elnagary, L
   Dakshinamurti, S
AF Bhatia, Vikram
   Elnagary, Lara
   Dakshinamurti, Shyamala
TI Tracing the path of inhaled nitric oxide: Biological consequences of
   protein nitrosylation
SO PEDIATRIC PULMONOLOGY
LA English
DT Article; Early Access
DE guanylate cyclase; hyperoxia; hypoxia; nitric oxide; nitrosohemoglobin;
   nitrosothiol; S&#8208; nitrosylation
ID SOLUBLE GUANYLYL CYCLASE; PERSISTENT PULMONARY-HYPERTENSION;
   AMINO-ACID-COMPOSITION; S-NITROSYLATION; SMOOTH-MUSCLE; ENDOTHELIAL
   DYSFUNCTION; SUPEROXIDE-DISMUTASE; MOLECULAR-MECHANISMS; NITROSATIVE
   STRESS; BINDING-AFFINITY
AB Nitric oxide (NO) is a comprehensive regulator of vascular and airway tone. Endogenous NO produced by nitric oxide synthases regulates multiple signaling cascades, including activation of soluble guanylate cyclase to generate cGMP, relaxing smooth muscle cells. Inhaled NO is an established therapy for pulmonary hypertension in neonates, and has been recently proposed for the treatment of hypoxic respiratory failure and acute respiratory distress syndrome due to COVID-19. In this review, we summarize the effects of endogenous and exogenous NO on protein S-nitrosylation, which is the selective and reversible covalent attachment of a nitrogen monoxide group to the thiol side chain of cysteine. This posttranslational modification targets specific cysteines based on the acid/base sequence of surrounding residues, with significant impacts on protein interactions and function. S-nitrosothiol (SNO) formation is tightly compartmentalized and enzymatically controlled, but also propagated by nonenzymatic transnitrosylation of downstream protein targets. Redox-based nitrosylation and denitrosylation pathways dynamically regulate the equilibrium of SNO-proteins. We review the physiological roles of SNO proteins, including nitrosohemoglobin and autoregulation of blood flow through hypoxic vasodilation, and pathological effects of nitrosylation including inhibition of critical vasodilator enzymes; and discuss the intersection of NO source and dose with redox environment, in determining the effects of protein nitrosylation.
C1 [Bhatia, Vikram; Elnagary, Lara; Dakshinamurti, Shyamala] Univ Manitoba, Childrens Hosp, Res Inst Manitoba, Biol Breathing Grp, Winnipeg, MB, Canada.
   [Dakshinamurti, Shyamala] Univ Manitoba, Dept Pediat, Sect Neonatol, Winnipeg, MB, Canada.
   [Dakshinamurti, Shyamala] Univ Manitoba, Dept Physiol, Sect Neonatol, Winnipeg, MB, Canada.
RP Dakshinamurti, S (corresponding author), Univ Manitoba, Womens Hosp, Sect Neonatol, Pediat & Physiol, WN 2618,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.
EM shyamala.dakshinamurti@umanitoba.ca
FU Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of
   Canada; Children's Hospital Research Institute of Manitoba
FX Heart and Stroke Foundation of Canada; Children's Hospital Research
   Institute of Manitoba
CR Adam L, 1999, J BIOL CHEM, V274, P26337, DOI 10.1074/jbc.274.37.26337
   Akerstrom S, 2005, J VIROL, V79, P1966, DOI 10.1128/JVI.79.3.1966-1969.2005
   Anand P, 2012, J MOL MED, V90, P233, DOI 10.1007/s00109-012-0878-z
   Angelo M, 2006, P NATL ACAD SCI USA, V103, P8366, DOI 10.1073/pnas.0600942103
   ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231
   ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203
   ARONSTAM RS, 1995, ANN NY ACAD SCI, V757, P215, DOI 10.1111/j.1749-6632.1995.tb17477.x
   Baliga RS, 2012, CIRCULATION, V125, P2922, DOI 10.1161/CIRCULATIONAHA.112.100586
   BARNES PJ, 1993, THORAX, V48, P1034, DOI 10.1136/thx.48.10.1034
   Bateman RL, 2008, J BIOL CHEM, V283, P35756, DOI 10.1074/jbc.M807125200
   Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928
   Benedet PO, 2018, BBA-MOL BASIS DIS, V1864, P307, DOI 10.1016/j.bbadis.2017.10.029
   Benhar M, 2008, SCIENCE, V320, P1050, DOI 10.1126/science.1158265
   Benhar M, 2015, BBA-GEN SUBJECTS, V1850, P2476, DOI 10.1016/j.bbagen.2015.09.010
   Benhar M, 2009, NAT REV MOL CELL BIO, V10, P721, DOI 10.1038/nrm2764
   Beuve A, 2017, ANTIOXID REDOX SIGN, V26, P137, DOI 10.1089/ars.2015.6591
   Bhandari V, 2002, LUNG, V180, P301, DOI 10.1007/s00408-002-0102-y
   Brahmajothi MV, 2014, ANTIOXID REDOX SIGN, V21, P1823, DOI 10.1089/ars.2013.5664
   Broniowska KA, 2013, BBA-GEN SUBJECTS, V1830, P3173, DOI 10.1016/j.bbagen.2013.02.004
   Bryan NS, 2005, NAT CHEM BIOL, V1, P290, DOI 10.1038/nchembio734
   Chaki M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110232
   Chavez MD, 2007, P ANN INT IEEE EMBS, P1022, DOI 10.1109/IEMBS.2007.4352468
   Chen SC, 2008, BIOCHEM BIOPH RES CO, V377, P1274, DOI 10.1016/j.bbrc.2008.10.144
   Choi H, 2011, J HYPERTENS, V29, P2359, DOI 10.1097/HJH.0b013e32834d2554
   Choi H, 2011, J CARDIOVASC PHARM, V58, P522, DOI 10.1097/FJC.0b013e31822d80a5
   Collet JF, 2010, ANTIOXID REDOX SIGN, V13, P1205, DOI 10.1089/ars.2010.3114
   Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954
   Couroucli XI, 2006, PEDIATR RES, V59, P401, DOI 10.1203/01.pdr.0000199909.96576.7f
   Crassous PA, 2012, AM J PHYSIOL-HEART C, V303, pH597, DOI 10.1152/ajpheart.00138.2012
   CZAPSKI G, 1995, FREE RADICAL BIO MED, V19, P785, DOI 10.1016/0891-5849(95)00081-8
   Dalsgaard T, 2007, AM J PHYSIOL-HEART C, V292, pH3072, DOI 10.1152/ajpheart.01298.2006
   Das DK, 2003, ARCH BIOCHEM BIOPHYS, V420, P305, DOI 10.1016/j.abb.2003.09.023
   Davisson RL, 1996, CIRC RES, V79, P256, DOI 10.1161/01.RES.79.2.256
   Delyani JA, 1996, J PHARMACOL EXP THER, V279, P1174
   Dezfulian C, 2007, CARDIOVASC RES, V75, P327, DOI 10.1016/j.cardiores.2007.05.001
   Egemnazarov B, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-81
   Erwin PA, 2006, J BIOL CHEM, V281, P151, DOI 10.1074/jbc.M510421200
   Erwin PA, 2005, J BIOL CHEM, V280, P19888, DOI 10.1074/jbc.M413058200
   Espey MG, 2002, P NATL ACAD SCI USA, V99, P11127, DOI 10.1073/pnas.152157599
   Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4
   Evgenov OV, 2006, NAT REV DRUG DISCOV, V5, P755, DOI 10.1038/nrd2038
   Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7
   Filipovic MR, 2012, J AM CHEM SOC, V134, P12016, DOI 10.1021/ja3009693
   Fomenko DE, 2007, SCIENCE, V315, P387, DOI 10.1126/science.1133114
   Foster MW, 2009, TRENDS MOL MED, V15, P391, DOI 10.1016/j.molmed.2009.06.007
   Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5
   FOUBERT L, 1992, LANCET, V339, P1615, DOI 10.1016/0140-6736(92)91886-D
   Fulton D, 2004, J BIOL CHEM, V279, P30349, DOI 10.1074/jbc.M402155200
   Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200
   Furuta S, 2017, TRENDS CANCER, V3, P744, DOI 10.1016/j.trecan.2017.09.003
   Garat C, 1997, AM J RESP CRIT CARE, V155, P1957, DOI 10.1164/ajrccm.155.6.9196102
   GASTON B, 1994, J PHARMACOL EXP THER, V268, P978
   GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957
   Gaston Benjamin M, 2003, Mol Interv, V3, P253, DOI 10.1124/mi.3.5.253
   Gebistorf F, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002787.pub3
   Ghofrani HA, 2017, CHEST, V151, P468, DOI 10.1016/j.chest.2016.05.024
   Ghosh A, 2016, P NATL ACAD SCI USA, V113, pE2355, DOI 10.1073/pnas.1524398113
   Ghosh A, 2014, J BIOL CHEM, V289, P15259, DOI 10.1074/jbc.M114.559393
   Gladwin MT, 2006, J CLIN INVEST, V116, P2330, DOI 10.1172/JCI29807
   Go YM, 2015, FREE RADICAL BIO MED, V84, P227, DOI 10.1016/j.freeradbiomed.2015.03.022
   Go Young-Mi, 2011, J Proteomics Bioinform, V4, P196
   Goldman AP, 1996, PEDIATRICS, V98, P706
   Gong Y, 2010, FREE RADICAL BIO MED, V48, P882, DOI 10.1016/j.freeradbiomed.2010.01.009
   Gore A, 2010, J IMMUNOTOXICOL, V7, P239, DOI 10.3109/1547691X.2010.492254
   Gould N, 2013, J BIOL CHEM, V288, P26473, DOI 10.1074/jbc.R113.460261
   Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027
   Gow AJ, 2001, J CELL PHYSIOL, V187, P277, DOI 10.1002/jcp.1085
   Gow AJ, 2004, AM J PHYSIOL-LUNG C, V287, pL262, DOI 10.1152/ajplung.00295.2003
   Gow AJ, 1998, NATURE, V391, P169
   Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200
   Greco TM, 2006, P NATL ACAD SCI USA, V103, P7420, DOI 10.1073/pnas.0600729103
   Griffiths C, 2001, J PHYSIOL-LONDON, V536, P855, DOI 10.1111/j.1469-7793.2001.00855.x
   Guo CJ, 2019, AM J PHYSIOL-LUNG C, V317, pL539, DOI 10.1152/ajplung.00506.2018
   Guo CJ, 2008, PLOS BIOL, V6, P2414, DOI 10.1371/journal.pbio.0060266
   Gupta KJ, 2020, NEW PHYTOL, V225, P1828, DOI 10.1111/nph.16157
   Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851
   Heinrich TA, 2013, BRIT J PHARMACOL, V169, P1417, DOI 10.1111/bph.12217
   Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569
   Hoffmann A, 2001, J CELL PHYSIOL, V188, P33, DOI 10.1002/jcp.1092
   Hogg N, 1997, BIOCHEM J, V323, P477, DOI 10.1042/bj3230477
   Hopkins SR, 1997, AM J RESP CRIT CARE, V156, P484, DOI 10.1164/ajrccm.156.2.9607114
   Hoque A, 1999, EUR J PHARMACOL, V384, P169, DOI 10.1016/S0014-2999(99)00686-X
   IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265
   Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069
   Iwakiri Y, 2006, P NATL ACAD SCI USA, V103, P19777, DOI 10.1073/pnas.0605907103
   Iwakiri Y, 2011, NITRIC OXIDE-BIOL CH, V25, P95, DOI 10.1016/j.niox.2011.04.014
   Jaggupilli A, 2018, MOL CELL BIOCHEM, V446, P63, DOI 10.1007/s11010-018-3273-4
   Jagnandan D, 2005, AM J PHYSIOL-CELL PH, V289, pC1024, DOI 10.1152/ajpcell.00162.2005
   Jaitovich Ariel, 2017, Adv Exp Med Biol, V967, P71, DOI 10.1007/978-3-319-63245-2_6
   Jankov RP, 2018, AM J PHYSIOL-LUNG C, V315, pL742, DOI 10.1152/ajplung.00184.2018
   Jankov RP, 2003, FREE RADICAL BIO MED, V35, P200, DOI 10.1016/S0891-5849(03)00305-8
   Jensen DE, 1998, BIOCHEM J, V331, P659, DOI 10.1042/bj3310659
   Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0
   Jourd'heuil D, 2003, J BIOL CHEM, V278, P15720, DOI 10.1074/jbc.M300203200
   Kang TM, 2019, PFLUG ARCH EUR J PHY, V471, P1245, DOI 10.1007/s00424-019-02308-w
   Keyaerts E, 2004, INT J INFECT DIS, V8, P223, DOI 10.1016/j.ijid.2004.04.012
   Kim JH, 2009, J APPL PHYSIOL, V107, P1249, DOI 10.1152/japplphysiol.91393.2008
   Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407
   Kluge I, 1997, J NEUROCHEM, V69, P2599
   Kneeshaw Sophie, 2018, Methods Mol Biol, V1747, P281, DOI 10.1007/978-1-4939-7695-9_22
   Kokkola T, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-21
   Kovacs I, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00137
   Kuhr FK, 2010, FASEB J, V24, P2475, DOI 10.1096/fj.09-148783
   Kumar V, 2013, BIOCHEMISTRY-US, V52, P3601, DOI 10.1021/bi301657w
   Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112
   Lauer T, 2001, P NATL ACAD SCI USA, V98, P12814, DOI 10.1073/pnas.221381098
   Leclerc PC, 2006, BRIT J PHARMACOL, V148, P306, DOI 10.1038/sj.bjp.0706725
   Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25
   Lima B, 2010, CIRC RES, V106, P633, DOI 10.1161/CIRCRESAHA.109.207381
   Lima B, 2009, P NATL ACAD SCI USA, V106, P6297, DOI 10.1073/pnas.0901043106
   Lin L, 2018, NITRIC OXIDE-BIOL CH, V74, P56, DOI 10.1016/j.niox.2018.01.007
   Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117
   LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0
   Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X
   Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596
   Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414
   Lorch SA, 2004, PEDIATR RES, V56, P345, DOI 10.1203/01.PDR.0000134256.30519.9B
   Lorch SA, 2000, PEDIATR RES, V47, P798, DOI 10.1203/00006450-200006000-00020
   Madej E, 2008, FREE RADICAL BIO MED, V44, P2013, DOI 10.1016/j.freeradbiomed.2008.02.015
   Man HSJ, 2014, VITAM HORM, V96, P161, DOI 10.1016/B978-0-12-800254-4.00007-6
   Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008
   Marino SM, 2010, J MOL BIOL, V404, P902, DOI 10.1016/j.jmb.2010.09.027
   Marino SM, 2010, J MOL BIOL, V395, P844, DOI 10.1016/j.jmb.2009.10.042
   Marozkina NV, 2012, BBA-GEN SUBJECTS, V1820, P722, DOI 10.1016/j.bbagen.2011.06.017
   Martin F, 2010, J BIOL CHEM, V285, P22651, DOI 10.1074/jbc.M110.111559
   Martinez-Ruiz A, 2005, P NATL ACAD SCI USA, V102, P8525, DOI 10.1073/pnas.0407294102
   Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264
   Mayer B, 2009, MOL PHARMACOL, V75, P886, DOI 10.1124/mol.108.052142
   McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718
   McMahon TJ, 2005, P NATL ACAD SCI USA, V102, P14801, DOI 10.1073/pnas.0506957102
   Miyamoto A, 1997, J BIOL CHEM, V272, P19601, DOI 10.1074/jbc.272.31.19601
   Moller MN, 2019, ADV EXP MED BIOL, V1127, P3, DOI 10.1007/978-3-030-11488-6_1
   Moya MP, 2002, LANCET, V360, P141, DOI 10.1016/S0140-6736(02)09385-6
   Moya MP, 2001, P NATL ACAD SCI USA, V98, P5792, DOI 10.1073/pnas.091109498
   Nakamura T, 2015, NEUROBIOL DIS, V84, P99, DOI 10.1016/j.nbd.2015.03.017
   Nakamura T, 2013, ANTIOXID REDOX SIGN, V18, P239, DOI 10.1089/ars.2012.4703
   NAKASHIMA H, 1994, J MOL BIOL, V238, P54, DOI 10.1006/jmbi.1994.1267
   NAKASHIMA H, 1992, FEBS LETT, V303, P141, DOI 10.1016/0014-5793(92)80506-C
   Nelin LD, 1998, PEDIATR RES, V43, P727, DOI 10.1203/00006450-199806000-00003
   Nozik-Grayck E, 2006, AM J PHYSIOL-LUNG C, V290, pL136, DOI 10.1152/ajplung.00230.2005
   Pabelick CM, 2000, AM J PHYSIOL-LUNG C, V278, pL521
   Paul BD, 2012, NAT REV MOL CELL BIO, V13, P499, DOI 10.1038/nrm3391
   Pei DS, 2009, NEUROCHEM RES, V34, P1507, DOI 10.1007/s11064-009-9938-3
   Poole LB, 2015, FREE RADICAL BIO MED, V80, P148, DOI 10.1016/j.freeradbiomed.2014.11.013
   Premont RT, 2020, CIRC RES, V126, P129, DOI 10.1161/CIRCRESAHA.119.315626
   Qin Y, 2013, METHOD ENZYMOL, V522, P409, DOI 10.1016/B978-0-12-407865-9.00019-4
   Radi R, 2013, ACCOUNTS CHEM RES, V46, P550, DOI 10.1021/ar300234c
   Radomski A, 1998, BRIT J PHARMACOL, V125, P1455, DOI 10.1038/sj.bjp.0702216
   Raffay TM, 2016, MOL PHARMACOL, V90, P418, DOI 10.1124/mol.116.104125
   Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101
   Robbins CG, 1997, AM J PHYSIOL-LUNG C, V272, pL903
   RUBBO H, 1994, J BIOL CHEM, V269, P26066
   Sawa T, 2007, NAT CHEM BIOL, V3, P727, DOI 10.1038/nchembio.2007.33
   Sayed N, 2008, CIRC RES, V103, P606, DOI 10.1161/CIRCRESAHA.108.175133
   Sayed N, 2007, P NATL ACAD SCI USA, V104, P12312, DOI 10.1073/pnas.0703944104
   Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8
   Schulman IH, 2012, BBA-GEN SUBJECTS, V1820, P752, DOI 10.1016/j.bbagen.2011.04.002
   Selemidis S, 2007, CARDIOVASC RES, V75, P349, DOI 10.1016/j.cardiores.2007.03.030
   Sengupta R, 2007, BIOCHEMISTRY-US, V46, P8472, DOI 10.1021/bi700449x
   Shen YH, 1998, FEBS LETT, V433, P125, DOI 10.1016/S0014-5793(98)00844-8
   Shi Y, 2002, CIRC RES, V91, P300, DOI 10.1161/01.RES.0000031799.12850.1E
   Shiva S, 2007, CIRC RES, V100, P654, DOI 10.1161/01.RES.0000260171.52224.6b
   Sikarwar AS, 2018, AM J PHYSIOL-LUNG C, V315, pL933, DOI 10.1152/ajplung.00130.2018
   Simon MA, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89620
   Sips PY, 2013, AM J PHYSIOL-HEART C, V304, pH1134, DOI 10.1152/ajpheart.00887.2012
   Smerjac SM, 2008, J NEUROCHEM, V105, P763, DOI 10.1111/j.1471-4159.2007.05178.x
   Smith KA, 2017, REDOX BIOL, V13, P228, DOI 10.1016/j.redox.2017.05.020
   Song WF, 2009, J BIOL CHEM, V284, P7294, DOI 10.1074/jbc.M806816200
   Stamler JS, 2010, NAT CELL BIOL, V12, P1024, DOI 10.1038/ncb1110-1024
   Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0
   STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087
   Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034
   Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4
   Steinhorn RH, 2008, J PERINATOL, V28, pS67, DOI 10.1038/jp.2008.158
   Stenger MR, 2010, LUNG, V188, P217, DOI 10.1007/s00408-010-9235-6
   Steverding D, 2001, REDOX REP, V6, P209, DOI 10.1179/135100001101536337
   Stomberski CT, 2019, ANTIOXID REDOX SIGN, V30, P1331, DOI 10.1089/ars.2017.7403
   Stoyanovsky DA, 2005, J AM CHEM SOC, V127, P15815, DOI 10.1021/ja0529135
   Stuesse DC, 2001, J THORAC CARDIOV SUR, V122, P371, DOI 10.1067/mtc.2001.115699
   Su YC, 2005, CELL BIOCHEM BIOPHYS, V43, P439, DOI 10.1385/CBB:43:3:439
   Tan CC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2144-6
   Tang JR, 2007, AM J PHYSIOL-LUNG C, V293, pL1271, DOI 10.1152/ajplung.00224.2007
   Tegeder I, 2011, PHARMACOL REV, V63, P366, DOI 10.1124/pr.110.004200
   ter Horst SAJ, 2007, AM J PHYSIOL-LUNG C, V293, P35, DOI 10.1152/ajplung.00381.2006
   Torok JA, 2012, AM J RESP CELL MOL, V47, P37, DOI 10.1165/rcmb.2011-0439OC
   Totapally BR, 1999, J CRIT CARE, V14, P141, DOI 10.1016/S0883-9441(99)90027-8
   Treuer AV, 2015, MOL MED REP, V11, P1555, DOI 10.3892/mmr.2014.2968
   Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055
   Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782
   van Faassen EE, 2009, MED RES REV, V29, P683, DOI 10.1002/med.20151
   VANGILS APG, 1991, RADIOGRAPHICS, V11, P37, DOI 10.1148/radiographics.11.1.1671719
   Villanueva C, 2010, FREE RADICAL BIO MED, V49, P307, DOI 10.1016/j.freeradbiomed.2010.04.004
   Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445
   Wadham C, 2007, DIABETES, V56, P2715, DOI 10.2337/db06-1294
   Wang GF, 2006, P NATL ACAD SCI USA, V103, P1295, DOI 10.1073/pnas.0508354103
   Wang ZQ, 2012, CANCER LETT, V320, P123, DOI 10.1016/j.canlet.2012.03.009
   Weerapana E, 2010, NATURE, V468, P790, DOI 10.1038/nature09472
   Weinberger B, 2001, TOXICOL SCI, V59, P5, DOI 10.1093/toxsci/59.1.5
   Whalen EJ, 2007, CELL, V129, P511, DOI 10.1016/j.cell.2007.02.046
   WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007
   Xue QJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123805
   Yingchoncharoen T, 2018, NITRIC OXIDE-BIOL CH, V76, P174, DOI 10.1016/j.niox.2017.09.010
   Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101
   Zhang YH, 2004, AM J PHYSIOL-LUNG C, V287, pL467, DOI 10.1152/ajplung.00350.2003
   Zuckerbraun BS, 2011, CARDIOVASC RES, V89, P542, DOI 10.1093/cvr/cvq370
   Zuckerbraun BS, 2010, CIRCULATION, V121, P98, DOI 10.1161/CIRCULATIONAHA.109.891077
NR 206
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
DI 10.1002/ppul.25201
EA DEC 2020
PG 14
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA PG0TM
UT WOS:000599457200001
PM 33289321
DA 2021-01-01
ER

PT J
AU Zhang, XH
   Wang, HL
   Wang, YW
   Lei, Y
   Xu, KJ
   Zhang, J
   Han, Y
   Zeng, J
   Deng, SP
   Wang, Y
AF Zhang, Xiaohong
   Wang, Hailian
   Wang, Youwei
   Lei, Yu
   Xu, Kaiju
   Zhang, Jie
   Han, Ying
   Zeng, Jun
   Deng, Shaoping
   Wang, Yi
TI Epidemiological and clinical based study on four passages of COVID-19
   patients: intervention at asymptomatic period contributes to early
   recovery
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE 2019 novel coronavirus (COVID-19); Transmission passage; Epidemiology;
   Clinical characteristics
AB Background With the worldwide spread of the 2019 novel coronavirus, scarce knowledge is available on the clinical features of more than two passages of patients. Further, in China, early intervention policy has been enacted since February. Whether early intervention contributes to swift recovery is still unknown. Hence, in this study, we focused on the patients from an isolated area, investigated the epidemiological and clinical characteristics of four serial passages of the virus. Methods From January 25 to February 29, 2020, all patient data on the SARS-CoV-2 passages in this isolated area were traced, and the patients were grouped according to the passaging of SARS-CoV-2. Clinical characteristics of patients, including laboratory, radiology, treatment and outcomes, were collected and analyzed. Results A total of 78 patients with four passages of virus transmission were included in this study. One patient transmitted SARS-CoV-2 to 8 patients (passage 2, P2), who next infected 23 patients (passage 3, P3), and then 46 patients (passage 4, P4). P2 received antiviral treatment when they had symptom, whereas P4 received antiviral treatment during their asymptomatic period. The incubation periods for P2, P3 and P4 patients were 7 days (IQR:2-12), 8 days (IQR:4-13) and 10 days (IQR:7-15), respectively. P2 patients showed lymphocytopenia (0.79 x 10(9)/L), decreased lymphocyte percentages (12.15%), increased white blood cell count (6.51 x 10(9)/L), increased total bilirubin levels (25% of P2 patients), increased C-reactive protein levels (100% of P2 patients) and abnormal liver function. By chest CT scans, all P2 patients (100%), 15 of P3 patients (65.22%) and 16 of P4 patients (34.78%) showed abnormality with typical feature of ground glass opacity. All of P2 patients (100%) received oxygen therapy, and in contrast, 19 of P4 patients (41.3%) received oxygen therapy. Further, significant decreased nucleic acid positive periods was found in P4 group (16 days, IQR: 10-23), compared with that of P2 group (22 days, IQR: 16-27). Moreover, the severity ratios were sharply decreased from 50% (P2 patients) to 4.35% (P4 patients), and the case fatality rate is zero. Conclusions Judged from four passages of patients, early intervention contributes to the early recovery of COVID-19 patients.
C1 [Zhang, Xiaohong; Wang, Youwei; Lei, Yu; Xu, Kaiju; Zeng, Jun] Sichuan Acad Med Sci, Dept Emergency Crit Care Med, Chengdu 610072, Peoples R China.
   [Zhang, Xiaohong; Wang, Hailian; Wang, Youwei; Lei, Yu; Xu, Kaiju; Zeng, Jun; Deng, Shaoping] Sichuan Prov Peoples Hosp, Chengdu 610072, Peoples R China.
   [Wang, Hailian; Deng, Shaoping] Sichuan Acad Med Sci, Clin Immunol Translat Med Key Lab Sichuan Prov, Chengdu 610072, Peoples R China.
   [Wang, Hailian; Deng, Shaoping] Sichuan Acad Med Sci, Inst Organ Transplantat, Chengdu 610072, Peoples R China.
   [Zhang, Jie] Chenfei Hosp, Dept Resp Med, Chengdu 610091, Peoples R China.
   [Han, Ying] Ganzi Tibetan Autonomous Prefecture Peoples Hosp, Dept Crit Care Med, Kangding 626000, Peoples R China.
   [Wang, Yi] Sichuan Acad Med Sci, Translat Med Ctr, Chengdu 610072, Peoples R China.
   [Wang, Yi] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Peoples R China.
RP Zeng, J (corresponding author), Sichuan Acad Med Sci, Dept Emergency Crit Care Med, Chengdu 610072, Peoples R China.; Zeng, J; Deng, SP (corresponding author), Sichuan Prov Peoples Hosp, Chengdu 610072, Peoples R China.; Deng, SP (corresponding author), Sichuan Acad Med Sci, Clin Immunol Translat Med Key Lab Sichuan Prov, Chengdu 610072, Peoples R China.; Deng, SP (corresponding author), Sichuan Acad Med Sci, Inst Organ Transplantat, Chengdu 610072, Peoples R China.; Wang, Y (corresponding author), Sichuan Acad Med Sci, Translat Med Ctr, Chengdu 610072, Peoples R China.; Wang, Y (corresponding author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Peoples R China.
EM junzeng88@126.com; sdeng10@163.com; w_yi@yahoo.com
OI Wang, Yi/0000-0001-9921-0304
FU National Key Research and Development Plan [2017YFC0113900]; National
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81802504]; Sichuan National Science Research Funding
   [2014FZ0123]; Sichuan Medical Association [Q19037]
FX This study was supported by National Key Research and Development Plan
   (no.2017YFC0113900), National Science Foundation of China (no.81571565)
   and the Sichuan National Science Research Funding (no.2014FZ0123) for
   Dr. Shaoping Deng. It was also sponsored by the National Science
   Foundation of China (no.81802504) the grant from Sichuan Medical
   Association (Q19037) for Dr. Yi Wang.
CR [Anonymous], 2020, Chin Med J (Engl), DOI 10.1097/CM9.0000000000000819
   Bai S L, 2020, Zhonghua Yu Fang Yi Xue Za Zhi, V54, pE005, DOI 10.3760/cma.j.issn.0253-9624.2020.0005
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   DeBiasi RL, 2020, J PEDIATR-US, V223, P199, DOI 10.1016/j.jpeds.2020.05.007
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Ryu S, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020006
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Zachariah P, 2020, JAMA PEDIATR, V174, DOI 10.1001/jamapediatrics.2020.2430
NR 17
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 17
PY 2020
VL 20
IS 1
AR 855
DI 10.1186/s12879-020-05570-x
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA PA0BS
UT WOS:000595282900001
PM 33203362
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bates, A
   Rushbrook, S
   Shapiro, E
   Grocott, M
   Cusack, R
AF Bates, Andrew
   Rushbrook, Sophie
   Shapiro, Elan
   Grocott, Michael
   Cusack, Rebecca
TI CovEMERALD: Assessing the feasibility and preliminary effectiveness of
   remotely delivered Eye Movement Desensitisation and Reprocessing
   following Covid-19 related critical illness: A structured summary of a
   study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomised controlled trial; Protocol; Eye-movement
   desensitisation and reprocessing; EMDR; Intensive Care; Survivors;
   Psychology; PTSD; Anxiety
AB ObjectivesPrimary Objective: To determine the feasibility of delivering a protocolised, remote, online, Eye Movement Desensitisation and Reprocessing (EMDR) intervention, within 12-weeks of hospital discharge, for adult survivors of Covid-19 related critical illness.Secondary objectives: To investigate whether remotely delivered EMDR can improve psychological outcome following Covid-19 related critical illness, specifically Post-Traumatic Stress Disorder (PTSD), anxiety and depression.Trial designThis is a single centre, randomised controlled cohort feasibility trial.ParticipantsParticipants will be recruited following discharge from the Intensive Care Unit at University Hospital Southampton, United Kingdom. Eligible patients will have received mechanical ventilation for a minimum of 24 hours, tested Covid-19 positive by polymerase chain reaction, will be over the age of 18 years and have the capacity to provide informed consent. Patients will be excluded if they have pre-existing cognitive impairment, pre-existing psychotic diagnosis or are not expected to survive post-hospital discharge.Intervention and comparatorGroup one: patients in the control arm will receive their standard package of prescribed care, following discharge home from hospital. If they experience any adverse physical or psychological health-conditions, they will access care through the usual available channels.Group two: patients randomly allocated to the intervention arm will receive their standard package of prescribed care, following discharge home from hospital. In addition, they will be referred to the Intensive Psychological Therapies Service in Poole, United Kingdom. They will receive an online appointment within 12-weeks of discharge home from hospital. They will receive a maximum of eight, weekly sessions of EMDR, delivered by a trained psychological therapist, following the Recent Traumatic Episode Protocol (R-TEP). Appendices 1 and 2 of the attached trial protocol contain a detailed description of the R-TEP intervention, written in accordance with the Template for Intervention Description and Replication (TIDieR) checklist and guide.Main outcomesThe primary outcome from this trial will be feasibility. Feasibility will be determined by recruitment rates, expressed as a percentage of eligible patients approached, completion of the EMDR intervention, completion of final assessment at 6-months, incidence of attributable adverse events and protocol adherence by the psychological therapists.Secondary, exploratory outcomes will be assessed by comparison between the control and intervention groups at 6-months post-hospital discharge. Psychometric evaluation will consist of the PTSD Checklist-Civilian Version and Hospital Anxiety and Depression Scale. In addition, we will assess health-related quality of life using the EQ5D-5L, physical activity using wrist worn activity monitors and nutritional state using the Council of Nutrition Appetite Questionnaire.RandomisationConsenting participants will be randomly allocated to intervention or usual care using an internet-based system (ALEA(TM)). Participants will be randomly assigned, on a 1:1 ratio, to receive either standard care (control) or the standard care plus online EMDR R-TEP (Intervention)Blinding (masking)Due to the nature of the intervention, participants cannot be blinded to group allocation. 6-month patient reported outcome measures will be completed using an online, electronic case report form. Group allocation will be masked during data analysis.
   Numbers to be randomised (sample size)This is a feasibility study, the results of which will be used to power a definitive study if appropriate. We anticipate a 25% mortality /loss to follow-up. A total of 26 patients will be recruited to this study, 13 patients in each arm.Trial StatusCovEMERALD opened to recruitment on 23(rd) September 2020 with an anticipated recruitment period of 6-months. We are using protocol version number 1.2 (1(st) June 2020)Trial registrationCovEMERALD was registered on clinicaltrials.gov NCT04455360 on 2(nd) July 2020Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
C1 [Bates, Andrew; Grocott, Michael; Cusack, Rebecca] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England.
   [Bates, Andrew; Grocott, Michael; Cusack, Rebecca] Univ Southampton, Southampton, Hants, England.
   [Rushbrook, Sophie] Dorset Healthcare Univ NHS Fdn Trust, Poole, Dorset, England.
RP Grocott, M (corresponding author), Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England.; Grocott, M (corresponding author), Univ Southampton, Southampton, Hants, England.
EM michael.grocott@soton.ac.uk
OI Bates, Andrew/0000-0002-3614-0270
FU National Institute for Health Research (NIHR)National Institute for
   Health Research (NIHR)
FX Andrew Bates is funded by a National Institute for Health Research
   (NIHR), (Pre-doctoral clinical academic fellowship) for this research
   project. This article presents independent research funded by the
   dNational Institute for Health Research (NIHR). The views expressed are
   those of the author and not necessarily those of the NHS, the NIHR or
   the Department of Health and Social Care.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 17
PY 2020
VL 21
IS 1
AR 929
DI 10.1186/s13063-020-04805-1
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OZ9RQ
UT WOS:000595256500003
PM 33203440
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Castillo, M
   Conte, B
   Hinkes, S
   Mathew, M
   Na, CJ
   Norindr, A
   Serota, DP
   Forrest, DW
   Deshpande, AR
   Bartholomew, TS
   Tookes, HE
AF Castillo, Marcus
   Conte, Brianna
   Hinkes, Sam
   Mathew, Megan
   Na, C. J.
   Norindr, Ainhoa
   Serota, David P.
   Forrest, David W.
   Deshpande, Amar R.
   Bartholomew, Tyler S.
   Tookes, Hansel E.
TI Implementation of a medical student-run telemedicine program for
   medications for opioid use disorder during the COVID-19 pandemic
SO HARM REDUCTION JOURNAL
LA English
DT Article
DE COVID-19; Telehealth; Medications for opioid use disorder; Student-run
   clinic
AB Objectives The COVID-19 pandemic led to the closure of the IDEA syringe services program medical student-run free clinic in Miami, Florida. In an effort to continue to serve the community of people who inject drugs and practice compassionate and non-judgmental care, the students transitioned the clinic to a model of TeleMOUD (medications for opioid use disorder). We describe development and implementation of a medical student-run telemedicine clinic through an academic medical center-operated syringe services program. Methods Students advertised TeleMOUD services at the syringe service program on social media and created an online sign-up form. They coordinated appointments and interviewed patients by phone or videoconference where they assessed patients for opioid use disorder. Supervising attending physicians also interviewed patients and prescribed buprenorphine when appropriate. Students assisted patients in obtaining medication from the pharmacy and provided support and guidance during home buprenorphine induction. Results Over the first 9 weeks in operation, 31 appointments were requested, and 22 initial telehealth appointments were completed by a team of students and attending physicians. Fifteen appointments were for MOUD and 7 for other health issues. All patients seeking MOUD were prescribed buprenorphine and 12/15 successfully picked up medications from the pharmacy. The mean time between appointment request and prescription pick-up was 9.5 days. Conclusions TeleMOUD is feasible and successful in providing people who inject drugs with low barrier access to life-saving MOUD during the COVID-19 pandemic. This model also provided medical students with experience treating addiction during a time when they were restricted from most clinical activities.
C1 [Castillo, Marcus; Conte, Brianna; Hinkes, Sam; Mathew, Megan; Na, C. J.; Norindr, Ainhoa; Deshpande, Amar R.] Univ Miami, Miller Sch Med, Dept Med Educ, Miami, FL 33136 USA.
   [Serota, David P.; Tookes, Hansel E.] Univ Miami, Miller Sch Med, Dept Med, Div Infect Dis, Miami, FL 33136 USA.
   [Forrest, David W.] Univ Miami, Coll Arts & Sci, Dept Anthropol, Miami, FL USA.
   [Bartholomew, Tyler S.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
RP Bartholomew, TS (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
EM tsb61@miami.edu
RI Serota, David P./AAB-8027-2019
OI Serota, David P./0000-0001-8505-6617
FU National Cancer Institute of the National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA240139]
FX This work was unfunded. Dr. Tookes is supported by the National Cancer
   Institute of the National Institutes of Health under Award Number
   P30CA240139. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health.
CR Bartholomew TS, 2020, INT J DRUG POLICY, V78, DOI 10.1016/j.drugpo.2020.102716
   Dunlop A, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00370-7
   Ginoza ME, 2020, STUDENT RUN FREE CLI
   Glick SN, 2020, AIDS BEHAV, V24, P2466, DOI 10.1007/s10461-020-02886-2
   Harris Miriam, 2020, J Addict Med, V14, pe136, DOI 10.1097/ADM.0000000000000682
   Huhn AS, 2017, J SUBST ABUSE TREAT, V78, P1, DOI 10.1016/j.jsat.2017.04.005
   Huskamp HA, 2018, HEALTH AFFAIR, V37, P1940, DOI 10.1377/hlthaff.2018.05134
   Khatri Utsha G, 2020, J Addict Med, V14, pe6, DOI 10.1097/ADM.0000000000000684
   Kimmel SD, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.16228
   Lin LA, 2020, JAMA PSYCHIAT
   Lin L, 2019, J SUBST ABUSE TREAT, V101, P38, DOI 10.1016/j.jsat.2019.03.007
   Rogers BG, 2020, AIDS BEHAV, V24, P2743, DOI 10.1007/s10461-020-02895-1
   SAMHSA, 2020, FAQS PROVISION METHA
   Samuels Elizabeth A, 2020, J Addict Med, V14, pe8, DOI 10.1097/ADM.0000000000000685
   Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550
   Tookes H, 2018, AIDS BEHAV, V2019, P1
   Wesson DR, 2003, J PSYCHOACTIVE DRUGS, V35, P253, DOI 10.1080/02791072.2003.10400007
NR 17
TC 0
Z9 0
U1 6
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7517
J9 HARM REDUCT J
JI Harm Reduct. J.
PD DEC 17
PY 2020
VL 17
IS 1
AR 88
DI 10.1186/s12954-020-00438-4
PG 6
WC Substance Abuse
SC Substance Abuse
GA OS5JY
UT WOS:000590201300001
PM 33203460
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shahnazi, H
   Ahmadi-Livani, M
   Pahlavanzadeh, B
   Rajabi, A
   Hamrah, MS
   Charkazi, A
AF Shahnazi, Hossein
   Ahmadi-Livani, Maryam
   Pahlavanzadeh, Bagher
   Rajabi, Abdolhalim
   Hamrah, Mohammad Shoaib
   Charkazi, Abdurrahman
TI Assessing preventive health behaviors from COVID-19: a cross sectional
   study with health belief model in Golestan Province, Northern of Iran
SO INFECTIOUS DISEASES OF POVERTY
LA English
DT Article
DE COVID-19; Health belief model; Fatalism; Preventive behavior; Iran
ID PSYCHOLOGICAL RESPONSES; GENERAL-POPULATION; INITIAL-STAGE; CANCER;
   EPIDEMIC; WOMEN
AB Background Coronavirus disease 2019 (COVID-19) is a new viral disease that has caused a pandemic in the world. Due to the lack of vaccines and definitive treatment, preventive behaviors are the only way to overcome the disease. Therefore, the present study aimed to determine the preventive behaviors from the disease based on constructs of the health belief model. Methods In the present cross-sectional study during March 11-16, 2020, 750 individuals in Golestan Province of Iran were included in the study using the convenience sampling and they completed the questionnaires through cyberspace. Factor scores were calculated using the confirmatory factor analysis. The effects of different factors were separately investigated using the univariate analyses, including students sample t-test, ANOVA, and simple linear regression. Finally, the effective factors were examined by the multiple regression analysis at a significant level of 0.05 and through Mplus 7 and SPSS 16. Results The participants' mean age was 33.9 +/- 9.45 years; and 57.1% of them had associate and bachelor's degrees. Multiple regression indicated that the mean score of preventive behavior from COVID-19 was higher in females than males, and greater in urban dwellers than rural dwellers. Furthermore, one unit increase in the standard deviation of factor scores of self-efficacy and perceived benefits increased the scores of preventive behavior from COVID-19 by 0.22 and 0.17 units respectively. On the contrary, one unit increase in the standard deviation of factor score of perceived barriers and fatalistic beliefs decreased the scores of the preventive behavior from COVID-19 by 0.36 and 0.19 units respectively. Conclusions Results of the present study indicated that female gender, perceived barriers, perceived self-efficacy, fatalistic beliefs, perceived interests, and living in city had the greatest preventive behaviors from COVID-19 respectively. Preventive interventions were necessary among males and villagers.
C1 [Shahnazi, Hossein] Isfahan Univ Med Sci, Sch Hlth, Dept Hlth Educ & Promot, Esfahan, Iran.
   [Ahmadi-Livani, Maryam] Golestan Univ Med Sci, Fac Hlth, Gorgan, Golestan, Iran.
   [Pahlavanzadeh, Bagher] Shahid Beheshti Univ Med Sci, Sch Allied Med Sci, Dept Biostat, Tehran, Iran.
   [Rajabi, Abdolhalim; Charkazi, Abdurrahman] Golestan Univ Med Sci, Fac Hlth, Environm Hlth Res Ctr, Gorgan, Golestan, Iran.
   [Hamrah, Mohammad Shoaib] Univ Tasmania, Sch Hlth Sci, Ctr Rural Hlth, Hobart, Tas, Australia.
   [Charkazi, Abdurrahman] Environm Hlth Res Ctr, Fac Hlth, Late Falsefi Univ Complex,KM 5of Gorgan Sari Rd, Golestan, Golestan, Iran.
RP Charkazi, A (corresponding author), Golestan Univ Med Sci, Fac Hlth, Environm Hlth Res Ctr, Gorgan, Golestan, Iran.
EM rcharkazi@yahoo.com
FU Golestan University of Medical Sciences, Gorgan, Iran
FX This work was supported by the Golestan University of Medical Sciences,
   Gorgan, Iran.
CR CHAMPION VL, 1993, NURS RES, V42, P139
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chew NWS, 2020, BRAIN BEHAV IMMUN, V88, P559, DOI 10.1016/j.bbi.2020.04.049
   COVID C, 2020, COVID C GLOB CAS J H
   Dodel M, 2017, COMPUT HUM BEHAV, V68, P359, DOI 10.1016/j.chb.2016.11.044
   Enjezab B, 2004, J SHAHID SADOUGHI U, V12, P78
   Ersin F, 2015, TURK J MED SCI, V45, P775, DOI 10.3906/sag-1406-74
   FREEMAN HP, 1989, CA-CANCER J CLIN, V39, P266, DOI 10.3322/canjclin.39.5.266
   Glanz K., 2008, HLTH BEHAV HLTH ED T
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Hao FY, 2020, BRAIN BEHAV IMMUN, V87, P100, DOI 10.1016/j.bbi.2020.04.069
   Ho CSH, 2020, ANN ACAD MED SINGAP, V49, P155
   Husnayain A, 2020, INT J INFECT DIS, V95, P221, DOI 10.1016/j.ijid.2020.03.021
   Kwok K., 2020, COMMUNITY RESPONSES, DOI [DOI 10.1101/2020.02.26.20028217, 10.1101/2020.02.26.20028217]
   Lau JTF, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-139
   Lau JTF, 2003, J EPIDEMIOL COMMUN H, V57, P864, DOI 10.1136/jech.57.11.864
   Leung CC, 2020, LANCET, V395, P945, DOI 10.1016/S0140-6736(20)30520-1
   Li JB, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09695-1
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M477
   Mo PKH, 2019, J ADV NURS, V75, P1188, DOI 10.1111/jan.13894
   Nahcivan NO, 2003, J CUMHURIYET U SCH N, V7, P33
   Nemcek M A, 1990, AAOHN J, V38, P127
   Niederdeppe J, 2007, CANCER EPIDEM BIOMAR, V16, P998, DOI 10.1158/1055-9965.EPI-06-0608
   PEREZSTABLE EJ, 1992, JAMA-J AM MED ASSOC, V268, P3219, DOI 10.1001/jama.268.22.3219
   PILL R, 1987, SOC SCI MED, V24, P125, DOI 10.1016/0277-9536(87)90245-0
   Powe BD, 2001, J PSYCHOSOC ONCOL, V19, P85, DOI 10.1300/J077v19n03_07
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403
   ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Straughan P.T., 1998, J GEND CULT HLTH, V3, P85, DOI DOI 10.1023/A:1023278230797
   Tan BYQ, 2020, ANN INTERN MED, V173, P317, DOI 10.7326/M20-1083
   Tan WQ, 2020, BRAIN BEHAV IMMUN, V87, P84, DOI 10.1016/j.bbi.2020.04.055
   Venturini E, 2020, ITAL J PEDIATR, V46, DOI 10.1186/s13052-020-00900-w
   Wang CY, 2020, BRAIN BEHAV IMMUN, V87, P40, DOI 10.1016/j.bbi.2020.04.028
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang LP, 2014, EMERG INFECT DIS, V20, P1296, DOI 10.3201/eid2008.131821
   World Heath Organization, 2020, 72 WHO
   Wu H, 2020, FACEMASK SHORTAGE CO, DOI [10.1101/2020.02.11.20020735, DOI 10.1101/2020.02.11.20020735]
   Zhao S, 2020, INT J INFECT DIS, V94, P148, DOI 10.1016/j.ijid.2020.02.025
NR 40
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-5162
EI 2049-9957
J9 INFECT DIS POVERTY
JI Infect. Dis. Poverty
PD DEC 17
PY 2020
VL 9
IS 1
AR 157
DI 10.1186/s40249-020-00776-2
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA OS5WJ
UT WOS:000590233600001
PM 33203453
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fernandes, ND
   Cummings, BM
   Naber, CE
   Salt, MD
   Lok, J
   Yager, PH
   Carroll, RW
AF Fernandes, Neil D.
   Cummings, Brian M.
   Naber, Catherine E.
   Salt, Michael D.
   Lok, Josephine
   Yager, Phoebe H.
   Carroll, Ryan W.
TI Adult COVID-19 Patients Cared For in a Pediatric ICU Embedded in a
   Regional Biothreat Center: Disease Severity and Outcomes
SO HEALTH SECURITY
LA English
DT Article; Early Access
DE COVID-19; Epidemic management; response; Pediatric critical care;
   Medical management; response; Infectious diseases; Biothreats
ID PICU
AB The objective of this study was to describe the clinical characteristics and outcomes of adult coronavirus disease 2019 (COVID-19) patients admitted to a pediatric intensive care unit (PICU), with assessment of respiratory clinical severity and outcomes when cared for by pediatric intensivists utilizing specific care processes. We conducted a retrospective cohort study of adult patients admitted to the 14-bed PICU of a quaternary referral center during the COVID-19 surge in Boston between April and June 2020. A total of 37 adults were admitted: 28 tested COVID-19 positive and 9 tested COVID-19 negative. Of the COVID-19-positive patients, 21 (75%), were male and 12 (60.7%) identified as Hispanic/Latino. Comorbidities in the patients included diabetes mellitus (39.3%), hyperlipidemia (39.3%), and hypertension (32.1%). Twenty-four (85.7%) required mechanical ventilation, in whom the lowest median ratio of arterial oxygen partial pressure to fractional inspired pressure was 161.5 (141.0 to 184.5), the median peak positive end-expiratory pressure (PEEP) was 14 (12.0 to 15.8) cmH(2)O and 15 (62.5%) underwent an optimal PEEP maneuver. Twelve (50%) patients were proned for a median of 3.0 (3.0 to 4.8) days. Of the 15 patients who were extubated, 3 (20%) required reintubation. Tracheostomy was performed in 10 patients: 3 after extubation failure and 7 for prolonged mechanical ventilation and weakness. Renal replacement therapy was required by 4 (14.3%) patients. There were 2 (7.1%) mortalities. We report detailed clinical outcomes of adult patients when cared for by intact pediatric critical care teams during the COVID-19 pandemic. Good clinical outcomes, when supported by adult critical care colleagues and dedicated operational processes are possible.
C1 [Fernandes, Neil D.; Naber, Catherine E.; Salt, Michael D.] Harvard Med Sch, MassGeneral Hosp Children, Boston, MA 02115 USA.
   [Cummings, Brian M.; Lok, Josephine; Yager, Phoebe H.] MassGeneral Hosp Children, Div Pediat Crit Care Med, Boston, MA USA.
   [Lok, Josephine; Carroll, Ryan W.] MassGeneral Hosp Children, Global Pediat Crit Care Med, Boston, MA USA.
   [Cummings, Brian M.; Lok, Josephine; Yager, Phoebe H.; Carroll, Ryan W.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
RP Carroll, RW (corresponding author), Massachusetts Gen Hosp Children, Div Pediat Crit Care Med, 175 Cambridge St,5th floor, Boston, MA 02114 USA.; Carroll, RW (corresponding author), Massachusetts Gen Hosp Children, Global Pediat Crit Care Med, Biothreats Response Team, 175 Cambridge St,5th floor, Boston, MA 02114 USA.; Carroll, RW (corresponding author), Harvard Med Sch, 175 Cambridge St,5th Floor, Boston, MA 02114 USA.
EM rcarroll4@mgh.harvard.edu
OI Fernandes, Neil/0000-0002-3024-1994
CR Fernandes ND, 2020, AM J BIOETHICS, V20, P147, DOI 10.1080/15265161.2020.1779856
   Joyce CL, 2020, CRIT CARE MED, V48, P1553, DOI 10.1097/CCM.0000000000004543
   Kneyber MCJ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03074-3
   Levin Amanda B, 2020, Crit Care Explor, V2, pe0201, DOI 10.1097/CCE.0000000000000201
   Mukherjee Vikramjit, 2020, Crit Care Explor, V2, pe0188, DOI 10.1097/CCE.0000000000000188
   Philips K, 2020, J PEDIATR-US, V222, P22, DOI 10.1016/j.jpeds.2020.04.060
   Raith Eamon P, 2021, J Neurosurg Anesthesiol, V33, P77, DOI 10.1097/ANA.0000000000000727
   Remy KE, 2020, PEDIATR CRIT CARE ME, V21, P607, DOI 10.1097/PCC.0000000000002429
   Yager PH, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2014819
   Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE
NR 10
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2326-5094
EI 2326-5108
J9 HEALTH SECUR
JI Health Secur.
DI 10.1089/hs.2020.0225
EA DEC 2020
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PG7ZU
UT WOS:000599949900001
PM 33326301
OA Bronze
DA 2021-01-01
ER

PT J
AU Faust, JS
   Krumholz, HM
   Du, CG
   Mayes, KD
   Lin, ZQ
   Gilman, C
   Walensky, RP
AF Faust, Jeremy Samuel
   Krumholz, Harlan M.
   Du, Chengan
   Mayes, Katherine Dickerson
   Lin, Zhenqiu
   Gilman, Cleavon
   Walensky, Rochelle P.
TI All-Cause Excess Mortality and COVID-19-Related Mortality Among US
   Adults Aged 25-44 Years, March-July 2020
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter; Early Access
AB This study compares all-cause excess mortality and COVID-19-related mortality during the early pandemic period (March-July 2020) with unintentional drug overdoses, the usual leading cause of death in young adults, during the same period in 2018 among adults aged 25 to 44 years.
C1 [Faust, Jeremy Samuel] Brigham & Womens Hosp, Dept Emergency Med, 10 Vining St, Boston, MA 02115 USA.
   [Krumholz, Harlan M.] Yale Sch Med, Sect Cardiovasc Med, New Haven, CT USA.
   [Du, Chengan; Lin, Zhenqiu] Yale Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT USA.
   [Mayes, Katherine Dickerson] Harvard Affiliated Emergency Med Residency, Boston, MA USA.
   [Gilman, Cleavon] Yuma Reg Med Ctr, Dept Emergency Med, Yuma, AZ USA.
   [Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Faust, JS (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 10 Vining St, Boston, MA 02115 USA.
EM jsfaust@gmail.com
CR Cunningham JW, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.5313
   Woolf SH, 2020, JAMA-J AM MED ASSOC, P1562, DOI 10.1001/jama.2020.19545
NR 2
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
DI 10.1001/jama.2020.24243
EA DEC 2020
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA PG5AJ
UT WOS:000599747200001
PM 33325994
OA Bronze
DA 2021-01-01
ER

PT J
AU Kleiman, EM
   Yeager, AL
   Grove, JL
   Kellerman, JK
   Kim, JS
AF Kleiman, Evan M.
   Yeager, April L.
   Grove, Jeremy L.
   Kellerman, John K.
   Kim, Joanne S.
TI Real-time Mental Health Impact of the COVID-19 Pandemic on College
   Students: Ecological Momentary Assessment Study
SO JMIR MENTAL HEALTH
LA English
DT Article
DE ecological momentary assessment; college students; COVID-19; anxiety;
   real-time; mental health; impact; student
ID UNREALISTIC OPTIMISM; CARE
AB Background: College students' mental health may be disproportionally affected by the COVID-19 pandemic because of the abrupt shift off campus and subsequent loss of a social network and potential long-term impact on job prospects.
   Objective: We sought to assess the nature of COVID-19's mental health impact among a sample of undergraduates who were experiencing the pandemic as it occurred in real time.
   Methods: In total, 140 college students completed smartphone-based ecological momentary assessments of anxiety and optimism related to COVID-19 and other generic mental health variables 6 times daily.
   Results: Participants completed >23,750 surveys. Overall, >75% of these surveys indicated at least some level of anxiety about COVID-19. On average, the proportion of responses each day at the highest levels of anxiety about COVID-19 was 7 times greater than the proportion of responses at the highest levels of non-COVID-19-specific anxiety. Structural change analyses indicated a significant downward trend in COVID-19 anxiety after the first week of June, but even at the lowest point, >15% of the participants in the sample still reported high levels of COVID-19 anxiety each day. Participants felt more anxious about COVID-19 on days when the number of new cases and deaths due to COVID-19 were higher. When participants felt anxious about COVID-19, they also felt sad, anxious (in general), and had a greater desire to drink and use drugs. Participants felt more optimistic about COVID-19 when they received more support from others and from their university.
   Conclusions: This study demonstrated the widespread mental health impact that COVID-19 has had on college students.
C1 [Kleiman, Evan M.; Yeager, April L.; Grove, Jeremy L.; Kellerman, John K.; Kim, Joanne S.] Rutgers State Univ, 53 Ave E,Tillett Hall Room 627, Piscataway, NJ 08854 USA.
RP Kleiman, EM (corresponding author), Rutgers State Univ, 53 Ave E,Tillett Hall Room 627, Piscataway, NJ 08854 USA.
EM evan.kleiman@rutgers.edu
OI Kleiman, Evan/0000-0001-8002-1167
CR Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Aucott C, 2016, EDUC PSYCHOL PRACT, V32, P85, DOI 10.1080/02667363.2015.1112257
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bodas M, 2015, PSYCHIATRY, V78, P265, DOI 10.1080/00332747.2015.1069658
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Fried E, 2020, MENTAL HLTH SOCIAL C, DOI [10.31234/osf.io/36xkp., DOI 10.31234/OSF.IO/36XKP, 10.31234/osf.io/36xkp]
   Gao JL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231924
   Guidotti E., 2020, J OPEN SOURCE SOFTWA, V5, P2376, DOI DOI 10.21105/J0SS.02376]
   KANIASTY K, 1993, J PERS SOC PSYCHOL, V64, P395, DOI 10.1037/0022-3514.64.3.395
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Liu JJ, 2020, LANCET CHILD ADOLESC, V4, P347, DOI 10.1016/S2352-4642(20)30096-1
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Sahu P, 2020, CUREUS, V12, DOI 10.7759/cureus.7541
   Shang Fanhong, 2020, Psychol Trauma, DOI 10.1037/tra0000541
   Tang WJ, 2020, J AFFECT DISORDERS, V274, P1, DOI 10.1016/j.jad.2020.05.009
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   Weinstein ND, 1996, J SOC CLIN PSYCHOL, V15, P1, DOI 10.1521/jscp.1996.15.1.1
   WEINSTEIN ND, 1987, J BEHAV MED, V10, P481, DOI 10.1007/BF00846146
   Zeileis A, 2003, COMPUT STAT DATA AN, V44, P109, DOI 10.1016/S0167-9473(03)00030-6
   Zeileis A., 2002, J STAT SOFTW, V7, P38, DOI DOI 10.18637/JSS.V007.I02
   Zhai YS, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.113003
   Zhai YS, 2020, LANCET PSYCHIAT, V7, pE22, DOI 10.1016/S2215-0366(20)30089-4
NR 26
TC 0
Z9 0
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2368-7959
J9 JMIR MENT HEALTH
JI JMIR Ment. Health
PD DEC 15
PY 2020
VL 7
IS 12
AR e24815
DI 10.2196/24815
PG 8
WC Psychiatry
SC Psychiatry
GA PF5LU
UT WOS:000599096500001
PM 33207308
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Karvigh, SA
   Vahabizad, F
   Banihashemi, G
   Sahraian, MA
   Gheini, MR
   Eslami, M
   Marhamati, H
   Mirhadi, MS
AF Karvigh, Sanaz Ahmadi
   Vahabizad, Fahimeh
   Banihashemi, Gelareh
   Sahraian, Mohammad Ali
   Gheini, Mohammad Reza
   Eslami, Mahdieh
   Marhamati, Hoora
   Mirhadi, Maryam Sadat
TI Ischemic Stroke in Patients with COVID-19 Disease: A Report of 10 Cases
   from Iran
SO CEREBROVASCULAR DISEASES
LA English
DT Article; Early Access
DE Coronavirus; COVID-19; Neurological manifestations; Case series study;
   Cerebrovascular diseases; Ischemic stroke
AB Ischemic stroke seems to be one of the most serious neurologic complications in patients with COVID-19 infection. Herein, we report a series of 10 ischemic stroke patients with concomitant COVID-19 disease. Out of 10, 8 had large infarcts (3 massive middle cerebral artery, 2 basilar artery, 2 posterior cerebral artery, and 1 internal carotid artery infarct territory). Two had cardiogenic embolic stroke due to atrial fibrillation. Almost half of our patients did not have a vascular risk factor. Nine did not have fever and were diagnosed with COVID-19 upon admission for stroke. Stroke occurred in the first week of respiratory symptoms with moderate pulmonary involvement. Most Patients did not have hypoxia and did not establish respiratory failure or acute respiratory distress syndrome. The blood pressures were low and hemorrhagic transformation did not occur even after antiplatelet or anticoagulant therapy. Patients had markedly increased levels of lactate dehydrogenase, C-reactive protein, and D-dimer. Three patients died. It seems that ischemic strokes in COVID-19 patients tend to occur as large infarct and can be seen in patients with mild to moderate pulmonary involvement.
C1 [Karvigh, Sanaz Ahmadi; Vahabizad, Fahimeh; Banihashemi, Gelareh; Sahraian, Mohammad Ali; Gheini, Mohammad Reza; Eslami, Mahdieh; Marhamati, Hoora; Mirhadi, Maryam Sadat] Univ Tehran Med Sci, Sina Hosp, Dept Neurol, Imam Khomeini St, Tehran 009821, Iran.
   [Sahraian, Mohammad Ali] Univ Tehran Med Sci, Multiple Sclerosis Res Ctr, Neurosci Inst, Tehran, Iran.
RP Vahabizad, F (corresponding author), Univ Tehran Med Sci, Sina Hosp, Dept Neurol, Imam Khomeini St, Tehran 009821, Iran.
EM fahime.vahabizad@gmail.com
FU Research Development Canter of Sina Hospital
FX We are indebted to the Research Development Canter of Sina Hospital for
   its support.
CR Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Desforges M, 2013, HUMAN CORONAVIRUSES
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hess DC, 2020, TRANSL STROKE RES, V11, P322, DOI 10.1007/s12975-020-00818-9
   Mao L, 2020, NEUROLOGICAL MANIFES
   Moores M, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014399
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Talebpour M, RATIONALE DESIGN REG
   Verschoof MA, 2020, STROKE, V51, P338, DOI 10.1161/STROKEAHA.119.027336
   Warner JJ, GUIDELINES EARLY MAN
NR 11
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
EI 1421-9786
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
DI 10.1159/000513279
EA DEC 2020
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA PG4DV
UT WOS:000599688100001
PM 33321492
DA 2021-01-01
ER

PT J
AU Sturman, D
   Auton, JC
   Thacker, J
AF Sturman, Daniel
   Auton, Jaime C.
   Thacker, Jemma
TI Knowledge of social distancing measures and adherence to restrictions
   during the COVID-19 pandemic
SO HEALTH PROMOTION JOURNAL OF AUSTRALIA
LA English
DT Article; Early Access
DE behavioural theory; epidemiology; local government; quantitative
   methods; social determinants
ID PREVENTION MEASURES; PLANNED BEHAVIOR; EXTENDED THEORY
AB Issue addressed With no efficacious treatments or vaccines available, social distancing measures remain the most effective approach for reducing the transmission of the COVID-19 virus. However, adherence to social distance measures presumably requires knowledge and understanding of the current social distancing restrictions.
   Methods A modified version of the Theory of Planned Behaviour examined the role of knowledge and understanding of current social distancing measures in predicting intentions to adhere to social distancing restrictions. An online survey was administered to respondents (N = 374) in Melbourne, Australia during a period of heightened social distancing restrictions. In addition to measuring respondents' general intentions to adhere to restrictions, vignettes were used to assess intended behaviour in specific situations.
   Results Knowledge of social distancing restrictions predicted intentions to adhere in specific situations, but not general intentions to adhere. Knowledge of restrictions also predicted positive attitudes towards current restrictions and a greater perceived ability to adhere to the restrictions, while positive attitudes was a good predictor of both general and specific intentions to adhere.
   Conclusions The findings suggest that attitudes towards restrictions may influence whether individuals attempt to adhere to restrictions, but knowledge of the restrictions influences whether the intended behaviour actually adheres to current restrictions.
   So what? These outcomes indicate that members of the public should be educated regarding the negative consequences associated with the COVID-19 virus and the capacity of social distancing to reduce transmission of the virus, and a need for social distancing restrictions to be uncomplicated and clearly communicated.
C1 [Sturman, Daniel; Auton, Jaime C.; Thacker, Jemma] Univ Adelaide, Adelaide, SA, Australia.
RP Sturman, D (corresponding author), Univ Adelaide, Adelaide, SA, Australia.
EM daniel.sturman@adelaide.edu.au
OI Sturman, Daniel/0000-0002-5025-598X
CR Adiyoso W, 2020, RES SQ, P1
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Alfahan A, 2016, J COMMUNITY HOSP INT, V6, DOI 10.3402/jchimp.v6.32151
   Bieleke M, 2020, PSYARXIV, P1, DOI [10.31234/osf.io/enzbv, DOI 10.31234/0SF.I0/ENZBV]
   Charles G, 2020, SSRN ELECT J, P1, DOI [10.2139/ssrn.3602166, DOI 10.2139/SSRN.3602166]
   Hagger MS, 2009, BRIT J HEALTH PSYCH, V14, P189, DOI 10.1348/135910708X397034
   Krawczyk A, 2012, J AM COLL HEALTH, V60, P316, DOI 10.1080/07448481.2011.615355
   McEachan RRC, 2011, HEALTH PSYCHOL REV, V5, P97, DOI 10.1080/17437199.2010.521684
   McMillan B, 2005, ADDICT RES THEORY, V13, P293, DOI 10.1080/16066350500053679
   Pedersen MJ, 2020, PUBLIC ADMIN REV, V80, P805, DOI 10.1111/puar.13240
   Rivis A, 2003, PSYCHOL HEALTH, V18, P567, DOI 10.1080/0887044032000069883
   Swanson V, 2006, PUBLIC HEALTH NUTR, V9, P297, DOI 10.1079/PHN2006845
   Tang CSK, 2003, AM J PUBLIC HEALTH, V93, P1887, DOI 10.2105/AJPH.93.11.1887
   Prasetyo YT, 2020, INT J INFECT DIS, V99, P312, DOI 10.1016/j.ijid.2020.07.074
   Van Rooij B, 2020, SSRN ELECT J, P1, DOI [10.2139/ssrn.3582626, DOI 10.2139/SSRN.3582626]
   Xie KF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176256
   Zhang XJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010197
NR 17
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1036-1073
EI 2201-1617
J9 HEALTH PROMOT J AUST
JI Health Promot. J. Aust.
DI 10.1002/hpja.443
EA DEC 2020
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PF0JQ
UT WOS:000598751300001
PM 33249695
OA Bronze
DA 2021-01-01
ER

PT J
AU Nzoghe, AM
   Essone, PN
   Leboueny, M
   Siawaya, ACM
   Bongho, EC
   Ndjindji, OM
   Houechenou, RMA
   Agnandji, ST
   Siawaya, JFD
AF Mveang Nzoghe, Amandine
   Essone, Paulin N.
   Leboueny, Marielle
   Maloupazoa Siawaya, Anicet Christel
   Bongho, Eliode Cyrien
   Mvoundza Ndjindji, Ofilia
   Avome Houechenou, Rotimi Myrabelle
   Agnandji, Selidji Todagbe
   Djoba Siawaya, Joel Fleury
TI Evidence and implications of pre-existing humoral cross-reactive
   immunity to SARS-CoV-2
SO IMMUNITY INFLAMMATION AND DISEASE
LA English
DT Article; Early Access
AB Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged throughout the world. Building knowledge around Covid-19 is crucial to devise facts based approaches to respond efficiently against this pandemic.
   Aim: We aimed to investigate pre-existing humoral cross-reactive immunity to SARS-CoV-2.
   Method: We have tested the reactivity against SARS-CoV-2 nucleocapsid (N) antigen of sera collected from healthy healthcare volunteers in 2014. We assessed immunoglobulins reactive against SARS-CoV-2 N-antigen using a well-validated serological platform; Elecsys assay.
   Results: Sera from 32 subjects (out of 135 [23.7%]) were reactive to SARS-CoV-2 N-antigen, suggesting the presence of anti-SARS-CoV-2 N-antigen antibodies.
   Conclusion: Although the clinical relevance of the observed reactivity can only be speculated and needs to be investigated, the implication of this finding for coronavirus disease 2019 seroepidemiological survey and vaccines' clinical trials is critical.
C1 [Mveang Nzoghe, Amandine; Leboueny, Marielle; Maloupazoa Siawaya, Anicet Christel; Bongho, Eliode Cyrien; Mvoundza Ndjindji, Ofilia; Avome Houechenou, Rotimi Myrabelle; Djoba Siawaya, Joel Fleury] Fdn Jeanne EBORI, CHU Mere Enfant, Serv Lab, Unite Rech & Diagnost Specialise, BP212, Libreville, Gabon.
   [Essone, Paulin N.; Agnandji, Selidji Todagbe] Ctr Recherches Med Lambarene, Lambarene, Gabon.
   [Essone, Paulin N.; Agnandji, Selidji Todagbe] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Essone, Paulin N.; Agnandji, Selidji Todagbe] Univ Tubingen, German Ctr Infect Res, Tubingen, Germany.
RP Siawaya, JFD (corresponding author), Fdn Jeanne EBORI, CHU Mere Enfant, Serv Lab, Unite Rech & Diagnost Specialise, BP212, Libreville, Gabon.
EM joel.djoba@gmail.com
FU Delegation of the European Union in Gabon, Sao Tome and Principe; ECCAS;
   CHU-Mere-Enfant; Fondation Jeanne EBORI
FX The Delegation of the European Union in Gabon, Sao Tome and Principe and
   ECCAS; CHU-Mere-Enfant; Fondation Jeanne EBORI
CR Assis RRd, 2020, BIORXIV
   Bradt V, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0133-5
   Chan CW, 2020, AM J CLIN PATHOL, V154, P620, DOI 10.1093/ajcp/aqaa155
   Essone PN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44294-0
   Grzelak L, 2020, SARS COV 2 SEROLOGIC
   Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453
   Herroelen PH, 2020, AM J CLIN PATHOL, V154, P610, DOI 10.1093/ajcp/aqaa140
   Muench P, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01694-20
   Roche-Diagnostics, 2020, EL ANT SARS COV 2
   Saron WAA, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar4297
   Saxena M, 2013, MICROBIOL-SGM, V159, P1, DOI 10.1099/mic.0.049601-0
   Sette A, 2020, NAT REV IMMUNOL, V20, P457, DOI 10.1038/s41577-020-0389-z
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
NR 13
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2050-4527
J9 IMMUN INFLAMM DIS
JI IMMUN. INFLAMM. DIS.
DI 10.1002/iid3.367
EA DEC 2020
PG 6
WC Immunology
SC Immunology
GA PE8QX
UT WOS:000598627100001
PM 33320447
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Ozdemir, IH
   Ozlek, B
   Ozen, MB
   Gunduz, R
   Cetin, N
   Bilge, AR
AF Ozdemir, Ibrahim Halil
   Ozlek, Bulent
   Ozen, Mehmet Burak
   Gunduz, Ramazan
   cetin, Nurullah
   Bilge, Ali Riza
TI Hydroxychloroquine/azithromycin treatment, QT interval and ventricular
   arrhythmias in hospitalised patients with COVID-19
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article; Early Access
ID DE-POINTES; PROLONGATION; AZITHROMYCIN; RISK
AB Background Hydroxychloroquine (HCQ) and azithromycin (AZM) are widely used in off-label treatment of novel coronavirus disease (COVID-19). However, cardiac safety of these drugs is still controversial in COVID-19. Therefore, we aimed to evaluate association of HCQ or HCQ + AZM treatment regimens, corrected QT (QTc) interval and malignant ventricular arrhythmias in hospitalized patients.
   Methods This is a single-center, retrospective and observational study. All data were extracted from the electronic medical records. The initial and post-treatment mean QTc intervals were calculated and compared in patients with HCQ alone or HCQ + AZM therapy. Associated factors with QTc prolongation, the incidence of ventricular arrhythmia during treatment and in-hospital mortality because of ventricular arrhythmias were evaluated.
   Results Our cohort comprised 101 hospitalized COVID-19 patients (mean age of 49.60 +/- 18 years, 54.4% men). HCQ + AZM combination therapy group (n = 56) was more likely to have comorbidities. After 5-days treatment, 19 (18.8%) patients had QTc prolongation, and significant increase in the QTc interval was observed in both two groups (P < .001). However, HCQ + AZM combination group had significantly higher Delta QTc compared to HCQ group (22.5 +/- 18.4 vs 7.5 +/- 15.3 ms, P < .001). All of 101 patients completed the 5-days treatment without interruption. Also, no malignant ventricular arrhythmia or death secondary to ventricular arrhythmia occurred during the treatment in both groups.
   Conclusions The present study revealed that although HCQ + AZM treatment was independently associated with QTc prolongation, none of patients experienced malignant ventricular arrhythmia or death during treatment. Further prospective studies are needed to determine the exact implications of these drugs on arrhythmias in patients with COVID-19.
C1 [Ozdemir, Ibrahim Halil; Ozen, Mehmet Burak; Gunduz, Ramazan] Manisa City Hosp, Dept Cardiol, Manisa, Turkey.
   [Ozlek, Bulent] Mugla Sitki Kocman Univ, Dept Cardiol, Training & Res Hosp, Mugla, Turkey.
   [cetin, Nurullah; Bilge, Ali Riza] Manisa Celal Bayar Univ, Dept Cardiol, Fac Med, Manisa, Turkey.
RP Ozlek, B (corresponding author), Mugla Sitki Kocman Univ, Tip Fak, Kotekli Mah Marmaris Yolu 48, TR-48000 Mugla, Turkey.
EM bulent_ozlek@hotmail.com
OI OZLEK, BULENT/0000-0001-5429-1323; CETIN, NURULLAH/0000-0002-4158-5469
CR Antoniou CK, 2017, EUR CARDIOL REV, V12, P112, DOI 10.15420/ecr.2017:16:1
   Bun SS, 2020, CLIN PHARMACOL THER, V108, P1090, DOI 10.1002/cpt.1968
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   COVID-19 Antimicrobial Management Working Group, 2020, REC ANT MAN AD HOSP
   Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Hama R, 2016, INFECT DIS-NOR, V48, P651, DOI 10.1080/23744235.2016.1189592
   Huang BH, 2007, PACE, V30, P1579, DOI 10.1111/j.1540-8159.2007.00912.x
   Kezerashvili A, 2007, J INTERV CARD ELECTR, V18, P243, DOI 10.1007/s10840-007-9124-y
   Lakkireddy DR, 2020, HEART RHYTHM, V17, pE233, DOI 10.1016/j.hrthm.2020.03.028
   Lopez-Izquierdo A, 2009, CELL PHYSIOL BIOCHEM, V24, P153, DOI 10.1159/000233241
   Malik M, 2001, J CARDIOVASC ELECTR, V12, P411, DOI 10.1046/j.1540-8167.2001.00411.x
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Morgan ND, 2013, JCR-J CLIN RHEUMATOL, V19, P286, DOI 10.1097/RHU.0b013e31829d5e50
   O'Connell TF, 2020, JACC-CLIN ELECTROPHY, DOI [10.1016/j.jacep.2020.07.016, DOI 10.1016/J.JACEP.2020.07.016]
   Ohara H, 2015, CARDIOVASC TOXICOL, V15, P232, DOI 10.1007/s12012-014-9289-4
   Ramireddy A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017144
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Shah RR, 2002, BRIT J CLIN PHARMACO, V54, P188, DOI 10.1046/j.1365-2125.2002.01627.x
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   Tisdale JE, 2010, DRUG INDUCED DIS PRE, P485
   Trinkley KE, 2013, CURR MED RES OPIN, V29, P1719, DOI 10.1185/03007995.2013.840568
   World Health Organization, PNEUM UNKN CAUS CHIN
   World Health Organization (WHO), 2020, NOV COR CHIN
   Wu CI, 2020, HEART RHYTHM, V17, P1456, DOI 10.1016/j.hrthm.2020.03.024
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 31
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
AR e13896
DI 10.1111/ijcp.13896
EA DEC 2020
PG 8
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA PE6PI
UT WOS:000598485900001
PM 33280207
OA Bronze
DA 2021-01-01
ER

PT J
AU Chen, ZW
   Ruan, PL
   Wang, LL
   Nie, XM
   Ma, XJ
   Tan, YR
AF Chen, Ziwei
   Ruan, Pinglang
   Wang, Lili
   Nie, Xinmin
   Ma, Xuejun
   Tan, Yurong
TI T and B cell Epitope analysis of SARS-CoV-2 S protein based on
   immunoinformatics and experimental research
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article; Early Access
DE immunoinformatics; molecular dynamics simulation; SARS-CoV-2; T and B
   cell epitopes; T cell immune response; vaccine design
ID PNEUMONIA OUTBREAK; WEB SERVER; PEPTIDE; CORONAVIRUS; PREDICTION; WUHAN;
   CHINA; RESOURCE; RECEPTOR; TCR
AB COVID-19 caused by SARS-CoV-2 is pandemic with a severe morbidity and mortality rate across the world. Despite the race for effective vaccine and drug against further expansion and fatality rate of this novel coronavirus, there is still lack of effective antiviral therapy. To this effect, we deemed it necessary to identify potential B and T cell epitopes from the envelope S protein. This can be used as potential targets to develop anti-SARS-CoV-2 vaccine preparations. In this study, we used immunoinformatics to identify conservative B and T cell epitopes for S proteins of SARS-CoV-2, which might play roles in the initiation of SARS-CoV-2 infection. We identified the B cell and T cell peptide epitopes of S protein and their antigenicity, as well as the interaction between the peptide epitopes and human leucocyte antigen (HLA). Among the B cell epitopes, 'EILDITPCSFGGVS' has the highest score of antigenicity and great immunogenicity. In T cell epitopes, MHC-I peptide 'KIADYNYKL' and MHC-II peptide 'LEILDITPC' were identified as high antigens. Besides, docking analysis showed that the predicted peptide 'KIADYNYKL' was closely bound to the HLA-A*0201. The results of molecular dynamics simulation through GROMACS software showed that 'HLA-A*0201 similar to peptide' complex was very stable. And the peptide we selected could induce the T cell response similar to that of SARS-CoV-2 infection. Moreover, the predicted peptides were highly conserved in different isolates from different countries. The antigenic epitopes presumed in this study were effective new vaccine targets to prevent SARS-CoV-2 infection.
C1 [Chen, Ziwei; Ruan, Pinglang; Wang, Lili; Tan, Yurong] Cent South Univ, Xiangya Sch Med, Dept Med Microbiol, Changsha 410078, Hunan, Peoples R China.
   [Chen, Ziwei; Nie, Xinmin] Cent South Univ, Xiangya Hosp 3, Dept Clin Lab, Changsha, Peoples R China.
   [Chen, Ziwei; Ma, Xuejun] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Dept NHC Key Lab Med Virol & Viral Dis, Beijing 102206, Peoples R China.
RP Tan, YR (corresponding author), Cent South Univ, Xiangya Sch Med, Dept Med Microbiol, Changsha 410078, Hunan, Peoples R China.; Ma, XJ (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Dept NHC Key Lab Med Virol & Viral Dis, Beijing 102206, Peoples R China.
EM maxj@ivdc.chinacdc.cn; yurongtan@csu.edu.cn
FU China Mega-Projects for Infectious Disease [2018ZX10711001,
   2019HYDQNJJ03]
FX This work was supported by grants from the China Mega-Projects for
   Infectious Disease (2018ZX10711001) and Academician Hou Yunde Research
   Youth Fund Project (2019HYDQNJJ03).
CR Adams JJ, 2016, NAT IMMUNOL, V17, P87, DOI 10.1038/ni.3310
   Adams JJ, 2011, IMMUNITY, V35, P681, DOI 10.1016/j.immuni.2011.09.013
   Alicia SM, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20248
   Buchan DWA, 2013, NUCLEIC ACIDS RES, V41, pW349, DOI 10.1093/nar/gkt381
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Coles CH, 2020, J IMMUNOL, V204, P1943, DOI 10.4049/jimmunol.1900915
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dev S, 2016, COMB CHEM HIGH T SCR, V19, P752, DOI 10.2174/1386207319666160810154346
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Ferre F, 2006, NUCLEIC ACIDS RES, V34, pW182, DOI 10.1093/nar/gkl189
   Folaranmi T, 2015, MMWR-MORBID MORTAL W, V64, P806
   Garboczi DN, 2010, J IMMUNOL, V185, P134
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Habel JR, 2020, P NATL ACAD SCI USA, V117, P24384, DOI 10.1073/pnas.2015486117
   Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266
   Iturrieta-Zuazo I, 2020, CLIN IMMUNOL, V219, DOI 10.1016/j.clim.2020.108572
   Janson G, 2017, BIOINFORMATICS, V33, P444, DOI 10.1093/bioinformatics/btw638
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Kalergis AM, 2000, J IMMUNOL, V165, P280, DOI 10.4049/jimmunol.165.1.280
   Koehl P, 1999, P NATL ACAD SCI USA, V96, P12524, DOI 10.1073/pnas.96.22.12524
   La Gruta NL, 2018, NAT REV IMMUNOL, V18, P467, DOI 10.1038/s41577-018-0007-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu IH, 2011, NUCLEIC ACIDS RES, V39, pW254, DOI 10.1093/nar/gkr434
   Maupetit J, 2009, NUCLEIC ACIDS RES, V37, pW498, DOI 10.1093/nar/gkp323
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Olwenyi OA, 2020, J MOL MED, V98, P1369, DOI 10.1007/s00109-020-01961-4
   Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Ren JG, 2020, INFECT DIS-NOR, V52, P571, DOI 10.1080/23744235.2020.1766105
   Sasmal DK, 2020, CELL MOL IMMUNOL, V17, P203, DOI 10.1038/s41423-019-0273-6
   Sayers EW, 2020, NUCLEIC ACIDS RES, V48, pD84, DOI 10.1093/nar/gkz956
   Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236
   Sun PP, 2013, COMPUT MATH METHOD M, DOI 10.1155/2013/943636
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang FS, 2020, LANCET, V395, P391, DOI 10.1016/S0140-6736(20)30300-7
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XD, 2009, REV MED VIROL, V19, P77, DOI 10.1002/rmv.602
   Yao B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062249
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 52
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
DI 10.1111/jcmm.16200
EA DEC 2020
PG 16
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA PF0IN
UT WOS:000598748300001
PM 33325143
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Shen, LY
   Cui, SJ
   Zhang, DT
   Lin, CY
   Chen, LJ
   Wang, QY
AF Shen, Lingyu
   Cui, Shujuan
   Zhang, Daitao
   Lin, Changying
   Chen, Lijuan
   Wang, Quanyi
TI Comparison of four commercial RT-PCR diagnostic kits for COVID-19 in
   China
SO JOURNAL OF CLINICAL LABORATORY ANALYSIS
LA English
DT Article; Early Access
DE COVID&#8208; 19; RT&#8208; PCR; sensitivity; specificity
AB We compared the sensitivity and specificity of four commercial coronavirus disease (COVID-19) diagnostic kits using real-time reverse transcription-polymerase chain reaction (RT-PCR). Kits I-IV approved by the State Drug Administration of China were selected, and the detection targets were ORF1ab gene and N gene. Specificity was evaluated by detecting other respiratory viruses. The sensitivity and batch effect of each kit were evaluated by testing 10-fold dilutions of RNA. Clinical application was verified by testing nasopharyngeal swab and sputum specimens from COVID-19 patients. Among the 78 cases infected by other respiratory viruses, no amplification curve was observed using these four COVID-19 RT-PCR kits. The minimum detection limits of kits I-IV were 10(-6), 10(-5), 10(-5), and 10(-6) dilutions, respectively, and concentrations were 10 copies/mL (10(-5) dilution) and 1 copies/mL (10(-6) dilution). The sensitivities of kits I-IV detected using 142 nasopharyngeal swab specimens from COVID-19 patients were 91.55%, 81.69%, 80.28%, and 90.85%, respectively, while they were 92.68%, 85.37%, 82.93%, and 93.90%, respectively, for the 82 sputum samples. The specificity of each kit was 100.00% (77/77). The total expected detection rate using sputum samples was 88.59% (691/780) higher than 86.15% (672/780) of nasopharyngeal swabs. Comparison of nasopharyngeal swab and sputum samples from the same COVID-19 patient led to the detection of ORF1ab and N genes in 16 (100%) sputum samples; only ORF1ab and N genes were detected in 12 (75%) and 14 (87.5%) nasopharyngeal swab specimens, respectively. In conclusion, comparison of commercial COVID-19 RT-PCR kits should be performed before using a new batch of such kits in routine diagnostics.
C1 [Shen, Lingyu; Cui, Shujuan; Zhang, Daitao; Lin, Changying; Chen, Lijuan; Wang, Quanyi] Beijing Municipal Res Ctr Prevent Med, Beijing Municipal Ctr Dis Prevent & Control, Inst Infect Dis & Endem Dis Prevent & Control, 16 Hepingli Middle Ave Dongcheng Dist, Beijing 100013, Peoples R China.
RP Chen, LJ (corresponding author), Beijing Municipal Res Ctr Prevent Med, Beijing Municipal Ctr Dis Prevent & Control, Inst Infect Dis & Endem Dis Prevent & Control, 16 Hepingli Middle Ave Dongcheng Dist, Beijing 100013, Peoples R China.
EM cljbjcdc@126.com
FU Cultivation Fund of Beijing Center for Disease Prevention and Control,
   Beijing Research Center for Preventive Medicine [2020-BJYJ-21,
   2020-BJYJ-22]
FX Cultivation Fund of Beijing Center for Disease Prevention and Control,
   Beijing Research Center for Preventive Medicine, Grant/Award Number:
   2020-BJYJ-21 and 2020-BJYJ-22
CR Charlton CL, 2018, CLIN MICROBIOL REV, V32, P1
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Feng H, 2020, JPN J RADIOL, V38, P409, DOI 10.1007/s11604-020-00967-9
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gulati A, 2020, AM J MED SCI, V360, P5, DOI 10.1016/j.amjms.2020.05.006
   He JL, 2020, RESP MED, V168, DOI 10.1016/j.rmed.2020.105980
   Heymann DL, 2020, LANCET, V395, P469, DOI 10.1016/S0140-6736(20)30184-7
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Kim SY, 2020, ANTIVIR RES, V181, DOI 10.1016/j.antiviral.2020.104873
   Peihua Niu RL, 2020, CHINA CDC WEEKLY, V2, P453, DOI [10.46234/ccdcw2020.116., DOI 10.46234/CCDCW2020.116]
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tahamtan A, 2020, EXPERT REV MOL DIAGN, V20, P453, DOI [10.1080/14737159.2020.1757437, 10.1080/07435800.2020.1713802]
   Thiel V, 2003, J VIROL, V77, P9790, DOI 10.1128/JVI.77.18.9790-9798.2003
   van Kasteren Puck B, 2020, J Clin Virol, V128, P104412, DOI 10.1016/j.jcv.2020.104412
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wu YP, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23507
   Xiao Ai Tang, 2020, Clin Infect Dis, V71, P2249, DOI 10.1093/cid/ciaa460
   Yu N, 2020, LANCET INFECT DIS, V20, P559, DOI 10.1016/S1473-3099(20)30176-6
   [张新 Zhang Xin], 2020, [中华临床感染病杂志, Chinese Journal of Clinical Infectious Diseases], V13, P39
   Zhu H, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23392
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-8013
EI 1098-2825
J9 J CLIN LAB ANAL
JI J. Clin. Lab. Anal.
AR e23605
DI 10.1002/jcla.23605
EA DEC 2020
PG 7
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA PE8SC
UT WOS:000598630200001
PM 33320386
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Hussein, O
   Abd Elazim, A
   Torbey, MT
AF Hussein, Omar
   Abd Elazim, Ahmed
   Torbey, Michel T.
TI Covid-19 systemic infection exacerbates pre-existing acute disseminated
   encephalomyelitis (ADEM)
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE COVID-19; Acute disseminated encephalomyelitis; ADEM; Exacerbation;
   Encephalopathy
ID CYTOKINE
AB Acute disseminated encephalomyelitis (ADEM) is an uncommon diagnosis in adults. It is known to be due to an abnormal immune response to a systemic infection rather than direct viral invasion to the central nervous system. There have been few reports of ADEM diagnosed in the setting of COVID-19 systemic infection. However, we report a case of Coxsackie induced ADEM that remitted but got exacerbated by COVID-19 infection. The patient contracted the COVID-19 infection shortly after being discharged to a rehabilitation facility. Direct COVID-19 neuroinvasion was ruled out via CSF PCR testing for the virus. The patient responded well to pulse steroid therapy and plasmapheresis in both occasions. We hypothesize that COVID-19 infection can flare-up a recently remitted ADEM via altering the immune responses. It is known now that COVID-19 infection can produce cytokine storming. Cytokine pathway activation is known to be involved in the pathology of ADEM. Caution regarding discharging immune suppressed patient to the inpatient rehabilitation facility should be made in the era of COVID-19 pandemic.
C1 [Hussein, Omar; Abd Elazim, Ahmed; Torbey, Michel T.] Univ New Mexcio Hosp, Dept Neurol, MSC10 5620, Albuquerque, NM 87131 USA.
RP Hussein, O (corresponding author), Univ New Mexcio Hosp, Dept Neurol, MSC10 5620, Albuquerque, NM 87131 USA.
EM ohussein@salud.unm.edu; aabdelazim@salud.unm.edu; mtorbey@salud.unm.edu
OI Hussein, Omar/0000-0003-4853-0310
CR Abdi Siamak, 2020, J Neurol Sci, V416, P117001, DOI 10.1016/j.jns.2020.117001
   Agarwal P, 2020, J NEUROL, DOI 10.1007/s00415-020-10087-z
   Anand P, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.105212
   Balasubramanya KS, 2007, NEURORADIOLOGY, V49, P177, DOI 10.1007/s00234-006-0164-2
   BELL EJ, 1984, J HYG-CAMBRIDGE, V93, P197, DOI 10.1017/S0022172400064718
   GRIST NR, 1974, J HYG-CAMBRIDGE, V73, P165, DOI 10.1017/S0022172400023998
   Hepburn M, 2020, NEUROCRIT CARE, DOI 10.1007/s12028-020-01006-1
   Hussein O., 2017, ACUTE DISSEMINATED E, P161, DOI [10.1007/978-3-319-51220-4_7., DOI 10.1007/978-3-319-51220-4_7]
   Hynson JL, 2001, NEUROLOGY, V56, P1308, DOI 10.1212/WNL.56.10.1308
   Ishizu T, 2006, J NEUROIMMUNOL, V175, P52, DOI 10.1016/j.jneuroim.2006.03.020
   Kamr WH, 2017, EGYPT J RADIOL NUC M, V48, P215, DOI 10.1016/j.ejrnm.2017.01.004
   Koralnik IJ, 2020, ANN NEUROL, V88, P1, DOI 10.1002/ana.25807
   Lu ZK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028228
   Mangalmurti N, 2020, IMMUNITY, V53, P19, DOI 10.1016/j.immuni.2020.06.017
   Parsons T, 2020, J NEUROL, V267, P2799, DOI 10.1007/s00415-020-09951-9
   Reichard RR, 2020, ACTA NEUROPATHOL, V140, P1, DOI 10.1007/s00401-020-02166-2
   Stonehouse M, 2003, ARCH DIS CHILD, V88, P122, DOI 10.1136/adc.88.2.122
   Treger L.L., 2020, J CLIN IMMUNOL IMMUN, V6
NR 18
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165-5728
EI 1872-8421
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD DEC 15
PY 2020
VL 349
AR 577405
DI 10.1016/j.jneuroim.2020.577405
PG 5
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA OU6LW
UT WOS:000591639000009
PM 33002725
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Arora, S
   Singh, P
   Dohare, R
   Jha, R
   Syed, MA
AF Arora, Shweta
   Singh, Prithvi
   Dohare, Ravins
   Jha, Rishabh
   Syed, Mansoor Ali
TI Unravelling host-pathogen interactions: ceRNA network in SARS-CoV-2
   infection (COVID-19)
SO GENE
LA English
DT Article
DE COVID-19; SARS-CoV-2; miR-124-3p; ceRNA network; Long noncoding RNAs
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS CORONAVIRUS; IMMUNE-RESPONSES;
   TRANSCRIPTION; PROTEIN; RESTRICTION; EXPRESSION; PATHOLOGY; PACKAGE;
   CELLS
AB COVID-19 is a lurking calamitous disease caused by an unusual virus, SARS-CoV-2, causing massive deaths worldwide. Nonetheless, explicit therapeutic drugs or clinically approved vaccines are not available for COVID-19. Thus, a comprehensive research is crucially needed to decode the pathogenic tools, plausible drug targets, committed to the development of efficient therapy. Host-pathogen interactions via host cellular components is an emerging field of research in this respect. miRNAs have been established as vital players in host-virus interactions. Moreover, viruses have the capability to manoeuvre the host miRNA networks according to their own obligations. Besides protein coding mRNAs, noncoding RNAs might also be targeted in infected cells and viruses can exploit the host miRNA network via ceRNA effect. We have predicted a ceRNA network involving one miRNA (miR-124-3p), one mRNA (Ddx58), one lncRNA (Gm26917) and two circRNAs (Ppp1r10, C330019G07RiK) in SARS-CoV infected cells. We have identified 4 DEGs-Isg15, Ddx58, Oasl1, Usp18 by analyzing a mRNA GEO dataset. There is no notable induction of IFNs and IFN-induced ACE2, significant receptor responsible for S-protein binding mediated viral entry. Pathway enrichment and GO analysis conceded the enrichment of pathways associated with interferon signalling and antiviral-mechanism by IFN-stimulated genes. Further, we have identified 3 noncoding RNAs, playing as potential ceRNAs to the genes associated with immune mechanisms. This integrative analysis has identified noncoding RNAs and their plausible targets, which could effectively enhance the understanding of molecular mechanisms associated with viral infection. However, validation of these targets is further corroborated to determine their therapeutic efficacy.
C1 [Arora, Shweta; Syed, Mansoor Ali] Jamia Millia Islamia, Fac Nat Sci, Dept Biotechnol, Translat Res Lab, New Delhi 110025, India.
   [Singh, Prithvi; Dohare, Ravins; Jha, Rishabh] Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India.
RP Syed, MA (corresponding author), Jamia Millia Islamia, Fac Nat Sci, Dept Biotechnol, Translat Res Lab, New Delhi 110025, India.; Dohare, R (corresponding author), Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India.
EM shweta169213@st.jmi.ac.in; ravinsdohare@gmail.com; smansoor@jmi.ac.in
RI Dohare, Ravins/AAN-6883-2020
OI Dohare, Ravins/0000-0002-0602-3719; SINGH, PRITHVI/0000-0002-2562-0914
FU Science and Engineering Research Board (SERB), Department of Science and
   Technology [SB/S2/RJN-199/2014, EEQ/2016/000509]
FX The present study was supported by the Science and Engineering Research
   Board (SERB), Department of Science and Technology (grant numbers:
   SB/S2/RJN-199/2014 to Mansoor A Syed and EEQ/2016/000509 to Ravins
   Dohare).
CR Ahmad S, 2019, GENES-BASEL, V10, DOI 10.3390/genes10121005
   Andreakos E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01232
   Barbu MG, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00143
   Blanco-Melo D., 2020, BIORXIV, DOI [10.1101/2020.03.24.004655, DOI 10.1101/2020.03.24.004655]
   Cascella M, 2020, FEATURES EVALUATION
   Cheng WY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041122
   Choi UY, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.110
   Clough E, 2016, METHODS MOL BIOL, V1418, P93, DOI 10.1007/978-1-4939-3578-9_5
   Daffis S, 2010, NATURE, V468, P452, DOI 10.1038/nature09489
   Dardenne E, 2014, CELL REP, V7, P1900, DOI 10.1016/j.celrep.2014.05.010
   Farberov L, 2015, J CELL SCI, V128, P1607, DOI 10.1242/jcs.167817
   Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015
   Galani IE, 2017, IMMUNITY, V46, P875, DOI 10.1016/j.immuni.2017.04.025
   Ghosal S, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00249
   Gralinski LE, 2015, J PATHOL, V235, P185, DOI 10.1002/path.4454
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Harenberg J, 2020, CLIN CHEM LAB MED, V58, P1029, DOI 10.1515/cclm-2020-0502
   Hasan Md Mahmudul, 2014, Advances in Bioinformatics, V2014, P967946, DOI 10.1155/2014/967946
   Hobert O, 2008, SCIENCE, V319, P1785, DOI 10.1126/science.1151651
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Jiang LJ, 2011, P NATL ACAD SCI USA, V108, P1897, DOI 10.1073/pnas.1019059108
   Keenan AB, 2019, NUCLEIC ACIDS RES, V47, pW212, DOI 10.1093/nar/gkz446
   Kikkert M, 2020, J INNATE IMMUN, V12, P4, DOI 10.1159/000503030
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Lau SKP, 2015, J VIROL, V89, P10532, DOI 10.1128/JVI.01048-15
   Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Menachery VD, 2014, J VIROL, V88, P4251, DOI 10.1128/JVI.03571-13
   Mesev EV, 2019, NAT MICROBIOL, V4, P914, DOI 10.1038/s41564-019-0421-x
   Miao L, 2019, NUTR METAB, V16, DOI 10.1186/s12986-019-0366-3
   Pan Y, 2018, HEREDITAS, V155, DOI 10.1186/s41065-018-0061-9
   Perng YC, 2018, NAT REV MICROBIOL, V16, P423, DOI 10.1038/s41579-018-0020-5
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Qian ZH, 2013, AM J RESP CELL MOL, V48, P742, DOI 10.1165/rcmb.2012-0339OC
   Qin Z, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00406
   Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907
   Shalgi R, 2007, PLOS COMPUT BIOL, V3, P1291, DOI 10.1371/journal.pcbi.0030131
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shapiro JS, 2014, P NATL ACAD SCI USA, V111, P7108, DOI 10.1073/pnas.1319635111
   Shriwash N, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01707
   Singh P, 2020, MOL CLIN ONCOL, V12, P299, DOI 10.3892/mco.2020.1991
   Sticht C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206239
   Sun JC, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002488
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Tsang J, 2007, MOL CELL, V26, P753, DOI 10.1016/j.molcel.2007.05.018
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yee M, 2017, AM J RESP CELL MOL, V56, P453, DOI 10.1165/rcmb.2016-0150OC
   Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang HM, 2015, BRIEF BIOINFORM, V16, P45, DOI 10.1093/bib/bbt085
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 58
TC 1
Z9 1
U1 30
U2 30
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD DEC 15
PY 2020
VL 762
AR 145057
DI 10.1016/j.gene.2020.145057
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA OC3QA
UT WOS:000579071900012
PM 32805314
OA Green Published
DA 2021-01-01
ER

PT J
AU Russo, G
   Pennisi, M
   Fichera, E
   Motta, S
   Raciti, G
   Viceconti, M
   Pappalardo, F
AF Russo, Giulia
   Pennisi, Marzio
   Fichera, Epifanio
   Motta, Santo
   Raciti, Giuseppina
   Viceconti, Marco
   Pappalardo, Francesco
TI In silico trial to test COVID-19 candidate vaccines: a case study with
   UISS platform
SO BMC BIOINFORMATICS
LA English
DT Article; Proceedings Paper
CT 3rd International Workshop on Computational Methods for the Immune
   System Function (CMISF) in conjunction with IEEE International
   Conference on Bioinformatics and Biomedicine (BIBM)
CY NOV 18-21, 2019
CL San Diego, CA
DE Agent-based model; Human monoclonal antibodies; In silico trials;
   SARS-CoV-2; Vaccines
ID DENDRITIC CELLS; SARS-COV-2; PREDICT; MODELS
AB BackgroundSARS-CoV-2 is a severe respiratory infection that infects humans. Its outburst entitled it as a pandemic emergence. To get a grip on this outbreak, specific preventive and therapeutic interventions are urgently needed. It must be said that, until now, there are no existing vaccines for coronaviruses. To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects.ResultsWe present an in silico platform that showed to be in very good agreement with the latest literature in predicting SARS-CoV-2 dynamics and related immune system host response. Moreover, it has been used to predict the outcome of one of the latest suggested approach to design an effective vaccine, based on monoclonal antibody. Universal Immune System Simulator (UISS) in silico platform is potentially ready to be used as an in silico trial platform to predict the outcome of vaccination strategy against SARS-CoV-2.ConclusionsIn silico trials are showing to be powerful weapons in predicting immune responses of potential candidate vaccines. Here, UISS has been extended to be used as an in silico trial platform to speed-up and drive the discovery pipeline of vaccine against SARS-CoV-2.
C1 [Russo, Giulia; Raciti, Giuseppina; Pappalardo, Francesco] Univ Catania, Dept Drug Sci, I-95125 Catania, Italy.
   [Pennisi, Marzio] Univ Piemonte Orientale, Comp Sci Inst, DiSIT, I-15125 Alessandria, Italy.
   [Fichera, Epifanio] Etna Biotech SRL, I-95121 Catania, Italy.
   [Motta, Santo] Natl Res Council Italy, I-00185 Rome, Italy.
   [Viceconti, Marco] Alma Mater Studiorum Univ Bologna, Dept Ind Engn, I-40136 Bologna, Italy.
RP Raciti, G; Pappalardo, F (corresponding author), Univ Catania, Dept Drug Sci, I-95125 Catania, Italy.
EM racitigi@unict.it; francesco.pappalardo@unict.it
FU University of Catania
FX Publication costs are funded by the University of Catania internal
   grant.
CR AmanatFatima KF, 2020, CELL, V52, P1
   Aryal MR, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01327-9
   Bianca C, 2017, INT J BIOMATH, V10, DOI 10.1142/S1793524517500723
   Bianca C, 2015, EUR PHYS J PLUS, V130, DOI 10.1140/epjp/i2015-15159-4
   Bonabeau E, 2002, P NATL ACAD SCI USA, V99, P7280, DOI 10.1073/pnas.082080899
   Capobianchi MR, 2020, CLIN MICROBIOL INFEC, V26, P954, DOI 10.1016/j.cmi.2020.03.025
   Carlier A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20737-y
   Chen X, 2020, HUMAN MONOCLONAL ANT
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cosgrove J, 2015, CPT-PHARMACOMET SYST, V4, P615, DOI 10.1002/psp4.12018
   Falzone L, 2020, INT J MOL MED, V46, P957, DOI 10.3892/ijmm.2020.4673
   Gullo F, 2015, BIOINFORMATICS, V31, P2514, DOI 10.1093/bioinformatics/btv172
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743
   Komarova NL, 2010, J THEOR BIOL, V263, P530, DOI 10.1016/j.jtbi.2010.01.009
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Liu F, 2020, BRIEF BIOINFORM, V21, P198, DOI 10.1093/bib/bby118
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Matheoud D, 2010, BLOOD, V115, P4412, DOI 10.1182/blood-2009-11-255935
   Palladini A, 2010, CANCER RES, V70, P7755, DOI 10.1158/0008-5472.CAN-10-0701
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Pappalardo F, 2008, BIOINFORMATICS, V24, P1715, DOI 10.1093/bioinformatics/btn306
   Pappalardo F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030586
   Pappalardo F, 2019, BRIEF BIOINFORM, V20, P1699, DOI 10.1093/bib/bby043
   Pappalardo F, 2016, BIOINFORMATICS, V32, P2672, DOI 10.1093/bioinformatics/btw293
   Pappalardo F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026523
   Patel SK, 2020, PREPRINTS, V4, P1, DOI [10.20944/preprints202004.0075.v1, 10.20944/preprints202004.0075.v1., DOI 10.20944/PREPRINTS202004.0075.V1]
   Patente TA, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03176
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Pennisi M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155475
   Pennisi M, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3045-5
   Pennisi M, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1961-9
   Pennisi M, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S7-S13
   Ragusa MA, 2016, PHYS LIFE REV, V17, P112, DOI 10.1016/j.plrev.2016.05.012
   Raoult D, 2020, CELL STRESS, V4, P66, DOI 10.15698/cst2020.04.216
   Reche PA, 2020, CROSS REACTIVE IMMUN, DOI [10.31219/osf.io/sbgy3, DOI 10.31219/OSF.IO/SBGY3]
   Russo G, 2018, IEEE ACM T COMPUT BI, V15, P1492, DOI 10.1109/TCBB.2017.2733529
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Tahamtan A, 2020, EXPERT REV MOL DIAGN, V20, P453, DOI [10.1080/14737159.2020.1757437, 10.1080/07435800.2020.1713802]
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Viceconti Marco, 2020, Methods, DOI 10.1016/j.ymeth.2020.01.011
   Vivarelli S, 2020, CANCERS, V12, DOI 10.3390/cancers12082237
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu J, 2004, EMERG INFECT DIS, V10, P210, DOI 10.3201/eid1002.030730
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Zakhartchouk AN, 2007, DNA CELL BIOL, V26, P721, DOI 10.1089/dna.2007.0616
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 58
TC 1
Z9 1
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD DEC 14
PY 2020
VL 21
SU 17
SI SI
AR 527
DI 10.1186/s12859-020-03872-0
PG 16
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA PG6UD
UT WOS:000599867600006
PM 33308153
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nojomi, M
   Yassin, Z
   Keyvani, H
   Makiani, MJ
   Roham, M
   Laali, A
   Dehghan, N
   Navaei, M
   Ranjbar, M
AF Nojomi, Marzieh
   Yassin, Zeynab
   Keyvani, Hossein
   Makiani, Mahin Jamshidi
   Roham, Maryam
   Laali, Azadeh
   Dehghan, Nasir
   Navaei, Mehrnaz
   Ranjbar, Mitra
TI Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled
   trial
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Arbidol; Corona virus; COVID-19; Efficacy
AB BackgroundTreatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease.MethodsUsing an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05.ResultsThe mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6days; P=0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (P=0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19.ConclusionOur findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design.Trial registrationIRCT20180725040596N2 on 18 April 2020.
C1 [Nojomi, Marzieh] Iran Univ Med Sci, Dept Community & Family Med, Prevent Med & Publ Hlth Res Ctr, Psychosocial Hlth Res Inst,Sch Med, Tehran, Iran.
   [Yassin, Zeynab] Iran Univ Med Sci, Hazrate Rasool Gen Hosp, Antimicrobial Resistance Res Ctr, Dept Infect Dis,Sch Med, Tehran, Iran.
   [Keyvani, Hossein] Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Sch Med, Dept Virol, Tehran, Iran.
   [Makiani, Mahin Jamshidi; Roham, Maryam] Iran Univ Med Sci, Antimicrobial Resistance Res Ctr, Tehran, Iran.
   [Laali, Azadeh] Iran Univ Med Sci, Firoozgar Gen Hosp, Sch Med, Dept Infect Dis, Tehran, Iran.
   [Dehghan, Nasir] Iran Univ Med Sci, Sch Med, Dept Community & Family Med, Tehran, Iran.
   [Navaei, Mehrnaz; Ranjbar, Mitra] Iran Univ Med Sci, Sch Med, Dept Infect Dis, Tehran, Iran.
RP Ranjbar, M (corresponding author), Iran Univ Med Sci, Sch Med, Dept Infect Dis, Tehran, Iran.
EM mitraranjbar@yahoo.com
FU Iran University of Medical Sciences
FX The current study was funded by Iran University of Medical Sciences. The
   role of funding was financial.
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Amawi H, 2020, THER DELIV, V11, P245, DOI 10.4155/tde-2020-0035
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Campbell MJ, 2007, MED STAT TXB HLTH SC, P267
   CHEN X, 2020, GUANGZI SHIFAN DAXUE, V38, P8, DOI DOI 10.16088/j.issn.1001-6600.2020.02.002
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Fink SL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27224-4
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hulseberg CE, 2019, J VIROL, V93, DOI [10.1128/jvi.02185-18, 10.1128/JVI.02185-18]
   Leneva IA, 2019, J MED VIROL, V91, P588, DOI 10.1002/jmv.25358
   Li Y, 2020, EXPLORATORY RANDOMIZ
   Liu Q, 2020, EFFECT ARBIDOL HYDRO, DOI [10.1101/2020.04.11.20056523, DOI 10.1101/2020.04.11.20056523]
   Liu XF, 2020, J INFECTION, V81, pE95, DOI 10.1016/j.jinf.2020.04.008
   Pecheur EI, 2016, J VIROL, V90, P3086, DOI 10.1128/JVI.02077-15
   World Health Organization, COR VIR OV
   World Health Organization, EUR 2019 NCOV OUTBR
   Worldometer, COVID 19 COR PAND
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49, P1, DOI DOI 10.3785/J.ISSN.1008-9292.2020.02.02.0E0
   Zhang JN, 2020, CURR MED SCI, V40, P480, DOI 10.1007/s11596-020-2203-3
   Zheng H, 2020, BRIT J ANAESTH, V125, pE378, DOI 10.1016/j.bja.2020.07.001
   Zheng L, 2020, EUR J MED CHEM, V205, DOI 10.1016/j.ejmech.2020.112687
   Zhu YF, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00108
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 26
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 14
PY 2020
VL 20
IS 1
AR 954
DI 10.1186/s12879-020-05698-w
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA PG6NC
UT WOS:000599849300001
PM 33317461
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yuan, H
   Liu, JJ
   Gao, Z
   Hu, FQ
AF Yuan, Hai
   Liu, Jingjing
   Gao, Zhao
   Hu, Fengqi
TI Clinical Features and Outcomes of Acute Kidney Injury in Patients
   Infected with COVID-19 in Xiangyang, China
SO BLOOD PURIFICATION
LA English
DT Article; Early Access
DE Coronavirus disease 2019; Clinical features; Acute kidney injury;
   Multiple organ damage; Renal replacement therapy
ID CORONAVIRUS; PNEUMONIA
AB Background: In December 2019, pneumonia associated with COVID-19 has spread from Wuhan to other areas in China. In the present study, we aimed to further clarify the clinical features and outcomes of acute kidney injury (AKI) in patients infected with COVID-19 in Xiangyang, Hubei, China. Methods: All confirmed cases of COVID-19 with AKI in Xiangyang Central Hospital from January 22 to May 31, 2020, were included in this retrospective study. Data of epidemiological, clinical, laboratory, radiological tests, treatment, complication, and outcomes were collected and analyzed. Patients were divided into intensive care unit (ICU) group and isolation ward (non-ICU) group. Results: Of the total patients, 33.3% in the non-ICU group and 85.7% in the ICU group had chronic diseases. In addition, 85.7% of patients in the ICU group died. The most common symptoms were fever, cough, and fatigue. The lymphocyte count in the ICU group was significantly reduced compared with the non-ICU group. The chest computed tomography (CT) images appeared showed multiple mottles and ground-glass opacity. Strip shadow could be found in chest CT images of some recovered patients. All patients received antiviral treatment. Most patients in the ICU group were given methylprednisolone, immunoglobulin, antibiotics, and mechanical ventilation and 35.7% of patients in the ICU group received continuous renal replacement therapy. Conclusions: Elderly with chronic comorbidities were more susceptible to COVID-19, showing a higher mortality rate due to multiple organ damage, and 35.7% of patients with AKI in ICU received renal replacement therapy. Moreover, part of the cured patients might need additional time to recover for poor lung function.
C1 [Yuan, Hai; Liu, Jingjing; Gao, Zhao; Hu, Fengqi] Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Nephrol, Affiliated Hosp, Jingzhou Rd, Xiangyang 441000, Peoples R China.
RP Gao, Z; Hu, FQ (corresponding author), Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Nephrol, Affiliated Hosp, Jingzhou Rd, Xiangyang 441000, Peoples R China.
EM gaozhao1648@163.com; hufengqi1@gmail.com
FU Natural Science Foundation of Hubei ProvinceNatural Science Foundation
   of Hubei Province [2019CFB392]; Hubei Province Health and Family
   Planning Scientific Research Project [WJ2019Q018]
FX This study was funded by the Natural Science Foundation of Hubei
   Province (2019CFB392) and Hubei Province Health and Family Planning
   Scientific Research Project (WJ2019Q018).
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Gao C, 2020, CRIT CARE MED, V48, P451, DOI 10.1097/CCM.0000000000004207
   Gong J, 2020, CORRELATION ANAL DIS
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo XZJ, 2017, SEMIN IMMUNOPATHOL, V39, P541, DOI 10.1007/s00281-017-0636-y
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Z, 2020, ANTI 2019 N COV VOLU
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 12
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0253-5068
EI 1421-9735
J9 BLOOD PURIFICAT
JI Blood Purif.
DI 10.1159/000513163
EA DEC 2020
PG 7
WC Hematology; Urology & Nephrology
SC Hematology; Urology & Nephrology
GA PG3YH
UT WOS:000599673700001
PM 33316799
DA 2021-01-01
ER

PT J
AU Tree, JA
   Turnbull, JE
   Buttigieg, KR
   Elmore, MJ
   Coombes, N
   Hogwood, J
   Mycroft-West, CJ
   Lima, MA
   Skidmore, MA
   Karlsson, R
   Chen, YH
   Yang, Z
   Spalluto, CM
   Staples, KJ
   Yates, EA
   Gray, E
   Singh, D
   Wilkinson, T
   Page, CP
   Carroll, MW
AF Tree, Julia A.
   Turnbull, Jeremy E.
   Buttigieg, Karen R.
   Elmore, Michael J.
   Coombes, Naomi
   Hogwood, John
   Mycroft-West, Courtney J.
   Lima, Marcelo A.
   Skidmore, Mark A.
   Karlsson, Richard
   Chen, Yen-Hsi
   Yang, Zhang
   Spalluto, Cosma Mirella
   Staples, Karl J.
   Yates, Edwin A.
   Gray, Elaine
   Singh, Dave
   Wilkinson, Tom
   Page, Clive P.
   Carroll, Miles W.
TI Unfractionated heparin inhibits live wild type SARS-CoV-2 cell
   infectivity at therapeutically relevant concentrations
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article; Early Access
DE COVID-19; heparin; LMWH; nebulised; SARS-CoV-2; UFH
ID DIFFERENTIAL SCANNING FLUOROMETRY; PHARMACOLOGY; GUIDE
AB Background and Purpose: Currently, there are no licensed vaccines and limited antivirals for the treatment of COVID-19. Heparin (delivered systemically) is currently used to treat anticoagulant anomalies in COVID-19 patients. Additionally, in the United Kingdom, Brazil and Australia, nebulised unfractionated heparin (UFH) is being trialled in COVID-19 patients as a potential treatment. A systematic comparison of the potential antiviral effect of various heparin preparations on live wild type SARS-CoV-2, in vitro, is needed.
   Experimental Approach: Seven different heparin preparations including UFH and low MW heparins (LMWH) of porcine or bovine origin were screened for antiviral activity against live SARS-CoV-2 (Australia/VIC01/2020) using a plaque inhibition assay with Vero E6 cells. Interaction of heparin with spike protein RBD was studied using differential scanning fluorimetry and the inhibition of RBD binding to human ACE2 protein using elisa assays was examined.
   Key Results: All the UFH preparations had potent antiviral effects, with IC50 values ranging between 25 and 41 mu g.ml(-1), whereas LMWHs were less inhibitory by similar to 150-fold (IC50 range 3.4-7.8 mg.ml(-1)). Mechanistically, we observed that heparin binds and destabilizes the RBD protein and furthermore, we show heparin directly inhibits the binding of RBD to the human ACE2 protein receptor.
   Conclusion and Implications: This comparison of clinically relevant heparins shows that UFH has significantly stronger SARS-CoV-2 antiviral activity compared to LMWHs. UFH acts to directly inhibit binding of spike protein to the human ACE2 protein receptor. Overall, the data strongly support further clinical investigation of UFH as a potential treatment for patients with COVID-19.
C1 [Tree, Julia A.; Buttigieg, Karen R.; Elmore, Michael J.; Coombes, Naomi; Carroll, Miles W.] Publ Hlth England, Natl Infect Serv, Salisbury SP4 0JG, Wilts, England.
   [Turnbull, Jeremy E.] Univ Liverpool, Inst Syst Mol & Integrat Biol, Dept Biochem & Syst Biol, Liverpool, Merseyside, England.
   [Hogwood, John; Gray, Elaine] Natl Inst Biol Stand & Control NIBSC, Haemostasis Sect, Biotherapeut, Potters Bar, Herts, England.
   [Mycroft-West, Courtney J.; Lima, Marcelo A.; Skidmore, Mark A.] Keele Univ, Sch Life Sci, Mol & Struct Biosci, Newcastle Upon Tyne, Tyne & Wear, England.
   [Karlsson, Richard; Chen, Yen-Hsi; Yang, Zhang] Univ Copenhagen, Dept Cellular & Mol Med, Copenhagen Ctr Glyc, Copenhagen, Denmark.
   [Singh, Dave] Univ Manchester, Manchester Univ Hosp NHS Fdn Trust, Med Evaluat Unit, Manchester, Lancs, England.
   [Spalluto, Cosma Mirella; Staples, Karl J.; Wilkinson, Tom] Univ Southampton, Dept Resp Med, Southampton, Hants, England.
   [Gray, Elaine; Page, Clive P.] Kings Coll London, Sackler Inst Pulm Pharmacol, London, England.
   [Carroll, Miles W.] Univ Oxford, Wellcome Trust Ctr Human Genet, Nuffield Dept Med, Oxford, England.
RP Tree, JA (corresponding author), Publ Hlth England, Natl Infect Serv, Salisbury SP4 0JG, Wilts, England.
EM julia.tree@phe.gov.uk
OI Mycroft-West, Courtney/0000-0002-4963-363X
FU Public Health England; University of Liverpool; University of Keele
FX Public Health England; University of Liverpool; University of Keele
CR Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS1, DOI 10.1111/bph.13882
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Ayerbe L, 2020, J THROMB THROMBOLYS, V50, P298, DOI 10.1007/s11239-020-02162-z
   Bermejo-Jambrina M., 2020, BIORXIV, P1, DOI [10.1101/2020.08.18.255810, DOI 10.1101/2020.08.18.255810]
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Cassinelli G, 2020, ADV EXP MED BIOL, V1221, P493, DOI 10.1007/978-3-030-34521-1_20
   Clausen TM, 2020, CELL, V183, P1043, DOI 10.1016/j.cell.2020.09.033
   Conzelmann Carina, 2020, Clin Med (Lond), V20, pe218, DOI 10.7861/clinmed.2020-0351
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   Frohlich E, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00181
   Guimond S., 2020, BIORXIV, P1, DOI [10.1101/2020.06.24.169334, DOI 10.1101/2020.06.24.169334]
   HAYDEN FG, 1980, ANTIMICROB AGENTS CH, V17, P865, DOI 10.1128/AAC.17.5.865
   Hirsh J, 2001, CIRCULATION, V103, P2994, DOI 10.1161/01.CIR.103.24.2994
   Hogwood J, 2017, PHARMACEUTICALS-BASE, V10, DOI 10.3390/ph10030059
   Johnson RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054092
   Katarzna A. U., 2010, ANAL CHEM, V82, P3796
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Lewandowski K, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00963-19
   Lindahl U, 2020, J THROMB HAEMOST, V18, P2422, DOI 10.1111/jth.14898
   Liu Lin, 2020, bioRxiv, DOI 10.1101/2020.05.10.087288
   Mulloy B, 2016, PHARMACOL REV, V68, P76, DOI 10.1124/pr.115.011247
   Mulloy B, 2015, METHODS MOL BIOL, V1229, P105, DOI 10.1007/978-1-4939-1714-3_11
   Mycroft-West C., 2020, BIORXIV, P1, DOI [10.1101/2020.02.29.971093, DOI 10.1101/2020.02.29.971093]
   Mycroft-West C. J., 2020, BIORXIV, P1, DOI [10.1101/2020.04.29.068486, DOI 10.1101/2020.04.29.068486]
   Mycroft-West C.J., 2020, BIORXIV, DOI [10.1101/2020.04.28.066761, DOI 10.1101/2020.04.28.066761]
   Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321
   Partridge L. J., 2020, UNFRACTIONATED HEPAR, P1, DOI [10.1101/2020.05.21.107870, DOI 10.1101/2020.05.21.107870, 10. 1101/2020.05.21.107870.]
   Project R., 2019, R LANG ENV STAT COMP
   Schaefer IM, 2020, MODERN PATHOL, V33, P2104, DOI 10.1038/s41379-020-0595-z
   Szajek A, 2015, PHARM TECHNOL, V39, P11
   Tandon Ritesh, 2020, bioRxiv, DOI 10.1101/2020.06.08.140236
   Uniewicz KA, 2010, ANAL CHEM, V82, P3796, DOI 10.1021/ac100188x
   van Haren F., 2020, CRITICAL CARE, V24, P1
   YANG C, 2020, CH CRC BIG DATA SER, P1, DOI DOI 10.1101/2020.06.09.142794
NR 34
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
DI 10.1111/bph.15304
EA DEC 2020
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PE4AO
UT WOS:000598308000001
PM 33125711
OA Other Gold
DA 2021-01-01
ER

PT J
AU Tervonen, T
   Jimenez-Moreno, AC
   Krucien, N
   Gelhorn, H
   Marsh, K
   Heidenreich, S
AF Tervonen, Tommi
   Jimenez-Moreno, Aura Cecilia
   Krucien, Nicolas
   Gelhorn, Heather
   Marsh, Kevin
   Heidenreich, Sebastian
TI Willingness to Wait for a Vaccine Against COVID-19: Results of a
   Preference Survey
SO PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
LA English
DT Letter; Early Access
C1 [Tervonen, Tommi; Jimenez-Moreno, Aura Cecilia; Krucien, Nicolas; Marsh, Kevin; Heidenreich, Sebastian] Evidera, Patient Ctr Res, London, England.
   [Tervonen, Tommi] Univ Groningen, Univ Med Ctr Groningen, Dept Epidmiol, Groningen, Netherlands.
   [Jimenez-Moreno, Aura Cecilia] Newcastle Univ, Wellcome Trust Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Gelhorn, Heather] Evidera, Patient Ctr Res, Bethesda, MD USA.
RP Tervonen, T (corresponding author), Evidera, Patient Ctr Res, London, England.; Tervonen, T (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Epidmiol, Groningen, Netherlands.
EM tommi.tervonen@evidera.com
OI Tervonen, Tommi/0000-0001-7303-500X
CR Abrams EM, 2020, LANCET RESP MED, V323, P1915
   Agencia EFE, 2020, BRAS SE PREP IN REST
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Bartsch SM, 2020, HEALTH AFFAIR, V39, P927, DOI 10.1377/hlthaff.2020.00426
   Courtemanche C, 2020, HEALTH AFFAIR, V39, P1237, DOI 10.1377/hlthaff.2020.00608
   COVID-19 Clinical Res Coalition, 2020, LANCET, V395, P1322, DOI 10.1016/S0140-6736(20)30798-4
   Dunford D, 2020, CORONAVIRUS WORLD LO
   Giannakeas V, 2020, ANN INTERN MED, V173, P407, DOI 10.7326/M20-1169
   GlobalData Healthcare, 2020, COV 19 VACC MAY ONL
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Hirsch C., 2020, EUROPES CORONAVIRUS
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Imai Natsuko, 2020, Wellcome Open Res, V5, P59, DOI 10.12688/wellcomeopenres.15808.1
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Organisation for Economic Co-operation and Development, 2020, EV IN IMP COV 19 CON
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shoukat A, 2020, CAN MED ASSOC J, V192, pE1215, DOI 10.1503/cmaj.200457-f
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Statista.com, 2020, NUMB SCH DISTR CLOS
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   The Lancet, 2020, Lancet, V395, P537, DOI 10.1016/S0140-6736(20)30379-2
   Trogen B, 2020, JAMA-J AM MED ASSOC, V323, P2460, DOI 10.1001/jama.2020.8917
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1178-1653
EI 1178-1661
J9 PATIENT
JI Patient
DI 10.1007/s40271-020-00483-y
EA DEC 2020
PG 5
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA PE4CF
UT WOS:000598312300001
PM 33313991
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Saegerman, C
   Bianchini, J
   Snoeck, CJ
   Moreno, A
   Chiapponi, C
   Zohari, S
   Ducatez, MF
AF Saegerman, Claude
   Bianchini, Juana
   Snoeck, Chantal J.
   Moreno, Ana
   Chiapponi, Chiara
   Zohari, Siamak
   Ducatez, Mariette F.
TI First expert elicitation of knowledge on drivers of emergence of
   influenza D in Europe
SO TRANSBOUNDARY AND EMERGING DISEASES
LA English
DT Article; Early Access
DE clustering analysis; drivers; expert elicitation; influenza D virus;
   multi&#8208; criteria decision analysis; ruminants; sensitivity
   analysis; swine
ID D VIRUS-INFECTION; RESPIRATORY-DISEASE; SEROLOGICAL EVIDENCE;
   UNITED-STATES; RISK-FACTORS; CATTLE; TRANSPORTATION; PATHOGENESIS;
   CIRCULATION; POPULATIONS
AB The influenza D virus (IDV) was first identified and characterized in 2011. Considering the virus' zoonotic potential, its genome nature (segmented RNA virus), its worldwide circulation in livestock and its role in bovine respiratory disease, an increased interest is given to IDV. However, few data are available on drivers of emergence of IDV. We first listed fifty possible drivers of emergence of IDV in ruminants and swine. As recently carried out for COVID-19 in pets (Transboundary and Emerging Diseases, 2020), a scoring system was developed per driver and scientific experts (N = 28) were elicited to (a) allocate a score to each driver, (b) weight the drivers' scores within each domain and (c) weight the different domains among themselves. An overall weighted score was calculated per driver, and drivers were ranked in decreasing order. Drivers with comparable likelihoods to play a role in the emergence of IDV in ruminants and swine in Europe were grouped using a regression tree analysis. Finally, the robustness of the expert elicitation was verified. Eight drivers were ranked with the highest probability to play a key role in the emergence of IDV: current species specificity of the causing agent of the disease; influence of (il)legal movements of live animals (ruminants, swine) from neighbouring/European Union member states and from third countries for the disease to (re-)emerge in a given country; detection of emergence; current knowledge of the pathogen; vaccine availability; animal density; and transport vehicles of live animals. As there is still limited scientific knowledge on the topic, expert elicitation of knowledge and multi-criteria decision analysis, in addition to clustering and sensitivity analyses, are very important to prioritize future studies, starting from the top eight drivers. The present methodology could be applied to other emerging animal diseases.
C1 [Saegerman, Claude; Bianchini, Juana] Univ Liege, Fundamental & Appl Res Anim & Hlth FARAH Ctr, Liege, Belgium.
   [Snoeck, Chantal J.] Luxembourg Inst Hlth, Dept Infect & Immun, Clin & Appl Virol Grp, Esch Sur Alzette, Luxembourg.
   [Moreno, Ana; Chiapponi, Chiara] Ist Zooprofilatt Sperimentale Lombardia & Emilia, Brescia, Italy.
   [Zohari, Siamak] Natl Vet Inst, Uppsala, Sweden.
   [Ducatez, Mariette F.] Univ Toulouse, INRAE, IHAP, ENVT, Toulouse, France.
RP Saegerman, C (corresponding author), Univ Liege, Fundamental & Appl Res Anim & Hlth FARAH Ctr, Liege, Belgium.
EM claude.saegerman@uliege.be
OI Saegerman, Claude/0000-0001-9087-7436; Moreno, Ana/0000-0002-8497-9708
FU European Food Safety Authority [GP/EFSA/AFSCO/2017/01 -G]
FX European Food Safety Authority, Grant/Award Number:
   GP/EFSA/AFSCO/2017/01 -G
CR An JU, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03136
   Arthington JD, 2003, J ANIM SCI, V81, P1120
   Asha K, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020192
   Avila LN, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00230
   Bailey ES, 2020, TROP DIS TRAVEL MED, V6, DOI 10.1186/s40794-020-0105-9
   Bianchini J, 2020, TRANSBOUND EMERG DIS, V67, P344, DOI 10.1111/tbed.13356
   Borkenhagen LK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201295
   Cirone F, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9121093
   Cox R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068338
   Damiaans B, 2019, PREV VET MED, V172, DOI 10.1016/j.prevetmed.2019.104768
   Dane H, 2019, TRANSBOUND EMERG DIS, V66, P2184, DOI 10.1111/tbed.13273
   Earley B, 2017, ANIMAL, V11, P486, DOI 10.1017/S1751731116001622
   European Centre for Disease Prevention and Control, 2015, BEST PRACT RANK EM I
   Faccini S, 2017, J VIROL METHODS, V243, P31, DOI 10.1016/j.jviromet.2017.01.019
   Ferguson L, 2018, EMERG INFECT DIS, V24, P1020, DOI 10.3201/eid2406.172102
   Ferguson L, 2016, J VIROL, V90, P5636, DOI 10.1128/JVI.03122-15
   Ferguson L, 2015, VIROLOGY, V486, P28, DOI 10.1016/j.virol.2015.08.030
   Flynn O, 2018, EMERG INFECT DIS, V24, P389, DOI 10.3201/eid2402.170759
   Foni E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12012-3
   Fusade-Boyer M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020128
   Gaudino M, 2020, TRANSBOUND EMERG DIS, DOI 10.1111/tbed.13812
   Gore SM, 1987, MRC NEWS, V35, P19
   Gorin S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010025
   Griebel P, 2014, ANIM HEALTH RES REV, V15, P161, DOI 10.1017/S1466252314000280
   Hause BM, 2017, VET MICROBIOL, V199, P47, DOI 10.1016/j.vetmic.2016.12.024
   Hause BM, 2014, MBIO, V5, DOI 10.1128/mBio.00031-14
   Hause BM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003176
   Hayakawa J, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080877
   Holwerda M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040377
   Hudson RE, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10071119
   Kesinger E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199227
   King L., 2004, 72 GEN SESS 23 28 M
   Ma Wenjun, 2008, J Mol Genet Med, V3, P158
   Manore C, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-55
   Mitra N, 2016, J GEN VIROL, V97, P1771, DOI 10.1099/jgv.0.000492
   Moreno A, 2019, TRANSBOUND EMERG DIS, V66, P268, DOI 10.1111/tbed.13012
   Murakami S, 2020, EMERG INFECT DIS, V26, P168, DOI 10.3201/eid2601.191092
   Murakami S, 2019, EMERG INFECT DIS, V25, P1224, DOI 10.3201/eid2506.181158
   Murakami S, 2016, EMERG INFECT DIS, V22, P1517, DOI 10.3201/eid2208.160362
   Nedland H, 2018, ZOONOSES PUBLIC HLTH, V65, pE148, DOI 10.1111/zph.12423
   Ng TFF, 2015, J VIROL, V89, P5340, DOI 10.1128/JVI.00064-15
   O'Donovan T, 2019, IRISH VET J, V72, DOI 10.1186/s13620-019-0150-8
   Oliva J, 2020, J VIROL, V94, DOI 10.1128/JVI.01662-19
   Oliva J, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060516
   Quast M, 2015, VET MICROBIOL, V180, P281, DOI 10.1016/j.vetmic.2015.09.005
   Rashtibaf M, 2012, TRANSBOUND EMERG DIS, V59, P482, DOI 10.1111/j.1865-1682.2011.01299.x
   Saegerman C, 2015, TRANSBOUND EMERG DIS, V62, P46, DOI 10.1111/tbed.12070
   Saegerman C, 2020, TRANSBOUND EMERG DIS, DOI 10.1111/tbed.13805
   Saegerman C, 2020, TRANSBOUND EMERG DIS, DOI 10.1111/tbed.13724
   Salem E, 2019, J VIROL, V93, DOI 10.1128/JVI.01853-18
   Salem E, 2017, EMERG INFECT DIS, V23, P1556, DOI 10.3201/eid2309.170342
   Sanderson MW, 2008, CAN VET J, V49, P373
   Schimmer B, 2014, VET REC, V175, P17, DOI 10.1136/vr.102155
   Silva GS, 2019, PREV VET MED, V171, DOI 10.1016/j.prevetmed.2019.104749
   Silveira S, 2019, EMERG INFECT DIS, V25, P2074, DOI 10.3201/eid2511.190253
   Snedeker KG, 2014, ZOONOSES PUBLIC HLTH, V61, P124, DOI 10.1111/zph.12053
   Snoeck CJ, 2018, EMERG INFECT DIS, V24, P1388, DOI 10.3201/eid2407.171937
   Sporer KRB, 2008, J ANIM SCI, V86, P1325, DOI 10.2527/jas.2007-0762
   Sreenivasan C, 2015, J VIROL, V89, P11990, DOI 10.1128/JVI.01630-15
   Su S, 2017, VIRULENCE, V8, P1580, DOI 10.1080/21505594.2017.1365216
   Trombetta CM, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010030
   Van Engen NK, 2018, ANIM HEALTH RES REV, V19, P142, DOI 10.1017/S1466252318000075
   Wan XF, 2020, J VIROL, V94, DOI 10.1128/JVI.00240-20
   Wan YM, 2018, J VIROL, V92, DOI [10.1128/JVI.00110-18, 10.1128/jvi.00110-18]
   White SK, 2016, J CLIN VIROL, V81, P31, DOI 10.1016/j.jcv.2016.05.017
   Yilmaz A, 2020, RES VET SCI, V130, P98, DOI 10.1016/j.rvsc.2020.02.017
   Zhang MD, 2020, TRANSBOUND EMERG DIS, V67, P924, DOI 10.1111/tbed.13419
   Zhang MD, 2019, TRANSBOUND EMERG DIS, V66, P1379, DOI 10.1111/tbed.13172
   Zhang XJ, 2019, VET MICROBIOL, V231, P246, DOI 10.1016/j.vetmic.2019.03.027
NR 69
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1865-1674
EI 1865-1682
J9 TRANSBOUND EMERG DIS
JI Transbound. Emerg. Dis.
DI 10.1111/tbed.13938
EA DEC 2020
PG 11
WC Infectious Diseases; Veterinary Sciences
SC Infectious Diseases; Veterinary Sciences
GA PE4UN
UT WOS:000598362000001
PM 33249766
DA 2021-01-01
ER

PT J
AU Smith, M
   Nakamoto, M
   Crocker, J
   Morden, FT
   Liu, KK
   Ma, EZ
   Chong, A
   Van, N
   Vajjala, V
   Carrazana, E
   Viereck, J
   Liow, K
AF Smith, Maiya
   Nakamoto, Max
   Crocker, Julie
   Tiffany Morden, Frances
   Liu, Keke
   Ma, Enze
   Chong, Ariel
   Van, Nicholas
   Vajjala, Vimala
   Carrazana, Enrique
   Viereck, Jason
   Liow, Kore
TI Early impact of the COVID-19 pandemic on outpatient migraine care in
   Hawaii: Results of a quality improvement survey
SO HEADACHE
LA English
DT Article; Early Access
DE coronavirus 2019; migraine; neurology; telemedicine
ID DEPRESSION; MANAGEMENT; HEADACHE; ANXIETY
AB Objective A survey was implemented for early assessment of pandemic-related practice processes and quality improvement (QI).
   Background In response to the public health measures in Hawaii to curtail the coronavirus 2019 pandemic, Hawaii Pacific Neuroscience (HPN) adapted their patient care to ensure continuity of neurological treatment.
   Methods The telephone survey was conducted on patients seen at HPN during the period of April 22, 2020-May 18, 2020 to address four areas related to patients' outpatient experience: delivery of care, general well-being, experience with telemedicine, and disease-specific questions.
   Results A total of 928 patients were contacted of which 429 (46.2%) patients responded and 367 (85.5%) agreed to participate. A total of 133 patients with migraine and 234 patients with other neurological conditions provided responses. Our migraine patients' survey responses suggest that their well-being was disproportionately negatively affected by the pandemic. Survey respondents with migraine were significantly more likely than their non-migraine peers to report worsening anxiety and sleep problems [62/132 (47.0%) vs. 78/234 (33.3%), chi(2) = 6.64, p = 0.010, and 64/132 (48.5%) vs. 73/234 (31.2%), chi(2) = 10.77, p = 0.001]; migraine patients also reported worsening of depression as a result of the pandemic more than patients with other diagnoses, though this was not statistically significant [44/132 (33.3%) vs. 57/234 (24.4%), chi(2) = 3.40, p = 0.065]. In regard to access to healthcare, significantly more migraine patients reported running out of medications than those with other diagnoses [20/133 (15.0%) vs. 18/234 (7.7%), chi(2) = 4.93, p = 0.026]. More avoided seeking medical help for new health problems because of the pandemic [30/133 (22.6%) vs. 30/234 (12.8%), chi(2) = 5.88, p = 0.015]. Migraine patients were also significantly impacted economically by the pandemic; 43/132 (32.4%) of migraine patients reported losing their jobs as the result of the pandemic versus 34/234 (14.5%) of their peers (chi(2) = 11.20, p < 0.001). An increase in headache severity or frequency was reported in 39/118 (33.1%) of respondents and 19/118 (16.1%) reported to using more abortive therapy than usual. Telemedicine was well received by almost all patients who took advantage of the option. Most of those patients found telemedicine to be easy to use and as valuable as an in-person visit. Migraine patients indicated with more frequency that without the telemedicine option, they would have missed their medical appointments [37/68 (54.4%) vs. 56/144 (38.6%), chi(2) = 4.31, p = 0.038]; a majority would prefer or consider telemedicine for future appointments over in-person visits.
   Conclusions Insights gained from this QI survey to the practice's new pandemic-related processes include stressing lifestyle modification, optimizing treatment plans, and continuing the option of telemedicine.
C1 [Smith, Maiya; Nakamoto, Max; Crocker, Julie; Tiffany Morden, Frances; Liu, Keke; Ma, Enze] Univ Hawaii, John Burns Sch Med, Honolulu, HI 96822 USA.
   [Chong, Ariel; Van, Nicholas] Univ Hawaii Manoa, Undergrad Educ, Honolulu, HI 96822 USA.
   [Vajjala, Vimala] Hawaii Pacific Neurosci, Headache & Facial Pain Ctr, Honolulu, HI USA.
   [Carrazana, Enrique; Viereck, Jason; Liow, Kore] Hawaii Pacific Neurosci, Brain Res Innovat & Translat Labs, Clin Res Ctr, Honolulu, HI USA.
RP Smith, M (corresponding author), Univ Hawaii, John Burns Sch Med, Honolulu, HI 96822 USA.
EM maiyas22@hawaii.edu
CR Ali A, 2020, HEADACHE, V60, P1183, DOI 10.1111/head.13830
   Altemus M, 2014, FRONT NEUROENDOCRIN, V35, P320, DOI 10.1016/j.yfrne.2014.05.004
   Arafat SMY, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113061
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Brigo F, 2020, EPILEPSY BEHAV, V110, DOI 10.1016/j.yebeh.2020.107164
   Burch RC, 2015, HEADACHE, V55, P21, DOI 10.1111/head.12482
   Davis LE, 2019, TELEMED E-HEALTH, V25, P274, DOI 10.1089/tmj.2018.0067
   Dixit A, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113089
   Gonzalez-Sanguino C, 2020, BRAIN BEHAV IMMUN, V87, P172, DOI 10.1016/j.bbi.2020.05.040
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Humphreys KL, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-0982
   Johns Hopkins University School of Medicine, 2020, COVID 19 DASHB CTR S
   Li JF, 2020, WORLD PSYCHIATRY, V19, P249, DOI 10.1002/wps.20758
   Matias-Guiu J, 2020, NEUROLOGIA, V35, P233, DOI 10.1016/j.nrl.2020.04.001
   Mazza C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093165
   Moccia M, 2020, NEUROL SCI, V41, P1369, DOI 10.1007/s10072-020-04470-x
   Robblee J, 2019, CLEV CLIN J MED, V86, P741, DOI 10.3949/ccjm.86a.19009
   Santos-Lasaosa S, 2020, NEUROLOGIA, V35, P291, DOI 10.1016/j.nrl.2020.05.004
   Silvestro M, 2020, HEADACHE, V60, P988, DOI 10.1111/head.13803
   Szperka CL, 2020, HEADACHE, V60, P833, DOI 10.1111/head.13810
   Taylor S, 2020, J ANXIETY DISORD, V72, DOI 10.1016/j.janxdis.2020.102232
   Vindegaard N, 2020, BRAIN BEHAV IMMUN, V89, P531, DOI 10.1016/j.bbi.2020.05.048
NR 22
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-8748
EI 1526-4610
J9 HEADACHE
JI Headache
DI 10.1111/head.14030
EA DEC 2020
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA PE4DM
UT WOS:000598315600001
PM 33316097
DA 2021-01-01
ER

PT J
AU Buntzel, J
   Walter, S
   Hellmund, H
   Klein, M
   Hubner, J
   Vitek, P
   Buntzel, J
   Koscielny, S
   Sesterhenn, AM
   Bussing, A
AF Buentzel, Jens
   Walter, Stefanie
   Hellmund, Herbert
   Klein, Michael
   Huebner, Jutta
   Vitek, Petr
   Buntzel, Judith
   Koscielny, Sven
   Sesterhenn, Andreas M.
   Buessing, Arndt
TI Oncology Services for Patients with Head Neck Cancer during Corona-Times
   - Patients' Perspective
SO LARYNGO-RHINO-OTOLOGIE
LA German
DT Article; Early Access
DE COVID-19 pandemic; head and neck cancer patients; patients&#8217;
   perspective; burden; coping strategies
AB Zusammenfassung
   Fragestellung Die COVID-19-Pandemie hat Auswirkungen auf die Versorgung von Tumorpatienten. Wie erleben Patienten mit Kopf-Hals-Tumoren (KHT) diese Situation und welche Coping-Strategien ergeben sich?
   Material und Methode Wir befragten in Studie 1 wahrend des Lockdowns (15.04-15.05.2020) 433 Tumorpatienten nach ihren Eindrucken/Belastungen (online, standardisiert, anonym). In Studie 2 wurden 292 Patienten nach dem Lockdown (06.05.-10.06.2020) zu ihren wahrgenommenen Veranderungen, Perspektivwechseln und Coping-Strategien mit standardisierten Tools (WHO-5, MLQ-10, GrAw-7) befragt. Fur beide Studien analysierten wir die KHT.
   Ergebnisse An Studie 1 nahmen 91 Patienten mit KHT teil, in Studie 2 wurden 84 Patienten mit KHT aufgenommen. Studie 1 zeigte im Lockdown einen hohen Druck auf die Mehrheit der Patienten mit KHT (53,8%). Es waren Angste bezuglich der eigenen Krankheit (39,6%), aber auch erwartete physische (24,7%) und psychische Folgen (21,3%) der Pandemie. Die soziale Isolation (Besuchsverbot) wurde als ein Hauptproblem (58,5%) beschrieben. Studie 2 bestatigte diese Belastungen auch nach dem Lockdown. Intensivere Beziehungen in der Familie (60/100 Punkten) sowie eine Zuwendung zu Natur und Stille (58/100 Punkten) wurden als entlastend beschrieben. Eine hohe Inaktivitat (MLQ-10) sowie ein vermindertes Wohlbefinden (WHO-5) und eine reduzierte Achtsamkeit (GrAw-7) waren Charakteristiken der KHT, die Ansatzpunkte fur eine Starkung der Resilienz sein konnen.
   Schlussfolgerung Patienten mit KHT haben einen hohen mentalen und psychischen Druck durch die Pandemie. Ihr Blickwinkel erganzt unsere bisherige Sicht und kann zu einer verbesserten Gesamtversorgung dieser Patienten beitragen.
   Abstract
   Objective COVID-19 pandemic has impact on the oncology service system for tumor patients. What is the view of head and neck cancer patients (HNC) on this situation and which coping strategies were developed?
   Material & methods In study 1 PRIO asked 433 tumor patients regarding their impressions/fears during the lockdown between April 15 and May 15, 2020 (online, standardized questionnaire). In 2 (nd) study 292 tumor patients reported their pandemic-induced perceived changes and coping strategies by established questionnaires (WHO-5, MLQ, GrAw-7). An analysis of the HNC-data obtained by standardized questionnaires was performed.
   Results Study 1 had 91 HNC, study 2-84 HNC. Study 1 shows high stress levels for the majority of HNC (53,8%). Personal fears regarding the own disease and therapies (39.6%) are a central problem. The participants await physical (24.7%) as well as psychological (21.3%) consequences due to the pandemic and its current management. During the lockdown the isolation (banned visitors at any hospital) was discussed as critical main point by 58.5% of HNC patients. Study 2 (after lockdown) underlined the mental stress caused by pandemic. Intensified relations within the families (58/100 points) as well as more intensive experience of nature and silence (58/60 points) are the most perceived changes in corona-times. HNC showed increased own inactivity (MLQ) and depressed well-being (WHO-5) and attention to the moment (GrAw-7).
   Conclusions HNC patients have had high burden and fears due to the COVID-19 pandemic in spring 2020. Their views are important for further strategies to organize and stabilize the oncology service system during further pandemic periods.
C1 [Buentzel, Jens; Walter, Stefanie; Huebner, Jutta] German Canc Soc, AG Pravent & Integrat Onkol PRIO, Berlin, Germany.
   [Hellmund, Herbert] Bundesverband Kehlkopfoperierten eV, Geschaftsstelle, Bonn, Germany.
   [Klein, Michael] Univ Klinikum Jena, Klin Hamatoonkol, Jena, Germany.
   [Vitek, Petr] Sudharz Klinikum Nordhausen gGmbH, HNO Klin, Nordhausen, Germany.
   [Buntzel, Judith] Univ Med Gottingen, Klin Hamatol & Med Onkol, Gottingen, Germany.
   [Koscielny, Sven] Univ Klinikum Jena, HNO Klin, Jena, Germany.
   [Sesterhenn, Andreas M.] Stadt Klinikum Solingen, Klin Hals Nasen Ohrenheilkunde, Solingen, Germany.
   [Buessing, Arndt] Univ Witten Herdecke, Lebensqualitat Spiritualitat & Coping, Witten, Germany.
RP Buntzel, J (corresponding author), Sudharz Krankenhaus, HNO Klin, Dr R Koch Str 39, D-99734 Nordhausen, Germany.
EM jens.buentzel@shk-ndh.de
CR Arzteblatt DAG Redaktion Deutsches, 2020, COR KRANK SOLL AB MO
   Bruhns A, GESAMTE SYSTEM PATIE
   Buntzel J, 2020, J CANCER RES CLIN, V146, P2713, DOI 10.1007/s00432-020-03249-z
   Bussing A, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.574314
   Bundesregierung Deutschland, 2020, BESPR BUND REG REG L
   Buntzel J, 2020, SPIRITUAL CARE, V9, P69, DOI [10.1515/spircare-2019-0041, DOI 10.1515/SPIRCARE-2019-0041]
   Bussing A, 2020, SPIRIT CARE, V9, P3, DOI [10.1515/spircare-2019-0057, DOI 10.1515/SPIRCARE-2019-0057]
   Jansen F, 2018, PSYCHO-ONCOLOGY, V27, P2245, DOI 10.1002/pon.4816
   Korsten LHA, 2019, PSYCHO-ONCOLOGY, V28, P1159, DOI 10.1002/pon.5058
   Kruchem T, CORONA ALTENHEIM MAN
   Mehanna H, 2020, LANCET ONCOL, V21, P350, DOI 10.1016/S1470-2045(20)30334-X
   Naunheim MR, 2017, JAMA OTOLARYNGOL, V143, P971, DOI 10.1001/jamaoto.2017.1086
   Petzold MB, 2020, BRAIN BEHAV, V10, DOI 10.1002/brb3.1745
   Steger MF, 2006, J COUNS PSYCHOL, V53, P80, DOI 10.1037/0022-0167.53.1.80
   Stoever T, 2020, LARYNGO RHINO OTOL, V99, P694, DOI 10.1055/a-1232-4911
   Topp CW, 2015, PSYCHOTHER PSYCHOSOM, V84, DOI 10.1159/000376585
   Vernooij-Dassen M, 2020, INT PSYCHOGERIATR, V32, P1235, DOI 10.1017/S1041610220001350
   Weiss R, 2020, LARYNGO RHINO OTOL, V99, P552, DOI 10.1055/a-1174-0234
   Wu V, 2020, HEAD NECK-J SCI SPEC, V42, P1202, DOI 10.1002/hed.26205
NR 19
TC 0
Z9 0
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0935-8943
EI 1438-8685
J9 LARYNGO RHINO OTOL
JI Laryngo-Rhino-Otol.
DI 10.1055/a-1327-4234
EA DEC 2020
PG 7
WC Otorhinolaryngology
SC Otorhinolaryngology
GA PE5HB
UT WOS:000598395600001
PM 33316831
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhang, WW
   Gao, F
   Gross, J
   Shrum, LJ
   Hayne, H
AF Zhang, Weiwei
   Gao, Fei
   Gross, Julien
   Shrum, L. J.
   Hayne, Harlene
TI How does social distancing during COVID-19 affect negative moods and
   memory?
SO MEMORY
LA English
DT Article; Early Access
DE COVID-19; social distancing; false memory; negative mood; social
   isolation
ID FALSE MEMORY; INDIVIDUAL-DIFFERENCES; LONELINESS; IMMEDIATE; VACATION;
   HEALTH; RISK
AB In the absence of an effective vaccine or treatment, the current best defence against COVID-19 is social distancing - staying at home as much as possible, keeping distance from others, and avoiding large gatherings. Although social distancing improves physical health in terms of helping to reduce viral transmission, its psychological consequences are less clear, particularly its effects on memory. In this research, we investigated the effect of social distancing duration on negative moods and memory. The relation between social distancing duration and both negative mood and memory errors followed the same U-shaped function: negative moods and memory errors initially decreased as social distancing duration increased, and then at approximately 30 days, they began to increase. Subsequent analyses indicated that memory errors were mediated by lonely mood in particular. Thus, short-term social distancing might benefit psychological well-being and memory performance, but extended social distancing has a negative impact on mood and memory.
C1 [Zhang, Weiwei; Gross, Julien; Hayne, Harlene] Univ Otago, Dept Psychol, POB 56, Dunedin 9054, New Zealand.
   [Gao, Fei] Bentley Univ, Dept Mkt, Waltham, MA USA.
   [Shrum, L. J.] HEC Paris, Dept Mkt, Jouy En Josas, France.
RP Hayne, H (corresponding author), Univ Otago, Dept Psychol, POB 56, Dunedin 9054, New Zealand.
EM harlene.hayne@otago.ac.nz
FU Royal Society of New Zealand Marsden FundRoyal Society of New
   ZealandMarsden Fund (NZ) [18-UOO-014]
FX This work was supported by the Royal Society of New Zealand Marsden Fund
   [grant number 18-UOO-014].
CR Bookbinder SH, 2016, PSYCHOL BULL, V142, P1315, DOI 10.1037/bul0000077
   Brainerd C. J., 2005, SCI FALSE MEMORY
   Cacioppo JT, 2009, TRENDS COGN SCI, V13, P447, DOI 10.1016/j.tics.2009.06.005
   Cacioppo JT, 2000, INT J PSYCHOPHYSIOL, V35, P143, DOI 10.1016/S0167-8760(99)00049-5
   de Bloom J, 2014, TOURISM MANAGE, V44, P164, DOI 10.1016/j.tourman.2014.03.013
   de Bloom J, 2012, STRESS HEALTH, V28, P305, DOI 10.1002/smi.1434
   DEESE J, 1959, J EXP PSYCHOL, V58, P17, DOI 10.1037/h0046671
   Gallo DA, 2010, MEM COGNITION, V38, P833, DOI 10.3758/MC.38.7.833
   Ganster D. C., 1989, INT REV IND ORG PSYC
   Giacco D, 2016, COMPR PSYCHIAT, V66, P59, DOI 10.1016/j.comppsych.2015.12.008
   Hajcak G, 2004, BRAIN COGNITION, V56, P189, DOI 10.1016/j.bandc.2003.11.001
   Hawkley LC, 2010, ANN BEHAV MED, V40, P218, DOI 10.1007/s12160-010-9210-8
   Hayes A., 2018, INTRO MEDIATION MODE
   Hayes AF, 2010, MULTIVAR BEHAV RES, V45, P627, DOI 10.1080/00273171.2010.498290
   Holt-Lunstad J, 2015, PERSPECT PSYCHOL SCI, V10, P227, DOI 10.1177/1745691614568352
   Howe ML, 2010, MEMORY, V18, P58, DOI 10.1080/09658210903476514
   Kensinger EA, 2006, PSYCHON B REV, V13, P757, DOI 10.3758/BF03193993
   Kensinger EA, 2009, EMOT REV, V1, P99, DOI 10.1177/1754073908100432
   Lindsay DS, 2015, PSYCHOL SCI, V26, P1827, DOI 10.1177/0956797615616374
   Luu P, 2000, J EXP PSYCHOL GEN, V129, P43, DOI 10.1037//0096-3445.129.1.43
   Masten A. S., 2009, OXFORD LIB PSYCHOL O
   Morgan C, 2007, BRIT J PSYCHIAT, V191, P477, DOI 10.1192/bjp.bp.106.034942
   Pharo H, 2011, SOC INFLUENCE, V6, P22, DOI 10.1080/15534510.2010.525852
   ROEDIGER HL, 1995, J EXP PSYCHOL LEARN, V21, P803, DOI 10.1037/0278-7393.21.4.803
   Roediger HL, 2001, PSYCHON B REV, V8, P385, DOI 10.3758/BF03196177
   Schonbrodt FD, 2013, J RES PERS, V47, P609, DOI 10.1016/j.jrp.2013.05.009
   Sparks K, 2001, J OCCUP ORGAN PSYCH, V74, P489, DOI 10.1348/096317901167497
   Storbeck J, 2005, PSYCHOL SCI, V16, P785, DOI 10.1111/j.1467-9280.2005.01615.x
   Storbeck J, 2011, EMOTION, V11, P981, DOI 10.1037/a0022754
   van Beest I, 2006, J PERS SOC PSYCHOL, V91, P918, DOI 10.1037/0022-3514.91.5.918
   Watson JM, 2005, J EXP PSYCHOL LEARN, V31, P76, DOI 10.1037/0278-7393.31.1.76
   Wilson RS, 2007, ARCH GEN PSYCHIAT, V64, P234, DOI 10.1001/archpsyc.64.2.234
   World Health Organization, WHO COR DIS COVID 19
   Xie WZ, 2020, P NATL ACAD SCI USA, V117, P17667, DOI 10.1073/pnas.2008868117
   Zhang WW, 2017, COGNITION EMOTION, V31, P526, DOI 10.1080/02699931.2016.1138930
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0965-8211
EI 1464-0686
J9 MEMORY
JI Memory
DI 10.1080/09658211.2020.1857774
EA DEC 2020
PG 8
WC Psychology, Experimental
SC Psychology
GA PF3KB
UT WOS:000598956600001
PM 33320027
OA Bronze
DA 2021-01-01
ER

PT J
AU Sahin, D
   Tanacan, A
   Erol, SA
   Anuk, AT
   Yetiskin, FDY
   Keskin, HL
   Ozcan, N
   Ozgu-Erdinc, AS
   Eyi, EGY
   Yucel, A
   Tayman, C
   Unlu, S
   Dinc, B
   Sari, E
   Surel, AA
   Moraloglu, OT
AF Sahin, Dilek
   Tanacan, Atakan
   Erol, Seyit A.
   Anuk, Ali T.
   Yetiskin, Fatma D. Y.
   Keskin, Huseyin L.
   Ozcan, Namik
   Ozgu-Erdinc, A. Seval
   Eyi, Elif G. Y.
   Yucel, Aykan
   Tayman, Cuneyt
   Unlu, Serpil
   Dinc, Bedia
   Sari, Eyup
   Surel, Aziz A.
   Moraloglu, Ozlem T.
TI Updated experience of a tertiary pandemic center on 533 pregnant women
   with COVID-19 infection: A prospective cohort study from Turkey
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article; Early Access
DE COVID&#8208; 19; pandemic; perinatal outcomes; pregnancy; SARS&#8208;
   CoV&#8208; 2
ID MANAGEMENT; OUTCOMES
AB Objective To investigate the clinical course and impact of coronavirus disease 2019 (COVID-19) infection on pregnant women.
   Methods A prospective cohort study was conducted on pregnant women with confirmed COVID-19 infection. Demographic features, clinical characteristics, and perinatal outcomes were prospectively evaluated.
   Results Of the 533 cases, 161 (30.2%) had co-morbidities and 165 (30.9%) were asymptomatic. Cough (n = 178, 33.4%) and myalgia (n = 168, 31.5%) were the leading symptoms. In total, 261 patients (48.9%) received COVID-19 therapy, 509 (95.5%) had mild disease, 7 (1.3%) were admitted to the intensive care unit (ICU), and invasive mechanical ventilation was necessary in 2 (0.4%) patients. Maternal mortality was observed in 2 (0.4%) cases. Of the patients, 297 (55.7%) were hospitalized, 39 (7.3%) had suspicious radiologic imaging findings, 66 (12.4) had pregnancy complications (preterm delivery [n =22, 4.1%] and miscarriage [n =12, 2.2%] were the most common pregnancy complications), 131 births occurred, and the cesarean section rate was 66.4%. All neonates were negative for COVID-19. The rate of admission to the neonatal ICU was 9.9%. One specimen of breast milk was positive for the infection.
   Conclusion The course of COVID-19 was mild in the majority of cases. However, increased rates of pregnancy complications and cesarean delivery were observed.
C1 [Sahin, Dilek; Yucel, Aykan; Moraloglu, Ozlem T.] Univ Hlth Sci, Ankara City Hosp, Dept Obstet & Gynecol, Turkish Minist Hlth, Ankara, Turkey.
   [Tanacan, Atakan; Erol, Seyit A.; Anuk, Ali T.; Yetiskin, Fatma D. Y.; Ozgu-Erdinc, A. Seval; Eyi, Elif G. Y.] Ankara City Hosp, Dept Obstet & Gynecol, Turkish Minist Hlth, Ankara, Turkey.
   [Ozcan, Namik] Univ Hlth Sci, Ankara City Hosp, Dept Anesthesiol & Reanimat, Turkish Minist Hlth, Ankara, Turkey.
   [Tayman, Cuneyt] Ankara City Hosp, Univ Hlth Sci, Div Neonatol, Turkish Minist Hlth,Dept Pediat, Ankara, Turkey.
   [Unlu, Serpil] Ankara City Hosp, Dept Infect Dis, Turkish Minist Hlth, Ankara, Turkey.
   [Dinc, Bedia] Ankara City Hosp, Dept Med Microbiol, Turkish Minist Hlth, Ankara, Turkey.
   [Sari, Eyup] Gulhane Fac Med, Dept Med Educ & Informat, Ankara, Turkey.
   [Surel, Aziz A.] Ankara City Hosp, Gen Hosp, Turkish Minist Hlth, Ankara, Turkey.
RP Sahin, D (corresponding author), 1604th St,9, TR-06800 Ankara, Turkey.
EM dilekuygur@gmail.com
OI anuk, ali/0000-0001-5437-1008
CR Breslin N, COVID 19 INFECT ASYM
   Dubey P, 2020, EUR J OBSTET GYN R B, V252, P490, DOI 10.1016/j.ejogrb.2020.07.034
   Hachem R, 2020, EUR J OBSTET GYN R B, V252, P614, DOI 10.1016/j.ejogrb.2020.07.024
   Hessami K, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1806817
   Igbinosa I, 2020, AM J OBSTET GYNECOL, V223, P768, DOI 10.1016/j.ajog.2020.08.001
   Koca F, 2020, LANCET, V396, pE25, DOI 10.1016/S0140-6736(20)31864-X
   Kotlyar A, 2020, AM J OBSTET GYNECOL
   Lippi G, 2020, ANN CLIN BIOCHEM, V57, P262, DOI 10.1177/0004563220922255
   London V, 2020, AM J PERINAT, V37, P991, DOI 10.1055/s-0040-1712164
   Luo YW, 2020, LANCET INFECT DIS, V20, P513, DOI 10.1016/S1473-3099(20)30191-2
   Poon LC, 2020, ULTRASOUND OBST GYN, V55, P700, DOI 10.1002/uog.22013
   Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Sahin D, 2020, INT J GYNECOL OBSTET, V151, P74, DOI 10.1002/ijgo.13318
   Salvatore CM, 2020, LANCET CHILD ADOLESC, V4, P721, DOI 10.1016/S2352-4642(20)30235-2
   Takemoto MLS, 2020, INT J GYNECOL OBSTET, V151, P154, DOI 10.1002/ijgo.13300
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Turan O, 2020, INT J GYNECOL OBSTET, V151, P7, DOI 10.1002/ijgo.13329
   Turkish Ministry of Health General Directorate of Public Health, COVD 19 SARS COV 2 I
   Wadman M, 2020, SCIENCE, V369, P607, DOI 10.1126/science.369.6504.607
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Wu YQ, 2020, CLIN CHIM ACTA, V509, P220, DOI 10.1016/j.cca.2020.06.026
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 25
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
DI 10.1002/ijgo.13460
EA DEC 2020
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA PE4PC
UT WOS:000598346100001
PM 33131057
OA Bronze
DA 2021-01-01
ER

PT J
AU Kuwentrai, C
   Yu, JM
   Rong, L
   Zhang, BZ
   Hu, YF
   Gong, HR
   Dou, Y
   Deng, J
   Huang, JD
   Xu, CJ
AF Kuwentrai, Chaiyaporn
   Yu, Jinming
   Rong, Li
   Zhang, Bao-Zhong
   Hu, Ye-Fan
   Gong, Hua-Rui
   Dou, Ying
   Deng, Jian
   Huang, Jian-Dong
   Xu, Chenjie
TI Intradermal delivery of receptor-binding domain of SARS-CoV-2 spike
   protein with dissolvable microneedles to induce humoral and cellular
   responses in mice
SO BIOENGINEERING & TRANSLATIONAL MEDICINE
LA English
DT Article; Early Access
DE COVID&#8208; 19; intradermal delivery; microneedle; receptor&#8208;
   binding domain; SARS&#8208; CoV&#8208; 2; spike protein
AB The S1 subunit of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein contains an immunogenic receptor-binding domain (RBD), which is a promising candidate for the development of a potential vaccine. This study demonstrated that intradermal delivery of an S-RBD vaccine using a dissolvable microneedle skin patch can induce both significant B-cell and significant T-cell responses against S-RBD. Importantly, the outcomes were comparable to that of conventional bolus injection.
C1 [Kuwentrai, Chaiyaporn; Rong, Li; Zhang, Bao-Zhong; Hu, Ye-Fan; Gong, Hua-Rui; Dou, Ying; Deng, Jian; Huang, Jian-Dong] Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, 21 Sassoon Rd, Hong Kong, Peoples R China.
   [Yu, Jinming; Xu, Chenjie] City Univ Hong Kong, Dept Biomed Engn, Hong Kong, Peoples R China.
   [Zhang, Bao-Zhong; Huang, Jian-Dong] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Synthet Biol, Shenzhen, Peoples R China.
   [Hu, Ye-Fan] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China.
RP Huang, JD (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, 21 Sassoon Rd, Hong Kong, Peoples R China.; Xu, CJ (corresponding author), City Univ Hong Kong, Dept Biomed Engn, Kowloon, 83 Tat Chee Ave, Hong Kong, Peoples R China.
EM jdhuang@hku.hk; chenjie.xu@cityu.edu.hk
OI Xu, Chenjie/0000-0002-8278-3912
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2019M663167]; City University of Hong KongCity University of
   Hong Kong [9610472]; Health and Medical Research Fund of Hong Kong
   [COVID190117]; Shenzhen Peacock Team Project [KQTD2015033117210153];
   Shenzhen Science and Technology Innovation Committee Basic Science
   Research Grant [JCYJ20170413154523577]
FX China Postdoctoral Science Foundation, Grant/Award Number: 2019M663167;
   City University of Hong Kong, Grant/Award Number: 9610472; Health and
   Medical Research Fund of Hong Kong, Grant/Award Number: COVID190117;
   Shenzhen Peacock Team Project, Grant/Award Number: KQTD2015033117210153;
   Shenzhen Science and Technology Innovation Committee Basic Science
   Research Grant, Grant/Award Number: JCYJ20170413154523577
CR Bariya SH, 2012, J PHARM PHARMACOL, V64, P11, DOI 10.1111/j.2042-7158.2011.01369.x
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang H, 2020, ADV MATER TECHNOL-US, V5, DOI 10.1002/admt.201900552
   Dicko M, 2000, B WORLD HEALTH ORGAN, V78, P163
   Falo LD, 2020, J AM ACAD DERMATOL, V83, P1226, DOI 10.1016/j.jaad.2020.05.126
   Gao X, 2014, US patent, Patent No. [US8678686 B2, 8678686]
   Giudice EL, 2006, ADV DRUG DELIVER REV, V58, P68, DOI 10.1016/j.addr.2005.12.003
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743
   Larraneta E, 2018, CARBOHYD POLYM, V181, P1194, DOI 10.1016/j.carbpol.2017.12.015
   Li N, 2016, DRUG DELIV, V23, P3234, DOI 10.3109/10717544.2016.1165311
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Martanto W, 2004, PHARM RES-DORDR, V21, P947, DOI 10.1023/B:PHAM.0000029282.44140.2e
   Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539
   Shin CI, 2017, THER DELIV, V8, P447, DOI 10.4155/tde-2017-0032
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Waghule T, 2019, BIOMED PHARMACOTHER, V109, P1249, DOI 10.1016/j.biopha.2018.10.078
   Weir E, 2004, CAN MED ASSOC J, V171, P1050, DOI 10.1503/cmaj.1041565
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Xu B, 2016, INT J VACCINES IMMUN, V2, P1
   Zhang BZ, 2020, CELL RES, V30, P702, DOI 10.1038/s41422-020-0366-x
   Zheng MJ, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901683
NR 24
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2380-6761
J9 BIOENG TRANSL MED
JI Bioeng. Transl. Med.
AR e10202
DI 10.1002/btm2.10202
EA DEC 2020
PG 9
WC Biotechnology & Applied Microbiology; Engineering, Biomedical;
   Pharmacology & Pharmacy
SC Biotechnology & Applied Microbiology; Engineering; Pharmacology &
   Pharmacy
GA PD4IY
UT WOS:000597651600001
PM 33349797
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU D'Ambrosi, F
   Rossi, G
   Soldavini, CM
   Maggi, V
   Cetera, GE
   Carbone, IF
   Di Martino, D
   Di Maso, M
   Ferrazzi, E
AF D'Ambrosi, Francesco
   Rossi, Gabriele
   Soldavini, Chiara Maria
   Maggi, Valeria
   Cetera, Giulia Emily
   Carbone, Ilma Floriana
   Di Martino, Daniela
   Di Maso, Matteo
   Ferrazzi, Enrico
TI Management of gestational diabetes in women with a concurrent severe
   acute respiratory syndrome coronavirus 2 infection, experience of a
   single center in Northern Italy
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article; Early Access
DE Coronavirus disease 2019; Diet; Gestational diabetes; Insulin;
   International Association of Diabetes and Pregnancy Study Groups;
   Management; Northern Italy; Pandemic
AB Objective In this study we describe the management of women with gestational diabetes (GD) and an ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The aim of the study is to evaluate whether coronavirus disease 2019 (COVID-19) can further complicate pregnancies, and if the protocol we usually use for GD pregnancies is also applicable to patients who have contracted a SARS-CoV-2 infection.
   Methods This is a retrospective study analyzing all pregnant women with GD and concomitant COVID-19 admitted to our institution for antenatal care between March 1 and April 30, 2020.
   Results Among pregnant women with GD and a concomitant SARS-CoV-2 infection, the mean age was 32.9 (SD 5.6) years. Two patients (33%) were of white racial origin and four (67%) were of non-white racial origin. All patients were diagnosed with COVID-19 during the third trimester of pregnancy. Two women were asymptomatic and four were symptomatic. Only two (33.3%) women received treatment with insulin. None of the patients required intensive care or mechanical ventilation. No complications were found among the neonates.
   Conclusion COVID-19 was not found to worsen the prognosis of patients with GD or of their offspring. Glycemic monitoring, diet therapy, and insulin, when needed, are sufficient for good metabolic control and favorable maternal and fetal outcomes.
C1 [D'Ambrosi, Francesco; Rossi, Gabriele; Soldavini, Chiara Maria; Maggi, Valeria; Cetera, Giulia Emily; Carbone, Ilma Floriana; Di Martino, Daniela; Ferrazzi, Enrico] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Woman Child & Neonate, Milan, Italy.
   [Di Maso, Matteo] Univ Milan, Branch Med Stat Biometry & Epidemiol GA Maccacaro, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Ferrazzi, Enrico] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
RP D'Ambrosi, F (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Woman Child & Neonate, Milan, Italy.
EM dambrosifr@gmail.com
CR Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   D'Ambrosi F, 2020, ACTA OBSTET GYN SCAN, V99, P644, DOI 10.1111/aogs.13800
   Ferrazzi E, 2020, BJOG-INT J OBSTET GY, V127, P1116, DOI 10.1111/1471-0528.16278
   Gao YJ, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05274-2
   Mayo K, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.08.027
   Metzger BE, 2010, DIABETES CARE, V33, P676, DOI 10.2337/dc09-1848
   Michie S, 2020, BMJ OPINION
   Ministero della Salute, CIRC MIN SAL 9 MARZ
   Rossi G, 2000, ACTA OBSTET GYN SCAN, V79, P649
   Thangaratinam S, 2020, EUR J ENDOCRINOL, V183, pG49, DOI 10.1530/EJE-20-0401
NR 10
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
DI 10.1002/ijgo.13434
EA DEC 2020
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA PD6WZ
UT WOS:000597824100001
PM 33099770
OA Bronze
DA 2021-01-01
ER

PT J
AU Lei, H
   Alu, A
   Yang, JY
   He, C
   Hong, WQ
   Cheng, ZS
   Yang, L
   Li, J
   Wang, ZL
   Wang, W
   Lu, GW
   Wei, XW
AF Lei, Hong
   Alu, Aqu
   Yang, Jingyun
   He, Cai
   Hong, Weiqi
   Cheng, Zesheng
   Yang, Li
   Li, Jiong
   Wang, Zhenling
   Wang, Wei
   Lu, Guangwen
   Wei, Xiawei
TI Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine
   of SARS-CoV-2
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Letter
C1 [Lei, Hong; Alu, Aqu; Yang, Jingyun; He, Cai; Hong, Weiqi; Cheng, Zesheng; Yang, Li; Li, Jiong; Wang, Zhenling; Wang, Wei; Lu, Guangwen; Wei, Xiawei] Sichuan Univ, West China Hosp, Lab Aging Res & Canc Drug Target, State Key Lab Biotherapy & Canc Ctr,Natl Clin Res, Chengdu 610041, Sichuan, Peoples R China.
   [Lu, Guangwen] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Emergency Dept, Chengdu 610041, Sichuan, Peoples R China.
RP Wei, XW (corresponding author), Sichuan Univ, West China Hosp, Lab Aging Res & Canc Drug Target, State Key Lab Biotherapy & Canc Ctr,Natl Clin Res, Chengdu 610041, Sichuan, Peoples R China.
EM xiaweiwei@scu.edu.cn
FU National Key Research and Development Program of China [2016YFA0201402];
   National Natural Science Foundation Regional Innovation and Development
   [U19A2003]; National Major Scientific and Technological Special Project
   for "Significant New Drugs Development" [2018ZX09733001]
FX This work was supported by the National Key Research and Development
   Program of China (No. 2016YFA0201402), National Natural Science
   Foundation Regional Innovation and Development (U19A2003), The National
   Major Scientific and Technological Special Project for "Significant New
   Drugs Development" (No. 2018ZX09733001).
CR Cibrian D, 2017, EUR J IMMUNOL, V47, P946, DOI 10.1002/eji.201646837
   Gu PF, 2019, CARBOHYD POLYM, V223, DOI 10.1016/j.carbpol.2019.115128
   Roberts AD, 2005, J EXP MED, V202, P123, DOI 10.1084/jem.20050137
   Wang Q, 2014, BIOMATERIALS, V35, P8385, DOI 10.1016/j.biomaterials.2014.05.067
   Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD DEC 11
PY 2020
VL 5
IS 1
AR 291
DI 10.1038/s41392-020-00434-x
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA PG9KO
UT WOS:000600045500002
PM 33311439
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Loucera, C
   Esteban-Medina, M
   Rian, K
   Falco, MM
   Dopazo, J
   Pena-Chilet, M
AF Loucera, Carlos
   Esteban-Medina, Marina
   Rian, Kinza
   Falco, Matias M.
   Dopazo, Joaquin
   Pena-Chilet, Maria
TI Drug repurposing for COVID-19 using machine learning and mechanistic
   models of signal transduction circuits related to SARS-CoV-2 infection
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Letter
C1 [Loucera, Carlos; Esteban-Medina, Marina; Rian, Kinza; Falco, Matias M.; Dopazo, Joaquin; Pena-Chilet, Maria] Hosp Virgen del Rocio, Clin Bioinformat Area, FPS, CDCA, Seville 41013, Spain.
   [Loucera, Carlos; Esteban-Medina, Marina; Falco, Matias M.; Dopazo, Joaquin; Pena-Chilet, Maria] Hosp Virgen del Rocio, Inst Biomed Seville IBIS, Computat Syst Med, Seville 41013, Spain.
   [Falco, Matias M.; Dopazo, Joaquin; Pena-Chilet, Maria] Hosp Virgen del Rocio, CIBERER, Bioinformat Rare Dis BiER, FPS, Seville 41013, Spain.
   [Dopazo, Joaquin] Hosp Virgen del Rocio, FPS, ELIXIR Es, Seville 42013, Spain.
RP Dopazo, J; Pena-Chilet, M (corresponding author), Hosp Virgen del Rocio, Clin Bioinformat Area, FPS, CDCA, Seville 41013, Spain.; Dopazo, J; Pena-Chilet, M (corresponding author), Hosp Virgen del Rocio, Inst Biomed Seville IBIS, Computat Syst Med, Seville 41013, Spain.; Dopazo, J; Pena-Chilet, M (corresponding author), Hosp Virgen del Rocio, CIBERER, Bioinformat Rare Dis BiER, FPS, Seville 41013, Spain.; Dopazo, J (corresponding author), Hosp Virgen del Rocio, FPS, ELIXIR Es, Seville 42013, Spain.
EM joaquin.dopazo@juntadeandalucia.es;
   maria.pena.chilet.ext@juntadeandalucia.es
RI Dopazo, Joaquin/A-9270-2014
OI Dopazo, Joaquin/0000-0003-3318-120X; Marin Falco,
   Matias/0000-0002-6813-0050
FU Spanish Ministry of Economy and Competitiveness [SAF2017-88908-R];
   ISCIIIInstituto de Salud Carlos III [COV20/00788]; European Regional
   Development Funds (ERDF)European Union (EU); Fundacion BBVABBVA
   Foundation [G999088Q]; CIBER-ISCIII [PT17/0009/0006, ACCI2018/29]; H2020
   Programme of the European Union grants Marie Curie Innovative Training
   Network "Machine Learning Frontiers in Precision Medicine" (MLFPM) [GA
   813533]
FX This work is supported by grants SAF2017-88908-R from the Spanish
   Ministry of Economy and Competitiveness, PT17/0009/0006, ACCI2018/29
   from CIBER-ISCIII and COV20/00788 from the ISCIII, co-funded with
   European Regional Development Funds (ERDF), the grant "Large-scale drug
   repurposing in rare diseases by genomic Big Data analysis with machine
   learning methods" from the Fundacion BBVA (G999088Q), as well as H2020
   Programme of the European Union grants Marie Curie Innovative Training
   Network "Machine Learning Frontiers in Precision Medicine" (MLFPM) (GA
   813533).
CR Amadoz A, 2019, BRIEF BIOINFORM, V20, P1655, DOI 10.1093/bib/bby040
   Cheng F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07323-6
   Esteban-Medina M, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2969-0
   Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786
   Ostaszewski M, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-0477-8
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD DEC 11
PY 2020
VL 5
IS 1
AR 290
DI 10.1038/s41392-020-00417-y
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA PG9KO
UT WOS:000600045500001
PM 33311438
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kwan, J
   Brown, M
   Bentley, P
   Brown, Z
   D'Anna, L
   Hall, C
   Halse, O
   Jamil, S
   Jenkins, H
   Kalladka, D
   Patel, M
   Rane, N
   Singh, A
   Taylor, E
   Venter, M
   Lobotesis, K
   Banerjee, S
AF Kwan, Joseph
   Brown, Madison
   Bentley, Paul
   Brown, Zoe
   D'Anna, Lucio
   Hall, Charles
   Halse, Omid
   Jamil, Sohaa
   Jenkins, Harri
   Kalladka, Dheeraj
   Patel, Maneesh
   Rane, Neil
   Singh, Abhinav
   Taylor, Eleanor
   Venter, Marius
   Lobotesis, Kyriakos
   Banerjee, Soma
TI Impact of COVID-19 Pandemic on a Regional Stroke Thrombectomy Service in
   the United Kingdom
SO CEREBROVASCULAR DISEASES
LA English
DT Article; Early Access
DE Stroke; Thrombectomy; Coronavirus disease 2019; Coronavirus; Pandemic;
   Health service
ID ACUTE ISCHEMIC-STROKE; RECOMMENDATIONS; ASSOCIATION; THERAPY; SOCIETY;
   CARE
AB Introduction: We examined the impact of the coronavirus disease 2019 (COVID-19) pandemic on our regional stroke thrombectomy service in the UK. Methods: This was a single-center health service evaluation. We began testing for COVID-19 on 3 March and introduced a modified "COVID Stroke Thrombectomy Pathway" on 18 March. We analyzed the clinical, procedural and outcome data for 61 consecutive stroke thrombectomy patients between 1 January and 30 April. We compared the data for January and February ("pre-COVID," n = 33) versus March and April ("during COVID," n = 28). Results: Patient demographics were similar between the 2 groups (mean age 71 +/- 12.8 years, 39% female). During the COVID-19 pandemic, (a) total stroke admissions fell by 17% but the thrombectomy rate was maintained at 20% of ischemic strokes; (b) successful recanalization rate was maintained at 81%; (c) early neurological outcomes (neurological improvement following thrombectomy and inpatient mortality) were not significantly different; (d) use of general anesthesia fell significantly from 85 to 32% as intended; and (e) time intervals from onset to arrival, groin puncture, and recanalization were not significantly different, whereas internal delays for external referrals significantly improved for door-to-groin puncture (48 [interquartile range (IQR) 39-57] vs. 33 [IQR 27-44] minutes, p = 0.013) and door-to-recanalization (82.5 [IQR 61-110] vs. 60 [IQR 55-70] minutes, p = 0.018). Conclusion: The COVID-19 pandemic has had a negative impact on the stroke admission numbers but not stroke thrombectomy rate, successful recanalization rate, or early neurological outcome. Internal delays actually improved during the COVID-19 pandemic. Further studies should examine the effects of the COVID-19 pandemic on longer term outcome.
C1 [Kwan, Joseph; Brown, Madison; Bentley, Paul; Brown, Zoe; D'Anna, Lucio; Halse, Omid; Jamil, Sohaa; Jenkins, Harri; Kalladka, Dheeraj; Taylor, Eleanor; Venter, Marius; Banerjee, Soma] Imperial Coll London NHS Healthcare Trust, Dept Stroke Med, Fulham Palace Rd, London W6 8RF, England.
   [Kwan, Joseph; Bentley, Paul; D'Anna, Lucio; Lobotesis, Kyriakos; Banerjee, Soma] Imperial Coll London, Hammersmith Hosp, Dept Brain Sci, London, England.
   [Hall, Charles; Patel, Maneesh; Rane, Neil; Singh, Abhinav; Lobotesis, Kyriakos] Imperial Coll London NHS Healthcare Trust, Imaging Dept, Fulham Palace Rd, London W6 8RF, England.
RP Kwan, J (corresponding author), Imperial Coll London NHS Healthcare Trust, Dept Stroke Med, Fulham Palace Rd, London W6 8RF, England.; Lobotesis, K (corresponding author), Imperial Coll London NHS Healthcare Trust, Imaging Dept, Fulham Palace Rd, London W6 8RF, England.
EM joseph.kwan@nhs.net; k.lobotesis@nhs.net
OI Kwan, Joseph/0000-0003-4635-3322; Bentley, Paul/0000-0001-8036-7010;
   Kalladka, Dheeraj/0000-0002-0484-1494
CR Alqahtani SA, 2020, CUREUS, V12, DOI 10.7759/cureus.7808
   [Anonymous], 2020, STROKE, DOI [DOI 10.1161/STR0KEAHA.120.030023, 10.1161/STROKEAHA.120.030023]
   Fraser JF, 2020, J NEUROINTERV SURG, V12, P539, DOI 10.1136/neurintsurg-2020-016098
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Kansagra AP, 2020, NEW ENGL J MED, V383, P400, DOI 10.1056/NEJMc2014816
   Kerleroux B, 2020, STROKE, V51, P2012, DOI 10.1161/STROKEAHA.120.030373
   Khosravani H, 2020, STROKE, V51, P1891, DOI 10.1161/STROKEAHA.120.029838
   Li YN, 2020, STROKE VASC NEUROL, V5, P279, DOI 10.1136/svn-2020-000431
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Martin Daniel, 2020, J Intensive Care Soc, V21, P99, DOI 10.1177/1751143720918517
   Nguyen TN, 2020, STROKE, V51, P1896, DOI 10.1161/STROKEAHA.120.030100
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Rudilosso S, 2020, STROKE, V51, P1991, DOI 10.1161/STROKEAHA.120.030329
   Schonenberger S, 2019, JAMA-J AM MED ASSOC, V322, P1283, DOI 10.1001/jama.2019.11455
   Sharma D, 2020, J NEUROSURG ANESTH, V32, P193, DOI 10.1097/ANA.0000000000000688
   Smith MS, 2020, STROKE, V51, P1902, DOI 10.1161/STROKEAHA.120.029863
   Sweid A, 2020, WORLD NEUROSURG, V140, P491, DOI 10.1016/j.wneu.2020.06.053
   Teo KC, 2020, STROKE, V51, P2228, DOI 10.1161/STROKEAHA.120.030105
   THORNTON J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1406
   Yang B, 2020, J NEUROINTERV SURG, V12, P664, DOI 10.1136/neurintsurg-2020-016177
   Zaidat OO, 2013, STROKE, V44, P2650, DOI 10.1161/STROKEAHA.113.001972
NR 21
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
EI 1421-9786
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
DI 10.1159/000512603
EA DEC 2020
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA PG4AK
UT WOS:000599679200001
PM 33311017
OA Bronze
DA 2021-01-01
ER

PT J
AU Onsun, N
   Gunes, B
   Yabaci, A
AF Onsun, Nahide
   Gunes, Begum
   Yabaci, Aysegul
TI Retention and survival rate of etanercept in psoriasis over 15 years and
   patient outcomes during the COVID-19 pandemic: The real-world experience
   of a single center
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE anti&#8208; TNF treatment; COVID&#8208; 19; etanercept; psoriasis;
   retention rate
ID LONG-TERM EFFICACY; DRUG SURVIVAL; ANKYLOSING-SPONDYLITIS;
   RHEUMATOID-ARTHRITIS; ADALIMUMAB; INFLIXIMAB; BIOLOGICS; SAFETY; AGENTS;
   TRIAL
AB There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated.
C1 [Onsun, Nahide; Gunes, Begum] Bezmialem Vakif Univ, Fac Med, Dept Dermatol & Venereol, Adnan Menderes Blvd Vatan St, TR-34093 Istanbul, Turkey.
   [Yabaci, Aysegul] Bezmialem Vakif Univ, Fac Med, Dept Bioistat, Istanbul, Turkey.
RP Onsun, N (corresponding author), Bezmialem Vakif Univ, Fac Med, Dept Dermatol & Venereol, Adnan Menderes Blvd Vatan St, TR-34093 Istanbul, Turkey.
EM nonsun@bezmialem.edu.tr
CR Antunes Brito C, 2020, ANN RHEUM DIS, V0, P1
   Arnold T, 2016, J DTSCH DERMATOL GES, V14, P1089, DOI [10.1111/ddg.13152_g, 10.1111/ddg.13152]
   Bisonette R, 2006, SKIN THER, V11, P1
   Conti A, 2020, J EUR ACAD DERMATOL, V34, pE360, DOI 10.1111/jdv.16587
   Drug: Etanercept, 2007, DRUG ET
   Esposito M, 2013, BRIT J DERMATOL, V169, P666, DOI 10.1111/bjd.12422
   Frazier-Mironer A, 2014, JOINT BONE SPINE, V81, P352, DOI 10.1016/j.jbspin.2014.02.014
   Gniadecki R, 2015, BRIT J DERMATOL, V172, P244, DOI 10.1111/bjd.13343
   Gniadecki R, 2011, BRIT J DERMATOL, V164, P1091, DOI 10.1111/j.1365-2133.2011.10213.x
   Goffe B, 2003, J AM ACAD DERMATOL, V49, pS105, DOI 10.1016/mjd.2003.554
   Gottlieb AB, 2003, ARCH DERMATOL, V139, P1627, DOI 10.1001/archderm.139.12.1627
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Heiberg MS, 2008, ARTHRIT RHEUM-ARTHR, V59, P234, DOI 10.1002/art.23333
   Jimenez-Puya R, 2009, J EUR ACAD DERMATOL, V23, P402, DOI 10.1111/j.1468-3083.2008.03063.x
   Khraishi M, 2018, CLIN RHEUMATOL, V37, P2351, DOI 10.1007/s10067-018-4141-z
   Lie E, 2015, ANN RHEUM DIS, V74, P970, DOI 10.1136/annrheumdis-2014-206616
   Fernandez-Torres RM, 2015, VALUE HEALTH, V18, P1158, DOI 10.1016/j.jval.2015.07.010
   Menting SP, 2014, BRIT J DERMATOL, V171, P875, DOI 10.1111/bjd.13001
   Minozzi S, 2016, EXPERT OPIN DRUG SAF, V15, P11, DOI 10.1080/14740338.2016.1240783
   Papp KA, 2005, BRIT J DERMATOL, V152, P1304, DOI 10.1111/j.1365-2133.2005.06688.x
   Reich K, 2012, BRIT J DERMATOL, V166, P179, DOI 10.1111/j.1365-2133.2011.10583.x
   van Lumig PPM, 2012, BRIT J DERMATOL, V166, P445, DOI 10.1111/j.1365-2133.2011.10584.x
   van Lumig PPM, 2013, J AM ACAD DERMATOL, V68, P57, DOI 10.1016/j.jaad.2012.05.040
   Yousaf Ahmed, 2021, J Am Acad Dermatol, V84, P70, DOI 10.1016/j.jaad.2020.09.009
NR 24
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14623
DI 10.1111/dth.14623
EA DEC 2020
PG 9
WC Dermatology
SC Dermatology
GA PD1AQ
UT WOS:000597427100001
PM 33274541
OA Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article; Early Access
AB This Medical Letter review summarizes the evidence underlying the US Food and Drug Administration's emergency use authorization of bamlanivimab, an investigational neutralizing IgG1 monoclonal antibody for treatment of COVID-19, including specification of high-risk patient groups eligible for the drug and its dosage and administration.
CR Chen Peter, 2020, N Engl J Med, DOI 10.1056/NEJMoa2029849
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
DI 10.1001/jama.2020.24415
EA DEC 2020
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA PD9HJ
UT WOS:000597986500002
PM 33306087
OA Bronze
DA 2021-01-01
ER

PT J
AU Conway, J
   Gould, A
   Westley, R
   Raju, SA
   Oklopcic, A
   Broadbent, A
   Abdelhafiz, AH
AF Conway, Joanne
   Gould, Anna
   Westley, Richard
   Raju, Suneil A.
   Oklopcic, Anja
   Broadbent, Alex
   Abdelhafiz, Ahmed H.
TI Clinical characteristics and progression of COVID-19 confirmed cases
   admitted to a single British clinical centre-A brief case series report
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article; Early Access
ID RESPIRATORY SYNDROME; MORTALITY
AB Objectives In December 2019, a pneumonia-like illness was first reported in Wuhan-China caused by a new coronavirus named corona virus disease-2019 (COVID-19) which then spread to cause a global pandemic. Most of the available data in the literature is derived from Chinese cohorts and we aim to contribute the clinical experience of a single British clinical centre with the characteristics of a British cohort.
   Design A prospective case series. Setting: A single clinical centre in the UK. Methods: We have collected the demographics and medical characteristics of all COVID-19-positive cases admitted over 2-week period. All cases were diagnosed by PCR.
   Results Total of 71 COVID-19 patients were included in this case series. Majority of patients (75%) were >= 75 years old and 58% were men. Pre-existing comorbidities was common (85% of patients). Most patients presented with respiratory symptoms such as fever (59%), shortness of breath (56%) and cough (55%). Gastrointestinal symptoms were second-most common presenting compliant such as diarrhoea (10%) and abdominal pain (7%). Opacification in chest X-rays was demonstrated in 45% of patients. All patients received supportive treatment and no specific antiviral therapy was administered in this cohort. So far, 18 (25%) patients have fully recovered, 9 patients (13%) escalated to a higher level of care and 10 (14%) have died. Patients who died were non-significantly older than those who have recovered (78.0 vs 69.2 years, P = .15) but they had a significantly higher clinical frailty scores (5.75 vs 3.36, P = .005).
   Conclusion This case series demonstrated that the characteristics of British COVID-19 patients were generally similar to what is published in literature, although we report more gastrointestinal symptoms at presentation. We have identified frailty as a risk factor for adverse outcome in COVID-19 patients and suggest that it should be included in the future vaccination recommendations.
C1 [Conway, Joanne; Gould, Anna; Westley, Richard; Raju, Suneil A.; Oklopcic, Anja; Broadbent, Alex; Abdelhafiz, Ahmed H.] Rotherham Gen Hosp, Dept Geriatr Med, Rotherham S60 2UD, S Yorkshire, England.
RP Abdelhafiz, AH (corresponding author), Rotherham Gen Hosp, Dept Geriatr Med, Rotherham S60 2UD, S Yorkshire, England.
EM ahmedhafiz@hotmail.com
CR [Anonymous], 2020, COVID 19 INV IN CLIN
   [Anonymous], 2020, COVID 19 EP VIR CLIN
   [Anonymous], 2020, Q A SIM DIFF COVID 1
   Choi KW, 2003, ANN INTERN MED, V139, P715, DOI 10.7326/0003-4819-139-9-200311040-00005
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Hong KH, 2018, THORAX, V73, P286, DOI 10.1136/thoraxjnl-2016-209313
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
NR 14
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
AR e13807
DI 10.1111/ijcp.13807
EA DEC 2020
PG 5
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA PC9DC
UT WOS:000597297000001
PM 33128856
OA Bronze
DA 2021-01-01
ER

PT J
AU Jakob, CEM
   Kohlmayer, F
   Meurers, T
   Vehreschild, JJ
   Prasser, F
AF Jakob, Carolin E. M.
   Kohlmayer, Florian
   Meurers, Thierry
   Vehreschild, Jorg Janne
   Prasser, Fabian
TI Design and evaluation of a data anonymization pipeline to promote Open
   Science on COVID-19
SO SCIENTIFIC DATA
LA English
DT Article; Data Paper
AB The Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS) is a European registry for studying the epidemiology and clinical course of COVID-19. To support evidence-generation at the rapid pace required in a pandemic, LEOSS follows an Open Science approach, making data available to the public in real-time. To protect patient privacy, quantitative anonymization procedures are used to protect the continuously published data stream consisting of 16 variables on the course and therapy of COVID-19 from singling out, inference and linkage attacks. We investigated the bias introduced by this process and found that it has very little impact on the quality of output data. Current laws do not specify requirements for the application of formal anonymization methods, there is a lack of guidelines with clear recommendations and few real-world applications of quantitative anonymization procedures have been described in the literature. We therefore believe that our work can help others with developing urgently needed anonymization pipelines for their projects.
C1 [Jakob, Carolin E. M.; Vehreschild, Jorg Janne] Univ Hosp Cologne, Cologne, Germany.
   [Kohlmayer, Florian] Tech Univ Munich, Sch Med, Munich, Germany.
   [Meurers, Thierry; Prasser, Fabian] Berlin Inst Hlth BIH, Berlin, Germany.
   [Meurers, Thierry; Prasser, Fabian] Charite Univ Med Berlin, Berlin, Germany.
   [Meurers, Thierry; Prasser, Fabian] Free Univ Berlin, Berlin, Germany.
   [Meurers, Thierry; Prasser, Fabian] Humboldt Univ, Berlin, Germany.
   [Meurers, Thierry; Prasser, Fabian] Berlin Inst Hlth, Berlin, Germany.
   [Vehreschild, Jorg Janne] German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany.
   [Vehreschild, Jorg Janne] Goethe Univ Frankfurt, Dept Internal Med Hematol & Oncol, Frankfurt, Germany.
RP Prasser, F (corresponding author), Berlin Inst Hlth BIH, Berlin, Germany.; Prasser, F (corresponding author), Charite Univ Med Berlin, Berlin, Germany.; Prasser, F (corresponding author), Free Univ Berlin, Berlin, Germany.; Prasser, F (corresponding author), Humboldt Univ, Berlin, Germany.; Prasser, F (corresponding author), Berlin Inst Hlth, Berlin, Germany.
EM fabian.prasser@charite.de
FU German Center for Infection Research (DZIF); Willy Robert Pitzer
   Foundation
FX We thank all study sites participating in the LEOSS study and the LEOSS
   core team, including Jorg Janne Vehreschild, Melanie Stecher, Maximilian
   Schons, Lisa Pilgram, Carolin Jakob, Annika Classen, Sandra Fuhrmann,
   Nick Schulze and Bernd Franke. This study was supported by the German
   Center for Infection Research (DZIF) and the Willy Robert Pitzer
   Foundation. Open Access funding enabled and organized by Projekt DEAL.
CR Aggarwal C, 2005, P 31 INT C VER LARG, P901
   [Anonymous], 2020, LEAN EUROPEAN OPEN S
   Benitez K, 2010, J AM MED INFORM ASSN, V17, P169, DOI 10.1136/jamia.2009.000026
   Blischak JD, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004668
   Brat GA, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00308-0
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Danezis G, 2014, PRIVACY DATA PROTECT
   El Emam K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1139
   Elliot M., 2016, ANONYMISATION DECISI
   European Medicines Agency, 2018, EMA909152016
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Fung BCM, 2010, ACM COMPUT SURV, V42, DOI 10.1145/1749603.1749605
   Heatherly R, 2014, J BIOMED INFORM, V52, P243, DOI 10.1016/j.jbi.2014.07.005
   Jakob C, 2020, INFECTION, V48, P1, DOI [10.1007/s15010-019-01387-2, DOI 10.1007/S15010-019-01387-2]
   Keerie C, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2382-9
   Kuzilek J, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.171
   Li N, 2007, INT CONF NANO MICRO, P692, DOI 10.1109/icde.2007.367856
   Li XG, 2020, J MED VIROL, V92, P501, DOI 10.1002/jmv.25701
   Malin B, 2011, HUM GENET, V130, P383, DOI 10.1007/s00439-011-1042-5
   NHS Digital, 2020, POT COR COVID 19 SYM
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Norton A., 2020, GLOPID R ROADMAP DAT
   Nss-Schmidt H., 2020, EC CONSEQUENCES COVI
   Office for Civil Rights, 2012, METH DE ID PHI
   Office for Civil Rights HHS, 2002, Fed Regist, V67, P53181
   Prasser F, 2020, SOFTWARE PRACT EXPER, V50, P1277, DOI 10.1002/spe.2812
   SMITH CT, 2015, TRIALS S2, V16, DOI DOI 10.1186/1745-6215-16-S2-O1
   Sweeney L, 2002, INT J UNCERTAIN FUZZ, V10, P557, DOI 10.1142/S0218488502001648
   Tarrant D., 2020, ANONYMISING DATA TIM
   World Health Organization, 2020, WHO ACC RES INN NEW
NR 30
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2052-4463
J9 SCI DATA
JI Sci. Data
PD DEC 10
PY 2020
VL 7
IS 1
AR 435
DI 10.1038/s41597-020-00773-y
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PG5DI
UT WOS:000599754900002
PM 33303746
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Brandt, GS
   Novak, WRP
AF Brandt, Gabriel S.
   Novak, Walter R. P.
TI SARS-CoV-2 virtual biochemistry labs on bioinformatics and drug design
SO BIOCHEMISTRY AND MOLECULAR BIOLOGY EDUCATION
LA English
DT Article; Early Access
DE computational biology; enzymes and catalysis; laboratory exercises;
   molecular visualization; using simulation and internet resources for
   teaching
ID VISUALIZATION
AB Colleges and universities are learning to provide relevant virtual lab experiences for students due to the COVID-19 pandemic. Even schools attempting in-person instruction often need to utilize virtual experiences for students absent due to quarantine or illness. Much of biochemistry is amenable to molecular visualization and/or computational study; however, many faculty face learning how to utilize new computational and molecular visualization software. We present a set of virtual lab exercises with detailed instructions to engage students in the discovery of novel antiviral compounds against the SARS-CoV-2 main protease.
C1 [Brandt, Gabriel S.] Franklin & Marshall Coll, Dept Chem, Lancaster, PA 17604 USA.
   [Novak, Walter R. P.] Wabash Coll, Dept Chem, 301 W Wabash Ave, Crawfordsville, IN 47933 USA.
RP Novak, WRP (corresponding author), Wabash Coll, Dept Chem, 301 W Wabash Ave, Crawfordsville, IN 47933 USA.
EM novakw@wabash.edu
RI Novak, Walter/ABI-5802-2020
OI Novak, Walter/0000-0002-1311-5953
FU Franklin and Marshall College Eyler Fund; Wabash College Haines
   Biochemistry Fund
FX Franklin and Marshall College Eyler Fund; Wabash College Haines
   Biochemistry Fund
CR Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Dries DR, 2017, BIOCHEM MOL BIOL EDU, V45, P69, DOI 10.1002/bmb.20991
   Ghosh AK, 2005, J MED CHEM, V48, P6767, DOI 10.1021/JM050548m
   Gimeno A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113793
   Hanauer DI, 2014, CBE-LIFE SCI EDUC, V13, P149, DOI 10.1187/cbe.13-06-0123
   Ho BL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144865
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Su H.X., 2020, SARS COV 2 3CL PROTE
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Van Heuvelen KM, 2020, J CHEM EDUC, V97, P925, DOI 10.1021/acs.jchemed.9b00281
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1470-8175
EI 1539-3429
J9 BIOCHEM MOL BIOL EDU
JI Biochem. Mol. Biol. Educ.
DI 10.1002/bmb.21480
EA DEC 2020
PG 3
WC Biochemistry & Molecular Biology; Education, Scientific Disciplines
SC Biochemistry & Molecular Biology; Education & Educational Research
GA PC4HH
UT WOS:000596963900001
PM 33301634
OA Bronze
DA 2021-01-01
ER

PT J
AU Strohbehn, GW
   Heiss, BL
   Rouhani, SJ
   Trujillo, JA
   Yu, J
   Kacew, AJ
   Higgs, EF
   Bloodworth, JC
   Cabanov, A
   Wright, RC
   Koziol, AK
   Weiss, A
   Danahey, K
   Karrison, TG
   Edens, CC
   Ventura, IB
   Pettit, NN
   Patel, BK
   Pisano, J
   Strek, ME
   Gajewski, TF
   Ratain, MJ
   Reid, PD
AF Strohbehn, Garth W.
   Heiss, Brian L.
   Rouhani, Sherin J.
   Trujillo, Jonathan A.
   Yu, Jovian
   Kacew, Alec J.
   Higgs, Emily F.
   Bloodworth, Jeffrey C.
   Cabanov, Alexandra
   Wright, Rachel C.
   Koziol, Adriana K.
   Weiss, Alexandra
   Danahey, Keith
   Karrison, Theodore G.
   Edens, Cuoghi C.
   Ventura, Iazsmin Bauer
   Pettit, Natasha N.
   Patel, Bhakti K.
   Pisano, Jennifer
   Strek, Mary E.
   Gajewski, Thomas F.
   Ratain, Mark J.
   Reid, Pankti D.
TI COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the
   Treatment of Noncritical COVID-19 Pneumonia
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article; Early Access
AB Interleukin-6 (IL-6)-mediated hyperinflammation may contribute to the mortality of coronavirus disease 2019 (COVID-19). The IL-6 receptor-blocking monoclonal antibody tocilizumab has been repurposed for COVID-19, but prospective trials and dose-finding studies in COVID-19 have not yet fully reported. We conducted a single-arm phase II trial of low-dose tocilizumab in nonintubated hospitalized adult patients with COVID-19, radiographic pulmonary infiltrate, fever, and C-reactive protein (CRP) >= 40 mg/L. We hypothesized that doses significantly lower than the emerging standards of 400 mg or 8 mg/kg would resolve clinical and laboratory indicators of hyperinflammation. A dose range from 40 to 200 mg was evaluated, with allowance for one repeat dose at 24 to 48 hours. The primary objective was to assess the relationship of dose to fever resolution and CRP response. Thirty-two patients received low-dose tocilizumab, with the majority experiencing fever resolution (75%) and CRP decline consistent with IL-6 pathway abrogation (86%) in the 24-48 hours following drug administration. There was no evidence of a relationship between dose and fever resolution or CRP decline over the dose range of 40-200 mg. Within the 28-day follow-up, 5 (16%) patients died. For patients who recovered, median time to clinical recovery was 3 days (interquartile range, 2-5). Clinically presumed and/or cultured bacterial superinfections were reported in 5 (16%) patients. Low-dose tocilizumab was associated with rapid improvement in clinical and laboratory measures of hyperinflammation in hospitalized patients with COVID-19. Results of this trial provide rationale for a randomized, controlled trial of low-dose tocilizumab in COVID-19.
C1 [Strohbehn, Garth W.; Heiss, Brian L.; Rouhani, Sherin J.; Trujillo, Jonathan A.; Yu, Jovian; Bloodworth, Jeffrey C.; Wright, Rachel C.; Koziol, Adriana K.; Gajewski, Thomas F.; Ratain, Mark J.] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Kacew, Alec J.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
   [Higgs, Emily F.; Cabanov, Alexandra] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA.
   [Weiss, Alexandra; Patel, Bhakti K.; Strek, Mary E.] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Danahey, Keith; Ratain, Mark J.] Univ Chicago, Ctr Personalized Therapeut, Chicago, IL 60637 USA.
   [Danahey, Keith] Univ Chicago, Ctr Res Informat, Chicago, IL 60637 USA.
   [Karrison, Theodore G.] Univ Chicago, Dept Publ Hlth Policy, Chicago, IL 60637 USA.
   [Edens, Cuoghi C.; Ventura, Iazsmin Bauer; Reid, Pankti D.] Univ Chicago, Dept Med, Sect Rheumatol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Edens, Cuoghi C.] Univ Chicago, Dept Pediat, Sect Rheumatol, Chicago, IL 60637 USA.
   [Pettit, Natasha N.] Univ Chicago, Dept Pharm, Chicago, IL 60637 USA.
   [Pisano, Jennifer] Univ Chicago, Dept Med, Sect Infect Dis & Global Hlth, 5841 S Maryland Ave, Chicago, IL 60637 USA.
RP Reid, PD (corresponding author), Univ Chicago, Dept Med, Sect Rheumatol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM Pankti.reid@uchospitals.edu
FU University of ChicagoUniversity of Chicago
FX This trial was funded and sponsored by the University of Chicago. The
   institution had no role in the design, execution, or analysis of this
   trial. There was no industry involvement in COVIDOSE.
CR [Anonymous], 2020, ASSISTANCE PUBLIQUE
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Cabanov A., 2020, AACR VIRT M COVID CA
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Genentech/Roche, 2020, ROCH PHAS 3 EMPACTA
   Goldman J.D., 2020, NEW ENGL J MED, V383, P1817
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Gupta S, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.6252
   Hermine O, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.6820
   Hinton D.M., 2020, REMDESIVIR EUA LETT, P1
   Hoffmann-La Roche, STUD EV EFF SAF REMD
   Hoffmann-La Roche, STUD EV SAF EFF TOC
   Huang HY, 2018, P NATL ACAD SCI USA, V115, pE6826, DOI 10.1073/pnas.1712628115
   Kopf M, 1998, J EXP MED, V188, P1895, DOI 10.1084/jem.188.10.1895
   Liu T., 2020, SSRN ELECT J, DOI [DOI 10.2139/SSRN.3548761, 10.2139/ssrn.3548761]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332
   Parr JB, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.6557
   Patel A, 2020, JCO GLOB ONCOL, V6, P382, DOI 10.1200/JGO.19.00341
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   PR Newswire Association, 2020, BAR COMB REMD RED TI
   Prescott HC, 2020, JAMA-J AM MED ASSOC, V324, P1292, DOI 10.1001/jama.2020.16747
   Ratain MJ, 2019, JAMA ONCOL, V5, P1097, DOI 10.1001/jamaoncol.2019.1341
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rosas I., 2020, TOCILIZUMAB HOSP PAT, DOI [10.1101/2020.08.27.20183442, DOI 10.1101/2020.08.27.20183442]
   Salvarani C, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.6615
   Serritella AV, 2020, CLIN PHARMACOL THER, V108, P487, DOI 10.1002/cpt.1853
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Somers Emily C, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa954
   Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023
   Stone John H, 2020, N Engl J Med, V383, P2333, DOI 10.1056/NEJMoa2028836
   Stone JH, 2017, NEW ENGL J MED, V377, P1494, DOI 10.1056/NEJMc1711031
   Strohbehn G.W., 2020, AACR VIRT M COV 19 C
   Strohbehn GW, 2020, CLIN PHARMACOL THER, V108, P425, DOI 10.1002/cpt.1931
   University of Chicago, LOW DOS TOC VERS STA
   US Food and Drug Administration, 2017, MULT REV APPL NUMB B
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
NR 39
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
DI 10.1002/cpt.2117
EA DEC 2020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PC3YV
UT WOS:000596941900001
PM 33210302
OA Bronze
DA 2021-01-01
ER

PT J
AU Zabeen, B
   Ahmed, B
   Nahar, J
AF Zabeen, Bedowra
   Ahmed, Bulbul
   Nahar, Jebun
TI Young people with type 1 diabetes on insulin pump therapy could fast
   safely during COVID-19 pandemic Ramadan: A telemonitoring experience in
   Bangladesh
SO JOURNAL OF DIABETES INVESTIGATION
LA English
DT Article; Early Access
DE COVID&#8208; 19; Ramadan; Type&#160; 1 diabetes
ID GLYCEMIC CONTROL; GLUCOSE FLUCTUATION; SAUDI CHILDREN; ADOLESCENTS;
   INFUSION
AB Our aim was to report our telemedicine experience with type 1 diabetes patients using insulin pumps who fasted for Ramadan 2020 during the COVID-19 pandemic. The routine diabetes outpatient care in our Changing Diabetes in Children (CDiC) Pediatric Diabetes Center at the Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders hospital was closed, as there was a lockdown from 26 March in Bangladesh. The diabetes team in our center started telemedicine care for routine follow up of patients. Nine patients who wished to fast for Ramadan contacted our diabetes team over the phone. The mean age was 19.3 +/- 5.0 years, and five (55.6%) were female. Most of the patients fasted >20 days. Hyperglycemia and mild hypoglycemia were common complications during fasting. There was no episode of severe hypoglycemia or diabetic ketoacidosis, and none of the patients required admission. During the COVID-19 crisis in Bangladesh, patients with type 1 diabetes using an insulin pump could fast safely for Ramadan with the support of the telemedicine service by the diabetes team.
C1 [Zabeen, Bedowra; Ahmed, Bulbul; Nahar, Jebun] Bangladesh Inst Res & Rehabil Diabet Endocrine &, Dept Pediat, Dhaka, Bangladesh.
   [Zabeen, Bedowra] Bangladesh Inst Res & Rehabil Diabet Endocrine &, Changing Diabet Children Program, Dhaka, Bangladesh.
RP Zabeen, B (corresponding author), Bangladesh Inst Res & Rehabil Diabet Endocrine &, Dept Pediat, Dhaka, Bangladesh.; Zabeen, B (corresponding author), Bangladesh Inst Res & Rehabil Diabet Endocrine &, Changing Diabet Children Program, Dhaka, Bangladesh.
EM bzabeen@hotmail.com
CR Afandi B, 2017, J ENDOCRINOL INVEST, V40, P741, DOI 10.1007/s40618-017-0633-y
   Al-Arouj M, 2010, DIABETES CARE, V33, P1895, DOI 10.2337/dc10-0896
   Azad Kiswhar, 2012, Indian J Endocrinol Metab, V16, P516, DOI 10.4103/2230-8210.97998
   Bin-Abbas B, 2006, ANN SAUDI MED, V26, P327
   Bin-Abbas BS, 2006, ANN SAUDI MED, V26, P405, DOI 10.5144/0256-4947.2006.405
   Bin-Abbas BS, 2008, ANN SAUDI MED, V28, P305
   Bin-Abbas BS, 2005, SAUDI MED J, V26, P918
   Danne T, 2020, LANCET DIABETES ENDO, V8, P465, DOI 10.1016/S2213-8587(20)30155-8
   Deeb A, 2017, DIABETES RES CLIN PR, V126, P10, DOI 10.1016/j.diabres.2017.01.015
   Elbarbary NS, 2016, DIABETES-METAB RES, V32, P623, DOI 10.1002/dmrr.2781
   Hawli YMA, 2009, CURR THER RES CLIN E, V70, P29, DOI 10.1016/j.curtheres.2009.02.001
   Jaleel Mohammed Abdul, 2011, Indian J Endocrinol Metab, V15, P268, DOI 10.4103/2230-8210.85578
   Jawad F, 2015, J PAK MED ASSOC, V65, pS1
   Kaplan W, 2015, DIABETES CARE, V38, pE162, DOI 10.2337/dc15-1108
   Lee JY, 2015, DIABETIC MED, V32, P1658, DOI 10.1111/dme.12836
   Loh HH, 2019, J DIABETES INVEST, V10, P1490, DOI 10.1111/jdi.13054
   Salti I, 2004, DIABETES CARE, V27, P2306, DOI 10.2337/diacare.27.10.2306
   Zabeen Bedowra, 2014, Indian J Endocrinol Metab, V18, P44, DOI 10.4103/2230-8210.126530
NR 18
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2040-1116
EI 2040-1124
J9 J DIABETES INVEST
JI J. Diabetes Investig.
DI 10.1111/jdi.13449
EA DEC 2020
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA PC2CX
UT WOS:000596816400001
PM 33098746
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Shi, TH
   Huang, YL
   Chen, CC
   Pi, WC
   Hsu, YL
   Lo, LC
   Chen, WY
   Fu, SL
   Lin, CH
AF Shi, Tzu-Hau
   Huang, Yi-Long
   Chen, Chiao-Che
   Pi, Wen-Chieh
   Hsu, Yu-Ling
   Lo, Lee-Chiang
   Chen, Wei-Yi
   Fu, Shu-Ling
   Lin, Chao-Hsiung
TI Andrographolide and its fluorescent derivative inhibit the main
   proteases of 2019-nCoV and SARS-CoV through covalent linkage
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE 2019-nCoV; SARS-CoV; Main protease; Andrographolide
ID NATURAL-PRODUCTS; CORONAVIRUS; DRUGS
AB The coronavirus disease 2019 (COVID-19) pandemic caused by 2019 novel coronavirus (2019-nCoV) has been a crisis of global health, whereas the effective vaccines against 2019-nCoV are still under development. Alternatively, utilization of old drugs or available medicine that can suppress the viral activity or replication may provide an urgent solution to suppress the rapid spread of 2019-nCoV. Andrographolide is a highly abundant natural product of the medicinal plant, Andrographis paniculata, which has been clinically used for inflammatory diseases and anti-viral therapy. We herein demonstrate that both andrographolide and its fluorescent derivative, the nitrobenzoxadiazole-conjugated andrographolide (Andro-NBD), suppressed the main protease (M-pro) activities of 2019-nCoV and severe acute respiratory syndrome coronavirus (SARS-CoV). Moreover, Andro-NBD was shown to covalently link its fluorescence to these proteases. Further mass spectrometry (MS) analysis suggests that andrographolide formed a covalent bond with the active site Cys145 of either 2019-nCoV M-pro or SARS-CoV M-pro. Consistently, molecular modeling analysis supported the docking of andrographolide within the catalytic pockets of both viral M(pro)s. Considering that andrographolide is used in clinical practice with acceptable safety and its diverse pharmacological activities that could be beneficial for attenuating COVID-19 symptoms, extensive investigation of andrographolide on the suppression of 2019-nCoV as well as its application in COVID-19 therapy is suggested. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Shi, Tzu-Hau; Chen, Chiao-Che; Lin, Chao-Hsiung] Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan.
   [Shi, Tzu-Hau; Chen, Chiao-Che; Lin, Chao-Hsiung] Natl Yang Ming Univ, Inst Genome Sci, Taipei 112, Taiwan.
   [Shi, Tzu-Hau] Natl Yang Ming Univ, Biomed Ind PhD Program, Taipei 112, Taiwan.
   [Huang, Yi-Long; Lin, Chao-Hsiung] Natl Yang Ming Univ, Aging & Hlth Res Ctr, Taipei 112, Taiwan.
   [Pi, Wen-Chieh; Chen, Wei-Yi] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.
   [Hsu, Yu-Ling; Lo, Lee-Chiang] Natl Taiwan Univ, Dept Chem, Taipei 106, Taiwan.
   [Fu, Shu-Ling] Natl Yang Ming Univ, Inst Tradit Med, Taipei 112, Taiwan.
   [Lin, Chao-Hsiung] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan.
RP Lin, CH (corresponding author), Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan.; Lin, CH (corresponding author), Natl Yang Ming Univ, Inst Genome Sci, Taipei 112, Taiwan.; Fu, SL (corresponding author), Natl Yang Ming Univ, Inst Tradit Med, Taipei 112, Taiwan.
EM slfu@ym.edu.tw; chlin2@ym.edu.tw
RI Lo, Lee-Chiang/G-9165-2015
OI Lo, Lee-Chiang/0000-0002-5821-1690
FU Ministry of Science and Technology in TaiwanMinistry of Science and
   Technology, Taiwan [MOST 106-2320-B-010-006-MY3, MOST
   106-2311-B-010-004-MY3, MOST 109-2327-B-010-005, MOST
   109-2321-B-010-003]
FX This work was supported by grants from the Ministry of Science and
   Technology in Taiwan (MOST 106-2320-B-010-006-MY3, MOST
   106-2311-B-010-004-MY3 and MOST 109-2327-B-010-005, MOST
   109-2321-B-010-003).
CR Burgos RA, 2009, CLIN RHEUMATOL, V28, P931, DOI 10.1007/s10067-009-1180-5
   Calabrese C, 2000, PHYTOTHER RES, V14, P333, DOI 10.1002/1099-1573(200008)14:5&lt;333::AID-PTR584&gt;3.0.CO;2-D
   Chang Jing, 2008, Zhong Xi Yi Jie He Xue Bao, V6, P1238, DOI 10.3736/jcim20081206
   Cheng SC, 2010, BIOPHYS J, V98, P1327, DOI 10.1016/j.bpj.2009.12.4272
   Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237
   Dai Y, 2019, CRIT REV FOOD SCI, V59, pS17, DOI 10.1080/10408398.2018.1501657
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Gersch M, 2012, NAT PROD REP, V29, P659, DOI 10.1039/c2np20012k
   Gupta S, 2017, ARCH VIROL, V162, P611, DOI 10.1007/s00705-016-3166-3
   Hsu YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152770
   Jantan I, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00655
   Jayakumar T., 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/846740
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joy Saju, 2006, In Silico Biology, V6, P601
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liao HC, 2019, BIOCHEM PHARMACOL, V163, P308, DOI 10.1016/j.bcp.2019.02.028
   Liao WP, 2020, BRIT J PHARMACOL, V177, P3662, DOI 10.1111/bph.15080
   Lin PY, 2008, ARCH BIOCHEM BIOPHYS, V472, P34, DOI 10.1016/j.abb.2008.01.023
   Liu SH, 2014, BIOCHEM PHARMACOL, V87, P229, DOI 10.1016/j.bcp.2013.10.014
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Nutho B., 2020, BIOCHEMISTRY
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Sandborn WJ, 2013, AM J GASTROENTEROL, V108, P90, DOI 10.1038/ajg.2012.340
   Sanders J.M., 2020, J AM MED ASS
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   ul Qamar M.T., 2020, J PHARM ANAL
   Nguyen VS, 2015, J NAT PROD, V78, P208, DOI 10.1021/np5007179
   Wang JG, 2014, MOL CELL PROTEOMICS, V13, P876, DOI 10.1074/mcp.M113.029793
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhu T, 2013, INT J MOL SCI, V14, P23581, DOI 10.3390/ijms141223581
NR 34
TC 0
Z9 0
U1 49
U2 49
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 10
PY 2020
VL 533
IS 3
BP 467
EP 473
DI 10.1016/j.bbrc.2020.08.086
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OP7LW
UT WOS:000588268300031
PM 32977949
OA Green Published
DA 2021-01-01
ER

PT J
AU Davitadze, A
   Meylakhs, P
   Lakhov, A
   King, EJ
AF Davitadze, Arsen
   Meylakhs, Peter
   Lakhov, Aleksey
   King, Elizabeth J.
TI Harm reduction via online platforms for people who use drugs in Russia:
   a qualitative analysis of web outreach work
SO HARM REDUCTION JOURNAL
LA English
DT Article
DE Harm reduction; Web outreach; People who use drugs (PWUD); Online
   platforms; Qualitative research; Russia
AB Background Harm reduction services to people who use drugs (PWUD) in Russia are insufficient in terms of quantity, government endorsement, and accessibility. The situation has recently deteriorated even further because of social distancing measures of the COVID-19 pandemic. Several organizations have started to provide some harm reduction services via online platforms by web outreach. However, little is known on how online outreach services are organized and implemented. Drawing on the example of St. Petersburg-based NGO "Humanitarian Action," we explored web outreach work in Telegram instant messenger. Methods Our data were comprised of 4 semi-structured interviews with the NGO staff and 301 cases of web outreach work with PWUD. We used thematic analysis to study the process of web outreach, harm reduction service provision, and needs of PWUD. Results Three stages of the process of web outreach work were identified: clients initiating communication, NGO workers addressing clients' needs, and NGO workers receiving clients' feedback. Communication proceeded in group chat or direct messages. Challenges in addressing clients' needs happened when clients turned for help after hours, sent recorded voice messages, sent unclear messages, and/or were unwilling to transition to telephone communication. All web outreach workers reported receiving only positive feedback on their work. The needs of PWUD were categorized into two major themes, depending on whether they can be addressed fully or partially online. In cases of online only provision of services, web outreach workers helped PWUD treat minor injection drug use complications, obtain verified harm reduction information and receive general psychological support. In instances of partial online services provision, PWUD were assisted in getting treatment of severe injection drug use complications, overdoses, and in accessing offline medical, psychological, social, legal and harm reduction services. Conclusions Our research demonstrated that web outreach work is a convenient tool for delivering some harm reduction services to PWUD either partially or completely online and for recruiting new clients (including hard-to-reach PWUD that avoid attending brick-and-mortar facilities). Harm reduction organizations should consider incorporating online harm reduction services into their activities. However, further research is needed to explore relative advantages and disadvantages of online harm reduction services.
C1 [Davitadze, Arsen; Meylakhs, Peter] Natl Res Univ Higher Sch Econ, Ctr Hlth Econ Management & Policy, Kantemirovstaya St 3a, St Petersburg 194100, Russia.
   [Lakhov, Aleksey] St Petersburg Charitable Fund Humanitarian Act, Kamennoostrovsky Prospekt,63,A,8-N, St Petersburg, Russia.
   [King, Elizabeth J.] Univ Michigan, Sch Publ Hlth, 1415 Washington Hts,SPH 1,Room 3842, Ann Arbor, MI 48104 USA.
RP Meylakhs, P (corresponding author), Natl Res Univ Higher Sch Econ, Ctr Hlth Econ Management & Policy, Kantemirovstaya St 3a, St Petersburg 194100, Russia.
EM peter.meylakhs@gmail.com
FU Russian Science FoundationRussian Science Foundation (RSF)
   [20-18-00307]; National Institutes of Health/Fogarty International
   CenterUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43-TW000233]; National Institute on Drug AbuseUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA)
FX This research was supported by the Russian Science Foundation under
   grant (Project No. 20-18-00307, The Health of Nation: the
   Multidimensional Analysis of Health, Health Inequality and
   Health-Related Quality of Life) and by the New York State International
   Training and Research Program grant D43-TW000233, from the National
   Institutes of Health/Fogarty International Center and the National
   Institute on Drug Abuse.
CR Cepeda JA, 2018, LANCET HIV, V5, pE578, DOI 10.1016/S2352-3018(18)30168-1
   Coffin P, 2008, OVERDOSE MAJOR CAUSE
   Davey Z, 2012, J MENT HEALTH, V21, P386, DOI 10.3109/09638237.2012.682265
   Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3
   Eurasian Harm Reduction Association, 2020, HARM RED PROGR COVID
   Federal scientific and methodological center for prevention and control of AIDS Central research Institute Central research Institute of epidemiology of Health-care regulation system, HIV INF RUSS 1 HALF
   Guest G, 2011, APPL THEMATIC ANAL
   Hagan H, 2011, J INFECT DIS, V204, P74, DOI 10.1093/infdis/jir196
   Heimer R, 2010, DRUG ALCOHOL DEPEN, V109, P79, DOI 10.1016/j.drugalcdep.2009.12.010
   Hoskins R, 2016, FOREIGN POLICY
   Humanitarian Action, HARM RED PROGR PEOPL
   Humanitarian Action, HIST FUND
   Humanitarian Action, SCHED MOB UN
   Karamouzian M, 2020, LANCET PSYCHIAT, V7, P390, DOI 10.1016/S2215-0366(20)30144-9
   Khurshudyan I, 2020, WASHINGTON POST
   Kozlov AP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005238
   Lakhov A, 2019, WEB OUTREACH HARM RE
   Logan DE, 2010, J CLIN PSYCHOL, V66, P201, DOI 10.1002/jclp.20669
   Lunze K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136030
   Masson K, 2018, INT J DRUG POLICY, V58, P78, DOI 10.1016/j.drugpo.2018.05.008
   Meylakhs P, 2019, AIDS BEHAV, V23, P3350, DOI 10.1007/s10461-019-02489-6
   Moro L, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-18
   Pires C, 2015, STREET SCREEN TRADIT, P57
   Power M, 2020, VICE
   Rhumorbarbe D, 2019, INT J DRUG POLICY, V73, P273, DOI 10.1016/j.drugpo.2019.03.025
   Rolando S, 2019, DRUGS ALCOHOL TODAY, V19, P282, DOI 10.1108/DAT-10-2018-0052
   Sarang A, 2010, SUBST USE MISUSE, V45, P813, DOI 10.3109/10826081003590938
   Tofighi B, 2020, DRUG ALCOHOL REV, V39, P205, DOI 10.1111/dar.13048
   Vale Pires C., 2016, ADIKTOLOGIE, V2, P182
   Van Hout MC, 2013, INT J DRUG POLICY, V24, P385, DOI 10.1016/j.drugpo.2013.01.005
   Vorobyev N, 2020, VICE
   Weese L, 2016, FORBES
NR 32
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7517
J9 HARM REDUCT J
JI Harm Reduct. J.
PD DEC 9
PY 2020
VL 17
IS 1
AR 98
DI 10.1186/s12954-020-00452-6
PG 9
WC Substance Abuse
SC Substance Abuse
GA PG5DG
UT WOS:000599754700002
PM 33298081
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chiba, S
AF Chiba, Satoru
TI Effect of early oseltamivir on outpatients without hypoxia with
   suspected COVID-19
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article; Early Access
DE COVID-19; Antiviral agents; Early treatment; Duration of fever;
   Levofloxacin
ID RESPIRATORY SYNDROME; INFLUENZA
AB Background Since December 2019 coronavirus disease 2019 (COVID-19) outbreaks have occurred in China and many countries around the world. The effectiveness of oseltamivir on COVID-19 suspected outpatients without hypoxia was evaluated. Methods A total of 16 COVID-19 suspected medical personnel and their cohabitation families without hypoxia, who came to the adult fever clinic from March to June 2020 were studied. All patients received antiviral therapy (oseltamivir) and antibacterial therapy together. Results Most of the infected patients were female (10, 63%), 1 had diabetes (6%) and 3 hypertension (19%). The median age was 45 years (interquartile range [IQR] 31-60 years). Oseltamivir administration made the temperature fall within 24 h in part (10, 63%). Clinical data were compared between patients receiving early treatment (ET) with oseltamivir, initiated within 24 h, and patients administered late treatment (LT), initiated after this time point. Duration of fever was shorter in the ET group than in the LT group (31 +/- 21 h versus 94 +/- 38 h; p < 0.001). The time from fever onset to treatment initiation correlated with duration of fever (r = 0.77; p < 0.001) and the time from peak to decline (r = 0.58; p < 0.05). Conclusion These findings suggest that early oseltamivir administration may lower the duration of fever in COVID-19 suspected outpatients without hypoxia when it is used in combination with antibacterial therapy.
C1 [Chiba, Satoru] Sapporo Suzuki Hosp, Dept Internal Med, Kita Ku, 1-27 Shinkotoni 3jo 1chome, Sapporo, Hokkaido 0010903, Japan.
RP Chiba, S (corresponding author), Sapporo Suzuki Hosp, Dept Internal Med, Kita Ku, 1-27 Shinkotoni 3jo 1chome, Sapporo, Hokkaido 0010903, Japan.
EM chibas_0317@yahoo.co.jp
CR Al-Tawfiq JA, 2017, TRAVEL MED INFECT DI, V20, P56, DOI 10.1016/j.tmaid.2017.10.004
   [Anonymous], 2020, Med Lett Drugs Ther, V62, P49
   Aoki FY, 2003, J ANTIMICROB CHEMOTH, V51, P123, DOI 10.1093/jac/dkg007
   Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coenen S, 2020, BRIT J GEN PRACT, V70, pE444, DOI 10.3399/bjgp20X711941
   Kakodkar P, 2020, CUREUS, V12, DOI 10.7759/cureus.7560
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Ono H, 2013, BASIC CLIN PHARMACOL, V113, P25, DOI 10.1111/bcpt.12058
   Patra JK, 2020, PHYTOTHER RES, V34, P1248, DOI 10.1002/ptr.6614
   Sheng ZM, 2011, P NATL ACAD SCI USA, V108, P16416, DOI 10.1073/pnas.1111179108
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   WHO, 2020, DIR GEN OP REM MED B
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yamanaka T, 2016, INFLUENZA OTHER RESP, V10, P127, DOI 10.1111/irv.12358
   Zusso M, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1538-9
NR 19
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
EI 1613-7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
DI 10.1007/s00508-020-01780-0
EA DEC 2020
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA PF3ZS
UT WOS:000598997500005
PM 33296027
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Baig, M
   Jameel, T
   Alzahrani, SH
   Mirza, AA
   Gazzaz, ZJ
   Ahmad, T
   Baig, F
   Almurashi, SH
AF Baig, Mukhtiar
   Jameel, Tahir
   Alzahrani, Sami H.
   Mirza, Ahmad A.
   Gazzaz, Zohair J.
   Ahmad, Tauseef
   Baig, Fizzah
   Almurashi, Saleh H.
TI Predictors of misconceptions, knowledge, attitudes, and practices of
   COVID-19 pandemic among a sample of Saudi population
SO PLOS ONE
LA English
DT Article
ID STUDENTS
AB This study intends to explore the predictors of misconceptions, knowledge, attitudes, and practices concerning the COVID-19 pandemic among a sample of the Saudi population and we also assessed their approaches toward its overall impact. This online cross-sectional survey was conducted at the Faculty of Medicine, Rabigh, King Abdulaziz University (KAU) in Jeddah, Saudi Arabia (SA). Participants were approached via social media (SM), and 2006 participants (953 [47.5%] females and 1053 [52.5%] males) were included in this study. SM was the leading source of information for 43.9% of the study participants. Most of the participants had various misconceptions such as "females are more vulnerable to develop this infection, rinsing the nose with saline and sipping water every 15 minutes protects against Coronavirus, flu and pneumonia vaccines protect against this virus." About one-third of participants (31.7%) had self-reported disturbed social, mental, and psychological wellbeing due to the pandemic. Many participants became more religious during this pandemic. Two-thirds of the study participants (68.1%) had good knowledge scores. Attitudes were highly positive in 93.1%, and practice scores were adequate in 97.7% of the participants. Participants' educational status was a predictor of high knowledge scores. Male gender and divorced status were predictors of low practice scores, and aged 51-61 years, private-sector jobs, and student status were predictors of high practice scores. Being Saudi was a predictor of a positive attitude, while the male gender and divorced status were predictors of a negative attitude. Higher education was a predictor of good concepts, while the older age and businessmen were predictors of misconceptions. Overall, our study participants had good knowledge, positive attitudes, and good practices, but several myths were also prevalent. Being a PhD and a Saudi national predicted high knowledge scores and positive attitudes, respectively. A higher education level was a predictor of good concepts, and students, private-sector jobs, and aged 51-61 years were predictors of high practice scores. Study participants had good understanding of the effects of this pandemic.
C1 [Baig, Mukhtiar] King Abdulaziz Univ, Fac Med, Dept Clin Biochem, Jeddah, Saudi Arabia.
   [Jameel, Tahir; Gazzaz, Zohair J.] King Abdulaziz Univ, Fac Med, Dept Internal Med, Jeddah, Saudi Arabia.
   [Alzahrani, Sami H.] King Abdulaziz Univ, Fac Med, Dept Family Med, Jeddah, Saudi Arabia.
   [Mirza, Ahmad A.] King Abdulaziz Univ, Fac Med Rabigh, Dept Otolaryngol Head & Neck Surg, Jeddah, Saudi Arabia.
   [Ahmad, Tauseef] Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Nanjing, Peoples R China.
   [Baig, Fizzah] Ziauddin Univ, Ziauddin Med Coll, Karachi, Pakistan.
   [Almurashi, Saleh H.] King Abdulaziz Univ, Fac Med, Jeddah, Saudi Arabia.
RP Baig, M (corresponding author), King Abdulaziz Univ, Fac Med, Dept Clin Biochem, Jeddah, Saudi Arabia.
EM drmukhtiarbaig@yahoo.com
RI Baig, Mukhtiar/M-7274-2014; alzahrani, sami/C-8235-2015
OI Baig, Mukhtiar/0000-0003-0058-2031; alzahrani, sami/0000-0001-6786-7184
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V27, P1
   [Anonymous], BBC NEWS
   Azlan AA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233668
   Chew QH, 2020, SINGAP MED J, V61, P350, DOI 10.11622/smedj.2020046
   Clements John M, 2020, JMIR Public Health Surveill, V6, pe19161, DOI 10.2196/19161
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Depoux A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa031
   Ebrahim SH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1066
   Faasse K, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.551004
   Geldsetzer P, 2020, J MED INTERNET RES, V22, DOI 10.2196/18790
   Geldsetzer P, 2020, ANN INTERN MED, V173, P157, DOI 10.7326/M20-0912
   Gros C, 2020, ARXIV200400493
   Hager E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236918
   Haleem Abid, 2020, Curr Med Res Pract, V10, P78, DOI 10.1016/j.cmrp.2020.03.011
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Hussain ZA, 2012, AM J INFECT CONTROL, V40, pE11, DOI 10.1016/j.ajic.2011.12.004
   Giao H, 2020, ASIAN PAC J TROP MED, V13, P260, DOI 10.4103/1995-7645.280396
   Hyman I, 2001, MEDSCAPE WOMENS HEAL, V6
   Meier K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236917
   Mohamad E, 2020, J KOMUN, V36
   Mohamed Rania Ali El Hadi, 2020, Pak J Biol Sci, V23, P119, DOI 10.3923/pjbs.2020.119.125
   Muto K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234292
   Naser AY, 2020, KNOWLEDGE PRACTICES, DOI [10.1101/2020.04.13.20063560, DOI 10.1101/2020.04.13.20063560]
   Pennycook G, 2020, PSYARXIV, DOI [10.31234/osf.io/zhjkp, DOI 10.31234/0SF.I0/ZHJKP]
   Rugarabamu S, 2020, INF DIS, DOI [10.1101/2020.04.26.20080820, DOI 10.1101/2020.04.26.20080820]
   Shi Yudong, 2020, Brain Behav Immun Health, V4, P100064, DOI 10.1016/j.bbih.2020.100064
   Singh A, 2011, J DENT EDUC, V75, P421
   Tariq Saba, 2020, Disaster Med Public Health Prep, P1, DOI 10.1017/dmp.2020.408
   Tenkorang EY, 2013, CULT HEALTH SEX, V15, P296, DOI 10.1080/13691058.2012.752107
   Vraga EK, 2020, POLIT COMMUN, V37, P136, DOI 10.1080/10584609.2020.1716500
   World Health Organization, 2020, COR DIS COVID 19 ADV
   Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221
NR 32
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 9
PY 2020
VL 15
IS 12
AR e0243526
DI 10.1371/journal.pone.0243526
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PE8QN
UT WOS:000598626100041
PM 33296420
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Fudolig, M
   Howard, R
AF Fudolig, Miguel
   Howard, Reka
TI The local stability of a modified multi-strain SIR model for emerging
   viral strains
SO PLOS ONE
LA English
DT Article
ID PULSE VACCINATION STRATEGY; INFLUENZA EPIDEMIC; ANTIGENIC DRIFT; VIRUS;
   EMERGENCE; MUMPS
AB We study a novel multi-strain SIR epidemic model with selective immunity by vaccination. A newer strain is made to emerge in the population when a preexisting strain has reached equilbrium. We assume that this newer strain does not exhibit cross-immunity with the original strain, hence those who are vaccinated and recovered from the original strain become susceptible to the newer strain. Recent events involving the COVID-19 virus shows that it is possible for a viral strain to emerge from a population at a time when the influenza virus, a well-known virus with a vaccine readily available, is active in a population. We solved for four different equilibrium points and investigated the conditions for existence and local stability. The reproduction number was also determined for the epidemiological model and found to be consistent with the local stability condition for the disease-free equilibrium.
C1 [Fudolig, Miguel; Howard, Reka] Univ Nebraska, Dept Stat, Lincoln, NE 68588 USA.
RP Fudolig, M (corresponding author), Univ Nebraska, Dept Stat, Lincoln, NE 68588 USA.
EM mfudolig@huskers.unl.edu
CR Albertson JP, 2016, MMWR-MORBID MORTAL W, V65, P731, DOI 10.15585/mmwr.mm6529a2
   Allen LJ, 2007, INTRO MATH BIOL
   [Anonymous], 2016, EVIDENCE, V8, pe1000
   Attanayake A, 2020, PHENOMENOLOGICAL MOD
   Biggerstaff M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-480
   Binti Hamzah FA, 2020, B WORLD HEALTH ORGAN, DOI [10.2471/BLT.20.255695, DOI 10.2471/BLT.20.255695]
   Blackwood J. C., 2018, LETT BIOMATH, V5, P195, DOI DOI 10.1080/23737867.2018.1509026
   Boni MF, 2008, VACCINE, V26, pC8, DOI 10.1016/j.vaccine.2008.04.011
   Carrat F, 2007, VACCINE, V25, P6852, DOI 10.1016/j.vaccine.2007.07.027
   Casagrandi R, 2006, MATH BIOSCI, V200, P152, DOI 10.1016/j.mbs.2005.12.029
   Centers for Disease Control and Prevention, 2018, FLU SEAS
   Centers for Disease Control and Prevention, 2019, FLU VACC COV US 2018
   Centers for Disease Control and Prevention, 2019, MEASL CAS OUTBR
   Centers for Disease Control and Prevention, 2019, MUMPS CAS OUTBR
   Centers for Disease Control and Prevention, 2017, FLU VIR CAN CHANG DR
   Centers for Disease Control and Prevention, 2020, SYMPT COR DIS
   Centers for Disease Control and Prevention, 2020, FREQ ASK INFL FLU QU
   Chauhan S., 2014, AM J COMP APPL MATH, V4, P17
   Coburn BJ, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-30
   Cowling BJ, 2010, EPIDEMIOLOGY, V21, P842, DOI 10.1097/EDE.0b013e3181f20977
   Cuadrado-Payan E, 2020, LANCET, V395, pE84, DOI 10.1016/S0140-6736(20)31052-7
   d'Onofrio A, 2005, APPL MATH LETT, V18, P729, DOI 10.1016/j.aml.2004.05.012
   d'Onofrio A, 2002, MATH BIOSCI, V179, P57, DOI 10.1016/S0025-5564(02)00095-0
   Dayan GH, 2008, NEW ENGL J MED, V358, P1580, DOI 10.1056/NEJMoa0706589
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Dusheck J., 2015, VIRAL INFECT LEAVE S
   Edelstein-Keshet L, 2005, MATH MODELS BIOL
   Finkenstadt BF, 2005, STAT MED, V24, P3447, DOI 10.1002/sim.2196
   Han LT, 2001, MATH COMPUT MODEL, V34, P849, DOI 10.1016/S0895-7177(01)00104-2
   He SB, 2020, NONLINEAR DYNAM, V101, P1667, DOI 10.1007/s11071-020-05743-y
   Holmes EC, 2005, PLOS BIOL, V3, P1579, DOI 10.1371/journal.pbio.0030300
   Iwami S, 2007, MATH BIOSCI, V207, P1, DOI 10.1016/j.mbs.2006.08.001
   Jacquez JA, 1996, COMPARTMENTAL ANAL B
   Jung SM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020523
   Keeling M. J., 2011, MODELING INFECT DIS
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   Li T, 2016, PHYSICA A, V450, P649, DOI 10.1016/j.physa.2016.01.045
   Liu ZF, 2015, INT J INFECT DIS, V41, P73, DOI 10.1016/j.ijid.2015.11.003
   Lopez L, 2020, MODIFIED SEIR MODEL
   Maier BF, 2020, ARXIV200207572
   Nelson MI, 2007, NAT REV GENET, V8, P196, DOI 10.1038/nrg2053
   Ning J, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9867-x
   O'Neill PD, 2002, MATH BIOSCI, V180, P103, DOI 10.1016/S0025-5564(02)00109-8
   Pan J, 2020, EFFECTIVENESS CONTRO
   Pandey G, 2020, ARXIV200400958
   Park JK, 2018, MBIO, V9, DOI [10.1128/mBio.02284-17, 10.1128/mbio.02284-17]
   Park M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040967
   Peirlinck M, 2020, BIOMECH MODEL MECHAN, V19, P2179, DOI 10.1007/s10237-020-01332-5
   Pell B, 2018, EPIDEMICS-NETH, V22, P62, DOI 10.1016/j.epidem.2016.11.002
   Peng L, 2020, ARXIV200206563
   R Core Team, 2020, R LANG ENV STAT COMP
   Roche B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-87
   Sanchez DA, 1979, ORDINARY DIFFERENTIA
   Schuster M, 2015, VACCINE, V33, P4157, DOI 10.1016/j.vaccine.2015.04.035
   Shi P, 2010, EPIDEMIOL INFECT, V138, P1472, DOI 10.1017/S0950268810000300
   Shrestha S, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002135
   Shulgin B, 1998, B MATH BIOL, V60, P1123, DOI 10.1016/S0092-8240(98)90005-2
   Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046
   Steinmeyer SH, 2010, PHILOS T R SOC B, V365, P1931, DOI 10.1098/rstb.2010.0065
   Stilianakis NI, 1998, J INFECT DIS, V177, P863, DOI 10.1086/515246
   Stockdale JE, 2017, EPIDEMICS-NETH, V19, P13, DOI 10.1016/j.epidem.2016.11.005
   Tang L, 2020, INT STAT REV, V88, P462, DOI 10.1111/insr.12402
   Tolles J, 2020, JAMA-J AM MED ASSOC, V323, P2515, DOI 10.1001/jama.2020.8420
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   van den Driessche Pauline, 2017, Infect Dis Model, V2, P288, DOI 10.1016/j.idm.2017.06.002
   Wendorf K, 2014, MMWR-MORBID MORTAL W, V63
   Wilson JN, 2000, EPIDEMIOL INFECT, V124, P295, DOI 10.1017/S0950268800003605
   Wolfram Research Inc., 2018, MATH VERS 11 3
   World Health Organization, 2020, WHO COR DIS COVID 19
   Yaari R, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0298
   Yamauchi T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39057-w
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
   Yee Jane, 2020, J Am Coll Emerg Physicians Open, DOI 10.1002/emp2.12034
   Youssef M, 2011, J THEOR BIOL, V283, P136, DOI 10.1016/j.jtbi.2011.05.029
   Zaman G, 2008, BIOSYSTEMS, V93, P240, DOI 10.1016/j.biosystems.2008.05.004
   Zhang JP, 2011, APPL MATH COMPUT, V217, P7053, DOI 10.1016/j.amc.2010.09.063
   Zipprich J, 2014, MMWR-MORBID MORTAL W, V63, P362
NR 77
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 9
PY 2020
VL 15
IS 12
AR e0243408
DI 10.1371/journal.pone.0243408
PG 27
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PE8QN
UT WOS:000598626100074
PM 33296417
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Rana, MM
   Karim, MR
   Wadood, MA
   Kabir, MM
   Alam, MM
   Yeasmin, F
   Islam, MR
AF Rana, Md. Masud
   Karim, Md. Reazul
   Wadood, Md. Abdul
   Kabir, Md. Mahbubul
   Alam, Md. Mahidul
   Yeasmin, Farhana
   Islam, Md. Rafiqul
TI Knowledge of prevention of COVID-19 among the general people in
   Bangladesh: A cross-sectional study in Rajshahi district
SO PLOS ONE
LA English
DT Article
AB Background
   Until now, no vaccine or effective drug is available for the control, prevention, and treatment of COVID-19. Preventive measures are the only ways to be protected from the disease and knowledge of the people about the preventive measures is a vital matter.
   Objectives
   The aim of the study was to assess the knowledge of the general people in Rajshahi district, Bangladesh regarding the COVID-19 preventive measures.
   Methodology
   This cross sectional study was conducted from March 10 to April 25, 2020. Data were collected with a semi-structured questionnaire from 436 adult respondents selected by using a mixed sampling technique. Frequency analysis, chi-square test, and logistic regression model were utilized in this study. SPSS (IBM, Version 22) was used for data analysis. 95% confidence interval and p-value = 0.05 were accepted for statistical significance.
   Results
   Only 21.6% of the respondents had good knowledge of the COVID-19 preventive measures. The highest 67.2% of them knew that washing hands with soap could prevent the disease, but contrarily, the highest 72.5% did not know that avoidance of touching mouth, nose, and eyes without washing hands was a preventive measure. Only 28.4% and 36.9% of the respondents knew that maintaining physical distancing and avoiding mass gatherings were measures of prevention of COVID-19 respectively. The younger age (<= 25 years), low family income (<= 15,000 Bangladeshi Taka (BDT), occupation others than business and service, and nuclear family had the lower odds of having no/less knowledge about the preventive measures.
   Conclusions
   The knowledge level of the general people regarding prevention of COVID-19 was alarmingly low in Bangladesh. The government of Bangladesh, health policy makers and donor agencies should consider the findings and take immediate steps for improving knowledge of the public about prevention of the disease.
C1 [Rana, Md. Masud; Karim, Md. Reazul] Univ Rajshahi, Dept Stat, Rajshahi, Bangladesh.
   [Wadood, Md. Abdul] Univ Rajshahi, Med Ctr, Rajshahi, Bangladesh.
   [Kabir, Md. Mahbubul] Univ Rajshahi, Dept Management Studies, Rajshahi, Bangladesh.
   [Alam, Md. Mahidul] Rajshahi Med Coll Hosp, Dept Med, Rajshahi, Bangladesh.
   [Yeasmin, Farhana] Univ Dhaka, Dept Tourism & Hospitality Management, Dhaka, Bangladesh.
   [Islam, Md. Rafiqul] Univ Rajshahi, Dept Populat Sci & Human Resource Dev, Rajshahi, Bangladesh.
RP Islam, MR (corresponding author), Univ Rajshahi, Dept Populat Sci & Human Resource Dev, Rajshahi, Bangladesh.
EM rafique_pops@yahoo.com
OI Islam, Md. Rafiqul/0000-0001-6959-4554
CR Abdelhafiz AS, 2020, J COMMUN HEALTH, V45, P881, DOI 10.1007/s10900-020-00827-7
   [Anonymous], COVID 19 DASHB CTR S
   BBS.2011, 2011, BANGL BUR STAT RAJSH
   European Centre for Disease Prevention and Control, GEOGR DISTR 2019 NCO
   Farhana KM, 2020, INT RES J BUSINESS S, V6, P76
   Mamun MA, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102073
   Mohammed K, FRONT PUBLIC HEALTH, V8, P217, DOI [10.3389/fpubh.2020.00217, DOI 10.3389/FPUBH.2020.0021732574300]
   National guideline on infection prevention and control in healthcare settings with additional measures for COVID-19, 2020, NAT GUID INF PREV CO
   National Health Commission of the People's Republic of China, 2020, NEW COR CAS RIS 571, V23, P2020
   Olapegba PO, 2020, BMJ-BRIT MED J, DOI 10.1101/2020.04.11.20061408
   Rana M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2071-0
   Rana MM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232027
   WHO, INF PREV CONTR SAF M
   World Health Organization, 2020, INT GUID, DOI 10.15585/mmwr.mm6942a5
   World Health Organization, 2020, COVID 19 SIT
   World Health Organization, 2020, 2 WHO, V22, P2020, DOI [10.33321/cdi.2020.44.14, DOI 10.33321/CDI.2020.44.1432050080]
   Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221
NR 17
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 9
PY 2020
VL 15
IS 12
AR e0243410
DI 10.1371/journal.pone.0243410
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PE8QN
UT WOS:000598626100057
PM 33296403
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Aydemir, S
   Ocak, S
   Saygili, S
   Hopurcuoglu, D
   Haslak, F
   Kiykim, E
   Zeybek, CA
   Celkan, T
   Demirgan, EB
   Kasapcopur, O
   Cokugras, H
   Kiykim, A
   Canpolat, N
AF Aydemir, Sezin
   Ocak, Suheyla
   Saygili, Seha
   Hopurcuoglu, Duhan
   Haslak, Fatih
   Kiykim, Ertugrul
   Aktuglu Zeybek, Cigdem
   Celkan, Tiraje
   Demirgan, Ebru Burcu
   Kasapcopur, Ozgur
   Cokugras, Haluk
   Kiykim, Ayca
   Canpolat, Nur
TI Telemedicine Applications in a Tertiary Pediatric Hospital in Turkey
   During COVID-19 Pandemic
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article; Early Access
DE telehealth; telemedicine; SARS-CoV-2; coronavirus; pandemics;
   pediatrics; health care; Turkey; Istanbul
AB Background: A novel type of Coronavirus emerged at Wuhan in late 2019 involving preferentially the respiratory system. Owing to the rapid spread, almost 22 million people became infected and 700,000 died. Similar to other countries, the need for additional hospital beds and intensive care units required diversion of health care resources toward the care for those with COVID-19 in Turkey. Telemedicine appeared as a safe and low-cost alternative for the maintainability of pediatric health services during the pandemics. Within this context, we aimed to deliver the health services through telemedicine during the follow-up of chronic childhood diseases.
   Materials and Methods: This prospective study included five pediatric subspecialties, including allergy immunology, hematology and oncology, nephrology, rheumatology, and inborn metabolic disorders. After the interview, patients and involved physicians were requested to fill out a questionnaire designed to measure the level of satisfaction and the quality of the service we offered.
   Results: Of the 263 interviews, overall patient and physician satisfaction was 99% and 87%, respectively. As results of the interviews, 250 routine visits were performed, 181 acute complaints were assessed, drug changes were made in 118 patients, 9 patients were determined to be unable to get their drugs, and 12 who misused their drugs. The main advantage of the telemedicine declared by the patients was "not to waste time for transportation." The main concerns of the participants were inability to perform physical and laboratory examinations.
   Conclusion: Consequently, we considered telemedicine as a feasible alternative not only during pandemics but also in daily practice in Turkey.
C1 [Aydemir, Sezin; Cokugras, Haluk; Kiykim, Ayca] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Pediat, Div Pediat Allergy & Immunol, TR-34098 Istanbul, Turkey.
   [Ocak, Suheyla; Celkan, Tiraje] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Pediat, Div Pediat Hematol & Oncol, Istanbul, Turkey.
   [Saygili, Seha; Demirgan, Ebru Burcu; Canpolat, Nur] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Pediat, Div Pediat Nephrol, Istanbul, Turkey.
   [Hopurcuoglu, Duhan; Kiykim, Ertugrul; Aktuglu Zeybek, Cigdem] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Pediat, Div Inborn Disorders Metab, Istanbul, Turkey.
   [Haslak, Fatih; Kasapcopur, Ozgur] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Pediat, Div Pediat Rheumatol, Istanbul, Turkey.
RP Kiykim, A (corresponding author), Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Pediat, Div Pediat Allergy & Immunol, TR-34098 Istanbul, Turkey.
EM ayca.kiykim@istanbul.edu.tr
OI Saygili, Seha Kamil/0000-0002-2424-6959
CR Abbas SN, 2020, INT J INNOV SCI TECH, V2, P46
   Barnett ML, 2018, JAMA-J AM MED ASSOC, V320, P2147, DOI 10.1001/jama.2018.12354
   Burke BL, 2015, PEDIATRICS, V136, pE293, DOI 10.1542/peds.2015-1517
   Fisk M, 2020, J MED INTERNET RES, V22, DOI 10.2196/19264
   Marcin JP, 2004, PEDIATRICS, V113, P1, DOI 10.1542/peds.113.1.1
   Masys DR, 1996, TELEMEDICINE GUIDE A
   Portnoy JM, 2016, ANN ALLERG ASTHMA IM, V117, P241, DOI 10.1016/j.anai.2016.07.012
   Ray KN, 2017, TELEMED E-HEALTH, V23, P852, DOI 10.1089/tmj.2016.0236
   Rimsza ME, 2015, PEDIATRICS, V136, P202, DOI 10.1542/peds.2015-1253
   Tomines Alan, 2019, Adv Pediatr, V66, P55, DOI 10.1016/j.yapd.2019.04.005
   Utidjian L, 2016, PEDIATR CLIN N AM, V63, P367, DOI 10.1016/j.pcl.2015.11.006
   World Economic Outlook Database Outlook, 2019, WEOIMFO 2019
NR 12
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
EI 1556-3669
J9 TELEMED E-HEALTH
JI Telemed. e-Health
DI 10.1089/tmj.2020.0381
EA DEC 2020
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA PE6ZG
UT WOS:000598511700001
PM 33301373
OA Bronze
DA 2021-01-01
ER

PT J
AU Camela, E
   Fabbrocini, G
   Cinelli, E
   Lauro, W
   Megna, M
AF Camela, Elisa
   Fabbrocini, Gabriella
   Cinelli, Eleonora
   Lauro, Wanda
   Megna, Matteo
TI Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the
   Psoriasis Unit of the University of Naples Federico II
SO DERMATOLOGY
LA English
DT Article; Early Access
C1 [Camela, Elisa; Fabbrocini, Gabriella; Cinelli, Eleonora; Lauro, Wanda; Megna, Matteo] Univ Naples Federico II, Sect Dermatol, Dept Clin Med & Surg, Via Pansini 5, IT-80131 Naples, Italy.
RP Megna, M (corresponding author), Univ Naples Federico II, Sect Dermatol, Dept Clin Med & Surg, Via Pansini 5, IT-80131 Naples, Italy.
EM mat24@libero.it
CR Amerio P, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13434
   Carugno A, 2020, J AM ACAD DERMATOL, V83, P292, DOI 10.1016/j.jaad.2020.04.165
   Ebrahimi A, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1789051
   Nogueira Miguel, 2020, Drugs Context, V9, DOI 10.7573/dic.2020-4-10
   Strippoli D, 2020, INT J DERMATOL, V59, pE266, DOI 10.1111/ijd.15002
NR 5
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1018-8665
EI 1421-9832
J9 DERMATOLOGY
JI Dermatology
DI 10.1159/000513575
EA DEC 2020
PG 2
WC Dermatology
SC Dermatology
GA PD9DO
UT WOS:000597976600001
PM 33296899
OA Bronze
DA 2021-01-01
ER

PT J
AU Reichert, M
   Sartelli, M
   Weigand, MA
   Doppstadt, C
   Hecker, M
   Reinisch-Liese, A
   Bender, F
   Askevold, I
   Padberg, W
   Coccolini, F
   Catena, F
   Hecker, A
AF Reichert, Martin
   Sartelli, Massimo
   Weigand, Markus A.
   Doppstadt, Christoph
   Hecker, Matthias
   Reinisch-Liese, Alexander
   Bender, Fabienne
   Askevold, Ingolf
   Padberg, Winfried
   Coccolini, Federico
   Catena, Fausto
   Hecker, Andreas
CA WSES COVID-19 Emergency Surg Surve
TI Impact of the SARS-CoV-2 pandemic on emergency surgery services-a
   multi-national survey among WSES members
SO WORLD JOURNAL OF EMERGENCY SURGERY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Emergency surgery; Appendicitis; Cholecystitis;
   WSES
ID APPENDICITIS; MANAGEMENT; DIAGNOSIS
AB Background The SARS-CoV-2 pandemic is a major challenge for health care services worldwide. It's impact on oncologic therapies and elective surgery has been described recently, and the literature provides guidelines regarding appropriate elective patient treatment during the pandemic. However, the impact of SARS-CoV-2 pandemic on emergency surgery services has been poorly investigated up to now. Methods A 17-item web survey had been distributed to emergency surgeons in June 2020 around the world, investigating the impact of SARS-CoV-2 pandemic on patients and septic diseases both requiring emergency surgery and the time-to-intervention in emergency surgery routine, as well as experiences with surgery in COVID-19 patients. Results Ninety-eight collaborators from 31 countries responded to the survey. The majority (65.3%) estimated the impact of the SARS-CoV-2 pandemic on emergency surgical patient care as being strong or very strong. Due to the pandemic, 87.8% reported a decrease in the total number of patients undergoing emergency surgery and approximately 25% estimated a delay of more than 2 h in the time-to-diagnosis and another 2 h in the time-to-intervention. Fifty percent make structural problems with in-hospital logistics (e.g. transport of patients, closed normal wards etc.) mainly responsible for delayed emergency surgery and the frequent need (56.1%) for a triage of emergency surgical patients. 56.1% of the collaborators observed more severe septic abdominal diseases during the pandemic, especially for perforated appendicitis and severe septic cholecystitis (41.8% and 40.2%, respectively). 62.2% had experiences with surgery in COVID-19-infected patients. Conclusions The results of The WSES COVID-19 emergency surgery survey are alarming. The combination of an estimated decrease in numbers of emergency surgical patients and an observed increase in more severe septic diseases may be a result of the fear of patients from infection with COVID-19 and a consecutive delayed hospital admission and diagnosis. A critical delay in time-to-diagnosis and time-to-intervention may be a result of changes in in-hospital logistics and operating room as well as intensive care capacities. Both reflect the potentially harmful impact of SARS-CoV-2 pandemic on emergency surgery services.
C1 [Reichert, Martin; Doppstadt, Christoph; Bender, Fabienne; Askevold, Ingolf; Padberg, Winfried; Hecker, Andreas] Univ Hosp Giessen, Dept Gen Visceral Thorac Transplant & Pediat Surg, Giessen, Germany.
   [Sartelli, Massimo] Macerata Hosp, Dept Surg, Macerata, Italy.
   [Weigand, Markus A.] Univ Hosp Heidelberg, Dept Anesthesiol, Heidelberg, Germany.
   [Hecker, Matthias] Univ Hosp Giessen, Dept Pulm & Crit Care Med, Giessen, Germany.
   [Hecker, Matthias] Univ Hosp Giessen, Marburg Lung Ctr UGMLC, Giessen, Germany.
   [Reinisch-Liese, Alexander] Hosp & Clin Wetzlar, Dept Gen Visceral & Oncol Surg, Wetzlar, Germany.
   [Coccolini, Federico] Pisa Univ Hosp, Dept Gen Emergency & Trauma Surg, Pisa, Italy.
   [Catena, Fausto] Parma Maggiore Hosp, Dept Emergency Surg, Parma, Italy.
RP Hecker, A (corresponding author), Univ Hosp Giessen, Dept Gen Visceral Thorac Transplant & Pediat Surg, Giessen, Germany.
EM andreas.hecker@chiru.med.uni-giessen.de
RI Bains, Lovenish/T-4675-2019; Litvin, Andrey/B-2254-2017; Kavalakat,
   Alfie J./AAR-1801-2020; Magnone, Stefano/R-6719-2016
OI Bains, Lovenish/0000-0002-8627-0452; Litvin, Andrey/0000-0002-9330-6513;
   Kavalakat, Alfie J./0000-0001-9756-2605; Mantoglu,
   Baris/0000-0002-2161-3629; Chichom-Mefire, Alain/0000-0001-7230-567X;
   Slavchev, Mihail/0000-0003-4412-7604; Magnone,
   Stefano/0000-0002-8001-3754
FU Projekt DEAL
FX No funding was received for this research. Open Access funding enabled
   and organized by Projekt DEAL.
CR Anteby R, 2020, J LAPAROENDOSC ADV S, V30, P1001, DOI 10.1089/lap.2020.0465
   Barbieri L, 2020, DIS ESOPHAGUS, V33, DOI 10.1093/dote/doaa028
   Boyd-Carson H, 2020, WORLD J SURG, V44, P869, DOI 10.1007/s00268-019-05254-x
   Brindle ME, 2020, ANN SURG, V272, pE1, DOI 10.1097/SLA.0000000000003923
   Campanile FC, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00317-0
   Coccolini F, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00304-5
   Coccolini F, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00307-2
   COVIDsurg Collaborative, 2020, LANCET, V396, P27, DOI 10.1016/S0140-6736(20)31182-X
   Cozza V, 2020, UPDATES SURG, V72, P297, DOI 10.1007/s13304-020-00832-4
   De Simone B, 2020, ANN ROY COLL SURG, V102, P323, DOI 10.1308/rcsann.2020.0097
   Diaz A, 2020, AM J SURG, V219, P900, DOI 10.1016/j.amjsurg.2020.04.014
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Hecker A, 2015, WORLD J EMERG SURG, V10, DOI 10.1186/s13017-015-0047-0
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Kamarajah SK, 2020, DIS ESOPHAGUS, V33, DOI 10.1093/dote/doaa054
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Oba A, 2020, ANN SURG, V272, pE87, DOI 10.1097/SLA.0000000000004006
   Patriti A, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00314-3
   Pellino G, 2020, DIS COLON RECTUM, V63, P720, DOI 10.1097/DCR.0000000000001685
   Pepper VK, 2012, SURG CLIN N AM, V92, P505, DOI 10.1016/j.suc.2012.03.011
   Peter SDS, 2008, J PEDIATR SURG, V43, P2242, DOI 10.1016/j.jpedsurg.2008.08.051
   ROTHROCK SG, 1991, ANN EMERG MED, V20, P45, DOI 10.1016/S0196-0644(05)81117-5
   Rothrock SG, 2000, ANN EMERG MED, V36, P39, DOI 10.1067/mem.2000.105658
   Snapiri O, 2020, ACTA PAEDIATR, V109, P1672, DOI 10.1111/apa.15376
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Zhou ZL, 2020, GASTROENTEROLOGY, V158, P2294, DOI 10.1053/j.gastro.2020.03.020
NR 27
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-7922
J9 WORLD J EMERG SURG
JI World J. Emerg. Surg.
PD DEC 9
PY 2020
VL 15
IS 1
AR 64
DI 10.1186/s13017-020-00341-0
PG 10
WC Emergency Medicine; Surgery
SC Emergency Medicine; Surgery
GA PC8PM
UT WOS:000597260800001
PM 33298131
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lie, RK
   Miller, FG
AF Lie, Reidar K.
   Miller, Franklin G.
TI Allocating a COVID-19 Vaccine: Balancing National and International
   Responsibilities
SO MILBANK QUARTERLY
LA English
DT Article; Early Access
AB Policy Points
   In this paper we propose a middle-ground policy for the distribution of an effective COVID-19 vaccine, between a cosmopolitan approach that rejects entirely nation-state priority and unbridled vaccine nationalism that disregards obligations to promote an equitable global allocation of an effective vaccine over time.
   Features of the COVAX partnership, a collaboration among the Global Alliance for Vaccines and Immunizations (GAVI), the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO) to develop and distribute COVID-19 vaccines make it an appropriate framework for a middle-ground policy.
C1 [Lie, Reidar K.] Univ Bergen, Bergen, Norway.
   [Miller, Franklin G.] Weill Cornell Med Coll, New York, NY USA.
RP Lie, RK (corresponding author), Univ Bergen, Dept Philosophy, Bergen, Norway.
EM Reidar.Lie@uib.no
CR [Anonymous], 2020, POLITICO
   Baker B, 2020, US CHINA EU 1 NATL C
   Consultative Expert Working Group on Research and Development: Financing and Coordination, 2012, RES DEV MEET HLTH NE
   Emanuel EJ, 2020, SCIENCE, V369, P1309, DOI 10.1126/science.abe2803
   G20 leaders' statement, 2020, EXTR G20 LEAD SUMM S
   GAVI, 2020, GAVI COVAX AMC INV O
   Gostin LO, 2014, GLOBAL HLTH LAW
   Kupferschmidt K., 2020, SCIENCE
   National Academies of Sciences Engineering and Medicine, 2020, FRAM EQ ALL COVID 19
   The Guardian, 2020, GUARDIAN
   Weintraub R, 2020, HARVARD BUSINESS REV
   World Health Organization, 2020, US 2 BILL RAIS SUPP
   World Health Organization, 2020, BOOST GLOB RESP COVI
NR 13
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0887-378X
EI 1468-0009
J9 MILBANK Q
JI Milbank Q.
DI 10.1111/1468-0009.12494
EA DEC 2020
PG 17
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA PB8RO
UT WOS:000596581800001
PM 33295679
OA Bronze
DA 2021-01-01
ER

PT J
AU Wood, WA
   Neuberg, DS
   Thompson, JC
   Tallman, MS
   Sekeres, MA
   Sehn, LH
   Anderson, KC
   Goldberg, AD
   Pennell, NA
   Niemeyer, CM
   Tucker, E
   Hewitt, K
   Plovnick, RM
   Hicks, LK
AF Wood, William A.
   Neuberg, Donna S.
   Thompson, J. Colton
   Tallman, Martin S.
   Sekeres, Mikkael A.
   Sehn, Laurie H.
   Anderson, Kenneth C.
   Goldberg, Aaron D.
   Pennell, Nathan A.
   Niemeyer, Charlotte M.
   Tucker, Emily
   Hewitt, Kathleen
   Plovnick, Robert M.
   Hicks, Lisa K.
TI Outcomes of patients with hematologic malignancies and COVID-19: a
   report from the ASH Research Collaborative Data Hub
SO BLOOD ADVANCES
LA English
DT Article
ID INTENSIVE-CARE-UNIT; CLINICAL CHARACTERISTICS; DRUG-INTERACTIONS;
   RISK-FACTORS; CANCER; MULTICENTER; MORTALITY; SEVERITY
AB Coronavirus disease 2019 (COVID-19) is an illness resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in late 2019. Patients with cancer, and especially those with hematologic malignancies, may be at especially high risk of adverse outcomes, including mortality resulting from COVID-19 infection. The ASH Research Collaborative COVID-19 Registry for Hematology was developed to study features and outcomes of COVID-19 infection in patients with underlying blood disorders, such as hematologic malignancies. At the time of this report, data from 250 patients with blood cancers from 74 sites around the world had been entered into the registry. The most commonly represented malignancies were acute leukemia (33%), non-Hodgkin lymphoma (27%), and myeloma or amyloidosis (16%). Patients presented with a myriad of symptoms, most frequently fever (73%), cough (67%), dyspnea (50%), and fatigue (40%). Use of COVID19-directed therapies, such as hydroxychloroquine (n 5 76) or azithromycin (n 5 59), was common. Overall mortality was 28%. Patients with a physician-estimated prognosis from the underlying hematologic malignancy of,12 months at the time of COVID-19 diagnosis and those with relapsed/refractory disease experienced a higher proportion of moderate/severe COVID-19 disease and death. In some instances, death occurred after a decision was made to forgo intensive care unit admission in favor of a palliative approach. Taken together, these data support the emerging consensus that patients with hematologic malignancies experience significant morbidity and mortality resulting from COVID-19 infection. Batch submissions from sites with high incidence of COVID-19 infection are planned to support future analyses.
C1 [Wood, William A.] Univ N Carolina, Div Hematol, Dept Med, Chapel Hill, NC 27599 USA.
   [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02115 USA.
   [Thompson, J. Colton; Tucker, Emily; Hewitt, Kathleen; Plovnick, Robert M.] ASH Res Collaborat, Washington, DC USA.
   [Tallman, Martin S.; Goldberg, Aaron D.] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Malignancies, 1275 York Ave, New York, NY 10021 USA.
   [Sekeres, Mikkael A.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA.
   [Sehn, Laurie H.] British Columbia Canc Ctr Lymphoid Canc, Vancouver, BC, Canada.
   [Sehn, Laurie H.] Univ British Columbia, Dept Med, Div Med Oncol, Vancouver, BC, Canada.
   [Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Pennell, Nathan A.] Cleveland Clin, Lung Canc Program, Cleveland, OH 44106 USA.
   [Niemeyer, Charlotte M.] Med Ctr Freiburg, Dept Pediat Hematol & Oncol, Freiburg, Germany.
   [Hicks, Lisa K.] St Michaels Hosp, Div Hematol Oncol, Dept Med, Toronto, ON, Canada.
RP Wood, WA (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol, Campus Box 7305,3rd Floor,Phys Off Bldg, Chapel Hill, NC 27599 USA.
EM wawood@med.unc.edu
OI Goldberg, Aaron/0000-0002-2892-2643
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   ASH Research Collaborative, ASH RES COLL COVID 1
   Benoit DD, 2003, CRIT CARE MED, V31, P104, DOI 10.1097/00003246-200301000-00017
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cook G, 2020, BRIT J HAEMATOL, V190, pE83, DOI 10.1111/bjh.16874
   Fontana L, 2019, INFECT DIS CLIN N AM, V33, P523, DOI 10.1016/j.idc.2019.02.004
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee AYY, 2003, CIRCULATION, V107, pI17, DOI 10.1161/01.CIR.0000078466.72504.AC
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liu J, 2015, HEMATOLOGY, V20, P494, DOI 10.1179/1607845414Y.0000000216
   Nass SJ, 2010, NATL CANC CLIN TRIAL
   Owczuk R, 2005, SUPPORT CARE CANCER, V13, P332, DOI 10.1007/s00520-004-0750-y
   Passamonti F, 2020, LANCET HAEMATOL, V7, pE737, DOI 10.1016/S2352-3026(20)30251-9
   Phua J, 2020, LANCET RESP MED, V8, pE42
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Riechelmann RP, 2005, CANCER CHEMOTH PHARM, V56, P286, DOI 10.1007/s00280-004-0998-4
   Rivera DR, 2020, CANCER DISCOV, V10, P1514, DOI 10.1158/2159-8290.CD-20-0941
   Soares M, 2004, CRIT CARE, V8, pR194, DOI 10.1186/cc2870
   Steensma DP, 2018, CANCER-AM CANCER SOC, V124, P4601, DOI 10.1002/cncr.31769
   van Leeuwen RWF, 2015, ANN ONCOL, V26, P992, DOI 10.1093/annonc/mdv029
   Vergano M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02891-w
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
   Zeidan AM, 2020, LANCET HAEMATOL, V7, pE601, DOI 10.1016/S2352-3026(20)30205-2
NR 26
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 2473-9529
EI 2473-9537
J9 BLOOD ADV
JI Blood Adv.
PD DEC 8
PY 2020
VL 4
IS 23
BP 5966
EP 5975
DI 10.1182/bloodadvances.2020003170
PG 10
WC Hematology
SC Hematology
GA PC4CH
UT WOS:000596950900010
PM 33278301
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wang, P
   Luo, RH
   Zhang, M
   Wang, YQ
   Song, TZ
   Tao, TT
   Li, ZY
   Jin, L
   Zheng, HY
   Chen, WW
   Zhao, MQ
   Zheng, YT
   Qin, JH
AF Wang, Peng
   Luo, Ronghua
   Zhang, Min
   Wang, Yaqing
   Song, Tianzhang
   Tao, Tingting
   Li, Zhongyu
   Jin, Lin
   Zheng, Hongyi
   Chen, Wenwen
   Zhao, Mengqian
   Zheng, Yongtang
   Qin, Jianhua
TI A cross-talk between epithelium and endothelium mediates human
   alveolar-capillary injury during SARS-CoV-2 infection
SO CELL DEATH & DISEASE
LA English
DT Article
ID SARS CORONAVIRUS; PROTEIN; CELLS; MITOCHONDRIA; OXIDASE; ACE2
AB COVID-19, caused by SARS-CoV-2, is an acute and rapidly developing pandemic, which leads to a global health crisis. SARS-CoV-2 primarily attacks human alveoli and causes severe lung infection and damage. To better understand the molecular basis of this disease, we sought to characterize the responses of alveolar epithelium and its adjacent microvascular endothelium to viral infection under a co-culture system. SARS-CoV-2 infection caused massive virus replication and dramatic organelles remodeling in alveolar epithelial cells, alone. While, viral infection affected endothelial cells in an indirect manner, which was mediated by infected alveolar epithelium. Proteomics analysis and TEM examinations showed viral infection caused global proteomic modulations and marked ultrastructural changes in both epithelial cells and endothelial cells under the co-culture system. In particular, viral infection elicited global protein changes and structural reorganizations across many sub-cellular compartments in epithelial cells. Among the affected organelles, mitochondrion seems to be a primary target organelle. Besides, according to EM and proteomic results, we identified Daurisoline, a potent autophagy inhibitor, could inhibit virus replication effectively in host cells. Collectively, our study revealed an unrecognized cross-talk between epithelium and endothelium, which contributed to alveolar-capillary injury during SARS-CoV-2 infection. These new findings will expand our understanding of COVID-19 and may also be helpful for targeted drug development.
C1 [Wang, Peng; Zhang, Min; Wang, Yaqing; Tao, Tingting; Li, Zhongyu; Chen, Wenwen; Zhao, Mengqian; Qin, Jianhua] Chinese Acad Sci, Dalian Inst Chem Phys, Div Biotechnol, CAS Key Lab SSAC, Dalian, Peoples R China.
   [Luo, Ronghua; Song, Tianzhang; Zheng, Hongyi; Zheng, Yongtang] Chinese Acad Sci, Ctr Biosafety Megasci, Kunming Inst Zool, Kunming Natl High Level Biosafety Res Ctr Nonhuma, Kunming 650107, Yunnan, Peoples R China.
   [Luo, Ronghua; Song, Tianzhang; Zheng, Hongyi; Zheng, Yongtang] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, KIZ CUHK Joint Lab Bioresources & Mol Res Common, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.
   [Zhang, Min; Wang, Yaqing; Tao, Tingting; Chen, Wenwen; Zhao, Mengqian; Zheng, Yongtang; Qin, Jianhua] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Jin, Lin] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Yunnan, Peoples R China.
   [Qin, Jianhua] Chinese Acad Sci, CAS Ctr Excellence Brain Sci & Intelligence Techn, Shanghai, Peoples R China.
   [Qin, Jianhua] Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing, Peoples R China.
RP Qin, JH (corresponding author), Chinese Acad Sci, Dalian Inst Chem Phys, Div Biotechnol, CAS Key Lab SSAC, Dalian, Peoples R China.; Zheng, YT (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Kunming Inst Zool, Kunming Natl High Level Biosafety Res Ctr Nonhuma, Kunming 650107, Yunnan, Peoples R China.; Zheng, YT (corresponding author), Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, KIZ CUHK Joint Lab Bioresources & Mol Res Common, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.; Zheng, YT; Qin, JH (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.; Qin, JH (corresponding author), Chinese Acad Sci, CAS Ctr Excellence Brain Sci & Intelligence Techn, Shanghai, Peoples R China.; Qin, JH (corresponding author), Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing, Peoples R China.
EM zhengyt@mail.kiz.ac.cn; jhqin@dicp.ac.cn
FU Strategic Priority Research Program of the Chinese Academy of
   SciencesChinese Academy of Sciences [XDB29050301, XDA16020900,
   XDB32030200]; National Key R&D Program of China [2020YFC0842000,
   2017YFB0405404]; National Science and Technology Major Project
   [2018ZX09201017-001-001]; National Nature Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [31671038,
   31971373, 81703470, 81803492]; Innovation Program of Science and
   Research from the DICP, CAS [DICP I201934]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2019M660065]; Yunnan
   Key Research and Development Program [202003AD150009]
FX The authors thank Prof. Yonggang Yao (Kunming Institute of Zoology, CAS)
   for his strong support on this work. We thank the Kunming Biological
   Diversity Regional Center of Instruments, Kunming Institute of Zoology,
   CAS for our electron microscopy work, and we are grateful to Yingqi Guo
   for her help with preparing EM samples. We thank Can Peng (Center for
   Biological Imaging (CBI), Institute of Biophysics, Chinese Academy of
   Science) for her advice on EM samples preparation. We thank Jingjie PTM
   BioLab (Hangzhou) Co. Ltd for their service on mass spectrometry
   analysis of the protein samples. This research was supported by the
   Strategic Priority Research Program of the Chinese Academy of Sciences,
   Grant (Nos. XDB29050301, XDA16020900, XDB32030200), National Key R&D
   Program of China (Nos. 2020YFC0842000, 2017YFB0405404), National Science
   and Technology Major Project (No. 2018ZX09201017-001-001), National
   Nature Science Foundation of China (Nos. 31671038, 31971373, 81703470,
   81803492), Innovation Program of Science and Research from the DICP, CAS
   (DICP I201934), China Postdoctoral Science Foundation (No. 2019M660065)
   and Yunnan Key Research and Development Program (202003AD150009).
CR Balsa E, 2012, CELL METAB, V16, P378, DOI 10.1016/j.cmet.2012.07.015
   Beltran PMJ, 2018, CELL HOST MICROBE, V24, P526, DOI 10.1016/j.chom.2018.09.002
   Beltran PMJ, 2016, CELL SYST, V3, P361, DOI 10.1016/j.cels.2016.08.012
   Bestwick M, 2010, MOL CELL BIOL, V30, P4480, DOI 10.1128/MCB.00228-10
   Bode M, 2013, ANTIOXID REDOX SIGN, V18, P1597, DOI 10.1089/ars.2012.4685
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Chan MCW, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-102
   Cui YJ, 2020, J PROTEOME RES, V19, P2443, DOI 10.1021/acs.jproteome.0c00173
   Dunn JD, 2015, REDOX BIOL, V6, P472, DOI 10.1016/j.redox.2015.09.005
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Goshua G, 2020, LANCET HAEMATOL, V7, pE575, DOI 10.1016/S2352-3026(20)30216-7
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu XX, 2019, J CELL BIOCHEM, V120, P8956, DOI 10.1002/jcb.27615
   Janga H, 2018, J CELL MOL MED, V22, P982, DOI 10.1111/jcmm.13421
   Liu QN, 2012, J NAT PROD, V75, P1539, DOI 10.1021/np300232b
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Meier F, 2018, MOL CELL PROTEOMICS, V17, P2534, DOI 10.1074/mcp.TIR118.000900
   Messina F, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02405-w
   Mitsopoulos P, 2010, CHEM-BIOL INTERACT, V188, P427, DOI 10.1016/j.cbi.2010.09.022
   Ostaszewski M, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-0477-8
   Oyewole AO, 2015, FASEB J, V29, P4766, DOI 10.1096/fj.15-275404
   Peng L, 2020, J MED VIROL, V92, P1676, DOI 10.1002/jmv.25936
   Pesaresi M, 2020, EUR REV MED PHARMACO, V24, P5186, DOI 10.26355/eurrev_202005_21217
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Prieto-Ruiz JA, 2018, BBA-GENE REGUL MECH, V1861, P80, DOI 10.1016/j.bbagrm.2018.01.006
   Qian W, 2019, P NATL ACAD SCI USA, V116, P18435, DOI 10.1073/pnas.1910574116
   Qin XF, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/240659
   Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129
   Sun J, 2020, EMERG MICROBES INFEC, V9, P991, DOI 10.1080/22221751.2020.1760144
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tanaka Y, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9298052
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wiedemann N, 2017, ANNU REV BIOCHEM, V86, P685, DOI 10.1146/annurev-biochem-060815-014352
   Wu MY, 2017, ONCOTARGET, V8, P77673, DOI 10.18632/oncotarget.20767
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang YH, 2013, INT REV IMMUNOL, V32, P249, DOI 10.3109/08830185.2012.755176
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhang M, 2016, LIFE SCI, V164, P1, DOI 10.1016/j.lfs.2016.09.001
   Zhang QF, 2004, J MED VIROL, V73, P332, DOI 10.1002/jmv.20095
   Zhong YZ, 2019, J CELL BIOCHEM, V120, P12500, DOI 10.1002/jcb.28516
   Zhou HS, 2018, MICROVASC RES, V115, P58, DOI 10.1016/j.mvr.2017.08.008
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 45
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD DEC 8
PY 2020
VL 11
IS 12
AR 1042
DI 10.1038/s41419-020-03252-9
PG 17
WC Cell Biology
SC Cell Biology
GA PC8UV
UT WOS:000597275300001
PM 33293527
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tilotta, G
   Pistone, G
   Caruso, P
   Gurreri, R
   Castelli, E
   Curiale, S
   Caputo, V
   Bongiorno, MR
AF Tilotta, Giovanna
   Pistone, Giuseppe
   Caruso, Paolo
   Gurreri, Rosario
   Castelli, Elena
   Curiale, Salvatrice
   Caputo, Valentina
   Bongiorno, Maria R.
TI Adherence to biological therapy in dermatological patients during the
   COVID-19 pandemic in Western Sicily
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Letter; Early Access
C1 [Tilotta, Giovanna; Pistone, Giuseppe; Caruso, Paolo; Gurreri, Rosario; Castelli, Elena; Curiale, Salvatrice; Caputo, Valentina; Bongiorno, Maria R.] Univ Palermo, Dept Hlth Promot Mother & Child Care, Sect Dermatol, Internal Med & Med Specialties, Palermo, Italy.
RP Bongiorno, MR (corresponding author), Univ Palermo, Dept Hlth Promot Mother & Child Care, Sect Dermatol, Internal Med & Med Specialties, Palermo, Italy.
EM mariarita.bongiorno@unipa.it
CR Amerio P, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13434
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Micali G, 2020, GIORN ITAL DERMAT V, V155, P123, DOI 10.23736/S0392-0488.20.06670-5
   Talamonti M, 2020, J EUR ACAD DERMATOL, DOI 10.1111/jdv.16841
   Vakirlis E, 2020, J Eur Acad Dermatol Venereol, V34, pe673, DOI 10.1111/jdv.16759
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
DI 10.1111/ijd.15352
EA DEC 2020
PG 2
WC Dermatology
SC Dermatology
GA PB6GY
UT WOS:000596418300001
OA Bronze
DA 2021-01-01
ER

PT J
AU Guzman, MI
AF Guzman, Marcelo I.
TI An overview of the effect of bioaerosol size in coronavirus disease 2019
   transmission
SO INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT
LA English
DT Article; Early Access
DE aerodynamic size; bioaerosol; COVID&#8208; 19; infection; SARS&#8208;
   CoV&#8208; 2; social distancing; virus
ID ACUTE RESPIRATORY SYNDROME; MUCOCILIARY CLEARANCE; SARS CORONAVIRUS;
   PNEUMONIA; WUHAN; CHINA; DROPLETS; OUTBREAK; TRACHEAL; HEALTH
AB The fast spread of coronavirus disease 2019 (COVID-19) constitutes a worldwide challenge to the public health, educational and trade systems, affecting the overall well-being of human societies. The high transmission and mortality rates of this virus, and the unavailability of a vaccine or treatment, resulted in the decision of multiple governments to enact measures of social distancing. Such measures can reduce the exposure to bioaerosols, which can result in pathogen deposition in the respiratory tract of the host causing disease and an immunological response. Thus, it is important to consider the validity of the proposal for keeping a distance of at least 2 m from other persons to avoid the spread of COVID-19. This work reviews the effect of aerodynamic diameter (size) of particles carrying RNA copies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A SARS-CoV-2 carrier person talking, sneezing or coughing at distance of 2 m can still provide a pathogenic bioaerosol load with submicron particles that remain viable in air for up to 3 h for exposure of healthy persons near and far from the source in a stagnant environment. The deposited bioaerosol creates contaminated surfaces, which if touched can act as a path to introduce the pathogen by mouth, nose or eyes and cause disease.
C1 [Guzman, Marcelo I.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Guzman, MI (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM marcelo.guzman@uky.edu
RI Guzman, Marcelo/C-5966-2008
OI Guzman, Marcelo/0000-0002-6730-7766
FU National Science FoundationNational Science Foundation (NSF) [1903744]
FX National Science Foundation, Grant/Award Number: 1903744
CR Alves W, 2020, AURIS NASUS LARYNX, V47, P692, DOI 10.1016/j.anl.2020.05.003
   [Anonymous], 2007, INT PREP PLANN GUID
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Beule Achim G, 2010, GMS Curr Top Otorhinolaryngol Head Neck Surg, V9, pDoc07, DOI 10.3205/cto000071
   Booth TF, 2005, J INFECT DIS, V191, P1472, DOI 10.1086/429634
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Bui VKH, 2020, ATMOSPHERE-BASEL, V11, DOI 10.3390/atmos11020137
   Centers for Disease Control and Prevention, 2020, INT INF PREV CONTR R
   Centers for Disease Control and Prevention Public Health, REC COMM REL EXP
   Centers for Disease Control and Prevention Public Health, REC TRAV ASS COVID 1
   Chao CYH, 2009, J AEROSOL SCI, V40, P122, DOI 10.1016/j.jaerosci.2008.10.003
   Chen C, 2020, ANN INTERN MED, V172, P832, DOI 10.7326/M20-0991
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chia PY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16670-2
   Contini D, 2020, ATMOSPHERE-BASEL, V11, DOI 10.3390/atmos11040377
   DUGUID J P, 1945, Edinb Med J, V52, P385
   Eddens T, 2012, CURR OPIN IMMUNOL, V24, P424, DOI 10.1016/j.coi.2012.07.005
   Fears A C, 2020, medRxiv, DOI 10.1101/2020.04.13.20063784
   Fernstrom A, 2013, J PATHOG, V2013, DOI [10.1155/013/493960, 10.1155/2013/493960]
   FOSTER WM, 1980, J APPL PHYSIOL, V48, P965
   Geddes L, DOES HIGH VIRAL LOAD
   GIROD S, 1992, EUR RESPIR J, V5, P477
   Gralton J, 2011, J INFECTION, V62, P1, DOI 10.1016/j.jinf.2010.11.010
   Guzman MI, 2020, BIOAEROSOL SIZE EFFE
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hersen G, 2008, CLEAN-SOIL AIR WATER, V36, P572, DOI 10.1002/clen.200700189
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   ICRP, 1995, ICRP PUBL, V66
   Jennison MW, 1942, AEROBIOLOGY, V17, P106
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Lai KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020086
   LAMBLIN G, 1992, EUR RESPIR J, V5, P247
   Leung Nancy H L, 2020, Nat Med, V26, P676, DOI 10.1038/s41591-020-0843-2
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li Y, 2005, INDOOR AIR, V15, P83, DOI 10.1111/j.1600-0668.2004.00317.x
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Lindsley WG, 2012, J OCCUP ENVIRON HYG, V9, P443, DOI 10.1080/15459624.2012.684582
   Lindsley WG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015100
   Liu L, 2017, INDOOR AIR, V27, P452, DOI 10.1111/ina.12314
   Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3
   Lu JY, 2020, EMERG INFECT DIS, V26, P1628, DOI [10.3201/eid2607.200764, 10.3201/eid2611.203774]
   Misra C, 2002, J AEROSOL SCI, V33, P1027, DOI 10.1016/S0021-8502(02)00055-1
   Morawska L, 2009, J AEROSOL SCI, V40, P256, DOI 10.1016/j.jaerosci.2008.11.002
   Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730
   Napoli PE, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051269
   Olsen SJ, 2003, NEW ENGL J MED, V349, P2416, DOI 10.1056/NEJMoa031349
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Prussin AJ, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0144-z
   PUCHELLE E, 1982, CLIN SCI, V62, P13, DOI 10.1042/cs0620013
   REGNIS JA, 1994, AM J RESP CRIT CARE, V150, P66, DOI 10.1164/ajrccm.150.1.8025774
   Reviglio Victor Eduardo, 2020, Med Hypothesis Discov Innov Ophthalmol, V9, P71
   SHERMAN MP, 1992, ANNU REV PHYSIOL, V54, P331, DOI 10.1146/annurev.physiol.54.1.331
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Singh M, 2003, ATMOS ENVIRON, V37, P4781, DOI 10.1016/j.atmosenv.2003.08.013
   Tang JW, 2006, J HOSP INFECT, V64, P100, DOI 10.1016/j.jhin.2006.05.022
   Tellier R, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3707-y
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang CS, 2005, INTERFACE SCI TECHNO, V5, P1
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   WHO, COR DIS COVID 19 PAN
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xie XJ, 2009, J R SOC INTERFACE, V6, pS703, DOI 10.1098/rsif.2009.0388.focus
   Yan J, 2018, P NATL ACAD SCI USA, V115, P1081, DOI 10.1073/pnas.1716561115
   Yang SH, 2007, J AEROSOL MED, V20, P484, DOI 10.1089/jam.2007.0610
   Yang W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021481
   YEATES DB, 1975, J APPL PHYSIOL, V39, P487
   Yoshida M, 2004, CELL MOL BIOL, V50, P639
   Zayas G, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-11
NR 68
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0749-6753
EI 1099-1751
J9 INT J HEALTH PLAN M
JI Int. J. Health Plan. Manag.
DI 10.1002/hpm.3095
EA DEC 2020
PG 10
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA PB8AM
UT WOS:000596537400001
PM 33295073
OA Other Gold
DA 2021-01-01
ER

PT J
AU Nishi, A
   Dewey, G
   Endo, A
   Neman, S
   Iwamoto, SK
   Ni, MY
   Tsugawa, Y
   Iosifidis, G
   Smith, JD
   Young, SD
AF Nishi, Akihiro
   Dewey, George
   Endo, Akira
   Neman, Sophia
   Iwamoto, Sage K.
   Ni, Michael Y.
   Tsugawa, Yusuke
   Iosifidis, Georgios
   Smith, Justin D.
   Young, Sean D.
TI Network interventions for managing the COVID-19 pandemic and sustaining
   economy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE COVID-19; pandemic preparedness; agent-based simulation; network
   interventions
ID TRANSMISSION; BEHAVIOR; SPREAD; MODELS
AB Sustaining economic activities while curbing the number of new coronavirus disease 2019 (COVID-19) cases until effective vaccines or treatments become available is a major public health and policy challenge. In this paper, we use agent-based simulations of a network-based susceptible-exposed-infectious-recovered (SEIR) model to investigate two network intervention strategies for mitigating the spread of transmission while maintaining economic activities. In the simulations, we assume that people engage in group activities in multiple sectors (e.g., going to work, going to a local grocery store), where they interact with others in the same group and potentially become infected. In the first strategy, each group is divided into two subgroups (e.g., a group of customers can only go to the grocery store in the morning, while another separate group of customers can only go in the afternoon). In the second strategy, we balance the number of group members across different groups within the same sector (e.g., every grocery store has the same number of customers). The simulation results show that the dividing groups strategy substantially reduces transmission, and the joint implementation of the two strategies could effectively bring the spread of transmission under control (i.e., effective reproduction number approximate to 1.0).
C1 [Nishi, Akihiro; Dewey, George] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA.
   [Nishi, Akihiro] Univ Calif Los Angeles, Calif Ctr Populat Res, Los Angeles, CA 90095 USA.
   [Nishi, Akihiro] Univ Calif Los Angeles, Bedari Kindness Inst, Los Angeles, CA 90095 USA.
   [Endo, Akira] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England.
   [Endo, Akira] Alan Turing Inst, London NW1 2DB, England.
   [Neman, Sophia] Med Coll Wisconsin, Sch Med, Wauwatosa, WI 53213 USA.
   [Iwamoto, Sage K.] Univ Calif Berkeley, Coll Letters & Sci, Berkeley, CA 94720 USA.
   [Ni, Michael Y.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong 999077, Peoples R China.
   [Ni, Michael Y.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong 999077, Peoples R China.
   [Ni, Michael Y.] Univ Hong Kong, Hlth High Dens Cities Lab, HKUrban Lab, Hong Kong 999077, Peoples R China.
   [Tsugawa, Yusuke] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA.
   [Tsugawa, Yusuke] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA.
   [Iosifidis, Georgios] Trinity Coll Dublin, Comp Sci & Stat, Dublin 2, Ireland.
   [Smith, Justin D.] Univ Utah, Sch Med, Dept Populat Hlth Sci, Salt Lake City, UT 84108 USA.
   [Smith, Justin D.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
   [Smith, Justin D.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
   [Smith, Justin D.] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA.
   [Young, Sean D.] Univ Calif Irvine, Inst Predict Technol, Dept Informat, Irvine, CA 92617 USA.
   [Young, Sean D.] Univ Calif Irvine, Dept Emergency Med, Irvine, CA 92868 USA.
RP Nishi, A (corresponding author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA.; Nishi, A (corresponding author), Univ Calif Los Angeles, Calif Ctr Populat Res, Los Angeles, CA 90095 USA.; Nishi, A (corresponding author), Univ Calif Los Angeles, Bedari Kindness Inst, Los Angeles, CA 90095 USA.
EM akihironishi@ucla.edu
OI Neman, Sophia/0000-0002-8345-9321; Iosifidis, George
   (Georgios)/0000-0003-1001-2323; Dewey, George/0000-0001-5661-6494;
   Tsugawa, Yusuke/0000-0002-1937-4833; Ni, Michael/0000-0002-1217-5858;
   Young, Sean D./0000-0001-6052-4875; Nishi, Akihiro/0000-0003-1629-5985
FU UCLA FSPH High-Impact Data Initiative; Nakajima Foundation; Alan Turing
   Institute; National Institute on Drug AbuseUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [P30DA027828]; National
   Institute of Mental HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH); National Center for Complementary and
   Alternative MedicineUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Complementary & Alternative Medicine; Science Foundation IrelandScience
   Foundation Ireland [16/IA/4610]; National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID)
FX We thank Lily F. Lee, Xinyue Liu, and Jiwoo Ha for their comments.
   Support for this research was provided by a grant from the UCLA FSPH
   High-Impact Data Initiative (A.N. and Y.T.). A.E. was financially
   supported by The Nakajima Foundation and The Alan Turing Institute.
   Additional support for A.N., J.D.S., and S.D.Y. was provided by Grant
   P30DA027828 from the National Institute on Drug Abuse, awarded to C.
   Hendricks Brown, and, for S.D.Y., from grants from the National
   Institute of Mental Health, National Institute of Allergy and Infectious
   Diseases, and National Center for Complementary and Alternative
   Medicine. G.I. acknowledges support from Science Foundation Ireland
   through Grant 16/IA/4610. The opinions expressed herein are the views of
   the authors and do not necessarily reflect the official policy or
   position of the National Institute on Drug Abuse, or any other part of
   the US Department of Health and Human Services.
CR ANDERSON R M, 1986, IMA Journal of Mathematics Applied in Medicine and Biology, V3, P229
   ANDERSON R M, 1991
   Angell S. Y., ORDER STATE PUBLIC H
   [Anonymous], 2020, JAPAN TIMES
   [Anonymous], 1974, TIME MAGAZINE
   Bansal S, 2007, J R SOC INTERFACE, V4, P879, DOI 10.1098/rsif.2007.1100
   Bavel Jay J Van, 2020, Nat Hum Behav, V4, P460, DOI 10.1038/s41562-020-0884-z
   Begon M, 2002, EPIDEMIOL INFECT, V129, P147, DOI 10.1017/S0950268802007148
   Bhattarai A., 2020, WASHINGTON POST 0317
   Block P, 2020, NAT HUM BEHAV, V4, P588, DOI 10.1038/s41562-020-0898-6
   Bradbury-Jones C, 2020, J CLIN NURS, V29, P2047, DOI 10.1111/jocn.15296
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Burke RM, 2020, MMWR-MORBID MORTAL W, V69, P245, DOI 10.15585/mmwr.mm6909e1
   Busteed B., 2020, FORBES
   Centola D, 2010, SCIENCE, V329, P1194, DOI 10.1126/science.1185231
   Chen Y, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P667, DOI 10.3760/cma.j.cn112338-20200304-00251
   CLARK AE, 1994, ECON J, V104, P648, DOI 10.2307/2234639
   Coibion O., LABOR MARKETS COVID
   Congressional Research Service, 2020, R46270 C RES SERV
   Crawford FW, 2018, J AM STAT ASSOC, V113, P755, DOI 10.1080/01621459.2017.1285775
   Cuomo A., NEW YORK STATE PAUSE
   DESAI S, 2020, JAMA INTERN MED, DOI DOI 10.1001/JAMAINTERNMED.2020.3862
   Di Domenico L., EXPECTED IMPACT REOP
   Endo Akira, 2020, Wellcome Open Res, V5, P67, DOI 10.12688/wellcomeopenres.15842.1
   Ferguson N., 2020, IMPACT NONPHARMACEUT
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799
   Gressman PT, 2020, MATH BIOSCI, V328, DOI 10.1016/j.mbs.2020.108436
   He DH, 2020, INT J INFECT DIS, V94, P145, DOI 10.1016/j.ijid.2020.04.034
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hirschhorn L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1888
   Hladish T, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-76
   Hoang T, 2019, EPIDEMIOLOGY, V30, P723, DOI 10.1097/EDE.0000000000001047
   Hobbs WR, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0092
   Hoertel N, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1001-6
   Hunter P. R., 2020, IMPACT NONPHARMACEUT, DOI [DOI 10.1101/2020.05.01.20088260, 10.1101/2020.05.01.20088260]
   Ibuka Y, 2016, J EPIDEMIOL COMMUN H, V70, P162, DOI 10.1136/jech-2015-205777
   Islam N, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2743
   KAHNEMAN D, 1990, J POLIT ECON, V98, P1325, DOI 10.1086/261737
   Kassraie A., 2020, SUPERMARKETS OFFER S
   KBTX-TV, 2020, KBTX TV         0703
   Kim DA, 2015, LANCET, V386, P145, DOI 10.1016/S0140-6736(15)60095-2
   Klompas M, 2020, JAMA-J AM MED ASSOC, V324, P441, DOI 10.1001/jama.2020.12458
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Leclerc Quentin J, 2020, Wellcome Open Res, V5, P83, DOI 10.12688/wellcomeopenres.15889.1
   Lippi G, 2020, DIAGNOSIS, V7, P85, DOI 10.1515/dx-2020-0041
   Liu FZ, 2020, IEEE T CONTROL NETW, V7, P1115, DOI 10.1109/TCNS.2019.2963488
   MCPHERSON JM, 1987, AM SOCIOL REV, V52, P370, DOI 10.2307/2095356
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   Murray CJ, 2020, MEDRXIV, DOI [10.1101/2020.04.21.20074732, DOI 10.1101/2020.04.21.20074732]
   Nakajima Y, 2015, AM J EMERG MED, V33, P818, DOI 10.1016/j.ajem.2015.03.005
   Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480
   Newman MEJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.208701
   Nishi A., 2020, COVID 19 PNAS PROJEC
   Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012
   Physical Activity Council, PAC PART REP
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Rader B, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1104-0
   Read JM, 2008, J R SOC INTERFACE, V5, P1001, DOI 10.1098/rsif.2008.0013
   Redman R., 2020, SUPER MARKET NE 0417
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Shim E, 2020, INT J INFECT DIS, V93, P339, DOI 10.1016/j.ijid.2020.03.031
   Smith Jeffrey A, 2020, Sociol Methodol, V50, P215, DOI 10.1177/0081175020922879
   Tappe A., 2020, CNN
   THORNTON J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1401
   Tian HY, 2020, SCIENCE, V368, P638, DOI 10.1126/science.abb6105
   Tuller D., 2016, HLTH AFF, DOI [10.1377/hpb20160602.353150, DOI 10.1377/HPB20160602.353150]
   Ueno T, 2008, J THEOR BIOL, V254, P655, DOI 10.1016/j.jtbi.2008.07.001
   Unwin H. J. T., 2020, 23 IMP COLL LOND
   US Census Bureau, 2018, AM COMMUNITY SURVEY
   US Census Bureau, QUICKFACTS SIERR MAD
   Valente TW, 2012, SCIENCE, V337, P49, DOI 10.1126/science.1217330
   Wang C, 2016, SOC NETWORKS, V45, P89, DOI 10.1016/j.socnet.2015.12.003
   Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918
   Zhao J., 2020, ARXIV200603716V2
NR 78
TC 0
Z9 0
U1 2
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 8
PY 2020
VL 117
IS 48
BP 30285
EP 30294
DI 10.1073/pnas.2014297117
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB8LQ
UT WOS:000596566400001
PM 33177237
OA Other Gold
DA 2021-01-01
ER

PT J
AU Yuan, FF
   Wang, LP
   Fang, Y
   Wang, LY
AF Yuan, Fangfeng
   Wang, Liping
   Fang, Ying
   Wang, Leyi
TI Global SNP analysis of 11,183 SARS-CoV-2 strains reveals high genetic
   diversity
SO TRANSBOUNDARY AND EMERGING DISEASES
LA English
DT Article; Early Access
DE 3CL(pro); complete genome sequence; PLpro; RdRp; S protein; SARS&#8208;
   CoV&#8208; 2; SNP analysis
ID NEUTRALIZING ANTIBODY
AB Since first identified in December of 2019, COVID-19 has been quickly spreading to the world in few months and COVID-19 cases are still undergoing rapid surge in most countries worldwide. The causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), adapts and evolves rapidly in nature. With the availability of 16,092 SARS-CoV-2 full genomes in GISAID as of 13 May, we removed the poor-quality genomes and performed mutational profiling analysis for the remaining 11,183 viral genomes. Global analysis of all sequences identified all single nucleotide polymorphisms (SNPs) across the whole genome and critical SNPs with high mutation frequency that contributes to five-clade classification of global strains. A total of 119 SNPs were found with 74 non-synonymous mutations, 43 synonymous mutations and two mutations in intergenic regions. Analysis of geographic pattern of mutational profiling for the whole genome reveals differences between each continent. A transition mutation from C to T represents the most mutation types across the genome, suggesting rapid evolution and adaptation of the virus in host. Amino acid (AA) deletions and insertions found across the genome results in changes in viral protein length and potential function alteration. Mutational profiling for each gene was analysed, and results show that nucleocapsid gene demonstrates the highest mutational frequency, followed by Nsp2, Nsp3 and Spike gene. We further focused on non-synonymous mutational distributions on four key viral proteins, spike with 75 mutations, RNA-dependent-RNA-polymerase with 41 mutations, 3C-like protease with 22 mutations and Papain-like protease with 10 mutations. Results show that non-synonymous mutations on critical sites of these four proteins pose great challenge for development of anti-viral drugs and other countering measures. Overall, this study provides more understanding of genetic diversity/variability of SARS-CoV-2 and insights for development of anti-viral therapeutics.
C1 [Yuan, Fangfeng; Fang, Ying] Univ Illinois, Coll Vet Med, Dept Pathobiol, Urbana, IL USA.
   [Wang, Liping] Kansas State Univ, Coll Vet Med, Dept Diagnost Med & Pathobiol, Manhattan, KS 66506 USA.
   [Wang, Leyi] Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Vet Diagnost Lab, Urbana, IL 61801 USA.
RP Wang, LY (corresponding author), Univ Illinois, Vet Diagnost Lab, Coll Vet Med, Urbana, IL 61801 USA.; Wang, LY (corresponding author), Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Urbana, IL 61801 USA.
EM leyiwang@illinois.edu
RI Wang, Leyi/G-9448-2014
OI Wang, Leyi/0000-0001-5813-9505
CR Aftab SO, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02439-0
   Alsoussi WB, 2020, J IMMUNOL, V205, P915, DOI 10.4049/jimmunol.2000583
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Arya R, 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11860011.v2, DOI 10.26434/CHEMRXIV.11860011.V2, 10.26434/chemrxiv.11860011.v2.]
   Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364
   Bal A, 2020, CLIN MICROBIOL INFEC, V26, P960, DOI 10.1016/j.cmi.2020.03.020
   Balcioglu BK, 2020, TURK J BIOL, V44, P203, DOI 10.3906/biy-2005-91
   Cagliani R, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104353
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Caudill V. R., 2019, BIORXIV, V34, P339, DOI [10.1101/702175, DOI 10.1101/702175]
   Chand GB, 2020, PEERJ, V8, DOI 10.7717/peerj.9492
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Chitranshi N, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02448-z
   Daniloski Zharko, 2020, bioRxiv, DOI 10.1101/2020.06.14.151357
   di Gioacchino Andrea, 2020, bioRxiv, DOI 10.1101/2020.05.06.074039
   Elena SF, 2005, J VIROL, V79, P11555, DOI 10.1128/JVI.79.18.11555-11558.2005
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Erasmus JH, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc9396
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gallaher WR, 2020, ARCH VIROL, V165, P2341, DOI 10.1007/s00705-020-04750-z
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Graham RL, 2005, J VIROL, V79, P13399, DOI 10.1128/JVI.79.21.13399-13411.2005
   Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040
   Guan Q., 2020, PREPRINT, DOI [10.1101/2020.04.21.054221, DOI 10.1101/2020.04.21.054221]
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Han AX, 2019, MOL BIOL EVOL, V36, P1580, DOI 10.1093/molbev/msz053
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Hu J., 2020, BIORXIV, DOI [10.1101/2020.06.20.161323, DOI 10.1101/2020.06.20.161323]
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li JY, 2020, BRIT J HAEMATOL, V190, P24, DOI 10.1111/bjh.16797
   Liu D. X., 2020, REFERENCE MODULE LIF, DOI [10.1016/B978-0-12-809633-8.21501-X, DOI 10.1016/B978-0-12-809633-8.21501-X]
   Liu PC, 2020, EMERG MICROBES INFEC, V9, P1254, DOI 10.1080/22221751.2020.1772677
   Matyasek R, 2020, GENES-BASEL, V11, DOI 10.3390/genes11070761
   Mercatelli D, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01800
   Mercurio I, 2020, CELL MOL LIFE SCI, DOI 10.1007/s00018-020-03580-1
   Ogawa Junko, 2020, bioRxiv, DOI 10.1101/2020.07.21.214932
   Ozono S, 2020, BIORXIV, DOI [10.1101/2020.06.15.151779, DOI 10.1101/2020.06.15.151779]
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Qiu Y, 2020, J POPUL ECON, V33, P1127, DOI 10.1007/s00148-020-00778-2
   Rambaut Andrew, 2020, Nat Microbiol, V5, P1403, DOI 10.1038/s41564-020-0770-5
   Rozewicki J, 2019, NUCLEIC ACIDS RES, V47, pW5, DOI 10.1093/nar/gkz342
   Ruan SG, 2020, LANCET INFECT DIS, V20, P630, DOI 10.1016/S1473-3099(20)30257-7
   Rut Wioletta, 2020, bioRxiv, DOI 10.1101/2020.04.29.068890
   Saha I, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104457
   Sashittal P., 2020, BIORXIV, DOI [10.1101/2020.05.07.083410, DOI 10.1101/2020.05.07.083410]
   Schmidt Fabian, 2020, bioRxiv, DOI 10.1101/2020.06.08.140871
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Simmonds P, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00408-20.
   Singh N, 2020, EUR J PHARM SCI, V153, DOI 10.1016/j.ejps.2020.105495
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tubiana L, 2015, BIOPHYS J, V108, P194, DOI 10.1016/j.bpj.2014.10.070
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia XH, 2020, MOL BIOL EVOL, V37, P2699, DOI 10.1093/molbev/msaa094
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yurkovetskiy Leonid, 2020, bioRxiv, DOI 10.1101/2020.07.04.187757
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 70
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1865-1674
EI 1865-1682
J9 TRANSBOUND EMERG DIS
JI Transbound. Emerg. Dis.
DI 10.1111/tbed.13931
EA DEC 2020
PG 17
WC Infectious Diseases; Veterinary Sciences
SC Infectious Diseases; Veterinary Sciences
GA PC1TZ
UT WOS:000596793100001
PM 33207070
OA Bronze
DA 2021-01-01
ER

PT J
AU Limaye, RJ
   Sauer, M
   Truelove, SA
AF Limaye, Rupali J.
   Sauer, Molly
   Truelove, Shaun A.
TI Politicizing public health: the powder keg of rushing COVID-19 vaccines
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE COVID-19 vaccines; vaccine safety; vaccine acceptance; vaccine approval;
   vaccine hesitancy
AB Vaccine hesitancy is on the rise, as more individuals are delaying or refusing vaccines. This rise in hesitancy has been primarily driven by vaccine safety concerns, even though the vaccine development process is regulated by a robust and rigorous scientific system. Recent data suggest that many individuals would be unwilling to take a COVID-19 vaccine, once one is available. The Trump administration's Operation Warp Speed aims to deliver a vaccine in the near future, even though no American or European COVID-19 vaccine has yet completed Phase 3 trials. The administration has used the emergency use authorization mechanism to fast track therapeutic products through the Food and Drug Administration and has not ruled out using the mechanism to fast track a COVID-19 vaccine. Perceived political pressure to push a COVID-19 vaccine will have a multitude of negative consequences. Not only will it lead to sub-optimal levels of vaccine acceptance toward a COVID-19 vaccine, it will reverse progress made in controlling vaccine preventable disease for years to come.
C1 [Limaye, Rupali J.; Sauer, Molly; Truelove, Shaun A.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Int Hlth, Baltimore, MD 21205 USA.
   [Limaye, Rupali J.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Epidemiol, Baltimore, MD 21205 USA.
   [Limaye, Rupali J.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA.
RP Limaye, RJ (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Int Hlth, Baltimore, MD 21205 USA.; Limaye, RJ (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Epidemiol, Baltimore, MD 21205 USA.; Limaye, RJ (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA.
EM rlimaye@jhu.edu
OI Limaye, Rupali/0000-0002-3883-9720
CR Cornwall W, 2020, SCIENCE, V369, P14, DOI 10.1126/science.369.6499.14
   Dudley MZ, 2020, LANCET INFECT DIS, V20, pE80, DOI 10.1016/S1473-3099(20)30130-4
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Malik Amyn A, 2020, EClinicalMedicine, V26, P100495, DOI 10.1016/j.eclinm.2020.100495
   Omer SB, 2017, JAMA PEDIATR, V171, P929, DOI 10.1001/jamapediatrics.2017.2219
   Soborg C, 2009, VACCINE, V27, P3295, DOI 10.1016/j.vaccine.2009.02.030
   Walldorf JA, 2019, VACCINE, V37, P7190, DOI 10.1016/j.vaccine.2017.08.058
NR 7
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1846400
EA DEC 2020
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA PF9SK
UT WOS:000599385900001
PM 33327848
OA Bronze
DA 2021-01-01
ER

PT J
AU You, JHS
AF You, Joyce H. S.
TI Impact of COVID-19 infection control measures on influenza-related
   outcomes in Hong Kong
SO PATHOGENS AND GLOBAL HEALTH
LA English
DT Article; Early Access
DE Seasonal influenza; COVID-19; face mask; health economics;
   disability-adjusted life-years
ID VACCINE
AB Following the announcement of coronavirus disease 2019 (COVID-19) cases in Wuhan on 31 December 2019, government officials in Hong Kong recommended the wearing of face masks as a public infection control measure against the COVID-19 virus and curtail the impact of the concurrent influenza season. The present study evaluated the influenza-related outcomes between the influenza season 2019 and 2020 in Hong Kong as a result of these infection control measures. A Monte Carlo simulation model was designed to estimate the number of influenza cases, clinic visits, hospitalization, deaths, direct medical cost and disability-adjusted life-years (DALYs) for the season 2018-2019 and 2019-2020 in six age groups: 0-5 years, 6-11 years, 12-17 years, 18-49 years, 50-64 years and >= 65 years in Hong Kong. Model inputs were derived from public data and existing literature. The model findings showed significant reduction in influenza-related cases, clinic visits, hospitalization, and deaths in 2020 versus 2019 (p < 0.05). Influenza-related direct costs in all age-groups were significantly reduced by 56%-82% (p < 0.01) in 2020 versus 2019. DALYs were also significantly decreased by 58%-85% (p < 0.01). The direct cost and DALYs avoided in 2020 was the highest among the age group of 0-5 years with a cost-saving of USD593,763 (95%CI 590,730-596,796) per 10,000 population and a DALY reduction of 57.67 (95%CI 57.54-57.83) per 10,000 population. This study illustrated the reduction of all influenza-related outcome measures in Hong Kong as a result of the implementation of public infection control measures against COVID-19.
C1 [You, Joyce H. S.] Chinese Univ Hong Kong, Sch Pharm, Fac Med, Shatin, Hong Kong, Peoples R China.
RP You, JHS (corresponding author), Chinese Univ Hong Kong, Sch Pharm, Fac Med, Hong Kong, Peoples R China.
EM joyceyou@cuhk.edu.hk
CR Biggerstaff M, 2012, AM J PUBLIC HLTH, V102, pe21
   Census and Statistics Department The Government of Hong Kong SAR, POPULATION ESTIMATES
   Census and Statistics Department The Government of Hong Kong SAR, HONG KONG LIF TABL 1
   Centers for Disease Control and Prevention, CDC EST BURD SEAS IN
   Centers for Disease Control and Prevention, US FLU DAT 2018 2019
   Centre for Health Protection Department of Health The Government of Hong Kong SAR, STAT VACC PROGR 3 YE
   Centre for Health Protection Department of Health The Government of Hong Kong SAR, FLU EXPR
   Chan YK, 2017, ANTIVIR THER, V22, P173, DOI 10.3851/IMP3102
   Cheng VCC, 2020, J INFECTION, V81, P107, DOI 10.1016/j.jinf.2020.04.024
   Dawood FS, 2020, MMWR-MORBID MORTAL W, V69, P177, DOI 10.15585/mmwr.mm6907a1
   Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002
   Hospital Authority, FEES CHARG
   Lee BY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011284
   Reed C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118369
   Reed C, 2009, EMERG INFECT DIS, V15, P2004, DOI 10.3201/eid1512.091413
   Tang CSK, 2004, PREV MED, V39, P1187, DOI 10.1016/j.ypmed.2004.04.032
   The Centre for Health Protection, LAT SIT CAS COVID 19
   Tong E., FLU SEASON ALL HONG
   Tsang E, 2019, S CHINA MORNING POST
   World Health Organization, ARCH WHO TIM COVID 1
   You JHS, 2015, HUM VACC IMMUNOTHER, V11, P564, DOI 10.1080/21645515.2015.1011016
   You JHS, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0618-9
NR 22
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2047-7724
EI 2047-7732
J9 PATHOG GLOB HEALTH
JI Pathog. Glob. Health
DI 10.1080/20477724.2020.1857492
EA DEC 2020
PG 7
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA PF2YZ
UT WOS:000598927700001
PM 33320773
OA Bronze
DA 2021-01-01
ER

PT J
AU Llabres, M
   Valiente, G
AF Llabres, Merce
   Valiente, Gabriel
TI Alignment of virus-host protein-protein interaction networks by integer
   linear programming: SARS-CoV-2
SO PLOS ONE
LA English
DT Article
ID SEQUENCE
AB Motivation
   Beside socio-economic issues, coronavirus pandemic COVID-19, the infectious disease caused by the newly discovered coronavirus SARS-CoV-2, has caused a deep impact in the scientific community, that has considerably increased its effort to discover the infection strategies of the new virus. Among the extensive and crucial research that has been carried out in the last months, the analysis of the virus-host relationship plays an important role in drug discovery. Virus-host protein-protein interactions are the active agents in virus replication, and the analysis of virus-host protein-protein interaction networks is fundamental to the study of the virus-host relationship.
   Results
   We have adapted and implemented a recent integer linear programming model for protein-protein interaction network alignment to virus-host networks, and obtained a consensus alignment of the SARS-CoV-1 and SARS-CoV-2 virus-host protein-protein interaction networks. Despite the lack of shared human proteins in these virus-host networks, and the low number of preserved virus-host interactions, the consensus alignment revealed aligned human proteins that share a function related to viral infection, as well as human proteins of high functional similarity that interact with SARS-CoV-1 and SARS-CoV-2 proteins, whose alignment would preserve these virus-host interactions.
C1 [Llabres, Merce] Univ Balearic Isl, Dept Math & Comp Sci, Palma De Mallorca, Spain.
   [Valiente, Gabriel] Tech Univ Catalonia, Algorithms Bioinformat Complex & Formal Methods R, Barcelona, Spain.
RP Valiente, G (corresponding author), Tech Univ Catalonia, Algorithms Bioinformat Complex & Formal Methods R, Barcelona, Spain.
EM gabriel.valiente@upc.edu
RI Llabres, Merce/K-8725-2014; Valiente, Gabriel/K-4265-2014
OI Llabres, Merce/0000-0002-5358-6768; Valiente,
   Gabriel/0000-0001-9194-2703
FU Spanish Ministry of Science, Innovation and Universities
   [PGC2018-096956-B-C43]; European Regional Development FundEuropean Union
   (EU) [PGC2018-096956-B-C43]
FX This work has been supported by the Spanish Ministry of Science,
   Innovation and Universities and the European Regional Development Fund
   through project PGC2018-096956-B-C43 (FEDER/MICINN/AEI). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alcala A, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-3502-1
   [Anonymous], 2014, J ORTHOP RES S1, V32, pS158
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163
   Fourer Robert, 2002, AMPL MODELING LANGUA
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guirimand T, 2015, NUCLEIC ACIDS RES, V43, pD583, DOI 10.1093/nar/gku1121
   Hashemifar S, 2014, BIOINFORMATICS, V30, pI438, DOI 10.1093/bioinformatics/btu450
   Li Zhenping, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P5527
   Llabres M, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-03733-w
   Malod-Dognin N, 2015, BIOINFORMATICS, V31, P2182, DOI 10.1093/bioinformatics/btv130
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4
   Orchard S, 2014, NUCLEIC ACIDS RES, V42, pD358, DOI 10.1093/nar/gkt1115
   Pan A, 2016, BRIEF BIOINFORM, V17, P517, DOI 10.1093/bib/bbv059
   Phan HTT, 2012, BIOINFORMATICS, V28, P1239, DOI 10.1093/bioinformatics/bts119
   Pomaznoy M, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2533-3
   Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016
   Zhao CG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33219-y
NR 20
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 7
PY 2020
VL 15
IS 12
AR e0236304
DI 10.1371/journal.pone.0236304
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PD8LW
UT WOS:000597930500028
PM 33284827
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Aghili, ZS
   Mirzaei, SA
   Banitalebi-Dehkordi, M
AF Aghili, Zahra Sadat
   Mirzaei, Seyed Abbas
   Banitalebi-Dehkordi, Mehdi
TI A potential hypothesis for 2019-nCoV infection therapy through delivery
   of recombinant ACE2 by red blood cell-hitchhiking
SO JOURNAL OF BIOLOGICAL RESEARCH-THESSALONIKI
LA English
DT Article
DE ACE2; Drug delivery; Nanoparticles; 2019-nCoV; RBC hitchhiking
ID ANGIOTENSIN-CONVERTING ENZYME-2; NANOPARTICLES;
   ANGIOTENSIN-CONVERTING-ENZYME-2; ADSORPTION; PROTECTS; RECEPTOR
AB A novel infectious disease, caused by 2019 Novel Coronavirus (2019-nCoV) is responsible for the recent outbreak of severe respiratory disease. The 2019-nCoV spread rapidly and reaching epidemic proportions in many countries of the world. ACE2 was identified as a key receptor for 2019-nCoV infections. Excessive form of soluble ACE2 rescues cellular ACE2 activity which has a protective role in acute lung failure and neutralizes the virus. The short half-life of ACE2 is a major limitation to its practical application. Nanoparticle-based drug delivery systems are one of the most widely investigated approaches for developing novel therapies for a variety of diseases. Nevertheless, nanoparticles suffer from the rapid removal from the bloodstream by the reticuloendothelial system (RES). A noncovalent attachment of nanoparticles to RBCs increases their half-life in blood and allows transient accumulation in the lungs, while decreases their uptake by the liver and spleen. Connecting the recombinant ACE2 into the surface of nanoparticles that were attached to RBCs can be a potential therapeutic approach for 2019-nCoV infection through increasing their lung targeting to naturalize the virus and also acting as a bioreactor in the blood circulation to decrease serum level of Angiotensin II and protects lungs from injury/ARDS.
C1 [Mirzaei, Seyed Abbas; Banitalebi-Dehkordi, Mehdi] Shahrekord Univ Med Sci, Basic Hlth Sci Inst, Cellular & Mol Res Ctr, Shahrekord, Iran.
   [Aghili, Zahra Sadat; Banitalebi-Dehkordi, Mehdi] Shahrekord Univ Med Sci, Sch Adv Technol, Dept Mol Med, Shahrekord, Iran.
   [Mirzaei, Seyed Abbas] Shahrekord Univ Med Sci, Sch Adv Technol, Dept Med Biotechnol, Shahrekord, Iran.
RP Banitalebi-Dehkordi, M (corresponding author), Shahrekord Univ Med Sci, Basic Hlth Sci Inst, Cellular & Mol Res Ctr, Shahrekord, Iran.; Banitalebi-Dehkordi, M (corresponding author), Shahrekord Univ Med Sci, Sch Adv Technol, Dept Mol Med, Shahrekord, Iran.
EM banitalebi.m@skums.ac.ir
RI Mirzaei, Seyed Abbas/L-7207-2017
OI Mirzaei, Seyed Abbas/0000-0003-0307-3750
CR Anselmo AC, 2013, ACS NANO, V7, P11129, DOI 10.1021/nn404853z
   Brenner JS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05079-7
   Chambers E, 2004, J CONTROL RELEASE, V100, P111, DOI 10.1016/j.jconrel.2004.08.005
   Ferrario CM, 2005, AM J PHYSIOL-HEART C, V289, pH2281, DOI 10.1152/ajpheart.00618.2005
   Glassman PM, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12050440
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Pan D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152074
   Pan DC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19897-8
   Sanchis-Gomar F, 2020, MAYO CLIN PROC, V95, P1222, DOI 10.1016/j.mayocp.2020.03.026
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   Villa CH, 2016, TRANSFUS APHER SCI, V55, P275, DOI 10.1016/j.transci.2016.10.017
   Villa CH, 2015, THER DELIV, V6, P795, DOI [10.4155/TDE.15.34, 10.4155/tde.15.34]
   Xia Q, 2019, ACTA PHARM SIN B, V9, P675, DOI 10.1016/j.apsb.2019.01.011
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Zhao Y, 2020, AM J RESP CRIT CARE, V202, P756, DOI 10.1164/rccm.202001-0179LE
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 28
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1790-045X
EI 2241-5793
J9 J BIOL RES-THESSALON
JI J. Biol. Res.
PD DEC 7
PY 2020
VL 27
IS 1
AR 17
DI 10.1186/s40709-020-00129-y
PG 5
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA PD8UY
UT WOS:000597954200001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Oh, TK
   Park, HY
   Song, IA
AF Oh, Tak Kyu
   Park, Hye Youn
   Song, In-Ae
TI Risk of psychological sequelae among coronavirus disease-2019 survivors:
   A nationwide cohort study in South Korea
SO DEPRESSION AND ANXIETY
LA English
DT Article; Early Access
DE depression; drug abuse; epidemiology; gender
ID COVID-19
AB Background We sought to investigate the risk of psychological diseases among coronavirus disease-2019 (COVID-19) survivors in South Korea.
   Methods The National Health Insurance Service (NHIS) COVID-19 cohort database, comprising COVID-19 patients and a control population from January 1, 2020 to June 4, 2020, was used in this study. COVID-19 patients were defined as individuals who were confirmed as COVID-19 positive, regardless of disease severity, and COVID-19 survivors were defined as individuals who recovered from COVID-19. The control population was extracted using stratification methods according to the age, sex, and residence of COVID-19 patients. Individuals previously diagnosed with any psychological disease were excluded from the analysis. The primary endpoint was a new diagnosis of psychological disease. Multivariable logistic modeling was used for statistical analyses.
   Results A total of 99,742 individuals (5879 [5.9%] COVID-19 survivors and 93,863 [94.1%] controls) were included in the final analysis. The incidence of newly diagnosed psychological disease, depression, psychosis, alcohol abuse, and drug abuse was 1438 (1.4%), 1268 (1.3%), 44 (0.0%), 173 (0.2%), and 2 (0.0%), respectively. In the multivariable model after adjusting for confounders, the COVID-19 survivors had a 2.98-fold higher probability of developing the psychological disease compared with the control group. Specifically, the odds of depression and psychosis in the COVID-19 survivors were 3.34-fold and 2.49-fold higher than that in the control group, respectively.
   Conclusion COVID-19 survivors had a higher risk of experiencing psychological disease than the control population in South Korea. Particularly, COVID-19 may increase the risk of developing depression and psychosis.
C1 [Oh, Tak Kyu; Song, In-Ae] Seoul Natl Univ, Dept Anesthesiol & Pain Med, Bundang Hosp, Gumi Ro 173 Beon Gil, Seongnam 13620, South Korea.
   [Park, Hye Youn] Seoul Natl Univ, Dept Psychiat, Bundang Hosp, Seongnam, South Korea.
RP Song, IA (corresponding author), Seoul Natl Univ, Dept Anesthesiol & Pain Med, Bundang Hosp, Gumi Ro 173 Beon Gil, Seongnam 13620, South Korea.
EM songoficu@outlook.kr
CR Bagcchi S, 2020, LANCET INFECT DIS, V20, P782, DOI 10.1016/S1473-3099(20)30498-9
   Bakunina N, 2015, IMMUNOLOGY, V144, P365, DOI 10.1111/imm.12443
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Berg-Weger M., 2020, J NUTR HEALTH AGING, V24, P685
   Bodrud-Doza Md, 2020, Front Public Health, V8, P341, DOI 10.3389/fpubh.2020.00341
   Brown E, 2020, SCHIZOPHR RES, V222, P79, DOI 10.1016/j.schres.2020.05.005
   Cerbara L, 2020, EUR REV MED PHARMACO, V24, P7155, DOI 10.26355/eurrev_202006_21711
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   DOOLEY D, 1994, AM J COMMUN PSYCHOL, V22, P745, DOI 10.1007/BF02521557
   Dragano N., 2020, HIGHER RISK COVID 19, DOI [10.1101/2020.06.17.20133918, DOI 10.1101/2020.06.17.20133918]
   Hu W., 2020, COVID 19 OUTBREAK IN, DOI [10.12074/202003.00003, DOI 10.12074/202003.00003]
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Jones P B, 2013, Br J Psychiatry Suppl, V54, ps5, DOI 10.1192/bjp.bp.112.119164
   Kang LJ, 2020, BRAIN BEHAV IMMUN, V87, P11, DOI 10.1016/j.bbi.2020.03.028
   Kim HC, 2018, PSYCHIAT INVEST, V15, P355, DOI 10.30773/pi.2017.10.25.1
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Li SJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062032
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Marques TR, 2019, PSYCHOL MED, V49, P2186, DOI 10.1017/S0033291718003057
   Moore JT, 2020, MMWR-MORBID MORTAL W, V69, P1122, DOI 10.15585/mmwr.mm6933e1
   Nguyen HC, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040965
   O'Hanlon S, 2020, AGE AGEING, V49, P497, DOI 10.1093/ageing/afaa094
   Paniz-Mondolfi A, 2020, J MED VIROL, V92, P699, DOI 10.1002/jmv.25915
   Riecher-Rossler A, 2018, ARCH WOMEN MENT HLTH, V21, P627, DOI 10.1007/s00737-018-0847-9
   Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Scott KM, 2010, J AFFECT DISORDERS, V125, P207, DOI 10.1016/j.jad.2010.06.022
   Severance EG, 2011, SCHIZOPHRENIA BULL, V37, P101, DOI 10.1093/schbul/sbp052
   Singh Rakesh, 2020, Asian J Psychiatr, V53, P102222, DOI 10.1016/j.ajp.2020.102222
   Steardo L, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00949-5
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Troyer EA, 2020, BRAIN BEHAV IMMUN, V87, P34, DOI 10.1016/j.bbi.2020.04.027
   Tu HL, 2020, J INFECTION, V81, P1, DOI 10.1016/j.jinf.2020.04.011
   Vaira LA, 2020, LARYNGOSCOPE, V130, P1787, DOI 10.1002/lary.28692
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Zhang J, 2020, BRAIN BEHAV IMMUN, V87, P49, DOI 10.1016/j.bbi.2020.04.031
   Zhou ZQ, 2020, J NEUROL, V267, P2179, DOI 10.1007/s00415-020-09929-7
NR 38
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
DI 10.1002/da.23124
EA DEC 2020
PG 8
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA PB6YI
UT WOS:000596464000001
OA Bronze
DA 2021-01-01
ER

PT J
AU Teovanovic, P
   Lukic, P
   Zupan, Z
   Lazic, A
   Ninkovic, M
   Zezelj, I
AF Teovanovic, Predrag
   Lukic, Petar
   Zupan, Zorana
   Lazic, Aleksandra
   Ninkovic, Milica
   Zezelj, Iris
TI Irrational beliefs differentially predict adherence to guidelines and
   pseudoscientific practices during the COVID-19 pandemic
SO APPLIED COGNITIVE PSYCHOLOGY
LA English
DT Article; Early Access
DE cognitive biases; conspiracy theories; COVID&#8208; 19 health behavior;
   knowledge overestimation; pseudoscience
ID COGNITIVE REFLECTION; CONSPIRACY THEORIES; BIASES; HEURISTICS;
   ASSOCIATIONS; RATIONALITY; PERSPECTIVE; PREVENTION; ABILITY
AB In the coronavirus "infodemic," people are exposed to official recommendations but also to potentially dangerous pseudoscientific advice claimed to protect against COVID-19. We examined whether irrational beliefs predict adherence to COVID-19 guidelines as well as susceptibility to such misinformation. Irrational beliefs were indexed by belief in COVID-19 conspiracy theories, COVID-19 knowledge overestimation, type I error cognitive biases, and cognitive intuition. Participants (N = 407) reported (1) how often they followed guidelines (e.g., handwashing, physical distancing), (2) how often they engaged in pseudoscientific practices (e.g., consuming garlic, colloidal silver), and (3) their intention to receive a COVID-19 vaccine. Conspiratorial beliefs predicted all three outcomes in line with our expectations. Cognitive intuition and knowledge overestimation predicted lesser adherence to guidelines, while cognitive biases predicted greater adherence, but also greater use of pseudoscientific practices. Our results suggest an important relation between irrational beliefs and health behaviors, with conspiracy theories being the most detrimental.
C1 [Teovanovic, Predrag] Univ Belgrade, Fac Special Educ & Rehabil, Belgrade, Serbia.
   [Teovanovic, Predrag; Lukic, Petar; Zupan, Zorana; Lazic, Aleksandra; Ninkovic, Milica; Zezelj, Iris] Univ Belgrade, Fac Philosophy, Dept Psychol, Lab Res Individual Differences, Belgrade, Serbia.
   [Zupan, Zorana; Zezelj, Iris] Univ Belgrade, Fac Philosophy, Inst Psychol, Belgrade, Serbia.
RP Zezelj, I (corresponding author), Univ Belgrade, Dept Psychol, Belgrade, Serbia.
EM izezelj@f.bg.ac.rs
OI Ninkovic, Milica/0000-0003-4294-1426; Lazic,
   Aleksandra/0000-0002-0433-0483; Zezelj, Iris/0000-0002-9527-1406
FU University of Belgrade [2020-018]
FX University of Belgrade, Grant/Award Number: #2020-018
CR Ackerman PL, 2002, PERS INDIV DIFFER, V33, P587, DOI 10.1016/S0191-8869(01)00174-X
   [Anonymous], 2020, ASS PRESS
   [Anonymous], SERB COR 10496 CAS 2
   avojova V., 2020, SCI REASONING PREDIC, DOI [10.31234/osf.io/tfy5q, DOI 10.31234/OSF.IO/TFY5Q]
   Bogart LM, 2010, JAIDS-J ACQ IMM DEF, V53, P648, DOI 10.1097/QAI.0b013e3181c57dbc
   Bressan P, 2002, APPL COGNITIVE PSYCH, V16, P17, DOI 10.1002/acp.754
   Brotherton R, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00279
   Browne M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132562
   Depoux A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa031
   Dunning David, 2004, Psychol Sci Public Interest, V5, P69, DOI 10.1111/j.1529-1006.2004.00018.x
   Dunning D, 2011, ADV EXP SOC PSYCHOL, V44, P247, DOI 10.1016/B978-0-12-385522-0.00005-6
   Erceg N., 2020, PSYARXIV PREPR, DOI [10.31234/osf.io/cgjw8, DOI 10.31234/OSF.IO/CGJW8]
   Frederick S, 2005, J ECON PERSPECT, V19, P25, DOI 10.1257/089533005775196732
   GILOVICH T, 1985, COGNITIVE PSYCHOL, V17, P295, DOI 10.1016/0010-0285(85)90010-6
   Goncalves-Sa J, 2020, NAT MED, V26, P305, DOI 10.1038/s41591-020-0802-y
   Gordi T, 2004, CLIN THER, V26, P780, DOI 10.1016/S0149-2918(04)90078-1
   Harvey N, 1997, TRENDS COGN SCI, V1, P78, DOI 10.1016/S1364-6613(97)01014-0
   Haselton MG, 2009, SOC COGNITION, V27, P733, DOI 10.1521/soco.2009.27.5.733
   Haselton MG, 2000, J PERS SOC PSYCHOL, V78, P81, DOI 10.1037/0022-3514.78.1.81
   Imhoff R, 2020, SOC PSYCHOL PERS SCI, V11, P1110, DOI 10.1177/1948550620934692
   John OP, 2000, HDB RES METHODS SOCI, P339
   Jolley D, 2017, J APPL SOC PSYCHOL, V47, P459, DOI 10.1111/jasp.12453
   Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177
   Kahneman D., 2005, CAMBRIDGE HDB THINKI, P267, DOI DOI 10.1111/COGS.12119
   King DB, 2014, CAN PSYCHOL, V55, P240, DOI 10.1037/a0038087
   Kleitman S, 2001, APPL COGNITIVE PSYCH, V15, P321, DOI 10.1002/acp.705
   Kouzy R, 2020, CUREUS, V12, DOI 10.7759/cureus.7255
   Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121
   Lamberty P, 2018, SOC PSYCHOL-GERMANY, V49, P255, DOI 10.1027/1864-9335/a000347
   Lazi A., 2020, TELLING STORIES COUN
   Lep Z, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01846
   Lindeman M, 2011, PSYCHOL HEALTH, V26, P371, DOI 10.1080/08870440903440707
   Lobato E, 2014, APPL COGNITIVE PSYCH, V28, P617, DOI 10.1002/acp.3042
   Lukic P, 2019, EUR J PSYCHOL, V15, P94, DOI 10.5964/ejop.v15i1.1690
   McPhetres J., 2019, SCI BELIEFS POLITICA, DOI [10.31219/osf.io/ad9v7, DOI 10.31219/OSF.IO/AD9V7]
   Mian A, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01556-3
   Mooney T., 2020, CBS NEWS
   Oliver JE, 2014, JAMA INTERN MED, V174, P817, DOI 10.1001/jamainternmed.2014.190
   Pavela Banai I., 2020, BELIEFS COVID 19 CON, DOI [10.13140/RG.2.2.29313.89443, DOI 10.13140/RG.2.2.29313.89443]
   Pennycook G., 2020, PREDICTORS ATTITUDES, DOI [10.31234/OSF.IO/ZHJKP, DOI 10.31234/OSF.IO/ZHJKP, 10.31234/osf.io/zhjkp]
   Pennycook G, 2017, PSYCHON B REV, V24, P1774, DOI 10.3758/s13423-017-1242-7
   Pennycook G, 2015, JUDGM DECIS MAK, V10, P549
   Pennycook G, 2015, CURR DIR PSYCHOL SCI, V24, P425, DOI 10.1177/0963721415604610
   Pennycook G, 2012, COGNITION, V123, P335, DOI 10.1016/j.cognition.2012.03.003
   Plohl N, 2020, PSYCHOL HEALTH MED, DOI 10.1080/13548506.2020.1772988
   Pohl RF, 2004, COGNITIVE ILLUSIONS: A HANDBOOK ON FALLACIES AND BIASES IN THINKING, JUDGEMENT AND MEMORY, P1
   Porter E., 2018, J EXP POLIT SCI, V5, P159, DOI DOI 10.1017/XPS.2017.32
   Porter E, 2019, RES POLITICS, V6, DOI 10.1177/2053168019864784
   Pummerer L., 2020, CONSPIRACY THEORIES, DOI [10.31234/osf.io/y5grn, DOI 10.31234/OSF.IO/Y5GRN]
   Redelmeier DA, 1996, P NATL ACAD SCI USA, V93, P2895, DOI 10.1073/pnas.93.7.2895
   Rizeq J, 2020, THINK REASONING, DOI 10.1080/13546783.2020.1759688
   ROOZENBEEK J, 2019, PALGR COMMUN, V5, DOI DOI 10.1057/S41599-019-0279-9
   Setbon M, 2010, EUR J PUBLIC HEALTH, V20, P490, DOI 10.1093/eurpub/ckq054
   Shenhav A, 2012, J EXP PSYCHOL GEN, V141, P423, DOI 10.1037/a0025391
   SMEDSLUND J, 1963, SCAND J PSYCHOL, V4, P165, DOI 10.1111/j.1467-9450.1963.tb01324.x
   Srol J., 2020, INDIVIDUAL DIFFERENC, DOI [10.31234/osf.io/4jcf7, DOI 10.31234/OSF.IO/4JCF7]
   Stahl T, 2018, PERS INDIV DIFFER, V122, P155, DOI 10.1016/j.paid.2017.10.026
   Stankov L, 2000, INTELLIGENCE, V28, P121, DOI 10.1016/S0160-2896(99)00033-1
   Stanley ML, 2020, THINK REASONING, DOI 10.1080/13546783.2020.1813806
   Stanovich K. E., 2009, 2 MINDS DUAL PROCESS, P55, DOI DOI 10.1093/ACPROF:OSO/9780199230167.003.0003
   Stanovich KE, 2016, RATIONALITY QUOTIENT: TOWARD A TEST OF RATIONAL THINKING, P1, DOI 10.7551/mitpress/9780262034845.001.0001
   Swami V., 2020, ANAL THINKING REJECT, DOI 10.31219/osf.io/nmx9w
   Swami V, 2011, BRIT J PSYCHOL, V102, P443, DOI 10.1111/j.2044-8295.2010.02004.x
   Swami V, 2010, APPL COGNITIVE PSYCH, V24, P749, DOI 10.1002/acp.1583
   Teovanovic P, 2015, INTELLIGENCE, V50, P75, DOI 10.1016/j.intell.2015.02.008
   Thompson B., 2005, ENCY STAT BEHAV SCI, P192
   Thomson KS, 2016, JUDGM DECIS MAK, V11, P99
   Thorburn S, 2005, HEALTH EDUC BEHAV, V32, P474, DOI 10.1177/1090198105276220
   Toplak ME, 2011, MEM COGNITION, V39, P1275, DOI 10.3758/s13421-011-0104-1
   TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124
   Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z
   Van Prooijen J. W., 2017, EUROPEAN J SOCIAL PS, V48, P320, DOI DOI 10.1002/EJSP.2331
   van Prooijen JW, 2017, MEM STUD, V10, P323, DOI 10.1177/1750698017701615
   West RF, 2008, J EDUC PSYCHOL, V100, P930, DOI 10.1037/a0012842
   Wood MJ, 2012, SOC PSYCHOL PERS SCI, V3, P767, DOI 10.1177/1948550611434786
   World Health Organisation, 2020, MUN SEC C WHO
   World Health Organization, COR DIS COVID 19 ADV
   Zarocostas J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X
   Zezelj I, 2019, EUR J PSYCHOL, V15, P1, DOI 10.5964/ejop.v15i1.1903
NR 79
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0888-4080
EI 1099-0720
J9 APPL COGNITIVE PSYCH
JI Appl. Cogn. Psychol.
DI 10.1002/acp.3770
EA DEC 2020
PG 11
WC Psychology, Experimental
SC Psychology
GA PB1MZ
UT WOS:000596094900001
PM 33362344
OA Bronze
DA 2021-01-01
ER

PT J
AU Drury, J
   Carter, H
   Ntontis, E
   Guven, ST
AF Drury, John
   Carter, Holly
   Ntontis, Evangelos
   Guven, Selin Tekin
TI Public behaviour in response to the COVID-19 pandemic: understanding the
   role of group processes
SO BJPSYCH OPEN
LA English
DT Article
DE COVID-19; behaviour; groups; public health; resilience
ID SOCIAL IDENTITY; COMMUNICATION; PERCEPTION; ADHERENCE; CROWD
AB Background
   In the absence of a vaccine, behaviour by the public is key to the response to the COVID-19 pandemic. Yet, as with other types of crises and emergencies, there have been doubts about the extent to which the public are able to engage effectively with the required behaviour. These doubts are based on outdated models of group psychology.
   Aims and argument
   We analyse the role of group processes in the COVID-19 pandemic in three domains: recognition of threat, adherence by the public to the required public health behaviours (and the factors that increase such adherence) and actions of the many community mutual aid groups that arose during lockdown. In each case, we draw upon the accumulated research on behaviour in emergencies and disasters, as well as the latest findings in relation to the COVID-19 pandemic, to show that explanations in terms of social identity processes make better sense of the patterns of evidence than alternative explanations.
   Conclusions
   If behaviour in the pandemic is a function of mutable group processes rather than fixed tendencies, then behavioural change is possible. There was evidence of significant change in behaviour from the public, particularly in the early days of the pandemic. Understanding the role of group processes means we can help design more effective interventions to support collective resilience in the public in the face of the pandemic and other threats. We draw out from the evidence a set of recommendations on facilitating the public response to COVID-19 by harnessing group processes.
C1 [Drury, John; Guven, Selin Tekin] Univ Sussex, Sch Psychol, Brighton BN1 9RH, E Sussex, England.
   [Carter, Holly] Publ Hlth England, Hlth Protect Directorate, Emergency Response Dept Sci & Technol, London, England.
   [Ntontis, Evangelos] Canterbury Christ Church Univ, Sch Psychol & Hlth Sci, Canterbury, Kent, England.
RP Drury, J (corresponding author), Univ Sussex, Sch Psychol, Brighton BN1 9RH, E Sussex, England.
EM j.drury@sussex.ac.uk
RI Drury, John/A-6479-2012
OI Drury, John/0000-0002-7748-5128; Ntontis, Evangelos/0000-0001-8284-6015
FU UK Research and Innovation/Economic and Social Research Council
   [ES/V005383/1]
FX This work was supported by UK Research and Innovation/Economic and
   Social Research Council (J.D., H.C. and E.N., grant reference number
   ES/V005383/1).
CR Abrams D, 2020, US THEM PERCEPTION C
   Aguilar-Garcia C, 2020, SKY NEWS
   Aldrich DP, 2015, AM BEHAV SCI, V59, P254, DOI 10.1177/0002764214550299
   Atwood LE, 2000, PUBLIC UNDERST SCI, V9, P417, DOI 10.1088/0963-6625/9/4/305
   BBC, 2020, BBC
   Becker JS, 2017, INT J DISAST RISK RE, V22, P179, DOI 10.1016/j.ijdrr.2017.03.006
   Biddlestone M, 2020, BRIT J SOC PSYCHOL, V59, P663, DOI 10.1111/bjso.12397
   Bonell C, 2020, J EPIDEMIOL COMMUN H, V74, P617, DOI 10.1136/jech-2020-214290
   Butler P., 2020, GUARDIAN
   Cabinet Office, 2011, STRAT NAT FRAM COMM
   Canter D, 1990, FIRES HUMAN BEHAV
   Carter H, 2015, HEALTH SECUR, V13, P45, DOI 10.1089/hs.2014.0061
   Carter H, 2013, BASIC APPL SOC PSYCH, V35, P575, DOI 10.1080/01973533.2013.840634
   Carter H, 2013, INT J EMERG SERV, V2, P29, DOI 10.1108/IJES-06-2012-0026
   Carter H, 2013, DISASTER PREV MANAG, V22, P132, DOI 10.1108/09653561311325280
   Charles M, 2019, GRENFELL VIOLENCE RE, P167
   Chater AM, 2020, BEHAV SCI DIS PREVET
   Clark Cory, 2020, Glob Transit, V2, P76, DOI 10.1016/j.glt.2020.06.003
   Clarke L., 2002, CONTEXTS, V1, P21, DOI DOI 10.1525/CTX.2002.1.3.21
   Conn D, 2020, GUARDIAN
   Cruwys T, 2020, BRIT J SOC PSYCHOL, V59, P584, DOI 10.1111/bjso.12391
   Drury J, 2020, NOVARA MEDIA
   Drury J, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00141
   Drury J, 2018, EUR REV SOC PSYCHOL, V29, P38, DOI 10.1080/10463283.2018.1471948
   Drury J, 2016, EUR J SOC PSYCHOL, V46, P209, DOI 10.1002/ejsp.2146
   Drury J, 2013, RESILIENCE, V1, P18, DOI 10.1080/21693293.2013.765740
   Drury J, 2015, EUR J SOC PSYCHOL, V45, P533, DOI 10.1002/ejsp.2108
   Duffy B, 2020, TRUSTING DISSENTING
   Elcheroth G, 2020, BRIT J SOC PSYCHOL, V59, P703, DOI 10.1111/bjso.12403
   Everett JA, 2020, EFFECTIVENESS MORAL
   Fancourt D., 2020, COVID 19 SOCIAL STUD
   Fancourt D, 2020, LANCET, V396, P464, DOI 10.1016/S0140-6736(20)31690-1
   Fladerer MP, 2020, J BUS PSYCHOL, DOI 10.1007/s10869-019-09677-0
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Forsyth DR, 1983, INTRO GROUP DYNAMICS
   Foster L, 2020, BBC NEWS
   Fritz CE, 1961, HIST COMP DISASTER S, V10
   Goldberg M, 2020, SOCIAL NORMS MOTIVAT
   Haslam C, 2015, ENCY GEROPSYCHOLOGY, P1
   Haslam SA, 2020, TOGETHER APART PSYCH
   HM Government, 2019, COMM RES DEV FRAM
   Hogan G, 2020, GOTHAMIST
   Independent SAGE, 2020, FIN REP FIND TEST TR
   Jackson J, 2020, PUBLIC COMPLIANCE CO
   Jackson J, 2020, BRIT POLITICS POLICY
   Jetten J., 2020, TOGETHER APART PSYCH
   Jones E, 2016, PSYCHOLOGIST, V29, P486
   Kaniasty K., 1999, RESPONSE DISASTER PS, P25, DOI 10.1016/S0022-3999%2802%2900418-X
   Kinsey MJ, 2019, FIRE TECHNOL, V55, P465, DOI 10.1007/s10694-018-0708-0
   Monbiot G., 2020, GUARDIAN
   Ntontis E, 2020, TRAUMATOLOGY, V26, P253
   Ntontis E, 2020, INT J DISAST RISK RE, V45, DOI 10.1016/j.ijdrr.2020.101493
   Office for National Statistics, 2020, COR SOC IMP GREAT BR
   Parveen N, 2020, GUARDIAN
   Pfattheicher S, 2020, EMOTIONAL PATH ACTIO
   Prosser AMB, 2020, BRIT J SOC PSYCHOL, V59, P653, DOI 10.1111/bjso.12399
   Proulx G, 2000, WHY BUILDING OCCUPAN
   Public Health England, 2020, DISP RISK OUTC COVID
   Reicher S, 2020, PSYCHOLOGIST
   Rubin GJ, 2020, BMJ OPINION
   Scally G, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1932
   Sharkey P, 2020, VOX
   Sime JD, 1980, FIRES HUMAN BEHAV, P63
   Smith LE, 2020, PUBLIC HEALTH, V187, P41, DOI 10.1016/j.puhe.2020.07.024
   STAPEL DA, 1994, SOC COGNITION, V12, P1, DOI 10.1521/soco.1994.12.1.1
   Symons C, 2020, J CONTING CRISIS MAN, DOI 10.1111/1468-5973.12320
   Templeton A, 2020, BRIT J SOC PSYCHOL, V59, P674, DOI 10.1111/bjso.12400
   Tiratelli L, 2020, COMMUNITIES VS CORON
   Turk V, 2020, WIRED
   Turner J. C., 1991, SOCIAL INFLUENCE
   Van Bavel JJ, 2020, NATL IDENTITY PREDIC
   Vignoles V, 2020, HARNESSING SHARED ID
   Webster RK, 2020, PUBLIC HEALTH, V182, P163, DOI 10.1016/j.puhe.2020.03.007
   Wolf LJ, 2020, BRIT J SOC PSYCHOL, V59, P618, DOI 10.1111/bjso.12401
   Wormwood JB, 2016, COGNITION EMOTION, V30, P539, DOI 10.1080/02699931.2015.1010487
   2014, REG ANESTH PAIN MED, V9
NR 76
TC 0
Z9 0
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 2056-4724
J9 BJPSYCH OPEN
JI BJPsych Open
PD DEC 7
PY 2020
VL 7
IS 1
AR e11
DI 10.1192/bjo.2020.139
PG 6
WC Psychiatry
SC Psychiatry
GA PB5DD
UT WOS:000596340400001
PM 33283693
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Dey, P
AF Dey, Priyankar
TI Low bioavailability hinders drug discovery against COVID-19, guided by
   in silico docking
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Letter; Early Access
C1 [Dey, Priyankar] Thapar Inst Engn & Technol, Dept Biotechnol, Patiala, Punjab, India.
RP Dey, P (corresponding author), Thapar Inst Engn & Technol, Dept Biotechnol, Patiala, Punjab, India.
EM priyankar.dey@thapar.edu
OI Dey, Priyankar/0000-0002-9513-425X
CR Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Aqil F, 2013, CANCER LETT, V334, P133, DOI 10.1016/j.canlet.2013.02.032
   Chirico F, 2020, CROAT MED J, V61, P300, DOI 10.3325/cmj.2020.61.300
   Dey P, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104367
   Jasial S, 2017, J MED CHEM, V60, P3879, DOI 10.1021/acs.jmedchem.7b00154
   Kambakamba P, 2020, BRIT J SURG, V107, pE334, DOI 10.1002/bjs.11785
   Mereles D, 2011, INT J MOL SCI, V12, P5592, DOI 10.3390/ijms12095592
   Parada J, 2007, J FOOD SCI, V72, pR21, DOI 10.1111/j.1750-3841.2007.00274.x
NR 8
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
DI 10.1111/bph.15325
EA DEC 2020
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PB9ZN
UT WOS:000596670300001
PM 33283265
OA Bronze
DA 2021-01-01
ER

PT J
AU Kasetsirikul, S
   Umer, M
   Soda, N
   Sreejith, KR
   Shiddiky, MJA
   Nguyen, NT
AF Kasetsirikul, Surasak
   Umer, Muhammad
   Soda, Narshone
   Sreejith, Kamalalayam Rajan
   Shiddiky, Muhammad J. A.
   Nam-Trung Nguyen
TI Detection of the SARS-CoV-2 humanized antibody with paper-based ELISA
SO ANALYST
LA English
DT Article
AB This work reports the development of a rapid, simple and inexpensive colorimetric paper-based assay for the detection of the severe acute respiratory symptom coronavirus 2 (SARS-CoV-2) humanized antibody. The paper device was prepared with lamination for easy sample handling and coated with the recombinant SARS-CoV-2 nucleocapsid antigen. This assay employed a colorimetric reaction, which is followed by horseradish peroxidase (HRP) conjugated detecting antibody in the presence of the 3,3 ',5,5 '-tetramethylbenzidine (TMB) substrate. The colorimetric readout was evaluated and quantified for specificity and sensitivity. The characterization of this assay includes determining the linear regression curve, the limit of detection (LOD), the repeatability, and testing complex biological samples. We found that the LOD of the assay was 9.00 ng mu L-1 (0.112 IU mL(-1)). The relative standard deviation was approximately 10% for a sample number of n = 3. We believe that our proof-of-concept assay has the potential to be developed for clinical screening of the SARS-CoV-2 humanized antibody as a tool to confirm infected active cases or to confirm SARS-CoV-2 immune cases during the process of vaccine development.
C1 [Kasetsirikul, Surasak; Sreejith, Kamalalayam Rajan] Griffith Univ, Sch Engn & Build Environm EBE, Nathan Campus, Brisbane, Qld 4222, Australia.
   [Kasetsirikul, Surasak; Umer, Muhammad; Soda, Narshone; Sreejith, Kamalalayam Rajan; Shiddiky, Muhammad J. A.; Nam-Trung Nguyen] Griffith Univ, Queensland Micro & Nanotechnol Ctr QMNC, Nathan Campus, Brisbane, Qld 4111, Australia.
   [Soda, Narshone; Shiddiky, Muhammad J. A.] Griffith Univ, Sch Environm & Sci ESC, Nathan Campus, Brisbane, Qld 4111, Australia.
RP Shiddiky, MJA; Nguyen, NT (corresponding author), Griffith Univ, Queensland Micro & Nanotechnol Ctr QMNC, Nathan Campus, Brisbane, Qld 4111, Australia.; Shiddiky, MJA (corresponding author), Griffith Univ, Sch Environm & Sci ESC, Nathan Campus, Brisbane, Qld 4111, Australia.
EM m.shiddiky@griffith.edu.au; nam-trung.nguyen@griffith.edu.au
OI Rajan, Sreejith/0000-0002-4901-2550; Kasetsirikul,
   Surasak/0000-0001-9767-1254
FU Australian Research CouncilAustralian Research Council [DP180100055];
   higher degree research scholarship GUIPRS from Griffith University;
   higher degree research scholarship GUPRS from Griffith University
FX The authors acknowledge the support of the Australian Research Council
   (DP180100055) and higher degree research scholarships GUIPRS and GUPRS
   to S. K. from Griffith University.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Carter LJ, 2020, ACS CENTRAL SCI, V6, P591, DOI 10.1021/acscentsci.0c00501
   Caruana G, 2020, CLIN MICROBIOL INFEC, V26, P1178, DOI 10.1016/j.cmi.2020.06.019
   Cheng CM, 2010, ANGEW CHEM INT EDIT, V49, P4771, DOI 10.1002/anie.201001005
   EPITOPE DIAGNOSTICS INC, EDI NOVEL CORONAVIRU
   Hsu CK, 2014, ANAL CHEM, V86, P4605, DOI 10.1021/ac500835k
   Katis IN, 2014, BIOMICROFLUIDICS, V8, DOI 10.1063/1.4878696
   Koczula KM, 2016, ESSAYS BIOCHEM, V60, P111, DOI 10.1042/EBC20150012
   Koo KM, 2016, THERANOSTICS, V6, P1415, DOI 10.7150/thno.15250
   Kumar Ramesh, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00599-7
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lipsitch M, 2020, NAT MED, V26, P818, DOI 10.1038/s41591-020-0887-3
   Mazzu-Nascimento T, 2017, ANAL CHIM ACTA, V950, P156, DOI 10.1016/j.aca.2016.11.011
   Murdock RC, 2013, ANAL CHEM, V85, P11634, DOI 10.1021/ac403040a
   MyBioSource Inc, COVID 19 ELISA KIT H
   Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012
   Regmi K., 2020, MEDRXIV20130294, DOI [10.1101/2020.06.13.20130294, DOI 10.1101/2020.06.13.20130294]
   Suhandynata RT, 2020, J APPL LAB MED, V5, P908, DOI 10.1093/jalm/jfaa079
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   Tok TT., 2017, INT J VIROL INFECT D, V2, P001
   Verma MS, 2018, BIOSENS BIOELECTRON, V99, P77, DOI 10.1016/j.bios.2017.07.034
   Wang M, 2020, CLIN DIAGNOSIS 8274, DOI [10.1101/2020.02.12.20022327, DOI 10.1101/2020.02.12.20022327]
   WHO. World Health Organization, ROLLING UPDATES CORO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Zhao Juanjuan, 2020, Clin Infect Dis, V71, P2027, DOI 10.1093/cid/ciaa344
   Zhu XX, 2018, SENSOR ACTUAT B-CHEM, V255, P598, DOI 10.1016/j.snb.2017.08.090
NR 29
TC 0
Z9 0
U1 12
U2 12
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PD DEC 7
PY 2020
VL 145
IS 23
BP 7680
EP 7686
DI 10.1039/d0an01609h
PG 7
WC Chemistry, Analytical
SC Chemistry
GA OV6KA
UT WOS:000592315100021
PM 32975254
DA 2021-01-01
ER

PT J
AU Ruiz-Antoran, B
   Sancho-Lopez, A
   Torres, F
   Moreno-Torres, V
   de Pablo-Lopez, I
   Garcia-Lopez, P
   Abad-Santos, F
   Rosso-Fernandez, CM
   Aldea-Perona, A
   Montane, E
   Aparicio-Hernandez, RM
   Llop-Rius, R
   Pedros, C
   Gijon, P
   Hernandez-Carballo, C
   Pedrosa-Martinez, MJ
   Rodriguez-Jimenez, C
   Prada-Ramallal, G
   Cabrera-Garcia, L
   Aguilar-Garcia, JA
   Sanjuan-Jimenez, R
   Ortiz-Barraza, EI
   Sanchez-Chica, E
   Fernandez-Cruz, A
AF Ruiz-Antoran, Belen
   Sancho-Lopez, Aranzazu
   Torres, Ferran
   Moreno-Torres, Victor
   de Pablo-Lopez, Itziar
   Garcia-Lopez, Paulina
   Abad-Santos, Francisco
   Rosso-Fernandez, Clara M.
   Aldea-Perona, Ana
   Montane, Eva
   Aparicio-Hernandez, Ruth M.
   Llop-Rius, Roser
   Pedros, Consuelo
   Gijon, Paloma
   Hernandez-Carballo, Carolina
   Pedrosa-Martinez, Maria J.
   Rodriguez-Jimenez, Consuelo
   Prada-Ramallal, Guillermo
   Cabrera-Garcia, Lourdes
   Aguilar-Garcia, Josefa A.
   Sanjuan-Jimenez, Rocio
   Ortiz-Barraza, Evelyn I.
   Sanchez-Chica, Enrique
   Fernandez-Cruz, Ana
CA TOCICOV-Study Grp
TI Combination of Tocilizumab and Steroids to Improve Mortality in Patients
   with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study
SO INFECTIOUS DISEASES AND THERAPY
LA English
DT Article; Early Access
DE COVID-19; Mortality; SARS-CoV-2; Steroids; Tocilizumab
ID PROPENSITY SCORE METHODS; COULD
AB Background We aimed to determine the impact of tocilizumab use on severe COVID-19 (coronavirus disease 19) pneumonia mortality. Methods We performed a multicentre retrospective cohort study in 18 tertiary hospitals in Spain from March to April 2020. Consecutive patients admitted with severe COVID-19 treated with tocilizumab were compared to patients not treated with tocilizumab, adjusting by inverse probability of the treatment weights (IPTW). Tocilizumab's effect in patients receiving steroids during the 48 h following inclusion was analysed. Results During the study period, 506 patients with severe COVID-19 fulfilled the inclusion criteria. Among them, 268 were treated with tocilizumab and 238 patients were not. Median time to tocilizumab treatment from onset of symptoms was 11 days [interquartile range (IQR) 8-14]. Global mortality was 23.7%. Mortality was lower in patients treated with tocilizumab than in controls: 16.8% versus 31.5%, hazard ratio (HR) 0.514 [95% confidence interval (95% CI) 0.355-0.744], p < 0.001; weighted HR 0.741 (95% CI 0.619-0.887), p = 0.001. Tocilizumab treatment reduced mortality by 14.7% relative to no tocilizumab treatment [relative risk reduction (RRR) 46.7%]. We calculated a number necessary to treat of 7. Among patients treated with steroids, mortality was lower in those treated with tocilizumab than in those treated with steroids alone [10.9% versus 40.2%, HR 0.511 (95% CI 0.352-0.741), p = 0.036; weighted HR 0.6 (95% CI 0.449-0.804), p < 0.001] (interaction p = 0.094). Conclusions These results show that survival of patients with severe COVID-19 is higher in those treated with tocilizumab than in those not treated and that tocilizumab's effect adds to that of steroids administered to non-intubated patients with COVID-19 during the first 48 h of presenting with respiratory failure despite oxygen therapy. Randomised controlled studies are needed to confirm these results.
C1 [Ruiz-Antoran, Belen; Sancho-Lopez, Aranzazu] Hosp Univ Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Clin Pharmacol Dept, Madrid, Spain.
   [Torres, Ferran] Hosp Clin Barcelona, August Pi & Sunyer Biomed Res Inst, Med Stat Core Facil, Barcelona, Spain.
   [Torres, Ferran] Autonomous Univ Barcelona, Fac Med, Biostat Unit, Barcelona, Spain.
   [Moreno-Torres, Victor; Sanchez-Chica, Enrique] Hosp Univ Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Internal Med Dept, Madrid, Spain.
   [de Pablo-Lopez, Itziar] Hosp Univ Ramon & Cajal IRYCIS, Clin Pharmacol Unit, Madrid, Spain.
   [Garcia-Lopez, Paulina] Hosp Univ Torrecardenas, Pneumol Dept, Almeria, Spain.
   [Abad-Santos, Francisco] Univ Autonoma Madrid UAM, Hosp Univ Princesa, Inst Invest Sanitaria Princesa IP, Clin Pharmacol Dept,Inst Teofilo Hernando,Fac Med, Madrid, Spain.
   [Rosso-Fernandez, Clara M.] Hosp Univ Virgen Rocio, Unit Clin Invest & Clin Trials, Unit Clin Pharmacol, Seville, Spain.
   [Aldea-Perona, Ana] Univ Autonoma Barcelona UAB, Consorcio Parc Salut MarInst Hosp Del Mar Invest, Clin Pharmacol Dept, Barcelona, Spain.
   [Montane, Eva] Hosp Badalona Germans Trias & Pujol, Clin Pharmacol Dept, Barcelona, Spain.
   [Montane, Eva] Dept Pharmacol Therapeut & Toxicol, Barcelona, Spain.
   [Aparicio-Hernandez, Ruth M.] Hosp Univ Cent Defensa Gomez Ulla, Clin Pharmacol Dept, Madrid, Spain.
   [Llop-Rius, Roser] Hosp Univ Bellvitge, Clin Pharmacol Dept, Barcelona, Spain.
   [Pedros, Consuelo] Univ Valencia, Consorci Hosp Gen, Clin Pharmacol Unit, Valencia, Spain.
   [Gijon, Paloma] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Clin Microbiol & Infect Dis Dept, Madrid, Spain.
   [Hernandez-Carballo, Carolina] Hosp Univ Nuestra Senora Candelaria, Internal Med Dept, Tenerife, Spain.
   [Pedrosa-Martinez, Maria J.] Hosp Univ Puerto Real, Clin Pharmacol Dept, Cadiz, Spain.
   [Rodriguez-Jimenez, Consuelo] Hosp Univ Canarias, Clin Pharmacol Dept, Tenerife, Spain.
   [Rodriguez-Jimenez, Consuelo] Univ La Laguna ULL, Fac Med, Dept Med Fis & Farmacol, Tenerife, Spain.
   [Prada-Ramallal, Guillermo] Inst Hlth Res Fdn FIDIS, Epidemiol Stat & Res Methodol Unit, Santiago De Compostela, Spain.
   [Cabrera-Garcia, Lourdes] Hosp Univ Clinico San Carlos, Clin Pharmacol Dept, Madrid, Spain.
   [Aguilar-Garcia, Josefa A.] Hosp Costa Sol Marbella, Internal Med Dept, Malaga, Spain.
   [Sanjuan-Jimenez, Rocio] Plataforma SCReN, UICEC IBIMA, Malaga, Spain.
   [Sanjuan-Jimenez, Rocio] Hosp Univ Virgen Victoria, Serv Farmacol Clin, Malaga, Spain.
   [Ortiz-Barraza, Evelyn I.] Hosp Univ Ramon & Cajal IRYCIS, Internal Med Dept, Madrid, Spain.
   [Fernandez-Cruz, Ana] Hosp Univ Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Internal Med Dept, Infect Dis Unit, Madrid, Spain.
RP Ruiz-Antoran, B (corresponding author), Hosp Univ Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Clin Pharmacol Dept, Madrid, Spain.; Fernandez-Cruz, A (corresponding author), Hosp Univ Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Internal Med Dept, Infect Dis Unit, Madrid, Spain.
EM bruizantoran@gmail.com; anafcruz999@gmail.com
RI Prada-Ramallal, Guillermo/ABB-5901-2020; Ruiz-Antoran, Belen/F-3580-2017
OI Prada-Ramallal, Guillermo/0000-0002-2264-4232; Montane,
   Eva/0000-0002-1691-7652; Ruiz-Antoran, Belen/0000-0002-2020-9077;
   Zubiaur, Pablo/0000-0002-6150-4320
CR Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Campins L, 2020, CLIN EXP RHEUMATOL, V38, P578
   Cascella M, 2020, FEATURES EVALUATION
   Cohen DJ, 2013, STAT POWER ANAL BEHA, DOI [10.4324/9780203771587, DOI 10.4324/9780203771587]
   D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
   Fadel Raef, 2020, Clin Infect Dis, V71, P2114, DOI 10.1093/cid/ciaa601
   Fernandez-Cruz A, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01168-20
   Foca E., 2020, LINEE GUIDA GESTIONE
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Gorgolas M, 2020, COMPASSIONATE USE TO
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Martinez-Sanz Javier, 2020, Clin Microbiol Infect, DOI 10.1016/j.cmi.2020.09.021
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mikulska M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237831
   Narain Sonali, 2020, Chest, DOI 10.1016/j.chest.2020.09.275
   Rodriguez-Bano Jesus, 2020, Clin Microbiol Infect, DOI 10.1016/j.cmi.2020.08.010
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Salvarani C, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.6615
   Herrero FS, 2020, J INTERN MED, DOI 10.1111/joim.13145
   Somers Emily C, 2020, medRxiv, DOI 10.1101/2020.05.29.20117358
   WHO, 2020, 164 WHO
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
NR 25
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 2193-8229
EI 2193-6382
J9 INFECT DIS THER
JI Infect. Dis. Ther.
DI 10.1007/s40121-020-00373-8
EA DEC 2020
PG 16
WC Infectious Diseases
SC Infectious Diseases
GA PF4OE
UT WOS:000599035100001
PM 33280066
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhu, HM
   Li, Y
   Li, BY
   Yang, S
   Peng, D
   Yang, XJ
   Sun, XL
   Zhang, M
AF Zhu, Hong-Ming
   Li, Yan
   Li, Bang-Yi
   Yang, Shuang
   Peng, Ding
   Yang, Xiaojiao
   Sun, Xue-Lian
   Zhang, Mei
TI Effect of methylprednisolone in severe and critical COVID-19: Analysis
   of 102 cases
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE COVID-19; Glucocorticoids; Methylprednisolone; Cytokine storm;
   Coronavirus infections; Cytokines
ID ACUTE-RESPIRATORY-SYNDROME; CORTICOSTEROID TREATMENT; SYNDROME SARS;
   THERAPY; MANAGEMENT; GUANGZHOU; PNEUMONIA; ADULTS
AB BACKGROUND
   The coronavirus disease 2019 (COVID-19) outbreak has brought great challenges to public health. Aggravation of COVID-19 is closely related to the secondary systemic inflammatory response. Glucocorticoids are used to control severe diseases caused by the cytokine storm, owing to their anti-inflammatory effects. However, glucocorticoids are a double-edged sword, as the use of large doses has the potential risk of secondary infection and long-term serious complications, and may prolong virus clearance time. Nonetheless, the risks and benefits of glucocorticoid adjuvant therapy for COVID-19 are inconclusive.
   AIM
   To determine the effect of methylprednisolone in severe and critically ill patients with COVID-19.
   METHODS
   This single-center retrospective study included 102 adult COVID-19 patients admitted to a ward of a designated hospital in Wuhan, Hubei Province from January to March 2020. All patients received general symptomatic treatment and organ function support, and were given different respiratory support measures according to their conditions. In case of deterioration, considering the hyperinflammatory state of the patients, methylprednisolone was intravenously administered at 0.75-1.5 mg/kg/d, usually for less than 14 d. Patient vital signs and oxygenation were closely monitored, in combination with imaging and routine blood tests such as C-reactive protein, biochemical indicators (liver and kidney function, myocardial enzymes, electrolytes, etc.), and coagulation function. Patient clinical outcomes were discharge or death.
   RESULTS
   A total of 102 severe and critically ill COVID-19 patients were included in this study. They were divided into treatment (69, 67.6%) and control groups (33, 32.4%) according to methylprednisolone use. Comparison of baseline data between the two groups showed that the treatment group patients had higher aspartic acid aminotransferase, globulin, hydroxybutyrate dehydrogenase, and lactate dehydrogenase. There was no significant difference in other baseline data between the two groups. With regard to prognosis, 29 (78.4%) patients in the treatment group died as opposed to 40 (61.5%) in the control group. The mortality was higher in the treatment group than in the control group; however, according to the log-rank test and the Kaplan-Meier survival curve, the difference in mortality between both groups was insignificant (P = 0.655). The COX regression equation was used to correct the variables with differences, and the results showed that methylprednisolone treatment did not improve prognosis.
   CONCLUSION
   Methylprednisolone treatment does not improve prognosis in severe and critical COVID-19 patients.
C1 [Zhu, Hong-Ming; Li, Bang-Yi; Yang, Shuang; Peng, Ding; Zhang, Mei] Capital Med Univ, Dept Gastroenterol, Xuanwu Hosp, 45 Changchun St, Beijing 100053, Peoples R China.
   [Li, Yan] Capital Med Univ, Dept Pulmonol, Xuanwu Hosp, Beijing 100053, Peoples R China.
   [Yang, Xiaojiao] McGill Univ, Sch Human Nutr, Fac Agr & Environm Sci, Montreal, PQ H9X 3V9, Canada.
   [Sun, Xue-Lian] Capital Med Univ, Dept Emergency Med, Xuanwu Hosp, Beijing 100053, Peoples R China.
RP Zhang, M (corresponding author), Capital Med Univ, Dept Gastroenterol, Xuanwu Hosp, 45 Changchun St, Beijing 100053, Peoples R China.
EM zhang2955@sina.com
CR [Anonymous], 2020, CHINESE MED J-PEKING, V133, P1087, DOI 10.1097/CM9.0000000000000819
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arisan ED, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060614
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Ayittey FK, 2020, J MED VIROL, V92, P403, DOI 10.1002/jmv.25695
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Chinese Thoracic Society, 2003, ZHONGHUA JIE HE HE H, V26, P323
   Darwish I, 2011, EXPERT REV ANTI-INFE, V9, P807, DOI [10.1586/ERI.11.56, 10.1586/eri.11.56]
   EL-Arabey AA, 2020, J MED VIROL, V92, P2293, DOI 10.1002/jmv.25958
   Fang XW, 2020, J INFECTION, V81, P147, DOI 10.1016/j.jinf.2020.03.039
   FERRARA JLM, 1993, CURR OPIN IMMUNOL, V5, P794, DOI 10.1016/0952-7915(93)90139-J
   Gong Y, 2020, J MED VIROL, V92, P2551, DOI 10.1002/jmv.26052
   Guo KJ, 2014, BONE JOINT J, V96B, P259, DOI 10.1302/0301-620X.96B2.31935
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Lim WS, 2004, J INFECTION, V49, P1, DOI 10.1016/j.jinf.2004.04.001
   Liu J, 2020, J ALLERGY CLIN IMMUN, V146, P325, DOI 10.1016/j.jaci.2020.05.021
   Lu XF, 2020, CRIT CARE, V24, DOI [10.1186/s13054-020-02964-w, 10.1186/s13054-020-02914-6]
   Pelaia C, 2020, THER ADV RESPIR DIS, V14, DOI 10.1177/1753466620933508
   Rodrigo C, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub2
   Ruan SY, 2014, CRIT CARE, V18, DOI 10.1186/cc13819
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shao MM, 2014, ZHONGYAO XINYAO YU L, V25, P236
   Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715
   Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076
   Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Xiao Jian-zhong, 2004, Zhonghua Nei Ke Za Zhi, V43, P179
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yam LYC, 2007, J INFECTION, V54, P28, DOI 10.1016/j.jinf.2006.01.005
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhou YG, 2020, PATHOGENIC T CELLS I, P2020
NR 40
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD DEC 6
PY 2020
VL 8
IS 23
BP 5952
EP 5961
DI 10.12998/wjcc.v8.i23.5952
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA PF0KX
UT WOS:000598754700013
PM 33344594
OA Other Gold
DA 2021-01-01
ER

PT J
AU Hu, CC
   Huang, JW
   Wei, N
   Hu, SH
   Hu, JB
   Li, SG
   Lai, JB
   Huang, ML
   Wang, DD
   Chen, JK
   Zhou, XY
   Wang, Z
   Xu, Y
AF Hu, Chan-Chan
   Huang, Jin-Wen
   Wei, Ning
   Hu, Shao-Hua
   Hu, Jian-Bo
   Li, Shu-Guang
   Lai, Jian-Bo
   Huang, Man-Li
   Wang, Dan-Dan
   Chen, Jing-Kai
   Zhou, Xiao-Yi
   Wang, Zhong
   Xu, Yi
TI Interpersonal psychotherapy-based psychological intervention for patient
   suffering from COVID-19: A case report
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE COVID-19; Psychological intervention; Interpersonal therapy;
   Interpersonal disputes; Case report
ID DEPRESSION
AB BACKGROUND
   Novel coronavirus disease 2019 (COVID-19) was first found in Wuhan, China, and it has rapidly spread worldwide since the end of 2019. There is an urgent need to treat the physical and psychological aspects of COVID-19. Interpersonal psychotherapy (IPT)-based psychological intervention is an evidence-based therapy for depression and post-traumatic stress disorder.
   CASE SUMMARY
   This report describes a case of COVID-19 in a patient who transmitted the disease to his entire family. The patient received four sessions of IPT-based psychological intervention. We used the Hamilton Rating Scale for Depression and Patient Health Questionnaire to measure depression level, and the Hamilton Anxiety Scale and Generalized Anxiety Disorder to measure anxiety among the patients.
   CONCLUSION
   This case shows that IPT-based therapy can reduce COVID-19 patient depression and anxiety and the advantage of IPT-based therapy.
C1 [Hu, Chan-Chan; Huang, Jin-Wen; Wei, Ning; Hu, Shao-Hua; Hu, Jian-Bo; Li, Shu-Guang; Lai, Jian-Bo; Wang, Dan-Dan; Chen, Jing-Kai; Zhou, Xiao-Yi; Wang, Zhong; Xu, Yi] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Mental Hlth, 79 Qingchun Rd, Hangzhou 310000, Zhejiang, Peoples R China.
   [Huang, Man-Li] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Psychiat, Hangzhou 310000, Zhejiang, Peoples R China.
RP Xu, Y (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Mental Hlth, 79 Qingchun Rd, Hangzhou 310000, Zhejiang, Peoples R China.
EM xuyizju@zju.edu.cn
FU Medical and Health Science and Technology Plan Project of Zhejiang
   Province [2015KYB123]; General Research Project (Humanities and Social
   Sciences) of Zhejiang Provincial Department of Education [Y201840048]
FX Supported by Medical and Health Science and Technology Plan Project of
   Zhejiang Province, No. 2015KYB123; and General Research Project
   (Humanities and Social Sciences) of Zhejiang Provincial Department of
   Education, No. Y201840048.
CR Bleiberg KL, 2005, AM J PSYCHIAT, V162, P181, DOI 10.1176/appi.ajp.162.1.181
   Bowlby J., 1969, ATTACHMENT LOSS, V1
   Di Carlo DT, 2020, J NEUROL, V1, P1
   DIMASCIO A, 1979, ARCH GEN PSYCHIAT, V36, P1450
   Evans FB, 2017, ENCY PERSONALITY IND
   Foa EB, 1998, TREATING TRAUMA RAPE
   Henderson AS, 1981, NEUROSIS SOCIAL ENV
   Kang LJ, 2020, LANCET PSYCHIAT, V7, pE14, DOI 10.1016/S2215-0366(20)30047-X
   Kiesler D. J., 1997, J PSYCHOTHERAPY PRAC, V6, P339
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Markowitz JC, 2009, J PSYCHIATR PRACT, V15, P133, DOI 10.1097/01.pra.0000348366.34419.28
   Miranda J, 2003, JAMA-J AM MED ASSOC, V290, P57, DOI 10.1001/jama.290.1.57
   Montemurro N, 2020, BRIT J NEUROSURG, DOI 10.1080/02688697.2020.1773399
   Montemurro N, 2020, BRAIN BEHAV IMMUN, V87, P23, DOI 10.1016/j.bbi.2020.03.032
   O'Hara MW, 2000, ARCH GEN PSYCHIAT, V57, P1039, DOI 10.1001/archpsyc.57.11.1039
   Swartz HA, 2004, PSYCHIAT SERV, V55, P448, DOI 10.1176/appi.ps.55.4.448
   Swartz Holly A, 2014, Am J Psychother, V68, P443
   Weissman MM, 2000, COMPREHENSIVE GUIDE
   Weissman MM, 2018, COMPREHENSIVE GUIDE
NR 19
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD DEC 6
PY 2020
VL 8
IS 23
BP 6064
EP 6070
DI 10.12998/wjcc.v8.i23.6064
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA PF0KX
UT WOS:000598754700025
PM 33344606
OA Other Gold
DA 2021-01-01
ER

PT J
AU Gao, ZA
   Gao, LB
   Chen, XJ
   Xu, Y
AF Gao, Zi-Ang
   Gao, Ling-Bao
   Chen, Xin-Jie
   Xu, Yu
TI Fourty-nine years old woman co-infected with SARS-CoV-2 and Mycoplasma:
   A case report
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE CoVID-19; SARS-CoV-2; Mycoplasma; Co-infection; Computed tomography;
   Infectious disease; Case report
AB BACKGROUND
   Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus responsible for the outbreak of respiratory illness known as coronavirus disease 2019 (CoVID-19). Mycoplasma is an uncommon co-infected pathogen with SARS-CoV-2 and has not yet been reported. Computed tomography (CT), used as an accessory examination, may play a more significant role in this co-infection.
   CASE SUMMARY
   A 49-year-old female presented with a cough, expectoration and chest congestion followed by elevated C-reactive protein and erythrocyte sedimentation rate. CT images showed ground-glass opacities in bilateral lower lobes and a patchy and striate shadow in the right upper lobe. Immunoglobulin M antibody of Mycoplasma pneumoniae was positive and real-time fluorescence polymerase chain reaction of sputum was positive for SARS-CoV-2 nucleic acid. The diagnosis of CoVID-19 was made based on laboratory results, chest CT images, clinical manifestations and epidemiologic characteristics. She was treated with combination therapy for 17 d and showed a marked reCoVery.
   CONCLUSION
   Co-infection with SARS-CoV-2 and Mycoplasma in CoVID-19 patients appears to be uncommon. CT is an acceptable method for the primary diagnosis and treatment should be initiated as soon as possible. Combination therapy with antiviral, anti-inflammatory, traditional Chinese herbal medicine and interferon inhalation may be a reference for further progress in treating this co-infection.
C1 [Gao, Zi-Ang; Xu, Yu] Wuhan Univ, Renmin Hosp, Dept Otolaryngol Head & Neck Surg, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China.
   [Gao, Ling-Bao] Taizhou Peoples Hosp, Dept Transfus, Taizhou 225300, Jiangsu, Peoples R China.
   [Chen, Xin-Jie] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Neurol, Guangzhou 510006, Guangdong, Peoples R China.
RP Xu, Y (corresponding author), Wuhan Univ, Renmin Hosp, Dept Otolaryngol Head & Neck Surg, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China.
EM xuy@whu.edu.cn
CR Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   [汪明 Wang Ming], 2020, [中华检验医学杂志, Chinese Journal of Laboratory Medicine], V43, P341
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 5
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD DEC 6
PY 2020
VL 8
IS 23
BP 6080
EP 6085
DI 10.12998/wjcc.v8.i23.6080
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA PF0KX
UT WOS:000598754700027
PM 33344608
OA Other Gold
DA 2021-01-01
ER

PT J
AU Boban, M
AF Boban, Marko
TI Novel coronavirus disease (COVID-19) update on epidemiology,
   pathogenicity, clinical course and treatments
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article; Early Access
DE ARDS&#8208; acute respiratory distress syndrome; CoV&#8208; coronavirus;
   COVID&#8208; 19&#8208; coronavirus disease 2019; ECMO&#8208;
   extracorporeal membranous oxygenation; SARS&#8208; severe acute
   respiratory syndrome
ID SARS; INFECTION; RECEPTOR; PATHOGENESIS; PNEUMONIA; SYSTEM; ACE2
AB During the December of 2019, a series of patients with pneumonia caused by novel coronavirus; the severe acute respiratory syndrome (SARS) corona (COV-2), that is, COVID-19. Since the first cluster of cases was reported in China on 31 December 2019 until the 28 April 2020, there were internationally reported 3'000'000 cases, in over 185 countries, and 207'265 deaths. To date, it is still not unanimously clear which effects parameters of virus and host are important for the development of severe disease course. According to the most updated internationally available online cases register, COVID-19 disease has mild symptoms in around 85% of cases, there are 3%-10% of critical cases, and mortality is around 5%-7%. Since currently there is no available vaccine and no well-established specific antiviral therapy, numerous agents are being tested in clinical scenarios. The most common regimens include remdesivir, convalescent plasma. Widely used chloroquine, hydroxychloroquine and azithromycin combinations, as well as lopinavir-ritonavir were shown to have less efficient treatment effects. More severe cases of pneumonia and dyspnoea, or uncontrollable fever are treated as inpatients, and nearly 10% in intensive care units. Oxygen supplementation is indicated to maintain peripheral blood oxygenation over 90%-96%. Advanced support systems include mechanical ventilation and extracorporeal membranous support; however, those without targeted antiviral therapy represent only temporary bridge for scarce potential restitution in patient themselves. The aim of review is to present current state of the art in epidemiology, pathogenesis, clinical course and treatment of COVID-19 patients.
C1 [Boban, Marko] Sisters Char Univ Hosp, Zagreb, Croatia.
   [Boban, Marko] Fac Dent Med & Hlth, Osijek, Croatia.
   [Boban, Marko] Univ Rijeka, Med Fac, Rijeka, Croatia.
   [Boban, Marko] Univ Osijek, Med Fac, Osijek, Croatia.
RP Boban, M (corresponding author), Sisters Char Univ Hosp, Dept Cardiol & Internal Med, Vinogradska 29, Zagreb 10000, Croatia.
EM marcoboban@yahoo.com
OI Boban, Marko/0000-0002-6129-575X
CR Akil Ali, 2020, Thorac Cardiovasc Surg, DOI 10.1055/s-0040-1708479
   Calabro MG, 2019, ARTIF ORGANS, V43, P189, DOI 10.1111/aor.13327
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Cheng CY, 2020, J MICROBIOL IMMUNOL, V53, P488, DOI 10.1016/j.jmii.2020.03.032
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Gomez CC, 2020, MED INTENSIVA, V44, P429, DOI 10.1016/j.medin.2020.03.005
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334
   He DH, 2020, INT J INFECT DIS, V94, P145, DOI 10.1016/j.ijid.2020.04.034
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Jacobs JP, 2020, ASAIO J, V66, P722, DOI 10.1097/MAT.0000000000001185
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Kuba K, 2010, PHARMACOL THERAPEUT, V128, P119, DOI 10.1016/j.pharmthera.2010.06.003
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li H, 2020, J CELL MOL MED, V24, P6558, DOI 10.1111/jcmm.15364
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Nassar MS, 2018, EUR REV MED PHARMACO, V22, P4956, DOI 10.26355/eurrev_201808_15635
   Oesterle A, 2017, CIRC RES, V120, P229, DOI 10.1161/CIRCRESAHA.116.308537
   Pan C, 2020, AM J RESP CRIT CARE, V201, P1294, DOI 10.1164/rccm.202003-0527LE
   Peterson SJ, 2018, JPEN-PARENTER ENTER, V42, P739, DOI 10.1177/0148607117713483
   Piva S, 2020, J CRIT CARE, V58, P29, DOI 10.1016/j.jcrc.2020.04.004
   Richardson S, 2020, JAMA-J AM MED ASSOC, V382, P1708
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Sultan I, 2020, J CARDIAC SURG, V35, P1410, DOI 10.1111/jocs.14583
   Testa S, 2020, J THROMB HAEMOST, V18, P1320, DOI 10.1111/jth.14871
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wang RC, 2020, J INFECTION, V80, P354, DOI 10.1016/j.jinf.2020.01.017
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YL, 2020, ANN PALLIAT MED, V9, P428, DOI 10.21037/apm.2020.03.26
NR 53
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
AR e13868
DI 10.1111/ijcp.13868
EA DEC 2020
PG 7
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA PA7UR
UT WOS:000595836100001
PM 33244856
OA Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Riahi, S
   Sombra, LRS
   Lo, KB
   Chacko, SR
   Neto, AGM
   Azmaiparashvili, Z
   Patarroyo-Aponte, G
   Rangaswami, J
   Anastasopoulou, C
AF Riahi, Shayan
   Sombra, Lorenna Rodrigues Silva
   Lo, Kevin Bryan
   Chacko, Shireen R.
   Neto, Alvaro Goncalves Mendes
   Azmaiparashvili, Zurab
   Patarroyo-Aponte, Gabriel
   Rangaswami, Janani
   Anastasopoulou, Catherine
TI Insulin Use, Diabetes Control, and Outcomes in Patients with COVID-19
SO ENDOCRINE RESEARCH
LA English
DT Article; Early Access
DE COVID-19; novel coronavirus; diabetes; mortality; outcomes
AB Background: The novel coronavirus (SARS CoV-2) has caused significant morbidity and mortality in patients with diabetes. However, the effects of diabetes control including insulin use remain uncertain in terms of clinical outcomes of patients with COVID-19.
   Methods: In this single-center, retrospective observational study, all adult patients admitted to Einstein Medical Center, Philadelphia, from March 1 through April 24, 2020 with a diagnosis of COVID-19 and diabetes were included. Demographic, clinical and laboratory data, insulin dose at home and at the hospital, other anti-hyperglycemic agents use, and outcomes were obtained. Multivariate logistic regression was used to evaluate the factors associated with diabetes control and mortality.
   Results: Patients who used insulin at home had higher mortality compared to those who did not (35% vs 18% p = .015), this was true even after adjustment for demographics, comorbidities and a1c OR 2.65 95% CI (1.23-5.71) p = .013. However, the mean a1c and the median home requirements of insulin did not significantly differ among patients who died compared to the ones that survived. Patients who died had significantly higher inpatient insulin requirements (highest day insulin requirement recorded in units during hospitalization) 36 (11-86) vs 21 (8-52) p = .043 despite similar baseline a1c and steroid doses received. After adjusting for demographics, comorbidities and a1c, peak insulin requirements remained significantly associated with inpatient mortality OR 1.022 95% CI (1.00-1.04) p = .044.
   Conclusion: Among diabetic patients infected with COVID-19, insulin therapy at home was significantly independently associated with increased mortality. Peak daily inpatient insulin requirements was also independently associated with increased inpatient mortality.
C1 [Riahi, Shayan; Sombra, Lorenna Rodrigues Silva; Lo, Kevin Bryan; Chacko, Shireen R.; Neto, Alvaro Goncalves Mendes; Azmaiparashvili, Zurab; Patarroyo-Aponte, Gabriel; Rangaswami, Janani; Anastasopoulou, Catherine] Einstein Med Ctr Philadelphia, Dept Med, Philadelphia, PA USA.
   [Patarroyo-Aponte, Gabriel; Rangaswami, Janani] Thomas Jefferson Univ, Dept Med, Sidney Kimmel Coll, Philadelphia, PA 19107 USA.
   [Patarroyo-Aponte, Gabriel] Einstein Med Ctr Philadelphia, Pulm Crit Care & Sleep Med, Philadelphia, PA USA.
   [Anastasopoulou, Catherine] Einstein Med Ctr Philadelphia, Dept Endocrinol, Philadelphia, PA USA.
RP Riahi, S (corresponding author), Einstein Med Ctr, Philadelphia, PA 19141 USA.
EM RiahiSha@einstein.edu
OI Lo, Kevin Bryan/0000-0001-7088-6677
CR ALEXIEWICZ JM, 1995, ANN INTERN MED, V123, P919, DOI 10.7326/0003-4819-123-12-199512150-00004
   Allard R, 2010, DIABETES CARE, V33, P1491, DOI 10.2337/dc09-2215
   Bellaver P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55080-3
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Calvet HM, 2001, INFECT DIS CLIN N AM, V15, P407, DOI 10.1016/S0891-5520(05)70153-7
   Centers for Disease Control and Prevention, 2020, US COVID 19 CAS DEAT
   Cyrus E, 2020, medRxiv, DOI 10.1101/2020.05.15.20096552
   Delamaire M, 1997, DIABETIC MED, V14, P29, DOI 10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO;2-V
   Fox T, 2020, ACTA DIABETOL, DOI 10.1007/s00592-020-01592-8
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018
   Iqbal A, 2019, J CLIN ENDOCR METAB, V104, P1187, DOI 10.1210/jc.2018-01168
   Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507
   Kornum JB, 2007, DIABETES CARE, V30, P2251, DOI 10.2337/dc06-2417
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Kumar A, 2020, DIABETES METAB SYND, V14, P535, DOI 10.1016/j.dsx.2020.04.044
   Lian JS, 2020, CLIN INFECT DIS, V71, P740, DOI 10.1093/cid/ciaa242
   Ma RCW, 2020, DIABETIC MED, V37, P723, DOI 10.1111/dme.14300
   Ma Y., 2020, COVID 19 HEMODIALYSI, DOI [10.1101/2020.02.24.20027201v3, DOI 10.1101/2020.02.24.20027201V3]
   Muller LMAJ, 2005, CLIN INFECT DIS, V41, P281, DOI 10.1086/431587
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Pal Rimesh, 2020, Diabetes Res Clin Pract, V162, P108132, DOI 10.1016/j.diabres.2020.108132
   Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262
   Sabatino J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237131
   Shah BR, 2003, DIABETES CARE, V26, P510, DOI 10.2337/diacare.26.2.510
   Wu LD, 2020, CLIN ENDOCRINOL, V93, P390, DOI 10.1111/cen.14288
   Zhou J, 2020, METABOLISM, V107, DOI 10.1016/j.metabol.2020.154216
NR 28
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0743-5800
EI 1532-4206
J9 ENDOCR RES
JI Endocr. Res.
DI 10.1080/07435800.2020.1856865
EA DEC 2020
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA PB3JC
UT WOS:000596220100001
PM 33275067
OA Bronze
DA 2021-01-01
ER

PT J
AU Obeidat, M
   Isaacson, AL
   Chen, SJ
   Ivanovic, M
   Holanda, D
AF Obeidat, Mohammad
   Isaacson, Alexandra L.
   Chen, Stephanie J.
   Ivanovic, Marina
   Holanda, Danniele
TI Zebra-like bodies in COVID-19: is phospholipidosis evidence of
   hydroxychloroquine induced acute kidney injury?
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article; Early Access
DE Pandemic; Covid-19; hydroxychloroquine; zebra bodies; acute kidney
   injury; acute tubular injury
AB COVID-19 (from SARS-CoV-2) is the cause of an ongoing pandemic, with an increasing number of cases and significant mortality worldwide. Clinical trials and extensive studies are being conducted on a large scale for a better understanding of the pathophysiology of this disease and its effect on different organs. Several experimental treatment protocols have been introduced, in which hydroxychloroquine (HCQ) was one of the first drugs used. While patients can develop many side effects of HCQ, studies have documented a rare association of long-term HCQ treatment with zebra-like bodies in the ultrastructural examination of kidney biopsies, a finding typically seen in Fabry's disease, as well as in association with chronic HCQ use, among other drugs. We present a similar finding in the postmortem examination of a male in his early seventies with COVID-19 infection, who received five days of HCQ treatment before stopping the medication due to cardiac and renal toxicity.
C1 [Obeidat, Mohammad; Isaacson, Alexandra L.; Chen, Stephanie J.; Ivanovic, Marina; Holanda, Danniele] Univ Iowa Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA.
RP Holanda, D (corresponding author), Univ Iowa Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA.
EM danniele-holanda@uiowa.edu
CR Albay D, 2005, MODERN PATHOL, V18, P733, DOI 10.1038/modpathol.3800344
   Bracamonte ER, 2006, AM J KIDNEY DIS, V48, P844, DOI 10.1053/j.ajkd.2006.05.034
   Costa RM, 2013, CLIN KIDNEY J, V6, P533, DOI 10.1093/ckj/sft089
   Das S, 2020, CLIN DRUG INVEST, V40, P591, DOI 10.1007/s40261-020-00927-1
   Ding HJ, 2016, RHEUMATOLOGY, V55, P957, DOI 10.1093/rheumatology/kev357
   Littlejohn E., CLEVE CLIN J MED, P1
   Neves PDMD, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0571-0
   Pintavorn P, 2008, KIDNEY INT, V74, P1354, DOI 10.1038/ki.2008.229
   Reasor MJ, 2001, EXP BIOL MED, V226, P825
   Sperati CJ, 2018, KIDNEY INT, V94, P634, DOI 10.1016/j.kint.2018.02.003
   Stokkermans TJ, 2020, CHLOROQUINE HYDROXYC
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   WHO, WHO DISC HYDR LOP RI
   Wu SZ, 2019, WORLD J CLIN CASES, V7, P4377, DOI 10.12998/wjcc.v7.i24.4377
NR 14
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0191-3123
EI 1521-0758
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
DI 10.1080/01913123.2020.1850966
EA DEC 2020
PG 5
WC Microscopy; Pathology
SC Microscopy; Pathology
GA PB2NB
UT WOS:000596162800001
PM 33274661
OA Bronze
DA 2021-01-01
ER

PT J
AU Mikuls, TR
   Johnson, SR
   Fraenkel, L
   Arasaratnam, RJ
   Baden, LR
   Bermas, BL
   Chatham, W
   Cohen, S
   Costenbader, K
   Gravallese, EM
   Kalil, AC
   Weinblatt, ME
   Winthrop, K
   Mudano, AS
   Turner, A
   Saag, KG
AF Mikuls, Ted R.
   Johnson, Sindhu R.
   Fraenkel, Liana
   Arasaratnam, Reuben J.
   Baden, Lindsey R.
   Bermas, Bonnie L.
   Chatham, Winn
   Cohen, Stanley
   Costenbader, Karen
   Gravallese, Ellen M.
   Kalil, Andre C.
   Weinblatt, Michael E.
   Winthrop, Kevin
   Mudano, Amy S.
   Turner, Amy
   Saag, Kenneth G.
TI American College of Rheumatology Guidance for the Management of
   Rheumatic Disease in Adult Patients During the COVID-19 Pandemic:
   Version 3
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article; Early Access
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HERPES-ZOSTER; SERIOUS INFECTIONS;
   INCREASED RISK; ARTHRITIS; METHOTREXATE; CRITERIA; OUTCOMES; THERAPY;
   DISCONTINUATION
AB Objective To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic.
   Methods A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included asynchronous anonymous voting by email and webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus.
   Results Draft guidance statements approved by the task force have been combined to form final guidance.
   Conclusion These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.
C1 [Mikuls, Ted R.; Kalil, Andre C.] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Mikuls, Ted R.] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA.
   [Johnson, Sindhu R.] Mt Sinai Hosp, Toronto Western Hosp, Toronto, ON, Canada.
   [Johnson, Sindhu R.] Univ Toronto, Toronto, ON, Canada.
   [Fraenkel, Liana] Berkshire Hlth Syst, Pittsfield, MA USA.
   [Fraenkel, Liana] Yale Univ, New Haven, CT USA.
   [Arasaratnam, Reuben J.; Bermas, Bonnie L.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
   [Baden, Lindsey R.; Costenbader, Karen; Gravallese, Ellen M.; Weinblatt, Michael E.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Chatham, Winn; Mudano, Amy S.; Saag, Kenneth G.] Univ Alabama, Tuscaloosa, AL 35487 USA.
   [Cohen, Stanley] Metroplex Clin Res Ctr, Dallas, TX USA.
   [Winthrop, Kevin] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Turner, Amy] Amer Coll Rheumatol, 60 Execut Pk S,Suite 150, Atlanta, GA 30329 USA.
RP Mikuls, TR (corresponding author), Univ Nebraska Med Ctr, Div Rheumatol, 986270 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM tmikuls@unmc.edu
OI Mikuls, Ted/0000-0002-0897-2272; Johnson, Sindhu R./0000-0003-0591-2976
FU American College of Rheumatology
FX Supported by the American College of Rheumatology.
CR Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   American College of Rheumatology, 2020, COVID 19 PRACT ADV R
   American Heart Association, 2020, PAT TAK ACE I ARBS W
   Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013
   Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003
   Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637
   Bernatsky S, 2007, RHEUMATOLOGY, V46, P1157, DOI 10.1093/rheumatology/kem076
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Bichile T, 2014, PRESSE MED, V43, pE187, DOI 10.1016/j.lpm.2014.03.009
   Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105
   Brook R, 1994, CLIN PRACTICE GUIDEL, P59
   Burner TW, 2009, CURR OPIN RHEUMATOL, V21, P50, DOI 10.1097/BOR.0b013e32831bc0c4
   Centers for Disease Control and Prevention, 2020, WHAT DO YOU AR SICK
   Centers for Disease Control and Prevention, 2020, PROT YOURS OTH
   Chen DY, 2017, EXP THER MED, V14, P6222, DOI 10.3892/etm.2017.5297
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   de Vries-Bouwstra JK, 2020, J RHEUMATOL, V47, P249, DOI 10.3899/jrheum.181173
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   ESDAILE J, 1991, NEW ENGL J MED, V324, P150
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Farre N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092712
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   Galloway JB, 2011, RHEUMATOLOGY, V50, P124, DOI 10.1093/rheumatology/keq242
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geraldino-Pardilla L, 2019, LUPUS, V28, P862, DOI 10.1177/0961203319851558
   Giwa A L, 2020, Pediatr Emerg Med Pract, V17, P1
   Grijalva CG, 2011, JAMA-J AM MED ASSOC, V306, P2331, DOI 10.1001/jama.2011.1692
   Hemingway H, 2008, ANN INTERN MED, V149, P221, DOI 10.7326/0003-4819-149-4-200808190-00003
   Ibrahim A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010015
   KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632
   LAROCHELLE GE, 1993, AM J MED, V95, P258, DOI 10.1016/0002-9343(93)90277-V
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Listing J, 2013, RHEUMATOLOGY, V52, P53, DOI 10.1093/rheumatology/kes305
   Liu Z, 2020, J INFECTION, V6, P43
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Mikuls TR, 2003, BEST PRACT RES CL RH, V17, P729, DOI 10.1016/S1521-6942(03)00041-X
   Mok CC, 2016, ARTHRIT CARE RES, V68, P1295, DOI 10.1002/acr.22837
   Naksuk N, 2020, EUR HEART J-ACUTE CA, V9, P215, DOI 10.1177/2048872620922784
   National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID MA
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Nurmohamed MT, 2015, NAT REV RHEUMATOL, V11, P693, DOI 10.1038/nrrheum.2015.112
   Pappas DA, 2015, ARTHRIT CARE RES, V67, P1671, DOI 10.1002/acr.22628
   Peart E, 2014, CURR OPIN RHEUMATOL, V26, P118, DOI 10.1097/BOR.0000000000000030
   Pimentel-Quiroz VR, 2019, LUPUS, V28, P1101, DOI 10.1177/0961203319860579
   Qin X, 2020, LANCET
   RECOVERY Collaborative Group, 2020, N ENGL J MED
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Richter A, 2016, ANN RHEUM DIS, V75, P1667, DOI 10.1136/annrheumdis-2015-207838
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Rose-John S, 2017, NAT REV RHEUMATOL, V13, P399, DOI 10.1038/nrrheum.2017.83
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022
   Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607
   Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Singh JA, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-016-0609-5
   Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140-6736(14)61704-9
   Smolen JS, 2014, LANCET, V383, P321, DOI 10.1016/S0140-6736(13)61751-1
   Smolen JS, 2013, LANCET, V381, P918, DOI 10.1016/S0140-6736(12)61811-X
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Strangfeld A, 2011, ANN RHEUM DIS, V70, P1914, DOI 10.1136/ard.2011.151043
   Strangfeld A, 2009, JAMA-J AM MED ASSOC, V301, P737, DOI 10.1001/jama.2009.146
   Takeuchi T, 2019, ANN RHEUM DIS, V78, P171, DOI 10.1136/annrheumdis-2018-213271
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tsakonas E, 1998, LUPUS, V7, P80
   Tselios K, 2014, SEMIN ARTHRITIS RHEU, V43, P521, DOI 10.1016/j.semarthrit.2013.07.007
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Tudesq JJ, 2018, AUTOIMMUN REV, V17, P115, DOI 10.1016/j.autrev.2017.11.015
   US Food and Drug Administration, 2020, COR COVID 19 UPD DAI
   US Food and Drug Administration, 2020, FDA ADV PAT US NONST
   US Food and Drug Administration, 2020, FDA DRUG SHORT
   van Vollenhoven RF, 2016, ANN RHEUM DIS, V75, P52, DOI 10.1136/annrheumdis-2014-205726
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, REP WHO CHIN JOINT M
   Winthrop KL, 2017, ARTHRITIS RHEUMATOL, V69, P1960, DOI 10.1002/art.40189
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu X, 2020, EFFECTIVE TREATMENT
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yao X, 2020, CLIN INFECT DIS
   Younes A, 2011, ONCOLOGIST, V16, P730, DOI 10.1634/theoncologist.2010-0318
   Youssef J, 2016, RHEUM DIS CLIN N AM, V42, P157, DOI 10.1016/j.rdc.2015.08.004
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang N, 2012, CLIN EXP RHEUMATOL, V30, P962
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 97
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
DI 10.1002/art.41596
EA DEC 2020
PG 12
WC Rheumatology
SC Rheumatology
GA PA4VW
UT WOS:000595636400001
PM 33277981
OA Bronze
DA 2021-01-01
ER

PT J
AU Abbas, HM
   Al-Jumaili, AA
   Nassir, KF
   Al-Obaidy, MW
   Al Jubouri, AM
   Dakhil, BD
   Abdulelah, MM
   Al Khames, QA
AF Abbas, Hassan M.
   Al-Jumaili, Ali Azeez
   Nassir, Kawthar F.
   Al-Obaidy, Muhammed Waheeb
   Al Jubouri, Adnan Mohammed
   Dakhil, Basim Dhawi
   Abdulelah, Mohammed Mahir
   Al Khames, Qutaiba Ahmed
TI Assessment of COVID-19 Treatment containing both Hydroxychloroquine and
   Azithromycin: A natural clinical trial
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article; Early Access
DE azithromycin; COVID&#8208; 19; effectiveness; hydroxychloroquine;
   natural trial; safety; treatment
AB The goal of this study was to assess the clinical effectiveness and safety profile of the COVID-19 treatment protocol (containing both hydroxychloroquine (HCQ) and azithromycin) in an Iraqi specialised hospital.
   Methods This prospective study used a pre- and post-intervention design without a comparison group. The intervention was routine Ministry of Health (MOH) approved the management of COVID-19 for all patients. The study was conducted in a public healthcare setting in Baghdad, Iraq from March 1st to May 25, 2020. The study outcome measures included the changes in clinical and biochemical parameters during the hospitalisation period. Paired t-test and Chi-square test were used to compare the measures of vital signs, lab tests and symptoms before and after treatment.
   Results The study included 161 patients who were admitted with positive RT-PCR and clinical symptoms of COVID-19. In terms of severity, 53 (32.9%) patients had amild condition, 47 (29.2%) had moderate condition, 35 (21.7%) had severe condition and 26 (16.1%) had critical condition. Most patients (84.5%) recovered and were discharged without symptoms after testing negative with RT-PCR, while 11 (6.8%) patients died during the study period. The signs and symptoms of COVID-19 were reduced significantly in response to a therapy regimen containing HCQ and azithromycin. The most common reported side effects were stomach pain, hypoglycemia, dizziness, itching, skin rash, QT prolongation, arrhythmia, and conjunctivitis.
   Conclusions This natural trial showed that the COVID-19 regimen containing both HCQ and azithromycin can be helpful to promote the recovery of most patients and reduced their signs and symptoms significantly. It also shows some manageable side effects mostly those related to heart rhythm. In the absence of FDA-approved medications to treat COVID-19, the repurposing of HCQ and azithromycin to control the disease signs and symptoms can be useful.
C1 [Abbas, Hassan M.] Minist Hlth, Baghdad, Iraq.
   [Al-Jumaili, Ali Azeez] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA.
   [Al-Jumaili, Ali Azeez] Univ Baghdad, Coll Pharm, Clin Pharm Dept, Baghdad, Iraq.
   [Nassir, Kawthar F.] Baghdad Teaching Hosp, Therapeut Drug Monitoring Ctr, Med City Complex, Baghdad, Iraq.
   [Al-Obaidy, Muhammed Waheeb; Al Jubouri, Adnan Mohammed] Univ Baghdad, Coll Med, Baghdad, Iraq.
   [Al Jubouri, Adnan Mohammed] Baghdad Teaching Hosp, Med City Teaching Complex, Baghdad, Iraq.
   [Dakhil, Basim Dhawi] Bagdad Teaching Hosp, Internal Med Dept, Al Shifa Ctr Treatment COVID 19, Crit Care Unit, Med City Complex, Baghdad, Iraq.
   [Abdulelah, Mohammed Mahir] Bagdad Teaching Hosp, Intens Care Unit, Med City Complex, Baghdad, Iraq.
   [Al Khames, Qutaiba Ahmed] Philadelphia Univ, Fac Pharm, Amman, Jordan.
RP Al-Jumaili, AA (corresponding author), Univ Iowa, Iowa City, IA 52242 USA.
EM Aliazeezali-aljumaili@uiowa.edu
OI Al-Jumaili, Ali Azeez/0000-0003-4691-0280
CR Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Allawi JS, 2019, J FM BAGHDAD, V61
   [Anonymous], 2020, COVID 19 PREV CONTR
   [Anonymous], 2020, CORONAVIRUS COVID 19, P1
   Center WHO-TUM, 2009, GOOD PHARM PRACT GUI, P39
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   D'Acquarica I, 2020, DRUG DISCOV TODAY, V25, P1121, DOI 10.1016/j.drudis.2020.04.021
   Damle B, 2020, CLIN PHARMACOL THER, V108, P201, DOI 10.1002/cpt.1857
   FDA, 2020, COR TREATM ACC PROGR
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gbinigie Kome, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101069
   Gerard A, 2020, THERAPIE, V75, P371, DOI 10.1016/j.therap.2020.05.002
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Haladyj Ewa, 2018, Reumatologia (Warsaw), V56, P164, DOI 10.5114/reum.2018.76904
   Ikeda Y, 2018, ST LUKES INT HOSP S1, V5, pA1
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Mackenzie JS, 2020, MICROBIOL AUST, V41, P45, DOI 10.1071/MA20013
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919
   Mikhael EM, 2020, PUBLIC HLTH PRACT, V1, P100004, DOI 10.1016/j.puhip.2020.100004
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   Ramireddy A, 2020, EXPERIENCE HYDROXYCH, V21, P1, DOI [10.1016/j.solener.2019.02.027, DOI 10.1016/J.SOLENER.2019.02.027]
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Tamblyn S, 2020, CLIN MANAGEMENT PATI, P1
   Tetu P, 2018, ANN DERMATOL VENER, V145, P395, DOI 10.1016/j.annder.2018.03.168
   Ullah MA, 2020, PATHOGENESIS DIAGNOS, DOI [10.20944/PREPRINTS202004.0372.V1, DOI 10.20944/PREPRINTS202004.0372.V1]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
AR e13856
DI 10.1111/ijcp.13856
EA DEC 2020
PG 9
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA PA4JI
UT WOS:000595603700001
PM 33231925
OA Bronze
DA 2021-01-01
ER

PT J
AU Wang, K
   Chen, W
   Zhang, Z
   Deng, YQ
   Lian, JQ
   Du, P
   Wei, D
   Zhang, Y
   Sun, XX
   Gong, L
   Yang, X
   He, L
   Zhang, L
   Yang, ZW
   Geng, JJ
   Chen, R
   Zhang, H
   Wang, B
   Zhu, YM
   Nan, G
   Jiang, JL
   Li, L
   Wu, J
   Lin, P
   Huang, W
   Xie, LZ
   Zheng, ZH
   Zhang, K
   Miao, JL
   Cui, HY
   Huang, M
   Zhang, J
   Fu, L
   Yang, XM
   Zhao, ZP
   Sun, SH
   Gu, HJ
   Wang, Z
   Wang, CF
   Lu, YC
   Liu, YY
   Wang, QY
   Bian, HJ
   Zhu, P
   Chen, ZN
AF Wang, Ke
   Chen, Wei
   Zhang, Zheng
   Deng, Yongqiang
   Lian, Jian-Qi
   Du, Peng
   Wei, Ding
   Zhang, Yang
   Sun, Xiu-Xuan
   Gong, Li
   Yang, Xu
   He, Lei
   Zhang, Lei
   Yang, Zhiwei
   Geng, Jie-Jie
   Chen, Ruo
   Zhang, Hai
   Wang, Bin
   Zhu, Yu-Meng
   Nan, Gang
   Jiang, Jian-Li
   Li, Ling
   Wu, Jiao
   Lin, Peng
   Huang, Wan
   Xie, Liangzhi
   Zheng, Zhao-Hui
   Zhang, Kui
   Miao, Jin-Lin
   Cui, Hong-Yong
   Huang, Min
   Zhang, Jun
   Fu, Ling
   Yang, Xiang-Min
   Zhao, Zhongpeng
   Sun, Shihui
   Gu, Hongjing
   Wang, Zhe
   Wang, Chun-Fu
   Lu, Yacheng
   Liu, Ying-Ying
   Wang, Qing-Yi
   Bian, Huijie
   Zhu, Ping
   Chen, Zhi-Nan
TI CD147-spike protein is a novel route for SARS-CoV-2 infection to host
   cells
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
AB In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2, no specific and effective drugs for treating this disease have been reported until today. Angiotensin-converting enzyme 2 (ACE2), a receptor of SARS-CoV-2, mediates the virus infection by binding to spike protein. Although ACE2 is expressed in the lung, kidney, and intestine, its expressing levels are rather low, especially in the lung. Considering the great infectivity of COVID-19, we speculate that SARS-CoV-2 may depend on other routes to facilitate its infection. Here, we first discover an interaction between host cell receptor CD147 and SARS-CoV-2 spike protein. The loss of CD147 or blocking CD147 in Vero E6 and BEAS-2B cell lines by anti-CD147 antibody, Meplazumab, inhibits SARS-CoV-2 amplification. Expression of human CD147 allows virus entry into non-susceptible BHK-21 cells, which can be neutralized by CD147 extracellular fragment. Viral loads are detectable in the lungs of human CD147 (hCD147) mice infected with SARS-CoV-2, but not in those of virus-infected wild type mice. Interestingly, virions are observed in lymphocytes of lung tissue from a COVID-19 patient. Human T cells with a property of ACE2 natural deficiency can be infected with SARS-CoV-2 pseudovirus in a dose-dependent manner, which is specifically inhibited by Meplazumab. Furthermore, CD147 mediates virus entering host cells by endocytosis. Together, our study reveals a novel virus entry route, CD147-spike protein, which provides an important target for developing specific and effective drug against COVID-19.
C1 [Wang, Ke; Zhang, Zheng; Wei, Ding; Zhang, Yang; Sun, Xiu-Xuan; Yang, Xu; Geng, Jie-Jie; Chen, Ruo; Zhang, Hai; Wang, Bin; Zhu, Yu-Meng; Nan, Gang; Jiang, Jian-Li; Li, Ling; Wu, Jiao; Lin, Peng; Huang, Wan; Miao, Jin-Lin; Cui, Hong-Yong; Huang, Min; Yang, Xiang-Min; Bian, Huijie; Chen, Zhi-Nan] Fourth Mil Med Univ, Natl Translat Sci Ctr Mol Med, Xian 710032, Peoples R China.
   [Wang, Ke; Zhang, Zheng; Wei, Ding; Zhang, Yang; Sun, Xiu-Xuan; Yang, Xu; Geng, Jie-Jie; Chen, Ruo; Zhang, Hai; Wang, Bin; Zhu, Yu-Meng; Nan, Gang; Jiang, Jian-Li; Li, Ling; Wu, Jiao; Lin, Peng; Huang, Wan; Miao, Jin-Lin; Cui, Hong-Yong; Huang, Min; Yang, Xiang-Min; Bian, Huijie; Chen, Zhi-Nan] Fourth Mil Med Univ, Dept Cell Biol, Xian 710032, Peoples R China.
   [Chen, Wei; Du, Peng; Zhang, Jun; Fu, Ling] Beijing Inst Biotechnol, Beijing 100071, Peoples R China.
   [Deng, Yongqiang; He, Lei; Zhao, Zhongpeng; Sun, Shihui; Gu, Hongjing] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
   [Lian, Jian-Qi; Gong, Li; Wang, Chun-Fu] Fourth Mil Med Univ, Tangdu Hosp, Xian 710038, Peoples R China.
   [Zhang, Lei; Yang, Zhiwei] Xi An Jiao Tong Univ, MOE Key Lab Nonequilibrium Synth & Modulat Conden, Xian 710049, Peoples R China.
   [Xie, Liangzhi] Sino Biol Inc, Beijing 100176, Peoples R China.
   [Zheng, Zhao-Hui; Zhang, Kui; Zhu, Ping] Fourth Mil Med Univ, Xijing Hosp, Dept Clin Immunol, Xian 710032, Peoples R China.
   [Wang, Zhe; Lu, Yacheng; Liu, Ying-Ying; Wang, Qing-Yi] Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Peoples R China.
RP Bian, HJ; Chen, ZN (corresponding author), Fourth Mil Med Univ, Natl Translat Sci Ctr Mol Med, Xian 710032, Peoples R China.; Bian, HJ; Chen, ZN (corresponding author), Fourth Mil Med Univ, Dept Cell Biol, Xian 710032, Peoples R China.; Zhu, P (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Clin Immunol, Xian 710032, Peoples R China.
EM hjbian@fmmu.edu.cn; zhuping@fmmu.edu.cn; znchen@fmmu.edu.cn
FU National Science and Technology Major Project of China
   [2019ZX09732-001]; Key R & D Plan Projects in Shaanxi Province
   [2020ZDXM2-SF-01]; Young Talent fund of the University Association for
   Science and Technology in Shaanxi, China [20200304]
FX We thank Prof. Nanshan Zhong, academician of the Chinese Academy of
   Engineering, and members of Zhong's Lab for their guidance. We also
   thank Prof. Youchun Wang from the National Institutes for Food and Drug
   Control for donating SARS-CoV-2 pseudovirus and Prof. Chuan Qin from the
   Chinese Academy of Medical Sciences for helping us to conduct animal
   experiments. This work was supported by the National Science and
   Technology Major Project of China (2019ZX09732-001), the Key R & D Plan
   Projects in Shaanxi Province (2020ZDXM2-SF-01), and Young Talent fund of
   the University Association for Science and Technology in Shaanxi, China
   (20200304).
CR Almabouada F, 2013, J BIOL CHEM, V288, P3112, DOI 10.1074/jbc.M112.404624
   Barth K, 2006, HISTOCHEM CELL BIOL, V126, P563, DOI 10.1007/s00418-006-0192-3
   Bernard SC, 2014, NAT MED, V20, P725, DOI 10.1038/nm.3563
   Cantuti-Castelvetri L, 2020, SCIENCE, V370, P856, DOI 10.1126/science.abd2985
   Chen ZN, 2005, J INFECT DIS, V191, P755, DOI 10.1086/427811
   Daly JL, 2020, SCIENCE, V370, P861, DOI 10.1126/science.abd3072
   Eyster CA, 2009, TRAFFIC, V10, P590, DOI 10.1111/j.1600-0854.2009.00894.x
   Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030
   Grigorieff N, 2007, J STRUCT BIOL, V157, P117, DOI 10.1016/j.jsb.2006.05.004
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Harrison SC, 2015, VIROLOGY, V479, P498, DOI 10.1016/j.virol.2015.03.043
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hulswit RJG, 2016, ADV VIRUS RES, V96, P29, DOI 10.1016/bs.aivir.2016.08.004
   Jiang SB, 2020, CELL MOL IMMUNOL, V17, P554, DOI 10.1038/s41423-020-0372-4
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2010, PHARMACOL THERAPEUT, V128, P119, DOI 10.1016/j.pharmthera.2010.06.003
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li Y, 2009, HISTOPATHOLOGY, V54, P677, DOI 10.1111/j.1365-2559.2009.03280.x
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Lu M, 2018, HEPATOLOGY, V68, P317, DOI 10.1002/hep.29798
   Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174
   Maldonado-Baez L, 2013, J CELL BIOL, V201, P233, DOI 10.1083/jcb.201208172
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Ohi Melanie, 2004, Biol Proced Online, V6, P23, DOI 10.1251/bpo70
   Pushkarsky T, 2001, P NATL ACAD SCI USA, V98, P6360, DOI 10.1073/pnas.111583198
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Rentzsch B, 2008, HYPERTENSION, V52, P967, DOI 10.1161/HYPERTENSIONAHA.108.114322
   Saitoh S, 2017, P NATL ACAD SCI USA, V114, pE2327, DOI 10.1073/pnas.1602349114
   Sarkissian SD, 2008, HYPERTENSION, V51, P712, DOI 10.1161/HYPERTENSIONAHA.107.100693
   Slonska A, 2016, POSTEP HIG MED DOSW, V70, P572, DOI 10.5604/17322693.1203721
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Urra JM, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108486
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Wang K, 2019, AGING-US, V11, P11170, DOI 10.18632/aging.102521
   Wong DW, 2007, AM J PATHOL, V171, P438, DOI 10.2353/ajpath.2007.060977
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao H, 2014, INT J BIOL SCI, V10, P43, DOI 10.7150/ijbs.6818
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
   Zhang L, 2020, D614G MUTATION SARS
   Zhang L, 2011, J LIPID RES, V52, P175, DOI 10.1194/jlr.D010959
   Zhang MY, 2018, BLOOD, V131, P1111, DOI 10.1182/blood-2017-08-802918
   Zhao P, 2011, HEPATOLOGY, V54, P2012, DOI 10.1002/hep.24592
NR 46
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD DEC 4
PY 2020
VL 5
IS 1
AR 283
DI 10.1038/s41392-020-00426-x
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA PC9TF
UT WOS:000597339100001
PM 33277466
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brown, SA
   Zaharova, S
   Mason, P
   Thompson, J
   Thapa, B
   Ishizawar, D
   Wilkes, E
   Ahmed, G
   Rubenstein, J
   Sanchez, J
   Joyce, D
   Kalyanaraman, B
   Widlansky, M
AF Brown, Sherry-Ann
   Zaharova, Svetlana
   Mason, Peter
   Thompson, Jonathan
   Thapa, Bicky
   Ishizawar, David
   Wilkes, Erin
   Ahmed, Gulrayz
   Rubenstein, Jason
   Sanchez, Joyce
   Joyce, David
   Kalyanaraman, Balaraman
   Widlansky, Michael
TI Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE cardio-oncology; COVID-19; pandemic; telemedicine; inflammation;
   cytokine release syndrome; right ventricle; health disparities
ID CYTOKINE-RELEASE SYNDROME; RECEPTOR TYROSINE KINASE; RENIN-ANGIOTENSIN
   SYSTEM; T-CELL THERAPY; CARDIOVASCULAR COMPLICATIONS; SARS-CORONAVIRUS;
   CANCER-THERAPY; VENOUS THROMBOEMBOLISM; INDUCED CARDIOMYOPATHY;
   MYOCARDIAL-INFARCTION
AB Overlapping commonalities between coronavirus disease of 2019 (COVID-19) and cardio-oncology regarding cardiovascular toxicities (CVT), pathophysiology, and pharmacology are special topics emerging during the pandemic. In this perspective, we consider an array of CVT common to both COVID-19 and cardio-oncology, including cardiomyopathy, ischemia, conduction abnormalities, myopericarditis, and right ventricular (RV) failure. We also emphasize the higher risk of severe COVID-19 illness in patients with cardiovascular disease (CVD) or its risk factors or cancer. We explore commonalities in the underlying pathophysiology observed in COVID-19 and cardio-oncology, including inflammation, cytokine release, the renin-angiotensin-aldosterone-system, coagulopathy, microthrombosis, and endothelial dysfunction. In addition, we examine common pharmacologic management strategies that have been elucidated for CVT from COVID-19 and various cancer therapies. The use of corticosteroids, as well as antibodies and inhibitors of various molecules mediating inflammation and cytokine release syndrome, are discussed. The impact of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is also addressed, since these drugs are used in cardio-oncology and have received considerable attention during the COVID-19 pandemic, since the culprit virus enters human cells via the angiotensin converting enzyme 2 (ACE2) receptor. There are therefore several areas of overlap, similarity, and interaction in the toxicity, pathophysiology, and pharmacology profiles in COVID-19 and cardio-oncology syndromes. Learning more about either will likely provide some level of insight into both. We discuss each of these topics in this viewpoint, as well as what we foresee as evolving future directions to consider in cardio-oncology during the pandemic and beyond. Finally, we highlight commonalities in health disparities in COVID-19 and cardio-oncology and encourage continued development and implementation of innovative solutions to improve equity in health and healing.
C1 [Brown, Sherry-Ann; Zaharova, Svetlana] Med Coll Wisconsin, Cardiooncol Program, Div Cardiovasc Med, Milwaukee, WI 53226 USA.
   [Mason, Peter; Ishizawar, David; Rubenstein, Jason; Widlansky, Michael] Med Coll Wisconsin, Div Cardiovasc Med, Milwaukee, WI 53226 USA.
   [Thompson, Jonathan; Thapa, Bicky; Ahmed, Gulrayz] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA.
   [Wilkes, Erin] Froedtert Hlth, Dept Pharm, Milwaukee, WI USA.
   [Wilkes, Erin] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
   [Sanchez, Joyce] Med Coll Wisconsin, Div Infect Dis, Milwaukee, WI 53226 USA.
   [Joyce, David] Med Coll Wisconsin, Div Cardiothorac Surg, Milwaukee, WI 53226 USA.
   [Kalyanaraman, Balaraman] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA.
RP Brown, SA (corresponding author), Med Coll Wisconsin, Cardiooncol Program, Div Cardiovasc Med, Milwaukee, WI 53226 USA.
EM shbrown@mcw.edu
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01 HL144098, R01 HL128240] Funding Source: Medline
CR Abboud R, 2016, BIOL BLOOD MARROW TR, V22, P1851, DOI 10.1016/j.bbmt.2016.06.010
   Alashi A, 2019, CARDIOVASC DIAGN THE, V9, P214, DOI 10.21037/cdt.2019.04.05
   Alvi RM, 2019, J AM COLL CARDIOL, V74, P3099, DOI 10.1016/j.jacc.2019.10.038
   Angiolillo Dominick J, 2004, J Invasive Cardiol, V16, P169
   Anguiano L, 2015, NEPHROL DIAL TRANSPL, V30, P1176, DOI 10.1093/ndt/gfv025
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Argulian E, 2020, JACC-CARDIOVASC IMAG, V13, P2459, DOI 10.1016/j.jcmg.2020.05.010
   Asokan I, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00945-4
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Barac A, 2015, J AM COLL CARDIOL, V65, P2739, DOI 10.1016/j.jacc.2015.04.059
   Baron KB, 2014, J CARD FAIL, V20, P555, DOI 10.1016/j.cardfail.2014.05.012
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bick RL, 2003, NEW ENGL J MED, V349, P109, DOI 10.1056/NEJMp030086
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Blumenthal D, 2020, NEW ENGL J MED, V383, P1483, DOI 10.1056/NEJMsb2021088
   Boczar KE, 2016, ECHO RES PRACT, V3, P79, DOI 10.1530/ERP-16-0020
   Bonaca MP, 2019, CIRCULATION, V140, P80, DOI 10.1161/CIRCULATIONAHA.118.034497
   Brahmer JR, 2018, J ONCOL PRACT, V14, P247, DOI 10.1200/JOP.18.00005
   Braithwaite D, 2009, INT J CANCER, V124, P1213, DOI 10.1002/ijc.24054
   Breathett K, 2018, JACC-HEART FAIL, V6, P413, DOI 10.1016/j.jchf.2018.02.015
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Brown SA, 2017, CLIN PHARMACOL THER, V101, P65, DOI 10.1002/cpt.552
   Brown SA, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00145
   Brown SA, 2020, J CARDIOVASC TRANSL, V13, P402, DOI 10.1007/s12265-020-09992-5
   Brown SA, 2020, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00187
   Brown SA, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015327
   Brown SA, 2015, NAT REV CLIN ONCOL, V12, P718, DOI 10.1038/nrclinonc.2015.168
   Bull TM, 2010, AM J RESP CRIT CARE, V182, P1123, DOI 10.1164/rccm.201002-0250OC
   Calcagnile M, 2020, MICROBIOLOGY, DOI [10.1101/2020.04.23.057042, DOI 10.1101/2020.04.23.057042]
   Caldentey G, 2019, EUR HEART J-ACUTE CA, V8, P708, DOI 10.1177/2048872617740833
   Calvillo-Arguelles Oscar, 2020, JACC CardioOncol, V2, P345, DOI 10.1016/j.jaccao.2020.04.001
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Caplin DA, 2017, J ADOLESC YOUNG ADUL, V6, P74, DOI 10.1089/jayao.2016.0016
   Cardiology ACo, 2020, J CARD FAIL, V26, P370, DOI [10.1016/j.cardfail.2020.04.013, DOI 10.1016/J.CARDFAIL.2020.04.013]
   Carnethon MR, 2017, CIRCULATION, V136, pE393, DOI 10.1161/CIR.0000000000000534
   Cascella M, 2020, FEATURES EVALUATION
   Chang HM, 2017, J AM COLL CARDIOL, V70, P2552, DOI 10.1016/j.jacc.2017.09.1095
   Chang HM, 2017, J AM COLL CARDIOL, V70, P2536, DOI 10.1016/j.jacc.2017.09.1096
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Cheng P, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01293-2
   Chung RYN, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1329
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cook D, 2005, CRIT CARE MED, V33, P1565, DOI 10.1097/01.CCM.0000171207.95319.B2
   Cook D, 2011, NEW ENGL J MED, V364, P1305, DOI 10.1056/NEJMoa1014475
   Dabbagh Mohammed F, 2020, JACC Case Rep, V2, P1326, DOI 10.1016/j.jaccas.2020.04.009
   Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226
   de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8
   Delanghe JR, 2020, CLIN CHIM ACTA, V505, P192, DOI 10.1016/j.cca.2020.03.031
   Dessap AM, 2016, INTENS CARE MED, V42, P862, DOI 10.1007/s00134-015-4141-2
   Dolhnikoff M, 2020, LANCET CHILD ADOLESC, V4, P790, DOI 10.1016/S2352-4642(20)30257-1
   Douglas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1557
   Doyen D, 2020, LANCET, V395, P1516, DOI 10.1016/S0140-6736(20)30912-0
   Farge D, 2019, LANCET ONCOL, V20, pE566, DOI 10.1016/S1470-2045(19)30336-5
   Fatunde OA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020604
   Finkelman BS, 2017, J AM COLL CARDIOL, V70, P152, DOI 10.1016/j.jacc.2017.05.019
   FLOE A, 2014, DAN MED J, V61
   Frierson GM, 2013, ETHNIC DIS, V23, P35
   Fujimori T, 2015, MUCOSAL IMMUNOL, V8, P1021, DOI 10.1038/mi.2014.129
   Ganatra Sarju, 2020, JACC CardioOncol, V2, P350, DOI 10.1016/j.jaccao.2020.03.001
   Garcia-Diaz A, 2019, CELL REP, V29, P3766, DOI 10.1016/j.celrep.2019.11.113
   Ghelichkhani P, 2020, ARCH ACAD EMERG MED, V8
   Ghosh AK, 2020, JACC CARDIOONCOLOGY, V2, P97, DOI DOI 10.1016/j.jaccao.2020.02.011
   Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7
   Giblin EM, 2019, AM J CARDIOL, V124, P1900, DOI 10.1016/j.amjcard.2019.09.020
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Gulati G, 2016, EUR HEART J, V37, P1671, DOI 10.1093/eurheartj/ehw022
   Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106
   Hasan S, 2004, J NATL MED ASSOC, V96, P196
   Hashmi H, 2020, BIOL BLOOD MARROW TR, V26, pS265
   Haslam A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2535
   Haynes N, 2020, CIRCULATION, V142, P105, DOI 10.1161/CIRCULATIONAHA.120.048126
   Heaton NS, 2010, CELL HOST MICROBE, V8, P422, DOI 10.1016/j.chom.2010.10.006
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Henry BM, 2020, CLIN CHIM ACTA, V507, P167, DOI 10.1016/j.cca.2020.04.027
   Hicks BM, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4209
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Hu JR, 2019, CARDIOVASC RES, V115, P854, DOI 10.1093/cvr/cvz026
   Huang L, 2020, CELL MOL IMMUNOL, V17, P1092, DOI 10.1038/s41423-020-00522-6
   Iacovelli R, 2015, EUR J CANCER, V51, P1970, DOI 10.1016/j.ejca.2015.06.106
   Iba T, 2018, J THROMB HAEMOST, V16, P231, DOI 10.1111/jth.13911
   Iliescu CA, 2016, CATHETER CARDIO INTE, V87, pE202, DOI 10.1002/ccd.26379
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Karlamangla AS, 2010, ANN EPIDEMIOL, V20, P617, DOI 10.1016/j.annepidem.2010.05.003
   Kewan Tariq, 2020, EClinicalMedicine, V24, P100418, DOI 10.1016/j.eclinm.2020.100418
   Key NS, 2019, J ONCOL PRACT, V15, P661, DOI 10.1200/JOP.19.00368
   Key NS, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01461
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Khera Rohan, 2020, medRxiv, DOI 10.1101/2020.05.17.20104943
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kochav SM, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008719
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Ky Bonnie, 2020, JACC Basic Transl Sci, V5, P501, DOI 10.1016/j.jacbts.2020.04.003
   Lackland DT, 2014, AM J MED SCI, V348, P135, DOI 10.1097/MAJ.0000000000000308
   Lang JP, 2020, AM HEART J, V226, P29, DOI 10.1016/j.ahj.2020.04.025
   Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Lee AYY, 2003, CIRCULATION, V107, pI17, DOI 10.1161/01.CIR.0000078466.72504.AC
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Leisman DE, 2020, INTENS CARE MED, V46, P1105, DOI 10.1007/s00134-020-06059-6
   Li YM, 2020, JACC-CARDIOVASC IMAG, V13, P2287, DOI 10.1016/j.jcmg.2020.04.014
   Libby P, 2018, J AM COLL CARDIOL, V72, P2071, DOI 10.1016/j.jacc.2018.08.1043
   Litvak A, 2018, CANCER-AM CANCER SOC, V124, P1904, DOI 10.1002/cncr.31260
   Liu HY, 2019, ONCOTARGETS THER, V12, P8955, DOI 10.2147/OTT.S223697
   Liu Q, 2016, J CLIN ONCOL, V34, P1634, DOI 10.1200/JCO.2015.66.3567
   Liu ZM, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01093
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Lotrionte M, 2013, AM J CARDIOL, V112, P1980, DOI 10.1016/j.amjcard.2013.08.026
   Lu-Yao G, 2020, EUR UROL, V77, P158, DOI 10.1016/j.eururo.2019.07.031
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Luther JM, 2006, HYPERTENSION, V48, P1050, DOI 10.1161/01.HYP.0000248135.97380.76
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Mahmood SS, 2018, J AM COLL CARDIOL, V71, P1755, DOI 10.1016/j.jacc.2018.02.037
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   Medjebar S, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e20512
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Meinardi MT, 2002, HEART, V88, P81, DOI 10.1136/heart.88.1.81
   Mekontso DA, 2009, INTENS CARE MED, V35, P1850, DOI DOI 10.1007/S00134-009-1569-2
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Mirsaeidi M, 2015, CHEST, V147, P438, DOI 10.1378/chest.14-1120
   Moazeni S, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-017-0148-3
   Morizono K, 2011, CELL HOST MICROBE, V9, P286, DOI 10.1016/j.chom.2011.03.012
   Musher DM, 2019, NEW ENGL J MED, V380, pE21, DOI 10.1056/NEJMc1901647
   Nagata Y, 2017, CIRC-CARDIOVASC IMAG, V10, DOI 10.1161/CIRCIMAGING.116.005384
   National Institutes of Health, 2020, COR DIS 2019 COVID 1
   Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047
   Nebigil CG, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01262
   Ned RM, 2012, AM J HYPERTENS, V25, P209, DOI 10.1038/ajh.2011.182
   Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447
   Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148
   Oliveira GH, 2014, J AM COLL CARDIOL, V63, P240, DOI 10.1016/j.jacc.2013.09.040
   Oren O, 2020, AM J CARDIOL, V125, P1920, DOI 10.1016/j.amjcard.2020.02.016
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Parikh Amar, 2020, JACC CardioOncol, V2, P356, DOI 10.1016/j.jaccao.2020.04.003
   Park TS, 2009, HAEMATOL-HEMATOL J, V94, P745, DOI 10.3324/haematol.2009.006965
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Pathan N, 2004, LANCET, V363, P203, DOI 10.1016/S0140-6736(03)15326-3
   Perlot T, 2013, MICROBES INFECT, V15, P866, DOI 10.1016/j.micinf.2013.08.003
   Pinter M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan5616
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Ratajczak MZ, 2020, STEM CELL REV REP, DOI 10.1007/s12015-020-10010-z
   Ratajczak MZ, 2020, LEUKEMIA, V34, P1726, DOI 10.1038/s41375-020-0887-9
   Ren XS, 2017, CELL PHYSIOL BIOCHEM, V44, P2269, DOI 10.1159/000486061
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Rosamond WD, 2012, CIRCULATION, V125, P1848, DOI 10.1161/CIRCULATIONAHA.111.047480
   Rotzinger DC, 2020, THROMB RES, V190, P58, DOI 10.1016/j.thromres.2020.04.011
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Saltalamacchia G, 2020, CANCERS, V12, DOI 10.3390/cancers12071750
   Sanz J, 2019, J AM COLL CARDIOL, V73, P1463, DOI 10.1016/j.jacc.2018.12.076
   Schieffer B, 2004, J AM COLL CARDIOL, V44, P362, DOI 10.1016/j.jacc.2004.03.065
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   Sharma Arun, 2020, bioRxiv, DOI 10.1101/2020.04.21.051912
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Simone Gd, 2020, POSITION STATEMENT E
   Singh Dhssraj, 2015, Curr Heart Fail Rep, V12, P255, DOI 10.1007/s11897-015-0258-4
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Stawiski EW, 2020, BIORXIV, DOI [10.1101/2020.04.07.024752, DOI 10.1101/2020.04.07.024752]
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Taylor AL, 2004, NEW ENGL J MED, V351, P2049, DOI 10.1056/NEJMoa042934
   Thachil J, 2015, J THROMB HAEMOST, V13, P671, DOI 10.1111/jth.12838
   Trojanowicz B, 2018, NEPHROL DIAL TRANSPL, V33, P34, DOI 10.1093/ndt/gfx206
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vejpongsa P, 2014, CLIN PHARMACOL THER, V95, P45, DOI 10.1038/clpt.2013.201
   Vieillard-Baron A, 2007, CHEST, V132, P1440, DOI 10.1378/chest.07-1013
   Wang L, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00078
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   World Health Organization, 2020, WHO COR DIS COVID 19
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie GZ, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0401-3
   Xie Y, 2020, RADIOL CARDIOTHORAC, V2, pe200067, DOI [10.1148/ryct.2020200067, DOI 10.1148/RYCT.2020200067]
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Yanez L, 2019, HEMASPHERE, V3, DOI 10.1097/HS9.0000000000000186
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Yang K, 2020, CTS-CLIN TRANSL SCI, V13, P842, DOI 10.1111/cts.12815
   Zeng JH, 2020, INFECTION, V48, P773, DOI 10.1007/s15010-020-01424-5
   Zhang CL, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015833
   Zhang P, 2020, CIRC RES, V126, pE142, DOI 10.1161/CIRCRESAHA.120.317242
   Zhang ZL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00286
   Zhao R, 2020, JACC CARDIOONCOL, V2, P13, DOI [10.1016/j.jaccao.2020.01.007, DOI 10.1016/J.JACCAO.2020.01.007]
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu CJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1090-3
   Zhu H, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01292-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 203
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2297-055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD DEC 4
PY 2020
VL 7
AR 568720
DI 10.3389/fcvm.2020.568720
PG 16
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA PG2JV
UT WOS:000599567900001
PM 33344513
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Masaud, SM
   Szasz, O
   Szasz, AM
   Ejaz, H
   Anwar, RA
   Szasz, A
AF Masaud, Syed Muzzammil
   Szasz, Oliver
   Szasz, A. Marcell
   Ejaz, Hume
   Anwar, Rana Attique
   Szasz, Andras
TI A Potential Bioelectromagnetic Method to Slow Down the Progression and
   Prevent the Development of Ultimate Pulmonary Fibrosis by COVID-19
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-21; rehabilitation; electric field; immune-effect; heat-shock
   protein; modulated electro-hyperthermia
ID HEAT-SHOCK PROTEINS; ACUTE RESPIRATORY SYNDROME; PROGRAMMED CELL-DEATH;
   HYPERTHERMIC TREATMENT; SARS-CORONAVIRUS; IMMUNE-RESPONSES; GENOME
   SEQUENCE; LIPID RAFTS; LUNG INJURY; APOPTOSIS
AB Introduction
   Right now, we are facing a global pandemic caused by the coronavirus SARS-CoV-2 that causes the highly contagious human disease COVID-19. The number of COVID-19 cases is increasing at an alarming rate, more and more people suffer from it, and the death toll is on the rise since December 2019, when COVID-19 has presumably appeared. We need an urgent solution for the prevention, treatment, and recovery of the involved patients.
   Methods
   Modulated electro-hyperthermia (mEHT) is known as an immuno-supportive therapy in oncology. Our proposal is to apply this method to prevent the progression of the disease after its identification, to provide treatment when necessary, and deliver rehabilitation to diminish the fibrotic-often fatal-consequences of the infection.
   Hypothesis
   The effects of mEHT, which are proven for oncological applications, could be utilized for the inactivation of the virus or for treating the fibrotic consequences. The hypothesized mEHT effects, which could have a role in the antiviral treatment, it could be applied for viral-specific immune-activation and for anti-fibrotic treatments.
C1 [Masaud, Syed Muzzammil] OncoTreatments Pvt Ltd, Karachi, Pakistan.
   [Szasz, Oliver; Szasz, Andras] St Istvan Univ, Biotech Dept, Godollo, Hungary.
   [Szasz, A. Marcell] Semmelweis Univ, Dept Internal Med & Oncol, Budapest, Hungary.
   [Ejaz, Hume] Univ Turku, Dept Biochem, Turku, Finland.
   [Anwar, Rana Attique] Nishtar Med Coll Multan, Dept Oncol, Multan, Pakistan.
RP Szasz, A (corresponding author), St Istvan Univ, Biotech Dept, Godollo, Hungary.
EM Szasz.Andras@gek.szie.hu
CR Andocs G, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.39
   Andocs G, 2015, CELL STRESS CHAPERON, V20, P37, DOI 10.1007/s12192-014-0523-6
   Andocs G, 2009, STRAHLENTHER ONKOL, V185, P120, DOI 10.1007/s00066-009-1903-1
   Asai A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082839
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364
   Baglivo Mirko, 2020, Acta Biomed, V91, P161, DOI 10.23750/abm.v91i1.9402
   Ballerini M, 2013, ANDROTHERM APPL PEYR, DOI 10.1155/2013/962349
   Banoun H, 2020, EVOLUTION SARS COV 2, DOI [10.2139/ssrn.3637909, DOI 10.2139/SSRN.3637909]
   Barry CA, 1983, PARETO DISTRIBUTIONS
   Batawi S, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1165-2
   Cabrera-Benitez NE, 2012, CRIT CARE MED, V40, P510, DOI 10.1097/CCM.0b013e31822f09d7
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chi K-H, 2020, BOOK CHALLENGES SOLU, V12, P206
   Cohen Marc, 2020, F1000Res, V9, P292, DOI 10.12688/f1000research.23299.1
   Conti C, 1999, ANTIMICROB AGENTS CH, V43, P822, DOI 10.1128/AAC.43.4.822
   Cunha L, 2014, DRUG DISCOV TODAY, V19, P936, DOI 10.1016/j.drudis.2014.01.003
   Dank M, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e14571
   de Araujo AR, 2015, AN BRAS DERMATOL, V90, P707, DOI 10.1590/abd1806-4841.20153605
   DEMARCO A, 1993, J GEN VIROL, V74, P1685, DOI 10.1099/0022-1317-74-8-1685
   Dezso Z, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.055103
   Evans SS, 2015, NAT REV IMMUNOL, V15, P335, DOI 10.1038/nri3843
   Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243
   Feys BJ, 2000, TRENDS GENET, V16, P449, DOI 10.1016/S0168-9525(00)02107-7
   Fischer H, 2004, P NATL ACAD SCI USA, V101, P3691, DOI 10.1073/pnas.0308393100
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Fung TS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00296
   Galvani AP, 2005, NATURE, V438, P293, DOI 10.1038/438293a
   Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180
   George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3
   Goldberg A, 2020, ACE2 COVID 19 IS IT
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Gurkan OU, 2003, AM J PHYSIOL-LUNG C, V285, pL710, DOI 10.1152/ajplung.00044.2003
   Hagiwara S, 2007, LUNG, V185, P287, DOI 10.1007/s00408-007-9018-x
   He JH, 2008, CHAOS SOLITON FRACT, V38, P1390, DOI 10.1016/j.chaos.2008.04.018
   Hegyi G, 2017, CLIN PRACT, V14, P73, DOI [10.4172/clinical-practice.100098, DOI 10.4172/CLINICAL-PRACTICE.100098]
   Hegyi G, 2012, OPEN J BIOPHYS, V2, P64, DOI DOI 10.4236/ojbiphy.2012.23009
   Hegyi G, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/672873
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang QC, 2014, J HEPATOL, V61, P859, DOI 10.1016/j.jhep.2014.04.035
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Hui DS, 2005, THORAX, V60, P401, DOI 10.1136/thx.2004.030205
   Human Coronavirus Types, HUM COR TYP
   Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5
   Jansen MAA, 2018, IMMUNOLOGY, V153, P51, DOI 10.1111/imm.12811
   Jeung TS, 2015, CASE REP CLIN MED, V4, P157, DOI DOI 10.4236/crcm.2015.45033
   Kang D, 2020, ROLE TEMPERATURE COV, DOI [10.20944/preprints202005.0070.v12020, DOI 10.20944/PREPRINTS202005.0070.V12020]
   Kendrick AA, 2017, ONCOTARGET, V8, P6742, DOI 10.18632/oncotarget.14272
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001
   Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee K, 2012, INT REV CEL MOL BIO, V294, P171, DOI 10.1016/B978-0-12-394305-7.00004-5
   Lee YN, 2005, J VIROL METHODS, V129, P152, DOI 10.1016/j.jviromet.2005.05.022
   Lei JQ, 2020, RADIOLOGY, V295, P18, DOI 10.1148/radiol.2020200236
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li GM, 2007, MICROBES INFECT, V9, P96, DOI 10.1016/j.micinf.2006.10.015
   Li XD, 2012, INT J HYPERTHER, V28, P451, DOI 10.3109/02656736.2012.677929
   Li XF, 2020, CANCER IMMUNOL IMMUN, V69, P535, DOI 10.1007/s00262-019-02457-y
   Lionetti V, 2005, CURR OPIN CRIT CARE, V11, P82, DOI 10.1097/00075198-200502000-00013
   Liu Anding, 2020, Clin Microbiol Infect, V26, P1703, DOI 10.1016/j.cmi.2020.07.009
   Liu L, 2020, MICROBES INFECT, V22, P206, DOI 10.1016/j.micinf.2020.05.008
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   LWOFF A, 1969, BACTERIOL REV, V33, P390, DOI 10.1128/MMBR.33.3.390-403.1969
   LWOFF A, 1959, BACTERIOL REV, V23, P109, DOI 10.1128/MMBR.23.3.109-124.1959
   Ma T, 2015, DISTRIBUTION HUMAN R, DOI [10.1002/cplx.21666, DOI 10.1002/CPLX.21666]
   Mahmudpour M, 2020, CYTOKINE, V133, DOI 10.1016/j.cyto.2020.155151
   Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Maruyama H, 2018, VIRUS RES, V257, P94, DOI 10.1016/j.virusres.2018.09.011
   Mate A, 2017, ACUPUNCTURE ELECTRO, V42, P121, DOI 10.3727/036012917X15004036818267
   Matricardi PM, 2020, PEDIAT ALLERG IMM-UK, V31, P454, DOI 10.1111/pai.13271
   Mayer KA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01533
   Meggyeshazi N, 2014, STRAHLENTHER ONKOL, V190, P815, DOI 10.1007/s00066-014-0617-1
   Meggyeshazi N, 2015, THESIS
   Meggyeshazi N, 2013, PROGRAMMED CELL DEAT
   MIKKELSEN RB, 1981, CANCER RES, V41, P209
   Milani A, 2019, IMMUNOTHERAPY-UK, V11, P215, DOI 10.2217/imt-2018-0105
   Minnaar CA, 2020, INT J HYPERTHER, V37, P263, DOI 10.1080/02656736.2020.1737253
   Mo HY, 2006, RESPIROLOGY, V11, P49, DOI 10.1111/j.1440-1843.2006.00783.x
   Nagy G, 2013, DEEP TEMPERATURE MEA, DOI 10.1155/2013/685264
   Ngai JC, 2010, RESPIROLOGY, V15, P543, DOI 10.1111/j.1440-1843.2010.01720.x
   Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581
   Oei AL, 2015, CANCER RES, V75, P5120, DOI 10.1158/0008-5472.CAN-15-0816
   Ortiz-Prado E, 2020, DIAGN MICR INFEC DIS, V98, DOI 10.1016/j.diagmicrobio.2020.115094
   Ou JW, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735419895591
   Papp E, 2017, OPEN J BIOPHYS, V7, P216, DOI DOI 10.4236/OJBIPHY.2017.74016
   Pathak N, 2020, GREAT IMITATOR COVID
   PENNYPACKER C, 1995, J ACQ IMMUN DEF SYND, V8, P321
   Prasad B, 2018, J THERM BIOL, V74, P281, DOI 10.1016/j.jtherbio.2018.04.007
   Qin W, 2014, ONCOL REP, V32, P2373, DOI 10.3892/or.2014.3500
   Qing EY, 2020, MBIO, V11, DOI 10.1128/mBio.02764-19
   Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681
   Raoult D, 2020, CELL STRESS
   Ren LL, 2005, DNA CELL BIOL, V24, P496, DOI 10.1089/dna.2005.24.496
   Ren Y, 2015, INT J HYPERTHER, V31, P5, DOI 10.3109/02656736.2014.993339
   Ritchie H, 2020, MORTALITY RISK COVID
   Rokni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2107
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Sanchez EL, 2015, VIROLOGY, V479, P609, DOI 10.1016/j.virol.2015.02.038
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Singanayagam A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-27
   Sun PF, 2020, J MED VIROL, V92, P612, DOI 10.1002/jmv.25735
   Szasz A, 2003, ELECTROMAGN BIOL MED, V22, P103, DOI 10.1081/JBC-120024620
   Szasz A, 2020, PREFACE BOOK CHALLEN
   Szasz A, 2013, HYPERTHERMIA, P1, DOI DOI 10.5772/52208
   Szasz A, 2019, J RAD CANC RES, V10, P1, DOI DOI 10.4103/jrcr.jrcr_25_18
   Szasz A, 2020, BOOK CHALLENGES SOLU, P377
   Szasz A, 2010, ONCOTHERMIA PRINCIPL, DOI [10.1007/978-90-481-9498-8, DOI 10.1007/978-90-481-9498-8]
   Szasz A, 2017, J ADV BIOL, V10, P2061, DOI [10.24297/jab.v10i2.6328, DOI 10.24297/JAB.V10I2.6328]
   Szasz A, 2014, 31 URSI GEN ASS SCI, DOI [10.1109/URSIGASS.2014.6930100, DOI 10.1109/URSIGASS.2014.6930100]
   Szasz A, 2015, BIOELECTROMAGNETIC S, P323
   Szasz AM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01012
   Szasz O, 2017, ADV BIOSCI BIOTECHNO, V8, P434, DOI [10.4236/abb.2017.811032, DOI 10.4236/ABB.2017.811032]
   Szasz O, 2017, OJBIPHY, V7, P183, DOI [10.4236/ojbiphy.2017.74014, DOI 10.4236/OJBIPHY.2017.74014]
   Szasz O, 2018, OPEN J BIOPHYS, V8, P31, DOI DOI 10.4236/ojbiphy.2018.81004
   Szasz O, 2018, OJBIPHY, V8, P49, DOI [10.4236/ojbiphy.2018.82005, DOI 10.4236/OJBIPHY.2018.82005]
   Szasz O, 2017, OPEN J BIOPHYS, V7, P116, DOI [10.4236/ojbiphy.2017.73010, DOI 10.4236/OJBIPHY.2017.73010]
   Szasz O, 2014, J CANC SCI THER, V6, P4, DOI [10.4172/1948-5956.1000259, DOI 10.4172/1948-5956.1000259]
   Szasz O, 2018, MED HYPOTHESES, V116, P74, DOI 10.1016/j.mehy.2018.03.015
   Szasz O, 2015, J CLIN ONCOL, V33
   Szigeti K, 2016, BMC MED IMAGING, V16, DOI 10.1186/s12880-016-0118-z
   Taha EA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184588
   TAKAHASHI T, 2009, OPEN DERMATOLOGY J, V3, P178, DOI DOI 10.2174/1874372200903010178
   Tan YX, 2007, J VIROL, V81, P6346, DOI 10.1128/JVI.00090-07
   Thaker SK, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0678-9
   Tharakan S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03045-8
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tsan MF, 2004, CELL MOL IMMUNOL, V1, P274
   Tsang YW, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1690-2
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   da Silva RMV, 2013, DERMAT RES PRACT, DOI 10.1155/2013/715829
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   Van Gool SW, 2018, AUSTIN ONCOL CASE RE, V3, P1, DOI DOI 10.1093/neuonc/noy059.323
   Vancsik T, 2019, CANCER MED-US, V8, P4292, DOI 10.1002/cam4.2330
   Vancsik T, 2018, J CANCER, V9, P41, DOI 10.7150/jca.21520
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Vincze G, 2016, J ADV BIOL, V9, P1872
   Vincze GY, 2015, BIOL MED, V7, P249
   Vincze GY, 2015, J ADV BIOL, V8, P1514
   Voronov S, 2002, FEBS LETT, V522, P77, DOI 10.1016/S0014-5793(02)02888-0
   Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang TT, 2020, EFFECTIVE HEAT INACT, P1, DOI [10.1101/2020.04.29.20085498, DOI 10.1101/2020.04.29.20085498]
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Watanabe T, 1999, J PHYSIOL-LONDON, V515, P881, DOI 10.1111/j.1469-7793.1999.881ab.x
   Weinrauch Y, 1999, ANNU REV MICROBIOL, V53, P155, DOI 10.1146/annurev.micro.53.1.155
   WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0
   Xiong LJ, 2014, INT J MOL SCI, V15, P17411, DOI 10.3390/ijms151017411
   Xu YH, 2020, J INFECTION, V80, P394, DOI 10.1016/j.jinf.2020.02.017
   Yang KL, 2016, ONCOTARGET, V7, P84082, DOI 10.18632/oncotarget.11444
   Yang XM, 2020, EMERG MICROBES INFEC, V9, P1287, DOI 10.1080/22221751.2020.1773745
   YERUSHALMI A, 1982, P NATL ACAD SCI-BIOL, V79, P4766, DOI 10.1073/pnas.79.15.4766
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 162
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD DEC 4
PY 2020
VL 11
AR 556335
DI 10.3389/fimmu.2020.556335
PG 14
WC Immunology
SC Immunology
GA PG2OC
UT WOS:000599579000001
PM 33343561
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Wang, Q
   Yang, T
   Wang, Y
AF Wang, Qiang
   Yang, Tong
   Wang, Yang
TI Reduced Treatment Sensitivity of SARS-CoV-2 After Multigenerational
   Human-to-Human Transmission
SO FRONTIERS IN PHYSICS
LA English
DT Article
DE COVID-19; human-to-human transmission; treatment sensitivity;
   generation; region
AB Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a rapidly spreading worldwide pandemic, seriously threatening global public health security. At present, there is still no vaccine or specific drug available for the virus. Therefore, epidemiological prevention and control is crucial to block further spread of the disease. In this present study, based on the public information of COVID-19 in Qingdao, Shandong Province, China, we analyzed the epidemiological characteristics and treatment effects of 60 confirmed cases. It was revealed that the hospital stay of patients were imported from Wuhan or infected by Wuhan patients was obviously shorter than that of those who were imported from other regions or infected by them. In addition, in Hubei-related patients, the earlier transmission generation, which refers to the imported patients (G0) and the first-generation infections (G1), was associated with reduced cure time. Therefore, we speculated that the treatment sensitivity of SARS-CoV-2 decreased within interpersonal transmission in the early stage of this epidemic.
C1 [Wang, Qiang; Yang, Tong; Wang, Yang] Navy 971 Hosp PLA, Qingdao, Peoples R China.
RP Wang, Y (corresponding author), Navy 971 Hosp PLA, Qingdao, Peoples R China.
EM wy971@yandex.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81972793, 81502283]; Shandong province
   Medical Health Science and Technology Project [2018WS447]; Qingdao
   Science and Technology Program for Benefiting People Special Project
   2019 [19-6-1-25-nsh, 2019WJZD170]; Qingdao Outstanding Health
   Professional Development Fund
FX This research was supported by grants from the National Natural Science
   Foundation of China (81972793, 81502283), Shandong province Medical
   Health Science and Technology Project (2018WS447), Qingdao Science and
   Technology Program for Benefiting People Special Project 2019
   (19-6-1-25-nsh, 2019WJZD170), and Qingdao Outstanding Health
   Professional Development Fund.
CR Burki T, 2020, LANCET INFECT DIS, V48, P151, DOI [10.1007/s15010-020-01409-4, DOI 10.1007/S15010-020-01409-4]
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Z, 2020, CAUTION CLIN CHARACT, V4, P32, DOI [10.1101/2020.03.03.20030833, DOI 10.1101/2020.03.03.20030833]
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Forster P, 2020, P NATL ACAD SCI USA, V117, P12524, DOI 10.1073/pnas.2007433117
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lavezzo E, 2020, NATURE, V584, P425, DOI 10.1038/s41586-020-2488-1
   Plante JA, 2020, NATURE, DOI 10.1038/s41586-020-2895-3
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Tan Y, 2020, FRONT MED-PRC, DOI 10.1007/s11684-020-0822-5
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Wang Zhishuang, 2020, IEEE Trans Cybern, VPP, DOI 10.1109/TCYB.2019.2960605
   Yin Q, 2020, APPL MATH COMPUT, V386, DOI 10.1016/j.amc.2020.125517
NR 18
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-424X
J9 FRONT PHYS-LAUSANNE
JI Front. Physics
PD DEC 4
PY 2020
VL 8
AR 578024
DI 10.3389/fphy.2020.578024
PG 6
WC Physics, Multidisciplinary
SC Physics
GA PG2JX
UT WOS:000599568100001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Gao, F
   Tao, L
   Ma, X
   Lewandowski, D
   Shu, ZQ
AF Gao, Frank, I
   Tao, Liang
   Ma, Xiao
   Lewandowski, David
   Shu, Zhiquan
TI A Study of Policies and Guidelines for Collecting, Processing, and
   Storing Coronavirus Disease 2019-Patient Biospecimens for Biobanking and
   Research
SO BIOPRESERVATION AND BIOBANKING
LA English
DT Article
DE COVID-19; biospecimens; biobanking; processing; policy; guideline
AB Biobanking has been playing a crucial role in the development of new vaccines, drugs, biotechnology, and therapeutics for the prevention and treatment of a wide range of human diseases. This puts biobanks at the forefront of responding to the ongoing worldwide outbreak of the severe pandemic, coronavirus disease 2019 (COVID-19). The leading public health institutions around the world have developed and established interim policies and guidelines for researchers and biobank staff to handle the infectious biospecimens safely and adequately from COVID-19 patients. A study of these important and complementary policies and guidelines is conducted in this study. It should be emphasized that the COVID-19 biospecimens must be collected, processed, and preserved by trained personnel equipped with right personal protective equipment to prevent the transmission of the coronavirus and ensure the specimen quality for testing and research. Six of the leading global public health organizations or institutions included in this study are the World Health Organization, the Pan American Health Organization, the U.S. Centers for Disease Control and Prevention, the Public Health England, the U.S. Food and Drug Administration, and the Office of Research at the University of California, San Francisco. In conclusion, following the recommended guidance and policies with extreme precautions is essential to ensure the quality of the collected COVID-19 biospecimens and accuracy of the conducted research or treatment, and prevent any possible transmission. Efforts from cryobiologist and biobanking engineers to optimize the protocol of COVID-19 biospecimen cryopreservation and develop the user-friendly and cost-effective devices are urgently required to meet the urgent and increased needs in the specimen biobanking and transportation.
C1 [Gao, Frank, I] Univ Sci & Technol China, Sch Publ Affairs, Hefei, Anhui, Peoples R China.
   [Tao, Liang] Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA.
   [Ma, Xiao; Shu, Zhiquan] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA.
   [Lewandowski, David] Brooks Life Sci, Global Business Dev, Chelmsford, MA USA.
   [Shu, Zhiquan] Univ Washington, Sch Engn & Technol, 1900 Commerce St, Tacoma, WA 98402 USA.
RP Shu, ZQ (corresponding author), Univ Washington, Sch Engn & Technol, 1900 Commerce St, Tacoma, WA 98402 USA.
EM zqshu@uw.edu
CR [Anonymous], COVID 19 BIOSP GUID
   [Anonymous], 2020, COVID 19 LAB INV SAM
   [Anonymous], COVID 19 SAF HANDL P
   [Anonymous], 2020, LAB GUID DET DIAGN N
   [Anonymous], 2020, DIS COMM PACK NOV CO
   [Anonymous], 2020, INT GUID CLIN SPEC C
   [Anonymous], 2020, INT GUID BIOS COVID
   [Anonymous], BIOH WAST
   [Anonymous], 2019, IS PREC
   [Anonymous], THE JAPAN TIMES
   Center for Devices and Radiological Health, 2020, POL COVID 19 TEST PU
   Costa E. C., 2011, Revista do Instituto Adolfo Lutz, V70, P106
   FAHY GM, 1986, CRYOBIOLOGY, V23, P1, DOI 10.1016/0011-2240(86)90013-1
   Gao D, 2000, ILAR J, V41, P187
   GAO DY, 1995, HUM REPROD, V10, P1109, DOI 10.1093/oxfordjournals.humrep.a136103
   Gould EA, 1999, MOL BIOTECHNOL, V13, P57, DOI 10.1385/MB:13:1:57
   HECKLY RJ, 1985, DEV IND MICROBIOL, V26, P379
   Malenovska H, 2014, J APPL MICROBIOL, V117, P1810, DOI 10.1111/jam.12654
   MAZUR P, 1970, SCIENCE, V168, P939, DOI 10.1126/science.168.3934.939
   MAZUR P, 1977, CRYOBIOLOGY, V14, P251, DOI 10.1016/0011-2240(77)90175-4
   MERYMAN HT, 1971, CRYOBIOLOGY, V8, P173, DOI 10.1016/0011-2240(71)90024-1
   Pan JJ, 2019, LANGMUIR, V35, P7560, DOI 10.1021/acs.langmuir.8b03060
   RIGHTSEL WA, 1967, CRYOBIOLOGY, V3, P423, DOI 10.1016/S0011-2240(67)80152-4
   Rowe T W, 1976, Dev Biol Stand, V36, P79
   TEDDER RS, 1995, LANCET, V346, P137, DOI 10.1016/S0140-6736(95)91207-X
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
NR 29
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1947-5535
EI 1947-5543
J9 BIOPRESERV BIOBANK
JI Biopreserv. Biobank.
PD DEC 1
PY 2020
VL 18
IS 6
BP 511
EP 516
DI 10.1089/bio.2020.0099
EA DEC 2020
PG 6
WC Cell Biology; Chemistry, Applied; Medical Laboratory Technology
SC Cell Biology; Chemistry; Medical Laboratory Technology
GA PF0CN
UT WOS:000597897400001
PM 33290126
OA Bronze
DA 2021-01-01
ER

PT J
AU Han, YJ
   Luo, ZJ
   Zhai, WL
   Zheng, Y
   Liu, H
   Wang, YR
   Wu, ED
   Xiong, F
   Ma, YM
AF Han, Yujuan
   Luo, Zujin
   Zhai, Wenliang
   Zheng, Yue
   Liu, Huan
   Wang, Yanran
   Wu, Endong
   Xiong, Fang
   Ma, Yingmin
TI Comparison of the clinical manifestations between different age groups
   of patients with overseas imported COVID-19
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY SYNDROME; CORONAVIRUS; PNEUMONIA; WUHAN
AB The current study investigated the clinical manifestations and outcomes of different age groups of patients with overseas imported COVID-19. In total, 53 COVID-19 patients admitted to the designated Beijing Xiaotangshan Hospital between March 16 and April 15 of 2020 were included. Based on the percentage of disease aggravation during hospital stay according to CT, the patients were divided into two groups: <= 40 years (group A; n = 41) and >40 years (group B; n = 12). The demographic data, epidemiological history, disease courses, potential complications, clinical symptoms, lab indices, chest CT outcomes, treatment protocols and turnovers of the two groups were compared. According to clinical typing, compared with group A, group B had a significantly greater proportion of the common type of COVID-19 (P<0.05) and greater comorbidity of type 2 diabetes (P<0.001). The two groups presented significantly different lab indices. Group B showed significantly more frequent CT abnormalities, with greater proportions of multiple lesions and bilateral lung involvement (P<0.05). During hospitalization, group B had a greater proportion of disease aggravation according to CT (P<0.01). Compared with group A, group B received a significantly greater proportion of antiviral therapy and presented a significantly greater occurrence of adverse drug reactions (P<0.05). The two groups did not significantly differ in time from admission to clinical symptom improvement or from disease onset to negative outcomes according to nucleic acid testing, the appearance of IgG or the appearance of IgM. They also did not significantly differ in length of stay. Older imported COVID-19 patients, particularly those with type 2 diabetes, showed a broader pulmonary extent and faster development of the disease, more severe pathogenetic conditions and a greater risk of developing a critically severe type. Increased attention should be given to this population in clinical practice.
C1 [Han, Yujuan] Beijing Xiaotangshan Hosp, Dept Internal Med, Beijing, Peoples R China.
   [Luo, Zujin; Ma, Yingmin] Capital Med Univ, Beijing Chao Yang Hosp, Beijing Engn Res Ctr Resp & Crit Care Med, Dept Resp & Crit Care Med,Beijing Inst Resp Med, Beijing, Peoples R China.
   [Zhai, Wenliang] Capital Med Univ, Xuanwu Hosp, Emergence Dept, Beijing, Peoples R China.
   [Zheng, Yue] Beijing Chao Yang Hosp, Dept Surg Intens Care Unit, Beijing, Peoples R China.
   [Liu, Huan] Beijing Xiaotangshan Hosp, Dept Hlth Educ, Beijing, Peoples R China.
   [Wang, Yanran] Childrens Hosp, Capital Inst Pediat, Dept Nephrol, Beijing, Peoples R China.
   [Wu, Endong] Capital Med Univ, Beijing Chest Hosp, Crit Care Med Dept, Beijing, Peoples R China.
   [Xiong, Fang] Capital Med Univ, Beijing Youan Hosp, Oncol Dept, Beijing, Peoples R China.
RP Ma, YM (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Beijing Engn Res Ctr Resp & Crit Care Med, Dept Resp & Crit Care Med,Beijing Inst Resp Med, Beijing, Peoples R China.
EM mayingminicu@sina.com
FU National Key Research and Development Program of China [2019YFC0121700];
   Beijing Hospitals Authority Clinical Medicine Development of Special
   Funding Support [XMLX201709]; Beijing Hospitals Authority Youth
   Programme [QML20180303]
FX The study was funded by the National Key Research and Development
   Program of China (Dr Ma; No. 2019YFC0121700), Beijing Hospitals
   Authority Clinical Medicine Development of Special Funding Support (Dr
   Ma; No. XMLX201709), and Beijing Hospitals Authority Youth Programme (Dr
   Luo; No. QML20180303). The funders had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim H, 2020, EUR RADIOL, V30, P3266, DOI 10.1007/s00330-020-06748-2
   Koo HJ, 2018, RADIOGRAPHICS, V38, P719, DOI 10.1148/rg.2018170048
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lei JQ, 2020, RADIOLOGY, V295, P18, DOI 10.1148/radiol.2020200236
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM NOV COR
   Otter JA, 2016, J HOSP INFECT, V92, P235, DOI 10.1016/j.jhin.2015.08.027
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   SS V et al. on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, 2020, CIRCULATION, V2020, pe1
   World Health Organization (WHO), 2020, NOV COR 2019 NCOV AD
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P167, DOI 10.3760/cma.j.issn.1001-0939.2020.03.003
NR 23
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 4
PY 2020
VL 15
IS 12
AR e0243347
DI 10.1371/journal.pone.0243347
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PC7AS
UT WOS:000597150200007
PM 33275609
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, PP
   Huang, ZJ
   Yin, MZ
   Liu, C
   Chen, X
   Pan, PH
   Kuang, YH
AF Liu, Panpan
   Huang, Zhijun
   Yin, Mingzhu
   Liu, Chun
   Chen, Xiang
   Pan, Pinhua
   Kuang, Yehong
TI Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients
   with COVID-19: A structured summary of a study protocol for a Pilot
   Randomized Controlled Trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized controlled trial; protocol; Ixekizumab; IL-17A;
   Safety; Efficacy
AB Objectives: A severe epidemic of COVID-19 has broken out in China and has become a major global public health event. We focus on the Acute Respiratory Distress Syndrome (ARDS)-like changes and overactivation of Th17 cells (these produce cytokines) in patients with COVID-19. We aim to explore the safety and efficacy of ixekizumab (an injectable drug for the treatment of autoimmune diseases) to prevent organ injury caused by the immune response to COVID-19. Ixekizumab is a human monoclonal antibody that binds to interleukin-17A and inhibits the release of pro-inflammatory cytokines and chemokines.
   Trial design: The experiment is divided into two stages. In the first stage, the open trial, 3 patients with COVID-19 are treated with ixekizumab, and the safety and efficacy are observed for 7 days. In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. This is a two-center, open-label, randomized controlled pilot trial with 2-arm parallel group design (1:1 ratio).
   Participants: Patients with COVID-19 aged 18-75 with increased Interleukin (IL)-6 levels will be enrolled, but patients with severe infections requiring intensive care will be excluded. The trial will be undertaken in two centers. The first stage is carried out in Xiangya Hospital of Central South University, and the second stage is carried out simultaneously in the Third Xiangya Hospital of Central South University.
   Intervention and comparator: In the first stage, three subjects are given ixekizumab ("Taltz") (80 mg/ml, 160 mg as a single hypodermic injection) and antiviral therapy (a-interferon (administer 5 million U by aerosol inhalation twice daily), lopinavir/ritonavir (administer 100mg by mouth twice daily, for the course of therapy no more than 10 days), chloroquine (administer 500mg by mouth twice daily, for the course of therapy no more than 10 days), ribavirin (administer 500mg by intravenous injection two to three times a day, for the course of therapy no more than 10 days), or arbidol (administer 200mg by mouth three times a day, for the course of therapy no more than 10 days), but not more than 3 types). The treatment course of the first stage is 7 days. In the second stage, 40 randomized patients will receive the following treatments--Group 1: ixekizumab (80 mg/ml, 160 mg as a single hypodermic injection) with antiviral therapy (the same scheme as in the first stage); Group 2: antiviral therapy alone (the same scheme as in the first stage). The length of the second treatment course is 14 days.
   Main outcomes: The primary outcome is a change in pulmonary CT severity score (an imaging tool for assessing COVID-19, which scores on the basis of all abnormal areas involved). Pulmonary CT severity score is assessed on the 7th day, 14th day, or at discharge.
   Randomisation: In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. The eLite random system of Nanjing Medical University is used for randomization.
   Blinding (masking): The main efficacy indicator, the CT results, will be evaluated by the third-party blinded and independent research team.
   Numbers to be randomised (sample size): In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days.
   Trial Status: Trial registration number is ChiCTR2000030703 (version 1.7 as of March 19, 2020). The recruitment is ongoing, and the date recruitment was initiated in June 2020. The anticipated date of the end of data collection is June 2021.
   Trial registration: The name of the trial register is the Chinese Clinical Trial Registry. The trial registration number is ChiCTR2000030703 (http://www.chictr.org.cn/). The date of trial registration is 10 March 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
C1 [Liu, Panpan; Yin, Mingzhu; Chen, Xiang; Kuang, Yehong] Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Peoples R China.
   [Liu, Panpan; Yin, Mingzhu; Chen, Xiang; Kuang, Yehong] Hunan Key Lab Skin Canc & Psoriasis, Changsha, Peoples R China.
   [Liu, Panpan; Yin, Mingzhu; Chen, Xiang; Kuang, Yehong] Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Skin Hlth & Dis, 87 XiangYa Rd, Changsha 410008, Hunan, Peoples R China.
   [Huang, Zhijun] Cent South Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Changsha, Peoples R China.
   [Liu, Chun] Cent South Univ, Xiangya Hosp 3, Dept Resp & Crit Care Med, Changsha, Peoples R China.
   [Chen, Xiang] Cent South Univ, Xiangya Hosp, Gerontol Ctr, Changsha, Peoples R China.
   [Pan, Pinhua] Cent South Univ, Xiangya Hosp, Resp Dept, 87 XiangYa Rd, Changsha 410008, Hunan, Peoples R China.
RP Kuang, YH (corresponding author), Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Peoples R China.; Pan, PH (corresponding author), Cent South Univ, Xiangya Hosp, Resp Dept, 87 XiangYa Rd, Changsha 410008, Hunan, Peoples R China.
EM pinhuapan668@126.com; yh_927@126.com
FU key project of the National Science Foundation [81430075, 81830096];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81573049]; Key R&D Program of Hunan Province
   [2018SK2082]; National key RD program [2018YFC0117004]; Emergency
   Project of Prevention and Control for COVID-19 of Central South
   University [50270100]; Hunan Provincial Innovation Foundation For
   Postgraduate [2020zzts251]
FX This work was supported by the key project of the National Science
   Foundation (81430075, 81830096), National Natural Science Foundation of
   China (81573049), Key R&D Program of Hunan Province (2018SK2082),
   National key R&D program (2018YFC0117004), Emergency Project of
   Prevention and Control for COVID-19 of Central South University
   (50270100), and Hunan Provincial Innovation Foundation For Postgraduate
   (2020zzts251). The sponsors have no role in study design, collection,
   analysis, interpretation of data, and writing the manuscript.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 4
PY 2020
VL 21
IS 1
AR 999
DI 10.1186/s13063-020-04925-8
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PC8ZB
UT WOS:000597286300003
PM 33276811
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, DY
   Wang, J
   Dokholyan, NV
AF Zhang, Dong Yan
   Wang, Jian
   Dokholyan, Nikolay, V
TI Prefusion spike protein stabilization through computational mutagenesis
SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article; Early Access
DE computational mutagenesis; coronavirus; protein stabilization; spike
   protein
ID DISCRETE MOLECULAR-DYNAMICS; PREDICTION; STABILITY; EVOLUTION; MUTATION;
   BINDING; VIRUS; SOD1; ACE2
AB A novel severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2) has emerged as a human pathogen, causing global pandemic and resulting in over 400 000 deaths worldwide. The surface spike protein of SARS-CoV-2 mediates the process of coronavirus entry into human cells by binding angiotensin-converting enzyme 2 (ACE2). Due to the critical role in viral-host interaction and the exposure of spike protein, it has been a focus of most vaccines' developments. However, the structural and biochemical studies of the spike protein are challenging because it is thermodynamically metastable. Here, we develop a new pipeline that automatically identifies mutants that thermodynamically stabilize the spike protein. Our pipeline integrates bioinformatics analysis of conserved residues, motion dynamics from molecular dynamics simulations, and other structural analysis to identify residues that significantly contribute to the thermodynamic stability of the spike protein. We then utilize our previously developed protein design tool, Eris, to predict thermodynamically stabilizing mutations in proteins. We validate the ability of our pipeline to identify protein stabilization mutants through known prefusion spike protein mutants. We finally utilize the pipeline to identify new prefusion spike protein stabilization mutants.
C1 [Zhang, Dong Yan; Wang, Jian; Dokholyan, Nikolay, V] Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.
   [Dokholyan, Nikolay, V] Penn State Coll Med, Dept Biochem, Hershey, PA 17033 USA.
   [Dokholyan, Nikolay, V] Penn State Coll Med, Dept Mol Biol, Hershey, PA 17033 USA.
RP Dokholyan, NV (corresponding author), Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.
EM dokh@psu.edu
RI Dokholyan, Nikolay/B-2238-2009
OI Dokholyan, Nikolay/0000-0002-8225-4025
FU National Institutes for HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1R35 GM134864]; Huck
   Institutes of the Life Sciences; Passan Foundation; National Center for
   Advancing Translational Sciences, National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1 TR002014]
FX We acknowledge support from the National Institutes for Health 1R35
   GM134864, The Huck Institutes of the Life Sciences, and the Passan
   Foundation. The project described was also supported by the National
   Center for Advancing Translational Sciences, National Institutes of
   Health, through Grant UL1 TR002014. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NIH.
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bloom JD, 2005, CURR OPIN STRUC BIOL, V15, P447, DOI 10.1016/j.sbi.2005.06.004
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brodie NI, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700479
   Cascella M, 2020, STATPEARLS
   Convertino M, 2016, METHODS MOL BIOL, V1414, P23, DOI 10.1007/978-1-4939-3569-7_2
   Dagliyan O, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06531-4
   Dagliyan O, 2016, SCIENCE, V354, P1441, DOI 10.1126/science.aah3404
   Dagliyan O, 2013, P NATL ACAD SCI USA, V110, P6800, DOI 10.1073/pnas.1218319110
   DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Ding F, 2008, STRUCTURE, V16, P1010, DOI 10.1016/j.str.2008.03.013
   Ding F, 2008, RNA, V14, P1164, DOI 10.1261/rna.894608
   Ding F, 2006, PLOS COMPUT BIOL, V2, P725, DOI 10.1371/journal.pcbi.0020085
   Dokholyan NV, 2016, CHEM REV, V116, P6463, DOI 10.1021/acs.chemrev.5b00544
   Dokholyan NV, 1998, FOLD DES, V3, P577, DOI 10.1016/S1359-0278(98)00072-8
   Dokholyan NV, 2001, J MOL BIOL, V312, P289, DOI 10.1006/jmbi.2001.4949
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Fay JM, 2016, STRUCTURE, V24, P1898, DOI 10.1016/j.str.2016.08.011
   FLAVELL RA, 1975, P NATL ACAD SCI USA, V72, P367, DOI 10.1073/pnas.72.1.367
   Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163
   Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Heffernan R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11476
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li B, 2018, J BIOL CHEM, V293, P4752, DOI 10.1074/jbc.RA117.000163
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Michaud-Agrawal N, 2011, J COMPUT CHEM, V32, P2319, DOI 10.1002/jcc.21787
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, P1026
   Proctor EA, 2016, CURR OPIN STRUC BIOL, V37, P9, DOI 10.1016/j.sbi.2015.11.001
   Proctor EA, 2016, P NATL ACAD SCI USA, V113, P614, DOI 10.1073/pnas.1516725113
   Proctor EA, 2011, WIRES COMPUT MOL SCI, V1, P80, DOI 10.1002/wcms.4
   Repici A, 2020, GASTROINTEST ENDOSC, V92, P192, DOI 10.1016/j.gie.2020.03.019
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Shang J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008392
   Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606
   SHORTLE D, 1981, ANNU REV GENET, V15, P265, DOI 10.1146/annurev.ge.15.120181.001405
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Torres MP, 2009, J BIOL CHEM, V284, P8931, DOI 10.1074/jbc.M809058200
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wang J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17618-2
   Watanabe Y, 2019, BBA-GEN SUBJECTS, V1863, P1480, DOI 10.1016/j.bbagen.2019.05.012
   WATANABE Yasunori, 2020, NATURE COMMUNICATION, V11, P1
   Wong TS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh028
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yin S, 2007, STRUCTURE, V15, P1567, DOI 10.1016/j.str.2007.09.024
   Yin SY, 2007, NAT METHODS, V4, P466, DOI 10.1038/nmeth0607-466
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhu C, 2019, PROTEINS, V87, P878, DOI 10.1002/prot.25751
   Zhu C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08876-w
   Zhu C, 2018, P NATL ACAD SCI USA, V115, P4661, DOI 10.1073/pnas.1800187115
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 61
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0887-3585
EI 1097-0134
J9 PROTEINS
JI Proteins
DI 10.1002/prot.26025
EA DEC 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA PB0AD
UT WOS:000595989500001
PM 33231324
OA Bronze
DA 2021-01-01
ER

PT J
AU Cagno, V
   Magliocco, G
   Tapparel, C
   Daali, Y
AF Cagno, Valeria
   Magliocco, Gaelle
   Tapparel, Caroline
   Daali, Youssef
TI The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro
SO BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
LA English
DT Article; Early Access
DE COVID&#8208; 19; nilotinib; SARS&#8208; CoV&#8208; 2; tyrosine kinases
   inhibitors
ID RESPIRATORY SYNDROME CORONAVIRUS
AB Since the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the end of 2019, no vaccine has been approved to counter this infection and the available treatments are mainly directed against the immune pathology caused by the infection. The coronavirus disease 2019 (COVID-19) is currently causing a worldwide pandemic, pointing the urgent need for effective treatment. In such emergency, drug repurposing presents the best option for a rapid antiviral response. We assess here the in vitro activity of nilotinib, imatinib and dasatinib, three Abl tyrosine kinase inhibitors, against SARS-CoV-2. Although the last two compounds do not show antiviral efficacy, we observe inhibition with nilotinib in Vero-E6 cells and Calu-3 cells with EC50s of 1.44 mu M and 3.06 mu M, respectively. These values are close to the mean peak concentration of nilotinib observed at steady state in serum, making this compound a potential candidate for treatment of COVID-19 in vivo.
C1 [Cagno, Valeria; Tapparel, Caroline] Univ Geneva, Dept Microbiol & Mol Med, Fac Med, Geneva, Switzerland.
   [Magliocco, Gaelle; Daali, Youssef] Geneva Univ Hosp, Div Clin Pharmacol & Toxicol, Geneva, Switzerland.
   [Magliocco, Gaelle; Daali, Youssef] Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Geneva, Switzerland.
   [Daali, Youssef] Swiss Ctr Appl Human Toxicol, Geneva, Switzerland.
RP Daali, Y (corresponding author), Geneva Univ Hosp, Div Clin Pharmacol & Toxicol, Geneva, Switzerland.
EM youssef.daali@hcuge.ch
OI Youssef, Daali/0000-0002-8391-9383
FU Fondation privee des HUG; Carigest Foundation
FX The study was funded thanks to the financial support of the "Fondation
   privee des HUG" and the Carigest Foundation to CT.
CR Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Deganutti G, 2020, J COMPUT AID MOL DES, DOI 10.1007/s10822-020-00356-4
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   European Medicines Agency, TAS
   Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104
   Lisi L, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114169
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Tveden-Nyborg P, 2018, BASIC CLIN PHARMACOL, V123, P233, DOI 10.1111/bcpt.13059
   Zhao HL, 2020, LEUKEMIA, V34, P3085, DOI 10.1038/s41375-020-01045-9
NR 11
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-7835
EI 1742-7843
J9 BASIC CLIN PHARMACOL
JI Basic Clin. Pharmacol. Toxicol.
DI 10.1111/bcpt.13537
EA DEC 2020
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA PA3UW
UT WOS:000595565400001
PM 33232578
OA Bronze
DA 2021-01-01
ER

PT J
AU Cardozo, T
   Veazey, R
AF Cardozo, Timothy
   Veazey, Ronald
TI Informed consent disclosure to vaccine trial subjects of risk of
   COVID-19 vaccines worsening clinical disease
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article; Early Access
ID SARS CORONAVIRUS
AB Aims of the study Patient comprehension is a critical part of meeting medical ethics standards of informed consent in study designs. The aim of the study was to determine if sufficient literature exists to require clinicians to disclose the specific risk that COVID-19 vaccines could worsen disease upon exposure to challenge or circulating virus.
   Methods used to conduct the study Published literature was reviewed to identify preclinical and clinical evidence that COVID-19 vaccines could worsen disease upon exposure to challenge or circulating virus. Clinical trial protocols for COVID-19 vaccines were reviewed to determine if risks were properly disclosed.
   Results of the study COVID-19 vaccines designed to elicit neutralising antibodies may sensitise vaccine recipients to more severe disease than if they were not vaccinated. Vaccines for SARS, MERS and RSV have never been approved, and the data generated in the development and testing of these vaccines suggest a serious mechanistic concern: that vaccines designed empirically using the traditional approach (consisting of the unmodified or minimally modified coronavirus viral spike to elicit neutralising antibodies), be they composed of protein, viral vector, DNA or RNA and irrespective of delivery method, may worsen COVID-19 disease via antibody-dependent enhancement (ADE). This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVID-19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials.
   Conclusions drawn from the study and clinical implications The specific and significant COVID-19 risk of ADE should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.
C1 [Cardozo, Timothy] NYU, Langone Hlth, Dept Biochem & Mol Pharmacol, 550 First Ave,MSB 222, New York, NY 10016 USA.
   [Veazey, Ronald] Tulane Univ, Div Comparat Pathol, Dept Pathol & Lab Med, Sch Med,Tulane Natl Primate Res Ctr, Covington, LA USA.
RP Cardozo, T (corresponding author), NYU, Langone Hlth, Dept Biochem & Mol Pharmacol, 550 First Ave,MSB 222, New York, NY 10016 USA.
EM cardot01@nyumc.org
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R21AI157604]
FX Supported by NIH award R21AI157604 (to TC).
CR Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Boyoglu-Barnum S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01675
   Chen WH, 2020, HUM VACC IMMUNOTHER, V16, P1239, DOI 10.1080/21645515.2020.1740560
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Huisman W, 2009, VACCINE, V27, P505, DOI 10.1016/j.vaccine.2008.10.087
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Liu ZL, 2020, CLIN CHEM, V66, P1102, DOI 10.1093/clinchem/hvaa137
   Mansbach RA, 2020, BIORXIV
   McNamara D, 2020, 3 MAJOR COVID VACCIN
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Piccoli L, 2020, CELL, VS0092-8674, P31234
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wendler D, 2013, AM J BIOETHICS, V13, P3, DOI 10.1080/15265161.2013.851578
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
NR 20
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
AR e13795
DI 10.1111/ijcp.13795
EA DEC 2020
PG 3
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA PA2LP
UT WOS:000595465600001
PM 33113270
OA Green Published
DA 2021-01-01
ER

PT J
AU Chan, LN
AF Chan, Lingtak-Neander
TI Forty-fourth ASPEN Presidential Address: "The 2020 Overture: A New Tune
   for the Future"
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article; Early Access
DE American Society for Parenteral and Enteral Nutrition; antioxidants;
   binary thinking; burnout; enteral nutrition; parenteral nutrition;
   premature factulation
ID INTENSIVE INSULIN THERAPY; TOTAL PARENTERAL-NUTRITION; GASTRIC RESIDUAL
   VOLUME; CRITICALLY-ILL PATIENTS; VITAMIN-C; SEPTIC SHOCK; MECHANICAL
   VENTILATION; ENTERAL NUTRITION; BURNOUT; THIAMINE
AB The provision of safe nutrition care to patients is the fundamental vision of the American Society for Parenteral and Enteral Nutrition (ASPEN). Yet we are facing important challenges in our field and society, requiring us to reflect, rethink, and adjust to make new breakthroughs to meet the needs for the future. In developing new plans to address these challenges, we must focus on 2 critical elements: people and the scientific process. Government and organizations cannot carry on their missions without people. But with the challenges of healthcare finance, biotechnology disruption, the desire to facilitate knowledge transfer and now the impact of the global pandemic, we need to develop a forward-thinking and sustainable approach to connect people and foster continued learning. Burnout is a recognized occupational problem that affects providers and researchers across all disciplines. The coronavirus disease 2019 pandemic has amplified the challenges associated with burnout. Supporting the needs and promoting the well-being of people, therefore, are critical to move forward successfully. At the same time, the scientific advances in our field rely on sound scientific principles and integrity. Information overload, pressure to produce immediate outcomes (such as cost-saving initiatives), and misinformation can compromise the scientific process and research evidence. The two common missteps that affect researchers, clinicians, and administrators include premature factulation and binary thinking. We will discuss how these missteps can occur and the approaches to minimize their influence in making sound decisions and policies to meet the future's needs.
C1 [Chan, Lingtak-Neander] Univ Washington, Sch Pharm, Dept Pharm, Interdisciplinary Fac Nutr Sci, Seattle, WA 98195 USA.
RP Chan, LN (corresponding author), Univ Washington, Sch Pharm, Dept Pharm, Interdisciplinary Fac Nutr Sci,Pharm, Box 357630,1959 NE Pacific St, Seattle, WA 98195 USA.
EM neander@uw.edu
CR Andrews PJD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1542
   Angstwurm MWA, 2007, CRIT CARE MED, V35, P118, DOI 10.1097/01.CCM.0000251124.83436.0E
   [Anonymous], ASPEN 2021 NUTR SCI
   Arabi YM, 2008, CRIT CARE MED, V36, P3190, DOI 10.1097/CCM.0b013e31818f21aa
   Ball AM, 2020, AM J HEALTH-SYST PH, V77, P790, DOI 10.1093/ajhp/zxaa043
   Berger MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6981
   Bharal Mina, 2019, J Intensive Care Soc, V20, P299, DOI 10.1177/1751143719847321
   Brierley-Hobson S, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2388-7
   Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716
   Center for the Disease Control and Prevention, 2020, DECR INFL ACT COVID
   Chow Y, 2018, ADV MED SCI-POLAND, V63, P192, DOI 10.1016/j.advms.2017.11.004
   Coloretti I, 2020, J CRIT CARE, V59, P37, DOI 10.1016/j.jcrc.2020.04.014
   Dickinson KJ, 2020, AM J SURG, VS0002-9610, P30520
   Duke NN, 2020, TEACH LEARN MED, V32, P61, DOI 10.1080/10401334.2019.1638263
   Dyrbye LN, 2019, BMC NURS, V18, DOI 10.1186/s12912-019-0382-7
   Dyrbye LN, 2014, ACAD MED, V89, P443, DOI 10.1097/ACM.0000000000000134
   Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625
   Forceville X, 2007, CRIT CARE, V11, DOI 10.1186/cc5960
   Fujii T, 2020, JAMA-J AM MED ASSOC, V323, P423, DOI 10.1001/jama.2019.22176
   Garton E., 2017, HARVARD BUS REV
   Gates MC, 2021, NEW ZEAL VET J, V69, P27, DOI 10.1080/00480169.2020.1803156
   Gingras J, 2010, J HUM NUTR DIET, V23, P238, DOI 10.1111/j.1365-277X.2010.01062.x
   Hager DN, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3254-2
   Hansten PD, 2009, PREMATURE FACTULATIO
   Haskins IN, 2017, JPEN-PARENTER ENTER, V41, P607, DOI 10.1177/0148607115617441
   Hemila H, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-0432-y
   Heyland DK, 1998, JAMA-J AM MED ASSOC, V280, P2013, DOI 10.1001/jama.280.23.2013
   Holyk A, 2020, JPEN-PARENTER ENTER, V44, P1038, DOI 10.1002/jpen.1727
   Honiden S, 2015, SEMIN RESP CRIT CARE, V36, P859, DOI 10.1055/s-0035-1565253
   Hsu CW, 2011, WORLD J GASTROENTERO, V17, P2007, DOI 10.3748/wjg.v17.i15.2007
   Hudson EP, 2019, CRIT CARE RESUSC, V21, P236
   Jeejeebhoy KN, 2001, AM J CLIN NUTR, V74, P160
   Kolodny ZB, 1996, AIDS PATIENT CARE ST, V10, P368, DOI 10.1089/apc.1996.10.368
   Koohestani H, 2020, J EDUC HEALTH PROMOT, V9, DOI 10.4103/jehp.jehp_224_20
   Kraus S, 2020, AM J HEALTH-SYST PH, V77, P781, DOI 10.1093/ajhp/zxaa042
   Krebs ED, 2018, AM J SURG, V216, P1155, DOI 10.1016/j.amjsurg.2018.05.016
   Laramee J, 2019, CAN FAM PHYSICIAN, V65, P730
   Leclerc Quentin J, 2020, Wellcome Open Res, V5, P83, DOI 10.12688/wellcomeopenres.15889.1
   Lemaire JB, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3360
   Lemaire JB, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-208
   Lessing Juan N, 2020, Acad Med, V95, P1834, DOI 10.1097/ACM.0000000000003680
   Marik PE, 2017, CHEST, V151, P1229, DOI 10.1016/j.chest.2016.11.036
   McClave SA, 2015, JPEN-PARENTER ENTER, V39, P707, DOI 10.1177/0148607114540004
   Mehta NM, 2020, JPEN-PARENTER ENTER, V44, P567, DOI 10.1002/jpen.1810
   Melnick ER, 2020, MAYO CLIN PROC, V95, P476, DOI 10.1016/j.mayocp.2019.09.024
   Melnyk BM, 2020, WORLDV EVID-BASED NU, V17, P2, DOI 10.1111/wvn.12416
   Mishra V, 2007, CLIN NUTR, V26, P41, DOI 10.1016/j.clnu.2006.10.003
   Montejo JC, 2010, INTENS CARE MED, V36, P1386, DOI 10.1007/s00134-010-1856-y
   Moskowitz A, 2020, JAMA-J AM MED ASSOC, V324, P642, DOI 10.1001/jama.2020.11946
   Moss J, 2019, BURNOUT IS YOUR WORK
   Nathens AB, 2002, ANN SURG, V236, P814, DOI 10.1097/00000658-200212000-00014
   National Academy of Medicine, 2019, TAK ACT CLIN BURN SY
   Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2
   Prest PJ, 2020, JPEN-PARENTER ENTER, V44, P880, DOI 10.1002/jpen.1712
   Protano C, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8590430
   Rabatin J, 2016, J PRIM CARE COMMUNIT, V7, P41, DOI 10.1177/2150131915607799
   Reignier J, 2013, JAMA-J AM MED ASSOC, V309, P249, DOI 10.1001/jama.2012.196377
   Skeff K, 2010, STRATOS G METHODS TE
   Swamy L, 2020, AM J CRIT CARE, V29, P380, DOI 10.4037/ajcc2020831
   Swensen S, NEJM CATALYST LEADER, DOI 10.1056/CAT.18.0209
   Tajirian T, 2020, J MED INTERNET RES, V22, DOI 10.2196/19274
   Valenta J, 2011, INTENS CARE MED, V37, P808, DOI 10.1007/s00134-011-2153-0
   Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521
   Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
   Weintraub K, US TODAY
   West CP, 2018, J INTERN MED, V283, P516, DOI 10.1111/joim.12752
   Wigert B, 2018, EMPLOYEE BURNOUT 1
   World Health Organization, 2020, WEEKL COR DIS COVID
   Yedidia MJ, 2014, J NURS EDUC, V53, P569, DOI 10.3928/01484834-20140922-03
NR 69
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
DI 10.1002/jpen.2044
EA DEC 2020
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA PA2LJ
UT WOS:000595464900001
PM 33180961
DA 2021-01-01
ER

PT J
AU Sourij, H
   Aziz, F
   Brauer, A
   Ciardi, C
   Clodi, M
   Fasching, P
   Karolyi, M
   Kautzky-Willer, A
   Klammer, C
   Malle, O
   Oulhaj, A
   Pawelka, E
   Peric, S
   Ress, C
   Sourij, C
   Stechemesser, L
   Stingl, H
   Stulnig, T
   Tripolt, N
   Wagner, M
   Wolf, P
   Zitterl, A
   Kaser, S
AF Sourij, Harald
   Aziz, Faisai
   Braeuer, Alexander
   Ciardi, Christian
   Clodi, Martin
   Fasching, Peter
   Karolyi, Mario
   Kautzky-Willer, Alexandra
   Klammer, Carmen
   Malle, Oliver
   Oulhaj, Abderrahim
   Pawelka, Erich
   Peric, Slobodan
   Ress, Claudia
   Sourij, Caren
   Stechemesser, Lars
   Stingl, Harald
   Stulnig, Thomas
   Tripolt, Norbert
   Wagner, Michael
   Wolf, Peter
   Zitterl, Andreas
   Kaser, Susanne
CA COVID 19 Diabet Austria Study Grp
TI COVID-19 fatality prediction in people with diabetes and prediabetes
   using a simple score upon hospital admission
SO DIABETES OBESITY & METABOLISM
LA English
DT Article; Early Access
DE coronavirus infection; diabetes; prediabetic state
AB Aim To assess predictors of in-hospital mortality in people with prediabetes and diabetes hospitalized for COVID-19 infection and to develop a risk score for identifying those at the greatest risk of a fatal outcome.
   Materials and Methods A combined prospective and retrospective, multicentre, cohort study was conducted at 10 sites in Austria in 247 people with diabetes or newly diagnosed prediabetes who were hospitalized with COVID-19. The primary outcome was in-hospital mortality and the predictor variables upon admission included clinical data, co-morbidities of diabetes or laboratory data. Logistic regression analyses were performed to identify significant predictors and to develop a risk score for in-hospital mortality.
   Results The mean age of people hospitalized (n = 238) for COVID-19 was 71.1 +/- 12.9 years, 63.6% were males, 75.6% had type 2 diabetes, 4.6% had type 1 diabetes and 19.8% had prediabetes. The mean duration of hospital stay was 18 +/- 16 days, 23.9% required ventilation therapy and 24.4% died in the hospital. The mortality rate in people with diabetes was numerically higher (26.7%) compared with those with prediabetes (14.9%) but without statistical significance (P = .128). A score including age, arterial occlusive disease, C-reactive protein, estimated glomerular filtration rate and aspartate aminotransferase levels at admission predicted in-hospital mortality with a C-statistic of 0.889 (95% CI: 0.837-0.941) and calibration of 1.000 (P = .909).
   Conclusions The in-hospital mortality for COVID-19 was high in people with diabetes but not significantly different to the risk in people with prediabetes. A risk score using five routinely available patient variables showed excellent predictive performance for assessing in-hospital mortality.
C1 [Sourij, Harald; Aziz, Faisai; Malle, Oliver; Tripolt, Norbert] Med Univ Graz, Clin Div Endocrinol & Diabetol, Graz, Austria.
   [Sourij, Harald; Aziz, Faisai] Ctr Biomarker Res Med CBMed, Graz, Austria.
   [Braeuer, Alexander; Fasching, Peter] Wilhelminen Hosp Vienna, Med Div Endocrinol Rheumatol & Acute Geriatr, Vienna, Austria.
   [Ciardi, Christian] St Vinzenz Hosp Zams, Clin Div Internal Med Endocrinol Diabetol & Metab, Zams, Austria.
   [Clodi, Martin; Klammer, Carmen] Konventhosp Barmherzige Bruder Linz, Clin Div Internal Med, Linz, Austria.
   [Karolyi, Mario; Pawelka, Erich] SMZ Sud KFJ Hosp Vienna, Med Div Infectiol 4, Vienna, Austria.
   [Kautzky-Willer, Alexandra; Wolf, Peter] AKH Vienna, Clin Div Endocrinol & Diabetol & Metab Dis, Vienna, Austria.
   [Oulhaj, Abderrahim] United Arab Emirates Univ, Inst Publ Hlth, Coll Med & Hlth Sci, Al Ain, U Arab Emirates.
   [Peric, Slobodan; Stulnig, Thomas; Zitterl, Andreas] Vienna Hlth Care Grp, Dept 3, Vienna, Austria.
   [Peric, Slobodan; Stulnig, Thomas; Zitterl, Andreas] Vienna Hlth Care Grp, Karl Landsteiner Inst Metab Dis & Nephrol, Clin Hietzing, Vienna, Austria.
   [Ress, Claudia; Kaser, Susanne] Med Univ Innsbruck, Dept Internal Med 1, Innsbruck, Austria.
   [Sourij, Caren] Med Univ Graz, Clin Div Cardiol, Graz, Austria.
   [Stechemesser, Lars] Paracelsus Med Univ, Dept Internal Med 1, Salzburg, Austria.
   [Stingl, Harald; Wagner, Michael] Hosp Melk, Clin Div Internal Med, Melk, Austria.
RP Sourij, H (corresponding author), Med Univ Graz, Div Endocrinol & Diabetol, Auenbruggerpl 15, A-8036 Graz, Austria.
EM ha.sourij@medunigraz.at
RI ; Aziz, Faisal/O-3263-2016
OI Karolyi, Mario/0000-0002-9870-2339; Aziz, Faisal/0000-0002-0109-2969;
   Kautzky-Willer, Alexandra/0000-0002-3520-4105; Wolf,
   Peter/0000-0001-6779-734X
FU NovoNordiskNovo Nordisk; NovartisNovartis; Sanofi;
   AstraZenecaAstraZeneca; Boehringer IngelheimBoehringer Ingelheim
FX This study was supported by unrestricted research grants to the Austrian
   Diabetes Association from NovoNordisk, Novartis, Sanofi, AstraZeneca and
   Boehringer Ingelheim.
CR Abbasi-Oshaghi E, 2020, INT J SURG, V79, P143, DOI 10.1016/j.ijsu.2020.05.018
   Barron E, 2020, LANCET DIABETES ENDO, V8, P813, DOI 10.1016/S2213-8587(20)30272-2
   Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x
   Chen YC, 2020, DIABETES CARE, V43, P1399, DOI 10.2337/dc20-0660
   Coppelli A, 2020, DIABETES CARE, V43, P2345, DOI 10.2337/dc20-1380
   Farahani Farhad, 2020, Int J Surg, V83, P1, DOI 10.1016/j.ijsu.2020.08.048
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harreiter J, 2019, WIEN KLIN WOCHENSCHR, V131, P6, DOI 10.1007/s00508-019-1450-4
   Holman N, 2020, LANCET DIABETES ENDO, V8, P823, DOI 10.1016/S2213-8587(20)30271-0
   Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507
   Katulanda P, 2020, DIABETOLOGIA, V63, P1440, DOI 10.1007/s00125-020-05164-x
   Klein SJ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03139-3
   Pearson-Stuttard J, 2016, LANCET DIABETES ENDO, V4, P148, DOI 10.1016/S2213-8587(15)00379-4
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shi Q, 2020, DIABETES CARE, V43, P1382, DOI 10.2337/dc20-0598
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 18
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
EI 1463-1326
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
DI 10.1111/dom.14256
EA DEC 2020
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA PA3MV
UT WOS:000595543300001
PM 33200501
OA Other Gold
DA 2021-01-01
ER

PT J
AU Korn, SM
   Lambertz, R
   Furtig, B
   Hengesbach, M
   Lohr, F
   Richter, C
   Schwalbe, H
   Weigand, JE
   Wohnert, J
   Schlundt, A
AF Korn, Sophie M.
   Lambertz, Roderick
   Fuertig, Boris
   Hengesbach, Martin
   Loehr, Frank
   Richter, Christian
   Schwalbe, Harald
   Weigand, Julia E.
   Woehnert, Jens
   Schlundt, Andreas
TI H-1, C-13, and N-15 backbone chemical shift assignments of the
   C-terminal dimerization domain of SARS-CoV-2 nucleocapsid protein
SO BIOMOLECULAR NMR ASSIGNMENTS
LA English
DT Article; Early Access
DE SARS-CoV-2; Structural protein; Nucleocapsid; Dimerization domain;
   Solution NMR-spectroscopy; Protein druggability; Covid19-NMR
ID TRIPLE-RESONANCE EXPERIMENTS; NMR-SPECTROSCOPY; TROSY; ENHANCEMENT;
   RELAXATION; COHERENCE; SOFTWARE
AB The current outbreak of the highly infectious COVID-19 respiratory disease is caused by the novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). To fight the pandemic, the search for promising viral drug targets has become a cross-border common goal of the international biomedical research community. Within the international Covid19-NMR consortium, scientists support drug development against SARS-CoV-2 by providing publicly available NMR data on viral proteins and RNAs. The coronavirus nucleocapsid protein (N protein) is an RNA-binding protein involved in viral transcription and replication. Its primary function is the packaging of the viral RNA genome. The highly conserved architecture of the coronavirus N protein consists of an N-terminal RNA-binding domain (NTD), followed by an intrinsically disordered Serine/Arginine (SR)-rich linker and a C-terminal dimerization domain (CTD). Besides its involvement in oligomerization, the CTD of the N protein (N-CTD) is also able to bind to nucleic acids by itself, independent of the NTD. Here, we report the near-complete NMR backbone chemical shift assignments of the SARS-CoV-2 N-CTD to provide the basis for downstream applications, in particular site-resolved drug binding studies.
C1 [Korn, Sophie M.; Lambertz, Roderick; Woehnert, Jens; Schlundt, Andreas] Goethe Univ Frankfurt, Inst Mol Biosci, Max von Laue Str 9, D-60438 Frankfurt, Germany.
   [Fuertig, Boris; Hengesbach, Martin; Richter, Christian; Schwalbe, Harald] Goethe Univ Frankfurt, Inst Organ Chem & Chem Biol, Max von Laue Str 7, D-60438 Frankfurt, Germany.
   [Loehr, Frank] Goethe Univ Frankfurt, Inst Biophys Chem, Max von Laue Str 9, D-60438 Frankfurt, Germany.
   [Korn, Sophie M.; Fuertig, Boris; Loehr, Frank; Richter, Christian; Schwalbe, Harald; Woehnert, Jens; Schlundt, Andreas] Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance BMRZ, D-60438 Frankfurt, Germany.
   [Weigand, Julia E.] Tech Univ Darmstadt, Dept Biol, Schnittspahnstr 10, D-64287 Darmstadt, Germany.
RP Schlundt, A (corresponding author), Goethe Univ Frankfurt, Inst Mol Biosci, Max von Laue Str 9, D-60438 Frankfurt, Germany.; Schlundt, A (corresponding author), Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance BMRZ, D-60438 Frankfurt, Germany.
EM schlundt@bio.uni-frankfurt.de
RI ; Schlundt, Andreas/D-2951-2017
OI Weigand, Julia/0000-0003-4247-1348; Korn, Sophie/0000-0003-3798-3277;
   Schlundt, Andreas/0000-0003-2254-7560; Furtig,
   Boris/0000-0001-6443-7656; Lohr, Frank/0000-0001-6399-9497
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Chang CK, 2009, J VIROL, V83, P2255, DOI 10.1128/JVI.02001-08
   Chang CK, 2005, FEBS LETT, V579, P5663, DOI 10.1016/j.febslet.2005.09.038
   Chen CY, 2007, J MOL BIOL, V368, P1075, DOI 10.1016/j.jmb.2007.02.069
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   CLUBB RT, 1992, J BIOMOL NMR, V2, P203, DOI 10.1007/BF01875531
   Czisch M, 1998, J MAGN RESON, V134, P158, DOI 10.1006/jmre.1998.1483
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Huang QL, 2004, BIOCHEMISTRY-US, V43, P6059, DOI 10.1021/bi036155b
   Kuo L, 2002, J VIROL, V76, P4987, DOI 10.1128/JVI.76.10.4987-4999.2002
   Lakomek NA, 2012, J BIOMOL NMR, V53, P209, DOI 10.1007/s10858-012-9626-5
   Lee W, 2015, BIOINFORMATICS, V31, P1325, DOI 10.1093/bioinformatics/btu830
   Lescop E, 2007, J MAGN RESON, V187, P163, DOI 10.1016/j.jmr.2007.04.002
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo HB, 2006, BIOCHEMISTRY-US, V45, P11827, DOI 10.1021/bi0609319
   MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004
   METZLER WJ, 1993, BIOCHEMISTRY-US, V32, P13818, DOI 10.1021/bi00213a010
   Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366
   PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855
   Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585
   Schanda P, 2006, J AM CHEM SOC, V128, P9042, DOI 10.1021/ja062025p
   SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301
   SCHLEUCHER J, 1993, ANGEW CHEM INT EDIT, V32, P1489, DOI 10.1002/anie.199314891
   Schulte-Herbruggen T, 2000, J MAGN RESON, V144, P123, DOI 10.1006/jmre.2000.2020
   Takeda M, 2008, J MOL BIOL, V380, P608, DOI 10.1016/j.jmb.2007.11.093
   Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449
   WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777
   WISHART DS, 1994, J BIOMOL NMR, V4, P171
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Ye QZ, 2020, PROTEIN SCI, V29, P1890, DOI 10.1002/pro.3909
   Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4
   Zhou R, 2020, MOL BIOMED, V1, P11, DOI [10.1186/s43556-020-00001-4, DOI 10.1186/S43556-020-00001-4]
   ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008
NR 32
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1874-2718
EI 1874-270X
J9 BIOMOL NMR ASSIGN
JI Biomol. NMR Assign.
DI 10.1007/s12104-020-09995-y
EA DEC 2020
PG 7
WC Biophysics; Spectroscopy
SC Biophysics; Spectroscopy
GA PF4BN
UT WOS:000599002200001
PM 33270159
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Golubev, AG
AF Golubev, Aleksei G.
TI COVID-19: A Challenge to Physiology of Aging
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE COVID-19; aging; theories; physiological balances; public health;
   anti-aging drugs; signaling pathways
ID NITRIC-OXIDE PRODUCTION; ALL-CAUSE MORTALITY; FREE-RADICAL THEORY;
   ENDOTHELIAL DYSFUNCTION; PHYSICAL-ACTIVITY; OXIDATIVE STRESS;
   DOSE-RESPONSE; AGE; MECHANISMS; PREVENTION
AB The death toll of the current COVID-19 pandemic is strongly biased toward the elderly. COVID-19 case fatality rate (CFR) increases with age exponentially, its doubling time being about 7 years, irrespective of countries and epidemic stages. The same age-dependent mortality pattern known as the Gompertz law is featured by the total mortality and its main constituents attributed to cardiovascular, metabolic, neurological, and oncological diseases. Among patients dying of COVID-19, most have at least one of these conditions, whereas none is found in most of those who pass it successfully. Thus, gerontology is indispensable in dealing with the pandemic, which becomes a benchmark for validating the gerontological concepts and advances. The two basic alternative gerontological concepts imply that either aging results from the accumulation of stochastic damage, or is programmed. Based on these different grounds, several putative anti-aging drugs have been proposed as adjuvant means for COVID-19 prevention and/or treatment. These proposals are reviewed in the context of attributing the molecular targets of these drugs to the signaling pathways between the sensors of resource availability and the molecular mechanisms that allocate resources to storage, growth and reproduction or to self-maintenance and repair. Each of the drugs appears to reproduce only a part of the physiological responses to reduced resource availability caused by either dietary calories restriction or physical activity promotion, which are the most robust means of mitigating the adverse manifestations of aging. In the pathophysiological terms, the conditions of the endothelium, which worsen as age increases and may be significantly improved by the physical activity, is a common limiting factor for the abilities to withstand both physical stresses and challenges imposed by COVID-19. However, the current anti-epidemic measures promote sedentary indoor lifestyles, at odds with the most efficient behavioral interventions known to decrease the vulnerability to both the severe forms of COVID-19 and the prevalent aging-associated diseases. To achieve a proper balance in public health approaches to COVID-19, gerontologists should be involved in crosstalk between virologists, therapists, epidemiologists, and policy makers. The present publication suggests a conceptual background for that.
C1 [Golubev, Aleksei G.] NN Petrov Natl Med Res Ctr Oncol, St Petersburg, Russia.
RP Golubev, AG (corresponding author), NN Petrov Natl Med Res Ctr Oncol, St Petersburg, Russia.
EM lxglbv@rambker.ru
CR Abouhashem AS, 2020, ANTIOXID REDOX SIGN, V33, P59, DOI 10.1089/ars.2020.8111
   Ahrendt N, 2020, AM J PHYSIOL-LUNG C, V319, pL312, DOI 10.1152/ajplung.00423.2019
   Aird W. C., 2013, CONSULTATIVE HEMOSTA, P33
   Akaberi Dario, 2020, Redox Biol, V37, P101734, DOI 10.1016/j.redox.2020.101734
   Alijotas-Reig J, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102569
   Altschul A., 1954, ENDOTHELIUM ITS DEV
   Anisimov VN, 2015, ONCOTARGET, V6, P39398, DOI 10.18632/oncotarget.6347
   Annunziata G, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00240
   Apelo SIA, 2016, J GERONTOL A-BIOL, V71, P876, DOI 10.1093/gerona/glw064
   Aune D, 2018, AM J CLIN NUTR, V108, P1069, DOI 10.1093/ajcn/nqy097
   Ayyadevara S, 2017, ANTIOXID REDOX SIGN, V27, P1383, DOI 10.1089/ars.2016.6978
   Banerjee S, 2020, SAR QSAR ENVIRON RES, V31, P325, DOI 10.1080/1062936X.2020.1734080
   Barja G, 2014, PROG MOL BIOL TRANSL, V127, P1, DOI 10.1016/B978-0-12-394625-6.00001-5
   Barzilai N, 2020, AGING DIS, V11, P725, DOI 10.14336/AD.2020.0629
   Bharath LP, 2020, CELL METAB, V32, P44, DOI 10.1016/j.cmet.2020.04.015
   Blagosklonny MV, 2020, AGING-US, V12, P10004, DOI 10.18632/aging.103493
   Blagosklonny MV, 2018, AGING-US, V10, P3067, DOI 10.18632/aging.101647
   Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93
   Bramante Carolyn, 2020, medRxiv, DOI 10.1101/2020.06.19.20135095
   Brawner C. A., 2020, MAYO CLIN P, DOI [10.1016/j.mayocp.2020.10.003, DOI 10.1016/J.MAYOCP.2020.10.003]
   Brooke RT, 2020, AGING-US, V12, P11161, DOI 10.18632/aging.103636
   Campbell JM, 2017, AGEING RES REV, V40, P31, DOI 10.1016/j.arr.2017.08.003
   Celis-Morales CA, 2019, MED SCI SPORT EXER, V51, P472, DOI 10.1249/MSS.0000000000001795
   Colantuoni A, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00747
   Cuadrado A, 2020, TRENDS PHARMACOL SCI, V41, P598, DOI 10.1016/j.tips.2020.07.003
   Curtin N, 2020, BRIT J PHARMACOL, V177, P3635, DOI 10.1111/bph.15137
   Cuyas E, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00657
   da Silveira MP, 2020, CLIN EXP MED, DOI 10.1007/s10238-020-00650-3
   Damiot A, 2020, GERONTOLOGY, V66, P431, DOI 10.1159/000509216
   DANESHKHAH A, 2020, AGING CLIN EXP 0902, DOI DOI 10.1101/2020.04.08.20058578
   Das S., 2020, IDENTIFICATION ANAL, DOI [10.1101/2020.05.05.20091918, DOI 10.1101/2020.05.05.20091918]
   Davies Sean S, 2017, Curr Pharmacol Rep, V3, P51, DOI 10.1007/s40495-017-0081-6
   Delgado-Roche L, 2020, ARCH MED RES, V51, P384, DOI 10.1016/j.arcmed.2020.04.019
   DeLuccia Rosemary, 2020, Nutr Rev, DOI 10.1093/nutrit/nuaa092
   Di Francescomarino S, 2009, SPORTS MED, V39, P797, DOI 10.2165/11317750-000000000-00000
   DILMAN VM, 1986, INT REV NEUROBIOL, V28, P89, DOI 10.1016/S0074-7742(08)60107-5
   Dominski Fabio Hech, 2020, Sport Sci Health, P1, DOI 10.1007/s11332-020-00673-z
   Donato AJ, 2015, J MOL CELL CARDIOL, V89, P122, DOI 10.1016/j.yjmcc.2015.01.021
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Evangelista FS, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.561403
   Froldi G, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110015
   Fuellen G, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101091
   Furrer R, 2020, AGING-US, V12, P5, DOI 10.18632/aging.102741
   Gassen N. C., 2020, BIORXIV, DOI [10.1101/2020.04.15.997254, DOI 10.1101/2020.04.15.997254]
   Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041
   Goldsmith TC, 2016, MED HYPOTHESES, V86, P92, DOI 10.1016/j.mehy.2015.10.015
   Golubev A, 2019, BIOGERONTOLOGY, V20, P799, DOI 10.1007/s10522-019-09828-z
   Golubev A, 2009, J THEOR BIOL, V258, P1, DOI 10.1016/j.jtbi.2009.01.009
   Golubev A G, 2020, Adv Gerontol, V33, P397
   Golubev AG, 2019, ADV GERONTOL, V9, P1, DOI 10.1134/S2079057019010065
   Golubev AG, 1996, BIOCHEMISTRY-MOSCOW+, V61, P1443
   Golubev AG, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00073
   Golubev A, 2018, ANTIOXID REDOX SIGN, V29, P1003, DOI 10.1089/ars.2017.7105
   Golubev A, 2017, J BIOL CHEM, V292, P6029, DOI 10.1074/jbc.R116.751164
   Golubev Alexey G, 2019, Oncotarget, V10, P6758, DOI 10.18632/oncotarget.27344
   Gonzalez-Freire M, 2020, AGEING RES REV, V59, DOI 10.1016/j.arr.2020.101037
   Green SJ, 2020, MICROBES INFECT, V22, P149, DOI 10.1016/j.micinf.2020.05.006
   Guan Shou Ping, 2020, Ageing Res Rev, V64, P101201, DOI 10.1016/j.arr.2020.101201
   Guilmoto C. Z. Z., 2020, COVID 19 DEATH RATES, DOI [10.1101/2020.05.17.20097410, DOI 10.1101/2020.05.17.20097410]
   HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S
   Hassan Saif M, 2020, Med Arch, V74, P134, DOI 10.5455/medarh.2020.74.134-138
   Heer Collin D, 2020, bioRxiv, DOI 10.1101/2020.04.17.047480
   Heffernan KS, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.110197
   Hill Tom R, 2018, Subcell Biochem, V90, P191, DOI 10.1007/978-981-13-2835-0_8
   Hipkiss AR, 2016, MATURITAS, V93, P28, DOI 10.1016/j.maturitas.2016.06.002
   Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018
   Jakobsson Johan, 2020, Front Sports Act Living, V2, P57, DOI 10.3389/fspor.2020.00057
   Jenkins DJA, 2018, J AM COLL CARDIOL, V71, P2570, DOI 10.1016/j.jacc.2018.04.020
   Jia GH, 2019, BBA-MOL BASIS DIS, V1865, P1802, DOI 10.1016/j.bbadis.2018.08.008
   Jindal C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113986
   Kaur S, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00989
   Kellogg C, 2020, HUM VACC IMMUNOTHER, DOI 10.1080/21645515.2020.1818519
   Kenyon C, 2020, MICROBES INFECT, V22, P151, DOI 10.1016/j.micinf.2020.05.003
   Kikusui T, 2018, ELIFE, V7, DOI 10.7554/eLife.43666
   Korybalska K, 2017, J PHYSIOL PHARMACOL, V68, P597
   Kowald A, 2016, AGING CELL, V15, P986, DOI 10.1111/acel.12510
   Kulkarni SS, 2015, BBA-MOL BASIS DIS, V1852, P1114, DOI 10.1016/j.bbadis.2014.10.005
   Lamming DW, 2020, J GERONTOL A-BIOL, V75, P1, DOI 10.1093/gerona/glz212
   Laxminarayan R, 2020, SCIENCE, V370, P691, DOI 10.1126/science.abd7672
   Lee DC, 2017, PROG CARDIOVASC DIS, V60, P45, DOI 10.1016/j.pcad.2017.03.005
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li HG, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092155
   Liang YR, 2018, ADV EXP MED BIOL, V1086, P267, DOI 10.1007/978-981-13-1117-8_17
   Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y
   Madeo F, 2019, CELL METAB, V29, P592, DOI 10.1016/j.cmet.2019.01.018
   Madeo F, 2018, SCIENCE, V359, P410, DOI 10.1126/science.aan2788
   Marhl M, 2020, DIABETES METAB SYND, V14, P671, DOI 10.1016/j.dsx.2020.05.013
   Gimenez VMM, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117808
   Mateuszuk L, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114019
   Matsui T, 2016, NUTR METAB CARDIOVAS, V26, P797, DOI 10.1016/j.numecd.2016.04.008
   Mayr FB, 2014, VIRULENCE, V5, P4, DOI 10.4161/viru.27372
   McCord JM, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060518
   Meftahi GH, 2020, INFLAMM RES, V69, P825, DOI 10.1007/s00011-020-01372-8
   Menendez JA, 2020, AGING-US, V12, P8760, DOI 10.18632/aging.103347
   Mohamed AA, 2020, DIABETES METAB SYND, V14, P489, DOI 10.1016/j.dsx.2020.04.038
   Mueller AL, 2020, AGING-US, V12, P9959, DOI 10.18632/aging.103344
   Muller AWJ, 2018, MED HYPOTHESES, V119, P68, DOI 10.1016/j.mehy.2018.07.020
   Nasi Aikaterini, 2020, Toxicol Rep, V7, P768, DOI 10.1016/j.toxrep.2020.06.003
   Navaratnarajah A, 2017, MEDICINE, V45, P6, DOI [DOI 10.HTTPS://D0I.0RG/10.1016/J.MPMED.2016.10.008, DOI 10.1016/J.MPMED.2016.10.008]
   Neto LO, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00354
   Newman S. J., 2017, BIORXIV, DOI [10.1101/124792, DOI 10.1101/124792]
   Nieman DC, 2019, J SPORT HEALTH SCI, V8, P201, DOI 10.1016/j.jshs.2018.09.009
   Nishiga M, 2020, NAT REV CARDIOL, V17, P543, DOI 10.1038/s41569-020-0413-9
   Noreen F, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju161
   O'Driscoll M., 2020, AGE SPECIFIC MORTALI, DOI [10.1101/2020.08.24.20180851, DOI 10.1101/2020.08.24.20180851]
   Oak MH, 2018, FREE RADICAL BIO MED, V122, P161, DOI 10.1016/j.freeradbiomed.2018.03.018
   Omori R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73777-8
   Otsuki T, 2020, J CLIN BIOCHEM NUTR, V66, P62, DOI 10.3164/jcbn.19-81
   Padhi S, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.107001
   Pan H, 2017, J BIOL CHEM, V292, P6452, DOI 10.1074/jbc.R116.771915
   Panfoli I, 2020, CLIN MED, V20, pE146, DOI 10.7861/clinmed.2020-0252
   Piskovatska Veronika, 2019, Subcell Biochem, V91, P339, DOI 10.1007/978-981-13-3681-2_13
   Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5
   Promislow DEL, 2020, J GERONTOL A-BIOL, V75, pE30, DOI 10.1093/gerona/glaa094
   Puca AA, 2012, IMMUN AGEING, V9, DOI 10.1186/1742-4933-9-26
   Qian MX, 2018, ADV EXP MED BIOL, V1086, P235, DOI 10.1007/978-981-13-1117-8_15
   Quiles JL, 2020, ENVIRON RES, V191, DOI 10.1016/j.envres.2020.110053
   Ravalli S., 2020, J FUNCT MORPHOL KINE, V5, DOI [10.3390/jfmk5020031, DOI 10.3390/JFMK5020031]
   Reineke DC, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0150-4
   Reiter RJ, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00226
   Rodella Luigi Fabrizio, 2013, Front Biosci (Elite Ed), V5, P119
   Russo GL, 2020, BIOCHEM PHARMACOL, V173, DOI 10.1016/j.bcp.2019.113719
   Sadowska-Bartosz I, 2016, MECH AGEING DEV, V160, P1, DOI 10.1016/j.mad.2016.09.006
   Sahebnasagh A, 2020, EUR J PHARMACOL, V887, DOI 10.1016/j.ejphar.2020.173530
   Salmanoglu DS, 2016, REDOX BIOL, V8, P199, DOI 10.1016/j.redox.2015.11.007
   Santesmasses D, 2020, AGING CELL, V19, DOI 10.1111/acel.13230
   Santin-Marquez R, 2019, GEROSCIENCE, V41, P655, DOI 10.1007/s11357-019-00061-7
   Santini ZI, 2020, SOC SCI MED, V251, DOI 10.1016/j.socscimed.2020.112906
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Sassi F, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111656
   Semchyshyn HM, 2014, SCI WORLD J, DOI 10.1155/2014/417842
   Shamshirian A., 2020, CARDIOVASCULAR DIS C, DOI [10.1101/2020.04.12.20062869., DOI 10.1101/2020.04.12.20062869, 10.1101/2020.04.12.20062869]
   Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787-007-0013-x
   Sharma S, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108183
   Shintani H, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121821
   Starr ME, 2014, AGING DIS, V5, P126, DOI 10.14336/AD.2014.0500126
   Sverdlov AL, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000973
   Takahashi S, 2009, BIOL PHARM BULL, V32, P1836, DOI 10.1248/bpb.32.1836
   Terrazzano G, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00856
   Thomas R, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-0173-8
   Thune I, 2001, MED SCI SPORT EXER, V33, pS530, DOI 10.1097/00005768-200106001-00025
   Tian X, 2019, CELL, V177, P622, DOI 10.1016/j.cell.2019.03.043
   Triggle CR, 2020, CAN J PHYSIOL PHARM, V98, P415, DOI 10.1139/cjpp-2019-0677
   Vadasz Z, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-94
   van Beek JHGM, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0079
   Vitale G, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00027
   Wang SF, 2020, DIABETOLOGIA, V63, P2102, DOI 10.1007/s00125-020-05209-1
   Wang ZL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01013
   Williams Alexander T, 2020, Free Radic Biol Med, V161, P15, DOI 10.1016/j.freeradbiomed.2020.09.025
   Wood T. R., 2020, LIFESTYLE MED, V1, pe2, DOI [10.1002/lim2.2, DOI 10.1002/LIM2.2]
   Wray DW, 2012, HYPERTENSION, V59, P818, DOI 10.1161/HYPERTENSIONAHA.111.189456
   Yamasaki H, 2020, NITRIC OXIDE-BIOL CH, V103, P29, DOI 10.1016/j.niox.2020.07.005
   Yang YC, 2016, P NATL ACAD SCI USA, V113, P578, DOI 10.1073/pnas.1511085112
   Yousefifard M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13557
   Zhang BC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235458
   Zhou MS, 2004, SEMIN NEPHROL, V24, P366, DOI 10.1016/j.semnephrol.2004.04.008
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
   Zhu WM, 2020, J SPORT HEALTH SCI, V9, P105, DOI 10.1016/j.jshs.2020.01.005
NR 158
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD DEC 3
PY 2020
VL 11
AR 584248
DI 10.3389/fphys.2020.584248
PG 14
WC Physiology
SC Physiology
GA PG3CY
UT WOS:000599618100001
PM 33343386
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Riebeling, T
   Jamal, K
   Wilson, R
   Kolbrink, B
   von Samson-Himmelstjerna, FA
   Moerke, C
   Garcia, LR
   Dahlke, E
   Michels, F
   Luhder, F
   Schunk, D
   Doldi, P
   Tyczynski, B
   Kribben, A
   Fluh, C
   Theilig, F
   Kunzendorf, U
   Meier, P
   Krautwald, S
AF Riebeling, Theresa
   Jamal, Kunzah
   Wilson, Rebecca
   Kolbrink, Benedikt
   von Samson-Himmelstjerna, Friedrich Alexander
   Moerke, Caroline
   Ramos Garcia, Laura
   Dahlke, Eileen
   Michels, Friederike
   Luehder, Fred
   Schunk, Domagoj
   Doldi, Philipp
   Tyczynski, Bartosz
   Kribben, Andreas
   Flueh, Charlotte
   Theilig, Franziska
   Kunzendorf, Ulrich
   Meier, Pascal
   Krautwald, Stefan
TI Primidone blocks RIPK1-driven cell death and inflammation
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article; Early Access
ID NF-KAPPA-B; RIP1 KINASE; NECROPTOSIS; ACTIVATION; NECROSIS; INFECTION;
   RELEASE; TARGET; IKK
AB The receptor-interacting serine/threonine protein kinase 1 (RIPK1) is a key mediator of regulated cell death and inflammation. Recent studies suggest that RIPK1 inhibition would fundamentally improve the therapy of RIPK1-dependent organ damage in stroke, myocardial infarction, kidney failure, and systemic inflammatory response syndrome. Additionally, it could ameliorate or prevent multi-organ failure induced by cytokine release in the context of hyperinflammation, as seen in COVID-19 patients. Therefore, we searched for a RIPK1 inhibitor and present the aromatic antiepileptic and FDA-approved drug primidone (Liskantin (R)) as a potent inhibitor of RIPK1 activation in vitro and in a murine model of TNF alpha-induced shock, which mimics the hyperinflammatory state of cytokine release syndrome. Furthermore, we detected for the first time RIPK1 activation in the respiratory tract epithelium of hospitalized patients who tested positive for SARS-CoV-2 infection. Our data provide a strong rationale for evaluating the drug primidone in conditions of hyperinflammation in humans.
C1 [Riebeling, Theresa; Kolbrink, Benedikt; von Samson-Himmelstjerna, Friedrich Alexander; Moerke, Caroline; Kunzendorf, Ulrich; Krautwald, Stefan] Univ Hosp Schleswig Holstein, Dept Hypertens & Nephrol, D-24105 Kiel, Germany.
   [Jamal, Kunzah; Wilson, Rebecca; Ramos Garcia, Laura; Meier, Pascal] Breast Canc Now Toby Robins Res Ctr, Inst Canc Res, Fulham Rd, London SW3 6JB, England.
   [Dahlke, Eileen; Theilig, Franziska] Christian Albrechts Univ Kiel, Inst Anat, D-24118 Kiel, Germany.
   [Michels, Friederike; Flueh, Charlotte] Univ Hosp Schleswig Holstein, Dept Neurosurg, D-24105 Kiel, Germany.
   [Luehder, Fred] Univ Med Ctr Gottingen, Inst Neuroimmunol & Multiple Sclerosis Res, D-37075 Gottingen, Germany.
   [Schunk, Domagoj] Univ Hosp Schleswig Holstein, Dept Emergency Med, D-24105 Kiel, Germany.
   [Doldi, Philipp] Ludwig Maximilians Univ Munchen, Med Klin & Poliklin 1, D-81377 Munich, Germany.
   [Tyczynski, Bartosz; Kribben, Andreas] Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, D-45147 Essen, Germany.
   [Jamal, Kunzah] AstraZeneca, DDR Biol Biosci Oncol R&D, Cambridge, England.
RP Krautwald, S (corresponding author), Univ Hosp Schleswig Holstein, Dept Hypertens & Nephrol, D-24105 Kiel, Germany.
EM krautwald@nephro.uni-kiel.de
OI von Samson-Himmelstjerna, Friedrich/0000-0002-4492-696X
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064
   Annibaldi A, 2018, TRENDS MOL MED, V24, P49, DOI 10.1016/j.molmed.2017.11.002
   Berger SB, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.9
   Berger SB, 2014, J IMMUNOL, V192, P5476, DOI 10.4049/jimmunol.1400499
   Choi ME, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128834
   Cuchet-Lourenco D, 2018, SCIENCE, V361, P810, DOI 10.1126/science.aar2641
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Degterev A, 2019, P NATL ACAD SCI USA, V116, P9714, DOI 10.1073/pnas.1901179116
   Dondelinger Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09690-0
   Dondelinger Y, 2016, CELL MOL LIFE SCI, V73, P2165, DOI 10.1007/s00018-016-2191-4
   Dondelinger Y, 2015, MOL CELL, V60, P63, DOI 10.1016/j.molcel.2015.07.032
   Feltham R, 2018, CELL REP, V23, P470, DOI 10.1016/j.celrep.2018.03.054
   Geng JF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00406-w
   Hausenloy DJ, 2013, J CLIN INVEST, V123, P92, DOI 10.1172/JCI62874
   Imre Gergely, 2020, Int Rev Cell Mol Biol, V353, P211, DOI 10.1016/bs.ircmb.2019.12.008
   Jaco I, 2017, MOL CELL, V66, P698, DOI 10.1016/j.molcel.2017.05.003
   JING L, 2020, J CLIN ONCOL S, V38
   Jouan-Lanhouet S, 2014, SEMIN CELL DEV BIOL, V35, P2, DOI 10.1016/j.semcdb.2014.08.010
   Kaiser WJ, 2013, J BIOL CHEM, V288, P31268, DOI 10.1074/jbc.M113.462341
   Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169
   Kolbrink B, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00817
   Kondylis V, 2017, IMMUNOL REV, V277, P113, DOI 10.1111/imr.12550
   Laurien L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15466-8
   Li W, 2018, NEUROSCIENCE, V390, P12, DOI 10.1016/j.neuroscience.2018.07.044
   Linkermann A, 2014, NAT REV IMMUNOL, V14, P759, DOI 10.1038/nri3743
   Linkermann A, 2012, MOL MED, V18, P577, DOI 10.2119/molmed.2011.00423
   Linkermann A, 2012, KIDNEY INT, V81, P751, DOI 10.1038/ki.2011.450
   Martens S, 2020, TRENDS PHARMACOL SCI, V41, P209, DOI 10.1016/j.tips.2020.01.002
   Meng HY, 2018, P NATL ACAD SCI USA, V115, pE2001, DOI 10.1073/pnas.1722013115
   Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X
   Mifflin L, 2020, NAT REV DRUG DISCOV, DOI 10.1038/s41573-020-0071-y
   Moerke C, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00019
   Moerke C, 2019, CELL DEATH DIFFER, V26, P1631, DOI 10.1038/s41418-018-0232-2
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Muller T, 2017, CELL MOL LIFE SCI, V74, P3631, DOI 10.1007/s00018-017-2547-4
   Newton K, 2016, CELL DEATH DIFFER, V23, P1565, DOI 10.1038/cdd.2016.46
   Newton K, 2016, NATURE, V540, P129, DOI 10.1038/nature20559
   Newton K, 2014, SCIENCE, V343, P1357, DOI 10.1126/science.1249361
   Ofengeim D, 2015, CELL REP, V10, P1836, DOI 10.1016/j.celrep.2015.02.051
   Pai MY, 2015, METHODS MOL BIOL, V1263, P287, DOI 10.1007/978-1-4939-2269-7_22
   Pierotti CL, 2020, ACS CHEM BIOL, V15, P2702, DOI 10.1021/acschembio.0c00482
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shan B, 2018, GENE DEV, V32, P327, DOI 10.1101/gad.312561.118
   Sheridan C, 2019, NAT BIOTECHNOL, V37, P111, DOI 10.1038/s41587-019-0023-4
   Silke J, 2015, NAT IMMUNOL, V16, P689, DOI [10.1038/ni.3206, 10.1038/ni0815-889b]
   Simpson J, 2020, AM J RESP CRIT CARE, V201, P1358, DOI 10.1164/rccm.201906-1149OC
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Tanzer MC, 2015, BIOCHEM J, V471, P255, DOI 10.1042/BJ20150678
   Ting AT, 2016, TRENDS IMMUNOL, V37, P535, DOI 10.1016/j.it.2016.06.002
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vlantis K, 2016, IMMUNITY, V44, P553, DOI 10.1016/j.immuni.2016.02.020
   Wegner KW, 2017, TRENDS PHARMACOL SCI, V38, P202, DOI 10.1016/j.tips.2016.12.005
   Weinlich R, 2017, NAT REV MOL CELL BIO, V18, P127, DOI 10.1038/nrm.2016.149
   Yue Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0917-y
   Zelic M, 2018, J CLIN INVEST, V128, P2064, DOI 10.1172/JCI96147
   Zhang ST, 2019, P NATL ACAD SCI USA, V116, P5675, DOI 10.1073/pnas.1819917116
NR 56
TC 0
Z9 0
U1 1
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
DI 10.1038/s41418-020-00690-y
EA DEC 2020
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA PF4JZ
UT WOS:000599024200001
PM 33273695
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fatima, S
   Zaidi, SS
   Alsharidah, AS
   Aljaser, FS
   Banu, N
AF Fatima, Sabiha
   Zaidi, Syed Shams
   Alsharidah, Ashwag Saleh
   Aljaser, Feda S.
   Banu, Naheed
TI Possible Prophylactic Approach for SARS-CoV-2 Infection by Combination
   of Melatonin, Vitamin C and Zinc in Animals
SO FRONTIERS IN VETERINARY SCIENCE
LA English
DT Article
DE chronic immobilization stress; oxidative biomarkers; inflammation;
   melatonin; vitamin C; zinc
ID NF-KAPPA-B; STRESS; INFLAMMATION; ANTIOXIDANT; GLUTATHIONE; IMMUNITY;
   OXYGEN; CELLS; BAT
AB SARS-CoV-2, an epidemic, causes severe stress in both human and animals and may induce oxidative stress (OS) and increases susceptibility to infection. Domestic animals are found infected by their COVID-2 suffering owners. Chronic immobilization stress (CIS), a model of psychological and physical stress of confinement, can trigger depression and anxiety in animals. We evaluated the ameliorative effect of the proposed SARS-CoV-2 prophylactic drugs melatonin, vitamin C, and zinc on CIS-induced OS, inflammation, and DNA damage in rats. Forty male Swiss albino rats (200-250 g, 7-9 weeks old) were divided into five groups as controls, CIS, treated with melatonin (20 mg/kg), and vitamin C plus zinc [VitC+Zn (250 + 2.5 mg/kg)] alone or in combination (melatonin+VitC+zinc) subjected to CIS for 3 weeks. CIS was induced by immobilizing the whole body of the rats in wire mesh cages of their size with free movement of head. Exposure to CIS significantly compromised the circulatory activities of superoxide dismutase, catalase, and glutathione with enhanced malondialdehyde, inflammatory markers (IL-6, IL10, and TNF alpha), and lymphocyte DNA damage in comparison to controls. Treatment with melatonin and VitC+Zn alone or in combination significantly restored the altered biochemical parameters and DNA damage of stressed rats to their respective control values. However, the cumulative action of melatonin with VitC+Zn was more effective in alleviating the CIS-induced OS, inflammation, and DNA damage. The present study indicates that the antioxidant combination can be an effective preventive measure to combat severe psychological and confinement stress-induced biochemical changes in animals due to abnormal conditions such as SARS-CoV-2.
C1 [Fatima, Sabiha] King Saud Univ, Dept Clin Lab Sci, Coll Appl Med Sci, Riyadh, Saudi Arabia.
   [Zaidi, Syed Shams] Goulburn Valley Hlth, Pharm, Shepparton, Vic, Australia.
   [Alsharidah, Ashwag Saleh] Qassim Univ, Dept Physiol, Coll Med, Buraydah, Saudi Arabia.
   [Aljaser, Feda S.] King Saud Univ, Dept Clin Lab Sci, Coll Appl Med Sci, Chair Med & Mol Genet Res, Riyadh, Saudi Arabia.
   [Banu, Naheed] Qassim Univ, Dept Phys Therapy, Coll Med Rehabil, Buraydah, Saudi Arabia.
RP Banu, N (corresponding author), Qassim Univ, Dept Phys Therapy, Coll Med Rehabil, Buraydah, Saudi Arabia.
EM nbanuamu@gmail.com
CR Bilal N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00360
   Buege J A, 1978, Methods Enzymol, V52, P302
   Cano G, 2008, J NEUROSCI, V28, P10167, DOI 10.1523/JNEUROSCI.1809-08.2008
   Carr AC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111211
   Claiborne A, 1985, CRC HDB METHODS OXYG, P283
   DIMEO S, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/1245049
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gentile F, 2017, AIMS GENET, V4, P103, DOI 10.3934/genet.2017.2.103
   Haldar C, 2006, COMP BIOCHEM PHYS A, V144, P395, DOI 10.1016/j.cbpa.2006.02.041
   Han Kuem Sun, 2012, Exp Neurobiol, V21, P141, DOI 10.5607/en.2012.21.4.141
   Hardeland R, 2017, CELL MOL LIFE SCI, V74, P3883, DOI 10.1007/s00018-017-2615-9
   Heideman PD, 1996, J PINEAL RES, V20, P90
   Henderson F, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00227
   Herbet M, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/7313090
   Hooper MH, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2332-x
   Ibarra-Coronado EG, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/678164
   Jacob Robert A, 2002, Nutr Clin Care, V5, P66, DOI 10.1046/j.1523-5408.2002.00005.x
   Jarosz M, 2017, INFLAMMOPHARMACOLOGY, V25, P11, DOI 10.1007/s10787-017-0309-4
   JOLLOW DJ, 1974, PHARMACOLOGY, V11, P151, DOI 10.1159/000136485
   Jung T, 2014, REDOX BIOL, V2, P388, DOI 10.1016/j.redox.2013.12.029
   Kloubert V, 2018, J TRACE ELEM MED BIO, V49, P231, DOI 10.1016/j.jtemb.2018.01.006
   Kori RS, 2016, J CLIN DIAGN RES, V10, pAF7, DOI 10.7860/JCDR/2016/21355.8380
   Li B, 2014, J CELL MOL MED, V18, P895, DOI 10.1111/jcmm.12239
   Lingappan Krithika, 2018, Current Opinion in Toxicology, V7, P81, DOI 10.1016/j.cotox.2017.11.002
   Lopez-Patino MA, 2014, J EXP BIOL, V217, P1407, DOI 10.1242/jeb.087916
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Maggini S, 2010, J INT MED RES, V38, P386, DOI 10.1177/147323001003800203
   Mallapaty S, 2020, NATURE, V583, P344, DOI 10.1038/d41586-020-02052-7
   Marik PE, 2020, J THORAC DIS, V12, pS84, DOI 10.21037/jtd.2019.12.64
   MARKLUND S, 1974, EUR J BIOCHEM, V47, P469
   Murata Y, 2002, EUR J IMMUNOL, V32, P2866, DOI 10.1002/1521-4141(2002010)32:10<2866::AID-IMMU2866>3.0.CO;2-V
   Rahman I, 2005, MUTAT RES-FUND MOL M, V579, P58, DOI 10.1016/j.mrfmmm.2005.02.025
   Read SA, 2019, ADV NUTR, V10, P696, DOI 10.1093/advances/nmz013
   Reiter RJ, 2020, MELATONIN RES, V3, P43, DOI [10.32794/mr11250047, DOI 10.32794/MR11250047]
   Shneider A, 2020, INT REV IMMUNOL, V39, P153, DOI 10.1080/08830185.2020.1756284
   Srivastava KK, 2015, INDIAN J CLIN BIOCHE, V30, P3, DOI 10.1007/s12291-014-0441-5
   Stroehle Alexander, 2011, Inflammation & Allergy Drug Targets, V10, P54
   Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x
   Tao LP, 2013, BIOL TRACE ELEM RES, V155, P65, DOI 10.1007/s12011-013-9762-0
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   Villafuerte G, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/234952
   Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x
   Wessels I, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121286
   Wintergerst ES, 2006, ANN NUTR METAB, V50, P85, DOI 10.1159/000090495
   Wrotek S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041393
   Wu HM, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.117067
   Wu X, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4087298
   Zaidi SK, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/912450
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zhao RZ, 2019, INT J MOL MED, V44, P3, DOI 10.3892/ijmm.2019.4188
NR 51
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2297-1769
J9 FRONT VET SCI
JI Front. Vet. Sci.
PD DEC 3
PY 2020
VL 7
AR 585789
DI 10.3389/fvets.2020.585789
PG 7
WC Veterinary Sciences
SC Veterinary Sciences
GA PF7TA
UT WOS:000599251000001
PM 33344529
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Cox, RM
   Wolf, JD
   Plemper, RK
AF Cox, Robert M.
   Wolf, Josef D.
   Plemper, Richard K.
TI Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801
   blocks SARS-CoV-2 transmission in ferrets
SO NATURE MICROBIOLOGY
LA English
DT Article; Early Access
AB Treatment of SARS-CoV-2-infected ferrets with a nucleoside analogue (MK-4482/EIDD-2801) reduced the viral load in the upper respiratory tract and suppressed the spread of the virus to untreated ferrets. Therapeutic administration of MK-4482/EIDD-2801 may have the potential to break SARS-CoV-2 transmission chains.
   The coronavirus disease 2019 (COVID-19) pandemic is having a catastrophic impact on human health(1). Widespread community transmission has triggered stringent distancing measures with severe socio-economic consequences. Gaining control of the pandemic will depend on the interruption of transmission chains until vaccine-induced or naturally acquired protective herd immunity arises. However, approved antiviral treatments such as remdesivir and reconvalescent serum cannot be delivered orally(2,3), making them poorly suitable for transmission control. We previously reported the development of an orally efficacious ribonucleoside analogue inhibitor of influenza viruses, MK-4482/EIDD-2801 (refs. (4,5)), that was repurposed for use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is currently in phase II/III clinical trials (NCT04405570 and NCT04405739). Here, we explored the efficacy of therapeutically administered MK-4482/EIDD-2801 to mitigate SARS-CoV-2 infection and block transmission in the ferret model, given that ferrets and related members of the weasel genus transmit the virus efficiently with minimal clinical signs(6-9), which resembles the spread in the human young-adult population. We demonstrate high SARS-CoV-2 burden in nasal tissues and secretions, which coincided with efficient transmission through direct contact. Therapeutic treatment of infected animals with MK-4482/EIDD-2801 twice a day significantly reduced the SARS-CoV-2 load in the upper respiratory tract and completely suppressed spread to untreated contact animals. This study identified oral MK-4482/EIDD-2801 as a promising antiviral countermeasure to break SARS-CoV-2 community transmission chains.
C1 [Cox, Robert M.; Wolf, Josef D.; Plemper, Richard K.] Georgia State Univ, Inst Biomed Sci, Atlanta, GA 30303 USA.
RP Plemper, RK (corresponding author), Georgia State Univ, Inst Biomed Sci, Atlanta, GA 30303 USA.
EM rplemper@gsu.edu
FU Public Health Service grant from the NIH/NIAID [AI071002, AI141222]
FX We thank M. Kumar for providing an aliquot of 2019-nCoV/USA-WA1/2020
   stock, members of the GSU High Containment Core and the Department for
   Animal Research for support, and J. Sourimant and A. L. Hammond for
   critical reading of the manuscript. This work was supported, in part, by
   Public Health Service grant nos AI071002 (to R.K.P.) and AI141222 (to
   R.K.P.) from the NIH/NIAID. The funders had no role in the study design,
   data collection and interpretation or the decision to submit the work
   for publication.
CR Agostini ML, 2019, J VIROL, V93, DOI 10.1128/JVI.01348-19
   Bruschke C., 2020, NATURE FOOD QUALITY
   Cox RM, 2020, NAT MICROBIOL, V5, P1232, DOI 10.1038/s41564-020-0752-7
   Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598
   Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9
   DESMYTER J, 1968, J VIROL, V2, P955, DOI 10.1128/JVI.2.10.955-961.1968
   Enserink M, 2020, SCIENCE, V368, P1169, DOI 10.1126/science.368.6496.1169
   Han K., 2020, AM J RESP CELL MOL B, DOI [10.1165/rcmb.2020-0354OC, DOI 10.1165/RCMB.2020-03540C]
   Humeniuk R, 2020, CTS-CLIN TRANSL SCI, V13, P896, DOI 10.1111/cts.12840
   Kutter J. S., 2020, SARS COV SARS COV 2, DOI [10.1101/2020.10.19.345363, DOI 10.1101/2020.10.19.345363]
   LES A, 1993, BIOCHIM BIOPHYS ACTA, V1173, P39, DOI 10.1016/0167-4781(93)90240-E
   Martinot Martin, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1474
   Merck & Co, 2020, GENETIC ENG BIOTECHN
   Oreshkova N, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.23.2001005
   Oude Munnink Bas B, 2020, Science, DOI 10.1126/science.abe5901
   Painter GR, 2019, ANTIVIR RES, V171, DOI 10.1016/j.antiviral.2019.104597
   Park SJ, 2020, MBIO, V11, DOI 10.1128/mBio.01114-20
   Richard M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17367-2
   Rodriguez Mega Emiliano, 2020, Nature, DOI 10.1038/d41586-020-02762-y
   Tazerji SS, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02534-2
   Schlottau Kore, 2020, Lancet Microbe, V1, pe218, DOI 10.1016/S2666-5247(20)30089-6
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Toots M, 2020, TRANSL RES, V220, P33, DOI 10.1016/j.trsl.2020.01.005
   Toots M, 2020, TRANSL RES, V218, P16, DOI 10.1016/j.trsl.2019.12.002
   Toots M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax5866
   Urakova N, 2018, J VIROL, V92, DOI 10.1128/JVI.01965-17
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Yoon JJ, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.00766-18;e00766-18
NR 29
TC 0
Z9 0
U1 3
U2 3
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2058-5276
J9 NAT MICROBIOL
JI NAT. MICROBIOL
DI 10.1038/s41564-020-00835-2
EA DEC 2020
PG 15
WC Microbiology
SC Microbiology
GA PF3WI
UT WOS:000598988700001
PM 33273742
OA Bronze
DA 2021-01-01
ER

PT J
AU Yang, Y
   Shi, J
   Ge, SW
   Guo, SM
   Xing, X
   Wang, YN
   Cheng, AY
   Liu, QQ
   Li, JH
   Ning, Y
   He, F
   Xu, G
AF Yang, Yi
   Shi, Jia
   Ge, Shuwang
   Guo, Shuiming
   Xing, Xue
   Wang, Yanan
   Cheng, Anying
   Liu, Qingquan
   Li, Junhua
   Ning, Yong
   He, Fan
   Xu, Gang
TI Association between Prolonged Intermittent Renal Replacement Therapy and
   All-Cause Mortality in COVID-19 Patients Undergoing Invasive Mechanical
   Ventilation: A Retrospective Cohort Study
SO BLOOD PURIFICATION
LA English
DT Article; Early Access
DE Prolonged intermittent renal replacement therapy; Coronavirus disease
   2019; Invasive mechanical ventilation; Mortality
ID CONTINUOUS VENOVENOUS HEMOFILTRATION; RESPIRATORY SYNDROME-CORONAVIRUS;
   SARS CORONAVIRUS; EARLY INITIATION; SEPSIS; CYTOKINES; DISEASE; INJURY;
   ARDS; CARE
AB Background: The mortality rate of critically ill patients with coronavirus disease 2019 (COVID-19) was high. We aimed to assess the association between prolonged intermittent renal replacement therapy (PIRRT) and mortality in patients with COVID-19 undergoing invasive mechanical ventilation. Methods: This retrospective cohort study included all COVID-19 patients receiving invasive mechanical ventilation between February 12 and March 2, 2020. All patients were followed until death or March 28, and all survivors were followed for at least 30 days. Results: For 36 hospitalized COVID-19 patients receiving invasive mechanical ventilation, the mean age was 69.4 (+/- 10.8) years, and 30 patients (83.3%) were men. Twenty-two (61.1%) patients received PIRRT (PIRRT group), and 14 cases (38.9%) were managed with conventional strategy (non-PIRRT group). There were no differences in age, sex, comorbidities, complications, treatments, and most of the laboratory findings. During the median follow-up period of 9.5 (interquartile range 4.3-33.5) days, 13 of 22 (59.1%) patients in the PIRRT group and 11 of 14 (78.6%) patients in the non-PIRRT group died. Kaplan-Meier analysis demonstrated prolonged survival in patients in the PIRRT group compared with that in the non-PIRRT group (p = 0.042). The association between PIRRT and a reduced risk of mortality remained significant in 3 different models, with adjusted hazard ratios varying from 0.332 to 0.398. Increased IL-2 receptor, TNF-alpha, procalcitonin, prothrombin time, and NT-proBNP levels were significantly associated with an increased risk of mortality in patients with PIRRT. Conclusion: PIRRT may be beneficial for the treatment of COVID-19 patients with invasive mechanical ventilation. Further prospective multicenter studies with larger sample sizes are required.
C1 [Yang, Yi; Shi, Jia; Ge, Shuwang; Guo, Shuiming; Xing, Xue; Wang, Yanan; Cheng, Anying; Liu, Qingquan; Li, Junhua; Ning, Yong; He, Fan; Xu, Gang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nephrol, 1095 Jie Fang Ave, Wuhan 430030, Peoples R China.
RP He, F (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nephrol, 1095 Jie Fang Ave, Wuhan 430030, Peoples R China.
EM fhe@tjh.tjmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [NSFC 81974089]; international (regional)
   cooperation and exchange projects (NSFC-DFG) [81761138041]; Frontier
   Application Basic Project of Wuhan Science and Technology Bureau
   [2020020601012235]; Major Research Plan of the National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [91742204]; Science Foundation of Hubei Province [2019CFB675]
FX This study was funded by the National Natural Science Foundation of
   China (NSFC 81974089), international (regional) cooperation and exchange
   projects (NSFC-DFG, Grant No. 81761138041), Frontier Application Basic
   Project of Wuhan Science and Technology Bureau (2020020601012235), the
   Major Research Plan of the National Natural Science Foundation of China
   (Grant No. 91742204), and the Science Foundation of Hubei Province
   (2019CFB675).
CR Alfaraj SH, 2019, TRAVEL MED INFECT DI, V29, P48, DOI 10.1016/j.tmaid.2019.03.004
   Allegretti AS, 2020, AM J NEPHROL, V51, P318, DOI 10.1159/000506412
   Bar-Or D, 2015, REDOX REP, V20, P193, DOI 10.1179/1351000215Y.0000000005
   Cha RH, 2015, J KOREAN MED SCI, V30, P1807, DOI 10.3346/jkms.2015.30.12.1807
   Chakraborty RK, 2020, SYSTEMIC INFLAMMATOR
   Chen S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01393
   China NHCo, 2020, NEW COR PNEUM PREV C
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   DiCarlo JV, 2003, J PEDIAT HEMATOL ONC, V25, P801, DOI 10.1097/00043426-200310000-00012
   Edrees F, 2016, ADV CHRONIC KIDNEY D, V23, P195, DOI 10.1053/j.ackd.2016.03.003
   Elbahlawan L, 2010, PEDIATR BLOOD CANCER, V55, P540, DOI 10.1002/pbc.22561
   Fathima N, 2019, CUREUS, V11, DOI 10.7759/cureus.5558
   Fayad AI, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010613.pub2
   Forni LG, 2019, NAT REV NEPHROL, V15, P5, DOI [10.1038/s41581-018-0088-1, 10.1038/s41581-018-0088]
   Giamarellos-Bourboulis EJ, 2013, IMMUNOTHERAPY-UK, V5, P207, DOI [10.2217/IMT.13.8, 10.2217/imt.13.8]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Ha SO, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3571-9
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Han F, 2015, AM J MED SCI, V349, P199, DOI 10.1097/MAJ.0000000000000379
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Fayad AII, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010612.pub2
   Joannidis M, 2011, CRIT CARE, V15, DOI 10.1186/cc10109
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Karkar A, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-0648-y
   Kennedy JR, 2020, MED HYPOTHESES, V135, DOI 10.1016/j.mehy.2019.109462
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   Li Y, 2013, MICROBES INFECT, V15, P88, DOI 10.1016/j.micinf.2012.10.008
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Matsuda K, 2010, CONTRIB NEPHROL, V166, P83, DOI 10.1159/000314856
   Miao HJ, 2019, CRIT CARE MED, V47, pE806, DOI 10.1097/CCM.0000000000003901
   Putzu A, 2017, MINERVA ANESTESIOL, V83, P867, DOI 10.23736/S0375-9393.17.11946-2
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Rewa OG, 2017, INTENS CARE MED, V43, P750, DOI 10.1007/s00134-016-4579-x
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sethi SK, 2020, HEMODIAL INT, V24, P237, DOI 10.1111/hdi.12821
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   Sun M L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P219, DOI [10.3760/cma.j.issn.1001-0939.2020.0014, 10.3760/cma.j.issn.1001-0939.2020.03.016]
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Vincent JL, 2019, KIDNEY INT, V96, P52, DOI 10.1016/j.kint.2018.11.047
   Wolf T, 2015, LANCET, V385, P1428, DOI 10.1016/S0140-6736(14)62384-9
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Xie JF, 2020, CRIT CARE MED, V48, pE209, DOI 10.1097/CCM.0000000000004155
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y, 2020, ASS PROLONGED INTERM, DOI [10.1101/2020.03.16.20036780, DOI 10.1101/2020.03.16.20036780]
   Zarbock A, 2014, CURR OPIN CRIT CARE, V20, P588, DOI 10.1097/MCC.0000000000000153
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 47
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0253-5068
EI 1421-9735
J9 BLOOD PURIFICAT
JI Blood Purif.
DI 10.1159/000512099
EA DEC 2020
PG 8
WC Hematology; Urology & Nephrology
SC Hematology; Urology & Nephrology
GA PC9XC
UT WOS:000597349200001
PM 33271549
DA 2021-01-01
ER

PT J
AU Gaiha, SM
   Lempert, LK
   Halpern-Felsher, B
AF Gaiha, Shivani Mathur
   Lempert, Lauren Kass
   Halpern-Felsher, Bonnie
TI Underage Youth and Young Adult e-Cigarette Use and Access Before and
   During the Coronavirus Disease 2019 Pandemic
SO JAMA NETWORK OPEN
LA English
DT Article
ID HIGH-SCHOOL-STUDENTS; ELECTRONIC CIGARETTES; NICOTINE DEPENDENCE;
   TOBACCO PRODUCT; UNITED-STATES; ADOLESCENTS; ADVERTISEMENTS;
   PERCEPTIONS; EXPOSURE; MIDDLE
AB Importance Understanding patterns of e-cigarette use and access during the coronavirus disease 2019 (COVID-19) pandemic is important because e-cigarettes may put users at risk for more severe respiratory effects and other health problems. Objective To examine whether underage youth and young adults who ever used e-cigarettes self-reported changes in access and use of e-cigarettes since the COVID-19 pandemic began. Design, Setting, and Participants A national, cross-sectional online survey study was conducted from May 6 to May 14, 2020. This sample of 4351 participants aged 13 to 24 years across the US included 2167 e-cigarette ever-users. Quota sampling was used to balance for age, sex, race/ethnicity, and 50% having ever used e-cigarettes. Main Outcomes and Measures Change in e-cigarette use (increase, decrease, quit, no change, and switch to another product) and access to e-cigarettes (easier or harder, and change in point-of-purchase) before and after the COVID-19 pandemic began, reasons for change, number of times e-cigarettes were used, nicotine dependence, and sociodemographic data. Results This study focused on 2167 e-cigarette ever-users among 4351 participants who completed the survey. Among 2167 e-cigarette users, a total of 1442 were younger than 21 years and 725 were aged 21 years or older; 1397 were female (64.5%) and 438 identified as lesbian, gay, bisexual, transgender, queer (20.2%). The survey completion rate was 40%. Since the COVID-19 pandemic began, 1198 of 2125 e-cigarette users (56.4%) changed their use: 388 individuals (32.4%) quit, 422 individuals (35.3%) reduced the amount of nicotine, 211 individuals (17.6%) increased nicotine use, 94 individuals (7.8%) increased cannabis use, and 82 individuals (6.9%) switched to other products. Participants reported that not being able to go to vape shops and product unavailability were the reasons accessing e-cigarettes was difficult after the pandemic began. Since the COVID-19 pandemic began, individuals reported purchasing from alternative retail stores (disposables, 150 of 632 [23.7%]; pod-based, 144 of 797 [18.1%]; and other e-cigarette, 125 of 560 [22.3%], ie, between 18.1% and 23.7%), purchasing online instead of retail (disposables, 115 of 632 [18.2%]; pod-based, 156 of 797 [19.6%]; and other e-cigarette, 111 of 560 [19.8%], ie, between 18.2% to 19.8%), and shifted to retail instead of online (disposables, 11 of 632 [1.7%]; pod-based, 17 of 797 [2.0%]; and other e-cigarette, 13 of 560 [2.3%], ie, between 1.7%-2.3%). Other individuals reported no change: from retail stores (disposables 262 of 632 [41.5%]; pod-based 344 of 797 [43.2%]; and other e-cigarette, 223 of 560 [39.8%], ie, between 39.8% and 43.2%) and online (disposables 94 of 632 [14.9%]; pod-based 136 of 797 [17.1%]; and other e-cigarette, 88 of 560 [15.8%], ie, between 14.9% and 17.1%). Underage youth reported e-cigarette deliveries from vape shops and/or dealers or friends who received such deliveries, and 63 of 229 (27.5%) self-reported accessing e-cigarettes without age verification. e-Cigarette users were 52% less likely to quit or reduce their use if they previously used e-cigarettes between 11 and 99 times (adjusted odds ratio, 0.48; 95% CI, 0.30-0.78), 68% less likely to quit if they previously used e-cigarettes more than 100 times (adjusted odds ratio, 0.32; 95% CI, 0.20-0.51), and 51% were less likely to quit if they were nicotine dependent (adjusted odds ratio, 0.49; 95% CI, 0.35-0.70).
   Conclusions and Relevance During the COVID-19 pandemic, youth e-cigarette users reported changes in e-cigarette use, point-of-purchase, and ability to purchase e-cigarettes without age verification. The US Food and Drug Administration and local policy makers may find these data useful to inform policies to prevent e-cigarette sales to underage youth.
   Question Did underage youth and young adults (13-24 years) self-report changes in use and access to e-cigarettes during the coronavirus disease 2019 pandemic? Findings In this national, online, cross-sectional survey study of 2167 youth and young adults using e-cigarettes, 1198 respondents reported changing their amount of e-cigarette use, with 810 reducing or quitting e-cigarette use; e-cigarette access shifted to alternative retail stores and online. Reduced e-cigarette use or quitting was associated with adhering to shelter-in-place guidelines and was less likely if participants had used e-cigarettes more than 10 times or were nicotine dependent. Meaning Individuals younger than 21 years reported e-cigarette use and accessed e-cigarettes from online and retail stores during the coronavirus disease 2019 pandemic, suggesting a need to strengthen prevention of e-cigarette sales to such youth, including age verification, and provide cessation resources.
   This survey study examines changes in use of e-cigarettes by individuals aged 24 years and younger during the coronavirus 2019 pandemic.
C1 [Gaiha, Shivani Mathur; Halpern-Felsher, Bonnie] Stanford Univ, Dept Pediat, Div Adolescent Med, Palo Alto, CA 94304 USA.
   [Lempert, Lauren Kass] Univ Calif San Francisco, Ctr Tobacco Control Res & Educ, San Francisco, CA 94143 USA.
RP Halpern-Felsher, B (corresponding author), Stanford Univ, 770 Welch Rd,Ste 100, Palo Alto, CA 94304 USA.
EM bonnie.halpernfelsher@stanford.edu
OI Gaiha, Shivani/0000-0002-0636-8936
FU Taube Research Faculty Scholar Endowment [U54 HL147127]; National Heart,
   Lung, and Blood InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI); Food and Drug Administration Center for
   Tobacco Products
FX The research reported in this article was supported by the Taube
   Research Faculty Scholar Endowment (Dr Halpern-Felsher). Additional
   support was received from grant U54 HL147127 from the National Heart,
   Lung, and Blood Institute and the Food and Drug Administration Center
   for Tobacco Products.
CR American Association for Public Opinion Research, 2016, STAND DEF FIN DISP C
   [Anonymous], 2017, STAT STAT SOFTW REL
   Callegaro M, 2008, PUBLIC OPIN QUART, V72, P1008, DOI 10.1093/poq/nfn065
   Centers for Disease Control and Prevention, 2019, HIST NYTS DAT DOC
   Centers for Disease Control and Prevention, 2020, QUICK FACTS RISKS EC
   Cullen KA, 2019, JAMA-J AM MED ASSOC, V322, P2095, DOI 10.1001/jama.2019.18387
   Cullen KA, 2019, MMWR-MORBID MORTAL W, V68, P839, DOI 10.15585/mmwr.mm6839a2
   Cullen KA, 2018, MMWR-MORBID MORTAL W, V67, P1276, DOI 10.15585/mmwr.mm6745a5
   Czogala J, 2014, NICOTINE TOB RES, V16, P655, DOI 10.1093/ntr/ntt203
   DiFranza JR, 2002, ARCH PEDIAT ADOL MED, V156, P397, DOI 10.1001/archpedi.156.4.397
   Drummond M Bradley, 2014, Ann Am Thorac Soc, V11, P236, DOI 10.1513/AnnalsATS.201311-391FR
   Food and Drug Administration, 2020, WARN LETT PROV ENT I
   Food and Drug Administration, 2020, ENF PRIOR EL NIC DEL
   Food and Drug Administration, 2020, WARN LETT VAP PLUS O
   Food and Drug Administration, 2020, WARN LETT EJ MARCS C
   Gaiha SM, 2020, J ADOLESCENT HEALTH, V67, P519, DOI 10.1016/j.jadohealth.2020.07.002
   Ghosh A, 2019, AM J RESP CRIT CARE, V200, P1392, DOI 10.1164/rccm.201903-0615OC
   Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859
   Gorukanti A, 2017, PREV MED, V94, P65, DOI 10.1016/j.ypmed.2016.10.019
   Jackler RK, 2017, TOB CONTROL, V26, P471, DOI 10.1136/tobaccocontrol-2016-053206
   Javelle E, 2020, ARCH TOXICOL, V94, P2261, DOI 10.1007/s00204-020-02744-z
   Kim M, 2019, HEALTH COMMUN, V34, P290, DOI 10.1080/10410236.2017.1407230
   Kim M, 2019, TOB REGUL SCI, V5, P94, DOI 10.18001/TRS.5.2.1
   Kong G, 2015, NICOTINE TOB RES, V17, P847, DOI 10.1093/ntr/ntu257
   Krishnan-Sarin S, 2019, DRUG ALCOHOL DEPEN, V194, P395, DOI 10.1016/j.drugalcdep.2018.10.022
   McConnell R, 2017, AM J RESP CRIT CARE, V195, P1043, DOI 10.1164/rccm.201604-0804OC
   McKelvey K, 2020, J ADOLESCENT HEALTH, V67, P46, DOI 10.1016/j.jadohealth.2020.01.017
   McKelvey K, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3535
   McKelvey K, 2018, J ADOLESCENT HEALTH, V62, pS136
   Meyers MJ, 2017, J ADOLESCENT HEALTH, V61, P385, DOI 10.1016/j.jadohealth.2017.04.012
   Morean ME, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.05.032
   Morean ME, 2016, DRUG ALCOHOL DEPEN, V167, P224, DOI 10.1016/j.drugalcdep.2016.06.031
   National Institute of Drug Abuse, 2020, COVID 19 POT IMPL IN
   Qualtrics, 2014, ESOMAR 28 28 QUEST H
   Ramamurthi D, 2019, TOB CONTROL, V28, P610, DOI 10.1136/tobaccocontrol-2018-054455
   Truth Initiative, 2018, AR KIDS GETT JUUL
   Unger JB, 2018, ADDICT BEHAV, V78, P120, DOI 10.1016/j.addbeh.2017.11.012
   Villarroel MA, 2020, ELECT CIGARETTE USE
   Wheeler KC, 2004, J ADOLESCENT HEALTH, V35, P225, DOI 10.1016/j.jadohealth.2003.10.004
   Williams RS, 2018, TOB CONTROL, V27, P287, DOI 10.1136/tobaccocontrol-2016-053616
   Williams RS, 2015, JAMA PEDIATR, V169, DOI 10.1001/jamapediatrics.2015.63
   Wills TA, 2019, DRUG ALCOHOL DEPEN, V194, P363, DOI 10.1016/j.drugalcdep.2018.10.004
NR 42
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD DEC 3
PY 2020
VL 3
IS 12
DI 10.1001/jamanetworkopen.2020.27572
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA PC9JR
UT WOS:000597314200009
PM 33270127
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Miryan, M
   Soleimani, D
   Dehghani, L
   Sohrabi, K
   Khorvash, F
   Bagherniya, M
   Sayedi, SM
   Askari, G
AF Miryan, Mahsa
   Soleimani, Davood
   Dehghani, Leila
   Sohrabi, Karim
   Khorvash, Farzin
   Bagherniya, Mohammad
   Sayedi, Sayed Mazaher
   Askari, Gholamreza
TI The effect of propolis supplementation on clinical symptoms in patients
   with coronavirus (COVID-19): A structured summary of a study protocol
   for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Coronavirus; Protocol study; Propolis; Randomised controlled
   trial
AB Objectives: This study aims to assess the effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19).
   Trial design: This is a Double-Blind, Placebo-Controlled, Parallel Arm, Randomized Phase Iota Iota Clinical Trial.
   Participants: Patients with the confirmed COVID-19 based on the PCR test are eligible to participate in the trial if they are 18 to 75 years of age and have no history of the current use of warfarin or propolis supplement and presence of sensitivity to bee products. Patients will be recruited from the Al-Zahra hospital in Isfahan city, Isfahan, Iran.
   Intervention and comparator: Participants (N=40) in the intervention group will receive an identical propolis tablet (containing 300 mg Iranian green propolis extract) three times a day for a period of 2 weeks. Participants (N=40) in the control group will receive an identical placebo tablet (containing 300 mg microcrystalline cellulose) three times a day for 2 weeks. All tablets are prepared by the Reyhan Naghsh Jahan Pharmaceutical Co., Isfahan, Iran.
   Main outcomes: The main outcomes are changes in the coronavirus disease's clinical symptoms including duration and severity from baseline to the end of 2 weeks.
   Randomization: Eligible patients will be randomly allocated in a 1:1 ratio to the intervention or control group. Randomization will be performed on the basis of permuted block sizes of 4 and will be stratified according to sex categories. Randomization sequences will be prepared by the trial's pharmacist with the use of random-number tables.
   Blinding (masking): The trial-group assignment will be concealed from all participants, clinicians, and investigators throughout the trial. To ensure blinding, randomization sequences will be kept in identical, opaque, sealed, sequentially numbered envelopes. Only the trial's pharmacist has access to the randomization list. Also, the placebo tablet will be similar to the propolis tablet in terms of texture, taste, color, odor, and weight. Both tablets will be provided in containers that are completely identical in weight, shape, labelling, and packaging.
   Numbers to be randomized (sample size): The calculated total sample size is 80 patients, with 40 patients in each group.
   Trial status: The protocol is Version 1.0, October 10, 2020. Recruitment began August 22, 2020, and is anticipated to be completed by March 21, 2021.
   Trial registration: The name of the trial register:
   The effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19): A randomized, double-blind, placebo-controlled clinical trial.
   IRCT registration number:
   IRCT20200802048267N1.
   Date of trial registration:
   20 October 2020, retrospectively registered.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Miryan, Mahsa] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Miryan, Mahsa] Tabriz Univ Med Sci, Sch Nutr & Food Sci, Dept Clin Nutr, Nutr Res Ctr, Tabriz, Iran.
   [Soleimani, Davood] Kermanshah Univ Med Sci, Sch Nutr Sci & Food Technol, Nutr Sci Dept, Kermanshah, Iran.
   [Dehghani, Leila] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Regenerat Med, Tehran, Iran.
   [Sohrabi, Karim] Isfahan Univ Med Sci, Alzahra Univ Hosp, Dept Emergency Med, Esfahan, Iran.
   [Khorvash, Farzin] Isfahan Univ Med Sci, Fac Med, Dept Infect Dis, Nosocomial Infect Res Ctr, Esfahan, Iran.
   [Bagherniya, Mohammad; Askari, Gholamreza] Isfahan Univ Med Sci, Food Secur Res Ctr, Esfahan, Iran.
   [Bagherniya, Mohammad; Askari, Gholamreza] Isfahan Univ Med Sci, Anesthesia & Crit Care Res Ctr, Esfahan, Iran.
   [Bagherniya, Mohammad; Askari, Gholamreza] Isfahan Univ Med Sci, Sch Nutr & Food Sci, Dept Community Nutr, Esfahan, Iran.
   [Sayedi, Sayed Mazaher] Honey Bee Expert Isfahan Agr & Nat Resources Res, Arib Ave, Esfahan 8174673461, Iran.
RP Askari, G (corresponding author), Isfahan Univ Med Sci, Food Secur Res Ctr, Esfahan, Iran.; Askari, G (corresponding author), Isfahan Univ Med Sci, Anesthesia & Crit Care Res Ctr, Esfahan, Iran.
EM askari@mui.ac.ir
OI Bagherniya, Mohammad/0000-0002-5861-6129
FU Isfahan University of Medical [199131]
FX This study was funded and supported by the Isfahan University of Medical
   (Grant number: 199131). The Isfahan University of Medical Sciences, and
   Reyhan Naghsh Jahan Pharmaceutical Co., Isfahan, Iran have no role in
   the design of this study, collection, analysis, interpretation of data,
   and in writing the manuscript.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 3
PY 2020
VL 21
IS 1
AR 996
DI 10.1186/s13063-020-04934-7
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PC8KT
UT WOS:000597246200003
PM 33272309
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tverring, J
   Akesson, A
   Nielsen, N
AF Tverring, Jonas
   Akesson, Anna
   Nielsen, Niklas
TI Helmet continuous positive airway pressure versus high-flow nasal
   cannula in COVID-19: a pragmatic randomised clinical trial (COVID
   HELMET)
SO TRIALS
LA English
DT Article
DE COVID-19; Randomised controlled trial protocol; Helmet CPAP; HFNC;
   Ventilator-free days
ID RESPIRATORY-FAILURE; VENTILATION; OXYGEN
AB Background: Patients with COVID-19 and hypoxaemia despite conventional low-flow oxygen therapy are often treated with high-flow nasal cannula (HFNC) in line with international guidelines. Oxygen delivery by helmet continuous positive airway pressure (CPAP) is a feasible option that enables a higher positive end-expiratory pressure (PEEP) and may theoretically reduce the need for intubation compared to HFNC but direct comparative evidence is lacking.
   Methods: We plan to perform an investigator-initiated, pragmatic, randomised trial at an intermediate-level COVID-19 cohort ward in Helsingborg Hospital, southern Sweden. We have estimated a required sample size of 120 patients randomised 1:1 to HFNC or Helmet CPAP to achieve 90% power to detect superiority at a 0.05 significance level regarding the primary outcome of ventilator free days (VFD) within 28 days using a Mann-Whitney U test. Patient recruitment is planned to being June 2020 and be completed in the first half of 2021.
   Discussion: We hypothesise that the use of Helmet CPAP will reduce the need for invasive mechanical ventilation compared to the use of HFNC without having a negative effect on survival. This could have important implications during the current COVID-19 epidemic.
C1 [Tverring, Jonas; Akesson, Anna; Nielsen, Niklas] Lund Univ, Med Fak, Lund, Sweden.
RP Tverring, J (corresponding author), Lund Univ, Med Fak, Lund, Sweden.
EM jonas.tverring@med.lu.se
FU Swedish Government Research Grant (ALF); Swedish Research CouncilSwedish
   Research Council; Swedish Heart and Lung FoundationSwedish Heart-Lung
   Foundation; Lund University
FX This trial is investigator-initiated and no specific funding was
   received. The sponsor purchased the medical devices used in this trial
   in the context of state-funded healthcare and not for the main purpose
   of use in a trial. The sponsor also paid for the application for ethical
   approval. The principal investigator (JT) has previously received
   funding from Swedish Government Research Grant (ALF), and the senior
   investigator (NN) has previously received funding from The Swedish
   Research Council and the Swedish Heart and Lung Foundation. The study
   statistician (AA) is funded by the sponsor. Open Access funding provided
   by Lund University.
CR Agency SPH, VARDB SCEN LOMB GRAF
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Alraddadi BM, 2019, INFLUENZA OTHER RESP, V13, P382, DOI 10.1111/irv.12635
   Caputo ND, 2020, ACAD EMERG MED, V27, P375, DOI 10.1111/acem.13994
   Fay MP, 2018, STAT MED, V37, P3991, DOI 10.1002/sim.7890
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hagg S, 2020, J AM MED DIR ASS
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   ICNARC, 2020, ICNARC REP COVID 19
   Longhini F, 2020, PULMONOLOGY, V26, P186, DOI 10.1016/j.pulmoe.2020.04.014
   Manca D, 2020, ANAL NUMBER GROWTH I
   Mills K, 2010, MED SCI SPORT EXER, V42, P1966, DOI 10.1249/MSS.0b013e3181dbacc8
   Myrstad M, 2020, SCAND J TRAUMA RESUS, V28, DOI 10.1186/s13049-020-00764-3
   Parke RL, 2013, RESP CARE, V58, P1621, DOI 10.4187/respcare.02358
   Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338
   Pelosi P, 2010, CURR OPIN ANESTHESIO, V23, P233, DOI 10.1097/ACO.0b013e328335daec
   Principi T, 2004, INTENS CARE MED, V30, P147, DOI 10.1007/s00134-003-2056-9
   Ryan P, 1997, STAT SOFTW COMPONENT
   Sartini C, 2020, JAMA-J AM MED ASSOC, V323, P2338, DOI 10.1001/jama.2020.7861
   Schettino G, 2008, CRIT CARE MED, V36, P441, DOI 10.1097/01.CCM.0000300084.67277.90
   Xu XP, 2017, CRIT CARE MED, V45, pE727, DOI 10.1097/CCM.0000000000002361
   Yehya N, 2019, AM J RESP CRIT CARE, V200, P828, DOI 10.1164/rccm.201810-2050CP
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 24
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 3
PY 2020
VL 21
IS 1
AR 994
DI 10.1186/s13063-020-04863-5
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PC8KT
UT WOS:000597246200001
PM 33272319
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lampe, C
   Dionisi-Vici, C
   Bellettato, CM
   Paneghetti, L
   van Lingen, C
   Bond, S
   Brown, C
   Finglas, A
   Francisco, R
   Sestini, S
   Heard, JM
   Scarpa, M
AF Lampe, C.
   Dionisi-Vici, C.
   Bellettato, C. M.
   Paneghetti, L.
   van Lingen, C.
   Bond, S.
   Brown, C.
   Finglas, A.
   Francisco, R.
   Sestini, S.
   Heard, J. M.
   Scarpa, M.
CA MetabERN Collaboration Grp
TI The impact of COVID-19 on rare metabolic patients and healthcare
   providers: results from two MetabERN surveys
SO ORPHANET JOURNAL OF RARE DISEASES
LA English
DT Letter
DE COVID-19; SARS-CoV-2; Coronavirus; Pandemic; Rare diseases; Inherited
   metabolic diseases; IMD; Survey
AB The ongoing coronavirus disease 2019 (COVID-19) pandemic has caused disruption in all aspects of daily life, including the management and treatment of rare inherited metabolic disorders (IMDs). To perform a preliminary assessment of the incidence of COVID-19 in IMD patients and the impact of the coronavirus emergency on the rare metabolic community between March and April 2020, the European Reference Network for Hereditary Metabolic Diseases (MetabERN) has performed two surveys: one directed to patients' organizations (PO) and one directed to healthcare providers (HCPs). The COVID-19 incidence in the population of rare metabolic patients was lower than that of the general European population (72.9 x 100,000 vs. 117 x 100,000). However, patients experienced extensive disruption of care, with the majority of appointments and treatments cancelled, reduced, or postponed. Almost all HCPs (90%) were able to substitute face-to-face visits with telemedicine, about half of patients facing treatment changes switched from hospital to home therapy, and a quarter reported difficulties in getting their medicines. During the first weeks of emergency, when patients and families lacked relevant information, most HCPs contacted their patients to provide them with support and information. Since IMD patients require constant follow-up and treatment adjustments to control their disease and avoid degradation of their condition, the results of our surveys are relevant for national health systems in order to ensure appropriate care for IMD patients. They highlight strong links in an interconnected community of HCPs and PO, who are able to work quickly and effectively together to support and protect fragile persons during crisis. However, additional studies are needed to better appreciate the actual impact of COVID-19 on IMD patients' health and the mid- and long-term effects of the pandemic on their wellbeing.
C1 [Lampe, C.] Univ Hosp Giessen, Ctr Rare Dis Giessen ZSEGI, Giessen, Germany.
   [Dionisi-Vici, C.] Bambino Gesu Pediat Hosp, Div Metab, IRCCS, Rome, Italy.
   [Bellettato, C. M.; Paneghetti, L.; van Lingen, C.; Bond, S.; Heard, J. M.; Scarpa, M.] Udine Univ Hosp, MetabERN, Reg Coordinating Ctr Rare Dis, Udine, Italy.
   [Brown, C.] Krabbe UK, London, England.
   [Finglas, A.] MSD Act Fdn, Dublin, Ireland.
   [Francisco, R.] Portuguese Assoc CDG & Other Rare Metab Dis APCDG, Almada, Portugal.
   [Sestini, S.] Italian Assoc Patients Alkaptonuria aimAKU, Siena, Italy.
RP Scarpa, M (corresponding author), Udine Univ Hosp, MetabERN, Reg Coordinating Ctr Rare Dis, Udine, Italy.
EM maurizio.scarpa@metab.ern-net.eu
FU European UnionEuropean Union (EU) [739543]
FX This work was generated within the European Reference Network for Rare
   Hereditary Metabolic Disorders (MetabERN), co-funded by the European
   Union within the framework of the Third Health Programme ERN-2016
   Framework Partnership Agreement 2017-2021, Project ID No. 739543.
CR [Anonymous], 2020, COVID 19 COMMUNITY S
   [Anonymous], 2020, 51 WHO
   Cancer Research UK, 2020, IMP COVID 19 CANC PA
   de Joode K, 2020, EUR J CANCER, V136, P132, DOI 10.1016/j.ejca.2020.06.019
   European Centre for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   European Centre for Disease Control and Prevention, 2020, COR DIS 2019 COV 19
   Gruppo di lavoro ISS Malattie Rare COVID-19, 2020, CENS BIS 23 MARZ 5 A
   Joensen LE, 2020, DIABETIC MED, V37, P1146, DOI 10.1111/dme.14319
   MetabERN, 2020, COVID 19 RES
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Rare Diseases Ireland, 2020, LIV RAR DIS IR COVID
   Sechi A, 2020, MOL GENET METAB, V130, P170, DOI 10.1016/j.ymgme.2020.04.002
   World Health Organization, 2020, WHO COR DIS COVID 19
NR 13
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1750-1172
J9 ORPHANET J RARE DIS
JI Orphanet J. Rare Dis.
PD DEC 3
PY 2020
VL 15
IS 1
AR 341
DI 10.1186/s13023-020-01619-x
PG 14
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA PB5WV
UT WOS:000596391900002
PM 33272301
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Segrelles-Calvo, G
   Araujo, GRS
   Llopis-Pastor, E
   Carrillo, J
   Hernandez-Hernandez, M
   Rey, L
   Melean, NR
   Escribano, I
   Anton, E
   Zamarro, C
   Garcia-Salmones, M
   Frases, S
AF Segrelles-Calvo, Gonzalo
   Araujo, Glauber R. S.
   Llopis-Pastor, Estefania
   Carrillo, Javier
   Hernandez-Hernandez, Marta
   Rey, Laura
   Rodriguez Melean, Nestor
   Escribano, Ines
   Anton, Esther
   Zamarro, Celia
   Garcia-Salmones, Mercedes
   Frases, Susana
TI Prevalence of opportunistic invasive aspergillosis in COVID-19 patients
   with severe pneumonia
SO MYCOSES
LA English
DT Article; Early Access
DE COVID-19; invasive aspergillosis; lung disease; opportunistic mycosis
ID PULMONARY ASPERGILLOSIS; TOCILIZUMAB; INFECTIONS
AB Background: As the global coronavirus pandemic (COVID-19) spreads across the world, new clinical challenges emerge in the hospital landscape. Among these challenges, the increased risk of coinfections is a major threat to the patients. Although still in a low number, due to the short time of the pandemic, studies that identified a significant number of hospitalised patients with COVID-19 who developed secondary fungal infections that led to serious complications and even death have been published.
   Objectives: In this scenario, we aim to determine the prevalence of invasive fungal infections (IFIs) and describe possible associated risk factors in patients admitted due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
   Patients/Methods: We designed an open prospective observational study at the Rey Juan Carlos University Hospital (Mostoles, Spain), during the period from February 1 to April 30, 2020.
   Results: In this article, we reported seven patients with COVID-19-associated pulmonary aspergillosis (CAPA) who had a poor prognosis. Severely ill patients represent a high-risk group; therefore, we must actively investigate the possibility of aspergillosis in all of these patients. Larger cohort studies are needed to unravel the role of COVID-19 immunosuppressive therapy as a risk factor for aspergillosis.
   Conclusions: As the pandemic continues to spread across the world, further reports are needed to assess the frequency of emergent and highly resistant reemergent fungal infections during severe COVID-19. These coinfections are leading a significant number of patients with COVID-19 to death due to complications following the primary viral disease.
C1 [Segrelles-Calvo, Gonzalo; Llopis-Pastor, Estefania; Carrillo, Javier; Hernandez-Hernandez, Marta; Rey, Laura; Rodriguez Melean, Nestor; Escribano, Ines; Anton, Esther; Zamarro, Celia; Garcia-Salmones, Mercedes] Hosp Univ Rey Juan Carlos, Serv Neumol, Madrid, Spain.
   [Segrelles-Calvo, Gonzalo; Escribano, Ines] Fdn Jimenez Diaz, Inst Invest Biomed, Madrid, Spain.
   [Araujo, Glauber R. S.; Frases, Susana] Univ Fed Rio Janeiro, Inst Biofis Carlos Chagas Filho, Lab Biofis Fungos, Cidade Univ, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Carrillo, Javier; Garcia-Salmones, Mercedes] Hosp Univ Infanta Elena, Serv Neumol, Madrid, Spain.
RP Frases, S (corresponding author), Univ Fed Rio Janeiro, Inst Biofis Carlos Chagas Filho, Lab Biofis Fungos, Cidade Univ, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM susanafrases@biof.ufrj.br
OI FRASES, SUSANA/0000-0001-5875-9886; Araujo, Glauber Ribeiro de
   Sousa/0000-0002-5478-9006
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq)
FX Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
CR Alanio A, 2020, LANCET RESP MED, V8, pE48, DOI 10.1016/S2213-2600(20)30237-X
   Bradley BT, 2020, LANCET, V396, P320, DOI 10.1016/S0140-6736(20)31305-2
   Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404
   Brown L-AK, 2020, LANCET MICROBE, V1, pe152, DOI DOI 10.1016/S2666-5247(20)30091-4
   Bulpa P, 2007, EUR RESPIR J, V30, P782, DOI 10.1183/09031936.00062206
   Cala-Garcia JD, 2020, IMMUNOTHERAPY-UK, V12, P1127, DOI 10.2217/imt-2020-0154
   Das R, 2012, OVERVIEW CHANGING TR
   De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660
   Donnelly JP, 2020, CLIN INFECT DIS, V71, P1367, DOI 10.1093/cid/ciz1008
   Gastaldi R, 2017, JCR-J CLIN RHEUMATOL, V23, P451, DOI 10.1097/RHU.0000000000000592
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Hwang DM, 2005, MODERN PATHOL, V18, P1, DOI 10.1038/modpathol.3800247
   Jabaudon Matthieu, 2020, Chest, V158, P2394, DOI 10.1016/j.chest.2020.06.070
   Koehler P, 2020, MYCOSES, V63, P528, DOI 10.1111/myc.13096
   Mohamed A, 2020, J FUNGI, V6, DOI 10.3390/jof6030115
   Nasri E, 2020, MYCOPATHOLOGIA, DOI 10.1007/s11046-020-00493-2
   Nguyen Y, 2020, J INFECTION, V81, pE96, DOI 10.1016/j.jinf.2020.05.049
   Prattes Juergen, 2020, Med Mycol Case Rep, DOI 10.1016/j.mmcr.2020.05.001
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rutsaert L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00686-4
   Salehi M, 2020, MYCOPATHOLOGIA, V185, P607, DOI 10.1007/s11046-020-00472-7
   Salehi M, 2020, MYCOSES, V63, P771, DOI 10.1111/myc.13137
   Santana Monique Freire, 2020, Rev. Soc. Bras. Med. Trop., V53, pe20200401, DOI 10.1590/0037-8682-0401-2020
   Schauwvlieghe AFAD, 2018, LANCET RESP MED, V6, P782, DOI 10.1016/S2213-2600(18)30274-1
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   van Arkel ALE, 2020, AM J RESP CRIT CARE, V202, P132, DOI 10.1164/rccm.202004-1038LE
   Verweij Paul E, 2020, Lancet Microbe, V1, pe53, DOI 10.1016/S2666-5247(20)30027-6
   Verweij PE, 2020, INTENS CARE MED, V46, P1524, DOI 10.1007/s00134-020-06091-6
   Wu J H, 2020, Zhonghua Bing Li Xue Za Zhi, V49, P568, DOI 10.3760/cma.j.cn112151-20200405-00291
   Yamaguchi T, 2012, INTERNAL MED, V51, P2035, DOI 10.2169/internalmedicine.51.7342
   Zhang LP, 2020, FUTURE MICROBIOL, V15, P905, DOI 10.2217/fmb-2020-0063
NR 32
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0933-7407
EI 1439-0507
J9 MYCOSES
JI Mycoses
DI 10.1111/myc.13219
EA DEC 2020
PG 8
WC Dermatology; Mycology
SC Dermatology; Mycology
GA PA8SL
UT WOS:000595899100001
PM 33217071
OA Bronze
DA 2021-01-01
ER

PT J
AU Owusu-Mensah, I
   Akinyemi, L
   Oduro, B
   Iyiola, OS
AF Owusu-Mensah, Isaac
   Akinyemi, Lanre
   Oduro, Bismark
   Iyiola, Olaniyi S.
TI A fractional order approach to modeling and simulations of the novel
   COVID-19
SO ADVANCES IN DIFFERENCE EQUATIONS
LA English
DT Article
DE COVID-19 pandemic; Transmission rate; Fractional calculus; Modeling;
   Simulations
AB The novel coronavirus (SARS-CoV-2), or COVID-19, has emerged and spread at fast speed globally; the disease has become an unprecedented threat to public health worldwide. It is one of the greatest public health challenges in modern times, with no proven cure or vaccine. In this paper, our focus is on a fractional order approach to modeling and simulations of the novel COVID-19. We introduce a fractional type susceptible-exposed-infected-recovered (SEIR) model to gain insight into the ongoing pandemic. Our proposed model incorporates transmission rate, testing rates, and transition rate (from asymptomatic to symptomatic population groups) for a holistic study of the coronavirus disease. The impacts of these parameters on the dynamics of the solution profiles for the disease are simulated and discussed in detail. Furthermore, across all the different parameters, the effects of the fractional order derivative are also simulated and discussed in detail. Various simulations carried out enable us gain deep insights into the dynamics of the spread of COVID-19. The simulation results confirm that fractional calculus is an appropriate tool in modeling the spread of a complex infectious disease such as the novel COVID-19. In the absence of vaccine and treatment, our analysis strongly supports the significance reduction in the transmission rate as a valuable strategy to curb the spread of the virus. Our results suggest that tracing and moving testing up has an important benefit. It reduces the number of infected individuals in the general public and thereby reduces the spread of the pandemic. Once the infected individuals are identified and isolated, the interaction between susceptible and infected individuals diminishes and transmission reduces. Furthermore, aggressive testing is also highly recommended.
C1 [Owusu-Mensah, Isaac] Ohio Univ, Dept Math, Athens, OH 45701 USA.
   [Akinyemi, Lanre] Prairie View A&M Univ, Dept Math, Prairie View, TX USA.
   [Oduro, Bismark; Iyiola, Olaniyi S.] Calif Univ Penn, Dept Math & Phys Sci, California, PA 15419 USA.
   [Owusu-Mensah, Isaac] Univ Educ, Dept Sci Educ, Winneba, Mampong Ashanti, Ghana.
RP Iyiola, OS (corresponding author), Calif Univ Penn, Dept Math & Phys Sci, California, PA 15419 USA.
EM iyiola@calu.edu
CR Abu Arqub O, 2013, ABSTR APPL ANAL, DOI 10.1155/2013/378593
   Adeniyi M.O., 2020, SCI AFR, V9
   Ahmad R.S., 2015, THESIS ZARQA U, P10
   Akinyemi L, 2020, MATH COMPUT SIMULAT, V177, P556, DOI 10.1016/j.matcom.2020.05.021
   Akinyemi L, 2020, COMPUT APPL MATH, V39, DOI 10.1007/s40314-020-01212-9
   Akinyemi L, 2020, MATH METHOD APPL SCI, V43, P7442, DOI 10.1002/mma.6484
   Akinyemi L, 2020, ADV DIFFER EQU-NY, V2020, DOI 10.1186/s13662-020-02625-w
   Akinyemi L, 2020, MATH METHOD APPL SCI, V43, P4050, DOI 10.1002/mma.6173
   Akinyemi L, 2019, COMPUT APPL MATH, V38, DOI 10.1007/s40314-019-0977-3
   Alquran M, 2014, MATH SCI, V8, P153, DOI 10.1007/s40096-015-0141-1
   Anastassopoulou C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230405
   Arikoglu A, 2007, CHAOS SOLITON FRACT, V34, P1473, DOI 10.1016/j.chaos.2006.09.004
   Arqub O.A., 2013, J ADV RES APPL MATH, V5, P31, DOI [10.5373/jaram.1447.051912, DOI 10.5373/JARAM.1447.051912, 10.5373/jaram]
   Atilgan E, 2019, CHINA OCEAN ENG, V33, P477, DOI 10.1007/s13344-019-0045-1
   Baleanu D., 2010, NEW TRENDS NANOTECHN, DOI [10.1007/978-90-481-3293-5, DOI 10.1007/978-90-481-3293-5]
   Baleanu D, 2017, CHAOS SOLITON FRACT, V102, P99, DOI 10.1016/j.chaos.2017.02.007
   BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510
   CDC, COR DIS 2019 COVID 1
   Centers for Disease Control, COR DIS COVID 19 PAN
   Chitnis N, 2008, B MATH BIOL, V70, P1272, DOI 10.1007/s11538-008-9299-0
   Diekmann O., 2012, MATH TOOLS UNDERSTAN, DOI [10.1515/9781400845620, DOI 10.1515/9781400845620]
   Diethelm K, 2002, NONLINEAR DYNAM, V29, P3, DOI 10.1023/A:1016592219341
   El-Tawil M. A., 2012, INT J APPL MATH MECH, V8, P51
   Fang YQ, 2020, J MED VIROL, V92, P645, DOI 10.1002/jmv.25750
   Garrappa R, 2020, MATLAB CENTRAL FILE
   Garrappa R, 2010, INT J COMPUT MATH, V87, P2281, DOI 10.1080/00207160802624331
   Gbadamosi B, 2018, MATH COMPUT APPL, V23, DOI 10.3390/mca23030033
   Gumel AB, 2018, MATH METHOD APPL SCI, V41, P8488, DOI 10.1002/mma.4734
   He JH, 2003, APPL MATH COMPUT, V135, P73, DOI 10.1016/S0096-3003(01)00312-5
   He JH, 1999, COMPUT METHOD APPL M, V178, P257, DOI 10.1016/S0045-7825(99)00018-3
   Heesterbeek JAP, 2002, ACTA BIOTHEOR, V50, P189, DOI 10.1023/A:1016599411804
   Heinzel S., 1999, FORSCHUNG WISSENSCHA, P57
   HILFER R, 1995, PHYS REV E, V51, pR848, DOI 10.1103/PhysRevE.51.R848
   Iyiola O.S, 2015, INT J PURE APPL MATH, V98, P491, DOI [10.12732/ijpam.v98i4.8, DOI 10.12732/IJPAM.V98I4.8]
   Keeling M.J., 2008, MODELING INFECT DIS, DOI [DOI 10.1515/9781400841035, 10.1515/9781400841035]
   Kilbas A.A., 2006, THEORY APPL FRACTION, DOI [10.1016/S0304-0208(06)80001-0, DOI 10.1016/S0304-0208(06)80001-0, 10. 1016/S0304-0208(06)80001-0]
   Kumar A., 2016, COMMUNICATION NUMERI, V2016, P1, DOI [DOI 10.5899/2016/CNA-00235, 10.5899/2016/cna-00235]
   Kumar D, 2017, MATH METHOD APPL SCI, V40, P5642, DOI 10.1002/mma.4414
   Kumar D, 2018, CHINESE J PHYS, V56, P75, DOI 10.1016/j.cjph.2017.11.020
   Li KX, 2011, APPL MATH LETT, V24, P2019, DOI 10.1016/j.aml.2011.05.035
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Lin W, 2007, J MATH ANAL APPL, V332, P709, DOI 10.1016/j.jmaa.2006.10.040
   Liu T., 2020, TRANSMISSION DYNAMIC
   Mainardi F., 2010, FRACTIONAL CALCULUS, DOI [10.1142/p614, DOI 10.1142/P614]
   Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011
   Nasrolahpour H, 2013, COMMUN NONLINEAR SCI, V18, P2589, DOI 10.1016/j.cnsns.2013.01.005
   Nkamba LN, 2019, J BIOL DYNAM, V13, P26, DOI 10.1080/17513758.2018.1563218
   Odibat ZM, 2007, APPL MATH COMPUT, V186, P286, DOI 10.1016/j.amc.2006.07.102
   Oke SI, 2020, COMMUN MATH BIOL NEU, DOI 10.28919/cmbn/4513
   Okedoye A.M., 2020, SCI AFR, V2020
   Okosun KO, 2013, BIOSYSTEMS, V111, P83, DOI 10.1016/j.biosystems.2012.09.008
   Pu YF, 2007, J ALGORITHMS COMPUT, V1, P357, DOI 10.1260/174830107782424075
   Ray SS, 2005, APPL MATH COMPUT, V167, P561, DOI 10.1016/j.amc.2004.07.020
   Rong XM, 2020, MATH BIOSCI ENG, V17, P2725, DOI 10.3934/mbe.2020149
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Senol M., 2018, BALIKESIR UNIV BILIM, V20, P430, DOI DOI 10.25092/baunfbed.418471
   Senol M, 2020, COMMUN THEOR PHYS, V72, DOI 10.1088/1572-9494/ab7707
   Senol M, 2019, ADV DIFFER EQU-NY, V2019, DOI 10.1186/s13662-019-2397-5
   Senol M, 2016, J KING SAUD UNIV SCI, V28, P69, DOI 10.1016/j.jksus.2015.09.005
   Stutt ROJH, 2020, P ROY SOC A-MATH PHY, V476, DOI 10.1098/rspa.2020.0376
   Sun HG, 2018, COMMUN NONLINEAR SCI, V64, P213, DOI 10.1016/j.cnsns.2018.04.019
   Suryanto A, 2019, MATHEMATICS-BASEL, V7, DOI 10.3390/math7111100
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Tarasov VE, 2017, ANN PHYS-NEW YORK, V383, P579, DOI 10.1016/j.aop.2017.05.017
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   Yildirim A, 2009, INT J NONLIN SCI NUM, V10, P445
   Zhang Y, 2012, APPL MATH INFORM SCI, V6, P299
   Zurigat M, 2010, APPL MATH MODEL, V34, P24, DOI 10.1016/j.apm.2009.03.024
NR 68
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1687-1847
J9 ADV DIFFER EQU-NY
JI Adv. Differ. Equ.
PD DEC 3
PY 2020
VL 2020
IS 1
AR 683
DI 10.1186/s13662-020-03141-7
PG 21
WC Mathematics, Applied; Mathematics
SC Mathematics
GA PA3WH
UT WOS:000595569300001
PM 33288983
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Anantharaman, A
   Dusendang, JR
   Schmittdiel, JA
   Harzstark, AL
AF Anantharaman, Archana
   Dusendang, Jennifer R.
   Schmittdiel, Julie A.
   Harzstark, Andrea L.
TI SARS-CoV-2 Clinical Outcomes in Patients with Cancer in a Large
   Integrated Health Care System in Northern California
SO ONCOLOGIST
LA English
DT Article; Early Access
AB The SARS-CoV-2 (COVID-19) pandemic continues to affect many lives globally. Patients with cancer undergoing potentially immunosuppressive therapies appear to be at particular risk for the disease and its complications. Here, we describe the experience of patients with cancer within Kaiser Permanente, a large, integrated health system in Northern California. Between February 25, 2020, and June 8, 2020, 4,627 patients were diagnosed with COVID-19, of whom 33 had active cancer treatment within 180 days and 214 had a history of cancer. Patients with active cancer treatment had a statistically higher risk of requiring noninvasive ventilation (odds ratio [OR], 2.57; confidence interval [CI], 1.10-6.01), and there was a nonsignificant trend toward higher risk of death (OR, 2.78; CI, 0.92-8.43). Those with a history of cancer had comparable outcomes to those without cancer. These data demonstrate an increased risk of complications from COVID-19 for patients with active cancer treatment.
C1 [Anantharaman, Archana] Kaiser Permanente Northern Calif, Dept Hematol & Oncol, 501 J St,6th Floor, Sacramento, CA 95814 USA.
   [Dusendang, Jennifer R.; Schmittdiel, Julie A.] Kaiser Permanente Northern Calif, Div Res, Sacramento, CA 95814 USA.
   [Harzstark, Andrea L.] Kaiser Permanente Northern Calif, Dept Urol, Sacramento, CA 95814 USA.
RP Anantharaman, A (corresponding author), Kaiser Permanente Northern Calif, Dept Hematol & Oncol, 501 J St,6th Floor, Sacramento, CA 95814 USA.
EM archana.anatharaman@kp.org
CR Barlesi F, 2020, AM ASS CANC RES AACR, P28
   Garassino M, 2020, AM ASS CANC RES AACR, P28
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Myers LC, 2020, JAMA-J AM MED ASSOC, V323, P2195, DOI 10.1001/jama.2020.7202
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
DI 10.1002/onco.13602
EA DEC 2020
PG 5
WC Oncology
SC Oncology
GA PA0WR
UT WOS:000595337700001
PM 33210439
OA Bronze
DA 2021-01-01
ER

PT J
AU Indini, A
   Cattaneo, M
   Ghidini, M
   Rijavec, E
   Bareggi, C
   Galassi, B
   Gambini, D
   Ceriani, R
   Ceriotti, F
   Berti, E
   Grossi, F
AF Indini, Alice
   Cattaneo, Monica
   Ghidini, Michele
   Rijavec, Erika
   Bareggi, Claudia
   Galassi, Barbara
   Gambini, Donatella
   Ceriani, Rosalia
   Ceriotti, Ferruccio
   Berti, Emilio
   Grossi, Francesco
TI Triage process for the assessment of coronavirus disease 2019-positive
   patients with cancer: The ONCOVID prospective study
SO CANCER
LA English
DT Article; Early Access
DE coronavirus disease 2019 (COVID&#8208; 19); COVID&#8208; 19 antibody;
   COVID&#8208; 19 infection; triage; severe acute respiratory syndrome
   coronavirus 2 (SARS&#8211; CoV&#8208; 2)
ID COVID-19; SARS-COV-2; MILAN; RISK
AB Background Patients with cancer are considered at high risk for the novel respiratory illness coronavirus disease 2019 (COVID-19). General measures to keep COVID-19-free cancer divisions have been adopted worldwide. The objective of this study was to evaluate the efficacy of triage to identify COVID-19 among patients with cancer.
   Methods From March 20 to April 17, 2020, data were collected from patients who were treated or followed at the authors' institution in a prospective clinical trial. The primary endpoint was to estimate the cumulative incidence of COVID-19-positive patients who were identified using a triage process through the aid of medical and patient questionnaires. Based on a diagnostic algorithm, patients with suspect symptoms underwent an infectious disease specialist's evaluation and a COVID-19 swab. Serologic tests were proposed for patients who had symptoms or altered laboratory tests that did not fall into the diagnostic algorithm but were suspicious for COVID-19.
   Results Overall, 562 patients were enrolled. Six patients (1%) were diagnosed with COVID-19, of whom 4 (67%) had the disease detected through telehealth triage, and 2 patients (33%) without suspect symptoms at triage had the disease detected later. Seventy-one patients (13%) had suspect symptoms and/or altered laboratory tests that were not included in the diagnostic algorithm and, of these, 47 patients (73%) underwent testing for severe acute respiratory syndrome coronavirus 2 antibody: 6 (13%) were positive for IgG (n = 5) or for both IgM and IgG (n = 1), and antibody tests were negative in the remaining 41 patients.
   Conclusions The triage process had a positive effect on the detection of COVID-19 in patients with cancer. Telehealth triage was helpful in detecting suspect patients and to keep a COVID-19-free cancer center. The overall incidence of COVID-19 diagnosis (1%) and antibody positivity (13%) in patients with suspect symptoms was similar to that observed in the general population.
C1 [Indini, Alice; Cattaneo, Monica; Ghidini, Michele; Rijavec, Erika; Bareggi, Claudia; Galassi, Barbara; Gambini, Donatella; Ceriani, Rosalia; Grossi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Via Francesco Sforza 35, I-20122 Milan, Italy.
   [Cattaneo, Monica] Univ Udine, Dept Med, Udine, Italy.
   [Ceriotti, Ferruccio] IRCCS Fdn Ca Granda Maggiore Hosp Policlin, Clin Lab, Milan, Italy.
   [Berti, Emilio] IRCCS Fdn Ca Granda Maggiore Hosp Policlin, Dept Dermatol, Milan, Italy.
   [Berti, Emilio] Univ Milan, Dept Pathophysiol Surg & Transplantat, Milan, Italy.
RP Grossi, F (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM francesco.grossi@policlinico.mi.it
OI Gambini, Donatella/0000-0002-0709-536X
FU Italian fiscal contribution "5 x 1000" 2016
FX This work was supported in part by the Italian fiscal contribution "5 x
   1000" 2016 devolved to the Fondazione IRCCS Ca' Granda Ospedale Maggiore
   Policlinico.
CR Bogani G, 2020, GYNECOL ONCOL, V158, P262, DOI 10.1016/j.ygyno.2020.06.161
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   DiaSorin, DIAS LIAIS SARS COV
   Fondato da Enrico Mentana, 2020, COR ANC NUM DRAMM LO
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Indini A, 2020, EUR J CANCER, V135, P47, DOI 10.1016/j.ejca.2020.05.017
   Indini A, 2020, EUR J CANCER, V132, P17, DOI 10.1016/j.ejca.2020.03.024
   Kaltsas A, 2012, CURR OPIN INFECT DIS, V25, P423, DOI 10.1097/QCO.0b013e328355660b
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lazzerini M, 2020, LANCET GLOB HEALTH, V8, pE641, DOI 10.1016/S2214-109X(20)30110-8
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1156, DOI 10.1515/cclm-2020-0473
   Menges P, 2012, EUR SURG RES, V48, P180, DOI 10.1159/000338196
   Montesinos I, 2020, J CLIN VIROL, V128
   Morrison A, 2020, 188 CADTH, V188
   Nicastri E, 2020, INFECT DIS REP, V12, P3, DOI 10.4081/idr.2020.8543
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Snibe Diagnostics Shenzhen New Industries Biomedical Engineering Company Ltd, M5001E01 MAGLUMI 201
   Spina S, 2020, LANCET, V395, pE49, DOI 10.1016/S0140-6736(20)30493-1
   Tre-Hardy M, 2020, CLIN CHEM LAB MED, V58, P1357, DOI [10.1515/cclm-2020-0594, 10.1515/cclm-2020-0594.]
   Valenza F, 2020, TUMORI J, V106, P193, DOI 10.1177/0300891620923790
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Wang ZJ, 2020, JAMA ONCOL, V6, P631, DOI 10.1001/jamaoncol.2020.1198
   Warner JL, 2020, J CLIN ONCOL, V38, pLBA110, DOI [DOI 10.1200/JCO.2020.38.18_suppl.LBA110, 10.1200/JCO.2020.38.18_suppl.LBA110, DOI 10.1200/JCO.2020.38.18_SUPPL.LBA110]
   WHISENANT JG, 2020, J CLIN ONCOL S, V38, pNIL9, DOI DOI 10.1200/JCO.2020.38.18_suppl.LBA111
   WHO, 2020, COR DIS COVID 19 PAN
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 31
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
DI 10.1002/cncr.33366
EA DEC 2020
PG 11
WC Oncology
SC Oncology
GA OZ9DD
UT WOS:000595216800001
PM 33270908
OA Bronze
DA 2021-01-01
ER

PT J
AU Crowley, JP
   Bleakley, A
   Silk, K
   Young, DG
   Lambe, JL
AF Crowley, John P.
   Bleakley, Amy
   Silk, Kami
   Young, Dannagal G.
   Lambe, Jennifer L.
TI Uncertainty Management and Curve Flattening Behaviors in the Wake of
   COVID-19's First Wave
SO HEALTH COMMUNICATION
LA English
DT Article
AB The coronavirus (COVID-19) outbreak poses a substantial threat to public health. Individual efforts to engage in COVID-19 precautionary behaviors are necessary to flatten the pandemic's curve in the waiting period before a vaccine is developed. This study sought to apply the Theory of Motivated Information Management to investigate the relationships among COVID-19 illness uncertainty, information management, and actual precautionary behaviors, both preparatory and preventative. The results of a national opt-in online panel demonstrate that uncertainty discrepancy, anxiety, and information management strategies are key predictors of the adoption of COVID-19 preparation and prevention behaviors. The results further identify diverging associations across age groups with respect to associations between information management and precautionary behaviors. Implications for theory and practice are discussed.
C1 [Crowley, John P.; Bleakley, Amy; Silk, Kami; Young, Dannagal G.; Lambe, Jennifer L.] Univ Delaware, Dept Commun, 250 Pearson Hall, Newark, DE 19716 USA.
RP Crowley, JP (corresponding author), Univ Delaware, Dept Commun, 250 Pearson Hall, Newark, DE 19716 USA.
EM jpcrow@udel.edu
OI Bleakley, Amy/0000-0002-4539-4424
FU College of Arts AMP; Sciences, University of Delaware
FX This research was supported by the College of Arts & Sciences,
   University of Delaware.
CR Afifi WA, 2004, PERS RELATIONSHIP, V11, P429, DOI 10.1111/j.1475-6811.2004.00091.x
   Afifi WA, 2004, COMMUN THEOR, V14, P167, DOI 10.1111/j.1468-2885.2004.tb00310.x
   Berger C.R., 1975, HUMAN COMMUNICATION, V1       (2), DOI [10.1111/j.1468-2958.1975.tb00258.x, DOI 10.1111/J.1468-2958.1975.TB00258.X]
   Brashers DE, 2000, COMMUN MONOGR, V67, P63, DOI 10.1080/03637750009376495
   Center for Disease Control, 2020, SEV OUTC PAT COR DIS
   Center for Disease Control, 2020, PEOPL WHO NEED TAK E
   Chater N, 2020, NAT HUM BEHAV, V4, P439, DOI 10.1038/s41562-020-0865-2
   Enli G, 2018, SOC MEDIA SOC, V4, DOI 10.1177/2056305118764430
   Goodall CE, 2013, HEALTH COMMUN, V28, P63, DOI 10.1080/10410236.2012.689096
   Heilman RM, 2010, EMOTION, V10, P257, DOI 10.1037/a0018489
   Kuang K., 2020, COMMUN THEOR, DOI [10.1093/ct/qtz025, DOI 10.1093/CT/QTZ025]
   Kuang K, 2017, J COMMUN, V67, P378, DOI 10.1111/jcom.12299
   Mishel M H, 1990, Image J Nurs Sch, V22, P256
   Thunstrom L., 2020, BEHAV PUBLIC POLICY, P1, DOI [10.1017/bpp.2020.15, DOI 10.1017/BPP.2020.15]
   Van Volkom M, 2013, EDUC GERONTOL, V39, P729, DOI 10.1080/03601277.2012.756322
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wong NCH, 2014, COMMUN Q, V62, P75, DOI 10.1080/01463373.2013.860905
   World Health Organization, 2020, COR DIS 2019 COVID 1
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1041-0236
EI 1532-7027
J9 HEALTH COMMUN
JI Health Commun.
PD JAN 2
PY 2021
VL 36
IS 1
SI SI
BP 32
EP 41
DI 10.1080/10410236.2020.1847452
EA DEC 2020
PG 10
WC Communication; Health Policy & Services
SC Communication; Health Care Sciences & Services
GA PC2WI
UT WOS:000596216400001
PM 33256466
OA Bronze
DA 2021-01-01
ER

PT J
AU Wu, YY
   Wang, SH
   Wu, CH
   Yen, LC
   Lai, HF
   Ho, CL
   Chiu, YL
AF Wu, Yi-Ying
   Wang, Sheng-Huei
   Wu, Chih-Hsien
   Yen, Li-Chen
   Lai, Hsing-Fan
   Ho, Ching-Liang
   Chiu, Yi-Lin
TI In silico immune infiltration profiling combined with functional
   enrichment analysis reveals a potential role for naive B cells as a
   trigger for severe immune responses in the lungs of COVID-19 patients
SO PLOS ONE
LA English
DT Article
ID EXPRESSION; MACROPHAGES; FIBROSIS; DIFFERENTIATION; POPULATION;
   INFECTION; ADHESION; PATHWAY; IL-12; LFA-1
AB COVID-19, caused by SARS-CoV-2, has rapidly spread to more than 160 countries worldwide since 2020. Despite tremendous efforts and resources spent worldwide trying to explore antiviral drugs, there is still no effective clinical treatment for COVID-19 to date. Approximately 15% of COVID-19 cases progress to pneumonia, and patients with severe pneumonia may die from acute respiratory distress syndrome (ARDS). It is believed that pulmonary fibrosis from SARS-CoV-2 infection further leads to ARDS, often resulting in irreversible impairment of lung function. If the mechanisms by which SARS-CoV-2 infection primarily causes an immune response or immune cell infiltration can be identified, it may be possible to mitigate excessive immune responses by modulating the infiltration and activation of specific targets, thereby reducing or preventing severe lung damage. However, the extent to which immune cell subsets are significantly altered in the lung tissues of COVID-19 patients remains to be elucidated. This study applied the CIBERSORT-X method to comprehensively evaluate the transcriptional estimated immune infiltration landscape in the lung tissues of COVID-19 patients and further compare it with the lung tissues of patients with idiopathic pulmonary fibrosis (IPF). We found a variety of immune cell subtypes in the COVID-19 group, especially naive B cells were highly infiltrated. Comparison of functional transcriptomic analyses revealed that non-differentiated naive B cells may be the main cause of the over-active humoral immune response. Using several publicly available single-cell RNA sequencing data to validate the genetic differences in B-cell populations, it was found that the B-cells collected from COVID-19 patients were inclined towards naive B-cells, whereas those collected from IPF patients were inclined towards memory B-cells. Further differentiation of B cells between COVID-19 mild and severe patients showed that B cells from severe patients tended to be antibody-secreting cells, and gene expression showed that B cells from severe patients were similar to DN2 B cells that trigger extrafollicular response. Moreover, a higher percentage of B-cell infiltration seems associated with poorer clinical outcome. Finally, a comparison of several specific COVID-19 cases treated with targeted B-cell therapy suggests that appropriate suppression of naive B cells might potentially be a novel strategy to alleviate the severe symptoms of COVID-19.
C1 [Wu, Yi-Ying; Ho, Ching-Liang] Tri Serv Gen Hosp, Div Hematol & Oncol Med, Dept Internal Med, Natl Def Med Ctr, Taipei, Taiwan.
   [Wang, Sheng-Huei] Tri Serv Gen Hosp, Div Pulm & Crit Care Med, Dept Internal Med, Natl Def Med Ctr, Taipei, Taiwan.
   [Wang, Sheng-Huei] Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan.
   [Wu, Chih-Hsien; Lai, Hsing-Fan; Chiu, Yi-Lin] Natl Def Med Ctr, Dept Biochem, Taipei, Taiwan.
   [Yen, Li-Chen] Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei, Taiwan.
   [Lai, Hsing-Fan] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.
RP Chiu, YL (corresponding author), Natl Def Med Ctr, Dept Biochem, Taipei, Taiwan.
EM yc566@georgetown.edu
OI Chiu, Yilin/0000-0002-1827-6924
FU Ministry of National Defense-Medical Affairs Bureau [MND-MAB-109-021];
   Tri-Service General Hospital [TSGH-C108-044, TSGH-E-109213]; Ministry of
   Science and Technology, Taiwan (R.O.C.)Ministry of Science and
   Technology, Taiwan [MOST108-2311-B-016-001-, MOST109-2320-B-016-004-,
   MOST108-2635-B-016-001-, MOST108-2314-B-016-036-,
   MOST109-2314-B-016-050-]
FX This work was supported by grants from Ministry of National
   Defense-Medical Affairs Bureau [MND-MAB-109-021 to YLC], Tri-Service
   General Hospital [TSGH-C108-044 and TSGH-E-109213 to YYW] and the
   Ministry of Science and Technology, Taiwan (R.O.C.)
   [MOST108-2311-B-016-001-and MOST109-2320-B-016-004-to YLC;
   MOST108-2635-B-016-001-to YYW; MOST108-2314-B-016-036-and
   MOST109-2314-B-016-050-to CLH].
CR Agematsu K, 2002, CLIN IMMUNOL, V103, P34, DOI 10.1006/clim.2001.5197
   Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033]
   Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Asai Y, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1216-6
   Benson MJ, 2008, J IMMUNOL, V180, P3655, DOI 10.4049/jimmunol.180.6.3655
   Borriello G, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102165
   Byrne AJ, 2016, TRENDS MOL MED, V22, P303, DOI 10.1016/j.molmed.2016.02.004
   Cabrera-Benitez NE, 2014, ANESTHESIOLOGY, V121, P189, DOI 10.1097/ALN.0000000000000264
   Carrasco YR, 2004, IMMUNITY, V20, P589, DOI 10.1016/S1074-7613(04)00105-0
   Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12
   Chen TL, 2020, J GERONTOL A-BIOL, V75, P1788, DOI 10.1093/gerona/glaa089
   Choi YS, 2008, J EXP MED, V205, P3053, DOI 10.1084/jem.20080979
   Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4
   Chun J, 2010, CLIN NEUROPHARMACOL, V33, P91, DOI 10.1097/WNF.0b013e3181cbf825
   Davids MS, 2014, FUTURE ONCOL, V10, P957, DOI 10.2217/fon.14.51
   DePianto DJ, 2015, THORAX, V70, P48, DOI 10.1136/thoraxjnl-2013-204596
   Drennan S, 2019, CLIN CANCER RES, V25, P2503, DOI 10.1158/1078-0432.CCR-18-1286
   Dubois B, 1998, J IMMUNOL, V161, P2223
   Ehrhardt GRA, 2008, J EXP MED, V205, P1807, DOI 10.1084/jem.20072682
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3
   Giblin PA, 2006, CURR PHARM DESIGN, V12, P2771, DOI 10.2174/138161206777947731
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guilliams M, 2013, J EXP MED, V210, P1977, DOI 10.1084/jem.20131199
   Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004
   Heukels P, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1195-7
   Hjelmesath Joran, 2020, Tidsskr Nor Laegeforen, V140, DOI 10.4045/tidsskr.20.0287
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huaux F, 2003, J IMMUNOL, V170, P2083, DOI 10.4049/jimmunol.170.4.2083
   Hull J.H., 2020, LANCET RESP MED
   Huse K, 2019, CYTOM PART A, V95A, P442, DOI 10.1002/cyto.a.23737
   Hussein HAM, 2015, ARCH VIROL, V160, P2669, DOI 10.1007/s00705-015-2579-8
   Huwiler A, 2018, MATRIX BIOL, V68-69, P230, DOI 10.1016/j.matbio.2018.01.006
   Jenks SA, 2019, IMMUNOL REV, V288, P136, DOI 10.1111/imr.12741
   Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015
   Keane MP, 2001, AM J PHYSIOL-LUNG C, V281, pL92
   Klopfenstein T, 2020, CLIN RES HEPATOL GAS, V44, P282, DOI 10.1016/j.clinre.2020.04.002
   Lam JH, 2019, J IMMUNOL, V202, P351, DOI 10.4049/jimmunol.1801208
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Libraty DH, 2007, VIROLOGY, V368, P317, DOI 10.1016/j.virol.2007.07.015
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lu TT, 2002, SCIENCE, V297, P409, DOI 10.1126/science.1071632
   Luca Carsana M., 2020, LANCET INFECT DIS
   Ma DY, 2009, SEMIN IMMUNOL, V21, P265, DOI 10.1016/j.smim.2009.05.010
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   McDonough JE, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131597
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Mo XN, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01217-2020
   Morse C, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.02441-2018
   Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nielsen Sandra C. A., 2020, INFECT DIS
   Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795
   Patruno C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13502
   Putzki N, 2010, EUR NEUROL, V63, P311, DOI 10.1159/000302687
   Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013
   Raedler Lisa A, 2016, Am Health Drug Benefits, V9, P89
   Rohr-Udilova N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24437-5
   Saraste M, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000292
   Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653
   Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070
   Sorman A, 2014, MOL IMMUNOL, V61, P79, DOI 10.1016/j.molimm.2014.06.010
   Spaargaren M, 2003, J EXP MED, V198, P1539, DOI 10.1084/jem.20011866
   Spagnolo P, 2020, LANCET RESP MED, V8, P750, DOI 10.1016/S2213-2600(20)30222-8
   Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Teoh AKY, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01855-2019
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   The Lancet Hiv null, 2020, LANCET HIV, V7, pe75
   Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175
   Treon SP, 2020, BLOOD, V135, P1912, DOI 10.1182/blood.2020006288
   Verma NK, 2017, J IMMUNOL, V199, P1213, DOI 10.4049/jimmunol.1700495
   Vihinen M, 2000, FRONT BIOSCI-LANDMRK, V5, pD917, DOI 10.2741/vihinen
   Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605
   Waffarn EE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9991
   Waffarn EE, 2011, J IMMUNOL, V186, P3823, DOI 10.4049/jimmunol.1002090
   Wang HS, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00099
   Wang WJ, 2020, CELL MOL IMMUNOL, V17, P650, DOI 10.1038/s41423-020-0447-2
   Wei C, 2007, J IMMUNOL, V178, P6624, DOI 10.4049/jimmunol.178.10.6624
   Wen Wen, 2020, IMMUNE CELL PROFILIN
   Woodruff Matthew, 2020, B CELL ACTIVATION
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   WYNN TA, 1995, NATURE, V376, P594, DOI 10.1038/376594a0
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xu HP, 2015, NAT IMMUNOL, V16, P1274, DOI 10.1038/ni.3287
   Xue JM, 2013, J IMMUNOL, V191, P2089, DOI 10.4049/jimmunol.1203476
   Yang XD, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1964-6
   Yao X, 2020, CLIN INFECT DIS
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zemans RL, 2009, AM J RESP CELL MOL, V40, P519, DOI 10.1165/rcmb.2008-0348TR
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 94
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2020
VL 15
IS 12
AR e0242900
DI 10.1371/journal.pone.0242900
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB8MS
UT WOS:000596569200020
PM 33264345
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ramirez-Guerrero, G
   Cifuentes, VT
   Hernandez, RB
   Cortes, FV
   Doll, SR
   Alarcon, RO
   Cordova, CL
   Fernandez, PF
   Coloma, OG
AF Ramirez-Guerrero, Gonzalo
   Torres Cifuentes, Vicente
   Baghetti Hernandez, Romyna
   Villagran Cortes, Francisco
   Rojas Doll, Simon
   Oliva Alarcon, Rocio
   Lucero Cordova, Cristian
   Flores Fernandez, Pablo
   Garay Coloma, Osvaldo
TI Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal
   Therapies (HA-380 plus High Volume Hemofiltration) May Prevent
   Progression of Acute Respiratory Distress Syndrome: Case Report
SO BLOOD PURIFICATION
LA English
DT Article; Early Access
DE COVID-19; Acute respiratory distress syndrome; Cytokine release
   syndrome; Hemadsorption
AB We present the case of a patient who suffered from acute respiratory distress syndrome caused by pneumonia associated with COVID-19 and cytokine release syndrome. This patient received a high-volume hemofiltration plus adsorption, solving the hemodynamic deterioration, pulmonary infiltrates, and gas exchange. Our clinical case proposes that the extracorporeal therapies can have a role in the management of severe COVID-19. (c) 2020 S. Karger AG, Basel
C1 [Ramirez-Guerrero, Gonzalo; Torres Cifuentes, Vicente; Baghetti Hernandez, Romyna; Villagran Cortes, Francisco; Rojas Doll, Simon; Oliva Alarcon, Rocio; Lucero Cordova, Cristian; Flores Fernandez, Pablo; Garay Coloma, Osvaldo] Carlos Van Buren Hosp, Crit Care Unit, Valparaiso, Chile.
   [Ramirez-Guerrero, Gonzalo; Torres Cifuentes, Vicente; Villagran Cortes, Francisco] Carlos Van Buren Hosp, Dialysis & Renal Trasplant Unit, Valparaiso, Chile.
RP Ramirez-Guerrero, G (corresponding author), Carlos Van Buren Hosp, Nephrol & Crit Care, San Ignacio 725, Valparaiso, Chile.
EM ramirezguerrero.g@gmail.com
CR Esmaeili Vardanjani Ali, 2020, Blood Purif, P1, DOI 10.1159/000509107
   Huang Z, 2013, THER APHER DIAL, V17, P454, DOI 10.1111/j.1744-9987.2012.01083.x
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Ronco C, 2020, BLOOD PURIFICAT, V49, P255, DOI [10.1159/000507039, 10.1159/000508125]
   Tapia P, 2012, J TRAUMA ACUTE CARE, V72, P1228, DOI 10.1097/TA.0b013e318248bc6c
   You B, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2095-9
NR 6
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0253-5068
EI 1421-9735
J9 BLOOD PURIFICAT
JI Blood Purif.
DI 10.1159/000512982
EA DEC 2020
PG 3
WC Hematology; Urology & Nephrology
SC Hematology; Urology & Nephrology
GA PA2FJ
UT WOS:000595448600001
PM 33264786
DA 2021-01-01
ER

PT J
AU Huang, S
   Shen, CX
   Xia, CL
   Huang, XX
   Fu, YR
   Tian, L
AF Huang, Shuang
   Shen, Changxin
   Xia, Chengliang
   Huang, Xiaoxing
   Fu, Yourong
   Tian, Li
TI A Retrospective Study on the Effects of Convalescent Plasma Therapy in
   24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020
   at 2 Centers in Wuhan, China
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE COVID-19; Plasma; SARS Virus
AB Background: This retrospective study aimed to describe the effects of convalescent plasma therapy in 24 patients diagnosed with coronavirus disease 2019 (COVID-19) pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during February and March 2020 in Wuhan, China.
   Materia/Methods: The confirmation of SARS-CoV-2 infection was made by the reverse transcription-polymerase chain reaction test. We retrospectively analyzed the clinical data and laboratory test reports of patients with severe COVID-19 pneumonia who received a convalescent plasma transfusion.
   Results: A total of 24 patients with COVID-19 pneumonia who were transfused with ABO-compatible convalescent plasma were enrolled in the study. Convalescent plasma transfusion showed an effective clinical outcome in 14 of 24 patients (an effective rate of 58.3%). No patients had an adverse reaction to the transfusion. Compared with before convalescent plasma transfusion, the lymphocyte count after convalescent plasma transfusion increased to a normal level (median: 0.80x10(9)/L vs. 1.12x10(9)/L, P=0.004). Other laboratory indicators such as white blood cells, high-sensitivity C-reactive protein, procalcitonin, alanine aminotransferase, and aspartate transaminase showed a decreasing trend after transfusion.
   Conclusions: This retrospective observational clinical study showed that convalescent plasma therapy could have beneficial effects on patient outcomes. Recently, regulatory authorization has been given for the use of convalescent plasma therapy, and clinical guidelines have been developed for the collection and use of convalescent plasma and hyperimmune immunoglobulin in patients with COVID-19.
C1 [Huang, Shuang; Shen, Changxin; Xia, Chengliang; Huang, Xiaoxing; Fu, Yourong; Tian, Li] Wuhan Univ, Dept Blood Transfus, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
RP Tian, L (corresponding author), Wuhan Univ, Dept Blood Transfus, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
EM litian1971@126.com
FU Zhongnan Hospital of Wuhan University
FX We would like to thank Zhongnan Hospital of Wuhan University and Wuhan
   Leishenshan Hospital for their assistance in completing this study and
   all COVID-19 patients who participated in this study for their active
   cooperation.
CR Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Factsheet F, 2020, EM US AUTH EUA REC U
   Harvala H, 2020, EUROSURVEILLANCE, V25
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P1, DOI DOI 10.1001/jama.2020.10044
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Pal P, 2020, TRANSFUSION MED, DOI 10.1111/tme.12729
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   TANNE JH, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1256
   Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002
   US Food and Drug Administration, 2020, COVID 19 CONV PLASM
   VALK SJ, 2020, COCHRANE DB SYST REV, V5
   WHO, 2020, US LAB METH SARS DIA
   World Health Organization, 2020, EU PROGR COVID 19 CO
   Zeng H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00329-x
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 22
TC 0
Z9 0
U1 0
U2 0
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD DEC 2
PY 2020
VL 26
AR e928755
DI 10.12659/MSM.928755
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OZ6SU
UT WOS:000595054200001
PM 33264276
OA Green Published
DA 2021-01-01
ER

PT J
AU Norgard, BM
   Nielsen, J
   Knudsen, T
   Nielsen, RG
   Larsen, MD
   Jolving, LR
   Kjeldsen, J
AF Norgard, Bente Mertz
   Nielsen, Jan
   Knudsen, Torben
   Nielsen, Rasmus Gaardskaer
   Larsen, Michael Due
   Jolving, Line Riis
   Kjeldsen, Jens
TI Hospitalization for COVID-19 in patients treated with selected
   immunosuppressant and immunomodulating agents, compared to the general
   population: A Danish cohort study
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Early Access
DE biologics; clinical epidemiology; COVID&#8208; 19; hospitalization;
   immunosuppressive; pharmacoepidemiology; thiopurines
ID CIVIL REGISTRATION SYSTEM; MECHANISMS; MAINTENANCE; PREVENTION; DISEASE;
   RISK
AB Aims In the Danish population, we examined whether patients treated with thiopurines, methotrexate, systemic corticosteroids, anti-tumour necrosis factor (TNF)-alpha agents, anti-interleukin therapeutic agents, selective immunosuppressive agents and cyclosporine/tacrolimus had an increased risk of hospitalization for COVID- 19, compared to the background population.
   Methods A nationwide cohort study including all people alive in Denmark on 1 March 2020. Exposed patients constituted those exposed to thiopurines (n = 5484), methotrexate (n = 17 977), systemic corticosteroids (n = 55 868), anti-TNF-alpha agents (n = 17 857), anti-interleukin therapeutic agents (n = 3744), selective immunosuppressive agents (n = 3026) and cyclosporine/tacrolimus (n = 1143) in a period of 12 months prior to 1 March 2020 (estimated time of outbreak in Denmark). We estimated the adjusted risk of hospitalization for COVID-19 for patients treated with the above-mentioned categories of medications, compared to the rest of the population.
   Results The adjusted odds ratios of hospitalization in patients treated with corticosteroids and cyclosporine/tacrolimus were 1.64 (95% confidence interval [CI] 1.35 to 2.00) and 4.75 (95% CI 1.96 to 11.49), respectively. The risks of hospitalization in patients treated with thiopurines, methotrexate, and anti-TNF-alpha agents, were 1.93 (95% CI 0.91 to 4.08), 0.74 (95% CI 0.43 to 1.28), 1.00 (95% CI 0.52 to 1.94), respectively. The number of outcomes in patients treated with anti-interleukin therapeutic agents and selective immunosuppressive agents was too small for analysis.
   Conclusion Patients treated with systemic corticosteroids and cyclosporine/tacrolimus had a significantly increased risk of being hospitalized for COVID-19. Our study does not uncover whether the increased risk is related to the drug itself, the underlying condition for which the patient is treated or other factors.
C1 [Norgard, Bente Mertz; Nielsen, Jan; Larsen, Michael Due; Jolving, Line Riis] Odense Univ Hosp, Ctr Clin Epidemiol, Sdr Blvd 29,Entrance 216, DK-5000 Odense C, Denmark.
   [Norgard, Bente Mertz; Nielsen, Jan; Jolving, Line Riis] Univ Southern Denmark, Dept Clin Res, Res Unit Clin Epidemiol, Odense, Denmark.
   [Knudsen, Torben] Hosp Southwest Jutland, Dept Med, Esbjerg, Denmark.
   [Knudsen, Torben] Univ Southern Denmark, Ctr Southwest Jutland, Dept Reg Hlth Sci, Esbjerg, Denmark.
   [Nielsen, Rasmus Gaardskaer] Odense Univ Hosp, Hans Christian Andersen Childrens Hosp, Odense, Denmark.
   [Nielsen, Rasmus Gaardskaer] Univ Southern Denmark, Dept Clin Res, Res Unit Pediat, Odense, Denmark.
   [Larsen, Michael Due] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway.
   [Kjeldsen, Jens] Odense Univ Hosp, Dept Med Gastroenterol S, Odense, Denmark.
   [Kjeldsen, Jens] Univ Southern Denmark, Dept Clin Res, Res Unit Med Gastroenterol, Odense, Denmark.
RP Norgard, BM (corresponding author), Odense Univ Hosp, Ctr Clin Epidemiol, Sdr Blvd 29,Entrance 216, DK-5000 Odense C, Denmark.
EM bente.noergaard@rsyd.dk
RI ; Knudsen, Torben/V-6176-2018
OI Larsen, Michael Due/0000-0002-0623-2481; Knudsen,
   Torben/0000-0003-0726-0115; Norgard, Bente Mertz/0000-0002-9514-3033
FU PfizerPfizer; Beckett foundation
FX Pfizer; the Beckett foundation, Grant/Award Number: No number
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Al-Ani AH, 2020, ALIMENT PHARM THER, V52, P54, DOI 10.1111/apt.15779
   An P, 2020, LANCET GASTROENTEROL, V5, P525, DOI 10.1016/S2468-1253(20)30121-7
   Barshes NR, 2004, FRONT BIOSCI-LANDMRK, V9, P411, DOI 10.2741/1249
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Bruno V, 2011, NEUROL SCI, V31, pS283, DOI 10.1007/s10072-010-0382-6
   Ceribelli A, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102442
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Cholapranee A, 2017, ALIMENT PHARM THER, V45, P1291, DOI 10.1111/apt.14030
   Coates PT, 2020, KIDNEY INT, V97, P1074, DOI 10.1016/j.kint.2020.04.001
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Gisondi P, 2020, J AM ACAD DERMATOL, V83, P285, DOI 10.1016/j.jaad.2020.04.085
   Gutin LS, 2020, DIGEST DIS SCI, V65, P1571, DOI 10.1007/s10620-020-06299-y
   Hafeez U, 2018, CURR OPIN PHARMACOL, V41, P114, DOI 10.1016/j.coph.2018.05.010
   Hamer M, 2020, BRAIN BEHAV IMMUN, V87, P184, DOI 10.1016/j.bbi.2020.05.059
   Jamilloux Y, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102390
   Kirchgesner J, 2018, GASTROENTEROLOGY, V155, P337, DOI 10.1053/j.gastro.2018.04.012
   Kutlu O, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13383
   Lauterio A, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13334
   Leroy C, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0332-8
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lukin DJ, 2020, GASTROENTEROLOGY, V159, P1541, DOI 10.1053/j.gastro.2020.05.066
   Nasiri S, 2020, J DERMATOL TREAT, V31, P448, DOI 10.1080/09546634.2020.1764904
   Neurath MF, 2020, GUT, V69, P1335, DOI 10.1136/gutjnl-2020-321269
   O'Shea JJ, 2013, ANN RHEUM DIS, V72, P111, DOI 10.1136/annrheumdis-2012-202576
   Pedersen CB, 2006, DAN MED BULL, V53, P441
   Pottegard A, 2017, INT J EPIDEMIOL, V46, P798, DOI 10.1093/ije/dyw213
   Rahier JF, 2014, J CROHNS COLITIS, V8, P443, DOI 10.1016/j.crohns.2013.12.013
   Ramamoorthy S, 2016, RHEUM DIS CLIN N AM, V42, P15, DOI 10.1016/j.rdc.2015.08.002
   Sarzi-Puttini P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102574
   Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8
   Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125
   Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3
   Song J, 2020, RHEUMATOL INT, V40, P991, DOI 10.1007/s00296-020-04584-7
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 38
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
DI 10.1111/bcp.14622
EA DEC 2020
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ7HP
UT WOS:000595092900001
PM 33098713
OA Bronze
DA 2021-01-01
ER

PT J
AU Mariottini, C
   Ojanpera, I
   Kriikku, P
AF Mariottini, Claudia
   Ojanpera, Ilkka
   Kriikku, Pirkko
TI Increase in drugs-of-abuse findings in post-mortem toxicology due to
   COVID-19 restrictions-First observations in Finland
SO DRUG TESTING AND ANALYSIS
LA English
DT Article; Early Access
DE COVID&#8208; 19; drug&#8208; related death; harm&#8208; reduction;
   post&#8208; mortem toxicology
AB A lot has been published on the anticipated effects of the current COVID-19 pandemic on users of illegal drugs. In this study, we present evidence-based data on such effects, namely, the increased number of drug findings in post-mortem investigations. All post-mortem toxicology cases positive for at least one of the following: buprenorphine, amphetamine or cannabis, were investigated in the first 8 months of the year 2020, and the monthly numbers were compared to those in the previous 5 years from 2015 to 2019. These substances served as indicator analytes that could reveal changes in the drug using population. Right after the government restrictions came into force in March 2020, the numbers of buprenorphine, amphetamine and cannabis findings increased. The increase was most noticeable for amphetamine and was evident in all age groups. Our findings indicate that the assumptions on the increased risk of drug-related harm (including death) have become reality. Reduced access to harm-reduction services seems to have increased the mortality among individuals that use buprenorphine, amphetamine or cannabis. Significant and prompt actions need to be taken in order to find new ways in helping this vulnerable group of people.
C1 [Mariottini, Claudia; Ojanpera, Ilkka; Kriikku, Pirkko] Univ Helsinki, Dept Forens Med, Helsinki, Finland.
   [Ojanpera, Ilkka; Kriikku, Pirkko] Finnish Inst Hlth & Welf, Forens Toxicol Unit, POB 30, Helsinki 00271, Finland.
RP Kriikku, P (corresponding author), Finnish Inst Hlth & Welf, Forens Toxicol Unit, POB 30, Helsinki 00271, Finland.
EM pirkko.kriikku@thl.fi
RI ; Kriikku, Pirkko/G-5962-2012
OI Mariottini, Claudia/0000-0002-6744-7689; Kriikku,
   Pirkko/0000-0002-5721-2827
CR Chiappini S, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00767
   Dietze PM, 2020, DRUG ALCOHOL REV, V39, P297, DOI 10.1111/dar.13079
   Dunlop A, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00370-7
   EMCDDA, 2020, TRENDSP BRIEF IMP CO
   Jacka Brendan P, 2020, Int J Drug Policy, V83, P102895, DOI 10.1016/j.drugpo.2020.102895
   Kriikku P, 2020, DUODECIM, V136, P1389
   Mallet Jasmina, 2021, Prog Neuropsychopharmacol Biol Psychiatry, V106, P110070, DOI 10.1016/j.pnpbp.2020.110070
   Marsden J, 2020, ADDICTION, V115, P1007, DOI 10.1111/add.15080
   Tyndall Mark, 2020, Int J Drug Policy, V83, P102880, DOI 10.1016/j.drugpo.2020.102880
   Vasylyeva TI, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25583
   Vecchio S, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113047
   Whitfield Mark, 2020, Int J Drug Policy, V83, P102851, DOI 10.1016/j.drugpo.2020.102851
   Zaami S, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00700
NR 13
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1942-7603
EI 1942-7611
J9 DRUG TEST ANAL
JI Drug Test. Anal.
DI 10.1002/dta.2982
EA DEC 2020
PG 4
WC Biochemical Research Methods; Chemistry, Analytical; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA OZ5JS
UT WOS:000594962600001
PM 33217177
OA Bronze
DA 2021-01-01
ER

PT J
AU Brustowicz, RM
   Yuki, K
AF Brustowicz, Robert M.
   Yuki, Koichi
TI A simple screening test of filtration efficiency for protecting the gas
   sampling line from coronavirus using fluorescent microspheres
SO PEDIATRIC ANESTHESIA
LA English
DT Article
DE anesthesia machine; coronavirus; dead space; filter; fluorescence
   microsphere
AB Background During the coronavirus pandemic, preventing contamination of the anesthesia machine, critical to avoid cross-contamination between patients, has proven challenging when treating premature infants and neonates. While attaching a HEPA filter to the endotracheal tube will protect the anesthesia machine and the gas sampling line from contamination, this contribution to the dead space makes ventilation of these small patients challenging. Direct filtration of the gas sampling line eliminates this problem; however, appropriate filters are not readily available.
   Aims Identify a small filter capable of filtering out particles of a size similar to the SARS-CoV-2 virus for the gas sampling line.
   Methods We used fluorescence microspheres suspended in a solution for a challenge test to determine the filtration efficiency of various filters. The microspheres varied in diameter (0.02 mu m, 0.042 mu m, 0.109 mu m, and 0.989 mu m). A fluorescence plate reader was used to evaluate the degree of fluorescence intensity in the flow-through from various filters and referenced to the fluorescence intensity of the input.
   Results AHEPA filter, as recommended as an anti-viral filter, effectively filtered all the particles tested. The B. Braun PERIFIX Flat Epidural Filter was the second most effective filter, filtering particles larger than 0.042 mu m. Other filters tested did not filter fluorescence microspheres equivalent in size to a single coronavirus particle (0.07 mu m).
   Conclusions Although the Food and Drug Administration (FDA) has not approved the Flat Epidural Filter for use as an anesthesia machine gas filter, our simple challenge test suggests that it could be used to effectively filter the anesthesia gas sampling line.
C1 [Brustowicz, Robert M.; Yuki, Koichi] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, 300 Longwood Ave, Boston, MA 02115 USA.
   [Brustowicz, Robert M.; Yuki, Koichi] Harvard Med Sch, Dept Anaesthesia, 300 Longwood Ave, Boston, MA 02115 USA.
RP Brustowicz, RM (corresponding author), Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, 300 Longwood Ave, Boston, MA 02115 USA.; Brustowicz, RM (corresponding author), Harvard Med Sch, Dept Anaesthesia, 300 Longwood Ave, Boston, MA 02115 USA.
EM Robert.Brustowicz@childrens.harvard.edu
FU CHMC Anesthesia Foundation; Department of Anesthesiology, Critical Care
   and Pain Medicine at Boston Children's Hospital
FX This study was funded by CHMC Anesthesia Foundation. The authors would
   like to thank Dr Paul R. Hickey and the Department of Anesthesiology,
   Critical Care and Pain Medicine at Boston Children's Hospital for their
   support and funding of this work.
CR [Anonymous], 2020, SARS COV 2 HANDLING
   [Anonymous], BACT VIR FILTR EFF B
   [Anonymous], WHAT TYP BREATH CIRC
   Chia PY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16670-2
   Heuer JF, 2013, GMS HYG INFECT CONTR, V8, DOI 10.3205/dgkh000209
   Rengasamy S, 2017, J OCCUP ENVIRON HYG, V14, P92, DOI 10.1080/15459624.2016.1225157
   Scott DHT, 2010, ANAESTHESIA, V65, P670, DOI 10.1111/j.1365-2044.2010.06327.x
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 9
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1155-5645
EI 1460-9592
J9 PEDIATR ANESTH
JI Pediatr. Anesth.
PD NOV
PY 2020
VL 30
IS 11
BP 1269
EP 1274
DI 10.1111/pan.13990
EA DEC 2020
PG 6
WC Anesthesiology; Pediatrics
SC Anesthesiology; Pediatrics
GA PA7VC
UT WOS:000594988400001
PM 32748414
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Carrion, DM
   Mantica, G
   Anton-Juanilla, M
   Pang, KH
   Tappero, S
   Rodriguez-Serrano, A
   Parodi, S
   Crespo-Atin, V
   Cansino, R
   Terrone, C
   Nikles, S
   Rivas, JG
   Esperto, F
AF Carrion, D. M.
   Mantica, G.
   Anton-Juanilla, M.
   Pang, K. H.
   Tappero, S.
   Rodriguez-Serrano, A.
   Parodi, S.
   Crespo-Atin, V
   Cansino, R.
   Terrone, C.
   Nikles, S.
   Gomez Rivas, J.
   Esperto, F.
TI Assessment of trends and clinical presentation in the emergency
   department of patients with renal colic during the COVID-19 pandemic era
SO ACTAS UROLOGICAS ESPANOLAS
LA Spanish
DT Article
DE COVID-19; Renal coli; Lithiasis; Emergency department
AB Introduction: We hypothesized that the recent COVID-19 pandemic may lead to a delay in renal colic patients presenting to the Emergency Department due to the fear of getting infected. This delay may lead to a more severe clinical condition at presentation with possible complications for the patients.
   Material and methods: Retrospective review of data collected from three institutions from Spain and Italy. Patients who presented to Emergency Department with unilateral or bilateral renal colic caused by imaging confirmed urolithiasis during the 45 days before and after each national lockdown were included. Data collected included patients' demographics, biochemical urine and blood tests, radiological tests, signs, symptoms and the therapeutic management. Analysis was performed between two groups, Group A: patients presenting prior to the national lockdown date; and Group B: patients presenting after the national lockdown date.
   Results: A total of 397 patients presented to Emergency Department with radiology confirmed urolithiasis and were included in the study. The number of patients presenting to Emergency Department with renal/ureteric colic was 285 (71.8%) patients in Group A and 112 (28.2%) patients in Group B (p < 0.001). The number of patients reporting a delay in presentation was 135 (47.4%) in Group A and 63 (56.3%) in Group B (p=0.11). At presentation, there were no statistical differences between Group A and Group B regarding the serum creatinine level, C reactive protein, white blood cell count, fever, oliguria, flank pain and hydronephrosis. In addition, no significant differences were observed with the length of stay, Urology department admission requirement and type of therapy.
   Conclusion: Data from our study showed a significant reduction in presentations to Emergency Department for renal colic after the lockdown in Spain and Italy. However, we did not find any significant difference with the length of stay, Urology department admission requirement and type of therapy. (C) 2020 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
C1 [Carrion, D. M.; Rodriguez-Serrano, A.; Cansino, R.; Gomez Rivas, J.] Autonomous Univ Madrid, La Paz Univ Hosp, Urol Dept, Madrid, Spain.
   [Carrion, D. M.; Mantica, G.; Pang, K. H.; Nikles, S.; Gomez Rivas, J.; Esperto, F.] European Soc Residents Urol ESRU, Madrid, Spain.
   [Mantica, G.; Tappero, S.; Parodi, S.; Terrone, C.] Univ Genoa, Policlin San Martino Hosp, Dept Urol, Genoa, Italy.
   [Anton-Juanilla, M.; Crespo-Atin, V] Cruces Univ Hosp, Dept Urol, Baracaldo, Vizcaya, Spain.
   [Pang, K. H.] Univ Sheffield, Acad Urol Unit, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
   [Nikles, S.] Sestre Milosrdnice Univ Hosp Ctr, Dept Urol, Zagreb, Croatia.
   [Esperto, F.] Univ Rome, Dept Urol, Campus Biomed, Rome, Italy.
RP Nikles, S (corresponding author), European Soc Residents Urol ESRU, Madrid, Spain.; Nikles, S (corresponding author), Sestre Milosrdnice Univ Hosp Ctr, Dept Urol, Zagreb, Croatia.
EM sven.nikles@gmail.com
OI Parodi, Stefano/0000-0003-1507-8858
CR Antonucci M, 2020, ACTAS UROL ESP, DOI [10.1016/j.acuro.2070.06.005, DOI 10.1016/J.ACURO.2070.06.005]
   Casas RS, 2020, MED EDUC, V54, P670, DOI 10.1111/medu.14211
   Cervino G, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56050250
   De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166
   Flammia S, 2020, UROLITHIASIS, V48, P467, DOI 10.1007/s00240-020-01198-3
   Judson TJ, 2020, J AM MED INFORM ASSN, V27, P860, DOI 10.1093/jamia/ocaa051
   Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5
   Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77
   Mantica G, 2020, EUR UROL, V78, pE42, DOI 10.1016/j.eururo.2020.04.045
   Mantica G, 2020, PUBLIC HEALTH, V183, P40, DOI 10.1016/j.puhe.2020.04.046
   Miah S, 2017, J PAIN RES, V10, P1553, DOI 10.2147/JPR.S135901
   Proietti S, 2020, EUR UROL, V78, P131, DOI 10.1016/j.eururo.2020.03.042
   Ribal MJ, 2020, EUR UROL, V78, P21, DOI 10.1016/j.eururo.2020.04.056
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   World Health Organization, 2020, WHO STAT REG CLUST P
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ENE EDICIONES SL
PI MADRID
PA REDACCION, ADMINISTRACION & PUBLICIDAD, ORURO 9 - BAJO IZDA, MADRID,
   28016, SPAIN
SN 0210-4806
EI 1699-7980
J9 ACTAS UROL ESP
JI Actas Urol. Esp.
PD DEC
PY 2020
VL 44
IS 10
BP 653
EP 658
DI 10.1016/j.acuro.2020.08.006
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA PA5BM
UT WOS:000595651000003
PM 32993921
OA Green Published
DA 2021-01-01
ER

PT J
AU Lee, JD
   Burger, CD
   Delossantos, GB
   Grinnan, D
   Ralph, DD
   Rayner, SG
   Ryan, JJ
   Safdar, Z
   Ventetuolo, CE
   Zamanian, RT
   Leary, PJ
AF Lee, Joshua D.
   Burger, Charles D.
   Delossantos, Genecelle B.
   Grinnan, Daniel
   Ralph, David D.
   Rayner, Sam G.
   Ryan, John J.
   Safdar, Zeenat
   Ventetuolo, Corey E.
   Zamanian, Roham T.
   Leary, Peter J.
TI A Survey-based Estimate of COVID-19 Incidence and Outcomes among
   Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic
   Pulmonary Hypertension and Impact on the Process of Care
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
DE outcomes; clinic operations; telehealth; COVID-19
AB Rationale: Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) typically undergo frequent clinical evaluation. The incidence and outcomes of coronavirus disease (COVID-19) and its impact on routine management for patients with pulmonary vascular disease is currently unknown.
   Objectives: To assess the cumulative incidence and outcomes of recognized COVID-19 for patients with PAH/CTEPH followed at accredited pulmonary hypertension centers, and to evaluate the pandemic's impact on clinic operations at these centers.
   Methods: A survey was e-mailed to program directors of centers accredited by the Pulmonary Hypertension Association. Descriptive analyses and linear regression were used to analyze results.
   Results: Seventy-seven center directors were successfully e-mailed a survey, and 58 responded (75%). The cumulative incidence of COVID-19 recognized in individuals with PAH/CTEPH was 2.9 cases per 1,000 patients, similar to the general U.S. population. In patients with PAH/CTEPH for whom COVID-19 was recognized, 30% were hospitalized and 12% died. These outcomes appear worse than the general population. A large impact on clinic operations was observed including fewer clinic visits and substantially increased use of telehealth. A majority of centers curtailed diagnostic testing and a minority limited new starts of medical therapy. Most centers did not use experimental therapies in patients with PAH/CTEPH diagnosed with COVID-19.
   Conclusions: The cumulative incidence of COVID-19 recognized in patients with PAH/CTEPH appears similar to the broader population, although outcomes may be worse. Although the total number of patients with PAH/CTEPH recognized to have COVID-19 was small, the impact of COVID-19 on broader clinic operations, testing, and treatment was substantial.
C1 [Lee, Joshua D.; Delossantos, Genecelle B.; Ralph, David D.; Rayner, Sam G.; Leary, Peter J.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
   [Leary, Peter J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Burger, Charles D.] Mayo Clin Florida, Dept Pulm Med, Jacksonville, FL USA.
   [Grinnan, Daniel] Virginia Commonwealth Univ, Dept Med, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Ryan, John J.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA.
   [Safdar, Zeenat] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Ventetuolo, Corey E.] Brown Univ, Dept Med & Hlth Serv Policy & Practice, Providence, RI 02912 USA.
   [Zamanian, Roham T.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
RP Leary, PJ (corresponding author), Univ Washington, Med Ctr, Med & Epidemiol Adjunct, AMDG BB 1361,Box 356522,1959 NE Pacific St, Seattle, WA 98195 USA.
EM learyp@uw.edu
RI Ventetuolo, Corey/W-4871-2017
OI Ventetuolo, Corey/0000-0002-4223-4775; Lee, Joshua/0000-0001-7715-2107;
   Rayner, Samuel/0000-0002-2541-4221
CR [Anonymous], 2020, PRIM CAR COVID 19 WE
   Badagliacca R, 2020, J HEART LUNG TRANSPL, V39, P729, DOI 10.1016/j.healun.2020.04.007
   Badlam JB, 2017, THER ADV CHRONIC DIS, V8, P47, DOI 10.1177/2040622317693218
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   CDC, 2020, COR DIS 2019 COVID 1
   CDC, 2020, INF CLIN INV THER PA
   Chakinala MM, 2016, CARDIOL CLIN, V34, P489, DOI 10.1016/j.ccl.2016.04.008
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Galie N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Horn EM, 2020, PULM CIRC, V10, DOI 10.1177/2045894020922799
   Khanji C, 2019, BMC FAM PRACT, V20, DOI 10.1186/s12875-019-0979-7
   Kirson NY, 2011, APPL HEALTH ECON HEA, V9, P377, DOI 10.2165/11592440-000000000-00000
   Kirson NY, 2011, APPL HEALTH ECON HEA, V9, P293, DOI 10.2165/11592430-000000000-00000
   Link J, 2011, CHEST, V139, P497, DOI 10.1378/chest.10-0837
   Lipsitch M, 2009, NEW ENGL J MED, V361, P112, DOI 10.1056/NEJMp0904380
   Mehrotra A, 2020, IMPACT COVID 19 PAND, DOI [10.26099/ds9e-jm36, DOI 10.26099/DS9E-JM36]
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Polanco-Briceno S, 2016, CONT CLIN TRIAL COMM, V2, P54, DOI 10.1016/j.conctc.2015.12.006
   Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ryan JJ, 2020, PULM CIRC, V10, DOI 10.1177/2045894020920153
   Safdar N, 2016, INFECT CONT HOSP EP, V37, P1272, DOI 10.1017/ice.2016.171
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Smith WR, 2020, J AM COLL SURGEONS, V231, P216, DOI 10.1016/j.jamcollsurg.2020.04.030
   Welt FGP, 2020, J AM COLL CARDIOL, V75, P2372, DOI 10.1016/j.jacc.2020.03.021
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yue M, 2020, EPIDEMIOLOGY, V31, P567, DOI 10.1097/EDE.0000000000001202
NR 29
TC 1
Z9 1
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD DEC
PY 2020
VL 17
IS 12
BP 1576
EP 1582
DI 10.1513/AnnalsATS.202005-521OC
PG 7
WC Respiratory System
SC Respiratory System
GA PA4IC
UT WOS:000595600500014
PM 32726561
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hihara, A
AF Hihara, A.
TI Drug Information Association (DIA) Japan-17th Annual Meeting (November
   8-10, 2020-Virtual Meeting)
SO DRUGS OF TODAY
LA English
DT Article
DE Patient engagement; Patient-public involvement; Patient centricity;
   Decentralized clinical trials; Electronic product information; Digital
   risk minimization; e-Labeling; Benefit-risk assessment; Risk
   minimization measures; Real-world data; Postmarketing safety
   information; Pharmacovigilance; Digital therapeutics
AB As many other conferences held in 2020, the 17th Drug Information Association (DIA) Japan Annual Meeting 2020 was held virtually for the first time due to the COVID-19 crisis. The virtual platform delivered 64 sessions across 3 days and allowed participants to join the sessions flexibly, interactively participate in Q&A and connect with fellows without boundaries. The opening speech was addressed by Hajime Saijo (DIA Japan) to introduce the conference theme "Beyond Innovation" and key sessions featured discussions on future healthcare, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) 30-year anniversary, the Pharmaceuticals and Medical Devices Agency (PMDA) town hall, patient-focused drug development and global drug development. This meeting report covers the topics discussed from the programs featuring patient engagement, innovative drug development and new technologies.
C1 [Hihara, A.] Clarivate, Paris, France.
RP Hihara, A (corresponding author), Clarivate, Paris, France.
EM akiko.hihara@clarivate.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD DEC
PY 2020
VL 56
IS 12
BP 787
EP 793
DI 10.1358/dot.2020.56.12.3255085
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PG3KZ
UT WOS:000599639100004
PM 33332485
DA 2021-01-01
ER

PT J
AU Komlos, D
AF Komlos, D.
TI 2020 Food and Drug Law Institute (FDLI) Annual Conference (October 6-8,
   2020 Virtual Meeting)
SO DRUGS OF TODAY
LA English
DT Article
DE Real-world data (RWD); Real-world evidence (RWE); New Drugs Regulatory
   Program; FDA-regulated products; FDA regulatory field activity; Patient
   experience data (PED); Individualized medicine
AB This year's annual conference of the Food and Drug Law Institute (FDLI) drew more than 700 attendees, including over 200 from the U.S. Food and Drug Administration (FDA), and featured 93 speakers. Despite being held virtually for the first time, the event offered a full agenda comprising breakout sessions, award presentations, and opportunities for networking that included postsession roundtable discussions and a sponsor virtual exhibit hall. Not surprisingly, the reality of the COVID-19 public health emergency was a recurrent and emphasized theme throughout the 3 days of the conference. This report summarizes several of the 29 breakout sessions from the event.
C1 [Komlos, D.] Clarivate, Philadelphia, PA 19130 USA.
RP Komlos, D (corresponding author), Clarivate, Philadelphia, PA 19130 USA.
EM deborah.komlos@clarivate.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD DEC
PY 2020
VL 56
IS 12
BP 795
EP 802
DI 10.1358/dot.2020.56.12.3241213
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PG3KZ
UT WOS:000599639100005
PM 33332486
DA 2021-01-01
ER

PT J
AU Ogando, NS
   Zevenhoven-Dobbe, JC
   van der Meer, Y
   Bredenbeek, PJ
   Posthuma, CC
   Snijder, EJ
AF Ogando, Natacha S.
   Zevenhoven-Dobbe, Jessika C.
   van der Meer, Yvonne
   Bredenbeek, Peter J.
   Posthuma, Clara C.
   Snijder, Eric J.
TI The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for
   Replication of MERS-CoV and SARS-CoV-2
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE replicase; nonstructural protein; RNA synthesis; proofreading; reverse
   genetics; guanine-N7-methyltransferase; nidovirus
ID LASSA VIRUS NUCLEOPROTEIN; DNA-POLYMERASE-I; SARS-CORONAVIRUS;
   ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; STRUCTURAL BASIS;
   RNA-POLYMERASE; SITE; METHYLTRANSFERASE; MUTAGENESIS
AB Coronaviruses (CoVs) stand out for their large RNA genome and complex RNA-synthesizing machinery comprising 16 nonstructural proteins (nsps). The bifunctional nsp14 contains 3'-to-5' exoribonuclease (ExoN) and guanine-N7-methyltransferase (N7-MTase) domains. While the latter presumably supports mRNA capping, ExoN is thought to mediate proofreading during genome replication. In line with such a role, ExoN knockout mutants of mouse hepatitis virus (MHV) and severe acute respiratory syndrome coronavirus (SARS-CoV) were previously reported to have crippled but viable hypermutation phenotypes. Remarkably, using reverse genetics, a large set of corresponding ExoN knockout mutations has now been found to be lethal for another betacoronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV). For 13 mutants, viral progeny could not be recovered, unless-as happened occasionally-reversion had first occurred. Only a single mutant was viable, likely because its E191D substitution is highly conservative. Remarkably, a SARSCoV-2 ExoN knockout mutant was found to be unable to replicate, resembling observations previously made for alphaand gammacoronaviruses, but starkly contrasting with the documented phenotype of ExoN knockout mutants of the closely related SARS-CoV. Subsequently, we established in vitro assays with purified recombinant MERS-CoV nsp14 to monitor its ExoN and N7-MTase activities. All ExoN knockout mutations that proved lethal in reverse genetics were found to severely decrease ExoN activity while not affecting N7-MTase activity. Our study strongly suggests that CoV nsp14 ExoN has an additional function, which apparently is critical for primary viral RNA synthesis and thus differs from the proofreading function that, based on previous MHV and SARS-CoV studies, was proposed to boost longer-term replication fidelity. fidelity.
   IMPORTANCE The bifunctional nsp14 subunit of the coronavirus replicase contains 3'-to-5' exoribonuclease (ExoN) and guanine-N7-methyltransferase domains. For the betacoronaviruses MHV and SARS-CoV, ExoN was reported to promote the fidelity of genome replication, presumably by mediating a form of proofreading. For these viruses, ExoN knockout mutants are viable while displaying an increased mutation frequency. Strikingly, we have now established that the equivalent ExoN knockout mutants of two other betacoronaviruses, MERS-CoV and SARS-CoV-2, are nonviable, suggesting an additional and critical ExoN function in their replication. This is remarkable in light of the very limited genetic distance between SARS-CoV and SARS-CoV-2, which is highlighted, for example, by 95% amino acid sequence identity in their nsp14 sequences. For (recombinant) MERSCoV nsp14, both its enzymatic activities were evaluated using newly developed in vitro assays that can be used to characterize these key replicative enzymes in more detail and explore their potential as target for antiviral drug development.
C1 [Ogando, Natacha S.; Zevenhoven-Dobbe, Jessika C.; van der Meer, Yvonne; Bredenbeek, Peter J.; Posthuma, Clara C.; Snijder, Eric J.] Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Leiden, Netherlands.
   [Posthuma, Clara C.] Netherlands Commiss Genet Modificat, Bilthoven, Netherlands.
RP Snijder, EJ (corresponding author), Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Leiden, Netherlands.
EM E.J.Snijder@lumc.nl
OI Posthuma, Clara/0000-0003-4839-2077; Ogando, Natacha/0000-0002-3577-4909
FU Marie Sklodowska-Curie ETN European Training Network 'ANTIVIRALS' (EU)
   [642434]; TOP-GO grant from the Netherlands Organization for Scientific
   Research [700.10.352]; SCORE project (EU Horizon 2020 research and
   innovation program) [101003627]
FX N.S.O. was supported by the Marie Sklodowska-Curie ETN European Training
   Network 'ANTIVIRALS' (EU grant agreement no. 642434). C.C.P. and E.J.S.
   were supported in part by TOP-GO grant 700.10.352 from the Netherlands
   Organization for Scientific Research and by the SCORE project (EU
   Horizon 2020 research and innovation program, grant agreement
   101003627).
CR Abbehausen C, 2019, METALLOMICS, V11, P15, DOI 10.1039/c8mt00262b
   Al-Tawfiq JA, 2016, EXPERT REV RESP MED, V10, P331, DOI 10.1586/17476348.2016.1150784
   Almazan F, 2013, MBIO, V4, DOI 10.1128/mBio.00650-13
   Aouadi W, 2017, ANTIVIR RES, V144, P330, DOI 10.1016/j.antiviral.2017.06.021
   Baddock HT, 2020, BIORXIV, DOI [10.1101/2020.08.13.248211v1, DOI 10.1101/2020.08.13.248211V1]
   BARNES MH, 1995, GENE, V165, P45, DOI 10.1016/0378-1119(95)00530-J
   Becares M, 2016, J VIROL, V90, P5399, DOI 10.1128/JVI.03259-15
   BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x
   BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0
   Bouvet M, 2014, J BIOL CHEM, V289, P25783, DOI 10.1074/jbc.M114.577353
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Bukhari K, 2018, VIROLOGY, V524, P160, DOI 10.1016/j.virol.2018.08.010
   Case JB, 2018, J VIROL, V92, DOI 10.1128/JVI.01531-17
   Case JB, 2016, J VIROL, V90, P7248, DOI 10.1128/JVI.00542-16
   Chan JFW, 2013, J INFECT DIS, V207, P1743, DOI 10.1093/infdis/jit123
   Chang Guo-hui, 2010, Virologica Sinica, V25, P361, DOI 10.1007/s12250-010-3124-2
   Chen P, 2007, J BIOCHEM MOL BIOL, V40, P649
   Chen Y, 2013, J VIROL, V87, P6296, DOI 10.1128/JVI.00061-13
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Chen Y, 2009, P NATL ACAD SCI USA, V106, P3484, DOI 10.1073/pnas.0808790106
   Cotten M, 2014, MBIO, V5, DOI 10.1128/mBio.01062-13
   de Wilde AH, 2017, VIRUS RES, V228, P7, DOI 10.1016/j.virusres.2016.11.011
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x
   DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067
   Domingo E, 2012, MICROBIOL MOL BIOL R, V76, P159, DOI 10.1128/MMBR.05023-11
   Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910
   Durzynska I, 2018, J GEN VIROL, V99, P1253, DOI 10.1099/jgv.0.001120
   Eckerle LD, 2007, J VIROL, V81, P12135, DOI 10.1128/JVI.01296-07
   Eckerle LD, 2006, ADV EXP MED BIOL, V581, P55
   Eckerle LD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000896
   EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633
   EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322
   Eigen M, 2002, P NATL ACAD SCI USA, V99, P13374, DOI 10.1073/pnas.212514799
   Farag E, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010022
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Graepel KW, 2019, J VIROL, V93, DOI 10.1128/JVI.00711-19
   Graepel KW, 2017, MBIO, V8, DOI 10.1128/mBio.01503-17
   Graham RL, 2012, NAT MED, V18, P1820, DOI 10.1038/nm.2972
   GREENHALGH DA, 1990, BRIT J CANCER, V61, P415, DOI 10.1038/bjc.1990.91
   Gribble J, 2020, BIORXIV, DOI [10.1101/2020.04.23.057786v1, DOI 10.1101/2020.04.23.057786V1]
   Habjan M, 2008, J GEN VIROL, V89, P2157, DOI 10.1099/vir.0.2008/002097-0
   Hastie KM, 2011, P NATL ACAD SCI USA, V108, P2396, DOI 10.1073/pnas.1016404108
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Imanishi M, 2012, BIOCHEMISTRY-US, V51, P3342, DOI 10.1021/bi300236m
   Jin X, 2013, VIRUS RES, V176, P45, DOI 10.1016/j.virusres.2013.05.001
   Kindler E, 2014, CURR OPIN MICROBIOL, V20, P69, DOI 10.1016/j.mib.2014.05.005
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Lauber C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003500
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li X, 2020, SCI CHINA LIFE SCI, V63, P461, DOI 10.1007/s11427-020-1645-7
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Matrosovich M, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-63
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Nedialkova DD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000772
   Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07
   Neuman BW, 2016, ANTIVIR RES, V135, P97, DOI 10.1016/j.antiviral.2016.10.005
   Noordhuis P, 2004, ANN ONCOL, V15, P1025, DOI 10.1093/annonc/mdh264
   Ogando NS, 2020, J GEN VIROL, V101, P925, DOI 10.1099/jgv.0.001453
   Ogando NS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01813
   Pan JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003299
   Pfefferle S, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-131
   Nga PT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002215
   Pyrc K, 2007, EXPERT REV ANTI-INFE, V5, P245, DOI 10.1586/14787210.5.2.245
   Rabaan AA, 2017, J INFECT PUBLIC HEAL, V10, P702, DOI 10.1016/j.jiph.2017.05.005
   Rabouw HH, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005982
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rosas-Lemus M, 2020, BIORXIV, DOI [10.1101/2020.04.17.047498v2, DOI 10.1101/2020.04.17.047498V2]
   Russier M, 2014, J VIROL, V88, P13811, DOI 10.1128/JVI.01908-14
   Saberi A, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007314
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   Sanjuan R, 2010, PHILOS T R SOC B, V365, P1975, DOI 10.1098/rstb.2010.0063
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Siddell SG, 2019, ARCH VIROL, V164, P943, DOI 10.1007/s00705-018-04136-2
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Snijder EJ, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000715
   STEINHAUER DA, 1992, GENE, V122, P281, DOI 10.1016/0378-1119(92)90216-C
   STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Thiel V, 2003, J VIROL, V77, P9790, DOI 10.1128/JVI.77.18.9790-9798.2003
   Tischer BK, 2010, METHODS MOL BIOL, V634, P421, DOI 10.1007/978-1-60761-652-8_30
   Thao TTN, 2020, NATURE, V582, P561, DOI 10.1038/s41586-020-2294-9
   Ulferts R, 2011, J VIROL, V85, P1348, DOI 10.1128/JVI.01716-10
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van den Worm SHE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032857
   van Hemert MJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000054
   Vignuzzi M, 2006, NATURE, V439, P344, DOI 10.1038/nature04388
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006
   Wolff G, 2020, SCIENCE, V369, P1395, DOI 10.1126/science.abd3629
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yekwa E, 2019, BIORXIV, DOI [10.1101/541698v3., DOI 10.1101/541698V3]
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017
NR 105
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2020
VL 94
IS 23
AR e01246-20
DI 10.1128/JVI.01246-20
PG 24
WC Virology
SC Virology
GA PA8GC
UT WOS:000595866900004
PM 32938769
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Webb, BJ
   Peltan, ID
   Jensen, P
   Hoda, D
   Hunter, B
   Silver, A
   Starr, N
   Buckel, W
   Grisel, N
   Hummel, E
   Snow, G
   Morris, D
   Stenehjem, E
   Srivastava, R
   Brown, SM
AF Webb, Brandon J.
   Peltan, Ithan D.
   Jensen, Paul
   Hoda, Daanish
   Hunter, Bradley
   Silver, Aaron
   Starr, Nathan
   Buckel, Whitney
   Grisel, Nancy
   Hummel, Erika
   Snow, Gregory
   Morris, Dave
   Stenehjem, Eddie
   Srivastava, Rajendu
   Brown, Samuel M.
TI Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a
   cohort study
SO LANCET RHEUMATOLOGY
LA English
DT Article
ID MACROPHAGE ACTIVATION SYNDROME; JUVENILE IDIOPATHIC ARTHRITIS;
   CYTOKINE-RELEASE SYNDROME; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS;
   VALIDATION; THERAPY; IDENTIFICATION; DIAGNOSIS; COVID-19; OUTCOMES
AB Background A subset of patients with COVID-19 develops a hyperinflammatory syndrome that has similarities with other hyperinflammatory disorders. However, clinical criteria specifically to define COVID-19-associated hyperinflammatory syndrome (cHIS) have not been established. We aimed to develop and validate diagnostic criteria for cHIS in a cohort of inpatients with COVID-19.
   Methods We searched for clinical research articles published between Jan 1, 1990, and Aug 20, 2020, on features and diagnostic criteria for secondary haemophagocytic lymphohistiocytosis, macrophage activation syndrome, macrophage activation-like syndrome of sepsis, cytokine release syndrome, and COVID-19. We compared published clinical data for COVID-19 with clinical features of other hyperinflammatory or cytokine storm syndromes. Based on a framework of conserved clinical characteristics, we developed a six-criterion additive scale for cHIS: fever, macrophage activation (hyperferritinaemia), haematological dysfunction (neutrophil to lymphocyte ratio), hepatic injury (lactate dehydrogenase or asparate aminotransferase), coagulopathy (D-dimer), and cytokinaemia (C-reactive protein, interleukin-6, or triglycerides). We then validated the association of the cHIS scale with in-hospital mortality and need for mechanical ventilation in consecutive patients in the Intermountain Prospective Observational COVID-19 (IPOC) registry who were admitted to hospital with PCR-confirmed COVID-19. We used a multistate model to estimate the temporal implications of cHIS.
   Findings We included 299 patients admitted to hospital with COVID-19 between March 13 and May 5, 2020, in analyses. Unadjusted discrimination of the maximum daily cHIS score was 0.81 (95% CI 0.74-0.88) for in-hospital mortality and 0.92 (0.88-0.96) for mechanical ventilation; these results remained significant in multivariable analysis (odds ratio 1.6 [95% CI 1.2-2.1], p=0.0020, for mortality and 4.3 [3.0-6.0], p<0.0001, for mechanical ventilation). 161 (54%) of 299 patients met two or more cHIS criteria during their hospital admission; these patients had higher risk of mortality than patients with a score of less than 2 (24 [15%] of 138 vs one [1%] of 161) and for mechanical ventilation (73 [45%] vs three [2%]). In the multistate model, using daily cHIS score as a time-dependent variable, the cHIS hazard ratio for worsening from low to moderate oxygen requirement was 1.4 (95% CI 1.2-1.6), from moderate oxygen to high-flow oxygen 2.2 (1.1-4.4), and to mechanical ventilation 4.0 (1.9-8.2).
   Interpretation We proposed and validated criteria for hyperinflammation in COVID-19. This hyperinflammatory state, cHIS, is commonly associated with progression to mechanical ventilation and death. External validation is needed. The cHIS scale might be helpful in defining target populations for trials and immunomodulatory therapies. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Webb, Brandon J.; Grisel, Nancy; Stenehjem, Eddie] Intermt Med Ctr, Div Infect Dis & Clin Epidemiol, Salt Lake City, UT USA.
   [Webb, Brandon J.; Stenehjem, Eddie] Intermt Med Ctr, Intermt Healthcare, Salt Lake City, UT USA.
   [Webb, Brandon J.; Stenehjem, Eddie] Stanford Med, Div Infect Dis & Geog Med, Palo Alto, CA USA.
   [Peltan, Ithan D.; Brown, Samuel M.] Intermt Med Ctr, Pulm & Crit Care Med, Salt Lake City, UT USA.
   [Peltan, Ithan D.; Brown, Samuel M.] Univ Utah, Sch Med, Dept Pulm & Crit Care Med, Salt Lake City, UT USA.
   [Jensen, Paul] Dixie Reg Med Ctr, Intermt Healthcare, Div Rheumatol, St George, UT USA.
   [Hoda, Daanish; Hunter, Bradley] LDS Hosp, Blood & Marrow Transplant Program, Intermt Acute Leukemia, Salt Lake City, UT USA.
   [Silver, Aaron; Starr, Nathan] Intermt Med Ctr, Intermt Healthcare, Div Hosp Med, Salt Lake City, UT USA.
   [Buckel, Whitney] Intermt Healthcare, Antimicrobial Stewardship, Pharm Serv, Salt Lake City, UT USA.
   [Hummel, Erika] Intermt Healthcare Off Res, Salt Lake City, UT USA.
   [Snow, Gregory; Srivastava, Rajendu] Intermt Healthcare, Healthcare Delivery Inst, Murray, UT USA.
   [Morris, Dave] Intermt Med Ctr, Div Trauma & Crit Care, Murray, UT USA.
   [Stenehjem, Eddie] Intermt Healthcare, Off Patient Experience, Salt Lake City, UT USA.
   [Srivastava, Rajendu] Univ Utah, Dept Pediat, Div Inpatient Med, Salt Lake City, UT USA.
RP Webb, BJ (corresponding author), Intermt Med Ctr, Intermt Healthcare, Div Infect Dis & Clin Epidemiol, Murray, UT 84157 USA.
EM brandon.webb@imail.org
FU Intermountain Research and Medical Foundation
FX Intermountain Research and Medical Foundation.
CR Abboud R, 2016, BIOL BLOOD MARROW TR, V22, P1851, DOI 10.1016/j.bbmt.2016.06.010
   Bracaglia C, 2017, ANN RHEUM DIS, V76, P166, DOI 10.1136/annrheumdis-2015-209020
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Brisse E, 2016, BRIT J HAEMATOL, V174, P175, DOI 10.1111/bjh.14144
   Brisse E, 2015, CYTOKINE GROWTH F R, V26, P263, DOI 10.1016/j.cytogfr.2014.10.001
   Brito-Zeron Pilar, 2018, Mayo Clin Proc Innov Qual Outcomes, V2, P267, DOI 10.1016/j.mayocpiqo.2018.06.006
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen HL, 2019, FRONT MED-PRC, V13, P610, DOI 10.1007/s11684-019-0714-8
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Davi S, 2011, J RHEUMATOL, V38, P764, DOI 10.3899/jrheum.100996
   Deng Y, 2020, CHINESE MED J-PEKING, V133, P1261, DOI 10.1097/CM9.0000000000000824
   Diamanti AP, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093330
   Eloseily Esraa M A, 2019, ACR Open Rheumatol, V1, P345, DOI 10.1002/acr2.11048
   Espinosa PS, 2020, CUREUS, V12, DOI 10.7759/cureus.7930
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Filatov A, 2020, CUREUS, V12, DOI 10.7759/cureus.7352
   Frey Noelle, 2019, Biol Blood Marrow Transplant, V25, pe123, DOI 10.1016/j.bbmt.2018.12.756
   Goshua G, 2020, LANCET HAEMATOL, V7, pE575, DOI 10.1016/S2352-3026(20)30216-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Halyabar O, 2019, PEDIATR RHEUMATOL, V17, DOI 10.1186/s12969-019-0309-6
   Hayashi M, 2020, J NEUROL SCI, V415, DOI 10.1016/j.jns.2020.116941
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039
   Hou H, 2020, CLIN EXP IMMUNOL, V201, P76, DOI 10.1111/cei.13450
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Karakike E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00055
   Keller MJ, 2020, J HOSP MED, V15, P489, DOI 10.12788/jhm.3497
   Khadka RH, 2019, IMMUNOTHERAPY-UK, V11, P851, DOI 10.2217/imt-2019-0074
   Kishfy L, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116943
   Kostik MM, 2015, SEMIN ARTHRITIS RHEU, V44, P417, DOI 10.1016/j.semarthrit.2014.09.004
   Kumakura S, 2014, ARTHRITIS RHEUMATOL, V66, P2297, DOI 10.1002/art.38672
   Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   Lehmberg K, 2013, J PEDIATR-US, V162, P1245, DOI 10.1016/j.jpeds.2012.11.081
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Maude S, 2016, BRIT J HAEMATOL, V172, P11, DOI 10.1111/bjh.13792
   Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Minoia F, 2019, ANN RHEUM DIS, V78, P1357, DOI 10.1136/annrheumdis-2019-215211
   Minoia F, 2017, J PEDIATR-US, V189, P72, DOI 10.1016/j.jpeds.2017.06.005
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Nigrovic PA, 2011, ARTHRITIS RHEUM-US, V63, P545, DOI 10.1002/art.30128
   Parodi A, 2009, ARTHRITIS RHEUM-US, V60, P3388, DOI 10.1002/art.24883
   Put K, 2015, RHEUMATOLOGY, V54, P1507, DOI 10.1093/rheumatology/keu524
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ramiro S, ANN RHEUM DIS
   Ravelli A, 2016, ANN RHEUM DIS, V75, P481, DOI 10.1136/annrheumdis-2015-208982
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rouce RH, 2019, BLOOD, V134, P2119, DOI 10.1182/blood.2019003618
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schulert GS, 2014, BEST PRACT RES CL RH, V28, P277, DOI 10.1016/j.berh.2014.03.002
   Shimazaki C, 2000, LEUKEMIA LYMPHOMA, V38, P121, DOI 10.3109/10428190009060325
   Sinha P, 2020, JAMA INTERN MED, V180, P1152, DOI 10.1001/jamainternmed.2020.3313
   Sinha P, 2020, LANCET RESP MED, V8, P247, DOI 10.1016/S2213-2600(19)30369-8
   SUHRHEINRICH J, 2020, IMPLEMENT SCI S2, V15
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Y, 2018, J THORAC DIS, V10, P273, DOI 10.21037/jtd.2017.12.131
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang D, 2020, J INFECT DIS, V222, P734, DOI 10.1093/infdis/jiaa356
   YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
   Zayet S, 2020, J MED VIROL, DOI 10.1002/jmv.26027
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 77
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2665-9913
J9 LANCET RHEUMATOL
JI Lancet Rheumatol.
PD DEC
PY 2020
VL 2
IS 12
BP E754
EP E763
DI 10.1016/S2665-9913(20)30343-X
PG 10
WC Rheumatology
SC Rheumatology
GA PA2OV
UT WOS:000595474100012
PM 33015645
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zizzo, G
   Cohen, PL
AF Zizzo, Gaetano
   Cohen, Philip L.
TI Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?
SO LANCET RHEUMATOLOGY
LA English
DT Article
ID INNATE LYMPHOID-CELLS; DELTA-T-LYMPHOCYTES; GM-CSF; HELPER-CELLS; IL-33;
   DISEASE; ACTIVATION; CYTOKINE; EXPRESSION; INHIBITOR
AB The unique cytokine signature of COVID-19 might provide clues to disease mechanisms and possible future therapies. Here, we propose a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild-moderate, severe-critical, and chronic-fibrotic). In susceptible individ-uals, IL-33 release by damaged lower respiratory cells might induce dysregulated GATA-binding factor 3-expressing regulatory T cells, thereby breaking immune tolerance and eliciting severe acute respiratory syndrome coronavirus 2-induced autoinflammatory lung disease. Such disease might be initially sustained by IL-33-differentiated type-2 innate lymphoid cells and locally expanded gamma delta T cells. In severe COVID-19 cases, the IL-33-ST2 axis might act to expand the number of pathogenic granulocyte-macrophage colony-stimulating factor-expressing T cells, dampen antiviral interferon responses, elicit hyperinflammation, and favour thromboses. In patients who survive severe COVID-19, IL-33 might drive pulmonary fibrosis by inducing myofibroblasts and epithelial-mesenchymal transition. We discuss the therapeutic implications of these hypothetical pathways, including use of therapies that target IL-33 (eg, anti-ST2), T helper 17-like gamma delta T cells, immune cell homing, and cytokine balance.
C1 [Zizzo, Gaetano; Cohen, Philip L.] Temple Univ, Lewis Katz Sch Med, Temple Autoimmun Ctr, Philadelphia, PA 19140 USA.
   [Cohen, Philip L.] Temple Univ, Lewis Katz Sch Med, Dept Med, Sect Rheumatol, Philadelphia, PA 19140 USA.
   [Zizzo, Gaetano] ASST Ovest Milanese, Dept Internal Med, Unit Rheumatol, Milan, Italy.
RP Cohen, PL (corresponding author), Temple Univ, Lewis Katz Sch Med, Temple Autoimmun Ctr, Philadelphia, PA 19140 USA.
EM philco@temple.edu
CR Accardo-Palumbo A, 2007, INT J IMMUNOPATH PH, V20, P601, DOI 10.1177/039463200702000318
   Altara R, 2018, CARDIOVASC RES, V114, P1578, DOI 10.1093/cvr/cvy166
   Alvarez F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00522
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Behrens EM, 2011, J CLIN INVEST, V121, P2264, DOI 10.1172/JCI43157
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Burn TN, 2020, ARTHRITIS RHEUMATOL, V72, P335, DOI 10.1002/art.41076
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Cayrol C, 2018, IMMUNOL REV, V281, P154, DOI 10.1111/imr.12619
   Chen CC, 2017, J ALLERGY CLIN IMMUN, V140, P1351, DOI 10.1016/j.jaci.2017.01.015
   Cheng M, 2017, IMMUNOLOGY, V151, P375, DOI 10.1111/imm.12764
   Cho KA, 2012, AM J PHYSIOL-LUNG C, V302, pL429, DOI 10.1152/ajplung.00252.2011
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Cifaldi L, 2015, ARTHRITIS RHEUMATOL, V67, P3037, DOI 10.1002/art.39295
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119
   De Luca G, 2020, LANCET RHEUMATOL, V2, pE465, DOI 10.1016/S2665-9913(20)30170-3
   Della-Torre E, 2020, ANN RHEUM DIS, V79, P1277, DOI [10.1136/annrheumdis-2020-218122, 10.1136/annrheumdis-2020-218759, 10.1136/annrheumdis-2020-218724]
   Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007
   El-Behi M, 2011, NAT IMMUNOL, V12, P568, DOI 10.1038/ni.2031
   Farag NS, 2020, INT J BIOCHEM CELL B, V122, DOI 10.1016/j.biocel.2020.105738
   Folco EJ, 2018, ARTERIOSCL THROM VAS, V38, P1901, DOI 10.1161/ATVBAHA.118.311150
   Gabryelska A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00692
   Gao HC, 2017, XENOTRANSPLANTATION, V24, DOI 10.1111/xen.12291
   George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3
   Glatzel A, 2002, J IMMUNOL, V168, P4920, DOI 10.4049/jimmunol.168.10.4920
   Guggino G, 2016, CLIN EXP IMMUNOL, V186, P277, DOI 10.1111/cei.12853
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020
   Hamzaoui K, 2014, CELL MOL IMMUNOL, V11, P613, DOI 10.1038/cmi.2014.31
   Hawill B, 2020, REPURPOSING DUPILUMA, DOI [10.31219/osf.io/hk7ep, DOI 10.31219/OSF.IO/HK7EP]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacques A, 2009, IMMUNOLOGY, V128, pe181, DOI 10.1111/j.1365-2567.2008.02946.x
   Jang WC, 2008, RHEUMATOL INT, V29, P173, DOI 10.1007/s00296-008-0664-y
   Kaabachi W, 2019, IMMUNOL LETT, V211, P3, DOI 10.1016/j.imlet.2019.05.004
   Kara EE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9644
   Kass DA, 2020, LANCET, V395, P1544, DOI 10.1016/S0140-6736(20)31024-2
   Kim DJ, 2013, J KOREAN MED SCI, V28, P1145, DOI 10.3346/jkms.2013.28.8.1145
   Ko TM, 2015, CIRC RES, V116, P876, DOI 10.1161/CIRCRESAHA.116.305834
   Kotsiou OS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02432
   Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas
   Lei L, 2020, PHENOTYPIC CHANGES G, DOI [10.1101/2020.04.05.20046433, DOI 10.1101/2020.04.05.20046433]
   Li D, 2014, J ALLERGY CLIN IMMUN, V134, P1422, DOI 10.1016/j.jaci.2014.05.011
   Li H, 2013, CELL MOL IMMUNOL, V10, P159, DOI 10.1038/cmi.2012.70
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu Y, 2020, 2019 NOVEL CORONAVIR, DOI [10.12074/202002.00018, DOI 10.12074/202002.00018]
   Llop-Guevara A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088714
   Lukens JR, 2012, J IMMUNOL, V188, P3107, DOI 10.4049/jimmunol.1103308
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Marcu-Malina V, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00414
   Matta BM, 2014, J IMMUNOL, V193, P4010, DOI 10.4049/jimmunol.1400481
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   McKenzie DR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15632
   Michel ML, 2012, P NATL ACAD SCI USA, V109, P17549, DOI 10.1073/pnas.1204327109
   Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59
   Pacha O, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0328-z
   Papotto PH, 2018, J AUTOIMMUN, V87, P26, DOI 10.1016/j.jaut.2017.11.006
   Patterson Bruce K, 2020, medRxiv, DOI 10.1101/2020.05.02.20084673
   Perricone C, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102468
   Peters C, 2016, P NATL ACAD SCI USA, V113, P12520, DOI 10.1073/pnas.1607136113
   Primiano MJ, 2016, J IMMUNOL, V197, P2421, DOI 10.4049/jimmunol.1600035
   Ravanetti L, 2019, J ALLERGY CLIN IMMUN, V143, P1355, DOI 10.1016/j.jaci.2018.08.051
   Rijkers G, 2020, CELL MOL IMMUNOL, V17, P771, DOI 10.1038/s41423-020-0473-0
   Rodriguez AE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212236
   Ryan PL, 2016, P NATL ACAD SCI USA, V113, P14378, DOI 10.1073/pnas.1611098113
   Sato YZ, 2013, INT J CARDIOL, V164, P58, DOI 10.1016/j.ijcard.2011.06.065
   Schafer PH, 2010, BRIT J PHARMACOL, V159, P842, DOI 10.1111/j.1476-5381.2009.00559.x
   Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577
   Severa M, 2014, J IMMUNOL, V192, P2291, DOI 10.4049/jimmunol.1301799
   Sheng W, 2014, CELL RES, V24, P1387, DOI 10.1038/cr.2014.154
   Stanczak MA, 2020, IL 33 EXPRESSION RES, DOI [10.1101/2020.07.09.20148056, DOI 10.1101/2020.07.09.20148056]
   Stock AT, 2016, J EXP MED, V213, P1983, DOI 10.1084/jem.20151853
   Stojkovic S, 2016, SCI REP-UK, V6, DOI 10.1038/srep25171
   Tan MK, 2020, IMMUNOLOGY, V160, P261, DOI 10.1111/imm.13223
   Tan QY, 2018, CELL PHYSIOL BIOCHEM, V50, P757, DOI 10.1159/000494241
   Temesgen Zelalem, 2020, medRxiv, DOI 10.1101/2020.06.08.20125369
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Van Belle TL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109194
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wang L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13734-w
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   Wilkinson T, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04584-9
   Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Workalemahu G, 2003, J IMMUNOL, V170, P153, DOI 10.4049/jimmunol.170.1.153
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027
   Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96
   Zaibi MS, 2018, CYTOKINE, V110, P189, DOI 10.1016/j.cyto.2018.05.008
   Zhang JL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0166
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou SH, 2010, ANTIVIR RES, V87, P295, DOI 10.1016/j.antiviral.2010.06.011
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 100
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2665-9913
J9 LANCET RHEUMATOL
JI Lancet Rheumatol.
PD DEC
PY 2020
VL 2
IS 12
BP E779
EP E790
DI 10.1016/S2665-9913(20)30340-4
PG 12
WC Rheumatology
SC Rheumatology
GA PA2OV
UT WOS:000595474100015
PM 33073244
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hendeles, L
   Prabhakaran, S
AF Hendeles, Leslie
   Prabhakaran, Sreekala
TI Nationwide Shortage of Albuterol Inhalers and Off-Label Use in COVID-19
   Patients
SO PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY
LA English
DT Article
DE albuterol; COVID-19; HFA MDI; drug shortages
AB The surge in COVID-19 cases during the 2020 Spring led to a nationwide shortage of albuterol inhalers. As a new surge has begun, shortages may make it difficult for patients with obstructive lung disease, including children with asthma, to obtain refills. Since there is no evidence that albuterol relieves symptoms in COVID-19 patients with respiratory symptoms not caused by bronchospasm, it is reasonable for clinicians to not prescribe it for COVID-19 patients unless they also have asthma or chronic obstructive pulmonary disease.
C1 [Hendeles, Leslie] Univ Florida, Coll Pharm, Gainesville, FL USA.
   [Hendeles, Leslie; Prabhakaran, Sreekala] Univ Florida, Dept Pediat, Gainesville, FL USA.
RP Hendeles, L (corresponding author), 3549 NW 30th Blvd, Gainesville, FL 32605 USA.
EM lhendeles@gmail.com
CR American Society of Health-System Pharmacists, 2020, DRUG SHORT LIST
   American Thoracic Society, 2020, AM J RESP CRIT CARE, V202, P13
   Blake K, 2014, PEDIAT ALLER IMM PUL, V27, P143, DOI 10.1089/ped.2014.0399
   Budinger GRS, 2014, AM J RESP CRIT CARE, V189, P624, DOI 10.1164/rccm.201401-0170ED
   Claesson J, 2016, ACTA ANAESTH SCAND, V60, P697, DOI 10.1111/aas.12713
   ElMallah MK, 2012, PEDIAT ALLER IMM PUL, V25, P236, DOI 10.1089/ped.2012.0197
   FDA, 2020, SEARCH LIST EXT US D
   FDA, 2020, FDA APPR 1 GEN COMM
   FDA, 2020, FDA APPR 1 GEN PROAI
   Grasselli Giacomo, 2020, Lancet Respir Med, V8, P1201, DOI 10.1016/S2213-2600(20)30370-2
   Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3
   Hendeles L, 2005, ANN ALLERG ASTHMA IM, V95, P530, DOI 10.1016/S1081-1206(10)61014-9
   Lupin, 2020, LUP REC APPR GEN ALB
   Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC
   New York City COVID-19 Tracking Project, 2020, HOSP ADM COVID 19 MA
   Perkins GD, 2014, AM J RESP CRIT CARE, V189, P674, DOI 10.1164/rccm.201308-1549OC
   Perkins GD, 2006, AM J RESP CRIT CARE, V173, P281, DOI 10.1164/rccm.200508-1302OC
   Premier  Inc, 2020, DAT SHOWS DRUGS ESSE
   Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1
   Tang JW, 2020, J INFECTION, V81, P650, DOI 10.1016/j.jinf.2020.05.025
NR 20
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2151-321X
EI 2151-3228
J9 PEDIAT ALLER IMM PUL
JI Pediatr. Allergy Immunol. Pulmonol.
PD DEC 1
PY 2020
VL 33
IS 4
BP 216
EP 219
DI 10.1089/ped.2020.1300
PG 4
WC Allergy; Immunology; Pediatrics; Respiratory System
SC Allergy; Immunology; Pediatrics; Respiratory System
GA PG6GB
UT WOS:000599830600011
DA 2021-01-01
ER

PT J
AU Bozzani, A
   Arici, V
   Tavazzi, G
   Franciscone, MM
   Danesino, V
   Rota, M
   Rossini, R
   Sterpetti, AV
   Ticozzelli, G
   Rumi, E
   Mojoli, F
   Bruno, R
   Ragni, F
AF Bozzani, Antonio
   Arici, Vittorio
   Tavazzi, Guido
   Franciscone, Mila Maria
   Danesino, Vittorio
   Rota, Monica
   Rossini, Rosa
   Sterpetti, Antonio V.
   Ticozzelli, Giulia
   Rumi, Elisa
   Mojoli, Francesco
   Bruno, Raffaele
   Ragni, Franco
TI Acute arterial and deep venous thromboembolism in COVID-19 patients:
   Risk factors and personalized therapy
SO SURGERY
LA English
DT Article
AB Background: The Lombardy region suffered severely during the acute phase of the coronavirus disease 2019 outbreak in Italy (Mar-Apr 2020) with 16,000 diagnosed coronavirus disease 2019-related deaths (49% of the total coronavirus disease 2019-related deaths in Italy). In the area surrounding Pavia during the critical stage of the outbreak (Mar-Apr 2020), 1,225 of the documented 4,200 deaths were related to coronavirus disease 2019 infection, with a mortality rate of 181/100,000 inhabitants and an increase in deaths of 138% compared with the same period during previous years. Our aim was to report the experience of the Department of Vascular Surgery of Pavia (Lombardy, Italy), including the lessons learned and future perspectives regarding the management of coronavirus disease 2019 patients who developed severe acute ischemia with impending lower limb loss or deep vein thrombosis.
   Materials and Methods: We carried out a retrospective data collection of coronavirus disease 2019 patients with severe acute ischemia of the lower limbs or deep vein thrombosis, which we observed in our department during the period March 1, 2020, to April 30, 2020. Primary outcomes of the analysis were postoperative mortality for all patients and amputation rates only in those coronavirus disease 2019 patients suffering from acute lower limb ischemia. Secondary outcomes were the prevalence of the disease among admitted coronavirus disease 2019 patients, and any possible correlation among inflammatory parameters, thrombolytic status, and the presence of acute ischemia or deep vein thrombosis.
   Results: We observed 38 patients (28 male) with severe coronavirus disease 2019 infection (6 with lower limb arterial thrombosis and 32 with deep vein thrombosis). The median patient age was 64 years (range 30-94 y). In the arterial group, 3 had thrombosis on plaque and 3 on healthy arteries ("simple" arterial thrombosis). All underwent operative or hybrid (open/endo) revascularization; 1 patient died from major organ failure and 1 patient underwent major amputation. In the deep vein thrombosis group, 9 (28%) patients died from major organ failure, despite aggressive medical therapy. In patients with simple arterial thrombosis and those with deep vein thrombosis, we observed a decrease in inflammatory parameters (C-reactive protein) and in D-dimer and fibrinogen after aggressive therapy (P <.001).
   Conclusion: Our study confirms that critically ill, coronavirus disease 2019 patients who develop arterial and deep vein thrombosis have a high risk of mortality, but, if treated properly, there is an improvement in overall survival, especially in patients of 60 years of age or younger. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Bozzani, Antonio; Arici, Vittorio; Franciscone, Mila Maria; Danesino, Vittorio; Rota, Monica; Rossini, Rosa; Ragni, Franco] Fdn IRCCS Policlin San Matteo, Vasc & Endovasc Surg Unit, Pavia, Italy.
   [Tavazzi, Guido; Ticozzelli, Giulia; Mojoli, Francesco] Fdn IRCCS Policlin San Matteo, Anesthesiol & Intens Care Unit, Pavia, Italy.
   [Tavazzi, Guido; Mojoli, Francesco; Bruno, Raffaele] Univ Pavia, Dept Med Surg Diagnost & Pediat Sci, Pavia, Italy.
   [Sterpetti, Antonio V.] Univ Rome Sapienza, Rome, Italy.
   [Rumi, Elisa] Fdn IRCCS Policlin San Matteo, Hematol Unit, Pavia, Italy.
   [Rumi, Elisa] Univ Pavia, Dept Mol Med, Pavia, Italy.
   [Bruno, Raffaele] Fdn IRCCS Policlin San Matteo, Infect Dis Unit, Pavia, Italy.
RP Bozzani, A (corresponding author), Policlin San Matteo, Ple 19, Pavia, Italy.
EM a.bozzani@smatteo.pv.it
OI Bozzani, Antonio/0000-0003-3274-6248; Tavazzi, Guido/0000-0002-9560-5138
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arici V, 2014, VASC ENDOVASC SURG, V48, P61, DOI 10.1177/1538574413510619
   Beamish AJ, 2020, BRIT J SURG, V107, P1450, DOI 10.1002/bjs.11747
   Bellosta Raffaello, 2020, J Vasc Surg, V72, P1864, DOI 10.1016/j.jvs.2020.04.483
   Bikdeli B, 2020, THROMB HAEMOSTASIS, V120, P1004, DOI 10.1055/s-0040-1713152
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bozzani A, 2020, ANN VASC SURG, V66, P11, DOI 10.1016/j.avsg.2020.04.037
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Edler C, 2020, INT J LEGAL MED, V134, P1275, DOI 10.1007/s00414-020-02317-w
   Epicentro. Istituto Superiore Sanita, STAT COVID19
   Fara MG, 2020, J THROMB HAEMOST, V18, P2031, DOI 10.1111/jth.14938
   GANDHI M, 2020, NEW ENGL J MED, V383, DOI DOI 10.10056/NEJMCP2009249
   Kreuziger L, COVID 19 VTE ANTICOA
   Lancaster EM, 2020, J AM COLL SURGEONS, V230, P1064, DOI 10.1016/j.jamcollsurg.2020.04.007
   Levi M, 2020, SEMIN THROMB HEMOST, V46, P781, DOI 10.1055/s-0040-1712156
   McFadyen JD, 2020, CIRC RES, V127, P571, DOI 10.1161/CIRCRESAHA.120.317447
   Miesbach W, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620938149
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Rusch VW, 2020, J AM COLL SURGEONS, V231, P490, DOI 10.1016/j.jamcollsurg.2020.06.020
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Smith WR, 2020, J AM COLL SURGEONS, V231, P216, DOI 10.1016/j.jamcollsurg.2020.04.030
   Spyropoulos AC, 2020, CIRCULATION, V142, P129, DOI 10.1161/CIRCULATIONAHA.120.048020
   Sterpetti AV, 2020, J AM COLL SURGEONS, V230, P1092, DOI 10.1016/j.jamcollsurg.2020.03.018
   Sterpetti AV, 2019, VASC PHARMACOL, V117, P1, DOI 10.1016/j.vph.2017.06.001
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu JF, RISK ASSESSMENT VENO
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 29
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6060
J9 SURGERY
JI Surgery
PD DEC
PY 2020
VL 168
IS 6
BP 987
EP 992
DI 10.1016/j.surg.2020.09.009
PG 6
WC Surgery
SC Surgery
GA OY9GX
UT WOS:000594548300005
PM 33039110
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sbidian, E
AF Sbidian, E.
TI What's new in dermatological treatment?
SO ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
LA French
DT Article
ID SEVERE ATOPIC-DERMATITIS; COVID-19 INFECTION; ADULT PATIENTS;
   DOUBLE-BLIND; OPEN-LABEL; PSORIASIS; MODERATE; THERAPY; PHASE-3; TRIAL
C1 [Sbidian, E.] Univ Paris Est Creteil, EpiDermE, F-94010 Creteil, France.
   [Sbidian, E.] Hop Univ Henri Mondor, AP HP, Serv Dermatol, F-94010 Creteil, France.
   [Sbidian, E.] INSERM, Ctr Invest Clin 1430, F-94010 Creteil, France.
RP Sbidian, E (corresponding author), Univ Paris Est Creteil, EpiDermE, F-94010 Creteil, France.; Sbidian, E (corresponding author), Hop Univ Henri Mondor, AP HP, Serv Dermatol, F-94010 Creteil, France.; Sbidian, E (corresponding author), INSERM, Ctr Invest Clin 1430, F-94010 Creteil, France.
EM emilie.sbidian@aphp.fr
CR Abdat R, 2020, J AM ACAD DERMATOL, V83, P46, DOI 10.1016/j.jaad.2020.01.089
   [Anonymous], 2020, SYST PHARM TREATM CH
   [Anonymous], 2020, INTERVENTIONS AMERIC
   Atalay S, 2020, JAMA DERMATOL, V156, P393, DOI 10.1001/jamadermatol.2019.4897
   Bachelez H, 2019, NEW ENGL J MED, V380, P981, DOI 10.1056/NEJMc1811317
   Bae JM, 2020, JAMA DERMATOL, V156, P529, DOI 10.1001/jamadermatol.2020.0218
   Bataille P, 2020, ALIMENT PHARM THER, V52, P1245, DOI 10.1111/apt.16040
   Baudou E, 2020, NEW ENGL J MED, V383, P787, DOI 10.1056/NEJMc1917344
   Bertolotti A, 2019, J AM ACAD DERMATOL, V81, P1203, DOI 10.1016/j.jaad.2019.04.008
   Bissonnette R, 2019, BRIT J DERMATOL, V181, P733, DOI 10.1111/bjd.17932
   Boehringer Ingelheim, 2019, MULT DOUBL BLIND RAN
   Brindle R, 2019, JAMA DERMATOL
   Carugno A, 2020, J AM ACAD DERMATOL, V83, P292, DOI 10.1016/j.jaad.2020.04.165
   Casseres RG, 2020, J AM ACAD DERMATOL, V82, P1524, DOI 10.1016/j.jaad.2020.02.005
   Chang HC, 2020, J AM ACAD DERMATOL, V82, P243, DOI 10.1016/j.jaad.2019.07.108
   Chiricozzi A, 2020, J AM ACAD DERMATOL, V83, P39, DOI 10.1016/j.jaad.2020.03.049
   D'Arcy ME, 2020, JAMA DERMATOL, V156, P772, DOI 10.1001/jamadermatol.2020.1141
   Dauden E, 2020, J AM ACAD DERMATOL, V83, P139, DOI 10.1016/j.jaad.2020.03.033
   Delamere FM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004413.pub2
   Deleuran M, 2020, J AM ACAD DERMATOL, V82, P377, DOI 10.1016/j.jaad.2019.07.074
   Dermatologie SFde, 2020, ALGORITHME RECOMMAND
   Dermavant Sciences GmbH, 2020, PHAS 2A RAND DOUBL B
   Esse S, 2020, JAMA DERMATOL, V156, P787, DOI 10.1001/jamadermatol.2020.1300
   Foley K, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012093.pub2
   Frew JW, 2020, J INVEST DERMATOL
   Gelfand JM, 2020, JAMA DERMATOL, DOI 10.1001/jamadermatol.2020.4456
   Ghias MH, 2020, J AM ACAD DERMATOL, V82, P1094, DOI 10.1016/j.jaad.2019.09.071
   Gisondi P, 2020, J AM ACAD DERMATOL, V83, P285, DOI 10.1016/j.jaad.2020.04.085
   Gold LS, 2020, J AM ACAD DERMATOL, V82, P1166, DOI 10.1016/j.jaad.2020.01.043
   Gooderham MJ, 2019, JAMA DERMATOL, V155, P1371, DOI 10.1001/jamadermatol.2019.2855
   Gupta AK, 2020, BRIT J DERMATOL, V182, P287, DOI 10.1111/bjd.18155
   Guttman-Yassky E, 2020, JAMA DERMATOL, V156, P411, DOI 10.1001/jamadermatol.2020.0079
   Guttman-Yassky E, 2020, J ALLERGY CLIN IMMUN, V145, P877, DOI 10.1016/j.jaci.2019.11.025
   Hebert A, 2020, JAMA DERMATOL, V156, P621, DOI 10.1001/jamadermatol.2020.0465
   Huang AH, 2020, J AM ACAD DERMATOL, V82, P34, DOI 10.1016/j.jaad.2019.09.007
   Hubiche T, 2020, JAMA DERMATOL, DOI 10.1001/jamadermatol.2020.4324
   Incyte Corporation, 2020, TOP RUX EV VIT STUD
   Jabbari A, 2018, J INVEST DERMATOL, V138, P1539, DOI 10.1016/j.jid.2018.01.032
   Joly P, 2020, J AM ACAD DERMATOL
   Jung JM, 2020, BRIT J DERMATOL, V183, P24, DOI 10.1111/bjd.18638
   Kabashima K, 2020, NEW ENGL J MED, V383, P141, DOI 10.1056/NEJMoa1917006
   Kim BS, 2020, J AM ACAD DERMATOL, V82, P1305, DOI 10.1016/j.jaad.2020.02.009
   Kim BS, 2020, J ALLERGY CLIN IMMUN, V145, P572, DOI 10.1016/j.jaci.2019.08.042
   Kushner CJ, 2019, JAMA DERMATOL
   Lebwohl MG, 2020, NEW ENGL J MED, V383, P229, DOI 10.1056/NEJMoa2000073
   Leducq S, 2020, J AM ACAD DERMATOL, V82, P240, DOI 10.1016/j.jaad.2019.07.097
   Liu H, 2020, COCHRANE DB SYST REV, V5
   Liu SD, 2020, JAMA DERMATOL, V156, P891, DOI 10.1001/jamadermatol.2020.1587
   Llanos R, 2020, HUM DIMENS WILDL, V25, P1, DOI 10.1080/10871209.2019.1668987
   Logger JGM, 2020, J AM ACAD DERMATOL, V83, P1088, DOI 10.1016/j.jaad.2020.04.129
   Menlo Therapeutics Inc, 2020, RAND DOUBL BLIND PLA
   Mignard C, 2020, JAMA DERMATOL, V156, P545, DOI 10.1001/jamadermatol.2020.0290
   Murrell DF, 2020, J AM ACAD DERMATOL, V82, P575, DOI 10.1016/j.jaad.2018.02.021
   Nakagawa H, 2020, J AM ACAD DERMATOL, V82, P823, DOI 10.1016/j.jaad.2019.12.015
   Nofal A, 2020, J AM ACAD DERMATOL, V82, P94, DOI 10.1016/j.jaad.2019.07.070
   Obeid G, 2020, BRIT J DERMATOL, DOI 10.1111/bjd.19560
   Olsen EA, 2020, J AM ACAD DERMATOL, V82, P412, DOI 10.1016/j.jaad.2019.10.016
   Pham CT, 2020, J AM ACAD DERMATOL, V82, P202, DOI 10.1016/j.jaad.2019.04.067
   Phillips RO, 2020, LANCET, V395, P1259, DOI 10.1016/S0140-6736(20)30047-7
   Qureshi AA, 2019, J AM ACAD DERMATOL, V80, P756, DOI 10.1016/j.jaad.2018.09.020
   Reich K, 2019, LANCET, V394, P831, DOI 10.1016/S0140-6736(19)31773-8
   Rosmarin D, 2020, LANCET, V396, P110, DOI 10.1016/S0140-6736(20)30609-7
   Sach TH, 2020, BRIT J DERMATOL, DOI [10.1111/bjd.19554, 10.1111/bjd.19592]
   Sawangjit R, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013206.pub2
   Schaller M, 2020, BRIT J DERMATOL, V182, P1269, DOI 10.1111/bjd.18420
   Schaller M, 2020, J AM ACAD DERMATOL, V82, P336, DOI 10.1016/j.jaad.2019.05.063
   Silverberg JI, 2020, JAMA DERMATOL, V156, P863, DOI 10.1001/jamadermatol.2020.1406
   Silverberg JI, 2020, J ALLERGY CLIN IMMUN, V145, P173, DOI 10.1016/j.jaci.2019.08.013
   Simpson EL, 2020, BRIT J DERMATOL, V183, P242, DOI 10.1111/bjd.18898
   Simpson EL, 2020, LANCET, V396, P255, DOI 10.1016/S0140-6736(20)30732-7
   Smith CH, 2020, BRIT J DERMATOL, V183, P628, DOI 10.1111/bjd.19039
   Soria A, 2019, JAMA DERMATOL
   Stander S, 2020, NEW ENGL J MED, V382, P706, DOI 10.1056/NEJMoa1908316
   Tharp MD, 2019, JAMA DERMATOL, V155, P29, DOI 10.1001/jamadermatol.2018.3447
   Thiboutot D, 2020, J AM ACAD DERMATOL, V82, P1501, DOI 10.1016/j.jaad.2020.01.077
   Trubiano JA, 2020, JAMA INTERN MED, V180, P745, DOI 10.1001/jamainternmed.2020.0403
   Tsakok T, 2019, JAMA DERMATOL
   University Hospital Bordeaux, 2020, BORD EFF TOL COMB ME
   Waldman RA, 2020, J AM ACAD DERMATOL, V82, P230, DOI 10.1016/j.jaad.2019.06.026
   Webb E, 2020, NEW ENGL J MED, V383, P630, DOI 10.1056/NEJMoa1917197
   Webster G, 2020, BRIT J DERMATOL, V183, P471, DOI 10.1111/bjd.18857
   Willsmore ZN, 2019, BRIT J DERMATOL, V181, P1068, DOI 10.1111/bjd.18031
   Worm M, 2020, JAMA DERMATOL, V156, P131, DOI 10.1001/jamadermatol.2019.3617
   YANG Z, 2020, COCHRANE DB SYST REV, V16
NR 84
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0151-9638
EI 2214-5451
J9 ANN DERMATOL VENER
JI Ann. Dermatol. Venereol.
PD DEC
PY 2020
VL 147
IS 12
SU 2
BP 43
EP 50
PG 8
WC Dermatology
SC Dermatology
GA PE8MQ
UT WOS:000598616000007
DA 2021-01-01
ER

PT J
AU Algwaiz, G
   Aljurf, M
   Koh, M
   Horowitz, MM
   Ljungman, P
   Weisdorf, D
   Saber, W
   Kodera, Y
   Szer, J
   Jawdat, D
   Wood, WA
   Brazauskas, R
   Lehmann, L
   Pasquini, MC
   Seber, A
   Lu, PH
   Atsuta, Y
   Riches, M
   Perales, MA
   Worel, N
   Okamoto, S
   Srivastava, A
   Chemaly, RF
   Cordonnier, C
   Dandoy, CE
   Wingard, JR
   Kharfan-Dabaja, MA
   Hamadani, M
   Majhail, NS
   Waghmare, AA
   Chao, N
   Kroger, N
   Shaw, B
   Mohty, M
   Niederwieser, D
   Greinix, H
   Hashmi, SK
AF Algwaiz, Ghada
   Aljurf, Mahmoud
   Koh, Mickey
   Horowitz, Mary M.
   Ljungman, Per
   Weisdorf, Daniel
   Saber, Wael
   Kodera, Yoshihisa
   Szer, Jeff
   Jawdat, Dunia
   Wood, William A.
   Brazauskas, Ruta
   Lehmann, Leslie
   Pasquini, Marcelo C.
   Seber, Adriana
   Lu, Pei Hua
   Atsuta, Yoshiko
   Riches, Marcie
   Perales, Miguel-Angel
   Worel, Nina
   Okamoto, Shinichiro
   Srivastava, Alok
   Chemaly, Roy F.
   Cordonnier, Catherine
   Dandoy, Christopher E.
   Wingard, John R.
   Kharfan-Dabaja, Mohamed A.
   Hamadani, Mehdi
   Majhail, Navneet S.
   Waghmare, Alpana A.
   Chao, Nelson
   Kroger, Nicolaus
   Shaw, Bronwen
   Mohty, Mohamad
   Niederwieser, Dietger
   Greinix, Hildegard
   Hashmi, Shahrukh K.
CA WBMT
   CIBMTR Hlth Serv Int Studies Com
TI Real-World Issues and Potential Solutions in Hematopoietic Cell
   Transplantation during the COVID-19 Pandemic: Perspectives from the
   Worldwide Network for Blood and Marrow Transplantation and Center for
   International Blood and Marrow Transplant Research Health Services and
   International Studies Committee
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Transplantation; COVID-19; Pandemic; Stem cells
ID AMERICAN SOCIETY; THERAPY; RISK
AB The current COVID-19 pandemic, caused by SARS-CoV-2, has impacted many facets of hematopoietic cell transplantation (HCT) in both developed and developing countries. Realizing the challenges as a result of this pandemic affecting the daily practice of the HCT centers and the recognition of the variability in practice worldwide, the Worldwide Network for Blood and Marrow Transplantation (WBMT) and the Center for International Blood and Marrow Transplant Research's (CIBMTR) Health Services and International Studies Committee have jointly produced an expert opinion statement as a general guide to deal with certain aspects of HCT, including diagnostics for SARS-CoV-2 in HCT recipient, pre- and post-HCT management, donor issues, medical tourism, and facilities management. During these crucial times, which may last for months or years, the HCT community must reorganize to proceed with transplantation activity in those patients who urgently require it, albeit with extreme caution. This shared knowledge may be of value to the HCT community in the absence of high-quality evidencebased medicine. (C) 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
C1 [Algwaiz, Ghada] King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh, Saudi Arabia.
   [Aljurf, Mahmoud; Hashmi, Shahrukh K.] King Faisal Specialist Hosp & Res Ctr, Dept Adult Hematol & Stem Cell Transplant, Riyadh, Saudi Arabia.
   [Koh, Mickey] St Georges Hosp & Med Sch, Dept Haematol, London, England.
   [Koh, Mickey] Hlth Sci Author, Blood Serv Grp, Cell Therapy Facil, Singapore, Singapore.
   [Horowitz, Mary M.; Saber, Wael; Pasquini, Marcelo C.; Hamadani, Mehdi; Shaw, Bronwen] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA.
   [Ljungman, Per] Karolinska Univ Hosp Huddinge, Dept Cellular Therapy & Allogene Stem Cell Transp, Stockholm, Sweden.
   [Ljungman, Per] Karolinska Inst, Dept Med Huddinge, Div Hematol, Stockholm, Sweden.
   [Weisdorf, Daniel] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Kodera, Yoshihisa; Atsuta, Yoshiko] Aichi Med Univ Hosp, Ctr Hematopoiet Stem Cell Transplantat, Nagakute, Aichi, Japan.
   [Szer, Jeff] Peter MacCallum Canc Ctr, Clin Haematol, Melbourne, Vic, Australia.
   [Szer, Jeff] Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Jawdat, Dunia] Minist Natl Guard Hlth Affairs, Coll Sci & Hlth Profess, King Abdullah Int Med Res Ctr, King Saud Bin Abdulaziz Univ Hlth Sci,Cord Blood, Riyadh, Saudi Arabia.
   [Wood, William A.; Riches, Marcie] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol, Chapel Hill, NC 27515 USA.
   [Brazauskas, Ruta] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.
   [Lehmann, Leslie] Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA 02115 USA.
   [Seber, Adriana] Univ Fed Sao Paulo, Dept Med, Escola Paulista Med, Sao Paulo, Brazil.
   [Lu, Pei Hua] Hebei Yanda Ludaopei Hosp, Hematol & Oncol Dept, Langfang, Peoples R China.
   [Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, 1275 York Ave, New York, NY 10021 USA.
   [Perales, Miguel-Angel] Weill Cornell Med Coll, New York, NY USA.
   [Worel, Nina] Med Univ Vienna, Dept Blood Grp Serol & Transfus Med, Vienna, Austria.
   [Okamoto, Shinichiro] Keio Univ, Dept Med, Div Hematol, Sch Med, Tokyo, Japan.
   [Srivastava, Alok] Christian Med Coll & Hosp, Dept Haematol, Vellore, Tamil Nadu, India.
   [Chemaly, Roy F.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA.
   [Cordonnier, Catherine] Henri Mondor Hosp, Hematol Dept, Creteil, France.
   [Cordonnier, Catherine] Univ Paris Est Creteil, Creteil, France.
   [Dandoy, Christopher E.] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH USA.
   [Wingard, John R.] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA.
   [Kharfan-Dabaja, Mohamed A.] Mayo Clin, Div Hematol Oncol, Jacksonville, FL 32224 USA.
   [Majhail, Navneet S.] Cleveland Clin, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA.
   [Waghmare, Alpana A.] Univ Washington, Dept Pediat, Div Pediat Infect Dis, Seattle, WA 98195 USA.
   [Waghmare, Alpana A.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Chao, Nelson] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA.
   [Kroger, Nicolaus] Univ Hosp Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany.
   [Mohty, Mohamad] Sorbonne Univ, INSERM UMRS 938, Hop St Antoine, Serv Hematol Clin & Therapie Cellulaire, Paris, France.
   [Niederwieser, Dietger] Univ Leipzig, Div Hematol & Med Oncol, Leipzig, Germany.
   [Greinix, Hildegard] Med Univ Graz, Div Hematol, Graz, Austria.
   [Hashmi, Shahrukh K.] Mayo Clin, Dept Internal Med, Rochester, MN USA.
RP Aljurf, M (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Adult Hematol & Stem Cell Transplant, Riyadh, Saudi Arabia.; Aljurf, M (corresponding author), Zahrawi St, Riyadh 12713, Saudi Arabia.
EM maljurf@kfshrc.edu.sa
CR American Association of Blood Banks, 2020, UPD IMP 2019 NOV COR
   American Society for Transplantation and Cellular Therapy, INT GUID COV 19 MAN
   Bachanova V, 2020, BIOL BLOOD MARROW TR, V26, P1239, DOI 10.1016/j.bbmt.2020.04.008
   Balduzzi A, 2020, BONE MARROW TRANSPL, V55, P1900, DOI 10.1038/s41409-020-0895-4
   Bouchentouf S, 2020, 2020040079 MEDRXIV
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention, COR DIS SYMPT
   Chang L, 2020, EMERG INFECT DIS, V26, P1631, DOI 10.3201/eid2607.200839
   Chen C, 2020, 20037432 MEDRXIV
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875
   Duan K, 2020, FEASIBILITY CONVALES
   Food and Drug Administration, IMP INF HUM CELL TIS
   Fung Monica, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa863
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gritti G, 2020, USE SILTUXIMAB PATIE, V04, P1912, DOI [10. 1101/2020.04.01.20048561., DOI 10.1101/2020.04.01.20048561, 10.1101/2020.04.01.20048561]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Kimmig LM, 2020, IL6 INHIBITION CRITI
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li Y, 2020, 20038984 MEDRXIV
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Liu R, 2020, CHINA APPROVES USE R
   Ljungman P, 2020, BONE MARROW TRANSPL, V55, P2071, DOI 10.1038/s41409-020-0919-0
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mahmoudjafari Z, 2020, BIOL BLOOD MARROW TR, V26, P1043, DOI 10.1016/j.bbmt.2020.04.005
   Majhail NS, 2015, BIOL BLOOD MARROW TR, V21, P1863, DOI 10.1016/j.bbmt.2015.07.032
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehra MR, 2020, LANCET, DOI [10.1016/S0140-6736(20) 31180-6., DOI 10.1016/S0140-6736(20)31180-6., 10.1016/S0140-6736(20)31180-6.]
   Nawar T, 2020, AM J HEMATOL, V95, pE210, DOI 10.1002/ajh.25870
   Niederwieser D, 2016, BONE MARROW TRANSPL, V51, P778, DOI 10.1038/bmt.2016.18
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Stanworth SJ, 2013, NEW ENGL J MED, V368, P1771, DOI 10.1056/NEJMoa1212772
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Tay J, 2020, J CLIN ONCOL, V38, P1463, DOI 10.1200/JCO.19.01836
   US Food and Drug Administration, COR COVID 19 UPD FDA
   Voiriot G, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060786
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang Y, 2020, NPJ SCHIZOPHR, V6, DOI 10.1038/s41537-020-0095-7
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wernike K, 2020, TRANSBOUND EMERG DIS, DOI 10.1111/tbed.13684
   World Health Organization, 2020, 181 WHO
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Xu BY, 2020, EUR RADIOL, V30, P5720, DOI 10.1007/s00330-020-06934-2
   Xu X, 2020, 20200300026V1 CHINAX
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhao R, 2017, OSTEOPOROSIS INT, V28, P1027, DOI 10.1007/s00198-016-3824-z
NR 58
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD DEC
PY 2020
VL 26
IS 12
BP 2181
EP 2189
DI 10.1016/j.bbmt.2020.07.021
PG 9
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA OY9EO
UT WOS:000594542200012
PM 32717432
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tamaki, M
   Nakasone, H
   Aikawa, T
   Nakamura, Y
   Kawamura, M
   Kawamura, S
   Takeshita, J
   Yoshino, N
   Misaki, Y
   Yoshimura, K
   Matsumi, S
   Gomyo, A
   Tanihara, A
   Kusuda, M
   Akahoshi, Y
   Kimura, S
   Kako, S
   Oyama-Manabe, N
   Kanda, Y
AF Tamaki, Masaharu
   Nakasone, Hideki
   Aikawa, Tadao
   Nakamura, Yuhei
   Kawamura, Masakatsu
   Kawamura, Shunto
   Takeshita, Junko
   Yoshino, Nozomu
   Misaki, Yukiko
   Yoshimura, Kazuki
   Matsumi, Shinpei
   Gomyo, Ayumi
   Tanihara, Aki
   Kusuda, Machiko
   Akahoshi, Yu
   Kimura, Shun-ichi
   Kako, Shinichi
   Oyama-Manabe, Noriko
   Kanda, Yoshinobu
TI Pre-Hematopoietic Stem Cell Transplantation Lung Computed Tomography as
   an Alternative to the Pulmonary Function Test during the COVID-19
   Pandemic
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Pulmonary function test; Computed tomography; COVID-19
ID ASPERGILLOSIS; COMPLICATIONS; FLUCONAZOLE; CAPACITY
AB The pulmonary function test (PFT) is an important test for risk stratification before allogeneic transplantation (allo-HCT). However, it might be preferable to avoid PFT as much as possible in the recent era of coronavirus disease 2019 (COVID-19), because PFT requires forced expirations and might produce aerosols, increasing the risk of COVID-19 transmission. Therefore, we tried to predict normal PFT results before allo-HCT based on computed tomography (CT) findings. This study included 390 allo-HCT recipients at our center for whom lung CT images and PFT results before allo-HCT were available. Abnormal CT findings were less likely to be observed in the normal PFT group (47.0% versus 67.4%, P = .015), with a high negative predictive value of 92.9%. In a multivariate analysis, normal CT was significantly associated with normal PFT (odds ratio, 2.47; 95% confidence interval, 1.22 to 4.97; P = .012). A model for predicting normal PFT was constructed based on the results of amultivariate analysis, and the area under the curve of the receiver operating characteristic analysis was 0.656, which gave a sensitivity of 45.5% and a specificity of 86.0%. The relatively high specificity of the model suggested that PFT can be omitted in patients with normal CT findings before allo-HCT. (C) 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
C1 [Tamaki, Masaharu; Nakasone, Hideki; Nakamura, Yuhei; Kawamura, Masakatsu; Kawamura, Shunto; Takeshita, Junko; Yoshino, Nozomu; Misaki, Yukiko; Yoshimura, Kazuki; Matsumi, Shinpei; Gomyo, Ayumi; Tanihara, Aki; Kusuda, Machiko; Akahoshi, Yu; Kimura, Shun-ichi; Kako, Shinichi; Kanda, Yoshinobu] Jichi Med Univ, Div Hematol, Saitama Med Ctr, Saitama, Japan.
   [Aikawa, Tadao; Oyama-Manabe, Noriko] Jichi Med Univ, Dept Radiol, Saitama Med Ctr, Saitama, Japan.
RP Kanda, Y (corresponding author), Jichi Med Univ, Div Hematol, Saitama Med Ctr, Omiya Ku, 1-847 Amanuma Cho, Saitama 3308503, Japan.
EM ycanda-tky@umin.ac.jp
OI Akahoshi, Yu/0000-0001-6825-9340
CR Akahoshi Y, 2018, INFECT DIS-NOR, V50, P280, DOI 10.1080/23744235.2017.1396621
   Anderson EL, 2020, RISK ANAL, V40, P902, DOI 10.1111/risa.13500
   Arcadu A, 2017, RESP MED, V129, P152, DOI 10.1016/j.rmed.2017.06.013
   Bergeron A, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02617-2017
   Bergeron A, 2017, CLIN CHEST MED, V38, P607, DOI 10.1016/j.ccm.2017.07.003
   DINAKARA P, 1970, AM REV RESPIR DIS, V102, P965
   Duque-Afonso J, 2018, BIOL BLOOD MARROW TR, V24, P2277, DOI 10.1016/j.bbmt.2018.06.024
   Gold WM, 2016, MURRAY NADELS TXB RE
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Hasegawa M, 2006, AM J RESP CRIT CARE, V173, P1309, DOI 10.1164/rccm.200601-037OC
   Horger M, 2005, EUR J RADIOL, V55, P437, DOI 10.1016/j.ejrad.2005.01.001
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kasow KA, 2009, BIOL BLOOD MARROW TR, V15, P490, DOI 10.1016/j.bbmt.2008.11.033
   Kaste Sue C, 2015, Biol Blood Marrow Transplant, V21, P1132, DOI 10.1016/j.bbmt.2015.02.023
   Kubota M, 2014, RESPIR INVESTIG, V52, P242, DOI 10.1016/j.resinv.2014.03.003
   Kunihiro Y, 2019, EUR RADIOL, V29, P6089, DOI 10.1007/s00330-019-06235-3
   Kuster S, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12981
   Pinana JL, 2012, AM J HEMATOL, V87, P9, DOI 10.1002/ajh.22183
   Oshima K, 2008, AM J HEMATOL, V83, P226, DOI 10.1002/ajh.21087
   Sorror ML, 2005, BLOOD, V106, P2912, DOI 10.1182/blood-2005-05-2004
   Task Force of Pulmonary Function Testing and Clinical Respiratory Physiology Chinese Association of Chest Physicians, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P302, DOI 10.3760/cma.j.cn112147-20200225-00175
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wingard JR, 2010, BLOOD, V116, P5111, DOI 10.1182/blood-2010-02-268151
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD DEC
PY 2020
VL 26
IS 12
BP 2318
EP 2322
DI 10.1016/j.bbmt.2020.08.025
PG 5
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA OY9EO
UT WOS:000594542200031
PM 32860909
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Fernandez, J
   Gratacos-Gines, J
   Olivas, P
   Costa, M
   Nieto, S
   Mateo, D
   Sanchez, MB
   Aguilar, F
   Bassegoda, O
   Ruiz, P
   Caballol, B
   Pocurull, A
   Llach, J
   Mustieles, MJ
   Cid, J
   Reverter, E
   Toapanta, ND
   Hernandez-Tejero, M
   Martinez, JA
   Claria, J
   Fernandez, C
   Mensa, J
   Arroyo, V
   Castro, P
   Lozano, M
AF Fernandez, Javier
   Gratacos-Gines, Jordi
   Olivas, Pol
   Costa, Montserrat
   Nieto, Susana
   Mateo, Dolors
   Belen Sanchez, Maria
   Aguilar, Ferran
   Bassegoda, Octavi
   Ruiz, Pablo
   Caballol, Berta
   Pocurull, Anna
   Llach, Joan
   Jesus Mustieles, Maria
   Cid, Joan
   Reverter, Enric
   David Toapanta, Nestor
   Hernandez-Tejero, Maria
   Antonio Martinez, Jose
   Claria, Joan
   Fernandez, Carlos
   Mensa, Jose
   Arroyo, Vicente
   Castro, Pedro
   Lozano, Miquel
CA Covid Clinic Critical Care CCCC Gr
TI Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients
   With Coronavirus Disease 2019 Infection
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE human albumin; inflammation; mortality; prognosis
AB Objectives:
   Infection by severe acute respiratory syndrome coronavirus-2 can induce uncontrolled systemic inflammation and multiple organ failure. The aim of this study was to evaluate if plasma exchange, through the removal of circulating mediators, can be used as rescue therapy in these patients.
   Design:
   Single center case series.
   Setting:
   Local study.
   Subjects:
   Four critically ill adults with coronavirus disease 19 pneumonia that failed conventional interventions.
   Interventions:
   Plasma exchange. Two to six sessions (1.2 plasma volumes). Human albumin (5%) was used as the main replacement fluid. Fresh frozen plasma and immunoglobulins were administered after each session to avoid coagulopathy and hypogammaglobulinemia.
   Measurements and Main Results:
   Serum markers of inflammation and macrophage activation. All patients showed a dramatic reduction in inflammatory markers, including the main cytokines, and improved severity scores after plasma exchange. All survived to ICU admission.
   Conclusions:
   Plasma exchange mitigates cytokine storm, reverses organ failure, and could improve survival in critically ill patients with coronavirus disease 2019 infection.
C1 [Fernandez, Javier; Gratacos-Gines, Jordi; Olivas, Pol; Costa, Montserrat; Nieto, Susana; Bassegoda, Octavi; Ruiz, Pablo; Caballol, Berta; Pocurull, Anna; Llach, Joan; Reverter, Enric; David Toapanta, Nestor; Hernandez-Tejero, Maria] Univ Barcelona, Liver ICU, Liver Unit, IDIBAPS,Inst Digest & Metab Dis,Hosp Clin, Barcelona, Spain.
   [Fernandez, Javier; Gratacos-Gines, Jordi; Olivas, Pol; Costa, Montserrat; Nieto, Susana; Belen Sanchez, Maria; Bassegoda, Octavi; Ruiz, Pablo; Caballol, Berta; Pocurull, Anna; Llach, Joan; Reverter, Enric; David Toapanta, Nestor; Hernandez-Tejero, Maria; Claria, Joan] CIBERehd, Barcelona, Spain.
   [Aguilar, Ferran; Claria, Joan; Arroyo, Vicente] EASL CLIF Consortium, EF Clif, Barcelona, Spain.
   [Mateo, Dolors; Jesus Mustieles, Maria; Cid, Joan; Lozano, Miquel] Univ Barcelona, Hosp Clin, Hemotherapy & Hemostasis Dept, IDIBAPS,Apheresis Unit, Barcelona, Spain.
   [Belen Sanchez, Maria; Claria, Joan] Univ Barcelona, Hosp Clin, IDIBAPS, CDB, Barcelona, Spain.
   [Antonio Martinez, Jose; Mensa, Jose] Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain.
   [Fernandez, Carlos] Med Emergency Serv, Berga, Berga, Catalonia, Spain.
   [Castro, Pedro] Univ Barcelona, Hosp Clin, Internal Med Dept, IDIBAPS,Med Intens Care Unit, Barcelona, Spain.
RP Fernandez, J (corresponding author), Univ Barcelona, Liver ICU, Liver Unit, IDIBAPS,Inst Digest & Metab Dis,Hosp Clin, Barcelona, Spain.; Fernandez, J (corresponding author), CIBERehd, Barcelona, Spain.
EM Jfdez@clinic.cat
RI ; Cid, Joan/F-7778-2016
OI Bassegoda, Octavi/0000-0002-6036-6026; Castro Rebollo,
   Pedro/0000-0002-6118-8970; Almuedo Riera, Alex/0000-0003-4643-4456; Cid,
   Joan/0000-0001-5445-4508
CR [Anonymous], 2020, CHINESE CLIN TRIAL R
   Arroyo V, 2014, J HEPATOL, V61, P396, DOI 10.1016/j.jhep.2014.04.012
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kinjo N, 2018, J CLIN APHERESIS, V33, P117, DOI 10.1002/jca.21570
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   Patel P, 2011, PEDIATR CRIT CARE ME, V12, pE87, DOI 10.1097/PCC.0b013e3181e2a569
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Reeves HM, 2014, BRIT J HAEMATOL, V164, P342, DOI 10.1111/bjh.12629
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
NR 14
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD DEC
PY 2020
VL 48
IS 12
BP E1350
EP E1355
DI 10.1097/CCM.0000000000004613
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA OZ3WK
UT WOS:000594860400026
PM 32833695
OA Green Published
DA 2021-01-01
ER

PT J
AU Ghoreishi, A
   Arsang-Jang, S
   Sabaa-Ayoun, Z
   Yassi, N
   Sylaja, PN
   Akbari, Y
   Divani, AA
   Biller, J
   Phan, T
   Steinwender, S
   Silver, B
   Zand, R
   Bin Basri, H
   Iqbal, OM
   Ranta, A
   Ruland, S
   Macri, E
   Ma, H
   Nguyen, TN
   Abootalebi, S
   Gupta, A
   Alet, M
   Lattanzi, S
   Desai, M
   Gagliardi, RJ
   Girotra, T
   Inoue, M
   Yoshimoto, T
   Isaac, CF
   Mayer, SA
   Morovatdar, N
   Nilanont, Y
   Nobleza, COS
   Saber, H
   Kamenova, S
   Kondybayeva, A
   Krupinski, J
   Siegler, JE
   Stranges, S
   Torbey, MT
   Yorio, D
   Zurru, MC
   Rubinos, CA
   Shahripour, RB
   Borhani-Haghighi, A
   Di Napoli, M
   Azarpazhooh, MR
AF Ghoreishi, Abdoreza
   Arsang-Jang, Shahram
   Sabaa-Ayoun, Ziad
   Yassi, Nawaf
   Sylaja, P. N.
   Akbari, Yama
   Divani, Afshin A.
   Biller, Jose
   Thanh Phan
   Steinwender, Sandy
   Silver, Brian
   Zand, Ramin
   Bin Basri, Hamidon
   Iqbal, Omer M.
   Ranta, Annemarei
   Ruland, Sean
   Macri, Elizabeth
   Ma, Henry
   Nguyen, Thanh N.
   Abootalebi, Shahram
   Gupta, Animesh
   Alet, Matias
   Lattanzi, Simona
   Desai, Masoom
   Gagliardi, Rubens J.
   Girotra, Tarun
   Inoue, Manabu
   Yoshimoto, Takeshi
   Isaac, Cristian Flavo
   Mayer, Stephan A.
   Morovatdar, Negar
   Nilanont, Yongchai
   Nobleza, Christa O'Hana S.
   Saber, Hamidreza
   Kamenova, Saltanat
   Kondybayeva, Aida
   Krupinski, Jerzy
   Siegler, James E.
   Stranges, Saverio
   Torbey, Michel T.
   Yorio, Diana
   Zurru, Maria Cristina
   Rubinos, Clio Aracelli
   Shahripour, Reza Bavarsad
   Borhani-Haghighi, Afshin
   Di Napoli, Mario
   Azarpazhooh, M. Reza
TI Stroke Care Trends During COVID-19 Pandemic in Zanjan Province, Iran.
   From the CASCADE Initiative: Statistical Analysis Plan and Preliminary
   Results
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Stroke; COVID-19; Epidemiology; Outcome; Mortality; Disability; Stroke
   care
ID TRANSIENT ISCHEMIC ATTACK; CARDIOVASCULAR EVENTS; POPULATION; WORLD
AB Background: The emergence of the COVID-19 pandemic has significantly impacted global healthcare systems and this may affect stroke care and outcomes. This study examines the changes in stroke epidemiology and care during the COVID-19 pandemic in Zanjan Province, Iran. Methods: This study is part of the CASCADE international initiative. From February 18, 2019, to July 18, 2020, we followed ischemic and hemorrhagic stroke hospitalization rates and outcomes in Valiasr Hospital, Zanjan, Iran. We used a Bayesian hierarchical model and an interrupted time series analysis (ITS) to identify changes in stroke hospitalization rate, baseline stroke severity [measured by the National Institutes of Health Stroke Scale (NIHSS)], disability [measured by the modified Rankin Scale (mRS)], presentation time (last seen normal to hospital presentation), thrombolytic therapy rate, median door-to-needle time, length of hospital stay, and in-hospital mortality. We compared in-hospital mortality between study periods using Cox-regression model. Results: During the study period, 1,026 stroke patients were hospitalized. Stroke hospitalization rates per 100,000 population decreased from 68.09 before the pandemic to 44.50 during the pandemic, with a significant decline in both Bayesian [Beta:-1.034; Standard Error (SE): 0.22, 95% CrI:-1.48,-0.59] and ITS analysis (estimate:-1.03, SE = 0.24, p < 0.0001). Furthermore, we observed lower admission rates for patients with mild (NIHSS < 5) ischemic stroke (p < 0.0001). Although, the presentation time and door-to-needle time did not change during the pandemic, a lower proportion of patients received thrombolysis (-10.1%; p = 0.004). We did not see significant changes in admission rate to the stroke unit and in-hospital mortality rate; however, disability at discharge increased (p < 0.0001). Conclusion: In Zanjan, Iran, the COVID-19 pandemic has significantly impacted stroke outcomes and altered the delivery of stroke care. Observed lower admission rates for milder stroke may possibly be due to fear of exposure related to COVID-19. The decrease in patients treated with thrombolysis and the increased disability at discharge may indicate changes in the delivery of stroke care and increased pressure on existing stroke acute and subacute services. The results of this research will contribute to a similar analysis of the larger CASCADE dataset in order to confirm findings at a global scale and improve measures to ensure the best quality of care for stroke patients during the COVID-19 pandemic.
C1 [Ghoreishi, Abdoreza] Zanjan Univ Med Sci, Vali E Asr Hosp, Sch Med, Dept Neurol, Zanjan, Iran.
   [Ghoreishi, Abdoreza] Zanjan Univ Med Sci, Vali E Asr Hosp, Sch Med, Stroke Unit, Zanjan, Iran.
   [Arsang-Jang, Shahram] Zanjan Univ Med Sci, Sch Med, Dept Biostat & Epidemiol, Zanjan, Iran.
   [Sabaa-Ayoun, Ziad] Western Univ, Stroke Prevent & Atherosclerosis Res Ctr, Robarts Res Inst, London, ON, Canada.
   [Sabaa-Ayoun, Ziad] Western Univ, Schulich Sch Med & Dent, London, ON, Canada.
   [Yassi, Nawaf] Univ Melbourne, Melbourne Brain Ctr, Dept Med & Neurol, Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Yassi, Nawaf] Walter & Eliza Hall Inst Med Res, Populat Hlth & Immun Div, Parkville, Vic, Australia.
   [Sylaja, P. N.] Sree Chitra Tirunal Inst Med Sci & Technol SCTIMS, Comprehens Stroke Care Program, Trivandrum, Kerala, India.
   [Akbari, Yama] Univ Calif Irvine, Dept Neurol, Beckman Laser Inst & Med Clin, Irvine, CA 92717 USA.
   [Akbari, Yama] Univ Calif Irvine, Dept Neurol Surg, Beckman Laser Inst & Med Clin, Irvine, CA USA.
   [Akbari, Yama] Univ Calif Irvine, Dept Anat & Neurobiol, Beckman Laser Inst & Med Clin, Irvine, CA 92717 USA.
   [Divani, Afshin A.; Macri, Elizabeth; Gupta, Animesh; Girotra, Tarun; Torbey, Michel T.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA.
   [Biller, Jose; Ruland, Sean] Loyola Univ, Stritch Sch Med, Dept Neurol, Chicago, IL USA.
   [Thanh Phan; Ma, Henry] Monash Univ, Monash Hlth, Dept Neurol, Clayton, Vic, Australia.
   [Thanh Phan; Ma, Henry] Monash Univ, Sch Clin Sci, Dept Med, Clayton, Vic, Australia.
   [Steinwender, Sandy] Western Univ, Hlth Informat Sci, London, ON, Canada.
   [Steinwender, Sandy] London Hlth Sci, Southwestern Ontario Stroke Network, Reg Stroke Prevent, London, ON, Canada.
   [Silver, Brian] Univ Massachusetts, Dept Neurol, Med Sch, Worcester, MA USA.
   [Zand, Ramin] Geisinger Med Ctr, Neurosci Inst, Dept Neurol, Danville, PA USA.
   [Bin Basri, Hamidon] Univ Putra Malaysia, Dept Med, Fac Med & Hlth Sci, Serdang, Malaysia.
   [Iqbal, Omer M.] Loyola Univ, Ctr Translat Res & Educ, Dept Pathol & Ophthalmol, Stritch Sch Med, Maywood, IL USA.
   [Ranta, Annemarei] Univ Otago, Dept Med & Neurol, Dunedin, New Zealand.
   [Ranta, Annemarei] Wellington Hosp, Wellington, New Zealand.
   [Nguyen, Thanh N.] Boston Univ, Boston Med Ctr, Sch Med, Boston, MA USA.
   [Abootalebi, Shahram] Dalhousie Univ, Dr Everett Chalmers Reg Hosp, New Brunswick, NJ USA.
   [Alet, Matias] Fleni, Vasc Neurol Div, Dept Neurol, Buenos Aires, DF, Argentina.
   [Lattanzi, Simona] Marche Polytech Univ, Dept Expt & Clin Med, Neurol Clin, Via Conca, Ancona, Italy.
   [Desai, Masoom] Univ Oklahoma, Dept Neurol, Hlth Sci Ctr, Oklahoma City, OK USA.
   [Gagliardi, Rubens J.] Santa Casa Sao Paulo Med Sch, Neurol Dept, Sao Paulo, SP, Brazil.
   [Inoue, Manabu; Yoshimoto, Takeshi] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Div Stroke Care Unit, Osaka, Japan.
   [Isaac, Cristian Flavo] Hosp Dr Arturo Ativia, Alte Brown, Pcia De Bs As, Argentina.
   [Mayer, Stephan A.] Westchester Med Ctr Hlth Network, Director Neurocrit Care & Emergency Neurol Serv, Valhalla, NY USA.
   [Mayer, Stephan A.] New York Med Coll, Westchester Med Ctr Hlth Network, Valhalla, NY 10595 USA.
   [Morovatdar, Negar] Mashhad Univ Med Sci, Fac Med, Clin Res Dev Unit, Mashhad, Razavi Khorasan, Iran.
   [Nilanont, Yongchai] Mahidol Univ, Siriraj Hosp, Siriraj Stroke Ctr, Dept Med, Bangkok, Thailand.
   [Nobleza, Christa O'Hana S.] Univ Mississippi, Dept Neurol, Div Neurosci Crit Care, Med Ctr, Jackson, MS USA.
   [Saber, Hamidreza] Wayne State Univ, Detroit, MI USA.
   [Kamenova, Saltanat] Al Farabi Kazakh Natl Univ, Dept Med, Alma Ata, Kazakhstan.
   [Kondybayeva, Aida] Asfendiyarov Kazakh Natl Med Univ, Dept Neurol, Alma Ata, Kazakhstan.
   [Krupinski, Jerzy] Hosp Univ MutuaTerrassa, Dept Neurol, Barcelona, Spain.
   [Krupinski, Jerzy] Manchester Metropolitan Univ, Dept Life Sci, CBS, Manchester, Lancs, England.
   [Siegler, James E.] Cooper Univ Hosp, Dept Neurol, Camden, NJ USA.
   [Stranges, Saverio] Western Univ, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON, Canada.
   [Stranges, Saverio] Western Univ, Schulich Sch Med & Dent, Dept Family Med, London, ON, Canada.
   [Stranges, Saverio] Luxembourg Inst Hlth, Dept Populat Hlth, Luxembourg, Luxembourg.
   [Yorio, Diana] British Hosp, Dept Neurol, Montevideo, Uruguay.
   [Zurru, Maria Cristina] Hosp Italiano Buenos Aires, Dept Neurol, Buenos Aires, DF, Argentina.
   [Rubinos, Clio Aracelli] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA.
   [Shahripour, Reza Bavarsad] Univ Calif San Diego, UCSD Stroke Ctr, Dept Neurosci, San Diego, CA USA.
   [Borhani-Haghighi, Afshin] Shiraz Univ Med Sci, Clin Neurol Res Ctr, Shiraz, Iran.
   [Di Napoli, Mario] San Camillo de Lellis Gen Dist Hosp, Dept Neurol, Rieti, Italy.
   [Di Napoli, Mario] San Camillo de Lellis Gen Dist Hosp, Stroke Unit, Rieti, Italy.
   [Di Napoli, Mario] SMDN Ctr Cardiovasc Med & Cerebrovasc Dis Prevent, Neuroepidemiol Unit, Neurol Sect, Laquila, Italy.
   [Azarpazhooh, M. Reza] Western Univ, Dept Clin Neurol Sci, London, ON, Canada.
   [Azarpazhooh, M. Reza] Mashhad Univ Med Sci, Sch Med, Dept Neurol, Mashhad, Razavi Khorasan, Iran.
RP Azarpazhooh, MR (corresponding author), Western Univ, Dept Clin Neurol Sci, London, ON, Canada.; Azarpazhooh, MR (corresponding author), Mashhad Univ Med Sci, Sch Med, Dept Neurol, Mashhad, Razavi Khorasan, Iran.
EM reza.azarpazhooh@lhsc.on.ca
OI Arsang-Jang, Shahram/0000-0001-7476-0414; Yoshimoto,
   Takeshi/0000-0003-3178-8171
FU SITS
FX The authors have no conflict of interest related to this paper to
   declare. We would like to sincerely thank all centers participating in
   the CASCADE study during this extremely difficult period. The authors
   have not received any compensation for the current study. Valiasr
   Hospital is an active participating center in the Safe Implementation of
   Treatments in Stroke (SITS) registry, and we would like to thank SITS
   for its support.
CR Aboa-Eboule C, 2014, J STROKE CEREBROVASC, V23, pE229, DOI 10.1016/j.jstrokecerebrovasdis.2013.10.004
   Abootalebi S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104938
   Adhanom Ghebreyesus T., 2020, WE NOW HAVE NAME DIS
   Amarenco P, 2008, STROKE, V39, P2400, DOI 10.1161/STROKEAHA.108.514166
   Appleby J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1607
   Avan A, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1397-3
   Azarpazhooh MR, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.105089
   Azarpazhooh M Reza, 2020, J Neurol Sci, V416, P117013, DOI 10.1016/j.jns.2020.117013
   Azarpazhooh MR, 2010, STROKE, V41, pE3, DOI 10.1161/STROKEAHA.109.559708
   Bersano A, 2020, EUR J NEUROL
   Farzadfard MT, 2019, INT J STROKE, V14, P44, DOI 10.1177/1747493018789839
   Farzadfard MT, 2018, J STROKE CEREBROVASC, V27, P1085, DOI 10.1016/j.jstrokecerebrovasdis.2017.11.018
   Gelman A, 2015, J EDUC BEHAV STAT, V40, P530, DOI 10.3102/1076998615606113
   Institute for Statistics and Mathematics of WU, 2020, COMPREHENSIVE R ARCH
   Lavallee PC, 2007, LANCET NEUROL, V6, P953, DOI 10.1016/S1474-4422(07)70248-X
   Martinez R, 2020, LANCET GLOB HEALTH, V8, pE511, DOI 10.1016/S2214-109X(20)30035-8
   Ministry of Health and Medical Education in Iran, 2020, COVID 19 IR
   Montaner J, 2020, STROKE, V51, P2307, DOI 10.1161/STROKEAHA.120.030106
   Morens DM, 2010, CRIT CARE MED, V38, pE10, DOI 10.1097/CCM.0b013e3181ceb25b
   Nguyen TN, 2020, STROKE, V51, P1896, DOI 10.1161/STROKEAHA.120.030100
   Nozaki E, 2013, INT HEART J, V54, P247, DOI 10.1536/ihj.54.247
   Owen N, 2010, MAYO CLIN PROC, V85, P1138, DOI 10.4065/mcp.2010.0444
   Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca
   SADIGHI A, 2019, ENEUROLOGICALSCI, V10
   Salehi M, 2018, NEUROEPIDEMIOLOGY, V50, P18, DOI 10.1159/000485509
   Wilbert-Lampen U, 2008, NEW ENGL J MED, V358, P475, DOI 10.1056/NEJMoa0707427
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD DEC
PY 2020
VL 29
IS 12
AR 105321
DI 10.1016/j.jstrokecerebrovasdis.2020.105321
PG 10
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA OV0NF
UT WOS:000591917200022
PM 33069086
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, J
   Chaudhry, SA
   Tahsili-Fahadan, P
   Altaweel, LR
   Bashir, S
   Bahiru, Z
   Fang, Y
   Qureshi, AI
AF Wang, Jing
   Chaudhry, Saqib A.
   Tahsili-Fahadan, Pouya
   Altaweel, Laith R.
   Bashir, Sairah
   Bahiru, Zelalem
   Fang, Yun
   Qureshi, Adnan, I
TI The impact of COVID-19 on acute ischemic stroke admissions: Analysis
   from a community-based tertiary care center
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE COVID-19; Pandemic; Acute Ischemic Stroke; IV thrombolysis; Mechanical
   Thrombectomy; Hospital Admission; Mortality
AB Background/Objective: To evaluate the impact of the COVID-19 pandemic on hospital admissions and outcomes in patients admitted with acute ischemic stroke. Methods: Single-center retrospective analysis of patients admitted to the hospital with acute ischemic stroke, between December 1st, 2019 and June 30th, 2020. Outcomes were classified as none-to-minimal disability, moderate-to-severe disability, and death based on discharge disposition, and compared between two time periods: pre-COVID-19 era (December 1st, 2019 to March 11th, 2020) and COVID19 era (March 12th to June 30th, 2020). We also performed a comparative trend analysis for the equivalent period between 2019 and 2020. Results: Five hundred and seventy-five patients with a mean age (years +/- SD) of 68 +/- 16 were admitted from December 1st, 2019 to June 30th, 2020, with a clinical diagnosis of acute ischemic stroke. Of these, 255 (44.3%) patients were admitted during the COVID-19 era. We observed a 22.1% and 39.5% decline in admission for acute ischemic stroke in April and May 2020, respectively. A significantly higher percentage of patients with acute ischemic stroke received intravenous thrombolysis during the COVID-1 9 era (p = 0.020). In patients with confirmed COVID-19, we found a higher percentage of older men with preexisting comorbidities such as hyperlipidemia, coronary artery disease, and diabetes mellitus but a lower rate of atrial fibrillation. In addition, we found a treatment delay in both intravenous thrombolysis (median 94.5 min versus 38 min) and mechanical thrombectomy (median 244 min versus 86 min) in patients with confirmed COVID-19 infection. There were no differences in patients' disposition including home, short-term, and long-term facility (p = 0.60). Conclusions: We observed a reduction of hospital admissions in acute ischemic strokes and some delay in reperfusion therapy during the COVID-1 9 pandemic. Prospective studies and a larger dataset analysis are warranted.
C1 [Wang, Jing; Chaudhry, Saqib A.; Tahsili-Fahadan, Pouya; Altaweel, Laith R.; Bahiru, Zelalem] INOVA Fairfax Med Campus, Neurosci Intens Care Unit, Dept Med, Falls Church, VA 22042 USA.
   [Wang, Jing; Chaudhry, Saqib A.; Tahsili-Fahadan, Pouya; Altaweel, Laith R.; Fang, Yun] INOVA Fairfax Med Campus, Neurosci Res, Neurosci & Spine Inst, Falls Church, VA 22042 USA.
   [Tahsili-Fahadan, Pouya] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.
   [Bashir, Sairah] INOVA Fairfax Med Campus, Dept Neurol, Falls Church, VA USA.
   [Qureshi, Adnan, I] Zeenat Qureshi Stroke Inst, Columbia, MO USA.
RP Chaudhry, SA (corresponding author), INOVA Fairfax Med Campus, Neurosci Intens Care Unit, Dept Med, Falls Church, VA 22042 USA.; Chaudhry, SA (corresponding author), INOVA Fairfax Med Campus, Neurosci Res, Neurosci & Spine Inst, Falls Church, VA 22042 USA.
EM Saqib.Chaudhry@inova.org
CR Bullrich MB, 2020, CAN J NEUROL SCI, V47, P693, DOI 10.1017/cjn.2020.101
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166
   De Rosa S, 2020, EUR HEART J, V41, P2083, DOI 10.1093/eurheartj/ehaa409
   Diegoli H, 2020, STROKE, V51, P2315, DOI 10.1161/STROKEAHA.120.030481
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Hoyer C, 2020, STROKE, V51, P2224, DOI 10.1161/STROKEAHA.120.030395
   Kerleroux B, 2020, STROKE, V51, P2012, DOI 10.1161/STROKEAHA.120.030373
   Mahase Elisabeth, 2020, BMJ, V368, pm1282, DOI 10.1136/bmj.m1282
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Metzler B, 2020, EUR HEART J, V41, P1852, DOI 10.1093/eurheartj/ehaa314
   Meza HT, 2020, INT J STROKE, V15, P755, DOI 10.1177/1747493020938301
   Montaner J, 2020, STROKE, V51, P2307, DOI 10.1161/STROKEAHA.120.030106
   Morelli N, 2020, EUR NEUROL, V83, P213, DOI 10.1159/000507666
   Niccoli G, 2020, CARDIOVASC RES, V116, pE126, DOI 10.1093/cvr/cvaa146
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Pessoa-Amorim G, 2020, EUR HEART J-QUAL CAR, V6, P210, DOI 10.1093/ehjqcco/qcaa046
   Pop R, 2020, EUR J NEUROL, V27, P1783, DOI 10.1111/ene.14316
   Qureshi AI, 2020, INT J STROKE, V15, P540, DOI 10.1177/1747493020923234
   Qureshi AI, 2012, ARCH PHYS MED REHAB, V93, P1408, DOI 10.1016/j.apmr.2012.02.032
   Siegler JE, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104953
   Solomon MD, 2020, NEW ENGL J MED, V383, P691, DOI 10.1056/NEJMc2015630
   Meza HT, 2020, EUR J NEUROL, V27, P1788, DOI 10.1111/ene.14327
   Zhao J, 2020, STROKE, V51, P1996, DOI 10.1161/STROKEAHA.120.030225
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD DEC
PY 2020
VL 29
IS 12
AR 105344
DI 10.1016/j.strokecerebrovasdis.2020.105344
PG 5
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA OV0NF
UT WOS:000591917200008
PM 33049464
DA 2021-01-01
ER

PT J
AU Sacco, MD
   Ma, CL
   Lagarias, P
   Gao, A
   Townsend, JA
   Meng, XZ
   Dube, P
   Zhang, XJ
   Hu, YM
   Kitamura, N
   Hurst, B
   Tarbet, B
   Marty, MT
   Kolocouris, A
   Xiang, Y
   Chen, Y
   Wang, J
AF Sacco, Michael Dominic
   Ma, Chunlong
   Lagarias, Panagiotis
   Gao, Ang
   Townsend, Julia Alma
   Meng, Xiangzhi
   Dube, Peter
   Zhang, Xiujun
   Hu, Yanmei
   Kitamura, Naoya
   Hurst, Brett
   Tarbet, Bart
   Marty, Michael Thomas
   Kolocouris, Antonios
   Xiang, Yan
   Chen, Yu
   Wang, Jun
TI Structure and inhibition of the SARS-CoV-2 main protease reveal strategy
   for developing dual inhibitors against M-pro and cathepsin L
SO SCIENCE ADVANCES
LA English
DT Article
ID PARTICLE MESH EWALD; 3CL PROTEASE; FORCE-FIELD; MODEL
AB The main protease (M-pro) of SARS-CoV-2 is a key antiviral drug target. While most M-pro inhibitors have a gamma-lactam glutamine surrogate at the P1 position, we recently found that several M-pro inhibitors have hydrophobic moieties at the P1 site, including calpain inhibitors II and XII, which are also active against human cathepsin L, a host protease that is important for viral entry. In this study, we solved x-ray crystal structures of M-pro in complex with calpain inhibitors II and XII and three analogs of GC-376. The structure of M-pro with calpain inhibitor II confirmed that the S1 pocket can accommodate a hydrophobic methionine side chain, challenging the idea that a hydrophilic residue is necessary at this position. The structure of calpain inhibitor XII revealed an unexpected, inverted binding pose. Together, the biochemical, computational, structural, and cellular data presented herein provide new directions for the development of dual inhibitors as SARS-CoV-2 antivirals.
C1 [Sacco, Michael Dominic; Zhang, Xiujun; Chen, Yu] Univ S Florida, Dept Mol Med, Morsani Coll Med, Tampa, FL 33612 USA.
   [Ma, Chunlong; Gao, Ang; Hu, Yanmei; Kitamura, Naoya; Wang, Jun] Univ Arizona, Dept Pharmacol & Toxicol, Coll Pharm, Tucson, AZ 85721 USA.
   [Lagarias, Panagiotis; Kolocouris, Antonios] Natl & Kapodistrian Univ Athens, Fac Pharm, Dept Pharmaceut Chem, Athens 15771, Greece.
   [Townsend, Julia Alma; Marty, Michael Thomas] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA.
   [Meng, Xiangzhi; Dube, Peter; Xiang, Yan] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA.
   [Hurst, Brett; Tarbet, Bart] Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA.
   [Hurst, Brett; Tarbet, Bart] Utah State Univ, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA.
RP Chen, Y (corresponding author), Univ S Florida, Dept Mol Med, Morsani Coll Med, Tampa, FL 33612 USA.; Wang, J (corresponding author), Univ Arizona, Dept Pharmacol & Toxicol, Coll Pharm, Tucson, AZ 85721 USA.
EM ychen1@usf.edu; junwang@pharmacy.arizona.edu
OI Ma, Chunlong/0000-0002-5766-8189
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI147325, AI157046, R35 GM128624,
   AI151638]; Arizona Biomedical Research Centre Young Investigator grant
   [ADHS18-198859]; National Institute of General Medical SciencesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS); COVID-19 pilot grant from UTHSCSA
FX This research was partially supported by the NIH (grants AI147325 and
   AI157046) and the Arizona Biomedical Research Centre Young Investigator
   grant (ADHS18-198859) to J.W. J.A.T. and M.T.M. were funded by the
   National Institute of General Medical Sciences and NIH (grant R35
   GM128624 to M.T.M.). Y.X. was funded by the NIH (grant AI151638). The
   SARS-CoV-2 experiments were supported by a COVID-19 pilot grant from
   UTHSCSA to Y.X.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Cady SD, 2011, J AM CHEM SOC, V133, P4274, DOI 10.1021/ja102581n
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Choe Y, 2006, J BIOL CHEM, V281, P12824, DOI 10.1074/jbc.M513331200
   Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237
   Chuck CP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013197
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Dana D, 2020, MOLECULES, V25, DOI 10.3390/molecules25030698
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   HUMPHREYS DD, 1994, J PHYS CHEM-US, V98, P6885, DOI 10.1021/j100078a035
   Izaguirre JA, 2001, J CHEM PHYS, V114, P2090, DOI 10.1063/1.1332996
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu TX, 2020, PHARMACOL THERAPEUT, V213, DOI 10.1016/j.pharmthera.2020.107587
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Mandadapu SR, 2013, BIOORG MED CHEM LETT, V23, P62, DOI 10.1016/j.bmcl.2012.11.026
   Marty MT, 2015, ANAL CHEM, V87, P4370, DOI 10.1021/acs.analchem.5b00140
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Musharrafieh Rami, 2020, ACS Pharmacol Transl Sci, V3, P666, DOI 10.1021/acsptsci.0c00018
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pedersen NC, 2018, J FELINE MED SURG, V20, P378, DOI 10.1177/1098612X17729626
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Rut W., 2020, BIORXIV
   Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shie JJ, 2005, BIOORGAN MED CHEM, V13, P5240, DOI 10.1016/j.bmc.2005.05.065
   Shivakumar D, 2010, J CHEM THEORY COMPUT, V6, P1509, DOI 10.1021/ct900587b
   Ullrich S, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2020.127377
   Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589
   Verschueren KHG, 2008, CHEM BIOL, V15, P597, DOI 10.1016/j.chembiol.2008.04.011
   Vuong W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18096-2
   Wang YY, 2020, J MED VIROL, DOI 10.1002/jmv.26264
   Xia B, 2011, PROTEIN CELL, V2, P282, DOI 10.1007/s13238-011-1034-1
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Yang S, 2006, J MED CHEM, V49, P4971, DOI 10.1021/jm0603926
   Ye G, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020240
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
NR 59
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD DEC
PY 2020
VL 6
IS 50
AR eabe0751
DI 10.1126/sciadv.abe0751
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PD0UO
UT WOS:000597410300021
PM 33158912
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gao, F
   Tao, L
   Huang, Y
   Shu, ZQ
AF Gao, Frank
   Tao, Liang
   Huang, Yu
   Shu, Zhiquan
TI Management and Data Sharing of COVID-19 Pandemic Information
SO BIOPRESERVATION AND BIOBANKING
LA English
DT Article
DE COVID-19 information management; data sharing; research; database;
   policy
AB The coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2. During the past 10 months, COVID-19 has killed over 1 million people worldwide. Under this global crisis, data sharing and management of the COVID-19 information are urgently needed and critical for researchers, epidemiologists, physicians, bioengineers, funding agencies, and governments to work together in developing new vaccines, drugs, methods, therapeutics, and strategies for the prevention and treatment of this deadly and rapidly spreading disease. The COVID-19 pandemic information includes the database of COVID-19-patient biospecimen resources in hospitals or biorepositories, electronic patient health records, ongoing clinical trials and research results on this disease, policies, guidelines, and regulations related to COVID-19, and the COVID-19 outbreak tracking records, and so on. A study of the current management and data-sharing approaches, tools, software, network, and internet systems developed in the United States is conducted in this article. Based on this study, it is revealed that the existing data-sharing and management systems are facing many big challenges and problems associated with data decentralization, inconsistencies, security and legal issues, limited financial support, international communications, standardization, and globalization. To overcome and solve these problems, several integrated platform models for national and international data-sharing and management are developed and proposed in this article to meet the unprecedented need and demand for COVID-19 pandemic information sharing and research worldwide.
C1 [Gao, Frank] Univ Sci & Technol China, Sch Publ Affairs, Hefei, Anhui, Peoples R China.
   [Tao, Liang] Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA.
   [Tao, Liang; Shu, Zhiquan] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA.
   [Huang, Yu] Anhui Med Univ, Coll Clin Med, Hefei, Anhui, Peoples R China.
   [Shu, Zhiquan] Univ Washington Tacoma, Sch Engn & Technol, 1900 Commerce St, Tacoma, WA 98402 USA.
RP Shu, ZQ (corresponding author), Univ Washington Tacoma, Sch Engn & Technol, 1900 Commerce St, Tacoma, WA 98402 USA.
EM zqshu@uw.edu
CR Allam Z, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8010046
   [Anonymous], 2020, COVID 19 RESP
   [Anonymous], LAB TEST 2019 NOV CO
   [Anonymous], COVID 19 SAF HANDL P
   [Anonymous], SAMPL TRACK SOFTW SP
   [Anonymous], COVID 19 LIMS LIMS C
   [Anonymous], 2018, WHAT AR EL HLTH REC
   [Anonymous], COVID 19 SURV DASHB
   [Anonymous], 2020, INT GUID CLIN SPEC C
   [Anonymous], HLTH IT PLAYB
   [Anonymous], COVID 19 MAP
   [Anonymous], 2020, COVID 19 BIOSP GUID
   [Anonymous], 2020, EL HLTH REC EHRS
   [Anonymous], 2020, SENATE DATA EXCHANGE
   [Anonymous], 2020, 2020 3 F LAB GUID DE
   BaseSpace Clarity LIMS (Laboratory Information Management System), BASESPACE CLAR LIMS
   BBMRI/ISBER Biobank Collaboration, BBMRI ERIC MAK NEW T
   Biologics Research & Development Software, 2020, BENCHL
   Bo Zhao FX, NOVEL CORONAVIRUS IN
   CAICT (China Academy of Telecommunication Planning Research of Ministry of Industry and Information Technology), 2020, RES REP DAT SMART AP
   Comtron USA . Labgen LIS, 2020, COMTR US
   Coppola L, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1922-3
   Core LIMS, 2019, COREINFORMATICS
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Duffy RL, 2010, FAM MED, V42, P358
   Gao F, 2020, BIOPRESERV BIOBANKIN
   Home . Agilent, 2020, HOME
   Integrated Solution, 2020, BUILD INT DAT MAN SO
   International Data Corporation (IDC), 2020, IDC ID CHIN EM HEALT
   Jamoom EW, 2014, HEALTHCARE, V2, P33, DOI 10.1016/j.hjdsi.2013.12.004
   Jiang F, 2017, STROKE VASC NEUROL, V2, P230, DOI 10.1136/svn-2017-000101
   Mannheimer S, 2019, AM BEHAV SCI, V63, P643, DOI 10.1177/0002764218784991
   Mate S, 2017, STUD HEALTH TECHNOL, V243, P100, DOI 10.3233/978-1-61499-808-2-100
   Patel Pious D, 2020, J Am Med Inform Assoc, V27, P1116, DOI 10.1093/jamia/ocaa065
   Raposo VL, 2020, J MED ETHICS, V46, P451, DOI 10.1136/medethics-2020-106210
   Tacoma-Pierce County Health Department, COVID 19 TAC PIERC C
   World Health Organization, 2020, 30 WHO
   World Health Organization, 2020, WHO COR DIS COVID 19
   Zhongguozhengfuwang, 2020, ZHONGGUOZHENGFUWANG
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 40
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1947-5535
EI 1947-5543
J9 BIOPRESERV BIOBANK
JI Biopreserv. Biobank.
PD DEC 1
PY 2020
VL 18
IS 6
BP 570
EP 580
DI 10.1089/bio.2020.0134
PG 11
WC Cell Biology; Chemistry, Applied; Medical Laboratory Technology
SC Cell Biology; Chemistry; Medical Laboratory Technology
GA PF0CN
UT WOS:000598732500011
PM 33320734
DA 2021-01-01
ER

PT J
AU Dubey, AK
   Singh, A
   Prakash, S
   Kumar, M
   Singh, AK
AF Dubey, Ankit Kumar
   Singh, Aakansha
   Prakash, Shardendu
   Kumar, Manoj
   Singh, Ashok K.
TI Race to arsenal COVID-19 therapeutics: Current alarming status and
   future directions
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS DISEASE 2019; NUCLEOCAPSID
   PROTEIN; TREATMENT OPTIONS; SARS; TRANSMISSION; INFECTION; PNEUMONIA;
   CHINA; EPIDEMIOLOGY
AB The on-going pandemic of COVID-19 wreaked by a viral infection of SARS-CoV-2, has generated a catastrophic plight across the globe. Interestingly, one of the hallmarks of COVID-19 is the so-called 'cytokine storm' due to attack of SARS-Cov-2 in the lungs. Considering, mesenchymal stem cells (MSCs) therapy could contribute against SARS-CoV-2 viruses attack because of their immune modulatory and anti-inflammatory ability linked to their stemness, to the arsenal of treatments for COVID-19. Another novel therapeutic strategies include the blockade of rampant generation of pro-inflammatory mediators like acute respiratory distress syndrome (ARDS), degradation of viral protein capsids by PROTACs, composed of Ubiquitin-proteasome framework, and ubiquitination-independent pathway directing the SARS-CoV-2 nucleocapsid protein (nCoV N) and proteasome activator (PA28 gamma), etc. This review is consequently an endeavour to highlight the several aspects of COVID-19 with incorporation of important treatment strategies discovered to date and putting the real effort on the future directions to put them into the perspective.
C1 [Dubey, Ankit Kumar] Indian Inst Technol Madras, Dept Biotechnol, Madras 600036, Tamil Nadu, India.
   [Singh, Aakansha] CSIR Cent Drug Res Inst, Lucknow 226014, Uttar Pradesh, India.
   [Prakash, Shardendu] Sardar Patel Coll Pharm, Dept Pharm, Gorakhpur 273013, Uttar Pradesh, India.
   [Kumar, Manoj] SGPGIMS, Dept Microbiol, Lucknow 226014, Uttar Pradesh, India.
   [Singh, Ashok K.] Penn State Univ, Penn State Coll Med, Hershey, PA 17033 USA.
RP Singh, AK (corresponding author), Penn State Univ, Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.
EM indianashoksingh@gmail.com
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Ahmad S., 2020, EJMO, V4, P116, DOI DOI 10.14744/EJMO.2020.90853
   Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   AminJafari A, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106455
   Andersen PI, 2020, INT J INFECT DIS, V93, P268, DOI 10.1016/j.ijid.2020.02.018
   [Anonymous], 2020, DRUG VIRUS
   Anupam R, 2011, J BIOL CHEM, V286, P7661, DOI 10.1074/jbc.M110.176354
   Argyropoulos KV, 2020, AM J PATHOL, V190, P1881, DOI 10.1016/j.ajpath.2020.07.001
   Badyal DK, 2020, CHLOROQUINE, V10, P128, DOI [10.4103/ijabmr.IJABMR_141_20, DOI 10.4103/IJABMR.IJABMR_141_20]
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bhagavathula AS, 2020, CUREUS, V12, DOI 10.7759/cureus.8342
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bosl K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02186
   Carlos W.G., 2020, AM J RESP CRIT CARE, V201, pP7, DOI [10.1164/rccm.2014P7, DOI 10.1164/RCCM.2014P7.P7-P8]
   Centers for Disease Control and Prevention, 2010, COR DIS 2019
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   Chin Alex W H, 2020, Lancet Microbe, V1, pe10, DOI 10.1016/S2666-5247(20)30003-3
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   De Groot Raoul, 2012, VIRUS TAXONOMY, P806
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Delang L, 2020, EUR HEART J-ACUTE CA, V9, P209, DOI 10.1177/2048872620922790
   Depfenhart M, 2020, INTERN EMERG MED, V15, P801, DOI 10.1007/s11739-020-02383-3
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fu JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020648
   Gao GA, 2010, J VIROL, V84, P11056, DOI 10.1128/JVI.00008-10
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Geller C, 2012, VIRUSES-BASEL, V4, P3044, DOI 10.3390/v4113044
   Gil C, 2020, J MED CHEM, V63, P12359, DOI 10.1021/acs.jmedchem.0c00606
   Gilardin L, 2015, CAN MED ASSOC J, V187, P257, DOI 10.1503/cmaj.130375
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Han H., 2020, ESTIMATE INCUBATION, DOI [10.1101/ 2020.02.24.20027474, DOI 10.1101/2020.02.24.20027474]
   Hartman ME, 2020, ASAIO J, V66, P603, DOI 10.1097/MAT.0000000000001177
   Hoffmann M, 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang PK, 2020, RADIOLOGY, V295, P22, DOI 10.1148/radiol.2020200330
   Huang XH, 2002, J MOL BIOL, V323, P771, DOI 10.1016/S0022-2836(02)00998-1
   Jaimes JA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010083
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Jordan Paul C., 2018, Antiviral Chemistry & Chemotherapy, V26, p2040206618764483, DOI 10.1177/2040206618764483
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Ko NL, 2013, BLOOD, V121, P791, DOI 10.1182/blood-2012-03-420414
   Kumar GV, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100682
   Kumar V, 2013, EXPERT OPIN THER PAT, V23, P1337, DOI 10.1517/13543776.2013.823159
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li T., 2020, MED J PEK UNI MED CO
   Li Z, 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212, DOI 10.1101/2020.02.08.20021212]
   LiverTox, 2012, NUCL AN
   Loon SC, 2004, BRIT J OPHTHALMOL, V88, P861, DOI 10.1136/bjo.2003.035931
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Mielech AM, 2014, VIROLOGY, V450, P64, DOI 10.1016/j.virol.2013.11.040
   Moriishi K, 2003, J VIROL, V77, P10237, DOI 10.1128/JVI.77.19.10237-10249.2003
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Mu JF, 2020, SCI CHINA LIFE SCI, DOI 10.1007/s11427-020-1692-1
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Mustafa S, 2018, J INFECT PUBLIC HEAL, V11, P9, DOI 10.1016/j.jiph.2017.08.009
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Nguyen AA, 2020, CLIN IMMUNOL, V216, DOI 10.1016/j.clim.2020.108459
   Ooi GC, 2004, RADIOLOGY, V230, P836, DOI 10.1148/radiol.2303030853
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Pawlitzki M, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102822
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Poti Francesco, 2020, Acta Biomed, V91, P118, DOI 10.23750/abm.v91i2.9639
   Pruijssers AJ, 2019, CURR OPIN VIROL, V35, P57, DOI 10.1016/j.coviro.2019.04.002
   Raaben M, 2010, J VIROL, V84, P7869, DOI 10.1128/JVI.00485-10
   Raizada MK, 2007, J CARDIOVASC PHARM, V50, P112, DOI 10.1097/FJC.0b013e3180986219
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sahu KK, 2020, MONALDI ARCH CHEST D, V90, P197
   Schwarz K, 2000, J IMMUNOL, V165, P768, DOI 10.4049/jimmunol.165.2.768
   Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Siordia JA, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104357
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stohwasser R, 2003, BIOL CHEM, V384, P39, DOI 10.1515/BC.2003.005
   Sun W, 2016, DRUG DISCOV TODAY, V21, P1189, DOI 10.1016/j.drudis.2016.05.015
   Surjit M, 2006, J BIOL CHEM, V281, P10669, DOI 10.1074/jbc.M509233200
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   WHO, 2020, REP WHO CHIN JOINT M
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang CL, 2020, EUR REV MED PHARMACO, V24, P4585, DOI 10.26355/eurrev_202004_21045
   Yang PH, 2020, CELL MOL IMMUNOL, V17, P555, DOI 10.1038/s41423-020-0407-x
   Yeom S, 2018, J GEN VIROL, V99, P655, DOI 10.1099/jgv.0.001054
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
   Zheng W, 2018, BRIT J PHARMACOL, V175, P181, DOI 10.1111/bph.13895
   Zhong JX, 2020, LANCET RHEUMATOL, V2, pE428, DOI 10.1016/S2665-9913(20)30120-X
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 128
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD DEC 1
PY 2020
VL 332
AR 109298
DI 10.1016/j.cbi.2020.109298
PG 25
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA PA9NT
UT WOS:000595955200002
PM 33121920
OA Green Published
DA 2021-01-01
ER

PT J
AU Khan, AA
   Khan, Z
AF Khan, Abdul Arif
   Khan, Zakir
TI System biological investigations of hydroxychloroquine and azithromycin
   targets and their implications in QT interval prolongation
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Drug targets; COVID-19; Adverse reactions; Network pharmacology; Cardiac
   arrhythmia
AB COVID-2019 pandemic is affecting people worldwide in the absence of an effective treatment strategy. Several suggestive therapeutic options through drug repurposing are recommended, but a complete consensus is not reached. A combination of Hydroxychloroquine (HCQ) and Azithromycin (AZM) has been widely tried and discussed but its administration has also led to potential adversities in patients. Studies are suggesting that most prominent adverse event with HCQ and AZM combination is QT interval prolongation. We studied interaction of HCQ with AZM and subsequent effect of this drug combination on QT interval prolongation. We performed system biological investigation of HCQ and AZM targets and screened important targets and pathways possibly involved in QT interval prolongation. The best core hub protein drug targets involved in QT interval prolongation were identified as HSP90AA1 exclusively associated with HCQ, while AKT1 exclusively associated with AZM on the basis of node degree value. It was found that PI3K/Akt, VEGF, ERBB2 pathways must be given consideration for understanding the role of HCQ and AZM in QT interval prolongation. Conclusion: Computational methods have certain limitations based on source database coverage and prediction algorithms and therefore this data needs experimental correlation to draw final conclusion, but current findings screen targets for QT interval prolongation associated with HCQ and AZM. These proteins and pathways may provide ways to reduce this major risk associated with this combination.
C1 [Khan, Abdul Arif] Indian Council Med Res Natl AIDS Res Inst, Pune 411026, Maharashtra, India.
   [Khan, Zakir] Cedars Sinai Med Ctr, Dept Biomed Sci, Dept Pathol & Lab Med, Bldg Rm 2014 8700 Beverly Blvd Angeles, Davis, CA 20148 USA.
RP Khan, AA (corresponding author), Indian Council Med Res Natl AIDS Res Inst, Pune 411026, Maharashtra, India.
EM abdularifkhan@gmail.com
CR Ballou LM, 2015, CIRC RES, V116, P127, DOI 10.1161/CIRCRESAHA.116.303975
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Chatterjee P, 2020, INDIAN J MED RES, V151, P459, DOI 10.4103/ijmr.IJMR_2234_20
   Cheng XB, 2020, BIOORG CHEM, V100, DOI 10.1016/j.bioorg.2020.103914
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Coppola C, 2018, CANCER TREAT REV, V63, P135, DOI 10.1016/j.ctrv.2017.11.009
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Garcia O, 2007, BIOINFORMATICS, V23, P394, DOI 10.1093/bioinformatics/btl605
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ge B, 2019, BIOFACTORS, DOI 10.1002/biof.1558
   Ghatalia P, 2015, BRIT J CANCER, V112, P296, DOI 10.1038/bjc.2014.564
   Jadapalli JK, 2018, FASEB J, V32, P5227, DOI 10.1096/fj.201800254R
   Jassal B, 2020, NUCLEIC ACIDS RES, V48, pD498, DOI 10.1093/nar/gkz1031
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Kapoor Aditya, 2020, Indian Pacing Electrophysiol J, V20, P117, DOI 10.1016/j.ipej.2020.04.003
   Li R, 2020, FOOD FUNCT, V11, P4765, DOI [10.1039/D0FO00421A, 10.1039/d0fo00421a]
   Li R, 2019, J CELL BIOCHEM, V120, P11265, DOI 10.1002/jcb.28404
   Liu FX, 2020, BIOFACTORS, V46, P675, DOI 10.1002/biof.1639
   Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Nickel J, 2014, NUCLEIC ACIDS RES, V42, pW26, DOI 10.1093/nar/gku477
   Pinero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Ramireddy A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017144
   Scherrmann JM, 2020, AAPS J, V22, DOI 10.1208/s12248-020-00465-w
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wright Christopher, 2020, Evid Based Dent, V21, P64, DOI 10.1038/s41432-020-0098-2
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD DEC 1
PY 2020
VL 332
AR 109299
DI 10.1016/j.cbi.2020.109299
PG 7
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA PA9NT
UT WOS:000595955200001
PM 33098839
OA Green Published
DA 2021-01-01
ER

PT J
AU Bergquist, S
   Otten, T
   Sarich, N
AF Bergquist, Savannah
   Otten, Thomas
   Sarich, Nick
TI COVID-19 pandemic in the United States
SO HEALTH POLICY AND TECHNOLOGY
LA English
DT Article
DE Coronavirus; Pandemic; Federalist policy; United States
ID HEALTH-CARE; INCOME
AB Objectives: The paper highlights US health policy and technology responses to the COVID-19 pandemic from January 1, 2020 - August 9, 2020.
   Methods: A review of primary data sources in the US was conducted. The data were summarized to describe national and state-level trends in the spread of COVID-19 and in policy and technology solutions.
   Results: COVID-19 cases and deaths initially peaked in late March and April, but after a brief reduction in June cases and deaths began rising again during July and continued to climb into early August. The US policy response is best characterized by its federalist, decentralized nature. The national government has led in terms of economic and fiscal response, increasing funding for scientific research into testing, treatment, and vaccines, and in creating more favorable regulations for the use of telemedicine. State governments have been responsible for many of the containment, testing, and treatment responses, often with little federal government support. Policies that favor economic re-opening are often followed by increases in state-level case numbers, which are then followed by stricter containment measures, such as mask wearing or pausing re-opening plans.
   Conclusions: While all US states have begun to "re-open" economic activities, this trend appears to be largely driven by social tensions and economic motivations rather than an ability to effectively test and surveil populations. (c) 2020 Fellowship of Postgraduate Medicine. Published by Elsevier Ltd. All rights reserved.
C1 [Bergquist, Savannah] Univ Calif Berkeley, Haas Sch Business, Berkeley, CA 94720 USA.
   [Otten, Thomas] EUR, Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands.
   [Sarich, Nick] MCI, Management Ctr Innsbruck, Innsbruck, Austria.
RP Bergquist, S (corresponding author), Univ Calif Berkeley, Haas Sch Business, Berkeley, CA 94720 USA.
EM bergquist@berkeley.edu; 517320to@student.eur.nl; nw.sarich@mci4me.at
CR Abrams HR, 2020, J AM GERIATR SOC, V68, P1653, DOI 10.1111/jgs.16661
   American Association of Nurse Practitioners COVID-19 State Emer- gency Response, 2020, COVID 19 STAT EM RES
   American Hospital Association, 2020, FAST FACTS US HOSP
   American Telemedicine Association, 2019, 2019 STAT STAT REP C
   [Anonymous], 2017, TOT NUMB RES CERT NU
   [Anonymous], 2020, COVID 19 DAT REP
   [Anonymous], 2020, EST HYP PREV TREATM
   [Anonymous], 2020, STAT DAT POL ACT ADD
   [Anonymous], 2020, QUEST MEDIA NEWSROOM
   [Anonymous], 2020, CRIM JUST RESP COR P
   [Anonymous], 2020, ASS NEW CDC COVID 19
   [Anonymous], 2020, FRANCE24
   [Anonymous], 2020, COVID TRACK PROJ COV
   [Anonymous], 2020, PBS NEWSHOUR WEEKEND
   Ashley Kirzinger, 2020, KFF HLTH TRACKING PO
   Augenblick N, 2020, GROUP TESTING PANDEM
   Augenstein J., 2020, HLTH AFFAIRS BLOG, DOI DOI 10.1377/HBL0G20200315.319008/FULL/
   BASU A, 2020, HLTH AFF, DOI DOI 10.1080/13691058.2020.1817562
   Batalova J, 2020, FREQUENTLY REQUESTED
   Bosman J., 2020, NY TIMES
   Breuninger K., 2020, TRUMP SAYS CORONAVIR
   Bui Q, 2020, NY TIMES
   Centers for Disease Control and Prevention, 2020, COVID 19 PROV COUNTS
   Centers for Disease Control and Prevention, FASTSTATS OV PREV
   Centers for Disease Control and Prevention, 2020, NAT DIAB STAT REP 20
   Centers for Disease Control and Prevention, CHRON DIS AM CDC
   Centers for Disease Control and Prevention CDC COVID Data Tracker, 2020, CDC COVID DAT TRACK
   Centers for Disease Control and Prevention FastStats-leading causes of death, 2017, FASTST LEAD CAUS DEA
   Chetty R, 2016, JAMA-J AM MED ASSOC, V315, P1750, DOI 10.1001/jama.2016.4226
   Clemens J, 2017, J POLIT ECON, V125, P1, DOI 10.1086/689772
   CMS.gov, 2020, UPCOMING REQUIREMENT
   covidexitstrategy.org, 2020, CONT ICU INP BED DAT
   Cox C, 2020, HLTH COSTS MIGHT CHA
   Cutler D, 2020, JAMA HLTH FORUM, V1
   Cutler DM, 2020, JAMA-J AM MED ASSOC, V323, P2003, DOI 10.1001/jama.2020.7242
   Data.CMS.gov, 2020, COVID 19 NURSING HOM
   Dave DM, 2020, NBER WORKING PAPER S
   DePillis L, 2020, PROPUBLICA
   Division UNS, 2020, UNDATA US
   Dolovich S, 2020, UCLA PRISON LAW POLI
   Dwyer J., 2020, NY TIMES
   Fernandez M., 2020, AXIOS HLTH
   Fisher KA, 2020, MMWR-MORBID MORTAL W, V69, P933, DOI 10.15585/mmwr.mm6928e3
   Galea S, 2020, JAMA
   Galewitz P., 2020, KAISER HLTH NEWS
   Golberstein E, 2020, JAMA PEDIAT AM MED A
   Gold H, 2020, CNN BUS
   Grabowski DC, 2020, JAMA, P2020
   Greiner A, 2020, GOOGLE DRIVE
   Gt Walker P, 2020, REPORT 12 GLOBAL IMP, DOI [10.25561/77735, DOI 10.25561/77735, 10.25561/77735.]
   Halpern NA, 2020, SOC CRIT CARE MED
   Haridasani Gupta A, 2020, NY TIMES
   Harris R., 2020, NPR MORNING ED
   Hartnett KP, 2019, MORBIDITY MORTALITY
   Hentze I., 2020, COVID 19 OCCUPATIONA
   HHS, 2019, HHS GOV OPIOIDS EP
   Holgash K, 2019, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20190401.678690/full/., DOI 10.1377/HBL0G20190401.678690/FULL/]
   Holmes A, 2020, APPLE GOOGLES AMBITI
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Indian Health Service, DISP FACT SHEETS
   Iversen B, 2020, NORWEGIAN I PUBLIC H, P43
   Jacobs J, 2020, BLOOMBERG
   Jeffrey A., 2020, CNBC
   Katz J, 2020, NY TIMES
   KIM K, 2020, FED REGISTER, V85
   LabCorp, 2020, LABCORP NEWSROOM
   Ladyzhets Glassman R., 2020, HOSP DATA REPORTED H
   Lee JC, 2020, NY TIMES
   Leibrand S, 2020, OUTPACING VIRUS DIGI
   Liesman S., 2020, CNBC
   Lopez G., 2020, VOX
   LSHTM, 2020, COVID 19 VACC DEV TI
   Madrigal AC, 2020, ATLANTIC
   Mann DM, COVID 19 TRANSFORMS, DOI [10.1093/jamia/ocaa072/5824298., DOI 10.1093/JAMIA/0CAA072/5824298]
   Mansfield E., 2020, US TODAY
   Mehrotra A, 2020, IMPACT COVID OUTPATI
   Neeman A., 2018, HLTH AFFAIRS BLOG, DOI DOI 10.1377/HBLOG20181025.42661/FULL/
   OECD, 2020, EV IN IMP COVID 19 I
   OECD, HLTH OECD DAT
   OECD, 2020, CONT HLTH SYST RESP
   OECD, 2020, DOCT IND
   OECD, 2020, CONS CONF IND CCI
   Office of Governor Newsom, 2020, GOV NEWS LAUNCH CAL
   ONeill Patrick Howell, 2020, MIT TECHNOLOGY REV
   Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150
   Paz C., 2020, ATLANTIC
   Perry SL, 2020, J SCI STUDY RELIG
   Peterson-Kaiser Family Foundation Out-of-pocket spending, 2020, HLTH SYST TRACK
   Pew Research Center, 2020, 3 IN 10 AM HAV LOST
   Pifer R., 2020, HEALTHCAREDIVE
   Pitt AL, 2018, AM J PUBLIC HEALTH, V108, P1394, DOI 10.2105/AJPH.2018.304590
   Popescu I, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8577
   Proctor BD, 2016, CURRENT POPULATION R, V256
   Public Health England, 2020, DISP RISK OUTC COVID
   Rama A., 2018, POLICY RES PERSPECTI
   Ransing R, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102085
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roubein R., 2020, POLITICO
   Rubin R., 2020, WALL STREET J
   Schwartz MS, 2020, EXECUTIVE ACTIONS TR
   Scott D., 2020, VOX
   Shepardson D, 2020, REUTERS
   Slat S, 2020, JAMA HLTH FORUM, V1
   Smith D., 2020, GUARDIAN
   Stolberg S, 2020, NY TIMES
   The Federal Reserve, 2020, FED RES BOARD OP MAR
   Torbati Yeganeh, 2020, PROPUBLICA
   Trading Economics, 2020, US INFL RAT
   U.S. Bureau of Economic Analysis (BEA), GROSS DOM PROD 1 QUA
   US Bureau of Labor Statistics, 2020, FOOD HOM PRIC GAS AI
   US Environmental Protection Agency, MORT RISK VAL
   Wagner P, 2020, STATES INCARCERATION
   Wan W., 2020, WASHINGTON POST
   Weigel G, 2020, OPPORTUNITIES BARRIE
   Whittington M, 2020, ALTERNATIVE PRICING
   Whoriskey P, 2020, WASHINGTON POST
   William D., 2020, WASHINGTON POST
   Woodall J, 2020, CRIT PUBLIC HEALTH, V30, P555, DOI 10.1080/09581596.2019.1612516
   World Health Organization, 2020, 1 WHO
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
NR 120
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-8837
J9 HEALTH POLICY TECHN
JI Health Policy Technol.
PD DEC
PY 2020
VL 9
IS 4
BP 623
EP 638
DI 10.1016/j.hlpt.2020.08.007
PG 16
WC Health Policy & Services
SC Health Care Sciences & Services
GA OX7TZ
UT WOS:000593763800018
PM 32874854
OA Green Published
DA 2021-01-01
ER

PT J
AU Ameri, A
   Rahnama, N
   Bozorgmehr, R
   Mokhtari, M
   Farahbakhsh, M
   Nabavi, M
   Shoaei, SD
   Izadi, H
   Kashi, ASY
   Dehbaneh, HS
   Taghizadeh-Hesary, F
AF Ameri, Ahmad
   Rahnama, Nazanin
   Bozorgmehr, Rama
   Mokhtari, Majid
   Farahbakhsh, Mohammad
   Nabavi, Mahmood
   Shoaei, Simin Dokht
   Izadi, Hossein
   Kashi, Amir Shahram Yousefi
   Dehbaneh, Hadiseh Shabanpour
   Taghizadeh-Hesary, Farzad
TI Low-Dose Whole-Lung Irradiation for COVID-19 Pneumonia: Short Course
   Results
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID THERAPY
AB Purpose: The COVID-19 outbreak is affecting people worldwide. Many infected patients have respiratory involvement that may progress to acute respiratory distress syndrome. This pilot study aimed to evaluate the clinical efficacy of low-dose whole-lung radiation therapy in patients with COVID-19 pneumonia.
   Methods and Materials: In this clinical trial, conducted in Iran, we enrolled patients with COVID-19 who were older than 60 years and hospitalized to receive supplementary oxygen for their documented pneumonia. Participants were treated with whole-lung irradiation in a single fraction of 0.5 Gy plus the national protocol for the management of COVID-19. Vital signs (including blood oxygenation and body temperature) and laboratory findings (interleukin-6 and C-reactive peptide) were recorded before and after irradiation.
   Results: Between May 21, 2020 and June 24, 2020, 5 patients received whole-lung irradiation. They were followed for 5 to 7 days to evaluate the response to treatment and toxicities. The clinical and paraclinical findings of 4 of the 5 patients (patient 4 worsened and died on day 3) improved on the first day of irradiation. Patient 3 opted out of the trial on the third day after irradiation. The mean time to discharge was 6 days for the other 3 patients. No acute radiation-induced toxicity was recorded.
   Conclusions: With a response rate of 80%, whole-lung irradiation in a single fraction of 0.5 Gy had encouraging results in oxygen-dependent patients with COVID-19 pneumonia. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Ameri, Ahmad; Rahnama, Nazanin] Shahid Beheshti Univ Med Sci, Imam Hossein Hosp, Dept Clin Oncol, Tehran, Iran.
   [Bozorgmehr, Rama] Shahid Beheshti Univ Med Sci, Shohadaye Tajrish Hosp, Clin Res Dev Unit, Tehran, Iran.
   [Mokhtari, Majid] Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Tehran, Iran.
   [Farahbakhsh, Mohammad] IDTM Res Ctr, Tehran, Iran.
   [Nabavi, Mahmood] Minist Hlth & Med Educ, Ctr Communicable Dis Control, Tehran, Iran.
   [Shoaei, Simin Dokht] Shahid Beheshti Univ Med Sci, Imam Hossein Hosp, Clin Res & Dev Ctr, Tehran, Iran.
   [Izadi, Hossein] Shahid Beheshti Univ Med Sci, Dept Internal Med, Tehran, Iran.
   [Kashi, Amir Shahram Yousefi] Shahid Beheshti Univ Med Sci, Fac Med, Canc Res Ctr, Tehran, Iran.
   [Dehbaneh, Hadiseh Shabanpour] Shahid Beheshti Univ Med Sci, Imam Hossein Hosp, Dept Infect Dis, Tehran, Iran.
   [Taghizadeh-Hesary, Farzad] Shahid Beheshti Univ Med Sci, Dept Clin Oncol, Tehran, Iran.
RP Rahnama, N (corresponding author), Shahid Beheshti Univ Med Sci, Imam Hossein Hosp, Dept Clin Oncol, Tehran, Iran.
EM Yasamin98522@gmail.com
RI ; Yousefi Kashi, Amir Shahram/G-8686-2015
OI Mokhtari, Majid/0000-0001-5980-1003; Yousefi Kashi, Amir
   Shahram/0000-0002-0787-2480
CR Arenas M, 2012, STRAHLENTHER ONKOL, V188, P975, DOI 10.1007/s00066-012-0170-8
   De Sanctis V, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/523568
   Gadrey SM, 2019, PHYSIOL MEAS, V40, DOI 10.1088/1361-6579/ab5154
   Hess CB, LOW DOSE WHOLE LUNG, DOI [10.1101/2020.06.03.20116988, DOI 10.1101/2020.06.03.20116988]
   Kefayat A, 2020, RADIOTHER ONCOL, V147, P224, DOI 10.1016/j.radonc.2020.04.026
   Kirkby C, 2020, RADIOTHER ONCOL, V147, P221, DOI 10.1016/j.radonc.2020.04.004
   Lara PC, 2020, CLIN TRANSL RAD ONCO, V23, P27, DOI 10.1016/j.ctro.2020.04.006
   Ministry of Health, FLOWCH DIAGN TREATM
   Our World in Data, MORT RISK COVID 19
   Powell EV, 1938, J AMER MED ASSOC, V110, P19, DOI 10.1001/jama.1938.02790010021004
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Shankar Abhishek, 2020, Asian Pac J Cancer Prev, V21, P569, DOI 10.31557/APJCP.2020.21.3.569
   Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5
   Taghizadeh-Hesary F, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109762
   World Health Organization, 46 WHO
NR 15
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD DEC 1
PY 2020
VL 108
IS 5
BP 1134
EP 1139
DI 10.1016/j.ijrobp.2020.07.026
PG 6
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA OV0PX
UT WOS:000591924200007
PM 32707264
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lerm, M
AF Lerm, M.
TI On the relationship between BCG coverage and national COVID-19 outcome:
   could 'heterologous' herd immunity explain why some countries are better
   off?
SO JOURNAL OF INTERNAL MEDICINE
LA English
DT Article
DE infectious disease; vaccine; virology; immunology
ID NONSPECIFIC PROTECTION; IMMUNIZATION; VACCINATION; CELLS
AB The COVID-19 pandemic has affected most parts of the global society since its emergence, and the scientific community has been challenged with questions urgently demanding answers. One of the early hypotheses on COVID-19 outcome was that some protection could be offered by the tuberculosis vaccine (BCG), and several clinical studies were initiated along with the emergence of numerous observational studies on the relationship between BCG and COVID-19 severity. In the present work, I demonstrate a strong correlation between the number of years that countries implemented BCG vaccination plans and age-standardized mortality rates during the first months of the pandemic in Europe. Further analyses of age groups in two European countries with comparably few confounding factors and easily identifiable groups of BCG-vaccinated and non-vaccinated subgroups suggest a population-level effect of BCG on national outcomes of COVID-19. This phenomenon of 'heterologous herd immunity' deserves further investigation, both in epidemiological and experimental studies.
C1 [Lerm, M.] Linkoping Univ, Div Inflammat & Infect, Fac Med & Hlth Sci, Dept Biomed & Clin Sci, Lab 1,Floor 12, SE-58185 Linkoping, Sweden.
RP Lerm, M (corresponding author), Linkoping Univ, Div Inflammat & Infect, Fac Med & Hlth Sci, Dept Biomed & Clin Sci, Lab 1,Floor 12, SE-58185 Linkoping, Sweden.
EM maria.lerm@liu.se
OI Lerm, Maria/0000-0002-5092-9892
FU Hjart-Lungfonden [20200319] Funding Source: Medline
CR Aibin W, 2020, MED SCI MONITOR, V26, pe925974
   Allel K, 2020, COUNTRY LEVEL FACTOR
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Benn CS, 2020, J INTERN MED, V288, P614, DOI 10.1111/joim.13084
   Bi QF, 2020, LANCET INFECT DIS, V20, P911, DOI 10.1016/S1473-3099(20)30287-5
   Boman G, 2016, ACTA PAEDIATR, V105, P1417, DOI 10.1111/apa.13585
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810
   Caminati M, 2020, MED HYPOTHESES, V144, P110109
   Campbell A, COMPARISONS ALL CAUS
   Cheng KJG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234715
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002
   de Chaisemartin C, 2020, CLIN INFECT DIS, V1223
   Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117
   Geller A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01782
   Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Hauer J, 2020, LEUKEMIA, V34, P2217, DOI 10.1038/s41375-020-0871-4
   Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7
   Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031
   Klein S, 2012, BUNDESGESUNDHEITSBLA, V55, P1512, DOI 10.1007/s00103-012-1539-7
   Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Korablioviene J, 2018, J Prev Med Hyg, V59, pE328, DOI 10.15167/2421-4248/jpmh2018.59.4.926
   Lau H, 2020, PULMONOLOGY
   Naeslund C, 1931, REV TUBERCULOSE, V12, P617
   Ozdemir C, 2020, ALLERGY, V75, P1824, DOI 10.1111/all.14344
   Paget J, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020421
   Pfeiffer G, 2017, VACCINE, V35, P7114, DOI 10.1016/j.vaccine.2017.10.089
   Rosano A, 2019, INT J INFECT DIS, V88, P127, DOI 10.1016/j.ijid.2019.08.003
   Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086
   Sekine T, 2020, CELL, V183, P158, DOI [10.10160.cell.2020.08.017, 10.1016/j.cell.2020.08.017]
   Stich HL, 2000, GESUNDHEITSWESEN, V62, P320, DOI 10.1055/s-2000-11466
   Thysen SM, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035595
   Verma D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12110-2
   Yao YS, 2018, CELL, V175, P1634, DOI 10.1016/j.cell.2018.09.042
   Zwerling A, 2011, EXPERT REV ANTI-INFE, V9, P559, DOI [10.1586/ERI.11.71, 10.1586/eri.11.71]
NR 38
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0954-6820
EI 1365-2796
J9 J INTERN MED
JI J. Intern. Med.
PD DEC
PY 2020
VL 288
IS 6
BP 682
EP 688
DI 10.1111/joim.13198
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA PE2UT
UT WOS:000598224700007
PM 33107999
OA Other Gold
DA 2021-01-01
ER

PT J
AU Nalivaeva, NN
   Zhuravin, IA
   Turner, AJ
AF Nalivaeva, N. N.
   Zhuravin, I. A.
   Turner, A. J.
TI Neprilysin expression and functions in development, ageing and disease
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE Ageing; AICD; Alzheimer's disease; A beta peptide; amyloid-degrading
   enzyme; CALLA; cancer; CD10; cognitive behaviour; cortex; diabetes;
   embryogenesis; endopeptidase 24.11; enkephalinase; epigenetic
   regulation; HDACs; hippocampus; memory; hypertension; neprilysin; NEP
   inhibitors olfactory bulbs; prenatal hypoxia; striatum
ID ANGIOTENSIN-CONVERTING-ENZYME; NEUTRAL ENDOPEPTIDASE ACTIVITY;
   BETA-DEGRADING ENZYMES; AMINO-ACID-SEQUENCE; APP INTRACELLULAR DOMAIN;
   LEUKEMIA ANTIGEN CD10; ALZHEIMERS-DISEASE; A-BETA; AMYLOID-BETA; MOUSE
   MODEL
AB Neprilysin (NEP) is an integral membrane-bound metallopeptidase with a wide spectrum of substrates and physiological functions. It plays an important role in proteolytic processes in the kidney, cardiovascular regulation, immune response, cell proliferation, foetal development etc. It is an important neuropeptidase and amyloid-degrading enzyme which makes NEP a therapeutic target in Alzheimer's disease (AD). Moreover, it plays a preventive role in development of cancer, obesity and type-2 diabetes. Recently a role of NEP in COVID-19 pathogenesis has also been suggested. Despite intensive research into NEP structure and functions in different organisms, changes in its expression and regulation during brain development and ageing, especially in age-related pathologies, is still not fully understood. This prevents development of pharmacological treatments from various diseases in which NEP is implicated although recently a dual-acting drug sacubitril-valsartan (LCZ696) combining a NEP inhibitor and angiotensin receptor blocker has been approved for treatment of heart failure. Also, various natural compounds capable of upregulating NEP expression, including green tea (EGCG), have been proposed as a preventive medicine in prostate cancer and AD. This review summarizes the existing literature and our own research on the expression and activity of NEP in normal brain development, ageing and under pathological conditions.
C1 [Nalivaeva, N. N.; Zhuravin, I. A.] Russian Acad Sci, IM Sechenov Inst Evolutionary Physiol & Biochem, 44 Thorez Ave, St Petersburg 194223, Russia.
   [Nalivaeva, N. N.; Turner, A. J.] Univ Leeds, Sch Biomed Sci, Fac Biol Sci, Leeds, W Yorkshire, England.
RP Nalivaeva, NN (corresponding author), Russian Acad Sci, IM Sechenov Inst Evolutionary Physiol & Biochem, 44 Thorez Ave, St Petersburg 194223, Russia.
EM n.n.nalivaeva@leeds.ac.uk
FU RFBRRussian Foundation for Basic Research (RFBR) [19-015-00232]; Russian
   Federation state budget [AAAA-A18-118012290373-7]
FX Supported by RFBR (19-015-00232) and Russian Federation state budget
   (assignment AAAA-A18-118012290373-7).
CR Ahn S, 2013, MED MOL MORPHOL, V46, P225, DOI 10.1007/s00795-013-0028-x
   Angulo J, 2010, BRIT J PHARMACOL, V160, P48, DOI 10.1111/j.1476-5381.2010.00693.x
   Arrigo M, 2018, EUR HEART J, V39, P1794, DOI 10.1093/eurheartj/ehx679
   Aykan DA, 2019, PHARMACOL REP, V71, P306, DOI 10.1016/j.pharep.2018.12.002
   BARNES K, 1988, NEUROSCIENCE, V27, P799, DOI 10.1016/0306-4522(88)90184-4
   BARNES K, 1995, J NEUROCHEM, V64, P1826
   Bayes-Genis A, 2016, J AM COLL CARDIOL, V68, P639, DOI 10.1016/j.jacc.2016.04.060
   Belyaev ND, 2010, J BIOL CHEM, V285, P41443, DOI 10.1074/jbc.M110.141390
   Belyaev ND, 2009, EMBO REP, V10, P94, DOI 10.1038/embor.2008.222
   Bland ND, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-16
   BORSON DB, 1991, AM J PHYSIOL, V260, pL21, DOI DOI 10.1152/AJPLUNG.1991.260.4.L212
   Bosler JS, 2014, REPROD SCI, V21, P1334, DOI 10.1177/1933719114536473
   BOURNE A, 1990, BIOCHEM J, V271, P381, DOI 10.1042/bj2710381
   BOWES MA, 1986, BIOCHEM J, V236, P801, DOI 10.1042/bj2360801
   Broccolini A, 2008, J NEUROCHEM, V105, P971, DOI 10.1111/j.1471-4159.2007.05208.x
   Brodl UC, 2010, DIABETOLOGIA, V53
   Burgos-Ramos E, 2008, MOL CELL ENDOCRINOL, V286, P104, DOI 10.1016/j.mce.2008.01.014
   Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013
   Campbell DJ, 2017, NAT REV CARDIOL, V14, DOI 10.1038/nrcardio.2016.200
   Carpentier M, 2002, J NEUROPATH EXP NEUR, V61, P849, DOI 10.1093/jnen/61.10.849
   Carty N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059626
   CHANG S, 2017, LUNG CANC INT, V2017
   Chen PT, 2016, SCI REP-UK, V6, DOI 10.1038/srep29760
   Chen XY, 2020, PEPTIDES, V124, DOI 10.1016/j.peptides.2019.170210
   Clarimon J, 2003, J NEURAL TRANSM, V110, P651, DOI 10.1007/s00702-002-0807-3
   Claus R, 2020, CLIN RES CARDIOL, V109, P1035, DOI 10.1007/s00392-020-01597-x
   Cutrona G, 2002, BRIT J CANCER, V86, P1776, DOI 10.1038/sj.bjc.6600329
   DADAMIO L, 1989, P NATL ACAD SCI USA, V86, P7103, DOI 10.1073/pnas.86.18.7103
   Dai J, 2001, CLIN CANCER RES, V7, P1370
   Daily A, 2006, J NEUROVIROL, V12, P153, DOI 10.1080/13550280600760677
   DAUCH P, 1993, PEPTIDES, V14, P593, DOI 10.1016/0196-9781(93)90150-F
   Dawson LA, 2004, BRIT J CANCER, V90, P1577, DOI 10.1038/sj.bjc.6601717
   de Almeida SM, 2018, JAIDS-J ACQ IMM DEF, V78, P248, DOI 10.1097/QAI.0000000000001666
   de Jong D, 2007, J CLIN ONCOL, V25, P805, DOI 10.1200/JCO.2006.09.4490
   DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x
   Devi L, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0110-5
   Dubrovskaya N., 2010, NEUROSCI BEHAV PHYSL, V40, P975
   DUTRIEZ I, 1992, EXPERIENTIA, V48, P290, DOI 10.1007/BF01930479
   El Tabaa MM, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114057
   El-Amouri SS, 2008, AM J PATHOL, V172, P1342, DOI 10.2353/ajpath.2008.070620
   Erin N, 2016, CANCER MICROENVIRON, V9, P141, DOI 10.1007/s12307-016-0189-y
   Esser N, 2019, DIABETOLOGIA, V62, P1113, DOI 10.1007/s00125-019-4889-y
   Eyre MD, 2019, FRONT NEURAL CIRCUIT, V13, DOI 10.3389/fncir.2019.00056
   Faa G, 2012, J MATERN-FETAL NEO M, V25, P904, DOI 10.3109/14767058.2011.599457
   Facchinetti P, 2003, NEUROSCIENCE, V118, P627, DOI 10.1016/S0306-4522(02)01002-3
   Farris W, 2007, AM J PATHOL, V171, P241, DOI 10.2353/ajpath.2007.070105
   Fischer HS, 2002, J MOL NEUROSCI, V18, P129, DOI 10.1385/JMN:18:1-2:129
   Fischer HS, 2000, REGUL PEPTIDES, V96, P53, DOI 10.1016/S0167-0115(00)00200-7
   Fu Y, 2009, INT PSYCHOGERIATR, V21, P354, DOI 10.1017/S1041610208008338
   Fukami S, 2002, NEUROSCI RES, V43, P39, DOI 10.1016/S0168-0102(02)00015-9
   FULCHER IS, 1982, BIOCHEM J, V203, P519, DOI 10.1042/bj2030519
   FULCHER IS, 1983, BIOCHEM J, V211, P743, DOI 10.1042/bj2110743
   FULCHER IS, 1983, BIOCHEM J, V215, P317, DOI 10.1042/bj2150317
   Gahete MD, 2010, J ALZHEIMERS DIS, V20, P465, DOI 10.3233/JAD-2010-1385
   Ganju RK, 1996, BLOOD, V88, P4159
   Genova RM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32773-9
   Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419
   Gill M, 2019, HYPERTENSION, V73, P1112, DOI 10.1161/HYPERTENSIONAHA.119.12707
   Guerin S, 1997, FASEB J, V11, P376
   Gutta S, 2018, AM J PHYSIOL-RENAL, V315, pF263, DOI 10.1152/ajprenal.00565.2017
   Hafez D, 2011, AM J PATHOL, V178, P306, DOI 10.1016/j.ajpath.2010.11.012
   Hanson LR, 2011, J MOL NEUROSCI, V43, P424, DOI 10.1007/s12031-010-9460-8
   Hara H, 2006, MOL VIS, V12, P977
   Hayashi M, 1997, BRAIN RES, V749, P283, DOI 10.1016/S0006-8993(96)01317-0
   Helisalmi S, 2004, J NEUROL NEUROSUR PS, V75, P1746, DOI 10.1136/jnnp.2004.036574
   Hellstrom-Lindahl E, 2008, NEUROBIOL AGING, V29, P210, DOI 10.1016/j.neurobiolaging.2006.10.010
   Higuchi Y, 2016, ANN NEUROL, V79, P659, DOI 10.1002/ana.24612
   Hong Y, 2012, INT J CANCER, V130, P775, DOI 10.1002/ijc.26028
   HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B
   Huang JY, 2012, J ALZHEIMERS DIS, V28, P433, DOI 10.3233/JAD-2011-111307
   Huttenrauch M, 2015, J ALZHEIMERS DIS, V44, P1291, DOI 10.3233/JAD-142463
   IMAI K, 1994, AM J OBSTET GYNECOL, V170, P1163, DOI 10.1016/S0002-9378(94)70115-6
   Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004
   Iwata N, 2000, NAT MED, V6, P143
   Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946
   Jang TJ, 2013, KOREAN J PATHOL, V47, P340, DOI 10.4132/KoreanJPathol.2013.47.4.340
   JOHNSON AR, 1990, J CELL BIOCHEM, V43, P243, DOI 10.1002/jcb.240430305
   JOHNSON AR, 1984, PEPTIDES, V5, P789, DOI 10.1016/0196-9781(84)90023-8
   Kario K, 2018, CURR CARDIOL REP, V20, DOI 10.1007/s11886-018-0944-4
   KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477
   Kerridge C, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.2015.00426, 10.3339/fhins.2075.00426]
   Kim J, 2017, MOL CELL BIOCHEM, V430, P1, DOI 10.1007/s11010-017-2948-6
   KING KA, 1993, J CLIN INVEST, V91, P1969, DOI 10.1172/JCI116417
   KIOUSSI C, 1995, EUR J NEUROSCI, V7, P951, DOI 10.1111/j.1460-9568.1995.tb01083.x
   KIOUSSI C, 1992, NEUROSCIENCE, V50, P69, DOI 10.1016/0306-4522(92)90382-C
   Kiss A, 2006, PHYTOMEDICINE, V13, P284, DOI 10.1016/j.phymed.2004.08.002
   Kletsas D, 1998, MECH AGEING DEV, V102, P15, DOI 10.1016/S0047-6374(98)00003-7
   KOMIYAMA T, 1975, BIOCHEM BIOPH RES CO, V65, P352, DOI 10.1016/S0006-291X(75)80100-8
   Kozlova DI, 2015, J EVOL BIOCHEM PHYS+, V51, P480, DOI 10.1134/S0022093015060046
   KUMAR GK, 1990, BRAIN RES, V517, P341, DOI 10.1016/0006-8993(90)91047-K
   LAFRANCE MH, 1994, BIOCHEM J, V302, P451, DOI 10.1042/bj3020451
   Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015
   LEBIEN TW, 1989, BLOOD, V73, P625
   Lebouvier T, 2020, EXPERT REV NEUROTHER, V20, P175, DOI 10.1080/14737175.2020.1708195
   Leoni LM, 1996, J ACQ IMMUN DEF SYND, V11, P188, DOI 10.1097/00042560-199602010-00011
   LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247
   LI CW, 1995, J BIOL CHEM, V270, P5723, DOI 10.1074/jbc.270.11.5723
   Li WD, 2010, METAB BRAIN DIS, V25, P277, DOI 10.1007/s11011-010-9207-9
   LI XM, 1995, PLACENTA, V16, P435, DOI 10.1016/0143-4004(95)90101-9
   Lilius L, 2003, NEUROSCI LETT, V337, P111, DOI 10.1016/S0304-3940(02)01300-9
   Liu YX, 2010, MOL CELL NEUROSCI, V45, P101, DOI 10.1016/j.mcn.2010.05.014
   Liu YX, 2009, MOL THER, V17, P1381, DOI 10.1038/mt.2009.115
   LLORENS C, 1982, J NEUROCHEM, V39, P1081, DOI 10.1111/j.1471-4159.1982.tb11500.x
   Louhichi T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3951-8
   LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271
   Madani R, 2006, J NEUROSCI RES, V84, P1871, DOI 10.1002/jnr.21074
   Maetzler W, 2010, J ALZHEIMERS DIS, V22, P933, DOI 10.3233/JAD-2010-101197
   Maguer-Satta V, 2011, STEM CELLS, V29, P389, DOI 10.1002/stem.592
   MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7
   MALFROY B, 1987, BIOCHEM BIOPH RES CO, V144, P59, DOI 10.1016/S0006-291X(87)80475-8
   Manolis AS, 2020, J CARDIOVASC PHARM, V76, P397, DOI 10.1097/FJC.0000000000000894
   Marr RA, 2003, J NEUROSCI, V23, P1992
   MARTINEZMAZA O, 1987, J IMMUNOL, V138, P3720
   Maruyama M, 2005, ANN NEUROL, V57, P832, DOI 10.1002/ana.20494
   MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111
   MATSAS R, 1986, NEUROSCIENCE, V18, P991, DOI 10.1016/0306-4522(86)90113-2
   Menendez L, 2008, EUR J PHARMACOL, V596, P50, DOI 10.1016/j.ejphar.2008.07.043
   Miners JS, 2010, BRAIN PATHOL, V20, P794, DOI 10.1111/j.1750-3639.2010.00375.x
   Mohajeri MH, 2009, NEUROCHEM RES, V34, P717, DOI 10.1007/s11064-009-9919-6
   Morales-Corraliza J, 2016, J NEUROSCI, V36, P4248, DOI 10.1523/JNEUROSCI.4640-14.2016
   Morisaki N, 2010, J BIOL CHEM, V285, P39819, DOI 10.1074/jbc.M110.161547
   Mothapo KM, 2015, J NEUROIMMUNOL, V282, P73, DOI 10.1016/j.jneuroim.2015.03.017
   Mouri A, 2006, BEHAV BRAIN RES, V168, P83, DOI 10.1016/j.bbr.2005.10.014
   Muangman P, 2003, SHOCK, V19, P508, DOI 10.1097/01.shk.0000055815.40894.16
   Muenzner M, 2016, INT J OBESITY, V40, P1850, DOI 10.1038/ijo.2016.172
   Nagata K, 2018, NEUROSCI LETT, V670, P8, DOI 10.1016/j.neulet.2018.01.003
   Nalivaeva N N, 2012, Int J Alzheimers Dis, V2012, P383796, DOI 10.1155/2012/383796
   Nalivaeva NN, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00825
   Nalivaeva NN, 2012, J MOL NEUROSCI, V46, P569, DOI 10.1007/s12031-011-9644-x
   Nalivaeva NN, 2004, ANN NY ACAD SCI, V1035, P21, DOI 10.1196/annals.1332.002
   Naliyaeya NN, 2019, BRIT J PHARMACOL, V176, P3447, DOI 10.1111/bph.14593
   Newell AJ, 2003, NEUROSCI LETT, V350, P178, DOI 10.1016/S0304-3940(03)00902-9
   Nilsson P, 2015, PROTEOMICS, V15, P3349, DOI 10.1002/pmic.201400211
   Pacheco-Quinto J, 2016, NEUROBIOL AGING, V48, P83, DOI 10.1016/j.neurobiolaging.2016.08.011
   Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050
   Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008
   Parilla JH, 2018, J HISTOCHEM CYTOCHEM, V66, P523, DOI 10.1369/0022155418765164
   PEKONEN F, 1995, BRIT J CANCER, V71, P59, DOI 10.1038/bjc.1995.12
   Ramirez-Sanchez M, 2019, VITAM HORM, V111, P105, DOI 10.1016/bs.vh.2019.05.007
   Rempel HC, 2005, AIDS, V19, P127, DOI 10.1097/00002030-200501280-00004
   Rice GI, 2006, HYPERTENSION, V48, P914, DOI 10.1161/01.HYP.0000244543.91937.79
   Roques BP, 2018, HANDB EXP PHARMACOL, V247, P53, DOI 10.1007/164_2016_17
   ROQUES BP, 1982, LIFE SCI, V31, P1749, DOI 10.1016/0024-3205(82)90201-6
   ROQUES BP, 1990, TRENDS PHARMACOL SCI, V11, P245
   Rougeot C, 2003, P NATL ACAD SCI USA, V100, P8549, DOI 10.1073/pnas.1431850100
   Ruchon AF, 2000, J BONE MINER RES, V15, P1266, DOI 10.1359/jbmr.2000.15.7.1266
   Saito T, 2005, NAT MED, V11, P434, DOI 10.1038/nm1206
   SALES N, 1991, REGUL PEPTIDES, V33, P209, DOI 10.1016/0167-0115(91)90215-3
   Sandoval KE, 2012, EUR J PHARMACOL, V683, P116, DOI 10.1016/j.ejphar.2012.03.020
   Santos AN, 2002, BIOCHEM BIOPH RES CO, V295, P423, DOI 10.1016/S0006-291X(02)00675-7
   Saria A, 1997, NEUROSCI LETT, V234, P27, DOI 10.1016/S0304-3940(97)00660-5
   Seferovic JP, 2017, LANCET DIABETES ENDO, V5, P333, DOI 10.1016/S2213-8587(17)30087-6
   Shen RQ, 2000, MOL CELL ENDOCRINOL, V170, P131, DOI 10.1016/S0303-7207(00)00326-9
   Shi XL, 2020, INT J CANCER, V146, P475, DOI 10.1002/ijc.32422
   SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662
   Siems WE, 2000, EUR J PHARMACOL, V397, P327, DOI 10.1016/S0014-2999(00)00222-3
   Siepmann M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013134
   SPENCERDENE B, 1994, DEVELOPMENT, V120, P3213
   Spenny ML, 2002, WOUND REPAIR REGEN, V10, P295, DOI 10.1046/j.1524-475X.2002.10504.x
   SPILLANTINI MG, 1990, BIOCHEM PHARMACOL, V39, P1353, DOI 10.1016/0006-2952(90)90012-A
   Standeven KF, 2011, INT J OBESITY, V35, P1031, DOI 10.1038/ijo.2010.227
   Sumitomo M, 2005, BBA-PROTEINS PROTEOM, V1751, P52, DOI 10.1016/j.bbapap.2004.11.001
   SUNDAY ME, 1992, J CLIN INVEST, V90, P2517, DOI 10.1172/JCI116145
   Tao CC, 2017, CELL DEATH DIFFER, V24, P597, DOI 10.1038/cdd.2016.161
   Terauchi M, 2005, ONCOLOGY-BASEL, V69, P52, DOI 10.1159/000087476
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Torlakovic E, 2005, J PATHOL, V205, P311, DOI 10.1002/path.1705
   Turner AJ, 2007, INT REV NEUROBIOL, V82, P113, DOI 10.1016/S0074-7742(07)82006-X
   Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K
   Usmani BA, 2000, CLIN CANCER RES, V6, P1664
   Vasilev DS, 2016, NEUROCHEM J+, V10, P144, DOI 10.1134/S1819712416020100
   Velazquez EF, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-2
   Walther T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004590
   Wang DS, 2005, J NEUROPATH EXP NEUR, V64, P378, DOI 10.1093/jnen/64.5.378
   Wang HZ, 2016, MOL NEUROBIOL, V53, P4883, DOI 10.1007/s12035-015-9411-z
   Wang SQ, 2010, J NEUROCHEM, V115, P47, DOI 10.1111/j.1471-4159.2010.06899.x
   Weiss E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030834
   Whyteside AR, 2008, FEBS LETT, V582, P2382, DOI 10.1016/j.febslet.2008.05.046
   Wick MJ, 2011, AM J RESP CRIT CARE, V183, P330, DOI 10.1164/rccm.201002-0154OC
   Wisner A, 2006, P NATL ACAD SCI USA, V103, P17979, DOI 10.1073/pnas.0605865103
   Xiao ZM, 2009, J MOL NEUROSCI, V39, P22, DOI 10.1007/s12031-008-9168-1
   Yang XL, 2017, CHINESE MED J-PEKING, V130, P1973, DOI 10.4103/0366-6999.211879
   Yasojima K, 2001, BRAIN RES, V919, P115, DOI 10.1016/S0006-8993(01)03008-6
   Zappulla JP, 2001, COMP BIOCHEM PHYS B, V129, P863, DOI 10.1016/S1096-4959(01)00390-6
   Zhang HF, 2017, NEUROSCI LETT, V657, P69, DOI 10.1016/j.neulet.2017.07.060
   Zheng R, 2010, MOL CELL BIOCHEM, V335, P173, DOI 10.1007/s11010-009-0253-8
   Zhuravin I А, 2015, Zh Nevrol Psikhiatr Im S S Korsakova, V115, P110, DOI 10.17116/jnevro2015115112110-117
   Zhuravin IA, 2019, NEUROCHEM RES, V44, P1387, DOI 10.1007/s11064-019-02796-3
   Zou LB, 2006, J PHARMACOL EXP THER, V317, P334, DOI 10.1124/jpet.105.095687
NR 189
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
EI 1872-6216
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD DEC
PY 2020
VL 192
AR 111363
DI 10.1016/j.mad.2020.111363
PG 13
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA OY0ZC
UT WOS:000593982200013
PM 32987038
OA Green Published
DA 2021-01-01
ER

PT J
AU Padmanabhan, P
   Desikan, R
   Dixit, NM
AF Padmanabhan, Pranesh
   Desikan, Rajat
   Dixit, Narendra M.
TI Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against
   SARS-CoV-2 infection
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID VERO-CELL GROWTH; C VIRUS ENTRY; SERINE-PROTEASE; POLIOVIRUS PRODUCTION;
   SPIKE PROTEIN; CORONAVIRUS; INHIBITORS; TRANSMEMBRANE; THERAPY; MODEL
AB The entry of SARS-CoV-2 into target cells requires the activation of its surface spike protein, S, by host proteases. The host serine protease TMPRSS2 and cysteine proteases Cathepsin B/L can activate S, making two independent entry pathways accessible to SARS-CoV-2. Blocking the proteases prevents SARS-CoV-2 entry in vitro. This blockade may be achieved in vivo through 'repurposing' drugs, a potential treatment option for COVID-19 that is now in clinical trials. Here, we found, surprisingly, that drugs targeting the two pathways, although independent, could display strong synergy in blocking virus entry. We predicted this synergy first using a mathematical model of SARS-CoV-2 entry and dynamics in vitro. The model considered the two pathways explicitly, let the entry efficiency through a pathway depend on the corresponding protease expression level, which varied across cells, and let inhibitors compromise the efficiency in a dose-dependent manner. The synergy predicted was novel and arose from effects of the drugs at both the single cell and the cell population levels. Validating our predictions, available in vitro data on SARS-CoV-2 and SARS-CoV entry displayed this synergy. Further, analysing the data using our model, we estimated the relative usage of the two pathways and found it to vary widely across cell lines, suggesting that targeting both pathways in vivo may be important and synergistic given the broad tissue tropism of SARS-CoV-2. Our findings provide insights into SARS-CoV-2 entry into target cells and may help improve the deployability of drug combinations targeting host proteases required for the entry.
   Author summary
   The COVID-19 pandemic has triggered urgent efforts to repurpose available drugs for the treatment of SARS-CoV-2 infection. Synergistic drug combinations are particularly desirable because they allow the achievement of desired efficacies with minimal toxicities. Here, we predict that drugs targeting the host proteases, TMPRSS2 and Cathepsin B/L, which facilitate SARS-CoV-2 entry into cells through independent pathways, would be synergistic. We identified the synergy using a mathematical model and found evidence for it in available in vitro data. We found the estimated usage of the two pathways to vary vastly across cell types, highlighting the need to target both pathways. Our findings would help maximize the impact of combination therapies targeting host proteases involved in SARS-CoV-2 entry, which are currently in clinical trials.
C1 [Padmanabhan, Pranesh] Univ Queensland, Clem Jones Ctr Ageing Dementia Res, Queesnsland Brain Inst, Brisbane, Qld, Australia.
   [Desikan, Rajat; Dixit, Narendra M.] Indian Inst Sci, Dept Chem Engn, Bengaluru, India.
   [Dixit, Narendra M.] Indian Inst Sci, Ctr Biosyst Sci & Engn, Bengaluru, India.
   [Desikan, Rajat] Certara UK Ltd, Certara QSP, Sheffield, S Yorkshire, England.
RP Dixit, NM (corresponding author), Indian Inst Sci, Dept Chem Engn, Bengaluru, India.; Dixit, NM (corresponding author), Indian Inst Sci, Ctr Biosyst Sci & Engn, Bengaluru, India.
EM narendra@iisc.ac.in
FU DBT/Wellcome Trust India Alliance Senior Fellowship [IA/S/14/1/501307]
FX This work was supported by the DBT/Wellcome Trust India Alliance Senior
   Fellowship IA/S/14/1/501307 to NMD. URL: https://www.indiaalliance.org/.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2020, ADV US HYDR PROPH SA
   Baeder DY, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2015.0294
   Beauchemin CAA, 2008, J THEOR BIOL, V254, P439, DOI 10.1016/j.jtbi.2008.05.031
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Boianelli A, 2015, VIRUSES-BASEL, V7, P5274, DOI 10.3390/v7102875
   Brandenberg OF, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006313
   Brandenberg OF, 2015, TRENDS MICROBIOL, V23, P763, DOI 10.1016/j.tim.2015.09.003
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dittmar M, 2020, DRUG REPURPOSING SCR, DOI [10.1101/2020.06.19.161042, DOI 10.1101/2020.06.19.161042]
   Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817
   Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149
   Gibo J, 2005, LAB INVEST, V85, P75, DOI 10.1038/labinvest.3700203
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Goncalves A, 2020, CPT-PHARMACOMET SYST, V9, P509, DOI 10.1002/psp4.12543
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gupta V, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006004
   Hoffmann M, 2018, ACTIVATION VIRUSES H, P71, DOI DOI 10.1007/978-3-319-75474-1_4
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann Markus, 2020, bioRxiv, DOI 10.1101/2020.08.05.237651
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Ivashchenko Andrey A, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1176
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jiang Y, 2019, PROCESS BIOCHEM, V81, P156, DOI 10.1016/j.procbio.2019.03.010
   Jilek BL, 2012, NAT MED, V18, P446, DOI 10.1038/nm.2649
   Kalemera M, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006905
   Karakus U, 2020, J VIROL, V94, DOI 10.1128/JVI.01357-19
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   KEUPP H, 2020, NATURE, P1, DOI DOI 10.1021/ACSCHEMBIO.0C00553
   Kramer L, 2017, TRENDS PHARMACOL SCI, V38, P873, DOI 10.1016/j.tips.2017.06.003
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li X., 2011, THE OPEN SURF SCI J, V3, P91
   Li YY, 2017, EXPERT OPIN THER PAT, V27, P643, DOI 10.1080/13543776.2017.1272572
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lokugamage Kumari G, 2020, bioRxiv, DOI 10.1101/2020.03.07.982264
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Magnus C, 2009, J VIROL, V83, P1523, DOI 10.1128/JVI.01764-08
   Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Melville K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01207
   Meyer CT, 2020, TRENDS PHARMACOL SCI, V41, P266, DOI 10.1016/j.tips.2020.01.011
   Meyer CT, 2019, CELL SYST, V8, P97, DOI 10.1016/j.cels.2019.01.003
   Mulampaka SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019941
   Ou T, BIORXIV, DOI [10.1101/2020.07.22.216150, DOI 10.1101/2020.07.22.216150]
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Padmanabhan P, 2015, CPT-PHARMACOMET SYST, V4, P445, DOI 10.1002/psp4.12005
   Padmanabhan P, 2017, P NATL ACAD SCI USA, V114, pE4524, DOI 10.1073/pnas.1704531114
   Padmanabhan P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4872
   Padmanabhan P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036107
   Padmanabhan P, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002307
   PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Raja R, 2018, IMMUNOL REV, V285, P55, DOI 10.1111/imr.12689
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sen P, 2019, TRENDS PHARMACOL SCI, V40, P811, DOI 10.1016/j.tips.2019.08.008
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   Shirato K, 2017, J VIROL, V91, DOI [10.1128/JVI.01387-16, 10.1128/jvi.01387-16]
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Ursache RV, 2015, BIOPROC BIOSYST ENG, V38, P543, DOI 10.1007/s00449-014-1294-2
   Vaarala MH, 2001, J PATHOL, V193, P134, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH743>3.0.CO;2-T
   Venugopal V, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006335
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   WHO, 2020, 206 WHO
   Wong VC, 2014, CELL MOL BIOENG, V7, P320, DOI 10.1007/s12195-014-0336-9
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao F, 2015, GUT, V64, P483, DOI 10.1136/gutjnl-2013-306155
   Yang XZ, 2005, J VIROL, V79, P12132, DOI 10.1128/JVI.79.19.12132-12147.2005
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu RF, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02442-5
   Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008
NR 84
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD DEC
PY 2020
VL 16
IS 12
AR e1008461
DI 10.1371/journal.pcbi.1008461
PG 28
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA PE8KT
UT WOS:000598611100003
PM 33290397
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Iqbal, SZ
   Li, B
   Onigu-Otito, E
   Naqvi, MF
   Shah, AA
AF Iqbal, Syed Z.
   Li, Benjamin
   Onigu-Otito, Edore
   Naqvi, Mohammad Faraz
   Shah, Asim A.
TI The Long-Term Mental Health Effects of COVID-19
SO PSYCHIATRIC ANNALS
LA English
DT Article
AB The novel coronavirus 2019 (COVID-19) has affected the mental health of health care professionals and the general population. Most of the research has focused on the immediate and short-term implications of the COVID-19 pandemic, with a paucity of research available exploring the long-term mental health effects. Experience with previous disasters has shown that survivors suffer from various mental health problems including posttraumatic stress disorder, major depressive disorder, anxiety disorders, phobias, fears with avoidant behaviors, and various neuropsychiatric disorders. There has been an increased incidence of substance use and internet addiction along with increased rates of domestic violence and child abuse. Social distancing is helpful in limiting the spread of the disease, but the impact of social distancing and quarantine has resulted in increased anxiety among the general population. The long-term mental health effects are anticipated to be intensified due to the pandemic affecting people worldwide. Mitigation strategies need to be implemented as there will be no vaccine available to limit the long-term mental health effects of this pandemic.
C1 [Iqbal, Syed Z.] Baylor Coll Med, Dept Psychiat & Behav Sci, One Baylor Plaza,BCM350, Houston, TX 77030 USA.
   [Li, Benjamin; Onigu-Otito, Edore] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
   [Naqvi, Mohammad Faraz] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA.
   [Shah, Asim A.] Baylor Coll Med, Psychiat, Houston, TX 77030 USA.
   [Shah, Asim A.] Baylor Coll Med, Psychiat Family & Community Med, Houston, TX 77030 USA.
   [Shah, Asim A.] Harris Hlth Syst, Ben Taub Hosp, Psychiat, Houston, TX USA.
   [Shah, Asim A.] Ben Taub Hosp, Div Community Psychiat, Houston, TX USA.
   [Shah, Asim A.] Ben Taub Hosp, Mood Disorder Res Program, Houston, TX USA.
RP Iqbal, SZ (corresponding author), Baylor Coll Med, Dept Psychiat & Behav Sci, One Baylor Plaza,BCM350, Houston, TX 77030 USA.
EM Syed.Iqbal@bcm.edu
CR Aishworiya R, 2020, J AUTISM DEV DISORD, DOI 10.1007/s10803-020-04670-6
   Barzilay R, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00982-4
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Bryant DJ, 2020, PSYCHOL TRAUMA-US, V12, pS193, DOI 10.1037/tra0000711
   Centers for Disease Control and Prevention, US COVID 19 CAS DEAT
   Chi XL, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00803
   Cullen W, 2020, QJM-INT J MED, V113, P311, DOI 10.1093/qjmed/hcaa110
   Fegert JM, 2020, CHILD ADOL PSYCH MEN, V14, DOI 10.1186/s13034-020-00329-3
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Goldmann E, 2014, ANNU REV PUBL HEALTH, V35, P169, DOI 10.1146/annurev-publhealth-032013-182435
   Hall Heather, 2020, JAAPA, V33, P45, DOI 10.1097/01.JAA.0000669772.78848.8c
   Lee J, 2020, LANCET CHILD ADOLESC, V4, P421, DOI 10.1016/S2352-4642(20)30109-7
   Melamed OC, 2020, SUBST ABUS, V41, P286, DOI 10.1080/08897077.2020.1784363
   Reis AM, 2016, PSYCHIAT RES, V241, P91, DOI 10.1016/j.psychres.2016.04.099
   Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0
   Sederer LI, WHAT DISASTERS TELL
   Sun Y, 2020, AM J ADDICTION, V29, P268, DOI 10.1111/ajad.13066
   Talevi D, 2020, RIV PSICHIATR, V55, P137, DOI 10.1708/3382.33569
   Vindegaard N, 2020, BRAIN BEHAV IMMUN, V89, P531, DOI 10.1016/j.bbi.2020.05.048
NR 19
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
EI 1938-2456
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD DEC
PY 2020
VL 50
IS 12
BP 522
EP 525
DI 10.3928/00485713-20201103-01
PG 4
WC Psychiatry
SC Psychiatry
GA PE2ED
UT WOS:000598181500003
DA 2021-01-01
ER

PT J
AU Mirani, M
   Favacchio, G
   Carrone, F
   Betella, N
   Biamonte, E
   Morenghi, E
   Mazziotti, G
   Lania, AG
AF Mirani, Marco
   Favacchio, Giuseppe
   Carrone, Flaminia
   Betella, Nazarena
   Biamonte, Emilia
   Morenghi, Emanuela
   Mazziotti, Gherardo
   Lania, Andrea Gerardo
TI Impact of Comorbidities and Glycemia at Admission and Dipeptidyl
   Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A
   Case Series From an Academic Hospital in Lombardy, Italy
SO DIABETES CARE
LA English
DT Article
ID NEW-YORK-CITY; OUTCOMES; MELLITUS; GLUCOSE; HYPERGLYCEMIA; EPIDEMIOLOGY;
   INFECTIONS; SEPSIS; RISK
AB OBJECTIVE Diabetes may unfavorably influence the outcome of coronavirus disease 19 (COVID-19), but the determinants of this effect are still poorly understood. In this monocentric study, we aimed at evaluating the impact of type 2 diabetes, comorbidities, plasma glucose levels, and antidiabetes medications on the survival of COVID-19 patients. RESEARCH DESIGN AND METHODS This was a case series involving 387 COVID-19 patients admitted to a single center in the region of Lombardy, the epicenter of the severe acute respiratory syndrome coronavirus 2 pandemic in Italy, between 20 February and 9 April 2020. Medical history, pharmacological treatments, laboratory findings, and clinical outcomes of patients without diabetes and patients with type 2 diabetes were compared. Cox proportional hazards analysis was applied to investigate risk factors associated with mortality. RESULTS Our samples included 90 patients (23.3%) with type 2 diabetes, who displayed double the mortality rate of subjects without diabetes (42.3% vs. 21.7%, P < 0.001). In spite of this, after correction for age and sex, risk of mortality was significantly associated with a history of hypertension (adjusted hazard ratio [aHR] 1.84, 95% CI 1.15-2.95; P = 0.011), coronary artery disease (aHR 1.56, 95% CI 1.04-2.35; P = 0.031), chronic kidney disease (aHR 2.07, 95% CI 1.27-3.38; P = 0.003), stroke (aHR 2.09, 95% CI 1.23-3.55; P = 0.006), and cancer (aHR 1.57, 95% CI 1.08-2.42; P = 0.04) but not with type 2 diabetes (P = 0.170). In patients with diabetes, elevated plasma glucose (aHR 1.22, 95% CI 1.04-1.44, per mmol/L; P = 0.015) and IL-6 levels at admission (aHR 2.47, 95% CI 1.28-4.78, per 1-SD increase; P = 0.007) as well as treatment with insulin (aHR 3.05, 95% CI 1.57-5.95; P = 0.001) and beta-blockers (aHR 3.20, 95% CI 1.50-6.60; P = 0.001) were independently associated with increased mortality, whereas the use of dipeptidyl peptidase 4 inhibitors was significantly and independently associated with a lower risk of mortality (aHR 0.13, 95% CI 0.02-0.92; P = 0.042). CONCLUSIONS Plasma glucose levels at admission and antidiabetes drugs may influence the survival of COVID-19 patients affected by type 2 diabetes.
C1 [Mirani, Marco; Favacchio, Giuseppe; Carrone, Flaminia; Betella, Nazarena; Biamonte, Emilia; Mazziotti, Gherardo; Lania, Andrea Gerardo] IRCCS, Endocrinol & Diabetol Unit, Humanitas Clin & Res Ctr, Milan, Italy.
   [Morenghi, Emanuela] IRCCS, Biostat Unit, Humanitas Clin & Res Ctr, Milan, Italy.
   [Mazziotti, Gherardo; Lania, Andrea Gerardo] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
RP Mirani, M (corresponding author), IRCCS, Endocrinol & Diabetol Unit, Humanitas Clin & Res Ctr, Milan, Italy.
EM marco.mirani@humanitas.it
OI Favacchio, Giuseppe/0000-0002-2815-8892; , Marco/0000-0002-4187-5378
CR Aghemo A, 2020, CLIN GASTROENTEROL H, V18, P2366, DOI 10.1016/j.cgh.2020.05.011
   Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS98, DOI 10.2337/dc20-S009
   [Anonymous], 2020, INFEZ MED, V28, P143
   Cecconi M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051548
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen YC, 2020, DIABETES CARE, V43, P1399, DOI 10.2337/dc20-0660
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Ciardullo S, 2020, J ENDOCRINOL INVEST, DOI 10.1007/s40618-020-01382-7
   Coppelli A, 2020, DIABETES CARE, V43, P2345, DOI 10.2337/dc20-1380
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Dalan R, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108216
   Daryabor G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01582
   Fox T, 2020, ACTA DIABETOL, DOI 10.1007/s00592-020-01592-8
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Hodgson K, 2015, IMMUNOLOGY, V144, P171, DOI 10.1111/imm.12394
   Iaccarino G, 2020, HYPERTENSION, V76, P366, DOI 10.1161/HYPERTENSIONAHA.120.15324
   Iacobellis G, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108125
   Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Lania A, 2020, EUR J ENDOCRINOL, V183, P381, DOI 10.1530/EJE-20-0335
   Ling J, 2019, ACTA DIABETOL, V56, P249, DOI 10.1007/s00592-018-1222-z
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Muller LMAJ, 2005, CLIN INFECT DIS, V41, P281, DOI 10.1086/431587
   Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sardu C, 2020, DIABETES CARE, V43, P1408, DOI 10.2337/dc20-0723
   Seshasai SRK, 2011, NEW ENGL J MED, V364, P829, DOI 10.1056/NEJMoa1008862
   Shi Q, 2020, DIABETES CARE, V43, P1382, DOI 10.2337/dc20-0598
   Suleyman G, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.12270
   Trevelin SC, 2017, SHOCK, V47, P276, DOI 10.1097/SHK.0000000000000778
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yan YL, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001343
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Zarbock A, 2014, CURR OPIN CRIT CARE, V20, P588, DOI 10.1097/MCC.0000000000000153
   Zheng Y, 2018, NAT REV ENDOCRINOL, V14, P88, DOI 10.1038/nrendo.2017.151
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 40
TC 3
Z9 3
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD DEC
PY 2020
VL 43
IS 12
BP 3042
EP 3049
DI 10.2337/dc20-1340
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OT4YY
UT WOS:000590854800029
PM 33023989
OA Bronze
DA 2021-01-01
ER

PT J
AU Tabish, TA
   Narayan, RJ
   Edirisinghe, M
AF Tabish, Tanveer A.
   Narayan, Roger J.
   Edirisinghe, Mohan
TI Rapid and label-free detection of COVID-19 using coherent anti-Stokes
   Raman scattering microscopy
SO MRS COMMUNICATIONS
LA English
DT Article
ID 2-PHOTON FLUORESCENCE; LIPID-METABOLISM; SKIN-CANCER; CARS; SPECTROSCOPY
AB From the 1918 influenza pandemic (H1N1) until the recent 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, no efficient diagnostic tools have been developed for sensitive identification of viral pathogens. Rigorous, early, and accurate detection of viral pathogens is not only linked to preventing transmission but also to timely treatment and monitoring of drug resistance. Reverse transcription-polymerase chain reaction (RT-PCR), the gold standard method for microbiology and virology testing, suffers from both false-negative and false-positive results arising from the detection limit, contamination of samples/templates, exponential DNA amplification, and variation of viral ribonucleic acid sequences within a single individual during the course of the infection. Rapid, sensitive, and label-free detection of SARS-CoV-2 can provide a first line of defense against the current pandemic. A promising technique is non-linear coherent anti-Stokes Raman scattering (CARS) microscopy, which has the ability to capture rich spatiotemporal structural and functional information at a high acquisition speed in a label-free manner from a biological system. Raman scattering is a process in which the distinctive spectral signatures associated with light-sample interaction provide information on the chemical composition of the sample. In this prospective, we briefly discuss the development and future prospects of CARS for real-time multiplexed label-free detection of SARS-CoV-2 pathogens.
C1 [Tabish, Tanveer A.] UCL, UCL Canc Inst, London WC1E 6DD, Bloomsbury, England.
   [Narayan, Roger J.] Univ North Carolina & North Carolina State Univ, Joint Dept Biomed Engn, Chapel Hill, NC 27599 USA.
   [Edirisinghe, Mohan] UCL, Dept Mech Engn, Torrington Pl, London WC1E 7JE, England.
RP Narayan, RJ (corresponding author), Univ North Carolina & North Carolina State Univ, Joint Dept Biomed Engn, Chapel Hill, NC 27599 USA.
EM roger_narayan@unc.edu
CR Abu-Farha M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103544
   Alvarez-Moreno CA, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101743
   [Anonymous], 2020, J KOREAN MED SCI, V35, pe112
   [Anonymous], 2018, CLIN DIABETOLOGY, V7, P1, DOI [10.5603/dk.2018.0001, DOI 10.5603/DK.2018.0001]
   [Anonymous], 2019, INT J GYNECOL CANC, V29(Suppl4, pA1
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Bae K, 2019, THERANOSTICS, V9, P1348, DOI 10.7150/thno.32043
   Camp CH, 2015, NAT PHOTONICS, V9, P295, DOI 10.1038/NPHOTON.2015.60
   Cheng JX, 2004, J PHYS CHEM B, V108, P827, DOI 10.1021/jp035693v
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Deckert V., 2020, PNAS, P1
   Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Freeman Brandi, 2020, bioRxiv, DOI 10.1101/2020.04.24.057323
   Heaton NS, 2011, TRENDS MICROBIOL, V19, P368, DOI 10.1016/j.tim.2011.03.007
   Hellerer T, 2007, P NATL ACAD SCI USA, V104, P14658, DOI 10.1073/pnas.0703594104
   Heuke S, 2013, HEALTHCARE-BASEL, V1, P64, DOI 10.3390/healthcare1010064
   Jones RR, 2019, NANOSCALE RES LETT, V14, DOI 10.1186/s11671-019-3039-2
   Kennedy DC, 2009, J AM CHEM SOC, V131, P2444, DOI 10.1021/ja809451w
   Kilic T, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101406
   Ko ACT, 2011, PROC SPIE, V7903, DOI 10.1117/12.873867
   Le TT, 2010, J LIPID RES, V51, P672, DOI 10.1194/jlr.D000638
   Le VH, 2017, BIOMED OPT EXPRESS, V8, P2148, DOI 10.1364/BOE.8.002148
   Li YF, 2020, J MED VIROL, V92, P903, DOI 10.1002/jmv.25786
   Lui H, 2012, CANCER RES, V72, P2491, DOI 10.1158/0008-5472.CAN-11-4061
   Lyn RK, 2010, BIOCHEM BIOPH RES CO, V399, P518, DOI 10.1016/j.bbrc.2010.07.101
   Lyn RK, 2009, VIROLOGY, V394, P130, DOI 10.1016/j.virol.2009.08.022
   Mansouri K, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110694
   Masihzadeh O, 2013, INVEST OPHTH VIS SCI, V54, P3094, DOI 10.1167/iovs.13-11642
   Matharu RK, 2020, J COLLOID INTERF SCI, V571, P239, DOI 10.1016/j.jcis.2020.03.037
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mitra R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-540
   Muller C, 2018, J VIROL, V92, DOI 10.1128/JVI.01463-17
   Nan XL, 2006, CHEMBIOCHEM, V7, P1895, DOI 10.1002/cbic.200600330
   Rabiee N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145126
   Rafalsky V., 2020, CARDIOVAS THERAP PRE, V19, P70
   Rakic B, 2006, CHEM BIOL, V13, P23, DOI 10.1016/j.chembiol.2005.10.006
   Robinson I, 2010, J BIOPHOTONICS, V3, P138, DOI 10.1002/jbio.200910054
   Saleem M, 2013, LASER PHYS LETT, V10, DOI 10.1088/1612-2011/10/3/035602
   Schie IW, 2015, ANALYST, V140, P3897, DOI 10.1039/c5an00178a
   SinoBiological, 2020, ANT DET ASS
   Tabish TA, 2020, ADV SCI, V7, DOI 10.1002/advs.201903441
   Tahamtan A, 2020, EXPERT REV MOL DIAGN, V20, P453, DOI [10.1080/14737159.2020.1757437, 10.1080/07435800.2020.1713802]
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Verwer PEB, 2014, EUR J CLIN MICROBIOL, V33, P245, DOI 10.1007/s10096-013-1951-4
   Vijay R, 2015, J EXP MED, V212, P1851, DOI 10.1084/jem.20150632
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Willemse-Erix DFM, 2009, J CLIN MICROBIOL, V47, P652, DOI 10.1128/JCM.01900-08
   Wu Q, 2017, SCI REP, V7, P1, DOI DOI 10.1038/S41598-017-09536-Z
   Xiao AT, 2020, J MED VIROL, V92, P1755, DOI 10.1002/jmv.25855
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Zhang JS, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02286
   Zhang Y., 2020, RAPID MOL DETECTION, DOI [10.1101/2020.02.26.20028373, DOI 10.1101/2020.02.26.20028373]
   Zumbusch A, 1999, PHYS REV LETT, V82, P4142, DOI 10.1103/PhysRevLett.82.4142
NR 58
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 2159-6859
EI 2159-6867
J9 MRS COMMUN
JI MRS Commun.
PD DEC
PY 2020
VL 10
IS 4
BP 566
EP 572
DI 10.1557/mrc.2020.81
PG 7
WC Materials Science, Multidisciplinary
SC Materials Science
GA PD7MV
UT WOS:000597865400005
DA 2021-01-01
ER

PT J
AU Ashton, JJ
   Kammermeier, J
   Spray, C
   Russell, RK
   Hansen, R
   Howarth, LJ
   Torrente, F
   Deb, P
   Renji, E
   Muhammed, R
   Paul, T
   Kiparissi, F
   Epstein, J
   Lawson, M
   Hope, B
   Zamvar, V
   Narula, P
   Kadir, A
   Devadason, D
   Bhavsar, H
   Beattie, RM
AF Ashton, James John
   Kammermeier, Jochen
   Spray, Christine
   Russell, Richard K.
   Hansen, Richard
   Howarth, Lucy J.
   Torrente, Franco
   Deb, Protima
   Renji, Elizabeth
   Muhammed, Rafeeq
   Paul, Thankam
   Kiparissi, Fevronia
   Epstein, Jenny
   Lawson, Maureen
   Hope, Ben
   Zamvar, Veena
   Narula, Priya
   Kadir, Ahmed
   Devadason, David
   Bhavsar, Hemant
   Beattie, Robert Mark
TI Impact of COVID-19 on diagnosis and management of paediatric
   inflammatory bowel disease during lockdown: a UK nationwide study
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID CROHNS-DISEASE; CHILDREN; IBD
AB Background COVID-19 has impacted on healthcare provision. Anecdotally, investigations for children with inflammatory bowel disease (IBD) have been restricted, resulting in diagnosis with no histological confirmation and potential secondary morbidity. In this study, we detail practice across the UK to assess impact on services and document the impact of the pandemic.
   Methods For the month of April 2020, 20 tertiary paediatric IBD centres were invited to contribute data detailing: (1) diagnosis/management of suspected new patients with IBD; (2) facilities available; (3) ongoing management of IBD; and (4) direct impact of COVID-19 on patients with IBD.
   Results All centres contributed. Two centres retained routine endoscopy, with three unable to perform even urgent IBD endoscopy. 122 patients were diagnosed with IBD, and 53.3% (n=65) were presumed diagnoses and had not undergone endoscopy with histological confirmation. The most common induction was exclusive enteral nutrition (44.6%). No patients with a presumed rather than confirmed diagnosis were started on anti-tumour necrosis factor (TNF) therapy. Most IBD follow-up appointments were able to occur using phone/webcam or face to face. No biologics/immunomodulators were stopped. All centres were able to continue IBD surgery if required, with 14 procedures occurring across seven centres.
   Conclusions Diagnostic IBD practice has been hugely impacted by COVID-19, with >50% of new diagnoses not having endoscopy. To date, therapy and review of known paediatric patients with IBD has continued. Planning and resourcing for recovery is crucial to minimise continued secondary morbidity.
C1 [Ashton, James John; Beattie, Robert Mark] Southampton Childrens Hosp, Dept Paediat Gastroenterol, Southampton, Hants, England.
   [Ashton, James John] Univ Southampton, Human Genet & Genom Med, Southampton, Hants, England.
   [Kammermeier, Jochen] Evelina London Childrens Hosp, Dept Paediat Gastroenterol, London, England.
   [Spray, Christine] Bristol Royal Childrens Hosp, Dept Paediat Gastroenterol, Bristol, Avon, England.
   [Russell, Richard K.] Royal Hosp Sick Children, Dept Paediat Gastroenterol, Edinburgh, Midlothian, Scotland.
   [Hansen, Richard] Royal Hosp Children Glasgow, Dept Paediat Gastroenterol, Glasgow, Lanark, Scotland.
   [Howarth, Lucy J.] Oxford Univ Hosp, Dept Paediat Gastroenterol, Oxford, England.
   [Torrente, Franco] Addenbrookes Hosp, Dept Paediat Gastroenterol, Cambridge, England.
   [Deb, Protima] Royal London Hosp Barts Hlth NHS Trust, Dept Paediat Gastroenterol, London, England.
   [Renji, Elizabeth] Alder Hey Childrens Hosp NHS Fdn Trust, Dept Paediat Gastroenterol, Liverpool, Merseyside, England.
   [Muhammed, Rafeeq] Birmingham Childrens Hosp, Dept Paediat Gastroenterol, Birmingham, W Midlands, England.
   [Paul, Thankam] St Georges Univ Hosp NHS Fdn Trust, Dept Paediat Gastroenterol, London, England.
   [Kiparissi, Fevronia] Great Ormond St Hosp Sick Children, Dept Paediat Gastroenterol, London, England.
   [Epstein, Jenny] Chelsea & Westminster Hosp, Dept Paediat Gastroenterol, London, England.
   [Lawson, Maureen] Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Paediat Gastroenterol, Newcastle Upon Tyne, Tyne & Wear, England.
   [Hope, Ben] Kings Coll London, Dept Paediat Gastroenterol, London, England.
   [Zamvar, Veena] Leeds Childrens Hosp, Dept Paediat Gastroenterol, Leeds, W Yorkshire, England.
   [Narula, Priya] Sheffield Childrens NHS Fdn Trust, Dept Paediat Gastroenterol, Sheffield, S Yorkshire, England.
   [Kadir, Ahmed] Manchester Childrens Hosp, Dept Paediat Gastroenterol, Manchester, Lancs, England.
   [Devadason, David] Nottingham Univ Hosp NHS Trust, Dept Paediat Gastroenterol, Nottingham, England.
   [Bhavsar, Hemant] Univ Hosp Leicester NHS Trust, Dept Paediat Gastroenterol, Leicester, Leics, England.
RP Beattie, RM (corresponding author), Southampton Childrens Hosp, Dept Paediat Gastroenterol, Southampton, Hants, England.
EM mark.beattie@uhs.nhs.uk
OI Hansen, Richard/0000-0002-3944-6646
FU British Society of Paediatric Gastroenterology, Hepatology and Nutrition
   IBD working group; action medical research training fellowship; ESPEN
   fellowship; National Health Service Research Scotland Career Researcher
   Fellowship
FX The study was supported by the British Society of Paediatric
   Gastroenterology, Hepatology and Nutrition IBD working group. JJA is
   funded by an action medical research training fellowship and by an ESPEN
   fellowship. RH is supported by a National Health Service Research
   Scotland Career Researcher Fellowship.
CR An P, 2020, LANCET GASTROENTEROL, V5, P525, DOI 10.1016/S2468-1253(20)30121-7
   Ashton JJ, 2015, ACTA PAEDIATR, V104, P831, DOI 10.1111/apa.13017
   Ashton JJ, 2020, ARCH DIS CHILD, V105, P706, DOI 10.1136/archdischild-2020-319482
   Ashton JJ, 2019, CLIN NUTR, V38, P80, DOI 10.1016/j.clnu.2018.01.020
   Ashton JJ, 2018, ARCH DIS CHILD, V103, P307, DOI 10.1136/archdischild-2017-313955
   Ashton JJ, 2018, ARCH DIS CHILD, V103, P1093, DOI 10.1136/archdischild-2018-315038
   ASHTON JJ, 2018, PAEDIAT CHILD HLTH O, V28, P507
   Barnes C, 2020, ARCH DIS CHILD, V105, P671, DOI 10.1136/archdischild-2019-317765
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Edwards C, 2020, FRONTLINE GASTROENTE, V11, P256, DOI 10.1136/flgastro-2020-101492
   Fell JM, 2016, ARCH DIS CHILD, V101, P469, DOI 10.1136/archdischild-2014-307218
   Gasparetto M, 2014, WORLD J GASTROENTERO, V20, P13219, DOI 10.3748/wjg.v20.i37.13219
   Isba R, 2020, ARCH DIS CHILD, V105, DOI 10.1136/archdischild-2020-319385
   Jones GR, 2019, GUT, V68, P1953, DOI 10.1136/gutjnl-2019-318936
   Kammermeier J, 2016, ARCH DIS CHILD, V101, P475, DOI 10.1136/archdischild-2014-307217
   Kennedy NA, 2020, GUT, V69, P984, DOI 10.1136/gutjnl-2020-321244
   Levine A, 2013, J PEDIAT GASTROENTER, P795
   Mazza S, 2020, GUT, V69, P1148, DOI 10.1136/gutjnl-2020-321183
   Norsa L, 2020, GASTROENTEROLOGY
   Office for National Statistics, POPULATION ESTIMATES
   Ricciuto A, 2018, ARCH DIS CHILD, V103, P319, DOI 10.1136/archdischild-2017-313060
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Sawczenko A, 2006, PEDIATRICS, V118, P124, DOI 10.1542/peds.2005-2931
   Storr M, 2009, ALIMENT PHARM THER, V29, P542, DOI 10.1111/j.1365-2036.2008.03910.x
   Taxonera C, 2020, ALIMENT PHARM THER, V52, P276, DOI 10.1111/apt.15804
   The British Society of Gastroenterology, ENDOSCOPY ACTIVITY C
   Turner D, 2020, J PEDIATR GASTR NUTR, V70, P727, DOI 10.1097/MPG.0000000000002729
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
NR 29
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
EI 1468-2044
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD DEC
PY 2020
VL 105
IS 12
BP 1186
EP 1191
DI 10.1136/archdischild-2020-319751
PG 6
WC Pediatrics
SC Pediatrics
GA OY2JA
UT WOS:000594076300011
PM 32732316
OA Bronze
DA 2021-01-01
ER

PT J
AU Iglesias-Julian, E
   Lopez-Veloso, M
   de-la-Torre-Ferrera, N
   Barraza-Vengoechea, JC
   Delgado-Lopez, PD
   Colazo-Burlato, M
   Ubeira-Iglesias, M
   Montero-Baladia, M
   Lorenzo-Martin, A
   Minguito-de-la-Iglesia, J
   Garcia-Munoz, JP
   Sanllorente-Sebastian, R
   Vicente-Gonzalez, B
   Aleman-Aleman, A
   Buzon-Martin, L
AF Iglesias-Julian, Enrique
   Lopez-Veloso, Maria
   de-la-Torre-Ferrera, Noelia
   Barraza-Vengoechea, Julio Cesar
   Delgado-Lopez, Pedro David
   Colazo-Burlato, Maria
   Ubeira-Iglesias, Marta
   Montero-Baladia, Miguel
   Lorenzo-Martin, Andres
   Minguito-de-la-Iglesia, Javier
   Garcia-Munoz, Juan Pablo
   Sanllorente-Sebastian, Rodrigo
   Vicente-Gonzalez, Blanca
   Aleman-Aleman, Ana
   Buzon-Martin, Luis
TI High dose subcutaneous Anakinra to treat acute respiratory distress
   syndrome secondary to cytokine storm syndrome among severely ill
   COVID-19 patients
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE IL-1; Anakinra; Tocilizumab; COVID-19; SARS-CoV2; Acute respiratory
   distress syndrome; Cytokine storm syndrome
ID MACROPHAGE ACTIVATION SYNDROME
AB Objective: Severely ill COVID-19 patients may end in acute respiratory distress syndrome (ARDS) and multi-organ failure. Some of them develop a systemic hyperinflammatory state produced by the massive release of inflammatory agents, known as cytokine storm syndrome (CSS). Inhibition of IL-1 by Anakinra (ANK) is a potential lifesaving therapy for severe CSS cases. We propose a rationale for the use of subcutaneous ANK and review our initial experience in a small cohort of severe COVID-19 CSS patients.
   Methods: Retrospective cohort study of COVID-19 patients developing ARDS (PaO2/FiO2 <300) and exhibiting signs of hyperinflammation (ferritin >1000 ng/mL and/or d-dimers > 1.5 mu g/mL, plus IL-6 < 40 mg/mL) that received ANK. For comparison, a propensity score matched historical cohort of patients treated with IL-6 inhibitor Tocilizumab (TCZ) was used. Patients had previously received combinations of azithromycin, hydroxychloroquine, and methyl-prednisolone. Laboratory findings, respiratory function and adverse effects were monitored. Resolution of ARDS within the first 7 days of treatment was considered a favorable outcome.
   Results: Subcutaneous ANK (100 mg every 6 h) was given to 9 COVID-19 ARDS CSS patients (77.8% males). Median age was 62 years (range, 42 to 87). A TCZ cohort of 18 patients was selected by propensity score matching and treated with intravenous single dose of 600 mg for patients weighing 75 Kg, or 400 mg if < 75 Kg. Prior to treatment, median PaO2/FiO(2) ratio of the ANK and TCZ cohorts were 193 and 249, respectively (p = 0.131). After 7 days of treatment, PaO2/FiO(2) ratio improved in both groups to 279 (104-335) and 331 (140-476, p = 0.099) respectively. On day 7, there was significant reduction of ferritin (p = 0.046), CRP (p = 0.043), and IL-6 (p = 0.043) levels in the ANK cohort but only of CRP (p = 0.001) in the TCZ group. Favorable outcome was achieved in 55.6% and 88.9% of the ANK and TCZ cohorts, respectively (p = 0.281). Two patients that failed to respond to TCZ improved after ANK treatment. Aminotransferase levels significantly increased between day 1 and day 7 (p = 0.004) in the TCZ group. Mortality was the same in both groups (11%). There were not any opportunistic infection in the groups nor other adverse effects attributable to treatment.
   Conclusion: Overall, 55.6% of COVID-19 ARDS CSS patients treated with ANK exhibited favorable outcome, not inferior to a TCZ treated matched cohort. ANK may be a potential alternative to TCZ for patients with elevated aminotransferases, and may be useful in non-responders to TCZ.
C1 [Iglesias-Julian, Enrique; Lopez-Veloso, Maria; de-la-Torre-Ferrera, Noelia; Barraza-Vengoechea, Julio Cesar] Burgos Univ Hosp, Dept Internal Med, System Autoimmune Dis Unit, Ave Islas Baleares 3, Burgos 09006, Spain.
   [Delgado-Lopez, Pedro David] Burgos Univ Hosp, Dept Neurosurg, Burgos, Spain.
   [Colazo-Burlato, Maria; Lorenzo-Martin, Andres] Burgos Univ Hosp, Dept Rheumatol, Burgos, Spain.
   [Ubeira-Iglesias, Marta; Vicente-Gonzalez, Blanca] Burgos Univ Hosp, Dept Pharm, Burgos, Spain.
   [Montero-Baladia, Miguel] Burgos Univ Hosp, Dept Intens Care Med, Burgos, Spain.
   [Minguito-de-la-Iglesia, Javier; Garcia-Munoz, Juan Pablo] Burgos Univ Hosp, Dept Pneumol, Burgos, Spain.
   [Sanllorente-Sebastian, Rodrigo] Burgos Univ Hosp, Dept Anesthesiol, Burgos, Spain.
   [Aleman-Aleman, Ana] Burgos Univ Hosp, Dept Internal Med, Burgos, Spain.
   [Buzon-Martin, Luis] Burgos Univ Hosp, Dept Internal Med, Infect Dis Unit, Burgos, Spain.
RP Iglesias-Julian, E (corresponding author), Burgos Univ Hosp, Dept Internal Med, System Autoimmune Dis Unit, Ave Islas Baleares 3, Burgos 09006, Spain.
EM eiglesiasjulian@gmail.com
CR Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706
   Borrego F., 2020, RECOMENDACIONES SOLI
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chen H, 2019, PROCEEDINGS OF 2019 CHINA INTERNATIONAL CONFERENCE ON INSURANCE AND RISK MANAGEMENT (CICIRM), P2
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Corral L., 2020, GLUCOCOVID CONTROLLE, DOI [10.1101/2020.06.17.20133579, DOI 10.1101/2020.06.17.20133579]
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Gubernatorova EO, 2020, CYTOKINE GROWTH F R, V53, P13, DOI 10.1016/j.cytogfr.2020.05.009
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Kaneko N, 2019, INFLAMM REGEN, V39, DOI 10.1186/s41232-019-0101-5
   King A, 2020, LANCET RHEUMATOL, V2, pE379, DOI 10.1016/S2665-9913(20)30160-0
   MartinezSanz J., 2020, EFFECTS TOCILIZUMAB, DOI [DOI 10.1101/2020.06.08.20125245, 10.1101/2020.06.08.20125245]
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   Miettunen PM, 2011, RHEUMATOLOGY, V50, P417, DOI 10.1093/rheumatology/keq218
   Montero-Baladia M, 2020, J INFECTION, V81, P468, DOI 10.1016/j.jinf.2020.06.006
   Munoz-Jimenez Alejandro, 2020, Reumatol Clin, DOI 10.1016/j.reuma.2020.04.009
   Navarro-Millan I, 2020, ARTHRITIS RHEUMATOL, V72, P1990, DOI 10.1002/art.41422
   Parisi F, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006656
   Perricone C, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102468
   Rajasekaran S, 2014, PEDIATR CRIT CARE ME, V15, P401, DOI 10.1097/PCC.0000000000000078
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ravelli A, 2012, GENES IMMUN, V13, P289, DOI 10.1038/gene.2012.3
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Sun RH, 2020, KOREAN J RADIOL, V21, P541, DOI 10.3348/kjr.2020.0180
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Wohlfarth P, 2019, J INTENSIVE CARE MED, V34, P723, DOI 10.1177/0885066617711386
   Yang M, 2020, NEURAL GENERATION AND TRANSLATION, P119
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD DEC
PY 2020
VL 115
AR 102537
DI 10.1016/j.jaut.2020.102537
PG 7
WC Immunology
SC Immunology
GA OV9GV
UT WOS:000592510100004
PM 32843231
OA Green Published
DA 2021-01-01
ER

PT J
AU Pan, JH
   Tian, J
   Xiong, HY
   Liu, ZX
   Yao, Y
   Wang, YS
   Zhu, WL
   Wang, Y
   Wang, WB
AF Pan, Jinhua
   Tian, Jie
   Xiong, Haiyan
   Liu, Zhixi
   Yao, Ye
   Wang, Yesheng
   Zhu, Wenlong
   Wang, Yue
   Wang, Weibing
TI Risk assessment and evaluation of China's policy to prevent COVID-19
   cases imported by plane
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
AB Author summary
   The epidemic of the COVID-19 has greatly affected the lives of people all over the world. Before the vaccine has been widely covered, we can only reduce the transmissibility of the virus through the implementation of strong non-pharmaceutical interventions. In response to air passengers who may be carrying the SARS-CoV-2, the Chinese plan is a comprehensive measure of reduction, centralized isolation, and completely testing. We conducted a retrospective assessment of the time and intensity of the implementation of China's policy in order to provide data support for the normal implementation of future measures. The model results indicate that the measures currently taken by China were implemented at an appropriate time to prevent the epidemic spreading and have achieved relatively good effect. This means that these measures need to be strictly implemented for a period of time as the global epidemic situation is still serious. Although our model refers to the seven countries with more severe epidemics in April, the assessment method can be applied to assess the importation risks brought by other countries.
   As of October 5, 2020, China has reported 2,921 cases imported from overseas. Assessing the effectiveness of China's current policies on imported cases abroad is very important for China and other countries that are facing or will face overseas imported cases. In April, we used a susceptible-exposed-infectious-recovered metapopulation model to simulate the epidemic in seven foreign countries, China and the three Chinese key cities. Based on the model outside China, we estimated the proportion of people in incubation period and calculated the risk indexes for Chinese cities through analyzing aviation traffic data from these countries. Based on the model in China and the three key cities, we collected information on control measures and quantified the effectiveness of implementing the current policies at different times and intensities. Our model results showed that Shanghai, Beijing, Qingdao, Guangzhou, and Tianjin have the top five risk indexes. As of April 20, 2020, under current measures, the number of confirmed cases could be reduced by 99% compared with no air traffic restrictions and isolation measures; the reduction could be 93% with isolation of passengers only from key countries. If the current policy were postponed for 7, 10, or 20 days, the increase in the number of confirmed cases would be 1,329, 5,524, and 779,245 respectively, which is 2(.)1, 5(.)7, and 662(.)9 times the number of confirmed cases under current measures. Our research indicates that the importation control measures currently taken by China were implemented at an appropriate time to prevent the epidemic spreading and have achieved relatively good control results. However, it is necessary to remain vigilant; otherwise, another outbreak peak could occur.
C1 [Pan, Jinhua; Tian, Jie; Xiong, Haiyan; Liu, Zhixi; Wang, Yesheng; Zhu, Wenlong; Wang, Yue; Wang, Weibing] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai, Peoples R China.
   [Pan, Jinhua; Tian, Jie; Xiong, Haiyan; Liu, Zhixi; Wang, Yesheng; Zhu, Wenlong; Wang, Yue; Wang, Weibing] Fudan Univ, Minist Educ, Key Lab Publ Hlth Safety, Shanghai, Peoples R China.
   [Yao, Ye] Fudan Univ, Sch Publ Hlth, Dept Biostat, Shanghai, Peoples R China.
RP Wang, WB (corresponding author), Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai, Peoples R China.; Wang, WB (corresponding author), Fudan Univ, Minist Educ, Key Lab Publ Hlth Safety, Shanghai, Peoples R China.
EM wwb@fudan.edu.cn
FU Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR
   [INV-006277]
FX This study was sponsored by the Bill & Melinda Gates Foundation (Grant
   No. INV-006277); The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 2020, NOT CONTR VOL INT PA
   [Anonymous], 2020, EP SIT COVID 19 HUB
   [Anonymous], 2020, NOV COR COVID 19 CAS
   [Anonymous], 2020, UPD COVID 19 EP SIT
   Champredon D, 2017, EPIDEMIOL INFECT, V145, P1256, DOI 10.1017/S0950268817000115
   Costantino V, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa081
   Daon Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa093
   De Salazar PM, 2020, EMERG INFECT DIS, V26, P1465, DOI 10.3201/eid2607.200250
   Fang YQ, 2020, J MED VIROL, V92, P645, DOI 10.1002/jmv.25750
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033
   Nussbaumer-Streit B, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013574
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   WHO, 2020, COR DIS COVID 19 SIT
   World Health Organization, 2020, COR DIS COVID 2019 S
   Zhang Juanjuan, 2020, medRxiv, DOI 10.1101/2020.03.19.20039107
   Zhang JJ, 2020, LANCET INFECT DIS, V20, P793, DOI 10.1016/S1473-3099(20)30230-9
NR 19
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD DEC
PY 2020
VL 14
IS 12
AR e0008908
DI 10.1371/journal.pntd.0008908
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA PD8MH
UT WOS:000597931600007
PM 33284804
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Sagnelli, C
   Gentile, V
   Tirri, R
   Macera, M
   Cappabianca, S
   Ciccia, F
   Coppola, N
AF Sagnelli, Caterina
   Gentile, Valeria
   Tirri, Rosella
   Macera, Margherita
   Cappabianca, Salvatore
   Ciccia, Francesco
   Coppola, Nicola
TI Chronic conventional disease-modifying anti-rheumatic drugs masking
   severe SARS-CoV-2 manifestations in an elderly rheumatic patient
SO JOURNAL OF INFECTION
LA English
DT Letter
ID COVID-19
C1 [Sagnelli, Caterina; Gentile, Valeria; Macera, Margherita; Coppola, Nicola] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Publ Med, I-80131 Naples, Italy.
   [Tirri, Rosella; Cappabianca, Salvatore; Ciccia, Francesco] Univ Campania Luigi Vanvitelli, Dept Sci Med Traslaz, Naples, Italy.
RP Sagnelli, C (corresponding author), Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Publ Med, I-80131 Naples, Italy.
CR Ciotti M, 2020, CHEMOTHERAPY, V64, P215, DOI [10.1159/000507423, 10.1080/10408363.2020.1783198]
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Magro Giuseppe, 2020, Cytokine X, V2, P100029, DOI 10.1016/j.cytox.2020.100029
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 8
TC 6
Z9 6
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD DEC
PY 2020
VL 81
IS 6
BP 980
EP 983
DI 10.1016/j.jinf.2020.05.043
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA PC2BK
UT WOS:000596812500029
PM 32474034
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bonkowsky, JL
   DeVeber, G
   Kosofsky, BE
AF Bonkowsky, Joshua L.
   DeVeber, Gabrielle
   Kosofsky, Barry E.
CA Child Neurology Soc Res Comm
TI Pediatric Neurology Research in the Twenty-First Century: Status,
   Challenges, and Future Directions Post-COVID-19
SO PEDIATRIC NEUROLOGY
LA English
DT Article
DE Pediatric; Research; Training; NIH; Disparities; Career; Funding;
   Neuroscience
ID CHILD NEUROLOGY; EPILEPSY SURGERY; DISPARITIES; US; WORKFORCE; ACCESS
AB Background: The year 2020 marked a fundamental shift in the pediatric neurology field. An impressive positive trajectory of advances in patient care and research faced sudden global disruptions by the coronavirus disease 2019 pandemic and by an international movement protesting racial, socioeconomic, and health disparities. The disruptions revealed obstacles and fragility within the pediatric neurology research mission. However, renewed commitment offers unique opportunities for the pediatric neurology research community to enhance and prioritize research directions for the coming decades.
   Methods: The Research Committee of the Child Neurology Society evaluated the challenges and oppor-tunities facing the pediatric neurology research field, including reviewing published literature, synthesizing publically available data, and conducting a survey of pediatric neurologists.
   Results: We identified three priority domains for the research mission: funding levels, active guidance, and reducing disparities. Funding levels: to increase funding to match the burden of pediatric neurological disease; to tailor funding mechanisms and strategies to support clinical trial efforts unique to pediatric neurology; and to support investigators across their career trajectory. Active guidance: to optimize infrastructure and strategies, to leverage novel therapeutics, enhance data collection, and improve inclusion of children in clinical trials. Reducing disparities: to reduce health disparities in children with neurological disease, to develop proactive measures to enhance workforce diversity and inclusion, and increase avenues to balance work-life obligations for investigators.
   Conclusions: In this uniquely challenging epoch, the pediatric neurology research community has a timely and important mission to re-engage the public and government, advancing the health of children with neurological conditions. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Bonkowsky, Joshua L.] Univ Utah, Dept Pediat, Div Pediat Neurol, Sch Med, Salt Lake City, UT 84132 USA.
   [Bonkowsky, Joshua L.] Primary Childrens Med Ctr, Intermt Healthcare, Salt Lake City, UT 84113 USA.
   [DeVeber, Gabrielle] Univ Toronto, Hosp Sick Children, Res Inst, Toronto, ON, Canada.
   [Kosofsky, Barry E.] New York Presbyterian Weill Cornell Med, Dept Pediat, New York, NY USA.
RP Bonkowsky, JL (corresponding author), Univ Utah, Dept Pediat, Div Pediat Neurol, Sch Med, Salt Lake City, UT 84132 USA.; Bonkowsky, JL (corresponding author), Primary Childrens Med Ctr, Intermt Healthcare, Salt Lake City, UT 84113 USA.
OI /0000-0002-9584-0576
CR Augustine EF, 2013, J CHILD NEUROL, V28, P1142, DOI 10.1177/0883073813495959
   Begley CE, 2009, EPILEPSIA, V50, P1040, DOI 10.1111/j.1528-1167.2008.01898.x
   Berry SA, 2020, GENET MED, V22, P219, DOI 10.1038/s41436-019-0616-9
   Bonkowsky JL, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.5031
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]
   Busis NA, 2017, NEUROLOGY, V89, P1650, DOI 10.1212/WNL.0000000000004484
   Cech EA, 2019, P NATL ACAD SCI USA, V116, P4182, DOI 10.1073/pnas.1810862116
   Clayton EW, 2019, J LAW BIOSCI, V6, P1, DOI 10.1093/jlb/lsz007
   Collins FS, 2018, NEW ENGL J MED, V379, P1393, DOI 10.1056/NEJMp1810628
   Cooney T, 2018, J NEURO-ONCOL, V138, P83, DOI 10.1007/s11060-018-2773-0
   Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752
   Galea S, 2020, JAMA-J AM MED ASSOC, V324, P227, DOI 10.1001/jama.2020.11132
   Gilbert DL, 2017, PEDIATR NEUROL, V66, P89, DOI 10.1016/j.pediatrneurol.2016.08.018
   Gregerson CHY, 2019, J CHILD NEUROL, V34, P928, DOI 10.1177/0883073819866623
   Griggs RC, 2009, MOL GENET METAB, V96, P20, DOI 10.1016/j.ymgme.2008.10.003
   Grineski S, 2020, J PEDIATR-US, V220, P193, DOI 10.1016/j.jpeds.2020.01.063
   Grinspan Zachary M, 2018, Epilepsia Open, V3, P91, DOI 10.1002/epi4.12095
   Hernandez I, 2019, HEALTH AFFAIR, V38, P76, DOI 10.1377/hlthaff.2018.05147
   Jordan LC, 2018, NEUROLOGY, V91, pE509, DOI 10.1212/WNL.0000000000005946
   Joss-Moore LA, 2018, J PEDIATR-US, V197, P5, DOI 10.1016/j.jpeds.2018.02.060
   Kang PB, 2016, NEUROLOGY, V87, P1384, DOI 10.1212/WNL.0000000000003147
   Kim J, 2019, NEW ENGL J MED, V381, P1644, DOI 10.1056/NEJMoa1813279
   Knight EMP, 2015, EPILEPSIA, V56, P375, DOI 10.1111/epi.12912
   Kroner BL, 2013, EPILEPSY RES, V103, P279, DOI 10.1016/j.eplepsyres.2012.07.005
   Kutscher EJ, 2017, PEDIATR NEUROL, V73, P28, DOI 10.1016/j.pediatrneurol.2017.04.014
   LaGrant B, 2020, EPILEPSY BEHAV, V103, DOI 10.1016/j.yebeh.2019.106828
   Malone Daniel C, 2019, J Mark Access Health Policy, V7, P1601484, DOI 10.1080/20016689.2019.1601484
   Mbwana JS, 2019, NEUROL-CLIN PRACT, V9, P83, DOI 10.1212/CPJ.0000000000000575
   McCarthy Lucas H, 2015, Neurol Clin Pract, V5, P67
   Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198
   Moses H, 2015, JAMA-J AM MED ASSOC, V313, P174, DOI 10.1001/jama.2014.15939
   Natale JE, 2017, J PEDIATR-US, V184, P204, DOI 10.1016/j.jpeds.2017.02.006
   Okubo Y, 2020, SEIZURE-EUR J EPILEP, V80, P263, DOI 10.1016/j.seizure.2020.05.013
   Pearl PL, 2020, ANN NEUROL, V88, P209, DOI 10.1002/ana.25828
   Pereira S, 2019, PEDIATRICS, V143, pS6, DOI 10.1542/peds.2018-1099C
   Saunders CJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004041
   Schiltz NK, 2013, EPILEPSY RES, V107, P172, DOI 10.1016/j.eplepsyres.2013.08.003
   Schulz A, 2018, NEW ENGL J MED, V378, P1898, DOI 10.1056/NEJMoa1712649
   Sessler DI, 2020, ANESTHESIOLOGY, V132, P69, DOI 10.1097/ALN.0000000000002989
   Sutherland SM, 2016, PEDIATR CLIN N AM, V63, P251, DOI 10.1016/j.pcl.2015.12.002
   Winestone LE, 2019, LEUKEMIA LYMPHOMA, V60, P2190, DOI 10.1080/10428194.2019.1574002
   Wizemann T, 2019, ROLE NIH DRUG DEV IN
   Zupanc ML, 2020, NEUROLOGY, V94, P75, DOI 10.1212/WNL.0000000000008784
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0887-8994
EI 1873-5150
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD DEC
PY 2020
VL 113
BP 2
EP 12
DI 10.1016/j.pediatrneurol.2020.08.012
PG 11
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA OU6MH
UT WOS:000591640100002
PM 32979654
DA 2021-01-01
ER

PT J
AU Rodrigues, JPGLM
   Barrera-Vilarmau, S
   Teixeira, JMC
   Sorokina, M
   Seckel, E
   Kastritis, PL
   Levitt, M
AF Rodrigues, Joao P. G. L. M.
   Barrera-Vilarmau, Susana
   Teixeira, Joao M. C.
   Sorokina, Marija
   Seckel, Elizabeth
   Kastritis, Panagiotis L.
   Levitt, Michael
TI Insights on cross-species transmission of SARS-CoV-2 from structural
   modeling
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID DESIGN; SERVER; MAFFT
AB Author summary
   SARS-CoV-2 infects multiple animal species, including humans. Like many other viruses, the first step in its infection cycle is the interaction between a viral protein and a receptor protein on the host cell membrane. Characterizing the three-dimensional structure of such protein interactions, at the atomic level, is very important to understand the infection process, to help develop therapeutics against it, and to predict which other animal species are at risk. Experimentally, this characterization is usually difficult, expensive, and not applicable on a large scale. Here, we show that computational modeling can fill in some of the gaps, namely provide a structural framework to explain why humans are susceptible to SARS-CoV-2 infection, while mice and chicken are not. Our models also map, with reasonable accuracy, key amino acids of the host receptor, which can help guide the development of antiviral therapeutics. Our work serves as a blueprint for studying viral-host protein interactions using computational modeling, providing a quick and inexpensive complement to experiments, and benefits both our basic understanding of viral infections and drug development.
   Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing global pandemic that has infected more than 31 million people in more than 180 countries worldwide. Like other coronaviruses, SARS-CoV-2 is thought to have been transmitted to humans from wild animals. Given the scale and widespread geographical distribution of the current pandemic and confirmed cases of cross-species transmission, the question of the extent to which this transmission is possible emerges, as well as what molecular features distinguish susceptible from non-susceptible animal species. Here, we investigated the structural properties of several ACE2 orthologs bound to the SARS-CoV-2 spike protein. We found that species known not to be susceptible to SARS-CoV-2 infection have non-conservative mutations in several ACE2 amino acid residues that disrupt key polar and charged contacts with the viral spike protein. Our models also allow us to predict affinity-enhancing mutations that could be used to design ACE2 variants for therapeutic purposes. Finally, our study provides a blueprint for modeling viral-host protein interactions and highlights several important considerations when designing these computational studies and analyzing their results.
C1 [Rodrigues, Joao P. G. L. M.; Levitt, Michael] Stanford Univ, Sch Med, Dept Struct Biol, Stanford, CA 94305 USA.
   [Barrera-Vilarmau, Susana] CSIC, Inst Adv Chem Catalonia IQAC, Barcelona, Spain.
   [Teixeira, Joao M. C.] Hosp Sick Children, Program Mol Med, Toronto, ON, Canada.
   [Sorokina, Marija; Kastritis, Panagiotis L.] Martin Luther Univ Halle Wittenberg, Biozentrum, ZIK HALOMEM, Halle, Saale, Germany.
   [Sorokina, Marija; Kastritis, Panagiotis L.] Martin Luther Univ Halle Wittenberg, Biozentrum, Inst Biochem & Biotechnol, Halle, Saale, Germany.
   [Seckel, Elizabeth] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA.
RP Rodrigues, JPGLM (corresponding author), Stanford Univ, Sch Med, Dept Struct Biol, Stanford, CA 94305 USA.
EM joaor@stanford.edu
RI ; Rodrigues, Joao/J-6579-2013
OI Kastritis, Panagiotis/0000-0002-1463-8422; Teixeira, Joao Miguel
   Correia/0000-0002-9113-0622; Rodrigues, Joao/0000-0001-9796-3193
FU Molecular Sciences Software Institute [ACI1547580]; National Institutes
   of Health USAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R35GM122543]; Federal Ministry for
   Education and Research (BMBF, ZIK program)Federal Ministry of Education
   & Research (BMBF) [03Z22HN23]; European Regional Development Funds for
   Saxony-Anhalt [EFRE: ZS/2016/04/78115]
FX JPGLMR acknowledges support from the Molecular Sciences Software
   Institute (ACI1547580) (https://molssi.org).JPGLMR and ML acknowledge
   funding from the National Institutes of Health USA (R35GM122543)
   (https://www.nigms.nih.gov).PLK acknowledges funding from the Federal
   Ministry for Education and Research (BMBF, ZIK program) (03Z22HN23)
   (https://www.bmbf.de) and the European Regional Development Funds for
   Saxony-Anhalt (EFRE: ZS/2016/04/78115) (https://www.efre.nrw.de).The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alexander MR, 2020, BIORXIV, DOI [10.1101/2020.07.09.194563, DOI 10.1101/2020.07.09.19456332676592]
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, REUTERS
   [Anonymous], 2020, ANIMALS
   [Anonymous], 2020, SCI NEWS
   Armijos-Jaramillo V, EVOL APPL, DOI [10.1111/eva.12980, DOI 10.1111/EVA.1298032837536]
   Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406
   Casalino L, 2020, BIORXIV, DOI [10.1101/2020.06.11.146522, DOI 10.1101/2020.06.11.14652232577644]
   Chan JF-W, CLIN INFECT DIS, DOI [10.1093/cid/ciaa325, DOI 10.1093/CID/CIAA32532215622]
   Chen JH, 2020, J MOL BIOL, V432, P5212, DOI 10.1016/j.jmb.2020.07.009
   Damas J, 2020, P NATL ACAD SCI USA, V117, P22311, DOI 10.1073/pnas.2010146117
   DeSancho D., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.05.07.083212., DOI 10.1101/2020.05.07.083212, 10.1101/2020.05.07.083212]
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Feng YG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189700
   Fleishman SJ, 2011, SCIENCE, V332, P816, DOI 10.1126/science.1202617
   Kastritis PL, 2014, J MOL BIOL, V426, P2632, DOI 10.1016/j.jmb.2014.04.017
   Kastritis PL, 2010, J PROTEOME RES, V9, P2216, DOI 10.1021/pr9009854
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Kuraku S, 2013, NUCLEIC ACIDS RES, V41, pW22, DOI 10.1093/nar/gkt389
   Lam S. D., 2020, BIORXIV, DOI [10.1101/2020.05.01.072371, DOI 10.1101/2020.05.01.072371]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.04.10.032342, DOI 10.1101/2020.04.10.032342]
   Mehdipour AR, 2020, BIORXIV, DOI [10.1101/2020.07.09.193680, DOI 10.1101/2020.07.09.193680]
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Procko E., 2020, BIOCHEMISTRY-US, DOI [10.1101/2020.03.16.994236, DOI 10.1101/2020.03.16.99423632511321]
   Rodrigues JPGLM, 2012, PROTEINS, V80, P1810, DOI 10.1002/prot.24078
   Rodrigues JPGLM, 2018, F1000RESEARCH, P7, DOI [10.12688/f1000research.13350.2, DOI 10.12688/F1000RESEARCH.13350.229527296]
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Silva DA, 2019, NATURE, V565, P186, DOI 10.1038/s41586-018-0830-7
   Sorokina M, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-00652-6
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   van Wijk SJL, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002754
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 41
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD DEC
PY 2020
VL 16
IS 12
AR e1008449
DI 10.1371/journal.pcbi.1008449
PG 19
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA PC7BC
UT WOS:000597151200002
PM 33270653
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wu, NC
   Yuan, M
   Bangaru, S
   Huang, DL
   Zhu, XY
   Lee, CCD
   Turner, HL
   Peng, LH
   Yang, LL
   Burton, DR
   Nemazee, D
   Ward, AB
   Wilson, IA
AF Wu, Nicholas C.
   Yuan, Meng
   Bangaru, Sandhya
   Huang, Deli
   Zhu, Xueyong
   Lee, Chang-Chun D.
   Turner, Hannah L.
   Peng, Linghang
   Yang, Linlin
   Burton, Dennis R.
   Nemazee, David
   Ward, Andrew B.
   Wilson, Ian A.
TI A natural mutation between SARS-CoV-2 and SARS-CoV determines
   neutralization by a cross-reactive antibody
SO PLOS PATHOGENS
LA English
DT Article
ID CRYO-EM STRUCTURE; CORONAVIRUS; SPIKE; ALIGNMENT; BINDING; PROTEIN
AB Epitopes that are conserved among SARS-like coronaviruses are attractive targets for design of cross-reactive vaccines and therapeutics. CR3022 is a SARS-CoV neutralizing antibody to a highly conserved epitope on the receptor binding domain (RBD) on the spike protein that is able to cross-react with SARS-CoV-2, but with lower affinity. Using x-ray crystallography, mutagenesis, and binding experiments, we illustrate that of four amino acid differences in the CR3022 epitope between SARS-CoV-2 and SARS-CoV, a single mutation P384A fully determines the affinity difference. CR3022 does not neutralize SARS-CoV-2, but the increased affinity to SARS-CoV-2 P384A mutant now enables neutralization with a similar potency to SARS-CoV. We further investigated CR3022 interaction with the SARS-CoV spike protein by negative-stain EM and cryo-EM. Three CR3022 Fabs bind per trimer with the RBD observed in different up-conformations due to considerable flexibility of the RBD. In one of these conformations, quaternary interactions are made by CR3022 to the N-terminal domain (NTD) of an adjacent subunit. Overall, this study provides insights into antigenic variation and potential cross-neutralizing epitopes on SARS-like viruses.
   Author summary
   The ongoing COVID-19 pandemic is caused by SARS-CoV-2. Due to the genetic similarity of SARS-CoV-2 and SARS-CoV, which caused an epidemic in 2003, a few of the SARS-CoV antibodies have now been found to also cross-react with SARS-CoV-2. One such antibody is CR3022, which was isolated from a convalescent SARS patient 14 years ago. However, the 100-fold lower binding to SARS-CoV-2 does not enable neutralization of SARS-CoV-2 compared to SARS-CoV. This study shows that one (P384A) of the four mutational differences in the CR3022 epitope between SARS-CoV and SARS-COV-2 fully accounts for the differences in CR3022 binding affinity and neutralization. These findings advance our understanding of antibody cross-reactivity among SARS-like CoVs with implications for vaccine and therapeutic design.
C1 [Wu, Nicholas C.] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.
   [Wu, Nicholas C.] Univ Illinois, Carl R Woese Inst Genom Biol, Urbana, IL USA.
   [Yuan, Meng; Bangaru, Sandhya; Zhu, Xueyong; Lee, Chang-Chun D.; Turner, Hannah L.; Ward, Andrew B.; Wilson, Ian A.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
   [Huang, Deli; Peng, Linghang; Yang, Linlin; Burton, Dennis R.; Nemazee, David] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.
   [Burton, Dennis R.; Ward, Andrew B.; Wilson, Ian A.] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
   [Burton, Dennis R.; Ward, Andrew B.; Wilson, Ian A.] Scripps Res Inst, Consortium HIV AIDS Vaccine Dev CHAVD, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] Massachusetts Gen Hosp, Ragon Inst, MIT, Cambridge, MA USA.
   [Burton, Dennis R.] Harvard Univ, Cambridge, MA 02138 USA.
   [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
RP Ward, AB; Wilson, IA (corresponding author), Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.; Ward, AB; Wilson, IA (corresponding author), Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.; Ward, AB; Wilson, IA (corresponding author), Scripps Res Inst, Consortium HIV AIDS Vaccine Dev CHAVD, La Jolla, CA 92037 USA.; Wilson, IA (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
EM andrew@scripps.edu; wilson@scripps.edu
RI ; Wu, Nicholas/H-3822-2015
OI Yang, Linlin/0000-0001-5602-4157; Huang, Deli/0000-0002-6989-639X;
   Turner, Hannah/0000-0002-4745-8057; Wu, Nicholas/0000-0002-9078-6697;
   Bangaru, Sandhya/0000-0001-7994-4693; Lee,
   Chang-Chun/0000-0002-5470-2484
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R00 AI139445, R01 AI073148]; Bill and
   Melinda Gates FoundationBill & Melinda Gates Foundation [OPP1170236];
   NIH CHAVDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [UM1 AI44462]; U.S. Department of
   Energy, Office of Science, Office of Basic Energy SciencesUnited States
   Department of Energy (DOE) [DE-AC02-76SF00515]; DOE Office of Biological
   and Environmental ResearchUnited States Department of Energy (DOE);
   National Institutes of Health, National Institute of General Medical
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [P41GM103393]
FX This work was supported by NIH R00 AI139445 (N.C.W.), NIH R01 AI073148
   (D.N.), the Bill and Melinda Gates Foundation OPP1170236 (D.R.B., A.B.W.
   and I.A.W.) and NIH CHAVD UM1 AI44462 (D.R.B., A.B.W. and I.A.W.). Use
   of the SSRL, SLAC National Accelerator Laboratory, is supported by the
   U.S. Department of Energy, Office of Science, Office of Basic Energy
   Sciences under Contract No. DE-AC02-76SF00515. The SSRL Structural
   Molecular Biology Program is supported by the DOE Office of Biological
   and Environmental Research, and by the National Institutes of Health,
   National Institute of General Medical Sciences (including P41GM103393).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2016, FARADAY DISCUSS, V193, P1
   [Anonymous], 2020, J GYNECOL ONCOL, V31, pe69
   Bailey LJ, 2018, J MOL BIOL, V430, P337, DOI 10.1016/j.jmb.2017.12.012
   Barnes CO, 2020, NATURE, DOI 10.1038/s41586-020-2852-1
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Ke ZL, 2020, NATURE, DOI 10.1038/s41586-020-2665-2
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460
   Lander GC, 2009, J STRUCT BIOL, V166, P95, DOI 10.1016/j.jsb.2009.01.002
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Liu Hejun, 2020, bioRxiv, DOI 10.1101/2020.08.02.233536
   Liu LH, 2020, NATURE, DOI 10.1038/s41586-020-2571-7
   Lv Z, 2020, SCIENCE, V369, P1505, DOI 10.1126/science.abc5881
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Voss NR, 2009, J STRUCT BIOL, V166, P205, DOI 10.1016/j.jsb.2009.01.004
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu NC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15371
   Yao HP, 2020, CELL, V183, P730, DOI 10.1016/j.cell.2020.09.018
   Yi CY, 2020, CELL MOL IMMUNOL, V17, P621, DOI 10.1038/s41423-020-0458-z
   Yuan Meng, 2020, Biochem Biophys Res Commun, DOI 10.1016/j.bbrc.2020.10.012
   Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou DRN, 2020, NAT STRUCT MOL BIOL, V27, P950, DOI 10.1038/s41594-020-0480-y
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
NR 62
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD DEC
PY 2020
VL 16
IS 12
AR e1009089
DI 10.1371/journal.ppat.1009089
PG 18
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA PC7DJ
UT WOS:000597157100001
PM 33275640
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Weston, S
   Baracco, L
   Keller, C
   Matthews, K
   McGrath, ME
   Logue, J
   Liang, J
   Dyall, J
   Holbrook, MR
   Hensley, LE
   Jahrling, PB
   Yu, WB
   MacKerell, AD
   Frieman, MB
AF Weston, Stuart
   Baracco, Lauren
   Keller, Chloe
   Matthews, Krystal
   McGrath, Marisa E.
   Logue, James
   Liang, Janie
   Dyall, Julie
   Holbrook, Michael R.
   Hensley, Lisa E.
   Jahrling, Peter B.
   Yu, Wenbo
   MacKerell, Alexander D., Jr.
   Frieman, Matthew B.
TI The SKI complex is a broad-spectrum, host-directed antiviral drug target
   for coronaviruses, influenza, and filoviruses
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE broad-spectrum antiviral; coronavirus; influenza; filovirus; antiviral
   host factor
ID RNA; EXOSOME
AB The SARS-CoV-2 pandemic has made it clear that we have a desperate need for antivirals. We present work that the mammalian SKI complex is a broad-spectrum, host-directed, antiviral drug target. Yeast suppressor screening was utilized to find a functional genetic interaction between proteins from influenza A virus (IAV) and Middle East respiratory syndrome coronavirus (MERS-CoV) with eukaryotic proteins that may be potential host factors involved in replication. This screening identified the SKI complex as a potential host factor for both viruses. In mammalian systems siRNA-mediated knockdown of SKI genes inhibited replication of IAV and MERS-CoV. In silico modeling and database screening identified a binding pocket on the SKI complex and compounds predicted to bind. Experimental assays of those compounds identified three chemical structures that were antiviral against IAV and MERS-CoV along with the filoviruses Ebola and Marburg and two further coronaviruses, SARS-CoV and SARS-CoV-2. The mechanism of antiviral activity is through inhibition of viral RNA production. This work defines the mammalian SKI complex as a broad-spectrum antiviral drug target and identifies lead compounds for further development.
C1 [Weston, Stuart; Baracco, Lauren; Keller, Chloe; Matthews, Krystal; McGrath, Marisa E.; Logue, James; Frieman, Matthew B.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   [Liang, Janie; Dyall, Julie; Holbrook, Michael R.; Hensley, Lisa E.; Jahrling, Peter B.] NIAID, Integrated Res Facil, NIH, Frederick, MD 21702 USA.
   [Jahrling, Peter B.] NIAID, Emerging Viral Pathogens Sect, NIH, Frederick, MD 21702 USA.
   [Yu, Wenbo; MacKerell, Alexander D., Jr.] Univ Maryland, Ctr Biomol Therapeut, Sch Med, Baltimore, MD 21201 USA.
   [Yu, Wenbo; MacKerell, Alexander D., Jr.] Univ Maryland, Comp Aided Drug Design Ctr, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
RP Frieman, MB (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
EM mfrieman@som.umaryland.edu
OI Weston, Stuart/0000-0001-9840-2953; Logue, James/0000-0002-7410-9741
FU Emergent BioSolutions; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [GM131710]; University
   of Maryland Baltimore Computer-Aided Drug Design Center; National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health, Department of Health and Human ServicesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201800013C]; Battelle Memorial Institute;  [R21 AI153480-01]
FX We kindly thank Emergent BioSolutions for financial support to perform
   these experiments. We also thank Dr. Natalie Thornburg (CDC) for the
   SARS-CoV-2 (WA1) strain. M.B.F. was supported in part by R21
   AI153480-01. A.D.M. was supported by NIH GM131710 and the University of
   Maryland Baltimore Computer-Aided Drug Design Center. The content of
   this publication does not necessarily reflect the views or policies of
   the US Department of Health and Human Services (DHHS) or of the
   institutions and companies affiliated with the authors. This project has
   been partially funded with federal funds from the National Institute of
   Allergy and Infectious Diseases, National Institutes of Health,
   Department of Health and Human Services, to Laulima Government
   Solutions, LLC contract No. HHSN272201800013C and Battelle Memorial
   Institute former contract No. HHSN272200700016I. A.A., B.B., and C.C.
   performed this work as previous employees of Battelle Memorial Institute
   and current employees of Laulima Government Solutions, LLC.
   Subcontractors to Laulima Government Solutions, LLC who performed this
   work are: D.D., E.E., and F.F., all employees of Tunnell Government
   Services, Inc.
CR Aly HH, 2016, J BIOL CHEM, V291, P15958, DOI 10.1074/jbc.M116.724641
   Banerjee I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068450
   Basu D, 2009, J VIROL, V83, P1881, DOI 10.1128/JVI.01805-08
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cong Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166318
   Eckard SC, 2014, NAT IMMUNOL, V15, P839, DOI 10.1038/ni.2948
   Guvench O, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000435
   Halbach F, 2013, CELL, V154, P814, DOI 10.1016/j.cell.2013.07.017
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Houseley J, 2009, CELL, V136, P763, DOI 10.1016/j.cell.2009.01.019
   Januszyk K, 2014, CURR OPIN STRUC BIOL, V24, P132, DOI 10.1016/j.sbi.2014.01.011
   Johansen LM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005471
   Johnson SJ, 2013, RNA BIOL, V10, P33, DOI 10.4161/rna.22101
   Koes DR, 2011, J CHEM INF MODEL, V51, P1307, DOI 10.1021/ci200097m
   Laske T, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006944
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   MacKerell AD, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2020.129519
   Molleston JM, 2016, GENE DEV, V30, P1658, DOI 10.1101/gad.284604.116
   Rialdi A, 2017, CELL, V169, P679, DOI 10.1016/j.cell.2017.04.021
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Schneider C, 2014, NAT STRUCT MOL BIOL, V21, P17, DOI 10.1038/nsmb.2750
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shiromoto F, 2018, BIOCHEM BIOPH RES CO, V503, P1854, DOI 10.1016/j.bbrc.2018.07.126
   TOHE A, 1978, J BACTERIOL, V136, P1002, DOI 10.1128/JB.136.3.1002-1007.1978
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Weston S, 2019, J VIROL, V93, DOI 10.1128/JVI.00197-19
   WIDNER WR, 1993, MOL CELL BIOL, V13, P4331, DOI 10.1128/MCB.13.7.4331
   Yu WB, 2015, J CHEM INF MODEL, V55, P407, DOI 10.1021/ci500691p
   Zhou Bin, 2012, Methods Mol Biol, V865, P175, DOI 10.1007/978-1-61779-621-0_11
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 30
TC 0
Z9 0
U1 0
U2 0
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 1
PY 2020
VL 117
IS 48
BP 30687
EP 30698
DI 10.1073/pnas.2012939117
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB7CZ
UT WOS:000596476100018
PM 33184176
OA Bronze
DA 2021-01-01
ER

PT J
AU Doi, Y
   Hibino, M
   Hase, R
   Yamamoto, M
   Kasamatsu, Y
   Hirose, M
   Mutoh, Y
   Homma, Y
   Terada, M
   Ogawa, T
   Kashizaki, F
   Yokoyama, T
   Koba, H
   Kasahara, H
   Yokota, K
   Kato, H
   Yoshida, J
   Kita, T
   Kato, Y
   Kamio, T
   Kodama, N
   Uchida, Y
   Ikeda, N
   Shinoda, M
   Nakagawa, A
   Nakatsumi, H
   Horiguchi, T
   Iwata, M
   Matsuyama, A
   Banno, S
   Koseki, T
   Teramachi, M
   Miyata, M
   Tajima, S
   Maeki, T
   Nakayama, E
   Taniguchi, S
   Lim, CK
   Saijo, M
   Imai, T
   Yoshida, H
   Kabata, D
   Shintani, A
   Yuzawa, Y
   Kondo, M
AF Doi, Yohei
   Hibino, Masaya
   Hase, Ryota
   Yamamoto, Michiko
   Kasamatsu, Yu
   Hirose, Masahiro
   Mutoh, Yoshikazu
   Homma, Yoshito
   Terada, Masaki
   Ogawa, Taku
   Kashizaki, Fumihiro
   Yokoyama, Toshihiko
   Koba, Hayato
   Kasahara, Hideki
   Yokota, Kazuhisa
   Kato, Hideaki
   Yoshida, Junichi
   Kita, Toshiyuki
   Kato, Yasuyuki
   Kamio, Tadashi
   Kodama, Nobuhiro
   Uchida, Yujiro
   Ikeda, Nobuhiro
   Shinoda, Masahiro
   Nakagawa, Atsushi
   Nakatsumi, Hiroki
   Horiguchi, Tomoya
   Iwata, Mitsunaga
   Matsuyama, Akifumi
   Banno, Sumi
   Koseki, Takenao
   Teramachi, Mayumi
   Miyata, Masami
   Tajima, Shigeru
   Maeki, Takahiro
   Nakayama, Eri
   Taniguchi, Satoshi
   Lim, Chang Kweng
   Saijo, Masayuki
   Imai, Takumi
   Yoshida, Hisako
   Kabata, Daijiro
   Shintani, Ayumi
   Yuzawa, Yukio
   Kondo, Masashi
TI A Prospective, Randomized, Open-Label Trial of Early versus Late
   Favipiravir Therapy in Hospitalized Patients with COVID-19
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE COVID-19; antiviral therapy; randomized clinical trial; Avigan
AB Favipiravir is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase that is approved for treatment of influenza in Japan. We conducted a prospective, randomized, open- label, multicenter trial of favipiravir for the treatment of COVID-19 at 25 hospitals across Japan. Eligible patients were adolescents and adults admitted with COVID-19 who were asymptomatic or mildly ill and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients were randomly assigned at a 1:1 ratio to early or late favipiravir therapy (in the latter case, the same regimen starting on day 6 instead of day 1). The primary endpoint was viral clearance by day 6. The secondary endpoint was change in viral load by day 6. Exploratory endpoints included time to defervescence and resolution of symptoms. Eighty-nine patients were enrolled, of whom 69 were virologically evaluable. Viral clearance occurred within 6 days in 66.7% and 56.1% of the early and late treatment groups (adjusted hazard ratio [aHR], 1.42; 95% confidence interval [95% CI], 0.76 to 2.62). Of 30 patients who had a fever (>= 37.5 degrees C) on day 1, times to defervescence were 2.1 days and 3.2 days in the early and late treatment groups ( aHR, 1.88; 95% CI, 0.81 to 4.35). During therapy, 84.1% developed transient hyperuricemia. Favipiravir did not significantly improve viral clearance as measured by reverse transcription-PCR (RT- PCR) by day 6 but was associated with numerical reduction in time to defervescence. Neither disease progression nor death occurred in any of the patients in either treatment group during the 28-day participation.
C1 [Doi, Yohei; Hase, Ryota] Fujita Hlth Univ, Sch Med, Dept Microbiol, Toyoake, Aichi, Japan.
   [Doi, Yohei; Hase, Ryota] Fujita Hlth Univ, Sch Med, Dept Infect Dis, Toyoake, Aichi, Japan.
   [Doi, Yohei] Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA 15260 USA.
   [Hibino, Masaya; Iwata, Mitsunaga] Fujita Hlth Univ, Sch Med, Dept Emergency & Gen Internal Med, Toyoake, Aichi, Japan.
   [Hase, Ryota] Japanese Red Cross Narita Hosp, Dept Infect Dis, Narita, Chiba, Japan.
   [Yamamoto, Michiko] Sagamihara Kyodo Hosp, Dept Resp Med, Sagamihara, Kanagawa, Japan.
   [Kasamatsu, Yu] Kyoto Prefectural Univ Med, Infect Control Arid Clin Lab, Kyoto, Kyoto, Japan.
   [Hirose, Masahiro] Fujita Hlth Univ, Bantane Hosp, Dept Resp Med, Nagoya, Aichi, Japan.
   [Mutoh, Yoshikazu] Tosei Gen Hosp, Dept Infect Dis, Seto, Aichi, Japan.
   [Homma, Yoshito] Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan.
   [Terada, Masaki] Saiseikai Niigata Hosp, Dept Resp Med, Niigata, Niigata, Japan.
   [Ogawa, Taku] Nara Med Univ, Ctr Infect Dis, Kashihara, Nara, Japan.
   [Kashizaki, Fumihiro] Isehara Kyodo Hosp, Dept Resp Med, Isehara, Kanagawa, Japan.
   [Yokoyama, Toshihiko] Japanese Red Cross Nagoya Daiichi Hosp, Dept Resp Med, Nagoya, Aichi, Japan.
   [Koba, Hayato] Komatsu Municipal Hosp, Dept Resp Med, Komatsu, Ishikawa, Japan.
   [Kasahara, Hideki] NTT East Sapporo Hosp, Dept Rheumatol, Sapporo, Hokkaido, Japan.
   [Yokota, Kazuhisa] Tokyo Metropolitan Hlth & Med Corp Ebara Hosp, Dept Infect Dis, Ohta, Gumma, Japan.
   [Kato, Hideaki] Yokohama City Univ Med, Infect Prevent & Control Dept, Yokohama, Kanagawa, Japan.
   [Yoshida, Junichi] Shimonoseki City Hosp, Dept Chest Surg, Shimonoseki, Yamaguchi, Japan.
   [Kita, Toshiyuki] Natl Hosp Org, Kanazawa Med Ctr, Dept Resp Med, Kanazawa, Ishikawa, Japan.
   [Kato, Yasuyuki] Int Univ Hlth & Welf, Narita Hosp, Dept Infect Dis, Narita, Chiba, Japan.
   [Kamio, Tadashi] Shonan Kamakura Gen Hosp, Dept Intens Care, Kamakura, Kanagawa, Japan.
   [Kodama, Nobuhiro] Fukuoka Tokushukai Hosp, Dept Gen Internal Med, Kasuga, Fukuoka, Japan.
   [Uchida, Yujiro] Kitakyushu Municipal Med Ctr, Dept Gen Med, Kitakyushu, Fukuoka, Japan.
   [Ikeda, Nobuhiro] Eiju Gen Hosp, Dept Gen Internal Med, Taito, Tokyo, Japan.
   [Shinoda, Masahiro] Tokyo Shinagawa Hosp, Dept Resp Med, Shinagawa, Tokyo, Japan.
   [Nakagawa, Atsushi] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan.
   [Nakatsumi, Hiroki] Ishikawa Prefectural Cent Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan.
   [Horiguchi, Tomoya; Kondo, Masashi] Fujita Hlth Univ, Sch Med, Dept Resp Med, Toyoake, Aichi, Japan.
   [Matsuyama, Akifumi] Fujita Hlth Univ, Sch Med, Dept Regenerat Med & Stem Cell Biol, Toyoake, Aichi, Japan.
   [Banno, Sumi; Koseki, Takenao; Teramachi, Mayumi; Miyata, Masami; Kondo, Masashi] Fujita Hlth Univ, Sch Med, Ctr Clin Trial & Res Support, Toyoake, Aichi, Japan.
   [Koseki, Takenao] Fujita Hlth Univ, Sch Med, Dept Clin Pharm, Toyoake, Aichi, Japan.
   [Tajima, Shigeru; Maeki, Takahiro; Nakayama, Eri; Taniguchi, Satoshi; Lim, Chang Kweng; Saijo, Masayuki] Natl Inst Infect Dis, Dept Virol 1, Shinjuku Ku, Tokyo, Japan.
   [Imai, Takumi; Yoshida, Hisako; Kabata, Daijiro; Shintani, Ayumi] Osaka City Univ, Grad Sch Med, Dept Med Stat, Osaka, Osaka, Japan.
   [Yuzawa, Yukio] Fujita Hlth Univ, Sch Med, Dept Nephrol, Toyoake, Aichi, Japan.
RP Doi, Y (corresponding author), Fujita Hlth Univ, Sch Med, Dept Microbiol, Toyoake, Aichi, Japan.; Doi, Y (corresponding author), Fujita Hlth Univ, Sch Med, Dept Infect Dis, Toyoake, Aichi, Japan.; Doi, Y (corresponding author), Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA 15260 USA.
EM yoheidoi@fujita-hu.ac.jp
OI Reis, AlessanRSS/0000-0001-8486-7469; Doi, Yohei/0000-0002-9620-2525
FU Japan Agency for Medical Research and Development (AMED)Japan Agency for
   Medical Research and Development (AMED) [JP19fk0108150]
FX This study was supported by the Japan Agency for Medical Research and
   Development (AMED) under grant number JP19fk0108150.
CR Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Ivashchenko Andrey A, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1176
   Jung Y, 2020, ACS INFECT DIS, V6, P2513, DOI 10.1021/acsinfecdis.0c00464
   McCullough Peter A, 2021, Am J Med, V134, P16, DOI 10.1016/j.amjmed.2020.07.003
   Mishima E, 2020, TOHOKU J EXP MED, V251, P87, DOI 10.1620/tjem.251.87
   Okamaoto Kiyoko, 2020, Jpn J Infect Dis, V73, P366, DOI 10.7883/yoken.JJID.2020.108
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Shiraki K, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107512
   Shirato Kazuya, 2020, Jpn J Infect Dis, V73, P304, DOI 10.7883/yoken.JJID.2020.061
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 12
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD DEC
PY 2020
VL 64
IS 12
AR e01897-20
DI 10.1128/AAC.01897-20
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA OV7DU
UT WOS:000592366500019
PM 32958718
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU de Souza, MKB
AF Bomfim de Souza, Mariluce Karla
TI Social distancing measures and demands for the reorganization of
   hemotherapy services in the context of Covid-19
SO CIENCIA & SAUDE COLETIVA
LA English
DT Article
DE Coronavirus infections; Brazil; Blood Therapy Service; Organization and
   administration
ID TRANSFUSION
AB The article aims to discuss the consequences of social distancing measures on the availability of blood and organization of blood therapy services at the beginning of the Covid-19 pandemic in Brazil. News published in April 2020 on the websites of the country's state Blood Service Networks were consulted and organized in an Excel spreadsheet, presented in summary charts, and descriptions of results were prepared. A critical situation of blood supply, especially of some blood types, has been observed in many states. This situation is influenced by the circulation of the new coronavirus. The adoption of social distancing measures associated with unchanged transfusion demands for outpatient, urgency and emergency care required the implementation of strategies and actions for the reorganization of the services. Protection measures were incorporated, flows were changed and new routines were established. This study shows the extent to which the epidemiological situation of Covid-19 and the necessary measures for its control influenced the stocks and availability of blood. Changes in the organization of blood therapy services were fundamental in order to ensure protection, mitigate the risks of spreading the virus, and ensure the blood supply to meet the needs of the health system.
C1 [Bomfim de Souza, Mariluce Karla] Univ Fed Bahia, Inst Saude Colet, R Basilio da Gama S-N, BR-40110040 Salvador, BA, Brazil.
RP de Souza, MKB (corresponding author), Univ Fed Bahia, Inst Saude Colet, R Basilio da Gama S-N, BR-40110040 Salvador, BA, Brazil.
EM marilucejbv@yahoo.com.br
CR Aquino EML, 2020, CIENC SAUDE COLETIVA, V25, P2423, DOI 10.1590/1413-81232020256.1.10502020
   Baron DM, 2020, ANAESTHESIA, V75, P1105, DOI 10.1111/anae.15095
   Cai XH, 2020, BLOOD TRANSFUS-ITALY, V18, P79, DOI 10.2450/2020.0076-20
   Cioffi JGM, 2016, VIROSES TRANSFUSOES
   Fan BE, 2020, AM J HEMATOL, V95, pE158, DOI 10.1002/ajh.25823
   Franchini M, 2020, VOX SANG, V115, P603, DOI 10.1111/vox.12928
   Garraud O, 2020, TRANSFUS CLIN BIOL, V27, P59, DOI 10.1016/j.tracli.2020.03.005
   Kwon SY, 2020, VOX SANG, V115, P601, DOI 10.1111/vox.12925
   Mascaretti L, 2020, BLOOD TRANSFUS-ITALY, V18, P77, DOI 10.2450/2020.0071-20
   Pagano MB, 2020, TRANSFUSION, V60, P908, DOI 10.1111/trf.15789
   Raturi M, 2020, TRANSFUS CLIN BIOL, V27, P169, DOI 10.1016/j.tracli.2020.04.004
   Raturi M, 2020, TRANSFUS CLIN BIOL, V27, P96, DOI 10.1016/j.tracli.2020.03.004
   Roy NBA, 2020, BRIT J HAEMATOL, V189, P635, DOI 10.1111/bjh.16687
   Shander A, 2020, ANESTH ANALG, V131, P74, DOI 10.1213/ANE.0000000000004844
   Souza MKB, 2020, ABASTECIMENTO ESTOQU
   Souza MKB, REVISAO RECOMENDACOE
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Yazer MH, 2020, VOX SANG, V115, P536, DOI 10.1111/vox.12943
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ABRASCO-ASSOC BRASILEIRA POS-GRADUACAO & SAUDE COLETIVA
PI RIO DE JANEIRO
PA AVENIDA BRASIL, 4036, SALA 700 MANGUINHOS-1, RIO DE JANEIRO, 21040-36,
   BRAZIL
SN 1413-8123
EI 1678-4561
J9 CIENC SAUDE COLETIVA
JI Cienc. Saude Coletiva
PD DEC
PY 2020
VL 25
IS 12
BP 4969
EP 4978
DI 10.1590/1413-812320202512.34422020
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PB7DB
UT WOS:000596476300029
PM 33295515
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Dalai, CK
   Sarkar, D
   Ghosh, A
   Ahmed, SN
   Das, SK
   Roy, SK
   Mukhopadhyay, K
AF Dalai, Chanchal Kumar
   Sarkar, Deblina
   Ghosh, Abhishek
   Ahmed, Shah Newaz
   Das, Subir Kumar
   Roy, Suman Kumar
   Mukhopadhyay, Keshab
TI Acute effects of hydroxychloroquine prophylaxis for COVID-19 in health
   care professionals - An online survey
SO INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS
LA English
DT Article
DE Hydroxychloroquine; Ondansetron; Prophylaxis; Systemic lupus
   erythematous
AB Hydroxychloroquine, an antimalarial, is being used worldwide for prophylaxis and treatment of Corona virus disease-19 (COVID-19). Though the drug is commonly used in many chronic inflammatory diseases for protracted periods, its safety in the new indication is still under scrutiny. Therefore, this institute based study sought to assess the acute adverse effects of hydroxychloroquine among in-house health care professionals who were taking the drug for COVID-19 prophylaxis. A questionnaire seeking information on the use of the drug was prepared and disseminated electronically to the target population. The responses were also received electronically and analysed. The participants (n=54) had taken prophylaxis for 1-7 weeks. The most common adverse effects in the cohort were nausea (02) and skin rash (02). The total number of adverse effects reported by the participants was 08. One incidence each of gastric upset (01), dizziness (01), pain abdomen (01), and chest tightness (01) was reported. None of the adverse effects were serious. Our study indicates that the prophylactic weekly single dose of hydroxychloroquine is not associated with any serious adverse effects within 1-7 weeks of initiation. Elucidation of the long term and chronic adverse effects, if any, requires further studies.
C1 [Dalai, Chanchal Kumar; Ghosh, Abhishek; Ahmed, Shah Newaz; Mukhopadhyay, Keshab] West Bengal Univ Hlth Sci, Coll Med, Dept Pharmacol, Nadia 741235, W Bengal, India.
   [Sarkar, Deblina; Roy, Suman Kumar] West Bengal Univ Hlth Sci, Coll Med, Dept Community Med, Nadia 741235, W Bengal, India.
   [Das, Subir Kumar] West Bengal Univ Hlth Sci, Coll Med, Dept Biochem, Nadia 741235, W Bengal, India.
   [Das, Subir Kumar] West Bengal Univ Hlth Sci, JNM Hosp, Nadia 741235, W Bengal, India.
RP Ahmed, SN (corresponding author), West Bengal Univ Hlth Sci, Coll Med, Dept Pharmacol, Nadia 741235, W Bengal, India.
EM shahnewazpharmacology@gmail.com
CR Abdelmaseih R, 2020, CUREUS, V12, DOI 10.7759/cureus.8415
   [Anonymous], 2020, REVISED ADVISORY USE
   [Anonymous], 2020, RECOMMENDATION EMPIR
   Choudhary R, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100684
   Das S, 2020, CLIN DRUG INVEST, V40, P591, DOI 10.1007/s40261-020-00927-1
   Das SK, INDIAN J CLIN BIOCH
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dorner T, 2010, NAT REV RHEUMATOL, V6, P10, DOI 10.1038/nrrheum.2009.235
   Li X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2721-8
   Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919
   Nagaraja BS, 2020, J PUBLIC HEALTH-UK, V42, P493, DOI 10.1093/pubmed/fdaa074
   Nina PB, 2020, INDIAN J PUBLIC HLTH, V64, P125
   Pandit K, 2020, INDIAN J BIOCHEM BIO, V57, P264
   Roldan EQ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104904
   Xu X, 2020, EUR J NUCL MED MOL I, V47, P1275, DOI 10.1007/s00259-020-04735-9
NR 15
TC 0
Z9 0
U1 0
U2 0
PU NATL INST SCIENCE COMMUNICATION-NISCAIR
PI NEW DELHI
PA DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA
SN 0301-1208
EI 0975-0959
J9 INDIAN J BIOCHEM BIO
JI Indian J. Biochem. Biophys.
PD DEC
PY 2020
VL 57
IS 6
BP 707
EP 712
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OW5RY
UT WOS:000592944700009
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Souza, PFN
   Lopes, FES
   Amaral, JL
   Freitas, CDT
   Oliveira, JTA
AF Souza, Pedro F. N.
   Lopes, Francisco E. S.
   Amaral, Jackson L.
   Freitas, Cleverson D. T.
   Oliveira, Jose T. A.
TI A molecular docking study revealed that synthetic peptides induced
   conformational changes in the structure of SARS-CoV-2 spike
   glycoprotein, disrupting the interaction with human ACE2 receptor
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE SARS-CoV-2; COVID-19; Synthetic peptides; Molecular docking; ACE2
   receptor
ID ENERGETICS; COVID-19; WUHAN
AB The global outbreak of COVID-19 (Coronavirus Disease 2019) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome caused by Coronavirus 2) began in December 2019. Its closest relative, SARS-CoV-1, has a slightly mutated Spike (S) protein, which interacts with ACE2 receptor in human cells to start the infection. So far, there are no vaccines or drugs to treat COVID-19. So, research groups worldwide are seeking new molecules targeting the S protein to prevent infection by SARS-CoV-2 and COVID-19 establishment. We performed molecular docking analysis of eight synthetic peptides against SARS-CoV-2 S protein. All interacted with the protein, but Mo-CBP3-PepII and PepKAA had the highest affinity with it. By binding to the S protein, both peptides led to conformational alterations in the protein, resulting in incorrect interaction with ACE2. Therefore, given the importance of the S protein-ACE2 interaction for SARS-CoV-2 infection, synthetic peptides could block SARS-CoV-2 infection. Moreover, unlike other antiviral drugs, peptides have no toxicity to human cells. Thus, these peptides are potential molecules to be tested against SARS-CoV-2 and to develop new drugs to treat COVID-19. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Souza, Pedro F. N.; Lopes, Francisco E. S.; Amaral, Jackson L.; Freitas, Cleverson D. T.; Oliveira, Jose T. A.] Univ Fed Ceara, Dept Biochem & Mol Biol, BR-60440554 Fortaleza, Ceara, Brazil.
RP Souza, PFN (corresponding author), Univ Fed Ceara, Biochem & Mol Biol Dept, Lab Plant Def Prot, Av Mister Hull,POB 60451, Fortaleza, Ceara, Brazil.
EM pedrofilhobio@gmail.com
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [308107/2013-6, 306202/2017-4]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; Fundacao Cearense de Apoio ao
   Desenvolvimento Cientifico e Tecnologico (FUNCAP)
FX This work was supported by grants from the following Brazilian agencies:
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   (process numbers 308107/2013-6 and 306202/2017-4); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES); and Fundacao
   Cearense de Apoio ao Desenvolvimento Cientifico e Tecnologico (FUNCAP).
CR Alifano M, 2020, BIOCHIMIE, V174, P30, DOI 10.1016/j.biochi.2020.04.008
   Almazan F, 2014, VIRUS RES, V189, P262, DOI 10.1016/j.virusres.2014.05.026
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Burrell C.J., 2017, FENNER WHITES MED VI, P437, DOI [10.1016/B978-0-12-375156-0.00031-X., DOI 10.1016/B978-0-12-375156-0.00031-X]
   Calligari P., 2020, MOL INVESTIGATION SA
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dias LP, 2020, BBA-BIOMEMBRANES, V1862, DOI 10.1016/j.bbamem.2019.183092
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Fujii Takeshi, 2004, Journal of Infection and Chemotherapy, V10, P1, DOI 10.1007/s10156-003-0296-9
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Inbar Y, 2005, PROTEINS, V60, P217, DOI 10.1002/prot.20561
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lima PG, 2020, J PEPT SCI, V26, DOI 10.1002/psc.3249
   Liu Q, 2013, ACTA PHARMACOL SIN, V34, P1075, DOI 10.1038/aps.2013.54
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moal IH, 2010, INT J MOL SCI, V11, P3623, DOI 10.3390/ijms11103623
   Oakes JM, 2018, AM J PHYSIOL-REG I, V315, pR895, DOI 10.1152/ajpregu.00099.2018
   Oliveira JTA, 2019, BIOCHIMIE, V157, P10, DOI 10.1016/j.biochi.2018.10.016
   Peiris J. S. M., 2012, Medical microbiology: a guide to microbial infections: pathogenesis, immunity, laboratory investigation and control, P587
   Robertson MJ, 2015, J CHEM THEORY COMPUT, V11, P3499, DOI 10.1021/acs.jctc.5b00356
   Robson B, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103749
   Serafin MB, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105969
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Souza PFN, 2020, BIOCHIMIE, V175, P132, DOI 10.1016/j.biochi.2020.05.016
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   WHO, 2020, COR DIS 2019, V2019, P2633, DOI 10.1001/jama.2020.2633.
   World Health Organization, 2020, MIDDL E RESP SYNDR C
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
NR 45
TC 3
Z9 3
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD DEC 1
PY 2020
VL 164
BP 66
EP 76
DI 10.1016/j.ijbiomac.2020.07.174
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA OP4ZV
UT WOS:000588093700007
PM 32693122
OA Green Published
DA 2021-01-01
ER

PT J
AU Sanami, S
   Zandi, M
   Pourhossein, B
   Mobini, GR
   Safaei, M
   Abed, A
   Arvejeh, PM
   Chermahini, FA
   Alizadeh, M
AF Sanami, Samira
   Zandi, Milad
   Pourhossein, Behzad
   Mobini, Gholam-Reza
   Safaei, Mohsen
   Abed, Atena
   Arvejeh, Pooria Mohammadi
   Chermahini, Fatemeh Amini
   Alizadeh, Morteza
TI Design of a multi-epitope vaccine against SARS-CoV-2 using
   immunoinformatics approach
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE COVID-19; Vaccine; Epitopes
ID PROTEIN; PREDICTION; CORONAVIRUS; SPIKE; GENOME; SERVER; INDEX
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused COVID-19 disease in China. So far, no vaccine has licensed to protect against infection with COVID-19, therefore an effective COVID-19 vaccine needed. The aim of this study was to predict antigenic peptides of SARS-CoV-2 for designing the COVID-19 vaccine using immunoinformatic analysis. In this study, T and B-cell epitopes of S protein were predicted and screened based on the antigenicity, toxicity, allergenicity, and cross-reactivity with human proteomes. The epitopes were joined by the appropriate linker. LT-IIc as an adjuvant was attached to the end of the structure. The secondary and 3D structure of the vaccine was predicted. The refinement process was performed to improve the quality of the 3D model structure; the validation process is performed using the Ramachandran plot and ProSA z-score. The proposed vaccine's binding affinity to the HLA-A11:01 and HLA-DRB1_01:01 molecule was evaluated by molecular docking. Using molecular dynamics, the stability of vaccine-HLA complexes was also evaluated. Finally, in silico gene cloning was performed in the pET30a (+) vector. The findings suggest that the current vaccine may be a promising vaccine to prevent SARS-CoV-2 infection. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Sanami, Samira; Safaei, Mohsen; Abed, Atena] Shahrekord Univ Med Sci, Sch Adv Technol, Dept Med Biotechnol, Shahrekord, Iran.
   [Zandi, Milad; Pourhossein, Behzad] Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran, Iran.
   [Mobini, Gholam-Reza; Arvejeh, Pooria Mohammadi; Chermahini, Fatemeh Amini] Shahrekord Univ Med Sci, Cellular & Mol Res Ctr, Basic Hlth Sci Inst, Shahrekord, Iran.
   [Alizadeh, Morteza] Shahrekord Univ Med Sci, Sch Adv Technol, Dept Tissue Engn, Shahrekord, Iran.
RP Alizadeh, M (corresponding author), Shahrekord Univ Med Sci, Sch Adv Technol, Dept Tissue Engn, Shahrekord, Iran.
EM mor1361@gmail.com
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w
   Barh D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052773
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Carbone A, 2003, BIOINFORMATICS, V19, P2005, DOI 10.1093/bioinformatics/btg272
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty C, 2020, ASIAN PAC J TROP MED, V13, P242, DOI 10.4103/1995-7645.281613
   Chakraborty C, 2020, J MED VIROL, V92, P2314, DOI 10.1002/jmv.25997
   Chen CM, 2013, BIOINFORMATICS, V29, P2808, DOI 10.1093/bioinformatics/btt484
   Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396
   CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   Doytchinova I. A, 2008, OPEN VACCINE J, V1, P4, DOI DOI 10.2174/1875035400801010022
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Doytchinova IA, 2007, VACCINE, V25, P856, DOI 10.1016/j.vaccine.2006.09.032
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Garnier J, 1996, METHOD ENZYMOL, V266, P540
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   GURUPRASAD K, 1990, PROTEIN ENG, V4, P155, DOI 10.1093/protein/4.2.155
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895
   Kalisman N, 2005, BIOINFORMATICS, V21, P3931, DOI 10.1093/bioinformatics/bti630
   Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236
   Kalita P, 2019, INT J BIOL MACROMOL, V138, P224, DOI 10.1016/j.ijbiomac.2019.07.024
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kozakov D, 2013, PROTEINS, V81, P2159, DOI 10.1002/prot.24403
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lucchese G, 2020, CELL MOL IMMUNOL, V17, P539, DOI 10.1038/s41423-020-0377-z
   Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Meza B, 2017, INFECT GENET EVOL, V49, P309, DOI 10.1016/j.meegid.2017.02.007
   Nawar HF, 2010, INFECT IMMUN, V78, P4705, DOI 10.1128/IAI.00730-10
   Nezafat N, 2016, COMPUT BIOL CHEM, V62, P82, DOI 10.1016/j.compbiolchem.2016.04.006
   Pergande MR, 2017, PROTEOMES, V5, DOI 10.3390/proteomes5010004
   Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111
   Poland GA, 2009, PHARMACOGENOMICS, V10, P837, DOI [10.2217/pgs.09.25, 10.2217/PGS.09.25]
   Ramakrishnan C, 2001, RESONANCE, V6, P48, DOI DOI 10.1007/BF02836967
   Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3
   Saha A, 2020, ARCH MED RES, V51, P585, DOI 10.1016/j.arcmed.2020.05.001
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Singh H, 2003, BIOINFORMATICS, V19, P1009, DOI 10.1093/bioinformatics/btg108
   Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Vajda S, 2017, PROTEINS, V85, P435, DOI 10.1002/prot.25219
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   WOLD S, 1993, ANAL CHIM ACTA, V277, P239, DOI 10.1016/0003-2670(93)80437-P
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Yang P., 2020, CELL MOL IMMUNOL, P1
   Zhang H, 2004, J VIROL, V78, P6938, DOI 10.1128/JVI.78.13.6938-6945.2004
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 56
TC 2
Z9 2
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD DEC 1
PY 2020
VL 164
BP 871
EP 883
DI 10.1016/j.ijbiomac.2020.07.117
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA OP4ZV
UT WOS:000588093700083
PM 32682041
OA Green Published
DA 2021-01-01
ER

PT J
AU Abian, O
   Ortega-Alarcon, D
   Jimenez-Alesanco, A
   Ceballos-Laita, L
   Vega, S
   Reyburn, HT
   Rizzuti, B
   Velazquez-Campoy, A
AF Abian, Olga
   Ortega-Alarcon, David
   Jimenez-Alesanco, Ana
   Ceballos-Laita, Laura
   Vega, Sonia
   Reyburn, Hugh T.
   Rizzuti, Bruno
   Velazquez-Campoy, Adrian
TI Structural stability of SARS-CoV-2 3CLpro and identification of
   quercetin as an inhibitor by experimental screening
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE SARS-CoV-2 3CL protease; Structural stability; Drug discovery
ID MAIN PROTEASE; PHARMACOLOGICAL CHAPERONES; 3C-LIKE PROTEASE; MECHANISM;
   DOCKING; DOMAIN
AB The global health emergency generated by coronavirus disease 2019 (COVID-19) has prompted the search for preventive and therapeutic treatments for its pathogen, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are many potential targets for drug discovery and development to tackle this disease. One of these targets is the main protease, Mpro or 3CLpro, which is highly conserved among coronaviruses. 3CLpro is an essential player in the viral replication cycle, processing the large viral polyproteins and rendering the individual proteins functional. We report a biophysical characterization of the structural stability and the catalytic activity of 3CLpro from SARS-CoV-2, from which a suitable experimental in vitro molecular screening procedure has been designed. By screening of a small chemical library consisting of about 150 compounds, the natural product quercetin was identified as reasonably potent inhibitor of SARS-CoV-2 3CLpro (K-i similar to 7 mu M). Quercetin could be shown to interact with 3CLpro using biophysical techniques and bind to the active site in molecular simulations. Quercetin, with well-known pharmacokinetic and ADMET properties, can be considered as a good candidate for further optimization and development, or repositioned for COVID-19 therapeutic treatment. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Abian, Olga] Inst Aragones Ciencias Salud IACS, San Juan Bosco 13, Zaragoza 50009, Spain.
   [Abian, Olga; Ceballos-Laita, Laura; Velazquez-Campoy, Adrian] Inst Invest Sanitaria Aragon IIS Aragon, Zaragoza 50009, Spain.
   [Abian, Olga; Velazquez-Campoy, Adrian] Ctr Invest Biomed Red Area Temat Enfermedades Hep, Madrid 28029, Spain.
   [Abian, Olga; Ortega-Alarcon, David; Jimenez-Alesanco, Ana; Ceballos-Laita, Laura; Vega, Sonia; Velazquez-Campoy, Adrian] Univ Zaragoza, Joint Units IQFR CSIC BIFI & GBsC CSIC BIFI, Inst Biocomputat & Phys Complex Syst BIFI, Zaragoza 50009, Spain.
   [Abian, Olga; Ortega-Alarcon, David; Jimenez-Alesanco, Ana; Velazquez-Campoy, Adrian] Univ Zaragoza, Dept Bioquim & Biol Mol & Celular, Zaragoza 50009, Spain.
   [Reyburn, Hugh T.] CSIC, Natl Ctr Biotechnol CNB, Dept Immunol & Oncol, Madrid 28049, Spain.
   [Rizzuti, Bruno] Univ Calabria, Dept Phys, Licryl UOS Cosenza & CEMIF Cal, CNR NANOTEC, I-87036 Arcavacata Di Rende, Italy.
   [Velazquez-Campoy, Adrian] Fdn ARAID, Gobierno Aragon, Zaragoza 50018, Spain.
RP Abian, O (corresponding author), Inst Aragones Ciencias Salud IACS, San Juan Bosco 13, Zaragoza 50009, Spain.; Abian, O; Velazquez-Campoy, A (corresponding author), Univ Zaragoza, Inst BIFI, Mariano Esquillor S-N, Zaragoza 50018, Spain.
EM oabifra@unizar.es; adrianvc@unizar.es
RI Velazquez-Campoy, Adrian/E-7946-2012; /G-5658-2016; /K-8935-2014
OI Velazquez-Campoy, Adrian/0000-0001-5702-4538; /0000-0002-1232-6310;
   /0000-0001-5664-1729
FU Fundacion hna; Miguel Servet Program from Instituto de Salud Carlos III
   [CPII13/00017]; Fondo de Investigaciones Sanitarias from Instituto de
   Salud Carlos III; European Union (ERDF/ESF, 'Investing in your
   future')European Union (EU) [PI18/00343]; European Union (ERDF/ESF,
   'Investing in your future') (FIS Research Contract); SpanishMinistry of
   Economy and Competitiveness [BFU2016-78232-P, SAF2017-83265R]; Spanish
   Ministry of Science, Innovation and Universities (FPI Predoctoral
   Research) [BES-2017-080739]; Spanish National Research Council
   (CSIC)Consejo Superior de Investigaciones Cientificas (CSIC)
   [202020E079]; Diputacion General de AragonGobierno de Aragon [E45_20R,
   B25_20R]; Centro de Investigacion Biomedica en Red en Enfermedades
   Hepaticas y Digestivas (CIBERehd);  [PT17/0019]
FX This work was supported by Fundacion hna; Miguel Servet Program from
   Instituto de Salud Carlos III (CPII13/00017 to O.A.); Fondo de
   Investigaciones Sanitarias from Instituto de Salud Carlos III, and
   European Union (ERDF/ESF, 'Investing in your future') (PI18/00343 to
   O.A. and a FIS Research Contract to L.C.L.); SpanishMinistry of Economy
   and Competitiveness (BFU2016-78232-P to A.V.C. and SAF2017-83265R to
   H.T.R.); Spanish Ministry of Science, Innovation and Universities (FPI
   Predoctoral Research Contract BES-2017-080739 to D.O.A.); the Spanish
   National Research Council (CSIC, project 202020E079); Diputacion General
   de Aragon (Predoctoral Research Contract 2019 to A.J.A., 'Protein
   Targets and Bioactive Compounds Group' E45_20R to A.V.C., 'Digestive
   Pathology Group' B25_20R to O.A.); Centro de Investigacion Biomedica en
   Red en Enfermedades Hepaticas y Digestivas (CIBERehd). The proteomic
   analysis was performed in the Proteomics Facility of The Spanish
   National Center for Biotechnology (CNB-CSIC) that belongs to ProteoRed,
   PRB3-ISCIII, supported by grant PT17/0019.
CR Abad-Zapatero C, 2005, DRUG DISCOV TODAY, V10, P464, DOI 10.1016/S1359-6446(05)03386-6
   Abian O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069773
   Adams J.G., 2020, JAMA US
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Atzrodt CL, 2020, FEBS J, V287, P3633, DOI 10.1111/febs.15375
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Campos LA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13686-1
   Catanzaro M, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0191-1
   Cimmperman P, 2008, BIOPHYS J, V95, P3222, DOI 10.1529/biophysj.108.134973
   Clarke Lorcan, 2020, J Evid Based Med, V13, P161, DOI 10.1111/jebm.12395
   Claveria-Gimeno R, 2017, EXPERT OPIN DRUG DIS, V12, P363, DOI 10.1080/17460441.2017.1297418
   Cremades N, 2009, ACS CHEM BIOL, V4, P928, DOI 10.1021/cb900166q
   Ericsson UB, 2006, ANAL BIOCHEM, V357, P289, DOI 10.1016/j.ab.2006.07.027
   Gonzalez A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8040503
   Gonzalez A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47746-9
   Grande F., 2018, MOLECULES, V23
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225
   Hidalgo J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159002
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jo S, 2019, CHEM BIOL DRUG DES, V94, P2023, DOI 10.1111/cbdd.13604
   Kasimova MR, 1998, J MOL BIOL, V277, P409, DOI 10.1006/jmbi.1997.1613
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kuo CJ, 2004, BIOCHEM BIOPH RES CO, V318, P862, DOI 10.1016/j.bbrc.2004.04.098
   LAKOWICZ JR, 1990, ANAL CHEM, V62, P2005, DOI 10.1021/ac00217a020
   Lee H, 2014, BIOORGAN MED CHEM, V22, P167, DOI 10.1016/j.bmc.2013.11.041
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Muramatsu T, 2013, FEBS J, V280, P2002, DOI 10.1111/febs.12222
   Neira JL, 2017, SCI REP-UK, V7, DOI 10.1038/srep39732
   Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1177/108705710100600609
   Pey AL, 2008, J CLIN INVEST, V118, P2858, DOI 10.1172/JCI34355
   Pirrone V, 2011, ANTIMICROB AGENTS CH, V55, P1831, DOI 10.1128/AAC.00976-10
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Renu K, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117839
   SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4
   SantofimiaCastano P., 2019, J CLIN INVEST, P130
   Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200
   Shriver John W., 2009, V490, P57, DOI 10.1007/978-1-59745-367-7_3
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Velazquez-Campoy A, 2016, CURR DRUG TARGETS, V17, P1492, DOI 10.2174/1389450117666160201110449
   Villanueva R, 2019, ANTIOXID REDOX SIGN, V30, P2013, DOI 10.1089/ars.2018.7658
   Ward WHJ, 2001, PROGR MED CHEM, V38, P309, DOI 10.1016/S0079-6468(08)70097-3
   World Health Organization, NOV COR COVID 19 SIT
   Wu AD, 2015, VIRUS RES, V208, P56, DOI 10.1016/j.virusres.2015.05.018
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhang SN, 2010, PROTEIN CELL, V1, P371, DOI 10.1007/s13238-010-0044-8
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 51
TC 5
Z9 5
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD DEC 1
PY 2020
VL 164
BP 1693
EP 1703
DI 10.1016/j.ijbiomac.2020.07.235
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA OP4ZV
UT WOS:000588093700159
PM 32745548
OA Green Published
DA 2021-01-01
ER

PT J
AU Tripathi, PK
   Upadhyay, S
   Singh, M
   Raghavendhar, S
   Bhardwaj, M
   Sharma, P
   Patel, AK
AF Tripathi, Praveen Kumar
   Upadhyay, Saurabh
   Singh, Manju
   Raghavendhar, Siva
   Bhardwaj, Mohit
   Sharma, Pradeep
   Patel, Ashok Kumar
TI Screening and evaluation of approved drugs as inhibitors of main
   protease of SARS-CoV-2
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE 3CL-protease; Activity inhibition; Drug repurposing
ID SEVERE CORONAVIRUS DISEASE; SARS CORONAVIRUS; COV; FLUORESCENCE;
   IDENTIFICATION; MECHANISM; RESONANCE; COVID-19; VIRUS
AB The COVID-19 pandemic caused by SARS-CoV-2 has emerged as a global catastrophe. The virus requires main protease for processing the viral polyproteins PP1A and PP1AB translated from the viral RNA. In search of a quick, safe and successful therapeutic agent; we screened various clinically approved drugs for the in-vitro inhibitory effect on 3CL(Pro) which may be able to halt virus replication. The methods used includes protease activity assay, fluorescence quenching, surface plasmon resonance (SPR), Thermofluor (R) Assay, Size exclusion chromatography and in-silico docking studies. We found that Teicoplanin as most effective drug with IC50 similar to 1.5 mu M. Additionally, through fluorescence quenching Stern-Volmer quenching constant (K-SV) for Teicoplanin was estimated as 2.5 x 10(5) L.mol(-1), which suggests a relatively high affinity between Teicoplanin and 3CLPro protease. The SPR shows good interaction between Teicoplanin and 3CLPro with K-D similar to 1.6 mu M. Our results provide critical insights into the mechanism of action of Teicoplanin as a potential therapeutic against COVID-19. We found that Teicoplanin is about 10-20 fold more potent in inhibiting protease activity than other drugs in use, such as lopinavir, hydroxychloroquine, chloroquine, azithromycin, atazanavir etc. Therefore, Teicoplanin emerged as the best inhibitor among all drug molecules we screened against 3CLPro of SARS-CoV-2. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Tripathi, Praveen Kumar; Upadhyay, Saurabh; Raghavendhar, Siva; Bhardwaj, Mohit; Patel, Ashok Kumar] Indian Inst Technol Delhi, Kusuma Sch Biol Sci, New Delhi 110016, India.
   [Singh, Manju] Morarji Desai Natl Inst Yoga, New Delhi 110001, India.
   [Sharma, Pradeep] All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.
RP Patel, AK (corresponding author), Indian Inst Technol Delhi, Kusuma Sch Biol Sci, New Delhi 110016, India.
EM ashokpatel@bioschool.iitd.ac.in
FU ICMRIndian Council of Medical Research (ICMR); DBTDepartment of
   Biotechnology (DBT) India; IIT Delhi, New Delhi, India [MI02217G]
FX Facilities of Kusuma School of Biological Sciences, IIT Delhi are
   acknowledged. Authors acknowledge ICMR and DBT for research
   scholarships. We acknowledge the funding support from the Dean, Research
   and Development, IIT Delhi, New Delhi, India through Grant No MI02217G.
   We acknowledge Dr. Likhesh Sharma (GE Healthcare) for helping in
   analysis and interpretation of SPR experiments.
CR Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Azam F., 2020, TARGETING SARS COV 2, DOI [10.26434/chemrxiv.12408650.v1, DOI 10.26434/CHEMRXIV.12408650.V1]
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Banik Swarnali, 2018, F1000Res, V7, P1151, DOI 10.12688/f1000research.15642.1
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Ceccarelli G, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106029
   Chen LL, 2006, J BIOMOL SCREEN, V11, P915, DOI 10.1177/1087057106293295
   Cheng SC, 2010, BIOPHYS J, V98, P1327, DOI 10.1016/j.bpj.2009.12.4272
   Cupp-Enyard C., 2008, JOVE-J VIS EXP, V17, pe899, DOI [DOI 10.3791/899, 10.3791/899., 10.3791/899]
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Ghisaidoobe ABT, 2014, INT J MOL SCI, V15, P22518, DOI 10.3390/ijms151222518
   Hattori S, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.02635-18, 10.1128/aac.02635-18]
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Huynh Kathy, 2015, Curr Protoc Protein Sci, V79, DOI 10.1002/0471140864.ps2809s79
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kao RY, 2004, FEBS LETT, V576, P325, DOI 10.1016/j.febslet.2004.09.026
   Khan M, 2010, J MED VIROL, V82, P817, DOI 10.1002/jmv.21663
   Krichel B, 2020, BIOCHEM J, V477, P1009, DOI 10.1042/BCJ20200029
   Lakowicz JR, 2006, PRINCIPLES FLUORESCE, DOI [10.1007/978-0-387-46312-4, DOI 10.1007/978-0-387-46312-4]
   Li CM, 2010, J BIOL CHEM, V285, P28134, DOI 10.1074/jbc.M109.095851
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li H, 2020, J INFECTION, V80, P646, DOI 10.1016/j.jinf.2020.03.035
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Muramatsu T, 2013, FEBS J, V280, P2002, DOI 10.1111/febs.12222
   Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878
   Park JY, 2016, J ENZYM INHIB MED CH, V31, P23, DOI 10.3109/14756366.2014.1003215
   Qashqoosh MTA, 2019, BIONANOSCIENCE, V9, P848, DOI 10.1007/s12668-019-00663-7
   Ramos-Martin V, 2017, J ANTIMICROB CHEMOTH, V72, P3382, DOI 10.1093/jac/dkx289
   Rut W., 2020, SUBSTRATE SPECIFICIT, DOI [10.1101/2020.03.07.9819282020.03.07.981928, DOI 10.1101/2020.03.07.981928]
   Shamsi Anas, 2020, Biosci Rep, V40, DOI 10.1042/BSR20201256
   Shi JH, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001084
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   To KKW, 2013, J THORAC DIS, V5, pS103, DOI 10.3978/j.issn.2072-1439.2013.06.02
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Zhang J, 2020, BIORXIV, DOI [10.1101/2020.02.05.935387., 10.1101/2020.02.05.9353872020.02.05.935387, DOI 10.1101/2020.02.05.935387]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhou PC, 2020, INFECT CONT HOSP EP, V41, P1124, DOI 10.1017/ice.2020.156
NR 47
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD DEC 1
PY 2020
VL 164
BP 2622
EP 2631
DI 10.1016/j.ijbiomac.2020.08.166
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA OP4ZV
UT WOS:000588093700244
PM 32853604
OA Green Published
DA 2021-01-01
ER

PT J
AU Pillarsetty, N
   Carter, LM
   Lewis, JS
   Reiner, T
AF Pillarsetty, Nagavarakishore
   Carter, Lukas M.
   Lewis, Jason S.
   Reiner, Thomas
TI Oncology-Inspired Treatment Options for COVID-19
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE auger; radiotherapy; COVID-19; SARS-CoV-2; CR3022
ID MONOCLONAL-ANTIBODY; IMAGING BIOMARKER; SARS CORONAVIRUS; PHASE-I;
   THERAPY; RADIOTHERAPY; EVOLUTION; TRIAL
AB CR3022 is a human antibody that binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we explore the use of CR3022 as a molecularly targeted radiotherapeutic. Methods: CR3022 was labeled with I-131 and purified, yielding I-131-CR3022. Using a magnetic bead assay and a recombinant SARS-CoV-2 spike protein fragment, we tested binding of I-131-CR3022 in the presence and absence of CR3022. Results: We conjugated the antibody CR3022 with a purity of more than 98% and a specific activity of more than 292 MBq/mg. Using a bead-based assay, we confirmed that binding of I-131-CR3022 is selective and is significantly reduced in the presence of unlabeled antibody (3.14% +/- 0.14% specific uptake and 0.10% +/- 0.01% specific uptake, respectively; P < 0.0001). Conclusion: Our results confirm the potential of CR3022 as a molecularly targeted probe for SARS-CoV-2. A labeled version of CR3022 could potentially be used for Auger radiotherapy or noninvasive imaging.
C1 [Pillarsetty, Nagavarakishore; Carter, Lukas M.; Lewis, Jason S.; Reiner, Thomas] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA.
   [Lewis, Jason S.] Mem Sloan Kettering Canc Ctr, Mol Pharmacol Program, 1275 York Ave, New York, NY 10021 USA.
   [Reiner, Thomas] Mem Sloan Kettering Canc Ctr, Chem Biol Program, 1275 York Ave, New York, NY 10021 USA.
RP Reiner, T (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
EM reinert@mskcc.org
OI Reiner, Thomas/0000-0002-7819-5480
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 CA204441, R35
   CA232130, P30 CA008748]
FX This work was supported by National Institutes of Health grants R01
   CA204441, R35 CA232130, and P30 CA008748. No other potential conflict of
   interest relevant to this article was reported.
CR Bavelaar BM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00996
   Blower PJ, 2015, DALTON T, V44, P4819, DOI 10.1039/c4dt02846e
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   CHEUNG NKV, 1986, J NATL CANCER I, V77, P739, DOI 10.1093/jnci/77.3.739
   Dingli D, 2005, BIOCHEM BIOPH RES CO, V337, P22, DOI 10.1016/j.bbrc.2005.08.261
   Eckerman K., 2008, Annals of the ICRP, V38, P9, DOI 10.1016/j.icrp.2008.10.004
   HOFER KG, 1971, RADIAT RES, V47, P94, DOI 10.2307/3573291
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jadvar H, 2017, AM J ROENTGENOL, V209, P277, DOI 10.2214/AJR.17.18264
   Kassis AI, 2003, J NUCL MED, V44, P1479
   Kramer K, 2007, J CLIN ONCOL, V25, P5465, DOI 10.1200/JCO.2007.11.1807
   Kratochwil C, 2016, J NUCL MED, V57, P1941, DOI 10.2967/jnumed.116.178673
   Ku Anthony, 2019, EJNMMI Radiopharm Chem, V4, P27, DOI 10.1186/s41181-019-0075-2
   Liu C, 2020, BIORXIV
   McKelvey KJ, 2018, MAMM GENOME, V29, P843, DOI 10.1007/s00335-018-9777-0
   O'Connor JPB, 2017, NAT REV CLIN ONCOL, V14, P169, DOI 10.1038/nrclinonc.2016.162
   Pancer Z, 2006, ANNU REV IMMUNOL, V24, P497, DOI 10.1146/annurev.immunol.24.021605.090542
   Pirovano G, 2020, CLIN CANCER RES, V26, P2871, DOI 10.1158/1078-0432.CCR-19-2440
   Poty S, 2018, J NUCL MED, V59, P1020, DOI 10.2967/jnumed.117.204651
   Sharma SK, 2019, NUCL MED BIOL, V71, P32, DOI 10.1016/j.nucmedbio.2019.04.005
   Strosberg J, 2017, NEW ENGL J MED, V376, P125, DOI 10.1056/NEJMoa1607427
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang YB, 2017, CLIN CANCER RES, V23, P3053, DOI 10.1158/1078-0432.CCR-16-2197
   Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
NR 29
TC 0
Z9 0
U1 0
U2 0
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD DEC 1
PY 2020
VL 61
IS 12
DI 10.2967/jnumed.120.249748
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA PB7OL
UT WOS:000596505900010
PM 32680924
OA Other Gold
DA 2021-01-01
ER

PT J
AU Oliva, A
   Caputo, M
   Grassi, S
   Vetrugno, G
   Marazza, M
   Ponzanelli, G
   Cauda, R
   Scambia, G
   Forti, G
   Bellantone, R
   Pascali, VL
AF Oliva, Antonio
   Caputo, Matteo
   Grassi, Simone
   Vetrugno, Giuseppe
   Marazza, Marco
   Ponzanelli, Giulio
   Cauda, Roberto
   Scambia, Giovanni
   Forti, Gabrio
   Bellantone, Rocco
   Pascali, Vincenzo L.
TI Liability of Health Care Professionals and Institutions During COVID-19
   Pandemic in Italy: Symposium Proceedings and Position Statement
SO JOURNAL OF PATIENT SAFETY
LA English
DT Article
DE medical liability; COVID-19; SARS-CoV-2; pandemic medicolegal
   implications; forensic pathology
AB Background
   On May 12, 2020, a symposium titled "Liability of healthcare professionals and institutions during COVID-19 pandemic" was held in Italy with the participation of national experts in malpractice law, hospital management, legal medicine, and clinical risk management. The symposium's rationale was the highly likely inflation of criminal and civil proceedings concerning alleged errors committed by health care professionals and decision makers during the COVID-19 pandemic. Its aim was to identify and discuss the main issues of legal and medicolegal interest and thus to find solid solutions in the spirit of preparedness planning. Methods
   There were 5 main points of discussion: (A) how to judge errors committed during the pandemic because of the application of protocols and therapies based on no or weak evidence of efficacy, (B) whether hospital managers can be considered liable for infected health care professionals who were not given adequate personal protective equipment, (C) whether health care professionals and institutions can be considered liable for cases of infected inpatients who claim that the infection was transmitted in a hospital setting, (D) whether health care institutions and hospital managers can be considered liable for the hotspots in long-term care facilities/care homes, and (E) whether health care institutions and hospital managers can be considered liable for the worsening of chronic diseases. Results and Conclusion
   Limitation of the liability to the cases of gross negligence (with an explicit definition of this term), a no-fault system with statal indemnities for infected cases, and a rigorous methodology for the expert witnesses were proposed as key interventions for successfully facing future proceedings.
C1 [Oliva, Antonio; Grassi, Simone; Pascali, Vincenzo L.] Univ Cattolica Sacro Cuore, Dept Hlth Surveillance & Bioeth, Sect Legal Med, Largo F Vito 1, Rome, Italy.
   [Caputo, Matteo] Univ Cattolica Sacro Cuore, Dept Jurid Sci, Sect Criminal Law, Milan, Italy.
   [Vetrugno, Giuseppe] Fdn Policlin Univ Agostino Gemelli IRCCS, Unit Risk Management, Rome, Italy.
   [Marazza, Marco] Univ Cattolica Sacro Cuore, Dept Hlth Woman & Child & Publ Hlth, Labor Law, Rome, Italy.
   [Ponzanelli, Giulio] Univ Cattolica Sacro Cuore, Dept Jurid Sci, Sect Civil Law, Milan, Italy.
   [Cauda, Roberto] Univ Cattolica Sacro Cuore, Dept Healthcare Surveillance & Bioeth, Sect Infect Dis, Rome, Italy.
   [Scambia, Giovanni] Univ Cattolica Sacro Cuore, Dept Hlth Woman & Child & Publ Hlth, Sect Gynecol & Obstet, Rome, Italy.
   [Forti, Gabrio] Univ Cattolica Sacro Cuore, Alta Scuola Federico Stella Giustizia Penale, Milan, Italy.
   [Bellantone, Rocco] Univ Cattolica Sacro Cuore, Med & Surg Fac, Rome, Italy.
RP Grassi, S (corresponding author), Univ Cattolica Sacro Cuore, Dept Hlth Surveillance & Bioeth, Sect Legal Med, Largo F Vito 1, Rome, Italy.
EM antonio.oliva@unicatt.it; matteo.caputo@unicatt.it;
   simone.grassi@unicatt.it; giuseppe.vetrugno@unicatt.it;
   marco.marazza@unicatt.it; giulio.ponzanelli@unicatt.it;
   giulio.ponzanelli@unicatt.it; giovanni.scambia@unicatt.it;
   gabrio.forti@unicatt.it; legmcatt@gmail.com;
   vincenzolorenzo.pascali@unicatt.it
FU Italian Society of Legal Medicine; Bar Association of Rome; Criminal
   Chamber of Rome
FX The symposium was supported by the Italian Society of Legal Medicine,
   the Criminal Chamber of Rome, and the Bar Association of Rome. Professor
   Rocco Bellantone (Dean of Medicine and Surgery Faculty), Professor
   Giovanni Scambia (Scientific Director of the Foundation), Antonino
   Galletti (President of the Bar Association of Rome), Cesare Placanica
   (President of the Criminal Chamber of Rome), Professor Vincenzo L.
   Pascali (Professor of Legal Medicine), Professor Antonio Oliva
   (Professor of Legal Medicine), Professor Roberto Cauda (Director of the
   Department of Healthcare Surveillance and Bioethics), Nunzia D'Elia
   (Rome District Attorney-Procuratore Aggiunto alla Procura della
   Repubblica presso il Tribunale Ordinario di Roma), Professor Matteo
   Caputo (Professor of Criminal Law), Justice Andrea Montagni (Justice of
   the Italian Supreme Court), Professor Giulio Ponzanelli (Professor of
   Civil Law), Professor Marco Marazza (Professor of Labor Law), Professor
   Giuseppe Vetrugno (Risk manager of Policlinico A. Gemelli), Gaetano
   Scalise (Criminal Defense Lawyer), andMario Savini Nicci (Litigator)
   participated.
CR Aquila I, 2020, ARCH PATHOL LAB MED, V144, P1048, DOI 10.5858/arpa.2020-0165-SA
   Caputo M., 2019, RIV ITAL MED LEG, V1, P443
   Cenzato M, 2020, J NEUROSURG, V133, P33, DOI 10.3171/2020.3.JNS20960
   Comitato Nazionale per la Bioetica, 2020, COV 19 DEC CLIN COND
   Consiglio Nazionale Forense [National Bar Council], 2020, CORONAVIRUS CNF SANZ
   De Bartolo D., 2020, EUROMEDITERRANEAN BI, V15, P18
   De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166
   Dell'Aquila M, 2020, ARCH PATHOL LAB MED, V144, P1298, DOI 10.5858/arpa.2020-0362-SA
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   di Luca A, 2019, J PATIENT SAF, V15, pE78, DOI 10.1097/PTS.0000000000000460
   Epicentro-Istituto Superiore di Sanita, DAT EP INF GIORN
   Gualniera P, 2020, LEGAL MED-TOKYO, V42, DOI 10.1016/j.legalmed.2019.101657
   Indolfi Ciro, 2020, JACC Case Rep, V2, P1414, DOI 10.1016/j.jaccas.2020.03.012
   Kachalia A, 2014, HEALTH AFFAIR, V33, P59, DOI 10.1377/hlthaff.2013.0834
   Logar S, 2020, ARCH GERONTOL GERIAT, V89, DOI 10.1016/j.archger.2020.104087
   Oliva A., 2019, RIV ITAL MED LEG, V1, P429
   Ramirez PT, 2020, INT J GYNECOL CANCER, V30, P561, DOI 10.1136/ijgc-2020-001419
   SIAARTI, 2020, RACC ET CLIN AMM TRA
   SIMLA [Italian Society of Legal Medicine], 2020, RESP COVID19 LETT SI
   Spicer J, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0370-6
   Voultos P., 2020, ACTA OTORHINOLARYNGO, V40, P1
NR 21
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1549-8417
EI 1549-8425
J9 J PATIENT SAF
JI J. Patient Saf.
PD DEC
PY 2020
VL 16
IS 4
BP E299
EP E302
DI 10.1097/PTS.0000000000000793
PG 4
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA OZ8NY
UT WOS:000595177300027
PM 32941344
OA Green Published
DA 2021-01-01
ER

PT J
AU Zhang, Q
   Shen, J
   Chen, LK
   Li, SM
   Zhang, WK
   Jiang, C
   Ma, HL
   Lin, L
   Zheng, X
   Zhao, Y
AF Zhang, Qian
   Shen, Jun
   Chen, Liangkai
   Li, Sumeng
   Zhang, Wenkai
   Jiang, Cheng
   Ma, Haoli
   Lin, Lian
   Zheng, Xin
   Zhao, Yan
TI Timing of invasive mechanic ventilation in critically ill patients with
   coronavirus disease 2019
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE COVID-19; invasive mechanic ventilation; critically ill; APACHE II; PSI
ID PNEUMONIA
AB Background
   Invasive mechanical ventilation (IMV) is a lifesaving strategy for critically ill patients with coronavirus disease 2019 (COVID-19). We aim to report the case series of critical patients receiving IMV in Wuhan and to discuss the timing of IMV in these patients. Methods
   Data of 657 patients admitted to emergency intensive care unit of Zhongnan Hospital and isolated isolation wards of Wuhan Union Hospital from January 1 to March 10, 2020, were retrospectively reviewed. All medical records of 40 COVID-19 patients who required IMV were collected at different time points, including baseline (at admission), before receiving IMV, and before death or hospital discharge. Results
   Among 40 COVID-19 patients with IMV, 31 died, and 9 survived and was discharged. The median age was 70 years (interquartile range [IQR], 62-76 years), and nonsurvivors were older than survivors. The median period from the noninvasive mechanic ventilation (NIV) or high-flow nasal cannula oxygen therapy (HFNC) to intubation was 7 hours (IQR, 2-42 hours) in IMV survivors and 54 hours (IQR, 28-143 hours) in IMV nonsurvivors. We observed that, when the time interval from NIV/HFNC to intubation was less than 50 hours (about 2 calendar days), together with Acute Physiology and Chronic Health Evaluation II (APACHE II) score of less than 10 or pneumonia severity index (PSI) score of less than 100, mortality can be reduced to 60% or less. Prolonged interval from NIV/HFNC to intubation and high levels of APACHE II and PSI before intubation were associated with higher mortality in critically ill patients. Multiple organ damage was common among these nonsurvivors in the course of treatment. Conclusion
   Early initial intubation after NIV/HFNC might have a beneficial effect in reducing mortality for critically ill patients meeting IMV indication. Considering APACHE II and PSI scores might help physicians in decision making about timing of intubation for curbing subsequent mortality.
C1 [Zhang, Qian; Li, Sumeng; Zheng, Xin] Huazhong Univ Sci & Technol, Dept Infect Dis, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.
   [Zhang, Qian; Li, Sumeng; Zheng, Xin] Huazhong Univ Sci & Technol, Joint Int Lab Infect & Immun, Wuhan, Peoples R China.
   [Chen, Liangkai] Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll,Dept Nutr & Food Hyg, Hubei Key Lab Food Nutr & Safety,Minist Educ,Key, Wuhan, Peoples R China.
   [Shen, Jun; Jiang, Cheng; Ma, Haoli; Lin, Lian; Zhao, Yan] Wuhan Univ, Zhongnan Hosp, Emergency Ctr, Wuhan 430071, Hubei, Peoples R China.
   [Zhang, Wenkai] Huazhong Univ Sci & Technol, Maternal & Child Hlth Hosp Hubei Prov, Tongji Med Coll, Intens Care Unit, Wuhan, Peoples R China.
RP Zheng, X (corresponding author), Huazhong Univ Sci & Technol, Dept Infect Dis, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.; Zhao, Y (corresponding author), Wuhan Univ, Zhongnan Hosp, Emergency Ctr, Wuhan 430071, Hubei, Peoples R China.
EM xin11@hotmail.com; doctoryanzhao@whu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [8170080939]; Emergency Response Project of
   Hubei Science and Technology Department [2020FCA023]; Ethics Committees
   of Zhongnan Hospital of Wuhan University
FX For all authors, no conflicts are declared. This study was supported by
   the National Natural Science Foundation of China (grant number
   8170080939 to Q.Z.) and the Emergency Response Project of Hubei Science
   and Technology Department (2020FCA023 to Y.Z.). The funders had no role
   in the design and conduct of the study; collection, management,
   analysis, and interpretation of the data; preparation, review, or
   approval of the article; and decision to submit the article for
   publication.; The Ethics Committees of Zhongnan Hospital of Wuhan
   University approved this study.; The data that support the findings of
   this study are available from the corresponding authors on reasonable
   request. We can provide participant data without names and identifiers
   but not the study protocol or statistical analysis plan. After
   publication of study findings, the data will be available for others to
   request. Once the data can be made public, the research team will
   provide an email address for communication. The corresponding authors
   have the right to decide whether to share the data based on the research
   objectives and plan provided.
CR BENICHOU C, 1990, J HEPATOL, V11, P272
   Brodie D, 2019, JAMA-J AM MED ASSOC, V322, P557, DOI 10.1001/jama.2019.9302
   Brodie D, 2011, NEW ENGL J MED, V365, P1905, DOI 10.1056/NEJMct1103720
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   General Office of the National Health Commission Office of the State Administration of Traditional Chinese Medicine, 2020, DIAGN TREATM COVID 1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Munshi L, 2019, LANCET RESP MED, V7, P163, DOI 10.1016/S2213-2600(18)30452-1
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2
   Pierrakos Charalampos, 2012, J Clin Med Res, V4, P7, DOI 10.4021/jocmr761w
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Restrepo MI, 2008, CHEST, V133, P610, DOI 10.1378/chest.07-1456
   Uno H, 2007, J AM STAT ASSOC, V102, P527, DOI 10.1198/016214507000000149
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, CLIN MAN SEV AC RESP
   World Health Organization, 2020, 58 WHO
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 22
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD DEC
PY 2020
VL 89
IS 6
BP 1092
EP 1098
DI 10.1097/TA.0000000000002939
PG 7
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA OZ3WN
UT WOS:000594860700027
PM 32925581
OA Green Published
DA 2021-01-01
ER

PT J
AU Savioli, F
   Rocha, L
   Gois, A
   Nakano, LC
AF Savioli, Felicio
   Rocha, Leonardo
   Gois, Aecio
   Nakano, Luis Carlos
TI Fibrinolytic therapy in patients with COVID-19 and acute respiratory
   distress syndrome: Is this a feasible approach?
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Letter
C1 [Savioli, Felicio; Rocha, Leonardo] Hosp Alemao Oswaldo Cruz, Dept Crit Care Med, Sao Paulo, Brazil.
   [Gois, Aecio; Nakano, Luis Carlos] Univ Fed Sao Paulo, Dept Med, Sao Paulo, Brazil.
RP Savioli, F (corresponding author), Hosp Alemao Oswaldo Cruz, Dept Crit Care Med, Sao Paulo, Brazil.
EM feasavioli@gmail.com; lrocha23@gmail.com; aecio.gois@unifesp.br;
   luiscnakano@uol.com.br
CR Barrett CD, 2020, RES PRACT THROMB HAE, V4, P524, DOI 10.1002/rth2.12357
   Christie DB, 2020, J TRAUMA ACUTE CARE, V89, P448, DOI 10.1097/TA.0000000000002787
   Gunther A, 2000, AM J RESP CRIT CARE, V161, P454
   Hardaway RM, 2001, AM SURGEON, V67, P377
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01898
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Medcalf RL, 2020, J THROMB HAEMOST, V18, P2118, DOI 10.1111/jth.14960
   Moore EE, FIBRINOLYTIC THERAPY
   Moore HB, 2020, RES PRACT THROMB HAE, V4, P984, DOI 10.1002/rth2.12395
   Poor HD, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.44
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Whyte CS, 2020, J THROMB HAEMOST, V18, P1548, DOI 10.1111/jth.14872
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 15
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD DEC
PY 2020
VL 89
IS 6
BP E187
EP E188
DI 10.1097/TA.0000000000002931
PG 2
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA OZ3WN
UT WOS:000594860700009
PM 32868539
OA Green Published
DA 2021-01-01
ER

PT J
AU Lee, JH
   Kim, YC
   Cho, SH
   Lee, J
   You, SC
   Song, YG
   Won, YB
   Choi, YS
   Park, YS
AF Lee, Jae Hoon
   Kim, Yong Chan
   Cho, Si Hyun
   Lee, Jinae
   You, Seng Chan
   Song, Young Goo
   Won, Young Bin
   Choi, Young Sik
   Park, Yun Soo
TI Effect of sex hormones on coronavirus disease 2019: an analysis of 5,061
   laboratory-confirmed cases in South Korea
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Big data; COVID-19; Hormone therapy; SARS-CoV-2; Sex characteristics
ID CORE OUTCOME SET; MENOPAUSE; PROTOCOL
AB Objective: To evaluate the effect of female sex hormones on the clinical outcomes of coronavirus disease 2019 patients using national claims data.
   Methods: This retrospective cohort study used the Health Insurance Review and Assessment data of 5,061 adult patients with laboratory-confirmed coronavirus disease 2019 in South Korea from January 20 to April 8, 2020. To evaluate the effect of hormone therapy on clinical outcomes among women, subgroup analyses using age-matched case-control data were performed.
   Results: Coronavirus disease 2019 was most prevalent in women in the 20-39 years age group (1,250 [44.14%]). Men were more likely to receive oxygen therapy (144 [6.46%] vs 131 [4.63%], P = 0.004), be admitted to the intensive care unit (60 [2.69%] vs 53 [1.87%], P = 0.049), and have a longer length of stay after admission to the intensive care unit (19.70 +/- 11.80 vs 14.75 +/- 9.23, P = 0.016). However, there was no significant difference in the mortality rate (men vs women: 42 [1.88%] vs 42 [1.48%], P = 0.267). In the multivariable Cox analysis, older age and underlying comorbidities, but not sex, were independent risk factors for mortality. Hormone therapy was not significantly associated with clinical outcomes.
   Conclusions: This study, using nationwide data, suggests that female sex hormones are not associated with the morbidity and clinical outcomes of coronavirus disease 2019 in South Korea.
C1 [Lee, Jae Hoon; Cho, Si Hyun] Yonsei Univ, Gangnam Severance Hosp, Dept Obstet & Gynecol, Div Reprod Endocrinol,Coll Med, Seoul, South Korea.
   [Kim, Yong Chan; Song, Young Goo] Yonsei Univ, Gangnam Severance Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Eonju Ro 211, Seoul 06273, South Korea.
   [Lee, Jinae] DreamCIS, Biometr, Seoul, South Korea.
   [You, Seng Chan] Ajou Univ, Dept Biomed Informat, Sch Med, Suwon, South Korea.
   [Won, Young Bin; Choi, Young Sik] Yonsei Univ, Severance Hosp, Dept Obstet & Gynecol, Div Reprod Endocrinol,Coll Med, Seoul, South Korea.
   [Park, Yun Soo] Yonsei Univ, Yongin Severance Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Yongin, South Korea.
RP Kim, YC (corresponding author), Yonsei Univ, Gangnam Severance Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Eonju Ro 211, Seoul 06273, South Korea.
EM amomj@yuhs.ac
CR [Anonymous], 2005, NIH CONSENS STATE SC, V22, P1
   Carpenter JS, 2015, CLIMACTERIC, V18, P859, DOI 10.3109/13697137.2015.1083003
   Christmas Monica Michelle, 2020, Menopause, V27, P1070, DOI 10.1097/GME.0000000000001570
   COMET, DELPHIMANAGER
   Duffy JMN, 2020, BJOG-INT J OBSTET GY, V127, P967, DOI 10.1111/1471-0528.16157
   Duffy JMN, 2017, BJOG-INT J OBSTET GY, V124, P1481, DOI 10.1111/1471-0528.14694
   Duffy JMN, 2016, PREGNANCY HYPERTENS, V6, P274, DOI 10.1016/j.preghy.2016.04.008
   Duffy JMN, 2018, HUM REPROD OPEN, V2018, phoy007, DOI DOI 10.1093/HROPEN/HOY007
   Gargon E, 2018, PLOS ONE, V13, DOI [10.1371/journal.pone.0225980, 10.1371/journal.pone.0209869]
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Hickey M, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5101
   Hirsch M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013998
   Iliodromiti S, 2020, BJOG-INT J OBSTET GY, V127, P320, DOI 10.1111/1471-0528.15990
   Jansen LAW, 2020, BJOG-INT J OBSTET GY, V127, P983, DOI 10.1111/1471-0528.16172
   Khan K, 2014, BJOG-INT J OBSTET GY, V121, P1181, DOI 10.1111/1471-0528.12929
   Marjoribanks J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004143.pub5
   Portman DJ, 2014, MATURITAS, V79, P349, DOI 10.1016/j.maturitas.2014.07.013
   Prinsen CAC, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1555-2
   Santoro N, 2019, JAMA-J AM MED ASSOC, V322, P775, DOI 10.1001/jama.2019.6250
   Shifren JL, 2019, MENOPAUSE, V26, P341, DOI 10.1097/GME.0000000000001275
   Thomas F, 2001, HUM BIOL, V73, P271, DOI 10.1353/hub.2001.0029
   Webbe J, 2018, ARCH DIS CHILDHOOD-E, V103, P163, DOI 10.1136/archdischild-2016-312117
   Webbe JWH, 2020, ARCH DIS CHILD-FETAL, V105, pF425, DOI 10.1136/archdischild-2019-317501
   Whitehouse KC, 2017, CONTRACEPTION, V95, P437, DOI 10.1016/j.contraception.2016.12.009
   Williamson PR, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1978-4
NR 25
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072-3714
EI 1530-0374
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD DEC
PY 2020
VL 27
IS 12
BP 1376
EP 1381
DI 10.1097/GME.0000000000001657
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA OZ3VQ
UT WOS:000594858400008
PM 33003134
OA Green Published
DA 2021-01-01
ER

PT J
AU Kaunitz, AM
   Bitner, D
   Constantine, GD
   Bernick, B
   Graham, S
   Mirkin, S
AF Kaunitz, Andrew M.
   Bitner, Diana
   Constantine, Ginger D.
   Bernick, Brian
   Graham, Shelli
   Mirkin, Sebastian
TI Effect of sex hormones on coronavirus disease 2019: an analysis of 5,061
   laboratory-confirmed cases in South Korea
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Big data; COVID-19; Hormone therapy; SARS-CoV-2; Sex characteristics
ID MERS-COV OUTBREAK
AB Objective: To evaluate the effect of female sex hormones on the clinical outcomes of coronavirus disease 2019 patients using national claims data. Methods: This retrospective cohort study used the Health Insurance Review and Assessment data of 5,061 adult patients with laboratory-confirmed coronavirus disease 2019 in South Korea from January 20 to April 8, 2020. To evaluate the effect of hormone therapy on clinical outcomes among women, subgroup analyses using age-matched case-control data were performed. Results: Coronavirus disease 2019 was most prevalent in women in the 20-39 years age group (1,250 [44.14%]). Men were more likely to receive oxygen therapy (144 [6.46%] vs 131 [4.63%], P = 0.004), be admitted to the intensive care unit (60 [2.69%] vs 53 [1.87%], P = 0.049), and have a longer length of stay after admission to the intensive care unit (19.70 +/- 11.80 vs 14.75 +/- 9.23, P = 0.016). However, there was no significant difference in the mortality rate (men vs women: 42 [1.88%] vs 42 [1.48%], P = 0.267). In the multivariable Cox analysis, older age and underlying comorbidities, but not sex, were independent risk factors for mortality. Hormone therapy was not significantly associated with clinical outcomes. Conclusions: This study, using nationwide data, suggests that female sex hormones are not associated with the morbidity and clinical outcomes of coronavirus disease 2019 in South Korea.
C1 [Kaunitz, Andrew M.] Univ Florida, Coll Med Jacksonville, Jacksonville, FL USA.
   [Bitner, Diana] Spectrum Hlth, Grand Rapids, MI USA.
   [Constantine, Ginger D.] EndoRheum Consultants LLC, Malvern, PA USA.
   [Bernick, Brian; Graham, Shelli; Mirkin, Sebastian] TherapeuticsMD, Boca Raton, FL USA.
RP Kaunitz, AM (corresponding author), Dept Obstet & Gynecol, 3rd Floor,LRC 653-1,West 8th St,L17, Jacksonville, FL 32209 USA.
EM Andrew.Kauntiz@jax.ufl.edu
FU TherapeuticsMD
FX TherapeuticsMD sponsored the study and provided support for the medical
   writing assistance of Laura Ninger, ELS and Dominique Verlaan, PhD, CMPP
   (Precise Publications, LLC).
CR [Anonymous], 2020, CORONAVIRUS DIS 19
   Assessment RR, 2020, CORONAVIRUS DIS 2019
   Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Cho SY, 2016, LANCET, V388, P994, DOI 10.1016/S0140-6736(16)30623-7
   Dudley JP, 2020, CLIN INFECT DIS, V71, P863, DOI 10.1093/cid/ciaa354
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Kim KH, 2017, J HOSP INFECT, V95, P207, DOI 10.1016/j.jhin.2016.10.008
   Kim L, 2014, EPIDEMIOL HEALTH, V36, DOI 10.4178/epih/e2014008
   Kim SB, 2020, INFECT CHEMOTHER, V52, P281, DOI 10.3947/ic.2020.52.2.281
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   La Vignera S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082948
   Livingston E, JAMA
   McCoy J, 2020, J COSMET DERMATOL-US, V19, P1542, DOI 10.1111/jocd.13455
   Park SY, 2020, EMERG INFECT DIS, V26, P1666, DOI 10.3201/eid2608.201274
   Park YJ, 2001, KOREAN J WOMEN HLTH, V7, P473
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sue K, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5560
   Walter LA, 2020, WEST J EMERG MED, V21, P507, DOI 10.5811/westjem.2020.4.47536
NR 20
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072-3714
EI 1530-0374
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD DEC
PY 2020
VL 27
IS 12
BP 1382
EP 1387
DI 10.1097/GME.0000000000001615
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA OZ3VQ
UT WOS:000594858400009
PM 32740481
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Guo, QN
   Yang, PW
   Nampoukime, KPB
   Ma, K
   Wang, HH
AF Guo, Qiannan
   Yang, Peiwen
   Nampoukime, Kan-paatib Barnabo
   Ma, Ke
   Wang, Haihao
TI Spontaneous Pneumothorax: A Complication of Coronavirus Disease 2019
   (COVID-19) Patients
SO THORACIC AND CARDIOVASCULAR SURGEON
LA English
DT Article; Early Access
DE COVID-19; spontaneous pneumothorax; closed thoracic drainage; poor
   prognosis
ID ULTRASOUND
AB Background At present, the coronavirus disease 2019 (COVID-19) is spreading all over the world. The occurrence of spontaneous pneumothorax in these patients might be higher than the fact, and we should pay high clinical attention to them.
   Method Data regarding clinical investigation, laboratory investigation, diagnosis, and treatment measures of 21 COVID-19 patients with spontaneous pneumothorax from January to March of 2020 were collected and analyzed in this study.
   Results Seven patients had a history of basic lung diseases. All patients used different methods of oxygen therapy before the occurrence of spontaneous pneumothorax according to the severity of the COVID-19, including 18 patients with ventilator-assisted breathing, 2 patients with bilevel positive airway pressure assisted breathing, and 1 patient with mask oxygen inhalation. All patients were confirmed cases of COVID-19 by chest CT (computed tomography) and virus nucleic acid detection and were found to have spontaneous pneumothorax through physical examination, bedside X-ray, and/or bedside ultrasound. 13 of 21 patients combined with pleural effusion at the same time. All the patients underwent closed thoracic drainage for spontaneous pneumothorax and the pleural effusion, if any. Nine patients died, and 12 patients recovered smoothly.
   Conclusion Spontaneous pneumothorax might be an overlooked complication of COVID-19 patients and may be associated with poor prognosis.
C1 [Guo, Qiannan; Yang, Peiwen; Nampoukime, Kan-paatib Barnabo; Ma, Ke; Wang, Haihao] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
RP Wang, HH (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM hhwang@tjh.tjmu.edu.cn
CR [Anonymous], 2020, CORONAVIRUS DIS COVI
   Bosmuller H, 2020, VIRCHOWS ARCH, V477, P349, DOI 10.1007/s00428-020-02881-x
   Chan SSW, 2003, ACAD EMERG MED, V10, P91, DOI 10.1111/j.1553-2712.2003.tb01984.x
   Cheng S, 2020, MED J AUSTRALIA, V212, DOI 10.5694/mja2.50431
   Dahmarde H, 2019, CAN RESPIR J, V2019, DOI 10.1155/2019/5271982
   Lopez MIE, 2018, REV ESP ANEST REANIM, V65, P541, DOI 10.1016/j.redar.2018.04.003
   Hwang TS, 2018, J VET SCI, V19, P660, DOI 10.4142/jvs.2018.19.5.660
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V323, P1245, DOI 10.1001/jama.2020.2342
   Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m943
   Marty AM, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100123
   Ramos C, 2020, SALUD PUBLICA MEXICO, V62, P225, DOI 10.21149/11276
   Sayar A, 2014, ANN THORAC CARDIOVAS, V20, P192, DOI 10.5761/atcs.oa.12.02212
   Schilling T, 2014, MINERVA ANESTESIOL, V80, P3
   Swierzy M, 2014, ZBL CHIR, V139, pS69, DOI 10.1055/s-0034-1383029
   Swierzy M, 2014, ZENTRALBL CHIR S1, V139, pS87
   Taylor G, 2000, NEW ENGL J MED, V343, P300
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 19
TC 0
Z9 0
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0171-6425
EI 1439-1902
J9 THORAC CARDIOV SURG
JI Thorac. Cardiovasc. Surg.
DI 10.1055/s-0040-1721061
EA DEC 2020
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA OZ1MS
UT WOS:000594699400004
PM 33260236
DA 2021-01-01
ER

PT J
AU Huppe, D
   Niederau, C
   Serfert, Y
   Hartmann, H
   Wedemeyer, H
AF Hueppe, Dietrich
   Niederau, Claus
   Serfert, Yvonne
   Hartmann, Heinz
   Wedemeyer, Heiner
CA fuur das DHC-R
TI Problems in treating patients with chronic HCV infection due to the
   COVID-19 pandemic and during the lockdown phase in Germany
SO ZEITSCHRIFT FUR GASTROENTEROLOGIE
LA German
DT Article
DE German Hepatitis C Registry; COVID-19 pandemic; hepatitis C virus
   infection; lockdown; patient care
AB Background Healthcare services were faced with unprecedented challenges due to the COVID-19 pandemic and its associated lockdown regulations. In order to analyse the influence of the pandemic on the healthcare of patients with chronic hepatitis C in Germany, we carried out a structured questionnaire among all centres participating in the German Hepatitis C-Registry (DHC-R).
   Methods 320 centres of the DHC-R were invited to participate in an online survey. Of these, 74 centres had included >= 5 patients in the last 12 months.
   Findings A fully answered questionnaire was sent back by 64 centres. Due to the lockdown regulations, 11 % of the centres had stopped their regular consultation between March and May 2020; 58 % had reduced the consultations and 32 % did not change the consultations. More than 50 % of the appointment cancellations were done by the patients. 52 % of the centres offered a new or additional telephone consultation and 17 % offered a new video consultation. Between March and May 2020, the number of patients newly treated with antivirals was markedly lower when compared with the same period in 2019. All centres had returned to their usual consultation procedures in July 2020. Almost 80 % indicated that there were no significant limitations in patient's healthcare. However, 22 % of the centres stated that liver decompensation was diagnosed late and 9.4 % stated that diagnosis of hepatocellular carcinoma was delayed. An adequate amount of personal protective equipment (including disinfectants) was available in 56 % of the centres. Official information by public healthcare authorities was considered sufficient by 63 % of the centres.
   Summary Diagnosis, therapy and monitoring of patients with chronic hepatitis C were impaired during the COVID-19 pandemic. Nevertheless, the majority of the centres did not see healthcare problems for these patients in the medium and long term. However, the fact that the diagnosis of liver decompensations with potential lethal consequences was delayed in a considerable number of patients causes major concern.
C1 [Hueppe, Dietrich] Gastroenterol Gemeinschaftspraxis Herne, Herne, Germany.
   [Niederau, Claus] Postfach 10 12 03, D-46012 Oberhausen, Germany.
   [Serfert, Yvonne; Hartmann, Heinz; Wedemeyer, Heiner] Leberstiftungs GmbH Deutschland, Carl Neuberg Str 1, D-30625 Hannover, Germany.
   [Wedemeyer, Heiner] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany.
RP Wedemeyer, H (corresponding author), Leberstiftungs GmbH Deutschland, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM claus.niederau@yahoo.de; info@leberstiftungs-gmbh.de
CR [Anonymous], 2020, BUND STELL EP LAG NA
   Bohmer MM, 2020, LANCET INFECT DIS, V20, P920, DOI 10.1016/S1473-3099(20)30314-5
   Bujard M, 2020, ELTERN WAHREND CORON
   Bundesregierung. Erweiterung der beschlossenen Leitlinien zur Beschrankung sozialer Kontakte, 2020, BESPR BUND REG REG L
   Gesetz zum Schutz der Bevolkerung bei einer epidemischen Lage von nationaler Tragweite, 2020, BUND JAHRG 1, P587
   Haas S., 2020, OBERGRENZE UBERSCHRI
   Hagen B., FRUHERKENNUNGSKOLOSK
   Kuhlen R, 2020, DTSCH ARZTEBLATT, V27-28, P488
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Mangiapane S, 2020, VERANDERUNG VERTRAGS
   Ricciardiello Luigi, 2020, Clin Gastroenterol Hepatol, DOI 10.1016/j.cgh.2020.09.008
   RKI, 2020, EPIDEMIOLOGISCHES B, V2, P26, DOI 10.25646/6206.2
   Schmidt C, 2020, Z GASTROENTEROL, V58, P1
   Statistisches Bundesamt, 2020, AUSF ERG WIRTSCH QUA
   Tagesschau.de, 2020, EIN BUND LAND WEITR
   World Health Organization, WHO COR DIS COVID 19
NR 16
TC 0
Z9 0
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0044-2771
EI 1439-7803
J9 Z GASTROENTEROL
JI Z. Gastroent.
PD DEC
PY 2020
VL 58
IS 12
BP 1182
EP 1185
DI 10.1055/a-1291-8518
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA PB7ZC
UT WOS:000596533800017
PM 33167051
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhao, XM
   Liu, RX
   Miao, Z
   Ye, N
   Lu, WY
AF Zhao, Xiaomeng
   Liu, Ruixia
   Miao, Zhi
   Ye, Nan
   Lu, Wenyu
TI A Study of Potential SARS-CoV-2 Antiviral Drugs and Preliminary Research
   of Their Molecular Mechanism, Based on Anti-SARS-CoV Drug Screening and
   Molecular Dynamics Simulation
SO JOURNAL OF COMPUTATIONAL BIOLOGY
LA English
DT Article; Early Access
DE 2019-nCoV; COVID-19; molecular docking; remdesivir; SARS-CoV-2
ID CORONAVIRUS
AB This research was based on virtual docking screening and molecular dynamics simulation among the 30 drugs analyzed, which drug had the best inhibitory effect on 3CL protease (Mpro) hydrolase. AutoDock Vina is used for molecular docking. Through our research, the binding affinity of saquinavir and raltegravir to the protein is higher than other candidate drugs in molecular docking; they are -9.1 kcal/mol and -9 kcal/mol, respectively. Among them remdesivir performance was mediocre, only -7.9 kcal/mol. In our study, ultimately, these systems are also basically stable. The overall contraction of the protein structure is most obvious after the combination of remdesivir. In the remdesivir-protein system, the structure of the terminal end has undergone relatively large changes. And the total number of hydrogen bonds formed in the remdesivir-protein system is larger. The hydrogen bonds can be maintained for a longer time, and the final interaction energy is stronger than other systems. These amino acid sequence fragments have high affinity with the remdesivir molecule. Remdesivir can change the structure of the protein to make it stronger in binding with itself through the interaction with the protein. The simulation study of drug screening for new coronaviruses can provide further support for new coronavirus effective drugs and provide powerful support to defeat the virus.
C1 [Zhao, Xiaomeng; Liu, Ruixia; Miao, Zhi; Ye, Nan; Lu, Wenyu] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Miao, Zhi] Tianjin Cosmo Biotechnol Co Ltd, Tianjin, Peoples R China.
   [Lu, Wenyu] Tianjin Univ, Key Lab Syst Bioengn, Minist Educ, Tianjin, Peoples R China.
   [Lu, Wenyu] SynBio Res Platform, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin, Peoples R China.
RP Lu, WY (corresponding author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
EM wenyulu@tju.edu.cn
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Guo Q., 2020, HOST INFECTIVITY PRE
   Ju J., 2020, NUCLEOTIDE ANALOGUES
   Kawata M, 2001, CHEM PHYS LETT, V340, P165, DOI 10.1016/S0009-2614(01)00393-1
   Lei C., 2020, POTENT NEUTRALIZATIO
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lu JB, 2014, J CHEM THEORY COMPUT, V10, P4104, DOI 10.1021/ct500487h
   Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 17
TC 0
Z9 0
U1 3
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1066-5277
EI 1557-8666
J9 J COMPUT BIOL
JI J. Comput. Biol.
DI 10.1089/cmb.2020.0112
EA DEC 2020
PG 15
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA PA7XM
UT WOS:000595843400001
PM 33275483
OA Bronze
DA 2021-01-01
ER

PT J
AU Sokol, RL
   Grummon, AH
AF Sokol, Rebeccah L.
   Grummon, Anna H.
TI COVID-19 and Parent Intention to Vaccinate Their Children Against
   Influenza
SO PEDIATRICS
LA English
DT Article
ID BEHAVIOR
AB OBJECTIVES: Evaluate if the coronavirus disease 2019 (COVID-19) pandemic influences parents' intentions to have their children receive the 2020-2021 seasonal influenza vaccination. METHODS: In May 2020, we recruited 2164 US parents and guardians of children ages 6 months to 5 years to complete a brief online survey that examined parental behavior and decision-making in response to experimental stimuli and real-world events. We estimated a multivariate multinomial logistic regression (controlling for key demographics) to assess the relationship between a child's 2019-2020 influenza vaccination status and the COVID-19 pandemic's influence on a parent's intentions for their child's 2020-2021 influenza vaccination. RESULTS: Changes in vaccination intentions significantly differed between parents whose children received the 2019-2020 influenza vaccine compared with those whose children did not (P < .001). Specifically, among parents whose children did not receive the 2019-2020 vaccine, 34% (95% confidence interval [CI]: 30%-37%) reported that the COVID-19 pandemic made them less likely to have their child receive the 2020-2021 vaccine. Among those whose children did receive the 2019-2020 vaccine, this figure was just 24% (95% CI: 22%-27%). Conversely, only 21% (95% CI: 18%-24%) of parents whose children did not receive the 2019-2020 vaccine reported that the COVID-19 pandemic made them more likely to have their child receive the 2020-2021 vaccine, compared with 39% (95% CI: 36%-41%) of parents whose children did receive the 2019-2020 vaccine. CONCLUSIONS: The COVID-19 pandemic alone does not appear sufficient to encourage the uptake of pediatric seasonal influenza vaccination. Instead, the COVID-19 pandemic may exacerbate polarity in vaccination uptake.
   We evaluated if the COVID-19 pandemic influences parents' intentions to have their children receive the 2020-2021 seasonal influenza vaccination.
C1 [Sokol, Rebeccah L.] Wayne State Univ, Sch Social Work, 5447 Woodward Ave, Detroit, MI 48202 USA.
   [Grummon, Anna H.] Harvard Univ, Ctr Populat & Dev Studies, Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA.
   [Grummon, Anna H.] Harvard Univ, Harvard Med Sch, Dept Populat Med, Boston, MA 02115 USA.
   [Grummon, Anna H.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
RP Sokol, RL (corresponding author), Wayne State Univ, Sch Social Work, 5447 Woodward Ave, Detroit, MI 48202 USA.
EM rlsokol@wayne.edu
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development of the National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [F32HD100021-01]; National Institutes of Health
   (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA
FX Dr Sokol was supported by a postdoctoral award through the Eunice
   Kennedy Shriver National Institute of Child Health and Human Development
   (F32HD100021-01) of the National Institutes of Health. Funded by the
   National Institutes of Health (NIH).
CR Aarts H, 1998, J APPL SOC PSYCHOL, V28, P1355, DOI 10.1111/j.1559-1816.1998.tb01681.x
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Bourassa KJ, 2020, ANN BEHAV MED, V54, P548, DOI 10.1093/abm/kaaa049
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764
   Brown DJ, 2020, SOC SCI MED, V258, DOI 10.1016/j.socscimed.2020.113085
   Centers for Disease Control and Prevention, 2019, FLU VACC CONV US 201
   Gerend MA, 2012, ANN BEHAV MED, V44, P171, DOI 10.1007/s12160-012-9366-5
   Gostin LO, 2020, JAMA-J AM MED ASSOC, V324, P335, DOI 10.1001/jama.2020.10802
   Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9
   Harper Craig A, 2020, Int J Ment Health Addict, P1, DOI 10.1007/s11469-020-00281-5
   Juraskova I, 2012, INT J BEHAV MED, V19, P518, DOI 10.1007/s12529-011-9182-5
   Michiels B, 2011, VACCINE, V29, P9159, DOI 10.1016/j.vaccine.2011.08.008
   Milkman KL, 2011, P NATL ACAD SCI USA, V108, P10415, DOI 10.1073/pnas.1103170108
   Ouellette JA, 1998, PSYCHOL BULL, V124, P54, DOI 10.1037/0033-2909.124.1.54
   Plans-Rubio P, 2012, PREV MED, V55, P72, DOI 10.1016/j.ypmed.2012.02.015
   Sackey DM, 2018, INT J INTEGR CARE, V18, DOI 10.5334/ijic.s1079
   Schwarzer R., 2020, HDB BEHAV CHANGE, P89, DOI DOI 10.1017/9781108677318.007
   Sheeran P, 2019, SOC SCI MED, V228, P68, DOI 10.1016/j.socscimed.2019.03.015
   Strack F, 2004, PERS SOC PSYCHOL REV, V8, P220, DOI 10.1207/s15327957pspr0803_1
NR 20
TC 0
Z9 0
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD DEC
PY 2020
VL 146
IS 6
AR e2020022871
DI 10.1542/peds.2020-022871
PG 6
WC Pediatrics
SC Pediatrics
GA PA7FI
UT WOS:000595796200055
PM 32999011
OA Bronze
DA 2021-01-01
ER

PT J
AU Girmenia, C
   Gentile, G
   Micozzi, A
   Petrucci, L
   Malaspina, F
   Di Prima, A
   Baldacci, E
   Bianchi, S
   Pugliese, P
   Turriziani, O
   Antonelli, G
   Tombolini, V
   Foa, R
   Martelli, M
AF Girmenia, Corrado
   Gentile, Giuseppe
   Micozzi, Alessandra
   Petrucci, Luigi
   Malaspina, Francesco
   Di Prima, Alessio
   Baldacci, Erminia
   Bianchi, Simona
   Pugliese, Pellegrina
   Turriziani, Ombretta
   Antonelli, Guido
   Tombolini, Vincenzo
   Foa, Robin
   Martelli, Maurizio
TI COVID-19 in Patients with Hematologic Disorders Undergoing Therapy:
   Perspective of a Large Referral Hematology Center in Rome
SO ACTA HAEMATOLOGICA
LA English
DT Article
DE COVID-19; Hematological diseases; Prevalence; Infection control
ID CANCER
AB Introduction: Patients with cancer may be more susceptible to and have higher morbidity and mortality rates from COVID-19 than the general population, while epidemiologic data specifically addressed to hematologic patients are limited. To investigate whether patients with hematologic diseases undergoing therapy are at increased risk for acquiring SARS CoV-2 infection compared to the general population, a retrospective study was carried out at a referral hematologic center in Rome, Italy, during the period of the greatest epidemic spread (March 8 to May 14, 2020). Methods: All adult and pediatric patients with a diagnosis of a neoplastic or a nonneoplastic hematologic disease who underwent treatment (chemotherapy or immunosuppressive or supportive therapy) during the study period or in the previous 6 months were considered. The prevalence of COVID-19 in the overall outpatient and inpatient population undergoing hematologic treatment compared to that of the general population was analyzed. The measures taken to manage patients during the epidemic period are described. Results: Overall, 2,513 patients with hematological diseases were considered. Out of 243 (9.7%) patients who were screened for SARS CoV-2, three of 119 (2.5%) outpatients with fever or respiratory symptoms and none of 124 asymptomatic patients were diagnosed with COVID-19. Three further patients were diagnosed with COVID-19 and managed in other hospitals in Rome. As of May 14, 2020, the prevalence of COVID-19 in our hematologic population accounted for 0.24% (95% CI 0.23-0.25; 6 of 2,513 patients: 1 case in every 419 patients) as compared to 0.12% (7,280 of 5,879,082 residents; 1 case in every 807 residents) in the general population (p = 0.14). Three of 6 patients diagnosed with COVID-19 required critical care and 2 died while still positive for SARS CoV-2. Out of 225 healthcare providers on duty at our Institution during the study period, 2 (0.9%) symptomatic cases were diagnosed with COVID-19. Conclusion: In our experience, the prevalence of COVID-19 in hematologic patients, mainly affected by malignancies, was not significantly higher compared to that of the general population. Definition of adapted strategies for healthcare services, while continuing to administer the standard hematologic treatments, represents the crucial challenge for the management of hematologic diseases in the COVID-19 era.
C1 [Girmenia, Corrado; Gentile, Giuseppe; Micozzi, Alessandra; Petrucci, Luigi; Malaspina, Francesco; Di Prima, Alessio; Baldacci, Erminia; Bianchi, Simona; Foa, Robin; Martelli, Maurizio] Sapienza Univ Rome, Dept Hematol Oncol & Dermatol, AOU Policlin Umberto 1, Hematol, Rome, Italy.
   [Pugliese, Pellegrina] Sapienza Univ Rome, Thalassemia Unit, Immunohematol & Transfus Med Unit, AOU Policlin Umberto 1, Rome, Italy.
   [Turriziani, Ombretta; Antonelli, Guido] Sapienza Univ Rome, Dept Mol Med, Lab Virol, AOU Policlin Umberto 1, Rome, Italy.
   [Tombolini, Vincenzo] Sapienza Univ Rome, Dept Hematol Oncol & Dermatol, AOU Policlin Umberto 1, Radiotherapy, Rome, Italy.
RP Girmenia, C (corresponding author), Sapienza Univ Rome, Dept Hematol Oncol & Dermatol, AOU Policlin Umberto 1, Hematol, Rome, Italy.
EM girmenia@bce.uniroma1.it
CR Baldacini M, 2020, BRIT J HAEMATOL, V189, P1054, DOI 10.1111/bjh.16768
   Baumann T, 2020, LEUKEMIA, V34, P1954, DOI 10.1038/s41375-020-0870-5
   Boulad F, 2020, JAMA ONCOL, V6, P1459, DOI 10.1001/jamaoncol.2020.2028
   Breccia M, 2020, LEUKEMIA, V34, P2260, DOI 10.1038/s41375-020-0904-z
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Cinar P, 2020, J NATL COMPR CANC NE, V18, P504, DOI 10.6004/jnccn.2020.7572
   Cuneo A, 2020, BLOOD, V136, P763, DOI 10.1182/blood.2020006854
   Falandry C, 2020, J GERIATR ONCOL, V11, P747, DOI 10.1016/j.jgo.2020.03.020
   Farmer I, 2020, BRIT J HAEMATOL, V190, pE248, DOI 10.1111/bjh.16864
   Foa R, 2020, BRIT J HAEMATOL, V190, pE3, DOI 10.1111/bjh.16758
   Gale Robert Peter, 2020, Acta Haematol, P1, DOI 10.1159/000508021
   Gavillet M, 2020, LEUKEMIA RES, V92, DOI 10.1016/j.leukres.2020.106353
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Hrusak O, 2020, EUR J CANCER, V132, P11, DOI 10.1016/j.ejca.2020.03.021
   Jin XH, 2020, LANCET HAEMATOL, V7, pE351, DOI 10.1016/S2352-3026(20)30074-0
   Li WM, 2020, LEUKEMIA, V34, P1799, DOI 10.1038/s41375-020-0853-6
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Ljungman P, 2020, BONE MARROW TRANSPL, V55, P2071, DOI 10.1038/s41409-020-0919-0
   Paneesha S, 2020, LEUKEMIA RES, V93, DOI 10.1016/j.leukres.2020.106366
   Patnaik MM, 2020, AM J HEMATOL, V95, pE203, DOI 10.1002/ajh.25853
   Paul Shilpa, 2020, Acta Haematol, P1, DOI 10.1159/000508199
   Perini GF, 2020, HEMATOL TRANSF CELL, V42, P103, DOI 10.1016/j.htct.2020.04.002
   Psaltopoulou T, 2020, HEMASPHERE, V4, DOI 10.1097/HS9.0000000000000409
   Raza Azra, 2020, Leuk Res Rep, V13, P100201, DOI 10.1016/j.lrr.2020.100201
   Sieni E, 2020, BRIT J HAEMATOL, V189, pE222, DOI 10.1111/bjh.16781
   Sullivan M, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28409
   Terpos E, 2020, LEUKEMIA, V34, P2000, DOI 10.1038/s41375-020-0876-z
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Thibaud S, 2020, BRIT J HAEMATOL, V190, pE73, DOI 10.1111/bjh.16863
   Treon SP, 2020, BLOOD, V135, P1912, DOI 10.1182/blood.2020006288
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Von Lilienfeld-Toal M, 2020, LEUKEMIA, V34, P1487, DOI 10.1038/s41375-020-0832-y
   Wright Z, 2020, CLIN LYMPHOMA MYELOM
   Wu YL, 2020, BRIT J HAEMATOL, V190, pE13, DOI 10.1111/bjh.16799
   Xia XY, 2020, BLOOD, V136, P755, DOI 10.1182/blood.2020007079
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zeidan AM, 2020, LANCET HAEMATOL
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhao Y, 2020, PEDIATR INFECT DIS J, V39, pE142, DOI 10.1097/INF.0000000000002742
   Zheng R S, 2019, Zhonghua Zhong Liu Za Zhi, V41, P19, DOI 10.3760/cma.j.issn.0253-3766.2019.01.005
NR 41
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5792
EI 1421-9662
J9 ACTA HAEMATOL-BASEL
JI Acta Haematol.
PD DEC
PY 2020
VL 143
IS 6
BP 574
EP 582
DI 10.1159/000510769
PG 9
WC Hematology
SC Hematology
GA OZ8TC
UT WOS:000595190700010
PM 32932252
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Loo, SL
   Wark, PAB
   Esneau, C
   Nichol, KS
   Hsu, ACY
   Bartlett, NW
AF Loo, Su-Ling
   Wark, Peter A. B.
   Esneau, Camille
   Nichol, Kristy S.
   Hsu, Alan C-Y
   Bartlett, Nathan W.
TI Human coronaviruses 229E and OC43 replicate and induce distinct
   antiviral responses in differentiated primary human bronchial epithelial
   cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE coronavirus; epithelial cell; infection; 229E; OC43
ID RESPIRATORY SYNCYTIAL VIRUS; ASTHMA; PROTEIN; ACIDS; HKU1
AB The recurrent emergence of novel, pathogenic coronaviruses (CoVs) severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1; 2002), Middle East respiratory syndrome (MERS)-CoV (2012), and most recently SARS-CoV-2 (2019) has highlighted the need for physiologically informative airway epithelial cell infection models for studying immunity to CoVs and development of antiviral therapies. To address this, we developed an in vitro infection model for two human coronaviruses; alphacoronavirus 229E-CoV (229E) and betacoronavirus OC43-CoV (OC43) in differentiated primary human bronchial epithelial cells (pBECs). Primary BECs from healthy subjects were grown at air-liquid interface (ALI) and infected with 229E or OC43, and replication kinetics and time-course expression of innate immune mediators were assessed. OC43 and 229E-CoVs replicated in differentiated pBECs but displayed distinct replication kinetics: 229E replicated rapidly with viral load peaking at 24 h postinfection, while OC43 replication was slower peaking at 96 h after infection. This was associated with diverse antiviral response profiles defined by increased expression of type I/III interferons and interferon-stimulated genes (ISGs) by 229E compared with no innate immune activation with OC43 infection. Understanding the host-virus interaction for previously established coronaviruses will give insight into pathogenic mechanisms underpinning SARS-CoV-2-induced respiratory disease and other future coronaviruses that may arise from zoonotic sources.
C1 [Loo, Su-Ling; Esneau, Camille; Bartlett, Nathan W.] Univ Newcastle, Viral Immunol & Resp Dis Grp, Newcastle, NSW, Australia.
   [Loo, Su-Ling; Wark, Peter A. B.; Esneau, Camille; Nichol, Kristy S.; Hsu, Alan C-Y; Bartlett, Nathan W.] Univ Newcastle, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia.
   [Loo, Su-Ling; Wark, Peter A. B.; Esneau, Camille; Nichol, Kristy S.; Hsu, Alan C-Y; Bartlett, Nathan W.] Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Wark, Peter A. B.] John Hunter Hosp, Dept Resp & Sleep Med, Newcastle, NSW, Australia.
RP Bartlett, NW (corresponding author), Univ Newcastle, Viral Immunol & Resp Dis Grp, Newcastle, NSW, Australia.; Bartlett, NW (corresponding author), Univ Newcastle, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia.; Bartlett, NW (corresponding author), Hunter Med Res Inst, Newcastle, NSW, Australia.
EM nathan.bartlett@newcastle.edu.au
RI Wark, Peter/G-8267-2015
OI Wark, Peter/0000-0001-5676-6126; Esneau, Camille/0000-0002-5479-1851;
   Bartlett, Nathan/0000-0002-2715-5163
CR Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bullard Jared, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa638
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Corman VM, 2016, P NATL ACAD SCI USA, V113, P9864, DOI 10.1073/pnas.1604472113
   Corman VM, 2015, J VIROL, V89, P11858, DOI 10.1128/JVI.01755-15
   Crosse KM, 2018, J INNATE IMMUN, V10, P85, DOI 10.1159/000484258
   Falsey AR, 2003, J CLIN MICROBIOL, V41, P4160, DOI 10.1128/JCM.41.9.4160-4165.2003
   Galani IE, 2017, IMMUNITY, V46, P875, DOI 10.1016/j.immuni.2017.04.025
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Hackett TL, 2008, STEM CELLS, V26, P2576, DOI 10.1634/stemcells.2008-0171
   Hackett TL, 2011, AM J RESP CELL MOL, V45, P1090, DOI 10.1165/rcmb.2011-0031OC
   Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Hulswit RJG, 2019, P NATL ACAD SCI USA, V116, P2681, DOI 10.1073/pnas.1809667116
   HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808
   Huynh J, 2012, J VIROL, V86, P12816, DOI 10.1128/JVI.00906-12
   Ip DKM, 2016, CLIN INFECT DIS, V62, P431, DOI 10.1093/cid/civ909
   Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60
   Kindler E, 2013, MBIO, V4, DOI 10.1128/mBio.00611-12
   Krempl C, 1995, Adv Exp Med Biol, V380, P371
   KUNKEL F, 1993, VIROLOGY, V195, P195, DOI 10.1006/viro.1993.1360
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van der Hoek L, 2007, ANTIVIR THER, V12, P651
   Vijgen L, 2006, J VIROL, V80, P7270, DOI 10.1128/JVI.02675-05
   Wang GS, 2000, J VIROL, V74, P9234, DOI 10.1128/JVI.74.19.9234-9239.2000
   Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Yoneyama M, 2010, REV MED VIROL, V20, P4, DOI 10.1002/rmv.633
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 34
TC 0
Z9 0
U1 2
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD DEC
PY 2020
VL 319
IS 6
BP L926
EP L931
DI 10.1152/ajplung.00374.2020
PG 6
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA PA4PO
UT WOS:000595620000004
PM 32903043
OA Bronze
DA 2021-01-01
ER

PT J
AU Muteeb, G
   Alshoaibi, A
   Aatif, M
   Rehman, MT
   Qayyum, MZ
AF Muteeb, Ghazala
   Alshoaibi, Adil
   Aatif, Mohammad
   Rehman, Md. Tabish
   Qayyum, M. Zuhaib
TI Screening marine algae metabolites as high-affinity inhibitors of
   SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify
   novel drug candidates to combat COVID-19 pandemic
SO APPLIED BIOLOGICAL CHEMISTRY
LA English
DT Article
DE SARS-CoV-2; Marine-derived compounds; Callophysin A; Molecular docking
   and simulation; Seaweeds
AB The recent dissemination of SARS-CoV-2 from Wuhan city to all over the world has created a pandemic. COVID-19 has cost many human lives and created an enormous economic burden. Although many drugs/vaccines are in different stages of clinical trials, still none is clinically available. We have screened a marine seaweed database (1110 compounds) against 3CLpro of SARS-CoV-2 using computational approaches. High throughput virtual screening was performed on compounds, and 86 of them with docking score < - 5.000 kcal mol(-1) were subjected to standard-precision docking. Based on binding energies (< - 6.000 kcal mol(-1)), 9 compounds were further shortlisted and subjected to extra-precision docking. Free energy calculation by Prime-MM/GBSA suggested RC002, GA004, and GA006 as the most potent inhibitors of 3CLpro. An analysis of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of RC002, GA004, and GA006 indicated that only RC002 (callophysin A, from red alga Callophycus oppositifolius) passed Lipinski's, Veber's, PAINS and Brenk's filters and displayed drug-like and lead-like properties. Analysis of 3CLpro-callophysin A complex revealed the involvement of salt bridge, hydrogen bonds, and hydrophobic interactions. callophysin A interacted with the catalytic residues (His41 and Cys145) of 3CLpro; hence it may act as a mechanism-based competitive inhibitor. Docking energy and docking affinity of callophysin A towards 3CLpro was - 8.776 kcal mol(-1) and 2.73 x 10(6) M-1, respectively. Molecular dynamics simulation confirmed the stability of the 3CLpro-callophysin A complex. The findings of this study may serve as the basis for further validation by in vitro and in vivo studies.
C1 [Muteeb, Ghazala] King Faisal Univ, Coll Appl Med Sci, Dept Nursing, POB 400, Al Hasa 31982, Saudi Arabia.
   [Alshoaibi, Adil] King Faisal Univ, Dept Phys, Coll Sci, POB 400, Al Hasa 31982, Saudi Arabia.
   [Aatif, Mohammad] King Faisal Univ, Coll Appl Med Sci, Dept Publ Hlth, POB 400, Al Hasa 31982, Saudi Arabia.
   [Rehman, Md. Tabish] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh 11451, Saudi Arabia.
   [Qayyum, M. Zuhaib] Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, State Coll, PA USA.
RP Muteeb, G (corresponding author), King Faisal Univ, Coll Appl Med Sci, Dept Nursing, POB 400, Al Hasa 31982, Saudi Arabia.
EM graza@kfu.edu.sa
RI Muteeb, Ghazala/C-1697-2016
OI Muteeb, Ghazala/0000-0002-3328-3559
FU Deputyship for Research & Innovation, Ministry of Education in Saudi
   Arabia [IFT20066]
FX "The authors extend their appreciation to the Deputyship for Research &
   Innovation, Ministry of Education in Saudi Arabia for funding this
   research work through the project number IFT20066".
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Branka AC, 2000, PHYS REV E, V61, P4769, DOI 10.1103/PhysRevE.61.4769
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Daina A, 2016, CHEMMEDCHEM, V11, P1117, DOI 10.1002/cmdc.201600182
   Dicky G, 2011, BIOINFORMATION SEAWE
   Faheem M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056926
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gallimore W, 2017, PHARMACOGNOSY: FUNDAMENTALS, APPLICATIONS AND STRATEGIES, P377, DOI 10.1016/B978-0-12-802104-0.00018-4
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Jabir NR, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1784796
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kumar A, 2019, J MOL STRUCT, V1189, P299, DOI 10.1016/j.molstruc.2019.04.023
   Kumar N, 2020, J BIOMOL STRUCT DYN, V38, P3396, DOI 10.1080/07391102.2019.1657499
   KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Liang JL, 2020, COMPUT BIOL CHEM, V87, DOI 10.1016/j.compbiolchem.2020.107292
   Marques MR, 2005, CHEM BIODIVERS, V2, P525, DOI 10.1002/cbdv.200590034
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Munnink BOB, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0997-y
   Ovenden SPB, 2011, PHYTOCHEM LETT, V4, P69, DOI 10.1016/j.phytol.2010.07.010
   Palese LL, 2020, STRUCTURAL LANDSCAPE
   Rehman MT, 2016, J BIOMOL STRUCT DYN, V34, P1849, DOI 10.1080/07391102.2015.1094411
   Rehman MT, 2014, MOL PHARMACEUT, V11, P1785, DOI 10.1021/mp500116c
   Rodier F, 2005, PROTEINS, V60, P36, DOI 10.1002/prot.20478
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   She J, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-00271-z
   Shen L, 2011, BIOORGAN MED CHEM, V19, P6182, DOI 10.1016/j.bmc.2011.09.020
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P16719, DOI 10.1039/c4cp01388c
   Williams DE, 2007, J AM CHEM SOC, V129, P5822, DOI 10.1021/ja0715187
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 38
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER SINGAPORE PTE LTD
PI SINGAPORE
PA #04-01 CENCON I, 1 TANNERY RD, SINGAPORE 347719, SINGAPORE
SN 2468-0834
EI 2468-0842
J9 APPL BIOL CHEM
JI Appl. Biol. Chem.
PD DEC
PY 2020
VL 63
IS 1
AR 79
DI 10.1186/s13765-020-00564-4
PG 12
WC Food Science & Technology
SC Food Science & Technology
GA PA4SH
UT WOS:000595627100001
PM 33251389
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rajoli, RKR
   Pertinez, H
   Arshad, U
   Box, H
   Tatham, L
   Curley, P
   Neary, M
   Sharp, J
   Liptrott, NJ
   Valentijn, A
   David, C
   Rannard, SP
   Aljayyoussi, G
   Pennington, SH
   Hill, A
   Boffito, M
   Ward, SA
   Khoo, SH
   Bray, PG
   O'Neill, PM
   Hong, WD
   Biagini, G
   Owen, A
AF Rajoli, Rajith K. R.
   Pertinez, Henry
   Arshad, Usman
   Box, Helen
   Tatham, Lee
   Curley, Paul
   Neary, Megan
   Sharp, Joanne
   Liptrott, Neill J.
   Valentijn, Anthony
   David, Christopher
   Rannard, Steve P.
   Aljayyoussi, Ghaith
   Pennington, Shaun H.
   Hill, Andrew
   Boffito, Marta
   Ward, Stephen A.
   Khoo, Saye H.
   Bray, Patrick G.
   O'Neill, Paul M.
   Hong, W. Dave
   Biagini, Giancarlo
   Owen, Andrew
TI Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or
   chemoprophylaxis
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Early Access
DE coronavirus; COVID&#8208; 19; lung; pharmacokinetics; SARS&#8208;
   CoV&#8208; 2
ID TISSUE DISTRIBUTION; DOUBLE-BLIND; PHARMACOKINETICS; TIZOXANIDE; VIRUS;
   MODEL; HIV; ANTIRETROVIRALS; TRANSMISSION; TOLERABILITY
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a global pandemic and urgent treatment and prevention strategies are needed. Nitazoxanide, an anthelmintic drug, has been shown to exhibit in vitro activity against SARS-CoV-2. The present study used physiologically based pharmacokinetic (PBPK) modelling to inform optimal doses of nitazoxanide capable of maintaining plasma and lung tizoxanide exposures above the reported SARS-CoV-2 EC90.
   Methods A whole-body PBPK model was validated against available pharmacokinetic data for healthy individuals receiving single and multiple doses between 500 and 4000 mg with and without food. The validated model was used to predict doses expected to maintain tizoxanide plasma and lung concentrations above the EC90 in >90% of the simulated population. PopDes was used to estimate an optimal sparse sampling strategy for future clinical trials.
   Results The PBPK model was successfully validated against the reported human pharmacokinetics. The model predicted optimal doses of 1200 mg QID, 1600 mg TID and 2900 mg BID in the fasted state and 700 mg QID, 900 mg TID and 1400 mg BID when given with food. For BID regimens an optimal sparse sampling strategy of 0.25, 1, 3 and 12 hours post dose was estimated.
   Conclusion The PBPK model predicted tizoxanide concentrations within doses of nitazoxanide already given to humans previously. The reported dosing strategies provide a rational basis for design of clinical trials with nitazoxanide for the treatment or prevention of SARS-CoV-2 infection. A concordant higher dose of nitazoxanide is now planned for investigation in the seamless phase I/IIa AGILE trial.
C1 [Rajoli, Rajith K. R.; Pertinez, Henry; Arshad, Usman; Box, Helen; Tatham, Lee; Curley, Paul; Neary, Megan; Sharp, Joanne; Liptrott, Neill J.; Valentijn, Anthony; David, Christopher; Hill, Andrew; Khoo, Saye H.; Owen, Andrew] Univ Liverpool, Dept Mol & Clin Pharmacol, Mat Innovat Factory, 51 Oxford St, Liverpool L7 3NY, Merseyside, England.
   [Rannard, Steve P.; O'Neill, Paul M.; Hong, W. Dave] Univ Liverpool, Dept Chem, Liverpool, Merseyside, England.
   [Aljayyoussi, Ghaith; Pennington, Shaun H.; Ward, Stephen A.; Biagini, Giancarlo] Univ Liverpool Liverpool Sch Trop Med, Ctr Drugs & Diagnost, Liverpool, Merseyside, England.
   [Aljayyoussi, Ghaith; Pennington, Shaun H.; Ward, Stephen A.; Biagini, Giancarlo] Univ Liverpool Liverpool Sch Trop Med, Dept Trop Dis Biol, Liverpool, Merseyside, England.
   [Boffito, Marta] Chelsea & Westminster NHS Fdn Trust & St Stephens, Chelsea & Westminster Hosp, 4th Floor, London, England.
   [Boffito, Marta] Imperial Coll, Dept Med, Jefferiss Res Trust Labs, London, England.
   [Bray, Patrick G.] Pat Bray Elect, Orrell, Wigan, England.
RP Owen, A (corresponding author), Univ Liverpool, Dept Mol & Clin Pharmacol, Mat Innovat Factory, 51 Oxford St, Liverpool L7 3NY, Merseyside, England.
EM aowen@liverpool.ac.uk
RI ; Rajoli, Rajith Kumar Reddy/E-7974-2015
OI Arshad, Usman/0000-0003-1586-1885; Liptrott, Neill/0000-0002-5980-8966;
   Pennington, Shaun/0000-0002-7160-6275; Rajoli, Rajith Kumar
   Reddy/0000-0002-6015-5712
FU Medical Research CouncilMedical Research Council UK (MRC)
   [MR/S00467X/1]; European CommissionEuropean CommissionEuropean
   Commission Joint Research Centre [761104]; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [R24AI118397, R01AI134091]; EPSRCEngineering & Physical Sciences
   Research Council (EPSRC) [EP/S012265/1, EP/R024804/1]
FX Medical Research Council, Grant/Award Number: MR/S00467X/1; European
   Commission, Grant/Award Number: 761104; NIH, Grant/Award Numbers:
   R24AI118397, R01AI134091; EPSRC, Grant/Award Numbers: EP/S012265/1,
   EP/R024804/1
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Alexander SPH, 2020, BRIT J PHARMACOL, V177, P4942, DOI 10.1111/bph.15094
   Arshad U, 2020, CLIN PHARMACOL THER, V108, P775, DOI 10.1002/cpt.1909
   Belardo G, 2015, ANTIMICROB AGENTS CH, V59, P1061, DOI 10.1128/AAC.03947-14
   Bobrowski Tesia, 2020, bioRxiv, DOI 10.1101/2020.06.29.178889
   Boffito M, 2020, CLIN PHARMACOL THER, DOI 10.1002/cpt.2099
   Bosgra S, 2012, CRIT REV TOXICOL, V42, P751, DOI 10.3109/10408444.2012.709225
   Broekhuysen J, 2000, INT J CLIN PHARM TH, V38, P387
   Broliden K, 2010, J INFECT DIS, V202, pS351, DOI 10.1086/655964
   Cao JZ, 2015, ANTIVIR RES, V114, P1, DOI 10.1016/j.antiviral.2014.11.010
   Charlton RL, 2018, PARASITOLOGY, V145, P219, DOI 10.1017/S0031182017000993
   Chenel M, 2008, J PHARMACOKINET PHAR, V35, P635, DOI 10.1007/s10928-008-9104-6
   Clerici M, 2011, J IMMUNOL, V186
   Cottrell ML, 2015, EXPERT OPIN DRUG MET, V11, P893, DOI 10.1517/17425255.2015.1027682
   COVIDsurg Collaborative, 2020, LANCET, V396, P27, DOI 10.1016/S0140-6736(20)31182-X
   Dang W, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00707-18, 10.1128/aac.00707-18]
   Drugs.com, 2020, NIT
   Fryar CD, 2018, MEAN BODY WEIGHT HEI, V122
   Gertz M, 2010, DRUG METAB DISPOS, V38, P1147, DOI 10.1124/dmd.110.032649
   Giuseppe Belardo SLF, 2011, IDSA ANN M BOST MA U
   Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0
   Keiser J, 2010, ADV PARASIT, V73, P197, DOI 10.1016/S0065-308X(10)73008-6
   Korba BE, 2008, ANTIMICROB AGENTS CH, V52, P4069, DOI 10.1128/AAC.00078-08
   Korba BE, 2008, ANTIVIR RES, V77, P56, DOI 10.1016/j.antiviral.2007.08.005
   Koszalka P, 2017, INFLUENZA OTHER RESP, V11, P240, DOI 10.1111/irv.12446
   Machhi J, 2020, J NEUROIMMUNE PHARM, V15, P359, DOI 10.1007/s11481-020-09944-5
   Marcelin-Jimenez G, 2012, BIOANALYSIS, V4, P909, DOI [10.4155/BIO.12.41, 10.4155/bio.12.41]
   Marcellin F, 2008, TROP MED INT HEALTH, V13, P1470, DOI 10.1111/j.1365-3156.2008.02170.x
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538
   Miner K, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00051
   Nyberg J, 2015, BRIT J CLIN PHARMACO, V79, P6, DOI 10.1111/bcp.12352
   OpenData Portal, 2020, TIZ
   OpenData Portal, 2020, NIT
   Pepperrell T, 2020, J VIRUS ERAD, V6, P52
   Peters SA, 2008, CLIN PHARMACOKINET, V47, P261, DOI 10.2165/00003088-200847040-00004
   Pizzorno A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00531
   Rajoli RKR, 2019, J INFECT DIS, V219, P1735, DOI 10.1093/infdis/jiy726
   Rajoli RKR, 2015, CLIN PHARMACOKINET, V54, P639, DOI 10.1007/s40262-014-0227-1
   Ranjbar S, 2019, ISCIENCE, V22, P299, DOI 10.1016/j.isci.2019.11.001
   Rodgers T, 2005, J PHARM SCI-US, V94, P1259, DOI 10.1002/jps.20322
   Rodgers T, 2006, J PHARM SCI-US, V95, P1238, DOI 10.1002/jps.20502
   Rossignol JF, 2006, ALIMENT PHARM THERAP, V24, P1423, DOI 10.1111/j.1365-2036.2006.03128.x
   Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Schaefer IM, 2020, MODERN PATHOL, V33, P2104, DOI 10.1038/s41379-020-0595-z
   Senanayake S. L., 2020, FUTURE DRUG DISCOVER, V2, pFDD40, DOI [10.4155/fdd-2020-0010, DOI 10.4155/FDD-2020-0010]
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Sree GNSH, 2019, BIOMED PHARMACOTHER, V110, P700, DOI 10.1016/j.biopha.2018.11.127
   Stockis A, 2002, INT J CLIN PHARM TH, V40, P213
   Stockis A, 2002, INT J CLIN PHARM TH, V40, P221
   Sun DX, 2002, PHARMACEUT RES, V19, P1400, DOI 10.1023/A:1020483911355
   Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316
   Telleria Carlos M, 2012, J Cancer Sci Ther, V4, pix
   Tilmanis D, 2017, ANTIVIR RES, V147, P142, DOI 10.1016/j.antiviral.2017.10.002
   Toljan K, 2020, ACS CHEM NEUROSCI, V11, P1192, DOI 10.1021/acschemneuro.0c00174
   Trezza CR, 2014, CLIN PHARMACOKINET, V53, P611, DOI 10.1007/s40262-014-0148-z
   Venisse N, 2020, ANTIVIR RES, V181, DOI 10.1016/j.antiviral.2020.104866
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Williams L. R., 1994, REFERENCE VALUES TOT
   Wilson CM, 2012, PRINCIPLES PRACTICE, P1518
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yu LX, 1999, INT J PHARMACEUT, V186, P119, DOI 10.1016/S0378-5173(99)00147-7
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 67
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
DI 10.1111/bcp.14619
EA DEC 2020
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ0QQ
UT WOS:000594641800001
PM 33085781
OA Other Gold
DA 2021-01-01
ER

PT J
AU Quiles, JL
   Rivas-Garcia, L
   Varela-Lopez, A
   Llopis, J
   Battino, M
   Sanchez-Gonzalez, C
AF Quiles, Jose L.
   Rivas-Garcia, Lorenzo
   Varela-Lopez, Alfonso
   Llopis, Juan
   Battino, Maurizio
   Sanchez-Gonzalez, Cristina
TI Do nutrients and other bioactive molecules from foods have anything to
   say in the treatment against COVID-19?
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Curcumin; Polyphenols; Vitamin C; Vitamin D; Zinc
ID VITAMIN-D; NATURAL-PRODUCTS; OLIVE OIL; QUERCETIN; CURCUMIN;
   HYDROXYTYROSOL; VIRUS; ANTIOXIDANT; INHIBITION; INFECTION
AB The repositioning of therapeutic agents already approved by the regulatory agencies for the use of drugs is very interesting due to the immediacy of their use; similarly, the possibility of using molecules derived from foods, whether nutrients or not, is of great importance, also because of their immediate therapeutic applicability. Candidates for these natural therapies against COVID-19 should show certain effects, such as restoring mitochondria) function and cellular redox balance. This would allow reducing the susceptibility of risk groups and the cascade of events after SARS-CoV-2 infection, responsible for the clinical picture, triggered by the imbalance towards oxidation, inflammation, and cytokine storm. Possible strategies to follow through the use of substances of food origin would include: a) the promotion of mitophagy to remove dysfunctional mitochondria originating from free radicals, proton imbalance and virus evasion of the immune system; b) the administration of transition metals whose redox activity would lead to their own oxidation and the consequent generation of a reduced environment, which would normalize the oxidative state and the intracellular pH; c) the administration of molecules with demonstrated antioxidant capacity; d) the administration of compounds with anti-inflammatory and vasodilatory activity; e) the administration of immunomodulatory compounds.
C1 [Quiles, Jose L.; Rivas-Garcia, Lorenzo; Varela-Lopez, Alfonso; Llopis, Juan; Sanchez-Gonzalez, Cristina] Univ Granada, Fac Pharm, Biomed Res Ctr,Dept Physiol, Inst Nutr & Food Technol Jose Mataix Verdu, Avda Conocimiento S-n, Granada 18100, Spain.
   [Quiles, Jose L.] Northwest Univ, Coll Food Sci & Technol, Xian 710069, Peoples R China.
   [Rivas-Garcia, Lorenzo; Llopis, Juan; Sanchez-Gonzalez, Cristina] Univ Granada, Sport & Hlth Res Ctr, C Menendez Pelayo 32, Granada 18016, Spain.
   [Battino, Maurizio] Univ Politecn Marche, Dept Clin Sicences, I-60131 Ancona, Italy.
   [Battino, Maurizio] CACTICA Univ Vigo, Dept Analyt & Food Chem, CITACA, Nutr & Food Sci Grp, Vigo 36310, Spain.
   [Battino, Maurizio] Jiangsu Univ, Int Res Ctr Food Nutr & Safety, Zhenjiang 212013, Jiangsu, Peoples R China.
RP Quiles, JL (corresponding author), Univ Granada, Biomed Res Ctr, Avda Conocimiento S-N, Granada 18100, Spain.
EM jlquiles@ugr.es
OI /0000-0002-0413-8432
CR Adams KK, 2020, ANN PHARMACOTHER, V54, P820, DOI 10.1177/1060028020928052
   Anand David Alexander Victor, 2016, Pharmacogn Rev, V10, P84, DOI 10.4103/0973-7847.194044
   Aranow C, 2011, J INVEST MED, V59, P881, DOI 10.2310/JIM.0b013e31821b8755
   Arya A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1773929
   Bachmetov L, 2012, J VIRAL HEPATITIS, V19, pE81, DOI 10.1111/j.1365-2893.2011.01507.x
   Batiha GE, 2020, FOODS, V9, DOI 10.3390/foods9030374
   Bedoya LM, 2016, AIDS, V30, P2767, DOI 10.1097/QAD.0000000000001283
   Bielak-Zmijewska A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051239
   Bisignano G, 1999, J PHARM PHARMACOL, V51, P971, DOI 10.1211/0022357991773258
   Braga PC, 1997, DRUG EXP CLIN RES, V23, P33
   Carr AC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111211
   Chen L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041193
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   Cheng Richard Z, 2020, Med Drug Discov, V5, P100028, DOI 10.1016/j.medidd.2020.100028
   Biancatelli RMLC, 2020, EXPERT REV ANTI-INFE, V18, P99, DOI 10.1080/14787210.2020.1706483
   Costa-Pessoa Juliana Martins da, 2013, Eur J Pharmacol, V721, P322, DOI 10.1016/j.ejphar.2013.08.043
   Cure Erkan, 2020, Nephron, V144, P251, DOI 10.1159/000507786
   Cure E, 2020, DIABETES METAB SYND, V14, P349, DOI 10.1016/j.dsx.2020.04.019
   Cure E, 2020, J MED VIROL, V92, P1423, DOI 10.1002/jmv.25848
   D'Avolio A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051359
   Fan DS, 2011, FITOTERAPIA, V82, P805, DOI 10.1016/j.fitote.2011.04.007
   FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Giampieri F, 2019, ANTIOXID REDOX SIGN, V30, P577, DOI 10.1089/ars.2017.7234
   Glinsky GV, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050129
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Granados-Principal S, 2010, NUTR REV, V68, P191, DOI 10.1111/j.1753-4887.2010.00278.x
   Granger M, 2018, ADV FOOD NUTR RES, V83, P281, DOI 10.1016/bs.afnr.2017.11.006
   Haas R.H., 2019, BIOLOGY, P8, DOI [10.3390/biology8020048., DOI 10.3390/BIOLOGY8020048.]
   Hansdottir S, 2011, VITAM HORM, V86, P217, DOI 10.1016/B978-0-12-386960-9.00009-5
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Hemila H, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000980.pub4
   Henson D, 2008, INT J SPORTS MED, V29, P856, DOI 10.1055/s-2007-989424
   Hoang BX, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109866
   Holick MF, 2017, REV ENDOCR METAB DIS, V18, P153, DOI 10.1007/s11154-017-9424-1
   Horne JR, 2020, AM J PHYSIOL-ENDOC M, V318, pE830, DOI 10.1152/ajpendo.00150.2020
   Ibs KH, 2003, J NUTR, V133, p1452S, DOI 10.1093/jn/133.5.1452S
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Jayawardena R, 2020, DIABETES METAB SYND, V14, P367, DOI 10.1016/j.dsx.2020.04.015
   Johari J, 2012, INT J MOL SCI, V13, P16785, DOI 10.3390/ijms131216785
   Killeen MJ, 2014, DRUG DISCOV TODAY, V19, P373, DOI 10.1016/j.drudis.2013.11.002
   Komukai K, 2010, FUND CLIN PHARMACOL, V24, P687, DOI 10.1111/j.1472-8206.2010.00854.x
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lelis DD, 2019, METABOLISM, V95, P36, DOI 10.1016/j.metabol.2019.03.006
   Li Y, 2016, INFLAMMATION IMMUNIT, V8, P167, DOI DOI 10.3390/NU8030167
   Liu Y, 2017, APOPTOSIS, V22, P544, DOI 10.1007/s10495-016-1334-2
   Liu YN, 2019, J COLLOID INTERF SCI, V552, P388, DOI 10.1016/j.jcis.2019.05.066
   Liu Z.-H., 2015, INT J CLIN EXP PATHO, V8
   Malavolta M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040909
   Moran CS, 2017, ARTERIOSCL THROM VAS, V37, P2195, DOI 10.1161/ATVBAHA.117.310129
   Mounce BC, 2017, ANTIVIR RES, V142, P148, DOI 10.1016/j.antiviral.2017.03.014
   Navarro S, 2017, THORAX, V72, P451, DOI 10.1136/thoraxjnl-2016-208964
   Nehme A, 2019, J CARDIOVASC DEV DIS, V6, DOI 10.3390/jcdd6020014
   Nelson KM, 2017, J MED CHEM, V60, P1620, DOI 10.1021/acs.jmedchem.6b00975
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Nieman DC, 2007, MED SCI SPORT EXER, V39, P1561, DOI 10.1249/mss.0b013e318076b566
   O'Dowd Y, 2004, BIOCHEM PHARMACOL, V68, P2003, DOI 10.1016/j.bcp.2004.06.023
   Andrade JMO, 2014, PEPTIDES, V55, P158, DOI 10.1016/j.peptides.2014.03.006
   Padayatty SJ, 2000, AM J CLIN NUTR, V71, P1027
   Pang XF, 2015, DRUG DES DEV THER, V9, P6043, DOI 10.2147/DDDT.S95333
   Pineda-Ramirez N, 2020, MOL NEUROBIOL, V57, P1055, DOI 10.1007/s12035-019-01803-6
   Prasad S, 2015, FOOD FUNCT, V6, P3412, DOI [10.1039/c5fo00485c, 10.1039/C5FO00485C]
   Punithavathi D, 2000, BRIT J PHARMACOL, V131, P169, DOI 10.1038/sj.bjp.0703578
   Quiles JL, 2020, ANTIOXID REDOX SIGN, V33, P860, DOI 10.1089/ars.2020.8051
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Raharusun P., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3585561, DOI 10.2139/SSRN.3585561]
   Rambold AS, 2018, TRENDS IMMUNOL, V39, P6, DOI 10.1016/j.it.2017.08.006
   RESNICK LM, 1987, P NATL ACAD SCI USA, V84, P7663, DOI 10.1073/pnas.84.21.7663
   Ribeiro-Oliveira A, 2008, VASC HEALTH RISK MAN, V4, P787
   Robles-Almazan M, 2018, FOOD RES INT, V105, P654, DOI 10.1016/j.foodres.2017.11.053
   Roy A, 2020, PHYTOTHER RES, V34, P2425, DOI 10.1002/ptr.6766
   Santini A, 2018, BRIT J CLIN PHARMACO, V84, P659, DOI 10.1111/bcp.13496
   Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001
   Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   Song JH, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-460
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tiao MM, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-018-0824-3
   Utomo R. Y., 2020, REVEALING POTENCY CI, DOI [10.20944/preprints202003.0214.v1, DOI 10.20944/PREPRINTS202003.0214.V1, 10.20944/preprints202003.0214.v1.]
   Velthuis AJWT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001176
   Vera-Ramirez L, 2013, BIOFACTORS, V39, P88, DOI 10.1002/biof.1057
   Visioli F, 1998, BIOCHEM BIOPH RES CO, V247, P60, DOI 10.1006/bbrc.1998.8735
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang ZP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040920
   Xu D, 2019, MOLECULES, V24, DOI 10.3390/molecules24061123
   Xu J, 2017, MOL MED REP, V16, P7432, DOI 10.3892/mmr.2017.7546
   XUE J, 2014, PLOS ONE, V9, P1, DOI DOI 10.1371/JOURNAL.PONE.0109180.
   Yamada K, 2009, ANTIVIR RES, V83, P35, DOI 10.1016/j.antiviral.2009.03.002
   Yan C, 2018, ANTICANCER RES, V38, P617, DOI 10.21873/anticanres.12266
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Zabetakis I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051466
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zoric N, 2013, CURR DRUG TARGETS, V14, P992, DOI 10.2174/13894501113149990167
   Zwane RE, 2012, J AGR FOOD CHEM, V60, P11509, DOI 10.1021/jf300883h
NR 96
TC 2
Z9 2
U1 5
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD DEC
PY 2020
VL 191
AR 110053
DI 10.1016/j.envres.2020.110053
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OP3GW
UT WOS:000587971600040
PM 32835682
OA Green Published
DA 2021-01-01
ER

PT J
AU Jermain, B
   Hanafin, PO
   Cao, YG
   Lifschitz, A
   Lanusse, C
   Rao, GG
AF Jermain, Brian
   Hanafin, Patrick O.
   Cao, Yanguang
   Lifschitz, Adrian
   Lanusse, Carlos
   Rao, Gauri G.
TI Development of a Minimal Physiologically-Based Pharmacokinetic Model to
   Simulate Lung Exposure in Humans Following Oral Administration of
   Ivermectin for COVID-19 Drug Repurposing
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE COVID-19; Importins; Ivermectin; Minimal physiologically-based
   pharmacokinetic model; SARS-CoV-2; Pharmacokinetics; Pharmacometrics;
   Physiologically based pharmacokinetic modeling; Kinetics
   Pharmacokinetics pharmacodynamic (PK/PD) modeling
ID FUNCTIONAL RECEPTOR; PROTEIN; LOCALIZATION; CORONAVIRUS; INHIBITOR;
   TRANSPORT
AB SARS-CoV-2 utilizes the IMP alpha/beta 1 heterodimer to enter host cell nuclei after gaining cellular access through the ACE2 receptor. Ivermectin has shown antiviral activity by inhibiting the formation of the importin-alpha (IMP alpha) and IMP alpha/beta 1 subunits as well as dissociating the IMP alpha/beta 1 heterodimer and has in vitro efficacy against SARS-CoV-2. Plasma and lung ivermectin concentrations vs. time profiles in cattle were used to determine the apparent plasma to lung tissue partition coefficient of ivermectin. This coefficient, together with a simulated geometric mean plasma profile of ivermectin from a published population pharmacokinetic model, was utilized to develop a minimal physiologically-based pharmacokinetic (mPBPK) model. The mPBPK model accurately described the simulated ivermectin plasma concentration profile in humans. The mPBPK model was also used to simulate human lung exposure to ivermectin after 12, 30, and 120 mg oral doses. The simulated ivermectin lung exposures reached a maximum concen-tration of 772 ng/mL, far less than the estimated 1750 ng/mL IC50 reported for ivermectin against SARS-CoV-2 in vitro. Further studies of ivermectin either reformulated for inhaled delivery or in combination with other antivirals with differing mechanisms of action is needed to assess its therapeutic potential. (C) 2020 Published by Elsevier Inc. on behalf of the American Pharmacists Association.
C1 [Jermain, Brian; Hanafin, Patrick O.; Cao, Yanguang; Rao, Gauri G.] Univ N Carolina, Eshelman Sch Pharm, Div Pharmaceut & Expt Therapeut, Chapel Hill, NC 27599 USA.
   [Lifschitz, Adrian; Lanusse, Carlos] UNCPBA, Ctr Invest Vet Tandil CIVETAN, Fac Ciencias Vet, Lab Farmacol,UNCPBA CICPBA CONICET, Tandil, Argentina.
RP Rao, GG (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
EM gaurirao@live.unc.edu
FU CONICET (Argentina)Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET); Universidad Nacional del Centro (Argentina); Agencia
   Nacional de Promocion Cientifica y Tecnologica ArgentinaANPCyT [PICT
   08-00000-00817]
FX The study performed by Lifschitz and colleagues was partially supported
   by CONICET (Argentina), Universidad Nacional del Centro (Argentina), and
   Agencia Nacional de Promocion Cientifica y Tecnologica (PICT
   08-00000-00817) Argentina.
CR Bassissi MF, 2004, COMP BIOCHEM PHYS C, V138, P437, DOI 10.1016/j.cca.2004.07.011
   Boer F, 2003, BRIT J ANAESTH, V91, P50, DOI 10.1093/bja/aeg117
   Boron WF, 2016, MED PHYSL E BOOK
   Bray M, 2020, ANTIVIR RES, V178
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Canga AG, 2008, AAPS J, V10, P42, DOI 10.1208/s12248-007-9000-9
   Cao YG, 2012, J PHARMACOKINET PHAR, V39, P711, DOI 10.1007/s10928-012-9280-2
   Crump A, 2017, J ANTIBIOT, V70, P495, DOI 10.1038/ja.2017.11
   El-Tahtawy A, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000236
   Guzzo CA, 2002, J CLIN PHARMACOL, V42, P1122, DOI 10.1177/009127002401382731
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hiscox JA, 2001, J VIROL, V75, P506, DOI 10.1128/JVI.75.1.506-512.2001
   Jans DA, 2019, CURR OPIN CELL BIOL, V58, P50, DOI 10.1016/j.ceb.2019.01.001
   Jones HM, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.41
   KLOTZ U, 1990, EUR J CLIN PHARMACOL, V39, P607, DOI 10.1007/BF00316107
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lifschitz A, 2000, VET PARASITOL, V87, P327, DOI 10.1016/S0304-4017(99)00175-2
   Molina DK, 2012, AM J FOREN MED PATH, V33, P368, DOI 10.1097/PAF.0b013e31823d29ad
   Schmith VD, 2020, CLIN PHARM THER, DOI 10.1002/cpt.1889
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Timani KA, 2005, VIRUS RES, V114, P23, DOI 10.1016/j.virusres.2005.05.007
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wulan WN, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00553
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD DEC
PY 2020
VL 109
IS 12
BP 3574
EP 3578
DI 10.1016/j.xphs.2020.08.024
PG 5
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA OS8KF
UT WOS:000590406100007
PM 32891630
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pablos, JL
   Galindo, M
   Carmona, L
   Lled, A
   Retuerto, M
   Blanco, R
   Gonzalez-Gay, MA
   Martinez-Lopez, D
   Castrejon, I
   Alvaro-Gracia, JM
   Fernandez, DF
   Mera-Varela, A
   Manrique-Arija, S
   Vazquez, NM
   Fernandez-Nebro, A
AF Pablos, Jose L.
   Galindo, Maria
   Carmona, Loreto
   Lled, Ana
   Retuerto, Miriam
   Blanco, Ricardo
   Gonzalez-Gay, Miguel A.
   Martinez-Lopez, David
   Castrejon, Isabel
   Alvaro-Gracia, Jose M.
   Fernandez Fernandez, David
   Mera-Varela, Antonio
   Manrique-Arija, Sara
   Mena Vazquez, Natalia
   Fernandez-Nebro, Antonio
CA RIER Investigators Grp
TI Clinical outcomes of hospitalised patients with COVID-19 and chronic
   inflammatory and autoimmune rheumatic diseases: a multicentric matched
   cohort study
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
AB Objectives The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with a matched control cohort to identify potential risk factors for severe illness.
   Methods In this comparative cohort study, we identified hospital PCR+COVID-19 rheumatic patients with chronic inflammatory arthritis (IA) or connective tissue diseases (CTDs). Non-rheumatic controls were randomly sampled 1:1 and matched by age, sex and PCR date. The main outcome was severe COVID-19, defined as death, invasive ventilation, intensive care unit admission or serious complications. We assessed the association between the outcome and the potential prognostic variables, adjusted by COVID-19 treatment, using logistic regression.
   Results The cohorts were composed of 456 rheumatic and non-rheumatic patients, in equal numbers. Mean age was 63 (IQR 53-78) years and male sex 41% in both cohorts. Rheumatic diseases were IA (60%) and CTD (40%). Most patients (74%) had been hospitalised, and the risk of severe COVID-19 was 31.6% in the rheumatic and 28.1% in the non-rheumatic cohort. Ageing, male sex and previous comorbidity (obesity, diabetes, hypertension, cardiovascular or lung disease) increased the risk in the rheumatic cohort by bivariate analysis. In logistic regression analysis, independent factors associated with severe COVID-19 were increased age (OR 4.83; 95% CI 2.78 to 8.36), male sex (1.93; CI 1.21 to 3.07) and having a CTD (OR 1.82; CI 1.00 to 3.30).
   Conclusion In hospitalised patients with chronic inflammatory rheumatic diseases, having a CTD but not IA nor previous immunosuppressive therapies was associated with severe COVID-19.
C1 [Pablos, Jose L.; Galindo, Maria; Lled, Ana; Retuerto, Miriam] Inst Invest Hosp 12 Octubre, Serv Reumatol, Madrid 28040, Spain.
   [Pablos, Jose L.] Univ Complutense Madrid, Madrid, Spain.
   [Carmona, Loreto] Inst Salud Musculoesquelet INMUSC, Madrid, Spain.
   [Blanco, Ricardo; Gonzalez-Gay, Miguel A.; Martinez-Lopez, David] Hosp Univ Marques Valdecilla IDIVAL, Serv Reumatol, Santander, Spain.
   [Castrejon, Isabel; Alvaro-Gracia, Jose M.] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Serv Reumatol, Madrid, Spain.
   [Fernandez Fernandez, David; Mera-Varela, Antonio] Hosp Clin Univ Santiago, Inst Invest Sanitaria Santiago IDIS, Serv Reumatol, Santiago De Compostela, Spain.
   [Manrique-Arija, Sara; Mena Vazquez, Natalia; Fernandez-Nebro, Antonio] Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, UGC Reumatol, Malaga, Spain.
RP Pablos, JL (corresponding author), Inst Invest Hosp 12 Octubre, Serv Reumatol, Madrid 28040, Spain.
EM jlpablos@h12o.es
RI Castrejon, Isabel/ABH-5293-2020; Gonzalez, Antonio/C-4444-2008; VARELA,
   ANTONIO MERA/ABH-1886-2020; Fernandez, David Fernandez/AAW-3710-2020;
   Gonzalez-Gay, Miguel/B-2306-2008; Blanco Garcia, Francisco J/C-3192-2014
OI Gonzalez, Antonio/0000-0002-2624-0606; VARELA, ANTONIO
   MERA/0000-0001-9380-6975; Fernandez, David
   Fernandez/0000-0003-4590-7821; Gonzalez-Gay, Miguel/0000-0002-7924-7406;
   Blanco Garcia, Francisco J/0000-0001-9821-7635; Pablos, Jose
   L./0000-0001-7229-6005; Blanco, Ricardo/0000-0003-2344-2285
FU Fondo de Investigacion Sanitaria, Instituto de Salud Carlos IIIInstituto
   de Salud Carlos III [RD16/0012]; European Regional Development Fund
   (FEDER)European Union (EU)
FX The RIER network was supported by the Fondo de Investigacion Sanitaria,
   Instituto de Salud Carlos III (RD16/0012 RETICS program) and cofinanced
   by the European Regional Development Fund (FEDER).
CR Brenner EJ, 2020, GASTROENTEROLOGY
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cherkassky V, 2003, NEURAL COMPUT, V15, P1691, DOI 10.1162/089976603321891864
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   D'Silva KM, 2020, ANN RHEUM DIS, V79, P1156, DOI [10.1136/annrheumdis-2020-217888, 10.1136/annrheumdis-2020-218196, 10.1136/annrheumdis-2020-218179, 10.1136/annrheumdis-2020-218431]
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fredi M, 2020, LANCET RHEUMATOL
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL
   Pablos JL, 2020, ANN RHEUM DIS, V79, P1544, DOI [10.1136/annrheumdis-2020-217763, 10.1136/annrheumdis-2020-218296]
   Shoenfeld Y, 2005, CIRCULATION, V112, P3337, DOI 10.1161/CIRCULATIONAHA.104.507996
   Sidiropoulos PI, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2397
   Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140-6736(14)61704-9
   Stranieri A, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9100852
   ter Horst R, 2016, CELL, V167, P1111, DOI 10.1016/j.cell.2016.10.018
   Travi G, 2020, AM J TRANSPLANT, V20, P2628, DOI 10.1111/ajt.16069
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Vallejo AN, 2004, TRENDS MOL MED, V10, P119, DOI 10.1016/j.molmed.2004.01.002
   Wong KK, 2007, ONCOGENE, V26, P2815, DOI 10.1038/sj.onc.1210099
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 24
TC 10
Z9 10
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD DEC
PY 2020
VL 79
IS 12
BP 1544
EP 1549
DI 10.1136/annrheumdis-2020-218296
PG 6
WC Rheumatology
SC Rheumatology
GA OU4VU
UT WOS:000591528700017
PM 32796045
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, G
   Yang, ML
   Duan, ZL
   Liu, FL
   Jin, L
   Long, CB
   Zhang, M
   Tang, XP
   Xu, L
   Li, YC
   Kamau, PM
   Yang, L
   Liu, HQ
   Xu, JW
   Chen, JK
   Zheng, YT
   Peng, XZ
   Lai, R
AF Wang, Gan
   Yang, Meng-Li
   Duan, Zi-Lei
   Liu, Feng-Liang
   Jin, Lin
   Long, Cheng-Bo
   Zhang, Min
   Tang, Xiao-Peng
   Xu, Ling
   Li, Ying-Chang
   Kamau, Peter Muiruri
   Yang, Lian
   Liu, Hong-Qi
   Xu, Jing-Wen
   Chen, Jie-Kai
   Zheng, Yong-Tang
   Peng, Xiao-Zhong
   Lai, Ren
TI Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike
   protein and is effective in inhibiting SARS-CoV-2 infection in animal
   models
SO CELL RESEARCH
LA English
DT Article; Early Access
ID SARS; ENTRY; MERS
AB Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic worldwide. Currently, however, no effective drug or vaccine is available to treat or prevent the resulting coronavirus disease 2019 (COVID-19). Here, we report our discovery of a promising anti-COVID-19 drug candidate, the lipoglycopeptide antibiotic dalbavancin, based on virtual screening of the FDA-approved peptide drug library combined with in vitro and in vivo functional antiviral assays. Our results showed that dalbavancin directly binds to human angiotensin-converting enzyme 2 (ACE2) with high affinity, thereby blocking its interaction with the SARS-CoV-2 spike protein. Furthermore, dalbavancin effectively prevents SARS-CoV-2 replication in Vero E6 cells with an EC50 of similar to 12 nM. In both mouse and rhesus macaque models, viral replication and histopathological injuries caused by SARS-CoV-2 infection are significantly inhibited by dalbavancin administration. Given its high safety and long plasma half-life (8-10 days) shown in previous clinical trials, our data indicate that dalbavancin is a promising anti-COVID-19 drug candidate.
C1 [Wang, Gan; Duan, Zi-Lei; Liu, Feng-Liang; Jin, Lin; Long, Cheng-Bo; Zhang, Min; Tang, Xiao-Peng; Xu, Ling; Li, Ying-Chang; Kamau, Peter Muiruri; Zheng, Yong-Tang; Lai, Ren] Chinese Acad Sci, Kunming Primate Res Ctr, Key Lab Anim Models & Human Dis Mech,Natl Resourc, Key Lab Bioact Peptides Yunnan Prov,KIZ CUHK Join, Kunming 650107, Yunnan, Peoples R China.
   [Wang, Gan; Duan, Zi-Lei; Liu, Feng-Liang; Jin, Lin; Long, Cheng-Bo; Zhang, Min; Tang, Xiao-Peng; Xu, Ling; Li, Ying-Chang; Kamau, Peter Muiruri; Zheng, Yong-Tang; Lai, Ren] Kunming Inst Zool, Natl Res Facil Phenotyp & Genet Anal Model Anim P, Kunming 650107, Yunnan, Peoples R China.
   [Yang, Meng-Li; Liu, Hong-Qi; Xu, Jing-Wen; Peng, Xiao-Zhong] Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Biol, Kunming 650031, Yunnan, Peoples R China.
   [Zhang, Min; Kamau, Peter Muiruri] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Tang, Xiao-Peng; Kamau, Peter Muiruri; Lai, Ren] Chinese Acad Sci, Sino African Joint Res Ctr, Wuhan 430074, Hubei, Peoples R China.
   [Yang, Lian] Chinese Acad Sci, Kunming Inst Bot, Kunming 650201, Yunnan, Peoples R China.
   [Chen, Jie-Kai] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou 510530, Guangdong, Peoples R China.
   [Zheng, Yong-Tang; Lai, Ren] Chinese Acad Sci, Ctr Biosafety Megasci, Kunming Natl High Level Biosafety Res Ctr Nonhuma, Kunming Inst Zool, Kunming 650107, Yunnan, Peoples R China.
   [Lai, Ren] Chinese Acad Sci, Inst Drug Discovery & Dev, Shanghai 201203, Peoples R China.
RP Zheng, YT; Lai, R (corresponding author), Chinese Acad Sci, Kunming Primate Res Ctr, Key Lab Anim Models & Human Dis Mech,Natl Resourc, Key Lab Bioact Peptides Yunnan Prov,KIZ CUHK Join, Kunming 650107, Yunnan, Peoples R China.; Zheng, YT; Lai, R (corresponding author), Kunming Inst Zool, Natl Res Facil Phenotyp & Genet Anal Model Anim P, Kunming 650107, Yunnan, Peoples R China.; Peng, XZ (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Biol, Kunming 650031, Yunnan, Peoples R China.; Lai, R (corresponding author), Chinese Acad Sci, Sino African Joint Res Ctr, Wuhan 430074, Hubei, Peoples R China.; Zheng, YT; Lai, R (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Kunming Natl High Level Biosafety Res Ctr Nonhuma, Kunming Inst Zool, Kunming 650107, Yunnan, Peoples R China.; Lai, R (corresponding author), Chinese Acad Sci, Inst Drug Discovery & Dev, Shanghai 201203, Peoples R China.
EM zhengyt@mail.kiz.ac.cn; pengxiaozhong@pumc.edu.cn; rlai@mail.kiz.ac.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81903666, 21761142002, 31600721, 31930015];
   Chinese Academy of SciencesChinese Academy of Sciences [SAJC201606,
   ZSTH-034]; National Key Research and Development Program of China
   [2020YFC0842000]; Science and Technology Department of Yunnan Province
   [2019ZF003, 2019FB103]; Department of Industry and Information
   Technology of Yunnan Province [2019-YT-053]
FX We thank Minghua Li, Chao Liu, Yuhua Ma, Baojian Han, and Xiang Yang in
   Kunming National High-level Biosafety Research Center for Non-human
   Primates for technical advice and assistance. We thank Dr. Lin Zeng for
   technical advice and assistance with the LC-MS/MS spectrum analysis.
   This work was supported by fundings from the National Natural Science
   Foundation of China (81903666, 21761142002, 31600721, and 31930015),
   Chinese Academy of Sciences (SAJC201606 and ZSTH-034), the National Key
   Research and Development Program of China (2020YFC0842000), Science and
   Technology Department of Yunnan Province (2019ZF003 and 2019FB103), and
   Department of Industry and Information Technology of Yunnan Province
   (2019-YT-053).
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Andes D, 2007, ANTIMICROB AGENTS CH, V51, P1633, DOI 10.1128/AAC.01264-06
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Boucher HW, 2014, NEW ENGL J MED, V370, P2169, DOI 10.1056/NEJMoa1310480
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Cheng H, 2020, J MED VIROL, V92, P726, DOI [10.1002/jmv.25785, 10.2112/JCR-SI112-001.1]
   Dash RP, 2017, INFECT DIS-NOR, V49, P483, DOI 10.1080/23744235.2017.1296968
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1610
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Neerukonda SN, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9060426
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Shan C, 2020, CELL RES, V30, P670, DOI 10.1038/s41422-020-0364-z
   Shen CB, 2020, BLOOD, V136, P974, DOI 10.1182/blood.2019002314
   Sriram K, 2020, CLIN PHARMACOL THER, V108, P236, DOI 10.1002/cpt.1863
   Tirado-Rives J, 2006, J MED CHEM, V49, P5880, DOI 10.1021/jm060763i
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang XH, 2020, RESEARCH-CHINA, V2020, DOI 10.34133/2020/2402961
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu L, 2020, ZOOL RES, V41, P517, DOI 10.24272/j.issn.2095-8137.2020.053
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 38
TC 0
Z9 0
U1 2
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
DI 10.1038/s41422-020-00450-0
EA DEC 2020
PG 8
WC Cell Biology
SC Cell Biology
GA PA1OP
UT WOS:000595392700004
PM 33262453
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Blasiak, A
   Lim, JJ
   Seah, SGK
   Kee, T
   Remus, A
   Chye, D
   Wong, PS
   Hooi, L
   Truong, ATL
   Le, N
   Chan, CEZ
   Desai, R
   Ding, XT
   Hanson, BJ
   Chow, EKH
   Ho, D
AF Blasiak, Agata
   Lim, Jhin Jieh
   Seah, Shirley Gek Kheng
   Kee, Theodore
   Remus, Alexandria
   Chye, De Hoe
   Wong, Pui San
   Hooi, Lissa
   Truong, Anh T. L.
   Le, Nguyen
   Chan, Conrad E. Z.
   Desai, Rishi
   Ding, Xianting
   Hanson, Brendon J.
   Chow, Edward Kai-Hua
   Ho, Dean
TI IDentif.AI: Rapidly optimizing combination therapy design against severe
   Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug
   development
SO BIOENGINEERING & TRANSLATIONAL MEDICINE
LA English
DT Article; Early Access
DE artificial intelligence; combinatory treatment; COVID&#8208; 19; digital
   medicine; drug development; drug interactions; SARS&#8208; CoV&#8208; 2
ID CLINICAL PHARMACOKINETICS; OSELTAMIVIR; RITONAVIR; INHIBIT; OBESE
AB The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to multiple drug repurposing clinical trials that have yielded largely uncertain outcomes. To overcome this challenge, we used IDentif.AI, a platform that pairs experimental validation with artificial intelligence (AI) and digital drug development to rapidly pinpoint unpredictable drug interactions and optimize infectious disease combination therapy design with clinically relevant dosages. IDentif.AI was paired with a 12-drug candidate therapy set representing over 530,000 drug combinations against the SARS-CoV-2 live virus collected from a patient sample. IDentif.AI pinpointed the optimal combination as remdesivir, ritonavir, and lopinavir, which was experimentally validated to mediate a 6.5-fold enhanced efficacy over remdesivir alone. Additionally, it showed hydroxychloroquine and azithromycin to be relatively ineffective. The study was completed within 2 weeks, with a three-order of magnitude reduction in the number of tests needed. IDentif.AI independently mirrored clinical trial outcomes to date without any data from these trials. The robustness of this digital drug development approach paired with in vitro experimentation and AI-driven optimization suggests that IDentif.AI may be clinically actionable toward current and future outbreaks.
C1 [Blasiak, Agata; Kee, Theodore; Remus, Alexandria; Truong, Anh T. L.; Le, Nguyen; Chow, Edward Kai-Hua; Ho, Dean] Natl Univ Singapore, Inst Hlth N1 N1, Singapore 117456, Singapore.
   [Blasiak, Agata; Kee, Theodore; Remus, Alexandria; Truong, Anh T. L.; Le, Nguyen; Chow, Edward Kai-Hua; Ho, Dean] Natl Univ Singapore, Inst Digital Med WisDM, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Blasiak, Agata; Kee, Theodore; Remus, Alexandria; Truong, Anh T. L.; Le, Nguyen; Chow, Edward Kai-Hua; Ho, Dean] Natl Univ Singapore, Dept Biomed Engn, NUS Engn, Singapore, Singapore.
   [Lim, Jhin Jieh; Hooi, Lissa; Chow, Edward Kai-Hua] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.
   [Seah, Shirley Gek Kheng; Chye, De Hoe; Wong, Pui San; Chan, Conrad E. Z.; Hanson, Brendon J.] DSO Natl Labs, Def Med & Environm Res Inst, Singapore 117510, Singapore.
   [Desai, Rishi] Osmosis, Baltimore, MD USA.
   [Ding, Xianting] Shanghai Jiao Tong Univ, Inst Personalized Med, Sch Biomed Engn, Shanghai 200030, Peoples R China.
   [Chow, Edward Kai-Hua; Ho, Dean] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore.
RP Chow, EKH; Ho, D (corresponding author), Natl Univ Singapore, Inst Hlth N1 N1, Singapore 117456, Singapore.; Hanson, BJ (corresponding author), DSO Natl Labs, Def Med & Environm Res Inst, Singapore 117510, Singapore.; Ding, XT (corresponding author), Shanghai Jiao Tong Univ, Inst Personalized Med, Sch Biomed Engn, Shanghai 200030, Peoples R China.
EM dingxianting@sjtu.edu.cn; hbrendon@dso.org.sg; csikce@nus.edu.sg;
   biedh@nus.edu.sg
FU Future Systems and Technology Directorate, Singapore Ministry of
   Defence; Ministry of Education Tier 1 FRC Grant - Singapore; National
   Key Research and Development Program of China [2017ZX10203205];
   Singapore Ministry of Health's National Medical Research CouncilNational
   Medical Research Council, Singapore [MOH-OFLCG18May-0023,
   MOH-OFLCG18May-0028]; National Research Foundation SingaporeSingapore
   National Research Foundation [AISG-GC-2019-002, NRF-CRP-2017-05];
   National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81871448]; Ministry of Education Academic Research Fund
   [MOE2019-T2-1-115]; Sun Life Singapore; Micron Foundation
FX Future Systems and Technology Directorate, Singapore Ministry of
   Defence; Ministry of Education Tier 1 FRC Grant - Singapore; National
   Key Research and Development Program of China, Grant/Award Number:
   2017ZX10203205; Singapore Ministry of Health's National Medical Research
   Council, Grant/Award Numbers: MOH-OFLCG18May-0023, MOH-OFLCG18May-0028;
   National Research Foundation Singapore, Grant/Award Numbers:
   AISG-GC-2019-002, NRF-CRP-2017-05; National Science Foundation of China,
   Grant/Award Number: 81871448; Ministry of Education Academic Research
   Fund, Grant/Award Number: MOE2019-T2-1-115; Sun Life Singapore; Micron
   Foundation
CR Abdulla A, 2020, ADV THER-GERMANY, V3, DOI 10.1002/adtp.202000034
   Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Al-Shyoukh I, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-88
   Andrighetti-Frohner CR, 2003, MEM I OSWALDO CRUZ, V98, P843, DOI 10.1590/S0074-02762003000600023
   [Anonymous], 2020, REMD SUMM COMP US
   [Anonymous], 2017, PLAQ LAB
   [Anonymous], 2018, COZ HIGHL PRESCR INF
   [Anonymous], 2013, ZITHR LAB
   [Anonymous], 2011, AV REV REP
   [Anonymous], 2019, NATURE, V567, P283, DOI [10.1038/d41586-019-00874-830894740, DOI 10.1038/D41586-019-00874-8]
   [Anonymous], 2019, HEM HIGHL PRESCR INF
   [Anonymous], 2005, NORV EUR PUBL ASS RE
   [Anonymous], 2016, TAM HIGHL PRESCR INF
   [Anonymous], 2019, NORV EUR PUBL ASS RE
   Breilh D, 2009, ALIMENT PHARM THER, V30, P487, DOI 10.1111/j.1365-2036.2009.04065.x
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Damle B, 2020, CLIN PHARMACOL THER, V108, P201, DOI 10.1002/cpt.1857
   de Mel S, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0276-7
   DYKHUIZEN RS, 1995, ANTIMICROB AGENTS CH, V39, P1842, DOI 10.1128/AAC.39.8.1842
   Farrance Ian, 2012, Clin Biochem Rev, V33, P49
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Ho Dean, 2020, Adv Intell Syst, P2000070, DOI 10.1002/aisy.202000070
   Ho D, 2020, SCIENCE, V367, P982, DOI 10.1126/science.aaz3023
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, DOI 10.1056/NEJM0A2021436]
   Hsu A, 1998, CLIN PHARMACOKINET, V35, P275, DOI 10.2165/00003088-199835040-00002
   Jittamala P, 2014, ANTIMICROB AGENTS CH, V58, P1615, DOI 10.1128/AAC.01786-13
   Kuwajima K, 2019, J INTENSIVE CARE, V7, DOI 10.1186/s40560-019-0365-5
   la Porte CJL, 2004, ANTIMICROB AGENTS CH, V48, P1553, DOI 10.1128/AAC.48.5.1553-1560.2004
   Lim JJ, 2020, ADV THER-GERMANY, V3, DOI 10.1002/adtp.201900122
   Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7
   Mattern J, 2007, CANCER BIOL THER, V6, P1345, DOI 10.4161/cbt.6.9.4765
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Nah SY, 2014, INFECT CHEMOTHER, V46, P35, DOI 10.3947/ic.2014.46.1.35
   NIH, CONS CERT CONC MED P
   NIH, NIH CLIN TRIAL SHOWS
   OHTAWA M, 1993, BRIT J CLIN PHARMACO, V35, P290, DOI 10.1111/j.1365-2125.1993.tb05696.x
   Pai MP, 2011, ANTIMICROB AGENTS CH, V55, P5640, DOI 10.1128/AAC.00422-11
   Pantuck AJ, 2018, ADV THER-GERMANY, V1, DOI 10.1002/adtp.201800104
   Pereira D, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1530-0
   Rashid MBMA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan0941
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   SHEA KW, 1995, MED CLIN N AM, V79, P833, DOI 10.1016/S0025-7125(16)30042-6
   Sica DA, 2005, CLIN PHARMACOKINET, V44, P797, DOI 10.2165/00003088-200544080-00003
   Silva A, 2016, P NATL ACAD SCI USA, V113, pE2172, DOI 10.1073/pnas.1600812113
   Tekin E, 2016, J R SOC INTERFACE, V13, P119
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xu HQ, 2014, STAT SINICA, V24, P269, DOI 10.5705/ss.2012.210
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zarrinpar A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac5954
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zhang MY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42160-7
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zimmer A, 2016, P NATL ACAD SCI USA, V113, P10442, DOI 10.1073/pnas.1606301113
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 60
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2380-6761
J9 BIOENG TRANSL MED
JI Bioeng. Transl. Med.
AR e10196
DI 10.1002/btm2.10196
EA DEC 2020
PG 16
WC Biotechnology & Applied Microbiology; Engineering, Biomedical;
   Pharmacology & Pharmacy
SC Biotechnology & Applied Microbiology; Engineering; Pharmacology &
   Pharmacy
GA OY8NG
UT WOS:000594497200001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Schneeberger, T
   Jarosch, I
   Koczulla, AR
AF Schneeberger, Tessa
   Jarosch, Inga
   Koczulla, Andreas Rembert
TI What can pulmonary rehabilitation accomplish?
SO DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
LA German
DT Article
DE pulmonary rehabilitation; pulmonary fibrosis; asthma bronchiale;
   COVID-19; telehealth
ID FIBROSIS; DISEASE
AB The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has stated that pulmonary rehabilitation (PR) is the most effective therapeutic intervention to reduce dyspnoea and to improve physical performance and quality of life for patients with obstructive lung disease. New innovative studies raised in the area of PR: 1) Pulmonary fibrosis & asthma bronchiale - While PR is recommended for chronic respiratory diseases other than COPD (chronic obstructive pulmonary disease) in the respective disease-specific treatment guidelines, PR in some pathologies is underrated. For example, there is a growing body of evidence showing the effectiveness of structured and multidisciplinary PR programs in pulmonary fibrosis and asthma bronchial patients; 2) Coronavirus SARS-CoV-2 - There is preliminary evidence that COVID-19 patients can benefit from a PR program. The current COVID-19 position paper of the German Respiratory Society e.V. (DGP) regarding PR recommendations suggests that early rehabilitative therapies are already indicated during hospitalisation on the normal or intensive care unit and that rehabilitative interventions should be continued after discharge as a follow-up treatment in PR centres in order to reduce long-term consequences of COVID-19 disease; 3) Telehealth meets PR - To further improve the effectiveness of PR in COPD patients using recent technologies, a supplementary "digital exercise program" can contribute to greater benefits compared to PR alone.
C1 [Schneeberger, Tessa; Jarosch, Inga; Koczulla, Andreas Rembert] Philipps Univ Marburg, Deutsch Zentrum Lungenforsch DZL Standort Schonau, Pneumol Rehabil, Marburg, Germany.
   [Schneeberger, Tessa; Jarosch, Inga; Koczulla, Andreas Rembert] Forschungsinst Pneumol Rehabil, Schon Klin Berchtesgadener Land, Schonau, Germany.
   [Koczulla, Andreas Rembert] Privatuniv Salzbur, Lehrkrankenhaus Paracelsus Med, Salzburg, Austria.
RP Schneeberger, T (corresponding author), Philipps Univ Marburg, Standort Schonau Konigssee Pneumol Rehabil, Malterhoh 1, D-83471 Schonau, Germany.
EM TSchneeberger@Schoen-Klinik.de; ijarosch@schoen-klinik.de;
   rkoczulla@schoen-klinik.de
CR Carda S, 2020, ANN PHYS REHABIL MED
   Celli B, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00764-2020
   Global Initiative for Asthma, 2020, GLOB STRAT ASTHM MAN
   Global Initiative for Chronic Obstructive Lung Disease, 2020, GLOB STRAT DIAGN MAN
   Glockl R, 2020, DGP EMPFEHLUNGEN PNE
   Jarosch I, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051567
   Kenn K, 2013, RESPIRATION, V86, P89, DOI 10.1159/000354112
   Klok FA, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01494-2020
   Lingner H, 2015, J ASTHMA, V52, P614, DOI 10.3109/02770903.2014.996650
   Liu K, 2020, COMPLEMENT THER CLIN, V39, DOI 10.1016/j.ctcp.2020.101166
   Perez-Bogerd S, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0884-y
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Rutkowski S, 2020, INT J CHRONIC OBSTR, V15, P117, DOI 10.2147/COPD.S223592
   Schneeberger T, 2020, RESP MED, V165, DOI 10.1016/j.rmed.2020.105930
   Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST
   Sutanto YS, 2019, PULMONOLOGY, V25, P275, DOI 10.1016/j.pulmoe.2019.03.007
NR 16
TC 0
Z9 0
U1 1
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0012-0472
EI 1439-4413
J9 DEUT MED WOCHENSCHR
JI Dtsch. Med. Wochenschr.
PD DEC
PY 2020
VL 145
IS 24
BP 1782
EP 1785
DI 10.1055/a-1129-3375
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA OY5NE
UT WOS:000594292500011
PM 33254254
DA 2021-01-01
ER

PT J
AU Diaz, Y
   Ramos-Suzarte, M
   Martin, Y
   Calderon, NA
   Santiago, W
   Vinet, O
   Yulieski, L
   Oyarzabal, JPA
   Perez, Y
   Lorenzo, G
   Cepeda, M
   Saavedra, D
   Mazorra, Z
   Estevez, D
   Lorenzo-Luaces, P
   Valenzuela, C
   Caballero, A
   Leon, K
   Crombet, T
   Hidalgo, CJ
AF Diaz, Yayquier
   Ramos-Suzarte, Mayra
   Martin, Yordanis
   Antonio Calderon, Nestor
   Santiago, William
   Vinet, Orlando
   Yulieski, La O.
   Augusto Oyarzabal, Jorge Perez
   Perez, Yoan
   Lorenzo, Geidy
   Cepeda, Meylan
   Saavedra, Danay
   Mazorra, Zaima
   Estevez, Daymys
   Lorenzo-Luaces, Patricia
   Valenzuela, Carmen
   Caballero, Armando
   Leon, Kalet
   Crombet, Tania
   Jorge Hidalgo, Carlos
TI Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly
   Patients with Moderate COVID-19
SO GERONTOLOGY
LA English
DT Article
DE Itolizumab; Elderly; COVID-19; SARS-CoV-2; Immunomodulatory drugs
AB Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreak of coronavirus disease (COVID-19). In Cuba, the first case of COVID-19 was reported on March 11, 2020. Elderly individuals with multiple comorbidities are particularly susceptible to adverse clinical outcomes in the course of SARS-CoV-2 infection. During the outbreak, a local transmission event took place in a nursing home in Villa Clara province, Cuba, in which 19 elderly residents tested positive for SARS-CoV-2. Methods: Based on the increased susceptibility to cytokine release syndrome, inducing respiratory and systemic complications in this population, 19 patients were included in an expanded access clinical trial to receive itolizumab, an anti-CD6 monoclonal antibody. Results: All patients had underlying medical conditions. The product was well tolerated. After the first dose, the course of the disease was favorable, and 18 of the 19 patients (94.7%) were discharged clinically recovered with negative real-time reverse transcription polymerase chain reaction test results at 13 days. After one dose of itolizumab, circulating IL-6 decreased within the first 24-48 h in patients with high baseline values, whereas in patients with low levels, this concentration remained over low values. To preliminarily assess the effect of itolizumab, a control group was selected among the Cuban COVID-19 patients that did not receive immunomodulatory therapy. The control subjects were well matched regarding age, comorbidities, and severity of the disease. The percentage of itolizumab-treated, moderately ill patients who needed to be admitted to the intensive care unit was only one-third of that of the control group not treated with itolizumab. Additionally, treatment with itolizumab reduced the risk of death 10 times as compared with the control group. Conclusion: This study corroborates that the timely use of itolizumab in combination with other antivirals reduces COVID-19 disease worsening and mortality. The humanized antibody itolizumab emerges as a therapeutic alternative for patients with COVID-19. Our results suggest the possible use of itolizumab in patients with cytokine release syndrome from other pathologies.
C1 [Diaz, Yayquier; Martin, Yordanis; Antonio Calderon, Nestor; Santiago, William; Vinet, Orlando; Yulieski, La O.; Augusto Oyarzabal, Jorge Perez; Perez, Yoan; Jorge Hidalgo, Carlos] Manuel Fajardo Univ Hosp, Santa Clara, Cuba.
   [Ramos-Suzarte, Mayra; Lorenzo, Geidy; Cepeda, Meylan; Saavedra, Danay; Mazorra, Zaima; Estevez, Daymys; Lorenzo-Luaces, Patricia; Valenzuela, Carmen; Leon, Kalet; Crombet, Tania] Ctr Mol Immunol, Havana, Cuba.
   [Caballero, Armando] Arnaldo Milian Castro Univ Hosp, Santa Clara, Cuba.
RP Ramos-Suzarte, M (corresponding author), Ctr Mol Immunol, Clin Res Direct, Ave 216,Esq 15, Havana 11600, Cuba.
EM mayra@cim.sld.cu
OI Ramos Suzarte, Mayra/0000-0002-9058-3224
CR Alonso R, 2008, HYBRIDOMA, V27, P291, DOI 10.1089/hyb.2008.0007
   Arnaldez FI, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000930
   Elshazli RM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238160
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Jeronimo Christiane Maria Prado, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1177
   Krupashankar DS, 2014, J AM ACAD DERMATOL, V71, P484, DOI 10.1016/j.jaad.2014.01.897
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Maurel S, 2007, ARCH GERONTOL GERIAT, V45, P65, DOI 10.1016/j.archger.2006.09.003
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Ministerio de Salud Publica, CUB PART CIERR DIA 2
   Ministerio de Salud Publica, CUB PROT ACT NAC COV
   Nair P, 2010, CLIN EXP IMMUNOL, V162, P116, DOI 10.1111/j.1365-2249.2010.04235.x
   Perrotta F, 2020, AGING CLIN EXP RES, V32, P1599, DOI 10.1007/s40520-020-01631-y
   Potere N, 2020, INT J INFECT DIS, V100, P421, DOI 10.1016/j.ijid.2020.07.078
   Ramos-Suzarte M, USE HUMANIZED ANTICD, DOI [10.1101/2020.07.24.20153833, DOI 10.1101/2020.07.24.20153833V1]
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Robak T, 1998, MEDIAT INFLAMM, V7, P347, DOI 10.1080/09629359890875
   Rodriguez Pedro C, 2012, Results Immunol, V2, P204, DOI 10.1016/j.rinim.2012.11.001
   Silverio Renata, 2020, Adv Nutr, DOI 10.1093/advances/nmaa125
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 24
TC 1
Z9 1
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0304-324X
EI 1423-0003
J9 GERONTOLOGY
JI Gerontology
PD DEC
PY 2020
VL 66
IS 6
BP 553
EP 561
DI 10.1159/000512210
PG 9
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA OZ8SW
UT WOS:000595190100005
PM 33105142
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yung, YL
   Cheng, CK
   Chan, HY
   Xia, JT
   Lau, KM
   Wong, RSM
   Wu, AKL
   Chu, RW
   Wong, ACC
   Chow, EYD
   Yip, SF
   Leung, JNS
   Lee, CK
   Ng, MHL
AF Yung, Yuk-Lin
   Cheng, Chi-Keung
   Chan, Hoi-Yun
   Xia, Jenny T.
   Lau, Kin-Mang
   Wong, Raymond S. M.
   Wu, Alan K. L.
   Chu, Raymond W.
   Wong, Alice C. C.
   Chow, Eudora Y. D.
   Yip, Sze-Fai
   Leung, Jennifer N. S.
   Lee, Cheuk-Kwong
   Ng, Margaret H. L.
TI Association of HLA-B22 serotype with SARS-CoV-2 susceptibility in Hong
   Kong Chinese patients
SO HLA
LA English
DT Article; Early Access
DE Chinese; coronavirus; COVID&#8208; 19; HLA; SARS&#8208; CoV&#8208; 2
ID INFECTION; COVID-19; ALLELES
AB The coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by SARS-CoV-2. Since its first report in December 2019, COVID-19 has evolved into a global pandemic causing massive healthcare and socioeconomic challenges. HLA system is critical in mediating anti-viral immunity and recent studies have suggested preferential involvement of HLA-B in COVID-19 susceptibility. Here, by investigating the HLA-B genotypes in 190 unrelated Chinese patients with confirmed COVID-19, we identified a significant positive association between the B22 serotype and SARS-CoV-2 infection (p = 0.002, Bonferroni-corrected p = 0.032). Notably, the B22 serotype has been consistently linked to susceptibility to other viral infections. These data not only shed new insights into SARS-CoV-2 pathogenesis and vaccine development but also guide better infection prevention/control.
C1 [Yung, Yuk-Lin; Cheng, Chi-Keung; Chan, Hoi-Yun; Xia, Jenny T.; Lau, Kin-Mang; Ng, Margaret H. L.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Blood Canc Cytogenet & Genom Lab, Hong Kong, Peoples R China.
   [Wong, Raymond S. M.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China.
   [Wong, Raymond S. M.] Prince Wales Hosp, Sir YK Pao Ctr Canc, Hong Kong, Peoples R China.
   [Wu, Alan K. L.; Chu, Raymond W.] Pamela Youde Nethersole Eastern Hosp, Dept Clin Pathol, Hong Kong, Peoples R China.
   [Wong, Alice C. C.; Chow, Eudora Y. D.] United Christian Hosp, Dept Pathol, Hong Kong, Peoples R China.
   [Yip, Sze-Fai] Tuen Mun Hosp, Dept Med, Hong Kong, Peoples R China.
   [Leung, Jennifer N. S.; Lee, Cheuk-Kwong] Hong Kong Red Cross Blood Transfus Serv, Hong Kong, Peoples R China.
   [Ng, Margaret H. L.] Chinese Univ Hong Kong, State Key Lab Translat Oncol, Hong Kong, Peoples R China.
RP Ng, MHL (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Blood Canc Cytogenet & Genom Lab,Shatin, Hong Kong, Peoples R China.
EM margaretng@cuhk.edu.hk
FU Research Grants Council, University Grants Committee [CUHK M14108719]
FX Research Grants Council, University Grants Committee, Grant/Award
   Number: CUHK M14108719
CR Bafna Khushboo, 2020, ChemRxiv, DOI 10.26434/chemrxiv.12153615.v1
   Barquera R, 2020, HLA, DOI 10.1111/tan.13956
   Buonaguro L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02355-3
   Dorak MT, 2003, J INFECT DIS, V188, P856, DOI 10.1086/378071
   Galvez J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00349
   Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029
   Kuzushita N, 1998, HEPATOLOGY, V27, P240, DOI 10.1002/hep.510270136
   Kwok J, 2016, HUM IMMUNOL, V77, P1109, DOI 10.1016/j.humimm.2016.10.006
   Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9
   Liu X, 2015, PHARMACOGENOMICS J, V15, P467, DOI 10.1038/tpj.2015.7
   Neumann-Haefelin C, 2013, CURR OPIN RHEUMATOL, V25, P426, DOI 10.1097/BOR.0b013e328362018f
   Ng MHL, 2004, J INFECT DIS, V190, P515, DOI 10.1086/421523
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang W, 2020, HLA, V96, P194, DOI 10.1111/tan.13941
   World Health Organization, 2020, CLIN MAN COVID 19 IN
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
NR 18
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2059-2302
EI 2059-2310
J9 HLA
JI HLA
DI 10.1111/tan.14135
EA DEC 2020
PG 6
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA OY6ZA
UT WOS:000594392000001
PM 33179437
OA Other Gold
DA 2021-01-01
ER

PT J
AU Lyons-Weiler, J
   McFarland, G
   La Joie, E
AF Lyons-Weiler, James
   McFarland, Grant
   La Joie, Elaine
TI Impact of catch-up vaccination on aluminum exposure due to new laws and
   post social distancing
SO JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Aluminum; Vaccines; COVID-19; Vaccination
AB Background: The COVID-19 pandemic has placed significant stressors on the medical community and on the general public. Part of this includes patients skipping well-child visits to reduce risk of exposure to SARS-CoV-2 virus. Published estimates of the duration of whole-body aluminum (Al) toxicity from vaccines in infants from birth to six months indicate that CDC's recommended vaccination schedule leads to unacceptably long periods of time in which infants are in aluminum toxicity (as measured by %AlumTox).
   Methods: We utilize these established clearance and accumulation models to calculate expected per-body-weight whole-body toxicity of aluminum from vaccines considering for children of all ages under CDC's Catch-Up schedule from birth to ten years, assuming social distancing for 6 months. Our updated Pediatric Dose Limit (PDL) model assumes a linear improvement in renal function from birth to two years.
   Results: Our results indicate that due diligence in considering alternative spacing and use of non-aluminum containing vaccines when possible will reduce whole body toxicity and may reduce risk of morbidity associated with exposure to aluminum.
   Conclusions: While reduction or elimination of aluminum exposure from all sources is always a good idea, our results indicate that careful consideration of expected aluminum exposures during regular and Catch-Up vaccination is found to be especially important for infants and children below 2 years of age. We urge caution in the mass re-starting of vaccination under CDC's Catch-Up schedule for children under 12 months and offer alternative strategies to minimize per-day/week/month exposure to aluminum hydroxide following the COVID-19 period of isolation.
C1 [Lyons-Weiler, James; McFarland, Grant; La Joie, Elaine] Inst Pure & Appl Knowledge, Pittsburgh, PA 15213 USA.
RP Lyons-Weiler, J (corresponding author), Inst Pure & Appl Knowledge, Pittsburgh, PA 15213 USA.
EM jim@ipaknowledge.org
CR AAP, 2020, COVID 19 CLIN GUID Q
   Cappello F, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072038
   Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765
   Crepeaux G, 2018, J ALLER CL IMM-PRACT, V6, P707, DOI 10.1016/j.jaip.2017.10.039
   Dorea JG, 2015, INT J ENV RES PUB HE, V12, P1295, DOI 10.3390/ijerph120201295
   Elsakkar MG, 2016, EUR J PHARMACOL, V786, P100, DOI 10.1016/j.ejphar.2016.06.002
   Flarend RE, 1997, VACCINE, V15, P1314, DOI 10.1016/S0264-410X(97)00041-8
   Gherardi RK, 2019, AUTOIMMUN REV, V18, P691, DOI 10.1016/j.autrev.2019.05.006
   Han S, 2013, CELL BIOL TOXICOL, V29, P75, DOI 10.1007/s10565-013-9239-0
   Hlavinka E., 2020, MEDPAGE TODAY
   Kelly-Scumpia KM, 2007, ARTHRITIS RHEUM, V56, P3379, DOI 10.1002/art.22946
   Lemire J, 2009, J NEUROSCI RES, V87, P1474, DOI 10.1002/jnr.21965
   Lyons-Weiler James, 2020, J Transl Autoimmun, V3, P100051, DOI 10.1016/j.jtauto.2020.100051
   Lyons-Weiler J, 2018, J TRACE ELEM MED BIO, V48, P67, DOI 10.1016/j.jtemb.2018.02.025
   McFarland G, 2020, J TRACE ELEM MED BIO, V58, DOI 10.1016/j.jtemb.2019.126444
   Miller N.Z., 2016, J AM PHYS SURG, V21, P47
   Mitkus RJ, 2011, VACCINE, V29, P9538, DOI 10.1016/j.vaccine.2011.09.124
   Mold M, 2018, J TRACE ELEM MED BIO, V46, P76, DOI 10.1016/j.jtemb.2017.11.012
   Movsas TZ, 2013, JAMA PEDIATR, V167, P870, DOI 10.1001/jamapediatrics.2013.108
   National Academy of Sciences, 2013, CHILDH IMM SCHED SAF
   Otukesh H, 2012, IRAN J KIDNEY DIS, V6, P166
   Petrik MS, 2007, NEUROMOL MED, V9, P83, DOI 10.1385/NMM:9:1:83
   Redgrove J, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16050899
   Sebaiti MA, 2018, J INORG BIOCHEM, V181, P132, DOI 10.1016/j.jinorgbio.2017.09.019
   US Centers for Disease Control and Prevent, 2020, IMM SCHED TABL 2 CAT
   US HHS VAERS, 2020, VAERS VACC ADV EV RE
   Wolff GG, 2020, VACCINE, V38, P350, DOI 10.1016/j.vaccine.2019.10.005
   Yasar M, 2016, AM J OTOLARYNG, V37, P287, DOI 10.1016/j.amjoto.2016.03.007
NR 28
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0946-672X
J9 J TRACE ELEM MED BIO
JI J. Trace Elem. Med. Biol.
PD DEC
PY 2020
VL 62
AR 126649
DI 10.1016/j.jtemb.2020.126649
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA OM4WV
UT WOS:000586028000079
PM 32980768
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Belhassan, A
   En-nahli, F
   Zaki, H
   Lakhlifi, T
   Bouachrine, M
AF Belhassan, Assia
   En-nahli, Fatima
   Zaki, Hanane
   Lakhlifi, Tahar
   Bouachrine, Mohammed
TI Assessment of effective imidazole derivatives against SARS-CoV-2 main
   protease through computational approach
SO LIFE SCIENCES
LA English
DT Article
DE Coronavirus; COVID-19; Imidazole; Chloroquine; Hydroxychloroquine;
   Molecular docking
ID HYDROXYCHLOROQUINE; CHLOROQUINE; COVID-19; DOCKING
AB Because of the fast increase in deaths due to Corona Viral Infection in majority region in the world, the detection of drugs potent of this infection is a major need. With this idea, docking study was executed on eighteen imidazole derivatives based on 7-chloro-4-aminoquinoline against novel Coronavirus (SARS-CoV-2).
   In this study, we carried out a docking study of these molecules in the active site of SARS-CoV-2 main protease. The result indicate that Molecules No 3, 7 and 14 have more binding energy with SARS-CoV-2 main protease recently crystallized (pdb code 6LU7) in comparison with the other imidazole derivatives and the two drug; Chloroquine and hydroxychloroquine. Because of the best energy of interaction, these three molecules could have the most potential antiviral treatment of COVID-19 than the other studied compounds. The structures with best affinity in the binding site of the protease have more than 3 cycles and electronegative atoms in the structure. This may increase the binding affinity of these molecules because of formation of p-bonds, halogen interactions and/or Hydrogen bond interactions between compounds and the enzyme. So, compounds with more cycles and electronegative atoms could have a potent inhibition of SARS-CoV-2 main protease.
C1 [Belhassan, Assia; En-nahli, Fatima; Zaki, Hanane; Lakhlifi, Tahar; Bouachrine, Mohammed] Moulay Ismail Univ Meknes, Fac Sci, Mol Chem & Nat Subst Lab, Meknes, Morocco.
   [Bouachrine, Mohammed] Sultan Moulay Sliman Univ, EST Khenifra, Benimellal, Morocco.
RP Bouachrine, M (corresponding author), Moulay Ismail Univ Meknes, Fac Sci, Mol Chem & Nat Subst Lab, Meknes, Morocco.
EM m.bouachrine@est-umi.ac.ma
OI Bouachrine, Mohammed/0000-0002-8901-047X
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   [Anonymous], 2016, DASS SYST BIOVIA DIS
   Baildya N, 2020, J MOL STRUCT, V1219, DOI 10.1016/j.molstruc.2020.128595
   CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hakmi M, 2020, BIOINFORMATION, V16, P301, DOI 10.6026/97320630016301
   Hatada R., 2020, FRAGMENT MOL ORBITAL
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kang D, 2020, INT J INFECT DIS, V94, P96, DOI 10.1016/j.ijid.2020.03.076
   Kondaparla S, 2018, BIOORG CHEM, V80, P204, DOI 10.1016/j.bioorg.2018.06.012
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   PURCELL WP, 1967, J CHEM ENG DATA, V12, P235, DOI 10.1021/je60033a020
   Radke JB, 2019, TOXICOL REP, V6, P1040, DOI 10.1016/j.toxrep.2019.10.006
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Roldan EQ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104904
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Soni J, 2019, CURR ORG SYNTH, V16, P1078, DOI 10.2174/1570179416666191007092548
   Tang X, 2020, CHEST, V158, P195, DOI 10.1016/j.chest.2020.03.032
   Tosepu R, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138436
   Tripos Inc, SYBYL X 2 0
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsang AC, 2019, AM J OPHTHALMOL, V206, P132, DOI 10.1016/j.ajo.2019.04.025
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
NR 28
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD DEC 1
PY 2020
VL 262
AR 118469
DI 10.1016/j.lfs.2020.118469
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OY0YN
UT WOS:000593980700001
PM 32956664
OA Green Published
DA 2021-01-01
ER

PT J
AU Sadeghi, S
   Soudi, S
   Shafiee, A
   Hashemi, SM
AF Sadeghi, Somaye
   Soudi, Sara
   Shafiee, Abbas
   Hashemi, Seyed Mahmoud
TI Mesenchymal stem cell therapies for COVID-19: Current status and
   mechanism of action
SO LIFE SCIENCES
LA English
DT Article
DE Cell therapy; Coronavirus; Cytokine storm; Immunomodulatory effects;
   Clinical trials
ID ACUTE LUNG INJURY; CONVALESCENT PLASMA; CYTOKINE STORM; LYMPHOPENIA;
   SECRETION; INFECTION
AB The outbreak of COVID-19 in December 2019, has become an urgent and serious public health emergency. At present, there is no effective treatment or vaccine for COVID-19. Therefore, there is a crucial unmet need to develop a safe and effective treatment for COVID-19 patients. Mesenchymal stem cells (MSCs) are widely used in basic science and in a variety of clinical trials. MSCs are able to engraft to the damaged tissues after transplantation and promote tissue regeneration, besides MSCs able to secrete immunomodulatory factors that suppress the cytokine storms. Moreover, the contribution of MSCs to prevent cell death and inhibit tissue fibrosis is well established. In the current review article, the potential mechanisms by which MSCs contribute to the treatment of COVID-19 patients are highlighted. Also, current trials that evaluated the potential of MSC-based treatments for COVID-19 are briefly reviewed.
C1 [Sadeghi, Somaye; Hashemi, Seyed Mahmoud] Shahid Beheshti Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran.
   [Soudi, Sara] Tarbiat Modares Univ, Fac Med Sci, Dept Immunol, Tehran, Iran.
   [Shafiee, Abbas] Univ Queensland, Translat Res Inst, UQ Diamantina Inst, Brisbane, Qld, Australia.
   [Hashemi, Seyed Mahmoud] Shahid Beheshti Univ Med Sci, Urogenital Stem Cell Res Ctr, Tehran, Iran.
   [Hashemi, Seyed Mahmoud] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran, Iran.
RP Shafiee, A (corresponding author), Univ Queensland, Translat Res Inst, UQ Diamantina Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia.; Hashemi, SM (corresponding author), Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Appl Cell Sci, Dept Immunol,Sch Med, Tehran, Iran.
EM a.shafiee@uq.edu.au; smmhashemi@sbmu.ac.ir
RI Shafiee, Abbas/H-9230-2019
OI Shafiee, Abbas/0000-0002-8885-9025
CR Ai J.-W., 2020, OPTIMIZING DIAGNOSTI, DOI [10.1101/2020.02.13.20022673., DOI 10.1101/2020.02.13.20022673]
   Al-Anazi K., 2015, PROGR STEM CELL TRAN, DOI [10.5772/60640, DOI 10.5772/60640]
   Atluri S, 2020, PAIN PHYSICIAN, V23, pE71
   Baharlooi H, 2020, INT J STEM CELLS, V13, P13, DOI 10.15283/ijsc19108
   Behnke J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030682
   Bernard O, 2018, AM J PHYSIOL-LUNG C, V314, pL360, DOI 10.1152/ajplung.00153.2017
   Blackwell JM, 2009, CLIN MICROBIOL REV, V22, P370, DOI 10.1128/CMR.00048-08
   Boonnak K, 2014, J IMMUNOL, V192, P5906, DOI 10.4049/jimmunol.1302992
   Bridgeman JS, 2014, CLIN EXP IMMUNOL, V175, P258, DOI 10.1111/cei.12216
   Chan Sophelia H. S., 2008, Hong Kong Medical Journal, V14, P21
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Chen Jiajia, 2020, Engineering (Beijing), V6, P1153, DOI 10.1016/j.eng.2020.02.006
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Crux NB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00832
   Danchuk S, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt68
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   DiMarino AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00201
   Enes SR, 2020, CURR STEM CELL REP, V6, P30, DOI 10.1007/s40778-020-00171-5
   Fang XH, 2010, J BIOL CHEM, V285, P26211, DOI 10.1074/jbc.M110.119917
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Gorman E, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04416-w
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Han JB, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1518-0
   Han Y, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080886
   Harrell C.R., 2019, STEM CELLS INT, V2019
   Hatipoglu H, 2011, JOPP DERG, V3, P5
   Hayes M, 2012, CRIT CARE, V16, DOI 10.1186/cc10570
   Henter JI, 2006, LANCET, V367, P870, DOI 10.1016/S0140-6736(06)68232-9
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Horby P, 2020, EFFECT DEXAMETHASONE
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   HUANG SW, 1973, JAMA-J AM MED ASSOC, V225, P1120, DOI 10.1001/jama.1973.03220370058023
   Iyer SS, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/868076
   Jiang J., 2019, MEDICINE, V98
   Ju B, 2020, POTENT HUMAN NEUTRAL, DOI [10.1101/2020.03.21.990770, DOI 10.1101/2020.03.21.990770, 10.1101/2020.03.21.990770.]
   Kahan SM, 2015, VIROLOGY, V479, P180, DOI 10.1016/j.virol.2014.12.033
   Khoury M, 2020, CYTOTHERAPY, V22, P602, DOI 10.1016/j.jcyt.2020.04.089
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Kode JA, 2009, CYTOTHERAPY, V11, P377, DOI 10.1080/14653240903080367
   Krasnodembskaya A, 2014, EUR RESPIR J, V44
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   Laffey JG, 2017, AM J RESP CRIT CARE, V196, P266, DOI 10.1164/rccm.201701-0107CP
   Lee JW, 2011, STEM CELLS, V29, P913, DOI 10.1002/stem.643
   Lee JW, 2009, EXPERT OPIN BIOL TH, V9, P1259, DOI 10.1517/14712590903213651
   Lee KH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143529
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li LJ, 2003, J CLIN VIROL, V28, P239, DOI 10.1016/S1386-6532(03)00195-1
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liang B, 2020, CLIN REMISSION CRITI, V2, pv1
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   London AJ, 2020, SCIENCE, V368, P476, DOI 10.1126/science.abc1731
   Luckey D., 2019, SCI REP, V9, P1
   Maschalidi S, 2016, BLOOD, V128, P60, DOI 10.1182/blood-2016-02-700013
   Matthay Michael A, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS54, DOI 10.1513/AnnalsATS.201406-254MG
   Matthay MA, 2010, CHEST, V138, P965, DOI 10.1378/chest.10-0518
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Mei SHJ, 2010, AM J RESP CRIT CARE, V182, P1047, DOI 10.1164/rccm.201001-0010OC
   Moll G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01091
   Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94
   Norkaew T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204965
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536-019-0083-6
   Qian XJ, 2016, STEM CELL TRANSL MED, V5, P1190, DOI 10.5966/sctm.2015-0348
   Rajarshi Keshav, 2020, Biotechnology Reports, V26, pe00467, DOI 10.1016/j.btre.2020.e00467
   Sadeghi S, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.105879
   Salvatori O, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00689-20.
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Savukinas UB, 2016, STEM CELLS, V34, P1437, DOI 10.1002/stem.2357
   Shafiee A, 2015, STEM CELL TRANSL MED, V4, P419, DOI 10.5966/sctm.2014-0224
   Shafique A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00598-7
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Siegel M., 2019, ACUTE RESP DISTRESS
   Simonson OE, 2015, STEM CELL TRANSL MED, V4, P1199, DOI 10.5966/sctm.2015-0021
   Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622
   Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tang HL, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5173494
   Teijaro J.R., 2017, CYTOKINE STORMS INFE
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Tzouvelekis A, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-171
   Ubol S, 2010, CLIN VACCINE IMMUNOL, V17, P1829, DOI 10.1128/CVI.00316-10
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HL, 2008, AM J EMERG MED, V26, P711, DOI 10.1016/j.ajem.2007.10.031
   Wang SH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-19
   Wu F, 2020, NEUTRALIZING ANTIBOD
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
   Zhang BC, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00157
   Zhao B, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202002019
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 94
TC 1
Z9 1
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD DEC 1
PY 2020
VL 262
AR 118493
DI 10.1016/j.lfs.2020.118493
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OY0XW
UT WOS:000593979000006
PM 32979360
OA Green Published
DA 2021-01-01
ER

PT J
AU Gruner, S
   Kruger, F
AF Gruner, Sven
   Krueger, Felix
TI The intention to be vaccinated against COVID-19: stated preferences
   before vaccines were available
SO APPLIED ECONOMICS LETTERS
LA English
DT Article; Early Access
DE Willingness to be vaccinated; trust; COVID-19; healthcare professionals
AB The goal of this note is to better understand which determinants can explain the willingness to get vaccinated against COVID-19. For this purpose, we conduct a survey in Germany in which we ask ourselves whether this 'time is different' from the willingness to be vaccinated against infection by influenza viruses. Our sample does not only comprise students with and without healthcare background, we also analyse a notable amount of healthcare professionals. We find that healthcare professionals exhibit a considerably greater willingness to be vaccinated against flu than healthcare and non-healthcare students. In contrast, the willingness to be vaccinated against COVID-19 is quite similar among the populations. In both contexts, COVID-19 and flu, trust (e.g. media, activities of the government) seems to play a central role in the decision whether to be vaccinated or not.
C1 [Gruner, Sven] Martin Luther Univ Halle Wittenberg, Inst Agr & Nutr Sci, Agribusiness Management, D-06120 Halle, Saale, Germany.
   [Krueger, Felix] Martin Luther Univ Halle Wittenberg, Fac Law & Econ, Empir Microecon, Halle, Saale, Germany.
RP Gruner, S (corresponding author), Martin Luther Univ Halle Wittenberg, Inst Agr & Nutr Sci, Agribusiness Management, D-06120 Halle, Saale, Germany.
EM sven.gruener@landw.uni-halle.de
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)German
   Research Foundation (DFG) [388911356]
FX We are indebted to the very helpful comments of the anonymous reviewer.
   The financial support of Deutsche Forschungsgemeinschaft (DFG, German
   Research Foundation - 388911356) is gratefully acknowledged.
CR Baumgaertner B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191728
   Cameron AC, 2010, MICROECONOMETRICS US
   Carrieri V, 2019, HEALTH ECON, V28, P1377, DOI 10.1002/hec.3937
   de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0
   Emanuel EJ, 2020, SCIENCE, V369, P1309, DOI 10.1126/science.abe2803
   Frederick S, 2005, J ECON PERSPECT, V19, P25, DOI 10.1257/089533005775196732
   Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6
   STIKO-Standige Impfkommission, 2020, STELL STAND IMPFK KU, V35, P8
   WHO-Online, 2019, VAC EUR COMM WHO JOI
NR 9
TC 0
Z9 0
U1 3
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1350-4851
EI 1466-4291
J9 APPL ECON LETT
JI Appl. Econ. Lett.
DI 10.1080/13504851.2020.1854445
EA DEC 2020
PG 5
WC Economics
SC Business & Economics
GA OY2DR
UT WOS:000594062200001
OA Bronze
DA 2021-01-01
ER

PT J
AU Kwarteng, A
   Asiedu, E
   Sakyi, SA
   Asiedu, SO
AF Kwarteng, Alexander
   Asiedu, Ebenezer
   Sakyi, Samuel Amoah
   Asiedu, Samuel Opoku
TI Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics
   using immuno-informatics and structure-based drug discovery techniques
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE COVID-19; Vaccine; Immuno-informatics; Epitope; Molecular dynamics
   simulation; Zidovudine
ID N-TERMINAL DOMAIN; RNA-BINDING; CORONAVIRUS; MODEL; RECOGNITION;
   MATURATION; RESPONSES; PROGRAM; VIRUS
AB The occurrence of the SARS-CoV2 infection has become a worldwide threat and the urgent need to discover therapeutic interventions remains paramount. The primary roles of the coronavirus nucleocapsid (N) protein are to interact with the viral genome and pack them into ribonucleoprotein complex. It also plays critical roles at many stages of the viral life cycle. Herein, we explore the N protein of SARS-CoV2 to identify promising epitope-based vaccine candidates and target the N-terminal domain of SARS-CoV2 N-protein for potential inhibitors using an integrative bioinformatics approach. We identified B-cell epitopes and T-cell epitopes that are non-toxic, non-allergenic, capable of inducing IFN-gamma and structurally stable with high global population coverage of response. The (404)SKQLQQSMSSADS(416) and (92)RRIRGGDGKMKDL(104) sequences of N-protein were identified to induce B-cell immunity. We also identified (79)SSPDDQIGY(87) and (305)AQFAPSASAFFGMSR(319) as potential T-cell epitopes that form stable structures with human leucocyte antigens. We have also identified zidovudine triphosphate, an anti-HIV agent, as a potential inhibitor of the N-terminal domain of SARS-CoV2 N-protein based on docking and simulation analysis and should be considered for experimental validations. The findings of this study can help fast-track the discovery of therapeutic options to combat COVID-19.
C1 [Kwarteng, Alexander] Kwame Nkrumah Univ Sci & Technol KNUST, Dept Biochem & Biotechnol, Kumasi, Ghana.
   [Kwarteng, Alexander; Asiedu, Ebenezer; Asiedu, Samuel Opoku] Kumasi Ctr Collaborat Res Trop Med KCCR, Kumasi, Ghana.
   [Sakyi, Samuel Amoah] Kwame Nkrumah Univ Sci & Technol KNUST, Dept Mol Med, Kumasi, Ghana.
RP Kwarteng, A (corresponding author), KNUST, Dept Biochem & Biotechnol, Kumasi, Ghana.
EM akwarteng@knust.edu.gh
OI ASIEDU, EBENEZER/0000-0003-2867-1984
FU EDCTP; African Research Network for Neglected Tropical and Diseases
   SGP-III
FX AK is a grant recipient on EDCTP and African Research Network for
   Neglected Tropical and Diseases SGP-III. We are also indebted to the
   staff of the Kwarteng Lab (Kumasi Centre for Collaborative Research in
   Tropical Medicine) for their unflinching support in the preparation of
   this manuscript.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Adams E.R., 2020, EVALUATION ANTIBODY, DOI [10.1101/2020.04.15.20066407, DOI 10.1101/2020.04.15.20066407]
   ALLEN PM, 1987, IMMUNOL TODAY, V8, P270, DOI 10.1016/0167-5699(87)90187-3
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Azkur A.Z., 2020, ALLERGY, DOI [10.1111/all.14364, DOI 10.1111/ALL.14364.]
   Bao L, 2020, REINFECTION COULD NO, DOI [10.1101/2020.03.13.990226, DOI 10.1101/2020.03.13.990226, 10.1101/2020.03.13.990226.]
   BEREK C, 1993, IMMUNOL TODAY, V14, P400, DOI 10.1016/0167-5699(93)90143-9
   Berzofski J.A., 1985, T CELL ACTIVATION YE, P18
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Brenke R, 2012, BIOINFORMATICS, V28, P2608, DOI 10.1093/bioinformatics/bts493
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Cao ZL, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-299
   Cavanagh D., 2004, PRINCIPLES PRACTICE, P379
   CELADA F, 1992, IMMUNOL TODAY, V13, P56, DOI 10.1016/0167-5699(92)90135-T
   CELADA F, 1971, PROG ALLERGY, V15, P223
   Celada F, 1996, EUR J IMMUNOL, V26, P1350, DOI 10.1002/eji.1830260626
   de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Fan H, 2005, STRUCTURE, V13, P1859, DOI 10.1016/j.str.2005.08.021
   Fan YY, 2009, ARCH VIROL, V154, P1093, DOI 10.1007/s00705-009-0409-6
   Gioia C, 2005, INT J IMMUNOPATH PH, V18, P525, DOI 10.1177/039463200501800312
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957
   HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang QL, 2004, BIOCHEMISTRY-US, V43, P6059, DOI 10.1021/bi036155b
   JERATH MR, 2010, J VIROL, V8, DOI DOI 10.1128/JVI.01464-10
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Kozakov D, 2006, PROTEINS, V65, P392, DOI 10.1002/prot.21117
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liu J, 2020, PROTEOMICS, V20, DOI 10.1002/pmic.202000050
   Liu WB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00461-20
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Ortiz-Prado E, 2020, DIAGN MICR INFEC DIS, V98, DOI 10.1016/j.diagmicrobio.2020.115094
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto Dora, 2020, bioRxiv, DOI 10.1101/2020.04.07.023903
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Saikatend K.S., 2007, J VIROL, V81
   SEIDEN PE, 1992, J THEOR BIOL, V158, P329, DOI 10.1016/S0022-5193(05)80737-4
   Serafin MB, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105969
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Song C.-Y., 2020, COVID 19 EARLY WARNI, DOI [10.1101/2020.03.05.20031906, DOI 10.1101/2020.03.05.20031906]
   SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x
   Surjit M, 2005, J VIROL, V79, P11476, DOI 10.1128/JVI.79.17.11476-11486.2005
   Tan YW, 2006, NUCLEIC ACIDS RES, V34, P4816, DOI 10.1093/nar/gkl650
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   To KK-W, 2020, LANCET, V20, P5
   UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.immunol.2.1.395
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999
   Vartak A, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020012
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4
   Yuan SG, 2017, WIRES COMPUT MOL SCI, V7, DOI 10.1002/wcms.1298
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
NR 77
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2020
VL 132
AR 110914
DI 10.1016/j.biopha.2020.110914
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OX6WU
UT WOS:000593703200003
PM 33254432
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Frankel, M
   Feldman, I
   Levine, M
   Frank, Y
   Bogot, NR
   Benjaminov, O
   Kurd, R
   Breuer, GS
   Munter, G
AF Frankel, Meir
   Feldman, Itamar
   Levine, Michal
   Frank, Yigal
   Bogot, Naama R.
   Benjaminov, Ofer
   Kurd, Ramzi
   Breuer, Gabriel S.
   Munter, Gabriel
TI Bilateral Adrenal Hemorrhage in Coronavirus Disease 2019 Patient: A Case
   Report
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE COVID-19; adrenal insufficiency; antiphospholipid syndrome; adrenal
   hemorrhage; renal vein thrombosis
ID INSUFFICIENCY
AB Context: Bilateral adrenal hemorrhage is a rare condition with potentially life-threatening consequences such as acute adrenal insufficiency. Early adrenal axis testing, as well as directed imaging, is crucial for immediate diagnosis and treatment. Coronavirus disease 2019 (COVID-19) has been associated with coagulopathy and thromboembolic events.
   Case description: A 66-year-old woman presented with acute COVID-19 infection and primary adrenal insufficiency due to bilateral adrenal hemorrhage (BAH). She also had a renal vein thrombosis. Her past medical history revealed primary antiphospholipid syndrome (APLS). Four weeks after discharge she had no signs of COVID-19 infection and her polymerase chain reaction test for COVID-19 was negative, but she still needed glucocorticoid and mineralocorticoid replacement therapy.The combination of APLS and COVID-19 was probably responsible of the adrenal event as a "two-hit" mechanism.
   Conclusions: COVID-19 infection is associated with coagulopathy and thromboembolic events, including BAH. Adrenal insufficiency is life threatening; therefore, we suggest that early adrenal axis testing for COVID-19 patients with clinical suspicion of adrenal insufficiency should be carried out.
C1 [Frankel, Meir; Munter, Gabriel] Shaare Zedek Med Ctr, Endocrinol Unit, POB 3235, IL-9103102 Jerusalem, Israel.
   [Feldman, Itamar; Breuer, Gabriel S.] Shaare Zedek Med Ctr, Rheumatol Unit, Jerusalem, Israel.
   [Levine, Michal; Kurd, Ramzi; Breuer, Gabriel S.; Munter, Gabriel] Shaare Zedek Med Ctr, Dept Internal Med, Jerusalem, Israel.
   [Frank, Yigal; Bogot, Naama R.; Benjaminov, Ofer] Shaare Zedek Med Ctr, Dept Radiol, Jerusalem, Israel.
   [Bogot, Naama R.; Benjaminov, Ofer; Breuer, Gabriel S.; Munter, Gabriel] Hadassah Hebrew Univ, Sch Med, Jerusalem, Israel.
RP Frankel, M (corresponding author), Shaare Zedek Med Ctr, Endocrinol Unit, POB 3235, IL-9103102 Jerusalem, Israel.
EM meirf@szmc.org.il
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   ARNASON JA, 1995, SEMIN ARTHRITIS RHEU, V25, P109, DOI 10.1016/S0049-0172(95)80024-7
   Joob B, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620918308
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   MIGEON CJ, 1967, PEDIATRICS, V40, P163
   Ramon I, 2013, J CLIN ENDOCR METAB, V98, P3179, DOI 10.1210/jc.2012-4300
   Satta MA, 2000, CLIN ENDOCRINOL, V52, P123
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Vu D, 2020, EMERG RADIOL, V27, P229, DOI 10.1007/s10140-020-01775-4
   XARLI VP, 1978, MEDICINE, V57, P211, DOI 10.1097/00005792-197805000-00002
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD DEC
PY 2020
VL 105
IS 12
AR dgaa487
DI 10.1210/clinem/dgaa487
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OK3IU
UT WOS:000584547800007
PM 32738040
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wu, JF
   Huang, JQ
   Zhu, GC
   Liu, YH
   Xiao, H
   Zhou, Q
   Si, X
   Yi, H
   Wang, CP
   Yang, DY
   Chen, SL
   Liu, X
   Liu, ZL
   Wang, QY
   Lv, QY
   Huang, Y
   Yu, Y
   Guan, XD
   Li, YB
   Nirantharakumar, K
   Cheng, KK
   Peng, S
   Xiao, HP
AF Wu, Jianfeng
   Huang, Jianqiang
   Zhu, Guochao
   Liu, Yihao
   Xiao, Han
   Zhou, Qian
   Si, Xiang
   Yi, Hui
   Wang, Cuiping
   Yang, Daya
   Chen, Shuling
   Liu, Xin
   Liu, Zelong
   Wang, Qiongya
   Lv, Qingquan
   Huang, Ying
   Yu, Yang
   Guan, Xiangdong
   Li, Yanbing
   Nirantharakumar, Krishnarajah
   Cheng, KarKeung
   Peng, Sui
   Xiao, Haipeng
TI Systemic Corticosteroids and Mortality in Severe and Critical COVID-19
   Patients in Wuhan, China
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE systemic corticosteroids; mortality; severe and critical; COVID-19
ID ACUTE RESPIRATORY SYNDROME; RELATIVE HYPERGLYCEMIA; ILL PATIENTS; SARS;
   GLUCOCORTICOIDS
AB Background: Systemic corticosteroids are now recommended in many treatment guidelines, although supporting evidence is limited to 1 randomized controlled clinical trial (RECOVERY).
   Objective: To identify whether corticosteroids were beneficial to COVID-19 patients.
   Methods: A total of 1514 severe and 249 critical hospitalized COVID-19 patients from 2 medical centers in Wuhan, China. Multivariable Cox models, Cox model with time-varying exposure and propensity score analysis (inverse-probability-of-treatment-weighting (IPTWI and propensity score matching IPSMI) were used to estimate the association of corticosteroid use with risk of in-hospital mortality in severe and critical cases.
   Results: Corticosteroids were administered in 531 (35.1%) severe and 159 (63.9%) critical patients. Compared to the non-corticosteroid group, systemic corticosteroid use was not associated with beneficial effect in reducing in-hospital mortality in either severe cases (HR = 1.77; 95% CI, 1.08-2.89; P= 0.023), or critical cases (HR = 2.07; 95% CI, 1.08-3.98; P= 0.028). Findings were similar in time-varying Cox analysis. For patients with severe COVID-19 at admission, corticosteroid use was not associated with improved or harmful outcome in either PSM or IPTW analysis. For critical COVID-19 patients at admission, results were consistent with multivariable Cox model analysis.
   Conclusion: Corticosteroid use was not associated with beneficial effect in reducing in-hospital mortality for severe or critical cases in Wuhan. Absence of the beneficial effect in our study in contrast to that observed in the RECOVERY clinical trial may be due to biases in observational data, in particular prescription by indication bias, differences in clinical characteristics of patients, choice of corticosteroid used, timing of initiation of treatment, and duration of treatment.
C1 [Wu, Jianfeng; Si, Xiang; Wang, Cuiping; Guan, Xiangdong] Sun Yat Sen Univ, Dept Crit Care Med, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Huang, Jianqiang; Yi, Hui] Sun Yat Sen Univ, Div Pulm & Crit Care Med, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Zhu, Guochao] Jianghan Univ, Dept Crit Care Med, Affiliated Hosp, Hosp Wuhan 6, Wuhan 430014, Hubei, Peoples R China.
   [Liu, Yihao; Zhou, Qian; Peng, Sui] Sun Yat Sen Univ, Clin Trials Unit, Affiliated Hosp 1, 58,ZhongShan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.
   [Liu, Yihao; Li, Yanbing; Xiao, Haipeng] Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, 58,ZhongShan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.
   [Xiao, Han; Chen, Shuling; Liu, Zelong] Sun Yat Sen Univ, Inst Diagnost & Intervent Ultrasound, Dept Med Ultrason, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Yang, Daya] Sun Yat Sen Univ, Dept Cardiol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Liu, Xin] Sun Yat Sen Univ, Dept Liver Surg, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Wang, Qiongya] Wuhan Hankou Hosp, Dept Crit Care Med, Wuhan 430014, Hubei, Peoples R China.
   [Lv, Qingquan] Wuhan Hankou Hosp, Dept Gastrointestinal Surg, Wuhan 430014, Hubei, Peoples R China.
   [Huang, Ying] Wuhan Hankou Hosp, Sci & Educ Sect, Wuhan 430014, Hubei, Peoples R China.
   [Yu, Yang] Jianghan Univ, Dept Gastrointestinal Surg, Affiliated Hosp, Hosp Wuhan 6, Wuhan 430014, Hubei, Peoples R China.
   [Nirantharakumar, Krishnarajah; Cheng, KarKeung] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.
   [Nirantharakumar, Krishnarajah] Hlth Data Res UK, London, England.
   [Xiao, Haipeng] Sun Yat Sen Univ, Precis Med Inst, Affiliated Hosp 1, 58,ZhongShan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.
RP Peng, S (corresponding author), Sun Yat Sen Univ, Clin Trials Unit, Affiliated Hosp 1, 58,ZhongShan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.; Xiao, HP (corresponding author), Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, 58,ZhongShan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.; Xiao, HP (corresponding author), Sun Yat Sen Univ, Precis Med Inst, Affiliated Hosp 1, 58,ZhongShan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.
EM pengsui@vip.163.com; xiaohp@mail.sysu.edu.cn
CR Ali MS, 2015, J CLIN EPIDEMIOL, V68, P122, DOI 10.1016/j.jclinepi.2014.08.011
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Asare K, 2007, PHARMACOTHERAPY, V27, P1512, DOI 10.1592/phco.27.11.1512
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Brass D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1721
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Christ-Crain M, 2007, AM J RESP CRIT CARE, V176, P913, DOI 10.1164/rccm.200702-307OC
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Lee DTS, 2004, CLIN INFECT DIS, V39, P1247, DOI 10.1086/424016
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lee TF, 2020, CRIT CARE MED, V48, pE115, DOI 10.1097/CCM.0000000000004133
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Li Yu-ming, 2004, Zhonghua Yi Xue Za Zhi, V84, P1348
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Mansournia MA, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i189
   Masclee GMC, 2014, GASTROENTEROLOGY, V147, P784, DOI 10.1053/j.gastro.2014.06.007
   Meijvis SCA, 2011, LANCET, V377, P2023, DOI 10.1016/S0140-6736(11)60607-7
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Park BS, 2013, DIABETES METAB J, V37, P385, DOI 10.4093/dmj.2013.37.5.385
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Roberts GW, 2015, J CLIN ENDOCR METAB, V100, P4490, DOI 10.1210/jc.2015-2660
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tan T, 2020, LANCET DIABETES ENDO, V8, P659, DOI 10.1016/S2213-8587(20)30216-3
   Wei L, 2004, ANN INTERN MED, V141, P764, DOI 10.7326/0003-4819-141-10-200411160-00007
   Xiao Jian-zhong, 2004, Zhonghua Nei Ke Za Zhi, V43, P179
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 30
TC 0
Z9 0
U1 2
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD DEC
PY 2020
VL 105
IS 12
AR dgaa627
DI 10.1210/clinem/dgaa627
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OK3IU
UT WOS:000584547800056
PM 32880390
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Salvati, L
   Occhipinti, M
   Gori, L
   Ciani, L
   Mazzoni, A
   Maggi, L
   Capone, M
   Parronchi, P
   Liotta, F
   Miele, V
   Annunziato, F
   Lavorini, F
   Cosmi, L
AF Salvati, Lorenzo
   Occhipinti, Mariaelena
   Gori, Leonardo
   Ciani, Luca
   Mazzoni, Alessio
   Maggi, Laura
   Capone, Manuela
   Parronchi, Paola
   Liotta, Francesco
   Miele, Vittorio
   Annunziato, Francesco
   Lavorini, Federico
   Cosmi, Lorenzo
TI Pulmonary vascular improvement in severe COVID-19 patients treated with
   tocilizumab
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE Severe COVID-19; Tocilizumab; Alveolar-arterial oxygen gradient; Chest-X
   ray; Vascular score; IL-6
ID INTERLEUKIN-6; IL-6
AB As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and offlabel or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammatory syndrome occurs in many patients similarly to the cytokine release syndrome that develops after CAR-T cell therapy. In our retrospective observational study, 20 severe COVID-19 patients requiring intensive care were treated with tocilizumab in addition to standard-of-care therapy (SOC) and compared with 13 COVID-19 patients receiving only SOC. Clinical respiratory status, inflammatory markers and vascular radiologic score improved after one week from tocilizumab administration. On the contrary, these parameters were stable or worsened in patients receiving only SOC. Despite major study limitations, improvement of alveolar-arterial oxygen gradient as well as vascular radiologic score after one week may account for improved pulmonary vascular perfusion and could explain the more rapid recovery of COVID-19 patients receiving tocilizumab compared to controls.
C1 [Salvati, Lorenzo; Occhipinti, Mariaelena; Gori, Leonardo; Ciani, Luca; Mazzoni, Alessio; Maggi, Laura; Capone, Manuela; Parronchi, Paola; Liotta, Francesco; Annunziato, Francesco; Lavorini, Federico; Cosmi, Lorenzo] Univ Florence, Dept Expt & Clin Med, Florence, Italy.
   [Parronchi, Paola; Liotta, Francesco; Cosmi, Lorenzo] Careggi Univ Hosp, Immunol & Cell Therapy Unit, Florence, Italy.
   [Miele, Vittorio] Careggi Univ Hosp, Dept Emergency Radiol, Florence, Italy.
   [Annunziato, Francesco] Careggi Univ Hosp, Flow Cytometry Diagnost Ctr & Immunotherapy CDCI, Florence, Italy.
   [Lavorini, Federico] Careggi Univ Hosp, Pneumol & Intens Care Unit, Florence, Italy.
RP Cosmi, L (corresponding author), Viale Pieraccini 6, I-50139 Florence, Italy.
EM lorenzo.cosmi@unifi.it
RI Mazzoni, Alessio/AAB-4311-2019
OI Mazzoni, Alessio/0000-0001-7768-3805; CAPONE,
   MANUELA/0000-0002-4690-9960; Miele, Vittorio/0000-0002-7848-1567
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Archer SL, 2020, CIRCULATION, V142, P101, DOI 10.1161/CIRCULATIONAHA.120.047915
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   BOMBINO M, 1991, CHEST, V100, P762, DOI 10.1378/chest.100.3.762
   Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5
   Castelli V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02132
   Galvan-Roman Jose Maria, 2020, J Allergy Clin Immunol, DOI 10.1016/j.jaci.2020.09.018
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   HELMHOLZ HF, 1979, CHEST, V75, P748, DOI 10.1378/chest.75.6.748
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Hou TY, 2008, CURR CARDIOL REV, V4, P179, DOI 10.2174/157340308785160570
   Infectious Diseases Society of America (IDSA), 2020, IDSA GUID TREATM MAN
   Kerr R, 2001, BRIT J HAEMATOL, V115, P3, DOI 10.1046/j.1365-2141.2001.03061.x
   Kishimoto T, 2010, INT IMMUNOL, V22, P347, DOI 10.1093/intimm/dxq030
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Lang Min, 2020, Lancet Infect Dis, V20, P1365, DOI 10.1016/S1473-3099(20)30367-4
   Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]
   MCFARLANE MJ, 1994, AM J MED, V96, P57, DOI 10.1016/0002-9343(94)90116-3
   Middleton K, 2014, CRIT REV ONCOL HEMAT, V89, P129, DOI 10.1016/j.critrevonc.2013.08.004
   National Institutes of Health (NIH), 2020, NIH COR DIS 2019 COV
   Nicolai L, 2020, CIRCULATION, V142, P1176, DOI 10.1161/CIRCULATIONAHA.120.048488
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   PISTOLESI M, 1985, CLIN CHEST MED, V6, P315
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Reichert M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061896
   Rosas I., 2020, 20183442 MEDRXIV
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Stone John H, 2020, N Engl J Med, V383, P2333, DOI 10.1056/NEJMoa2028836
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tleyjeh Imad M, 2020, Clin Microbiol Infect, DOI 10.1016/j.cmi.2020.10.036
   Tobin MJ, 2020, AM J RESP CRIT CARE, V201, P1319, DOI 10.1164/rccm.202004-1076ED
   Vultaggio A, 2020, J ALLER CL IMM-PRACT, V8, P2575, DOI 10.1016/j.jaip.2020.06.013
   Wang WJ, 2020, J INFECT DIS, V222, P1444, DOI 10.1093/infdis/jiaa387
   WHO, 2020, LAB TEST COR DIS COV
   Wilson JG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140289
   Wong HYF, 2020, RADIOLOGY, V296, pE72, DOI 10.1148/radiol.2020201160
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
NR 40
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165-2478
EI 1879-0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD DEC
PY 2020
VL 228
BP 122
EP 128
DI 10.1016/j.imlet.2020.10.009
PG 7
WC Immunology
SC Immunology
GA OV9QO
UT WOS:000592535400016
PM 33161002
OA Green Published
DA 2021-01-01
ER

PT J
AU Austin, D
   John, C
   Hunt, BJ
   Carling, RS
AF Austin, Donna
   John, Catharine
   Hunt, Beverley J.
   Carling, Rachel S.
TI Validation of a liquid chromatography tandem mass spectrometry method
   for the simultaneous determination of hydroxychloroquine and metabolites
   in human whole blood
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE human whole blood; hydroxychloroquine; liquid chromatography tandem mass
   spectrometry; method validation
ID RESPIRATORY SYNDROME CORONAVIRUS; LUPUS-ERYTHEMATOSUS; VIRAL-INFECTIONS;
   CHLOROQUINE; QUANTIFICATION; RECOMMENDATIONS; MULTICENTER
AB Objectives: Hydroxychloroquine (HCQ) is an anti-malarial and immunomodulatory drug reported to inhibit the Corona virus, SARS-CoV-2, in vitro. At present there is insufficient evidence from clinical trials to determine the safety and efficacy of HCQ as a treatment for COVID-19. However, since the World Health Organisation declared COVID-19 a pandemic in March 2020, the US Food and Drug Administration issued an Emergency Use Authorisation to allow HCQ and Chloroquine (CQ) to be distributed and used for certain hospitalised patients with COVID-19 and numerous clinical trials are underway around the world, including the UK based RECOVERY trial, with over 1000 volunteers. The validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the simultaneous determination of HCQ and two of its major metabolites, desethylchloroquine (DCQ) and di-desethylchloroquine (DDCQ), in whole blood is described.
   Methods: Blood samples were deproteinised using acetonitrile. HCQ, DCQ and DDCQ were chromatographically separated on a biphenyl column with gradient elution, at a flow rate of 500 mu L/min. The analysis time was 8 min.
   Results: For each analyte linear calibration curves were obtained over the concentration range 50-2000 mu g/L, the lower limit of quantification (LLOQ) was 13 mu g/L, the inter-assay relative standard deviation (RSD) was <10% at 25, 800 and 1750 mu g/L and mean recoveries were 80, 81, 78 and 62% for HCQ, d4-HCQ, DCQ and DDCQ, respectively.
   Conclusion: This method has acceptable analytical performance and is applicable to the therapeutic monitoring of HCQ, evaluating the pharmacokinetics of HCQ in COVID-19 patients and supporting clinical trials.
C1 [Austin, Donna; John, Catharine; Carling, Rachel S.] Guys & St Thomas NHSFT, Biochem Sci, Viapath, 4th Floor,North Wing,St Thomas Hosp,Westminster B, London SE1 7EH, England.
   [Hunt, Beverley J.] Guys & St Thomas NHSFT, Thrombosis & Haemophilia Ctr, London, England.
   [Carling, Rachel S.] Kings Coll London, GKT Med Sch, London, England.
RP Carling, RS (corresponding author), Guys & St Thomas NHSFT, Biochem Sci, Viapath, 4th Floor,North Wing,St Thomas Hosp,Westminster B, London SE1 7EH, England.; Carling, RS (corresponding author), Kings Coll London, GKT Med Sch, London, England.
EM Rachel.carling@viapath.co.uk
OI Carling, Rachel/0000-0003-1988-3088
CR Alarcon GS, 2007, ANN RHEUM DIS, V66, P1168, DOI 10.1136/ard.2006.068676
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Balevic SJ, 2019, CLIN PHARMACOKINET, V58, P525, DOI 10.1007/s40262-018-0712-z
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Chambliss AB, 2016, METHODS MOL BIOL, V1383, P177, DOI 10.1007/978-1-4939-3252-8_19
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chen Z, 2020, INT J INFECT DIS, V97, P396
   Collins KP, 2018, J PHARMACOL EXP THER, V365, P447, DOI 10.1124/jpet.117.245639
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   DYALL J, 2017, DRUGS, V77, P1935, DOI [10.1007/s40265-017-0830-1, DOI 10.1007/S40265-017-0830-1]
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   FDA, 2018, GUID IND BIOAN METH
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gbinigie Kome, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101069
   Kalia S, 2007, DERMATOL THER, V20, P160, DOI 10.1111/j.1529-8019.2007.00131.x
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Kuhn A, 2011, J AM ACAD DERMATOL, V65, P54, DOI [10.1016/j.jaad.2010.06.018, 10.1016/j.jaad.2010.06.017, 10.1016/j.jaad.2010.03.037]
   Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Marmor MF, 2011, OPHTHALMOLOGY, V118, P415, DOI 10.1016/j.ophtha.2010.11.017
   Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s
   Munster T, 2002, ARTHRITIS RHEUM-US, V46, P1460, DOI 10.1002/art.10307
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   Petri M, 2020, ARTHRITIS RHEUMATOL, V72, P131
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Soichot M, 2014, J PHARMACEUT BIOMED, V100, P131, DOI 10.1016/j.jpba.2014.07.009
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   TETT SE, 1985, J CHROMATOGR, V344, P241, DOI 10.1016/S0378-4347(00)82024-1
   Tetu P, 2018, ANN DERMATOL VENER, V145, P395, DOI 10.1016/j.annder.2018.03.168
   U.S. Food and Drug Administration, EM US AUTH
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang LZ, 2012, J PHARMACEUT BIOMED, V61, P86, DOI 10.1016/j.jpba.2011.11.034
   WILLIAMS HJ, 1994, J RHEUMATOL, V21, P1457
   WILLIAMS SB, 1988, J CHROMATOGR-BIOMED, V433, P197, DOI 10.1016/S0378-4347(00)80598-8
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 47
TC 0
Z9 0
U1 4
U2 4
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
EI 1437-4331
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD DEC
PY 2020
VL 58
IS 12
BP 2047
EP 2061
DI 10.1515/cclm-2020-0610
PG 15
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA OR3SG
UT WOS:000589393000016
PM 32915766
DA 2021-01-01
ER

PT J
AU Keddie, S
   Ziff, O
   Chou, MKL
   Taylor, RL
   Heslegrave, A
   Garr, E
   Lakdawala, N
   Church, A
   Ludwig, D
   Manson, J
   Scully, M
   Nastouli, E
   Chapman, M
   Hart, M
   Lunn, M
AF Keddie, S.
   Ziff, O.
   Chou, M. K. L.
   Taylor, R. L.
   Heslegrave, A.
   Garr, E.
   Lakdawala, N.
   Church, A.
   Ludwig, D.
   Manson, J.
   Scully, M.
   Nastouli, E.
   Chapman, Md
   Hart, M.
   Lunn, Mp
TI Laboratory biomarkers associated with COVID-19 severity and management
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE COVID-19; Cytokines; Biomarkers; Intensive care; IL-6; CRP; IL-10; LDH
AB The heterogeneous disease course of COVID-19 is unpredictable, ranging from mild self-limiting symptoms to cytokine storms, acute respiratory distress syndrome (ARDS), multi-organ failure and death. Identification of high-risk cases will enable appropriate intervention and escalation. This study investigates the routine laboratory tests and cytokines implicated in COVID-19 for their potential application as biomarkers of disease severity, respiratory failure and need of higher-level care.
   From analysis of 203 samples, CRP, IL-6, IL-10 and LDH were most strongly correlated with the WHO ordinal scale of illness severity, the fraction of inspired oxygen delivery, radiological evidence of ARDS and level of respiratory support (p <= 0.001). IL-6 levels of >= 3.27 pg/ml provide a sensitivity of 0.87 and specificity of 0.64 for a requirement of ventilation, and a CRP of >= 37 mg/l of 0.91 and 0.66.
   Reliable stratification of high-risk cases has significant implications on patient triage, resource management and potentially the initiation of novel therapies in severe patients.
C1 [Keddie, S.; Ziff, O.; Chou, M. K. L.; Taylor, R. L.; Garr, E.; Lakdawala, N.; Church, A.; Chapman, Md; Hart, M.; Lunn, Mp] Univ Coll London Hosp NHS Trust Natl Hosp Neurol, Neuroimmunol & CSF Lab, Queen Sq, London, England.
   [Heslegrave, A.] UCL, UK Dementia Res Inst, London, England.
   [Ludwig, D.; Manson, J.] Univ Coll London Hosp NHS Trust, Dept Rheumatol, London, England.
   [Scully, M.] Univ Coll London Hosp NHS Fdn Trust & Cardiometab, Dept Haematol, London, England.
   [Nastouli, E.] Univ Coll London Hosp NHS Trust, Infect Control Dept, London, England.
RP Keddie, S (corresponding author), Univ Coll London Hosp NHS Trust Natl Hosp Neurol, Neuroimmunol & CSF Lab, Queen Sq, London, England.
EM stephen.keddie@nhs.net
OI keddie, stephen/0000-0002-2102-6053; Lunn, Michael/0000-0003-3174-6027
FU Association of British Neurologists and the Guarantors of Brain;
   National Institute of Health Research, University College London
   Hospitals, Biomedical Research Centre
FX Dr. Keddie is funded by the Association of British Neurologists and the
   Guarantors of Brain. Professor Mike Lunn is supported by the National
   Institute of Health Research, University College London Hospitals,
   Biomedical Research Centre.
CR [Anonymous], 2020, CHIN J TUBERC RESP D, V43
   Balcioglu YH, 2020, J NEUROIMMUNE PHARM, V15, P343, DOI 10.1007/s11481-020-09932-9
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Coomes EA, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2141
   European Center for Disease Prevention and Control, RAP RISK ASS COR DIS
   European center for disease prevention and control, 2020, CAS DEF COR DIS 2019
   He RY, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104361
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang W, 2020, CYTOM PART A, V97, P772, DOI 10.1002/cyto.a.24172
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   ICNARC, 2020, ICNARC REP COVID 19
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1789, DOI 10.1002/jmv.25900
   Liu F, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104370
   Maes B, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04453-5
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Rilinger J, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04447-3
   Wan S., 2020, BR J HAEMATOL, V189
   WHO, 2020, COR DIS COVID 19 SIT
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   World Health Organisation, 2020, BLUEPR NOV COR COVID
NR 21
TC 0
Z9 0
U1 2
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD DEC
PY 2020
VL 221
AR 108614
DI 10.1016/j.clim.2020.108614
PG 5
WC Immunology
SC Immunology
GA OU2RL
UT WOS:000591380800009
PM 33153974
OA Green Published
DA 2021-01-01
ER

PT J
AU Caban-Martinez, AJ
   Schaefer-Solle, N
   Santiago, K
   Louzado-Feliciano, P
   Brotons, A
   Gonzalez, M
   Issenberg, SB
   Kobetz, E
AF Caban-Martinez, Alberto J.
   Schaefer-Solle, Natasha
   Santiago, Katerina
   Louzado-Feliciano, Paola
   Brotons, Angel
   Gonzalez, Marco
   Issenberg, S. Barry
   Kobetz, Erin
TI Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a
   US fire department: a cross-sectional study
SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
DE virology; communicable diseases; biological monitoring; epidemiology;
   health and safety
ID OUTBREAK
AB Objectives
   We estimate the point seroprevalence of SARS-CoV-2 antibodies in the frontline firefighter/paramedic workforce of a South Florida fire department located in the epicentre of a State outbreak.
   Methods
   A cross-sectional study design was used to estimate the point seroprevalence of SARS-CoV-2 antibodies using a rapid immunoglobulin (Ig)M-IgG combined point-of-care lateral flow immunoassay among frontline firefighters/paramedics collected over a 2-day period, 16-17 April 2020. Fire department personnel were emailed a survey link assessing COVID-19 symptoms and work exposures the day prior to the scheduled drive-through antibody testing at a designated fire station. Off-duty and on-duty firefighter/paramedic personnel drove through the fire station/training facility in their personal vehicles or on-duty engine/rescue trucks for SARS-CoV-2 antibody testing.
   Results
   Among the 203 firefighters/paramedics that make up the fire department workforce, 18 firefighters/paramedics (8.9%) tested positive for SARS-CoV-2 antibodies, of which 8 firefighters/paramedics (3.9%) were IgG positive only, 8 (3.9%) were IgM positive only and 2 (0.1%) were IgG/IgM positive. The positive predictive value (PPV) of the serological test is estimated to be 33.2% and the negative predictive value is 99.3%. The average number of COVID-19 case contacts (ie, within 6 feet of an infected person (laboratory-confirmed or probable COVID-19 patient) for >= 15 min) experienced by firefighters/paramedics was higher for those with positive serology compared with those with negative (13.3 cases vs 7.31 cases; p=0.022). None of the antibody positive firefighters/paramedics reported receipt of the annual influenza vaccine compared with firefighters/paramedics who tested negative for SARS-CoV-2 antibodies (0.0% vs 21.0%; p=0.027).
   Conclusion
   Rapid SARS-CoV-2 IgM-IgG antibody testing documented early-stage and late-stage infection in a firefighter workforce providing insight to a broader medical surveillance project on return to work for firefighters/paramedics. Given the relatively low PPV of the serological test used in this study back in April 2020, caution should be used in interpreting test results.
C1 [Caban-Martinez, Alberto J.; Santiago, Katerina; Louzado-Feliciano, Paola; Kobetz, Erin] Univ Miami, Miller Sch Med, Publ Hlth Sci, Miami, FL 33136 USA.
   [Caban-Martinez, Alberto J.; Schaefer-Solle, Natasha; Kobetz, Erin] Sylvester Comprehens Canc Ctr, Miami, FL USA.
   [Schaefer-Solle, Natasha; Kobetz, Erin] Univ Miami, Sch Med, Med, Miami, FL USA.
   [Brotons, Angel; Gonzalez, Marco; Issenberg, S. Barry] Univ Miami, Miller Sch Med, Gordon Ctr Res Med Educ, Miami, FL 33136 USA.
RP Caban-Martinez, AJ (corresponding author), Univ Miami, Miller Sch Med, Publ Hlth Sci, Miami, FL 33136 USA.
EM acaban@med.miami.edu
OI Caban-Martinez, Alberto/0000-0002-5960-1308
FU State of Florida [2382A, 62]; Federal Emergency Management
   Administration (FEMA) [EMW-2017--FP-00860]; National Cancer Institute of
   the National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [P30CA240139]
FX Support for this research is, in part, by the State of Florida
   appropriation #2382A for Firefighter Cancer Initiative (principal
   investigator (PI): EK) to the University of Miami (UM) Sylvester
   Comprehensive Cancer Center; the Federal Emergency Management
   Administration (FEMA) Grant #EMW-2017--FP-00860 (PI: AJC--M); the State
   of Florida appropriation #62 for the Medical Training and Simulation
   Laboratory to the University of Miami Gordon Center for Simulation and
   Innovation in Medical Education (PI: SBI); and by the National Cancer
   Institute of the National Institutes of Health under Award Number
   P30CA240139. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health or Federal Emergency Management Agency of the
   Department of Homeland Security.
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Brouwer AF, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7134-1
   Burke RM, 2020, MMWR-MORBID MORTAL W, P69
   Caban-Martinez AJ, 2010, PREV MED, V50, P210, DOI 10.1016/j.ypmed.2010.01.001
   Gamio L, 2020, NY TIMES
   Goudsmit J, 2020, EUR J EPIDEMIOL, V35, P331, DOI 10.1007/s10654-020-00635-2
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1
   Kimball A, 2020, MMWR-MORBID MORTAL W, V69, P377, DOI 10.15585/mmwr.mm6913e1
   Li Z, 2020, DEV CLIN APPL RAPID
   Li Z, 2020, J MED VIROL
   Ling ZK, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108956
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Meader N, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3373-6
   NCfH S, 2000, NAT HLTH INT SURV QU
   Patel R, 2020, MBIO, V11, DOI 10.1128/mBio.00722-20
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   Spina S, 2020, LANCET, V395, pE49, DOI 10.1016/S0140-6736(20)30493-1
   Strickland JR, 2017, J OCCUP ENVIRON MED, V59, P673, DOI 10.1097/JOM.0000000000001051
NR 19
TC 2
Z9 2
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1351-0711
EI 1470-7926
J9 OCCUP ENVIRON MED
JI Occup. Environ. Med.
PD DEC
PY 2020
VL 77
IS 12
BP 857
EP 861
DI 10.1136/oemed-2020-106676
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OU9CC
UT WOS:000591820000007
PM 32764107
OA Bronze
DA 2021-01-01
ER

PT J
AU Okuhara, T
   Okada, H
   Kiuchi, T
AF Okuhara, Tsuyoshi
   Okada, Hiroko
   Kiuchi, Takahiro
TI Examining persuasive message type to encourage staying at home during
   the COVID-19 pandemic and social lockdown: A randomized controlled study
   in Japan
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE COVID-19; Novel coronavirus; Social lockdown; Protection motivation
   theory; Health communication; Persuasion
ID PROTECTION MOTIVATION; FEAR APPEALS
AB Objective: Behavioral change is the only prevention against the COVID-19 pandemic until vaccines become available. This is the first study to examine the most persuasive message type in terms of narrator difference in encouraging people to stay at home during the COVID-19 pandemic and social lockdown.
   Methods: Participants (n = 1,980) were randomly assigned to five intervention messages (from a governor, a public health expert, a physician, a patient, and a resident of an outbreak area) and a control message. Intention to stay at home before and after reading messages was assessed. A one-way ANOVA with Tukey's or Games-Howell test was conducted.
   Results: Compared with other messages, the message from a physician significantly increased participants' intention to stay at home in areas with high numbers of people infected (versus a governor, p = .002; an expert, p = .023; a resident, p = .004).
   Conclusion: The message from a physicianwhich conveyed the crisis of overwhelmed hospitals and consequent risk of people being unable to receive treatmentincreased the intent to stay at home the most.
   Practice implications: Health professionals and media operatives may be able to encourage people to stay at home by disseminating the physicians' messages through media and the internet. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Okuhara, Tsuyoshi; Okada, Hiroko; Kiuchi, Takahiro] Univ Tokyo, Sch Publ Hlth, Dept Hlth Commun, Tokyo, Japan.
RP Okuhara, T (corresponding author), Univ Tokyo, Sch Publ Hlth, Dept Hlth Commun, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM okuhara-ctr@umin.ac.jp
FU Japan Society for the Promotion of Science KAKENHIMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [19K10615]
FX This work was supported by the Japan Society for the Promotion of
   Science KAKENHI (grant number 19K10615).
CR [Anonymous], BBC NEWS
   [Anonymous], REUTERS
   [Anonymous], 2020, YAHOO JAPAN NEWS
   [Anonymous], 2020, BBC NEWS
   Betsch C, 2012, VACCINE, V30, P3727, DOI 10.1016/j.vaccine.2012.02.025
   Bults M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-2
   Hopfer S, 2012, PREV SCI, V13, P173, DOI 10.1007/s11121-011-0254-1
   IACOBUCCI G, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1204
   Kang YH, 2006, COMMUN MONOGR, V73, P351, DOI 10.1080/03637750601024164
   Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037
   Leask J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-535
   MADDUX JE, 1983, J EXP SOC PSYCHOL, V19, P469, DOI 10.1016/0022-1031(83)90023-9
   Paital B, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138914
   Renner B, 2012, VACCINE, V30, P7019, DOI 10.1016/j.vaccine.2012.09.064
   Reuter T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022130
   ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803
   Rubin GJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2651
   Ruhnke GW, 2000, CHEST, V118, P1172, DOI 10.1378/chest.118.4.1172
   Shen LJ, 2019, HEALTH COMMUN, V34, P1329, DOI 10.1080/10410236.2018.1485078
   Sibony AL, 2020, EUR J RISK REGUL, V11, P350, DOI 10.1017/err.2020.22
   WHO, 2020, COR DIS COVID 19 PAN
NR 21
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0738-3991
EI 1873-5134
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD DEC
PY 2020
VL 103
IS 12
BP 2588
EP 2593
DI 10.1016/j.pec.2020.08.016
PG 6
WC Public, Environmental & Occupational Health; Social Sciences,
   Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
   Topics
GA OR8XP
UT WOS:000589750600027
PM 32863098
OA Green Published
DA 2021-01-01
ER

PT J
AU Elgendy, MO
   El-Gendy, AO
   Abdelrahim, MEA
AF Elgendy, Marwa O.
   El-Gendy, Ahmed O.
   Abdelrahim, Mohamed E. A.
TI Public awareness in Egypt about COVID-19 spread in the early phase of
   the pandemic
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE COVID-19; Public awareness; Egypt; WHO
ID EAST RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS
AB Objective: This study aimed to evaluate public awareness in Egypt related to the coronavirus.
   Methods: An online structured survey was conducted during March and April 2020 to assess coronavirus knowledge. The questionnaire was divided into 6 parts consisting of 39 questions for a total possible score of 0 to 39; to assess the participants' general knowledge [10 items]; symptoms knowledge [2 items]; transmission knowledge [6 items]; preventive knowledge [4 items]; treatment knowledge [6 items], and public knowledge of governmental and international efforts [10 items].
   Results: A total of 726 participants participated, 97.5% of them knew the main clinical symptoms of coronaviruses. 99% believed that following the etiquette of coughing, sneezing, or wearing a medical mask is important to reduce infection transmission. 80.5% of the participants believed that there is no effective treatment or vaccine available for the coronavirus. The important role of the international organizations to overcome the coronavirus was known by (92.3%). 65.2% believed that the Ministry of Health provided reliable data on the number of infections or death. 27.9% of the participants consider coronavirus infection as a stigma. The average score of this survey was 31.75/39 (81.4%) regarding the knowledge about the disease.
   Conclusion: Overall, the study participants' had good knowledge of coronavirus and the international efforts to confront the coronavirus.
   Practice implications: Further study is required to evaluate the effect of such good knowledge on decreasing the infection rate. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Elgendy, Marwa O.] Beni Suef Univ, Teaching Hosp, Dept Clin Pharm, Fac Med, Bani Suwayf, Egypt.
   [Elgendy, Marwa O.] Nahda Univ, Dept Clin Pharm, Fac Pharm, Bani Suwayf, Egypt.
   [El-Gendy, Ahmed O.] Beni Suef Univ, Dept Microbiol & Immunol, Fac Pharm, Bani Suwayf, Egypt.
   [Abdelrahim, Mohamed E. A.] Beni Suef Univ, Clin Pharm Dept, Fac Pharm, Bani Suwayf, Egypt.
RP Abdelrahim, MEA (corresponding author), Beni Suef Univ, Clin Pharm Dept, Fac Pharm, Bani Suwayf, Egypt.
OI abdelrahim, mohamed/0000-0003-0227-8404
CR Al-Mohrej OA, 2016, J INFECT PUBLIC HEAL, V9, P259, DOI 10.1016/j.jiph.2015.10.003
   Al-Tawfiq JA, 2014, LANCET INFECT DIS, V14, P992, DOI 10.1016/S1473-3099(14)70840-0
   Alghamdi IG, 2014, INT J GEN MED, V7, P417, DOI 10.2147/IJGM.S67061
   Brindha M.D., 2020, ALOCHANA CHAKRA J, V9, P585
   Cherkaoui M., 2020, SHIFTING GEOPOLITI 2, P19
   El-Gendy AO, 2020, VACCINE, V38, P5564, DOI 10.1016/j.vaccine.2020.06.083
   Elbur A, 2016, IOSR J PHARM, V6, P33, DOI [10.9790/3021-068023340, DOI 10.9790/3021-068023340]
   Gao PC, 2020, ENVIRON PLANN A, V52, P698, DOI 10.1177/0308518X20910162
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Khan MU, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1281
   Mackay IM, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0439-5
   Mohamed M.B., 2018, EFFECTS ED PROGRAM M
   Momattin H, 2013, INT J INFECT DIS, V17, pE792, DOI 10.1016/j.ijid.2013.07.002
   Rabbani S.A., 2020, INT J MED PUBLIC HLT, V10
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0738-3991
EI 1873-5134
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD DEC
PY 2020
VL 103
IS 12
BP 2598
EP 2601
DI 10.1016/j.pec.2020.09.002
PG 4
WC Public, Environmental & Occupational Health; Social Sciences,
   Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
   Topics
GA OR8XP
UT WOS:000589750600029
PM 32912808
DA 2021-01-01
ER

PT J
AU Blondiaux, E
   Parisot, P
   Redheuil, A
   Tzaroukian, L
   Levy, Y
   Sileo, C
   Schnuriger, A
   Lorrot, M
   Guedj, R
   le Pointe, HD
AF Blondiaux, Eleonore
   Parisot, Pauline
   Redheuil, Alban
   Tzaroukian, Lucile
   Levy, Yael
   Sileo, Chiara
   Schnuriger, Aurelie
   Lorrot, Mathie
   Guedj, Romain
   le Pointe, Hubert Ducou
TI Cardiac MRI in Children with Multisystem Inflammatory Syndrome
   Associated with COVID-19
SO RADIOLOGY
LA English
DT Article
ID KAWASAKI-DISEASE; SHOCK
AB This case series examines cardiac MRI findings in four children and adolescents admitted to intensive care in April 2020 for multisystem inflammatory syndrome and Kawasaki disease-like features related to coronavirus disease 2019 (COVID-19). Acute myocarditis occurred less than 1 week after onset of fever and gastrointestinal symptoms. Physical examination showed rash and cheilitis or conjunctivitis. All patients recovered after intravenous immunoglobulin therapy. Severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction was negative in nasopharyngeal, stool, and respiratory samples and was positive on serology. Cardiac MRI showed diffuse myocardial edema on T2 short tau inversion-recovery sequences and native T1 mapping, with no evidence of late gadolinium enhancement suggestive of replacement fibrosis or focal necrosis. These findings favor postinfectious myocarditis in children and adolescents with COVID-19. (C) RSNA, 2020
C1 [Blondiaux, Eleonore; Sileo, Chiara; le Pointe, Hubert Ducou] Sorbonne Univ, Hop Armand Trousseau, Hop Trousseau, AP HP,Dept Imaging, 26 Ave Dr Arnold Netter, F-75012 Paris, France.
   [Parisot, Pauline] Sorbonne Univ, Hop Armand Trousseau, Hop Trousseau, AP HP,Pediat Cardiovasc Unit, 26 Ave Dr Arnold Netter, F-75012 Paris, France.
   [Tzaroukian, Lucile; Levy, Yael] Sorbonne Univ, Hop Armand Trousseau, Hop Trousseau, AP HP,Neonatal & Pediat Intens Care Unit, 26 Ave Dr Arnold Netter, F-75012 Paris, France.
   [Schnuriger, Aurelie] Sorbonne Univ, Hop Armand Trousseau, Hop Trousseau, AP HP,Virol Lab, 26 Ave Dr Arnold Netter, F-75012 Paris, France.
   [Lorrot, Mathie] Sorbonne Univ, Hop Armand Trousseau, Hop Trousseau, AP HP,Dept Pediat, 26 Ave Dr Arnold Netter, F-75012 Paris, France.
   [Guedj, Romain] Sorbonne Univ, Hop Armand Trousseau, Hop Trousseau, AP HP,Pediat Emergency Dept, 26 Ave Dr Arnold Netter, F-75012 Paris, France.
   [Blondiaux, Eleonore; Redheuil, Alban] Sorbonne Univ, INSERM, CNRS, Biomed Imaging Lab, Paris, France.
   [Redheuil, Alban] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Inst Cardiol,Dept Cardiovasc & Thorac Imaging & I, Paris, France.
   [Levy, Yael] Ecole Vet, INSERM, Lab U955 PHYDES IMRB Pharmacol & Therapeut Strate, Maisons Alfort, France.
RP Blondiaux, E (corresponding author), Sorbonne Univ, Hop Armand Trousseau, Hop Trousseau, AP HP,Dept Imaging, 26 Ave Dr Arnold Netter, F-75012 Paris, France.
EM eleonore.blondiaux@aphp.fr
RI ; guedj, romain/H-2550-2019
OI LEVY, YAEL/0000-0002-5325-5838; Sileo, Chiara/0000-0001-6406-1951;
   guedj, romain/0000-0002-9497-4396
CR AMERI P, 2020, JAMA CARDIOL, DOI DOI 10.1001/JAMACARDIO.2020.1096
   Belhadjer Z, 2020, CIRCULATION, V142, P429, DOI 10.1161/CIRCULATIONAHA.120.048360
   Burkhardt BEU, 2020, J MAGN RESON IMAGING, V51, P897, DOI 10.1002/jmri.26910
   Caruso D, 2020, RADIOLOGY, V296, pE79, DOI 10.1148/radiol.2020201237
   Ferreira VM, 2018, J AM COLL CARDIOL, V72, P3158, DOI 10.1016/j.jacc.2018.09.072
   Gatterre P, 2012, INTENS CARE MED, V38, P872, DOI 10.1007/s00134-012-2473-8
   Harada M, 2012, HISTOPATHOLOGY, V61, P1156, DOI 10.1111/j.1365-2559.2012.04332.x
   Howard A, 2020, PEDIATR CARDIOL, V41, P316, DOI 10.1007/s00246-019-02258-1
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Kim IC, 2020, EUR HEART J, V41, P1859, DOI 10.1093/eurheartj/ehaa288
   Mavrogeni S, 2011, JACC-CARDIOVASC IMAG, V4, P1140, DOI 10.1016/j.jcmg.2011.04.021
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Nathan N, 2020, LANCET, V395, P1481, DOI 10.1016/S0140-6736(20)30980-6
   Ou P, 2013, PEDIATR RADIOL, V43, P444, DOI 10.1007/s00247-012-2478-z
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Rowley AH, 2011, J INFECT DIS, V203, P1021, DOI 10.1093/infdis/jiq136
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
NR 17
TC 11
Z9 11
U1 0
U2 1
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD DEC
PY 2020
VL 297
IS 3
BP E283
EP E288
DI 10.1148/radiol.2020202288
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA OU6EM
UT WOS:000591619800001
PM 32515676
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lemos, ACB
   Santo, DAD
   Salvetti, MC
   Gilio, RN
   Agra, LB
   Pazin, A
   Miranda, CH
AF Bertoldi Lemos, Anna Cristina
   do Espirito Santo, Douglas Alexandre
   Salvetti, Maisa Cabetti
   Gilio, Renato Noffs
   Agra, Lucas Barbosa
   Pazin-Filho, Antonio
   Miranda, Carlos Henrique
TI Therapeutic versus prophylactic anticoagulation for severe COVID-19: A
   randomized phase II clinical trial (HESACOVID)
SO THROMBOSIS RESEARCH
LA English
DT Article
DE COVID-19; Mechanical ventilation; Anticoagulant treatment; D-dimer;
   Coagulopathy
ID ENOXAPARIN; FAILURE
AB Introduction: Coronavirus disease 2019 (COVID-19) causes a hypercoagulable state. Several autopsy studies have found microthrombi in pulmonary circulation.
   Methods: In this randomized, open-label, phase II study, we randomized COVID-19 patients requiring mechanical ventilation to receive either therapeutic enoxaparin or the standard anticoagulant thromboprophylaxis. We evaluated the gas exchange over time through the ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) at baseline, 7, and 14 days after randomization, the time until successful liberation from mechanical ventilation, and the ventilator-free days.
   Results: Ten patients were assigned to the therapeutic enoxaparin and ten patients to prophylactic anticoagulation. There was a statistically significant increase in the PaO2/FiO2 ratio over time in the therapeutic group (163 [95% confidence interval - CI 133-193] at baseline, 209 [95% CI 171-247] after 7 days, and 261 [95% CI 230-293] after 14 days), p = 0.0004. In contrast, we did not observe this improvement over time in the prophylactic group (184 [95% CI 146-222] at baseline, 168 [95% CI 142-195] after 7 days, and 195 [95% CI 128-262] after 14 days), p = 0.487. Patients of the therapeutic group had a higher ratio of successful liberation from mechanical ventilation (hazard ratio: 4.0 [95% CI 1.035-15.053]), p = 0.031 and more ventilator-free days (15 days [interquartile range IQR 6-16] versus 0 days [IQR 0-11]), p = 0.028 when compared to the prophylactic group.
   Conclusion: Therapeutic enoxaparin improves gas exchange and decreases the need for mechanical ventilation in severe COVID-19.
C1 [Bertoldi Lemos, Anna Cristina; do Espirito Santo, Douglas Alexandre; Agra, Lucas Barbosa; Pazin-Filho, Antonio; Miranda, Carlos Henrique] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Internal Med, Div Emergency Med, Rua Bernardino Campos 1000, BR-14020670 Ribeirao Preto, SP, Brazil.
   [Salvetti, Maisa Cabetti; Gilio, Renato Noffs] Univ Sao Paulo, Hosp Estadual Amer Brasiliense, Ribeirao Preto Sch Med, Ribeirao Preto, SP, Brazil.
RP Miranda, CH (corresponding author), Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Internal Med, Div Emergency Med, Rua Bernardino Campos 1000, BR-14020670 Ribeirao Preto, SP, Brazil.
EM chmiranda@fmrp.usp.br
RI Miranda, Carlos/B-6247-2014
OI Miranda, Carlos/0000-0002-5968-4879
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Al-Ani F, 2020, THROMB RES, V192, P152, DOI 10.1016/j.thromres.2020.05.039
   Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Berlin DA, 2020, N ENGL J MED
   Camprubi-Rimblas M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.08
   Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5
   Coppo A, 2020, LANCET RESP MED, V8, P765, DOI 10.1016/S2213-2600(20)30268-X
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Helms J., 2020, INTENSIVE CARE MED, V46
   Hulot JS, 2005, CLIN PHARMACOL THER, V77, P542, DOI 10.1016/j.clpt.2005.02.012
   Iba T, 2020, J THROMB HAEMOST, V18, P2103, DOI 10.1111/jth.14975
   Khider L., 2020, J THROMB HAEMOST
   Li LF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093097
   Li Y.L. Jianlin, 2018, INT J CLIN EXP MED, V11, P9
   Lu XF, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01455-4
   MacLaren R, 2007, PHARMACOTHERAPY, V27, P860, DOI 10.1592/phco.27.6.860
   Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rapkiewicz Amy V, 2020, EClinicalMedicine, V24, P100434, DOI 10.1016/j.eclinm.2020.100434
   Shaikh Suhail A, 2017, P T, V42, P245
   Weiss G, 2019, BLOOD, V133, P40, DOI 10.1182/blood-2018-06-856500
   Xie NL, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3169179
   Yu  BL, 2020, J THROMB THROMBOLYS, V50, P548, DOI 10.1007/s11239-020-02171-y
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 4
Z9 4
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
EI 1879-2472
J9 THROMB RES
JI Thromb. Res.
PD DEC
PY 2020
VL 196
BP 359
EP 366
DI 10.1016/j.thromres.2020.09.026
PG 8
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OV5GP
UT WOS:000592238500001
PM 32977137
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bikdeli, B
   Talasaz, AH
   Rashidi, F
   Sharif-Kashani, B
   Farrokhpour, M
   Bakhshandeh, H
   Sezavar, H
   Dabbagh, A
   Beigmohammadi, MT
   Payandemehr, P
   Yadollahzadeh, M
   Riahi, T
   Khalili, H
   Jamalkhani, S
   Rezaeifar, P
   Abedini, A
   Lookzadeh, S
   Shahmirzaei, S
   Tahamtan, O
   Matin, S
   Amin, A
   Parhizgar, SE
   Jimenez, D
   Gupta, A
   Madhavan, MV
   Parikh, SA
   Monreal, M
   Hadavand, N
   Hajighasemi, A
   Maleki, M
   Sadeghian, S
   Mohebbi, B
   Piazza, G
   Kirtane, AJ
   Lip, GYH
   Krumholz, HM
   Goldhaber, SZ
   Sadeghipour, P
AF Bikdeli, Behnood
   Talasaz, Azita H.
   Rashidi, Farid
   Sharif-Kashani, Babak
   Farrokhpour, Mohsen
   Bakhshandeh, Hooman
   Sezavar, Hashem
   Dabbagh, Ali
   Beigmohammadi, Mohammad Taghi
   Payandemehr, Pooya
   Yadollahzadeh, Mahdi
   Riahi, Taghi
   Khalili, Hossein
   Jamalkhani, Sepehr
   Rezaeifar, Parisa
   Abedini, Atefeh
   Lookzadeh, Somayeh
   Shahmirzaei, Shaghayegh
   Tahamtan, Ouria
   Matin, Samira
   Amin, Ahmad
   Parhizgar, Seyed Ehsan
   Jimenez, David
   Gupta, Aakriti
   Madhavan, Mahesh, V
   Parikh, Sahil A.
   Monreal, Manuel
   Hadavand, Naser
   Hajighasemi, Alireza
   Maleki, Majid
   Sadeghian, Saeed
   Mohebbi, Bahram
   Piazza, Gregory
   Kirtane, Ajay J.
   Lip, Gregory Y. H.
   Krumholz, Harlan M.
   Goldhaber, Samuel Z.
   Sadeghipour, Parham
TI Intermediate versus standard-dose prophylactic anticoagulation and
   statin therapy versus placebo in critically-ill patients with COVID-19:
   Rationale and design of the INSPIRATION/INSPIRATION-S studies
SO THROMBOSIS RESEARCH
LA English
DT Article
ID CLINICAL-TRIALS; SIMVASTATIN
AB Background: Microvascular and macrovascular thrombotic events are among the hallmarks of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is considered an important driver of pulmonary and extrapulmonary manifestations of COVID-19. The optimal management strategy to prevent thrombosis in critically-ill patients with COVID-19 remains unknown.
   Methods: The Intermediate versus Standard-dose Prophylactic anticoagulation In cRitically-ill pATIents with COVID-19: An opeN label randomized controlled trial (INSPIRATION) and INSPIRATION-statin (INSPIRATION-S) studies test two independent hypotheses within a randomized controlled trial with 2 x 2 factorial design. Hospitalized critically-ill patients with reverse transcription polymerase chain reaction confirmed COVID-19 will be randomized to intermediate-dose versus standard dose prophylactic anticoagulation. The 600 patients undergoing this randomization will be screened and if meeting the eligibility criteria, will undergo an additional double-blind stratified randomization to atorvastatin 20 mg daily versus matching placebo. The primary endpoint, for both hypotheses will be tested for superiority and includes a composite of adjudicated acute arterial thrombosis, venous thromboembolism (VTE), use of extracorporeal membrane oxygenation, or all-cause death within 30 days from enrollment. Key secondary endpoints include all-cause mortality, adjudicated VTE, and ventilator-free days. Key safety endpoints include major bleeding according to the Bleeding Academic Research Consortium definition and severe thrombocytopenia (platelet count < 20,000/fL) for the anticoagulation hypothesis. In a prespecified secondary analysis for non-inferiority, the study will test for the non-inferiority of intermediate intensity versus standard dose anticoagulation for major bleeding, considering a non-inferiority margin of 1.8 based on odds ratio. Key safety endpoints for the statin hypothesis include rise in liver enzymes > 3 times upper normal limit and clinically-diagnosed myopathy. The primary analyses will be performed in the modified intention-to-treat population.
   Results will be tested in exploratory analyses across key subgroups and in the intention-to-treat and per-protocol cohorts.
   Conclusions: INSPIRATION and INSPIRATON-S studies will help address clinically-relevant questions for antithrombotic therapy and thromboinflammatory therapy in critically-ill patients with COVID-19.
C1 [Bikdeli, Behnood; Piazza, Gregory; Goldhaber, Samuel Z.] Brigham & Womens Hosp, Harvard Med Sch, Cardiovasc Med Div, Boston, MA USA.
   [Bikdeli, Behnood; Krumholz, Harlan M.] Yale YNHH Ctr Outcomes Res & Evaluat, New Haven, CT USA.
   [Bikdeli, Behnood; Gupta, Aakriti; Madhavan, Mahesh, V; Parikh, Sahil A.; Kirtane, Ajay J.] Cardiovasc Res Fdn CRF, New York, NY USA.
   [Talasaz, Azita H.; Hajighasemi, Alireza; Sadeghian, Saeed] Univ Tehran Med Sci, Tehran Heart Ctr, Tehran, Iran.
   [Rashidi, Farid; Rezaeifar, Parisa; Tahamtan, Ouria; Matin, Samira] Tuberclosis & Lung Dis Res Ctr, Tabriz, Iran.
   [Sharif-Kashani, Babak] Shahid Beheshti Univ Med Sci, Tobacoo Prevent & Control Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
   [Sharif-Kashani, Babak] Shahid Beheshti Univ Med Sci, Lung Transplant Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Dept Cardiol, Tehran, Iran.
   [Farrokhpour, Mohsen; Yadollahzadeh, Mahdi] Iran Univ Med Sci, Firouzgar Hosp, Dept Internal Med, Tehran, Iran.
   [Bakhshandeh, Hooman; Amin, Ahmad; Parhizgar, Seyed Ehsan; Hadavand, Naser; Maleki, Majid; Mohebbi, Bahram] Iran Univ Med Sci, Rajaie Cardiovasc Med & Res Ctr, Tehran, Iran.
   [Sezavar, Hashem; Riahi, Taghi] Iran Univ Med Sci, Rasoul Akram Hosp, Tehran, Iran.
   [Dabbagh, Ali] Shahid Beheshti Univ Med Sci, Sch Med Anesthesiol Res Ctr Shahid Modarres Hosp, Dept Anesthesiol, Tehran, Iran.
   [Beigmohammadi, Mohammad Taghi] Univ Tehran Med Sci, Anesthesiol & Intens Care, Imam Khomeini Hosp Complex, Tehran, Iran.
   [Payandemehr, Pooya; Shahmirzaei, Shaghayegh] Univ Tehran Med Sci, Sina Hosp, Tehran, Iran.
   [Khalili, Hossein] Univ Tehran Med Sci, Dept Pharmacotherapy, Imam Khomeini Hosp Complex, Tehran, Iran.
   [Jamalkhani, Sepehr] Iran Univ Med Sci, Student Res Comm, Tehran, Iran.
   [Abedini, Atefeh; Lookzadeh, Somayeh] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, Chron Resp Dis Res Ctr, Tehran, Iran.
   [Jimenez, David] Hosp Ramon Y Cajal IRYCIS, Resp Dept, Madrid, Spain.
   [Jimenez, David] Univ Alcala IRYCIS, Med Dept, Madrid, Spain.
   [Jimenez, David] CIBER Enfermedades Respiratorias CIBERES, Madrid, Spain.
   [Gupta, Aakriti; Madhavan, Mahesh, V; Parikh, Sahil A.; Kirtane, Ajay J.] Columbia Univ, Div Cardiol, Irving Med Ctr, New York, NY USA.
   [Monreal, Manuel] Univ Catolica Murcia, Hosp Germans Trias & Pujol, Dept Internal Med, Murcia, Spain.
   [Lip, Gregory Y. H.] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England.
   [Lip, Gregory Y. H.] Liverpool Heart & Chest Hosp, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England.
   [Jamalkhani, Sepehr; Lip, Gregory Y. H.] Aalborg Univ, Aalborg, Denmark.
   [Krumholz, Harlan M.] Yale Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT USA.
   [Krumholz, Harlan M.] Yale Sch Publ Hlth, Dept Hlth Policy & Adminitrat, New Haven, CT USA.
   [Sadeghipour, Parham] Iran Univ Med Sci, Cardiovasc Intervent Res Ctr, Rajaie Cardiovasc Med & Res Ctr, Vali Asr Ave,Niyayesh Blvd, Tehran 1996911101, Iran.
   [Sadeghipour, Parham] Iran Univ Med Sci, Clin Trial Ctr, Rajaie Cardiovasc Med & Res Ctr, Tehran, Iran.
RP Sadeghipour, P (corresponding author), Iran Univ Med Sci, Cardiovasc Intervent Res Ctr, Rajaie Cardiovasc Med & Res Ctr, Vali Asr Ave,Niyayesh Blvd, Tehran 1996911101, Iran.; Bikdeli, B (corresponding author), Brigham & Womens Hosp, Cardiovasc Med Div, 75 Francis St,Shapiro 5,Suite 5156, Boston, MA 02115 USA.
EM bbikdelli@bwh.harvard.edu; psadeghipour@hotmail.com
FU Rajaie Cardiovascular Medical and Research Center [RHC-99060]
FX The study has been supported by a research grant RHC-99060 from the
   Rajaie Cardiovascular Medical and Research Center.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   [Anonymous], 2020, 150 WHO
   Bassler D, 2008, J CLIN EPIDEMIOL, V61, P241, DOI 10.1016/j.jclinepi.2007.07.016
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bikdeli B, 2020, THROMB HAEMOSTASIS, V120, P1004, DOI 10.1055/s-0040-1713152
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bohm M, 2020, CLIN RES CARDIOL, V109, P1446, DOI 10.1007/s00392-020-01656-3
   Calfee CS, 2018, LANCET RESP MED, V6, P691, DOI 10.1016/S2213-2600(18)30177-2
   Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Cook D, 2011, NEW ENGL J MED, V364, P1305, DOI 10.1056/NEJMoa1014475
   COVID-19 Treatment Guidelines, 2020, COVID 19 TREATM GUID
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Eck RJ, 2019, SEMIN THROMB HEMOST, V45, P810, DOI 10.1055/s-0039-1696965
   Fernandez-Capitan C, 2020, SEMIN THROMB HEMOST, DOI 10.1055/s-0040-1718402
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Gupta Aakriti, 2020, Res Sq, DOI 10.21203/rs.3.rs-56210/v1
   Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   Jalili Mohammad, 2020, Ann Intern Med, DOI 10.7326/M20-2911
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Klok FA, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01494-2020
   Kow S.S.H. Chia Siang, 2020, AM J CARDIOL, DOI [10.1016/j.amjcard.2020.08.004., DOI 10.1016/J.AMJCARD.2020.08.004]
   Kunutsor SK, 2020, THROMB RES, V196, P27, DOI 10.1016/j.thromres.2020.08.022
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214
   McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285
   Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Mitchell WB, 2020, PAEDIATR RESPIR REV, V35, P20, DOI 10.1016/j.prrv.2020.06.004
   Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929
   Stessel B, 2020, THROMB RES, V194, P209, DOI 10.1016/j.thromres.2020.07.038
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WHO, 2020, CLIN MAN SEV AC RESP
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 42
TC 1
Z9 1
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
EI 1879-2472
J9 THROMB RES
JI Thromb. Res.
PD DEC
PY 2020
VL 196
BP 382
EP 394
DI 10.1016/j.thromres.2020.09.027
PG 13
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OV5GP
UT WOS:000592238500006
PM 32992075
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hosseini, ES
   Kashani, NR
   Nikzad, H
   Azadbakht, J
   Bafrani, HH
   Kashani, HH
AF Hosseini, Elahe Seyed
   Kashani, Narjes Riahi
   Nikzad, Hossein
   Azadbakht, Javid
   Bafrani, Hassan Hassani
   Kashani, Hamed Haddad
TI The novel coronavirus Disease-2019 (COVID-19): Mechanism of action,
   detection and recent therapeutic strategies
SO VIROLOGY
LA English
DT Article
DE Coronavirus; Immune response; Respiratory syndrome; Treatment; Pathogen
ID RESPIRATORY SYNDROME CORONAVIRUS; GLOBAL HEALTH; PNEUMONIA;
   IDENTIFICATION; EVOLUTION; DISCOVERY; OUTBREAK; INSIGHTS; VIRUS; WUHAN
AB Novel coronavirus SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on the February 11, 2020, is one of the highly pathogenic beta-coronaviruses which infects human. Early diagnosis of COVID-19 is the most critical step to treat infection. The diagnostic tools are generally molecular methods, serology and viral culture. Recently CRISPR-based method has been investigated to diagnose and treat coronavirus infection. The emergence of 2019-nCoV during the influenza season, has led to the extensive use of antibiotics and neuraminidase enzyme inhibitors, taken orally and intravenously.
   Currently, antiviral inhibitors of SARS and MERS spike proteins, neuraminidase inhibitors, anti-inflammatory drugs and EK1 peptide are the available therapeutic options for SARS-CoV-2 infected individuals. In addition, Chloroquine, which was previously used for malarial and autoimmune disease, has shown efficacy in the 2019-nCoV infection treatment. In severe hypoxaemia, a combination of antibiotics, alpha-interferon, lopinavir and mechanical ventilation can effectively mitigate the symptoms. Comprehensive knowledge on the innate and adaptive immune responses, will make it possible to propose potent antiviral drugs with their effective therapeutic measures for the prevention of viral infection. This therapeutic strategy will help patients worldwide to protect themselves against severe and fatal viral infections, that potentially can evolve and develop drug resistance, and to reduce mortality rates.
C1 [Hosseini, Elahe Seyed; Kashani, Narjes Riahi; Nikzad, Hossein; Bafrani, Hassan Hassani; Kashani, Hamed Haddad] Kashan Univ Med Sci, Anat Sci Res Ctr, Basic Sci Res Inst, Kashan, Iran.
   [Hosseini, Elahe Seyed; Kashani, Narjes Riahi; Nikzad, Hossein; Bafrani, Hassan Hassani; Kashani, Hamed Haddad] Kashan Univ Med Sci, Gametogenesis Res Ctr, Kashan, Iran.
   [Azadbakht, Javid] Kashan Univ Med Sci, Fac Med, Dept Radiol, Kashan, Iran.
RP Kashani, HH (corresponding author), Kashan Univ Med Sci, Anat Sci Res Ctr, Inst Basic Sci, Kashan, Iran.
EM elaheir.66@gmail.com; riahir@yahoo.com; nikzad.kaums@gmail.com;
   javidazadbakht2@gmail.com; hassanibafrani.h@gmail.com;
   hamedir2010@gmail.com
OI haddad kashani, hamed/0000-0003-2606-2886
FU Kashan University of Medical Sciences, Kashan, Iran [99070]
FX We would like to thank all my colleagues for their assistance. The
   present work was part of research project (No. 99070), which was
   financially supported by Kashan University of Medical Sciences, Kashan,
   Iran.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Arabi YM, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3846-x
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13209
   Bleibtreu A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3223-5
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Chung M, 2020, RADIOLOGY
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   De Clercq E, 2019, CHEM-ASIAN J, V14, P3962, DOI 10.1002/asia.201900841
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Ding YW, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1585-7
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Fahimi H, 2018, APPL MICROBIOL BIOT, V102, P2977, DOI 10.1007/s00253-018-8822-y
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guan W, 2020, CLIN CHARACTERISTICS
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang PK, 2020, RADIOLOGY, V295, P22, DOI 10.1148/radiol.2020200330
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ji S, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109652
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Jung Y.J., 2020, BIORXIV
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Konermann S, 2018, CELL, V173, P665, DOI 10.1016/j.cell.2018.02.033
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li G, 2020, THERAPEUTIC OPTIONS
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lucia C., 2020, BIORXIV
   Luk H.K., 2019, INFECT GENET EVOL
   Metsky HC, 2020, BIORXIV
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Moxley G, 2002, ARTHRITIS RHEUM, V46, P250, DOI 10.1002/1529-0131(200201)46:1<250::AID-ART10064>3.0.CO;2-T
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Nguyen T.M., 2020, VIRUS VIRUS POTENTIA
   Perlman S., 2020, ANOTHER DECADE ANOTH
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sahin A., 2020, EURASIAN J MED ONCOL, V4, P1, DOI DOI 10.14744/ejmo.2020.12220
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sun J, 2020, TRENDS MOL MED
   Sun X., 2020, INFECT EVIDENCE SARS
   Tang X, 2020, NATL SCI REV
   Phan T, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104211
   Uyeki TM, 2020, NEW ENGL J MED, V382
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Y, 2019, J INFECT DIS
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   WHO, 2020, PNEUM UNK CAUS CHIN
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Wu C., 2020, HAS SIGNIFICANT EXPR
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xie XZ, 2020, EUR RADIOL, V30, P4347, DOI 10.1007/s00330-020-06821-w
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
   Zhu N., 2020, N ENGL J MED
   Zhu ZZ, 2018, INFECT GENET EVOL, V61, P183, DOI 10.1016/j.meegid.2018.03.028
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 86
TC 0
Z9 0
U1 12
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD DEC
PY 2020
VL 551
BP 1
EP 9
DI 10.1016/j.virol.2020.08.011
PG 9
WC Virology
SC Virology
GA OU9LQ
UT WOS:000591845000001
PM 33010669
OA Green Published
DA 2021-01-01
ER

PT J
AU O'Callaghan, ME
   Jay, A
   Kichenadasse, G
   Moretti, KL
AF O'Callaghan, M. E.
   Jay, A.
   Kichenadasse, G.
   Moretti, K. L.
TI Androgen deprivation therapy in unlikely to be effective for treatment
   of COVID-19
SO ANNALS OF ONCOLOGY
LA English
DT Letter
C1 [O'Callaghan, M. E.; Jay, A.] Flinders Med Ctr, Urol Unit, Bedford Pk, SA, Australia.
   [O'Callaghan, M. E.; Jay, A.; Kichenadasse, G.; Moretti, K. L.] Flinders Univ S Australia, Coll Med & Publ Hlth, Bedford Pk, SA, Australia.
   [O'Callaghan, M. E.; Moretti, K. L.] Adelaide Univ, Freemasons Ctr Male Hlth & Wellbeing, Adelaide, SA, Australia.
   [Kichenadasse, G.] Flinders Med Ctr, Med Oncol Unit, Bedford Pk, SA, Australia.
   [Moretti, K. L.] Queen Elizabeth Hosp, Urol Unit, Woodville, SA, Australia.
   [Moretti, K. L.] Univ South Australia, UniSA Allied Hlth & Human Performance, Adelaide, SA, Australia.
   [Moretti, K. L.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.
RP O'Callaghan, ME (corresponding author), Flinders Med Ctr, Urol Unit, Bedford Pk, SA, Australia.; O'Callaghan, ME (corresponding author), Flinders Univ S Australia, Coll Med & Publ Hlth, Bedford Pk, SA, Australia.; O'Callaghan, ME (corresponding author), Adelaide Univ, Freemasons Ctr Male Hlth & Wellbeing, Adelaide, SA, Australia.
EM michael.ocallaghan@health.sa.gov.au
CR Bagrodia A, 2009, INDIAN J UROL, V25, P169, DOI 10.4103/0970-1591.52907
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   O'Farrell S, 2015, J CLIN ONCOL, V33, P1243, DOI 10.1200/JCO.2014.59.1792
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD DEC
PY 2020
VL 31
IS 12
BP 1780
EP 1782
DI 10.1016/j.annonc.2020.09.014
PG 3
WC Oncology
SC Oncology
GA OU2DJ
UT WOS:000591343500025
PM 33007381
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Pavia, CS
   Wormser, GP
AF Pavia, Charles S.
   Wormser, Gary P.
TI COVID-19: Is there a role for Western blots and skin testing for
   determining immunity and development of a vaccine?
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Serology; Western blots; Delayed-type
   hypersensitivity; Vaccine development
ID DISEASE; VIRUS
AB Infection with the virus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) stimulates an immune response which can serve as a marker for current or past exposure to this pathogen, and possibly for resistance to re-infection. This response to COVID-19 can be monitored based on the production of antibodies, and thus, sero-logic tests have become available for diagnostic purposes. Despite progress in this area, concerns have been raised that too many of the commercially available serologic detection systems are not completely reliable. To address this issue, Western blots should be considered for confirming a positive or borderline-positive result from a screening test, such as an ELISA. An additional benefit of Western blots would be to identify antigens that could form the basis for developing a vaccine. Little is known about the cell-mediated immune response against COVID-19. One way to address this would be to use skin testing to measure the delayed-type hypersensitivity response in patients recovering from COVID-19. (c) 2020 Elsevier Inc. All rights reserved.
C1 [Pavia, Charles S.] New York Inst Technol, NYIT Coll Osteopath Med, Dept Biomed Sci, Old Westbury, NY 11568 USA.
   New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA.
RP Pavia, CS (corresponding author), New York Inst Technol, NYIT Coll Osteopath Med, Dept Biomed Sci, Old Westbury, NY 11568 USA.
EM cpavia@nyit.edu
CR Centers for Disease Control and Prevention (CDC), 1995, MMWR-MORBID MORTAL W, V46, pS20
   Guo L, 2020, CLIN INFECT DIS, V2020
   Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266
   Infantino M, 2020, ISR MED ASSOC J, V22, P203
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   LODMELL DL, 1973, J EXP MED, V137, P706, DOI 10.1084/jem.137.3.706
   Modhiran N, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000924
   Parham P, 2009, IMMUNE SYSTEM, P438
   Patel R, 2020, MBIO, V11, DOI 10.1128/mBio.00722-20
   SCHMIDT NJ, 1976, J CLIN MICROBIOL, V4, P61
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Weiss SH, 2020, DIAGN MICR INFEC DIS, V98, DOI 10.1016/j.diagmicrobio.2020.115078
   Zhao J, 2020, MEDRXIV, V03, P2020
NR 14
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD DEC
PY 2020
VL 98
IS 4
AR 115148
DI 10.1016/j.diagmicrobio.2020.115148
PG 3
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA OT0FF
UT WOS:000590529800001
PM 32920452
OA Green Published
DA 2021-01-01
ER

PT J
AU Tan, LF
   Tee, LYS
   Seetharaman, SK
AF Tan, Li Feng
   Tee, Louis Yun Shou
   Seetharaman, Santhosh Kumar
TI Virtual Intergenerational Therapy: New Platforms for Engagement of Older
   Adults During the COVID-19 Crisis
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Letter
C1 [Tan, Li Feng; Tee, Louis Yun Shou; Seetharaman, Santhosh Kumar] Natl Univ Hlth Syst, Div Hlth Aging, Alexandra Hosp, Singapore, Singapore.
RP Tan, LF (corresponding author), Natl Univ Hlth Syst, Div Hlth Aging, Alexandra Hosp, Singapore, Singapore.
CR Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Choi NG, 2020, AM J GERIAT PSYCHIAT, V28, P698, DOI 10.1016/j.jagp.2020.02.008
   Gualano MR, 2018, INT PSYCHOGERIATR, V30, P451, DOI 10.1017/S104161021700182X
   Horowitz BP, 2010, GERONTOL GERIATR EDU, V31, P75, DOI 10.1080/02701960903578345
   Morita K, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-111
   Teo AR, 2019, AM J GERIAT PSYCHIAT, V27, P254, DOI 10.1016/j.jagp.2018.10.014
   Yasunaga M, 2016, GERIATR GERONTOL INT, V16, P98, DOI 10.1111/ggi.12770
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD DEC
PY 2020
VL 28
IS 12
BP 1330
EP 1331
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA OQ2KS
UT WOS:000588619000013
PM 33011070
OA Green Published
DA 2021-01-01
ER

PT J
AU Thakur, A
   Tan, SPF
   Chan, JCY
AF Thakur, Aarzoo
   Tan, Shawn Pei Feng
   Chan, James Chun Yip
TI Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical
   Efficacy of the Coadministration of Lopinavir and Ritonavir against
   SARS-CoV-2
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID DRUG INTERACTIONS; IN-VITRO; LOPINAVIR/RITONAVIR; INHIBITORS;
   TRANSPORTERS; METABOLISM; COMBINATION; INDUCTION; EXPOSURE; ABT-378
AB Lopinavir/ritonavir, originally developed for treating HIV, is currently undergoing clinical studies for treating the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although recent reports suggest that lopinavir exhibits in vitro efficacy against SARS-CoV-2, it is a highly protein-bound drug and it remains unknown if it reaches adequate in vivo unbound (free) concentrations in lung tissue. We built a physiologically-based pharmacokinetic model of lopinavir/ritonavir in white and Chinese populations. Our aim was to perform pharmacokinetic/pharmacodynamic correlations by comparing simulated free plasma and lung concentration values achieved using different dosing regimens of lopinavir/ritonavir with unbound half-maximal effective concentration (EC50,unbound) and unbound effective concentration 90% values of lopinavir against SARS-CoV-2. The model was validated against multiple observed clinical datasets for single and repeated dosing of lopinavir/ritonavir. Predicted pharmacokinetic parameters, such as the maximum plasma concentration, area under the plasma concentration-time profile, oral clearance, half-life, and minimum plasma concentration at steady-state were within two-fold of clinical values for both populations. Using the current lopinavir/ritonavir regimen of 400/100 mg twice daily, lopinavir does not achieve sufficient free lung concentrations for efficacy against SARS-CoV-2. Although the Chinese population reaches greater plasma and lung concentrations as compared with whites, our simulations suggest that a significant dose increase from the current clinically used dosing regimen is necessary to reach the EC50,unbound value for both populations. Based on safety data, higher doses would likely lead to QT prolongation and gastrointestinal disorders (nausea, vomiting, and diarrhea), thus, any dose adjustment must be carefully weighed alongside these safety concerns.
C1 [Thakur, Aarzoo; Tan, Shawn Pei Feng; Chan, James Chun Yip] Agcy Sci Technol & Res, Innovat Food & Chem Safety, Singapore, Singapore.
   [Thakur, Aarzoo; Tan, Shawn Pei Feng; Chan, James Chun Yip] Agcy Sci Technol & Res, Skin Res Inst Singapore, Singapore, Singapore.
   [Chan, James Chun Yip] Agcy Sci Technol & Res, Singapore Inst Food & Biotechnol Innovat, Singapore, Singapore.
RP Chan, JCY (corresponding author), Agcy Sci Technol & Res, Innovat Food & Chem Safety, Singapore, Singapore.; Chan, JCY (corresponding author), Agcy Sci Technol & Res, Skin Res Inst Singapore, Singapore, Singapore.; Chan, JCY (corresponding author), Agcy Sci Technol & Res, Singapore Inst Food & Biotechnol Innovat, Singapore, Singapore.
EM james_chan@sifbi.a-star.edu.sg
OI Tan, Shawn Pei Feng/0000-0003-4195-9886
FU Agency for Science, Technology and Research (A*STAR) under its Industry
   Alignment Fund -Pre-Positioning Programme (IAF-PP) as part of the A*STAR
   Innovations in Food and Chemical Safety (IFCS) Programme
   [H18/01/a0/J14]; A*STAR Graduate AcademyAgency for Science Technology &
   Research (ASTAR)
FX This research was supported by the Agency for Science, Technology and
   Research (A*STAR) under its Industry Alignment Fund -Pre-Positioning
   Programme (IAF-PP) grant number H18/01/a0/J14 as part of the A*STAR
   Innovations in Food and Chemical Safety (IFCS) Programme (to J.C.Y.C.).
   S.P.F.T is supported by the A*STAR Graduate Academy.
CR Atzori C, 2003, AIDS, V17, P1710, DOI 10.1097/00002030-200307250-00022
   Barter ZE, 2013, CLIN PHARMACOKINET, V52, P1085, DOI 10.1007/s40262-013-0089-y
   Bierman WFW, 2010, J ANTIMICROB CHEMOTH, V65, P1672, DOI 10.1093/jac/dkq209
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centre for Drug Evaluation and Research, 2000, FDA KAL CLIN PHARM B
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chu X, 2013, CLIN PHARMACOL THER, V94, P126, DOI 10.1038/clpt.2013.78
   de Kanter CTMM, 2010, J ANTIMICROB CHEMOTH, V65, P538, DOI 10.1093/jac/dkp472
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Du XL, 2019, PHARMACOTHERAPY, V39, P1179, DOI 10.1002/phar.2333
   Eron JJ, 2004, J INFECT DIS, V189, P265, DOI 10.1086/380799
   Fukushima K, 2013, J PHARM SCI-US, V102, P2044, DOI 10.1002/jps.23545
   Hickman D, 2004, ANTIMICROB AGENTS CH, V48, P2911, DOI 10.1128/AAC.48.8.2911-2917.2004
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang SM, 2010, CLIN PHARMACOL THER, V87, P497, DOI 10.1038/clpt.2009.308
   Jackson A, 2011, J ANTIMICROB CHEMOTH, V66, P635, DOI 10.1093/jac/dkq468
   Jeon S., 2020, IDENTIFICATION ANTIV, DOI [10.1101/ 2020.03.20.999730., DOI 10.1101/2020.03.20.999730, 10.1101/2020.03.20.999730.]
   Kaspera R, 2014, BIOCHEM PHARMACOL, V91, P109, DOI 10.1016/j.bcp.2014.06.020
   Kirby BJ, 2011, DRUG METAB DISPOS, V39, P2329, DOI 10.1124/dmd.111.038646
   Kumar GN, 2004, PHARM RES-DORDR, V21, P1622, DOI 10.1023/B:PHAM.0000041457.64638.8d
   Kumar GN, 1996, J PHARMACOL EXP THER, V277, P423
   la Porte CJL, 2004, ANTIMICROB AGENTS CH, V48, P1553, DOI 10.1128/AAC.48.5.1553-1560.2004
   Liu L, 2013, BIOPHARM DRUG DISPOS, V34, P155, DOI 10.1002/bdd.1832
   Aspiroz EL, 2011, THER DRUG MONIT, V33, P573, DOI 10.1097/FTD.0b013e31822d578b
   Maisch B, 2020, HERZ, V45, P321, DOI 10.1007/s00059-020-04925-z
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Ohashi H., MULTIDRUG TREATMENT, DOI [10.1101/2020.04.14.03992, DOI 10.1101/2020.04.14.03992]
   Penzak SR, 2010, PHARMACOTHERAPY, V30, P797, DOI 10.1592/phco.30.8.797
   Podzamczer D, 2007, HIV CLIN TRIALS, V8, P193, DOI 10.1310/hct0804-193
   Ryu S, 2020, J PHARM SCI-US, V109, P1178, DOI 10.1016/j.xphs.2019.10.060
   Scholler-Gyure M, 2013, J CLIN PHARMACOL, V53, P202, DOI 10.1177/0091270012445205
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218
   Smith DA, 2010, NAT REV DRUG DISCOV, V9, P929, DOI 10.1038/nrd3287
   Smith PF, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14314
   Twigg Homer L. III, 2010, HIV Therapy, V4, P247, DOI [10.2217/hiv.10.5, 10.2217/HIV.10.5]
   Vicente J, 2019, CLIN PHARMACOL THER, V105, P943, DOI 10.1002/cpt.1303
   Wagner C, 2017, J CLIN PHARMACOL, V57, P1295, DOI 10.1002/jcph.936
   WHO, 2020, WHO DISC HYDR LOP RI
   WHO, 2020, INT CLIN TRIALS REG
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   World Health Organization, 2020, 167 WHO
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Yang WQ, 2017, XENOBIOTICA, V47, P133, DOI 10.3109/00498254.2016.1166532
NR 44
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD DEC
PY 2020
VL 108
IS 6
BP 1176
EP 1184
DI 10.1002/cpt.2014
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OQ4VZ
UT WOS:000588784300015
PM 32767755
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yan, HD
   Valdes, AM
   Vijay, A
   Wang, SB
   Liang, LL
   Yang, SQ
   Wang, HX
   Tan, XY
   Du, JY
   Jin, SS
   Huang, KC
   Jiang, FR
   Zhang, S
   Zheng, NH
   Hu, YR
   Cai, T
   Aithal, GP
AF Yan, Huadong
   Valdes, Ana M.
   Vijay, Amrita
   Wang, Shanbo
   Liang, Lili
   Yang, Shiqing
   Wang, Hongxia
   Tan, Xiaoyan
   Du, Jingyuan
   Jin, Susu
   Huang, Kecheng
   Jiang, Fanrong
   Zhang, Shun
   Zheng, Nanhong
   Hu, Yaoren
   Cai, Ting
   Aithal, Guruprasad P.
TI Role of Drugs Used for Chronic Disease Management on Susceptibility and
   Severity of COVID-19: A Large Case-Control Study
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID SARS CORONAVIRUS; ACE2; RECEPTOR; PROTEIN; HYPERTENSION; INHIBITION;
   ENTRY
AB This study aimed to investigate whether specific medications used in the treatment chronic diseases affected either the development and/ or severity of coronavirus disease 2019 (COVID-19) in a cohort of 610 COVID-19 cases and 48,667 population-based controls from Zhejiang, China. Using a cohort of 578 COVID-19 cases and 48,667 population-based controls from Zhejiang, China, we tested the role of usage of cardiovascular, antidiabetic, and other medications on risk and severity of COVID-19. Analyses were adjusted for age, sex, and body mass index and for presence of relevant comorbidities. Individuals with hypertension taking calcium channel blockers had significantly increased risk (odds ratio (OR) = 1.73, 95% confidence interval (CI) 1.2-2.3) of manifesting symptoms of COVID-19, whereas those taking angiotensin receptor blockers and diuretics had significantly lower disease risk (OR = 0.22, 95% CI 0.15-0.30 and OR = 0.30, 95% CI 0.19-0.58, respectively). Among those with type 2 diabetes, dipeptidyl peptidase-4 inhibitors (OR = 6.02, 95% CI 2.3-15.5) and insulin (OR = 2.71, 95% CI 1.6-5.5) were more and glucosidase inhibitors were less prevalent (OR = 0.11, 95% CI 0.1-0.3) among with patients with COVID-19. Drugs used in the treatment of hypertension and diabetes influence the risk of development of COVID-19, but, not its severity.
C1 [Yan, Huadong; Liang, Lili; Yang, Shiqing; Wang, Hongxia; Du, Jingyuan; Jin, Susu; Zheng, Nanhong; Hu, Yaoren; Cai, Ting] Univ Chinese Acad Sci, Hwamei Hosp, Dept Infect Dis, Ningbo 2 Hosp, Ningbo, Peoples R China.
   [Yan, Huadong; Zhang, Shun; Cai, Ting] Univ Chinese Acad Sci, Hwamei Hosp, Dept New Med Sci, Ningbo 2 Hosp,Key Lab Diag & Treatment Digest Sys, Ningbo, Peoples R China.
   [Valdes, Ana M.] Nottingham Univ Hosp NHS Trust, NIHR Nottingham Biomed Res Ctr, Nottingham, England.
   [Valdes, Ana M.] Univ Nottingham, Nottingham, England.
   [Valdes, Ana M.; Vijay, Amrita; Aithal, Guruprasad P.] Univ Nottingham, Sch Med, Div Rheumatol Orthopaed & Dermatol, Nottingham, England.
   [Vijay, Amrita; Aithal, Guruprasad P.] Univ Nottingham, Nottingham Digest Dis Ctr, Sch Med, Nottingham, England.
   [Wang, Shanbo; Tan, Xiaoyan; Huang, Kecheng] Gulin Township Hlth Ctr, Dept Gen Practice, Ningbo, Peoples R China.
   [Wang, Hongxia] Ninghai 1 Hosp, Dept Infect Dis, Ningbo, Peoples R China.
   [Jiang, Fanrong] Univ Chinese Acad Sci, Hwamei Hosp, Dept Pharmacol, Ningbo 2 Hosp, Ningbo, Peoples R China.
RP Cai, T (corresponding author), Univ Chinese Acad Sci, Hwamei Hosp, Dept Infect Dis, Ningbo 2 Hosp, Ningbo, Peoples R China.; Cai, T (corresponding author), Univ Chinese Acad Sci, Hwamei Hosp, Dept New Med Sci, Ningbo 2 Hosp,Key Lab Diag & Treatment Digest Sys, Ningbo, Peoples R China.; Vijay, A; Aithal, GP (corresponding author), Univ Nottingham, Sch Med, Div Rheumatol Orthopaed & Dermatol, Nottingham, England.; Vijay, A; Aithal, GP (corresponding author), Univ Nottingham, Nottingham Digest Dis Ctr, Sch Med, Nottingham, England.
EM Amrita.vijay@nottingham.ac.uk; caiting@ucas.ac.cn;
   Guru.Aithal@nottingham.ac.uk
OI Reis, AlessanRSS/0000-0001-8486-7469; Vijay, Amrita/0000-0002-9595-5680
FU Social Development Major Projects of Ningbo City [2016C51005]; Medical
   Health Science and Technology Project of Zhejiang Provincial Health
   Commission [2018ZD039]; Zhejiang Provincial Natural Science
   FoundationNatural Science Foundation of Zhejiang Province
   [LGF20H030006]; NIHR Nottingham Biomedical Research Centre
   [BRC-1215-20003]
FX This study was supported by the Social Development Major Projects of
   Ningbo City (2016C51005), Medical Health Science and Technology Project
   of Zhejiang Provincial Health Commission (2018ZD039), Zhejiang
   Provincial Natural Science Foundation (LGF20H030006), and by the NIHR
   Nottingham Biomedical Research Centre (Reference no: BRC-1215-20003).
CR Aronson JK, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1313
   Bornstein SR, 2020, NAT REV ENDOCRINOL, V16, P297, DOI 10.1038/s41574-020-0353-9
   Bozkurt B., AM HEART ASS PR 0319
   Caldeira D, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4260
   Czopek A, 2019, EUR HEART J, V40, P768, DOI 10.1093/eurheartj/ehy881
   Dijkman R, 2012, J GEN VIROL, V93, P1924, DOI 10.1099/vir.0.043919-0
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Filardi T, 2020, J ENDOCRINOL INVEST, P1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Head BM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226347
   Henry Christopher, 2018, Proc (Bayl Univ Med Cent), V31, P419, DOI 10.1080/08998280.2018.1499293
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li G, 2020, HYPERTENS RES, V43, P588, DOI 10.1038/s41440-020-0433-1
   Li W., 2011, NATURE, V24, P1634
   Lin HB, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019698
   Lu JP, 2017, LANCET, V390, P2549, DOI [10.1016/S0140-6736(17)32478-9, 10.1016/s0140-6736(17)32478-9]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mahmoudpour SH, 2018, BRIT J CLIN PHARMACO, V84, P2365, DOI 10.1111/bcp.13692
   Mancia G, 2013, J HYPERTENS, V31, DOI 10.1097/HJH.0000000000000006
   National Health Commission of the people's Republic of China, GUID DIAGN TREATM NE
   Phadke M.A., 2020, BMJ-BRIT MED J, V368, pm406, DOI [10.1136/bmj.m406, DOI 10.1136/BMJ.M406]
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634
   Shi Q., LANCET, DOI [10.2139/ssrn.3551369, DOI 10.2139/SSRN.3551369]
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Singanayagam A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04574-1
   Steiner G. S., 2018, AM HEART ASS SCI SES
   Thomas BJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep07176
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ZW, 2018, CIRCULATION, V137, P2344, DOI 10.1161/CIRCULATIONAHA.117.032380
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   World Health Organization (WHO), 90 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhao XS, 2015, ANTIMICROB AGENTS CH, V59, P206, DOI 10.1128/AAC.03999-14
NR 43
TC 0
Z9 0
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD DEC
PY 2020
VL 108
IS 6
BP 1185
EP 1194
DI 10.1002/cpt.2047
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OQ4VZ
UT WOS:000588784300016
PM 32910830
OA Other Gold
DA 2021-01-01
ER

PT J
AU Chen, F
   Gong, S
   Li, RQ
AF Chen, Fei
   Gong, Shuai
   Li, Run-Qian
TI Research on Drugs and Vaccines for COVID-19 Should Be Conducted and
   Published With Caution
SO JOURNAL OF EPIDEMIOLOGY
LA English
DT Letter
C1 [Chen, Fei; Li, Run-Qian] Jining Med Univ, Dept Physiol, 133 Hehua Rd, Jining 272067, Peoples R China.
   [Gong, Shuai] Shandong Agr Univ, Dept Anim Genet Breeding & Reprod, Tai An, Shandong, Peoples R China.
RP Chen, F (corresponding author), Jining Med Univ, Dept Physiol, 133 Hehua Rd, Jining 272067, Peoples R China.
EM chenfei0336@163.com
OI Chen, Fei/0000-0002-2578-7159
CR An MH, 2020, WITHDRAWN TREATMENT, DOI [10.1101/2020.05.13.20094193, DOI 10.1101/2020.05.13.20094193]
   [Anonymous], 2020, REUTERS
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Davido B, 2020, WITHDRAWN HYDROXY CH, DOI [10.1101/2020.05.05.20088757, DOI 10.1101/2020.05.05.20088757]
   Dinis-Oliveira RJ, 2020, FOREN SCI RES, V5, P174, DOI 10.1080/20961790.2020.1767754
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Funck-Brentano C, 2020, LANCET
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Raharusuna P, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3585561, DOI 10.2139/SSRN.3585561]
NR 10
TC 0
Z9 0
U1 1
U2 1
PU JAPAN EPIDEMIOLOGICAL ASSOC
PI TOKYO
PA HONGO MT BLDG, 4 FL, 7-2-2, HONGO, BUNKYO-KU, TOKYO, JAPAN
SN 0917-5040
J9 J EPIDEMIOL
JI J. Epidemiol.
PD DEC
PY 2020
VL 30
IS 12
BP 574
EP 575
DI 10.2188/jea.JE20200408
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OS8KR
UT WOS:000590407500007
PM 33041320
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Achilonu, I
   Iwuchukwu, EA
   Achilonu, OJ
   Fernandes, MA
   Sayed, Y
AF Achilonu, Ikechukwu
   Iwuchukwu, Emmanuel Amarachi
   Achilonu, Okechinyere Juliet
   Fernandes, Manuel Antonio
   Sayed, Yasien
TI Targeting the SARS-CoV-2 main protease using FDA-approved
   Isavuconazonium, a P2-P3 alpha-ketoamide derivative and Pentagastrin: An
   in-silico drug discovery approach
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE COVID-19; Antiretroviral; Main protease; Ligand docking; Molecular
   dynamics simulation; High-throughput virtual screening; FDA; DrugBank;
   PubChem; Pentagastrin; Ketoamide inhibitor; Isavuconazonium
ID ACTIVE-SITE; MOLECULAR-MECHANICS; CYSTEINE; INHIBITORS; HISTIDINE;
   CORONAVIRUS; PNEUMONIA; RESOURCE; PUBCHEM
AB The SARS-CoV-2 main protease (M-pro) is an attractive target towards discovery of drugs to treat COVID-19 because of its key role in virus replication. The atomic structure of M-pro in complex with an alpha-ketoamide inhibitor (Lig13b) is available (PDB ID:6Y2G). Using 6Y2G and the prior knowledge that protease inhibitors could eradicate COVID-19, we designed a computational study aimed at identifying FDA-approved drugs that could interact with M-pro. We searched the DrugBank and PubChem for analogs and built a virtual library containing similar to 33,000 conformers. Using high-throughput virtual screening and ligand docking, we identified Isavuconazonium, a ketoamide inhibitor (alpha-KI) and Pentagastrin as the top three molecules (Lig13b as the benchmark) based on docking energy. The Delta G(bind) of Lig13b, Isavucona-zonium, alpha-KI, Pentagastrin was -28.1, -45.7, -44.7, -34.8 kcal/mol, respectively. Molecular dynamics simulation revealed that these ligands are stable within the M-pro active site. Binding of these ligands is driven by a variety of non-bonded interaction, including polar bonds, H-bonds, van der Waals and salt bridges. The overall conformational dynamics of the complexed-M-pro was slightly altered relative to apo-M-pro. This study demonstrates that three distinct classes molecules, Isavuconazonium (triazole), alpha-KI (ketoamide) and Pentagastrin (peptide) could serve as potential drugs to treat patients with COVID-19. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Achilonu, Ikechukwu; Iwuchukwu, Emmanuel Amarachi; Sayed, Yasien] Univ Witwatersrand, Fac Sci, Sch Mol & Cell Biol, Prot Struct Funct Res Unit, ZA-2050 Johannesburg, South Africa.
   [Achilonu, Okechinyere Juliet] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Div Biostat, ZA-2050 Johannesburg, South Africa.
   [Fernandes, Manuel Antonio] Univ Witwatersrand, Sch Chem, Mol Sci Inst, ZA-2050 Johannesburg, South Africa.
RP Achilonu, I (corresponding author), Univ Witwatersrand, Fac Sci, Sch Mol & Cell Biol, Prot Struct Funct Res Unit, ZA-2050 Johannesburg, South Africa.
EM lkechukwu.Achilonu@wits.ac.za
FU University of the Witwatersrand; South African Research Chairs
   Initiative of the Department of Science and Technology; National
   Research Foundation [64788]; National Research Foundation; DELTAS Africa
   Initiative-SSACAB [107754/Z/15/Z]; GlaxoSmithKline (GSK), United Kingdom
   [107754/Z/15/Z]; South African Medical Research Council (SAMRC); South
   African National Research Foundation (NRF)National Research Foundation -
   South Africa [CSRP170428229183]
FX This work is supported by the University of the Witwatersrand, the South
   African Research Chairs Initiative of the Department of Science and
   Technology and National Research Foundation (grant 64788 to I.A.).
   A.E.I. acknowledges the South African Research Chairs Initiative of the
   Department of Science and Technology and National Research Foundation
   for supporting his post-doctoral fellowship studies. O.J.A. acknowledges
   the DELTAS Africa Initiative-SSACAB and the GlaxoSmithKline (GSK),
   United Kingdom Grant No. 107754/Z/15/Z-DELTAS Africa Sub-Saharan Africa
   Consortium for Advanced Biostatistics (SSACAB) programme for supporting
   her doctoral studies. The authors will like to acknowledge the Centre
   for High Performance Computing (CHPC), Cape Town, South Africa for
   providing access to Schrodinger Maestro v12 molecular modelling suite.
   YS acknowledges the South African Medical Research Council (SAMRC) under
   a Self-Initiated Research Grant and the South African National Research
   Foundation (NRF) via the Competitive Programme for Rated Researchers
   (CSRP170428229183). The views and opinions expressed are those of the
   authors and do not necessarily represent the official views of the SA
   MRC.
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   AMIDON GL, 1994, ANNU REV PHARMACOL, V34, P321
   [Anonymous], 2014, S 1 REL VERS 3 7 DES, V3
   Ayittey FK, 2020, J MED VIROL, V92, P403, DOI 10.1002/jmv.25695
   Bajorath J, 2001, DRUG DISCOV TODAY, V6, P989, DOI 10.1016/S1359-6446(01)01961-4
   Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099
   Batool M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112783
   Bergdorf M., 2014, DESRESTRD201401
   Blundell TL, 2002, NAT REV DRUG DISCOV, V1, P45, DOI 10.1038/nrd706
   Blundell TL, 1996, NATURE, V384, P23
   Braiuca P, 2006, TRENDS BIOTECHNOL, V24, P419, DOI 10.1016/j.tibtech.2006.07.001
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Chen Y, 2020, RES SER CHIN DREAM, P1, DOI [10.1142/S0192415X2050010X, 10.1007/978-981-13-9660-1_1]
   Chow E., 2008, DESRESTR200801
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Copeland RA, 2016, NAT REV DRUG DISCOV, V15, P87, DOI 10.1038/nrd.2015.18
   Copeland RA, 2011, FUTURE MED CHEM, V3, P1491, DOI [10.4155/fmc.11.112, 10.4155/FMC.11.112]
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Dahlin J. L., 2015, ASSAY GUIDANCE MANUA
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dunn BM, 2002, GENOME BIOL, V3
   Exscientia, 2019, CELG EXSC ENT 3 YEAR
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Grant BJ, 2006, BIOINFORMATICS, V22, P2695, DOI 10.1093/bioinformatics/btl461
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   HUSAIN SS, 1968, BIOCHEM J, V108, P855, DOI 10.1042/bj1080855
   Jarynowski A., 2020, ATTEMPT UNDERSTAND P
   Jeffs B, 2006, TROP DOCT, V36, P1, DOI 10.1258/004947506775598914
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Konvalinka J, 2015, VIROLOGY, V479, P403, DOI 10.1016/j.virol.2015.03.021
   Koska J, 2008, J CHEM INF MODEL, V48, P1965, DOI 10.1021/ci800081s
   KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413
   Kumar S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050486
   Kumar Y., 2020, SILICO IDENTIFICATIO
   Langedijk J, 2015, DRUG DISCOV TODAY, V20, P1027, DOI 10.1016/j.drudis.2015.05.001
   Li QL, 2010, DRUG DISCOV TODAY, V15, P1052, DOI 10.1016/j.drudis.2010.10.003
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207
   Matsumoto K, 1999, BIOPOLYMERS, V51, P99, DOI 10.1002/(SICI)1097-0282(1999)51:1<99::AID-BIP11>3.0.CO;2-R
   Mladenovic M, 2007, CHEMMEDCHEM, V2, P120, DOI 10.1002/cmdc.200600159
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Mottini C., 2019, SEMINARS CANC BIOL
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Papapetropoulos A, 2018, BRIT J PHARMACOL, V175, P165, DOI 10.1111/bph.14081
   Phadke M, 2020, DRUG DEVELOP RES, V81, P541, DOI 10.1002/ddr.21666
   Rishton GM, 1997, DRUG DISCOV TODAY, V2, P382, DOI 10.1016/S1359-6446(97)01083-0
   Roush WR, 1998, J AM CHEM SOC, V120, P10994, DOI 10.1021/ja981792o
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Sherman W, 2006, CHEM BIOL DRUG DES, V67, P83, DOI 10.1111/j.1747-0285.2005.00327.x
   Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Thorne N, 2010, CURR OPIN CHEM BIOL, V14, P315, DOI 10.1016/j.cbpa.2010.03.020
   Tsui V, 2001, BIOPOLYMERS, V56, P275, DOI 10.1002/1097-0282(2000)56:4<275::AID-BIP10024>3.0.CO;2-E
   Velthuis AJWT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001176
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang JL, 2006, J VIROL, V80, P6003, DOI 10.1128/JVI.00401-06
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Yu HS, 2003, DRUG DISCOV TODAY, V8, P852, DOI 10.1016/S1359-6446(03)02828-9
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 72
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD DEC
PY 2020
VL 101
AR 107730
DI 10.1016/j.jmgm.2020.107730
PG 14
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA OI6HW
UT WOS:000583378100022
PM 32920239
OA Green Published
DA 2021-01-01
ER

PT J
AU Kodchakorn, K
   Poovorawan, Y
   Suwannakarn, K
   Kongtawelert, P
AF Kodchakorn, Kanchanok
   Poovorawan, Yong
   Suwannakarn, Kamol
   Kongtawelert, Prachya
TI Molecular modelling investigation for drugs and nutraceuticals against
   protease of SARS-CoV-2
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE SARS-CoV-2; Protease inhibitors; Herbal medicines; Molecular docking;
   Molecular dynamics simulation
ID PARTICLE MESH EWALD; DYNAMICS SIMULATIONS; SOFTWARE; AMBER
AB The widespread problem of a 2019-novel coronavirus (SARS-CoV-2) strain outbreak inWuhan, China has prompted a search for new drugs to protect against and treat this disease. It is necessary to immediately investigate this due to the mutation of the viral genome and there being no current protective vaccines or therapeutic drugs. Molecular modelling and molecular docking based on in silico screening strategies were employed to determine the potential activities of seven HIV protease (HIV-PR) inhibitors, two flu drugs, and eight natural compounds. The computational approach was carried out to discover the structural modes with a high binding affinity for these drugs on the homology structure of the Wuhan coronavirus protease (SARS-CoV-2 PR). From the theoretical calculations, all the drugs and natural compounds demonstrated various favorable binding affinities. An interesting finding was that the natural compounds tested had a higher potential binding activity with the pocket sites of SARS-CoV-2 PR compared to the groups of HIV-PR inhibitors. The binding modes of each complex illustrated between the drugs and compounds interacted with the functional group of amino acids in the binding pocket via hydrophilic, hydrophobic, and hydrogen bond interactions using the molecular dynamics simulation technique. This result supports the idea that existing protease inhibitors and natural compounds could be used to treat the new coronavirus. This report sought to provide fundamental knowledge as preliminary experimental data to propose an existing nutraceutical material against viral infection. Collectively, it is suggested that molecular modelling and molecular docking are suitable tools to search and screen for new drugs and natural compounds that can be used as future treatments for viral diseases. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Kodchakorn, Kanchanok; Kongtawelert, Prachya] Chiang Mai Univ, Fac Med, Thailand Excellence Ctr Tissue Engn & Stem Cells, Dept Biochem, Chiang Mai 50200, Thailand.
   [Poovorawan, Yong] Chulalongkorn Univ, Fac Med, Ctr Excellence Clin Virol, Bangkok 10330, Thailand.
   [Suwannakarn, Kamol] Mahidol Univ, Fac Med, Dept Microbiol, Siriraj Hosp, Bangkok 10700, Thailand.
RP Kongtawelert, P (corresponding author), Chiang Mai Univ, Fac Med, Thailand Excellence Ctr Tissue Engn & Stem Cells, Dept Biochem, Chiang Mai 50200, Thailand.
EM kanchanok_k@cmu.ac.th; yong.p@chula.ac.th; kamol.suw@mahidol.ac.th;
   prachya.k@cmu.ac.th
OI Kodchakorn, Kanchanok/0000-0002-9250-661X
FU Thailand Excellence Center for Tissue Engineering and Stem Cells,
   Department of Biochemistry, Faculty of Medicine, Chiang Mai University,
   Chiang Mai, Thailand; Center of Excellence in Clinical Virology, Faculty
   of Medicine, Chulalongkorn UniversityChulalongkorn University; National
   Science and Technology Development Agency [P-15-50004]
FX This work was supported by grants from Thailand Excellence Center for
   Tissue Engineering and Stem Cells (PK and KK), Department of
   Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai,
   Thailand. The authors would like to thanks Dr. Christian C. Gruber and
   Dr. Georg Steinkellner, Innophore GmbH, Graz, Austria, for their
   information data of the Wuhan coronavirus (SARS-CoV-2) protease; and the
   Center of Excellence in Clinical Virology, Faculty of Medicine,
   Chulalongkorn University and the Research Chair Grant from the National
   Science and Technology Development Agency (P-15-50004) to support YP.
   The authors would like to appreciate Dr. Chanisorn Ngaojampa, Department
   of Chemistry, Faculty of Science, Chiang Mai University, for his
   valuable comments and suggestions.
CR Agoni C, 2018, RSC ADV, V8, P40187, DOI 10.1039/c8ra08427k
   [Anonymous], 2020, REPORT BNO NEWS TRAC
   [Anonymous], 2020, REPORT STAR NEW 0206
   [Anonymous], 2020, REPORT CBC NEWS 0120
   Byun EB, 2019, FOOD CHEM TOXICOL, V127, P19, DOI 10.1016/j.fct.2019.02.042
   Cao B, 2020, NEW ENGL J MED, V382
   Case D., 2018, AMBER 2018
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dong N., 2020, BIORXIV
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fanhchaksai K, 2016, IN VITRO CELL DEV-AN, V52, P107, DOI 10.1007/s11626-015-9950-7
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gotz AW, 2012, J CHEM THEORY COMPUT, V8, P1542, DOI 10.1021/ct200909j
   Gruber C.C., 2020, WUHAN CORONAVIRUS 20
   Huang C, 2020, LANCET
   HUNENBERGER PH, 1995, J MOL BIOL, V252, P492, DOI 10.1006/jmbi.1995.0514
   Kasahara K., 2014, FASEB J, V9, P1
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lu R, 2020, LANCET
   Paemanee A, 2019, BIOMED PHARMACOTHER, V109, P322, DOI 10.1016/j.biopha.2018.10.054
   Perlman S., 2020, N ENGL J MED
   Punfa W, 2012, ACTA PHARMACOL SIN, V33, P823, DOI 10.1038/aps.2012.34
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Udomruk S, 2018, J FUNCT FOODS, V49, P32, DOI 10.1016/j.jff.2018.08.020
   Wang EC, 2019, CHEM REV, V119, P9478, DOI 10.1021/acs.chemrev.9b00055
   Weber W, 2000, J PHYS CHEM B, V104, P3668, DOI 10.1021/jp9937757
   Wen L, 2014, EUR J PHARMACOL, V740, P421, DOI 10.1016/j.ejphar.2014.06.053
   World Health Organization, 2020, 2 M INT HLTH REG 200
   Wu F., 2020, NOVEL CORONAVIRUS AS
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Zhu N., 2020, N ENGL J MED
NR 36
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD DEC
PY 2020
VL 101
AR 107717
DI 10.1016/j.jmgm.2020.107717
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA OI6HW
UT WOS:000583378100009
PM 32861974
OA Green Published
DA 2021-01-01
ER

PT J
AU Prajapat, M
   Shekhar, N
   Sarma, P
   Avti, P
   Singh, S
   Kaur, H
   Bhattacharyya, A
   Kumar, S
   Sharma, S
   Prakash, A
   Medhi, B
AF Prajapat, Manisha
   Shekhar, Nishant
   Sarma, Phulen
   Avti, Pramod
   Singh, Sanjay
   Kaur, Hardeep
   Bhattacharyya, Anusuya
   Kumar, Subodh
   Sharma, Saurabh
   Prakash, Ajay
   Medhi, Bikash
TI Virtual screening and molecular dynamics study of approved drugs as
   inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE 2019 novel corona virus; SARS-CoV-2; Spike protein; 2019-nCoV,receptor
   binding domain; RBD; S1 domain; ACE2
ID FOLIC-ACID; PLASMA HOMOCYSTEINE; VIRUS-REPLICATION
AB Background: The receptor binding domain (RBD) of spike protein S1 domain SARS-CoV-2 plays a key role in the interaction with ACE2, which leads to subsequent S2 domain mediated membrane fusion and incorporation of viral RNA into host cells. In this study we tend to repurpose already approved drugs as inhibitors of the interaction between S1-RBD and the ACE2 receptor.
   Methods: 2456 approved drugs were screened against the RBD of S1 protein of SARS-CoV-2 (target PDB ID: 6M17). As the interacting surface between S1-RBD and ACE2 comprises of bigger region, the interacting surface was divided into 3 sites on the basis of interactions (site 1, 2 and 3) and a total of 5 grids were generated (site 1, site 2, site 3, site 1thornsite 2 and site 2thornsite 3). A virtual screening was performed using GLIDE implementing HTVS, SP and XP screening. The top hits (on the basis of docking score) were further screened for MM-GBSA. All the top hits were further evaluated in molecular dynamics studies. Performance of the virtual screening protocol was evaluated using enrichment studies.
   Result: and discussion: We performed 5 virtual screening against 5 grids generated. A total of 42 compounds were identified after virtual screening. These drugs were further assessed for their interaction dynamics in molecular dynamics simulation. On the basis of molecular dynamics studies, we come up with 10 molecules with favourable interaction profile, which also interacted with physiologically important residues (residues taking part in the interaction between S1-RBD and ACE2. These are antidiabetic (acarbose), vitamins (riboflavin and levomefolic acid), anti-platelet agents (cangrelor), aminoglycoside antibiotics (Kanamycin, amikacin) bronchodilator (fenoterol), immunomodulator (lamivudine), and anti-neoplastic agents (mitoxantrone and vidarabine). However, while considering the relative side chain fluctuations when compared to the S1-RBD: ACE2 complex riboflavin, fenoterol, cangrelor and vidarabine emerged out as molecules with prolonged relative stability.
   Conclusion: We identified 4 already approved drugs (riboflavin, fenoterol, cangrelor and vidarabine) as possible agents for repurposing as inhibitors of S1:ACE2 interaction. In-vitro validation of these findings are necessary for identification of a safe and effective inhibitor of S1: ACE2 mediated entry of SARS-CoV-2 into the host cell. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Prajapat, Manisha; Shekhar, Nishant; Sarma, Phulen; Kaur, Hardeep; Kumar, Subodh; Sharma, Saurabh; Prakash, Ajay; Medhi, Bikash] PGIMER, Dept Pharmacol, Chandigarh, India.
   [Avti, Pramod] PGIMER, Dept Biophys, Chandigarh, India.
   [Singh, Sanjay] Thapar Inst Engn & Technol, Dept Biotechnol, Patiala, Punjab, India.
   [Bhattacharyya, Anusuya] Dept Ophthalmol, GMCH 32, Chandigarh, India.
RP Medhi, B (corresponding author), Postgrad Inst Med Educ & Res, Dept Pharmacol, Chandigarh, India.
EM manisha.monu25@gmail.com; nishantmessi88@gmail.com; phulen10@gmail.com;
   pramod.avti@gmail.com; sanjaybiosoft@gmail.com;
   aspireachieve.shine@gmail.com; anusuya.8k@gmail.com;
   subodhbiotech@gmail.com; saurabh2804@gmail.com;
   ajayprakashpgi@gmail.com; drbikashus@yahoo.com
CR [Anonymous], 2017, RELEASE S 4 SCHR ODI
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   CLARK CH, 1977, MOD VET PRACT, V58, P594
   Deng L, 2007, J VIROL, V81, P13392, DOI 10.1128/JVI.00770-07
   Ferreiro Jose Luis, 2009, Expert Rev Cardiovasc Ther, V7, P1195, DOI 10.1586/erc.09.101
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   He J., 2020, MICROBIOLOGY, DOI [10.1101/2020.02.17.952903, DOI 10.1101/2020.02.17.952903]
   Hu RJ, 2015, CLIN THER, V37, P1798, DOI 10.1016/j.clinthera.2015.05.504
   Itelman E, 2020, ISR MED ASSOC J, V22, P269
   Keil SD, 2020, VOX SANG, V115, P495, DOI 10.1111/vox.12937
   Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu SH, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-8
   Magallon M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111953
   Manikyam Hemanth Kumar, 2020, J Pharm Drug Res, V3, P341
   Modaghegh Mohammad Hadi Saeed, 2016, Electron Physician, V8, P3138, DOI 10.19082/3138
   Mohamed A.A., 2019, ARC J ANIM VET SCI, V5, P24
   Mohs Richard C, 2017, Alzheimers Dement (N Y), V3, P651, DOI 10.1016/j.trci.2017.10.005
   Molina J.M., 2020, MED MALADIES INFECT
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Ponti G, 2020, CRIT REV CL LAB SCI, DOI [10.1080/10408363.2020.1803789, 10.1080/10408363.2020.1770685]
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P142, DOI 10.4103/ijp.IJP_338_20
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Ragan I, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233947
   RAHMAN MM, 1988, ANTIVIR RES, V9, P11, DOI 10.1016/0166-3542(88)90063-0
   Rydlewicz A, 2002, QJM-INT J MED, V95, P27, DOI 10.1093/qjmed/95.1.27
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sarma P, 2020, INDIAN J PHARMACOL, V52, P1, DOI 10.4103/ijp.IJP_119_20
   Senathilake K., 2020, VIRTUAL SCREENING IN
   Serseg T., 2020, CURR COMPUT AIDED DR
   Sherman K.E., 2016, TOP ANTIVIR MED, V23, P111
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   van Oort FVA, 2003, AM J CLIN NUTR, V77, P1318
   Vardanyan RS, 2006, SYNTHESIS OF ESSENTIAL DRUGS, P525, DOI 10.1016/B978-044452166-8/50034-0
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   YAMADA Y, 1991, ANTIVIR RES, V15, P171, DOI 10.1016/0166-3542(91)90064-X
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang ZG, 2020, AGING-US, V12, P6037, DOI 10.18632/aging.102999
   Zhang H., 2020, DEEP LEARNING BASED, DOI DOI 10.20944/PREPRINTS202002.0061.V1
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zou J., 2020, COMPUTATIONAL PRE DI
NR 43
TC 0
Z9 0
U1 12
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD DEC
PY 2020
VL 101
AR 107716
DI 10.1016/j.jmgm.2020.107716
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA OI6HW
UT WOS:000583378100008
PM 32866780
OA Green Published
DA 2021-01-01
ER

PT J
AU Tachoua, W
   Kabrine, M
   Mushtaq, M
   Ul-Haq, Z
AF Tachoua, Wafa
   Kabrine, Mohamed
   Mushtaq, Mamona
   Ul-Haq, Zaheer
TI An in-silico evaluation of COVID-19 main protease with clinically
   approved drugs
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE COVID-19 main protease; Molecular docking; SwissDock; Approved drugs; MD
   simulation; ADMET
ID ANTIVIRAL ACTIVITY; COMPLEX; SYSTEM
AB A novel strain of coronavirus, namely, SARS-CoV-2 identified in Wuhan city of China in December 2019, continues to spread at a rapid rate worldwide. There are no specific therapies available and investigations regarding the treatment of this disease are still lacking. In order to identify a novel potent inhibitor, we performed blind docking studies on the main virus protease M-pro with eight approved drugs belonging to four pharmacological classes such as: anti-malarial, anti-bacterial, anti-infective and anti-histamine. Among the eight studied compounds, Lymecycline and Mizolastine appear as potential inhibitors of this protease. When docked against M-pro crystal structure, these two compounds revealed a minimum binding energy of -8.87 and -8.71 kcal/mol with 168 and 256 binding modes detected in the binding substrate pocket, respectively. Further, to study the interaction mechanism and conformational dynamics of protein-ligand complexes, Molecular dynamic simulation and MM/PBSA binding free calculations were performed. Our results showed that both Lymecycline and Mizolastine bind in the active site. And exhibited good binding affinities towards target protein. Moreover, the ADMET analysis also indicated drug-likeness properties. Thus it is suggested that the identified compounds can inhibit Chymotrypsin-like protease (3CL(pro)) of SARS-CoV-2. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Tachoua, Wafa] Benyoucef Benkhedda Univ, Nat & Life Sci Dept, Algiers 16000, Algeria.
   [Kabrine, Mohamed] Univ Sci & Technol Houari Boumediene, Fac Biol Sci Cellular & Mol Biol, BP 32, Algiers 16111, Algeria.
   [Mushtaq, Mamona; Ul-Haq, Zaheer] Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, ICCBS, Karachi 75210, Pakistan.
RP Tachoua, W (corresponding author), Benyoucef Benkhedda Univ, Nat & Life Sci Dept, Algiers 16000, Algeria.
EM wtachoua@yahoo.fr
RI Ul-Haq, Zaheer/AAE-1628-2020
OI Ul-Haq, Zaheer/0000-0002-8530-8711; Mushtaq, Mamona/0000-0003-4320-9843
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x
   Boopathi S, 2019, J BIOMOL STRUCT DYN, V2020, P1
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DeLano W.L., 2002, PROTEIN CRYSTALLOGR, V40, P82
   Drwal MN, 2014, NUCLEIC ACIDS RES, V42, pW53, DOI 10.1093/nar/gku401
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Fahrrolfes R, 2017, NUCLEIC ACIDS RES, V45, pW337, DOI 10.1093/nar/gkx333
   Fricker PC, 2004, J CHEM INF COMP SCI, V44, P1065, DOI 10.1021/ci049958u
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Kupferschmidt K, 2020, SCIENCE, V367, P610, DOI 10.1126/science.367.6478.610
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Maffeo A, 2004, MICROBIOLOGICA, V27, P119
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Needle D, 2015, ACTA CRYSTALLOGR D, V71, P1102, DOI 10.1107/S1399004715003521
   Nelson M.L., 2007, ANTIBIOTIC NONANTIBI, P597, DOI [10.1016/B0-08-045044-X/00221-2, DOI 10.1016/B0-08-045044-X/00221-2]
   Nimgampalle M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1782265
   Odhar HA, 2020, BIOINFORMATION, V16, P236, DOI 10.6026/97320630016236
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101578
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Stierand K, 2006, BIOINFORMATICS, V22, P1710, DOI 10.1093/bioinformatics/btl150
   Turriziani O, 2000, ANTIMICROB AGENTS CH, V44, P473, DOI 10.1128/AAC.44.2.473-474.2000
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Volkamer A, 2012, J CHEM INF MODEL, V52, P360, DOI 10.1021/ci200454v
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
NR 44
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD DEC
PY 2020
VL 101
AR 107758
DI 10.1016/j.jmgm.2020.107758
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA OI6HW
UT WOS:000583378100041
PM 33007575
OA Green Published
DA 2021-01-01
ER

PT J
AU Emamaullee, J
   Bowdish, M
   Yan, PY
   Rodina, V
   Sher, LS
AF Emamaullee, Juliet
   Bowdish, Michael
   Yan, Pui Yuk
   Rodina, Valentina
   Sher, Linda S.
TI Rapid Adaptation of a Surgical Research Unit to Conduct Clinical Trials
   During the COVID-19 Pandemic
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE COVID-19 pandemic; SARS-CoV-2; Clinical trials unit; Surgical Research
AB The coronavirus disease 2019 (COVID-19) pandemic has brought most ongoing clinical trials to a standstill, while at the same time emphasizing the need for new therapeutic treatments and strategies to mitigate the morbidity and mortality related to COVID-19. Recent publication of several observational studies has generated much discussion surrounding efficacy of drugs including hydroxychloroquine, azithromycin, and remdesivir, stressing the need for high-quality prospective, randomized control trials in patients with COVID-19. Ongoing "stay at home" orders and institutional policies mandating "work from home" for nonessential employees, which includes most research personnel, have impacted the ability to implement and conduct clinical studies. This article discusses the approach of an experienced clinical trials unit to make adjustments for ongoing studies and ensure the safety of study participants. At the same time, plans were implemented to continue collection of data to achieve endpoints, safely enroll and follow participants in studies offering potential benefit, and quickly implement new COVID-19 clinical trials. The existence of a Division of Clinical Research with regulatory, budgeting, contracting, and coordinating expertise within a department of surgery can successfully accommodate a crisis situation and rapidly adapt to new requirements for the safe, efficient, and effective conversion to a remote work force without compromising the research process. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Emamaullee, Juliet; Bowdish, Michael; Yan, Pui Yuk; Rodina, Valentina; Sher, Linda S.] Univ Southern Calif, Dept Surg, Los Angeles, CA 90033 USA.
   [Emamaullee, Juliet; Bowdish, Michael; Sher, Linda S.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
RP Emamaullee, J (corresponding author), Univ Southern Calif, 1510 San Pablo St,Suite 412, Los Angeles, CA 90033 USA.
EM Juliet.emamaullee@med.usc.edu
RI Emamaullee, Juliet/Q-9249-2019
OI Emamaullee, Juliet/0000-0003-4238-3057
CR Food and Drug Administration, FDA GUID COND CLIN T
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Lupkin S., 2020, HEAL NEWS NPR
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   National Institutes of Health, GUID NIH FUND CLIN T
   University of Southern California, COVID 19 RES GUID PO
   World Health Organization, COVID 19 THER TRIAL
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 1
Z9 1
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD DEC
PY 2020
VL 256
BP 76
EP 82
DI 10.1016/j.jss.2020.06.049
PG 7
WC Surgery
SC Surgery
GA OH5EJ
UT WOS:000582602700011
PM 32683060
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Maltezou, HC
   Magaziotou, I
   Dedoukou, X
   Eleftheriou, E
   Raftopoulos, V
   Michos, A
   Lourida, A
   Panopoulou, M
   Stamoulis, K
   Papaevangelou, V
   Petinaki, E
   Mentis, A
   Papa, A
   Tsakris, A
   Roilides, E
   Syrogiannopoulos, GA
   Tsolia, M
AF Maltezou, Helena C.
   Magaziotou, Ioanna
   Dedoukou, Xanthi
   Eleftheriou, Eirini
   Raftopoulos, Vasilios
   Michos, Athanasios
   Lourida, Athanasia
   Panopoulou, Maria
   Stamoulis, Konstantinos
   Papaevangelou, Vasiliki
   Petinaki, Efthimia
   Mentis, Andreas
   Papa, Anna
   Tsakris, Athanasios
   Roilides, Emmanuel
   Syrogiannopoulos, George A.
   Tsolia, Maria
CA Greek Study Grp SARS-CoV-2 Infect
TI Children and Adolescents With SARS-CoV-2 Infection Epidemiology,
   Clinical Course and Viral Loads
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE SARS-CoV-2; COVID-19; children; viral load; families
AB Background:
   There is limited information on severe acute respiratory syndrome virus 2 (SARS-CoV-2) infection in children.
   Methods:
   We retrieved data from the national database on SARS-CoV-2 infections. We studied in-family transmission. The level of viral load was categorized as high, moderate, or low based on the cycle threshold values.
   Results:
   We studied 203 SARS-CoV-2-infected children (median age: 11 years; range: 6 days to 18.4 years); 111 (54.7%) had an asymptomatic infection. Among the 92 children (45.3%) with coronavirus disease 2019 (COVID-19), 24 (26.1%) were hospitalized. Infants <1 year were more likely to develop COVID-19 (19.5% of all COVID-19 cases) (P-value = 0.001). There was no significant difference between viral load and age, sex, underlying condition, fever and hospitalization, as well as between type of SARS-CoV-2 infection and age, sex, underlying condition and viral load. Transmission from a household member accounted for 132 of 178 (74.2%) children for whom the source of infection was identified. An adult member with COVID-19 was the first case in 125 (66.8%) family clusters. Child-to-adult transmission was found in one occasion only.
   Conclusions:
   SARS-CoV-2 infection is mainly asymptomatic or mild during childhood. Adults appear to play a key role in spread of the virus in families. Most children have moderate or high viral loads regardless of age, symptoms or severity of infection. Further studies are needed to elucidate the role of children in the ongoing pandemic and particularly in light of schools reopening and the need to prioritize groups for vaccination, when COVID-19 vaccines will be available.
C1 [Maltezou, Helena C.] Natl Publ Hlth Org, Directorate Res Studies & Documentat, 3-5 Agrafon St, Athens 15123, Greece.
   [Magaziotou, Ioanna; Dedoukou, Xanthi] Natl Publ Hlth Org, Directorate Epidemiol Surveillance & Intervent In, Athens, Greece.
   [Eleftheriou, Eirini; Tsolia, Maria] Natl & Kapodistrian Univ Athens, Aglaia Kyriakou Childrens Hosp, Dept Pediat 2, Athens, Greece.
   [Raftopoulos, Vasilios] Natl Publ Hlth Org, Epidemiol Surveillance HIV AIDS Dept, Athens, Greece.
   [Michos, Athanasios] Natl & Kapodistrian Univ Athens, Aghia Sophia Childrens Hosp, Dept Pediat 1, Athens, Greece.
   [Lourida, Athanasia] Aghia Sofia Childrens Hosp, Infect Prevent & Control Comm, Athens, Greece.
   [Panopoulou, Maria] Democritus Univ Thrace, Lab Microbiol, Alexandroupolis, Greece.
   [Stamoulis, Konstantinos] Natl Blood Transfus Ctr, Athens, Greece.
   [Papaevangelou, Vasiliki] Natl & Kapodistrian Univ Athens, Dept Pediat 3, Athens, Greece.
   [Petinaki, Efthimia] Univ Thessaly, Microbiol Lab, Larisa, Greece.
   [Mentis, Andreas] Hellenic Pasteur Inst, Natl Reference Lab Influenza & Other Resp Viruses, Athens, Greece.
   [Papa, Anna] Aristotle Univ Thessaloniki, Med Sch, Dept Microbiol, Thessaloniki, Greece.
   [Tsakris, Athanasios] Natl & Kapodistrian Univ Athens, Med Sch, Dept Microbiol, Athens, Greece.
   [Roilides, Emmanuel] Aristotle Univ Thessaloniki, Sch Hlth Sci, Dept Pediat 3, Thessaloniki, Greece.
   [Syrogiannopoulos, George A.] Univ Thessaly, Dept Pediat, Larisa, Greece.
RP Maltezou, HC (corresponding author), Natl Publ Hlth Org, Directorate Res Studies & Documentat, 3-5 Agrafon St, Athens 15123, Greece.
EM helen-maltezou@ath.forthnet.gr
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Danis K, 2020, CLIN INFECT DIS, V71, P825, DOI 10.1093/cid/ciaa424
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Du WJ, 2020, INFECTION, V48, P445, DOI 10.1007/s15010-020-01427-2
   Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756
   Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2
   Han MS, 2020, EMERG INFECT DIS, V26
   Heald Sargent T, 2020, JAMA PEDIAT
   Jiang XL, 2020, J INFECT DIS, V221, P1948, DOI 10.1093/infdis/jiaa206
   Jones TC, ANAL SARS COV 2 VIRA
   L'Huillier AG, SHEDDING INFECT SARS
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Maltezou HC, 2020, VACCINE, V38, P6078, DOI 10.1016/j.vaccine.2020.07.058
   Maltezou HC, 2020, J MED VIROL, DOI 10.1002/jmv.26394
   Park YJ, 2020, EMERG INFECT DIS, V26, P2465, DOI 10.3201/eid2610.201315
   Posfay-Barbe KM, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1576
   Song R, 2020, J INFECTION, V81, pE26, DOI 10.1016/j.jinf.2020.04.018
   WHO, COR DIS COVID 19 PAN
   Wolf GK, 2020, J PEDIAT INF DIS SOC, V9, P362, DOI 10.1093/jpids/piaa060
   Yang ZD, 2020, J INFECTION, V81, pE11, DOI 10.1016/j.jinf.2020.04.030
NR 20
TC 0
Z9 0
U1 7
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD DEC
PY 2020
VL 39
IS 12
BP E388
EP E392
DI 10.1097/INF.0000000000002899
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA OQ4YJ
UT WOS:000588790600001
PM 33031141
DA 2021-01-01
ER

PT J
AU Killick, R
   Ballard, C
   Doherty, P
   Williams, G
AF Killick, Richard
   Ballard, Clive
   Doherty, Patrick
   Williams, Gareth
TI Transcription-based drug repurposing for COVID-19
SO VIRUS RESEARCH
LA English
DT Article
DE COVID-19; Gene expression; Repurposing
ID CONNECTIVITY MAP; K+-ATPASE; EXPRESSION; DISCOVERY; RECEPTOR; NA+
AB We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activity. Nine of these have been tested against SARS-2 and found to potently antagonise SARS-2 infection/replication, with a number now being considered for clinical trials. It is hoped that this approach may serve to broaden the spectrum of approved drugs that should be further assessed as potential anti-COVID-19 agents and may help elucidate how this seemingly disparate collection of drugs are able to inhibit SARS-2 infection/replication.
C1 [Killick, Richard] Kings Coll London, Maurice Wohl Clin Neurosci Inst, London, England.
   [Ballard, Clive] Univ Exeter, Med Sch, Coll Med & Hlth, Exeter, Devon, England.
   [Doherty, Patrick; Williams, Gareth] Kings Coll London, Wolfson Ctr Age Related Dis, London, England.
RP Williams, G (corresponding author), Kings Coll London, Wolfson Ctr Age Related Dis, London, England.
EM gareth.2.williams@kcl.ac.uk
OI Williams, Gareth/0000-0001-9205-4943; Ballard, Clive/0000-0003-0022-5632
CR Bleasel MD, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13030051
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Deshotels MR, 2014, HYPERTENSION, V64, P1368, DOI 10.1161/HYPERTENSIONAHA.114.03743
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Grosso F, 2017, J VIROL, V91, DOI 10.1128/JVI.01623-16
   Hartley C, 2006, ARCH VIROL, V151, P2495, DOI 10.1007/s00705-006-0824-x
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Horby P., 2020, EFFECT DEXAMETHASONE
   Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Jurgeit A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002976
   Ketchem CJ, 2016, BBA-MOL CELL RES, V1863, P2624, DOI 10.1016/j.bbamcr.2016.07.008
   Kinoshita PF, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0218-z
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Laursen M, 2015, P NATL ACAD SCI USA, V112, P1755, DOI 10.1073/pnas.1422997112
   Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014
   Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282
   Ogawa H, 2009, P NATL ACAD SCI USA, V106, P13742, DOI 10.1073/pnas.0907054106
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Tatham KC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03216-7
   Walf-Vorderwulbecke V, 2018, LEUKEMIA, V32, P882, DOI 10.1038/leu.2017.317
   Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006
   Williams G, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0555-x
   Williams G, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-12
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Zhang DL, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00176
NR 26
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD DEC
PY 2020
VL 290
AR 198176
DI 10.1016/j.virusres.2020.198176
PG 3
WC Virology
SC Virology
GA OP1FO
UT WOS:000587826900013
PM 32987033
OA Green Published
DA 2021-01-01
ER

PT J
AU De Souza, L
   Nwanji, V
   Kaur, G
AF De Souza, Luisa
   Nwanji, Valerie
   Kaur, Gurwant
TI An auspicious triumph of recovery from dialysis-requiring acute kidney
   injury in COVID-19 in a patient with chronic kidney disease, alpha-1
   antitrypsin deficiency, and liver transplant: A case report
SO CLINICAL NEPHROLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; acute kidney injury; alpha-1 antitrypsin
   deficiency; continuous renal replacement therapy; hemodialysis
ID RESPIRATORY SYNDROME CORONAVIRUS; FRACTIONAL EXCRETION; UREA; SODIUM
AB We report a unique case of an immunosuppressed 67-year-old female with homozygous Z-allele mutation A1AT deficiency and liver transplant with baseline chronic kidney disease (CKD) stage lila with creatinine of 1 mg/dL and glomerular filtration rate (GFR) of 49 mL/min/1.73m(2) similar to 6 months before the presentation. She presented with COVID-19 mediated hypoxic respiratory failure complicated by AKI requiring provisional renal replacement therapy with recovery of kidney function with a new baseline of creatinine of 1.6 -1.8 mg/dL with GFR of 31 mL/min/1.73m(2).
C1 [De Souza, Luisa] Penn State Hershey Med Ctr, Penn State Coll Med, Hershey, PA 17033 USA.
   [Nwanji, Valerie] Penn State Hershey Med Ctr, Dept Med, Hershey, PA 17033 USA.
   [Kaur, Gurwant] Penn State Hershey Med Ctr, Div Nephrol, 500 Univ Dr, Hershey, PA 17033 USA.
RP Kaur, G (corresponding author), Penn State Hershey Med Ctr, Div Nephrol, 500 Univ Dr, Hershey, PA 17033 USA.
EM gkaur1@pennstatehealth.psu.edu
CR Carvounis CP, 2002, KIDNEY INT, V62, P2223, DOI 10.1046/j.1523-1755.2002.00683.x
   Chan Lili, 2020, medRxiv, DOI 10.1101/2020.05.04.20090944
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Coca SG, 2012, KIDNEY INT, V81, P442, DOI 10.1038/ki.2011.379
   Diskin CJ, 2010, NEPHRON CLIN PRACT, V114, pC145, DOI 10.1159/000254387
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Jansen MAM, 2002, KIDNEY INT, V62, P1046, DOI 10.1046/j.1523-1755.2002.00505.x
   Kes P, 2010, BOSNIAN J BASIC MED, V10, pS8
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006
   Lin W, 2020, SINGLE CELL ANAL ACE, DOI DOI 10.1101/2020.02.08.939892
   Liu F, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104370
   Ng JJ, 2020, J INFECT
   Pacciarini F, 2008, J VIROL, V82, P5137, DOI 10.1128/JVI.00096-08
   Pascarella G, 2020, J INTERN MED, V288, P192, DOI 10.1111/joim.13091
   Pepin MN, 2007, AM J KIDNEY DIS, V50, P566, DOI 10.1053/j.ajkd.2007.07.001
   Romagnoli S, 2018, CURR OPIN CRIT CARE, V24, P483, DOI 10.1097/MCC.0000000000000544
   Strnad P, 2020, NEW ENGL J MED, V382, P1443, DOI 10.1056/NEJMra1910234
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Wang CS, 2020, ANN INTERN MED, V173, P499, DOI 10.7326/L20-0354
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 28
TC 0
Z9 0
U1 1
U2 1
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0301-0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD DEC
PY 2020
VL 94
IS 6
BP 297
EP 306
DI 10.5414/CN110294
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA OP7PA
UT WOS:000588277700004
PM 32909541
DA 2021-01-01
ER

PT J
AU Ballivian, J
   Alcaide, ML
   Cecchini, D
   Jones, DL
   Abbamonte, JM
   Cassetti, I
AF Ballivian, Jamile
   Alcaide, Maria L.
   Cecchini, Diego
   Jones, Deborah L.
   Abbamonte, John M.
   Cassetti, Isabel
TI Impact of COVID-19-Related Stress and Lockdown on Mental Health Among
   People Living With HIV in Argentina
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE mental health; resilience; HIV; COVID-19; Argentina
ID RESILIENCE; OUTCOMES; WOMEN; INFECTIONS
AB Background: The spread of severe acute respiratory syndrome coronavirus 2, causative agent of the coronavirus disease 2019 (COVID-19), has necessitated widespread lockdown to mitigate the pandemic. This study examines the influence of resilience on the impact of COVID-related stress and enforced lockdown on mental health, drug use, and treatment adherence among people living with HIV (PLWH) in Argentina. Setting: PLWH residing predominantly in Buenos Aires Metropolitan Area and urban regions of Argentina were identified from a private clinic electronic database. Methods: Participants completed an anonymous online survey to evaluate the impact of COVID-19 on economic disruption, resilience, mental health outcomes (depression, anxiety, stress, and loneliness), adherence to HIV treatment, and substance use. We performed ordinary least squares and logistic regressions to test whether resilient coping buffered the impact of economic disruption on mental health and drug use during quarantine. Results: A total of 1336 PLWH aged 18-82 were enrolled. The impact of economic disruption on mental health Delta F(1,1321) = 8.86, P = 0.003 and loneliness Delta F(1,1326) = 5.77, P = 0.016 was buffered by resilience. A 3-way interaction between resilient buffering, stress, and sex was significant Delta F(1,1325) = 4.76, P = 0.029. Participants reported less than excellent adherence to medication (33%), disruption to mental health services (11%), and disruption to substance abuse treatment (1.3%) during lockdown. Discussion: The impact of COVID-stress and lockdown on emotional distress seemed mitigated by resilience coping strategies, and the buffering impact of resilience on perceived stress was greater among women. Results highlight PLWH's capacity to adhere to treatment in challenging circumstances and the importance of developing resilience skills for better coping with stress and adversity.
C1 [Ballivian, Jamile; Cecchini, Diego; Cassetti, Isabel] Helios Salud, Peru 1511 C1141ACG, Buenos Aires, DF, Argentina.
   [Alcaide, Maria L.] Univ Miami, Miller Sch Med, Div Infect Dis, Dept Med, Miami, FL 33136 USA.
   [Jones, Deborah L.; Abbamonte, John M.] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA.
RP Ballivian, J (corresponding author), Helios Salud, Peru 1511 C1141ACG, Buenos Aires, DF, Argentina.
EM jballivian@heliossalud.com
FU Helios Salud; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [R01MH110242]; Miami CFAR [P30AI073961]
FX Supported by Helios Salud and a grant from the National Institutes of
   Health, R01MH110242; the study was also supported by the Miami CFAR,
   P30AI073961, and by the generous contributions of the men and women
   participating, without whom none of this research would be possible.
CR American Psychological Association, 2012, BUILD YOUR RES
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, AL JAZEERA
   Aristide C, 2020, AIDS BEHAV, V24, P3295, DOI 10.1007/s10461-020-02955-6
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI DOI 10.15585/MMWR.MM6912E2
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Burke-Miller JK, 2016, AIDS CARE, V28, P1274, DOI 10.1080/09540121.2016.1173642
   Cella D, 2019, VALUE HEALTH, V22, P537, DOI 10.1016/j.jval.2019.02.004
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Dale SK, 2014, SEX ROLES, V70, P221, DOI 10.1007/s11199-014-0348-x
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dulin AJ, 2018, AIDS CARE, V30, pS6, DOI 10.1080/09540121.2018.1515470
   European AIDS Clinical Society, 2020, EACS BHIVA STAT RISK
   Fitch Solutions, 2020, ARG COVID 19 LOCKD I
   Fitzpatrick KM, 2020, DEPRESS ANXIETY, V37, P957, DOI 10.1002/da.23080
   Fletcher FE, 2020, AIDS PATIENT CARE ST, V34, P356, DOI 10.1089/apc.2019.0309
   Friedman MR, 2017, AIDS CARE, V29, P469, DOI 10.1080/09540121.2016.1211614
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Golden MR, 1999, SEX TRANSM DIS, V26, P543, DOI 10.1097/00007435-199910000-00011
   Halkitis PN, 2017, INTERD T GERONT GERI, V42, P187, DOI 10.1159/000448564
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Hoyer C, 2020, EUR ARCH PSY CLIN N, DOI 10.1007/s00406-020-01151-w
   International Monetary Fund, 2020, TECHN ASS REP STAFF
   Jiang HB, 2020, LANCET HIV, V7, pE308, DOI 10.1016/S2352-3018(20)30105-3
   King BM, 2019, GERONTOLOGIST, V59, P1122, DOI 10.1093/geront/gny115
   Kirby T, 2020, LANCET RESP MED, V8, P551, DOI 10.1016/S2213-2600(20)30218-6
   Krishnan S, 2008, ANN NY ACAD SCI, V1136, P101, DOI 10.1196/annals.1425.013
   Lebel S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234124
   MACS/WIHS Combined Cohort Study, 2020, MWCCS COVID FORMS
   Marg LZ, 2020, J WOMEN AGING, V32, P365, DOI 10.1080/08952841.2020.1751566
   Mengin A, 2020, ENCEPHALE, V46, pS43, DOI 10.1016/j.encep.2020.04.007
   Mukhtar S, 2020, INT J SOC PSYCHIATR, V66, P512, DOI 10.1177/0020764020925835
   Munoz N, 2020, COLOMB MEDICA, V51, DOI 10.25100/cm.v51i2.4366
   Noone C, 2020, COCHRANE DB SYST REV, V5
   Novotney A., 2019, MONITOR PSYCHOL, V50
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Petricone-Westwood D, 2020, SUPPORT CARE CANCER, DOI 10.1007/s00520-020-05599-3
   Pierce M, 2020, LANCET PSYCHIAT, V7, P883, DOI 10.1016/S2215-0366(20)30308-4
   Provenzi L, 2020, PSYCHOL TRAUMA-US, V12, pS252, DOI 10.1037/tra0000619
   Ran LY, 2020, SOC SCI MED, V262, DOI 10.1016/j.socscimed.2020.113261
   Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0
   Rosenberg AR, 2020, JAMA PEDIATR, V174, P817, DOI 10.1001/jamapediatrics.2020.1436
   Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2
   Schneiderman N, 2005, ANNU REV CLIN PSYCHO, V1, P607, DOI 10.1146/annurev.clinpsy.1.102803.144141
   Sinclair VG, 2004, ASSESSMENT, V11, P94, DOI 10.1177/1073191103258144
   Ungar M, 2020, LANCET PSYCHIAT, V7, P441, DOI 10.1016/S2215-0366(19)30434-1
   Weinstein TL, 2016, AIDS CARE, V28, P160, DOI 10.1080/09540121.2015.1090532
   World Health Organization, 2020, 200 WHO
   World Health Organization, 2020, WHO COR DIS COVID 19
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Ye Z, 2020, APPL PSYCHOL-HLTH WE, V12, P1074, DOI 10.1111/aphw.12211
   Yu Lifa, 2007, J Nurs Res, V15, P202
   Zhang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040793
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
NR 56
TC 0
Z9 0
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2020
VL 85
IS 4
BP 475
EP 482
DI 10.1097/QAI.0000000000002493
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA OP0VX
UT WOS:000587800200019
PM 33136748
DA 2021-01-01
ER

PT J
AU Brezing, CA
   Luo, SAX
   Mariani, JJ
   Levin, FR
AF Brezing, Christina A.
   Luo, Sean X.
   Mariani, John J.
   Levin, Frances R.
TI Digital Clinical Trials for Substance Use Disorders in the Age of
   Covid-19
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Article
DE clinical trials; Covid-19; substance use disorders; technology; digital
ID CANNABIS USE DISORDER; CONTINGENCY MANAGEMENT; URINE
AB As a result of the coronavirus 2019 (Covid-19) pandemic, clinical research for substance use disorders (SUDs) has been impeded due to widespread stay-at-home mandates limiting the operations of "non-essential" work. Although appropriate to proceed with an abundance of caution to prevent viral spread, there will be detrimental consequences for patients with SUDs if clinical trials research cannot adapt and continue uninterrupted. The field of digital health has strong evidence for its feasibility and effectiveness and offers tools that can facilitate the continuation of SUD clinical trials research remotely in accordance with Covid-19 precautions. Some digital tools have been used as components of SUD research in the past; however, no published clinical trial in SUDs to-date has been entirely virtual. This has important implications for disrupted clinical care, as providers seek guidelines for best digital practices. This paper provides a roadmap for integrating the fields of digital health and SUD clinical trials by proposing methods to complete recruitment, screening, informed consent, other study procedures, and internal lab operations digitally. The immediate future of SUD research depends on the ability to comply with social distancing. Investment in research of digital clinical trials for SUDs provides an opportunity to cultivate benefits for research and clinical care long-term as we can (1) define regulatory requirements for the implementation of digital systems, (2) develop consensus on system-wide standards and protocols in the appropriate use of technology, and (3) gain experience that can translate to the treatment of patients with SUDs through telehealth in the community.
C1 [Brezing, Christina A.; Luo, Sean X.; Mariani, John J.; Levin, Frances R.] New York State Psychiat Inst & Hosp, Div Subst Use Disorders, 1051 Riverside Dr, New York, NY 10032 USA.
   [Brezing, Christina A.; Luo, Sean X.; Mariani, John J.; Levin, Frances R.] Columbia Univ, Irving Med Ctr, Dept Psychiat, New York, NY USA.
RP Brezing, CA (corresponding author), New York State Psychiat Inst & Hosp, Div Subst Use Disorders, 1051 Riverside Dr, New York, NY 10032 USA.
EM Christina.brezing@nyspi.columbia.edu
FU National Institute on Drug AbuseUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [1K23DA045080, 5K23DA042136, K24
   DA029647, T32 DA007294, UG1 DA013035, R25 DA035161, R01 DA044171, U01
   DA045372, 1U01TR002763, UM1 DA04049415, R21 DA049037, R21AA028371];
   Substance Abuse and Mental Health Services Administration (SAMHSA)United
   States Department of Health & Human Services [H79 TI081968, H79
   T1080816]
FX Dr. Brezing is supported by grant 1K23DA045080 funded through the
   National Institute on Drug Abuse. She has no conflicts of interest. Dr.
   Luo is supported by grant 5K23DA042136 funded through the National
   Institute on Drug Abuse. He has no conflicts of interest. Dr. Mariani
   has served as a consultant to Indivior and Novartis. Dr. Levin is funded
   by the following grants from the National Institute on Drug Abuse: K24
   DA029647; T32 DA007294; UG1 DA013035; R25 DA035161; R01 DA044171; U01
   DA045372; 1U01TR002763; UM1 DA04049415; R21 DA049037; R21AA028371.
   Additionally, she is funded by the Substance Abuse and Mental Health
   Services Administration (SAMHSA) Collaborative Strategies for Training
   Health Professionals H79 TI081968 and Opioid Strategic Targeted
   Response-Technical Assistance H79 T1080816. She receives salary support
   as a Research Scientist from New York State. She receives medication for
   a research study from US World Meds. She serves as a consultant for
   Major League Baseball and unpaid on the Scientific Advisory Boards for
   Novartis, Alkermes, and Indivior.
CR Akers L, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9372
   Alosco ML, 2012, HEALTH PSYCHOL, V31, P754, DOI 10.1037/a0028711
   [Anonymous], RAND TRIAL HYDR POST, DOI 10.1056/NEJMoa2016638
   [Anonymous], DEM INT HOM BROADB U
   Applequist J, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-00926-y
   Beckham JC, 2018, ADDICT BEHAV, V79, P86, DOI 10.1016/j.addbeh.2017.12.007
   Bhutada NS, 2015, RES SOC ADMIN PHARM, V11, P891, DOI 10.1016/j.sapharm.2015.02.003
   Borodovsky JT, 2018, JMIR PUBLIC HLTH SUR, V4, P370, DOI 10.2196/publichealth.9408
   Brezing CA, 2018, NEUROPSYCHOPHARMACOL, V43, P173, DOI 10.1038/npp.2017.212
   Bucci S, 2019, PSYCHOL PSYCHOTHER-T, V92, P277, DOI 10.1111/papt.12222
   Burr C, 2020, SCI ENG ETHICS, V26, P2313, DOI 10.1007/s11948-020-00175-8
   Campbell ANC, 2014, AM J PSYCHIAT, V171, P683, DOI 10.1176/appi.ajp.2014.13081055
   CDC, 2020, COR DIS 2019 COVID 1
   Colombo D, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0899-y
   Commissioner O of the, 2020, COMM COR COVID 19 UP
   D'Souza DC, 2019, LANCET PSYCHIAT, V6, P35, DOI 10.1016/S2215-0366(18)30427-9
   Ferreri F, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00051
   Galbadage T, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00163
   Ginige Jeewani Anupama, 2020, Stud Health Technol Inform, V268, P97, DOI 10.3233/SHTI200009
   Hadland SE, 2016, CHILD ADOL PSYCH CL, V25, P549, DOI 10.1016/j.chc.2016.02.005
   Hick JL, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005118
   Inan OT, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0302-y
   Jain SH, 2015, NAT BIOTECHNOL, V33, P462, DOI 10.1038/nbt.3223
   Jain SH, 2009, NEW ENGL J MED, V361, P649, DOI 10.1056/NEJMp0901277
   Jain S, 2020, ANN INTERN MED, V173, P503, DOI 10.7326/M20-1201
   Keesara S, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005835
   Koffarnus MN, 2018, ALCOHOL CLIN EXP RES, V42, P2423, DOI 10.1111/acer.13891
   Kong T, 2020, DIGIT HLTH, V6, P1
   Lin KG, 2020, AM J PSYCHIAT, V177, P635, DOI 10.1176/appi.ajp.2020.20040374
   Lin L (Allison), JAMA PSYCHIAT
   Lin L, 2019, J SUBST ABUSE TREAT, V101, P38, DOI 10.1016/j.jsat.2019.03.007
   Liu S, JAMA PSYCHIAT
   Marsch LA, 2012, PSYCHIAT CLIN N AM, V35, P481, DOI 10.1016/j.psc.2012.03.009
   Melanson SEF, 2012, CLIN LAB MED, V32, P429, DOI 10.1016/j.cll.2012.06.004
   Myers US, J RURAL HEALTH
   Palen LA, 2008, EVALUATION REV, V32, P257, DOI 10.1177/0193841X07307829
   Petry NM, 2018, J CONSULT CLIN PSYCH, V86, P799, DOI 10.1037/ccp0000330
   Ramo DE, 2018, CONTEMP CLIN TRIALS, V68, P52, DOI 10.1016/j.cct.2018.02.014
   reSET & reSET-O, RESET RESET O
   Rosa C, 2015, CONTEMP CLIN TRIALS, V45, P41, DOI 10.1016/j.cct.2015.07.007
   Samuel G, 2020, J EMPIR RES HUM RES, V15, DOI 10.1177/1556264619901215
   Samuels Elizabeth A, 2020, J Addict Med, V14, pe8, DOI 10.1097/ADM.0000000000000685
   Shimbo D, 2015, ANN INTERN MED, V163, P691, DOI 10.7326/M15-1270
   Walker R, 2019, J ADDICT MED, V13, P372, DOI 10.1097/ADM.0000000000000509
   Welch BM, 2016, CONT CLIN TRIAL COMM, V3, P74, DOI 10.1016/j.conctc.2016.03.002
   Wycoff AM, 2018, DRUG ALCOHOL DEPEN, V191, P223, DOI 10.1016/j.drugalcdep.2018.07.001
NR 46
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-0620
EI 1935-3227
J9 J ADDICT MED
JI J. Addict. Med.
PD DEC
PY 2020
VL 14
IS 6
BP E297
EP E302
DI 10.1097/ADM.0000000000000733
PG 6
WC Substance Abuse
SC Substance Abuse
GA OQ0MN
UT WOS:000588486800006
PM 32956164
OA Green Published
DA 2021-01-01
ER

PT J
AU Pettigrew, S
   Jun, M
   Roberts, I
   Bullen, C
   Nallaiah, K
   Rodgers, A
AF Pettigrew, Simone
   Jun, Min
   Roberts, Ian
   Bullen, Chris
   Nallaiah, Kellie
   Rodgers, Anthony
TI Preferences for Tobacco Cessation Information and Support During
   Covid-19
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Article
DE counseling; information sources; nicotine replacement therapy; smoking
   cessation
ID SMOKING; PREVALENCE
AB Objective: To identify how best to provide smoking cessation advice and support during the Covid-19 pandemic. Preferences were assessed in relation to: (i) specific forms of tobacco cessation support (eg, nicotine replacement therapy (NRT) and various counseling formats); (ii) information sources (eg, government officials, doctors); and (iii) channels via which to receive relevant information (eg, television, social media). Methods: An online survey was administered to adults who smoke tobacco in Australia (n = 604) and the UK (n = 600). Descriptive analyses were conducted to identify levels of interest in cessation support and information provision. Differences in responses according to demographic characteristics and smoking history were assessed. Results: Around half of the respondents were interested in receiving personal counseling and/or participating in a text support program over the next month. By far the most popular delivery mechanism for personal counseling was email. Three-quarters of the sample expressed an interest in receiving free, home-delivered NRT. The most popular information sources nominated by respondents seeking more information about smokers' Covid-related risks were government departments and their doctor/general practitioner. Television and online news sources were the most preferred information dissemination channels. Conclusions: The substantial levels of interest expressed in accessing various forms of cessation assistance within the next month suggest that Covid-19 may be increasing receptiveness to quitting. The strong interest in free, home-delivered NRT indicates that this may be a useful mechanism for facilitating quit attempts during the pandemic.
C1 [Pettigrew, Simone; Jun, Min; Nallaiah, Kellie; Rodgers, Anthony] George Inst Global Hlth, 1 King St, Sydney, NSW 2042, Australia.
   [Roberts, Ian] London Sch Hyg & Trop Med, London, England.
   [Bullen, Chris] Univ Auckland, Natl Inst Hlth Innovat, Auckland, New Zealand.
   [Pettigrew, Simone; Jun, Min; Rodgers, Anthony] Univ New South Wales, Sydney, NSW, Australia.
RP Pettigrew, S (corresponding author), George Inst Global Hlth, 1 King St, Sydney, NSW 2042, Australia.
EM spettigrew@georgeinstitute.org.au
OI Pettigrew, Simone/0000-0003-3921-1174
FU National Health and Medical Research CouncilNational Health and Medical
   Research Council of Australia [GNT1149987]; University of New South
   Wales, Sydney, Australia
FX This study was funded by a National Health and Medical Research Council
   Program Grant (GNT1149987). MJ is supported by a Scientia Fellowship
   from the University of New South Wales, Sydney, Australia.
CR AIHW, 2017, AIHW NATL DRUG STRAT
   Amonini C, 2015, TOB CONTROL, V24, P436, DOI 10.1136/tobaccocontrol-2014-051737
   Australian Medical Association, TOB US COVID 19
   Fingrut Warren, 2016, Prev Med Rep, V4, P597
   Gram IT, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/12137
   Matkin W, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002850.pub4
   Parnell A, 2019, AUST NZ J PUBL HEAL, V43, P108, DOI 10.1111/1753-6405.12869
   Perski O, 2019, ADDICT BEHAV, V90, P306, DOI 10.1016/j.addbeh.2018.11.030
   Public Health England, SMOK GREAT RISK SEV
   US Surgeon General, SMOK CESS REP SURG G
   West R, 2017, PSYCHOL HEALTH, V32, P1018, DOI 10.1080/08870446.2017.1325890
   West R, 2015, ADDICTION, V110, P1388, DOI 10.1111/add.12998
   Westmaas JL, 2018, TOB CONTROL, V27, P136, DOI 10.1136/tobaccocontrol-2016-053056
   Whittaker R, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006611.pub5
NR 14
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-0620
EI 1935-3227
J9 J ADDICT MED
JI J. Addict. Med.
PD DEC
PY 2020
VL 14
IS 6
BP E362
EP E365
DI 10.1097/ADM.0000000000000743
PG 4
WC Substance Abuse
SC Substance Abuse
GA OQ0MN
UT WOS:000588486800017
PM 32941292
DA 2021-01-01
ER

PT J
AU Stowe, MJ
   Calvey, T
   Scheibein, F
   Arya, S
   Saad, NA
   Shirasaka, T
   Dannatt, L
   Ghosh, A
   Yee, A
   Ratta-Apha, W
   Vadivel, R
   Siste, K
   Shah, B
   Ramalho, R
   Narasimha, VL
   Delic, M
   Peyron, E
   Gumikiriza-Onoria, JL
   Pant, SB
   Boujraf, S
   Grandinetti, P
   Morgan, N
AF Stowe, M. J.
   Calvey, Tanya
   Scheibein, Florian
   Arya, Sidharth
   Saad, Noha Ahmed
   Shirasaka, Tomohiro
   Dannatt, Lisa
   Ghosh, Abhishek
   Yee, Anne
   Ratta-Apha, Woraphat
   Vadivel, Ramyadarshni
   Siste, Kristiana
   Shah, Bigya
   Ramalho, Rodrigo
   Narasimha, Venkata Lakshmi
   Delic, Mirjana
   Peyron, Eric
   Gumikiriza-Onoria, Joy Louise
   Pant, Sagun Ballav
   Boujraf, Said
   Grandinetti, Paolo
   Morgan, Nirvana
TI Access to Healthcare and Harm Reduction Services During the COVID-19
   Pandemic for People Who Use Drugs
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Article
DE addiction services; coronavirus disease 2019; drug use; opioid agonist
   maintenance treatment; people who use drugs
AB Globally, there are concerns about access to healthcare and harm reduction services for people who use drugs (PWUD) during the coronavirus disease 2019 (COVID-19) pandemic. Members from the Network of Early Career Professionals working in Addiction Medicine shared their experiences of providing treatment to PWUD during the COVID-19 pandemic. Drawing on these qualitative reports, we highlight the similarities and discrepancies in access to services for PWUD in 16 countries under COVID-10 restrictions. In most countries reported here, efforts have been made to ensure continued access to services, such as mobilising opioid agonist maintenance treatment and other essential medicines to patients. However, due to travel restrictions and limited telemedicine services, several Network of Early Career Professionals working in Addiction Medicine members from lower-resourced countries experienced challenges with providing care to their patients during periods of COVID-19 lock-down. The insights provided in this commentary illustrate how the COVID-19 lock-down restrictions have impacted access to services for PWUD.
C1 [Stowe, M. J.] Univ Pretoria, Dept Family Med, Sch Med, Fac Hlth Sci, Pretoria, South Africa.
   [Calvey, Tanya] Univ Witwatersrand, Fac Hlth Sci, Sch Anat Sci, Johannesburg, South Africa.
   [Scheibein, Florian] Waterford Inst Technol, Sch Hlth Sci, Waterford, Ireland.
   [Arya, Sidharth] Pt BDS Univ Hlth Sci, State Drug Dependence Treatment Ctr, Inst Mental Hlth, Rohtak, Haryana, India.
   [Saad, Noha Ahmed] Ain Shams Univ, State Drug Dependence Treatment Ctr, Cairo, Egypt.
   [Shirasaka, Tomohiro] Teine Keijinkai Hosp, Dept Psychiat, Sapporo, Hokkaido, Japan.
   [Dannatt, Lisa] Univ Cape Town, Dept Psychiat & Mental Hlth, Fac Hlth Sci, Rondebosch, South Africa.
   [Ghosh, Abhishek] Postgrad Inst Med Educ & Res, Drug Addict & Treatment Ctr, Chandigarh, India.
   [Ghosh, Abhishek] Postgrad Inst Med Educ & Res, Dept Psychiat, Chandigarh, India.
   [Yee, Anne] Univ Malaya, Fac Med, Univ Malaya Ctr Addict Sci UMCAS, Dept Psychol Med, Kuala Lumpur, Malaysia.
   [Ratta-Apha, Woraphat] Mahidol Univ, Fac Med, Dept Psychiat, Siriraj Hosp, Salaya, Thailand.
   [Vadivel, Ramyadarshni] Waikato Dist Hlth Board WDHB, Dept Mental Hlth & Addict, Hamilton, New Zealand.
   [Siste, Kristiana] Univ Indonesia, Fac Med, Dept Psychiat, Cipto Mangun Kusumo Hosp, Jakarta, Indonesia.
   [Shah, Bigya] Patan Acad Hlth Sci, Patan, Nepal.
   [Ramalho, Rodrigo] Univ Auckland, Dept Social & Community Hlth, Sch Populat Hlth, Auckland, New Zealand.
   [Narasimha, Venkata Lakshmi] Natl Inst Mental Hlth & Neurosci NIMHANS, Ctr Addict Med, Dept Psychiat, Bengaluru, India.
   [Delic, Mirjana] Univ Psychiat Clin Ljubljana, Ctr Treatment Drug Addict, Ljubljana, Slovenia.
   [Peyron, Eric] AddiPsy, Lyon, France.
   [Gumikiriza-Onoria, Joy Louise] Makerere Univ, Dept Psychiat, Sch Med, Kampala, Uganda.
   [Pant, Sagun Ballav] Tribhuvan Univ, Dept Psychiat & Mental Hlth, Teaching Hosp, Kathmandu, Nepal.
   [Boujraf, Said] Sidi Mohamed Ben Abdellah Univ Fez, Fac Med & Pharm, Fes, Morocco.
   [Grandinetti, Paolo] ASL 4 Teramo, Dept Terr Serv, Serv Addict SerD, Teramo, TE, Italy.
   [Morgan, Nirvana] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
RP Stowe, MJ (corresponding author), Univ Pretoria, Dept Family Med, Sch Med, Fac Hlth Sci, Pretoria, South Africa.
EM mj.stowe@up.ac.za
RI Narasimha, Venkata Lakshmi/ABH-7455-2020; Ann, Yee Hway/D-7968-2012
OI Ann, Yee Hway/0000-0002-9835-6798; Scheibein,
   Florian/0000-0001-9585-5068; Vadivel, Ramyadarshni/0000-0002-7055-5250
CR [Anonymous], 2020, SUGG TREATM CAR REH
   [Anonymous], 2020, INT STAND TREATM DRU
   Chiappini S, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00767
   Dunlop A, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00370-7
   Farhoudian A, 2020, BASIC CLIN NEUROSCI, V11, P133, DOI 10.32598/bcn.11.covid19.1
   Glick SN, 2020, AIDS BEHAV, V24, P2466, DOI 10.1007/s10461-020-02886-2
   Harris Miriam, 2020, J Addict Med, V14, pe136, DOI 10.1097/ADM.0000000000000682
   Marsden J, 2020, ADDICTION, V115, P1007, DOI 10.1111/add.15080
   Ohannessian R, 2020, JMIR PUBLIC HLTH SUR, V6, P121, DOI 10.2196/18810
   Peavy KM, 2020, AIDS BEHAV, V24, P2469, DOI 10.1007/s10461-020-02887-1
   Sun YK, 2020, AM J ADDICTION, V29, P174, DOI 10.1111/ajad.13031
   Vasylyeva TI, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25583
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
NR 13
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-0620
EI 1935-3227
J9 J ADDICT MED
JI J. Addict. Med.
PD DEC
PY 2020
VL 14
IS 6
BP E287
EP E289
DI 10.1097/ADM.0000000000000753
PG 3
WC Substance Abuse
SC Substance Abuse
GA OQ0MN
UT WOS:000588486800003
PM 33009167
DA 2021-01-01
ER

PT J
AU Sadia, A
   Azam, M
   Basra, MAR
AF Sadia, Aatika
   Azam, Muhammad
   Basra, Muhammad Asim Raza
TI Teicoplanin is a potential inhibitor of SARS CoV-2 replication enzymes:
   A docking study
SO ASIAN PACIFIC JOURNAL OF TROPICAL BIOMEDICINE
LA English
DT Article
AB Objective: To explore potential inhibitors of viral enzymes of SARS CoV-2. Methods: The in-silico docked potential of anti-viral, antibiotic, and analgesic drugs were studied for inhibition of the nonstructural protein (NSP) 9, NSP3, and NSP15 of SARS CoV-2 using recent structural peculiarities of these enzymes, 3D optimized structures of drugs and algorithm-based ligand inhibitory potential. Results: Teicoplanin, azithromycin, and remdesivir potentially inhibited NSP9 (Dock-score 9 620, 5 472 and 6 252, respectively), NSP3 (Dock-score 9 846, 5 604 and 5 548, respectively) and NSP15 (Dock-score 10 960, 6414 and 6 002, respectively). Conclusions: Teicoplanin acts as a significant receptor antagonist and potentially inhibits the SARS CoV-2 enzymes.
C1 [Sadia, Aatika; Azam, Muhammad; Basra, Muhammad Asim Raza] Univ Punjab, Inst Chem, New Campus, Lahore 54590, Pakistan.
RP Basra, MAR (corresponding author), Univ Punjab, Inst Chem, New Campus, Lahore 54590, Pakistan.
EM asimbasra@gmail.com
FU Institute of Chemistry, University of the Punjab Lahore, Pakistan
FX This work was supported by Institute of Chemistry, University of the
   Punjab Lahore, Pakistan.
CR Astani A, 2015, PHARMAZIE, V70, P331, DOI 10.1691/ph.2015.4791
   Culita DC, 2012, CELL, V7, P8
   Hackbart M, 2020, P NATL ACAD SCI USA, V117, P8094, DOI 10.1073/pnas.1921485117
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Jimenez J, 2017, BIOINFORMATICS, V33, P3036, DOI 10.1093/bioinformatics/btx350
   Jing HY, 2019, VIRUS RES, V268, P18, DOI 10.1016/j.virusres.2019.05.011
   Ohe M, 2020, BIOSCI TRENDS, V14, P159, DOI 10.5582/bst.2020.03058
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
NR 10
TC 0
Z9 0
U1 6
U2 6
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 2221-1691
EI 2588-9222
J9 ASIAN PAC J TROP BIO
JI Asian Pac. Trop. Biomed.
PD DEC
PY 2020
VL 10
IS 12
BP 563
EP 568
DI 10.4103/2221-1691.294093
PG 6
WC Tropical Medicine
SC Tropical Medicine
GA OL4KN
UT WOS:000585311200006
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU MacKinnon, L
   Socias, ME
   Bardwell, G
AF MacKinnon, Laura
   Socias, M. Eugenia
   Bardwell, Geoff
TI COVID-19 and overdose prevention: Challenges and opportunities for
   clinical practice in housing settings
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE COVID-19; Opioid overdose epidemic; Housing; Opioid agonist treatment;
   Pandemic withdrawal management
ID NEW-YORK-CITY
AB The global coronavirus disease 2019 (COVID-19) will exacerbate the negative health outcomes associated with the concurrent opioid overdose crisis in North America. COVID-19 brings unique challenges for practitioners who provide opioid use disorder (OUD) care. The majority of overdose deaths in the Canadian province of British Columbia occur in housing environments. Some supportive housing environments in Vancouver, British Columbia, have on-site primary care and substance use disorder treatment clinics. Some of these housing environments also include supervised consumption services. These housing environments needed to make adjustments to their care to adhere to COVID-19 physical distancing measures. Such adjustments included a pandemic withdrawal management program to provide patients with a pharmaceutical grade alternative to the toxic illicit drug supply, which allow patients to avoid the heightened overdose risk while using illicit drugs alone or potentially exposing themselves to COVID-19 while using drugs in a group setting. Other modifications to the OUD care continuum included modified supervised injection spaces to adhere to physical distancing, the use of personal protective equipment for overdose response, virtual platforms for clinical encounters, writing longer prescriptions, and providing take-home doses to promote opioid agonist treatment retention. These strategies aim to mitigate indoor overdose risk while also addressing COVID-19 risks.
C1 [MacKinnon, Laura] Univ British Columbia, Dept Family Practice, 5950 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.
   [MacKinnon, Laura; Socias, M. Eugenia; Bardwell, Geoff] British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada.
   [Socias, M. Eugenia; Bardwell, Geoff] Univ British Columbia, St Pauls Hosp, Dept Med, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
RP Bardwell, G (corresponding author), 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada.
EM geoff.bardwell@bccsu.ubc.ca
FU United States National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [R01DA044181]; Michael Smith Foundation for Health ResearchMichael Smith
   Foundation for Health Research; St. Paul's Foundation Scholar Award;
   Canadian Institutes of Health Research Postdoctoral FellowshipCanadian
   Institutes of Health Research (CIHR)
FX We would like to thank Edward Rooke, MD, and Kathy Larson, LPN, for
   providing their clinical perspectives on SUD housing-based treatment
   during COVID-19. This work is supported by a United States National
   Institutes of Health Grant (R01DA044181). MES is supported by a Michael
   Smith Foundation for Health Research and St. Paul's Foundation Scholar
   Award. GB is supported by a Canadian Institutes of Health Research
   Postdoctoral Fellowship.
CR Ahamad K, 2020, RISK MITIGATION CONT
   Bardwell G, 2019, AM J MENS HEALTH, V13, DOI 10.1177/1557988319859113
   Bardwell G, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0203-9
   BC CDC, 2020, PREV RISK FACT DEV S
   BC CDC, 2020, COVID 19 HARM RED OV
   BC Coroners Service, 2020, ILL DURG TOX DEATHS
   Becker WC, 2020, ANN INTERN MED, V173, P59, DOI 10.7326/M20-1210
   CBS Broadcasting Inc, 2020, SAN FRANC OFF APPR C
   Hales J., 2020, EMERGENCY SAFER SUPP
   Health Canada, 2020, GOV CAN SUPP SAF DRU
   Hembree C, 2005, HEALTH PLACE, V11, P147, DOI 10.1016/j.healthplace.2004.02.005
   Khatri Utsha G, 2020, J Addict Med, V14, pe6, DOI 10.1097/ADM.0000000000000684
   Rai N., 2019, URGENT CALL CLIN PRE
   Richardson LA, 2015, J EPIDEMIOL COMMUN H, V69, P686, DOI 10.1136/jech-2014-205079
   Schuchman M, 2018, GERIATRICS-BASEL, V3, DOI 10.3390/geriatrics3030041
   Siegler A, 2014, INT J DRUG POLICY, V25, P569, DOI 10.1016/j.drugpo.2013.10.015
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Yang YT, 2020, PREV MED, V135, DOI 10.1016/j.ypmed.2020.106070
NR 18
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD DEC
PY 2020
VL 119
AR 108153
DI 10.1016/j.jsat.2020.108153
PG 3
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA OI6ZA
UT WOS:000583423000013
PM 33032862
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ngo, A
   Masel, D
   Cahill, C
   Blumberg, N
   Refaai, MA
AF Ngo, Andy
   Masel, Debra
   Cahill, Christine
   Blumberg, Neil
   Refaai, Majed A.
TI Blood Banking and Transfusion Medicine Challenges During the COVID-19
   Pandemic
SO CLINICS IN LABORATORY MEDICINE
LA English
DT Article
DE COVID-19; Blood banking; Transfusion medicine; Blood shortage; Blood
   wastage; FDA donation policies; Convalescent plasma
ID PLASMA TRANSFUSION; TRANEXAMIC ACID; SURGERY; REQUIREMENTS; PLATELET
AB SARS-CoV-2 (also known as COVID-19) has been an unprecedented challenge in many parts of the medical field with blood banking being no exception. COVID-19 has had a distinctly negative effect on our blood collection nationwide forcing blood banks, blood centers, and the US government to adopt new policies to adapt to a decreased blood supply as well as to protect our donors from COVID-19. These policies can be seen distinctly in patient blood management and blood bank operations. We are also faced with developing policies and procedures for a nontraditional therapy, convalescent plasma; its efficacy and safety is still not completely elucidated as of yet.
C1 [Ngo, Andy; Masel, Debra; Cahill, Christine; Blumberg, Neil; Refaai, Majed A.] Univ Rochester, Dept Pathol & Lab Med, Transfus Med Unit, Strong Mem Hosp,Blood Bank, 601 Elmwood Ave,Box 608, Rochester, NY 14642 USA.
RP Refaai, MA (corresponding author), Univ Rochester, Dept Pathol & Lab Med, Transfus Med Unit, Strong Mem Hosp,Blood Bank, 601 Elmwood Ave,Box 608, Rochester, NY 14642 USA.
EM Majed_Refaai@URMC.Rochester.edu
CR AABB Interorganizational Task Force on Pandemic Influenza and the Blood Supply, 2020, AABB INT TASK FOR PA, P16
   [Anonymous], ALTERNATIVE PROCEDUR, P8
   [Anonymous], 2011, GUIDELINES BLOOD TRA
   [Anonymous], 2020, MESS BLOOD DON COVID, P2
   Bence Christina M, 2020, J Pediatr Surg, V55, P2387, DOI 10.1016/j.jpedsurg.2020.02.020
   Bernard AC, 2009, J AM COLL SURGEONS, V208
   Bernard AC, 2009, J AM COLL SURGEONS, V208, P931, DOI 10.1016/j.jamcollsurg.2008.11.019
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Cai XH, 2020, BLOOD TRANSFUS-ITALY, V18, P79, DOI 10.2450/2020.0076-20
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang L, 2020, EMERG INFECT DIS, V26, P1631, DOI 10.3201/eid2607.200839
   Chen WL, 2020, EMERG MICROBES INFEC, V9, P469, DOI 10.1080/22221751.2020.1732837
   Cho BC, 2019, ANESTH ANALG, V128, P981, DOI 10.1213/ANE.0000000000004005
   Dunn CJ, 1999, DRUGS, V57, P1005, DOI 10.2165/00003495-199957060-00017
   Dzik S, 2020, TRANSFUS MED REV, V34, P141, DOI 10.1016/j.tmrv.2020.04.002
   Ferraris VA, 2012, ARCH SURG-CHICAGO, V147, P49, DOI 10.1001/archsurg.2011.790
   Ferraris VA, 2011, ANN THORAC SURG, V91, P944, DOI 10.1016/j.athoracsur.2010.11.078
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446
   Hemingway JF, 2020, J VASC SURG, V72, P396, DOI 10.1016/j.jvs.2020.04.492
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Inaba K, 2010, ARCH SURG-CHICAGO, V145, P899, DOI 10.1001/archsurg.2010.175
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Lim Cynthia Ciwei, 2020, Intern Med J, DOI 10.1111/imj.14774
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Liu T, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012421
   Mazur H, 2019, CRIT CARE MED, V47
   Mehra T, 2015, TRANSFUSION, V55, P2807, DOI 10.1111/trf.13260
   Myles PS, 2017, NEW ENGL J MED, V376, P136, DOI 10.1056/NEJMoa1606424
   Nguyen AA, 2020, CLIN IMMUNOL, V216, DOI 10.1016/j.clim.2020.108459
   Nomoto H, 2020, AM J INFECT CONTROL, V48, P969, DOI 10.1016/j.ajic.2020.05.034
   Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012
   Pagano MB, 2020, TRANSFUSION, V60, P908, DOI 10.1111/trf.15789
   Pascarella G, 2020, J INTERN MED, V288, P192, DOI 10.1111/joim.13091
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Polito NB, 2019, TRANSFUSION, V59, P1202, DOI 10.1111/trf.15146
   Raturi M, 2020, TRANSFUS CLIN BIOL, V27, P96, DOI 10.1016/j.tracli.2020.03.004
   Refaai MA, 2018, ANESTH ANALG, V126, P2135, DOI 10.1213/ANE.0000000000002600
   Refaai MA, 2017, EMERG MED INT, V2017, DOI 10.1155/2017/8024356
   Refaai MA, 2011, VOX SANG, V101, P55, DOI 10.1111/j.1423-0410.2010.01464.x
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Schmidt AE, 2018, AM J CLIN PATHOL, V149, P87, DOI [10.1093/AJCP/AQX151, 10.1093/ajcp/aqx151]
   Subramanian A, 2012, J CARDIOTHOR VASC AN, V26, P569, DOI 10.1053/j.jvca.2011.12.015
   Sultan S, 2020, GASTROENTEROLOGY, V159, P320, DOI 10.1053/j.gastro.2020.05.001
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tokin Christopher, 2009, Perm J, V13, P18
   Twum-Barimah E, 2020, ALIMENT PHARM THER, V51, P1004, DOI 10.1111/apt.15761
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Warner MA, 2017, ANESTH ANALG, V124, P1636, DOI 10.1213/ANE.0000000000001730
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zeng FR, 2020, P NATL ACAD SCI USA, V117, P12528, DOI 10.1073/pnas.2006961117
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
NR 53
TC 0
Z9 0
U1 6
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-2712
EI 1557-9832
J9 CLIN LAB MED
JI Clin. Lab. Med.
PD DEC
PY 2020
VL 40
IS 4
BP 587
EP 601
DI 10.1016/j.cll.2020.08.013
PG 15
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA OI0DK
UT WOS:000582957600016
PM 33121624
OA Green Published
DA 2021-01-01
ER

PT J
AU Pecora, ND
   Zand, MS
AF Pecora, Nicole D.
   Zand, Martin S.
TI Measuring the Serologic Response to Severe Acute Respiratory Syndrome
   Coronavirus 2: Methods and Meaning
SO CLINICS IN LABORATORY MEDICINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; COVID-19 serology
ID SYNDROME SARS CORONAVIRUS; NUCLEOCAPSID PROTEIN; ANTIBODY-RESPONSES;
   IMMUNE-RESPONSE; SPIKE PROTEIN; COV; NEUTRALIZATION; VACCINE; ASSAYS
AB The entire spectrum of diagnostic testing, from reagent supply to test performance, has been a major focus during the coronavirus disease 2019 (COVID-19) pandemic. The hope for serologic testing is that it will provide both epidemiologic information about seroprevalence as well as individual information about previous infection. This information is particularly helpful for high-risk individuals who may be outside of the viral shedding window, such as children with suspected multisystem inflammatory syndrome. It is not yet understood whether serologic testing can be interpreted in terms of protective immunity. These concerns must be addressed using highly sensitive and specific tests.
C1 [Pecora, Nicole D.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
   [Zand, Martin S.] Clin Res Univ Rochester, Nephrol SMD Clin & Translat Sci Inst, Med Ctr, Dept Med,Sch Med & Dent, 601 Elmwood Ave,Box 675, Rochester, NY 14642 USA.
RP Pecora, ND (corresponding author), UR Med Cent Lab, 211 Bailey Rd, West Henrietta, NY 14586 USA.
EM Nicole_pecora@urmc.rochester.edu
FU National Institutes of Health Institute of Allergy, Immunology and
   Infectious Diseases [R01 AI129518, R21 AI138500]; University of
   Rochester Clinical and Translational Science Award from the National
   Center for Advancing Translational Sciences of the National Institutes
   of Health [UL1 TR002001]
FX This work was supported by the National Institutes of Health Institute
   of Allergy, Immunology and Infectious Diseases grants R01 AI129518 and
   R21 AI138500 (M.S. Zand), and the University of Rochester Clinical and
   Translational Science Award UL1 TR002001 from the National Center for
   Advancing Translational Sciences of the National Institutes of Health
   (M. S. Zand). The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the National
   Institutes of Health. None of the mentioned funders had any role in
   study design, data collection and analysis, decision to publish, or
   preparation of the article.
CR Abbasi J, 2020, JAMA-J AM MED ASSOC, V323, P1881, DOI 10.1001/jama.2020.6170
   Administration USFaD, 2020, WHAT TESTS SHOULD NO
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Bryan A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00941-20
   Burbelo PD, 2020, J INFECT DIS, V222, P206, DOI 10.1093/infdis/jiaa273
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Che XY, 2004, EMERG INFECT DIS, V10, P1947, DOI 10.3201/eid1011.040516
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Hoffman Tove, 2020, Infection Ecology & Epidemiology, V10, P1754538, DOI 10.1080/20008686.2020.1754538
   Huang AT, 2020, SYSTEMATIC REV ANTIB
   Infantino M, 2020, J MED VIROL, V92, P1671, DOI 10.1002/jmv.25932
   Jaimes JA, 2020, J MOL BIOL, V432, P3309, DOI 10.1016/j.jmb.2020.04.009
   Li DM, 2019, COMPUT MATH METHOD M, DOI 10.1155/2019/9287120
   Liu SJ, 2006, VACCINE, V24, P3100, DOI 10.1016/j.vaccine.2006.01.058
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Liu WB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00461-20
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Millet JK, 2018, VIROLOGY, V517, P3, DOI 10.1016/j.virol.2017.12.015
   Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286
   Niedrig M, 2005, J CLIN VIROL, V34, P22, DOI 10.1016/j.jcv.2005.01.004
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Phelan AL, 2020, LANCET, V395, P1595, DOI 10.1016/S0140-6736(20)31034-5
   Qiu MF, 2005, MICROBES INFECT, V7, P882, DOI 10.1016/j.micinf.2005.02.006
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Surjit M, 2008, INFECT GENET EVOL, V8, P397, DOI 10.1016/j.meegid.2007.07.004
   Tai WB, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104820
   Takita M, 2020, QJM
   Tan YJ, 2004, CLIN DIAGN LAB IMMUN, V11, P362, DOI 10.1128/CDLI.11.2.362-371.2004
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002
   Wajnberg A, 2020, HUMORAL IMMUNE RESPO
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang J, 2020, J CLIN TRANSL SCI, P1, DOI [DOI 10.1017/CTS.2020.39, 10.1017/cts.2020.39]
   Wang J, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040238
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Whitman J. D., 2020, TEST PERFORMANCE EVA
   Woo PCY, 2005, J CLIN MICROBIOL, V43, P3054, DOI 10.1128/JCM.43.7.3054-3058.2005
   Woo PCY, 2004, CLIN DIAGN LAB IMMUN, V11, P665, DOI 10.1128/CDLI.11.4.665-668.2004
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NEUTRALIZING ANTIBOD
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Yan Y, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2106
   Zainol Rashid Z, 2020, MALAYS J PATHOL, V42, P13
   Zeng WH, 2020, BIOCHEM BIOPH RES CO, V527, P618, DOI 10.1016/j.bbrc.2020.04.136
   Zhang GX, 2020, J INFECT DIS, V222, P183, DOI 10.1093/infdis/jiaa229
   Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 58
TC 0
Z9 0
U1 7
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-2712
EI 1557-9832
J9 CLIN LAB MED
JI Clin. Lab. Med.
PD DEC
PY 2020
VL 40
IS 4
BP 603
EP 614
DI 10.1016/j.cll.2020.08.014
PG 12
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA OI0DK
UT WOS:000582957600017
PM 33121625
OA Green Published
DA 2021-01-01
ER

PT J
AU Funari, R
   Chu, KY
   Shen, AQ
AF Funari, Riccardo
   Chu, Kang-Yu
   Shen, Amy Q.
TI Detection of antibodies against SARS-CoV-2 spike protein by gold
   nanospikes in an opto-microfluidic chip
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE SARS-CoV-2; COVID-19; Antibody; LSPR; Microfluidics; Gold
   electrodeposition
ID BIOSENSOR; COVID-19
AB The ongoing global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to active research in its associated diagnostics and medical treatments. While quantitative reverse transcription polymerase chain reaction (qRT-PCR) is the most reliable method to detect viral genes of SARS-CoV-2, serological tests for specific antiviral antibodies are also important as they identify false negative qRT-PCR responses, track how effectively the patient's immune system is fighting the infection, and are potentially helpful for plasma transfusion therapies. In this work, based on the principle of localized surface plasmon resonance (LSPR), we develop an opto-microfluidic sensing platform with gold nanospikes, fabricated by electrodeposition, to detect the presence and amount of antibodies specific to the SARS-CoV-2 spike protein in 1 mu L of human plasma diluted in 1 mL of buffer solution, within similar to 30 min. The target antibody concentration can be correlated with the LSPR wavelength peak shift of gold nanospikes caused by the local refractive index change due to the antigen-antibody binding. This label-free microfluidic platform achieves a limit of detection of similar to 0.08 ng/mL (similar to 0.5 pM), falling under the clinical relevant concentration range. We demonstrate that our opto-microfluidic platform offers a promising point-of-care testing tool to complement standard serological assays and make SARS-CoV-2 quantitative diagnostics easier, cheaper, and faster.
C1 [Funari, Riccardo; Chu, Kang-Yu; Shen, Amy Q.] Okinawa Inst Sci & Technol Grad Univ, Micro Bio Nanofluid Unit, 1919-1 Tancha, Onna Son, Okinawa 9040495, Japan.
RP Funari, R; Shen, AQ (corresponding author), Okinawa Inst Sci & Technol Grad Univ, Micro Bio Nanofluid Unit, 1919-1 Tancha, Onna Son, Okinawa 9040495, Japan.
EM riccardo.funari@oist.jp; amy.shen@oist.jp
RI Shen, Amy/B-5981-2015
OI Shen, Amy/0000-0002-1222-6264
FU Okinawa Institute of Science and Technology Graduate UniversityOkinawa
   Institute of Science & Technology Graduate University; Cabinet Office,
   Government of Japan; Japanese Society for the Promotion of
   ScienceMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of Science [18H01135,
   20K20237]
FX The authors thank Dr. Alessandro Giussani from Mathematics, Mechanics,
   and Materials Unit at OIST for the XRD analysis of the gold nanospikes,
   Ms. Shivani Sathish and Dr. Hsieh-Fu Tsai from Micro/Bio/Nanofluidics
   Unit at OIST for their constructive feedback on the manuscript. The
   authors acknowledge the support of the Okinawa Institute of Science and
   Technology Graduate University with subsidy funding from the Cabinet
   Office, Government of Japan. R.F. acknowledges funding from the Japanese
   Society for the Promotion of Science (Grants-in-Aid for Early-Career
   Scientists, Grant #20K20237). A.Q.S. acknowledges funding from the
   Japanese Society for the Promotion of Science (Grants-in-Aid for
   Scientific Research (B), Grant #18H01135).
CR Ahmadivand A, 2020, ARXIV200608536
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Bhalla N, 2020, ACS NANO, V14, P7783, DOI 10.1021/acsnano.0c04421
   Brown JF, 2018, J INFECT DIS, V218, P555, DOI 10.1093/infdis/jiy199
   Carter LJ, 2020, ACS CENTRAL SCI, V6, P591, DOI 10.1021/acscentsci.0c00501
   Chen HJ, 2008, LANGMUIR, V24, P5233, DOI 10.1021/la800305j
   Cherevko S, 2011, ELECTROCHEM COMMUN, V13, P16, DOI 10.1016/j.elecom.2010.11.001
   Choi JR, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00517
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cui FY, 2020, BIOSENS BIOELECTRON, V165, DOI 10.1016/j.bios.2020.112349
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1165
   Della Ventura B, 2019, ACS APPL MATER INTER, V11, P3753, DOI 10.1021/acsami.8b20501
   Dincer C, 2019, ADV MATER, V31, DOI 10.1002/adma.201806739
   Du Z, 2020, J MED VIROL, V92, P1735, DOI 10.1002/jmv.25820
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Huang Z, 2020, BIOSENS BIOELECTRON, V164, DOI 10.1016/j.bios.2020.112316
   HUMPHREY JH, 1974, CLIN EXP IMMUNOL, V17, P708
   John Hopkins Center for Health Security, 2020, GLOB PROGR SER BAS T
   Kausaite-Minkstimiene A, 2009, ANALYST, V134, P2051, DOI 10.1039/b907315a
   Krammer F, 2020, SCIENCE, V368, P1060, DOI 10.1126/science.abc1227
   Kurganov BI, 2001, ANAL CHIM ACTA, V427, P11, DOI 10.1016/S0003-2670(00)01167-3
   La Marca A, 2020, REPROD BIOMED ONLINE, V41, P483, DOI 10.1016/j.rbmo.2020.06.001
   Lee CYP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00879
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   LONG GL, 1983, ANAL CHEM, V55, pA712, DOI 10.1021/ac00258a001
   Long Q.-X., 2020, NAR MED, DOI [10.1038/s41591-020-0897-1, DOI 10.1038/S4591-020-0897-1]
   Lopa NS, 2019, BIOSENS BIOELECTRON, V126, P381, DOI 10.1016/j.bios.2018.11.012
   Mavrikou S, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20113121
   Mayer KM, 2011, CHEM REV, V111, P3828, DOI 10.1021/cr100313v
   Mohammadniaei M, 2019, BIOSENS BIOELECTRON, V141, DOI 10.1016/j.bios.2019.111468
   Moitra P, 2020, ACS NANO, V14, P7617, DOI 10.1021/acsnano.0c03822
   Morales-Narvaez E, 2020, BIOSENS BIOELECTRON, V163, DOI 10.1016/j.bios.2020.112274
   Muruato A.E., 2020, HIGH THROUGHPUT NEUT, DOI [10.1101/2020.05.21.109546, DOI 10.1101/2020.0.21.1096]
   Okba N.M.A., 2020, EMERG INFECT DIS, V26
   Paiva K.J., 2020, VALIDATION PERFORMAN, DOI [10.1101/2020.05.29.124776., DOI 10.1101/2020/05.29.124776]
   Qiu GG, 2020, ACS NANO, V14, P5268, DOI 10.1021/acsnano.0c02439
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Sabri YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep24625
   Sabri YM, 2014, SCI REP-UK, V4, DOI 10.1038/srep06741
   Santiago I, 2020, CHEMBIOCHEM, V21, P2880, DOI 10.1002/cbic.202000250
   Seo G, 2020, ACS NANO, V14, P5135, DOI 10.1021/acsnano.0c02823
   Stine KJ, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9040797
   Szunerits S, 2012, CHEM COMMUN, V48, P8999, DOI 10.1039/c2cc33266c
   Tian Y, 2006, J PHYS CHEM B, V110, P23478, DOI 10.1021/jp065292q
   U.S. Food and Drug Administration, 2020, EUA AUTH SER TEST PE
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   Vaisocherova H, 2007, BIOSENS BIOELECTRON, V22, P1020, DOI 10.1016/j.bios.2006.04.021
   Weiss JN, 1997, FASEB J, V11, P835
   Willets KA, 2007, ANNU REV PHYS CHEM, V58, P267, DOI 10.1146/annurev.physchem.58.032806.104607
   Winter AK, 2020, LANCET INFECT DIS, V20, P758, DOI 10.1016/S1473-3099(20)30322-4
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu W, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010134
   Zeng L, 2020, MATER CHEM FRONT, V4, P2000, DOI 10.1039/d0qm00294a
   Zhang SY, 2014, ANALYST, V139, P439, DOI 10.1039/c3an01835k
   Zhao S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020388
   Zhu HL, 2020, BIOSENS BIOELECTRON, V153, DOI 10.1016/j.bios.2020.112041
NR 58
TC 1
Z9 1
U1 96
U2 96
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD DEC 1
PY 2020
VL 169
AR 112578
DI 10.1016/j.bios.2020.112578
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA OH2JG
UT WOS:000582395000010
PM 32911317
OA Green Published
DA 2021-01-01
ER

PT J
AU Mao, K
   Zhang, H
   Yang, ZG
AF Mao, Kang
   Zhang, Hua
   Yang, Zhugen
TI An integrated biosensor system with mobile health and wastewater-based
   epidemiology (iBMW) for COVID-19 pandemic
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Point-of-use sensors; Wastewater-based epidemiology; Mobile health;
   Pandemic; Early warning
ID INFECTIOUS-DISEASES; POPULATION BIOMARKERS; DIAGNOSIS
AB The outbreak of coronavirus disease (COVID-19) has caused a significant public health challenge worldwide. A lack of effective methods for screening potential patients, rapidly diagnosing suspected cases, and accurately monitoring of the epidemic in real time to prevent the rapid spread of COVID-19 raises significant difficulties in mitigating the epidemic in many countries. As effective point-of-care diagnosis tools, simple, low-cost and rapid sensors have the potential to greatly accelerate the screening and diagnosis of suspected patients to improve their treatment and care. In particular, there is evidence that multiple pathogens have been detected in sewage, including SARS-CoV-2, providing significant opportunities for the development of advanced sensors for wastewater-based epidemiology that provide an early warning of the pandemic within the population. Sensors could be used to screen potential carriers, provide real-time monitoring and control of the epidemic, and even support targeted drug screening and delivery within the integration of emerging mobile health (mHealth) technology. In this communication, we discuss the feasibility of an integrated point-of-care biosensor system with mobile health for wastewater-based epidemiology (iBMW) for early warning of COVID-19, screening and diagnosis of potential infectors, and improving health care and public health. The iBMW will provide an effective approach to prevent, evaluate and intervene in a fast, affordable and reliable way, thus enabling real-time guidance for the government in providing effective intervention and evaluating the effectiveness of intervention.
C1 [Mao, Kang; Zhang, Hua] Chinese Acad Sci, Inst Geochem, State Key Lab Environm Geochem, Guiyang 550081, Peoples R China.
   [Yang, Zhugen] Cranfield Univ, Cranfield Water Sci Inst, Cranfield MK43 0AL, Beds, England.
RP Zhang, H (corresponding author), Chinese Acad Sci, Inst Geochem, State Key Lab Environm Geochem, Guiyang 550081, Peoples R China.; Yang, ZG (corresponding author), Cranfield Univ, Cranfield Water Sci Inst, Cranfield MK43 0AL, Beds, England.
EM zhanghua@mail.gyig.ac.cn; zhugen.yang@cranfield.ac.uk
RI YANG, Zhugen/A-7252-2010
OI YANG, Zhugen/0000-0003-4183-8160; Mao, Kang/0000-0002-1777-5959
FU Royal Academy of Engineering Frontier Follow-up Grant [FF\1920\1\36];
   China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2020M673302]; STS of CAS, China [KFJ-STS-QYZD-185]; UK NERC
   Fellowship grant [NE/R013349/2]
FX This work is funded by the Royal Academy of Engineering Frontier
   Follow-up Grant (FF\1920\1\36), the China Postdoctoral Science
   Foundation (2020M673302), STS of CAS (KFJ-STS-QYZD-185), China and the
   UK NERC Fellowship grant (NE/R013349/2).
CR Ahmed W, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138764
   Ahrberg CD, 2016, ANAL CHEM, V88, P4803, DOI 10.1021/acs.analchem.6b00278
   Bains RK, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0529-5
   Bhalla N., 2020, ACS NANO
   Bissonnette L, 2017, EXPERT REV MOL DIAGN, V17, P471, DOI 10.1080/14737159.2017.1310619
   Bivins A, 2020, ENVIRON SCI TECHNOL, V54, P7754, DOI 10.1021/acs.est.0c02388
   Chen YF, 2020, J MED VIROL, V92, P833, DOI 10.1002/jmv.25825
   Chunara R, 2012, PARASITOLOGY, V139, P1843, DOI 10.1017/S0031182012000923
   Dowell SF, 2016, NATURE, V540, P189, DOI 10.1038/540189a
   Estcourt CS, 2017, LANCET PUBLIC HEALTH, V2, pE182, DOI 10.1016/S2468-2667(17)30034-8
   Fallah MP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002227
   Hayward AC, 2014, LANCET RESP MED, V2, P445, DOI 10.1016/S2213-2600(14)70034-7
   Kozel TR, 2017, J CLIN MICROBIOL, V55, P2313, DOI 10.1128/JCM.00476-17
   La Rosa G, 2020, SCI TOTAL ENVIRON, V736, DOI 10.1016/j.scitotenv.2020.139652
   Lampos V, 2015, SCI REP-UK, V5, DOI 10.1038/srep12760
   Lee D, 2016, ANAL CHEM, V88, P12272, DOI 10.1021/acs.analchem.6b03460
   Mallapaty S, 2020, NATURE, V580, P176, DOI 10.1038/d41586-020-00965-x
   Mao K, 2020, ENVIRON SCI TECHNOL, V54, P3733, DOI 10.1021/acs.est.0c01174
   Mao K, 2020, BIOSENS BIOELECTRON, V148, DOI 10.1016/j.bios.2019.111785
   Murakami M, 2020, ENVIRON SCI TECHNOL, V54, P5311, DOI 10.1021/acs.est.0c02172
   Namisango E, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0092-9
   Peacock SJ, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0103-5
   Perkel JM, 2017, NATURE, V545, P119, DOI 10.1038/545119a
   Pokhrel P., 2020, ACS SENS
   Randazzo W., 2020, ACS SENSORS, V5, P1506
   Reboud J, 2019, P NATL ACAD SCI USA, V116, P4834, DOI 10.1073/pnas.1812296116
   Trinh TND, 2019, LAB CHIP, V19, P1397, DOI 10.1039/c8lc01389f
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   Veber M., 2018, Z STRATEGISCHE ANAL, V2, P85
   Wang JG, 2020, LANCET, V395, P1094, DOI 10.1016/S0140-6736(20)30561-4
   Yang ZG, 2018, ACS SENSORS, V3, P403, DOI 10.1021/acssensors.7b00825
   Yang ZG, 2017, ANAL CHEM, V89, P9941, DOI 10.1021/acs.analchem.7b02257
   Yang ZG, 2016, SCI REP-UK, V6, DOI 10.1038/srep21024
   Yang ZG, 2015, ENVIRON SCI TECHNOL, V49, P5845, DOI 10.1021/acs.est.5b01434
   Yang ZG, 2015, ENVIRON SCI TECHNOL, V49, P5609, DOI 10.1021/acs.est.5b00637
   Yom-Tov E, 2015, INFLUENZA OTHER RESP, V9, P191, DOI 10.1111/irv.12321
   Zhuang JJ, 2020, BIOSENS BIOELECTRON, V163, DOI 10.1016/j.bios.2020.112291
NR 37
TC 1
Z9 1
U1 34
U2 34
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD DEC 1
PY 2020
VL 169
AR 112617
DI 10.1016/j.bios.2020.112617
PG 6
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA OH2JG
UT WOS:000582395000034
PM 32998066
OA Green Published
DA 2021-01-01
ER

PT J
AU Steiner, DJ
   Cognetti, JS
   Luta, EP
   Klose, AM
   Bucukovski, J
   Bryan, MR
   Schmuke, JJ
   Nguyen-Contant, P
   Sangster, MY
   Topham, DJ
   Miller, BL
AF Steiner, Daniel J.
   Cognetti, John S.
   Luta, Ethan P.
   Klose, Alanna M.
   Bucukovski, Joseph
   Bryan, Michael R.
   Schmuke, Jon J.
   Nguyen-Contant, Phuong
   Sangster, Mark Y.
   Topham, David J.
   Miller, Benjamin L.
TI Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza
   antibodies in convalescent COVID-19 patients
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE SARS-CoV-2; Coronavirus; Influenza virus; Antigen microarray; Label-free
   biosensor
ID IMAGING REFLECTOMETRY; LABEL-FREE
AB Detection of antibodies to upper respiratory pathogens is critical to surveillance, assessment of the immune status of individuals, vaccine development, and basic biology. The urgent need for antibody detection tools has proven particularly acute in the COVID-19 era. We report a multiplex label-free antigen microarray on the Arrayed Imaging Reflectometry (AIR) platform for detection of antibodies to SARS-CoV-2, SARS-CoV-1, MERS, three circulating coronavirus strains (HKU1, 229E, OC43) and three strains of influenza. We find that the array is readily able to distinguish uninfected from convalescent COVID-19 subjects, and provides quantitative information about total Ig, as well as IgG- and IgM-specific responses.
C1 [Steiner, Daniel J.; Bucukovski, Joseph; Bryan, Michael R.; Miller, Benjamin L.] Biochem & Biophys, Rochester, NY USA.
   [Cognetti, John S.; Miller, Benjamin L.] Biomed Engn, Rochester, NY USA.
   [Luta, Ethan P.; Klose, Alanna M.; Miller, Benjamin L.] Dermatol, Rochester, NY USA.
   [Schmuke, Jon J.] Adarza BioSyst Inc, St Louis, MO 63146 USA.
   [Nguyen-Contant, Phuong; Sangster, Mark Y.; Topham, David J.] Univ Rochester, Microbiol & Immunol, Rochester, NY 14642 USA.
RP Miller, BL (corresponding author), Univ Rochester, Dept Dermatol, Med Ctr, 601 Elmwood Ave Box 697, Rochester, NY 14642 USA.
EM Benjamin_miller@urmc.rochester.edu
OI Steiner, Daniel/0000-0002-2351-8174
FU University of Rochester Department of Dermatology; Adarza BioSystems;
   Federal funds from the National Institute of Allergy and Infectious
   Diseases, National Institutes of Health, Department of Health and Human
   Services, under CEIRS [HHSN272201400005C]
FX We thank Alicia Papalia for assistance with human samples, and Florian
   Krammer for the generous donation of plasmids for SARS-CoV-2 antigen
   production (S1+S2 ECD and RBD). Support from the University of Rochester
   Department of Dermatology and Adarza BioSystems are gratefully
   acknowledged. This project has been funded in whole or in part with
   Federal funds from the National Institute of Allergy and Infectious
   Diseases, National Institutes of Health, Department of Health and Human
   Services, under CEIRS Contract No. yHHSN272201400005C.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Bucukovski J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134484
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Holstein CA, 2015, ANAL CHEM, V87, P9795, DOI 10.1021/acs.analchem.5b02082
   Jin YJ, 2020, INT J INFECT DIS, V94, P49, DOI 10.1016/j.ijid.2020.03.065
   Krammer F, 2020, SCIENCE, V368, P1060, DOI 10.1126/science.abc1227
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Mace CR, 2008, LANGMUIR, V24, P12754, DOI 10.1021/la801712m
   Mace CR, 2006, ANAL CHEM, V78, P5578, DOI 10.1021/ac060473+
   Mace CR, 2011, TALANTA, V83, P1000, DOI 10.1016/j.talanta.2010.11.002
   Martinez-Sobrido L, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008409
   Norman Maia, 2020, medRxiv, DOI 10.1101/2020.04.28.20083691
   Patel R, 2020, MBIO, V11, DOI 10.1128/mBio.00722-20
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   QUATAERT SA, 1995, CLIN DIAGN LAB IMMUN, V2, P590, DOI 10.1128/CDLI.2.5.590-597.1995
   Randad Pranay R, 2020, medRxiv, DOI 10.1101/2020.05.24.20112300
   Sriram R, 2011, ANAL CHEM, V83, P3750, DOI 10.1021/ac2001302
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Tesini BL, 2019, J VIROL, V93, DOI [10.1128/JVI.00169-19, 10.1128/jvi.00169-19]
   Trivedi SU, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37747-5
   Whitman J.D., 2020, TEST PERFORMANCE EVA, DOI [10.1101/2020.04.25.20074856v1.full.pdf, DOI 10.1101/2020.04.25.20074856V1.FULL.PDF]
   Zhang HY, 2018, ANAL CHEM, V90, P9583, DOI 10.1021/acs.analchem.8b02479
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
NR 24
TC 0
Z9 0
U1 35
U2 35
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD DEC 1
PY 2020
VL 169
AR 112643
DI 10.1016/j.bios.2020.112643
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA OH2JG
UT WOS:000582395000043
PM 33007615
OA Green Published
DA 2021-01-01
ER

PT J
AU Tan, XT
   Krel, M
   Dolgov, E
   Park, S
   Li, XZ
   Wu, WS
   Sun, YL
   Zhang, J
   Oo, MKK
   Perlin, DS
   Fan, XD
AF Tan, Xiaotian
   Krel, Mila
   Dolgov, Enriko
   Park, Steven
   Li, Xuzhou
   Wu, Weishu
   Sun, Yun-Lu
   Zhang, Jie
   Oo, Maung Kyaw Khaing
   Perlin, David S.
   Fan, Xudong
TI Rapid and quantitative detection of SARS-CoV-2 specific IgG for
   convalescent serum evaluation
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE COVID-19; Antibody detection; Immunoassay; Microfluidics
ID NEUTRALIZING ANTIBODIES; NUCLEOCAPSID PROTEIN; RESPONSES; ADJUVANT
AB Convalescent serum with a high abundance of neutralization IgG is a promising therapeutic agent for rescuing COVID-19 patients in the critical stage. Knowing the concentration of SARS-CoV-2 Sl-specific IgG is crucial in selecting appropriate convalescent serum donors. Here, we present a portable microfluidic ELISA technology for rapid (15 min), quantitative, and sensitive detection of anti-SARS-CoV-2 S1 IgG in human serum with only 8 mu L sample volume. We first identified a humanized monoclonal IgG that has a high binding affinity and a relatively high specificity towards SARS-CoV-2 S1 protein, which can subsequently serve as the calibration standard of anti-SARS-CoV-2 S1 IgG in serological analyses. We then measured the abundance of anti-SARS-CoV-2 S1 IgG in 16 convalescent COVID-19 patients. Due to the availability of the calibration standard and the large dynamic range of our assay, we were able to identify "qualified donors" for convalescent serum therapy with only one fixed dilution factor (200 x). Finally, we demonstrated that our technology can sensitively detect SARS-CoV-2 antigens (S1 and N proteins) with pg/mL level sensitivities in 40 min. Overall, our technology can greatly facilitate rapid, sensitive, and quantitative analysis of COVID-19 related markers for therapeutic, diagnostic, epidemiologic, and prognostic purposes.
C1 [Tan, Xiaotian; Li, Xuzhou; Wu, Weishu; Sun, Yun-Lu; Fan, Xudong] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Krel, Mila; Dolgov, Enriko; Park, Steven; Perlin, David S.] Hackensack Meridian Hlth, Ctr Discovery & Innovat, Nutley, NJ 07110 USA.
   [Zhang, Jie] Sino Biol Inc, Beijing 100176, Peoples R China.
   [Zhang, Jie] Beijing Key Lab Monoclonal Antibody Res & Dev, Beijing 100176, Peoples R China.
   [Oo, Maung Kyaw Khaing] Optofluid Bioassay LLC, Ann Arbor, MI 48103 USA.
RP Fan, XD (corresponding author), Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.; Perlin, DS (corresponding author), Hackensack Meridian Hlth, Ctr Discovery & Innovat, Nutley, NJ 07110 USA.; Oo, MKK (corresponding author), Optofluid Bioassay LLC, Ann Arbor, MI 48103 USA.
EM maungk@optobio.com; david.perlin@hmh-cdi.org; xsfan@umich.edu
FU NSFNational Science Foundation (NSF) [ECCS-2029484]; University of
   Michigan, Department of Biomedical Engineering
FX This work was supported by NSF, ECCS-2029484. The authors thank the
   financial support from the University of Michigan, Department of
   Biomedical Engineering. The authors also thank the help from Dr. C. Lin
   in Sino Biological.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Arnold S, 2008, FARADAY DISCUSS, V137, P65, DOI 10.1039/b702920a
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Che XY, 2004, EMERG INFECT DIS, V10, P1947, DOI 10.3201/eid1011.040516
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Gai Wei-wei, 2011, Virologica Sinica, V26, P81, DOI 10.1007/s12250-011-3183-z
   Gai WW, 2008, VIRAL IMMUNOL, V21, P27, DOI 10.1089/vim.2007.0079
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Li YH, 2005, J VIROL METHODS, V130, P45, DOI 10.1016/j.jviromet.2005.06.001
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   McDade TW, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237833
   Nachtigall F.M., 2020, NAT BIOTECHNOL, P1
   Padoan A, 2020, CLIN CHEM LAB MED, V58, P1081, DOI 10.1515/cclm-2020-0443
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Sabino-Silva R, 2020, CLIN ORAL INVEST, V24, P1619, DOI 10.1007/s00784-020-03248-x
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sun BQ, 2020, EMERG MICROBES INFEC, V9, P940, DOI 10.1080/22221751.2020.1762515
   Tan XT, 2020, LAB CHIP, V20, P634, DOI 10.1039/c9lc01006h
   Tan XT, 2018, ACS SENSORS, V3, P2327, DOI 10.1021/acssensors.8b00641
   Tan XT, 2017, ANALYST, V142, P2378, DOI 10.1039/c7an00523g
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Vinayachandran D, 2020, J DENT SCI, V15, P364, DOI 10.1016/j.jds.2020.04.006
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
NR 32
TC 0
Z9 0
U1 43
U2 43
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD DEC 1
PY 2020
VL 169
AR 112572
DI 10.1016/j.bios.2020.112572
PG 9
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA OH2JG
UT WOS:000582395000007
PM 32916610
OA Green Published
DA 2021-01-01
ER

PT J
AU Sakamaki, I
   Morinaga, Y
   Tani, H
   Takegoshi, Y
   Fukui, Y
   Kawasuji, H
   Ueno, A
   Miyajima, Y
   Wakasugi, M
   Kawagishi, T
   Kuwano, H
   Hatano, T
   Shibuya, T
   Okudera, H
   Yamamoto, Y
AF Sakamaki, Ippei
   Morinaga, Yoshitomo
   Tani, Hideki
   Takegoshi, Yusuke
   Fukui, Yasutaka
   Kawasuji, Hitoshi
   Ueno, Akitoshi
   Miyajima, Yuki
   Wakasugi, Masahiro
   Kawagishi, Toshiomi
   Kuwano, Hroyuki
   Hatano, Tomoya
   Shibuya, Tadaki
   Okudera, Hiroshi
   Yamamoto, Yoshihiro
TI Monitoring of viral load by RT-PCR caused decision making to continue
   ECMO therapy for a patient with COVID-19
SO JOURNAL OF INFECTION AND CHEMOTHERAPY
LA English
DT Article
DE Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome
   coronavirus 2 (SARS-CoV-2); Reverse transcription-polymerase chain
   reaction (RT-PCR); Extracorporeal membranous oxygenation (ECMO)
AB Most patients with coronavirus disease 2019 (COVID-19) have just only mild symptoms, but about 5% are very severe. Although extracorporeal membranous oxygenation (ECMO) is sometimes used in critically patients with COVID-19, ECMO is only an adjunct, not the main treatment. If the patient's condition deteriorates and it is determined to be irreversible, it is necessary to decide to stop ECMO.
   A 54-year-old man was admitted on day 6 of onset with a chief complaint of high fever and cough. Computed tomography (CT) showed a ground glass opacity in both lungs, and reverse transcription-polymerase chain reaction (RT-PCR) diagnosed COVID-19. He was admitted to the hospital and started to receive oxygen and favipiravir. After that, his respiratory condition deteriorated, and he was intubated and ventilated on day 9 of onset, and ECMO was introduced on day 12. Two days after the introduction of ECMO, C-reactive protein (CRP) increased, chest X-p showed no improvement in pneumonia, and PaO2/FiO2 decreased again. As D-dimer rose and found a blood clot in the ECMO circuit, we had to decide whether to replace the circuit and continue with ECMO or stop ECMO. At this time, the viral load by RTPCR was drastically reduced to about 1/1750. We decided to continue ECMO therapy and replaced the circuit. The patient's respiratory status subsequently improved and ECMO was stopped on day 21 of onset.
   In conclusion, viral load measurement by RT-PCR may be one of the indicators for promoting the treatment of severe COVID-19 patients. (c) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Sakamaki, Ippei; Takegoshi, Yusuke; Fukui, Yasutaka; Kawasuji, Hitoshi; Ueno, Akitoshi; Miyajima, Yuki; Yamamoto, Yoshihiro] Toyama Univ Hosp, Dept Clin Infect Dis, 2630 Sugitani, Toyama, Toyama 9300194, Japan.
   [Morinaga, Yoshitomo; Tani, Hideki] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Microbiol, Toyama, Japan.
   [Wakasugi, Masahiro; Kawagishi, Toshiomi; Kuwano, Hroyuki; Hatano, Tomoya; Shibuya, Tadaki; Okudera, Hiroshi] Univ Toyama, Dept Emergency & Disaster Med, Toyama, Japan.
RP Sakamaki, I (corresponding author), Toyama Univ Hosp, Dept Clin Infect Dis, 2630 Sugitani, Toyama, Toyama 9300194, Japan.
EM sakamaki@med.u-toyama.ac.jp
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Bartlett RH, 2020, ASAIO J, V66, P472, DOI 10.1097/MAT.0000000000001173
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hitoshi Kawasuji, 2020, HIGH NASOPHARYNGEAL, P4, DOI [10.1101/2020.06.02.20120014, DOI 10.1101/2020.06.02.20120014]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Pan Y, 2020, CLIN CHEM, V66, P794, DOI 10.1093/clinchem/hvaa091
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shirato Kazuya, 2020, Jpn J Infect Dis, V73, P304, DOI 10.7883/yoken.JJID.2020.061
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 20
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1341-321X
EI 1437-7780
J9 J INFECT CHEMOTHER
JI J. Infect. Chemother.
PD DEC
PY 2020
VL 26
IS 12
BP 1324
EP 1327
DI 10.1016/j.jiac.2020.08.014
PG 4
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA OC8XB
UT WOS:000579438400018
PM 32900659
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Boodoosingh, R
   Olayemi, LO
   Sam, FAL
AF Boodoosingh, Ramona
   Olayemi, Lawal Olatunde
   Sam, Filipina Amosa-Lei
TI COVID-19 vaccines: Getting Anti-vaxxers involved in the discussion
SO WORLD DEVELOPMENT
LA English
DT Article
DE Vaccines; Anti-vaxxer; Measles; COVID-19; Samoa; Pacific
AB As studies continue into the development of a vaccine for COVID-19, research to understand and address the concerns raised by anti-vaxxers about vaccinations should also be undertaken in tandem. Using the experience of Samoa, which was recently impacted by a measles epidemic, the authors discuss the importance of vaccination to developing countries and the devastation that can be wrought by vaccine-preventable diseases. There are fewer laws on vaccination of adults when compared to those applicable for children, and not all countries have mandatory vaccination laws in place. With increasing anti-vaxxer rhetoric towards the COVID-19 vaccine that is currently in development, the focus has been on reducing the spread of the misinformation through penalties or company interventions, but less so on addressing the underlying concerns of the anti-vaxxer community. The authors suggest that involving anti-vaxxers in the discussion is critical to the acceptance and uptake of the vaccine to COVID-19 when it becomes available. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Boodoosingh, Ramona] Natl Univ Samoa, Fac Hlth Sci, Sch Nursing, Toomatagi, Samoa.
   [Olayemi, Lawal Olatunde; Sam, Filipina Amosa-Lei] Natl Univ Samoa, Fac Hlth Sci, Sch Med, Toomatagi, Samoa.
RP Boodoosingh, R (corresponding author), Natl Univ Samoa, Fac Hlth Sci, Sch Nursing, Toomatagi, Samoa.
EM r.boodoosingh@nus.edu.ws; l.olayemi@nus.edu.ws; f.amosa@nus.edu.ws
CR [Anonymous], 2019, MEASLES OUTBREAK PAC
   [Anonymous], 2020, INF DEATHS SAM TRAG
   [Anonymous], 2020, DW NEWS         0707
   Hoffman BL, 2019, VACCINE, V37, P2216, DOI 10.1016/j.vaccine.2019.03.003
   Klepper D, 2020, TIMES ISRAEL    0409
   Leaky S, 2020, LEADING COVID 19 VAC
   Lundgren B., 2015, NARRATING NARCOLEPSY, V34, DOI DOI 10.1080/01459740.2014.962694
   Smith N, 2019, INFORM COMMUN SOC, V22, P1310, DOI 10.1080/1369118X.2017.1418406
   Watson J, 2019, AUSTRALAS J INF SYST, V23
   World Health Organization, 2020, IMPR VACC DEM ADDR H
NR 10
TC 0
Z9 0
U1 65
U2 65
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0305-750X
J9 WORLD DEV
JI World Dev.
PD DEC
PY 2020
VL 136
AR 105177
DI 10.1016/j.worlddev.2020.105177
PG 2
WC Development Studies; Economics
SC Development Studies; Business & Economics
GA NS7MR
UT WOS:000572442200006
PM 32904443
OA Green Published
DA 2021-01-01
ER

PT J
AU Han, D
   Peng, CF
   Meng, R
   Yao, J
   Zhou, Q
   Xiao, Y
   Ma, H
AF Han, Dan
   Peng, Chunfen
   Meng, Rui
   Yao, Jing
   Zhou, Qiong
   Xiao, Yong
   Ma, Hong
TI Estimating the release of inflammatory factors and use of glucocorticoid
   therapy for COVID-19 patients with comorbidities
SO AGING-US
LA English
DT Article
DE COVID-19; comorbidities; immunological characteristics; inflammatory
   cytokines; glucocorticoid therapy
ID SARS-CORONAVIRUS INFECTION; LYMPHOCYTE SUBSETS; PERSPECTIVE; 2019-NCOV;
   RESPONSES
AB COVID-19 exhibits both variability and rapid progression, particularly in patients with comorbidities such as diabetes, hypertension or cancer. To determine how these underlying disorders exacerbate pneumonia in COVID-19, we evaluated 79 patients with severe COVID-19 and grouped them according to whether or not they had comorbidities. Clinical information, laboratory examinations, immunological function, and treatment outcomes were retrospectively analyzed. Our study revealed that severe COVID-19 patients with comorbidities had higher levels of inflammatory indices, including blood interferon-gamma, interleukin (IL)-6 and c-reactive protein levels as well as the erythrocyte sedimentation rate. These were accompanied by lymphopenia, hypokalemia, hypoalbuminemia, a decrease in either CD4+ T cells or lymphocyte count, and coagulation disorders, which were closely related to poor prognosis. Patients with comorbidities also had longer disease remission times (27 +/- 6.7 days) than those without comorbidities (20 +/- 6.5 days). Cox multivariate analysis indicated that glucocorticoid therapy and IL-6 were independent prognostic factors. Our findings suggest that coexisting comorbidities aggravate COVID-19 through the excessive release of inflammatory factors and that glucocorticoid therapy may be beneficial.
C1 [Han, Dan; Peng, Chunfen; Meng, Rui; Yao, Jing; Ma, Hong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan, Hubei, Peoples R China.
   [Xiao, Yong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gastrointestinal Surg, Wuhan, Hubei, Peoples R China.
   [Zhou, Qiong] Huazhong Univ Sci & Technol, Union Hosp, Dept Resp & Crit Care Med, Tongji Med Coll, Wuhan, Peoples R China.
RP Ma, H (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan, Hubei, Peoples R China.; Xiao, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gastrointestinal Surg, Wuhan, Hubei, Peoples R China.
EM 2005XH0815@hust.edu.cn; 2003XH1043@hust.edu.cn
CR Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chien JY, 2006, RESPIROLOGY, V11, P715, DOI 10.1111/j.1440-1843.2006.00942.x
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Cui W, 2003, CLIN INFECT DIS, V37, P857, DOI 10.1086/378587
   Frasca L, 1998, CRIT REV IMMUNOL, V18, P569, DOI 10.1615/CritRevImmunol.v18.i6.50
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han QM, 2020, J INFECTION, V80, P373, DOI 10.1016/j.jinf.2020.02.010
   He ZP, 2005, INT J INFECT DIS, V9, P323, DOI 10.1016/j.ijid.2004.07.014
   Kim ES, 2016, J KOREAN MED SCI, V31, P1717, DOI 10.3346/jkms.2016.31.11.1717
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Veronese N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00170
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wong JP, 2017, FUTURE MED CHEM, V9, P169, DOI 10.4155/fmc-2016-0181
   Xu XJ, 2004, CELL MOL IMMUNOL, V1, P119
NR 22
TC 0
Z9 0
U1 0
U2 0
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD NOV 30
PY 2020
VL 12
IS 22
BP 22413
EP 22424
PG 12
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA PA8UY
UT WOS:000595905600009
PM 33232277
DA 2021-01-01
ER

PT J
AU Wang, B
   Kovalchuk, A
   Li, DP
   Rodriguez-Juarez, R
   Ilnytskyy, Y
   Kovalchuk, I
   Kovalchuk, O
AF Wang, Bo
   Kovalchuk, Anna
   Li, Dongping
   Rodriguez-Juarez, Rocio
   Ilnytskyy, Yaroslav
   Kovalchuk, Igor
   Kovalchuk, Olga
TI In search of preventive strategies: novel high-CBD Cannabis sativa
   extracts modulate ACE2 expression in COVID-19 gateway tissues
SO AGING-US
LA English
DT Article
DE COVID-19; SARS-CoV2; ACE2 receptor; medical cannabis; CBD
ID SARS CORONAVIRUS; GROWTH
AB With the current COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), there is an urgent need for new therapies and prevention strategies that can help curtail disease spread and reduce mortality. The inhibition of viral entry and thus spread is a plausible therapeutic avenue. SARS-CoV-2 uses receptor-mediated entry into a human host via the angiotensin-converting enzyme 2 (ACE2), which is expressed in lung tissue as well as the oral and nasal mucosa, kidney, testes and gastrointestinal tract. The modulation of ACE2 levels in these gateway tissues may be an effective strategy for decreasing disease susceptibility.
   Cannabis sativa, especially those high in the anti-inflammatory cannabinoid cannabidiol (CBD), has been found to alter gene expression and inflammation and harbour anti-cancer and anti-inflammatory properties. However, its effects on ACE2 expression remain unknown.
   Working under a Health Canada research license, we developed over 800 new C. sativa cultivars and hypothesized that high-CBD C. sativa extracts may be used to down-regulate ACE2 expression in target COVID19 tissues. Using artificial 3D human models of oral, airway and intestinal tissues, we identified 13 high-CBD C. sativa extracts that decrease ACE2 protein levels. Some C. sativa extracts down-regulate serine protease TMPRSS2, another critical protein required for SARS-CoV-2 entry into host cells.
   While our most effective extracts require further large-scale validation, our study is important for future analyses of the effects of medical cannabis on COVID-19. The extracts of our most successful novel high-CBD C. sativa lines, pending further investigation, may become a useful and safe addition to the prevention/treatment of COVID-19 as an adjunct therapy.
C1 [Wang, Bo; Kovalchuk, Anna; Li, Dongping; Rodriguez-Juarez, Rocio; Ilnytskyy, Yaroslav; Kovalchuk, Igor; Kovalchuk, Olga] Pathway Rx Inc, Lethbridge, AB T1K 7X8, Canada.
   [Kovalchuk, Anna; Kovalchuk, Igor; Kovalchuk, Olga] Swysh Inc, Lethbridge, AB T1K 7X8, Canada.
   [Wang, Bo; Li, Dongping; Rodriguez-Juarez, Rocio; Ilnytskyy, Yaroslav; Kovalchuk, Igor; Kovalchuk, Olga] Univ Lethbridge, Lethbridge, AB T1K 3M4, Canada.
   [Kovalchuk, Anna] Univ Calgary, Cumming Sch Med, Calgary, AB T2N 1N4, Canada.
RP Kovalchuk, I; Kovalchuk, O (corresponding author), Pathway Rx Inc, Lethbridge, AB T1K 7X8, Canada.; Kovalchuk, I; Kovalchuk, O (corresponding author), Swysh Inc, Lethbridge, AB T1K 7X8, Canada.; Kovalchuk, I; Kovalchuk, O (corresponding author), Univ Lethbridge, Lethbridge, AB T1K 3M4, Canada.
EM igor.kovalchuk@uleth.ca; olga.kovalchuk@uleth.ca
FU CIHRCanadian Institutes of Health Research (CIHR); MITACs
FX Research was partially funded by the CIHR and MITACs grants to O.K. and
   I.K.
CR Aizpurua-Olaizola O, 2016, J NAT PROD, V79, P324, DOI 10.1021/acs.jnatprod.5b00949
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Blagosklonny MV, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.520
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Cascella M, 2020, STATPEARLS
   De Petrocellis L, 2013, BRIT J PHARMACOL, V168, P79, DOI 10.1111/j.1476-5381.2012.02027.x
   Fitzcharles Mary-Ann, 2020, Arthritis Care Res (Hoboken), DOI 10.1002/acr.24176
   Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574-018-0059-4
   Gallo G, 2020, J INVEST SURG, V33, P687, DOI 10.1080/08941939.2020.1748147
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/nmeth.3317, 10.1038/NMETH.3317]
   Kovalchuk O, 2020, CELL CYCLE, V19, P961, DOI 10.1080/15384101.2020.1742952
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lamarre S, 2018, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.00108
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Ligresti A, 2006, J PHARMACOL EXP THER, V318, P1375, DOI 10.1124/jpet.106.105247
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Muus C, 2020, INTEGRATED ANAL SING
   Prattichizzo F, 2016, AGING-US, V8, P3159, DOI 10.18632/aging.101133
   Ribeiro A, 2015, IMMUNOPHARM IMMUNOT, V37, P35, DOI 10.3109/08923973.2014.976794
   Russo EB, 2011, BRIT J PHARMACOL, V163, P1344, DOI 10.1111/j.1476-5381.2011.01238.x
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Spinelli A, 2020, BRIT J SURG, V107, P785, DOI 10.1002/bjs.11627
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 34
TC 0
Z9 0
U1 0
U2 0
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD NOV 30
PY 2020
VL 12
IS 22
BP 22425
EP 22444
PG 20
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA PA8UY
UT WOS:000595905600010
PM 33221759
DA 2021-01-01
ER

PT J
AU Yoon, SH
   Ham, SY
   Nam, BD
   Chae, KJ
   Lee, D
   Yoo, JY
   Bak, SH
   Kim, JY
   Kim, JH
   Kim, KB
   Jung, JI
   Lim, JK
   Lee, JE
   Chung, MJ
   Lee, YK
   Kim, YS
   Jo, JE
   Lee, SM
   Kwon, W
   Park, CM
   Kim, YH
   Jeong, YJ
AF Yoon, Soon Ho
   Ham, Soo-Youn
   Nam, Bo Da
   Chae, Kum Ju
   Lee, Dabee
   Yoo, Jin Young
   Bak, So Hyeon
   Kim, Jin Young
   Kim, Jin Hwan
   Kim, Ki Beom
   Jung, Jung Im
   Lim, Jae-Kwang
   Lee, Jong Eun
   Chung, Myung Jin
   Lee, Young Kyung
   Kim, Young Seon
   Jo, Ji Eun
   Lee, Sang Min
   Kwon, Woocheol
   Park, Chang Min
   Kim, Yun-Hyeon
   Jeong, Yeon Joo
TI Establishment of a Nationwide Korean Imaging Cohort of Coronavirus
   Disease 2019
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE Coronavirus Infections; Radiography; Thoracic; Computed Tomography
ID COVID-19; PNEUMONIA; DAEGU; CHEST
AB Background: The Korean Society of Thoracic Radiology (KSTR) recently constructed a nation-wide coronavirus disease 2019 (COVID-19) database and imaging repository, referred to the Korean imaging cohort of COVID-19 (KICC-19) based on the collaborative efforts of its members. The purpose of this study was to provide a summary of the clinico-epidemiological data and imaging data of the KICC-19.
   Methods: The KSTR members at 17 COVID-19 referral centers retrospectively collected imaging data and clinical information of consecutive patients with reverse transcription polymerase chain reaction-proven COVID-19 in respiratory specimens from February 2020 through May 2020 who underwent diagnostic chest computed tomography (CT) or radiograph in each participating hospital.
   Results: The cohort consisted of 239 men and 283 women (mean age, 52.3 years; age range, 11-97 years). Of the 522 subjects, 201 (38.5%) had an underlying disease. The most common symptoms were fever (n = 292) and cough (n = 245). The 151 patients (28.9%) had lymphocytopenia, 86 had (16.5%) thrombocytopenia, and 227 patients (43.5%) had an elevated CRP at admission. The 121 (23.4%) needed nasal oxygen therapy or mechanical ventilation (n = 38; 7.3%), and 49 patients (9.4%) were admitted to an intensive care unit. Although most patients had cured, 21 patients (4.0%) died. The 465 (89.1%) subjects underwent a low to standard-dose chest CT scan at least once during hospitalization, resulting in a total of 658 CT scans. The 497 subjects (95.2%) underwent chest radiography at least once during hospitalization, which resulted in a total of 1,475 chest radiographs.
   Conclusion: The KICC-19 was successfully established and comprised of 658 CT scans and 1,475 chest radiographs of 522 hospitalized Korean COVID-19 patients. The KICC-19 will provide a more comprehensive understanding of the clinical, epidemiological, and radiologic characteristics of patients with COVID-19.
C1 [Yoon, Soon Ho; Park, Chang Min] Seoul Natl Univ Hosp, Dept Radiol, Seoul Natl Coll Med, Seoul, South Korea.
   [Ham, Soo-Youn] Kangbuk Samsung Hosp, Dept Radiol, Seoul, South Korea.
   [Nam, Bo Da] Soonchunhyang Univ, Coll Med, Dept Radiol, Seoul Hosp, Seoul, South Korea.
   [Chae, Kum Ju] Jeonbuk Natl Univ, Dept Radiol, Res Inst Clin, Biomed Res Inst, Jeonju, South Korea.
   [Lee, Dabee] Dankook Univ Hosp, Dept Radiol, Cheonan, South Korea.
   [Yoo, Jin Young] Chungbuk Natl Univ Hosp, Dept Radiol, Cheongju, South Korea.
   [Bak, So Hyeon] Keimyung Univ, Sch Med, Dept Radiol, Dongsan Hosp, Daegu, South Korea.
   [Kim, Jin Young] Keimyung Univ, Sch Med, Dept Radiol, Dongsan Hosp, Daegu, South Korea.
   [Kim, Jin Hwan] Chungnam Natl Univ Hosp, Dept Radiol, Coll Med, Daejeon, South Korea.
   [Kim, Ki Beom] Daegu Fatima Hosp, Dept Radiol, Daegu, South Korea.
   [Jung, Jung Im] Sungkyunkwan Univ, Dept Radiol, Samsung Med Ctr, Sch Med, Seoul, South Korea.
   [Lim, Jae-Kwang] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Radiol, Daegu, South Korea.
   [Lee, Jong Eun] Chonnam Natl Univ Hosp, Dept Radiol, Gwangju, South Korea.
   [Chung, Myung Jin] Sungkyunkwan Univ, Dept Radiol, Samsung Med Ctr, Sch Med, Seoul, South Korea.
   [Lee, Young Kyung] Seoul Med Ctr, Dept Radiol, Seoul, South Korea.
   [Lee, Young Kyung] Yeungnam Univ, Coll Med, Dept Radiol, Yeungnam Univ Hosp, Daegu, South Korea.
   [Jo, Ji Eun] Busan Med Ctr, Dept Radiol, Busan, South Korea.
   [Lee, Sang Min] Univ Ulsan, Dept Radiol, Asan Med Ctr, Coll Med, Seoul, South Korea.
   [Lee, Sang Min] Univ Ulsan, Res Inst Radiol, Asan Med Ctr, Coll Med, Seoul, South Korea.
   [Kwon, Woocheol] Ewha Womans Univ, Dept Radiol, Seoul Hosp, Seoul, South Korea.
   [Jeong, Yeon Joo] Pusan Natl Univ, Sch Med, Dept Radiol, Pusan Natl Univ Hosp, Busan, South Korea.
   [Jeong, Yeon Joo] Biomed Res Inst, Busan, South Korea.
RP Jeong, YJ (corresponding author), Pusan Natl Univ, Sch Med, Dept Radiol, Pusan Natl Univ Hosp, Busan, South Korea.; Jeong, YJ (corresponding author), Biomed Res Inst, Busan, South Korea.
EM jeongyj@pusan.ac.kr
OI Nam, Bo Da/0000-0001-7822-6104; Yoon, Soon Ho/0000-0002-3700-0165
FU Korean Society of Radiology; National IT Industry Promotion Agency
   [A2201-201002]; Korean Society of Thoracic Radiology
FX This study was supported by the Korean Society of Radiology and Korean
   Society of Thoracic Radiology on May 2020, and National IT Industry
   Promotion Agency (A2201-201002).
CR Choi H, 2020, RADIOL CARDIOTHORAC, V2, DOI DOI 10.1148/RYCT.2020200107
   Chon Y, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e316
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Hare SS, 2020, CLIN RADIOL, V75, P326, DOI 10.1016/j.crad.2020.03.005
   Herpe Guillaume, 2020, Radiology, P202568, DOI 10.1148/radiol.2020202568
   Hwang EJ, 2020, KOREAN J RADIOL, V21, P1150, DOI 10.3348/kjr.2020.0536
   Jeong YJ, 2020, J KOREAN SOC RADIOL, V81, P608
   Jin KN, 2020, J KOREAN SOC RADIOL, V81, P577
   Jung H, 2020, KOREAN J RADIOL, V21, P1265, DOI 10.3348/kjr.2020.0564
   Kim H, 2020, RADIOLOGY, V296, pE145, DOI 10.1148/radiol.2020201343
   Kundu S, 2020, RADIOLOGY ARTIFICIAL, DOI [10.1148/ryai.2020200053, DOI 10.1148/RYAI.2020200053]
   Lee HJ, 2020, J KOREAN SOC RADIOL, V81, P583
   Lee SE, 2020, J KOREAN SOC RADIOL, V81, P591
   Palmieri L, 2020, J GERONTOL A-BIOL, V75, P1796, DOI 10.1093/gerona/glaa146
   Park B, 2020, KOREAN J RADIOL, V21, P1256, DOI 10.3348/kjr.2020.0567
   Rho JY, 2020, KOREAN J RADIOL, V21, P1018, DOI 10.3348/kjr.2020.0541
   Rubin GD, 2020, RADIOLOGY, V296, P172, DOI 10.1148/radiol.2020201365
   Schalekamp Steven, 2021, Radiology, V298, pE46, DOI 10.1148/radiol.2020202723
   Shim SS, 2020, J KOREAN SOC RADIOL, V81, P604
   Sung HK, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e280
   Toussie D, 2020, RADIOLOGY, V297, pE197, DOI 10.1148/radiol.2020201754
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wong HYF, 2020, RADIOLOGY, V296, pE72, DOI 10.1148/radiol.2020201160
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yoon SH, 2020, RADIOLOGY, V297, pE276, DOI 10.1148/radiol.2020203043
   Yoon SH, 2020, KOREAN J RADIOL, V21, P494, DOI 10.3348/kjr.2020.0132
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 29
TC 0
Z9 0
U1 0
U2 0
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD NOV 30
PY 2020
VL 35
IS 46
AR e413
DI 10.3346/jkms.2020.35.e413
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA PA8XL
UT WOS:000595912100001
PM 33258333
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Cloeckaert, A
   Kuchler, K
AF Cloeckaert, Axel
   Kuchler, Karl
TI Grand Challenges in Infectious Diseases: Are We Prepared for Worst-Case
   Scenarios?
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE infectious diseases; mortality; antimicrobial multidrug resistance;
   host-pathogen interactions; research strategies; vaccines; COVID-19;
   polymicrobial disease
C1 [Cloeckaert, Axel] Univ Tours, INRAE, UMR ISP, Nouelly, France.
   [Kuchler, Karl] Med Univ Vienna, Dept Med Biochem, Max Perutz Labs Vienna, Vienna, Austria.
RP Cloeckaert, A (corresponding author), Univ Tours, INRAE, UMR ISP, Nouelly, France.; Kuchler, K (corresponding author), Med Univ Vienna, Dept Med Biochem, Max Perutz Labs Vienna, Vienna, Austria.
EM axel.cloeckaert@inrae.fr; karl.kuchler@meduniwien.ac.at
FU Austrian Science Fund FWFAustrian Science Fund (FWF) [SFB070-P08,
   Chromatin FWF-P25333-B22, ChromFunVir FWF-P-31712]; European FP7 program
   (FUNGITECT) [MSCA-ITN-ImResFun-MC-ITN-2013-606786]; National Institutes
   of HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [NIH-R01AI124499]; Agence Nationale de
   la Recherche GrantFrench National Research Agency (ANR)
   [ANR-14-ASMA-0002-02]
FX We are grateful to Helene Jensen, Lydia Nurse, Alberto Rossi and the
   entire Frontiers Editorial Office for help with background information
   and publication metrics on Frontiers publications. Infectious disease
   research in the KK group has been funded by recent grants of the
   Austrian Science Fund FWF (doc.funds Tissue Home, SFB070-P08, Chromatin
   FWF-P25333-B22, ChromFunVir FWF-P-31712), by grants from the European
   FP7 program (FUNGITECT, MSCA-ITN-ImResFun-MC-ITN-2013-606786), and by a
   grant from the National Institutes of Health (NIH-R01AI124499). AC
   infectious disease research was supported by the Agence Nationale de la
   Recherche Grant ANR-14-ASMA-0002-02. Finally, the authors apologize to
   all colleagues whose work could not be cited owing to strict space
   restrictions.
CR [Anonymous], 2019, LANCET INFECT DIS, V19, P559, DOI [10.1016/S1473-3099(19)30222-131122766, DOI 10.1016/S1473-3099(19)30222-131122766]
   Berman J, 2020, NAT REV MICROBIOL, V18, P319, DOI 10.1038/s41579-019-0322-2
   Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404
   Cao Y, 2020, ACTA VIROL, V64, P245, DOI 10.4149/av_2020_201
   Casadevall A, 2019, MBIO, V10, DOI 10.1128/mBio.01397-19
   Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2
   Chang SL, 2020, J BIOL DYNAM, V14, P57, DOI 10.1080/17513758.2020.1720322
   Cowman AF, 2016, CELL, V167, P610, DOI 10.1016/j.cell.2016.07.055
   De Oliveira DMP, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00181-19
   Drolet M, 2015, LANCET INFECT DIS, V15, P565, DOI 10.1016/S1473-3099(14)71073-4
   Falkow S, 2008, NAT MED, V14, P1053, DOI 10.1038/nm1008-1053
   Fiers WD, 2019, CURR OPIN MICROBIOL, V50, P79, DOI 10.1016/j.mib.2019.09.010
   FLEMING A, 1946, J Am Inst Homeopath, V39, P154
   Gambotto A, 2008, LANCET, V371, P1464, DOI 10.1016/S0140-6736(08)60627-3
   Hotez PJ, 2020, CURR OPIN VIROL, V41, P1, DOI 10.1016/j.coviro.2020.01.001
   Hussain A, 2018, CUREUS, V10, DOI 10.7759/cureus.2919
   Kalra RS, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9070546
   Le Magnen C, 2016, NAT REV CANCER, V16, P187, DOI 10.1038/nrc.2016.1
   Lockhart SR, 2017, CLIN INFECT DIS, V64, P134, DOI 10.1093/cid/ciw691
   Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935
   Meis JF, 2018, LANCET INFECT DIS, V18, P1298, DOI 10.1016/S1473-3099(18)30609-1
   Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   Perlin DS, 2017, LANCET INFECT DIS, V17, pE383, DOI 10.1016/S1473-3099(17)30316-X
   Plichta DR, 2019, CELL, V178, P1041, DOI 10.1016/j.cell.2019.07.045
   Poland G, 2009, CURR OPIN IMMUNOL, V21, P305, DOI 10.1016/j.coi.2009.05.014
   Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012
   Rocklov J, 2020, NAT IMMUNOL, V21, P479, DOI 10.1038/s41590-020-0648-y
   Schiller JT, 2015, LANCET ONCOL, V16, pE217, DOI 10.1016/S1470-2045(14)71179-9
   Schrager LK, 2020, LANCET INFECT DIS, V20, pE28, DOI 10.1016/S1473-3099(19)30625-5
   Singer M, 2018, CRIT CARE CLIN, V34, P153, DOI 10.1016/j.ccc.2017.08.011
   Singh TU, 2020, PHARMACOL REP, V72, P1479, DOI 10.1007/s43440-020-00155-6
   Tang DL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008536
   Walter J, 2020, CELL, V180, P221, DOI 10.1016/j.cell.2019.12.025
   Weber EW, 2020, CELL, V181, P46, DOI 10.1016/j.cell.2020.03.001
   Willis JCD, 2015, NAT REV IMMUNOL, V15, P323, DOI 10.1038/nri3820
   Wimmers Florian, 2020, Curr Opin Immunol, V65, P57, DOI 10.1016/j.coi.2020.05.001
   Wirnsberger G, 2016, NAT MED, V22, P915, DOI 10.1038/nm.4134
   Woolhouse MEJ, 2002, NAT GENET, V32, P569, DOI 10.1038/ng1202-569
NR 39
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD NOV 30
PY 2020
VL 11
AR 613383
DI 10.3389/fmicb.2020.613383
PG 7
WC Microbiology
SC Microbiology
GA PE1KI
UT WOS:000598129700001
PM 33329504
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abu-Raya, B
   Gantt, S
   Sadarangani, M
AF Abu-Raya, Bahaa
   Gantt, Soren
   Sadarangani, Manish
TI Challenges associated with the evaluation of SARS-CoV-2 vaccines during
   the COVID-19 pandemic
SO CANADIAN MEDICAL ASSOCIATION JOURNAL
LA French
DT Article
ID EFFICACY
C1 [Abu-Raya, Bahaa] Univ British Columbia, Hop Enfants Colombie Britannique, Inst Rech, Ctr Evaluat Vaccins, Vancouver, BC, Canada.
   Univ British Columbia, Dept Pediat, Div Infectiol, Vancouver, BC, Canada.
RP Abu-Raya, B (corresponding author), Univ British Columbia, Hop Enfants Colombie Britannique, Inst Rech, Ctr Evaluat Vaccins, Vancouver, BC, Canada.
EM baburaya@bcchr.ubc.ca
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2018, PHIL GRIPP DENG VACC
   Cheng MHP, 2020, CAN MED ASSOC J, V192, pE405, DOI 10.1503/cmaj.200438
   Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390
   Halstead SB, 2016, J INFECT DIS, V214, P1793, DOI 10.1093/infdis/jiw340
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Shoukat A, 2020, CAN MED ASSOC J, V192, pE489, DOI 10.1503/cmaj.200457
   Sood N, 2020, JAMA-J AM MED ASSOC, V323, P2425, DOI 10.1001/jama.2020.8279
   Stringhini S, 2020, REPEATED SEROPREVALE, DOI [10.1101/2020.05.02.20088898, DOI 10.1101/2020.05.02.20088898]
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Tuite AR, 2020, CAN MED ASSOC J, V192, pE497, DOI 10.1503/cmaj.200476
   Weinberg GA, 2010, J INFECT DIS, V201, P1607, DOI 10.1086/652404
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
NR 16
TC 0
Z9 0
U1 0
U2 0
PU CMA-CANADIAN MEDICAL ASSOC
PI OTTAWA
PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA
SN 0820-3946
EI 1488-2329
J9 CAN MED ASSOC J
JI Can. Med. Assoc. J.
PD NOV 30
PY 2020
VL 192
IS 48
BP E1691
EP E1695
DI 10.1503/cmaj.201237-f
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA PD8RL
UT WOS:000597945100016
PM 33257340
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ruiz-Sanchez, JG
   Nunez-Gil, IJ
   Cuesta, M
   Rubio, MA
   Maroun-Eid, C
   Arroyo-Espliguero, R
   Romero, R
   Becerra-Munoz, VM
   Uribarri, A
   Feltes, G
   Trabattoni, D
   Molina, M
   Aguado, MG
   Pepe, M
   Cerrato, E
   Alfonso, E
   Mejia, AFC
   Roubin, SR
   Buzon, L
   Bondia, E
   Marin, F
   Pais, JL
   Abumayyaleh, M
   D'Ascenzo, F
   Rondano, E
   Huang, J
   Fernandez-Perez, C
   Macaya, C
   Novoa, PD
   Calle-Pascual, AL
   Perez, VE
   Runkle, I
AF Gabriel Ruiz-Sanchez, Jorge
   Nunez-Gil, Ivan J.
   Cuesta, Martin
   Rubio, Miguel A.
   Maroun-Eid, Charbel
   Arroyo-Espliguero, Ramon
   Romero, Rodolfo
   Manuel Becerra-Munoz, Victor
   Uribarri, Aitor
   Feltes, Gisela
   Trabattoni, Daniela
   Molina, Maria
   Garcia Aguado, Marcos
   Pepe, Martino
   Cerrato, Enrico
   Alfonso, Emilio
   Castro Mejia, Alex Fernando
   Raposeiras Roubin, Sergio
   Buzon, Luis
   Bondia, Elvira
   Marin, Francisco
   Lopez Pais, Javier
   Abumayyaleh, Mohammad
   D'Ascenzo, Fabrizio
   Rondano, Elisa
   Huang, Jia
   Fernandez-Perez, Cristina
   Macaya, Carlos
   de Miguel Novoa, Paz
   Calle-Pascual, Alfonso L.
   Estrada Perez, Vicente
   Runkle, Isabelle
CA HOPE COVID-19 Investigators
TI Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19
   Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for
   COVID-19) Registry Analysis
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE hyponatremia; hypernatremia; COVID-19; SARS-COV2; mortality; sepsis
ID HOSPITALIZED-PATIENTS; RISK-FACTORS; VASOPRESSIN; MORTALITY; SODIUM
AB Dysnatremia is associated with increased mortality in patients with community-acquired pneumonia. SARS-COV2 (Severe-acute-respiratory syndrome caused by Coronavirus-type 2) pneumonia can be fatal. The aim of this study was to ascertain whether admittance dysnatremia is associated with mortality, sepsis, or intensive therapy (IT) in patients hospitalized with SARS-COV2 pneumonia. This is a retrospective study of the HOPE-COVID-19 registry, with data collected from January 1(th) through April 31(th), 2020. We selected all hospitalized adult patients with RT-PCR-confirmed SARS-COV2 pneumonia and a registered admission serum sodium level (SNa). Patients were classified as hyponatremic (SNa <135 mmol/L), eunatremic (SNa 135-145 mmol/L), or hypernatremic (SNa >145 mmol/L). Multivariable analyses were performed to elucidate independent relationships of admission hyponatremia and hypernatremia, with mortality, sepsis, or IT during hospitalization. Four thousand six hundred sixty-four patients were analyzed, median age 66 (52-77), 58% males. Death occurred in 988 (21.2%) patients, sepsis was diagnosed in 551 (12%) and IT in 838 (18.4%). Hyponatremia was present in 957/4,664 (20.5%) patients, and hypernatremia in 174/4,664 (3.7%). Both hyponatremia and hypernatremia were associated with mortality and sepsis. Only hyponatremia was associated with IT. In conclusion, hyponatremia and hypernatremia at admission are factors independently associated with mortality and sepsis in patients hospitalized with SARS-COV2 pneumonia.
C1 [Gabriel Ruiz-Sanchez, Jorge; Nunez-Gil, Ivan J.; Cuesta, Martin; Rubio, Miguel A.; Fernandez-Perez, Cristina; Macaya, Carlos; de Miguel Novoa, Paz; Calle-Pascual, Alfonso L.; Estrada Perez, Vicente; Runkle, Isabelle] Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Madrid, Spain.
   [Cuesta, Martin; Calle-Pascual, Alfonso L.] Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain.
   [Maroun-Eid, Charbel] Hosp Univ La Paz, Inst Invest Hosp Univ La Paz IdiPAZ, Madrid, Spain.
   [Arroyo-Espliguero, Ramon] Hosp Univ Guadalajara, Guadalajara, Spain.
   [Romero, Rodolfo] Univ Europea Madrid, Hosp Univ Getafe, Madrid, Spain.
   [Manuel Becerra-Munoz, Victor] Hosp Clin Univ Virgen Victoria, Malaga, Spain.
   [Uribarri, Aitor] Hosp Clin Univ Valladolid, Valladolid, Spain.
   [Feltes, Gisela] Hosp Nuestra Senora Amer, Madrid, Spain.
   [Trabattoni, Daniela] Ctr Cardiol Monzino, IRCCS, Milan, Italy.
   [Molina, Maria] Hosp Univ Severo Ochoa, Madrid, Spain.
   [Garcia Aguado, Marcos] Hosp Puerta Hierro Majadahonda, Madrid, Spain.
   [Pepe, Martino] Azienda Ospedaliero Univ Consorziale Policlin Bar, Bari, Italy.
   [Cerrato, Enrico] San Luigi Gonzaga Univ Hosp, Orbassano & Rivoli Infermi Hosp, Turin, Italy.
   [Alfonso, Emilio] Inst Cardiol & Cardiovasc Surg, Havana, Cuba.
   [Castro Mejia, Alex Fernando] Hosp Gen Norte Guayaquil IESS Los Ceibos, Guayaquil, Ecuador.
   [Raposeiras Roubin, Sergio] Univ Hosp Alvaro Cunqueiro, Vigo, Spain.
   [Buzon, Luis] Hosp Univ Burgos, Burgos, Spain.
   [Bondia, Elvira] Univ Valencia, Hosp Clin Univ, Incliva, Valencia, Spain.
   [Marin, Francisco] Hosp Arreixaca, Murcia, Spain.
   [Lopez Pais, Javier] Hosp Santiago Compostela, Santiago De Compostela, Spain.
   [Abumayyaleh, Mohammad] Heidelberg Univ, Med Fac Mannheim, Dept Med 1, Mannheim, Germany.
   [Abumayyaleh, Mohammad] DZHK German Ctr Cardiovasc Res, Partner Site, Mannheim, Germany.
   [D'Ascenzo, Fabrizio] San Giovanni Battista Hosp, Turin, Italy.
   [Rondano, Elisa] St Andrea Hosp, Vercelli, Italy.
   [Huang, Jia] Southern Univ Sci & Technol, Affiliated Hosp 2, Shenzhen, Peoples R China.
RP Ruiz-Sanchez, JG (corresponding author), Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Madrid, Spain.
EM gajo_saru@hotmail.com
OI RUIZ SANCHEZ, JORGE GABRIEL/0000-0003-1305-9354; MAROUN EID,
   CHARBEL/0000-0001-7684-868X
CR ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401
   Ayaz M, 2018, TURK NEUROSURG, V28, P421, DOI 10.5137/1019-5149.JTN.20238-17.2
   Ayus JC, 2006, KIDNEY INT, V69, P1319, DOI 10.1038/sj.ki.5000187
   Ayus JC, 2008, AM J PHYSIOL-RENAL, V295, pF619, DOI 10.1152/ajprenal.00502.2007
   Bataille S, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-37
   Benhamou D, 1998, Monaldi Arch Chest Dis, V53, P547
   Berni A, 2020, J ENDOCRINOL INVEST, V43, P1137, DOI 10.1007/s40618-020-01301-w
   Chan JCX, 2020, HONG KONG MED J, V26, P286, DOI 10.12809/hkmj205102
   Chawla A, 2011, CLIN J AM SOC NEPHRO, V6, P960, DOI 10.2215/CJN.10101110
   Cuesta M, 2019, CLIN ENDOCRINOL, V90, P744, DOI 10.1111/cen.13937
   De Freitas G, 2019, J COMMUNITY HOSP INT, V9, P296, DOI 10.1080/20009666.2019.1634407
   Deo P, 2019, PULMONOLOGY, V25, P79, DOI 10.1016/j.pulmoe.2018.06.002
   Flaatten H, 2017, INTENS CARE MED, V43, P1319, DOI 10.1007/s00134-017-4718-z
   General Office of National Health Committee, 2020, NOT ISS PROGR DIAGN
   Hauptman PJ, 2013, J CARD FAIL, V19, P390, DOI 10.1016/j.cardfail.2013.04.001
   Hoorn EJ, 2006, NEPHROL DIAL TRANSPL, V21, P70, DOI 10.1093/ndt/gfi082
   Jensen AG, 1999, ARCH INTERN MED, V159, P1437, DOI 10.1001/archinte.159.13.1437
   Kruger S, 2014, RESP MED, V108, P1696, DOI 10.1016/j.rmed.2014.09.014
   LANDGRAF R, 1995, EUR J NEUROSCI, V7, P592, DOI 10.1111/j.1460-9568.1995.tb00663.x
   Leung AA, 2012, ARCH INTERN MED, V172, P1474, DOI 10.1001/archinternmed.2012.3992
   MASTORAKOS G, 1994, J CLIN ENDOCR METAB, V79, P934, DOI 10.1210/jc.79.4.934
   Meinders AJ, 1996, AGE AGEING, V25, P353, DOI 10.1093/ageing/25.5.353
   Muller M, 2018, EUR J INTERN MED, V54, P46, DOI 10.1016/j.ejim.2018.04.008
   Nair V, 2007, AM J NEPHROL, V27, P184, DOI 10.1159/000100866
   Nigro N, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1955-7
   Nunez-Gill IJ, 2020, EMERGENCIAS, V32, P293
   Nzerue CM, 2003, J NATL MED ASSOC, V95, P335
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Rossignol B, 2007, CRIT CARE MED, V35, P351, DOI 10.1097/01.CCM.0000254335.88023.0E
   Shirazy M, 2020, J CRIT CARE MED, V6, P52, DOI 10.2478/jccm-2020-0001
   Squecco R, 2016, EXP PHYSIOL, V101, P1086, DOI 10.1113/EP085806
   Swart RM, 2011, NEPHRON PHYSIOL, V118, P45, DOI 10.1159/000322238
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   Tokgoz Akyil F, 2019, TUBERK TORAK, V67, P239, DOI 10.5578/tt.68779
   Uribarri A, 2020, J NEPHROL, V33, P737, DOI 10.1007/s40620-020-00790-5
   Vedantam A, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.7.FOCUS17418
   Waikar SS, 2009, AM J MED, V122, P857, DOI 10.1016/j.amjmed.2009.01.027
   Wald R, 2010, ARCH INTERN MED, V170, P294, DOI 10.1001/archinternmed.2009.513
   Yang WJ, 2020, RADIOLOGY, V295, pE3, DOI 10.1148/radiol.2020200702
   Zilberberg Marya D, 2008, BMC Pulm Med, V8, P16, DOI 10.1186/1471-2466-8-16
NR 40
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD NOV 30
PY 2020
VL 11
AR 599255
DI 10.3389/fendo.2020.599255
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA PE1JW
UT WOS:000598128500001
PM 33329400
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Qiu, Y
   Zhang, YF
   Zhu, LR
   He, JS
   Tan, JY
   Tan, ND
   Lin, SN
   Lin, XQ
   Ghosh, S
   Chen, MH
   Mao, R
AF Qiu, Yun
   Zhang, Ying-Fan
   Zhu, Liang-Ru
   He, Jin-Shen
   Tan, Jin-Yu
   Tan, Nian-Di
   Lin, Si-Nan
   Lin, Xiao-Qing
   Ghosh, Subrata
   Chen, Min-Hu
   Mao, Ren
TI Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel
   Disease: A Comparison Between Epicenter vs. Non-epicenter Areas
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; inflammatory bowel disease; medical care; telemedicine;
   epicenter; non-epicenter
ID IBD
AB Background and Aims: The COVID-19 pandemic poses a great challenge to healthcare. We aimed to investigate the impact of COVID-19 on the healthcare of patients with inflammatory bowel disease (IBD) in epicenter and non-epicenter areas.
   Methods: Patients with IBD from Hubei province (the epicenter of COVID-19) and Guangdong province (a non-epicenter area), China were surveyed during the pandemic. The questionnaire included change of medications (steroids, immunomodulators, and biologics), procedures (lab tests, endoscopy, and elective surgery), and healthcare mode (standard healthcare vs. telemedicine) during 1 month before and after the outbreak of COVID-19.
   Results: In total, 324 IBD patients from Guangdong province (non-epicenter) and 149 from Hubei province (epicenter) completed the questionnaire with comparable demographic characteristics. Compared to patients in Guangdong province (non-epicenter), significantly more patients in Hubei (epicenter) had delayed lab tests/endoscopy procedures [61.1% (91/149) vs. 25.3% (82/324), p < 0.001], drug withdrawal [28.6% (43/149) vs. 9.3% (30/324), p < 0.001], delayed biologics infusions [60.4% (90/149) vs. 19.1% (62/324), p < 0.001], and postponed elective surgery [16.1% (24/149) vs. 3.7% (12/324), p < 0.001]. There was an increased use of telemedicine after the outbreak compared to before the outbreak in Hubei province [38.9% (58/149) vs. 15.4% (23/149), p < 0.001], while such a significant increase was not observed in Guangdong province [21.9% (71/324) vs. 18.8% (61/324), p = 0.38]. Approximately two-thirds of IBD patients from both sites agreed that telemedicine should be increasingly used in future medical care.
   Conclusions: Our patient-based survey study in a real-world setting showed that COVID-19 resulted in a great impact on the healthcare of patients with IBD, and such an impact was more obvious in the epicenter compared to the non-epicenter area of COVID-19. Telemedicine offers a good solution to counteract the challenges in an unprecedented situation such as COVID-19.
C1 [Qiu, Yun; Zhang, Ying-Fan; He, Jin-Shen; Tan, Jin-Yu; Tan, Nian-Di; Lin, Si-Nan; Lin, Xiao-Qing; Chen, Min-Hu; Mao, Ren] Sun Yat Sen Univ, Dept Gastroenterol, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Zhu, Liang-Ru] Huazhong Univ Sci & Technol, Union Hosp, Tongi Med Coll, Div Gastroenterol, Wuhan, Peoples R China.
   [Ghosh, Subrata] Univ Birmingham, Natl Inst Hlth, Inst Translat Med, Res Biomed Res Inst, Birmingham, W Midlands, England.
   [Ghosh, Subrata] Univ Hosp Birmingham Nightingale Hosp NHS Fdn Tru, Birmingham, W Midlands, England.
RP Chen, MH; Mao, R (corresponding author), Sun Yat Sen Univ, Dept Gastroenterol, Affiliated Hosp 1, Guangzhou, Peoples R China.
EM chenminhu@mail.sysu.edu.cn; maoren2023@gmail.com
CR Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   D'Amico F, 2020, GASTROENTEROLOGY, V159, P14, DOI 10.1053/j.gastro.2020.04.059
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Hudesman David P, 2020, BMC Rheumatol, V4, P16, DOI 10.1186/s41927-020-0115-2
   Ma CX, 2020, AM J GASTROENTEROL, V115, P1003, DOI 10.14309/ajg.0000000000000691
   Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0
   Occhipinti V, 2020, INFLAMM BOWEL DIS, V26, P793, DOI 10.1093/ibd/izaa084
NR 9
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 30
PY 2020
VL 7
AR 576891
DI 10.3389/fmed.2020.576891
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA PE1JP
UT WOS:000598127800001
PM 33330534
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ota, T
   Shiokawa, Y
   Hirano, T
AF Ota, Takahiro
   Shiokawa, Yoshiaki
   Hirano, Teruyuki
TI Impact of COVID-19 on Stroke Admissions and the Medical Care System in
   the Tokyo Metropolitan Area
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE care system; COVID-19; Tokyo; stroke; thrombectomy
AB Aims: This study aimed to assess the number of patients with acute stroke seeking medical emergency care since the declaration of the state of emergency in the COVID-19 pandemic in the Tokyo metropolitan area of Japan.
   Methods: In this combined retrospective and prospective multicenter survey, data on the numbers of hospital admissions due to acute ischemic stroke, of large vessel occlusion (LVO) cases, and of reperfusion therapies performed from February to July 2020, restrictions of the medical care system, and comprehensive stroke center (CSC) scale scores were collected in 19 stroke centers in Tokyo.
   Results: In the survey period, 3,456 patients were admitted with acute stroke. There was a decrease in the number of admissions (-22%), LVO (-22%), thrombolysis (-6%), and thrombectomy (-23%) during the state of emergency, but the ratio of thrombectomy to LVO cases was not different. The acceptance of acute stroke cases by emergency transport and emergent operations in the central eastern area of Tokyo, was also significantly decreased to <50% and remains <60%. According to CSC scores, each hospital restricted their infrastructure or educational activities according to their medical resources. There was only one stroke case with COVID-19 (thrombectomy case) in all 3,456 patients in this study.
   Conclusion: The COVID-19 pandemic had a major impact on stroke care in Tokyo, including stroke admissions and medical care systems, resulting in a significant reduction in thrombolysis and thrombectomy. The extent of the drop may be the result of the number of COVID-19 patients.
C1 [Ota, Takahiro] Tokyo Metropolitan Tama Med Ctr, Dept Neurosurg, Fuchu, Tokyo, Japan.
   [Shiokawa, Yoshiaki] Kyorin Univ, Dept Neurosurg, Mitaka, Tokyo, Japan.
   [Hirano, Teruyuki] Kyorin Univ, Dept Stroke & Cerebrovasc Med, Mitaka, Tokyo, Japan.
RP Ota, T (corresponding author), Tokyo Metropolitan Tama Med Ctr, Dept Neurosurg, Fuchu, Tokyo, Japan.
EM toota-tky@umin.org
FU Taiju Life Social Welfare Foundation
FX This study was partially supported by Taiju Life Social Welfare
   Foundation.
CR Agarwal S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.105068
   Iihara K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096819
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kerleroux B, 2020, STROKE, V51, P2012, DOI 10.1161/STROKEAHA.120.030373
   Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472
   Ota T, 2018, J STROKE CEREBROVASC, V27, P3350, DOI 10.1016/j.jstrokecerebrovasdis.2018.07.044
   Teo KC, 2020, STROKE, V51, P2228, DOI 10.1161/STROKEAHA.120.030105
   Zhao J, 2020, STROKE, V51, P1996, DOI 10.1161/STROKEAHA.120.030225
NR 8
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD NOV 30
PY 2020
VL 11
AR 601652
DI 10.3389/fneur.2020.601652
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA PE1KH
UT WOS:000598129600001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Bonny-Noach, H
   Gold, D
AF Bonny-Noach, Hagit
   Gold, Dudi
TI Addictive behaviors and craving during the COVID-19 pandemic of people
   who have recovered from substance use disorder
SO JOURNAL OF ADDICTIVE DISEASES
LA English
DT Article; Early Access
DE COVID-19; addiction; recovery; craving; addictive behaviors
AB Stressors caused by the coronavirus pandemic (COVID-19) contribute to increased addictive behaviors in the general population worldwide. Little is known, however, about addictive behaviors of people who have recovered a long time ago, even years, from substance use disorder (SUD). The goal of the present research was to examine the craving for drug use and addictive behaviors (tobacco and alcohol consumption, viewing of pornography, gambling, and shopping online) of people who recovered from SUD, before and after the outbreak of the COVID-19 pandemic.
   Methods: During one week of isolation imposed in Israel following the outbreak of COVID-19 in April, 2020, a self-report questionnaire was distributed to a convenience sample of 113 people who had recovered from SUD, aged 22-69, 78% men.
   Results Fifty-one percent of participants reported craving drugs during the isolation period and engaging in addictive behaviors. Significant differences were found in tobacco and alcohol consumption, gambling, and viewing of pornography online, before and after the outbreak of the pandemic, especially in participants who reported having engaged in these addictive behaviors to some extent before the outbreak. A hierarchical linear regression showed a significant explained variance (R (2)=44%, p<.001), with stronger feelings of loneliness and shorter length of time free from drug use being associated with stronger craving for drugs.
   Conclusions: The drug addiction treatment establishment should pay close attention and strengthen communication with people who recovered from SUD. It is necessary to develop real-time anti-craving and anti-replacement addiction interventions to prevent relapses.
C1 [Bonny-Noach, Hagit] Ariel Univ, Dept Criminol, Ariel, Israel.
   [Bonny-Noach, Hagit] Israeli Soc Addict Med ILSAM, Ramat Gan, Israel.
   [Bonny-Noach, Hagit] Israel Natl Antidoping Org ISR NADO, Tel Aviv, Israel.
   [Gold, Dudi] Bar Ilan Univ, Ramat Gan, Israel.
RP Bonny-Noach, H (corresponding author), Ariel Univ, Fac Social Sci & Humanities, Dept Criminol, Ariel, Israel.
EM Hagitbo@gmail.com
OI Bonny-Noach, Hagit/0000-0002-5092-520X
CR Albrecht U., 2007, GMS PSYCHO SOC MED, V4
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
   [Anonymous], IBM SPSS STAT WINDOW
   Bjornestad J, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00689
   Bonny-Noach H, 2019, ISR J HEALTH POLICY, V8, DOI 10.1186/s13584-019-0343-3
   Breese GR, 2005, ALCOHOL CLIN EXP RES, V29, P185, DOI 10.1097/01.ALC.0000153544.83656.3C
   Ezrachi Y., 2017, PSYCHOACTIVE DRUG US
   Haylett SA, 2004, ADDICT BEHAV, V29, P61, DOI 10.1016/S0306-4603(03)00083-2
   Kervran C, 2020, DRUG ALCOHOL DEPEN, V212, DOI 10.1016/j.drugalcdep.2020.108036
   King DL, 2020, J BEHAV ADDICT, V9, P184, DOI 10.1556/2006.2020.00016
   Kiraly O, 2020, COMPR PSYCHIAT, V100, DOI 10.1016/j.comppsych.2020.152180
   Koball AM, 2019, ADDICT RES THEORY, V27, P322, DOI 10.1080/16066359.2018.1516757
   Lechner WV, 2020, ADDICT BEHAV, V110, DOI 10.1016/j.addbeh.2020.106527
   Lev-El N., 2013, SOCI WELFARE, V33, P470
   McKay D, 2020, ADDICT BEHAV, V110, DOI 10.1016/j.addbeh.2020.106522
   Neupert SD, 2017, PSYCHOL ADDICT BEHAV, V31, P315, DOI 10.1037/adb0000276
   Razali A., 2018, INT J ACAD RES BUS S, V8, P1404
   Rosca P., 2020, INT J DRUG POLICY, V83
   Scott CK, 2005, J SUBST ABUSE TREAT, V28, pS63, DOI 10.1016/j.jsat.2004.09.006
   Shabi A., 2020, REV SOCIAL SERVICES
   Silverman MJ, 2019, PSYCHOL MUSIC, V47, P241, DOI 10.1177/0305735617743103
   Sun Y, 2020, AM J ADDICTION, V29, P268, DOI 10.1111/ajad.13066
   Yehudai M, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00360-7
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1055-0887
EI 1545-0848
J9 J ADDICT DIS
JI J. Addict. Dis.
DI 10.1080/10550887.2020.1856298
EA NOV 2020
PG 8
WC Substance Abuse
SC Substance Abuse
GA PD0HI
UT WOS:000597375800001
PM 33305702
DA 2021-01-01
ER

PT J
AU Soliman, MS
   AbdelFattah, M
   Aman, SMN
   Ibrahim, LM
   Aziz, RK
AF Soliman, May S.
   AbdelFattah, May
   Aman, Soad M. N.
   Ibrahim, Lamyaa M.
   Aziz, Ramy K.
TI A Gapless, Unambiguous RNA Metagenome-Assembled Genome Sequence of a
   Unique SARS-CoV-2 Variant Encoding Spike S813I and ORF1a A859V
   Substitutions
SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
LA English
DT Article; Early Access
DE COVID-19; pandemic; genomic epidemiology; high-throughput sequencing;
   spike protein; replicase
AB The novel severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is causing an unprecedented pandemic, threatening planetary health, society, and economy. Genomic surveillance continues to be a critical effort toward tracking the virus and containing its spread, and more genomes from diverse geographical areas and different time points are needed to provide an appropriate representation of the virus evolution. In this study, we report the successful assembly of one single gapless, unambiguous contiguous sequence representing the complete viral genome from a nasopharyngeal swab of an infected health care worker in Cairo, Egypt. The sequence has all typical features of SARS-CoV-2 genomes, with no protein-disrupting mutations. However, three mutations are worth highlighting and future tracking: a synonymous mutation causing a rare spike S813I variation and two less frequent ones leading to an A41V variation in NSP3, encoded by ORF1a (ORF1a A895V), and a Q677H variation in the spike protein. Both affected proteins, S and NSP3, are relevant to vaccine and drug development. Although the genome, named CU_S3, belongs to the prevalent global genotype, marked by the D614G spike variation, the combined variations in the spike proteins and ORF1a do not co-occur in any of the 197,000 genomes reported to date. Future studies will assess the biological, pathogenic, and epidemiological implications of this set of genetic variations. This line of research is needed to inform vaccine and therapeutic innovation to stem the COVID-19 pandemic.
C1 [Soliman, May S.; AbdelFattah, May] Cairo Univ, Fac Med, Clin Pathol Dept, Cairo, Egypt.
   [AbdelFattah, May] Cairo Univ, Pediat Hosp, Cairo, Egypt.
   [Aman, Soad M. N.; Ibrahim, Lamyaa M.; Aziz, Ramy K.] Cairo Univ, Fac Pharm, Dept Microbiol & Immunol, Cairo 11562, Egypt.
   [Aziz, Ramy K.] Cairo Univ, Ctr Genome & Microbiome Res, Cairo, Egypt.
RP Aziz, RK (corresponding author), Cairo Univ, Fac Pharm, Dept Microbiol & Immunol, Cairo 11562, Egypt.
EM ramy.aziz@gmail.com
FU Cairo University, as part of the COVID-19 fund
FX This study was fully funded by Cairo University, as part of the COVID-19
   fund, established since April 2020. The funder had no role in the
   design, execution, or scientific content of this article.
CR Akar I, 2020, OMICS, V24, P515, DOI 10.1089/omi.2020.0111
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Dabravolski SA, 2020, J MED VIROL, V92, P1690, DOI 10.1002/jmv.25976
   Davis JJ, 2020, NUCLEIC ACIDS RES, V48, pD606, DOI 10.1093/nar/gkz943
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Diez-Fuertes F, 2020, J VIROL, V41, P605
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hou Yixuan J, 2020, bioRxiv, DOI 10.1101/2020.09.28.317685
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Plante JA, 2020, NATURE, DOI 10.1038/s41586-020-2895-3
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Price MN, 2009, MOL BIOL EVOL, V26, P1641, DOI 10.1093/molbev/msp077
   Rambaut A, 2018, FIGTREE V 1 4 4
   Rambaut Andrew, 2020, Nat Microbiol, V5, P1403, DOI 10.1038/s41564-020-0770-5
   Singer JB, 2020, COV GLUE WEB APPL TR, DOI [10.20944/preprints202006.0225.v1, DOI 10.20944/PREPRINTS202006.0225.V1]
   Springer S, 2020, DIALOGUES HUM GEOGR, V10, P112, DOI 10.1177/2043820620931277
   Wade F, 2020, NATION
   Zhou Bin, 2020, bioRxiv, DOI 10.1101/2020.10.27.357558
NR 24
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1536-2310
EI 1557-8100
J9 OMICS
JI OMICS
DI 10.1089/omi.2020.0194
EA NOV 2020
PG 6
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA PA6TC
UT WOS:000595764400001
PM 33253058
OA Bronze
DA 2021-01-01
ER

PT J
AU Tai, TT
   Wu, TJ
   Wu, HD
   Tsai, YC
   Wang, HT
   Wang, AM
   Shih, SF
   Chen, YC
AF Tai, Tien-Tzu
   Wu, Tzung-Ju
   Wu, Huey-Dong
   Tsai, Yi-Chen
   Wang, Hui-Ting
   Wang, An-Min
   Shih, Sheue-Fang
   Chen, Yee-Chun
TI A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable
   Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article; Early Access
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified pathogen causing the coronavirus disease 2019 (COVID-19) pandemic. Hydroxychloroquine (HCQ), an antimalarial and anti-inflammatory drug, has been shown to inhibit SARS-CoV-2 infection in vitro and tested in clinical studies. However, achievement of lung concentrations predicted to have in vivo antiviral efficacy might not be possible with the currently proposed oral dosing regimens. Further, high cumulative doses of HCQ raise concerns of systemic toxicity, including cardiotoxicity. Here, we describe a preclinical study to investigate the pharmacokinetics (PKs) of a novel formulation of liposomal HCQ administered by intratracheal (IT) instillation in Sprague-Dawley rats. Compared with unformulated HCQ administered intravenously, liposomal HCQ showed higher (similar to 30-fold) lung exposure, longer (similar to 2.5-fold) half-life in lungs, but lower blood exposure with similar to 20% of peak plasma concentration (C-max) and 74% of area under the curve from 0 to 72 hours (AUC(0-72)) and lower heart exposure with 23% of C-max and 58% of AUC(0-24) (normalized for dose). Similar results were observed relative to IT administration of unformulated HCQ. These PKs result in an animal model that demonstrated the proof of concept that inhalable liposomal HCQ may provide clinical benefit and serve as a potential treatment for COVID-19.
C1 [Tai, Tien-Tzu] Taiwan Liposome Co Ltd, Div Corp Dev, Dept Regulatory Affairs, Taipei, Taiwan.
   [Wu, Tzung-Ju; Tsai, Yi-Chen; Wang, Hui-Ting] Taiwan Liposome Co Ltd, Div Prod Dev, Dept Pharmacokinet, Taipei, Taiwan.
   [Wu, Huey-Dong] Natl Taiwan Univ Hosp, Div Resp Therapy, Dept Integrated Diagnost & Therapeut, Taipei, Taiwan.
   [Wang, An-Min] Taiwan Liposome Co Ltd, Div Prod Dev, Dept Med Sci, Taipei, Taiwan.
   [Shih, Sheue-Fang] Taiwan Liposome Co Ltd, Div Prod Dev, Taipei, Taiwan.
   [Chen, Yee-Chun] Natl Taiwan Univ Hosp & Coll Med, Div Infect Dis, Dept Internal Med, Taipei, Taiwan.
RP Chen, YC (corresponding author), Natl Taiwan Univ Hosp & Coll Med, Div Infect Dis, Dept Internal Med, Taipei, Taiwan.
EM yeechunchen@gmail.com
FU Taiwan Liposome Company, Ltd., Taiwan
FX This study was supported by Taiwan Liposome Company, Ltd., Taiwan.
CR Arnold SLM, 2020, CTS-CLIN TRANSL SCI, V13, P642, DOI 10.1111/cts.12797
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Centers for Disease Control and Prevention (CDC) . National Center for Immunization and Respiratory Diseases (NCIRD), NAT CTR IMM RESP DIS
   Chen Z., EFFICACY HYDROXYCHLO
   Chhonker YS, 2018, J CHROMATOGR B, V1072, P320, DOI 10.1016/j.jchromb.2017.11.026
   Dayton F., 2006, RESP DRUG DELIV, P429
   Fan Jianghong, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa623
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Kavanagh O, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.110110
   Klimke A, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109783
   Le MP, 2020, J ANTIMICROB CHEMOTH, V75, P2376, DOI 10.1093/jac/dkaa191
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shirley M, 2019, DRUGS, V79, P555, DOI 10.1007/s40265-019-01095-z
   Solitro AR, 2016, FUTURE MED CHEM, V8, P73, DOI 10.4155/fmc.15.166
   US Food & Drug Administration, 2020, FDA CAUT US HYDR CHL
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 18
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
DI 10.1111/cts.12923
EA NOV 2020
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1YJ
UT WOS:000594048200001
PM 33135382
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Kandeel, M
   Kitade, Y
   Almubarak, A
AF Kandeel, Mahmoud
   Kitade, Yukio
   Almubarak, Abdullah
TI Repurposing FDA-approved phytomedicines, natural products, antivirals
   and cell protectives against SARS-Cov-2 (COVID-19) RNA-dependent RNA
   polymerase
SO PEERJ
LA English
DT Article
DE SARS-CoV-2; COVID-19; Polymerase; Virtual screening
ID ACCURATE DOCKING; LOPINAVIR/RITONAVIR; DOCETAXEL; GLIDE
AB Following the recent emergence of SARS-CoV-2 or coronavirus disease 2019 (COVID-19), drug discovery and vaccine design to combat this fatal infection are critical. In this study, an essential enzyme in the SARS-CoV-2 replication machinery, RNA-dependent RNA polymerase (RDRP), is targeted in a virtual screening assay using a set of 1,664 FDA-approved drugs, including sets of botanical and synthetic derivatives. A set of 22 drugs showed a high docking score of >-7. Notably, approximately one-third of the top hits were either from natural products or biological molecules. The FDA-approved phytochemicals were sennosides, digoxin, asiaticoside, glycyrrhizin, neohesperidin, taxifolin, quercetin and aloin. These approved natural products and phytochemicals are used as general tonics, antioxidants, cell protectives, and immune stimulants (nadid, thymopentin, asiaticoside, glycyrrhizin) and in other miscellaneous systemic or topical applications. A comprehensive analysis was conducted on standard precision and extra precision docking, two-step molecular dynamics simulations, binding energy calculations and a post dynamics analysis. The results reveal that two drugs, docetaxel and neohesperidin, showed strong binding profiles with SARS CoV-2 RdRP. These results can be used as a primer for further drug discovery studies in the treatment of COVID-19. This initiative repurposes safe FDA-approved drugs against COVID-19 RdRP, providing a rapid channel for the discovery and application of new anti-CoV therapeutics.
C1 [Kandeel, Mahmoud; Almubarak, Abdullah] King Faisal Univ, Al Hasa, Saudi Arabia.
   [Kandeel, Mahmoud] Kafrelshikh Univ, Kafrelshikh, Egypt.
   [Kitade, Yukio] Gifu Univ, Gifu, Japan.
   [Kitade, Yukio] Aichi Inst Technol, Toyota, Aichi, Japan.
RP Kandeel, M (corresponding author), King Faisal Univ, Al Hasa, Saudi Arabia.; Kandeel, M (corresponding author), Kafrelshikh Univ, Kafrelshikh, Egypt.
EM mkandeel@kfu.edu.sa
FU Deputyship for Research & Innovation, Ministry of Education in Saudi
   Arabia [IFT20110]
FX This project is funded by the Deputyship for Research & Innovation,
   Ministry of Education in Saudi Arabia for funding this research work
   through the project number IFT20110. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Ahmad N, 2020, J MOL STRUCT, V1203, DOI 10.1016/j.molstruc.2019.127428
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Croxtall JD, 2010, DRUGS, V70, P1885, DOI 10.2165/11204950-000000000-00000
   Dash S, 2019, VIRAL POLYMERASES: STRUCTURES, FUNCTIONS, AND ROLES AS ANTIVIRAL DRUG TARGETS, P211, DOI 10.1016/B978-0-12-815422-9.00008-5
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gaurav A, 2019, VIRAL POLYMERASES: STRUCTURES, FUNCTIONS, AND ROLES AS ANTIVIRAL DRUG TARGETS, P271, DOI 10.1016/B978-0-12-815422-9.00010-3
   Gordon CJ, 2020, J BIOL CHEM AC, VAC120
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   LENGPESCHLOW E, 1986, J PHARM PHARMACOL, V38, P606, DOI 10.1111/j.2042-7158.1986.tb03089.x
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lyseng-Williamson KA, 2005, DRUGS, V65, P2513, DOI 10.2165/00003495-200565170-00007
   Niazi K, 2019, Google Patents, Patent No. [10,350,225, 10350225]
   Ryan ET., 2018, PRINCIPLES PRACTICE, P1567
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Shimizu H, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007894
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Walker R, 2014, POLYPHEN HUM HLTH DI, P1087
NR 20
TC 0
Z9 0
U1 1
U2 1
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD NOV 30
PY 2020
VL 8
AR e10480
DI 10.7717/peerj.10480
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OY2QL
UT WOS:000594095800005
PM 33335812
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mo, Y
   Adarkwah, O
   Zeibeq, J
   Pinelis, E
   Orsini, J
   Gasperino, J
AF Mo, Yoonsun
   Adarkwah, Obed
   Zeibeq, John
   Pinelis, Evgeny
   Orsini, Jose
   Gasperino, James
TI Treatment With Tocilizumab for Patients With COVID-19 Infections: A
   Case-Series Study
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Early Access
DE adverse drug events; COVID&#8208; 19; effectiveness; safety; tocilizumab
ID EFFICACY; SAFETY
AB Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 receptor, holds the potential for treating coronavirus disease 2019 (COVID-19) patients, particularly those at high risk of cytokine storm syndrome. However, data regarding the clinical impact of treatment with TCZ in patients with COVID-19 are limited. This study was conducted to evaluate the safety and effectiveness of TCZ as an adjunct therapy for the treatment of severe COVID-19 infection. This was a retrospective observational chart review of confirmed COVID-19 patients who received TCZ, along with other COVID-19 therapies. The outcomes of interest included changes in vital signs such as temperature and laboratory biomarkers, duration of mechanical ventilation, adverse events possibly associated with TCZ, and intensive care unit and hospital lengths of stay. This study included 38 patients with an average age of 63 years (IQR, 48-70 years). The average dose of TCZ given was 519 +/- 61 mg. Median C-reactive protein significantly decreased following TCZ administration (189.9 vs 54.8 mg/L, P = .003). Nineteen of all febrile patients before the initiation of TCZ (73%) became fever free on the fourth day of TCZ treatment. Following TCZ treatment, 11 patients developed infections because of multidrug-resistant bacteria, and elevated liver transaminases were observed in 6 patients. The preliminary findings of this study suggested TCZ appeared to ameliorate COVID-19-related cytokine storm syndrome. However, large randomized, controlled trials are needed to investigate whether treatment with TCZ is associated with better outcomes in COVID-19.
C1 [Mo, Yoonsun] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY 11201 USA.
   [Mo, Yoonsun; Adarkwah, Obed; Zeibeq, John; Pinelis, Evgeny; Orsini, Jose; Gasperino, James] Brooklyn Hosp Ctr, Ctr Crit Care Serv, Dept Med, Brooklyn, NY USA.
RP Mo, Y (corresponding author), Long Isl Univ, Pharm Practice, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, 75 DeKalb Ave, Brooklyn, NY 11201 USA.
EM Yoonsun.mo@liu.edu
CR Campbell L, 2011, RHEUMATOLOGY, V50, P552, DOI 10.1093/rheumatology/keq343
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Della-Torre E, 2020, ANN RHEUM DIS, V79, P1277, DOI [10.1136/annrheumdis-2020-218122, 10.1136/annrheumdis-2020-218759, 10.1136/annrheumdis-2020-218724]
   Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1
   Galvan-Roman Jose Maria, 2020, J Allergy Clin Immunol, DOI 10.1016/j.jaci.2020.09.018
   Genentech USA Inc, 2020, PRESCRIBING INFORM
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Hermine O, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.6820
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jones G, 2010, CLIN MED INSIGHTS-AR, V3, P81, DOI 10.4137/CMAMD.S4864
   Kewan Tariq, 2020, EClinicalMedicine, V24, P100418, DOI 10.1016/j.eclinm.2020.100418
   Klopfenstein T, 2020, MED MALADIES INFECT, V50, P397, DOI 10.1016/j.medmal.2020.05.001
   Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538
   Narain Sonali, 2020, Chest, DOI 10.1016/j.chest.2020.09.275
   Petrak Russell M, 2020, Clin Transl Sci, DOI 10.1111/cts.12894
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Salvarani C, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.6615
   Somers Emily C, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa954
   Stone JH, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2028836, DOI 10.1056/NEJM0A2028836]
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
NR 22
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0091-2700
EI 1552-4604
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
DI 10.1002/jcph.1787
EA NOV 2020
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ1EI
UT WOS:000594677600001
PM 33180360
OA Bronze
DA 2021-01-01
ER

PT J
AU Fung, M
   Nambiar, A
   Pandey, S
   Aldrich, JM
   Teraoka, J
   Freise, C
   Roberts, J
   Chandran, S
   Hays, SR
   Bainbridge, E
   DeVoe, C
   Gardner, AR
   Yokoe, D
   Henrich, TJ
   Babik, JM
   Chin-Hong, P
AF Fung, Monica
   Nambiar, Ashok
   Pandey, Suchi
   Aldrich, J. Matthew
   Teraoka, Justin
   Freise, Christopher
   Roberts, John
   Chandran, Sindhu
   Hays, Steven R.
   Bainbridge, Emma
   DeVoe, Catherine
   Roque Gardner, Annelys
   Yokoe, Deborah
   Henrich, Timothy J.
   Babik, Jennifer M.
   Chin-Hong, Peter
TI Treatment of immunocompromised COVID-19 patients with convalescent
   plasma
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article; Early Access
DE convalescent plasma; COVID&#8208; 19; immunocompromised; transplant
ID MORTALITY
AB Immunosuppressed patients such as solid organ transplant and hematologic malignancy patients appear to be at increased risk for morbidity and mortality due to coronavirus disease 2019 (COVID-19) caused by SARS coronavirus 2 (SARS-CoV-2). Convalescent plasma, a method of passive immunization that has been applied to prior viral pandemics, holds promise as a potential treatment for COVID-19. Immunocompromised patients may experience more benefit from convalescent plasma given underlying deficits in B and T cell immunity as well as contraindications to antiviral and immunomodulatory therapy. We describe our institutional experience with four immunosuppressed patients (two kidney transplant recipients, one lung transplant recipient, and one chronic myelogenous leukemia patient) treated with COVID-19 convalescent plasma through the Expanded Access Program (NCT 04338360). All patients clinically improved after administration (two fully recovered and two discharged to skilled nursing facilities) and none experienced a transfusion reaction. We also report the characteristics of convalescent plasma product from a local blood center including positive SARS-CoV-2 IgG and negative SARS-CoV-2 PCR in all samples tested. This preliminary evidence suggest that convalescent plasma may be safe among immunosuppressed patients with COVID-19 and emphasizes the need for further data on the efficacy of convalescent plasma as either primary or adjunctive therapy for COVID-19.
C1 [Fung, Monica; Teraoka, Justin; Bainbridge, Emma; DeVoe, Catherine; Roque Gardner, Annelys; Yokoe, Deborah; Henrich, Timothy J.; Babik, Jennifer M.; Chin-Hong, Peter] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA.
   [Nambiar, Ashok] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Pandey, Suchi] Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA.
   [Aldrich, J. Matthew] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA.
   [Freise, Christopher] Univ Calif San Francisco, Dept Surg, Div Transplant Surg, San Francisco, CA 94143 USA.
   [Chandran, Sindhu] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA.
   [Hays, Steven R.] Univ Calif San Francisco, Dept Med, Div Pulm Crit Care Allergy & Sleep Med, San Francisco, CA 94143 USA.
RP Fung, M (corresponding author), Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA.
EM monica.fung@ucsf.edu
OI Chandran, Sindhu/0000-0003-4547-3381
FU US Department of Health and Human Services (HHS), Biomedical Advanced
   Research and Development Authority (BARDA) [75A50120C00096]
FX This study was supported in part by a US Department of Health and Human
   Services (HHS), Biomedical Advanced Research and Development Authority
   (BARDA) contract 75A50120C00096 (MJ Joyner, PI).
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Centers for Disease Control and Prevention (CDC), REAL TIM RT PCR PAN
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fishman JA, 2017, AM J TRANSPLANT, V17, P856, DOI 10.1111/ajt.14208
   Fung M, 2020, AM J TRANSPLANT, V20, P3225, DOI 10.1111/ajt.16079
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028
   Kong YJ, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102820
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   MAHASE E, 2020, BMJ-BRIT MED J, V370, DOI DOI 10.1136/BMJ.M3327
   Montagud-Marrahi E, 2020, AM J TRANSPLANT, V20, P2958, DOI 10.1111/ajt.15970
   Naeem S, 2020, TRANSPL INFECT DIS, DOI 10.1111/tid.13451
   Nair V, 2020, AM J TRANSPLANT, V20, P1819, DOI 10.1111/ajt.15967
   PALADINO AJ, 2020, CANCER EPIDEM BIO S1, V29
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Salazar E, 2020, AM J PATHOL, V190, P1680, DOI 10.1016/j.ajpath.2020.05.014
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Webb GJ, 2020, LANCET GASTROENTEROL, V5, P643, DOI 10.1016/S2468-1253(20)30125-4
   World Health Organization, 2019, WHO STAT REG CLUST P
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
NR 33
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13477
DI 10.1111/tid.13477
EA NOV 2020
PG 7
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA OX6IA
UT WOS:000593664600001
PM 32989856
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Trujillo, H
   Fernandez-Ruiz, M
   Gutierrez, E
   Sevillano, A
   Caravaca-Fontan, F
   Morales, E
   Lopez-Medrano, F
   Aguado, JM
   Praga, M
   Andres, A
AF Trujillo, Hernando
   Fernandez-Ruiz, Mario
   Gutierrez, Eduardo
   Sevillano, Angel
   Caravaca-Fontan, Fernando
   Morales, Enrique
   Lopez-Medrano, Francisco
   Maria Aguado, Jose
   Praga, Manuel
   Andres, Amado
TI Invasive pulmonary aspergillosis associated with COVID-19 in a kidney
   transplant recipient
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article; Early Access
DE coronavirus disease 2019; invasive pulmonary aspergillosis; kidney
   transplantation; severe acute respiratory syndrome coronavirus 2; solid
   organ transplantation
ID RISK-FACTORS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might increase the risk of invasive pulmonary aspergillosis (IPA). Although several case reports and small series have been reported in the general population, scarce information is available regarding coronavirus disease 2019 (COVID-19)-associated IPA in the setting of solid organ transplantation. We describe a case of a kidney transplant recipient with severe COVID-19 that was subsequently diagnosed with probable IPA on the basis of the repeated isolation of Aspergillus fumigatus in sputum cultures, repeatedly increased serum (1 -> 3)-beta-d-glucan levels, and enlarging cavitary nodules in the CT scan. The evolution was favorable after initiation of isavuconazole and nebulized liposomal amphotericin B combination therapy and the withdrawal of immunosuppression.
C1 [Trujillo, Hernando; Gutierrez, Eduardo; Sevillano, Angel; Caravaca-Fontan, Fernando; Morales, Enrique; Praga, Manuel; Andres, Amado] Univ Hosp 12 Octubre, Dept Nephrol, Ave Cordoba S-N, Madrid 28041, Spain.
   [Fernandez-Ruiz, Mario; Caravaca-Fontan, Fernando; Lopez-Medrano, Francisco; Maria Aguado, Jose; Praga, Manuel] Res Inst Hosp 12 Octubre Imas12, Madrid, Spain.
   [Fernandez-Ruiz, Mario; Lopez-Medrano, Francisco; Maria Aguado, Jose] Univ Hosp 12 Octubre, Unit Infect Dis, Madrid, Spain.
   [Lopez-Medrano, Francisco; Maria Aguado, Jose; Andres, Amado] Univ Complutense, Dept Med, Madrid, Spain.
RP Gutierrez, E (corresponding author), Univ Hosp 12 Octubre, Dept Nephrol, Ave Cordoba S-N, Madrid 28041, Spain.
EM eduardogutmat90@gmail.com
OI Aguado, Jose Maria/0000-0002-9520-8255; Lopez-Medrano,
   Francisco/0000-0001-5333-7529; Fernandez-Ruiz,
   Mario/0000-0002-0315-8001; Morales, Enrique/0000-0002-5824-6973;
   Trujillo, Hernando/0000-0002-3520-1422
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos III [COV20/00181,
   CP18/00073]
FX Instituto de Salud Carlos III, Grant/Award Number: COV20/00181 and
   CP18/00073
CR Alanio A, 2020, LANCET RESP MED, V8, pE48, DOI 10.1016/S2213-2600(20)30237-X
   Alastruey-Izquierdo A, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00358-18, 10.1128/aac.00358-18]
   Arastehfar A, 2020, J FUNGI, V6, DOI 10.3390/jof6020091
   Bougnoux ME, 2020, CLIN MICROBIOL INFEC, V26, P1101, DOI 10.1016/j.cmi.2020.02.036
   Donnelly JP, 2020, CLIN INFECT DIS, V71, P1367, DOI 10.1093/cid/ciz1008
   Fernandez-Ruiz M, 2020, J MED VIROL, DOI 10.1002/jmv.26308
   Friedrich R, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/JCM.00464-18, 10.1128/jcm.00464-18]
   Gangneux JP, 2020, J MYCOL MED, V30, DOI 10.1016/j.mycmed.2020.100971
   Gavalda J, 2005, CLIN INFECT DIS, V41, P52, DOI 10.1086/430602
   Hughes S, 2020, CLIN MICROBIOL INFEC, V26, P1395, DOI 10.1016/j.cmi.2020.06.025
   Kates Olivia S, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1097
   Koehler P, 2020, MYCOSES, V63, P528, DOI 10.1111/myc.13096
   Lopez-Medrano F, 2016, AM J TRANSPLANT, V16, P3220, DOI 10.1111/ajt.13837
   Lopez-Medrano F, 2016, AM J TRANSPLANT, V16, P2148, DOI 10.1111/ajt.13735
   Munoz P, 2014, J HEART LUNG TRANSPL, V33, P1034, DOI 10.1016/j.healun.2014.05.003
   Rutsaert L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00686-4
   Sharma Aditi, 2020, Chest, V158, P1857, DOI 10.1016/j.chest.2020.06.010
   Valentin MO, 2016, TRANSPL P, V48, P2871, DOI 10.1016/j.transproceed.2016.09.024
   van Arkel ALE, 2020, AM J RESP CRIT CARE, V202, P132, DOI 10.1164/rccm.202004-1038LE
   Venanzi E, 2019, MYCOPATHOLOGIA, V184, P239, DOI 10.1007/s11046-019-00331-0
   Verweij PE, 2020, INTENS CARE MED, V46, P1524, DOI 10.1007/s00134-020-06091-6
   Winthrop KL, 2018, CLIN MICROBIOL INFEC, V24, pS21, DOI 10.1016/j.cmi.2018.02.002
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zhang GQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104364
   Zhou PC, 2020, INFECT CONT HOSP EP, V41, P1124, DOI 10.1017/ice.2020.156
NR 25
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13501
DI 10.1111/tid.13501
EA NOV 2020
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA OX6IN
UT WOS:000593665900001
PM 33185971
OA Bronze
DA 2021-01-01
ER

PT J
AU Lee, H
   Tay, J
   Duggan, P
   McCulloch, S
   Neri, P
   Bahlis, NJ
   Jimenez-Zepeda, VH
AF Lee, Holly
   Tay, Jason
   Duggan, Peter
   McCulloch, Sylvia
   Neri, Paola
   Bahlis, Nizar J.
   Jimenez-Zepeda, Victor H.
TI The impact of COVID-19 in the management of AL amyloidosis and
   Immunoglobulin Deposition Disease: A single-center experience
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article; Early Access
DE AL amyloidosis; COVID&#8208; 19; immunoglobulin deposition disease;
   plasma cell disorder
ID CLINICAL CHARACTERISTICS; RISK-FACTORS; CANCER; IMMUNOPARESIS;
   MULTICENTER; DIAGNOSIS; OUTCOMES; CHINA
AB Introduction Patients with AL amyloidosis and immunoglobulin deposition diseases (IDD) are vulnerable during the COVID-19 pandemic due to the immune compromise from the plasma cell disorder and therapy-related immune defects. We describe a local experience in providing care for patients with AL amyloidosis and IDD.
   Method Patient treatment and disease status since the beginning of the pandemic on March 11, 2020, as declared by WHO, were collected and analyzed.
   Results Ninety-six patients with AL amyloidosis and IDD were included. Four patients with IDD and 22 patients with systemic AL amyloidosis were receiving treatment during the pandemic. Since the pandemic, patients' treatments were discontinued if they achieved VGPR or better postinduction. Seven patients discontinued all treatment after achieving VGPR, and others required treatment modifications. 28 patients have been tested for COVID-19, and all tests have been negative. Three patients died since the pandemic, two from organ complications of systemic AL amyloidosis and one from an unrelated cause.
   Conclusion The management of AL amyloidosis and IDD must be individualized on the clinical characteristics, centers' access to care under the pandemic restrictions, and the epidemiological aspects of the outbreak.
C1 [Lee, Holly; Tay, Jason; Duggan, Peter; McCulloch, Sylvia; Neri, Paola; Bahlis, Nizar J.; Jimenez-Zepeda, Victor H.] Tom Baker Canc Clin, Dept Med Oncol & Hematol, 1331 29th St,NW, Calgary, AB T2N 4N2, Canada.
   [Tay, Jason; Neri, Paola; Bahlis, Nizar J.; Jimenez-Zepeda, Victor H.] Charbonneau Canc Res Inst, Calgary, AB, Canada.
RP Jimenez-Zepeda, VH (corresponding author), Tom Baker Canc Clin, Dept Med Oncol & Hematol, 1331 29th St,NW, Calgary, AB T2N 4N2, Canada.
EM Victor.Zepeda@albertahealthservices.ca
CR Al Saleh AS, 2020, ACTA HAEMATOL-BASEL, V143, P410, DOI [10.1159/000507690, 10.1007/978-3-030-44584-3_1]
   Alberta Go, 2020, COVID 19 AL STAT
   Alberta Go, 2020, POP STAT
   Alberta Go, 2020, SYMPT TEST
   Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Canada Go, 2020, COR DIS COVID 10 OUT
   Dhakal B, 2020, LEUKEMIA, V34, P1961, DOI 10.1038/s41375-020-0879-9
   Diaz-Pallares C, 2020, CL LYMPH MYELOM LEUK, V20, P394, DOI 10.1016/j.clml.2019.11.005
   Dietz JR, 2020, BREAST CANCER RES TR, V181, P487, DOI 10.1007/s10549-020-05644-z
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Rodriguez-Lobato LG, 2017, AMYLOID, V24, P245, DOI 10.1080/13506129.2017.1390451
   Gertz MA, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0080-9
   Giannakoulis VG, 2020, JCO GLOB ONCOL, V6, P799, DOI 10.1200/GO.20.00225
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Kastritis E, 2020, BRIT J HAEMATOL, V190, P346, DOI 10.1111/bjh.16898
   Kristinsson SY, 2012, HAEMATOL-HEMATOL J, V97, P854, DOI 10.3324/haematol.2011.054015
   Larochelle MR, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2013413
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lousada I, 2015, ADV THER, V32, P920, DOI 10.1007/s12325-015-0250-0
   Merlini G, 2017, HEMATOL-AM SOC HEMAT, P1, DOI 10.1182/asheducation-2017.1.1
   Molica M, 2020, BRIT J HAEMATOL, V190, pE5, DOI 10.1111/bjh.16785
   Muchtar E, 2017, AMYLOID, V24, P40, DOI 10.1080/13506129.2016.1277696
   Roustit M, 2020, THERAPIE, V75, P363, DOI 10.1016/j.therap.2020.05.010
   Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0
   World Health Organization, 2020, WHO COR DIS COVID 19
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
NR 26
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-4441
EI 1600-0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
DI 10.1111/ejh.13552
EA NOV 2020
PG 6
WC Hematology
SC Hematology
GA OY2HT
UT WOS:000594072900001
PM 33197297
OA Bronze
DA 2021-01-01
ER

PT J
AU Postiglione, E
   Pizza, F
   Ingravallo, F
   Vignatelli, L
   Filardi, M
   Mangiaruga, A
   Antelmi, E
   Moresco, M
   Oriolo, C
   Pagotto, U
   Plazzi, G
AF Postiglione, Emanuela
   Pizza, Fabio
   Ingravallo, Francesca
   Vignatelli, Luca
   Filardi, Marco
   Mangiaruga, Anastasia
   Antelmi, Elena
   Moresco, Monica
   Oriolo, Claudia
   Pagotto, Uberto
   Plazzi, Giuseppe
TI Impact of COVID-19 pandemic lockdown on narcolepsy type 1 management
SO BRAIN AND BEHAVIOR
LA English
DT Article; Early Access
DE behavioral therapy; COVID&#8208; 19; lockdown; narcolepsy type 1; smart
   working
ID SLEEPINESS; BURDEN
AB Study Objectives Narcolepsy type 1 (NT1) is a chronic rare hypersomnia of central origin requiring a combination of behavioral and pharmacological treatments. During the coronavirus disease 2019 (COVID-19) pandemic, in Italy the population was forced into a lockdown. With this study, we aimed to describe the lockdown impact on NT1 symptom management, according to different patients' working schedule.
   Methods In the period between 10 April and 15 May 2020, we performed routine follow-up visits by telephone (as recommended during the COVID-19 emergency) to 50 patients >18 years old (40% males) under stable long-term treatment. We divided patients into three groups: unchanged working schedule, forced working/studying at home, and those who lost their job ("lost occupation"). Current sleep-wake habit and symptom severity were compared with prelockdown assessment (six months before) in the three patient groups.
   Results At assessment, 20, 22, and eight patients belonged to the unchanged, working/studying at home, and lost occupation groups, respectively. While in the lost occupation group, there were no significant differences compared with prepandemic assessment, the patients with unchanged schedules reported more nocturnal awakenings, and NT1 patients working/studying at home showed an extension of nocturnal sleep time, more frequent daytime napping, improvement of daytime sleepiness, and a significant increase in their body mass index. Sleep-related paralysis/hallucinations, automatic behaviors, cataplexy, and disturbed nocturnal sleep did not differ.
   Conclusions Narcolepsy type 1 patients working/studying at home intensified behavioral interventions (increased nocturnal sleep time and daytime napping) and ameliorated daytime sleepiness despite presenting with a slight, but significant, increase of weight.
C1 [Postiglione, Emanuela; Pizza, Fabio; Filardi, Marco] Univ Bologna, Dept Biomed & Neuromotor Sci DIBINEM, Bologna, Italy.
   [Pizza, Fabio; Vignatelli, Luca; Moresco, Monica; Plazzi, Giuseppe] IRCCS Ist Sci Neurol Bologna, Bologna, Italy.
   [Ingravallo, Francesca; Mangiaruga, Anastasia] Univ Bologna, Dept Med & Surg Sci DIMEC, Bologna, Italy.
   [Antelmi, Elena] Univ Verona, Dept Neurosci Biomed & Movement Sci, Movement Disorders Div, Neurol Unit, Verona, Italy.
   [Oriolo, Claudia; Pagotto, Uberto] Univ Bologna, Dept Med & Surg Sci DIMEC, Endocrinol & Diabet Prevent & Care Unit, S Orsola Policlin, Bologna, Italy.
   [Plazzi, Giuseppe] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Modena, Italy.
RP Plazzi, G (corresponding author), Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Osped Bellaria, Padigl G,Via Altura 3, I-40139 Bologna, Italy.
EM giuseppe.plazzi@unibo.it
RI ; Vignatelli, Luca/J-4273-2016
OI Filardi, Marco/0000-0001-9702-8314; INGRAVALLO,
   FRANCESCA/0000-0002-5194-375X; Vignatelli, Luca/0000-0002-9051-7091
CR Altena E, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13052
   American Academy of Sleep Medicine, 2014, INT CLASSIFICATION S
   Bassetti CLA, 2019, NAT REV NEUROL, V15, P519, DOI 10.1038/s41582-019-0226-9
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Cellini N, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13074
   Filardi M, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00707
   Franceschini C, 2020, SLEEP BREATH, V24, P615, DOI 10.1007/s11325-019-01894-4
   Ingravallo F, 2012, SLEEP MED, V13, P1293, DOI 10.1016/j.sleep.2012.08.002
   Kaparounaki CK, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113111
   Krahn LE, 2015, J CLIN SLEEP MED, V11, P335, DOI 10.5664/jcsm.4554
   Li CY, 2020, INFECTION, V48, P483, DOI 10.1007/s15010-020-01420-9
   Maski K, 2020, SLEEP, V43, DOI 10.1093/sleep/zsaa066
   Maski K, 2017, J CLIN SLEEP MED, V13, P419, DOI 10.5664/jcsm.6494
   Raggi A, 2019, J NERV MENT DIS, V207, P84, DOI 10.1097/NMD.0000000000000918
   Rogers AE, 2001, SLEEP, V24, P385, DOI 10.1093/sleep/24.4.385
   Roth T, 2013, J CLIN SLEEP MED, V9, P955, DOI 10.5664/jcsm.3004
   Vignatelli L, 2003, NEUROL SCI, V23, P295, DOI 10.1007/s100720300004
NR 17
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2162-3279
J9 BRAIN BEHAV
JI Brain Behav.
AR e01955
DI 10.1002/brb3.1955
EA NOV 2020
PG 8
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA OW7BN
UT WOS:000593037500001
PM 33247632
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Barrett, JS
AF Barrett, Jeffrey S.
TI Risk assessment of therapeutic agents under consideration to treat
   COVID-19 in paediatric patients and pregnant women
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Early Access
DE Clinical pharmacology; Infectious diseases; Paediatrics
ID RIBAVIRIN TREATMENT; INTERFERON-ALPHA; CHILDREN; RITONAVIR; INFANTS;
   SAFETY; LOPINAVIR/RITONAVIR; HYDROXYCHLOROQUINE; AZITHROMYCIN;
   LEFLUNOMIDE
AB Aim Repurposing strategies to address the COVID-19 pandemic have been accelerated. As both pregnant and paediatric patients are likely to be excluded from most planned investigations, the list of repurposed options and the available data on these drugs and vaccines provide a baseline risk assessment and identify gaps for targeted investigation.
   Methods Clinical trials have been searched and reviewed; 23 repurposed drugs and drug combinations and nine candidate vaccines have been assessed regarding the availability of relevant data in paediatrics and pregnant women and to evaluate expected or unanticipated risk.
   Results Thirteen of the repurposed drugs or drug combinations are indicated for use in paediatrics in some age category albeit for indications other than COVID-19; 10 of these are indicated for use in pregnant women. Even in cases where these drugs are indicated in the populations, source data from which safety and or dosing could be extrapolated for use in COVID-19 is sparse. Vaccine trials are ongoing and generally exclude pregnant women; only in a few instances have paediatric subgroups been planned for enrolment. Data from individual case studies and RWD may suggest that subpopulations of both paediatric patients and pregnant women may be more at risk, particularly those in an increased inflammatory state.
   Conclusion In conjunction with more prospective collaboration, plans are evolving to ensure that we will be better prepared to address similar situations especially in paediatrics and pregnant women where experience is limited and actual practice relies heavily on leveraging data from other populations and indications.
C1 [Barrett, Jeffrey S.] Crit Path Inst, 1730 East River Rd, Tucson, AZ 85718 USA.
RP Barrett, JS (corresponding author), Crit Path Inst, 1730 East River Rd, Tucson, AZ 85718 USA.
EM jbarrett@c-path.org
CR Amadi B, 2002, LANCET, V360, P1375, DOI 10.1016/S0140-6736(02)11401-2
   [Anonymous], 2019, GUID IND PED INF INC
   [Anonymous], 2014, GUID IND GEN CLIN PH
   [Anonymous], 2005, DRAFT GUID IND COMPL
   [Anonymous], 2019, GUID IND POST PREGN
   Aronson JK, 2016, MEYLERS SIDE EFFECTS, P714
   Asami T, 2004, PEDIATR NEPHROL, V19, P313, DOI 10.1007/s00467-003-1377-9
   Barrett JS, 2018, CLIN PHARMACOL THER, V103, P419, DOI 10.1002/cpt.1000
   Bi QF, 2020, LANCET INFECT DIS, V20, P911, DOI 10.1016/S1473-3099(20)30287-5
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Boissy A, 2020, NEJM CATAL INNOVAT C, V1, P1
   Bouazza N, 2015, LANCET, V385, P603, DOI 10.1016/S0140-6736(15)60232-X
   Callaway E, 2020, NATURE, V581, P363, DOI 10.1038/d41586-020-01092-3
   Chambers CD, 2010, ARTHRITIS RHEUM-US, V62, P1494, DOI 10.1002/art.27358
   Chandwani Ashish, 2008, Ther Clin Risk Manag, V4, P1023
   Check Hayden E, 2011, NATURE
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coutre L, 2020, CLEVELAND CLIN EPIC
   Cristiani L, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00749-2020
   Dhama K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01803
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756
   EMA (European Medicines Agency), 2018, REFL PAP US EXTR DEV
   Equi A, 2002, LANCET, V360, P978, DOI 10.1016/S0140-6736(02)11081-6
   Faucette AN, 2015, HUM VACC IMMUNOTHER, V11, P2549, DOI 10.1080/21645515.2015.1070984
   Feghali M, 2015, SEMIN PERINATOL, V39, P512, DOI 10.1053/j.semperi.2015.08.003
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   GIARDINA ACV, 1975, CIRCULATION, V51, P713, DOI 10.1161/01.CIR.51.4.713
   Gomes MF, 2017, REPROD HLTH, V14, P47, DOI DOI 10.1186/S12978-017-0430-2
   GROOTHUIS JR, 1990, J PEDIATR-US, V117, P792, DOI 10.1016/S0022-3476(05)83347-5
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Habal FM, 2012, ALIMENT PHARM THER, V35, P501, DOI 10.1111/j.1365-2036.2011.04967.x
   HALL CB, 1993, PEDIATRICS, V92, P501
   Hara Tomomi, 2015, Case Rep Obstet Gynecol, V2015, P469527, DOI 10.1155/2015/469527
   Hasan A, 2020, CUREUS, V12, DOI 10.7759/cureus.7485
   Hoeltzenbein M, 2016, SEMIN ARTHRITIS RHEU, V46, P238, DOI 10.1016/j.semarthrit.2016.05.004
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Institute of Medicine, 2012, ADVERSE EFFECTS VACC
   Izmirly PM, 2012, CIRCULATION, V126, P76, DOI 10.1161/CIRCULATIONAHA.111.089268
   Jacobson GF, 2001, AM J OBSTET GYNECOL, V184, P1352, DOI 10.1067/mob.2001.115050
   Kimball A, 2020, MMWR-MORBID MORTAL W, V69, P377, DOI 10.15585/mmwr.mm6913e1
   Krogstad P, 2002, CLIN INFECT DIS, V34, P991, DOI 10.1086/338814
   LAAKSONEN AL, 1974, SCAND J RHEUMATOL, V3, P103, DOI 10.3109/03009747409115809
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   McGready R, 2012, LANCET INFECT DIS, V12, P388, DOI 10.1016/S1473-3099(11)70339-5
   Nagata T, 2015, DISASTER MED PUBLIC, V9, P79, DOI 10.1017/dmp.2014.151
   Neely Michael, 2009, Ther Clin Risk Manag, V5, P595
   NMPA (National Medical Products Administration), 2017, TECHN GUID POP EXTR
   OKITA GT, 1956, CIRC RES, V4, P376, DOI 10.1161/01.RES.4.4.376
   Paller AS, 2020, J AM ACAD DERMATOL, V82, P389, DOI 10.1016/j.jaad.2019.08.019
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   Park YJ, 2020, EMERG INFECT DIS, V26, P2465, DOI 10.3201/eid2610.201315
   Richard-Lenoble D, 2003, FUND CLIN PHARMACOL, V17, P199, DOI 10.1046/j.1472-8206.2003.00170.x
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roberts SS, 2009, JAIDS-J ACQ IMM DEF, V51, P456, DOI 10.1097/QAI.0b013e3181a2813f
   Rudin C, 2008, PEDIATR INFECT DIS J, V27, P431, DOI 10.1097/INF.0b013e3181646d5a
   Saez-de-Ocariz MD, 2002, CLIN EXP DERMATOL, V27, P264, DOI 10.1046/j.1365-2230.2002.01050.x
   Saji H, 2001, LANCET, V357, P363, DOI 10.1016/S0140-6736(00)03648-5
   Schlossberg D, 2017, ANTIBIOTICS MANUAL G, P432
   Seror J, 2009, FETAL DIAGN THER, V25, P136, DOI 10.1159/000207555
   Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948
   Shiau S, 2014, EXPERT REV ANTI-INFE, V12, P307, DOI 10.1586/14787210.2014.888311
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   SIEMIENIUK RAC, 2017, BMJ-BRIT MED J, V358, DOI DOI 10.1136/BMJ.J3961
   Simon A, 2011, JAMA-J AM MED ASSOC, V306, P70, DOI 10.1001/jama.2011.915
   Singh AK, 2020, DIABETES METAB SYND, V14, P641, DOI 10.1016/j.dsx.2020.05.018
   Smith ER, 2005, J EMERG MED, V28, P437, DOI 10.1016/j.jemermed.2004.12.011
   Smith Rebecca L, 2016, JAAD Case Rep, V2, P89, DOI 10.1016/j.jdcr.2015.12.005
   Sokal EM, 1998, GASTROENTEROLOGY, V114, P988, DOI 10.1016/S0016-5085(98)70318-X
   Soma-Pillay P, 2016, CARDIOVASC J AFR, V27, P89, DOI 10.5830/CVJA-2016-021
   Svenningsen P, 2015, PFLUG ARCH EUR J PHY, V467, P531, DOI 10.1007/s00424-014-1661-5
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Vivanti AJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17436-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Webb NJA, 2010, CLIN J AM SOC NEPHRO, V5, P417, DOI 10.2215/CJN.06620909
   Wilson KC, COVID 19 INTERIM GUI
   Wirth S, 2005, HEPATOLOGY, V41, P1013, DOI 10.1002/hep.20661
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu KH, 2014, PEDIATR INFECT DIS J, V33, P1193, DOI 10.1097/INF.0000000000000407
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yokota S, 2005, CLIN REV ALLERG IMMU, V28, P231, DOI 10.1385/CRIAI:28:3:231
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
   Zorrilla CD, 2014, HIV MED, V15, P50, DOI 10.1111/hiv.12047
   이상택, 2014, Childhood Kidney diseases, V18, P98
NR 90
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
DI 10.1111/bcp.14630
EA NOV 2020
PG 19
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OW8DC
UT WOS:000593109200001
PM 33125791
OA Bronze
DA 2021-01-01
ER

PT J
AU Gasparino, RC
   Lima, MHM
   Oliveira-Kumakura, ARD
   da Silva, VA
   Meszaros, MD
   Antunes, IR
AF Gasparino, Renata Cristina
   Lima, Maria Helena Melo
   de Souza Oliveira-Kumakura, Ana Railka
   da Silva, Vanessa Abreu
   de Jesus Meszaros, Mariana
   Antunes, Ivan Rogerio
TI Prophylactic dressings in the prevention of pressure ulcer related to
   the use of personal protective equipment by health professionals facing
   the COVID-19 pandemic: A randomized clinical trial
SO WOUND REPAIR AND REGENERATION
LA English
DT Article; Early Access
ID INJURIES; MASKS
AB Device-related pressure injury (DRPI) is a serious problem that is affecting professionals working on the front lines against COVID-19 due to the prolonged use of personal protective equipment (PPE). In addition to the physical and psychological integrity of professionals, these injuries can compromise the quality of care. Therefore, using technologies to prevent this adverse effect is an urgent matter. This is a parallel two-arm randomized clinical trial without the use of a control group to compare the use of foam and extra-thin hydrocolloid in preventing DRPI associated with the use of PPE by health professionals working on the front lines against coronavirus. In total, 88 professionals were divided into two groups: foam and hydrocolloid. Data were collected using two instruments and related to demographic and professional characteristics and skin evaluation. Each volunteer received one of the dressings, both with the same dimensions and arranged over similar regions, and data were gathered at baseline and after 6 or 12 hours. Descriptive and inferential analytic statistical methods were used; the significance level adopted was 5%. No participant developed DRPI, but four areas with hyperemia were observed in the foam group (two in the forehead, one in the cheeks, and one in the nose bridge), as well as four areas with hyperemia in the hydrocolloid group (two in the nose bridge, one in the right ear, and one in the left ear). There was no difference between the groups regarding skin conditions and discomfort (P > .05). The average cost obtained was $ 5.8/person and $ 4.4/person in the foam group and the hydrocolloid group, respectively, considering the dressing measurements. The results show that foam and extra-thin hydrocolloid were effective in preventing DRPI associated with the use of PPE.
C1 [Gasparino, Renata Cristina; Lima, Maria Helena Melo; de Souza Oliveira-Kumakura, Ana Railka] Univ Estadual Campinas, Sch Nursing, Rua Tessalia Vieira Camargo,126,Cidade Univ, BR-13083887 Campinas, SP, Brazil.
   [da Silva, Vanessa Abreu; de Jesus Meszaros, Mariana; Antunes, Ivan Rogerio] Univ Estadual Campinas, Univ Hosp, Campinas, SP, Brazil.
RP Gasparino, RC (corresponding author), Univ Estadual Campinas, Sch Nursing, Rua Tessalia Vieira Camargo,126,Cidade Univ, BR-13083887 Campinas, SP, Brazil.
EM grenata@unicamp.br
RI Gasparino, Renata/I-6930-2018
OI Gasparino, Renata/0000-0001-8729-4707
FU University of Campinas Research Fund - Faepex [2374/20]
FX This study was supported by grants from the University of Campinas
   Research Fund - Faepex (Grant No. 2374/20).
CR Alves P, 2020, PRPPE COVID 19 UPDAT
   Black JM, 2016, CHRONIC WOUND CARE M, V3, P91, DOI 10.2147/CWCMR.S82370
   Black JM, 2010, INT WOUND J, V7, P358, DOI 10.1111/j.1742-481X.2010.00699.x
   Center for Disease Control and Prevention, 2018, FILT OUT CONF FREQ A
   Clark M, 2014, INT WOUND J, V11, P460, DOI 10.1111/iwj.12212
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Galetto SGD, 2019, REV BRAS ENFERM, V72, P505, DOI 10.1590/0034-7167-2018-0530
   Ferreira RM, 2020, MAR DRUGS, V18
   Field MH, 2020, ANN ROY COLL SURG, V102, P394, DOI 10.1308/rcsann.2020.0095
   Gefen A, 2020, J WOUND CARE, V29, P245, DOI 10.12968/jowc.2020.29.5.245
   Hintze J, 2014, PASS 13
   Huang TT, 2009, J ORAL MAXIL SURG, V67, P543, DOI 10.1016/j.joms.2008.06.100
   Jackson D, 2019, INT J NURS STUD, V92, P109, DOI 10.1016/j.ijnurstu.2019.02.006
   Jackson ME, 2012, RESP CARE, V57, P311, DOI 10.4187/respcare.01235
   Jiang QX, 2020, ADV WOUND CARE, V9, P357, DOI 10.1089/wound.2020.1212
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Lam UM, 2020, INT WOUND J, V5, P1
   Lemyze M, 2013, CRIT CARE MED, V41, P481, DOI 10.1097/CCM.0b013e31826ab4af
   Mills J, 2020, MED LEFT SORE MARKS
   Miske LJ, 2017, CRIT CARE NURS CLIN, V29, P187, DOI 10.1016/j.cnc.2017.01.006
   National Pressure Injury Advisory Panel, 2020, NPIAP POS STAT PREV
   National Pressure Ulcer Advisory Panel, 2016, NPUAP IMM REL CHANG
   Phan LT, 2019, J OCCUP ENVIRON HYG, V16, P575, DOI 10.1080/15459624.2019.1628350
   Ramalho AO, 2020, SKIN INJURIES RELATE
   Ramundo J, 2018, J WOUND OSTOMY CONT, V45, P75, DOI 10.1097/WON.0000000000000400
   Schulz KF, 2011, INT J SURG, V9, P672, DOI [10.1016/j.ijsu.2011.09.004, 10.1016/j.jclinepi.2010.02.005]
   Weng Min-Hsueh, 2008, Intensive Crit Care Nurs, V24, P295, DOI 10.1016/j.iccn.2007.11.005
   World Health Organization, RAT US PERS PROT EQ
   World Health Organization (WHO), 2020, COVID 19 STRAT UPD
NR 29
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1067-1927
EI 1524-475X
J9 WOUND REPAIR REGEN
JI Wound Repair Regen.
DI 10.1111/wrr.12877
EA NOV 2020
PG 6
WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery
SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery
GA OW8FF
UT WOS:000593114700001
PM 33215768
OA Bronze
DA 2021-01-01
ER

PT J
AU Luther, T
   Bulow-Anderberg, S
   Larsson, A
   Rubertsson, S
   Lipcsey, M
   Frithiof, R
   Hultstrom, M
AF Luther, Tomas
   Bulow-Anderberg, Sara
   Larsson, Anders
   Rubertsson, Sten
   Lipcsey, Miklos
   Frithiof, Robert
   Hultstrom, Michael
TI COVID-19 patients in intensive care develop predominantly oliguric acute
   kidney injury
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article; Early Access
DE acute kidney injury; biomarkers; COVID&#8208; 19; intensive care
ID AKI
AB Background Acute kidney injury (AKI) is a syndrome of reduced glomerular filtration rate and/or reduced urine flow associated with mortality in corona virus disease 2019 (COVID-19). AKI is often associated with renal tissue damage, which may lead to chronic kidney disease. Biomarkers of tissue damage may identify patients of particular risk.
   Methods In a prospective observational study of 57 patients admitted to intensive care, AKI incidence and characteristics was evaluated according to KDIGO criteria and related to days after admission. Urinary albumin, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule 1 (KIM-1) and Plasma Tissue Inhibitor of MetalloProteinase 2 (TIMP-2) were analysed in 52 patients at admission.
   The majority (n = 51, 89%) of patients developed AKI, and 27 (47%) patients had predominantly oliguric AKI where oliguria was more severe than plasma Creatinine increase. Severe oliguria within first 2 days after admission was common (n = 37, 65%), whereas stage 2 and 3 AKI due to Creatinine occurred later than day 2 in 67% (12/18) of cases. Renal replacement therapy was started in 9 (16%) patients, and 30-day mortality was 28%. Urinary biomarkers were increased in a majority of patients, but did not robustly predict KDIGO stage. Most patients had microalbuminuria, and severe albuminuria (albumin Creatinine ratio > 30 mg/mmol) was found in n = 9 (17%) patients.
   Conclusions A majority of patients with COVID-19 admitted to the ICU develop AKI. The functional deficit is often low urinary volume, and initial levels of biomarkers are generally increased without clear relation to final AKI stage.
C1 [Luther, Tomas; Bulow-Anderberg, Sara; Rubertsson, Sten; Lipcsey, Miklos; Frithiof, Robert; Hultstrom, Michael] Uppsala Univ, Dept Surg Sci Anaesthesiol & Intens Care Med, Uppsala, Sweden.
   [Larsson, Anders] Uppsala Univ, Dept Med Sci, Clin Chem, Uppsala, Sweden.
   [Lipcsey, Miklos] Uppsala Univ, Dept Surg Sci, Hedenstierna Lab, CIRRUS,Anaesthesiol & Intens Care Med, Uppsala, Sweden.
   [Hultstrom, Michael] Uppsala Univ, Dept Med Cell Biol, Integrat Physiol, Uppsala, Sweden.
RP Luther, T (corresponding author), Uppsala Univ, Uppsala Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, SE-75185 Uppsala, Sweden.
EM tomas.luther@surgsci.uu.se
RI ; Lipcsey, Miklos/K-4308-2012
OI Larsson, Anders/0000-0003-3161-0402; Hultstrom,
   Michael/0000-0003-4675-1099; Lipcsey, Miklos/0000-0002-1976-4129
FU Knut och Alice Wallenbergs StiftelseKnut & Alice Wallenberg Foundation;
   Science for Life Laboratory; VetenskapsradetSwedish Research Council
   [2014-02569, 2014-07606]
FX Knut och Alice Wallenbergs Stiftelse; Science for Life Laboratory;
   Vetenskapsradet, Grant/Award Number: 2014-02569 and 2014-07606
CR Bennett M, 2008, CLIN J AM SOC NEPHRO, V3, P665, DOI 10.2215/CJN.04010907
   Bhatraju PK, 2019, AM J RESP CRIT CARE, V199, P863, DOI 10.1164/rccm.201807-1346OC
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Fisher M, 2020, J AM SOC NEPHROL, V31, P2145, DOI 10.1681/ASN.2020040509
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Hultstrom M, 2020, J HYPERTENS, V38, P1613, DOI 10.1097/HJH.0000000000002531
   James MT, 2017, JAMA-J AM MED ASSOC, V318, P1787, DOI 10.1001/jama.2017.16326
   Kellum JA, 2015, J AM SOC NEPHROL, V26, P2231, DOI 10.1681/ASN.2014070724
   Martensson J, 2010, INTENS CARE MED, V36, P1333, DOI 10.1007/s00134-010-1887-4
   Nisula S, 2013, INTENS CARE MED, V39, P420, DOI 10.1007/s00134-012-2796-5
   Ostermann M, 2018, CRIT CARE MED, V46, P375, DOI 10.1097/CCM.0000000000002847
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   Panitchote A, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0552-5
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Ralib AM, 2013, CRIT CARE, V17, DOI 10.1186/cc12784
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2
   Sohrabian A, 2012, CLIN BIOCHEM, V45, P339, DOI 10.1016/j.clinbiochem.2011.12.027
   Tornblom S, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00667-7
   Vaara ST, 2016, KIDNEY INT, V89, P200, DOI [10.1038/ki.2015.269, 10.1016/j.kint.2015.12.007]
   Vincent JL, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02858-x
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Xie YY, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1455-6
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 27
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-5172
EI 1399-6576
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
DI 10.1111/aas.13746
EA NOV 2020
PG 9
WC Anesthesiology
SC Anesthesiology
GA OX1VC
UT WOS:000593360200001
PM 33190222
OA Other Gold
DA 2021-01-01
ER

PT J
AU Nguyen, DD
   Gao, KF
   Chen, JH
   Wang, R
   Wei, GW
AF Nguyen, Duc Duy
   Gao, Kaifu
   Chen, Jiahui
   Wang, Rui
   Wei, Guo-Wei
TI Unveiling the molecular mechanism of SARS-CoV-2 main protease inhibition
   from 137 crystal structures using algebraic topology and deep learning
SO CHEMICAL SCIENCE
LA English
DT Article
ID ANTIVIRAL ACTIVITY; CORONAVIRUS; PREDICTION; DOCKING; DESIGN
AB Currently, there is neither effective antiviral drugs nor vaccine for coronavirus disease 2019 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to its high conservativeness and low similarity with human genes, SARS-CoV-2 main protease (M-pro) is one of the most favorable drug targets. However, the current understanding of the molecular mechanism of M-pro inhibition is limited by the lack of reliable binding affinity ranking and prediction of existing structures of M-pro-inhibitor complexes. This work integrates mathematics (i.e., algebraic topology) and deep learning (MathDL) to provide a reliable ranking of the binding affinities of 137 SARS-CoV-2 M-pro inhibitor structures. We reveal that Gly143 residue in M-pro is the most attractive site to form hydrogen bonds, followed by Glu166, Cys145, and His163. We also identify 71 targeted covalent bonding inhibitors. MathDL was validated on the PDBbind v2016 core set benchmark and a carefully curated SARS-CoV-2 inhibitor dataset to ensure the reliability of the present binding affinity prediction. The present binding affinity ranking, interaction analysis, and fragment decomposition offer a foundation for future drug discovery efforts.
C1 [Nguyen, Duc Duy] Univ Kentucky, Dept Math, Lexington, KY 40506 USA.
   [Gao, Kaifu; Chen, Jiahui; Wang, Rui; Wei, Guo-Wei] Michigan State Univ, Dept Math, E Lansing, MI 48824 USA.
   [Wei, Guo-Wei] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
   [Wei, Guo-Wei] Michigan State Univ, Dept Elect & Comp Engn, E Lansing, MI 48824 USA.
RP Wei, GW (corresponding author), Michigan State Univ, Dept Math, E Lansing, MI 48824 USA.; Wei, GW (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.; Wei, GW (corresponding author), Michigan State Univ, Dept Elect & Comp Engn, E Lansing, MI 48824 USA.
EM weig@msu.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM126189]; NSFNational Science
   Foundation (NSF) [DMS-1721024, DMS-1761320, IIS1900473]; Michigan
   Economic Development Corporation; George Mason University [PD45722];
   Bristol-Myers SquibbBristol-Myers Squibb; PfizerPfizer
FX This work was supported in part by NIH grant GM126189, NSF Grants
   DMS-1721024, DMS-1761320, and IIS1900473, Michigan Economic Development
   Corporation, George Mason University award PD45722, Bristol-Myers
   Squibb, and Pfizer. The authors thank The IBM TJ Watson Research Center,
   The COVID-19 High Performance Computing Consortium, and NVIDIA for
   computational assistance.
CR [Anonymous], 2020, PHASE III DOUBLE BLI
   [Anonymous], 2020, STATEMENT ASTRAZENEC
   Bacha U, 2008, CHEM BIOL DRUG DES, V72, P34, DOI 10.1111/j.1747-0285.2008.00679.x
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cang ZX, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1005929
   Carlsson G, 2009, B AM MATH SOC, V46, P255, DOI 10.1090/S0273-0979-09-01249-X
   Chang HP, 2007, BIOPHYS J, V92, P1374, DOI 10.1529/biophysj.106.091736
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Davies M, 2015, NUCLEIC ACIDS RES, V43, pW612, DOI 10.1093/nar/gkv352
   Degen J, 2008, CHEMMEDCHEM, V3, P1503, DOI 10.1002/cmdc.200800178
   Douangamath A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18709-w
   Nguyen DD, 2020, PHYS CHEM CHEM PHYS, V22, P4343, DOI 10.1039/c9cp06554g
   Nguyen DD, 2020, J COMPUT AID MOL DES, V34, P131, DOI 10.1007/s10822-019-00237-5
   Nguyen DD, 2019, J CHEM INF MODEL, V59, P3291, DOI 10.1021/acs.jcim.9b00334
   Nguyen DD, 2019, INT J NUMER METH BIO, V35, DOI 10.1002/cnm.3179
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Jimenez J, 2018, J CHEM INF MODEL, V58, P287, DOI 10.1021/acs.jcim.7b00650
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Kumar V, 2013, EXPERT OPIN THER PAT, V23, P1337, DOI 10.1517/13543776.2013.823159
   Landrum G., 2006, RDKIT OPEN SOURCE CH
   Li HJ, 2020, WIRES COMPUT MOL SCI, V10, DOI 10.1002/wcms.1465
   Liang PH, 2006, CURR TOP MED CHEM, V6, P361, DOI 10.2174/156802606776287090
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000
   Park BK, 2011, NAT REV DRUG DISCOV, V10, P292, DOI 10.1038/nrd3408
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Rathnayake AD, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc5332
   Su HX, 2020, ACTA PHARMACOL SIN, V41, P1167, DOI 10.1038/s41401-020-0483-6
   Su M., 2018, J CHEM INF MODEL
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Ullrich S, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2020.127377
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Wang H, 2020, ACS CATAL, V10, P5871, DOI 10.1021/acscatal.0c00110
   Wang HM, 2007, EXPERT OPIN THER PAT, V17, P533, DOI 10.1517/13543776.17.5.533
   Wojcikowski M., 2018, DEV PROTEIN LIGAND E
   Wu KD, 2018, J COMPUT CHEM, V39, P1444, DOI 10.1002/jcc.25213
   Wu KD, 2018, J CHEM INF MODEL, V58, P520, DOI 10.1021/acs.jcim.7b00558
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang S, 2006, J MED CHEM, V49, P4971, DOI 10.1021/jm0603926
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zheng LZ, 2019, ACS OMEGA, V4, P15956, DOI 10.1021/acsomega.9b01997
NR 44
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2041-6520
EI 2041-6539
J9 CHEM SCI
JI Chem. Sci.
PD NOV 28
PY 2020
VL 11
IS 44
BP 12036
EP 12046
DI 10.1039/d0sc04641h
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA OS8FG
UT WOS:000590392400004
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Kim, K
   Ko, Y
   Ko, DS
   Kim, YH
AF Kim, Kihun
   Ko, Yeji
   Ko, Dai Sik
   Kim, Yun Hak
TI Prognostic Significance of COVID-19 Receptor ACE2 and Recommendation for
   Antihypertensive Drug in Renal Cell Carcinoma
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID CONVERTING ENZYME 2; RESPIRATORY SYNDROME CORONAVIRUS; HIGH
   BLOOD-PRESSURE; FUNCTIONAL RECEPTOR; ANGIOTENSIN; HYPERTENSION;
   EPIDEMIOLOGY; ANGIOGENESIS; ASSOCIATION; PREVENTION
AB Purpose. Owing to its worldwide spread, the coronavirus disease (COVID-19) epidemic was declared a pandemic by the World Health Organization on March 11, 2020. Angiotensin-converting enzyme 2 (ACE2) is the outer surface protein of the cell membrane that is abundantly distributed in the heart, lungs, and kidneys and plays an important role in molecular docking of the severe acute respiratory syndrome coronavirus 2. In this study, we aimed to analyze the difference in the survival rate according to ACE2 expressions in pan-cancer. Materials and Methods. We downloaded clinical and genomic data from The Cancer Genome Atlas. We used Kaplan-Meier with a log-rank test, and the Cox proportional hazards regression to analyze prognostic significance. Results. In the Kaplan-Meier curve, clear cell renal cell carcinoma (ccRCC), uveal melanoma, and prostate adenocarcinoma showed statistical significance. In the Cox regression, thyroid carcinoma and glioblastoma multiforme and ccRCC showed significant results. Only ccRCC had statistical significance, and high ACE2 expression is related to good prognosis. It is known that the ACE inhibitor, a primary antihypertensive agent, increases ACE2 expression. Conclusion. Based on these results, we believe that the ACE inhibitor will be important to increase the lifespan of ccRCC patients. This study is the first research to offer a recommendation on the use of anti-hypertensive drugs to ccRCC patients.
C1 [Kim, Kihun] Kosin Univ, Gospel Hosp, Dept Occupat & Environm Med, Busan, South Korea.
   [Ko, Yeji] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA.
   [Ko, Dai Sik] Gachon Univ, Gil Med Ctr, Dept Surg, Div Vasc Surg, Seongnam, South Korea.
   [Kim, Yun Hak] Pusan Natl Univ, Sch Med, Dept Biomed Informat, Busan, South Korea.
   [Kim, Yun Hak] Pusan Natl Univ, Sch Med, Dept Anat, Busan, South Korea.
RP Ko, DS (corresponding author), Gachon Univ, Gil Med Ctr, Dept Surg, Div Vasc Surg, Seongnam, South Korea.; Kim, YH (corresponding author), Pusan Natl Univ, Sch Med, Dept Biomed Informat, Busan, South Korea.; Kim, YH (corresponding author), Pusan Natl Univ, Sch Med, Dept Anat, Busan, South Korea.
EM kihun7603@naver.com; koyezy@umich.edu; daisik.ko@gilhospital.com;
   yunhak10510@pusan.ac.kr
FU National Research Foundation of Korea (NRF) - Korean Government (MOE)
   [NRF-2018R1A5A2023879, NRF-2020R1C1C1003741, NRF-2017M3C9A6047610]
FX This work was supported by the Medical Research Center (MRC) program
   (NRF-2018R1A5A2023879), Basic Science Research Program
   (NRF-2020R1C1C1003741), and Collaborative Genome Program for Fostering
   New Post-Genome Industry (NRF-2017M3C9A6047610) through a National
   Research Foundation of Korea (NRF) grant funded by the Korean Government
   (MOE).
CR Anjorin AA, 2020, ASIAN PAC J TROP MED, V13, P199, DOI 10.4103/1995-7645.281612
   Baraniuk C., 2020, RECEPTOR SARS COV 2
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Chobanian AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI 10.1001/jama.289.19.2560
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Feng Y, 2010, ONCOL REP, V23, P941, DOI 10.3892/or_00000718
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Goh TS, 2019, J CELL PHYSIOL, V234, P13851, DOI 10.1002/jcp.28065
   Gorbalenya A. E., 2020, SEVERE ACUTE RESP SY
   Guo JY, 2020, J CELL PHYSIOL, V235, P9884, DOI 10.1002/jcp.29802
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   He F, 2020, J MED VIROL, V92, P719, DOI [10.1002/jmv.25766, 10.3171/2020.3.JNS193202]
   Jandeleit-Dahm K, 2006, ENDOCRIN METAB CLIN, V35, P469, DOI 10.1016/j.ecl.2006.06.007
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052
   Mancia G, 2013, J HYPERTENS, V31, P1925, DOI 10.1097/HJH.0b013e328364ca4c
   Pak K, 2020, J MED INTERNET RES, V22, DOI 10.2196/16084
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Rosendorff C, 2007, CIRCULATION, V115, P2761, DOI 10.1161/CIRCULATIONAHA.107.183885
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Wang W, 2016, HYPERTENSION, V68, P365, DOI 10.1161/HYPERTENSIONAHA.115.06892
   Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang WP, 2021, INT J BIOL SCI, V17, P20, DOI 10.7150/ijbs.51969
   Ye GX, 2015, BIOCHEM BIOPH RES CO, V459, P18, DOI 10.1016/j.bbrc.2015.02.030
   Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1156-5
   Zhang Y, 2005, COMPUT BIOL CHEM, V29, P254, DOI 10.1016/j.compbiolchem.2005.04.008
   Zhang Zhilan, 2020, Comput Struct Biotechnol J, V18, P2438, DOI 10.1016/j.csbj.2020.08.024
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhou L, 2009, TOHOKU J EXP MED, V217, P123, DOI 10.1620/tjem.217.123
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 36
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD NOV 27
PY 2020
VL 2020
AR 2054376
DI 10.1155/2020/2054376
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA PE5FR
UT WOS:000598392000004
PM 33274196
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shanmugaraj, B
   Rattanapisit, K
   Manopwisedjaroen, S
   Thitithanyanont, A
   Phoolcharoen, W
AF Shanmugaraj, Balamurugan
   Rattanapisit, Kaewta
   Manopwisedjaroen, Suwimon
   Thitithanyanont, Arunee
   Phoolcharoen, Waranyoo
TI Monoclonal Antibodies B38 and H4 Produced in Nicotiana benthamiana
   Neutralize SARS-CoV-2 in vitro
SO FRONTIERS IN PLANT SCIENCE
LA English
DT Article
DE molecular farming; transient expression; Nicotiana benthamiana; plant
   recombinant proteins; plant-produced monoclonal antibody; SARS-CoV-2;
   COVID-19
ID SARS CORONAVIRUS; VIRUS; PLANTS; GLYCOSYLATION; EXPRESSION; VACCINES;
   POTENT; AGROBACTERIUM; COMBINATION; INFECTION
AB The ongoing coronavirus disease 2019 (COVID-19) outbreak caused by novel zoonotic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was initially reported in Wuhan city, Hubei Province of China, in late December 2019. The rapid global spread of the virus calls for the urgent development of vaccines or therapeutics for human applications to combat the coronavirus infection. Monoclonal antibodies (mAbs) have been utilized as effective therapeutics for treating various infectious diseases. In the present study, we evaluated the feasibility of plant expression system for the rapid production of recently identified therapeutically suitable human anti-SARS-CoV-2 mAbs B38 and H4. Transient co-expression of heavy-chain and light-chain sequences of both the antibodies by using plant expression geminiviral vector resulted in rapid accumulation of assembled mAbs in Nicotiana benthamiana leaves within 4 days post-infiltration. Furthermore, both the mAbs were purified from the plant crude extracts with single-step protein A affinity column chromatography. The expression level of mAb B38 and H4 was estimated to be 4 and 35 mu g/g leaf fresh weight, respectively. Both plant-produced mAbs demonstrated specific binding to receptor binding domain (RBD) of SARS-CoV-2 and exhibited efficient virus neutralization activity in vitro. To the best of our knowledge, this is the first report of functional anti-SARS-CoV-2 mAbs produced in plants, which demonstrates the ability of using a plant expression system as a suitable platform for the production of effective, safe, and affordable SARS-CoV-2 mAbs to fight against the spread of this highly infectious pathogen.
C1 [Shanmugaraj, Balamurugan; Rattanapisit, Kaewta; Phoolcharoen, Waranyoo] Chulalongkorn Univ, Res Unit Plant Produced Pharmaceut, Bangkok, Thailand.
   [Shanmugaraj, Balamurugan; Rattanapisit, Kaewta; Phoolcharoen, Waranyoo] Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharmacocgnosy & Pharmaceut Bot, Bangkok, Thailand.
   [Manopwisedjaroen, Suwimon; Thitithanyanont, Arunee] Mahidol Univ, Dept Microbiol, Fac Sci, Bangkok, Thailand.
RP Phoolcharoen, W (corresponding author), Chulalongkorn Univ, Res Unit Plant Produced Pharmaceut, Bangkok, Thailand.; Phoolcharoen, W (corresponding author), Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharmacocgnosy & Pharmaceut Bot, Bangkok, Thailand.
EM Waranyoo.P@chula.ac.th
FU Baiya Phytopharm Co., Ltd.; Thailand Research FundThailand Research Fund
   (TRF) [RSA628006]; Second Century Fund (C2F); Chulalongkorn
   UniversityChulalongkorn University; Graduate School, Ratchadapisek
   Somphot Fund, Chulalongkorn University
FX This study was funded by Baiya Phytopharm Co., Ltd., and the Thailand
   Research Fund grant No. RSA628006. This study was also financially
   supported by The Second Century Fund (C2F), Chulalongkorn University
   (BS), and Graduate School, Ratchadapisek Somphot Fund, Chulalongkorn
   University (KR).
CR Buyel JF, 2017, BIOTECHNOL ADV, V35, P458, DOI 10.1016/j.biotechadv.2017.03.011
   Buyel JF, 2019, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01893
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Capell T, 2020, TRENDS PLANT SCI, V25, P635, DOI 10.1016/j.tplants.2020.04.009
   Chen Q., 2008, BIOL ENG, V1, P291, DOI DOI 10.13031/201326854
   Chen Q, 2011, HUM VACCINES, V7, P331, DOI 10.4161/hv.7.3.14262
   Chen QJ, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.127
   Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330
   Dent M, 2016, J GEN VIROL, V97, P3280, DOI 10.1099/jgv.0.000635
   Diamos AG, 2020, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00472
   Diamos AG, 2019, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01974
   Donini M, 2019, BIOTECHNOL LETT, V41, P335, DOI 10.1007/s10529-019-02651-z
   Fischer R, 2020, BIOTECHNOL ADV, V40, DOI 10.1016/j.biotechadv.2020.107519
   Fox J. L., 2012, Nature Biotechnology, V30, P472, DOI 10.1038/nbt0612-472
   Gelvin SB, 2010, ANNU REV PHYTOPATHOL, V48, P45, DOI 10.1146/annurev-phyto-080508-081852
   He JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093541
   Hehle VK, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-128
   Holtz BR, 2015, PLANT BIOTECHNOL J, V13, P1180, DOI 10.1111/pbi.12469
   Hurtado J, 2020, PLANT BIOTECHNOL J, V18, P266, DOI 10.1111/pbi.13194
   Iyappan G, 2018, INT J INFECT DIS, V73, P363, DOI 10.1016/j.ijid.2018.04.4236
   Jahanshahlu L, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110337
   Kelley B, 2009, MABS-AUSTIN, V1, P443, DOI 10.4161/mabs.1.5.9448
   Kesik-Brodacka M, 2018, BIOTECHNOL APPL BIOC, V65, P306, DOI 10.1002/bab.1617
   Ko KS, 2003, P NATL ACAD SCI USA, V100, P8013, DOI 10.1073/pnas.0832472100
   Lai HF, 2014, PLANT BIOTECHNOL J, V12, P1098, DOI 10.1111/pbi.12217
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Ma JKC, 2015, PLANT BIOTECHNOL J, V13, P1106, DOI 10.1111/pbi.12416
   Ma JKC, 2013, PLANT BIOTECHNOL J, V11, P1029, DOI 10.1111/pbi.12127
   Malla A, 2020, J PURE APPL MICROBIO, V14, P931, DOI 10.22207/JPAM.14.SPL1.30
   Massa S., 2018, PROGR BOT, V80, P65, DOI DOI 10.1007/124_2018_20
   McNulty MJ, 2020, BIOTECHNOL PROGR, V36, DOI 10.1002/btpr.2896
   Miranda LR, 2007, J IMMUNOL, V178, P7132, DOI 10.4049/jimmunol.178.11.7132
   Montero-Morales L, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00081
   Nandi S, 2016, MABS-AUSTIN, V8, P1456, DOI 10.1080/19420862.2016.1227901
   Olinger GG, 2012, P NATL ACAD SCI USA, V109, P18030, DOI 10.1073/pnas.1213709109
   Peyret H, 2015, PLANT BIOTECHNOL J, V13, P1121, DOI 10.1111/pbi.12412
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Rattanapisit K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74904-1
   Rattanapisit K, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8120560
   Rattanapisit K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51656-1
   Rosales-Mendoza S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020183
   Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999
   Rybicki EP, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1587
   Rybicki EP, 2017, HUM VACC IMMUNOTHER, V13, P2912, DOI 10.1080/21645515.2017.1356497
   Scallon BJ, 2007, MOL IMMUNOL, V44, P1524, DOI 10.1016/j.molimm.2006.09.005
   Schahs M, 2007, PLANT BIOTECHNOL J, V5, P657, DOI 10.1111/j.1467-7652.2007.00273.x
   Schillberg S, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00720
   Shahid N, 2016, PLANT BIOTECHNOL J, V14, P2079, DOI 10.1111/pbi.12604
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shanmugaraj B, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9070842
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Shanmugaraj B, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020148
   Strasser R, 2008, PLANT BIOTECHNOL J, V6, P392, DOI 10.1111/j.1467-7652.2008.00330.x
   Strasser R, 2009, J BIOL CHEM, V284, P20479, DOI 10.1074/jbc.M109.014126
   Sukenik SC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041205
   Sun HY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010054
   Teh AYH, 2014, PLANT BIOTECHNOL J, V12, P300, DOI 10.1111/pbi.12137
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tschofen M, 2016, ANNU REV ANAL CHEM, V9, P271, DOI 10.1146/annurev-anchem-071015-041706
   Tuse D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/256135
   Twyman RM, 2003, TRENDS BIOTECHNOL, V21, P570, DOI 10.1016/j.tibtech.2003.10.002
   van Dolleweerd CJ, 2014, J INFECT DIS, V210, P200, DOI 10.1093/infdis/jiu085
   Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
   Waheed MT, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-1713-8
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   World Health Organization, 2020, WHO COR DIS COVID 19
   World Health Organization [WHO], 2011, WHO GLOB INFL SURV N
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yao J, 2015, INT J MOL SCI, V16, P28549, DOI 10.3390/ijms161226122
   Zeitlin L, 2011, P NATL ACAD SCI USA, V108, P20690, DOI 10.1073/pnas.1108360108
   Zhang B, 2017, CURR OPIN CHEM BIOL, V38, P17, DOI 10.1016/j.cbpa.2017.02.007
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 77
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-462X
J9 FRONT PLANT SCI
JI Front. Plant Sci.
PD NOV 27
PY 2020
VL 11
AR 589995
DI 10.3389/fpls.2020.589995
PG 11
WC Plant Sciences
SC Plant Sciences
GA PC9DU
UT WOS:000597298800001
PM 33329653
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, RX
   Xiao, K
   Gu, Y
   Liu, HD
   Sun, X
AF Zhang, Rongxin
   Xiao, Ke
   Gu, Yu
   Liu, Hongde
   Sun, Xiao
TI Whole Genome Identification of Potential G-Quadruplexes and Analysis of
   the G-Quadruplex Binding Domain for SARS-CoV-2
SO FRONTIERS IN GENETICS
LA English
DT Article
DE G-quadruplex; SARS-CoV-2; COVID-19; G4; coronavirus; G-quadruplex
   binding domain; SUD-homology structure
ID RNA G-QUADRUPLEX; TELOMERE DNA; ORIGIN; REPLICATION; CORONAVIRUS;
   REGION; 5-UTR; SARS
AB The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has become a global public health emergency. G-quadruplex, one of the non-canonical secondary structures, has shown potential antiviral values. However, little is known about the G-quadruplexes of the emerging SARS-CoV-2. Herein, we characterized the potential G-quadruplexes in both positive and negative-sense viral strands. The identified potential G-quadruplexes exhibited similar features to the G-quadruplexes detected in the human transcriptome. Within some bat- and pangolin-related betacoronaviruses, the G-tracts rather than the loops were under heightened selective constraints. We also found that the amino acid sequence similar to SUD (SARS-unique domain) was retained in SARS-CoV-2 but depleted in some other coronaviruses that can infect humans. Further analysis revealed that the amino acid residues related to the binding affinity of G-quadruplexes were conserved among 16,466 SARS-CoV-2 samples. Moreover, the dimer of the SUD-homology structure in SARS-CoV-2 displayed similar electrostatic potential patterns to the SUD dimer from SARS. Considering the potential value of G-quadruplexes to serve as targets in antiviral strategy, our fundamental research could provide new insights for the SARS-CoV-2 drug discovery.
C1 [Zhang, Rongxin; Xiao, Ke; Gu, Yu; Liu, Hongde; Sun, Xiao] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing, Peoples R China.
RP Sun, X (corresponding author), Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing, Peoples R China.
EM xsun@seu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [61972084, 81830053]
FX This work was supported by the National Natural Science Foundation of
   China (No. 61972084 and 81830053).
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Andrews Ryan J, 2020, bioRxiv, DOI 10.1101/2020.04.17.045161
   Andrews RJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17510-y
   Balasubramanian S, 2011, NAT REV DRUG DISCOV, V10, P261, DOI 10.1038/nrd3428
   Beaudoin JD, 2014, NUCLEIC ACIDS RES, V42, P1209, DOI 10.1093/nar/gkt904
   Beaudoin JD, 2010, NUCLEIC ACIDS RES, V38, P7022, DOI 10.1093/nar/gkq557
   Bochman ML, 2012, NAT REV GENET, V13, P770, DOI 10.1038/nrg3296
   Broughton JP, 2020, NAT BIOTECHNOL, V38, P870, DOI 10.1038/s41587-020-0513-4
   Butovskaya E, 2019, ACS INFECT DIS, V5, P2127, DOI 10.1021/acsinfecdis.9b00272
   Butovskaya E, 2018, J AM CHEM SOC, V140, P13654, DOI 10.1021/jacs.8b05332
   Chen LH, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau021
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Davydov EV, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001025
   Doluca O, 2019, J THEOR BIOL, V463, P92, DOI 10.1016/j.jtbi.2018.12.007
   Fleming AM, 2016, ACS INFECT DIS, V2, P674, DOI 10.1021/acsinfecdis.6b00109
   Gomez D, 2010, NUCLEIC ACIDS RES, V38, P7187, DOI 10.1093/nar/gkq563
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Han HY, 2000, TRENDS PHARMACOL SCI, V21, P136, DOI 10.1016/S0165-6147(00)01457-7
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hon J, 2017, BIOINFORMATICS, V33, P3373, DOI 10.1093/bioinformatics/btx413
   Hoshina S, 2013, J BIOL CHEM, V288, P30161, DOI 10.1074/jbc.M113.492504
   Jansson LI, 2019, P NATL ACAD SCI USA, V116, P9350, DOI 10.1073/pnas.1814777116
   Jaubert C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26582-3
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Joachimi A, 2009, BIOORGAN MED CHEM, V17, P6811, DOI 10.1016/j.bmc.2009.08.043
   Jodoin R, 2019, NUCLEIC ACIDS RES, V47, P10247, DOI 10.1093/nar/gkz777
   Kikin O, 2006, NUCLEIC ACIDS RES, V34, pW676, DOI 10.1093/nar/gkl253
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Kumari S, 2007, NAT CHEM BIOL, V3, P218, DOI 10.1038/nchembio864
   Kusov Y, 2015, VIROLOGY, V484, P313, DOI 10.1016/j.virol.2015.06.016
   Kwok CK, 2017, TRENDS BIOTECHNOL, V35, P997, DOI 10.1016/j.tibtech.2017.06.012
   Kwok CK, 2016, NAT METHODS, V13, P841, DOI 10.1038/nmeth.3965
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lee DSM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14404-y
   Li L, 2020, RADIOLOGY, V296, pE65, DOI 10.1148/radiol.2020200905
   Lombardi EP, 2020, NUCLEIC ACIDS RES, V48, P1, DOI 10.1093/nar/gkz1097
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Majee P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58406-8
   Marusic M, 2017, BBA-GEN SUBJECTS, V1861, P1229, DOI 10.1016/j.bbagen.2016.11.007
   Metifiot M, 2014, NUCLEIC ACIDS RES, V42, P12352, DOI 10.1093/nar/gku999
   Miller Kyle M, 2011, Expert Rev Clin Pharmacol, V4, P139, DOI 10.1586/ecp.11.4
   Mishra A., 2020, BIORXIV, DOI [10.1101/2020.05.07.082768, DOI 10.1101/2020.05.07.082768]
   Moye AL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8643
   Murat P, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1602-2
   Murat P, 2014, NAT CHEM BIOL, V10, P358, DOI [10.1038/NCHEMBIO.1479, 10.1038/nchembio.1479]
   Neidle S, 2017, NAT REV CHEM, V1, DOI 10.1038/s41570-017-0041
   Okonechnikov K, 2012, BIOINFORMATICS, V28, P1166, DOI 10.1093/bioinformatics/bts091
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Perrone R, 2015, IFMBE PROC, V46, P207, DOI 10.1007/978-3-319-11776-8_50
   Perrone R, 2014, J ANTIMICROB CHEMOTH, V69, P3248, DOI 10.1093/jac/dku280
   Perrone R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073121
   Piekna-Przybylska D, 2014, BIOCHEMISTRY-US, V53, P2581, DOI 10.1021/bi4016692
   Prorok P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11104-0
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ruggiero Emanuela, 2020, Annu Rep Med Chem, V54, P101, DOI 10.1016/bs.armc.2020.04.001
   Ruggiero E, 2018, NUCLEIC ACIDS RES, V46, P3270, DOI 10.1093/nar/gky187
   Saranathan N, 2019, TRENDS MICROBIOL, V27, P148, DOI 10.1016/j.tim.2018.08.011
   Shahid R, 2010, BIOCHEMISTRY-US, V49, P8300, DOI 10.1021/bi100957h
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Spiegel J, 2020, TRENDS CHEM, V2, P123, DOI 10.1016/j.trechm.2019.07.002
   Takahama K, 2013, CHEM BIOL, V20, P341, DOI 10.1016/j.chembiol.2013.02.013
   Tan JZ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000428
   Tang J, 2008, NUCLEIC ACIDS RES, V36, P1200, DOI 10.1093/nar/gkm1137
   Tluckova K, 2013, BIOCHEMISTRY-US, V52, P7207, DOI 10.1021/bi400897g
   Valton AL, 2016, TRENDS GENET, V32, P697, DOI 10.1016/j.tig.2016.09.004
   Valton AL, 2014, EMBO J, V33, P732, DOI 10.1002/embj.201387506
   Varshney D, 2020, NAT REV MOL CELL BIO, V21, P459, DOI 10.1038/s41580-020-0236-x
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang Q, 2011, NUCLEIC ACIDS RES, V39, P6229, DOI 10.1093/nar/gkr164
   Wang SR, 2016, CELL CHEM BIOL, V23, P1113, DOI 10.1016/j.chembiol.2016.07.019
   Wang SR, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501535
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Xiao KP, 2020, NATURE, V583, P286, DOI 10.1038/s41586-020-2313-x
   Yao H., 2020, PATIENT DERIVED MUTA, DOI [10.1101/2020.04.14.20060160, DOI 10.1101/2020.04.14.20060160]
   Yin CC, 2020, GENOMICS, V112, P3588, DOI 10.1016/j.ygeno.2020.04.016
   Zaccaria F, 2018, CHEM-EUR J, V24, P16315, DOI 10.1002/chem.201803530
   Zahin M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195625
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhang YS, 2020, RNA BIOL, DOI 10.1080/15476286.2020.1731664
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 93
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD NOV 27
PY 2020
VL 11
AR 587829
DI 10.3389/fgene.2020.587829
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA PC9DJ
UT WOS:000597297700001
PM 33329730
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Russo, V
   Cardillo, G
   Viggiano, GV
   Mangiacapra, S
   Cavalli, A
   Fontanella, A
   Agrusta, F
   Bellizzi, A
   Amitrano, M
   Iannuzzo, M
   Sacco, C
   Lodigiani, C
   Castaldo, G
   Di Micco, P
AF Russo, Vincenzo
   Cardillo, Giuseppe
   Viggiano, Giuseppe Vito
   Mangiacapra, Sara
   Cavalli, Antonella
   Fontanella, Andrea
   Agrusta, Federica
   Bellizzi, Annamaria
   Amitrano, Maria
   Iannuzzo, Mariateresa
   Sacco, Clara
   Lodigiani, Corrado
   Castaldo, Giampiero
   Di Micco, Pierpaolo
CA Fondenoxavid Study Grp
TI Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized
   COVID-19 Patients: A Multicenter Italian Observational Study
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; fondaparinux; enoxaparin; major bleedings; thromboprofylaxis;
   pulmonary embolism; deep venous thrombosis; acute respiratory distress
   syndrome
AB Importance: The use of anticoagulant therapy with heparins decreased mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19). Even if enoxaparin and fondaparinux have the same clinical indication for venous thromboembolism (VTE) prevention; to date, there are no data about the use of fondaparinux in terms of safety, effectiveness, and impact on clinical prognosis among COVID-19 patients.
   Objective: To evaluate the safety, effectiveness, and clinical impact of VTE prophylaxis with fondaparinux and enoxaparin among COVID-19 patients hospitalized in internal medicine units.
   Design, Setting, and Participants: This was a retrospective multicenter observation study, including consecutive symptomatic patients with laboratory-proven COVID-19 admitted to internal medicine units of five Italian hospitals from 15th February to 15th March 2020.
   Main Outcomes and Measures: The primary safety outcome was the composite of major bleeding and clinically relevant non-major bleeding; the primary effectiveness outcome was the composite of all events classified as pulmonary embolism and deep venous thrombosis. The secondary effectiveness outcome included acute respiratory distress syndrome and all-cause death.
   Results: Among 120 COVID-19 patients enrolled in the study, 74 were taking enoxaparin (4,000 or 6,000 units/day) and 46 fondaparinux (2.5 units/day). No statistically significant difference in demographic and laboratory and clinical characteristics between the two groups has been shown. During a median follow-up of 32 (interquartile range: 14-51) days, the cumulative incidence rates of VTE and bleeding events on pharmacological thromboprophylaxis with heparins were 19% and 8%, respectively. The incidence of both VTE (6.5 vs. 13.5%; P = 0.36) and bleeding events (6.5 vs. 4.1%; P = 0.68) did not show a significant difference between COVID-19 patients on fondaparinux compared with those on enoxaparin therapy. The regression model for the risk of outcome events according to different VTE prophylaxis drugs did not show significant differences.
   Conclusions and Relevance: Although these results need confirmation by prospective studies including a larger population, our study provides preliminary evidence of a safe and efficacy use of fondaparinux for VTE prophylaxis in hospitalized COVID-19 patients.
C1 [Russo, Vincenzo] Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Naples, Italy.
   [Cardillo, Giuseppe] Adv Biochem Unit, Medylab, Naples, Italy.
   [Viggiano, Giuseppe Vito; Agrusta, Federica] Marazzini Hosp, Emergency Med Unit, Modena, Italy.
   [Mangiacapra, Sara; Amitrano, Maria] Moscati Hosp, Internal Med Unit, Avellino, Italy.
   [Cavalli, Antonella; Bellizzi, Annamaria] Frangipane Hosp, Internal Med Unit, Ariano Irpino, Italy.
   [Fontanella, Andrea; Iannuzzo, Mariateresa; Castaldo, Giampiero; Di Micco, Pierpaolo] Fatebenefratelli Hosp, Internal Med Unit, Naples, Italy.
   [Sacco, Clara; Lodigiani, Corrado] Humanitas Res Hosp, Thrombosis & Hemorrag Ctr, Rozzano, Italy.
   [Sacco, Clara; Lodigiani, Corrado] Univ Rozzano, Rozzano, Italy.
RP Russo, V (corresponding author), Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Naples, Italy.
EM vincenzo.russo@unicampania.it
OI Cardillo, Giuseppe/0000-0001-6414-8475
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Di Micco P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051371
   Ghezzi S, 2017, ANTIVIR RES, V140, P13, DOI 10.1016/j.antiviral.2016.12.023
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kaatz S, 2015, J THROMB HAEMOST, V13, P2119, DOI 10.1111/jth.13140
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405
   Levi M, 2018, BLOOD, V131, P845, DOI 10.1182/blood-2017-10-804096
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   McCloskey B, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000254
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559
   Pierre F, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20301
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Russo V, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061944
   Russo V, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104965
   Russo V, 2020, J CARDIOVASC PHARM, V76, P138, DOI 10.1097/FJC.0000000000000854
   Zhang Z, 2017, J THROMB THROMBOLYS, V43, P540, DOI 10.1007/s11239-017-1473-5
NR 20
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 27
PY 2020
VL 7
AR 569567
DI 10.3389/fmed.2020.569567
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA PC8TD
UT WOS:000597270900001
PM 33330530
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fuchs-Leitner, I
   Yazdi, K
   Gerstgrasser, NW
   Rosenleitner, J
AF Fuchs-Leitner, Isabella
   Yazdi, Kurosch
   Gerstgrasser, Nikolas W.
   Rosenleitner, Jan
TI Developments in Drug Addiction During COVID-19-An Austrian Perspective
   Based on a Clinical Sample
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE COVID-19; drug addiction; consumption pattern; illicit drug market;
   opioid substitution therapy (OST)
ID IMPACT
AB Concerns about the negative consequences of the COVID-19 pandemic on people with substance use disorder (SUD) were raised by experts in the field around the world. Here we provide an Austrian perspective, discussing the impact of the pandemic on help-seeking patient with drug use disorder during the initial stage of the pandemic. Our perspectives are based on the situation as perceived at our clinical facility, and supported by original data collected from a small clinical sample of patients with drug use disorder (N = 32). The viewpoints and related descriptive data include the perceived individual impact of COVID-19, as well as various aspects of drug use behavior and the Austrian drug market before and after the onset of the pandemic. The consequences for a subgroup of patients in opioid substitution treatment (N = 24) are discussed. Surprisingly and in contrast to anticipated developments, we had the impression of a rather stable situation in Austria, at least at this early stage of the pandemic. The immediate impact of COVID-19 on these help-seeking patients with high levels of drug dependency seemed less severe than anticipated so far. Importantly, this observation might be a short-term effect for this already fragile group and careful monitoring of further developments as well as preparation of long-term strategies are advised. In general, problematic drug use is associated with many health risk factors and finding appropriate long-term health care strategies has to remain a top priority facing the pandemic. Our perspectives are restricted to observations from help-seeking patients at our clinic, and no conclusions for the general population can be directly drawn.
C1 [Fuchs-Leitner, Isabella; Yazdi, Kurosch; Gerstgrasser, Nikolas W.; Rosenleitner, Jan] Kepler Univ Hosp, Dept Psychiat, Specializat Addict Med, Linz, Austria.
   [Fuchs-Leitner, Isabella; Yazdi, Kurosch; Gerstgrasser, Nikolas W.; Rosenleitner, Jan] Johannes Kepler Univ Linz, Fac Med, Linz, Austria.
RP Yazdi, K (corresponding author), Kepler Univ Hosp, Dept Psychiat, Specializat Addict Med, Linz, Austria.; Yazdi, K (corresponding author), Johannes Kepler Univ Linz, Fac Med, Linz, Austria.
EM kurosch.yazdi@kepleruniklinikum.at
CR Berman AH, 2005, EUR ADDICT RES, V11, P22, DOI 10.1159/000081413
   Columb D, 2020, IRISH J PSYCHOL MED, V37, P164, DOI 10.1017/ipm.2020.47
   Dale-Perera A, 2012, HEROIN ADDICT REL CL, V14, P23
   DeJong CAJ, 2020, BASIC CLIN NEUROSCI, V11, P207, DOI 10.32598/bcn.11.covid19.2543.1
   Dietze PM, 2020, DRUG ALCOHOL REV, V39, P297, DOI 10.1111/dar.13079
   Dubey MJ, 2020, DIABETES METAB SYND, V14, P817, DOI 10.1016/j.dsx.2020.06.008
   Dunlop A, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00370-7
   European Monitoring Centre for Drugs and Drug Addiction, 2020, EMCDDA UPD IMPL COVI
   European Monitoring Centre for Drugs and Drug Addiction, 2020, IMP COVID 19 PATT DR
   European Monitoring Centre for Drugs and Drug Addiction, 2020, EU DRUG MARK IMP COV
   Farhoudian A, 2020, BASIC CLIN NEUROSCI, V11, P133, DOI 10.32598/bcn.11.covid19.1
   Gibney E, 2020, NATURE, V581, P15, DOI 10.1038/d41586-020-01248-1
   Jemberie WB, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00714
   Khatri Utsha G, 2020, J Addict Med, V14, pe6, DOI 10.1097/ADM.0000000000000684
   Mackolil J, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102156
   Marsden J, 2020, ADDICTION, V115, P1007, DOI 10.1111/add.15080
   Martinotti G, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.572245
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Reimer J, 2016, EUR ADDICT RES, V22, P99, DOI 10.1159/000438988
   Saeedi M, 2020, IRAN J PSYCHIATRY BE, V14, DOI 10.5812/ijpbs.103509
   Sinadinovic K, 2014, J STUD ALCOHOL DRUGS, V75, P313, DOI 10.15288/jsad.2014.75.313
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Wakeman SE, 2020, NAT MED, V26, P819, DOI 10.1038/s41591-020-0898-0
NR 23
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD NOV 27
PY 2020
VL 11
AR 602033
DI 10.3389/fpsyt.2020.602033
PG 6
WC Psychiatry
SC Psychiatry
GA PC8WJ
UT WOS:000597279300001
PM 33329157
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU McClung, N
   Chamberland, M
   Kinlaw, K
   Matthew, DB
   Wallace, M
   Bell, BP
   Lee, GM
   Talbot, HK
   Romero, JR
   Oliver, SE
   Dooling, K
AF McClung, Nancy
   Chamberland, Mary
   Kinlaw, Kathy
   Matthew, Dayna Bowen
   Wallace, Megan
   Bell, Beth P.
   Lee, Grace M.
   Talbot, H. Keipp
   Romero, Jose R.
   Oliver, Sara E.
   Dooling, Kathleen
TI The Advisory Committee on Immunization Practices' Ethica Principles for
   Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID RECOMMENDATIONS
C1 [McClung, Nancy; Chamberland, Mary; Wallace, Megan; Oliver, Sara E.; Dooling, Kathleen] CDC, COVID 19 Response Team, Atlanta, GA 30333 USA.
   [Chamberland, Mary] Gen Dynam Informat Technol, Falls Church, VA USA.
   [Kinlaw, Kathy] Emory Univ, Atlanta, GA 30322 USA.
   [Matthew, Dayna Bowen] George Washington Univ, Sch Law, Washington, DC USA.
   [Wallace, Megan] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Bell, Beth P.] Univ Washington, Seattle, WA 98195 USA.
   [Lee, Grace M.] Stanford Univ, Sch Med, Stanford, CA USA.
   [Talbot, H. Keipp] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Romero, Jose R.] Arkansas Dept Hlth, Little Rock, AR 72205 USA.
RP McClung, N (corresponding author), CDC, COVID 19 Response Team, Atlanta, GA 30333 USA.
EM nmcclung@cdc.gov
CR BELL BP, 2020, JAMA J AM MED A 1022, DOI DOI 10.1001/JAMA.2020.20847
   Gibson DM, 2020, J GEN INTERN MED, V35, P2804, DOI 10.1007/s11606-020-05992-y
   Kinlaw K, 2009, DISASTER MED PUBLIC, V3, pS185, DOI 10.1097/DMP.0b013e3181ac194f
   Lee G, 2018, MMWR-MORBID MORTAL W, V67, P1271, DOI 10.15585/mmwr.mm6745a4
   National Academies of Sciences Engineering and Medicine, 2020, FRAM EQ ALL COVID 19
   Persad G, 2020, JAMA-J AM MED ASSOC, V324, P1601, DOI 10.1001/jama.2020.18513
   Toner E, 2020, INTERIM FRAMEWORK CO
   Williams DR, 2020, JAMA-J AM MED ASSOC, V323, P2478, DOI 10.1001/jama.2020.8051
   Williams JH, 2020, BMC MED ETHICS, V21, DOI 10.1186/s12910-020-00477-3
   World Health Organization, 2020, WHO SAGE VAL FRAM AL
NR 10
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 27
PY 2020
VL 69
IS 47
BP 1782
EP 1786
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PB7FK
UT WOS:000596482400006
PM 33237895
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Liu, ZZ
   Xu, W
   Xia, S
   Gu, CJ
   Wang, XL
   Wang, Q
   Zhou, J
   Wu, YL
   Cai, X
   Qu, D
   Ying, TL
   Xie, YH
   Lu, L
   Yuan, ZH
   Jiang, SB
AF Liu, Zezhong
   Xu, Wei
   Xia, Shuai
   Gu, Chenjian
   Wang, Xinling
   Wang, Qian
   Zhou, Jie
   Wu, Yanling
   Cai, Xia
   Qu, Di
   Ying, Tianlei
   Xie, Youhua
   Lu, Lu
   Yuan, Zhenghong
   Jiang, Shibo
TI RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2
   neutralizing antibody response
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
ID RECEPTOR-BINDING DOMAIN; SPIKE PROTEIN; SARS-COV; CORONAVIRUS; MERS;
   STRATEGIES; DESIGN
AB The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed serious threats to global health and economy, thus calling for the development of safe and effective vaccines. The receptor-binding domain (RBD) in the spike protein of SARS-CoV-2 is responsible for its binding to angiotensin-converting enzyme 2 (ACE2) receptor. It contains multiple dominant neutralizing epitopes and serves as an important antigen for the development of COVID-19 vaccines. Here, we showed that immunization of mice with a candidate subunit vaccine consisting of SARS-CoV-2 RBD and Fc fragment of human IgG, as an immunopotentiator, elicited high titer of RBD-specific antibodies with robust neutralizing activity against both pseudotyped and live SARS-CoV-2 infections. The mouse antisera could also effectively neutralize infection by pseudotyped SARS-CoV-2 with several natural mutations in RBD and the IgG extracted from the mouse antisera could also show neutralization against pseudotyped SARS-CoV and SARS-related coronavirus (SARSr-CoV). Vaccination of human ACE2 transgenic mice with RBD-Fc could effectively protect mice from the SARS-CoV-2 challenge. These results suggest that SARS-CoV-2 RBD-Fc has good potential to be further developed as an effective and broad-spectrum vaccine to prevent infection of the current SARS-CoV-2 and its mutants, as well as future emerging SARSr-CoVs and re-emerging SARS-CoV.
C1 [Liu, Zezhong; Xu, Wei; Xia, Shuai; Gu, Chenjian; Wang, Xinling; Wang, Qian; Zhou, Jie; Wu, Yanling; Cai, Xia; Qu, Di; Ying, Tianlei; Xie, Youhua; Lu, Lu; Yuan, Zhenghong; Jiang, Shibo] Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai 200032, Peoples R China.
   [Liu, Zezhong; Xu, Wei; Xia, Shuai; Gu, Chenjian; Wang, Xinling; Wang, Qian; Zhou, Jie; Wu, Yanling; Cai, Xia; Qu, Di; Ying, Tianlei; Xie, Youhua; Lu, Lu; Yuan, Zhenghong; Jiang, Shibo] Fudan Univ, BSL 3 Facil, Shanghai 200032, Peoples R China.
RP Lu, L; Yuan, ZH; Jiang, SB (corresponding author), Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai 200032, Peoples R China.; Lu, L; Yuan, ZH; Jiang, SB (corresponding author), Fudan Univ, BSL 3 Facil, Shanghai 200032, Peoples R China.
EM lul@fudan.edu.cn; zhyuan@shmu.edu.cn; shibojiang@fudan.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82041025, 81822045]; Development Programs
   for COVID-19 of Shanghai Science and Technology Commission [20431900401]
FX This study was supported by grants from National Natural Science
   Foundation of China (82041025 to S.J., 81822045 to L.L.). Development
   Programs for COVID-19 of Shanghai Science and Technology Commission
   (Grant No. 20431900401).
CR [Anonymous], 2020, LANCET, V395, P1883, DOI 10.1016/S0140-6736(20)31405-7
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Burton DR, 2020, CELL HOST MICROBE, V27, P695, DOI 10.1016/j.chom.2020.04.022
   Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473
   Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gu C, 2020, POTENT ANTIVIRAL EFF, DOI [10.1101/2020.04.30.071290, DOI 10.1101/2020.04.30.071290]
   He YX, 2006, J IMMUNOL, V176, P6085, DOI 10.4049/jimmunol.176.10.6085
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Jiang SB, 2012, EXPERT REV VACCINES, V11, P1405, DOI [10.1586/erv.12.126, 10.1586/ERV.12.126]
   Kontermann RE, 2011, CURR OPIN BIOTECH, V22, P868, DOI 10.1016/j.copbio.2011.06.012
   Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012
   Liu ZZ, 2020, VIROL SIN, V35, P340, DOI 10.1007/s12250-020-00214-5
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mullard A, 2020, LANCET, V395, P1751, DOI 10.1016/S0140-6736(20)31252-6
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
   Ou J, 2020, BIORXIV, DOI [10.1101/2020.03.15.991844, DOI 10.1101/2020.03.15.991844]
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Sahin U, 2020, NATURE, DOI 10.1038/s41586-020-2814-7
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Tai WB, 2020, CELL RES, V30, P932, DOI 10.1038/s41422-020-0387-5
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI 10.1172/JCI138759
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang BZ, 2020, CELL RES, V30, P702, DOI 10.1038/s41422-020-0366-x
   Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024
   Zhang NR, 2014, EXPERT REV VACCINES, V13, P761, DOI 10.1586/14760584.2014.912134
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu YM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc9999
NR 49
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD NOV 27
PY 2020
VL 5
IS 1
AR 282
DI 10.1038/s41392-020-00402-5
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA PB1KD
UT WOS:000596087400002
PM 33247109
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kluge, S
   Janssens, U
   Welte, T
   Weber-Carstens, S
   Schalte, G
   Salzberger, B
   Gastmeier, P
   Langer, F
   Welper, M
   Westhoff, M
   Pfeifer, M
   Hoffmann, F
   Bottiger, BW
   Marx, G
   Karagiannidis, C
AF Kluge, S.
   Janssens, U.
   Welte, T.
   Weber-Carstens, S.
   Schaelte, G.
   Salzberger, B.
   Gastmeier, P.
   Langer, F.
   Welper, M.
   Westhoff, M.
   Pfeifer, M.
   Hoffmann, F.
   Boettiger, B. W.
   Marx, G.
   Karagiannidis, C.
TI Recommendations for treatment of critically ill patients with COVID-19
   Version 3 S1 guideline
SO ANAESTHESIST
LA English
DT Article; Early Access
ID NONINVASIVE VENTILATION; OXYGEN-THERAPY; INTUBATION; INFECTION;
   MANAGEMENT; DISPERSION; 2019-NCOV; EPIDEMIC; OUTCOMES; FAILURE
AB Since December 2019 a novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) has rapidly spread around the world resulting in an acute respiratory illness pandemic. The immense challenges for clinicians and hospitals as well as the strain on many healthcare systems has been unprecedented.
   The majority of patients present with mild symptoms of coronavirus disease 2019 (COVID-19); however, 5-8% become critically ill and require intensive care treatment. Acute hypoxemic respiratory failure with severe dyspnea and an increased respiratory rate (>30/min) usually leads to intensive care unit (ICU) admission. At this point bilateral pulmonary infiltrates are typically seen. Patients often develop a severe acute respiratory distress syndrome (ARDS).
   So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients. The main goal of supportive treatment is to ascertain adequate oxygenation. Invasive mechanical ventilation and repeated prone positioning are key elements in treating severely hypoxemic COVID-19 patients.
   Strict adherence to basic infection control measures (including hand hygiene) and correct use of personal protection equipment (PPE) are essential in the care of patients. Procedures that lead to formation of aerosols should be carried out with utmost precaution and preparation.
C1 [Kluge, S.; Janssens, U.; Welte, T.; Karagiannidis, C.] Deutsch Gesell Internist Intens Med & Notfallmed, Berlin, Germany.
   [Kluge, S.; Janssens, U.; Weber-Carstens, S.; Hoffmann, F.; Boettiger, B. W.; Marx, G.; Karagiannidis, C.] Deutsch Interdisziplinare Vereinigung Intens & Na, Berlin, Germany.
   [Kluge, S.; Welte, T.; Westhoff, M.; Pfeifer, M.; Karagiannidis, C.] Deutsch Gesell Pneumol & Beatmungsmed DGP, Berlin, Germany.
   [Weber-Carstens, S.; Schaelte, G.; Welper, M.; Marx, G.] Deutsch Gesell Anasthesiol & Intens Med DGAI, Nurnberg, Germany.
   [Salzberger, B.] Deutsch Gesell Infektiol DGI, Munich, Germany.
   [Gastmeier, P.] Deutsch Gesell Hyg & Mikrobiol DGHM, Munster, Germany.
   [Langer, F.] Gesell Thrombose & Hamostaseforsch GTH, Cologne, Germany.
   [Hoffmann, F.] Deutsch Gesell Kinder & Jugendmed DGKJ, Berlin, Germany.
   [Boettiger, B. W.] GRC, Deutsch Wiederbelebung, Ulm, Germany.
   [Kluge, S.; Janssens, U.; Welte, T.; Weber-Carstens, S.; Marx, G.; Karagiannidis, C.] ARDS Netzwerk Deutschland, Berlin, Germany.
   [Kluge, S.] Univ Klinikum Hamburg Eppendorf, Klin Intens Med, Martinistr 52, D-20246 Hamburg, Germany.
RP Kluge, S (corresponding author), Univ Klinikum Hamburg Eppendorf, Klin Intens Med, Martinistr 52, D-20246 Hamburg, Germany.
EM skluge@uke.de
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Antoch G, 2020, ROFO-FORTSCHR RONTG, V192, P418, DOI 10.1055/a-1149-3625
   AWMF, 2019, S2K LEITL PROL WEAN
   AWMF, 2017, S3 LEITL INV BEATM E
   Begley JL, 2020, ANAESTHESIA, V75, P1014, DOI 10.1111/anae.15115
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bellani G, 2017, AM J RESP CRIT CARE, V195, P67, DOI 10.1164/rccm.201606-1306OC
   Bottiger BW, 2019, CHEST, V156, P1035, DOI 10.1016/j.chest.2019.08.1922
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Brunkhorst FM, 2020, MED KLIN-INTENSIVMED, DOI 10.1007/s00063-020-00685-0
   Cabrini L, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30359-7
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Caputo KM, 2006, CAN J ANAESTH, V53, P122, DOI 10.1007/BF03021815
   Carteaux G, 2016, CRIT CARE MED, V44, P282, DOI 10.1097/CCM.0000000000001379
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Dalli J, 2020, BRIT J ANAESTH, V125, pE293, DOI 10.1016/j.bja.2020.05.006
   Darwiche K, 2020, PNEUMOLOGIE, V74, P260, DOI 10.1055/a-1154-1814
   Deutsche Gesellschaft fur Palliativmedizin, 2020, STELL 2020
   Deutscher Rat fur Wiederbelebung-German Resuscitation Council (GRC) e.V, 2020, EMPF INT LIAIS COMM
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dutzmann J, 2020, ENTSCHEIDUNGEN ZUTEI
   Elkbuli A, 2019, AM SURGEON, V85, P370
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Greenland JR, 2020, ANESTHESIOLOGY, V132, P1346, DOI 10.1097/ALN.0000000000003303
   Griffiths RD, 2010, CRIT CARE MED, V38, P779, DOI 10.1097/CCM.0b013e3181cc4b53
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Hosokawa K, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1138-8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2006, CHEST, V130, P730, DOI 10.1378/chest.130.3.730
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Hui DS, 2009, CHEST, V136, P998, DOI 10.1378/chest.09-0434
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Janssens U, 2012, DIVI, V3, P103
   Langer F, 2020, HAMOSTASEOLOGIE, V40, P264, DOI 10.1055/a-1178-3551
   Leonard S, 2020, CHEST, V158, P1046, DOI 10.1016/j.chest.2020.03.043
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Liao XL, 2020, INTENS CARE MED, V46, P357, DOI 10.1007/s00134-020-05954-2
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   McGrath BA, 2020, LANCET RESP MED, V8, P717, DOI 10.1016/S2213-2600(20)30230-7
   Orser BA, 2020, ANESTH ANALG, V130, P1109, DOI 10.1213/ANE.0000000000004803
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Patel NA, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102573
   Peng PWH, 2020, BRIT J ANAESTH, V124, P497, DOI 10.1016/j.bja.2020.02.008
   Pfeifer M, 2020, PNEUMOLOGIE, V74, P337, DOI 10.1055/a-1157-9976
   Piepho T, 2015, S1 LEITLINIE ATEMWEG
   Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Robert F, 2020, INT J EMERG ELECTR P, V21, DOI 10.1515/ijeeps-2019-0202
   Robert Koch Institut, 2020, EMPF ROB KOCH I HYG
   Robert Koch Institut, 2020, HINW TEST PAT INF NE
   Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Schalte G, 2020, ANASTH INTENSIVMED, V61, pS132, DOI 10.19224/ai2020.S132
   Schwarz K, 2015, J AEROSOL MED PULM D, V28, P52, DOI 10.1089/jamp.2013.1104
   Shao F, 2020, RESUSCITATION, V151, P18, DOI 10.1016/j.resuscitation.2020.04.005
   Simonds AK, 2010, HEALTH TECHNOL ASSES, V14, P131, DOI 10.3310/hta14460-02
   Tagarro Alfredo, 2020, JAMA Pediatr, DOI 10.1001/jamapediatrics.2020.1346
   University of Liverpool, 2020, COVID 19 DRUG INT
   Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wachs C, 2020, DEUT MED WOCHENSCHR, V145, P693, DOI 10.1055/a-0948-8505
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang RH, 2019, HEART LUNG, V48, P46, DOI 10.1016/j.hrtlng.2018.09.005
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Westhoff M, 2015, PNEUMOLOGIE, V69, P719, DOI 10.1055/s-0034-1393309
   Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   World Health Organization, 2020, CLIN MAN COVID 19
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 88
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0003-2417
EI 1432-055X
J9 ANAESTHESIST
JI Anaesthesist
DI 10.1007/s00101-020-00879-3
EA NOV 2020
PG 11
WC Anesthesiology
SC Anesthesiology
GA OX2OB
UT WOS:000593409500001
PM 33245382
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Abd-Elsalam, S
   Soliman, S
   Esmail, ES
   Khalaf, M
   Mostafa, EF
   Medhat, MA
   Ahmed, OA
   Abd El Ghafar, MS
   Alboraie, M
   Hassany, SM
AF Abd-Elsalam, Sherief
   Soliman, Shaimaa
   Esmail, Eslam Saber
   Khalaf, Mai
   Mostafa, Ehab F.
   Medhat, Mohammed A.
   Ahmed, Ossama Ashraf
   Abd El Ghafar, Mohamed Samir
   Alboraie, Mohamed
   Hassany, Sahar M.
TI Do Zinc Supplements Enhance the Clinical Efficacy of
   Hydroxychloroquine?: a Randomized, Multicenter Trial
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article; Early Access
DE Zinc; Chloroquine; Antioxidants; COVID 19; Treatment
ID PNEUMONIA; COVID-19; WUHAN; CHINA
AB No specific treatment for COVID-19 infection is available up till now, and there is a great urge for effective treatment to reduce morbidity and mortality during this pandemic. We aimed to evaluate the effect of combining chloroquine/hydroxychloroquine (CQ/HCQ) and zinc in the treatment of COVID-19 patients. This was a randomized clinical trial conducted at three major University hospitals in Egypt. One hundred ninety-one patients with a confirmed diagnosis of COVID-19 infection were randomized into two groups: group I (96) patients received both HCQ and zinc, and group II (95) received HCQ only. The primary endpoints were the recovery within 28 days, the need for mechanical ventilation, and death. The two groups were matched for age and gender. They had no significant difference regarding any of the baseline laboratory parameters or clinical severity grading. Clinical recovery after 28 days was achieved by 79.2% in the zinc group and 77.9% in zinc-free treatment group, without any significant difference (p = 0.969). The need for mechanical ventilation and the overall mortality rates did not show any significant difference between the 2 groups either (p = 0.537 and 0.986, respectively). The age of the patient and the need for mechanical ventilation were the only risk factors associated with the patients' mortality by the univariate regression analysis (p = 0.001 and < 0.001, respectively). Zinc supplements did not enhance the clinical efficacy of HCQ. More randomized studies are needed to evaluate the value of adding zinc to other therapies for COVID 19.
C1 [Abd-Elsalam, Sherief; Esmail, Eslam Saber; Khalaf, Mai] Tanta Univ, Trop Med & Infect Dis Dept, Fac Med, El Giash St, Tanta 31527, Egypt.
   [Soliman, Shaimaa] Menoufia Univ, Publ Hlth & Community Med, Menoufia, Egypt.
   [Mostafa, Ehab F.; Medhat, Mohammed A.; Hassany, Sahar M.] Assiut Univ, Trop Med & Gastroenterol Dept, Fac Med, Assiut, Egypt.
   [Ahmed, Ossama Ashraf] Ain Shams Univ, Dept Internal Med, Cairo, Egypt.
   [Abd El Ghafar, Mohamed Samir] Tanta Univ, Dept Anesthesia Surg Intens Care & Pain Med, Fac Med, Tanta, Egypt.
   [Alboraie, Mohamed] Al Azhar Univ, Dept Internal Med, Cairo, Egypt.
RP Abd-Elsalam, S (corresponding author), Tanta Univ, Trop Med & Infect Dis Dept, Fac Med, El Giash St, Tanta 31527, Egypt.
EM sherif.abdelbaky@med.tanta.edu.eg
RI Alboraie, Mohamed/F-5688-2011; abd-elsalam, sherief/L-3274-2018
OI Alboraie, Mohamed/0000-0002-8490-9822; abd-elsalam,
   sherief/0000-0003-4366-2218
CR Abd-Elsalam S, 2020, AM J TROP MED HYG, V103, P1635, DOI 10.4269/ajtmh.20-0873
   Abd-Elsalam Sherief, 2020, Infect Disord Drug Targets, DOI 10.2174/1871526520666200726224802
   [Anonymous], COR DIS COVID 19 DAS
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Dabbagh-Bazarbachi H, 2014, J AGR FOOD CHEM, V62, P8085, DOI 10.1021/jf5014633
   Fiolet T, EFFECT HYDROXYCHLORO, DOI [10.1016/j.cmi.2020.08.022, DOI 10.1016/J.CMI.2020.08.022]
   Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lazarczyk M, 2008, J VIROL, V82, P11486, DOI 10.1128/JVI.01314-08
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu JY, 2020, EMERG INFECT DIS, V26, P1320, DOI 10.3201/eid2606.200239
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Marjot Thomas, 2020, J Hepatol, DOI 10.1016/j.jhep.2020.09.024
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Mohamed Amal A, 2020, Infect Disord Drug Targets, DOI 10.2174/1871526520666200520112848
   Pal A, 2020, BIOL TRACE ELEM RES, DOI 10.1007/s12011-020-02437-9
   Pal A, 2020, INDIAN J CLIN BIOCHE, V35, P274, DOI 10.1007/s12291-020-00900-x
   Pawar A, 2020, PHYTOTHER RES, V34, P3085, DOI 10.1002/ptr.6886
   Sarin SK, 2020, HEPATOL INT, V14, P690, DOI 10.1007/s12072-020-10072-8
   Shah GS, 2012, ITAL J PEDIATR, V38, DOI 10.1186/1824-7288-38-36
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   WHO, 2020, CLIN MAN SEV AC RESP
   Xue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109180
NR 28
TC 0
Z9 0
U1 2
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163-4984
EI 1559-0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
DI 10.1007/s12011-020-02512-1
EA NOV 2020
PG 5
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA OX2MQ
UT WOS:000593405800001
PM 33247380
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Louapre, C
   Maillart, E
   Papeix, C
   Zeidan, S
   Biotti, D
   Lepine, Z
   Wahab, A
   Zedet, M
   Labauge, P
   Tilikete, C
   Pique, J
   Tourbah, A
   Mathey, G
   Boulos, DD
   Branger, P
   Kremer, LD
   Marignier, R
   Collongues, N
   De Seze, JM
AF Louapre, Celine
   Maillart, Elisabeth
   Papeix, Caroline
   Zeidan, Sinead
   Biotti, Damien
   Lepine, Zoe
   Wahab, Abir
   Zedet, Mickael
   Labauge, Pierre
   Tilikete, Caroline
   Pique, Julie
   Tourbah, Ayman
   Mathey, Guillaume
   Dimitri Boulos, Dalia
   Branger, Pierre
   Kremer, Laurent Daniel
   Marignier, Romain
   Collongues, Nicolas
   De Seze, Jerome
TI Outcomes of coronavirus disease 2019 in patients with neuromyelitis
   optica and associated disorders
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article; Early Access
DE COVID&#8208; 19; immunosuppressant; MOGAD; NMOSD
ID SPECTRUM DISORDER; MULTICENTER; EFFICACY; SAFETY
AB Background Outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown.
   Methods We conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID-19 between 1 March 2020 and 30 June 2020. Main outcome was COVID-19 severity score assessed on a seven-point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death).
   Results Fifteen cases (mean [SD] age: 39.3 [14.3] years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24-year-old patient with positive aquaporine-4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti-CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean [SD] age: 37.0 [13.4] years), with a longer disease duration (mean [SD]: 8.3 [6.3] years) and had a lower expanded disability severity score (EDSS) score (median [range] EDSS: 2.5 [0-4]) relative to patients requiring hospitalization (mean [SD] age: 44.0 [16.4] years, mean [SD] disease duration: 5.8 [5.5] years, median [range] EDSS: 4 [0-6.5]).
   Conclusions COVID-19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID-19; however, we recommend personal protective measures to reduce risk of SARS-CoV-2 infection in this immunocompromised population.
C1 [Louapre, Celine; Maillart, Elisabeth; Papeix, Caroline; Zeidan, Sinead] Sorbonne Univ, Hop Pitie Salpetriere, Ctr Reference Malad Inflammatoires Rares Cerveau, Inst Cerveau,CIC Neurosci,ICM, Paris, France.
   [Biotti, Damien; Lepine, Zoe] CHU Purpan, Ctr Ressources & Competences Sclerose Plaques, Pole Neurosci, Neurol Unit B4, Toulouse, France.
   [Wahab, Abir] UPEC Univ, Grp Hosp Henri Mondor, AP HP, Serv Neurol, Creteil, France.
   [Wahab, Abir] UPEC Univ, Grp Hosp Henri Mondor, AP HP, CRC SEP, Creteil, France.
   [Zedet, Mickael] CHU Lille, Hop Roger Salengro, Dept Neurol, Unite Neurol Inflammatoire, Lille, France.
   [Labauge, Pierre] CHU Montpellier, Dept Neurol, Montpellier, France.
   [Tilikete, Caroline] Univ Lyon, Serv Neurocognit & Neuroophtalmol, Ctr Rech Neurosci Lyon, Equipe Impact,Grp Hosp Est,Hosp Civils Lyon, Lyon, France.
   [Pique, Julie; Marignier, Romain] Hosp Civils Lyon, Ctr Reference Malad Inflammatoires Rares Cerveau, Serv Neurol Sclerose Plaques Pathol Myeline & Neu, Hop Neurol Pierre Wertheimer, Lyon, France.
   [Tourbah, Ayman] Univ Paris Saclay, UFR Simone Veil UVSQ, Hop Raymond Poincare, Serv Neurol, Garches, France.
   [Mathey, Guillaume] Ctr Reg Hosp Univ Nancy, Hop Cent, Serv Neurol, Nancy, France.
   [Mathey, Guillaume] Univ Lorraine, Vandoeuvre Les Nancy, France.
   [Dimitri Boulos, Dalia] CHU Bicetre, Serv Neurol, Le Kremlin Bicetre, France.
   [Branger, Pierre] CHU Caen Normandie, Serv Neurol, Caen, France.
   [Kremer, Laurent Daniel; Collongues, Nicolas; De Seze, Jerome] CHU Strasbourg, Serv Neurol, Strasbourg, France.
   [Kremer, Laurent Daniel; Collongues, Nicolas; De Seze, Jerome] CHU Strasbourg, CIC INSERM 1434, Strasbourg, France.
RP Louapre, C (corresponding author), Sorbonne Univ, Hop Pitie Salpetriere, Inst Cerveau, ICM, F-75013 Paris, France.
EM celine.louapre@aphp.fr
OI Maillart, Elisabeth/0000-0001-7699-0328
FU French State [ANR-10-COHO-002]; ARSEP Foundation; Eugene Devic EDMUS
   Foundation
FX This study did not receive specific funding. French Clinical Research
   Infrastructure Network for Multiple Sclerosis (FCRIN4MS) is supported by
   a grant provided by the French State and handled by the 'Agence
   Nationale de la Recherche', within the framework of the 'Investments for
   the Future' program, and by the ARSEP Foundation. Paris Brain Institute
   (ICM) Clinical Research Infrastructure Network (iCRIN) is supported by a
   grant provided by the French State and handled by the 'Agence Nationale
   de la Recherche', within the framework of the 'Institut
   Hospitalo-Universitaire' program. The Observatoire Francais de la
   Sclerose en Plaques (OFSEP) is supported by a grant provided by the
   French State and handled by the 'Agence Nationale de la Recherche',
   within the framework of the 'Investments for the Future' program, under
   the reference ANR-10-COHO-002, by the Eugene Devic EDMUS Foundation
   against multiple sclerosis and by the ARSEP Foundation.
CR Abboud Hesham, 2020, Mult Scler Relat Disord, V44, P102249, DOI 10.1016/j.msard.2020.102249
   Ciampi E, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102392
   Creed Marina A, 2020, Mult Scler Relat Disord, V44, P102199, DOI 10.1016/j.msard.2020.102199
   Fan ML, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000787
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581
   Pittock SJ, 2019, NEW ENGL J MED, V381, P614, DOI 10.1056/NEJMoa1900866
   Sahraian MA, 2020, MULT SCLER RELAT DIS, V44
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Traboulsee A, 2020, LANCET NEUROL, V19, P402, DOI 10.1016/S1474-4422(20)30078-8
   Zhang C, 2020, LANCET NEUROL, V19, P391, DOI 10.1016/S1474-4422(20)30070-3
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
DI 10.1111/ene.14612
EA NOV 2020
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OX5WE
UT WOS:000593633800001
PM 33103295
OA Bronze
DA 2021-01-01
ER

PT J
AU Nunes-Santos, CJ
   Kuehn, HS
   Rosenzweig, SD
AF Nunes-Santos, Cristiane J.
   Kuehn, Hye Sun
   Rosenzweig, Sergio D.
TI N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural
   Changes with Limited Functional Effects
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Article; Early Access
DE Glycosylation; &#945; -glucosidase; miglustat; SARS-CoV-2; spike; ACE2
ID ENDOPLASMIC-RETICULUM; SPIKE; CORONAVIRUS; SARS-COV-2; MIGLUSTAT;
   TRANSMISSION; INFECTIVITY; INHIBITION; DISEASE; SAFETY
AB In 2014, we reported two siblings with a rare congenital disorder of glycosylation due to mutations in mannosyl-oligosaccharide glucosidase (MOGS). The glycan alteration derived from this disease resulted in an in vitro infection resistance to particular enveloped, N-glycosylation-dependent viruses as influenza and HIV. As part of the global effort to find safe and effective antiviral therapies for Covid-19, we assessed the in vitro activity of the FDA-approved alpha-glucosidase inhibitor miglustat against SARS-CoV-2. Expression plasmids encoding SARS-CoV-2 spike (S) and human ACE2 glycoproteins (GP) were tested to evaluate N-glycan modifications induced by alpha-glucosidase inhibition. Immunoprecipitation was used to assess binding between these two GP. Cell-to-cell fusion was assessed by immunofluorescence of cocultures of SARS-CoV-2 S and ACE2-expressing cells. Miglustat effect on immune response was tested by measuring cytokine release from PBMC exposed to purified SARS-CoV-2 S. In our overexpression system, miglustat successfully and specifically modified N-glycans in both SARS-CoV-2 S and its main receptor ACE2. Binding between these two GP was not affected by glycan modifications. A surrogate marker for viral cytopathic effect, measured as receptor-dependent SARS-CoV-2 S-driven cell-to-cell fusion, was not disrupted by miglustat treatment. This observation was further confirmed in MOGS-null transfected cells. Miglustat produced no statistically significant effects on cytokine production following SARS-CoV-2 S glycoprotein stimulation of PBMC. Our work shows that despite clear N-glycan alteration in the presence of miglustat, the functions of the Covid-19-related glycoproteins studied were not affected, making it unlikely that miglustat can change the natural course of the disease.
C1 [Nunes-Santos, Cristiane J.; Kuehn, Hye Sun; Rosenzweig, Sergio D.] NIH, Serv Immunol, Dept Lab Med, Ctr Clin, 10 Ctr Dr,Bldg 10,Rm 2C410F, Bethesda, MD 20892 USA.
RP Rosenzweig, SD (corresponding author), NIH, Serv Immunol, Dept Lab Med, Ctr Clin, 10 Ctr Dr,Bldg 10,Rm 2C410F, Bethesda, MD 20892 USA.
EM srosenzweig@cc.nih.gov
FU Intramural Research Program, National Institutes of Health Clinical
   CenterUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); NIH Clinical Center-Emergent
   BioSolutions Inc., M-CRADA "Antiviral activity of MOGS inhibitors"United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA
FX This work was supported by the Intramural Research Program, National
   Institutes of Health Clinical Center and National Institute of Allergy
   and Infectious Diseases, and the NIH Clinical Center-Emergent
   BioSolutions Inc., M-CRADA "Antiviral activity of MOGS inhibitors." We
   acknowledge Drs. Kevin Spurgers, Anthony Treston, and Kelly Warfield
   from Emergent BioSolutions for their review of the manuscript, financial
   support for research of the impact of iminosugars on N-glycosylation,
   and the provision of N-butyldeoxynojirimycin. The content of this
   article does not necessarily reflect the views or policies of the
   Department of Health and Human Services, nor does mention of trade
   names, commercial products, or organizations implying endorsement by the
   US government.
CR Alonzi DS, 2017, BIOCHEM SOC T, V45, P571, DOI 10.1042/BST20160182
   Brand M, 2015, PHARMACOEPIDEM DR S, V24, P329, DOI 10.1002/pds.3760
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Chang JH, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.77
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cox TM, 2003, J INHERIT METAB DIS, V26, P513, DOI 10.1023/A:1025902113005
   Fischer PB, 1996, J VIROL, V70, P7153, DOI 10.1128/JVI.70.10.7153-7160.1996
   FISCHL MA, 1994, J ACQ IMMUN DEF SYND, V7, P139
   Fukushi M, 2012, J VIROL, V86, P11745, DOI 10.1128/JVI.01250-12
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kartoglu UH, 2020, VACCINE, V38, P5393, DOI 10.1016/j.vaccine.2020.06.056
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012
   Mehdipour AR, 2020, BIORXIV, DOI [10.1101/2020.07.09.193680, DOI 10.1101/2020.07.09.193680]
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Patterson MC, 2007, LANCET NEUROL, V6, P765, DOI 10.1016/S1474-4422(07)70194-1
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Procko E., 2020, BIORXIV
   Proost P, 1998, J IMMUNOL, V160, P4034
   Rajasekharan S, 2020, REPURPOSING MIGLUSTA, DOI [10.1101/2020.05.18.101691, DOI 10.1101/2020.05.18.101691, 10.1101/2020.05.18.101691.]
   Riethmueller S, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2000080
   Sadat MA, 2014, NEW ENGL J MED, V370, P1615, DOI 10.1056/NEJMoa1302846
   Shajahan A, 2020, BIORXIV, DOI [10.1101/2020.05.01.071688, DOI 10.1101/2020.05.01.071688]
   Varshney S, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2637
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Warfield KL, 2015, VIRUSES-BASEL, V7, P2404, DOI 10.3390/v7052404
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Williams SJ, 2020, BIOCHEM SOC T, V48, P1287, DOI 10.1042/BST20200505
   World Health Organization, 2020, VIRT PRESS C COVID 1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhao P, 2020, BIORXIV
   Zhao XS, 2015, ANTIMICROB AGENTS CH, V59, P206, DOI 10.1128/AAC.03999-14
   Zhong P, 2013, CURR OPIN VIROL, V3, P44, DOI 10.1016/j.coviro.2012.11.004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu Yuanmei, 2020, J Virol, V94, DOI 10.1128/JVI.00635-20
NR 46
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
DI 10.1007/s10875-020-00905-4
EA NOV 2020
PG 10
WC Immunology
SC Immunology
GA OX2RH
UT WOS:000593417900001
PM 33245474
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Salas-Coronas, J
   Garcia-Jerez, MA
   Sandoval-Codoni, JL
   Lara-Rojas, CM
   Ruiz, JG
   Sanabria-Medina, MJ
   Cortes-Gonzalez, MD
   Vallejo-Godoy, S
   Aguilar-Martin, I
   Quesada-Yanez, E
   Martin-Linares, MA
   Alvarez-Moreno, ML
AF Salas-Coronas, Joaquin
   Angeles Garcia-Jerez, M.
   Luis Sandoval-Codoni, Javier
   Maria Lara-Rojas, Carmen
   Gamir Ruiz, Javier
   Jesus Sanabria-Medina, Maria
   del Carmen Cortes-Gonzalez, Maria
   Vallejo-Godoy, Silvia
   Aguilar-Martin, Ignacio
   Quesada-Yanez, Enriqueta
   Angeles Martin-Linares, M.
   Luisa Alvarez-Moreno, Maria
TI Medicalization of nursing facilities as a real alternative to
   hospitalization during the COVID-19 pandemic
SO REVISTA ESPANOLA DE SALUD PUBLICA
LA Spanish
DT Article
DE COVID-19; Nursing home; Socio-sanitary institution; Medicalization;
   Mortality
ID CORONAVIRUS DISEASE 2019; CONTACT PRECAUTIONS; RISK
AB Background: Nursing homes are high-risk environments for the transmission of the SARS-CoV-2 coronavirus, as they are a closed environment, with patients who present atypical manifestations of the disease, high risk of unfavorable evolution, and staff who frequently present a high mobility in relation to their jobs. On the other hand, in a pandemic situation, numerous hospitals have suffered periods of great healthcare pressure. The objective of this work was to present an experience of medicalization of a residence where almost 50% of the residents contracted the disease.
   Methods: A multidisciplinary intervention was carried out in a publicly owned nursing home with 99 residents. Specialists from Internal Medicine, Primary Care and health technicians worked together, in close collaboration with the residence workers. The presence of nursing personnel 24 hours a day and medical personnel with daily visits was enabled. The center was provided with the necessary means to administer the medication (oral and intravenous) and oxygen therapy necessary to care for patients with the disease. Analytical results were available within 24 hours. For data analysis, the percentages were calculated and the mean was used as a measure of central tendency.
   Results: Forty-eight residents (48.5%) and fifteen workers contracted the disease. The total number of deaths during that period was thirteen (13.1%), seven of them diagnosed with COVID-19 (mean age 84.4 years), with a fatality rate of 14.6%. Eleven patients (22%) diagnosed with COVID-19 were hospitalized, two of whom died during admission.
   Conclusions: The medicalization of nursing homes can help to reduce the pressure on care in hospitals and optimize care for these vulnerable people with more humanized care, which can ultimately lead to better health outcomes.
C1 [Salas-Coronas, Joaquin; Angeles Garcia-Jerez, M.; Maria Lara-Rojas, Carmen; Gamir Ruiz, Javier; Luisa Alvarez-Moreno, Maria] Hosp Poniente, Serv Med Interna, Almeria, Spain.
   [Salas-Coronas, Joaquin] Hosp Poniente, Unidad Med Trop, Almeria, Spain.
   [Luis Sandoval-Codoni, Javier; Jesus Sanabria-Medina, Maria; del Carmen Cortes-Gonzalez, Maria; Vallejo-Godoy, Silvia; Aguilar-Martin, Ignacio] Dist Poniente Almeria, Almeria, Spain.
   [Quesada-Yanez, Enriqueta; Angeles Martin-Linares, M.] Delegac Terr Salud & Familias, Almeria, Spain.
RP Salas-Coronas, J (corresponding author), Hosp Poniente, Ctra Almerimar S-N, El Ejidao, Almeria, Spain.
EM joaquin.salas@ephpo.es
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   [Anonymous], 2020, INF SEM ALERTA COVID
   D'Adamo H, 2020, J AM GERIATR SOC, V68, P912, DOI 10.1111/jgs.16445
   Danis K, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.22.2000956
   Day HR, 2011, J HOSP INFECT, V79, P103, DOI 10.1016/j.jhin.2011.03.026
   Evans HL, 2003, SURGERY, V134, P180, DOI 10.1067/msy.2003.222
   Inzitari M, 2020, J AM MED DIR ASSOC, V21, P954, DOI 10.1016/j.jamda.2020.06.015
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Morgan DJ, 2009, AM J INFECT CONTROL, V37, P85, DOI 10.1016/j.ajic.2008.04.257
   Pericas JM, 2020, INFECTION, V29, P1
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Shi SM, 2020, J AM MED DIR ASSOC, V21, P1378, DOI 10.1016/j.jamda.2020.08.027
   Taylor J, 2020, MMWR-MORBID MORTAL W, V69, P1288, DOI 10.15585/mmwr.mm6937a3
NR 13
TC 0
Z9 0
U1 3
U2 3
PU MINISTERIO DE SANIDAD Y CONSUMO
PI MADRID
PA PASEO DEL PRADO 18-20, MADRID, 28071, SPAIN
SN 1135-5727
J9 REV ESP SALUD PUBLIC
JI Rev. Esp. Salud Publica
PD NOV 27
PY 2020
VL 94
AR e1-7
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OX7CG
UT WOS:000593717500001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Salvarani, C
   Mancuso, P
   Gradellini, F
   Viani, N
   Pandolfi, P
   Reta, M
   Carrozzi, G
   Sandri, G
   Bajocchi, G
   Galli, E
   Muratore, F
   Boiardi, L
   Pipitone, N
   Cassone, G
   Croci, S
   Marata, AM
   Costantini, M
   Rossi, PG
AF Salvarani, Carlo
   Mancuso, Pamela
   Gradellini, Federica
   Viani, Nilla
   Pandolfi, Paolo
   Reta, Massimo
   Carrozzi, Giuliano
   Sandri, Gilda
   Bajocchi, Gianluigi
   Galli, Elena
   Muratore, Francesco
   Boiardi, Luigi
   Pipitone, Nicolo
   Cassone, Giulia
   Croci, Stefania
   Marata, Anna Maria
   Costantini, Massimo
   Giorgi Rossi, Paolo
TI Susceptibility to COVID-19 in Patients Treated With Antimalarials: A
   Population Based Study in Emilia-Romagna, Northern Italy
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article; Early Access
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS
AB Objective To evaluate the susceptibility to coronavirus disease 2019 (COVID-19) in patients with autoimmune conditions treated with antimalarials in a population-based study.
   Methods All residents treated with chloroquine (CQ)/hydroxychloroquine (HCQ) from July through December 2019 and living in 3 provinces of Regione Emilia-Romagna were identified by drug prescription registries and matched with the registry containing all residents living in the same areas who have had swabs and tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated.
   Results A total of 4,408 patients were identified. The prevalence of patients receiving antimalarials was 0.85 per 1,000 men and 3.3 per 1,000 women. The cumulative incidence of testing during the study period was 2.7% in the general population and 3.8% among those receiving CQ or HCQ, while the cumulative incidence of testing positive was 0.55% in the general population and 0.70% among those receiving CQ/HCQ. Multivariate models showed that those receiving CQ/HCQ had a slightly higher probability of being tested compared to the general population (OR 1.09 [95% CI 0.94-1.28]), the same probability of being diagnosed as having COVID-19 (OR 0.94 [95% CI 0.66-1.34]), and a slightly lower probability of being positive once tested (OR 0.83 [95% CI 0.56-1.23]). None of the differences were significant.
   Conclusion Our findings do not support the use of antimalarials as a prophylactic treatment of COVID-19.
C1 [Salvarani, Carlo] IRCCS Reggio Emilia, Azienda USL, Reggio Emilia, Italy.
   [Salvarani, Carlo] Univ Modena & Reggio Emilia, Reggio Emilia, Italy.
   [Mancuso, Pamela; Gradellini, Federica; Bajocchi, Gianluigi; Muratore, Francesco; Boiardi, Luigi; Pipitone, Nicolo; Croci, Stefania; Costantini, Massimo; Giorgi Rossi, Paolo] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy.
   [Viani, Nilla] Azienda USL Modena, Modena, Italy.
   [Viani, Nilla] Azienda OU Modena, Modena, Italy.
   [Pandolfi, Paolo; Reta, Massimo] Azienda USL Bologna, Bologna, Italy.
   [Sandri, Gilda; Galli, Elena; Cassone, Giulia] Univ Modena & Reggio Emilia, Modena, Italy.
RP Salvarani, C (corresponding author), Azienda Osped IRCCS Reggio Emilia, Unita Operat Reumatol, Viale Risorgimento 80, I-42100 Reggio Emilia, Italy.
EM salvarani.carlo@ausl.re.it
CR Balevic SJ, 2020, J RHEUMATOL, V47, DOI 10.3899/jrheum.200681
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cassione EB, 2020, ANN RHEUM DIS, V79, P1382, DOI 10.1136/annrheumdis-2020-217717
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gonzalez-Echavarri C, 2018, LUPUS, V27, P2253, DOI 10.1177/0961203318811598
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Kang CK, 2020, KOREAN J INTERN MED, V35, P782, DOI 10.3904/kjim.2020.157
   Mathian A, 2020, ANN RHEUM DIS, V79, P837, DOI 10.1136/annrheumdis-2020-217566
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Riccardo F, 2020, EPIDEMIOLOGICAL CHAR, DOI 10.1101/2020.04.08.20056861
   Rossi PG, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104415
   Salvarani C, 2020, ANN RHEUM DIS, V79, P986, DOI [10.1136/annrheumdis-2020-218364, 10.1136/annrheumdis-2020-217903]
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Spinelli FR, 2020, ANN RHEUM DIS, V79, P666, DOI [10.1136/annrheumdis-2020-217367, 10.1136/annrheumdis-2020-217557]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 18
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
DI 10.1002/art.41475
EA NOV 2020
PG 5
WC Rheumatology
SC Rheumatology
GA OV9BG
UT WOS:000592495600001
PM 32767527
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rawat, P
   Jemimah, S
   Ponnuswamy, PK
   Gromiha, MM
AF Rawat, Puneet
   Jemimah, Sherlyn
   Ponnuswamy, P. K.
   Gromiha, M. Michael
TI Why are ACE2 binding coronavirus strains SARS-CoV/SARS-CoV-2 wild and
   NL63 mild?
SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article; Early Access
DE ACE2 binding; coronavirus spike protein; COVID&#8208; 19; mutational
   analysis; NL63; SARS; surrounding hydrophobicity
ID FUNCTIONAL RECEPTOR; SPIKE; SARS; IDENTIFICATION; RESIDUES
AB Coronaviruses are responsible for several epidemics, including the 2002 SARS, 2012 MERS, and COVID-19. The emergence of recent COVID-19 pandemic due to SARS-CoV-2 virus in December 2019 has resulted in considerable research efforts to design antiviral drugs and other therapeutics against coronaviruses. In this context, it is crucial to understand the biophysical and structural features of the major proteins that are involved in virus-host interactions. In the current study, we have compared spike proteins from three strains of coronaviruses NL63, SARS-CoV, and SARS-CoV, known to bind human angiotensin-converting enzyme 2 (ACE2), in terms of sequence/structure conservation, hydrophobic cluster formation and importance of binding site residues. The study reveals that the severity of coronavirus strains correlates positively with the interaction area, surrounding hydrophobicity and interaction energy and inversely correlate with the flexibility of the binding interface. Also, we identify the conserved residues in the binding interface of spike proteins in all three strains. The systematic point mutations show that these conserved residues in the respective strains are evolutionarily favored at their respective positions. The similarities and differences in the spike proteins of the three viruses indicated in this study may help researchers to deeply understand the structural behavior, binding site properties and etiology of ACE2 binding, accelerating the screening of potential lead molecules and the development/repurposing of therapeutic drugs.
C1 [Rawat, Puneet; Jemimah, Sherlyn; Gromiha, M. Michael] Indian Inst Technol Madras, Bhupat & Jyoti Mehta Sch Biosci, Dept Biotechnol, Chennai, Tamil Nadu, India.
   [Ponnuswamy, P. K.] Bharathidasan Univ, Dept Phys, Tiruchirapalli, India.
RP Gromiha, MM (corresponding author), Indian Inst Technol Madras, Chennai, Tamil Nadu, India.
EM gromiha@iitm.ac.in
OI Michael, Gromiha/0000-0002-1776-4096
FU Department of Science and Technology, Government of IndiaDepartment of
   Science & Technology (India) [MSC/2020/000319]
FX Department of Science and Technology, Government of India, Grant/Award
   Number: MSC/2020/000319
CR [Anonymous], PYMOL MOL GRAPH SYST
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Chakraborti S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-73
   Chan CM, 2009, J VIROL, V83, P1026, DOI 10.1128/JVI.01387-08
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chen JM, 2013, PROTEIN SCI, V22, P510, DOI 10.1002/pro.2230
   CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940
   Delgado J, 2019, BIOINFORMATICS, V35, P4168, DOI 10.1093/bioinformatics/btz184
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Grunberg R, 2006, STRUCTURE, V14, P683, DOI 10.1016/j.str.2006.01.014
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Hu J., 2020, BIORXIV, DOI [10.1101/2020.06.20.161323, DOI 10.1101/2020.06.20.161323]
   JONES DD, 1975, J THEOR BIOL, V50, P167, DOI 10.1016/0022-5193(75)90031-4
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Khafaie Morteza Abdullatif, 2020, Osong Public Health Res Perspect, V11, P74, DOI 10.24171/j.phrp.2020.11.2.03
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100
   MANAVALAN P, 1978, NATURE, V275, P673, DOI 10.1038/275673a0
   NOZAKI Y, 1971, J BIOL CHEM, V246, P2211
   Parthiban V, 2006, NUCLEIC ACIDS RES, V34, pW239, DOI 10.1093/nar/gkl190
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Roser M., CORONAVIRUS PANDEMIC
   Stadnytskyi V, 2020, P NATL ACAD SCI USA, V117, P11875, DOI 10.1073/pnas.2006874117
   Tsai CJ, 1997, PROTEIN SCI, V6, P53
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 34
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0887-3585
EI 1097-0134
J9 PROTEINS
JI Proteins
DI 10.1002/prot.26024
EA NOV 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OV8QP
UT WOS:000592467600001
PM 33210300
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhou, JH
   Wu, B
   Wang, WX
   Lei, F
   Cheng, X
   Qin, JJ
   Cai, JJ
   Zhang, XJ
   Zhou, F
   Liu, YM
   Li, HM
   Zhu, LH
   She, ZG
   Zhang, X
   Yang, J
   Li, HL
AF Zhou, Jiang-Hua
   Wu, Bin
   Wang, Wen-Xin
   Lei, Fang
   Cheng, Xu
   Qin, Juan-Juan
   Cai, Jing-Jing
   Zhang, Xiao-Jing
   Zhou, Feng
   Liu, Ye-Mao
   Li, Hao-Miao
   Zhu, Li-Hua
   She, Zhi-Gang
   Zhang, Xin
   Yang, Juan
   Li, Hong-Liang
TI No significant association between dipeptidyl peptidase-4 inhibitors and
   adverse outcomes of COVID-19
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE COVID-19; SARS-CoV-2; DPP4 inhibitors; Diabetes; Glucose control;
   Adverse effects
ID CARDIOVASCULAR OUTCOMES; IV INHIBITION; TYPE-2; SITAGLIPTIN; IMMUNE
AB BACKGROUND
   Dipeptidyl peptidase-4 (DPP4) is commonly targeted to achieve glycemic control and has potent anti-inflammatory and immunoregulatory effects. Recent structural analyses indicated a potential tight interaction between DPP4 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), raising a promising hypothesis that DPP4 inhibitor (DPP4i) drugs might be an optimal strategy for treating coronavirus disease 2019 (COVID-19) among patients with diabetes. However, there has been no direct clinical evidence illuminating the associations between DPP4i use and COVID-19 outcomes.
   AIM
   To illuminate the associations between DPP4i usage and the adverse outcomes of COVID-19.
   METHODS
   We conducted a multicenter, retrospective analysis including 2563 patients with type 2 diabetes who were hospitalized due to COVID-19 at 16 hospitals in Hubei Province, China. After excluding ineligible individuals, 142 patients who received DPP4i drugs and 1115 patients who received non-DPP4i oral anti-diabetic drugs were included in the subsequent analysis. We performed a strict propensity score matching (PSM) analysis where age, sex, comorbidities, number of oral hypoglycemic agents, heart rate, blood pressure, pulse oxygen saturation (SpO(2)) < 95%, CT diagnosed bilateral lung lesions, laboratory indicators, and proportion of insulin usage were matched. Finally, 111 participants treated with DPP4i drugs were successfully matched to 333 non-DPP4i users. Then, a linear logistic model and mixed-effect Cox model were applied to analyze the associations between in-hospital DPP4i use and adverse outcomes of COVID-19.
   RESULTS
   After rigorous matching and further adjustments for imbalanced variables in the linear logistic model and Cox adjusted model, we found that there was no significant association between in-hospital DPP4i use (DPP4i group) and 28-d all-cause mortality (adjusted hazard ratio = 0.44, 95%CI: 0.09-2.11, P = 0.31). Likewise, the incidences and risks of secondary outcomes, including septic shock, acute respiratory distress syndrome, or acute organ (kidney, liver, and cardiac) injuries, were also comparable between the DPP4i and non-DPP4i groups. The performance of DPP4i agents in achieving glucose control (e.g., the median level of fasting blood glucose and random blood glucose) and inflammatory regulation was approximately equivalent in the DPP4i and non-DPP4i groups. Furthermore, we did not observe substantial side effects such as uncontrolled glycemia or acidosis due to DPP4i application relative to the use of non-DPP4i agents in the study cohort.
   CONCLUSION
   Our findings demonstrated that DPP4i use is not significantly associated with poor outcomes of COVID-19 or other adverse effects of anti-diabetic treatment. The data support the continuation of DPP4i agents for diabetes management in the setting of COVID-19.
C1 [Zhou, Jiang-Hua; Wu, Bin; Wang, Wen-Xin; Cheng, Xu; Qin, Juan-Juan; Liu, Ye-Mao; Li, Hao-Miao] Wuhan Univ, Basic Med Sch, Renmin Hosp, Dept Cardiol, Wuhan 430071, Hubei, Peoples R China.
   [Lei, Fang; Zhang, Xiao-Jing] Wuhan Univ, Inst Model Anim, Basic Med Sch, Wuhan 430071, Hubei, Peoples R China.
   [Cai, Jing-Jing] Cent South Univ, Xiangya Hosp 3, Dept Cardiol, Changsha 410013, Hunan, Peoples R China.
   [Zhou, Feng] Wuhan Univ, Inst Model Anim, Zhongnan Hosp, Med Sci Res Ctr, Wuhan 430072, Hubei, Peoples R China.
   [Zhu, Li-Hua; She, Zhi-Gang; Yang, Juan; Li, Hong-Liang] Wuhan Univ, Renmin Hosp, Dept Cardiol, 115 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
   [Zhu, Li-Hua; She, Zhi-Gang; Yang, Juan; Li, Hong-Liang] Wuhan Univ, Inst Model Anim, 115 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
   [Zhang, Xin] Wuhan Univ, Inst Model Anim, Dept Gastroenterol, Tongren Hosp,Wuhan Hosp 3, Wuhan 430072, Hubei, Peoples R China.
RP Li, HL (corresponding author), Wuhan Univ, Renmin Hosp, Dept Cardiol, 115 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.; Li, HL (corresponding author), Wuhan Univ, Inst Model Anim, 115 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
EM lihl@whu.edu.cn
FU National Key R&D Program of China [2019YFC2004702, 2020YFC0845500];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81970070, 81970011]; Hubei Science and
   Technology Support Project [2019BFC582, 2018BEC473]
FX Supported by National Key R&D Program of China, No. 2019YFC2004702 and
   No. 2020YFC0845500; the National Natural Science Foundation of China,
   No. 81970070 and No. 81970011; the Hubei Science and Technology Support
   Project, No. 2019BFC582 and No. 2018BEC473.
CR Bassendine MF, 2020, J DIABETES, V12, P649, DOI 10.1111/1753-0407.13052
   Bergman AJ, 2006, CLIN THER, V28, P55, DOI 10.1016/j.clinthera.2006.01.015
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Cefalu WT, 2019, DIABETES CARE, V42, pS13, DOI 10.2337/dc19-S002
   Donnan K, 2019, EUR J PHARMACOL, V846, P23, DOI 10.1016/j.ejphar.2019.01.002
   Dube MP, 2019, CLIN INFECT DIS, V69, P1165, DOI 10.1093/cid/ciy1051
   Freeman J, 2019, POSTGRAD MED, V131, P241, DOI 10.1080/00325481.2019.1578590
   Goodwin SR, 2013, J CLIN ENDOCR METAB, V98, P743, DOI 10.1210/jc.2012-3532
   Green JB, 2015, NEW ENGL J MED, V373, P232, DOI 10.1056/NEJMoa1501352
   Heller SR, 2017, DIABETES OBES METAB, V19, P664, DOI 10.1111/dom.12871
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Klemann C, 2016, CLIN EXP IMMUNOL, V185, P1, DOI 10.1111/cei.12781
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Marrone G, 2017, EUR REV MED PHARMACO, V21, P122
   Min SH, 2017, DIABETES-METAB RES, V33, DOI 10.1002/dmrr.2818
   Montvida O, 2018, DIABETES CARE, V41, P69, DOI 10.2337/dc17-1414
   NHCo China, 2020, NEW COR PNEUM PREV C
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rosenstock J, 2019, JAMA, P2019
   Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684
   Sromova L, 2016, DIABETES RES CLIN PR, V118, P183, DOI 10.1016/j.diabres.2016.06.020
   Strollo R, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3330
   Tahrani AA, 2016, NAT REV ENDOCRINOL, V12, P566, DOI 10.1038/nrendo.2016.86
   van Poppel PCM, 2014, DIABETES RES CLIN PR, V103, P395, DOI 10.1016/j.diabres.2013.12.039
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Zanden RWD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139367
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu L, 2020, CELL METAB, V31, p[e3, 1068]
NR 31
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD NOV 26
PY 2020
VL 8
IS 22
BP 5576
EP 5588
DI 10.12998/wjcc.v8.i22.5576
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA PF0KI
UT WOS:000598753100010
PM 33344548
OA Other Gold
DA 2021-01-01
ER

PT J
AU Wu, Q
   Wang, Y
   Chen, HQ
   Pan, H
AF Wu, Qi
   Wang, Ying
   Chen, Han-Qian
   Pan, Hui
TI Intraoperative care of elderly patients with COVID-19 undergoing double
   lung transplantation: Two case reports
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE Lung transplantation; Extracorporeal membrane oxygenation; COVID-19;
   Intraoperative care; Third-level protection; Case report
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; CORONAVIRUS; MANAGEMENT; SUPPORT;
   WUHAN
AB BACKGROUND
   Lung transplantation is considered an effective method for treating patients with end-stage coronavirus disease 2019 (COVID-19). The nurses play a pivotal role in lung transplantation for COVID-19 patients.
   CASE SUMMARY
   Two elderly patients were admitted to the emergency department due to cough, and the nucleic acid test was positive. The patients were preliminarily diagnosed with COVID-19. The chest computed tomography scan revealed massive lung consolidation, and the patients did not improve after treatment with antiviral drugs, glucocorticoids, antibiotics, and other drugs. Under the support of pure oxygen in extracorporeal membrane oxygenation, the patients' oxygen levels were still poor, indicating that they were in the terminal stage of viral pneumonia. The patients underwent double-lung transplantation and received intraoperative care. The extracorporeal membrane oxygenation device was removed within a week of the surgical procedure, and the respiratory circulation of the patients were stabilized.
   CONCLUSION
   High-quality care for COVID-19 patients undergoing lung transplantation ensures patient safety during operation while protecting the safety of the medical staff.
C1 [Wu, Qi; Wang, Ying; Chen, Han-Qian] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Operating Room,79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
   [Pan, Hui] Zhejiang Univ, Sch Med, Dept Lung Transplantat Surg, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.
RP Wu, Q (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Operating Room,79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM 1506143@zju.edu.cn
FU Medical and Health Science and Technology Project of Zhejiang Province
   [2019KY394]
FX Supported by Medical and Health Science and Technology Project of
   Zhejiang Province (Fund Project No. 2019KY394).
CR Biscotti M, 2014, J THORAC CARDIOV SUR, V148, P2410, DOI 10.1016/j.jtcvs.2014.07.061
   Bonicolini E, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2541-3
   Carney KC, 2019, CRIT CARE NURS CLIN, V31, P285, DOI 10.1016/j.cnc.2019.05.001
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Geube M, 2019, CRIT CARE CLIN, V35, P27, DOI 10.1016/j.ccc.2018.08.007
   Knisley J, 2019, CRIT CARE NURSE, V39, pE8, DOI 10.4037/ccn2019620
   Ko H, 2017, J CARDIOTHOR VASC AN, V31, P409, DOI 10.1053/j.jvca.2017.01.006
   Nicastri E, 2020, EURO SURVEILL, V25
   Reeb J, 2016, J THORAC DIS, V8, pS353, DOI 10.21037/jtd.2016.04.42
   Valapour M, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14129
   Weber U, 2018, TRANSPL INT, V31, P1245, DOI 10.1111/tri.13307
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
NR 13
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD NOV 26
PY 2020
VL 8
IS 22
BP 5765
EP 5772
DI 10.12998/wjcc.v8.i22.5765
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA PF0KI
UT WOS:000598753100034
PM 33344572
OA Other Gold
DA 2021-01-01
ER

PT J
AU Recasens, BB
   Rubio, MA
AF Bertran Recasens, Bernat
   Angel Rubio, Miguel
TI Neuromuscular Diseases Care in the Era of COVID-19
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE neuromuscular disease (NMD); COVID-19; ALS (amyotrophic lateral
   sclerosis); CIDP; myasthenia gravis; telemedicine; telehealth
AB The COVID-19 pandemic has pushed health systems to their limit and forced readjustment of standards of care for different pathologies. Management of neuromuscular diseases becomes a challenge since most of them are chronic, disabling, progressive, and/or require immunosuppressive drugs. There are three main aspects of COVID-19 that affect neuromuscular diseases care. The first one relates to how SARS-CoV2 directly affects different neuromuscular pathologies. Respiratory weakness, as seen in myasthenia gravis, amyotrophic lateral sclerosis, and myopathies, and the use of immunomodulatory drugs (Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy) make this group of patients potentially more vulnerable. Secondly, safety measures also affect proper care, limiting care continuity, and physical rehabilitation (one of the essential aspects of myopathies treatment). Telemedicine can partially solve the problem allowing for a continuum of close care, avoiding unnecessary visits, and even guaranteeing the attention of professionals from tertiary care centers. However, one of the crucial steps in neuromuscular diseases is diagnosis, and in most scenarios, more than one face-to-face visit is needed. Lastly, the global COVID-19 situation will also have an economic impact on patients and their families. This situation is of particular concern given that neuromuscular diseases already present difficulties due to the scarcity of resources in terms of public healthcare and research.
C1 [Bertran Recasens, Bernat; Angel Rubio, Miguel] Hosp del Mar, Neurol Dept, Neuromuscular Unit, Barcelona, Spain.
RP Rubio, MA (corresponding author), Hosp del Mar, Neurol Dept, Neuromuscular Unit, Barcelona, Spain.
EM merubio@parcdesalutmar.cat
CR Abu-Rumeileh S, 2020, J NEUROL, DOI 10.1007/s00415-020-10124-x
   Anand P, 2020, MUSCLE NERVE, V62, P254, DOI 10.1002/mus.26918
   Andrews JA, 2020, MUSCLE NERVE, V62, P182, DOI 10.1002/mus.26989
   [Anonymous], 2020, DRAFT LANDSC COVID 1
   Bagnato S, 2020, INT J INFECT DIS, V99, P276, DOI 10.1016/j.ijid.2020.07.072
   Bedlack RS, 2008, AMYOTROPH LATERAL SC, V9, P257, DOI 10.1080/17482960802195913
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Camacho A, 2018, NEUROLOGIA, V33, P35, DOI 10.1016/j.nrl.2015.02.003
   Consonni M, 2020, J NEUROL, DOI 10.1007/s00415-020-10080-6
   Costello F, 2020, NEUROLOGY, V95, P195, DOI 10.1212/WNL.0000000000009921
   Dalakas MC, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000781
   De Lucia N, 2020, NEUROL SCI, V41, P2339, DOI 10.1007/s10072-020-04592-2
   Desai U, 2020, MUSCLE NERVE, V62, P176, DOI 10.1002/mus.26990
   Di Stefano V, 2020, J NEUROL, DOI 10.1007/s00415-020-10064-6
   Dubbioso R, 2020, NEUROL SCI, V41, P1345, DOI 10.1007/s10072-020-04448-9
   Ebrahimi A, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1789051
   Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0
   Estraneo A, 2020, J NEUROL, DOI 10.1007/s00415-020-10077-1
   EURORDIS (Rare Diseases Europe), RAR DIS COMM RAIS AL
   Fan ML, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000787
   Feldman CH, 2017, ARTHRITIS RHEUMATOL, V69, P387, DOI 10.1002/art.39849
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gilhus NE, 2018, J NEUROL, V265, P1251, DOI 10.1007/s00415-018-8751-9
   Guidon AC, 2020, NEUROLOGY, V94, P959, DOI 10.1212/WNL.0000000000009566
   Guptill JT, 2016, AUTOIMMUNITY, V49, P472, DOI 10.1080/08916934.2016.1214823
   Johnson RM, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2648
   Kassardjian CD, 2020, EUR J NEUROL, V27, P702, DOI 10.1111/ene.14153
   Kelly M, 2020, AMYOTROPH LAT SCL FR, V21, P563, DOI 10.1080/21678421.2020.1773501
   Klug C, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0424-0
   Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581
   Paganoni S, 2019, MUSCLE NERVE, V60, P147, DOI 10.1002/mus.26606
   Paliwal VK, 2020, NEUROL SCI, V41, P3039, DOI 10.1007/s10072-020-04708-8
   Prada V, 2020, J NEUROL, DOI 10.1007/s00415-020-10146-5
   Rajabally YA, 2020, MUSCLE NERVE, V62, P34, DOI 10.1002/mus.26896
   Ramaswamy Swathi Beladakere, 2020, J Neuromuscul Dis, V7, P361, DOI 10.3233/JND-200520
   Rein N, 2020, J NEUROL SCI, V417, DOI 10.1016/j.jns.2020.117053
   Restivo Domenico A, 2020, Ann Intern Med, V173, P1027, DOI 10.7326/L20-0845
   Rondaan C, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-001035
   Sole G, 2020, REV NEUROL-FRANCE, V176, P507, DOI 10.1016/j.neurol.2020.04.004
   Tankisi H, 2020, Clin Neurophysiol, V131, P1931, DOI 10.1016/j.clinph.2020.06.003
   Uncini A, 2020, J NEUROL NEUROSUR PS, V91, P1105, DOI 10.1136/jnnp-2020-324491
   Vakil-Gilani K, 2020, CLIN RHEUMATOL, V39, P2067, DOI 10.1007/s10067-020-05184-3
   Veerapandiyan A, 2020, MUSCLE NERVE, V62, P41, DOI 10.1002/mus.26902
   Veerapandiyan A, 2020, MUSCLE NERVE, V62, P46, DOI 10.1002/mus.26903
   Whittaker A, 2020, ACTA NEUROL SCAND, V142, P14, DOI 10.1111/ane.13266
   Young EI, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116893
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 47
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD NOV 26
PY 2020
VL 11
AR 588929
DI 10.3389/fneur.2020.588929
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA PC2GK
UT WOS:000596825500001
PM 33329336
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, QQ
   Bai, C
   Yang, RC
   Xing, WY
   Pang, XH
   Wu, SY
   Liu, SY
   Chen, JX
   Liu, TG
   Gu, XH
AF Li, Qianqian
   Bai, Chen
   Yang, Ruocong
   Xing, Weiying
   Pang, Xiaohan
   Wu, Siying
   Liu, Shaoyang
   Chen, Jianxin
   Liu, Tiegang
   Gu, Xiaohong
TI Deciphering the Pharmacological Mechanisms of Ma Xing Shi Gan Decoction
   against COVID-19 through Integrating Network Pharmacology and
   Experimental Exploration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Ma Xing Shi Gan decoction; COVID-19; Traditional Chinese Medicine;
   immunomodulatory; antiviral
ID INFLUENZA A/PR/8 VIRUS; CORONAVIRUS PNEUMONIA; ACTIVE COMPONENT; HERBAL
   MEDICINE; LICORICE ROOTS; LUNG INJURY; GLYCYRRHIZIN; GROWTH; TANG
AB The outbreak of new infectious pneumonia caused by SARS-CoV-2 has posed a significant threat to public health, but specific medicines and vaccines are still being developed. Traditional Chinese medicine (TCM) has thousands of years of experience in facing the epidemic disease, such as influenza and viral pneumonia. In this study, we revealed the efficacy and pharmacological mechanism of Ma Xing Shi Gan (MXSG) Decoction against COVID-19. First, we used liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) to analyze the chemical components in MXSG and identified a total of 97 components from MXSG. Then, the intervention pathway of MXSG based on these components was analyzed with network pharmacology, and it was found that the pathways related to the virus infection process were enriched in some of MXSG component targets. Simultaneously, through literature research, it was preliminarily determined that MXSG, which is an essential prescription for treating COVID-19, shared the feature of antiviral, improving clinical symptoms, regulating immune inflammation, and inhibiting lung injury. The regulatory mechanisms associated with its treatment of COVID-19 were proposed. That MXSG might directly inhibit the adsorption and replication of SARS-CoV-2 at the viral entry step. Besides, MXSG might play a critical role in inflammation and immune regulatory, that is, to prevent cytokine storm and relieve lung injury through toll-like receptors signaling pathway. Next, in this study, the regulatory effect of MXSG on inflammatory lung injury was validated through transcriptome results. In summary, MXSG is a relatively active and safe treatment for influenza and viral pneumonia, and its therapeutic effect may be attributed to its antiviral and anti-inflammatory effects.
C1 [Li, Qianqian; Bai, Chen; Yang, Ruocong; Xing, Weiying; Pang, Xiaohan; Wu, Siying; Liu, Shaoyang; Chen, Jianxin; Liu, Tiegang; Gu, Xiaohong] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing, Peoples R China.
RP Chen, JX; Liu, TG; Gu, XH (corresponding author), Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing, Peoples R China.
EM cjx@bucm.edu.cn; liutiegang2009@163.com; guxh1003@126.com
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2019-JYB-JS-007]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2019M650593]
FX This study has been supported by the Fundamental Research Funds for the
   Central Universities (No. 2019-JYB-JS-007), and China Postdoctoral
   Science Foundation (No. 2019M650593).
CR Biondo C, 2019, BIOMED J, V42, P8, DOI 10.1016/j.bj.2018.12.009
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu X, 2012, J AGR FOOD CHEM, V60, P3947, DOI 10.1021/jf2051587
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Dei-Cas I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69537-3
   Duan C., 2020, J TRADIT CHIN MED, V61, P1
   Duan ZP, 2011, CHINESE MED J-PEKING, V124, P2925, DOI 10.3760/cma.j.issn.0366-6999.2011.18.024
   Fan YP, 2020, ZHONG YI ZA ZHI, V61, P921
   Fei Lin, 2017, Front Pharmacol, V8, P389, DOI 10.3389/fphar.2017.00389
   Fei YX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01361
   Gu M, 2020, ZHONGGUO ZHONG YAO Z, V45, P1253, DOI DOI 10.19540/j.cnki.cjcmm.20200225.501
   Harada S, 2005, BIOCHEM J, V392, P191, DOI 10.1042/BJ20051069
   Henry BM, 2020, NEW ENGL J MED, V382, P1860, DOI 10.1056/NEJMc2005203
   Hsieh CF, 2012, J ETHNOPHARMACOL, V143, P57, DOI 10.1016/j.jep.2012.05.061
   Hu K. E., 2020, PHYTOMEDICINE, P153242, DOI [10.1016/j.phymed.2020.153242, DOI 10.1016/J.PHYMED.2020.153242]
   Huang YX, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.105046
   Jiang SD, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104989
   Kong DL, 2019, J CELL PHYSIOL, V234, P4597, DOI 10.1002/jcp.27242
   Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y
   Lee SA, 2019, J THORAC DIS, V11, P1287, DOI 10.21037/jtd.2019.04.14
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Guo-Qin, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P1631
   [李旷宇 Li Kuangyu], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P2046
   LI Li, 2013, CHINESE J EXPT TRADI, V19, P346
   [李玲 Li Ling], 2017, [中草药, Chinese Traditional and Herbal Drugs], V48, P1591
   Li T, 2013, ANTIVIR RES, V97, P1, DOI 10.1016/j.antiviral.2012.10.006
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liu XM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004882.pub3
   Liu ZL, 2020, J TRADIT CHIN MED, V40, P467, DOI 10.19852/j.cnki.jtcm.2020.03.016
   Luo ED, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00317-x
   [吕睿冰 Lyu Ruibing], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P655
   Ma LQ, 2014, MICROCIRCULATION, V21, P649, DOI 10.1111/micc.12144
   Mantani N, 2001, PLANTA MED, V67, P240, DOI 10.1055/s-2001-12009
   Mantani N, 1999, ANTIVIR RES, V44, P193, DOI 10.1016/S0166-3542(99)00067-4
   Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08
   Narasaraju T, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00870
   Qu Y. F., 2020, HENAN TRADIT CHIN ME, V40, P666, DOI [10.16367/j.issn.1003-5028.2020.05.0167, DOI 10.16367/J.ISSN.1003-5028.2020.05.0167]
   Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X
   Stower Hannah, 2020, Nat Med, V26, P465, DOI 10.1038/s41591-020-0850-3
   Tang Xuan, 2020, Zhongguo Zhong Yao Za Zhi, V45, P3028, DOI 10.19540/j.cnki.cjcmm.20200405.401
   [仝小林 Tong Xiaolin], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P465
   Utsunomiya T, 1997, ANTIMICROB AGENTS CH, V41, P551, DOI 10.1128/AAC.41.3.551
   Wang C, 2011, ANN INTERN MED, V155, P217, DOI 10.7326/0003-4819-155-4-201108160-00005
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wei M, 2020, PROCEEDINGS OF THE 2020 14TH INTERNATIONAL CONFERENCE ON UBIQUITOUS INFORMATION MANAGEMENT AND COMMUNICATION (IMCOM)
   Wei WY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00961
   Wolkerstorfer A, 2009, ANTIVIR RES, V83, P171, DOI 10.1016/j.antiviral.2009.04.012
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Xiong F, 2020, J AM SOC NEPHROL, V31, P1387, DOI 10.1681/ASN.2020030354
   Yang RC, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104820
   Yazinski A, 2018, CLIN CANCER RES, V24, P17
   Zhang Bo, 2013, China Journal of Traditional Chinese Medicine and Pharmacy, V28, P1094
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 54
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 26
PY 2020
VL 11
AR 581691
DI 10.3389/fphar.2020.581691
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PC2GO
UT WOS:000596825900001
PM 33324213
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Singh, D
   Brown, PN
   Cinosi, E
   Corazza, O
   Henningfield, JE
   Garcia-Romeu, A
   McCurdy, CR
   McMahon, LR
   Prozialeck, WC
   Smith, KE
   Swogger, MT
   Veltri, C
   Walsh, Z
   Grundmann, O
AF Singh, Darshan
   Brown, Paula N.
   Cinosi, Eduardo
   Corazza, Ornella
   Henningfield, Jack E.
   Garcia-Romeu, Albert
   McCurdy, Christopher R.
   McMahon, Lance R.
   Prozialeck, Walter C.
   Smith, Kirsten E.
   Swogger, Marc T.
   Veltri, Charles
   Walsh, Zach
   Grundmann, Oliver
TI Current and Future Potential Impact of COVID-19 on Kratom (Mitragyna
   speciosa Korth.) Supply and Use
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE COVID-19; kratom; SUD; OUD; withdrawal
ID HEALTH
AB Kratom (Mitragyna speciosa Korth., Rubiaceae) is native to and has traditional use in Southeast Asia. The number of kratom users outside of Southeast Asia has increased significantly in recent decades with use spreading to the Unites States (US) and Europe. Because of its reputed opioid-like psychoactive effects at higher doses, kratom has been regulated in several countries and is subject to an import ban by the US Food and Drug Administration. Nonetheless, in the US it is estimated that 10-15 million people consume kratom primarily for the self-treatment of pain, psychiatric disorders, to mitigate withdrawal from or dependence on opioids, and to self-treat opioid use disorder or other substance use disorders (SUDs). Due to the global COVID-19 pandemic, a shortage in the supply of kratom products may place unexpected burdens on kratom users, potentially influencing some who use kratom for SUD self-treatment to regress to harmful drug use, hence increasing the likelihood of adverse outcomes, including overdose. Inadequate treatment, treatment barriers, and increases in the sales of adulterated kratom products on the internet or in convenience stores could exacerbate circumstances further. Although there are currently no verified indications of kratom scarcity, researchers and clinicians should be aware of and remain vigilant to this unanticipated possibility.
C1 [Singh, Darshan] Univ Sains Malaysia, Ctr Drug Res, George Town, Malaysia.
   [Brown, Paula N.] British Columbia Inst Technol, Ctr Appl Res & Innovat, Burnaby, BC, Canada.
   [Cinosi, Eduardo; Corazza, Ornella] Univ Hertfordshire, Sch Life & Med Sci, Dept Clin & Pharmaceut Sci, Hatfield, Herts, England.
   [Cinosi, Eduardo] Hertfordshire Partnership Natl Hlth Serv Univ Fdn, St Albans, England.
   [Henningfield, Jack E.; Garcia-Romeu, Albert] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
   [Henningfield, Jack E.] Pinney Associates, Bethesda, MD USA.
   [McCurdy, Christopher R.; Grundmann, Oliver] Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL 32611 USA.
   [McMahon, Lance R.] Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA.
   [Prozialeck, Walter C.] Midwestern Univ, Coll Grad Studies, Dept Pharmacol, Downers Grove, IL 60515 USA.
   [Smith, Kirsten E.] NIDA, Intramural Res Program, Baltimore, MD USA.
   [Swogger, Marc T.] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA.
   [Veltri, Charles] Midwestern Univ, Coll Pharm, Dept Pharmaceut Sci, Glendale, AZ USA.
   [Walsh, Zach] Univ British Columbia, Dept Psychol, Kelowna, BC, Canada.
RP Grundmann, O (corresponding author), Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL 32611 USA.
EM grundman@ufl.edu
CR Agapoff JR, 2019, J SUBST USE, V24, P575, DOI 10.1080/14659891.2019.1638459
   AKA, 2020, CONS AL COVID 19 CLA
   AMA, 2020, ISS BRIEF REP INCR O
   Cinosi E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/968786
   Coe MA, 2019, DRUG ALCOHOL DEPEN, V202, P24, DOI 10.1016/j.drugalcdep.2019.05.005
   Corkery JM, 2019, J PSYCHOPHARMACOL, V33, P1102, DOI 10.1177/0269881119862530
   [EUROPOL Europol EMCfDaDAa], 2020, EU DRUG MARK IMP COV
   FDA, 2019, IMP AL 54 15
   FDA, 2020, WARN LETT GOLD ROAD
   Garcia-Romeu A, 2020, DRUG ALCOHOL DEPEN, V208, DOI 10.1016/j.drugalcdep.2020.107849
   Grundmann O, 2017, DRUG ALCOHOL DEPEN, V176, P63, DOI 10.1016/j.drugalcdep.2017.03.007
   Henningfield JE, 2019, PREV MED, V128, DOI 10.1016/j.ypmed.2019.105851
   Henningfield JE, 2018, PSYCHOPHARMACOLOGY, V235, P573, DOI 10.1007/s00213-017-4813-4
   Kruegel AC, 2018, NEUROPHARMACOLOGY, V134, P108, DOI 10.1016/j.neuropharm.2017.08.026
   Post S, 2019, CLIN TOXICOL, V57, P847, DOI 10.1080/15563650.2019.1569236
   Rusmana Y, 2018, US HUNGER OPIOID ALT
   Sethi Roopa, 2020, Prim Care Companion CNS Disord, V22, DOI 10.4088/PCC.19nr02507
   Singh D, 2019, J ETHNOPHARMACOL, V233, P34, DOI 10.1016/j.jep.2018.12.038
   Singh D, 2016, BRAIN RES BULL, V126, P41, DOI 10.1016/j.brainresbull.2016.05.004
   Singh D, 2014, DRUG ALCOHOL DEPEN, V139, P132, DOI 10.1016/j.drugalcdep.2014.03.017
   Smith KE, 2017, DRUG ALCOHOL DEPEN, V180, P340, DOI 10.1016/j.drugalcdep.2017.08.034
   Swogger MT, 2018, DRUG ALCOHOL DEPEN, V183, P134, DOI 10.1016/j.drugalcdep.2017.10.012
   Takayama H, 2004, CHEM PHARM BULL, V52, P916, DOI 10.1248/cpb.52.916
   United States Food and Drug Administration, 2018, COMMUNICATION
   Varadi A, 2016, J MED CHEM, V59, P8381, DOI 10.1021/acs.jmedchem.6b00748
NR 25
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD NOV 26
PY 2020
VL 11
AR 574483
DI 10.3389/fpsyt.2020.574483
PG 4
WC Psychiatry
SC Psychiatry
GA PC2ER
UT WOS:000596821000001
PM 33324252
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Massoudi, N
   Mohit, B
AF Massoudi, Nilofar
   Mohit, Babak
TI A Case-Control Study of the 2019 Influenza Vaccine and Incidence of
   COVID-19 Among Healthcare Workers
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Article; Early Access
DE COVID-19; coronavirus; influenza; vaccine; healthcare workers;
   case&#8211; control
ID ACE2; CORONAVIRUS
AB Purpose The influenza vaccine is essential in reducing the influenza burden, especially among healthcare workers (HCW). Experimental studies suggest both coronaviruses and influenza viruses engage with the angiotensin-converting enzyme 2 (ACE 2) and tetraspanin antibodies, and that ACE 2 tetraspanin antibodies in turn may inhibit both coronavirus and low-pathogenicity influenza A viruses (LP IAV) infections. This study aims to investigate the potential clinical association between receiving the 2019 influenza vaccine and the incidence of COVID-19 among HCW. Methods We designed a case-control study within a hospital setting in Iran when it became a center for treating COVID-19 patients. We collected data and calculated relevant incidence and associative measures among HCW who had received the 2019 influenza vaccine as compared to HCW who had not received the vaccine. Results Our total sample size was 261 HCW. Of 80 COVID-19 incident cases, three cases had received the influenza vaccine, while 87 of 181 controls had received the vaccine. The odds ratio (OR) and confidence interval (CI) of being vaccinated were 0.04 (95% CI: 0.01 to 0.14) among COVID-19 cases as compared to controls. Conclusions Significant findings suggest that the 2019 influenza vaccine may have a protective association against COVID-19 among HCW.
C1 [Massoudi, Nilofar] Shahid Beheshti Univ Med Sci, Dept Anesthesiol, Anesthesiol Res Ctr, Tehran, Iran.
   [Mohit, Babak] Univ Maryland, Sch Med, Dept Med, Sleep Disorders Ctr,Div Pulm & Crit Care Med, 100 N Greene St,2nd Floor, Baltimore, MD 21201 USA.
RP Mohit, B (corresponding author), Univ Maryland, Sch Med, Dept Med, Sleep Disorders Ctr,Div Pulm & Crit Care Med, 100 N Greene St,2nd Floor, Baltimore, MD 21201 USA.
EM massodi@sbmu.ac.ir; bmohit1@alumni.jh.edu
CR Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   Aaby P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6495
   Abbot Labs, 2019, PACK LEAFL INF US IN
   Abramowicz M, 2020, JAMA-J AM MED ASSOC, V323, P84, DOI 10.1001/jama.2019.18016
   Caban-Martinez AJ, 2020, OCCUP ENVIRON MED, V77, P857, DOI 10.1136/oemed-2020-106676
   Chakraborty Saborni, 2020, medRxiv, DOI 10.1101/2020.05.15.20103341
   Clarke MS, 2015, VACCINE, V33, P3162, DOI 10.1016/j.vaccine.2015.04.076
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Earnest JT, 2015, J VIROL, V89, P6093, DOI 10.1128/JVI.00543-15
   Eldanasory OA, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101872
   Fiore AE, 2009, CURR TOP MICROBIOL, V333, P43, DOI 10.1007/978-3-540-92165-3_3
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4
   Imai C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198685
   Jehi L, 2020, CHEST, V158, P1364, DOI 10.1016/j.chest.2020.05.580
   Konala VM, 2020, J INVEST MED HIGH IM, V8, DOI 10.1177/2324709620934674
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Li Q, 2020, MATH BIOSCI, V325, DOI 10.1016/j.mbs.2020.108378
   Marin-Hernandez D, 2020, J MED VIROL, DOI 10.1002/jmv.26120
   Miller A, 2020, CORRELATION UNIVERSA, DOI [DOI 10.1101/2020.03.24.20042937, 10.1101/2020.03.24.20042937]
   Ministry of Health Treatment and Medical Education IR Iran, 2020, CHAIR PUBL REL MED M
   Nicoli Federico, 2020, J Clin Ethics, V31, P92
   Organization for Economic Cooperation and Development (OECD), 2018, INFL VACC RAT
   Ozaras R, 2020, J MED VIROL, V92, P2657, DOI 10.1002/jmv.26125
   Poulas K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01373
   Salem ML, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109752
   Sullivan KM, 2013, OPEN SOURCE STAT PUB
   Ting EEK, 2017, VACCINE, V35, P1828, DOI 10.1016/j.vaccine.2017.02.044
   Wambier CG, 2020, DRUG DEVELOP RES, V81, P771, DOI 10.1002/ddr.21688
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P308, DOI 10.1016/j.jaad.2020.04.032
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   WHO, 2020, LAB TEST COR DIS COV
   World Health Organization, 2020, GLOB SURV HUM INF NO
   Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027
   Zanettini Claudio, 2020, medRxiv, DOI 10.1101/2020.06.24.20129817
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 39
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
DI 10.1007/s10875-020-00925-0
EA NOV 2020
PG 11
WC Immunology
SC Immunology
GA OX4RZ
UT WOS:000593555000001
PM 33244671
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zeyfang, A
   Zeeh, J
   Bahrmann, A
   Kugler, JN
   Heppner, HJ
AF Zeyfang, Andrej
   Zeeh, Joachim
   Bahrmann, Anke
   Kugler, Janine N.
   Heppner, Hans Juergen
TI Diabetes mellitus in old age
SO ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE
LA German
DT Article; Early Access
DE Geriatric assessment; Hypoglycemia; Drug therapy; Diabetes technology;
   COVID-19
ID MUSCLE MASS; TYPE-2; THERAPY; EMPAGLIFLOZIN; PREVALENCE; QUALITY; RISK
AB In the treatment of diabetes in old age cognitive, functional and constitutional resources of the individual must be taken into account. Purely glycated hemoglobin (HbA1c)-oriented treatment goals are less relevant. The primary focus should be freedom from symptoms while avoiding hypoglycemia and maintaining the quality of life. The geriatric assessment helps to clarify the current functional, psychological and cognitive status as well as the need for support in multimorbid older people and to define appropriate treatment strategies. With drug treatment of diabetes in old age, particular attention must be paid to renal insufficiency and dehydration as well as slow dose adjustments. According to the Robert Koch Institute (RKI), diabetes patients belong to the risk group for a severe course of the coronavirus disease 2019 (COVID-19); further risk factors are high blood pressure, underlying oncological diseases, cerebrovascular and coronary heart diseases.
C1 [Zeyfang, Andrej; Kugler, Janine N.] Medius KLIN OSTFILDERNRUIT, Klin Innere Med Altersmed Diabetol & Palliat Med, Hedelfinger Str 166, D-73760 Ostfildern, Germany.
   [Zeyfang, Andrej] Univ Ulm, Inst Epidemiol, Ulm, Germany.
   [Zeeh, Joachim] Sozialwerk Meiningen gGmbH, Abt Hosp & Palliat Versorgung, Meiningen, Germany.
   [Bahrmann, Anke] Univ Klinikum Heidelberg, Klin Kardiol Angiol & Pneumol, Heidelberg, Germany.
   [Heppner, Hans Juergen] HELIOS Klin, Klin Geriatrie, Schwelm, Germany.
   [Heppner, Hans Juergen] FAU Erlangen, Inst Biomed Alterns, Erlangen, Germany.
RP Zeyfang, A (corresponding author), Medius KLIN OSTFILDERNRUIT, Klin Innere Med Altersmed Diabetol & Palliat Med, Hedelfinger Str 166, D-73760 Ostfildern, Germany.
EM a.zeyfang@medius-kliniken.de
CR Armstrong DG, 2017, NEW ENGL J MED, V376, P2367, DOI 10.1056/NEJMra1615439
   Bahrmann A, 2018, DIABETOL STOFFWECHS, V13, P423, DOI 10.1055/a-0666-0820
   Bahrmann A, 2014, PATIENT EDUC COUNS, V94, P417, DOI 10.1016/j.pec.2013.11.010
   Braun A, 2008, PATIENT EDUC COUNS, V73, P50, DOI 10.1016/j.pec.2008.05.005
   Braun AK, 2009, AGE AGEING, V38, P390, DOI 10.1093/ageing/afp056
   Dovjak P, 2019, Z GERONTOL GERIATR, V52, P624, DOI 10.1007/s00391-019-01593-5
   Fang JC, 2019, NEW ENGL J MED, V381, P2063, DOI 10.1056/NEJMe1912180
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fitchett D, 2016, EUR HEART J, V37, P1526, DOI 10.1093/eurheartj/ehv728
   Hess DA, 2019, CELL METAB, V30, P609, DOI 10.1016/j.cmet.2019.08.015
   Kim TN, 2010, DIABETES CARE, V33, P1497, DOI 10.2337/dc09-2310
   Leenders M, 2013, J AM MED DIR ASSOC, V14, P585, DOI 10.1016/j.jamda.2013.02.006
   McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303
   Menne J, 2019, PLOS MED, V16, DOI [10.1371/journal.pmed.1002983, 10.1371/journal.pmed.1002983.r001, 10.1371/journal.pmed.1002983.r002, 10.1371/journal.pmed.1002983.r003, 10.1371/journal.pmed.1002983.r004, 10.1371/journal.pmed.1002983.r005]
   NIKOLAUS T, 1995, AGE AGEING, V24, P257, DOI 10.1093/ageing/24.3.257
   Pazan F, 2019, DRUG AGING, V36, P481, DOI 10.1007/s40266-019-00669-6
   Reaven PD, 2019, NEW ENGL J MED, V381, P1293, DOI 10.1056/NEJMc1909041
   Rodriguez-Manas L, 2019, J CACHEXIA SARCOPENI, V10, P721, DOI 10.1002/jcsm.12432
   Scheen AJ, 2018, CIRC RES, V122, P1439, DOI 10.1161/CIRCRESAHA.117.311588
   Schloot NC, 2016, DIABETES-METAB RES, V32, P316, DOI 10.1002/dmrr.2722
   Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923
   Tamayo T, 2016, DTSCH ARZTEBL INT, V113, P177, DOI 10.3238/arztebl.2016.0177
   Volpato S, 2012, DIABETES CARE, V35, P1672, DOI 10.2337/dc11-2202
   Wanner C, 2016, NEW ENGL J MED, V375, P323, DOI [10.1056/NEJMoa1515920, 10.1056/NEJMc1611290]
   Zeyfang A, 2017, DIABETOL STOFFWECHS, V12, pS203, DOI 10.1055/s-0043-116005
   Zeyfang A, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2010.10.006
   Zeyfang Andrej, 2005, MMW Fortschr Med, V147, P39
NR 27
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0948-6704
EI 1435-1269
J9 Z GERONTOL GERIATR
JI Z. Gerontol. Geriatr.
DI 10.1007/s00391-020-01815-1
EA NOV 2020
PG 10
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA OW6TM
UT WOS:000593016600001
PM 33242104
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sharif, N
   Dey, SK
AF Sharif, Nadim
   Dey, Shuvra K.
TI Phylogenetic and whole genome analysis of first seven SARS-CoV-2
   isolates in Bangladesh
SO FUTURE VIROLOGY
LA English
DT Article
DE Bangladesh; genome; mutation; SARS-CoV-2; spike protein; therapeutics;
   vaccine
ID CORONAVIRUS; PNEUMONIA
AB Aim: Whole genome and peptide mutation analysis can specify effective vaccine and therapeutics against severe acute respiratory coronavirus-2 (SARS-CoV-2). Materials & methods: Whole genome similarity for Bangladeshi SARS-CoV-2 was determined using ClustalW and BLASTn. Phylogenetic analysis was conducted using neighbor-joining method. Results: 100% of isolates in Bangladesh were in the G clade. We found 99.98-100% sequence similarity among Bangladeshi isolates and isolates of England, Greece, USA, Saudi Arabia and India. Deletion of bases at 5 ' untranslated region and 3 ' untranslated region was detected. Substitution 261 (E -> D) at NSP13 and 1109 (F -> L) at spike (S) protein were detected. Substitution 377 (D -> G) at nucleocapsid with common substitution 614 (D -> G) at S were also detected. Conclusion: This study will provide baseline data for development of an effective vaccine or therapeutics against SARS-CoV-2.
C1 [Sharif, Nadim; Dey, Shuvra K.] Jahangirnagar Univ, Dept Microbiol, Dhaka 1342, Bangladesh.
RP Dey, SK (corresponding author), Jahangirnagar Univ, Dept Microbiol, Dhaka 1342, Bangladesh.
EM shuvradey@yahoo.com
OI Kanti Dey, Dr. Shuvra/0000-0002-2440-5673; Sharif,
   Nadim/0000-0003-2377-9726
CR Alexander SP, 2020, IUPHAR BPS GUIDE PHA, V2020, P1
   Battegay M, 2020, SWISS MED WKLY, V150, DOI [10.4414/smw.w20203, 10.4414/smw.2020.20203]
   Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Farsani SMJ, 2012, VIRUS GENES, V45, P433, DOI 10.1007/s11262-012-0807-9
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   HALL TA, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.5598/IMAFUNGUS.2011.02.02.06
   Hassan SA, 2020, CUREUS, V12, DOI 10.7759/cureus.7355
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Koyama T, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050324
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   Mu JF, 2020, SCI CHINA LIFE SCI, DOI 10.1007/s11427-020-1692-1
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Peng Q, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107774
   Qiu Y., 2020, STEMEDICINE, V1, pe39
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Satarker S, 2020, ARCH MED RES, V51, P482, DOI 10.1016/j.arcmed.2020.05.012
   Stefanelli LV, 2020, MATERIALS, V13, DOI 10.3390/ma13122806
   Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101
   White MS, 2020, INT J CONT RES REV, V11, P20773
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4
NR 32
TC 0
Z9 0
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PD NOV
PY 2020
VL 15
IS 11
BP 735
EP 746
DI 10.2217/fvl-2020-0201
EA NOV 2020
PG 12
WC Virology
SC Virology
GA PE5JH
UT WOS:000592404800001
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Guebre-Xabier, M
   Patel, N
   Tian, JH
   Zhou, B
   Maciejewski, S
   Lam, K
   Portnoff, AD
   Massare, MJ
   Frieman, MB
   Piedra, PA
   Ellingsworth, L
   Glenn, G
   Smith, G
AF Guebre-Xabier, Mimi
   Patel, Nita
   Tian, Jing-Hui
   Zhou, Bin
   Maciejewski, Sonia
   Lam, Kristal
   Portnoff, Alyse D.
   Massare, Michael J.
   Frieman, Matthew B.
   Piedra, Pedro A.
   Ellingsworth, Larry
   Glenn, Gregory
   Smith, Gale
TI NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways
   against SARS-CoV-2 challenge
SO VACCINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; Spike glycoprotein; NVX-CoV2373 nanoparticles;
   Matrix-M adjuvant; Nonhuman primate
AB There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion conformation. Cynomolgus macaques (Macaca fascicularis) immunized with NVX-CoV2373 and the saponin-based Matrix-MTM adjuvant induced anti-S antibody that was neutralizing and blocked binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2, immunized macaques were protected against upper and lower infection and pulmonary disease. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Guebre-Xabier, Mimi; Patel, Nita; Tian, Jing-Hui; Zhou, Bin; Maciejewski, Sonia; Lam, Kristal; Portnoff, Alyse D.; Massare, Michael J.; Ellingsworth, Larry; Glenn, Gregory; Smith, Gale] Novavax Inc, 21 Firstfield Rd, Gaithersburg, MD 20878 USA.
   [Frieman, Matthew B.] Univ Maryland, Sch Med, 685 West Baltimore St, Baltimore, MD 21201 USA.
   [Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
   [Piedra, Pedro A.] Baylor Coll Med, Pediat, Houston, TX 77030 USA.
RP Smith, G (corresponding author), Novavax Inc, 21 Firstfield Rd, Gaithersburg, MD 20878 USA.
EM mguebre-xabier@Novavax.com; npatel@novavax.com; jhtian@Novavax.com;
   bzhou@Novavax.com; smaciejewski@Novavavax.com; klam@Novavax.com;
   aportnoff@Novavax.com; mmassare@Novavax.com; mfrieman@som.umaryland.edu;
   ppiedra@bcm.edu; lellingsworth@novavax.com; gglenn@Novavax.com;
   gsmith@Novavax.com
FU Coalition for Epidemic Preparedness Innovations (CEPI), Torshov, Oslo,
   Norway
FX Funding for certain studies was provided by the Coalition for Epidemic
   Preparedness Innovations (CEPI), PO Box 123, Torshov, 0412 Oslo, Norway.
   The authors thank Drs. Hanna Andersen (BioQual, Inc.) for support in
   conducting the primate challenge study and Shannon Wallace (Experimental
   Pathology Laboratories) for providing histopathological services and
   support.
CR Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Keech Cheryl, 2020, N Engl J Med, V383, P2320, DOI 10.1056/NEJMoa2026920
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Shan C, 2020, CELL RES, V30, P670, DOI 10.1038/s41422-020-0364-z
   Tian Jing-Hui, 2020, PREPRINT, DOI [10.1101/2020.06.29.178509., DOI 10.1101/2020.06.29.178509, 10.1101/2020.06.29.178509]
   van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
NR 12
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 25
PY 2020
VL 38
IS 50
BP 7892
EP 7896
DI 10.1016/j.vaccine.2020.10.064
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OY9CF
UT WOS:000594536100005
PM 33139139
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jakhar, R
   Gakhar, SK
AF Jakhar, Renu
   Gakhar, S. K.
TI An Immunoinformatics Study to Predict Epitopes in the Envelope Protein
   of SARS-CoV-2
SO CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY
LA English
DT Article
ID CORONAVIRUS; PROTECTION; VACCINE; BINDING; SYSTEM; SERVER; QUERY
AB COVID-19 is a new viral emergent disease caused by a novel strain of coronavirus. This virus has caused a huge problem in the world as millions of people are affected by this disease. We aimed at designing a peptide vaccine for COVID-19 particularly for the envelope protein using computational methods to predict epitopes inducing the immune system. The envelope protein sequence of SARS-CoV-2 has been retrieved from the NCBI database. The bioinformatics analysis was carried out by using the Immune Epitope Database (IEDB) to predict B- and T-cell epitopes. The predicted HTL and CTL epitopes were docked with HLA alleles and binding energies were evaluated. The allergenicity of predicted epitopes was analyzed, the conservancy analysis was performed, and the population coverage was determined throughout the world. Some overlapped CTL, HTL, and B-cell epitopes were suggested to become a universal candidate for peptide-based vaccine against COVID-19. This vaccine peptide could simultaneously elicit humoral and cell-mediated immune responses. We hope to confirm our findings by adding complementary steps of both in vitro and in vivo studies to support this new universal predicted candidate.
C1 [Jakhar, Renu; Gakhar, S. K.] Maharshi Dayanand Univ, Ctr Med Biotechnol, Rohtak 124001, Haryana, India.
RP Jakhar, R (corresponding author), Maharshi Dayanand Univ, Ctr Med Biotechnol, Rohtak 124001, Haryana, India.
EM renujakhar22@gmail.com; surengak@gmail.com
OI JAKHAR, RENU/0000-0002-3556-6536
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Buus S, 2003, TISSUE ANTIGENS, V62, P378, DOI 10.1034/j.1399-0039.2003.00112.x
   Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chou P. Y., 1978, ADV ENZYMOL, V47, P145
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Deshpande N, 2005, NUCLEIC ACIDS RES, V33, pD233
   Dimitrov I., 2013, BMC BIOINFORMATICS, V14, P1
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Hasan M, 2019, MICROB PATHOGENESIS, V130, P19, DOI 10.1016/j.micpath.2019.02.023
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jakhar R, 2020, J MED VIROL, V92, P2114, DOI 10.1002/jmv.25993
   Jakhar R, 2019, BIOINFORMATION, V15, P600, DOI 10.6026/97320630015600
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Ka T., 2020, SCI REPORTS, V151
   Karosiene E, 2013, IMMUNOGENETICS, V65, P711, DOI 10.1007/s00251-013-0720-y
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768
   Khan A, 2020, INTERDISCIP SCI, V12, P335, DOI 10.1007/s12539-020-00381-9
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Ojha R, 2020, EUR J PHARM SCI, V151, DOI 10.1016/j.ejps.2020.105375
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224
   RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Srivastava S, 2018, INFECT DRUG RESIST, V11, P2377, DOI 10.2147/IDR.S175114
   Thevenet P, 2012, NUCLEIC ACIDS RES, V40, pW288, DOI 10.1093/nar/gks419
   Tilocca B, 2020, MICROBES INFECT, V22, P182, DOI 10.1016/j.micinf.2020.05.013
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938
   Wang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8712
   Wang Y, 2016, MBIO, V7, DOI 10.1128/mBio.01872-15
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wilson JA, 2001, J VIROL, V75, P2660, DOI 10.1128/JVI.75.6.2660-2664.2001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xie Q, 2018, IEEE ACM T COMPUT BI, V15, P1344, DOI 10.1109/TCBB.2017.2702588
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Zhang LM, 2012, BRIEF BIOINFORM, V13, P350, DOI 10.1093/bib/bbr060
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
NR 55
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1712-9532
EI 1918-1493
J9 CAN J INFECT DIS MED
JI Can. J. Infect. Dis. Med. Microbiol.
PD NOV 25
PY 2020
VL 2020
AR 7079356
DI 10.1155/2020/7079356
PG 14
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA PE5HN
UT WOS:000598396800002
PM 33299503
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pawlak, A
   Drezewski, K
   Szymanski, P
   Nowak, B
   Zaczynski, A
   Krol, Z
   Wierzba, W
   Gil, R
AF Pawlak, Agnieszka
   Drezewski, Karol
   Szymanski, Piotr
   Nowak, Blazej
   Zaczynski, Artur
   Krol, Zbigniew
   Wierzba, Waldemar
   Gil, Robert
TI Cardiovascular disease, therapy, and mortality of oligosymptomatic and
   symptomatic patients infected with SARS-CoV-2: experiences of a
   designated hospital in Poland
SO KARDIOLOGIA POLSKA
LA English
DT Article
ID COVID-19
C1 [Pawlak, Agnieszka; Drezewski, Karol; Szymanski, Piotr; Nowak, Blazej; Zaczynski, Artur; Krol, Zbigniew; Wierzba, Waldemar; Gil, Robert] Minist Interior & Adm, Cent Clin Hosp, Warsaw, Poland.
   [Pawlak, Agnieszka; Gil, Robert] Polish Acad Sci, Mossakowski Med Res Ctr, Warsaw, Poland.
   [Szymanski, Piotr] Ctr Postgrad Med Educ, Warsaw, Poland.
RP Pawlak, A (corresponding author), Minist Interior & Adm, Cent Clin Hosp, Intervent Cardiol Dept, Ul Woloska 137, PL-02507 Warsaw, Poland.
EM agnieszka.pawlak@cskmswia.pl
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Henry BM, 2020, CLIN CHIM ACTA, V507, P167, DOI 10.1016/j.cca.2020.04.027
   Pericas JM, 2020, EUR HEART J, V41, P2092, DOI 10.1093/eurheartj/ehaa462
   Raciborski F, 2020, POL ARCH INTERN MED, V130, P615, DOI 10.20452/pamw.15430
   Royal College of Physicians, 2012, NAT EARL WARN SCOR N
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 8
TC 0
Z9 0
U1 0
U2 0
PU POLSKIE TOWARZYSTOWO KARDIOLOGICZNE
PI WARSZAWA
PA UL STAWKI 3 A LOK 1-2, WARSZAWA, POLAND
SN 0022-9032
EI 1897-4279
J9 KARDIOL POL
JI Kardiol. Pol.
PD NOV 25
PY 2020
VL 78
IS 11
BP 1162
EP 1165
DI 10.33963/KP.15596
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OX0HN
UT WOS:000593257300014
PM 32897038
OA Bronze
DA 2021-01-01
ER

PT J
AU Xiao, X
   Wang, CH
   Chang, D
   Wang, Y
   Dong, XJ
   Jiao, T
   Zhao, ZD
   Ren, LL
   Dela Cruz, CS
   Sharma, L
   Lei, XB
   Wang, JW
AF Xiao, Xia
   Wang, Conghui
   Chang, De
   Wang, Ying
   Dong, Xiaojing
   Jiao, Tao
   Zhao, Zhendong
   Ren, Lili
   Dela Cruz, Charles S.
   Sharma, Lokesh
   Lei, Xiaobo
   Wang, Jianwei
TI Identification of Potent and Safe Antiviral Therapeutic Candidates
   Against SARS-CoV-2
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; antiviral; therapy; US Food and Drug
   Administration-approved compounds
ID CORONAVIRUS; CHLOROQUINE
AB COVID-19 pandemic has infected millions of people with mortality exceeding >1 million. There is an urgent need to find therapeutic agents that can help clear the virus to prevent severe disease and death. Identifying effective and safer drugs can provide more options to treat COVID-19 infections either alone or in combination. Here, we performed a high throughput screening of approximately 1,700 US FDA-approved compounds to identify novel therapeutic agents that can effectively inhibit replication of coronaviruses including SARS-CoV-2. Our two-step screen first used a human coronavirus strain OC43 to identify compounds with anti-coronaviral activities. The effective compounds were then screened for their effectiveness in inhibiting SARS-CoV-2. These screens have identified 20 anti-SARS-CoV-2 drugs including previously reported compounds such as hydroxychloroquine, amlodipine besylate, arbidol hydrochloride, tilorone 2HCl, dronedarone hydrochloride, mefloquine, and thioridazine hydrochloride. Five of the newly identified drugs had a safety index (cytotoxic/effective concentration) of >600, indicating a wide therapeutic window compared to hydroxychloroquine which had a safety index of 22 in similar experiments. Mechanistically, five of the effective compounds (fendiline HCl, monensin sodium salt, vortioxetine, sertraline HCl, and salifungin) were found to block SARS-CoV-2 S protein-mediated cell fusion. These FDA-approved compounds can provide much needed therapeutic options that we urgently need during the midst of the pandemic.
C1 [Xiao, Xia; Wang, Conghui; Wang, Ying; Dong, Xiaojing; Jiao, Tao; Zhao, Zhendong; Ren, Lili; Lei, Xiaobo; Wang, Jianwei] Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, NHC Key Lab Syst Biol Pathogens, Beijing, Peoples R China.
   [Xiao, Xia; Wang, Conghui; Wang, Ying; Dong, Xiaojing; Jiao, Tao; Ren, Lili; Lei, Xiaobo; Wang, Jianwei] Chinese Acad Med Sci, Key Lab Resp Pathogen, Beijing, Peoples R China.
   [Xiao, Xia; Wang, Conghui; Wang, Ying; Dong, Xiaojing; Jiao, Tao; Ren, Lili; Lei, Xiaobo; Wang, Jianwei] Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, Christophe Merieux Lab, Beijing, Peoples R China.
   [Chang, De] Chinese Peoples Liberat Army Gen Hosp, Dept Pulm & Crit Care Med, Med Ctr 3, Beijing, Peoples R China.
   [Dela Cruz, Charles S.; Sharma, Lokesh] Yale Univ, Sch Med, Dept Med, Sect Pulm & Crit Care & Sleep Med, New Haven, CT 06510 USA.
RP Wang, JW (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, NHC Key Lab Syst Biol Pathogens, Beijing, Peoples R China.; Wang, JW (corresponding author), Chinese Acad Med Sci, Key Lab Resp Pathogen, Beijing, Peoples R China.; Wang, JW (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, Christophe Merieux Lab, Beijing, Peoples R China.; Sharma, L (corresponding author), Yale Univ, Sch Med, Dept Med, Sect Pulm & Crit Care & Sleep Med, New Haven, CT 06510 USA.
EM lokeshkumar.sharma@yale.edu; wangjw28@163.com
FU National Major Sciences & Technology Project for Control and Prevention
   of Major Infectious Diseases in China [2018ZX10301401]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81930063, 81971948]; Chinese Academy of Medical Sciences (CAMS)
   Innovation Fund for Medical Sciences [2016-I2M-1-014, 2016-I2M-1-005];
   National Key R&D Program of China [2020YFA0707600]; Beijing Municipal
   Science and Technology Project [Z2011000010200005]; Parker B Francis
   Fellowship; American Lung Association Catalyst Award
FX This work was supported by grants from the National Major Sciences &
   Technology Project for Control and Prevention of Major Infectious
   Diseases in China (2018ZX10301401 to XL), the National Natural Science
   Foundation of China (81930063 and 81971948 to JW and XL), Chinese
   Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
   (2016-I2M-1-014 and 2016-I2M-1-005 to JW and XL), National Key R&D
   Program of China (2020YFA0707600 to XL), and Beijing Municipal Science
   and Technology Project (Z2011000010200005). LS is supported by Parker B
   Francis Fellowship and American Lung Association Catalyst Award.
CR Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Badyal DK, 2020, CHLOROQUINE, V10, P128, DOI [10.4103/ijabmr.IJABMR_141_20, DOI 10.4103/IJABMR.IJABMR_141_20]
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chandel V, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1811773
   Chtita Samir, 2020, Comb Chem High Throughput Screen, DOI 10.2174/1386207323999200730205447
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Elzupir Amin O, 2020, J Mol Struct, V1222, P128878, DOI 10.1016/j.molstruc.2020.128878
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Galimberti S, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01428
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gimeno A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113793
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Gul S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1802346
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jack Amanda, 2020, bioRxiv, DOI 10.1101/2020.09.14.295824
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Ke YY, 2020, BIOMED J, V43, P355, DOI 10.1016/j.bj.2020.05.001
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   McClenaghan C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.573339
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Rasaeifar B, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13090259
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Ruan ZJ, 2020, J MED VIROL, DOI 10.1002/jmv.26222
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Smetana K, 2020, IN VIVO, V34, P3027, DOI 10.21873/invivo.12135
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Vinetz JM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2018
   Virdi RS, 2020, SLAS DISCOV, V25, P1162, DOI 10.1177/2472555220960428
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Xiao X, 2020, BIORXIV, DOI [10.1101/2020.07.06.188953, DOI 10.1101/2020.07.06.188953]
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang Y, 2015, J INFECTION, V70, P641, DOI 10.1016/j.jinf.2014.12.005
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 43
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 25
PY 2020
VL 11
AR 586572
DI 10.3389/fimmu.2020.586572
PG 11
WC Immunology
SC Immunology
GA PC7EQ
UT WOS:000597160400001
PM 33324406
OA DOAJ Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Roncero, C
   Vicente-Hernandez, B
   Casado-Espada, NM
   Aguilar, L
   Gamonal-Limcaoco, S
   Garzon, MA
   Martinez-Gonzalez, F
   Llanes-Alvarez, C
   Martinez, R
   Franco-Martin, M
   Alvarez-Navares, A
AF Roncero, Carlos
   Vicente-Hernandez, Begona
   Casado-Espada, Nerea M.
   Aguilar, Lourdes
   Gamonal-Limcaoco, Sinta
   Garzon, Maria A.
   Martinez-Gonzalez, Fernando
   Llanes-Alvarez, Carlos
   Martinez, Ruth
   Franco-Martin, Manuel
   Alvarez-Navares, Ana
TI The Impact of COVID-19 Pandemic on the Castile and Leon Addiction
   Treatment Network: A Real-Word Experience
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE COVID-19; impact; network on drugs and drug addiction; assistance;
   relapse
ID DEPENDENT PATIENTS; SUBSTANCE USE; INTERVENTIONS; CHALLENGES; OUTBREAK;
   THERAPY
AB Background: Patients suffering from addiction are a vulnerable group in the midst of COVID-19, so their healthcare is considered essential. In this paper, the measures and responses of the Drug Addiction Assistance Network of Castile and Leon (DAACYL) in Spain during the first 6 weeks of the COVID-19 pandemic are explained. The aim is that this experience could be useful in places where this problem will continue and could help future interventions.
   Methods: A telephone survey was carried out as the main methodology, to collect information for the subsequent organization and repercussion on professionals and patients. This was carried out by the heads of the 18 DAACYL units. Among the interventions applied, the following stand out: implantation of telemedicine techniques, restriction of daily methadone dispensing, suspension of urine controls and initiation of care programs for the homeless.
   Results: As a result of these interventions, the professionals observed that patients are less demanding and mostly stable, with a low percentage of relapses. An increase in the consumption of alcohol and benzodiazepines have been reported as more common among people who relapse. Furthermore, the prevalence of COVID-19 infection in the sample is minimal; therefore, different hypotheses should be considered as an explanation (infra-diagnosis, immune system used to aggression, possible anti-inflammatory effect of some psychotropic drugs and a greater perception of danger against infection than the general population).
   Conclusions: The rapid adaptation and successful implementation of DAACYL have had satisfactory results. On the other hand, the prevention of the possible increase in the development of behavioral addictions and the use of homemade drugs should be considered.
C1 [Roncero, Carlos; Casado-Espada, Nerea M.; Gamonal-Limcaoco, Sinta] Univ Salamanca, Psychiat Serv, Hlth Care Complex, Salamanca, Spain.
   [Roncero, Carlos; Casado-Espada, Nerea M.; Aguilar, Lourdes; Franco-Martin, Manuel] Univ Salamanca, Inst Biomed Salamanca IBSAL, Salamanca, Spain.
   [Roncero, Carlos; Casado-Espada, Nerea M.; Aguilar, Lourdes] Univ Salamanca, Sch Med, Psychiat Unit, Salamanca, Spain.
   [Vicente-Hernandez, Begona; Aguilar, Lourdes; Garzon, Maria A.; Martinez, Ruth; Alvarez-Navares, Ana] Salamanca Univ, Psychiat Serv, Addict & Dual Disorders Unit, Hlth Care Complex, Salamanca, Spain.
   [Martinez-Gonzalez, Fernando] Castile & Leon Reg Govt, Reg Commissioner Drugs, Social Serv Management, Valladolid, Spain.
   [Llanes-Alvarez, Carlos; Franco-Martin, Manuel] Zamora Hlth Care Complex, Psychiat Serv, Zamora, Spain.
   [Franco-Martin, Manuel] Rio Hortega Univ Hosp, Psychiat Serv, Valladolid, Spain.
RP Roncero, C (corresponding author), Univ Salamanca, Psychiat Serv, Hlth Care Complex, Salamanca, Spain.; Roncero, C (corresponding author), Univ Salamanca, Inst Biomed Salamanca IBSAL, Salamanca, Spain.; Roncero, C (corresponding author), Univ Salamanca, Sch Med, Psychiat Unit, Salamanca, Spain.
EM croncero@saludcastillayleon.es
FU Castile and Leon's (Spain) Regional Management of Health [GRS COVID
   59/A/20]
FX The authors of this work want to thank the professionals from the ODCs
   of Caritas de avila, the Spanish Red Cross of Burgos, Leon, Salamanca,
   Segovia, Soria, and Valladolid, Bierzo de Ponferrada County Council, San
   Juan de Dios de Palencia, ACLAD of Valladolid and Caritas de Zamora, Day
   Center and ambulatory program of Caritas de Salamanca, the Unit of
   addictive behaviors and treatment of alcoholism of SACYL de Zamora, the
   Therapeutic Communities from San Juan de Dios in Palencia and Proyecto
   Hombre in Salamanca and from the Residential Centers for the
   Rehabilitation of Alcoholics of Caritas de Zamora and ALDAMA from
   Palencia, for their collaboration in reporting their situation and the
   execution of their actions through the phone. This research project was
   supported by Castile and Leon's (Spain) Regional Management of Health
   (GRS COVID 59/A/20) Scholarship for the project Impacto y abordaje de la
   salud mental de los pacientes afectados por COVID, sus familiares y del
   personal sanitario que los atiende. (Impact and approach on the mental
   health of patients affected by COVID, their families and the health
   professionals who care for them). This scholarship was awarded to CR
   (main researcher) and his research team.
CR Alho H, 2020, INT J DRUG POLICY, V76, DOI 10.1016/j.drugpo.2019.102616
   Arya S, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102086
   Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832
   Attwood S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4358-9
   Casas M, 2020, SPANISH SOC DUAL DIS
   Castile and Leon Regional Government, 2018, MEM 2018 PLAN REG DR
   Castile and Leon Regional Government, 2020, INSTR 1 2020 2 2020
   Castile and Leon Regional Government, 2017, 7 PLAN REG DROG 2017
   Castile and Leon Regional Government, 2020, CONT REG CASTL LEON
   Castile and Leon Regional Government, 2020, PLAN CONT ANT COR CO
   Chang HX, 2019, BEHAV BRAIN RES, V364, P157, DOI 10.1016/j.bbr.2019.02.026
   Druss BG, 2020, JAMA PSYCHIAT, V77, P891, DOI 10.1001/jamapsychiatry.2020.0894
   European Centre for Disease Prevention and Control, 2020, COVID 19 PAND
   European Monitoring Centre for Drug and Drug Addiction, 2020, IMPL COVID 19 PEOPL
   Fakhraei N, 2018, INFLAMMOPHARMACOLOGY, V26, P1399, DOI 10.1007/s10787-018-0538-1
   Grau-Lopez L, 2016, ACTAS ESP PSIQUIATRI, V44, P64
   Grau-Lopez L, 2012, ADICCIONES, V24, P115, DOI 10.20882/adicciones.103
   Green TC, 2020, SUBST ABUS, V41, P147, DOI 10.1080/08897077.2020.1752351
   HERNANDEZ A, 2020, REV ESP ANEST REANIM, V67, P245, DOI DOI 10.1016/j.redare.2020.05.002
   Jenkins WD, 2020, J RURAL HEALTH, DOI 10.1111/jrh.12442
   Kar SK, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102064
   Li W, 2020, INT J BIOL SCI, V16, P1732, DOI 10.7150/ijbs.45120
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Lozano R, 2019, ADICCIONES, V31, P78, DOI 10.20882/adicciones.1007
   Lu CY, 2020, ANN RHEUM DIS, V79, P737, DOI 10.1136/annrheumdis-2020-217460
   Makki MST, 2019, CURR ORG SYNTH, V16, P165, DOI 10.2174/1570179415666181105142247
   Ministry of Health Consumption and Social Welfare, COVID 19 SIT SPAIN
   Moreno-Arnedillo JJ, 2006, ADICCIONES, V18, P345
   Ondersma SJ, 2019, PEDIATR CLIN N AM, V66, P1203, DOI 10.1016/j.pcl.2019.08.009
   Lima NNR, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112945
   Roncero C, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113252
   Roncero C, 2018, EXPERT REV CLIN PHAR, V11, P999, DOI 10.1080/17512433.2018.1519392
   Roncero C, 2017, AIDS CARE, V29, P1551, DOI 10.1080/09540121.2017.1313384
   Roncero C, 2017, EUR J GASTROEN HEPAT, V29, P629, DOI 10.1097/MEG.0000000000000855
   Sun YK, 2020, AM J ADDICTION, V29, P174, DOI 10.1111/ajad.13031
   Tofighi B, 2018, MED CLIN N AM, V102, P715, DOI 10.1016/j.mcna.2018.02.011
   Tsai J, 2020, LANCET PUBLIC HEALTH, V5, pE186, DOI 10.1016/S2468-2667(20)30053-0
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Xiang YT, 2020, INT J BIOL SCI, V16, P1741, DOI 10.7150/ijbs.45072
   Xiang YT, 2020, LANCET, V395, P684, DOI 10.1016/S0140-6736(20)30375-5
   Zhang K, 2020, BRIT J PSYCHIAT, V217, P351, DOI 10.1192/bjp.2020.84
   Zielinska M, 2015, EUR J PHARMACOL, V765, P582, DOI 10.1016/j.ejphar.2015.09.021
NR 42
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD NOV 25
PY 2020
VL 11
AR 575755
DI 10.3389/fpsyt.2020.575755
PG 8
WC Psychiatry
SC Psychiatry
GA PB8KU
UT WOS:000596564200001
PM 33324254
OA DOAJ Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Wakchaure, PD
   Ghosh, S
   Ganguly, B
AF Wakchaure, Padmaja D.
   Ghosh, Shibaji
   Ganguly, Bishwajit
TI Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase
   (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular
   Dynamics Simulation Study
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
AB Antiviral drug therapy against SARS-CoV-2 is not yet established and posing a serious global health issue. Remdesivir is the first antiviral compound approved by the US FDA for the SARS-CoV-2 treatment for emergency use, targeting RNA-dependent RNA polymerase (RdRp) enzyme. In this work, we have examined the action of remdesivir and other two ligands screened from the library of nucleotide analogues using docking and molecular dynamics (MD) simulation studies. The MD simulations have been performed for all the ligand-bound RdRp complexes for the 30 ns time scale. This is one of the earlier reports to perform the MD simulations studies using the SARS-CoV-2 RdRp crystal structure (PDB ID 7BTF). The MD trajectories were analyzed and Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) calculations were performed to calculate the binding free energy. The binding energy data reveal that compound-17 (-59.6 kcal/mol) binds more strongly as compared to compound-8 (-46.3 kcal/mol) and remdesivir (-29.7 kcal/mol) with RdRp. The detailed analysis of trajectories shows that the remdesivir binds in the catalytic site and forms a hydrogen bond with the catalytic residues from 0 to 0.46 ns. Compound-8 binds in the catalytic site but does not form direct hydrogen bonds with catalytic residues. Compound-17 showed the formation of hydrogen bonds with catalytic residues throughout the simulation process. The MD simulation results such as hydrogen bonding, the center of mass distance analysis, snapshots at a different time interval, and binding energy suggest that compound-17 binds strongly with RdRp of SARS-CoV-2 and has the potential to develop as a new antiviral against COVID-19. Further, the frontier molecular orbital analysis and molecular electrostatic potential (MESP) iso-surface analysis using DFT calculations shed light on the superior binding of compound-17 with RdRp compared to remdesivir and compound-8. The computed as well as the experimentally reported pharmacokinetics and toxicity parameters of compound-17 is encouraging and therefore can be one of the potential candidates for the treatment of COVID-19.
C1 [Wakchaure, Padmaja D.; Ghosh, Shibaji; Ganguly, Bishwajit] CSIR Cent Salt & Marine Chem Res Inst, Computat & Simulat Unit, Analyt & Environm Sci Div, Bhavnagar 364002, Gujarat, India.
   [Wakchaure, Padmaja D.; Ghosh, Shibaji; Ganguly, Bishwajit] CSIR Cent Salt & Marine Chem Res Inst, Centralized Instrument Facil, Bhavnagar 364002, Gujarat, India.
   [Wakchaure, Padmaja D.; Ghosh, Shibaji; Ganguly, Bishwajit] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.
RP Ganguly, B (corresponding author), CSIR Cent Salt & Marine Chem Res Inst, Computat & Simulat Unit, Analyt & Environm Sci Div, Bhavnagar 364002, Gujarat, India.; Ganguly, B (corresponding author), CSIR Cent Salt & Marine Chem Res Inst, Centralized Instrument Facil, Bhavnagar 364002, Gujarat, India.; Ganguly, B (corresponding author), Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.
EM ganguly@csmcri.res.in
FU CSIR, New Delhi, IndiaCouncil of Scientific & Industrial Research (CSIR)
   - India; Department of Science and TechnologyDepartment of Science &
   Technology (India) [EMR/2017/004652]; Department of biotechnology
   Government of India, New DelhiDepartment of Biotechnology (DBT) India
   [BT/PR12730/BID/7/523/2015]
FX P.D.W. acknowledges CSIR, New Delhi, India, for the GATE-junior research
   fellowship, and P.D.W. and S.G. are thankful to AcSIR Ghaziabad, Uttar
   Pradesh-201002, India, for their Ph.D. registration. B.G. thanks the
   Department of Science and Technology, under Grant EMR/2017/004652 and
   Department of biotechnology (Grant BT/PR12730/BID/7/523/2015) Government
   of India, New Delhi, for financial support. The CSIR-CSMCRI reference
   number is 155/2020. We thank the reviewers for their valuable comments
   and suggestions that have helped us to improve the article.
CR Ahmad M, 2020, ACS OMEGA, V5, P18356, DOI 10.1021/acsomega.0c02096
   Aihara J, 1999, J PHYS CHEM A, V103, P7487, DOI 10.1021/jp990092i
   Aihara J, 2000, PHYS CHEM CHEM PHYS, V2, P3121, DOI 10.1039/b002601h
   [Anonymous], 2012, Patent No. [US 2012/0009147 A1, 20120009147]
   Arber W., 1977, CURR TOP MICROBIOL, V6, P207
   Arjunan V, 2013, SPECTROCHIM ACTA A, V107, P62, DOI 10.1016/j.saa.2013.01.037
   Asthana S, 2015, INDIAN J PHARM SCI, V77, P439
   BECKE AD, 1993, J CHEM PHYS, V98, P1372, DOI 10.1063/1.464304
   Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng JZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep24454
   Chidangil S, 1998, J MOL MODEL, V4, P250, DOI 10.1007/s008940050082
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   FDA, 2020, EM US AUTH EM US AUT, V3
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Fleming FF, 2010, J MED CHEM, V53, P7902, DOI 10.1021/jm100762r
   Fleming I., 2010, MOL ORBITALS ORGANIC, DOI [10.1002/9780470689493, DOI 10.1002/9780470689493]
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Jesudason EP, 2009, EUR J MED CHEM, V44, P2307, DOI 10.1016/j.ejmech.2008.03.043
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kirschberg TA, 2017, BIOORG MED CHEM LETT, V27, P1840, DOI 10.1016/j.bmcl.2017.02.037
   Koulgi S, 2020, RSC ADV, V10, P26792, DOI 10.1039/d0ra04743k
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lee S.K., 2003, EUROQSAR 2002 DESIGN, P418
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Liu HX, 2010, MOL PHARMACEUT, V7, P75, DOI 10.1021/mp900131p
   Ng KKS, 2008, CURR TOP MICROBIOL, V320, P137
   O'Keefe LC, 2016, WORKPLACE HEALTH SAF, V64, P184, DOI 10.1177/2165079915607497
   Patlewicz G, 2008, SAR QSAR ENVIRON RES, V19, P495, DOI 10.1080/10629360802083871
   PEPE G, 1992, J MOL STRUC-THEOCHEM, V88, P175
   Portmann S., 2000, MOLEKEL 4 3
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Rahman MU, 2016, MOL BIOSYST, V12, P3280, DOI 10.1039/c6mb00521g
   Rashid M, 2020, BIOORG CHEM, V96, DOI 10.1016/j.bioorg.2020.103576
   Rassolov VA, 2001, J COMPUT CHEM, V22, P976, DOI 10.1002/jcc.1058.abs
   Raya A, 2011, EUR J MED CHEM, V46, P2463, DOI 10.1016/j.ejmech.2011.03.032
   Saurabh S., 2020, INTEGRATIVE NANOMEDI, P275
   Shang J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008392
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Singh A., 2014, INT J PHARM PHARM SC, V6, P155
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   Suwannarach N, 2020, MOLECULES, V25, DOI 10.3390/molecules25081800
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YX, 2018, FUTURE MED CHEM, V10, P2713, DOI 10.4155/fmc-2018-0252
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   WHO, COR DIS COVID 19 PAN
   World Health Organization, Q A COR COVID 19
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yu HJ, 2014, CHEM BIOL DRUG DES, V83, P89, DOI 10.1111/cbdd.12203
   Zhang LL, 2020, J PHYS CHEM B, V124, P6955, DOI 10.1021/acs.jpcb.0c04198
   Zheng YG, 2013, BIOORG MED CHEM LETT, V23, P3523, DOI 10.1016/j.bmcl.2013.04.039
NR 67
TC 0
Z9 0
U1 2
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
EI 1520-5207
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD NOV 25
PY 2020
VL 124
IS 47
BP 10641
EP 10652
DI 10.1021/acs.jpcb.0c06747
PG 12
WC Chemistry, Physical
SC Chemistry
GA PA3MR
UT WOS:000595542900007
PM 33190493
DA 2021-01-01
ER

PT J
AU Chen, HY
   Zhang, ZC
   Wang, L
   Huang, ZH
   Gong, FH
   Li, XD
   Chen, YH
   Wu, JZJ
AF Chen, Hongyi
   Zhang, Zhicheng
   Wang, Li
   Huang, Zhihua
   Gong, Fanghua
   Li, Xiaodong
   Chen, Yahong
   Wu, Jinzi J.
TI First clinical study using HCV protease inhibitor danoprevir to treat
   COVID-19 patients
SO MEDICINE
LA English
DT Article
DE COVID-19; danoprevir; HCV protease inhibitor; ritonavir; SARS-COV-2;
   treatment
AB Introduction: As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, which was approved and marketed in China since 2018 to treat chronic hepatitis C patients. Methods: This is an open-label, single arm study evaluating the effects of danoprevir boosted by ritonavir on treatment naive and experienced COVID-19 patients for the first time. Patients received danoprevir boosted by ritonavir (100 mg/100 mg, twice per day). The primary endpoint was the rate of composite adverse outcomes and efficacy was also evaluated. Results: The data showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients. No patient had composite adverse outcomes during this study. After initiation of danoprevir/ritonavir treatment, the first negative reverse real-time PCR (RT-PCR) test occurred at a median of 2 days, ranging from 1 to 8 days, and the obvious absorption in CT scans occurred at a median 3 days, ranging from 2 to 4 days. After 4 to 12-day treatment of danoprevir boosted by ritonavir, all enrolled 11 patients were discharged from the hospital. Conclusion: Our findings suggest that repurposing danoprevir for COVID-19 is a promising therapeutic option.
C1 [Chen, Hongyi; Wang, Li] Ninth Hosp Nanchang, Dept Infect Dis 1, Nanchang 330002, Jiangxi, Peoples R China.
   [Zhang, Zhicheng] Ninth Hosp Nanchang, Intens Care Unit, Nanchang 330002, Jiangxi, Peoples R China.
   [Huang, Zhihua] Ninth Hosp Nanchang, Radiol Dept, Nanchang 330002, Jiangxi, Peoples R China.
   [Gong, Fanghua] Ninth Hosp Nanchang, Dept Infect Dis 2, Nanchang 330002, Jiangxi, Peoples R China.
   [Li, Xiaodong; Chen, Yahong; Wu, Jinzi J.] Ascletis Biosci Co Ltd, Hangzhou 310051, Peoples R China.
   [Wu, Jinzi J.] Ascletis Pharmaceut Co Ltd, Shaoxing 310051, Zhejiang, Peoples R China.
RP Chen, HY (corresponding author), Room 1201,Bldg 3,371 Xingxing Rd, Hangzhou 310051, Zhejiang, Peoples R China.; Wu, JZJ (corresponding author), 167 Hongdu Middle Rd, Nanchang 330002, Jiangxi, Peoples R China.
EM Chenhongyi8660@163.com; jinzi.wu@ascletis.com
CR [Anonymous], 2020, COMMUNICATION   0311
   [Anonymous], 2020, ST VIRTUAL HIGH THOU
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen J., 2020, J CHIN J INFECT DIS, V38, pE008
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Garcia-Serradilla M, 2019, VIRUS RES, V264, P22, DOI 10.1016/j.virusres.2019.02.011
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee JW, 2018, COMPUT METH PROG BIO, V153, P253, DOI 10.1016/j.cmpb.2017.10.007
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Nguyen D., 2020, POTENTIALLY HIGHLY P
   Seiwert SD, 2008, ANTIMICROB AGENTS CH, V52, P4432, DOI 10.1128/AAC.00699-08
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wei L, 2019, J CLIN TRANSL HEPATO, V7, P221, DOI 10.14218/JCTH.2019.00018
   Xu XY, 2019, J CLIN TRANSL HEPATO, V7, P213, DOI 10.14218/JCTH.2019.00033
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
NR 18
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV 25
PY 2020
VL 99
IS 48
DI 10.1097/MD.0000000000023357
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA PB0WH
UT WOS:000596048000053
PM 33235105
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Walls, AC
   Fiala, B
   Schafer, A
   Wrenn, S
   Pham, MN
   Murphy, M
   Tse, LV
   Shehata, L
   O'Connor, MA
   Chen, CB
   Navarro, MJ
   Miranda, MC
   Pettie, D
   Ravichandran, R
   Kraft, JC
   Ogohara, C
   Palser, A
   Chalk, S
   Lee, EC
   Guerriero, K
   Kepl, E
   Chow, CM
   Sydeman, C
   Hodge, EA
   Brown, B
   Fuller, JT
   Dinnon, KH
   Gralinski, LE
   Leist, SR
   Gully, KL
   Lewis, TB
   Guttman, M
   Chu, HLY
   Lee, KK
   Fuller, DH
   Baric, RS
   Kellam, P
   Carter, L
   Pepper, M
   Sheahan, TP
   Veesler, D
   King, NP
AF Walls, Alexandra C.
   Fiala, Brooke
   Schafer, Alexandra
   Wrenn, Samuel
   Pham, Minh N.
   Murphy, Michael
   Tse, Longping, V
   Shehata, Laila
   O'Connor, Megan A.
   Chen, Chengbo
   Navarro, Mary Jane
   Miranda, Marcos C.
   Pettie, Deleah
   Ravichandran, Rashmi
   Kraft, John C.
   Ogohara, Cassandra
   Palser, Anne
   Chalk, Sara
   Lee, E-Chiang
   Guerriero, Kathryn
   Kepl, Elizabeth
   Chow, Cameron M.
   Sydeman, Claire
   Hodge, Edgar A.
   Brown, Brieann
   Fuller, Jim T.
   Dinnon, Kenneth H., III
   Gralinski, Lisa E.
   Leist, Sarah R.
   Gully, Kendra L.
   Lewis, Thomas B.
   Guttman, Miklos
   Chu, Helen Y.
   Lee, Kelly K.
   Fuller, Deborah H.
   Baric, Ralph S.
   Kellam, Paul
   Carter, Lauren
   Pepper, Marion
   Sheahan, Timothy P.
   Veesler, David
   King, Neil P.
TI Elicitation of Potent Neutralizing Antibody Responses by Designed
   Protein Nanoparticle Vaccines for SARS-CoV-2
SO CELL
LA English
DT Article
AB A safe, effective, and scalable vaccine is needed to halt the ongoing SARS-CoV-2 pandemic. We describe the structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice. The nanoparticle vaccines display 60 SARS-CoV-2 spike receptor-binding domains (RBDs) in a highly immunogenic array and induce neutralizing antibody titers 10-fold higher than the prefusion-stabilized spike despite a 5-fold lower dose. Antibodies elicited by the RBD nanoparticles target multiple distinct epitopes, suggesting they may not be easily susceptible to escape mutations, and exhibit a lower binding:neutralizing ratio than convalescent human sera, which may minimize the risk of vaccine-associated enhanced respiratory disease. The high yield and stability of the assembled nanoparticles suggest that manufacture of the nanoparticle vaccines will be highly scalable. These results highlight the utility of robust antigen display platforms and have launched cGMP manufacturing efforts to advance the SARS-CoV-2-RBD nanoparticle vaccine into the clinic.
C1 [Walls, Alexandra C.; Fiala, Brooke; Wrenn, Samuel; Pham, Minh N.; Murphy, Michael; Navarro, Mary Jane; Miranda, Marcos C.; Pettie, Deleah; Ravichandran, Rashmi; Kraft, John C.; Ogohara, Cassandra; Kepl, Elizabeth; Chow, Cameron M.; Sydeman, Claire; Carter, Lauren; Veesler, David; King, Neil P.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Fiala, Brooke; Wrenn, Samuel; Pham, Minh N.; Murphy, Michael; Miranda, Marcos C.; Pettie, Deleah; Ravichandran, Rashmi; Kraft, John C.; Ogohara, Cassandra; Kepl, Elizabeth; Chow, Cameron M.; Sydeman, Claire; Carter, Lauren; King, Neil P.] Univ Washington, Inst Prot Design, Seattle, WA 98195 USA.
   [Schafer, Alexandra; Tse, Longping, V; Gralinski, Lisa E.; Leist, Sarah R.; Gully, Kendra L.; Baric, Ralph S.; Sheahan, Timothy P.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27514 USA.
   [Shehata, Laila; Pepper, Marion] Univ Washington, Dept Immunol, Seattle, WA 98109 USA.
   [O'Connor, Megan A.; Guerriero, Kathryn; Brown, Brieann; Fuller, Jim T.; Lewis, Thomas B.; Fuller, Deborah H.] Univ Washington, Dept Microbiol, Seattle, WA 98109 USA.
   [O'Connor, Megan A.; Guerriero, Kathryn; Brown, Brieann; Lewis, Thomas B.; Fuller, Deborah H.] Washington Natl Primate Res Ctr, Seattle, WA 98121 USA.
   [Chen, Chengbo; Hodge, Edgar A.; Guttman, Miklos; Lee, Kelly K.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA.
   [Chen, Chengbo; Lee, Kelly K.] Univ Washington, Biol Phys Struct & Design Program, Seattle, WA 98195 USA.
   [Palser, Anne; Chalk, Sara; Lee, E-Chiang; Kellam, Paul] Kymab Ltd, Babraham Res Campus, Cambridge, England.
   [Dinnon, Kenneth H., III; Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27514 USA.
   [Chu, Helen Y.] Univ Washington, Dept Med, Seattle, WA 98109 USA.
   [Fuller, Deborah H.] Univ Washington, Ctr Innate Immun & Immune Dis, Seattle, WA 98109 USA.
   [Kellam, Paul] Imperial Coll, Dept Infect Dis, London, England.
RP Veesler, D; King, NP (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.; King, NP (corresponding author), Univ Washington, Inst Prot Design, Seattle, WA 98195 USA.
EM dveesler@uw.edu; neil@ipd.uw.edu
FU Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR
   [OPP1156262, OPP1126258, OPP1159947]; Defense Threat Reduction
   AgencyUnited States Department of DefenseDefense Threat Reduction Agency
   [HDTRA1-18-1-0001]; National Institute of General Medical SciencesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [R01GM120553, R01GM099989]; National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [DP1AI158186,
   HHSN272201700059C, 3U01AI42001-02S1]; Pew Biomedical Scholars Award;
   OD/NIH HHS/United States [P51 OD010425]; Burroughs Wellcome
   FundBurroughs Wellcome Fund; Fast Grants; Animal Models Contract
   [HHSN272201700036I-75N93020F00001]; University of Washington's
   Proteomics Resource [UWPR95794]; North Carolina Policy Collaboratory at
   the University of North Carolina at Chapel Hill; North Carolina
   Coronavirus Relief Fund
FX The authors gratefully acknowledge Caitlin Wolf, Naomi Wilcox, and
   Denise McCulloch for providing human convalescent serum samples; Adam
   Dingens and Jesse Bloom for facilitating acquisition of convalescent
   human serum samples and for comments on the manuscript; Maggie Ahlrichs
   for assistance with protein production; Karla-Luise Herpoldt for
   assistance and guidance with data analysis; and Ratika Krishnamurty for
   project management. This study was supported by the Bill & Melinda Gates
   Foundation (OPP1156262 to D.V. and N.P.K., OPP1126258 to K.K.L. and
   H.Y.C., and OPP1159947 to Kymab Ltd.), a generous gift from the
   Audacious Project, a generous gift from Jodi Green and Mike Halperin, a
   generous gift from the Hanauer family, the Defense Threat Reduction
   Agency (HDTRA1-18-1-0001 to N.P.K.), P51 OD010425/OD/NIH HHS/United
   States (D.H.F.), the National Institute of General Medical Sciences
   (R01GM120553 to D.V. and R01GM099989 to K.K.L.), the National Institute
   of Allergy and Infectious Diseases (DP1AI158186 and HHSN272201700059C to
   D.V. and 3U01AI42001-02S1 to M.P.), a Pew Biomedical Scholars Award
   (D.V.), Investigators in the Pathogenesis of Infectious Disease Awards
   from the Burroughs Wellcome Fund (D.V. and M.P.), Fast Grants (D.V. and
   M.P.), an Animal Models Contract HHSN272201700036I-75N93020F00001
   (R.S.B.), the University of Washington's Proteomics Resource
   (UWPR95794), and the North Carolina Policy Collaboratory at the
   University of North Carolina at Chapel Hill with funding from the North
   Carolina Coronavirus Relief Fund established and appropriated by the
   North Carolina General Assembly (R.S.B.).
CR Alsoussi WB, 2020, J IMMUNOL, V205, P915, DOI 10.4049/jimmunol.2000583
   Anthony SJ, 2017, MBIO, V8, DOI [10.1128/mBio.00373-17, 10.1128/mbio.00373-17]
   Anywaine Z, 2019, J INFECT DIS, V220, P46, DOI 10.1093/infdis/jiz070
   Bale JB, 2016, SCIENCE, V353, P389, DOI 10.1126/science.aaf8818
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Boyoglu-Barnum S., 2020, 202020052030125179 B
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Brouwer PJM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12080-1
   Bruun TUJ, 2018, ACS NANO, V12, P8855, DOI 10.1021/acsnano.8b02805
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035
   Davis AKF, 2018, J VIROL, V92, DOI 10.1128/JVI.00859-18
   Dinnon K.H., 2020, 202020052006081497 B
   Dinnon KH, 2020, NATURE, DOI 10.1038/s41586-020-2708-8
   Edwards R.J., 2020, 20200712199588 BIORX
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/NMETH.1318, 10.1038/nmeth.1318]
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Guttman M, 2013, J AM SOC MASS SPECTR, V24, P1906, DOI 10.1007/s13361-013-0727-5
   Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827
   Harvey DJ, 2011, PROTEOMICS, V11, P4291, DOI 10.1002/pmic.201100300
   Henderson R, 2020, NAT STRUCT MOL BIOL, V27, P925, DOI 10.1038/s41594-020-0479-4
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Hsia Y, 2016, NATURE, V535, P136, DOI 10.1038/nature18010
   Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Irvine Darrell J, 2020, Curr Opin Immunol, V65, P1, DOI 10.1016/j.coi.2020.01.007
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Kanekiyo Masaru, 2020, Cold Spring Harb Perspect Med, DOI 10.1101/cshperspect.a038448
   Kanekiyo M, 2019, J INFECT DIS, V219, pS88, DOI 10.1093/infdis/jiy745
   Kanekiyo M, 2019, NAT IMMUNOL, V20, P362, DOI 10.1038/s41590-018-0305-x
   Kanekiyo M, 2015, CELL, V162, P1090, DOI 10.1016/j.cell.2015.07.043
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Keech Cheryl, 2020, N Engl J Med, V383, P2320, DOI 10.1056/NEJMoa2026920
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   King NP, 2012, SCIENCE, V336, P1171, DOI 10.1126/science.1219364
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kreimer AR, 2018, VACCINE, V36, P4774, DOI 10.1016/j.vaccine.2017.12.078
   Krenkova J, 2013, J CHROMATOGR A, V1322, P54, DOI 10.1016/j.chroma.2013.10.087
   Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lee EC, 2014, NAT BIOTECHNOL, V32, P356, DOI 10.1038/nbt.2825
   Lee JM, 2019, ELIFE, V8, DOI 10.7554/eLife.49324
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li XG, 2020, J MED VIROL, V92, P501, DOI 10.1002/jmv.25701
   Liu LH, 2020, NATURE, DOI 10.1038/s41586-020-2571-7
   Lopez-Sagaseta J, 2016, COMPUT STRUCT BIOTEC, V14, P58, DOI 10.1016/j.csbj.2015.11.001
   Mandolesi M., 2020, 202020072031228486 B
   Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046
   McCallum M, 2020, NAT STRUCT MOL BIOL, DOI 10.1038/s41594-020-0483-8
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Millet Jean Kaoru, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.2035
   Mulligan M.J., 2020, 20202006203020142570
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rossen JWA, 1998, J VIROL, V72, P497, DOI 10.1128/JVI.72.1.497-503.1998
   Sahin U., 2020, 20202007201720140533
   Seydoux E., 2020, 202020052012091298 B
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Smith EC, 2014, ANNU REV VIROL, V1, P111, DOI 10.1146/annurev-virology-031413-085507
   Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tortorici M.A., 2020, SCIENCE
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Ueda G, 2020, ELIFE, V9, DOI 10.7554/eLife.57659
   Verkerke HP, 2016, J VIROL, V90, P9471, DOI 10.1128/JVI.01351-16
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Weis DD, 2006, J AM SOC MASS SPECTR, V17, P1700, DOI 10.1016/j.jasms.2006.07.025
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xiong X., NAT STRUCT MOL BIOL, V27, P934
   Xiong XL, 2018, J VIROL, V92
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang Y, 2015, J VIROL, V89, P9119, DOI 10.1128/JVI.01279-15
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang ZQ, 2012, ANAL CHEM, V84, P4942, DOI 10.1021/ac300535r
   Zhou DRN, 2020, NAT STRUCT MOL BIOL, V27, P950, DOI 10.1038/s41594-020-0480-y
   Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
NR 106
TC 0
Z9 0
U1 5
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD NOV 25
PY 2020
VL 183
IS 5
BP 1367
EP +
DI 10.1016/j.cell.2020.10.043
PG 33
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA OW9ND
UT WOS:000593203800018
PM 33160446
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sherman, SM
   Smith, LE
   Sim, J
   Amlot, R
   Cutts, M
   Dasch, H
   Rubin, GJ
   Sevdalis, N
AF Sherman, Susan M.
   Smith, Louise E.
   Sim, Julius
   Amlot, Richard
   Cutts, Megan
   Dasch, Hannah
   Rubin, G. James
   Sevdalis, Nick
TI COVID-19 vaccination intention in the UK: results from the COVID-19
   vaccination acceptability study (CoVAccS), a nationally representative
   cross-sectional survey
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE Hesitancy; beliefs; attitudes; barriers; vaccine; COVID-19
ID SPREAD; MODEL
AB To investigate factors associated with intention to be vaccinated against COVID-19 we conducted a cross-sectional survey of 1,500 UK adults, recruited from an existing online research panel. Data were collected between 14th and 17th July 2020. We used linear regression analyses to investigate associations between intention to be vaccinated for COVID-19 "when a vaccine becomes available to you" and sociodemographic factors, previous influenza vaccination, general vaccine attitudes and beliefs, attitudes and beliefs about COVID-19, and attitudes and beliefs about a COVID-19 vaccination. 64% of participants reported being very likely to be vaccinated against COVID-19, 27% were unsure, and 9% reported being very unlikely to be vaccinated. Personal and clinical characteristics, previous influenza vaccination, general vaccination beliefs, and beliefs and attitudes about COVID-19 and a COVID-19 vaccination explained 76% of the variance in vaccination intention. Intention to be vaccinated was associated with more positive general COVID-19 vaccination beliefs and attitudes, weaker beliefs that the vaccination would cause side effects or be unsafe, greater perceived information sufficiency to make an informed decision about COVID-19 vaccination, greater perceived risk of COVID-19 to others (but not risk to oneself), older age, and having been vaccinated for influenza last winter (2019/20). Despite uncertainty around the details of a COVID-19 vaccination, most participants reported intending to be vaccinated for COVID-19. Actual uptake may be lower. Vaccination intention reflects general vaccine beliefs and attitudes. Campaigns and messaging about a COVID-19 vaccination could consider emphasizing the risk of COVID-19 to others and necessity for everyone to be vaccinated.
C1 [Sherman, Susan M.; Cutts, Megan] Keele Univ, Sch Psychol, Newcastle Under Lyme, England.
   [Smith, Louise E.; Dasch, Hannah; Rubin, G. James; Sevdalis, Nick] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England.
   [Smith, Louise E.; Amlot, Richard; Rubin, G. James] Kings Coll London, NIHR Hlth Protect Res Unit Emergency Preparedness, London, England.
   [Sim, Julius] Keele Univ, Sch Med, Newcastle Under Lyme, England.
   [Amlot, Richard] Publ Hlth England, Emergency Response Dept Sci & Technol, Behav Sci Team, Salisbury, Wilts, England.
   [Dasch, Hannah; Sevdalis, Nick] Kings Coll London, Ctr Implementat Sci, London, England.
RP Sherman, SM (corresponding author), Keele Univ, Sch Psychol, Keele ST5 5BG, Staffs, England.
EM s.m.sherman@keele.ac.uk
RI ; Sevdalis, Nick/O-1419-2017
OI Sim, Julius/0000-0002-1816-1676; Sevdalis, Nick/0000-0001-7560-8924;
   Sherman, Susan/0000-0001-6708-3398
FU Keele University Faculty of Natural Sciences Research Development award;
   King's Together Rapid COVID-19 award; National Institute for Health
   Research Health Protection Research Unit (NIHR HPRU) in Emergency
   Preparedness and Response; National Institute for Health Research (NIHR)
   Applied Research Collaboration (ARC) South London at King's College
   Hospital NHS Foundation Trust; Guy's and St Thomas' NHS Foundation
   Trust; King's College Hospital NHS Foundation Trust; King's College
   London; South London and Maudsley NHS Foundation Trust; Guy's and St
   Thomas' Charity; Maudsley Charity
FX Data collection was funded by a Keele University Faculty of Natural
   Sciences Research Development award to SS, JS and NS, and a King's
   Together Rapid COVID-19 award granted jointly to LS, GJR, RA, NS, SS and
   JS. LS, RA and GJR are supported by the National Institute for Health
   Research Health Protection Research Unit (NIHR HPRU) in Emergency
   Preparedness and Response, a partnership between Public Health England,
   King's College London and the University of East Anglia. NS' research is
   supported by the National Institute for Health Research (NIHR) Applied
   Research Collaboration (ARC) South London at King's College Hospital NHS
   Foundation Trust. NS is a member of King's Improvement Science, which
   offers co-funding to the NIHR ARC South London and is funded by King's
   Health Partners (Guy's and St Thomas' NHS Foundation Trust, King's
   College Hospital NHS Foundation Trust, King's College London and South
   London and Maudsley NHS Foundation Trust), Guy's and St Thomas' Charity
   and the Maudsley Charity. The views expressed are those of the authors
   and not necessarily those of the NIHR, the charities, Public Health
   England or the Department of Health and Social Care.
CR AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Anderson RM, 2020, LANCET, V396, P587, DOI 10.1016/S0140-6736(20)31689-5
   [Anonymous], 2020, CORONAVIRUS VACCINAT
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810
   Cyranoski D, 2020, NATURE, V585, P331, DOI 10.1038/d41586-020-02633-6
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Gomes M Gabriela M, 2020, medRxiv, DOI 10.1101/2020.04.27.20081893
   Gostin LO, 2020, JAMA-J AM MED ASSOC, V324, P335, DOI 10.1001/jama.2020.10802
   HM Government, 2020, COR COVID 19 UK
   HM Government, 2020, OUR PLAN REB UK GOV
   JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101
   Joint Committee on Vaccination and Immunisation, 2020, JOINT COMM VACC IMM
   Kang SJ, 2020, INFECT CHEMOTHER, V52, P154, DOI 10.3947/ic.2020.52.2.154
   Kohler U., 2019, SURVEY METHODS, P1, DOI [10.13094/SMIF-00014, DOI 10.13094/SMIF-00014]
   Larson HJ, 2014, HUM VACC IMMUNOTHER, V10, P2543, DOI 10.4161/21645515.2014.969618
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lehmann BA, 2014, VACCINE, V32, P6986, DOI 10.1016/j.vaccine.2014.10.034
   Mortensen GL, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1863-6
   Myers LB, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-15
   Office for National Statistics, 2019, INT US UK 2019
   Public Health England, 2020, SURV INFL OTH RESP V
   Renner B, 2012, VACCINE, V30, P7019, DOI 10.1016/j.vaccine.2012.09.064
   Riley RD, 2019, STAT MED, V38, P1262, DOI 10.1002/sim.7993
   Rogers R.W., 1997, HDB HLTH BEHAV RES, P113
   Rubin G.J, 2014, HLTH SERV DELIV RES, DOI 10.3310/hsdr02410
   SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507
   Smith LE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240399
   Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046
   Sniehotta FF, 2005, PSYCHOL HEALTH, V20, P143, DOI 10.1080/08870440512331317670
   Thorneloe RT, 2020, WILLINGNESS RECEIVE, DOI [10.31234/osf.io/fs9wk, DOI 10.31234/OSF.IO/FS9WK]
   Wheelock A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014668
   Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468
   Wright KB, 2005, J COMPUT-MEDIAT COMM, V10
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
NR 35
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1846397
EA NOV 2020
PG 10
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA OW1DG
UT WOS:000592636100001
PM 33242386
OA Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Srivastava, A
   Siddiqui, S
   Ahmad, R
   Mehrotra, S
   Ahmad, B
   Srivastava, AN
AF Srivastava, Aditi
   Siddiqui, Sahabjada
   Ahmad, Rumana
   Mehrotra, Sudhir
   Ahmad, Bilal
   Srivastava, A. N.
TI Exploring nature's bounty: identification of Withania somnifera as a
   promising source of therapeutic agents against COVID-19 by virtual
   screening and in silico evaluation
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Withanolides; phytomedicine; SARS-CoV-2 target proteins; molecular
   docking; molecular chemoinformatics
ID CORONAVIRUS SPIKE PROTEIN; SARS-CORONAVIRUS; DRUG DISCOVERY; PREDICTION;
   INFECTION; COMBINATORIAL; ALGORITHM; DESIGN; BIOAVAILABILITY;
   WITHANOLIDES
AB Coronaviruses are etiological agents of extreme human and animal infection resulting in abnormalities primarily in the respiratory tract. Presently, there is no defined COVID-19 intervention and clinical trials of prospective therapeutic agents are still in the nascent stage. Withania somnifera (L.) Dunal (WS), is an important medicinal plant in Ayurveda. The present study aimed to evaluate the antiviral potential of selected WS phytoconstituents against the novel SARS-CoV-2 target proteins and human ACE2 receptor using in silico methods. Most of the phytoconstituents displayed good absorption and transport kinetics and were also found to display no associated mutagenic or adverse effect(s). Molecular docking analyses revealed that most of the WS phytoconstituents exhibited potent binding to human ACE2 receptor, SAR-CoV and SARS-CoV-2 spike glycoproteins as well as the two main SARS-CoV-2 proteases. Most of the phytoconstituents were predicted to undergo Phase-I metabolism prior to excretion. All phytoconstituents had favorable bioactivity scores with respect to various receptor proteins and target enzymes. SAR analysis revealed that the number of oxygen atoms in the withanolide backbone and structural rearrangements were crucial for effective binding. Molecular simulation analyses of SARS-CoV-2 spike protein and papain-like protease with Withanolides A and B, respectively, displayed a stability profile at 300 K and constant RMSDs of protein side chains and Ca atoms throughout the simulation run time. In a nutshell, WS phytoconstituents warrant further investigations in vitro and in vivo to unravel their molecular mechanism(s) and modes of action for their future development as novel antiviral agents against COVID-19.
   [GRAPHICS]
   .
C1 [Srivastava, Aditi; Ahmad, Rumana] Era Univ, Eras Lucknow Med Coll & Hosp, Dept Biochem, Hardoi Rd, Lucknow 226003, UP, India.
   [Siddiqui, Sahabjada] Era Univ, Eras Lucknow Med Coll & Hosp, Dept Biotechnol, Lucknow, UP, India.
   [Mehrotra, Sudhir] Univ Lucknow, Dept Biochem, Lucknow, UP, India.
   [Ahmad, Bilal] Era Univ, Eras Lucknow Med Coll & Hosp, Res Cell, Lucknow, UP, India.
   [Srivastava, A. N.] Era Univ, Eras Lucknow Med Coll & Hosp, Dept Pathol, Lucknow, UP, India.
RP Ahmad, R (corresponding author), Era Univ, Eras Lucknow Med Coll & Hosp, Dept Biochem, Hardoi Rd, Lucknow 226003, UP, India.
EM rumana_ahmad@yahoo.co.in
RI Siddiqui, Sahabjada/E-8383-2015
OI Siddiqui, Sahabjada/0000-0003-0982-1465
CR AHMAD R, 2019, PEERJ, V7, DOI DOI HTTPS://DOI.ORG/10.7717/PEERJ.6012
   AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Aniyery RB, 2015, J CHEM PHARM SCI, V8, P957
   [Anonymous], 2020, NEW DRUG TARG FOUND
   [Anonymous], 2020, WORLDOMETER
   Arya R, 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11860011.v2, DOI 10.26434/CHEMRXIV.11860011.V2, 10.26434/chemrxiv.11860011.v2.]
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bahar I, 2010, CHEM REV, V110, P1463, DOI 10.1021/cr900095e
   Balakrishnan N, 2015, INT J PHARM PHARM SC, V7, P295
   Balakrishnan N, 2014, INT J PHARM SCI, V6, P413
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Cai Z, 2015, CELL BIOCHEM BIOPHYS, V72, P727, DOI 10.1007/s12013-015-0524-9
   Campillos M, 2008, SCIENCE, V321, P263, DOI 10.1126/science.1158140
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chen Y, 2020, RES SER CHIN DREAM, P1, DOI [10.1142/S0192415X2050010X, 10.1007/978-981-13-9660-1_1]
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cheng TJ, 2012, AAPS J, V14, P133, DOI 10.1208/s12248-012-9322-0
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Delaney JS, 2004, J CHEM INF COMP SCI, V44, P1000, DOI 10.1021/ci034243x
   Dhar N, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.01031
   Dhar N, 2013, MOL BIOL REP, V40, P7007, DOI 10.1007/s11033-013-2820-z
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Dyalla J., 2014, INFECTION, V2
   Egan WJ, 2000, J MED CHEM, V43, P3867, DOI 10.1021/jm000292e
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   Galvelis R, 2019, J CHEM INF MODEL, V59, P3485, DOI 10.1021/acs.jcim.9b00439
   Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071
   GHOSE AK, 1987, J CHEM INF COMP SCI, V27, P21, DOI 10.1021/ci00053a005
   GHOSE TK, 1987, PURE APPL CHEM, V59, P257, DOI 10.1351/pac198759020257
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Guy JL, 2005, FEBS J, V272, P3512, DOI 10.1111/j.1742-4658.2005.04756.x
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004
   Khan T, 2018, COMPUT BIOL CHEM, V75, P178, DOI 10.1016/j.compbiolchem.2018.05.008
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Kumar Vikas, 2015, [CELLMED, 셀메드], V5, P1, DOI 10.5667/tang.2014.0030
   Kuzmanic A, 2010, BIOPHYS J, V98, P861, DOI 10.1016/j.bpj.2009.11.011
   Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Liu S, 2020, BIOINFORMATICS, V36, P1066, DOI 10.1093/bioinformatics/btz725
   Liu X., 2020, CRYSTAL STRUCTURE CO
   Martin YC, 2005, J MED CHEM, V48, P3164, DOI 10.1021/jm0492002
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Martinez-Rosell G, 2017, J CHEM INF MODEL, V57, P1511, DOI 10.1021/acs.jcim.7b00190
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   Mirjalili MH, 2009, MOLECULES, V14, P2373, DOI 10.3390/molecules14072373
   Misico RI, 2011, PROG CHEM ORG NAT PR, V94, P127, DOI 10.1007/978-3-7091-0748-5_3
   Misra L, 2008, PHYTOCHEMISTRY, V69, P1000, DOI 10.1016/j.phytochem.2007.10.024
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Mortelmans K, 2000, MUTAT RES-FUND MOL M, V455, P29, DOI 10.1016/S0027-5107(00)00064-6
   Muegge I, 2001, J MED CHEM, V44, P1841, DOI 10.1021/jm015507e
   Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7
   Oprea TI, 2001, J CHEM INF COMP SCI, V41, P1308, DOI 10.1021/ci010366a
   Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722
   Richman D.D., 2016, CLIN VIROLOGY
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Rohit Jain, 2012, Journal of Medicinal Plants Research, V6, P5388
   Rowe T, 2004, J VIROL, V78, P11401, DOI 10.1128/JVI.78.20.11401-11404.2004
   Sander T., 2001, OSIRIS PROPERTY EXPL
   Teague SJ, 1999, ANGEW CHEM INT EDIT, V38, P3743, DOI 10.1002/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.3.CO;2-L
   Tian S, 2015, ADV DRUG DELIVER REV, V86, P2, DOI 10.1016/j.addr.2015.01.009
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   van Breemen Richard B, 2005, Expert Opin Drug Metab Toxicol, V1, P175, DOI 10.1517/17425255.1.2.175
   Varshney A., 2020, VIROL J, DOI [10.21203/rs.3.rs-17806/v1, DOI 10.21203/RS.3.RS-17806/V1]
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Viswanadhan V. N., 1990, BIOCHIM BIOPHYS ACTA, V1039
   VISWANADHAN VN, 1991, BIOCHEMISTRY-US, V30, P11164, DOI 10.1021/bi00110a021
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Wirth M, 2011, MOL INFORM, V30, P677, DOI 10.1002/minf.201100034
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu CY, 2012, J CHEM INF MODEL, V52, P2840, DOI 10.1021/ci300400a
   Yang Jing-Fang, 2020, Brief Bioinform, V21, P2206, DOI 10.1093/bib/bbz141
   Yang JM, 2004, PROTEINS, V55, P288, DOI 10.1002/prot.20035
   Zaretzki J, 2013, BIOINFORMATICS, V29, P497, DOI 10.1093/bioinformatics/bts705
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 87
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1835725
EA NOV 2020
PG 51
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OW7YB
UT WOS:000593096100001
PM 33246398
OA Bronze
DA 2021-01-01
ER

PT J
AU van de Poll-franse, LV
   de Rooij, BH
   Horevoorts, NJE
   May, AM
   Vink, GR
   Koopman, M
   van Laarhoven, HWM
   Besselink, MG
   Oerlemans, S
   Husson, O
   Beijer, S
   Ezendam, NPM
   Raijmakers, NJH
   Wollersheim, BM
   Hoedjes, M
   Siesling, S
   van Eenbergen, MC
   Mols, F
AF van de Poll-franse, Lonneke V.
   de Rooij, Belle H.
   Horevoorts, Nicole J. E.
   May, Anne M.
   Vink, Geraldine R.
   Koopman, Miriam
   van Laarhoven, Hanneke W. M.
   Besselink, Marc G.
   Oerlemans, Simone
   Husson, Olga
   Beijer, Sandra
   Ezendam, Nicole P. M.
   Raijmakers, Natasja J. H.
   Wollersheim, Barbara M.
   Hoedjes, Meeke
   Siesling, Sabine
   van Eenbergen, Mies C.
   Mols, Floortje
TI Perceived Care and Well-being of Patients With Cancer and Matched Norm
   Participants in the COVID-19 Crisis Results of a Survey of Participants
   in the Dutch PROFILES Registry
SO JAMA ONCOLOGY
LA English
DT Article; Early Access
ID QUESTIONNAIRE; QLQ-C30
AB This cross-sectional study assesses how patients with cancer perceive cancer treatment and follow-up care (including experiences with telephone and video consultations) and patients' well-being in comparison with a norm population during the COVID-19 pandemic.
   Questions How do Dutch patients with cancer perceive care and well-being during the COVID-19 crisis, in comparison with a matched norm population? Findings In this cross-sectional analysis within a population-based registry of 4094 Dutch patients with cancer and 977 matched norm participants, up to 29% of patients reported that their appointment was canceled or replaced by a telephone or video consultation, related to systemic therapy. Quality of life, anxiety, and depression were comparable, but norm participants significantly more often reported loneliness (12% vs 7%) than patients with cancer. Meaning Long-term evaluation is needed, but additional supportive care for patients with cancer does not appear to be required at this moment.
   Importance As the resolution of the coronavirus disease 2019 (COVID-19) crisis is unforeseeable, and/or a second wave of infections may arrive in the fall of 2020, it is important to evaluate patients' perspectives to learn from this. Objective To assess how Dutch patients with cancer perceive cancer treatment and follow-up care (including experiences with telephone and video consultations [TC/VC]) and patients' well-being in comparison with a norm population during the COVID-19 crisis. Design, Setting, and Participants Cross-sectional study of patients participating in the Dutch Patient Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship (PROFILES) registry and a norm population who completed a questionnaire from April to May 2020. Main Outcomes and Measures Logistic regression analysis assessed factors associated with changes in cancer care (treatment or follow-up appointment postponed/canceled or changed to TC/VC). Differences in quality of life, anxiety/depression, and loneliness between patients and age-matched and sex-matched norm participants were evaluated with regression models. Results The online questionnaire was completed by 4094 patients (48.6% response), of whom most were male (2493 [60.9%]) and had a mean (SD) age of 63.0 (11.1) years. Of these respondents, 886 (21.7%) patients received treatment; 2725 (55.6%) received follow-up care. Treatment or follow-up appointments were canceled for 390 (10.8%) patients, whereas 160 of 886 (18.1%) in treatment and 234 of 2725 (8.6%) in follow-up had it replaced by a TC/VC. Systemic therapy, active surveillance, or surgery were associated with cancellation of treatment or follow-up appointment. Younger age, female sex, comorbidities, metastasized cancer, being worried about getting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and receiving supportive care were associated with replacement of a consultation with a TC/VC. Patients and norm participants reported that the COVID-19 crisis made them contact their general practitioner (852 of 4068 [20.9%] and 218 of 979 [22.3%]) or medical specialist/nurse (585 of 4068 [14.4%] and 144 of 979 [14.7%]) less quickly when they had physical complaints or concerns. Most patients who had a TC/VC preferred a face-to-face consultation, but 151 of 394 (38.3%) were willing to use a TC/VC again. Patients with cancer were more worried about getting infected with SARS-CoV-2 compared with the 977 norm participants (917 of 4094 [22.4%] vs 175 of 977 [17.9%]). Quality of life, anxiety, and depression were comparable, but norm participants more often reported loneliness (114 of 977 [11.7%] vs 287 of 4094 [7.0%]) than patients with cancer (P = .009). Conclusions and Relevance Among patients with cancer in the Netherlands, 1 in 3 reported changes in cancer care in the first weeks of the COVID-19 crisis. Long-term outcomes need to be monitored. The crisis may affect the mental well-being of the general population relatively more than that of patients with cancer.
C1 [van de Poll-franse, Lonneke V.; de Rooij, Belle H.; Horevoorts, Nicole J. E.; Vink, Geraldine R.; Oerlemans, Simone; Husson, Olga; Beijer, Sandra; Ezendam, Nicole P. M.; Raijmakers, Natasja J. H.; Siesling, Sabine; van Eenbergen, Mies C.; Mols, Floortje] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, POB 19079, NL-3501 DB Utrecht, Netherlands.
   [van de Poll-franse, Lonneke V.; Wollersheim, Barbara M.] Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, Amsterdam, Netherlands.
   [van de Poll-franse, Lonneke V.; de Rooij, Belle H.; Horevoorts, Nicole J. E.; Ezendam, Nicole P. M.; Hoedjes, Meeke; Mols, Floortje] Tilburg Univ, Ctr Res Psychol & Somat Disorders CoRPS, Dept Med & Clin Psychol, Tilburg, Netherlands.
   [May, Anne M.] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Vink, Geraldine R.; Koopman, Miriam] Univ Utrecht, Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands.
   [van Laarhoven, Hanneke W. M.] Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands.
   [Besselink, Marc G.] Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Dept Surg, Amsterdam, Netherlands.
   [Husson, Olga] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands.
   [Husson, Olga] Inst Canc Res, Div Clin Studies, London, England.
   [Raijmakers, Natasja J. H.] Netherlands Assoc Palliat Care PZNL, Utrecht, Netherlands.
   [Siesling, Sabine] Univ Twente, Tech Med Ctr, Dept Hlth Technol & Serv Res, Enschede, Netherlands.
RP van de Poll-franse, LV (corresponding author), Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, POB 19079, NL-3501 DB Utrecht, Netherlands.
EM l.vandepoll@iknl.nl
RI Husson, Olga/ABI-4686-2020; Besselink, Marc G/R-4268-2019
OI Husson, Olga/0000-0002-1387-8686; Besselink, Marc G/0000-0003-2650-9350
FU Dutch Research Council [2016/04981/ZONMW-91101002]
FX This work was supported by the Dutch Research Council-Investment Grant
   Large (2016/04981/ZONMW-91101002).
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Barsom EZ, 2020, NAT MED, V26, P632, DOI 10.1038/s41591-020-0845-0
   Barsom EZ, 2020, SURG ENDOSC, DOI 10.1007/s00464-020-07499-3
   Dinmohamed AG, 2020, LANCET ONCOL, V21, P750, DOI 10.1016/S1470-2045(20)30265-5
   European Organisation for Research and Treatment of Cancer Quality of Life Group, 2020, EORTC QUAL LIF GROUP
   Gierveld JDJ, 2010, EUR J AGEING, V7, P121, DOI 10.1007/s10433-010-0144-6
   Jones D, 2020, LANCET ONCOL, V21, P748, DOI 10.1016/S1470-2045(20)30242-4
   Mols F, 2018, ACTA ONCOL, V57, P1381, DOI 10.1080/0284186X.2018.1481293
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P2368, DOI 10.1056/NEJMms2009984
   Sangha O, 2003, ARTHRIT RHEUM-ARTHR, V49, P156, DOI 10.1002/art.10993
   Schrag D, 2020, JAMA-J AM MED ASSOC, V323, P2005, DOI 10.1001/jama.2020.6236
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   van de Poll-Franse LV, 2011, EUR J CANCER, V47, P2188, DOI 10.1016/j.ejca.2011.04.034
   Webster P, 2020, LANCET, V395, P1180, DOI 10.1016/S0140-6736(20)30818-7
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 15
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
DI 10.1001/jamaoncol.2020.6093
EA NOV 2020
PG 6
WC Oncology
SC Oncology
GA OX1HR
UT WOS:000593325300007
PM 33237294
OA Bronze
DA 2021-01-01
ER

PT J
AU Khavinson, VK
   Linkova, NS
   Kvetnoy, IM
   Polyakova, VO
   Drobintseva, AO
   Kvetnaia, TV
   Ivko, OM
AF Khavinson, V. Kh.
   Linkova, N. S.
   Kvetnoy, I. M.
   Polyakova, V. O.
   Drobintseva, A. O.
   Kvetnaia, T. V.
   Ivko, O. M.
TI Thymalin: Activation of Differentiation of Human Hematopoietic Stem
   Cells
SO BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE thymalin; peptides; hematopoietic stem cells; cell differentiation;
   COVID-19
ID CD44
AB Thymalin is a polypeptide complex isolated from the thymus and regulating the functions of the immune system. Thymalin is effective in therapy of acute respiratory syndrome, chronic obstructive bronchitis, and other immunopathology. Thymalin increases functional activity of T lymphocytes, but the targeted molecular mechanism of its biological activity requires further study. We studied the influence of thymalin on differentiation of human hematopoietic stem cells (HSC) and expression of CD28 molecule involved in the implementation of antiviral immunity in COVID-19 infection. It was found that thymalin reduced the expression of CD44 (stem cell marker) and CD117 (molecule of the intermediate stage of HSC differentiation) by 2-3 times and increased the expression of CD28 (marker of mature T lymphocytes) by 6.8 times. This indirectly indicates that thymalin stimulated differentiation of CD117(+) cells into mature CD28(+)T lymphocytes. It is known that in patients with severe COVID-19, the number of CD28(+), CD4(+), CD8(+)T lymphocytes in the blood decreased, which attested to a pronounced suppression of immunity. It is possible that the antiviral effect of thymalin consists in compensatory stimulation of HSC differentiation into CD28(+)T lymphocytes at the stage of immunity suppression in unfavorable course of viral infection. Thymalin can be considered as an immunoprotective peptide drug for the prevention of COVID-19.
C1 [Khavinson, V. Kh.; Linkova, N. S.; Kvetnoy, I. M.; Polyakova, V. O.; Drobintseva, A. O.; Kvetnaia, T. V.; Ivko, O. M.] St Petersburg Inst Bioregulat & Gerontol, Dept Biogerontol, St Petersburg, Russia.
   [Khavinson, V. Kh.] Russian Acad Sci, IP Pavlov Inst Physiol, Grp Peptide Regulat & Aging, St Petersburg, Russia.
   [Linkova, N. S.] Fed Med Biol Agcy Russia, Acad Postgrad Educ, Fed Res Clin Ctr, Dept Therapy Geriatr & Antiaging Med, Moscow, Russia.
RP Linkova, NS (corresponding author), St Petersburg Inst Bioregulat & Gerontol, Dept Biogerontol, St Petersburg, Russia.; Linkova, NS (corresponding author), Fed Med Biol Agcy Russia, Acad Postgrad Educ, Fed Res Clin Ctr, Dept Therapy Geriatr & Antiaging Med, Moscow, Russia.
EM linkova8101984@gmail.com
CR Anisimov VN, 2010, BIOGERONTOLOGY, V11, P139, DOI 10.1007/s10522-009-9249-8
   Chen C, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0605-5
   Frumento G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00468
   Godoy GJ, 2020, IMMUNOL LETT, V223, P17, DOI 10.1016/j.imlet.2020.04.006
   Khavinson VK, 2002, NEUROENDOCRINOL LETT, V23, P11
   Khavinson V, 2020, STEM CELL REV REP, V16, P118, DOI 10.1007/s12015-019-09938-8
   Khlystova ZS, 2003, B EXP BIOL MED+, V135, P600, DOI 10.1023/A:1025449923475
   Kim KH, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0427-6
   Li JP, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17092981
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morath I, 2016, INT J BIOCHEM CELL B, V81, P166, DOI 10.1016/j.biocel.2016.09.009
   Myburgh R, 2020, LEUKEMIA, V34, P2688, DOI 10.1038/s41375-020-0818-9
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799
   Zhukova GV, 2018, B EXP BIOL MED+, V165, P80, DOI 10.1007/s10517-018-4104-z
NR 15
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0007-4888
EI 1573-8221
J9 B EXP BIOL MED+
JI Bull. Exp. Biol. Med.
PD NOV
PY 2020
VL 170
IS 1
SI SI
BP 118
EP 122
DI 10.1007/s10517-020-05016-z
EA NOV 2020
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PE5ZS
UT WOS:000592536100002
PM 33237528
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Teo, KYC
   Nguyen, V
   Barthelmes, D
   Arnold, JJ
   Gillies, MC
   Cheung, CMG
AF Teo, Kelvin Yi Chong
   Nguyen, Vuong
   Barthelmes, Daniel
   Arnold, Jennifer J.
   Gillies, Mark C.
   Cheung, Chui Ming Gemmy
TI Extended intervals for wet AMD patients with high retreatment needs:
   informing the risk during COVID-19, data from real-world evidence
SO EYE
LA English
DT Article; Early Access
ID MACULAR DEGENERATION; RANIBIZUMAB TREATMENT; CLINICAL-PRACTICE; VISUAL
   OUTCOMES; SAFETY; TREAT; REGIMENS; EFFICACY; THERAPY
AB Background/Objective Some clinicians may be forced to temporarily extend treatment intervals in neovascular age-related macular degeneration (nAMD) eyes with frequent retreatments to reduce the number of visits during the COVID-19 pandemic. To provide an indication of what these outcomes may be, we studied eyes with active lesions with unplanned treatment interval extensions before the pandemic occurred. Methods We compared eyes with active disease despite <= 6 weekly injections whose next injection was extended to >= 7 weeks and those whose intervals were not extended. We identified 1559 (16%) of 9602 eyes from the Fight Retinal Blindness! (FRB!) registry (2013 and 2018) that fit this criteria. Eyes were further stratified into four groups by the mean interval over the following 6 months: (1) <= 6 weeks (81%), (2) 7-9 weeks (9%), (3) 10-12 weeks (5%) and (4) >12 weeks (5%). Results There was a significant loss in VA in eyes extended to >12 weeks compared to the non-extended group (adjusted VA change, mean (95% CI): <= 6 weeks, 0.4 (-1.5 to 2.2), versus >12 weeks, -4.7 (-7.4 to -2.1), letters, p = 0.03 and a threefold increase in relative risk of losing >= 15 letters (absolute risk (14% versus 4%, p < 0.01)). Conclusion Mean VA remained stable for 6 months in eyes requiring frequent treatment despite retreatment interval extension up to 10-12 weeks. There was a significant short-term risk to vision when retreatment interval was extended beyond 12 weeks, hence extensions to this level should be considered cautiously. These data may be useful for physicians who are considering reducing visits to mitigate the risk of COVID-19.
C1 [Teo, Kelvin Yi Chong; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Teo, Kelvin Yi Chong; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Teo, Kelvin Yi Chong; Nguyen, Vuong; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Zurich, Switzerland.
   [Arnold, Jennifer J.] Marsden Eye Specialist, Sydney, NSW, Australia.
RP Cheung, CMG (corresponding author), Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.; Cheung, CMG (corresponding author), Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
FU Royal Australian NZ College of Ophthalmologists Eye Foundation
   (2007-2009); National Health and Medical Research Council, Australia,
   (NHMRC 2010-2012)National Health and Medical Research Council of
   Australia; Macula Disease Foundation, Australia; NHMRC practitioner
   fellowshipNational Health and Medical Research Council of Australia;
   Walter and Gertrud Siegenthaler Foundation Zurich, Switzerland; Swiss
   National FoundationSwiss National Science Foundation (SNSF); National
   Medical Research Council Open Fund Large Collaborative grant
   [NMRC/LCG/0042018]
FX Supported by a grant from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009), a grant from the National
   Health and Medical Research Council, Australia, (NHMRC 2010-2012) and a
   grant from the Macula Disease Foundation, Australia. MCG is a Sydney
   Medical Foundation Fellow and is supported by an NHMRC practitioner
   fellowship. DB was supported by the Walter and Gertrud Siegenthaler
   Foundation Zurich, Switzerland, and the Swiss National Foundation. CMGC
   is supported grant by a grant from the National Medical Research Council
   Open Fund Large Collaborative grant no: NMRC/LCG/0042018).
CR Ahmed F, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5446-1
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chandra S, 2020, EYE, V34, P1200, DOI 10.1038/s41433-020-0956-3
   Chong Teo Kelvin Yi, 2020, Ophthalmol Retina, V4, P871, DOI 10.1016/j.oret.2020.03.017
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6
   Eldem B, 2018, GRAEF ARCH CLIN EXP, V256, P963, DOI 10.1007/s00417-017-3890-8
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Foundation for Statistical Computing, 2017, R LANG ENV STAT COMP
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Invernizzi A, 2019, AM J OPHTHALMOL, V204, P105, DOI 10.1016/j.ajo.2019.03.001
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Lanzetta P, 2018, ACTA OPHTHALMOL, V96, pE911, DOI 10.1111/aos.13751
   Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maberley DMZ, ADDITIONAL CONSIDERA
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nguyen Vuong, 2019, Ophthalmol Retina, V3, P623, DOI 10.1016/j.oret.2019.05.013
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Royal College of Ophthalmologists, MED RET MAN PLANS CO
   Steffens I, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.14.2000550
   Teo KYC, 2020, EYE, V34, P1161, DOI 10.1038/s41433-020-0960-7
   Wee LE, 2020, J HOSP INFECT, V105, P113, DOI 10.1016/j.jhin.2020.04.016
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   World Health Organisation, 2019, 51 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 37
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
DI 10.1038/s41433-020-01315-x
EA NOV 2020
PG 9
WC Ophthalmology
SC Ophthalmology
GA OW0EA
UT WOS:000592570400003
PM 33239765
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wegner, M
AF Wegner, Max
TI New Approaches to Regulatory Innovation Emerging During the Crucible of
   COVID-19 In Responding to a Global Health Crisis, Industry is
   Discovering New, Efficient Ways of Meeting Objectives
SO THERAPEUTIC INNOVATION & REGULATORY SCIENCE
LA English
DT Article; Early Access
DE Coronavirus pandemic; Regulatory policy; Decentralized trials;
   Cloud-based systems; Remote work
AB The urgency and impact of the ongoing COVID-19 pandemic are changing global drug development and regulatory processes. The need for speed to understand the virus and develop new vaccines, medicines, and therapies for patients has provided unprecedented learning opportunities and revealed how the pharmaceutical industry can improve upon traditional processes. To stay competitive while remaining compliant with agency regulations and guidance, companies need to implement new process/tools that allow for more flexible work models, consider expanding the use of decentralized/hybrid trials, and capitalize on the use of real-world evidence (RWE) and cloud-based data systems. In addition, regulatory agencies should retain the agility exhibited during current reviews of potential new therapies, applying this momentum to other areas of unmet medical need. Further, agencies should consider a globally acceptable application platform. This article, by the Pharmaceuticals' Head of Regulatory Affairs at Bayer AG, examines how impacts of the COVID-19 crisis will continue beyond the pandemic period to the benefit of patients, drug developers, regulators, clinicians, and caregivers.
C1 [Wegner, Max] Bayer AG, Wuppertal, Germany.
RP Wegner, M (corresponding author), Bayer AG, Wuppertal, Germany.
EM max.wegner@bayer.com
CR [Anonymous], 2020, EUROPEAN PHARM IND R
   [Anonymous], 2020, EFFECTS COVID 19 PUB
   [Anonymous], 2020, COVID 19 IMPORTANT U
   [Anonymous], 2020, CORONAVIRUS COVID 19
   FDA, 2020, MAINT PAC M ITS GOAL
   Ledford H, 2020, NATURE, V582, P160, DOI 10.1038/d41586-020-01695-w
   Meakin L, 2020, BLOOMBERG
   Pitts PJ, 2020, NAT BIOTECHNOL, V38, P788, DOI 10.1038/s41587-020-0589-x
   Robertson AS, 2020, NAT REV DRUG DISCOV, V19, P365, DOI 10.1038/d41573-019-00193-7
   Rome BN, 2020, NEW ENGL J MED, V382, P2282, DOI 10.1056/NEJMp2009457
   Useem J, 2017, ATLANTIC
NR 11
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2168-4790
EI 2168-4804
J9 THER INNOV REGUL SCI
JI Ther. Innov. Regul. Sci.
DI 10.1007/s43441-020-00239-8
EA NOV 2020
PG 4
WC Medical Informatics; Pharmacology & Pharmacy
SC Medical Informatics; Pharmacology & Pharmacy
GA OW0EZ
UT WOS:000592572900001
PM 33237474
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Saleh, A
   Sultan, A
   Elashry, MA
   Farag, A
   Mortada, MI
   Ghannam, MA
   Saed, AM
   Ghoneem, S
AF Saleh, Ahmed
   Sultan, Ahmed
   Elashry, Mohamed A.
   Farag, Ahmed
   Mortada, Metwaly Ibrahim
   Ghannam, Mayada A.
   Saed, Ahmed M.
   Ghoneem, Sayed
TI Association of TNF-alpha G-308 a Promoter Polymorphism with the Course
   and Outcome of COVID-19 Patients
SO IMMUNOLOGICAL INVESTIGATIONS
LA English
DT Article; Early Access
DE Tumor necrosis factor; COVID-19; Polymorphism
ID PATHOGENESIS; DISEASE
AB Background: Tumor necrosis factor-alpha (TNF-alpha) is one of the most important cytokines that manage the host defense mechanism, which may play a role in the pathogenesis of COVID-19 patients. The work aims to study the association of TNF-alpha G-308 A gene polymorphism with the course and outcome of COVID-19 patients in Mansoura University Hospital.
   Methods: 900 patients with COVID-19 infection and 184 controls were tested for TNF-alpha G-308 A promoter polymorphism. Different genotypes of TNF-alpha G-308 A were compared as regards the severity and prognosis of the disease.
   Results: No statistically significant difference was found between patients and controls as regards the demographic data. The AA genotype of TNF-alpha showed a higher incidence of the disease in comparison to the other genotypes. As regards the demographic and laboratory characters, no statistically significant difference was found between the different genotypes except for age, lymphopenia, CRP, and serum ferritin levels. In 336(80.0%) cases of the AA genotype, the disease was severe in comparison to 90(41.7%) cases in the GA genotype and no cases in the GG genotype with P = .001.
   Conclusion: People who carry the A allele of TNF-alpha polymorphism are more prone to COVID-19 infection. The AA genotype of TNF-alpha is associated with a more aggressive pattern of the disease. In those patients, the use of anti - TNF therapy may be promising.
C1 [Saleh, Ahmed; Sultan, Ahmed; Elashry, Mohamed A.; Farag, Ahmed; Saed, Ahmed M.; Ghoneem, Sayed] Mansoura Univ, Hepatol & Gastroenterol Unit, Dept Internal Med, Fac Med, Al Mansurah, Egypt.
   [Mortada, Metwaly Ibrahim; Ghannam, Mayada A.] Mansoura Univ, Haematol Unit, Dept Clin Pathol, Fac Med, Al Mansurah, Egypt.
RP Saed, AM (corresponding author), Mansoura Univ, Hepatol & Gastrenterol Unit, Al Mansurah 35511, Egypt.
EM drahmedsaleh1981@gmail.com
RI Akhtar, Muhmmmad Furqan/T-8811-2017; Akhtar, Muhammad
   Furqan/ABI-7498-2020; Jahan, Shah/G-3728-2017; huynh, Khang/Q-8094-2017
OI Akhtar, Muhmmmad Furqan/0000-0002-2407-1503; Akhtar, Muhammad
   Furqan/0000-0003-2270-6242; Jorswieck, Eduard/0000-0001-7893-8435;
   Aissa, Sonia/0000-0002-6880-4772; Jahan, Shah/0000-0002-1730-5025;
   Saleem, Ammara/0000-0002-2478-7800; huynh, Khang/0000-0002-0480-6859;
   Saleh, Ahmed/0000-0001-8028-1997
CR Bidwell J, 1999, GENES IMMUN, V1, P3, DOI 10.1038/sj.gene.6363645
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119
   Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Elahi MM, 2009, BBA-MOL BASIS DIS, V1792, P163, DOI 10.1016/j.bbadis.2009.01.007
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   Li MD, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0165-8
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   MOLVIG J, 1991, SCAND J IMMUNOL, V34, P399, DOI 10.1111/j.1365-3083.1991.tb01563.x
   Panigrahy D, 2020, CANCER METAST REV, V39, P337, DOI 10.1007/s10555-020-09889-4
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Rojas-Marte G, 2020, QJM-INT J MED, V113, P546, DOI 10.1093/qjmed/hcaa206
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tsukamoto K, 1998, J HUM GENET, V43, P278, DOI 10.1007/s100380050090
   Wan X, 2018, IMMUNOL INVEST, V47, P1, DOI 10.1080/08820139.2017.1367008
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Warzocha K, 1998, BLOOD, V91, P3574
   Weng NP, 2009, TRENDS IMMUNOL, V30, P306, DOI 10.1016/j.it.2009.03.013
   Westendorp RGJ, 1997, LANCET, V349, P1912, DOI 10.1016/S0140-6736(05)63910-4
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   Wong P, 2003, ANNU REV IMMUNOL, V21, P29, DOI 10.1146/annurev.immunol.21.120601.141114
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 28
TC 3
Z9 3
U1 2
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0139
EI 1532-4311
J9 IMMUNOL INVEST
JI Immunol. Invest.
DI 10.1080/08820139.2020.1851709
EA NOV 2020
PG 12
WC Immunology
SC Immunology
GA OV3LB
UT WOS:000592114800001
PM 32162074
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gogoi, N
   Chowdhury, P
   Goswami, AK
   Das, A
   Chetia, D
   Gogoi, B
AF Gogoi, Neelutpal
   Chowdhury, Purvita
   Goswami, Ashis Kumar
   Das, Aparoop
   Chetia, Dipak
   Gogoi, Bhaskarjyoti
TI Computational guided identification of a citrus flavonoid as potential
   inhibitor of SARS-CoV-2 main protease
SO MOLECULAR DIVERSITY
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Flavonoids; Main protease; Molecular docking;
   Molecular dynamic
ID MOLECULAR-DYNAMICS; DOCKING
AB Although vaccine development is being undertaken at a breakneck speed, there is currently no effective antiviral drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19. Therefore, the present study aims to explore the possibilities offered by naturally available and abundant flavonoid compounds, as a prospective antiviral drug to combat the virus. A library of 44 citrus flavonoids was screened against the highly conserved Main Protease (M-pro) of SARS-CoV-2 using molecular docking. The compounds which showed better CDocker energy than the co-crystal inhibitor of M-pro were further revalidated by flexible docking within the active site; followed by assessment of drug likeness and toxicity parameters. The non-toxic compounds were further subjected to molecular dynamics simulation and predicted activity (IC50) using 3D-QSAR analysis. Subsequently, hydrogen bonds and dehydration analysis of the best compound were performed to assess the binding affinity to M-pro. It was observed that out of the 44 citrus flavonoids, five compounds showed lower binding energy with M-pro than the co-crystal ligand. Moreover, these compounds also formed H-bonds with two important catalytic residues His41 and Cys145 of the active sites of M-pro. Three compounds which passed the drug likeness filter showed stable conformation during MD simulations. Among these, the lowest predicted IC50 value was observed for Taxifolin. Therefore, this study suggests that Taxifolin, could be a potential inhibitor against SARS-CoV-2 main protease and can be further analysed by in vitro and in vivo experiments for management of the ongoing pandemic.
   [GRAPHICS]
C1 [Gogoi, Neelutpal; Goswami, Ashis Kumar; Das, Aparoop; Chetia, Dipak] Dibrugarh Univ, Dept Pharmaceut Sci, Fac Sci & Engn, Dibrugarh 786004, Assam, India.
   [Chowdhury, Purvita] Model Rural Hlth Res Unit, Dept Hlth Res, Agartala 799035, India.
   [Das, Aparoop] Dibrugarh Univ, Fac Biol Sci, Ctr Biotechnol & Bioinformat, Dibrugarh 786004, Assam, India.
   [Gogoi, Bhaskarjyoti] Royal Global Univ, Royal Sch Biosci, Dept Biotechnol, Gauhati 781035, India.
RP Gogoi, B (corresponding author), Royal Global Univ, Royal Sch Biosci, Dept Biotechnol, Gauhati 781035, India.
EM gogoi.bhaskar2608@gmail.com
RI Gogoi, Neelutpal/AAA-2624-2020
OI Gogoi, Neelutpal/0000-0001-5419-3942; CHOWDHURY,
   PURVITA/0000-0002-8484-853X
FU Drug Design Software facility of the Department of Pharmaceutical
   Sciences, Dibrugarh University [F.3-13/2016/DRS-I (SAP-II)]; BioSolveIT
   GmbH, Sankt Augustin, Germany
FX We acknowledge the support of the Drug Design Software facility of the
   Department of Pharmaceutical Sciences, Dibrugarh University established
   by the support of University Grants Commission, New Delhi (India) under
   UGC-SAP (DRS-I) [F.3-13/2016/DRS-I (SAP-II)]. Neelutpal Gogoi also
   acknowledge the supports from BioSolveIT GmbH, Sankt Augustin, Germany,
   for providing the special licence of SeeSAR software to carry out a part
   of the computational analysis.
CR Ahmed N, 2017, FRONT CHEM, V5, DOI 10.3389/fchem.2017.00036
   Antonio AD, 2020, RSC ADV, V10, P23379, DOI 10.1039/d0ra03774e
   Cataneo AHD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52626-3
   Fischer A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103626
   Galochkina AV, 2016, ARCH VIROL, V161, P929, DOI 10.1007/s00705-016-2749-3
   Gattuso G, 2007, MOLECULES, V12, P1641, DOI 10.3390/12081641
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gildenhuys S, 2020, BIOCHEM J, V477, P1479, DOI 10.1042/BCJ20200223
   Gogoi Neelutpal, 2019, Curr Comput Aided Drug Des, DOI 10.2174/1573409916666191226103000
   Goswami AK, 2020, CURR DRUG THER, V15, P226, DOI 10.2174/1574885514666190801102336
   Islam MT, 2020, PHYTOTHER RES, V34, P2471, DOI 10.1002/ptr.6700
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Koska J, 2008, J CHEM INF MODEL, V48, P1965, DOI 10.1021/ci800081s
   Lexa KW, 2012, Q REV BIOPHYS, V45, P301, DOI 10.1017/S0033583512000066
   Li X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2721-8
   Lin CH, 2011, J BIOMOL STRUCT DYN, V28, P471, DOI 10.1080/07391102.2011.10508589
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Mahanta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768902
   Meneguzzo F, 2020, PROCESSES, V8, DOI 10.3390/pr8050549
   Noha SM, 2017, ACS CHEM NEUROSCI, V8, P1327, DOI 10.1021/acschemneuro.6b00460
   Rampogu S, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6068437
   Rastelli G, 2010, J COMPUT CHEM, V31, P797, DOI 10.1002/jcc.21372
   Roubalova L, 2015, BIOORGAN MED CHEM, V23, P5402, DOI 10.1016/j.bmc.2015.07.055
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Schneider N, 2012, J COMPUT AID MOL DES, V26, P701, DOI 10.1007/s10822-011-9531-0
   Selvaraj Chandrabose, 2011, CURR TRENDS BIOTECHN
   Vora J, 2019, J BIOMOL STRUCT DYN, V37, P3150, DOI 10.1080/07391102.2018.1509732
   Wang ZL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01013
   Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
NR 30
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1381-1991
EI 1573-501X
J9 MOL DIVERS
JI Mol. Divers.
DI 10.1007/s11030-020-10150-x
EA NOV 2020
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry,
   Medicinal; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA OV4LC
UT WOS:000592182500001
PM 33236176
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rocco, N
   Montagna, G
   Di Micco, R
   Benson, J
   Criscitiello, C
   Chen, L
   Di Pace, B
   Colmenarejo, AJE
   Harder, Y
   Karakatsanis, A
   Maglia, A
   Mele, M
   Nafissi, N
   Ferreira, PS
   Taher, W
   Tejerina, A
   Vinci, A
   Nava, M
   Catanuto, G
AF Rocco, Nicola
   Montagna, Giacomo
   Di Micco, Rosa
   Benson, John
   Criscitiello, Carmen
   Chen, Li
   Di Pace, Bruno
   Esgueva Colmenarejo, Antonio Jesus
   Harder, Yves
   Karakatsanis, Andreas
   Maglia, Anna
   Mele, Marco
   Nafissi, Nahid
   Ferreira, Pedro Santos
   Taher, Wafa
   Tejerina, Antonio
   Vinci, Alessio
   Nava, Maurizio
   Catanuto, Giuseppe
TI The Impact of the COVID-19 Pandemic on Surgical Management of Breast
   Cancer: Global Trends and Future Perspectives
SO ONCOLOGIST
LA English
DT Article; Early Access
DE Breast cancer surgery; COVID&#8208; 19; Triage; Surgical priorities;
   Alternatives to surgery
ID NEOADJUVANT ENDOCRINE THERAPY
AB Introduction The rapid spread of COVID-19 across the globe is forcing surgical oncologists to change their daily practice. We sought to evaluate how breast surgeons are adapting their surgical activity to limit viral spread and spare hospital resources.
   Methods A panel of 12 breast surgeons from the most affected regions of the world convened a virtual meeting on April 7, 2020, to discuss the changes in their local surgical practice during the COVID-19 pandemic. Similarly, a Web-based poll based was created to evaluate changes in surgical practice among breast surgeons from several countries.
   Results The virtual meeting showed that distinct countries and regions were experiencing different phases of the pandemic. Surgical priority was given to patients with aggressive disease not candidate for primary systemic therapy, those with progressive disease under neoadjuvant systemic therapy, and patients who have finished neoadjuvant therapy. One hundred breast surgeons filled out the poll. The trend showed reductions in operating room schedules, indications for surgery, and consultations, with an increasingly restrictive approach to elective surgery with worsening of the pandemic.
   Conclusion The COVID-19 emergency should not compromise treatment of a potentially lethal disease such as breast cancer. Our results reveal that physicians are instinctively reluctant to abandon conventional standards of care when possible. However, as the situation deteriorates, alternative strategies of de-escalation are being adopted.
   Implications for Practice This study aimed to characterize how the COVID-19 pandemic is affecting breast cancer surgery and which strategies are being adopted to cope with the situation.
C1 [Rocco, Nicola; Nava, Maurizio; Catanuto, Giuseppe] Grp Reconstruct & Therapeut Advancements, Catania, Italy.
   [Montagna, Giacomo] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA.
   [Di Micco, Rosa] San Raffaele Univ & Res Hosp, Breast Surg, Milan, Italy.
   [Di Micco, Rosa] Univ Naples Feder II, Dept Clin Med & Surg, Naples, Italy.
   [Di Pace, Bruno] Cambridge Univ Hosp NHS Fdn Trust, Dept Plast & Reconstruct Surg, Cambridge, England.
   [Benson, John] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge, England.
   [Benson, John; Di Pace, Bruno] Anglia Ruskin Univ, Sch Med, Cambridge, England.
   [Criscitiello, Carmen] European Inst Oncol IEO IRCCS, Milan, Italy.
   [Chen, Li] China Army Med Univ, Southwest Hosp, Breast Ctr, Chongqing, Peoples R China.
   [Di Pace, Bruno] Univ Salerno, Dept Med Surg & Dent, Scuola Medica Salernitana, PhD Sch Translat Med Dev & Act Aging, Salerno, Italy.
   [Esgueva Colmenarejo, Antonio Jesus] Clin Univ Navarra, Breast Canc Unit, Madrid, Spain.
   [Harder, Yves] Ente Osped Cantonale EOC, Dept Plast Reconstruct & Aesthet Surg, Lugano, Switzerland.
   [Harder, Yves] Univ Svizzera Italiana USI, Fac Biomed Sci 2, Lugano, Switzerland.
   [Karakatsanis, Andreas] Uppsala Univ Hosp, Dept Surg, Sect Breast Surg, Uppsala, Sweden.
   [Karakatsanis, Andreas] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden.
   [Maglia, Anna; Catanuto, Giuseppe] Azienda Osped Cannizzaro, Multidisciplinary Breast Unit, Catania, Italy.
   [Mele, Marco] Herlev & Gentofte Hosp, Breast Surg Dept, Copenhagen, Denmark.
   [Nafissi, Nahid] Iran Univ Med Sci, Dept Breast Surg, Tehran, Iran.
   [Ferreira, Pedro Santos] Setubal Med Ctr, Breast Unit, Setubal, Portugal.
   [Taher, Wafa] Northampton Gen Hosp, Breast Surg, Northampton, England.
   [Tejerina, Antonio] Fdn Tejerina, Ctr Patol Mama, Breast Surg Dept, Madrid, Spain.
   [Vinci, Alessio] Ninewells Hosp & Med Sch, Dept Breast Surg, Dundee, Scotland.
RP Rocco, N (corresponding author), Grp Reconstruct & Therapeut Advancements, Catania, Italy.
EM nicola.rocco@greta-oncoplastic.com
OI Rocco, Nicola/0000-0001-6941-7873; Di Pace, Bruno/0000-0002-5774-8832
CR Al-Hilli Z, 2015, ANN SURG ONCOL, V22, pS459, DOI 10.1245/s10434-015-4741-7
   American College of Surgeons, 2020, COVID 19 EL CAS TRAI
   Association of Breast Surgery, 2020, ABS STAT RE COVID 19
   Bashshur R, 2020, TELEMED E-HEALTH, V26, P571, DOI 10.1089/tmj.2020.29040.rb
   BERGMAN L, 1995, BREAST CANCER RES TR, V34, P77, DOI 10.1007/BF00666494
   Bleicher RJ, 2016, JAMA ONCOL, V2, P330, DOI 10.1001/jamaoncol.2015.4508
   Chia YH, 2010, BRIT J CANCER, V103, P759, DOI 10.1038/sj.bjc.6605845
   Curigliano G, 2020, BREAST, V52, P8, DOI 10.1016/j.breast.2020.04.006
   Dietz JR, 2020, BREAST CANCER RES TR, V181, P487, DOI 10.1007/s10549-020-05644-z
   Dowsett M, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-0168-9
   Elshof LE, 2015, EUR J CANCER, V51, P1497, DOI 10.1016/j.ejca.2015.05.008
   Fontein DBY, 2014, EUR J CANCER, V50, P2190, DOI 10.1016/j.ejca.2014.05.010
   Francis A, 2015, EUR J CANCER, V51, P2296, DOI 10.1016/j.ejca.2015.07.017
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Hind D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004272.pub2
   Hwang ES, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026797
   Italian Society of Surgical Oncology, 2020, RACC PRAT SOC IT CHI
   Johns Hopkins University Coronavirus Resource Centre, 2020, COVID 19 DASHB CTR S
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Krainick-Strobel UE, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-62
   Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037
   Mitchell R, 2020, EMERG MED J, V37, P258, DOI 10.1136/emermed-2020-209660
   National Comprehensive Cancer Network, 2020, PLYM M
   O'Connell RL, 2019, BRIT J CANCER, V120, P883, DOI 10.1038/s41416-019-0438-1
   Puxty K, 2018, JAMA SURG, V153, P834, DOI 10.1001/jamasurg.2018.1571
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rusz O, 2015, PATHOL ONCOL RES, V21, P977, DOI 10.1007/s12253-015-9911-1
   Ryser MD, 2019, JNCI-J NATL CANCER I, V111, P952, DOI 10.1093/jnci/djy220
   Sharma R, 2019, BREAST CANCER-TOKYO, V26, P428, DOI 10.1007/s12282-018-00941-4
   Society of Surgical Oncology, 2020, RES MAN OPT BREAST C
   Soran A, 2020, EUR J BREAST HEALTH, V16, P86, DOI 10.5152/ejbh.2020.240320
   The Lancet Oncology, 2020, Lancet Oncol, V21, P467, DOI 10.1016/S1470-2045(20)30175-3
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
NR 33
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
DI 10.1002/onco.13560
EA NOV 2020
PG 12
WC Oncology
SC Oncology
GA OV4HK
UT WOS:000592172900001
PM 33044007
OA Green Published
DA 2021-01-01
ER

PT J
AU Alsoufi, A
   Alsuyihili, A
   Msherghi, A
   Elhadi, A
   Atiyah, H
   Ashini, A
   Ashwieb, A
   Ghula, M
   Ben Hasan, H
   Abudabuos, S
   Alameen, H
   Abokhdhir, T
   Anaiba, M
   Nagib, T
   Shuwayyah, A
   Benothman, R
   Arrefae, G
   Alkhwayildi, A
   Alhadi, A
   Zaid, A
   Elhadi, M
AF Alsoufi, Ahmed
   Alsuyihili, Ali
   Msherghi, Ahmed
   Elhadi, Ahmed
   Atiyah, Hana
   Ashini, Aimen
   Ashwieb, Arwa
   Ghula, Mohamed
   Ben Hasan, Hayat
   Abudabuos, Salsabil
   Alameen, Hind
   Abokhdhir, Taqwa
   Anaiba, Mohamed
   Nagib, Taha
   Shuwayyah, Anshirah
   Benothman, Rema
   Arrefae, Ghalea
   Alkhwayildi, Abdulwajid
   Alhadi, Abdulmueti
   Zaid, Ahmed
   Elhadi, Muhammed
TI Impact of the COVID-19 pandemic on medical education: Medical students'
   knowledge, attitudes, and practices regarding electronic learning
SO PLOS ONE
LA English
DT Article
ID PRIMARY-CARE
AB The Coronavirus Disease 2019 (COVID-19) pandemic has caused an unprecedented disruption in medical education and healthcare systems worldwide. The disease can cause life-threatening conditions and it presents challenges for medical education, as instructors must deliver lectures safely, while ensuring the integrity and continuity of the medical education process. It is therefore important to assess the usability of online learning methods, and to determine their feasibility and adequacy for medical students. We aimed to provide an overview of the situation experienced by medical students during the COVID-19 pandemic, and to determine the knowledge, attitudes, and practices of medical students regarding electronic medical education. A cross-sectional survey was conducted with medical students from more than 13 medical schools in Libya. A paper-based and online survey was conducted using email and social media. The survey requested demographic and socioeconomic information, as well as information related to medical online learning and electronic devices; medical education status during the COVID-19 pandemic; mental health assessments; and e-learning knowledge, attitudes, and practices. A total of 3,348 valid questionnaires were retrieved. Most respondents (64.7%) disagreed that e-learning could be implemented easily in Libya. While 54.1% of the respondents agreed that interactive discussion is achievable by means of e-learning. However, only 21.1% agreed that e-learning could be used for clinical aspects, as compared with 54.8% who disagreed with this statement and 24% who were neutral. Only 27.7% of the respondents had participated in online medical educational programs during the COVID-19 pandemic, while 65% reported using the internet for participating in study groups and discussions. There is no vaccine for COVID-19 yet. As such, the pandemic will undeniably continue to disrupt medical education and training. As we face the prospect of a second wave of virus transmission, we must take certain measures and make changes to minimize the effects of the COVID-19 outbreak on medical education and on the progression of training. The time for change is now, and there should be support and enthusiasm for providing valid solutions to reduce this disruption, such as online training and virtual clinical experience. These measures could then be followed by hands-on experience that is provided in a safe environment.
C1 [Alsoufi, Ahmed; Alsuyihili, Ali; Msherghi, Ahmed; Elhadi, Ahmed; Atiyah, Hana; Ashini, Aimen; Ashwieb, Arwa; Ghula, Mohamed; Alameen, Hind; Abokhdhir, Taqwa; Nagib, Taha; Shuwayyah, Anshirah; Benothman, Rema; Arrefae, Ghalea; Zaid, Ahmed; Elhadi, Muhammed] Univ Tripoli, Fac Med, Tripoli, Libya.
   [Ben Hasan, Hayat] Zliten Med Univ, Zliten, Libya.
   [Abudabuos, Salsabil; Alkhwayildi, Abdulwajid; Alhadi, Abdulmueti] Univ Al Zawia, Fac Med, Al Zawia, Libya.
   [Anaiba, Mohamed] Misurata Hosp, Misurata, Libya.
RP Elhadi, M (corresponding author), Univ Tripoli, Fac Med, Tripoli, Libya.
EM muhammed.elhadi.uot@gmail.com
RI Alhadi, Abdulmueti/ABG-3342-2020; Elhadi, Muhammed/AAU-5641-2020
OI Elhadi, Muhammed/0000-0001-6406-4212; alsoufi, ahmed/0000-0001-6679-4972
CR a R-M, 2020, J CLIN MED, V9
   Akers A, 2020, CUREUS, V12, DOI 10.7759/cureus.7800
   [Anonymous], 2017, JLSRF, V3, pA104
   Arroll B, 2010, ANN FAM MED, V8, P348, DOI 10.1370/afm.1139
   Calhoun KE, 2020, AM J SURG, V220, P44, DOI 10.1016/j.amjsurg.2020.04.024
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Chandra S, 2020, MED EDUC, V54, P1182, DOI 10.1111/medu.14266
   Chiodini J, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101669
   Desalegn AA, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-81
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Edigin E, 2020, MED EDUC ONLINE, V25, DOI 10.1080/10872981.2020.1774318
   Elhadi M, 2020, PSYCHOL IMPACT CIVIL, V11, P2575
   George PP, 2014, J GLOB HEALTH, V4, DOI 10.7189/jogh.04.010406
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Khasawneh AI, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00253
   Kim CS, 2020, ACAD MED, V95, P1146, DOI 10.1097/ACM.0000000000003410
   Lee ICJ, 2020, MED EDUC, V54, P1184, DOI 10.1111/medu.14272
   Masic Izet, 2008, Acta Inform Med, V16, P102, DOI 10.5455/aim.2008.16.102-117
   McCullough LB, 2020, ACAD MED, V95, P1488, DOI 10.1097/ACM.0000000000003434
   Menon A, 2020, ACAD MED, V95, P1149, DOI 10.1097/ACM.0000000000003478
   Mian A, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01577-y
   Munshi F, ONLINE CLIN EXAM FEL, DOI [10.1111/medu.14267, DOI 10.1111/MEDU.14267]
   O'Doherty D, 2018, BMC MED EDUC, V18, DOI 10.1186/s12909-018-1240-0
   Organization WH, 2020, WHO DIR GEN OP REM M
   Quek TTC, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16152735
   Kazerooni AR, 2020, MED EDUC, V54, P762, DOI 10.1111/medu.14206
   Ricci L, 2019, QUAL HEALTH RES, V29, P149, DOI 10.1177/1049732318783186
   Ross DA, 2020, ACAD MED, V95, P1125, DOI 10.1097/ACM.0000000000003424
   Ruiz MA, 2011, J AFFECT DISORDERS, V128, P277, DOI 10.1016/j.jad.2010.07.010
   Sam AH, 2020, ACAD MED, V95, P1126, DOI 10.1097/ACM.0000000000003431
   Samarasekera DD, 2020, ACAD MED, V95, P1126, DOI 10.1097/ACM.0000000000003425
   Sharma S, 2020, INDIAN PEDIATR, V57, P772, DOI 10.1007/s13312-020-1940-5
   Sklar DP, 2020, ACAD MED, V95, P1631, DOI 10.1097/ACM.0000000000003547
   SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749
   Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Tapper J, 2020, MED STUDENTS TAKE FI
   Watson A, 2020, MED EDUC ONLINE, V25, DOI 10.1080/10872981.2020.1764741
   Wayne DB, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc7110
   Woolliscroft JO, 2020, ACAD MED, V95, P1140, DOI 10.1097/ACM.0000000000003402
NR 40
TC 0
Z9 0
U1 7
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 25
PY 2020
VL 15
IS 11
AR e0242905
DI 10.1371/journal.pone.0242905
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OX9PD
UT WOS:000593887000060
PM 33237962
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Desterke, C
   Griscelli, F
   Imeri, J
   Marcoux, P
   Lemonnier, T
   Latsis, T
   Turhan, AG
   Bennaceur-Griscelli, A
AF Desterke, Christophe
   Griscelli, Frank
   Imeri, Jusuf
   Marcoux, Paul
   Lemonnier, Thomas
   Latsis, Theodoros
   Turhan, Ali G.
   Bennaceur-Griscelli, Annelise
TI Molecular investigation of adequate sources of mesenchymal stem cells
   for cell therapy of COVID-19-associated organ failure
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article; Early Access
DE adult human bone marrow; embryonic stem cells; induced pluripotent stem
   cells; lymphocytes; mesenchymal stem cells
AB The use of mesenchymal stem cells (MSC) derived from several sources as a major anti-inflammation strategy has been suggested in the recent outbreak of Coronavirus-19 (COVID-19). As the virus enters the target cells through the receptor ACE2, it is important to determine if the MSC population transfused to patients could also be a target for the virus entry. We report here that ACE2 is highly expressed in adult bone marrow, adipose tissue or umbilical cord-derived MSC. On the other hand, placenta-derived MSC express low levels of ACE2 but only in early passages of cultures. MSC derived from human embryonic stem cell (hESC) or human induced pluripotent stem cells (hIPSC) express also very low levels of ACE2. The transcriptome analysis of the MSCs with lowest expression of ACE2 in fetal-like MSCs is found to be associated in particularly with an anti-inflammatory signature. These results are of major interest for designing future clinical MSC-based stem cell therapies for severe COVID-19 infections.
C1 [Desterke, Christophe; Griscelli, Frank; Imeri, Jusuf; Marcoux, Paul; Lemonnier, Thomas; Latsis, Theodoros; Turhan, Ali G.; Bennaceur-Griscelli, Annelise] INSERM UMR S 935, F-94800 Villejuif, France.
   [Desterke, Christophe; Griscelli, Frank; Imeri, Jusuf; Marcoux, Paul; Lemonnier, Thomas; Latsis, Theodoros; Turhan, Ali G.; Bennaceur-Griscelli, Annelise] Univ Paris Saclay, F-94800 Villejuif, France.
   [Desterke, Christophe; Griscelli, Frank; Latsis, Theodoros; Turhan, Ali G.; Bennaceur-Griscelli, Annelise] INGESTEM Natl IPSC Infrastruct, Villejuif, France.
   [Griscelli, Frank] Gustave Roussy Inst, Villejuif, France.
   [Griscelli, Frank] Paris Descartes Univ, Fac Pharm, Paris, France.
   [Turhan, Ali G.; Bennaceur-Griscelli, Annelise] APHP Paris Saclay, Div Hematol, Villejuif, France.
   [Turhan, Ali G.; Bennaceur-Griscelli, Annelise] Univ Paris Saclay, Fac Med, Villejuif, France.
RP Turhan, AG (corresponding author), INSERM UMR S 935, F-94800 Villejuif, France.; Turhan, AG (corresponding author), Univ Paris Saclay, F-94800 Villejuif, France.
EM turviv33@gmail.com
OI TURHAN, Ali/0000-0002-4861-0137
CR Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161
   Baulier E, 2014, STEM CELL TRANSL MED, V3, P809, DOI 10.5966/sctm.2013-0186
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Giuliani M, 2011, BLOOD, V118, P3254, DOI 10.1182/blood-2010-12-325324
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Shin TH, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.442
   Yang LX, 2017, ONCOTARGET, V8, P85549, DOI 10.18632/oncotarget.20935
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 9
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
DI 10.1002/sctm.20-0189
EA NOV 2020
PG 4
WC Cell & Tissue Engineering
SC Cell Biology
GA OV1XC
UT WOS:000592010600001
PM 33237619
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Barguilla, A
   Fernandez-Lebrero, A
   Estragues-Gazquez, I
   Garcia-Escobar, G
   Navalpotro-Gomez, I
   Manero, RM
   Puente-Periz, V
   Roquer, J
   Puig-Pijoan, A
AF Barguilla, Ainara
   Fernandez-Lebrero, Aida
   Estragues-Gazquez, Isabel
   Garcia-Escobar, Greta
   Navalpotro-Gomez, Irene
   Maria Manero, Rosa
   Puente-Periz, Victor
   Roquer, Jaume
   Puig-Pijoan, Albert
TI Effects of COVID-19 Pandemic Confinement in Patients With Cognitive
   Impairment
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE COVID; 19; SARS; CoV-2; dementia; depression; cognitive impairment;
   anxiety; neuropsychiatric
AB Introduction: State of emergency caused by COVID-19 pandemic and subsequent lockdown hit Spain on 14th March 2020 and lasted until 21st June 2020. Social isolation measures were applied. Medical attention was focused on COVID-19. Primary and social care were mainly performed by telephone. This exceptional situation may affect especially vulnerable patients such as people living with dementia. Our aim was to describe the influence of restrictive measures on patients living with mild cognitive decline and dementia evaluating SARS-CoV2 infection, changes in routines, cognitive decline stage, neuropsychiatric symptoms, delirium, falls, caregiver stress, and access to sanitary care.
   Materials and Methods: We gathered MCI and dementia patients with clinical follow-up before and after confinement from DegMar registry (Hospital del Mar). A telephone ad-hoc questionnaire was administered. Global status was assessed using CDR scale. Changes in neuropsychiatric symptoms were assessed by Neuropsychiatric Inventory (NPI) and retrospective interview for pre-confinement base characteristics.
   Results: We contacted a total of 60 patients, age 75.4 years +/- 5,192. 53.3% were women. Alzheimer's Disease (41.7%) and Mild Cognitive Impairment (25%) were the most prevalent diagnosis. Remaining cases included different dementia disorders. A total of 10% of patients had been diagnosed with SARS-CoV-2. During confinement 70% of patients abandoned previous daily activities, 60% had cognitive worsening reported by relatives/caretakers, 15% presented delirium episodes, and 13% suffered increased incidence of falls. Caregivers reported an increased burden in 41% cases and burnout in 11% cases. 16% reported difficulties accessing medical care, 33% received medical phone assistance, 20% needed emergency care and 21% had changes in psychopharmacological therapies. Neuropsychiatric profile globally worsened (p < 0.000), also in particular items like agitation (p = 0.003), depression (p < 0.000), anxiety (p < 0.000) and changes in appetite (p = 0.004).
   Conclusion: SARS-CoV2-related lockdown resulted in an important effect over social and cognitive spheres and worsening of neuropsychiatric traits in patients living with mild cognitive decline and dementia. Although the uncertainty regarding the evolution of the pandemic makes strategy difficult, we need to reach patients and caregivers and develop adequate strategies to reinforce and adapt social and health care.
C1 [Barguilla, Ainara; Fernandez-Lebrero, Aida; Estragues-Gazquez, Isabel; Navalpotro-Gomez, Irene; Puente-Periz, Victor; Roquer, Jaume; Puig-Pijoan, Albert] Hosp Mar, Neurol Dept, Barcelona, Spain.
   [Fernandez-Lebrero, Aida; Navalpotro-Gomez, Irene; Maria Manero, Rosa; Puente-Periz, Victor; Puig-Pijoan, Albert] Hosp Mar, Neurol Dept, Cognit Impairment & Movement Disorders Unit, Barcelona, Spain.
   [Fernandez-Lebrero, Aida; Garcia-Escobar, Greta; Navalpotro-Gomez, Irene; Maria Manero, Rosa; Puente-Periz, Victor; Puig-Pijoan, Albert] Hosp Mar Res Inst IMIM, Neurosci Program, Neurofunct & Language Grp, Barcelona, Spain.
RP Barguilla, A; Puig-Pijoan, A (corresponding author), Hosp Mar, Neurol Dept, Barcelona, Spain.; Puig-Pijoan, A (corresponding author), Hosp Mar, Neurol Dept, Cognit Impairment & Movement Disorders Unit, Barcelona, Spain.; Puig-Pijoan, A (corresponding author), Hosp Mar Res Inst IMIM, Neurosci Program, Neurofunct & Language Grp, Barcelona, Spain.
EM 62889@parcdesalutmar.cat; apuig@parcdesalutmar.cat
CR [Anonymous], 2020, WHO DIRECTOR GEN OPE
   Cohen G, 2020, INT PSYCHOGERIATR, V32, P1377, DOI 10.1017/S1041610220001593
   Conn D, 2007, CAN J NEUROL SCI, V34, pS67, DOI 10.1017/S0317167100005606
   Cuffaro L, 2020, NEUROL SCI, V41, P1977, DOI 10.1007/s10072-020-04512-4
   Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S
   Grande G, 2018, J GERIATR PSYCH NEUR, V31, P107, DOI 10.1177/0891988718774425
   Lara B, 2020, EUR J NEUROL, V27, P1744, DOI 10.1111/ene.14339
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Morley JE, 2018, CLIN GERIATR MED, V34, P505, DOI 10.1016/j.cger.2018.06.003
   Morris J C, 1997, Int Psychogeriatr, V9 Suppl 1, P173, DOI 10.1017/S1041610297004870
   MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a
   Nimon K, 2014, INT J RES METHOD EDU, V37, P256, DOI 10.1080/1743727X.2013.820644
   Roberts R, 2013, CLIN GERIATR MED, V29, P753, DOI 10.1016/j.cger.2013.07.003
   Rodriguez-Rey R, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01540
   Rosa Fernandez, 2020, IMPACTO BROTE CORONA
   Shahid Z, 2020, J AM GERIATR SOC, V68, P926, DOI 10.1111/jgs.16472
   Wang HL, 2020, LANCET, V395, P1190, DOI 10.1016/S0140-6736(20)30755-8
NR 17
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD NOV 24
PY 2020
VL 11
AR 589901
DI 10.3389/fneur.2020.589901
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA PG3FD
UT WOS:000599623800001
PM 33329337
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Duncan, H
AF Duncan, Hamish
TI Covid-19 vaccine: we are sleepwalking into a massive prospective cohort
   study
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Letter
C1 [Duncan, Hamish] Pinhoe Surg, Exeter EX1 3SY, Devon, England.
RP Duncan, H (corresponding author), Pinhoe Surg, Exeter EX1 3SY, Devon, England.
EM hamish.duncan@nhs.net
CR DOSHI P, 2020, BMJ-BRIT MED J, V371, DOI DOI 10.1136/BMJ.M4058
NR 1
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD NOV 24
PY 2020
VL 371
AR m4568
DI 10.1136/bmj.m4568
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA OZ9TG
UT WOS:000595260700002
PM 33234504
DA 2021-01-01
ER

PT J
AU Sriram, K
   Loomba, R
   Insel, PA
AF Sriram, Krishna
   Loomba, Rohit
   Insel, Paul A.
TI Targeting the renin-angiotensin signaling pathway in COVID-19:
   Unanswered questions, opportunities, and challenges
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE ACE2; SARS-CoV-2; angiotensin; ACE inhibitor; angiotensin receptor
   blocker
ID CONVERTING ENZYME; RECEPTOR BLOCKERS; SYSTEM INHIBITORS; ALISKIREN VS.;
   LUNG INJURY; EXPRESSION; CHYMASE; HYPERTENSION; METAANALYSIS; COUGH
AB The role of the renin-angiotensin signaling (RAS) pathway in COVID-19 has received much attention. A central mechanism for COVID-19 pathophysiology has been proposed: imbalance of angiotensin converting enzymes (ACE)1 and ACE2 (ACE2 being the severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] virus "receptor") that results in tissue injury from angiotensin II (Ang II)-mediated signaling. This mechanism provides a rationale for multiple therapeutic approaches. In parallel, clinical data from retrospective analysis of COVID-19 cohorts has revealed that ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be beneficial in COVID-19. These findings have led to the initiation of clinical trials using approved drugs that target the generation (ACEIs) and actions (ARBs) of Ang II. However, treatment of COVID-19 with ACEIs/ARBs poses several challenges. These include choosing appropriate inclusion and exclusion criteria, dose optimization, risk of adverse effects and drug interactions, and verification of target engagement. Other approaches related to the RAS pathway might be considered, for example, inhalational administration of ACEIs/ARBs (to deliver drugs directly to the lungs) and use of compounds with other actions (e.g., activation of ACE2, agonism of MAS1 receptors, beta-arrestin-based Angiotensin receptor agonists, and administration of soluble ACE2 or ACE2 peptides). Studies with animal models could test such approaches and assess therapeutic benefit. This Perspective highlights questions whose answers could advance RAS-targeting agents as mechanism-driven ways to blunt tissue injury, morbidity, and mortality of COVID-19.
C1 [Sriram, Krishna; Insel, Paul A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   [Loomba, Rohit; Insel, Paul A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
RP Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.; Insel, PA (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
EM pinsel@ucsd.edu
OI Insel, Paul/0000-0001-8521-5315
FU Academic Senate of the University of California San Diego; National
   Institute of Environmental Health SciencesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Environmental Health Sciences (NIEHS)
   [5P42ES010337]; National Center for Advancing Translational
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [5UL1TR001442]; National Institute of
   Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [R01DK106419, 1R01DK121378, R01 DK124318, P30DK120515]
FX Support was provided by Academic Senate of the University of California
   San Diego. R.L. receives funding support from National Institute of
   Environmental Health Sciences (Grant 5P42ES010337), National Center for
   Advancing Translational Sciences (Cooperative Agreement 5UL1TR001442),
   and National Institute of Diabetes and Digestive and Kidney Diseases
   (Grants R01DK106419, 1R01DK121378, R01 DK124318, and P30DK120515).
CR Acanfora D, 2020, EUR HEART J-CARD PHA, V6, P135, DOI 10.1093/ehjcvp/pvaa028
   Alexander W., 2019, IUPHAR BPS GUID PHAR, V2019, DOI [10.2218/gtopdb/F6/2019.4, DOI 10.2218/GTOPDB/F6/2019.4]
   Amirav I, 2020, CAN MED ASSOC J, V192, pE346, DOI 10.1503/cmaj.75066
   [Anonymous], 2020, EMERG MICROBES INFEC, V9, P757
   [Anonymous], 2020, CELL, V181
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bjarnadottir TK, 2006, GENOMICS, V88, P263, DOI 10.1016/j.ygeno.2006.04.001
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chandrashekar A., 2020, SCIENCE, V2020
   Chen LN, 2013, SHOCK, V40, P420, DOI 10.1097/SHK.0b013e3182a6953e
   Chen YF, 2013, HYPERTENS RES, V36, P252, DOI 10.1038/hr.2012.185
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Delanghe JR, 2020, CLIN CHIM ACTA, V505, P192, DOI 10.1016/j.cca.2020.03.031
   Dell'Italia LJ, 2018, CIRC RES, V122, P319, DOI 10.1161/CIRCRESAHA.117.310978
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   DuPont JJ, 2017, J ENDOCRINOL, V234, pT67, DOI 10.1530/JOE-17-0009
   El Tabaa MM, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114057
   Ferrario Carlos M, 2016, Ther Adv Cardiovasc Dis, V10, P162, DOI 10.1177/1753944716642677
   Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2
   Fix OK, 2020, HEPATOLOGY, V72, P287, DOI 10.1002/hep.31281
   Forrester SJ, 2018, PHYSIOL REV, V98, P1627, DOI 10.1152/physrev.00038.2017
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Gabrial S, 2020, NEW ENGL J MED, V383, P397, DOI 10.1056/NEJMc2005396
   Gao DF, 2011, AM J HYPERTENS, V24, P613, DOI 10.1038/ajh.2011.3
   Godugu C, 2013, J CONTROL RELEASE, V172, P86, DOI 10.1016/j.jconrel.2013.06.036
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Guo XM, 2020, HYPERTENSION, V76, pE13, DOI 10.1161/HYPERTENSIONAHA.120.15572
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hamada H, 1999, AM J RESP CRIT CARE, V160, P1303, DOI 10.1164/ajrccm.160.4.9810058
   He F, 2020, J MED VIROL, V92, P719, DOI [10.1002/jmv.25766, 10.3171/2020.3.JNS193202]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4
   Israelow Benjamin, 2020, bioRxiv, DOI 10.1101/2020.05.27.118893
   Karnik SS, 2017, BRIT J PHARMACOL, V174, P737, DOI 10.1111/bph.13742
   Kenyon C., 2020, ACE 1 I D POLYMORPHI
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Kim MD, 2020, AM J RESP CRIT CARE, V201, P313, DOI 10.1164/rccm.201905-0990OC
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Kosanovic D, 2015, EUR RESPIR J, V46, P1084, DOI 10.1183/09031936.00018215
   Lam KW, 2020, J INFECT DIS, V222, P1256, DOI 10.1093/infdis/jiaa447
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   LI X, 2020, CLIN INFECT DIS, DOI DOI 10.1093/CID/CIAA325
   Li YC, 2015, SHOCK, V43, P395, DOI 10.1097/SHK.0000000000000302
   Lippi G, 2020, PROG CARDIOVASC DIS, V63, P390, DOI 10.1016/j.pcad.2020.03.001
   Liu X, 2020, CLIN CARDIOL, DOI 10.1002/clc.23421
   Magalhaes GS, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151957
   Manglik A, 2020, CIRCULATION, V142, P318, DOI 10.1161/CIRCULATIONAHA.120.048723
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x
   Mishima E, 2019, HYPERTENS RES, V42, P469, DOI 10.1038/s41440-018-0116-3
   Mitrani RD, 2020, HEART RHYTHM, V17, P1984, DOI 10.1016/j.hrthm.2020.06.026
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   MORRELL NW, 1995, J CLIN INVEST, V96, P1823, DOI 10.1172/JCI118228
   Mossel EC, 2008, VIROLOGY, V372, P127, DOI 10.1016/j.virol.2007.09.045
   Pang PS, 2017, EUR HEART J, V38, P2364, DOI 10.1093/eurheartj/ehx196
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pylypchuk GB, 1998, ANN PHARMACOTHER, V32, P1060, DOI 10.1345/aph.17388
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rodrigues-Machado MG, 2013, BRIT J PHARMACOL, V170, P835, DOI 10.1111/bph.12318
   Sakaguchi M, 2004, EUR J PHARMACOL, V493, P173, DOI 10.1016/j.ejphar.2004.04.024
   Savage Paul D., 2016, Sarcoma, V2016, P4592768, DOI 10.1155/2016/4592768
   SEBASTIAN JL, 1991, CHEST, V99, P36, DOI 10.1378/chest.99.1.36
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   SIMON SR, 1992, ARCH INTERN MED, V152, P1698, DOI 10.1001/archinte.152.8.1698
   Skiba DS, 2017, BRIT J PHARMACOL, V174, P4055, DOI 10.1111/bph.13685
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   Sparks M. A., CORONAVIRUS CONUNDRU
   Sriram K, 2020, AM J PHYSIOL-LUNG C, V319, pL37, DOI 10.1152/ajplung.00262.2020
   Sriram K, 2020, BRIT J PHARMACOL, V177, P4971, DOI 10.1111/bph.15194
   Sriram K, 2020, BRIT J PHARMACOL, V177, P4825, DOI 10.1111/bph.15082
   Sriram K, 2020, CLIN PHARMACOL THER, V108, P236, DOI 10.1002/cpt.1863
   Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010
   Sweet M. G., 2019, THESIS
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Uno Y, 2020, INTERN EMERG MED, V15, P1577, DOI 10.1007/s11739-020-02345-9
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang XJ, 2020, CELL METAB, V32, P176, DOI 10.1016/j.cmet.2020.06.015
   Zheng ZF, 2011, J RENIN-ANGIO-ALDO S, V12, P102, DOI 10.1177/1470320310381912
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 94
TC 0
Z9 0
U1 1
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 24
PY 2020
VL 117
IS 47
BP 29274
EP 29282
DI 10.1073/pnas.2009875117
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OY1BM
UT WOS:000593988400010
PM 33203679
DA 2021-01-01
ER

PT J
AU Gomaa, MR
   Kandeil, A
   Mostafa, A
   Roshdy, WH
   Kayed, AE
   Shehata, M
   Kutkat, O
   Moatasim, Y
   El Taweel, A
   Mahmoud, SH
   Kamel, MN
   Shama, NMA
   El Sayes, M
   El-Shesheny, R
   Bakheet, OH
   Elgohary, MA
   Elbadry, M
   Nassif, NN
   Ahmed, SH
   Messih, IYA
   Kayali, G
   Ali, MA
AF Gomaa, Mokhtar R.
   Kandeil, Ahmed
   Mostafa, Ahmed
   Roshdy, Wael H.
   Kayed, Ahmed E.
   Shehata, Mahmoud
   Kutkat, Omnia
   Moatasim, Yassmin
   El Taweel, Ahmed
   Mahmoud, Sara H.
   Kamel, Mina Nabil
   Shama, Noura M. Abo
   El Sayes, Mohamed
   El-Shesheny, Rabeh
   Bakheet, Osama H.
   Elgohary, Mohamed A.
   Elbadry, Mohamed
   Nassif, Naguib N.
   Ahmed, Salwa H.
   Messih, Ibrahim Y. Abdel
   Kayali, Ghazi
   Ali, Mohamed A.
TI Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2
   Neutralizing Antibodies in Egyptian Convalescent Plasma Donors
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE severe acute respiratory syndrome coronavirus 2; Egypt; plasma donors;
   neutralizing antibodies; microneutralization assay
AB Using convalescent plasma as immunotherapy is an old method for treatment of infectious diseases. Several countries have recently allowed the use of such therapy for the treatment of COVID-19 patients especially those who are critically ill. A similar program is currently being tested in Egypt. Here, we tested 227 plasma samples from convalescent donors in Egypt for neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using a microneutralization (MN) assay. A third of the tested samples did not have antibody titers and 58% had titers between 1:10 and 1:80. Only 12% had titers >1:160. We also compared MN assays using different virus concentrations, plaque reduction neutralization (PRNT) assays, and a chemiluminescence assay that measures immunoglobulin G (IgG) binding to N and S proteins of SARS-CoV-2. Our results indicated that a MN assay using 100 TCID50/ml provides comparable results to PRNT and allows for high throughput testing.
C1 [Gomaa, Mokhtar R.; Kandeil, Ahmed; Mostafa, Ahmed; Kayed, Ahmed E.; Shehata, Mahmoud; Kutkat, Omnia; Moatasim, Yassmin; El Taweel, Ahmed; Mahmoud, Sara H.; Kamel, Mina Nabil; Shama, Noura M. Abo; El Sayes, Mohamed; El-Shesheny, Rabeh; Ali, Mohamed A.] Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Giza, Egypt.
   [Roshdy, Wael H.] Minist Hlth & Populat, Cent Publ Hlth Lab, Cairo, Egypt.
   [Bakheet, Osama H.] Mil Med Acad, Dept Clin Pathol, Cairo, Egypt.
   [Elgohary, Mohamed A.] Cairo Univ, Dept Trop Med, Cairo, Egypt.
   [Elbadry, Mohamed] Aswan Univ, Trop Med & Gastroenterol Dept, Aswan, Egypt.
   [Nassif, Naguib N.] Aswan Hlth Affairs Directorate, Prevent Med Dept, Aswan, Egypt.
   [Ahmed, Salwa H.] Aswan Fever Hosp, Clin Pharmacol Dept, Aswan, Egypt.
   [Messih, Ibrahim Y. Abdel] Ain Shams Univ, Fac Med, Cairo, Egypt.
   [Kayali, Ghazi] Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77204 USA.
   [Kayali, Ghazi] Human Link, Baabda, Lebanon.
RP Ali, MA (corresponding author), Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Giza, Egypt.; Kayali, G (corresponding author), Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77204 USA.; Kayali, G (corresponding author), Human Link, Baabda, Lebanon.
EM ghazi@human-link.org; mohamedahmedali2004@yahoo.com
RI Elsayed, Ahmed Moustafa Mohamed/S-7462-2016
OI Elsayed, Ahmed Moustafa Mohamed/0000-0002-2878-5714; El Badry,
   Mohamed/0000-0002-9020-8870
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, United States Department of Health and Human
   Services [HHSN272201400006C]; National Research CentreNational Research
   Centre (NRC) [MP120810]
FX Y This work was funded by the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, United States
   Department of Health and Human Services (under contract
   HHSN272201400006C) and by an internal grant from the National Research
   Centre (MP120810).
CR Adeli SH, 2020, POL ARCH INTERN MED, V130, P455, DOI 10.20452/pamw.15340
   Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Brown BL, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102790
   Chen BZ, 2020, VOX SANG, V115, P507, DOI 10.1111/vox.12968
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Harvala H, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.28.2001260
   Kong YJ, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102820
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   PALADINO AJ, 2020, CANCER EPIDEM BIO S1, V29, DOI DOI 10.1016/J.CRWH.2020.E00221
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Rajendran K, 2020, J MED VIROL, V92, P1475, DOI 10.1002/jmv.25961
   Salazar E, 2020, AM J PATHOL, V190, P1680, DOI 10.1016/j.ajpath.2020.05.014
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   TANNE JH, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1256
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   WHO, 2020, 147 WHO
   World Health Organization, 2020, DRAFT LANDSC COVID 1
NR 18
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD NOV 24
PY 2020
VL 11
AR 596851
DI 10.3389/fmicb.2020.596851
PG 7
WC Microbiology
SC Microbiology
GA PB5LP
UT WOS:000596362600001
PM 33329484
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Desai, S
   Baghal, A
   Wongsurawat, T
   Jenjaroenpun, P
   Powell, T
   Al-Shukri, S
   Gates, K
   Farmer, P
   Rutherford, M
   Blake, G
   Nolan, T
   Sexton, K
   Bennett, W
   Smith, K
   Syed, S
   Prior, F
AF Desai, Shivang
   Baghal, Ahmad
   Wongsurawat, Thidathip
   Jenjaroenpun, Piroon
   Powell, Thomas
   Al-Shukri, Shaymaa
   Gates, Kim
   Farmer, Phillip
   Rutherford, Michael
   Blake, Geri
   Nolan, Tracy
   Sexton, Kevin
   Bennett, William
   Smith, Kirk
   Syed, Shorabuddin
   Prior, Fred
TI Chest imaging representing a COVID-19 positive rural US population
SO SCIENTIFIC DATA
LA English
DT Article; Data Paper
ID IDENTIFICATION; RECOGNITION
AB As the COVID-19 pandemic unfolds, radiology imaging is playing an increasingly vital role in determining therapeutic options, patient management, and research directions. Publicly available data are essential to drive new research into disease etiology, early detection, and response to therapy. In response to the COVID-19 crisis, the National Cancer Institute (NCI) has extended the Cancer Imaging Archive (TCIA) to include COVID-19 related images. Rural populations are one population at risk for underrepresentation in such public repositories. We have published in TCIA a collection of radiographic and CT imaging studies for patients who tested positive for COVID-19 in the state of Arkansas. A set of clinical data describes each patient including demographics, comorbidities, selected lab data and key radiology findings. These data are cross-linked to SARS-COV-2 cDNA sequence data extracted from clinical isolates from the same population, uploaded to the GenBank repository. We believe this collection will help to address population imbalance in COVID-19 data by providing samples from this normally underrepresented population.
C1 [Desai, Shivang; Prior, Fred] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA.
   [Desai, Shivang] Univ Texas Southwestern Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA.
   [Baghal, Ahmad; Wongsurawat, Thidathip; Jenjaroenpun, Piroon; Powell, Thomas; Al-Shukri, Shaymaa; Gates, Kim; Farmer, Phillip; Rutherford, Michael; Blake, Geri; Nolan, Tracy; Sexton, Kevin; Bennett, William; Smith, Kirk; Syed, Shorabuddin; Prior, Fred] Univ Arkansas Med Sci, Dept Biomed Informat, Little Rock, AR 72205 USA.
   [Sexton, Kevin] Univ Arkansas Med Sci, Dept Surg, Little Rock, AR 72205 USA.
RP Prior, F (corresponding author), Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA.; Prior, F (corresponding author), Univ Arkansas Med Sci, Dept Biomed Informat, Little Rock, AR 72205 USA.
EM FWPrior@uams.edu
OI Rutherford, Michael/0000-0003-2665-753X; syed,
   shorabuddin/0000-0002-4761-5972
FU National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1 TR003107]; National Cancer InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [75N91019D00024, 20X023F]
FX This project has been funded in whole or in part with federal funds from
   the National Center for Advancing Translational Sciences UL1 TR003107
   and the National Cancer Institute, Contract No. 75N91019D00024,
   Subcontract 20X023F. The content of this publication does not
   necessarily reflect the views or policies of the Department of Health
   and Human Services, nor does mention of trade names, commercial
   products, or organizations imply endorsement by the U.S. Government. The
   authors wish to acknowledge and thank Dr. Sean Adams and Dr. Kikumi
   Ono-Moore of the Arkansas Children's Nutrition Center for graciously
   sharing their BLS2 laboratory, Dr. Joshua Kennedy of the Department of
   Allergy and Immunology of UAMS for providing residual patient samples
   and Dr. Joshua Quick, University of Birmingham for providing a
   SARS-CoV-2 specific primer set.
CR American College of Radiology, 2020, ACR REC US CHEST RAD
   Artic Network, 2020, SOURC COD READ ASS M
   Baghal Ahmad, 2019, Stud Health Technol Inform, V257, P31
   Bai HX, 2020, RADIOLOGY, V296, pE46, DOI 10.1148/radiol.2020200823
   Bennett W, 2018, J DIGIT IMAGING, V31, P783, DOI 10.1007/s10278-018-0097-4
   Bolin JN, 2015, J RURAL HEALTH, V31, P326, DOI 10.1111/jrh.12116
   Clark K, 2013, J DIGIT IMAGING, V26, P1045, DOI 10.1007/s10278-013-9622-7
   DICOM, 2020, NEMA PS3 ISO 12052 D
   DICOM, 2016, PS3 15 2016A SEC SYS
   Garcia MC, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6602a1
   Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9
   Grossberg AJ, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.173
   Jenjaroenpun P, 2020, SEVERE ACUTE RESP SY
   Li Y, 2020, ACROSS LANG CULT, V21, P1, DOI [10.1556/084.2020.00001, 10.2214/AJR.20.22954]
   Loman N., 2020, NCOV 2019 NOVEL CORO
   Mercatelli D, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01800
   Mills L, 2003, COMMON FILE FORMATS, V45, pA1B1, DOI [10.1002/0471250953.bia01bs45, DOI 10.1002/0471250953.BIA01BS45]
   Moore SM, 2015, RADIOGRAPHICS, V35, P727, DOI 10.1148/rg.2015140244
   Ostell J. M., 2001, BIOINFORMATICS PRACT
   Ou JH, 2019, NAT METHODS, V16, P453, DOI 10.1038/s41592-019-0430-y
   Prior F, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.124
   Prior FW, 2009, IEEE T INF TECHNOL B, V13, P5, DOI 10.1109/TITB.2008.2003335
   Quah P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03006-1
   Sayers EW, 2020, NUCLEIC ACIDS RES, V48, pD84, DOI 10.1093/nar/gkz956
   Schwarz CG, 2019, NEW ENGL J MED, V381, P1684, DOI 10.1056/NEJMc1908881
   Smith N, 2013, ARKANSASS BIG HLTH P
   Wick RR, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1727-y
   Ziegler E, 2020, CANC RES JCO CLIN CA, V4, P336, DOI [10.1200/cci.19.00131, DOI 10.1200/CCI.19.00131]
NR 28
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2052-4463
J9 SCI DATA
JI Sci. Data
PD NOV 24
PY 2020
VL 7
IS 1
AR 414
DI 10.1038/s41597-020-00741-6
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB4TA
UT WOS:000596313800001
PM 33235265
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cenciarelli, S
   Calbi, V
   Barzaghi, F
   Bernardo, ME
   Oltolini, C
   Migliavacca, M
   Gallo, V
   Tucci, F
   Fraschetta, F
   Albertazzi, E
   Fratini, ES
   Consiglieri, G
   Giannelli, S
   Dionisio, F
   Sartirana, C
   Racca, S
   Camesasca, C
   Peretto, G
   Daverio, R
   Esposito, A
   De Cobelli, F
   Silvani, P
   Rabusin, M
   Cara, A
   Trabattoni, D
   Dispinseri, S
   Scarlatti, G
   Piemonti, L
   Lampasona, V
   Cicalese, MP
   Aiuti, A
   Ferrua, F
AF Cenciarelli, Sabina
   Calbi, Valeria
   Barzaghi, Federica
   Bernardo, Maria Ester
   Oltolini, Chiara
   Migliavacca, Maddalena
   Gallo, Vera
   Tucci, Francesca
   Fraschetta, Federico
   Albertazzi, Elena
   Fratini, Elena Sophia
   Consiglieri, Giulia
   Giannelli, Stefania
   Dionisio, Francesca
   Sartirana, Claudia
   Racca, Sara
   Camesasca, Chiara
   Peretto, Giovanni
   Daverio, Rita
   Esposito, Antonio
   De Cobelli, Francesco
   Silvani, Paolo
   Rabusin, Marco
   Cara, Andrea
   Trabattoni, Daria
   Dispinseri, Stefania
   Scarlatti, Gabriella
   Piemonti, Lorenzo
   Lampasona, Vito
   Cicalese, Maria Pia
   Aiuti, Alessandro
   Ferrua, Francesca
TI Mild SARS-CoV-2 Infection After Gene Therapy in a Child With
   Wiskott-Aldrich Syndrome: A Case Report
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Wiskott-Aldrich Syndrome; primary immunodeficiencies; gene therapy;
   immune reconstitution; severe acute respiratory syndrome Coronavirus 2
   (2019-nCoV)
AB In this work we present the case of SARS-CoV-2 infection in a 1.5-year-old boy affected by severe Wiskott-Aldrich Syndrome with previous history of autoinflammatory disease, occurring 5 months after treatment with gene therapy. Before SARS-CoV-2 infection, the patient had obtained engraftment of gene corrected cells, resulting in WASP expression restoration and early immune reconstitution. The patient produced specific immunoglobulins to SARS-CoV-2 at high titer with neutralizing capacity and experienced a mild course of infection, with limited inflammatory complications, despite pre-gene therapy clinical phenotype.
C1 [Cenciarelli, Sabina; Calbi, Valeria; Barzaghi, Federica; Bernardo, Maria Ester; Migliavacca, Maddalena; Gallo, Vera; Tucci, Francesca; Fraschetta, Federico; Fratini, Elena Sophia; Consiglieri, Giulia; Cicalese, Maria Pia; Aiuti, Alessandro; Ferrua, Francesca] IRCCS San Raffaele Sci Inst, Pediat Immunohematol & Bone Marrow Transplantat U, Milan, Italy.
   [Cenciarelli, Sabina; Bernardo, Maria Ester; Fratini, Elena Sophia; Consiglieri, Giulia; Peretto, Giovanni; Esposito, Antonio; De Cobelli, Francesco; Aiuti, Alessandro] Univ Vita Salute San Raffaele, Milan, Italy.
   [Calbi, Valeria; Barzaghi, Federica; Bernardo, Maria Ester; Migliavacca, Maddalena; Gallo, Vera; Tucci, Francesca; Fraschetta, Federico; Albertazzi, Elena; Giannelli, Stefania; Dionisio, Francesca; Sartirana, Claudia; Cicalese, Maria Pia; Aiuti, Alessandro; Ferrua, Francesca] IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy.
   [Oltolini, Chiara] IRCCS San Raffaele Sci Inst, Clin Infect Dis, Div Immunol Transplantat & Infect Dis, Milan, Italy.
   [Racca, Sara] IRCCS San Raffaele Hosp, Lab Med Microbiol & Virol, Milan, Italy.
   [Camesasca, Chiara] IRCCS San Raffaele Sci Inst, Cardiothoracovasc Dept, Pediat Cardiol, Milan, Italy.
   [Peretto, Giovanni] IRCCS San Raffaele Sci Inst, Dept Cardiac Electrophysiol & Clin Arrhythmol, Myocarditis Unit, Milan, Italy.
   [Daverio, Rita] IRCCS San Raffaele Sci Inst, Dept Clin Biochem, Milan, Italy.
   [Esposito, Antonio; De Cobelli, Francesco] IRCCS San Raffaele Inst, Expt Imaging Ctr, Clin & Expt Radiol Unit, Milan, Italy.
   [Silvani, Paolo] IRCCS San Raffaele Sci Inst, Dept Anesthesia & Crit Care, Milan, Italy.
   [Rabusin, Marco] Inst Maternal & Child Hlth Burlo Garofolo, Dept Pediat, HematoOncol Unit, Trieste, Italy.
   [Cara, Andrea] Ist Super Sanita, Natl Ctr Global Hlth, Rome, Italy.
   [Trabattoni, Daria] Univ Milan, Dept Biomed & Clin Sci L Sacco, Milan, Italy.
   [Dispinseri, Stefania; Scarlatti, Gabriella] IRCCS San Raffaele Sci Inst, Viral Evolut & Transmiss Unit, Milan, Italy.
   [Piemonti, Lorenzo] IRCCS San Raffaele Sci Inst, Beta Cell Biol Unit, Diabet Res Inst, Milan, Italy.
   [Lampasona, Vito] IRCCS San Raffaele Sci Inst, Div Genet & Cell Biol, Milan, Italy.
RP Aiuti, A (corresponding author), IRCCS San Raffaele Sci Inst, Pediat Immunohematol & Bone Marrow Transplantat U, Milan, Italy.; Aiuti, A (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.; Aiuti, A (corresponding author), IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy.
EM aiuti.alessandro@hsr.it
RI calbi, valeria/K-4102-2018
OI calbi, valeria/0000-0003-3514-666X
FU Fondazione TelethonFondazione Telethon; European Community (E-rare
   EUROCID)European Community (EC); Orchard Therapeutics (OTL)
   [NCT03837483]; Program Project COVID-19 OSR-UniSR
FX Supported by Fondazione Telethon, European Community (E-rare EUROCID),
   and Program Project COVID-19 OSR-UniSR. Study NCT03837483 is sponsored
   by Orchard Therapeutics (OTL).
CR Abina SHB, 2015, JAMA-J AM MED ASSOC, V313, P1550, DOI 10.1001/jama.2015.3253
   Ahmed Mubbasheer, 2020, EClinicalMedicine, V26, P100527, DOI 10.1016/j.eclinm.2020.100527
   Candotti F, 2018, J CLIN IMMUNOL, V38, P13, DOI 10.1007/s10875-017-0453-z
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Ciceri F, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108509
   Ferrua F, 2020, J ALLERGY CLIN IMMUN, V146, P262, DOI 10.1016/j.jaci.2020.06.018
   Ferrua F, 2019, LANCET HAEMATOL, V6, pE239, DOI 10.1016/S2352-3026(19)30021-3
   Jiang L, 2020, LANCET INFECT DIS, V20, pE276, DOI 10.1016/S1473-3099(20)30651-4
   Labrosse R, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126161
   Liguoro I, 2020, EUR J PEDIATR, V179, P1029, DOI 10.1007/s00431-020-03684-7
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Massaad MJ, 2013, ANN NY ACAD SCI, V1285, P26, DOI 10.1111/nyas.12049
   Meyts Isabelle, 2020, J Allergy Clin Immunol, DOI 10.1016/j.jaci.2020.09.010
   Midulla F, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01617-2020
   Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013
   Secchi Massimiliano, 2020, J Clin Invest, V130, P6366, DOI 10.1172/JCI142804
   Sereni L, 2019, J ALLERGY CLIN IMMUN, V144, P825, DOI 10.1016/j.jaci.2019.03.012
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Vicent MG, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28514
NR 20
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 24
PY 2020
VL 11
AR 603428
DI 10.3389/fimmu.2020.603428
PG 6
WC Immunology
SC Immunology
GA PB3YH
UT WOS:000596259700001
PM 33329599
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fulbabu, M
   Jonniya, NA
   Roy, R
   Poddar, S
   Kar, P
AF Fulbabu, Md
   Jonniya, Nisha Amarnath
   Roy, Rajarshi
   Poddar, Sayan
   Kar, Parimal
TI Computational Investigation of Structural Dynamics of SARS-CoV-2
   Methyltransferase-Stimulatory Factor Heterodimer nsp16/nsp10 Bound to
   the Cofactor SAM
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE SARS-CoV-2; nsp16; nsp10; molecular dynamics; PCA; MM-PBSA
ID MOLECULAR-DYNAMICS; CONFIGURATIONAL ENTROPY; PNEUMONIA OUTBREAK; POLAR
   SOLVATION; FREE-ENERGIES; CORONAVIRUS; BINDING; SOLUTE; REPLICATION;
   INHIBITORS
AB Recently, a highly contagious novel coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has emerged, posing a global threat to public health. Identifying a potential target and developing vaccines or antiviral drugs is an urgent demand in the absence of approved therapeutic agents. The 5 '-capping mechanism of eukaryotic mRNA and some viruses such as coronaviruses (CoVs) are essential for maintaining the RNA stability and protein translation in the virus. SARS-CoV-2 encodes S-adenosyl-L-methionine (SAM) dependent methyltransferase (MTase) enzyme characterized by nsp16 (2 '-O-MTase) for generating the capped structure. The present study highlights the binding mechanism of nsp16 and nsp10 to identify the role of nsp10 in MTase activity. Furthermore, we investigated the conformational dynamics and energetics behind the binding of SAM to nsp16 and nsp16/nsp10 heterodimer by employing molecular dynamics simulations in conjunction with the Molecular Mechanics Poisson-Boltzmann Surface Area (MM/PBSA) method. We observed from our simulations that the presence of nsp10 increases the favorable van der Waals and electrostatic interactions between SAM and nsp16. Thus, nsp10 acts as a stimulator for the strong binding of SAM to nsp16. The hydrophobic interactions were predominately identified for the nsp16-nsp10 interactions. Also, the stable hydrogen bonds between Ala83 (nsp16) and Tyr96 (nsp10), and between Gln87 (nsp16) and Leu45 (nsp10) play a vital role in the dimerization of nsp16 and nsp10. Besides, Computational Alanine Scanning (CAS) mutagenesis was performed, which revealed hotspot mutants, namely I40A, V104A, and R86A for the dimer association. Hence, the dimer interface of nsp16/nsp10 could also be a potential target in retarding the 2 '-O-MTase activity in SARS-CoV-2. Overall, our study provides a comprehensive understanding of the dynamic and thermodynamic process of binding nsp16 and nsp10 that will contribute to the novel design of peptide inhibitors based on nsp16.
C1 [Fulbabu, Md; Jonniya, Nisha Amarnath; Roy, Rajarshi; Poddar, Sayan; Kar, Parimal] Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Khandwa, India.
RP Kar, P (corresponding author), Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Khandwa, India.
EM parimal@iiti.ac.in
FU Department of Biotechnology, Govt. of IndiaDepartment of Biotechnology
   (DBT) India [BT/RLF/REentry/40/2014]; Department of Biotechnology, Govt.
   of India (DBT Ramalingaswami Re-entry Fellowship); Department of Science
   and Technology (DST), Govt. of IndiaDepartment of Science & Technology
   (India) [ECR/2017/000010]; DST, Govt. of India under the INSPIRE
   Fellowship Scheme (DST/INSPIRE Fellowship) [IF170145]
FX This work was partially supported by the Department of Biotechnology,
   Govt. of India (Grant number BT/RLF/REentry/40/2014, DBT Ramalingaswami
   Re-entry Fellowship), and Department of Science and Technology (DST),
   Govt. of India (Grant number ECR/2017/000010). MS would like to thank
   DST, Govt. of India, for providing fellowship under the INSPIRE
   Fellowship Scheme (DST/INSPIRE Fellowship/2017/IF170145).
CR Amadei A, 1996, J BIOMOL STRUCT DYN, V13, P615, DOI 10.1080/07391102.1996.10508874
   Arabi YM, 2015, INFECTION, V43, P495, DOI 10.1007/s15010-015-0720-y
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa011
   Carlsson J, 2006, PHYS CHEM CHEM PHYS, V8, P5385, DOI 10.1039/b608486a
   Case D., 2018, AMBER 2018
   Chakrabarty B, 2019, NUCLEIC ACIDS RES, V47, pW462, DOI 10.1093/nar/gkz399
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Coleman CM, 2014, J VIROL, V88, P5209, DOI 10.1128/JVI.03488-13
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Eckerle LD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000896
   Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933
   Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Hawkins GD, 1996, J PHYS CHEM-US, V100, P19824, DOI 10.1021/jp961710n
   HAWKINS GD, 1995, CHEM PHYS LETT, V246, P122, DOI 10.1016/0009-2614(95)01082-K
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Hu GD, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060819
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   ICHIYE T, 1991, PROTEINS, V11, P205, DOI 10.1002/prot.340110305
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jeffrey G. A., 1997, INTRO HYDROGEN BONDI
   Jonniya NA, 2020, J BIOMOL STRUCT DYN, V38, P1306, DOI 10.1080/07391102.2019.1602079
   Jonniya NA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1827035
   Jonniya NA, 2019, ACS OMEGA, V4, P17404, DOI 10.1021/acsomega.9b02187
   Kar P, 2007, J COMPUT CHEM, V28, P2538, DOI 10.1002/jcc.20698
   Kar P, 2007, J PHYS CHEM B, V111, P8910, DOI 10.1021/jp072302u
   Kar P, 2013, J PHYS CHEM B, V117, P5793, DOI 10.1021/jp3085292
   Kar P, 2012, J PHYS CHEM B, V116, P6269, DOI 10.1021/jp300818c
   Kar P, 2012, J PHYS CHEM B, V116, P6137, DOI 10.1021/jp3022612
   Kar P, 2012, J COMPUT AID MOL DES, V26, P215, DOI 10.1007/s10822-012-9550-5
   Kar P, 2012, J PHYS CHEM B, V116, P2605, DOI 10.1021/jp211768n
   Kar P, 2011, J PHYS CHEM B, V115, P7661, DOI 10.1021/jp201538t
   KARPLUS M, 1981, MACROMOLECULES, V14, P325, DOI 10.1021/ma50003a019
   King A. M. Q., 2011, VIRUS TAXONOMY 9 REP
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Kozakov D, 2015, NAT PROTOC, V10, P733, DOI 10.1038/nprot.2015.043
   Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lin S, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00241-4
   Lin XQ, 2020, KOREAN J RADIOL, V21, P365, DOI 10.3348/kjr.2020.0078
   LONCHARICH RJ, 1992, BIOPOLYMERS, V32, P523, DOI 10.1002/bip.360320508
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lun ZR, 2004, EMERG INFECT DIS, V10, P959, DOI 10.3201/eid1005.040022
   Machado MR, 2020, J CHEM THEORY COMPUT, V16, P1367, DOI 10.1021/acs.jctc.9b00953
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Massova I, 1999, J AM CHEM SOC, V121, P8133, DOI 10.1021/ja990935j
   Minasov G., 2020, 1 80 ANGSTROM RESOLU
   Moreira IS, 2007, J COMPUT CHEM, V28, P644, DOI 10.1002/jcc.20566
   Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z
   PASTOR RW, 1988, MOL PHYS, V65, P1409, DOI 10.1080/00268978800101881
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117
   REMPE SB, 1998, CHEM ED, V3, P1
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rosas-Lemus Monica, 2020, bioRxiv, DOI 10.1101/2020.04.17.047498
   Roy R, 2020, ACS OMEGA, V5, P3932, DOI 10.1021/acsomega.9b03398
   Sanachai K, 2020, ACS OMEGA, V5, P369, DOI 10.1021/acsomega.9b02800
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shi SH, 2018, J BIOMOL STRUCT DYN, V36, P981, DOI 10.1080/07391102.2017.1305296
   Singh S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1796810
   SK M, 2020, J BIOMOL STRUCT 0527, DOI DOI 10.26434/CHEMRXIV.12084207
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1794965
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1724196
   Viswanathan T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17496-8
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Weiser J, 1999, J COMPUT CHEM, V20, P586, DOI 10.1002/(SICI)1096-987X(19990430)20:6<586::AID-JCC4>3.0.CO;2-J
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu BS, 2011, J COMPUT CHEM, V32, P3188, DOI 10.1002/jcc.21900
   Yang HT, 2005, PLOS BIOL, V3, P2044, DOI 10.1371/journal.pbio.0030428
   Zeng ZQ, 2018, EUR J CLIN MICROBIOL, V37, P363, DOI 10.1007/s10096-017-3144-z
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 85
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD NOV 24
PY 2020
VL 7
AR 590165
DI 10.3389/fmolb.2020.590165
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA PB4CI
UT WOS:000596270400001
PM 33330626
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Vaduganathan, M
   Butler, J
   Krumholz, HM
   Itchhaporia, D
   Stecker, EC
   Bhatt, DL
AF Vaduganathan, Muthiah
   Butler, Javed
   Krumholz, Harlan M.
   Itchhaporia, Dipti
   Stecker, Eric C.
   Bhatt, Deepak L.
TI Regulation of Cardiovascular Therapies During the COVID-19 Public Health
   Emergency
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE clinical trials; coronavirus; COVID-19; regulation
C1 [Vaduganathan, Muthiah; Bhatt, Deepak L.] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
   [Butler, Javed] Univ Mississippi, Dept Med, Jackson, MS 39216 USA.
   [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA.
   [Krumholz, Harlan M.] Yale Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT USA.
   [Krumholz, Harlan M.] Yale Sch Publ Hlth, Dept Hlth Policy & Adm, New Haven, CT USA.
   [Itchhaporia, Dipti] Univ Calif Irvine, Hoag Mem Hosp, Dept Med, Cardiol Div, Newport Beach, CA USA.
   [Stecker, Eric C.] Oregon Heath & Sci Univ, Knight Cardiovasc Inst, Electrophysiol Sect, Portland, OR USA.
RP Vaduganathan, M (corresponding author), Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA.; Vaduganathan, M (corresponding author), Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.
EM mvaduganathan@bwh.harvard.edu
FU KL2/Catalyst Medical Research Investigator Training award from Harvard
   Catalyst (NIH/NCATS Award) [UL 1TR002541]; Galmed; NovartisNovartis;
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; AbbottAbbott
   Laboratories; Edwards Lifesciences; Daiichi-SankyoDaiichi Sankyo Company
   Limited; Boehringer IngelheimBoehringer Ingelheim; CSL Behring; Ferring
   Pharmaceuticals; BayerBayer AG
FX Dr. Vaduganathan is supported by the KL2/Catalyst Medical Research
   Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL
   1TR002541); has received research support from Amgen; has served on
   Advisory Boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG,
   Boehringer Ingelheim, Cytokinetics, and Relypsa; and has participated on
   clinical endpoint committees for studies sponsored by Galmed, Novartis,
   and the National Institutes of Health. Dr. Butler has served as a
   consultant to Abbott, Adrenomed, Amgen, Applied Therapeutics, Array,
   AstraZeneca, Bayer, BerlinCures, Boehringer Ingelheim, Cardior, CVRx,
   Foundry, G3 Pharma, Imbria, Impulse Dynamics, Innolife, Janssen,
   LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa,
   Roche, Sanofi, Sequana Medical, V-Wave Limited, and Vifor. Dr. Krumholz
   has received expenses and/or personal fees from UnitedHealth, IBM Watson
   Health, Element Science, Aetna, Facebook, the Siegfried and Jensen Law
   Firm, Arnold and Porter Law Firm, Martin/Baughman Law Firm, F-Prime, and
   the National Center for Cardiovascular Diseases in Beijing; is an owner
   of Refactor Health and HugoHealth; and has had grants and/or contracts
   from the Centers for Medicare & Medicaid Services, Medtronic, the U.S.
   Food and Drug Administration, Johnson & Johnson, and the Shenzhen Center
   for Health Information. Dr. Bhatt has served on the Advisory Boards of
   Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update
   Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, and
   Regado Biosciences; has served on the boards of directors of the Boston
   VA Research Institute, Society of Cardiovascular Patient Care, and
   TobeSoft; has served as chair of the American Heart Association Quality
   Oversight Committee; has served on data monitoring committees for the
   Baim Institute for Clinical Research (formerly Harvard Clinical Research
   Institute, for the PORTICO trial, funded by St. Jude Medical, now
   Abbott), Cleveland Clinic (including for the ExCEED trial, funded by
   Edwards Lifesciences), Contego Medical (chair of the PERFORMANCE 2
   trial), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai
   School of Medicine (for the ENVISAGE trial, funded by Daiichi-Sankyo),
   and Population Health Research Institute; has received honoraria from
   the American College of Cardiology (senior associate editor, Clinical
   Trials and News, ACC.; org; and vice chair of the ACC Accreditation
   Committee), Baim Institute for Clinical Research (formerly Harvard
   Clinical Research Institute; RE-DUAL PCI clinical trial steering
   committee funded by Boehringer Ingelheim; AEGIS-II executive committee
   funded by CSL Behring), Belvoir Publications (Editor-in-Chief, Harvard
   Heart Letter), Duke Clinical Research Institute (clinical trial steering
   committees, including for the PRONOUNCE trial, funded by Ferring
   Pharmaceuticals), HMP Global (Editor-in-Chief, Journal of Invasive
   Cardiology), Journal of the American College of Cardiology (guest
   editor; associate editor), K2P (co-chair, interdisciplinary curriculum),
   Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life
   Sciences, Population Health Research Institute (for the COMPASS
   operations committee, publications committee, steering committee, and
   USA national co-leader, funded by Bayer), Slack Publications (chief
   medical editor, Cardiology Today's Intervention), Society of
   Cardiovascular Patient Care (secretary/treasurer), and WebMD (CME
   steering committees); has other relationships with Clinical Cardiology
   (deputy editor), NCDR-ACTION Registry Steering Committee (chair), and VA
   CART Research and Publications Committee (chair); has received research
   funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer,
   Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Chiesi, CSL Behring,
   Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl,
   Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer,
   PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, and The
   Medicines Company; has received royalties from Elsevier (editor,
   Cardiovascular Intervention: A Companion to Braunwald's Heart Disease);
   has been a site coinvestigator for Biotronik, Boston Scientific, CSI,
   St. Jude Medical (now Abbott), and Svelte; has been a trustee for the
   American College of Cardiology; and has performed unfunded research for
   FlowCo, Merck, Novo Nordisk, and Takeda. All other authors have reported
   that they have no relationships relevant to the contents of this paper
   to disclose.
CR Abraham WT, 2020, JACC-HEART FAIL, V8, P423, DOI 10.1016/j.jchf.2020.03.005
   Bagiella E, 2020, J AM COLL CARDIOL, V76, P342, DOI 10.1016/j.jacc.2020.05.041
   European Medicines Agency, POINTS CONS IMPL COR
   U.S. Food and Drug Administration, DRUG SHORT
   U. S. Food and Drug Administration, 2020, 2020 DEV APPR
   U. S. Food and Drug Administration, 2020, NOV DRUG APPR 2020
   U.S. Food and Drug Administration, 2020, FDA GUID COND CLIN T
   U.S. Food and Drug Administration, 2020, STAT CONS CLIN TRIAL
   Vaduganathan M, 2020, JAMA-J AM MED ASSOC, V323, P2524, DOI 10.1001/jama.2020.9184
NR 9
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD NOV 24
PY 2020
VL 76
IS 21
BP 2517
EP 2521
DI 10.1016/j.jacc.2020.09.594
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OU7XO
UT WOS:000591738100012
PM 33213730
OA Green Published
DA 2021-01-01
ER

PT J
AU Woolsey, C
   Borisevich, V
   Prasad, AN
   Agans, KN
   Deer, DJ
   Dobias, NS
   Heymann, JC
   Foster, SL
   Levine, CB
   Medina, L
   Melody, K
   Geisbert, JB
   Fenton, KA
   Geisbert, TW
   Cross, RW
AF Woolsey, Courtney
   Borisevich, Viktoriya
   Prasad, Abhishek N.
   Agans, Krystle N.
   Deer, Daniel J.
   Dobias, Natalie S.
   Heymann, John C.
   Foster, Stephanie L.
   Levine, Corri B.
   Medina, Liana
   Melody, Kevin
   Geisbert, Joan B.
   Fenton, Karla A.
   Geisbert, Thomas W.
   Cross, Robert W.
TI Establishment of an African green monkey model for COVID-19 and
   protection against re-infection
SO NATURE IMMUNOLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; PRIMATE MODEL; SARS-COV-2; INFECTION;
   VACCINE; MERS; RHESUS; SARS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an unprecedented global pandemic of COVID-19. Animal models are urgently needed to study the pathogenesis of COVID-19 and to screen vaccines and treatments. We show that African green monkeys (AGMs) support robust SARS-CoV-2 replication and develop pronounced respiratory disease, which may more accurately reflect human COVID-19 cases than other nonhuman primate species. SARS-CoV-2 was detected in mucosal samples, including rectal swabs, as late as 15 days after exposure. Marked inflammation and coagulopathy in blood and tissues were prominent features. Transcriptome analysis demonstrated stimulation of interferon and interleukin-6 pathways in bronchoalveolar lavage samples and repression of natural killer cell- and T cell-associated transcripts in peripheral blood. Despite a slight waning in antibody titers after primary challenge, enhanced antibody and cellular responses contributed to rapid clearance after re-challenge with an identical strain. These data support the utility of AGM for studying COVID-19 pathogenesis and testing medical countermeasures.
   Geisbert and colleagues report that African green monkeys infected with the SARS-CoV-2 virus develop disease symptoms that closely resemble those seen in infected humans, making this animal model a useful surrogate to investigate immune responses to coronavirus infection.
C1 [Woolsey, Courtney; Borisevich, Viktoriya; Prasad, Abhishek N.; Agans, Krystle N.; Deer, Daniel J.; Dobias, Natalie S.; Foster, Stephanie L.; Levine, Corri B.; Medina, Liana; Melody, Kevin; Geisbert, Joan B.; Fenton, Karla A.; Geisbert, Thomas W.; Cross, Robert W.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Woolsey, Courtney; Borisevich, Viktoriya; Prasad, Abhishek N.; Agans, Krystle N.; Deer, Daniel J.; Dobias, Natalie S.; Foster, Stephanie L.; Levine, Corri B.; Medina, Liana; Melody, Kevin; Geisbert, Joan B.; Fenton, Karla A.; Geisbert, Thomas W.; Cross, Robert W.] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA.
   [Heymann, John C.] Univ Texas Med Branch, Dept Radiol, Galveston, TX 77555 USA.
RP Geisbert, TW (corresponding author), Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.; Geisbert, TW (corresponding author), Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA.
EM twgeisbe@utmb.edu
OI Levine, Corri/0000-0003-0405-5191; Woolsey, Courtney/0000-0003-3389-0137
FU European UnionEuropean Union (EU) [653316]; Department of Microbiology
   and Immunology, UTMB; National Institute of Allergy and Infectious
   Diseases/National Institutes of HealthUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UC7AI094660]
FX The authors thank the UTMB Animal Resource Center for veterinary support
   and surgical implantation of temperature data loggers, as well as
   husbandry support. We thank V. Menachery, S. Makino, C.-T. Tseng, T.
   Ksiazek and K. Narayanan for their valuable insight and technical
   assistance with coronavirus protocols. The virus used in this
   publication was kindly provided by the European Virus Archive Goes
   Global project that has received funding from the European Union's
   Horizon 2020 research and innovation program under grant agreement no.
   653316. We thank L. Branco and M. Boisen (Zalgen Labs) for generously
   providing the SARS-CoV-2 anti-nucleoprotein ELISA assays. The following
   reagent was produced under HHSN272201400008C and obtained through BEI
   Resources, National Institute of Allergy and Infectious Diseases,
   National Institutes of Health: spike glycoprotein RBD from SARS-Related
   Coronavirus 2, Wuhan-Hu-1 with C-terminal histidine tag, recombinant
   from HEK293F cells, NR-52366. This study was supported by funds from the
   Department of Microbiology and Immunology, UTMB, to T.W.G. Operations
   support of the Galveston National Laboratory was provided by National
   Institute of Allergy and Infectious Diseases/National Institutes of
   Health grant UC7AI094660.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   American College of Radiology, 2020, ACR REC US CHEST RAD
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Capobianchi MR, 2020, CLIN MICROBIOL INFEC, V26, P954, DOI 10.1016/j.cmi.2020.03.025
   Caswell J., 2007, PALMERIS PATHOL DOME, V5, P523
   Centers for Disease Control and Prevention, 2020, CDC 2019 NCOV REAL T
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen X, 2020, CHINA PERSPECT-SER, P1
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Durbin AP, 2000, VACCINE, V18, P2462, DOI 10.1016/S0264-410X(99)00575-7
   Galanti Marta, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa392
   Geisbert TW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010690
   Grant MC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234765
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   KAKUK TJ, 1993, J INFECT DIS, V167, P553, DOI 10.1093/infdis/167.3.553
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Letsch A, 2003, METHODS, V31, P143, DOI 10.1016/S1046-2023(03)00124-5
   Martines RB, 2020, EMERG INFECT DIS, V26, P2005, DOI 10.3201/eid2609.202095
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Nalca A, 2019, INT J INFECT DIS, V79, P99, DOI 10.1016/j.ijid.2018.11.249
   Prasad AN, 2020, J INFECT DIS, V221, pS436, DOI 10.1093/infdis/jiz613
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rubin GD, 2020, RADIOLOGY, V296, P172, DOI 10.1148/radiol.2020201365
   Shan C, 2020, CELL RES, V30, P670, DOI 10.1038/s41422-020-0364-z
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Vogel A., 2020, BIORXIV, DOI [10.1101/2020.09.08.280818, DOI 10.1101/2020.09.08.280818]
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Weinstock MB, 2020, J URGENT CARE MED, V14, P13
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   WHO, 2020, COR DIS COVID 19 SIT
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   Zhou Y., 2019, NAT COMMUN, DOI [10.1038/s41467-019-09234-665, DOI 10.1038/S41467-019-09234-665]
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
NR 46
TC 1
Z9 1
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JAN
PY 2021
VL 22
IS 1
DI 10.1038/s41590-020-00835-8
EA NOV 2020
PG 24
WC Immunology
SC Immunology
GA PG2HK
UT WOS:000592575000001
PM 33235385
OA Bronze
DA 2021-01-01
ER

PT J
AU De Marchi, F
   Sarnelli, MF
   Serioli, M
   De Marchi, I
   Zani, E
   Bottone, N
   Ambrosini, S
   Garone, R
   Cantello, R
   Mazzini, L
   Solara, V
   Biroli, G
   Riso, S
   Vercelli, R
   Massara, M
AF De Marchi, Fabiola
   Sarnelli, Maria Francesca
   Serioli, Marcella
   De Marchi, Ilaria
   Zani, Ermes
   Bottone, Nicola
   Ambrosini, Serena
   Garone, Raffaella
   Cantello, Roberto
   Mazzini, Letizia
   Solara, Valentina
   Biroli, Giampaolo
   Riso, Sergio
   Vercelli, Renato
   Massara, Maurilio
CA CANPALS Study Grp
TI Telehealth approach for amyotrophic lateral sclerosis patients: the
   experience during COVID-19 pandemic
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article; Early Access
DE amyotrophic lateral sclerosis; COVID&#8208; 19; multidisciplinary care;
   telemedicine
ID AMERICAN ACADEMY; TELEMEDICINE; CARE
AB Background and objective Specialized multidisciplinary ALS care has been shown to extend survival and improve patient's and caregiver's quality of life. During the COVID-19 pandemic, the management of patients suddenly changed and telemedicine has been proven to be as effective as outpatient care. We elaborate the experience with Telemedicine of a Tertiary ALS Center from an Italian geographical area with high infectious risk during the COVID-19 pandemic.
   Methods 19 patients were evaluated in telemedicine by a multidisciplinary team including a neurologist (clinical evaluation, intercurrent events, and drug prescriptions); a dietician (diet and weight monitoring); a psychologist (psychological assessment and support); and a physiotherapist (physiotherapy treatment and device prescription). Telemedicine was performed using the online platform "IoMT Connected Care Platform (Ticuro Reply)."
   Results All patients reported a positive perception of talking face to face with healthcare professionals and were satisfied with how the team understood their problems. During video televisits, there was a change in the patient's medication regimen in 11/19; 2/19 required pneumological evaluation and started NIV; and 9/16 patients required prescription of devices. The mean monthly decline of ALSFRS-R before televisit was 0.88 (SD 1.17) and during televisit of 0.49 (SD 0.75). Bodyweight and daily caloric content remain stable. Reduction in HADS scores and stability in ALSAQ-40 were observed.
   Discussion Our study positively reproduced the multidisciplinary approach currently used with ALS patients, trying to stabilize the functional and metabolic status and improving the psychological one. Future directions include a personalized telemedicine program according to the patient's needs.
C1 [De Marchi, Fabiola; Sarnelli, Maria Francesca; De Marchi, Ilaria; Cantello, Roberto; Mazzini, Letizia; Solara, Valentina] Univ Piemonte Orientale, Maggiore della Carita Hosp, Dept Neurol, Corso Mazzini 18, I-28100 Novara, Italy.
   [De Marchi, Fabiola; Sarnelli, Maria Francesca; De Marchi, Ilaria; Cantello, Roberto; Mazzini, Letizia; Solara, Valentina] Univ Piemonte Orientale, Maggiore della Carita Hosp, ALS Ctr, Corso Mazzini 18, I-28100 Novara, Italy.
   [Serioli, Marcella; Biroli, Giampaolo; Riso, Sergio] Univ Piemonte Orientale, Maggiore della Carita Hosp, Dept Dietet & Clin Nutr, Novara, Italy.
   [Zani, Ermes; Bottone, Nicola] Santer Reply SpA, Business Unit, Hlth Reply, Turin, Italy.
   [Ambrosini, Serena] Consoft Sistemi, Turin, Italy.
   [Garone, Raffaella] Maggiore della Carita Hosp, Hlth Management, Novara, Italy.
   [Vercelli, Renato] Maggiore della Carita Hosp, Dept Resp Dis, Novara, Italy.
   [Massara, Maurilio] Univ Piemonte Orientale, Maggiore della Carita Hosp, Dept Phys Therapy, Novara, Italy.
RP De Marchi, F (corresponding author), Univ Piemonte Orientale, Maggiore della Carita Hosp, Dept Neurol, Corso Mazzini 18, I-28100 Novara, Italy.; De Marchi, F (corresponding author), Univ Piemonte Orientale, Maggiore della Carita Hosp, ALS Ctr, Corso Mazzini 18, I-28100 Novara, Italy.
EM fabiolademarchi@gmail.com
FU Regione Piemonte-Piattaforma tecnologica Salute e Benessere POR FESR
   2014-2020; AGING Project for Department of Excellence at the Department
   of Translational Medicine (DIMET), Universita del Piemonte Orientale,
   Novara, Italy
FX The CANP Project (http://casanelpar co-project.it/) is supported by
   Regione Piemonte-Piattaforma tecnologica Salute e Benessere POR FESR
   2014-2020 and by the AGING Project for Department of Excellence at the
   Department of Translational Medicine (DIMET), Universita del Piemonte
   Orientale, Novara, Italy.
CR Agosta F, 2015, AMYOTROPH LAT SCL FR, V16, P1, DOI 10.3109/21678421.2014.964258
   Amato Simona, 2019, Ig Sanita Pubbl, V75, P371
   Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x
   Andrews JA, 2020, MUSCLE NERVE, V62, P182, DOI 10.1002/mus.26989
   BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012
   Boylan K, 2016, AMYOTROPH LAT SCL FR, V17, P119, DOI 10.3109/21678421.2015.1091478
   Capozzo R, 2020, AMYOTROPH LAT SCL FR, V21, P542, DOI 10.1080/21678421.2020.1773502
   Consonni M, 2020, J NEUROL, DOI 10.1007/s00415-020-10080-6
   De Lucia N, 2020, NEUROL SCI, V41, P2339, DOI 10.1007/s10072-020-04592-2
   De Marchi F, 2020, NEUROL SCI, V41, P1365, DOI 10.1007/s10072-020-04457-8
   Geronimo A, 2017, AMYOTROPH LAT SCL FR, V18, P555, DOI 10.1080/21678421.2017.1338298
   Govindarajan R, 2020, MUSCLE NERVE, V62, P321, DOI 10.1002/mus.26921
   Hatcher-Martin JM, 2020, NEUROLOGY, V94, P30, DOI 10.1212/WNL.0000000000008708
   Haulman A, 2020, MUSCLE NERVE, V61, P682, DOI 10.1002/mus.26838
   Hobson EV, 2016, NAT REV NEUROL, V12, P526, DOI 10.1038/nrneurol.2016.111
   Hogden A, 2017, J MULTIDISCIP HEALTH, V10, P205, DOI 10.2147/JMDH.S134992
   Mahoney FI, 1965, MARYLAND STATE MED, V14, P61
   MCCORMACK HM, 1988, PSYCHOL MED, V18, P1007, DOI 10.1017/S0033291700009934
   Palmieri A, 2010, NEUROL RES, V32, P32, DOI 10.1179/174313209X385734
   Pulley MT, 2019, MUSCLE NERVE, V59, P34, DOI 10.1002/mus.26170
   Selkirk SM, 2017, AMYOTROPH LAT SCL FR, V18, P324, DOI 10.1080/21678421.2017.1313867
   Van De Rijn M, 2018, AMYOTROPH LAT SCL FR, V19, P143, DOI 10.1080/21678421.2017.1392577
   van Es MA, 2017, LANCET, V390, P2084, DOI 10.1016/S0140-6736(17)31287-4
   Vasta R, 2020, AMYOTROPH LAT SCL FR, DOI 10.1080/21678421.2020.1820043
NR 24
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
DI 10.1111/ane.13373
EA NOV 2020
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA OU7AV
UT WOS:000591678600001
PM 33185886
OA Bronze
DA 2021-01-01
ER

PT J
AU Tausche, AK
AF Tausche, Anne-Kathrin
TI Recent News Regarding Gout - A Selection of eEULAR 2020 Publications
SO AKTUELLE RHEUMATOLOGIE
LA German
DT Article; Early Access
DE gout; crystal arthropathies; urate; eEular congress; allopurinol
ID ALLOPURINOL; FEBUXOSTAT; SAFETY; CARE
AB Zusammenfassung Die Gicht ist die haufigste entzundliche Arthritis beim Mann. Zumeist stellen sich die Patienten mit einem ersten akuten Gichtanfall beim Hausarzt vor. In Kenntnis der existierenden Leitlinien sollte neben der antientzundlichen Therapie des Gichtanfalles zeitnah mit einer harnsauresenkenden Therapie begonnen werden, wenn sich die fur die Gicht ursachliche Hyperurikamie nicht durch diatetische Bemuhungen in den Zielwert senken lasst. Leider ist die Versorgungsrealitat von Gichtpatienten oft nicht optimal und komplizierte Verlaufe werden beim Rheumatologen vorstellig. Die Rheumatologen mit ihren Fachgesellschaften waren es auch, die sich initial der Erstellung von Leitlinien zur Diagnostik und Therapie der metabolisch verursachten Gelenkerkrankung angenommen haben; daruber hinaus tragen Rheumatologen seit vielen Jahren zum Wissensgewinn auf dem Gebiet der Gicht durch Grundlagenforschung sowie klinische Forschung bei. So wurde auch dieses Jahr, welches durch die Covid-19-Situation ein ganz besonderes Jahr ist, eine Vielzahl neuer Erkenntnisse zur Gicht auf dem EULAR erstmalig in virtueller Form prasentiert.
   Abstract Gout is the most common inflammatory arthritis in men. Most often, gout patients will consult their general practitioner with their first acute gout flare. With a view to the existing guidelines, urate-lowering therapy should be started at an early point in time in addition to anti-inflammatory treatment of the gout flare if low-purine diet alone is not sufficient in treating the underlying hyperuricemia to target. Unfortunately, the management of gout patients in general still does not seem to be optimal and rheumatologists often have to manage complicated or "difficult-to-treat" gout patients. Being aware of these problems, rheumatologists and their professional societies were the first to develop guidelines for the diagnosis and management of the metabolic joint disease. Furthermore, rheumatologists have contributed to basic and clinical research in the field. Even in 2020, which is a special year due to the Covid-19 situation, a variety of new, interesting findings concerning gout were presented at the first virtual eEuropean congress in the history of EULAR.
C1 [Tausche, Anne-Kathrin] Carl Gustav Carus TU Dresden, Med Klin 3, Abt Rheumatol, Univ Klinikum, Fetscherstr 74, D-01307 Dresden, Germany.
RP Tausche, AK (corresponding author), Carl Gustav Carus TU Dresden, Med Klin 3, Abt Rheumatol, Univ Klinikum, Fetscherstr 74, D-01307 Dresden, Germany.
EM anne-kathrin.tausche@uniklinikum-dresden.de
CR Alten R, 2020, INTERNIST, V61, P530, DOI 10.1007/s00108-020-00766-4
   Baharuddin H, 2020, ANN RHEUM DIS, V79, P1756, DOI 10.1136/annrheumdis-2020-eular.1679
   Chikina M, 2020, ANN RHEUM DIS, V79, P1757, DOI 10.1136/annrheumdis-2020-eular.5171
   Ghang B, 2020, RHEUMATOLOGY, V59, P1439, DOI 10.1093/rheumatology/kez552
   Kiltz U, 2017, Z RHEUMATOL, V76, P118, DOI 10.1007/s00393-016-0249-1
   Kim HJ, 2020, ANN RHEUM DIS, V79, P106, DOI 10.1136/annrheumdis-2020-eular.1909
   Lamoreaux B, 2020, ANN RHEUM DIS, V79, P106, DOI 10.1136/annrheumdis-2020-eular.2058
   Pou MA, 2020, ANN RHEUM DIS, V79, P1961, DOI 10.1136/annrheumdis-2020-eular.3117
   Richette P, 2017, ANN RHEUM DIS, V76, P29, DOI [10.1136/annrheumdis-2016-210356, 10.1136/annrheumdis-2016-209707]
   Saag K, 2020, ANN RHEUM DIS, V79, P438, DOI 10.1136/annrheumdis-2020-eular.3766
   Schlesinger N, 2020, ANN RHEUM DIS, V79, P1873, DOI 10.1136/annrheumdis-2020-eular.2340
   Sherman Y, 2020, ANN RHEUM DIS, V79, P1763, DOI 10.1136/annrheumdis-2020-eular.3833
   Tausche A K, 2019, GER MED SCI, V10, DOI 10.3205/18dgrh054
   Vazirpanah N, 2019, ANN RHEUM DIS, V78, P663, DOI 10.1136/annrheumdis-2018-214656
   Veenstra F, 2020, ANN RHEUM DIS, V79, P457, DOI 10.1136/annrheumdis-2020-eular.3635
   Veenstra F, 2020, ANN RHEUM DIS, V79, P439, DOI 10.1136/annrheumdis-2020-eular.3634
   White WB, 2018, NEW ENGL J MED, V378, P1200, DOI 10.1056/NEJMoa1710895
NR 17
TC 0
Z9 0
U1 1
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0341-051X
EI 1438-9940
J9 AKTUEL RHEUMATOL
JI Aktuelle Rheumatol.
DI 10.1055/a-1301-1584
EA NOV 2020
PG 6
WC Rheumatology
SC Rheumatology
GA OU9YG
UT WOS:000591878200001
DA 2021-01-01
ER

PT J
AU Sturm, T
   Albrecht, T
AF Sturm, Tristan
   Albrecht, Tom
TI 'Constituent Covid-19 apocalypses: contagious conspiracism, 5G, and
   viral vaccinations'
SO ANTHROPOLOGY & MEDICINE
LA English
DT Article; Early Access
DE Covid-19; apocalypticism; conspiracy theories; Christian right;
   alt-right; radical left
AB The uncertainties and scale of the Covid-19 pandemic has mobilised global anxieties and insecurities, and many cultural groups have conjuncturally embedded conspiracy theories within millennial and apocalyptic thought to explain and find meaning in the pandemic. The apocalypse lends itself well to conspiratorial thinking because conceptually it is flexible enough to reflect any crisis. To this end, the global development of Covid-19 conspiracism is what the authors term 'contagious conspiracism' which is defined as viral global cultural conspiracism. The paper explores how millennialist responses to Covid-19 in various media outlets transcend academic categories of analysis and cultural boundaries between, say, religious and secular, far-right and radical left. First explored is how the crisis became embedded in established (mainly American) contemporary millennial beliefs and prophecies through selected far-right, evangelical and radical left narratives. Second, it is shown how these theories have been 'improvised' to include 5 G and also travelled to Europe and taken on geographical significance in Belfast and Berlin. Third, the authors illustrate the shared ingredients, motivations, and semiotics across apocalyptic conspiratorial Covid-19 narratives, all of which resonate with concerns about power, specifically emergent surveillance technologies, governmental abuse of power, and neoliberal capital, with divergent truths about who is blame from 5 G/vaccine theories to corporate technocapitalism. The paper concludes that these shared discourses across apocalyptic and conspiratorial Covid-19 narratives mean many of us are conspiracists and/or conspiracy theorists at some level and is therefore both revealing of the similarities and has the potential to create democratic constituencies.
C1 [Sturm, Tristan; Albrecht, Tom] Queens Univ Belfast, Dept Geog, Belfast, Antrim, North Ireland.
RP Sturm, T (corresponding author), Queens Univ Belfast, SNBE, Belfast BT7 1NN, Antrim, North Ireland.
EM t.sturm@qub.ac.uk
OI Sturm, Tristan/0000-0001-5757-0117
FU ESRC NINE DTP (2017-2021): 'American Climate Change Millennialism: An
   Analysis of PostSecular Counter-Epistemic Narratives'
FX ESRC NINE DTP (2017-2021): 'American Climate Change Millennialism: An
   Analysis of PostSecular Counter-Epistemic Narratives'.
CR Agamben G., 2020, QUODLIBET
   Ali I, 2020, MED ANTHROPOL, V39, P376, DOI 10.1080/01459740.2020.1745481
   Bale JM, 2007, PATTERNS PREJUDICE, V41, P45, DOI 10.1080/00313220601118751
   Barkun M, 2013, COMP STUD RELIG SOC, V15, P1
   Barkun M., 1974, DISASTER MILLENNIUM
   Barkun M., 2010, MAPPING END TIMES AM
   BBC, 2020, BBC
   Bennhold K., 2020, NY TIMES
   Boyer P. S., 1992, TIME SHALL BE NO MOR
   Branco A. F., 2020, CONSERVATIVE DA 0315
   Brubaker R, 2013, ETHNIC RACIAL STUD, V36, P1, DOI 10.1080/01419870.2012.729674
   Bull M., 1996, APOCALYPSE THEORY EN
   Cantor N. F., 2015, WAKE PLAGUE BLACK DE
   Carrington D., 2020, GUARDIAN
   Cohn N., 1957, PURSUIT MILLENNIUM N
   Connolly WE, 2005, POLIT THEORY, V33, P869, DOI 10.1177/0090591705280376
   Davis M., 2005, MONSTER OUR DOOR GLO
   de Certeau M., 1984, PRACTICE EVERYDAY LI
   deHaven-Smith L., 2013, CONSPIRACY THEORY AM
   Dias E., 2020, NY TIMES
   Durand JY, 2020, SOC ANTHROPOL, V28, P259, DOI 10.1111/1469-8676.12805
   Durban S., 2018, RIGHTEOUS GENTILES R
   Farries E., 2020, IRISH TIMES
   Foucault M., 1980, POWERKNOWLEDGE SELEC
   Fraser G, 2020, J AM STUD, V54, P273, DOI 10.1017/S0021875818001408
   Goldstein W, 2001, CRITICAL SOCIOLOGY, V27, P246
   Hofstadter R., 1964, PARANOID STYLE AM PO
   Howard RG, 2006, J MEDIA RELIG, V5, P25, DOI 10.1207/s15328415jmr0501_2
   Hulme M, 2009, WHY WE DISAGREE ABOUT CLIMATE CHANGE: UNDERSTANDING CONTROVERSY, INACTION AND OPPORTUNITY, P1
   Humphreys M, 2002, AM LIT HIST, V14, P845, DOI 10.1093/alh/14.4.845
   Jones A., 2020, INFOWARS        0328
   Jordans F., 2020, ASS PRESS
   Kallsch M., 2020, SPIEGEL
   Keeley BL, 2007, EPISTEME-J INDIV SOC, V4, P135, DOI 10.3366/epi.2007.4.2.135
   Keller C., 1999, ECOTHEOLOGY, V7, DOI 10.1558/ecotheology.v4i1.1785
   Klein N., 2007, SHOCK DOCTRINE RISE
   Klein N., 2020, GUARDIAN
   Klein Naomi, 2020, THE INTERCEPT
   Klett L. M., 2020, THE CHRISTIAN POST
   Knowles S, 2013, J MEDIA RELIG, V12, P128, DOI 10.1080/15348423.2013.820527
   Kovel Joel, 2007, CAPITALISM NATURE SO, V18, P1
   Kurlander E., 2017, HITLERS MONSTERS SUP
   Landis R., 2011, HEAVEN EARTH VARIETI
   Lee M., 1995, EARTH 1 ENV APOCALYP
   Livingstone David N., 2003, PUTTING SCI ITS PLAC
   Long TL, 2012, LIT-LIT INTERPRET TH, V23, P226, DOI 10.1080/10436928.2012.703596
   Lovelock J., 2001, GAIA PRACTICAL MED P
   Manderson L, 2020, MED ANTHROPOL, V39, P367, DOI 10.1080/01459740.2020.1746301
   Mantyla, 2020, RICK WILES CORONAVIR
   Martin B., 2020, TEXAS MONTHLY
   Megoran N, 2013, AREA, V45, P141, DOI 10.1111/j.1475-4762.2012.01125.x
   Muirhead Russell, 2019, LOT PEOPLE ARE SAYIN, DOI DOI 10.1515/9780691190068
   Noor P., 2020, 3 AM BELIEVE COVID 1
   O'Donnell SJ, 2021, ETHNIC RACIAL STUD, V44, P39, DOI 10.1080/01419870.2019.1704042
   O'Leary S. D., 1998, ARGUING APOCALYPSE T
   OCEANS, 2020, CONSP BEL RED FOLL
   Palmer Susan, 1997, AIDS APOCALYPTIC MET
   Parveen N, 2020, GUARDIAN
   Pew, 2010, JES CHRISTS RET EART
   Pew Research Center, 2015, US PUBL BEC LESS REL
   Rathje J., 2018, VIRALITY MORPHOGENES
   Reese G., 2020, INFOWARS        0420
   Reese G., 2020, INFOWARS        0130
   Robertson DG, 2016, BLOOM ADV REL STUD, P1
   Robertson DG, 2015, NOVA RELIG, V19, P5, DOI 10.1525/nr.2015.19.2.5
   Robins R. S., 1997, POLITICAL PARANOIA
   Rodlach A., 2016, WITCHES WESTERNERS H
   Rosenberg J., 2020, CORONAVIRUS PANDEMIC
   Roy A, 2020, FINANCIAL TIMES
   Sams K, 2020, ANTHROPOL MED, V27, P1, DOI 10.1080/13648470.2019.1615749
   Snapes L., 2020, GUARDIAN
   Stetzer E., 2020, CHRISTIANITY TODAY
   Stetzer E., 2017, CHRISTIANITY TODAY
   Stewart K, 1999, ANNU REV ANTHROPOL, V28, P285, DOI 10.1146/annurev.anthro.28.1.285
   Sturm T., 2010, MAPPING END TIMES AM
   Sturm T., 2012, RELEGERE STUDIES REL, V2, P333, DOI DOI 10.11157/RSRR2-2-511
   Sturm T, 2018, NATL IDENTITIES, V20, P299, DOI 10.1080/14608944.2016.1255187
   Ungurean G., 2020, RAPTURE READY   0402
   Ungurean G., 2016, RAPTURE READY   0830
   Uscinski J. E., 2020, CONSPIRACY THEORIES
   Uscinski JE, 2016, POLIT RES QUART, V69, P57, DOI 10.1177/1065912915621621
   Van Overstraeten B., 2020, REUTERS
   van Prooijen JW, 2017, MEM STUD, V10, P323, DOI 10.1177/1750698017701615
   Vaswani K., 2020, BBC
   Wagner-Egger P, 2018, CURR BIOL, V28, pR867, DOI 10.1016/j.cub.2018.06.072
   Ward C, 2011, J CONTEMP RELIG, V26, P103, DOI 10.1080/13537903.2011.539846
   Werly J. M., 1977, AM STUD, V18
   Wilson AF, 2017, PATTERNS PREJUDICE, V51, P412, DOI 10.1080/0031322X.2017.1398963
   Zauzmer J., 2020, WASHINGTON POST
   Ziek S., 2020, PANDEMIC COVID 19 SH
   Ziek S., 2009, 1 TRAGEDY THEN FARCE
NR 91
TC 0
Z9 0
U1 2
U2 2
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1364-8470
EI 1469-2910
J9 ANTHROPOL MED
JI Anthropol. Med.
DI 10.1080/13648470.2020.1833684
EA NOV 2020
PG 18
WC Anthropology; Public, Environmental & Occupational Health; Social
   Sciences, Biomedical
SC Anthropology; Public, Environmental & Occupational Health; Biomedical
   Social Sciences
GA OV2FT
UT WOS:000592033100001
PM 33233926
OA Bronze
DA 2021-01-01
ER

PT J
AU Galarza-Delgado, DA
   Serna-Pena, G
   Compean-Villegas, JE
   Cardenas-de la Garza, JA
   Pineda-Sic, RA
   Colunga-Pedraza, IJ
   Vega-Morales, D
   Perez-Barbosa, L
   Skinner-Taylor, CM
   Flores-Alvarado, DE
AF Galarza-Delgado, Dionicio Angel
   Serna-Pena, Griselda
   Compean-Villegas, Jesus Eduardo
   Cardenas-de la Garza, Jesus Alberto
   Pineda-Sic, Rita Angelica
   Colunga-Pedraza, Iris Jazmin
   Vega-Morales, David
   Perez-Barbosa, Lorena
   Skinner-Taylor, Cassandra Michelle
   Flores-Alvarado, Diana Elsa
TI Characteristics and evolution of 38 patients with rheumatic diseases and
   COVID-19 under DMARD therapy
SO CLINICAL RHEUMATOLOGY
LA English
DT Letter; Early Access
C1 [Galarza-Delgado, Dionicio Angel; Serna-Pena, Griselda; Compean-Villegas, Jesus Eduardo; Cardenas-de la Garza, Jesus Alberto; Pineda-Sic, Rita Angelica; Colunga-Pedraza, Iris Jazmin; Vega-Morales, David; Perez-Barbosa, Lorena; Skinner-Taylor, Cassandra Michelle; Flores-Alvarado, Diana Elsa] Univ Autonoma Nuevo Leon, Univ Hosp, Hosp Univ, Serv Reumatol, Av Gonzalitos 235 Nte Col Mitras Ctr, Monterrey 64460, NL, Mexico.
RP Galarza-Delgado, DA (corresponding author), Univ Autonoma Nuevo Leon, Univ Hosp, Hosp Univ, Serv Reumatol, Av Gonzalitos 235 Nte Col Mitras Ctr, Monterrey 64460, NL, Mexico.
EM dgalarza@medicinauanl.mx
CR Duret PM, 2020, RHEUMATIC DISEASES C, DOI 10.1136/annrheumdis-2020-218147
   Galluccio F, 2020, CLIN RHEUMATOL, V39, P2077, DOI 10.1007/s10067-020-05179-0
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Ladani AP, 2020, CLIN RHEUMATOL, V39, P3245, DOI 10.1007/s10067-020-05387-8
   Messina F, 2020, J EUR ACAD DERMATOL, V34, pE254, DOI 10.1111/jdv.16468
   Messina Francesco, 2020, Ann Rheum Dis, DOI 10.1136/annrheumdis-2020-218029
   Popov GT, 2020, VECTOR-BORNE ZOONOT, V20, P910, DOI 10.1089/vbz.2020.2679
   Schulze-Koops H, 2020, INCREASED RISK SEVER, DOI 10.1136/annrheumdis-2020-218075
NR 8
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
DI 10.1007/s10067-020-05510-9
EA NOV 2020
PG 3
WC Rheumatology
SC Rheumatology
GA OV3UU
UT WOS:000592140100003
PM 33231774
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rachamim, L
   Zimmerman-Brenner, S
   Rachamim, O
   Mualem, H
   Zingboim, N
   Rotstein, M
AF Rachamim, Lilach
   Zimmerman-Brenner, Sharon
   Rachamim, Osnat
   Mualem, Hila
   Zingboim, Netanel
   Rotstein, Michael
TI Internet-based guided self-help comprehensive behavioral intervention
   for tics (ICBIT) for youth with tic disorders: a feasibility and
   effectiveness study with 6 month-follow-up
SO EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
LA English
DT Article; Early Access
DE Child tic disorders; Comprehensive behavioral intervention for tics;
   Internet-based CBIT; Guided self-help; COVID-19 pandemic
ID GLOBAL ASSESSMENT SCALE; TOURETTE SYNDROME; PILOT TRIAL; THERAPY;
   SEVERITY; CHILDREN; PREVALENCE; PARENT
AB Practice guidelines endorse comprehensive behavioral intervention for tics (CBIT) as first-line treatment for tic disorders (TD) in youth. Nevertheless, CBIT is rarely available due to various barriers. This study evaluated the feasibility and potential effectiveness of an Internet-based, self-help CBIT program (ICBIT) guided by parents with minimal therapist support delivered via telepsychotherapy. Forty-one youths, aged 7-18 years, were randomly assigned to receive either ICBIT (n = 25) or a wait-list (WL) condition (n = 16) in a crossover design. ICBIT was feasible to implement and at post-treatment, 64% of the participants have improved significantly. Results demonstrated clinically meaningful reductions in tic severity and improved youth global impairment and functioning. Gains were maintained over a 6-month follow-up period. The effect size for the primary outcome measure (Yale Global Tic Severity Scale) ranged between large effect size (Cohen"s d = 0.91) at post-intervention to very large effect size (Cohen's d = 2.25) 6 months after the end of the acute intervention. These were comparable to face-to-face delivery treatment trials for TD. Participants rated the intervention as highly acceptable and satisfactory. Youth receiving ICBIT experienced improvement in self-esteem and comorbidity. Finally, during the COVID-19 pandemic, the ICBIT program enabled the delivery of the intervention consecutively without interruption. The results observed provide preliminary evidence of the feasibility and effectiveness of this innovative modality to assist youth with TD and remove various barriers to treatment, including those during a public crisis, such as the COVID-19 pandemic. Larger studies with an active control group are warranted. Trial registration URL: http://clinicaltrials.gov, ClinicalTrials.gov Identifier: NCT04087616.
C1 [Rachamim, Lilach; Zimmerman-Brenner, Sharon; Mualem, Hila; Zingboim, Netanel] Interdisciplinary Ctr Herzliya, Sch Psychol, Herzliyya, Israel.
   [Rachamim, Lilach; Mualem, Hila] Assoc Children Risk, Donald J Cohen & Irving B Harris Resilience Ctr, Tel Aviv, Israel.
   [Zimmerman-Brenner, Sharon] Tourette Syndrome Assoc Israel TSAI, Raanana, Israel.
   [Rachamim, Osnat; Rotstein, Michael] Tel Aviv Sourasky Med Ctr, Pediat Movement Disorders Clin, Pediat Neurol Unit, Dana Dwek Childrens Hosp, Tel Aviv, Israel.
RP Rachamim, L (corresponding author), Interdisciplinary Ctr Herzliya, Sch Psychol, Herzliyya, Israel.; Rachamim, L (corresponding author), Assoc Children Risk, Donald J Cohen & Irving B Harris Resilience Ctr, Tel Aviv, Israel.
EM rlilach@idc.ac.il; zbsharon@idc.ac.il; osirach27@gmail.com;
   hilm140@gmail.com; zingboim.net@gmail.com; michaelr@tlvmc.gov.il
CR Altman G, 2009, J NERV MENT DIS, V197, P305, DOI 10.1097/NMD.0b013e3181a206b1
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
   Andren P, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024685
   Bennett SM, 2020, BEHAV THER, V51, P659, DOI 10.1016/j.beth.2019.10.004
   Birmaher B, 1997, J AM ACAD CHILD PSY, V36, P545, DOI 10.1097/00004583-199704000-00018
   Cavanna AE, 2013, BEHAV NEUROL, V27, P83, DOI [10.3233/BEN-120296, 10.1155/2013/732038]
   Chamberlain LR, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/19600
   Chang S, 2009, CHILD FAM BEHAV THER, V31, P181, DOI 10.1080/07317100903099100
   Foa EB, 2010, BEHAV THER, V41, P121, DOI 10.1016/j.beth.2009.02.001
   Ganos C, 2015, MOVEMENT DISORD, V30, P1198, DOI 10.1002/mds.26228
   Goldman KJ, 2020, BEHAV MODIF, V44, P296, DOI 10.1177/0145445518809046
   GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127
   GREEN B, 1994, J AM ACAD CHILD PSY, V33, P1158, DOI 10.1097/00004583-199410000-00011
   Guy W, 1976, CLIN GLOBAL IMPRESSI, P218, DOI DOI 10.1037/E591322011-001
   Heijerman-Holtgrefe AP, 2020, EUR CHILD ADOLES PSY, DOI 10.1007/s00787-020-01532-5
   Himle MB, 2012, BEHAV RES THER, V50, P565, DOI 10.1016/j.brat.2012.05.009
   Hollis C, 2016, HEALTH TECHNOL ASSES, V20, pI, DOI 10.3310/hta20040
   Jeon S, 2013, CONTEMP CLIN TRIALS, V36, P414, DOI 10.1016/j.cct.2013.08.012
   KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995
   Kurlan R, 2001, NEUROLOGY, V57, P1383, DOI 10.1212/WNL.57.8.1383
   LECKMAN JF, 1989, J AM ACAD CHILD PSY, V28, P566, DOI 10.1097/00004583-198907000-00015
   Lewin AB, 2012, COMPR PSYCHIAT, V53, P525, DOI 10.1016/j.comppsych.2011.07.004
   Liebowitz M R, 1987, Mod Probl Pharmacopsychiatry, V22, P141
   McCairn KW, 2016, NEURON, V89, P300, DOI 10.1016/j.neuron.2015.12.025
   McGuire JF, 2014, J PSYCHIATR RES, V50, P106, DOI 10.1016/j.jpsychires.2013.12.009
   Piacentini J, 2010, JAMA-J AM MED ASSOC, V303, P1929, DOI 10.1001/jama.2010.607
   Radomski AD, 2019, J MED INTERNET RES, V21, DOI 10.2196/11128
   Ricketts EJ, 2016, J TELEMED TELECARE, V22, P153, DOI 10.1177/1357633X15593192
   Rosenberg M, 1965, SOC ADOLESCENT SELF, DOI [10.1515/9781400876136, DOI 10.1515/9781400876136]
   Scharf JM, 2015, MOVEMENT DISORD, V30, P221, DOI 10.1002/mds.26089
   SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228
   SILVERMAN WK, 1988, J AM ACAD CHILD PSY, V27, P772, DOI 10.1097/00004583-198811000-00019
   Specht MW, 2011, J DEV PHYS DISABIL, V23, P15, DOI 10.1007/s10882-010-9223-z
   Weingarden H, 2018, COMPR PSYCHIAT, V84, P95, DOI 10.1016/j.comppsych.2018.04.008
   Woods DW, 2011, J CHILD NEUROL, V26, P858, DOI 10.1177/0883073810397046
   Woods DW, 2010, PROF PSYCHOL-RES PR, V41, P518, DOI 10.1037/a0021709
   Woods DW, 2008, MANAGING TOURETTE SY, DOI [10.1093/med:psych/9780195341294.001.0001, DOI 10.1093/MED:PSYCH/9780195341294.001.0001]
NR 37
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1018-8827
EI 1435-165X
J9 EUR CHILD ADOLES PSY
JI Eur. Child Adolesc. Psych.
DI 10.1007/s00787-020-01686-2
EA NOV 2020
PG 13
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA OV4AX
UT WOS:000592156000002
PM 33231786
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Renzi, A
   Verrusio, W
   Evangelista, A
   Messina, M
   Gaj, F
   Cacciafesta, M
AF Renzi, Alessia
   Verrusio, Walter
   Evangelista, Alessia
   Messina, Maurizio
   Gaj, Fabio
   Cacciafesta, Mauro
TI Using drawings to express and represent one's emotional experience
   during the coronavirus disease 2019 pandemic: a case report of a woman
   living in a nursing home
SO PSYCHOGERIATRICS
LA English
DT Article; Early Access
DE art therapy; COVID&#8208; 19; mood disorders
ID TERM MOOD REPAIR
C1 [Renzi, Alessia] Sapienza Univ Rome, Polyclin Umberto 1, Dept Dynam & Clin Psychol, Rome, Italy.
   [Verrusio, Walter; Cacciafesta, Mauro] Sapienza Univ Rome, Polyclin Umberto 1, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Rome, Italy.
   [Gaj, Fabio] Sapienza Univ Rome, Polyclin Umberto 1, Dept Gen Surg Surg Special & Organ Transplantat P, Rome, Italy.
   [Renzi, Alessia; Verrusio, Walter; Evangelista, Alessia; Messina, Maurizio] Jewish Nursing Home Rome, Rome, Italy.
RP Renzi, A (corresponding author), Sapienza Univ Rome, Dept Dynam & Clin Psychol, Via Apuli 1, I-00185 Rome, Italy.
EM alessia.renzi@uniroma1.it
OI RENZI, ALESSIA/0000-0002-8553-4444
CR Dalebroux A, 2008, MOTIV EMOTION, V32, P288, DOI 10.1007/s11031-008-9105-1
   Drake JE, 2011, ART THER, V28, P26, DOI 10.1080/07421656.2011.557032
   Istituto Superiore di Sanita, CHAR SARS COV 2 PAT
   Morley JE, 2020, J NUTR HEALTH AGING, V24, P364, DOI 10.1007/s12603-020-1349-9
   Teo AR, 2015, J AM GERIATR SOC, V63, P2014, DOI 10.1111/jgs.13667
NR 5
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1346-3500
EI 1479-8301
J9 PSYCHOGERIATRICS
JI Psychogeriatrics
DI 10.1111/psyg.12638
EA NOV 2020
PG 3
WC Geriatrics & Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA OU8OM
UT WOS:000591782400001
PM 33233022
OA Bronze
DA 2021-01-01
ER

PT J
AU Balconi, SN
   Lopes, NT
   Luzzatto, L
   Bonamigo, RR
AF Balconi, Sindy N.
   Lopes, Natane T.
   Luzzatto, Laura
   Bonamigo, Renan R.
TI Detection of SARS-CoV-2 in a case of DRESS by sulfasalazine: could there
   be a relationship with clinical importance?
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Letter; Early Access
ID SYSTEMIC SYMPTOMS DRESS; DRUG REACTION; EOSINOPHILIA
C1 [Balconi, Sindy N.; Luzzatto, Laura; Bonamigo, Renan R.] UFCSPA, Dermatol Serv Santa Casa de Misericordia Porto Al, Porto Alegre, RS, Brazil.
   [Lopes, Natane T.; Bonamigo, Renan R.] Dermatol Serv Ambulatorio Dermatol Sanitaria ADS, Porto Alegre, RS, Brazil.
   [Bonamigo, Renan R.] Univ Fed Rio Grande Sul UFRGS, Med Sch, Porto Alegre, RS, Brazil.
RP Balconi, SN (corresponding author), UFCSPA, Dermatol Serv Santa Casa de Misericordia Porto Al, Porto Alegre, RS, Brazil.
EM sindybalconi@gmail.com
CR Cho YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061243
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Marzano AV, 2020, BRIT J DERMATOL, V183, P431, DOI 10.1111/bjd.19264
   Roujeau JC, 2017, J ALLER CL IMM-PRACT, V5, P811, DOI 10.1016/j.jaip.2016.11.027
   Watanabe H, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5163129
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
DI 10.1111/ijd.15316
EA NOV 2020
PG 2
WC Dermatology
SC Dermatology
GA OU7NE
UT WOS:000591711100001
PM 33231286
OA Bronze
DA 2021-01-01
ER

PT J
AU Devasenapathy, N
   Ye, ZK
   Loeb, M
   Fang, F
   Najafabadi, BT
   Xiao, YQ
   Couban, R
   Begin, P
   Guyatt, G
AF Devasenapathy, Niveditha
   Ye, Zhikang
   Loeb, Mark
   Fang, Fang
   Najafabadi, Borna Tadayon
   Xiao, Yingqi
   Couban, Rachel
   Begin, Philippe
   Guyatt, Gordon
TI Efficacy and safety of convalescent plasma in severe form of COVID-19,
   extrapolated from data relating to other severe forms of viral
   respiratory infections: systematic review and meta-analysis
SO CANADIAN MEDICAL ASSOCIATION JOURNAL
LA French
DT Article
ID EBOLA-VIRUS DISEASE; FINDINGS TABLES; INFLUENZA; THERAPY; SARS
AB CONTEXTE: On ne connait pas encore avec certitude l'innocuite et l'efficacite du plasma de convalescent comme traitement de la forme grave de la maladie a coronavirus 2019 (COVID-2019). Afin d'appuyer la conception de lignes directrices sur la prise en charge de la COVID-19, nous avons effectue une revue systematique et une meta-analyse sur l'utilisation du plasma de convalescent pour le traitement de cette maladie et d'autres formes graves d'infections respiratoires virales.
   METHODES: En mars 2020, nous avons effectue des recherches dans des bases de donnees biomedicales internationales et chinoises, des registres d'essais cliniques et des sources prepubliees afin de recenser des essais randomises et controles (ERC) et des etudes non randomisees comparant les issues de patients ayant recu du plasma de convalescent a celles de patients n'en ayant pas recu. Ont ete inclus les patients ayant une infection aigue attribuable a un coronavirus, au virus de l'influenza ou au virus Ebola. Nous avons egalement realise une meta-analyse a l'aide d'un modele a effets aleatoires et evalue la qualite des donnees probantes au moyen de l'approche GRADE (Grading of Recommendations Assessment, Development, and Evaluation).
   RESULTATS: Sur les 1099 etudes uniques initialement reperees, 6 etaient admissibles, et aucune d'entre elles ne portait sur des patients atteints de la COVID-19. Une etude non randomisee (n = 40) sur l'administration de plasma de convalescent a des patients atteints du coronavirus du syndrome respiratoire aigu severe (SRAS-CoV) a fourni des donnees peu concluantes sur le taux de mortalite (risque relatif [RR] 0,10; intervalle de confiance [IC] de 95 % 0,01 a 1,70). Des estimations regroupees provenant de 4 ERC sur l'influenza (n = 572) n'ont pas montre d'effet manifeste sur le taux de mortalite (4 ERC; RR 0,94; IC de 95 % 0,49 a 1,81), le retablissement complet (2 ERC; rapports de cotes [RC] 1,04; IC de 95 % 0,69 a 1,64) et la duree d'hospitalisation (3 ERC; difference moyenne [DM] -1,62; IC de 95 % -3,82 a 0,58 jours). La qualite des donnees etait tres faible pour tous les parametres relatifs a l'efficacite. Dans les ERC sur l'influenza, aucun ou peu d'evenements indesirables graves ont ete associes au plasma de convalescent (RR 0,85; IC de 95 % 0,56 a 1,29; donnees de faible qualite).
   INTERPRETATION: Les etudes portant sur des formes graves d'infections respiratoires virales autres que la COVID-19 ont fourni des donnees indirectes de tres faible qualite semblant indiquer que le plasma de convalescent n'offre aucun benefice ou offre des benefices minimes pour le traitement de la COVID-19, de meme que des donnees de faible qualite montrant qu'il n'entraine pas d'evenements indesirables graves.
C1 [Devasenapathy, Niveditha] Fdn Sante Publ Inde, Inst Indiens Sante Publ Delhi, Gurgaon, Haryana, India.
   [Ye, Zhikang; Loeb, Mark; Fang, Fang; Najafabadi, Borna Tadayon; Xiao, Yingqi; Couban, Rachel; Guyatt, Gordon] Univ McMaster, Dept Methodes Donnees & Incidence Rech Sante, Hamilton, ON, Canada.
   [Fang, Fang] Univ Med Chinoise Guangzhou, Guangzhou, Guangdong, Peoples R China.
   [Xiao, Yingqi] Univ Sichuan, Ecole Soins Infirm Chine Occident, Chengdu, Sichuan, Peoples R China.
   [Xiao, Yingqi] Univ Sichuan, Hop Chine Occident, Chengdu, Sichuan, Peoples R China.
   [Begin, Philippe] Univ Montreal, Dept Med, Montreal, PQ, Canada.
RP Devasenapathy, N (corresponding author), Fdn Sante Publ Inde, Inst Indiens Sante Publ Delhi, Gurgaon, Haryana, India.
EM niveditha@iiphd.org
FU  [201906240082]
FX Les auteurs remercient Quazi Ibrahim pour ses conseils statistiques.
   Yingqi Xiao a recu une bourse du China Scholarship Council (no
   201906240082).
CR [Anonymous], 2020, COVID 19 SARS COV 2
   [Anonymous], 2020, REC INV COVID 19 CON
   Beigel JH, 2019, LANCET RESP MED, V7, P941, DOI 10.1016/S2213-2600(19)30199-7
   Beigel JH, 2017, LANCET RESP MED, V5, P500, DOI 10.1016/S2213-2600(17)30174-1
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Davey RT, 2019, LANCET RESP MED, V7, P951, DOI 10.1016/S2213-2600(19)30253-X
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guyatt G, 2016, GROWTH EVIDENCE
   Guyatt GH, METHODS COMMENTARY R
   Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012
   Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P173, DOI 10.1016/j.jclinepi.2012.08.001
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA, P187, DOI DOI 10.1002/9780470712184
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Kanjilal S, 2019, LANCET RESP MED, V7, P922, DOI 10.1016/S2213-2600(19)30265-6
   Lee JS, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3980-9
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Markowitz N, 2016, J INFECT DIS, V213, P574, DOI 10.1093/infdis/jiv453
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Schoofs T, 2016, SCIENCE, V352, P997, DOI 10.1126/science.aaf0972
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   WHO, 2014, US CONV WHOL BLOOD P
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, EFFICACY CONVALESCEN, DOI [10.1101/2020.02.20.20025593, DOI 10.1101/2020.02.20.20025593]
   Ye ZK, 2020, CAN MED ASSOC J, V192, pE536, DOI 10.1503/cmaj.200648
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou Xian-zhi, 2003, Zhonghua Yi Xue Za Zhi, V83, P1018
NR 40
TC 0
Z9 0
U1 1
U2 1
PU CMA-CANADIAN MEDICAL ASSOC
PI OTTAWA
PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA
SN 0820-3946
EI 1488-2329
J9 CAN MED ASSOC J
JI Can. Med. Assoc. J.
PD NOV 23
PY 2020
VL 192
IS 47
BP E1559
EP E1570
DI 10.1503/cmaj.200642-f
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA PD8RD
UT WOS:000597944300009
PM 33229354
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ye, ZK
   Wang, Y
   Colunga-Lozano, LE
   Prasad, M
   Tangamornsuksan, W
   Rochwerg, B
   Yao, L
   Motaghi, S
   Couban, RJ
   Ghadimi, M
   Bala, MM
   Gomaa, H
   Fang, F
   Xiao, YQ
   Guyatt, GH
AF Ye, Zhikang
   Wang, Ying
   Enrique Colunga-Lozano, Luis
   Prasad, Manya
   Tangamornsuksan, Wimonchat
   Rochwerg, Bram
   Yao, Liang
   Motaghi, Shahrzad
   Couban, Rachel J.
   Ghadimi, Maryam
   Bala, Malgorzata M.
   Gomaa, Huda
   Fang, Fang
   Xiao, Yingqi
   Guyatt, Gordon H.
TI Efficacy and Safety of Corticosteroids in the Treatment of COVID-19
   based on data for COVID-19, other Coronavirus Infections, Influenza,
   Out-of-Hospital Pneumonia and Acute Respiratory Distress Syndrome: A
   Systematic Review and Meta-analysis
SO CANADIAN MEDICAL ASSOCIATION JOURNAL
LA French
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; A H1N1; NEURAMINIDASE INHIBITORS;
   RISK-FACTORS; THERAPY; QUALITY; GRADE; HYDROCORTISONE; GLUCOCORTICOIDS;
   DEXAMETHASONE
AB CONTEXTE: Il existe tres peu de donnees directes sur l'administration de corticosteroides aux patients atteints de la maladie a coronavirus 2019 (COVID-19). Les donnees indirectes sur des maladies associees devront donc guider les conclusions quant aux benefices et aux prejudices associes a cette pratique. Dans le but d'appuyer la redaction d'une ligne directrice sur la prise en charge de la COVID-19, nous avons realise des revues systematiques sur les effets des corticosteroides dans le traitement de la COVID-19 et de maladies respiratoires aigues severes associees.
   METHODES: Dans des bases de donnees biomedicales chinoises et internationales et des sources de prepublications, nous avons cherche les essais randomises et controles (ERC) et les etudes d'observation comparant des patients atteints de la COVID-19, du syndrome respiratoire aigu severe (SRAS) ou du syndrome respiratoire du Moyen-Orient (SRMO) ayant recu des corticosteroides a des patients semblables n'ayant pas recu ce type de medicaments. Pour le syndrome de detresse respiratoire aigue (SDRA), l'influenza et la pneumonie extrahospitaliere (PEH), nous avons mis a jour les revues systematiques rigoureuses les plus recentes. Nous avons realise des meta-analyses a effets aleatoires pour cerner les risques relatifs, puis nous avons utilise le risque de reference des patients atteints de la COVID-19 pour calculer les effets absolus.
   RESULTATS: Pour le SDRA, selon 1 petite etude de cohorte sur des patients atteints de la COVID-19 et 7 ERC sur des patients atteints d'une autre maladie (risque relatif : 0,72, intervalle de confiance [IC] de 95 % 0,55-0,93, difference entre les moyennes [DM] 17,3 % plus faible, donnees de faible qualite), les corticosteroides pourraient reduire le risque de mortalite. Chez les patients atteints d'une forme grave de COVID-19 sans SDRA, 2 etudes d'observation ont genere des donnees directes de tres faible qualite montrant une augmentation du risque de mortalite avec l'administration de corticosteroides (rapport de risques 2,30, IC de 95 % 1,00-5,29, DM 11,9 % plus eleve). C'est aussi le cas de donnees observationnelles sur l'influenza. Des donnees observationnelles de tres faible qualite sur le SRAS et le SRMO montrent peu ou pas de reduction dans le risque de mortalite. Des essais randomises et controles sur la PEH suggerent que les corticosteroides pourraient reduire le risque de mortalite (risque relatif 0,70, IC de 95 % 0,50-0,98, DM 3,1 % plus faible, donnees de tres faible qualite), et augmenter le risque d'hyperglycemie.
   INTERPRETATION: Les corticosteroides pourraient reduire le risque de mortalite pour les patients atteints de la COVID-19 avec SDRA. Pour les patients atteints d'une forme grave de COVID-19 sans SDRA, les donnees sur les benefices provenant de differentes sources sont incoherentes et de tres faible qualite.
C1 [Ye, Zhikang; Enrique Colunga-Lozano, Luis; Tangamornsuksan, Wimonchat; Rochwerg, Bram; Yao, Liang; Motaghi, Shahrzad; Fang, Fang; Xiao, Yingqi; Guyatt, Gordon H.] Univ McMaster, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Wang, Ying] Capital Med Univ, Dept Pharm, Hop Chaoyang Beijing, Beijing, Peoples R China.
   [Enrique Colunga-Lozano, Luis] Univ Guadalajara, Ctr Sci Sante, Dept Med Clin, Guadalajara, Jalisco, Mexico.
   [Prasad, Manya] North DMC Med Coll, Dept Med Communautaire, New Delhi, India.
   [Tangamornsuksan, Wimonchat] Chulabhorn Royal Acad, HRH Princess Chulabhorn Coll Med Sci, Fac Med & Sante Publ, Bangkok, Thailand.
   [Rochwerg, Bram] Univ McMaster, Dept Med, Hamilton, ON, Canada.
   [Couban, Rachel J.] Univ McMaster, DeGroote Inst Pain Res & Care, Hamilton, ON, Canada.
   [Ghadimi, Maryam] Univ Tehran Med Sci, Dept Pharm Clin, Tehran, Iran.
   [Bala, Malgorzata M.] Univ Jagellonne, Ecole Med, Chaire Epidemiol & Med Prevent, Krakow, Poland.
   [Gomaa, Huda] Alexandria Univ, High Inst Publ Hlth, Dept Biostat, Alexandria, Egypt.
   [Gomaa, Huda] Minist Sante & Populat, Ctr Informat Medicaments, Tanta Chest Hosp, Cairo, Egypt.
   [Fang, Fang] Guangzhou Univ Chinese Med, Clin Med Coll Acupuncture Moxibust & Rehabil, Guangzhou, Guangdong, Peoples R China.
   [Xiao, Yingqi] Sichuan Univ, West China Sch Nursing, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP Guyatt, GH (corresponding author), Univ McMaster, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
EM guyatt@mcmaster.ca
CR Al-Busaidi Mujahid, 2016, Oman Med J, V31, P290, DOI 10.5001/omj.2016.56
   Alfaraj SH, 2019, TRAVEL MED INFECT DI, V29, P48, DOI 10.1016/j.tmaid.2019.03.004
   Annane D, 2011, AM J RESP CRIT CARE, V183, P1125, DOI 10.1164/rccm.201102-0345ED
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Balaganesakumar SR, 2013, J POSTGRAD MED, V59, P9, DOI 10.4103/0022-3859.109481
   Blum CA, 2015, LANCET, V385, P1511, DOI 10.1016/S0140-6736(14)62447-8
   Boudreault AA, 2011, BIOL BLOOD MARROW TR, V17, P979, DOI 10.1016/j.bbmt.2010.09.014
   Brun-Buisson C, 2011, AM J RESP CRIT CARE, V183, P1200, DOI 10.1164/rccm.201101-0135OC
   Busse JW, TOOL ASSESS RISK BIA
   Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616
   Chawla R, 2013, INDIAN J CRIT CARE M, V17, P275, DOI 10.4103/0972-5229.120318
   Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC
   Delaney JW, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1230-8
   Delgado-Rodriguez M, 2012, J ANTIMICROB CHEMOTH, V67, P1739, DOI 10.1093/jac/dks098
   El-Ghamrawy AH, 2006, EGYPT J CHEST DIS TU, V55, P91
   Fernandez-Serrano S, 2011, CRIT CARE, V15, DOI 10.1186/cc10103
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guyatt GH, MODIFICATION COCHRAN
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Han K, 2011, CLIN INFECT DIS, V53, P326, DOI 10.1093/cid/cir398
   Huang J, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014636
   Huang SF, 2017, J MICROBIOL IMMUNOL, V50, P586, DOI 10.1016/j.jmii.2015.08.016
   Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695
   Jiang S, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016239
   Kim SH, 2011, AM J RESP CRIT CARE, V183, P1207, DOI 10.1164/rccm.201101-0110OC
   Kinikar AA, 2012, INDIAN J PEDIATR, V79, P459, DOI 10.1007/s12098-011-0578-7
   Kudo K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032280
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Lau EHY, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.07.018
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lee N, 2015, EUR RESPIR J, V45, P1642, DOI 10.1183/09031936.00169714
   Lewis SR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004477.pub3
   Li FR, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000827
   [李刚 Li Gang], 2016, [中华危重病急救医学, Chinese Critical Care Medicine], V28, P780
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Linko R, 2011, ACTA ANAESTH SCAND, V55, P971, DOI 10.1111/j.1399-6576.2011.02491.x
   Liu Ling, 2012, Zhonghua Nei Ke Za Zhi, V51, P599
   Long Y, 2016, INT J CLIN EXP MED, V9, P8865
   Lu X, 2020, ADJUVANT CORTICOSTER
   Mady A, 2012, J Infect Public Health, V5, P52, DOI 10.1016/j.jiph.2011.10.005
   MARIK P, 1993, CHEST, V104, P389, DOI 10.1378/chest.104.2.389
   MCHARDY VU, 1972, BRIT MED J, V4, P569, DOI 10.1136/bmj.4.5840.569
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Meijvis SCA, 2011, LANCET, V377, P2023, DOI 10.1016/S0140-6736(11)60607-7
   Mikami K, 2007, LUNG, V185, P249, DOI 10.1007/s00408-007-9020-3
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Moreno G, 2018, INTENS CARE MED, V44, P1470, DOI 10.1007/s00134-018-5332-4
   Nafae RM, 2013, EGYPT J CHEST DIS TU, V62, P439, DOI 10.1016/j.ejcdt.2013.03.009
   Nguyen TL, 2009, CLIN INFECT DIS, V48, P1639, DOI 10.1086/599031
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Ono S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3602-z
   Patel KK, 2013, J GLOB INFECT DIS, V5, P93, DOI 10.4103/0974-777X.116868
   Rezk NA, 2013, EGYPT J CHEST DIS TU, V62, P167, DOI 10.1016/j.ejcdt.2013.02.013
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sabry NA, 2011, PHARM PHARM, V2, P9, DOI [10.4236/pp.2011.22009, DOI 10.4236/PP.2011.22009]
   Sertogullarindan B, 2011, AFR HEALTH SCI, V11, P163
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Sheu CC, 2017, AM J RESP CRIT CARE, V195
   Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715
   Snijders D, 2010, AM J RESP CRIT CARE, V181, P975, DOI 10.1164/rccm.200905-0808OC
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   Stern A, 2017, COCHRANE DB SYST REV, P1, DOI 10.1002/14651858.CD007720.pub3
   Tongyoo S, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1511-2
   Torres A, 2015, JAMA-J AM MED ASSOC, V313, P677, DOI 10.1001/jama.2015.88
   Tsai MJ, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-0642-4
   Viasus D, 2011, J INFECTION, V62, P193, DOI 10.1016/j.jinf.2011.01.014
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   WAGNER HN, 1956, B JOHNS HOPKINS HOSP, V98, P197
   Wang D, 2020, NO CLEAR BENEFIT USE, DOI [10.1101/2020.04.21.20066258., DOI 10.1101/2020.04.21.20066258, 10.1101/2020.04.21.20066258]
   Whiting P, 2016, J CLIN EPIDEMIOL, V69, P225, DOI 10.1016/j.jclinepi.2015.06.005
   WHO, 2020, CLIN MAN SEV AC RESP
   Wirz SA, 2016, EUR RESPIR J, V48, P1150, DOI 10.1183/13993003.00474-2016
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu UI, 2012, J FORMOS MED ASSOC, V111, P364, DOI 10.1016/j.jfma.2011.04.005
   Wu WF, 2018, AM J EMERG MED, V36, P179, DOI 10.1016/j.ajem.2017.07.050
   Xi XM, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-256
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Yan D, 2020, FACTORS ASS PROLONGE, DOI [10.1101/2020.03.22.20040832, DOI 10.1101/2020.03.22.20040832]
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Ye ZK, 2020, CAN MED ASSOC J, V192, pE536, DOI 10.1503/cmaj.200648
   Yu HT, 2011, CHIN J TCM WM CRIT C, V18, P142
   Zhang Y, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0764-5
   [赵文飚 Zhao Wenbiao], 2014, [解放军医学杂志, Medical Journal of Chinese People's Liberation Army], V39, P741
   Zhou Y, 2020, SCI REP-UK, V10, DOI [10.1038/s41598-020-59732-7, 10.1038/s41598-020-58796-9]
NR 88
TC 0
Z9 0
U1 1
U2 1
PU CMA-CANADIAN MEDICAL ASSOC
PI OTTAWA
PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA
SN 0820-3946
EI 1488-2329
J9 CAN MED ASSOC J
JI Can. Med. Assoc. J.
PD NOV 23
PY 2020
VL 192
IS 47
BP E1571
EP E1584
DI 10.1503/cmaj.200645-f
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA PD8RD
UT WOS:000597944300010
PM 33229355
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ng, JY
AF Ng, Jeremy Y.
TI Global research trends at the intersection of coronavirus disease 2019
   (COVID-19) and traditional, integrative, and complementary and
   alternative medicine: a bibliometric analysis
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Bibliometric analysis; Complementary and alternative medicine;
   Coronavirus; COVID-19; Herbal; Integrative medicine; Research trends;
   Traditional Chinese medicine; Traditional medicine
AB BackgroundCoronavirus disease 2019 (COVID-19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2, and responsible for a global pandemic. Despite there being no known vaccines or medicines that prevent or cure COVID-19, many traditional, integrative, complementary and alternative medicines (TICAMs) have been touted as the solution, as well as researched as a potential remedy globally. This study presents a bibliometric analysis of global research trends at the intersection of TICAM and COVID-19.MethodsSCOPUS, MEDLINE, EMBASE, AMED and PSYCINFO databases were searched on July 5, 2020, with results being exported on the same day. All publication types were included, however, articles were only deemed eligible if they made mention of one or more TICAMs for the potential prevention, treatment, and/or management of COVID-19 or a health issue indirectly resulting from the COVID-19 pandemic. The following eligible article characteristics were extracted: title; author names, affiliations, and countries; DOI; publication language; publication type; publication year; journal (and whether it is TICAM-focused); 2019 impact factor, and TICAMs mentioned.ResultsA total of 296 eligible articles were published by 1373 unique authors at 977 affiliations across 56 countries. The most common countries associated with author affiliation included China, the United States, India and Italy. The vast majority of articles were published in English, followed by Chinese. Eligible articles were published across 157 journals, of which 33 were TICAM-focused; a total of 120 journals had a 2019 impact factor, which ranged from 0.17 to 60.392. A total of 327 TICAMs were mentioned across eligible articles, with the most common ones including: traditional Chinese medicine (n=94), vitamin D (n=67), melatonin (n=16), phytochemicals (n=12), and general herbal medicine (n=11).ConclusionsThis study provides researchers and clinicians with a greater knowledge of the characteristics of articles that been published globally at the intersection of COVID-19 and TICAM to date. At a time where safe and effective vaccines and medicines for the prevention and treatment of COVID-19 have yet to be discovered, this study provides a current snapshot of the quantity and characteristics of articles written at the intersection of TICAM therapies and COVID-19.
C1 [Ng, Jeremy Y.] McMaster Univ, Fac Hlth Sci, Michael G DeGroote Ctr Learning & Discovery, Dept Hlth Res Methods Evidence & Impact, Room 2112,1280 Main St West, Hamilton, ON L8S 4K1, Canada.
RP Ng, JY (corresponding author), McMaster Univ, Fac Hlth Sci, Michael G DeGroote Ctr Learning & Discovery, Dept Hlth Res Methods Evidence & Impact, Room 2112,1280 Main St West, Hamilton, ON L8S 4K1, Canada.
EM ngjy2@mcmaster.ca
OI Ng, Jeremy/0000-0003-0031-5873
CR Ammon U, 2011, DOMINANCE ENGLISH LA
   Chahrour M, 2020, CUREUS, V12, DOI 10.7759/cureus.7357
   Cyranoski David, 2020, Nature, DOI 10.1038/d41586-020-01284-x
   Fan JC, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00477
   Gong Yue, 2020, Innovation (N Y), V1, P100027, DOI 10.1016/j.xinn.2020.100027
   Hossain MM, 2020, CURRENT STATUS GLOBA
   Index N, 2018, WHATS WRONG J IMPACT
   Lariviere V, 2016, BIORXIV, V6, P62109, DOI [10.1101/062109, DOI 10.1101/062109]
   Liu M, 2020, JAMA INTERN MED, V180, P1116, DOI 10.1001/jamainternmed.2020.1764
   Martinez-Perez C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17207690
   Ng JY, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1111-3
   Radanliev P, 2020, EPMA J, V11, P311, DOI 10.1007/s13167-020-00218-x
   Sa'ed HZ, 2020, BMC INFECT DIS, V20, P1, DOI [10.1186/s12879-019-4717-5, DOI 10.1186/S12879-019-4717-5]
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   World Health Organization, 2020, Q COR COVID 19
   World Health Organization. Regional Office for Africa, 2020, WHO SUPP SCI PROV TR
   Yang F, 2020, ANAL GLOBAL SITUATIO
   Zyoud SH, 2020, ENVIRON DEV SUSTAIN, DOI 10.1007/s10668-020-01004-5
NR 18
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD NOV 23
PY 2020
VL 20
IS 1
AR 353
DI 10.1186/s12906-020-03151-8
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA PB5KN
UT WOS:000596359600001
PM 33225948
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chatterjee, P
   Ponnapati, M
   Kramme, C
   Plesa, AM
   Church, GM
   Jacobson, JM
AF Chatterjee, Pranam
   Ponnapati, Manvitha
   Kramme, Christian
   Plesa, Alexandru M.
   Church, George M.
   Jacobson, Joseph M.
TI Targeted intracellular degradation of SARS-CoV-2 via computationally
   optimized peptide fusions
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID PROTEIN; UBIQUITINATION; CORONAVIRUS; SPECIFICITY; CRISPR
AB The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has elicited a global health crisis of catastrophic proportions. With only a few vaccines approved for early or limited use, there is a critical need for effective antiviral strategies. In this study, we report a unique antiviral platform, through computational design of ACE2-derived peptides which both target the viral spike protein receptor binding domain (RBD) and recruit E3 ubiquitin ligases for subsequent intracellular degradation of SARS-CoV-2 in the proteasome. Our engineered peptide fusions demonstrate robust RBD degradation capabilities in human cells and are capable of inhibiting infection-competent viral production, thus prompting their further experimental characterization and therapeutic development. Pranam Chatterjee et al. present a novel computational platform for engineering peptide fusions that bind to the SARS-CoV-2 spike protein and tag it for proteasomal degradation. They experimentally validate an optimal variant in human cells, showing that it inhibits production of infection-competent virus.
C1 [Chatterjee, Pranam; Ponnapati, Manvitha; Jacobson, Joseph M.] MIT, Ctr Bits & Atoms, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Chatterjee, Pranam; Ponnapati, Manvitha; Jacobson, Joseph M.] MIT, Media Lab, Cambridge, MA 02139 USA.
   [Chatterjee, Pranam; Kramme, Christian; Plesa, Alexandru M.; Church, George M.] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA.
   [Chatterjee, Pranam; Kramme, Christian; Plesa, Alexandru M.; Church, George M.] Harvard Univ, Ctr Life Sci Bldg, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.
RP Chatterjee, P (corresponding author), MIT, Ctr Bits & Atoms, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Chatterjee, P (corresponding author), MIT, Media Lab, Cambridge, MA 02139 USA.; Chatterjee, P (corresponding author), Harvard Med Sch, Dept Genet, Boston, MA 02115 USA.; Chatterjee, P (corresponding author), Harvard Univ, Ctr Life Sci Bldg, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.
EM pranam@mit.edu
FU MIT Media Lab; MIT Center for Bits and Atoms
FX We thank Dr. Neil Gershenfeld and Dr. Shuguang Zhang for shared lab
   equipment, and Amide Technologies for peptide synthesis. We further
   thank Eyal Perry for computational assistance, and James Weis and
   Nest.Bio Labs for access to flow cytometry. This work was supported by
   the consortia of sponsors of the MIT Media Lab and the MIT Center for
   Bits and Atoms, and by Jeremy and Joyce Wertheimer.
CR Abbott TR, 2020, CELL, V181, P865, DOI 10.1016/j.cell.2020.04.020
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Ardley HC, 2005, ESSAYS BIOCHEM, V41, P15, DOI 10.1042/EB0410015
   Barlow KA, 2018, J PHYS CHEM B, V122, P5389, DOI 10.1021/acs.jpcb.7b11367
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cagliani R, 2020, J VIROL, V94, DOI 10.1128/JVI.00411-20
   Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Clarke NE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034747
   Clift D, 2017, CELL, V171, P1692, DOI 10.1016/j.cell.2017.10.033
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Foss S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02049
   GOSINK MM, 1995, P NATL ACAD SCI USA, V92, P9117, DOI 10.1073/pnas.92.20.9117
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Lino CA, 2018, DRUG DELIV, V25, P1234, DOI 10.1080/10717544.2018.1474964
   London N, 2011, NUCLEIC ACIDS RES, V39, pW249, DOI 10.1093/nar/gkr431
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Nagae M, 2012, J CELL BIOL, V197, P131, DOI 10.1083/jcb.201111077
   Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172
   Portnoff AD, 2014, J BIOL CHEM, V289, P7844, DOI 10.1074/jbc.M113.544825
   Procko Erik, 2020, bioRxiv, DOI 10.1101/2020.03.16.994236
   Rohl CA, 2004, METHOD ENZYMOL, V383, P66
   Rothschild J, 2020, J GEN FAM MED, V21, P37, DOI 10.1002/jgf2.321
   Sedan Y, 2016, NUCLEIC ACIDS RES, V44, pW536, DOI 10.1093/nar/gkw385
   Senanayake S. L, 2020, FUTURE DRUG DISCOV, V2
   Su YY, 2003, P NATL ACAD SCI USA, V100, P12729, DOI 10.1073/pnas.2133261100
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Trigueiro-Louro Joao, 2020, Comput Struct Biotechnol J, V18, P2117, DOI 10.1016/j.csbj.2020.07.017
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wysocki J, 2010, HYPERTENSION, V55, P90, DOI 10.1161/HYPERTENSIONAHA.109.138420
   Zhang G., 2020, BIORXIV, DOI [10.1101/2020.03.19.999318, DOI 10.1101/2020.03.19.999318]
   Zhou PB, 2000, MOL CELL, V6, P751, DOI 10.1016/S1097-2765(00)00074-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 37
TC 0
Z9 0
U1 2
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2399-3642
J9 COMMUN BIOL
JI Commun. Biol.
PD NOV 23
PY 2020
VL 3
IS 1
AR 715
DI 10.1038/s42003-020-01470-7
PG 8
WC Biology; Multidisciplinary Sciences
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA PA6BZ
UT WOS:000595719900001
PM 33230174
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nand, M
   Maiti, P
   Joshi, T
   Chandra, S
   Pande, V
   Kuniyal, JC
   Ramakrishnan, MA
AF Nand, Mahesha
   Maiti, Priyanka
   Joshi, Tushar
   Chandra, Subhash
   Pande, Veena
   Kuniyal, Jagdish Chandra
   Ramakrishnan, Muthannan Andavar
TI Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine
   learning modeling, chemoinformatics and molecular dynamics simulation
   based analysis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SARS; CORONAVIRUS; HIV; DRUGS
AB COVID-19 caused by the SARS-CoV-2 is a current global challenge and urgent discovery of potential drugs to combat this pandemic is a need of the hour. 3-chymotrypsin-like cysteine protease (3CLpro) enzyme is the vital molecular target against the SARS-CoV-2. Therefore, in the present study, 1528 anti-HIV1compounds were screened by sequence alignment between 3CLpro of SARS-CoV-2 and avian infectious bronchitis virus (avian coronavirus) followed by machine learning predictive model, drug-likeness screening and molecular docking, which resulted in 41 screened compounds. These 41 compounds were re-screened by deep learning model constructed considering the IC50 values of known inhibitors which resulted in 22 hit compounds. Further, screening was done by structural activity relationship mapping which resulted in two structural clefts. Thereafter, functional group analysis was also done, where cluster 2 showed the presence of several essential functional groups having pharmacological importance. In the final stage, Cluster 2 compounds were re-docked with four different PDB structures of 3CLpro, and their depth interaction profile was analyzed followed by molecular dynamics simulation at 100 ns. Conclusively, 2 out of 1528 compounds were screened as potential hits against 3CLpro which could be further treated as an excellent drug against SARS-CoV-2.
C1 [Nand, Mahesha] GB Pant Natl Inst Himalayan Environm, Environm Informat Syst Himalayan Ecol, Almora 263643, Uttarakhand, India.
   [Maiti, Priyanka; Kuniyal, Jagdish Chandra] GB Pant Natl Inst Himalayan Environm, Ctr Environm Assessment & Climate Change, Almora 263643, Uttarakhand, India.
   [Joshi, Tushar; Pande, Veena] Kumaun Univ, Dept Biotechnol, Bhimtal Campus, Bhimtal 263136, Uttarakhand, India.
   [Chandra, Subhash] Kumaun Univ, Dept Bot, SSJ Campus, Almora 263601, Uttarakhand, India.
   [Ramakrishnan, Muthannan Andavar] ICAR Indian Vet Res Inst, Bengaluru 560024, Karnataka, India.
RP Maiti, P (corresponding author), GB Pant Natl Inst Himalayan Environm, Ctr Environm Assessment & Climate Change, Almora 263643, Uttarakhand, India.; Chandra, S (corresponding author), Kumaun Univ, Dept Bot, SSJ Campus, Almora 263601, Uttarakhand, India.; Ramakrishnan, MA (corresponding author), ICAR Indian Vet Res Inst, Bengaluru 560024, Karnataka, India.
EM priyankamaiti.06@gmail.com; scjnu@yahoo.co.in; maramakrishnan@gmail.com
RI Joshi, Tushar/AAJ-9626-2020
CR AID, 2005, AID 179 NCI AIDS ANT
   Alshammari M, 2020, INT J ADV COMPUT SC, V11, P224
   ANI R, 2018, BIOMED PHARMACOL J, V11, P1513, DOI DOI 10.13005/bpj/1518
   [Anonymous], DRUG LIK TOOL DRULIT
   Bickerton GR, 2012, NAT CHEM, V4, P90, DOI [10.1038/nchem.1243, 10.1038/NCHEM.1243]
   Cao Y, 2008, BIOINFORMATICS, V24, P1733, DOI 10.1093/bioinformatics/btn307
   Cascella M, 2020, FEATURES EVALUATION
   D Properties user's manual, 2013, D PROP US MAN SOFTW
   de Sousa ACC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60221-0
   Egieyeh S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204644
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Goyal B, 2020, ACS COMB SCI, V22, P297, DOI 10.1021/acscombsci.0c00058
   Gutlein M, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-7
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Joshi T, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1802341
   Kadioglu O, 2020, B WORLD HEALTH ORGAN, DOI [10.2471/BLT.20.255943, DOI 10.2471/BLT.20.255943]
   Kiranmai SA, 2018, PROT CONTR MOD POW, V3, DOI 10.1186/s41601-018-0103-3
   Kumar V, 2020, SAR QSAR ENVIRON RES, V31, P511, DOI 10.1080/1062936X.2020.1776388
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu ZH, 2019, DATABASE-OXFORD, DOI 10.1093/database/baz104
   Nand M, 2016, INT J RECENT SCI RES, V7, P10370
   National center for biotechnology information, 2020, PUBCHEM DATABASE
   National center for biotechnology information, 2020, PUBCHEM DATABASE
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Olier I, 2018, MACH LEARN, V107, P285, DOI 10.1007/s10994-017-5685-x
   Patrick G. L, 1995, INTRO MED CHEM, P154
   Poltronieri P, 2015, CURR GENOMICS, V16, P327, DOI 10.2174/1389202916666150707160613
   Robert J., 2014, ORGANIC CHEM, P240, DOI [10.1016/C2013-0-14256-0, DOI 10.1016/C2013-0-14256-0]
   Sang P, 2020, RSC ADV, V10, P15775, DOI 10.1039/d0ra01899f
   Santarpia JL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69286-3
   Savarino A, 2005, J CLIN VIROL, V34, P170, DOI 10.1016/j.jcv.2005.03.005
   Shahbaaz M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40621-7
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wallace IM, 2006, NUCLEIC ACIDS RES, V34, P1692, DOI 10.1093/nar/gkl091
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Zhang XW, 2004, BIOORGAN MED CHEM, V12, P2517, DOI 10.1016/j.bmc.2004.03.035
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
NR 39
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 23
PY 2020
VL 10
IS 1
AR 20397
DI 10.1038/s41598-020-77524-x
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PA7YJ
UT WOS:000595845700006
PM 33230180
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chan, WS
   Au, CH
   Lam, HY
   Wang, CLN
   Ho, DNY
   Lam, YM
   Chu, DKW
   Poon, LLM
   Chan, TL
   Zee, JST
   Ma, ESK
   Tang, BSF
AF Chan, Wai Sing
   Au, Chun Hang
   Lam, Ho Yin
   Wang, Candy Ling Na
   Ho, Dona Ngar-Yin
   Lam, Yuk Man
   Chu, Daniel Ka Wing
   Poon, Leo Lit Man
   Chan, Tsun Leung
   Zee, Jonpaul Sze-Tsing
   Ma, Edmond Shiu Kwan
   Tang, Bone Siu Fai
TI Evaluation on the use of Nanopore sequencing for direct characterization
   of coronaviruses from respiratory specimens, and a study on emerging
   missense mutations in partial RdRP gene of SARS-CoV-2
SO VIROLOGY JOURNAL
LA English
DT Article
DE Coronavirus; COVID-19; Flongle; MinION; Missense mutation; Nanopore;
   RdRP; SARS-CoV-2
ID PNEUMONIA
AB Coronavirus disease 2019 (COVID-19) pandemic has been a catastrophic burden to global healthcare systems. The fast spread of the etiologic agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlights the need to identify unknown coronaviruses rapidly for prompt clinical and public health decision making. Moreover, owing to the high mutation rate of RNA viruses, periodic surveillance on emerging variants of key virus components is essential for evaluating the efficacy of antiviral drugs, diagnostic assays and vaccines. These 2 knowledge gaps formed the basis of this study. In the first place, we evaluated the feasibility of characterizing coronaviruses directly from respiratory specimens. We amplified partial RdRP gene, a stable genetic marker of coronaviruses, from a collection of 57 clinical specimens positive for SARS-CoV-2 or other human coronaviruses, and sequenced the amplicons with Nanopore Flongle and MinION, the fastest and the most scalable massively-parallel sequencing platforms to-date. Partial RdRP sequences were successfully amplified and sequenced from 82.46% (47/57) of specimens, ranging from 75 to 100% by virus type, with consensus accuracy of 100% compared with Sanger sequences available (n=40). In the second part, we further compared 19 SARS-CoV-2 RdRP sequences collected from the first to third waves of COVID-19 outbreak in Hong Kong with 22,173 genomes from GISAID EpiCoV (TM) database. No single nucleotide variants (SNVs) were found in our sequences, and 125 SNVs were observed from global data, with 56.8% being low-frequency (n=1-47) missense mutations affecting the rear part of RNA polymerase. Among the 9 SNVs found on 4 conserved domains, the frequency of 15438G>T was highest (n=34) and was predominantly found in Europe. Our data provided a glimpse into the sequence diversity of a primary antiviral drug and diagnostic target. Further studies are warranted to investigate the significance of these mutations.
C1 [Chan, Wai Sing; Au, Chun Hang; Lam, Ho Yin; Wang, Candy Ling Na; Ho, Dona Ngar-Yin; Lam, Yuk Man; Chan, Tsun Leung; Zee, Jonpaul Sze-Tsing; Ma, Edmond Shiu Kwan; Tang, Bone Siu Fai] Hong Kong Sanat & Hosp, Dept Pathol, Hong Kong, Peoples R China.
   [Chu, Daniel Ka Wing; Poon, Leo Lit Man] Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, Hong Kong, Peoples R China.
RP Tang, BSF (corresponding author), Hong Kong Sanat & Hosp, Dept Pathol, Hong Kong, Peoples R China.
EM bsftang@gmail.com
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chu DKW, 2011, J VIROL, V85, P12815, DOI 10.1128/JVI.05838-11
   Cock PJA, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0080-7
   Gradel C, 2019, GENES-BASEL, V10, DOI 10.3390/genes10090659
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266
   Lelli D, 2013, VIRUSES-BASEL, V5, P2679, DOI 10.3390/v5112679
   Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191
   Marchler-Bauer A, 2015, NUCLEIC ACIDS RES, V43, pD222, DOI 10.1093/nar/gku1221
   Mendenhall IH, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040356
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   The Government of the Hong Kong Special Administrative Region, COR DIS COVID 19 HK
   WHO, COR DIS COVID 19 PAN
   WHO, DET 2019 NOV COR 201
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 17
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD NOV 23
PY 2020
VL 17
IS 1
AR 183
DI 10.1186/s12985-020-01454-3
PG 13
WC Virology
SC Virology
GA PA7TS
UT WOS:000595833600001
PM 33225958
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Heijkoop, B
   Galiabovitch, E
   York, N
   Webb, D
AF Heijkoop, B.
   Galiabovitch, E.
   York, N.
   Webb, D.
TI Consensus of multiple national guidelines: agreed strategies for initial
   stone management during COVID-19
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article; Early Access
DE COVID-19; Coronavirus; Pandemic; Urolithiasis; Urology
AB Purpose To review the existing available information regarding urolithiasis management and the impact of COVID-19 on this, and propose recommendations for management of emergency urolithiasis presentations in the COVID-19 era.
   Methods Review of published guidelines produced by Urological Governing Bodies, followed by the literature review regarding urolithiasis management during the COVID-19 pandemic.
   Results Consistent recommendations across guidelines and literature were that urolithiasis with concurrent sepsis or renal failure remains a urological emergency warranting urgent intervention within the pandemic environment. Ureteric stenting and percutaneous nephrostomy are considered equivalent for decompression in this setting, with both ideally to be performed under local anaesthesia where possible to spare ventilators and reduce aerosol-generating procedures. Greater utilization of medical expulsive therapy and dissolution chemolysis may occur during the pandemic, and longer indwelling stent times may be accepted while definite stone clearance is deferred.
   Conclusions Urolithiasis will continue to be a source of emergency presentations requiring urgent intervention during the COVID-19 pandemic. However, it is possible to limit these interventions to decompression of the collecting system in the setting of concurrent obstruction or infection, performed under local anaesthesia to limit use of resources and minimise aerosol-generating procedures, with deferral of definitive management.
C1 [Heijkoop, B.; Galiabovitch, E.; Webb, D.] Univ Adelaide, Austin Hlth, Heidelberg, Vic, Australia.
   [York, N.] Auckland Reg Urol Serv, Auckland, New Zealand.
RP Heijkoop, B (corresponding author), Univ Adelaide, Austin Hlth, Heidelberg, Vic, Australia.
EM bridgetcheijkoop@gmail.com
CR [Anonymous], 2020, GUID CAS DEF LAP VIR
   [Anonymous], 2020, CHOOS WUS COVID 19 R
   [Anonymous], 2020, GUID UR UN CONF CAS
   [Anonymous], 2020, GUID UR PRIOR COVID
   [Anonymous], 2020, GUID PERS PROT EQ PP
   Assimos DG, 2016, SURG MANAGEMENT STON
   Canadian Urological Association, 2020, CUA COVID 19 ED RES
   Canadian Urological Association, 2020, UPD CAN END GROUP CE
   Carneiro A, 2020, INT BR J UROL, V9, P46
   Chan VWS, 2020, WORLD J UROL, DOI 10.1007/s00345-020-03246-4
   Dion M, 2016, CUA GUIDELINE EVALUA
   Ficarra V, 2020, MINERVA UROL NEFROL, V72, P369, DOI 10.23736/S0393-2249.20.03846-1
   Goldman HB, 2020, J UROLOGY, V204, P11, DOI 10.1097/JU.0000000000001067
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Ho HC, 2020, TURK J UROL, V46, P169, DOI 10.5152/tud.2020.20119
   Hughes Thomas, 2020, Curr Opin Urol, V30, P610, DOI 10.1097/MOU.0000000000000786
   Katz EG, 2020, J UROLOGY, V204, P9, DOI 10.1097/JU.0000000000001034
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Metzler IS, 2020, J ENDOUROL, V34, P539, DOI 10.1089/end.2020.29080.ism
   Novara G, 2020, BJU INT, V126, P245, DOI 10.1111/bju.15107
   Ozma Mahdi Asghari, 2020, Infez Med, V28, P153
   Pang KH, UROLOGY, DOI [10.1016/j.urology.2020.04.56, DOI 10.1016/J.UROLOGY.2020.04.56]
   Pearle MS, 2014, MED MANAGEMENT KIDNE
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Porreca A, 2020, UROL INT, V104, P631, DOI 10.1159/000508512
   Proietti S, 2020, EUR UROL, V78, P131, DOI 10.1016/j.eururo.2020.03.042
   Puliatti S, 2020, BJU INT, V125, pE7, DOI 10.1111/bju.15071
   RACS Clinical Expert COVID-19 Working Group, 2020, R AUST COLL SURG
   Simonato A, 2020, UROLOGICA NEFROLOGIC, DOI [10.1111/BJU.15061, DOI 10.1111/BJU.15061]
   Stensland KD, 2020, EUR UROL, V77, P663, DOI 10.1016/j.eururo.2020.03.027
   Sun J, 2020, EMERG MICROBES INFEC, V9, P991, DOI 10.1080/22221751.2020.1760144
   Tabah A, 2020, J CRIT CARE, V59, P70, DOI 10.1016/j.jcrc.2020.06.005
   Tenke P, 2006, INT J ANTIMICROB AG, V28, pS82, DOI 10.1016/j.ijantimicag.2006.05.016
   Tsiotras A, 2018, J CLIN UROL, V11, P58, DOI 10.1177/2051415817740492
   Turk C, 2017, EAU GUIDELINES UROLI
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
   Yang MP, 2020, BRIT J ANAESTH, V124, P666, DOI 10.1016/j.bja.2020.03.022
NR 37
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0724-4983
EI 1433-8726
J9 WORLD J UROL
JI World J. Urol.
DI 10.1007/s00345-020-03491-7
EA NOV 2020
PG 14
WC Urology & Nephrology
SC Urology & Nephrology
GA OV3HS
UT WOS:000592106100002
PM 33226444
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Finsterer, J
AF Finsterer, J.
TI Myotoxic drugs and immunodeficiency may contribute to the poor outcome
   of COVID-19 patients with myotonic dystrophy
SO ACTA NEUROLOGICA BELGICA
LA English
DT Letter; Early Access
DE Brain; MRI; SARS-CoV-2; COVID-19; Encephalitis
ID AZITHROMYCIN
C1 [Finsterer, J.] Messerli Inst, Klin Landstr, Postfach 20, A-1180 Vienna, Austria.
RP Finsterer, J (corresponding author), Messerli Inst, Klin Landstr, Postfach 20, A-1180 Vienna, Austria.
EM fifigs1@yahoo.de
OI finsterer, josef/0000-0003-2839-7305
CR Desnica B, 2007, SCAND J INFECT DIS, V39, P186, DOI 10.1080/00365540600810018
   Dhont S, 2020, ACTA NEUROL BELG, DOI 10.1007/s13760-020-01514-z
   Haberl A, 2005, Z RHEUMATOL, V64, P274, DOI 10.1007/s00393-005-0576-0
   Poggiali Erika, 2020, Acta Biomed, V91, pe2020024, DOI 10.23750/abm.v91i3.9979
   Strandell J, 2009, BRIT J CLIN PHARMACO, V68, P427, DOI 10.1111/j.1365-2125.2009.03473.x
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-9009
EI 2240-2993
J9 ACTA NEUROL BELG
JI Acta Neurol. Belg.
DI 10.1007/s13760-020-01551-8
EA NOV 2020
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OU5AW
UT WOS:000591542000001
PM 33225405
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gallo, A
   Tsika, AC
   Fourkiotis, NK
   Cantini, F
   Banci, L
   Sreeramulu, S
   Schwalbe, H
   Spyroulias, GA
AF Gallo, Angelo
   Tsika, Aikaterini C.
   Fourkiotis, Nikolaos K.
   Cantini, Francesca
   Banci, Lucia
   Sreeramulu, Sridhar
   Schwalbe, Harald
   Spyroulias, Georgios A.
TI H-1,C-13 and N-15 chemical shift assignments of the SUD domains of
   SARS-CoV-2 non-structural protein 3c: "the N-terminal domain-SUD-N"
SO BIOMOLECULAR NMR ASSIGNMENTS
LA English
DT Article; Early Access
DE SARS-CoV-2; Non-structural protein; SARS unique domain (SUD); Solution
   NMR-spectroscopy; Protein druggability; Covid19-NMR
ID SARS-UNIQUE DOMAIN; CORONAVIRUS; REPLICATION
AB Among the proteins encoded by the SARS-CoV-2 RNA, nsP3 (non-structural Protein3) is the largest multi-domain protein. Its role is multifaceted and important for the viral life cycle. Nonetheless, regarding the specific role of each domain there are many aspects of their function that have to be investigated. SARS Unique Domains (SUDs), constitute the nsP3c region of the nsP3, and were observed for the first time in SARS-CoV. Two of them, namely SUD-N (the first SUD) and the SUD-M (sequential to SUD-N), exhibit structural homology with nsP3b ("X" or macro domain); indeed all of them are folded in a three-layer alpha/beta/alpha sandwich. On the contrary, they do not exhibit functional similarities, like ADP-ribose binding properties and ADP-ribose hydrolase activity. There are reports that suggest that these two SUDs may exhibit a binding selectivity towards G-oligonucleotides, a feature which may contribute to the characterization of their role in the formation of the replication/transcription viral complex (RTC) and of the interaction of various viral "components" with the host cell. While the structures of these domains of SARS-CoV-2 have not been determined yet, SUDs interaction with oligonucleotides and/or RNA molecules may provide a platform for drug discovery. Here, we report the almost complete NMR backbone and side-chain resonance assignment (H-1,C-13,N-15) of SARS-CoV-2 SUD-N protein, and the NMR chemical shift-based prediction of the secondary structure elements. These data may be exploited for its 3D structure determination and the screening of chemical compounds libraries, which may alter SUD-N function.
C1 [Gallo, Angelo; Tsika, Aikaterini C.; Fourkiotis, Nikolaos K.; Spyroulias, Georgios A.] Univ Patras, Dept Pharm, GR-26504 Patras, Greece.
   [Sreeramulu, Sridhar; Schwalbe, Harald] Goethe Univ Frankfurt, Inst Organ Chem & Chem Biol, Max von Laue Str 7, D-60438 Frankfurt, Germany.
   [Cantini, Francesca; Banci, Lucia] Univ Florence, Magnet Resonance Ctr CERM, Via Luigi Sacconi 6, I-50019 Florence, Italy.
   [Cantini, Francesca; Banci, Lucia] Univ Florence, Dept Chem, Via Lastruccia 3, I-50019 Florence, Italy.
RP Spyroulias, GA (corresponding author), Univ Patras, Dept Pharm, GR-26504 Patras, Greece.; Schwalbe, H (corresponding author), Goethe Univ Frankfurt, Inst Organ Chem & Chem Biol, Max von Laue Str 7, D-60438 Frankfurt, Germany.; Banci, L (corresponding author), Univ Florence, Magnet Resonance Ctr CERM, Via Luigi Sacconi 6, I-50019 Florence, Italy.; Banci, L (corresponding author), Univ Florence, Dept Chem, Via Lastruccia 3, I-50019 Florence, Italy.
EM banci@cerm.unifi.it; Schwalbe@nmr.uni-frankfurt.de;
   G.A.Spyroulias@upatras.gr
FU state of Hesse; Goethe Corona Funds; DFGGerman Research Foundation (DFG)
   [CRC902]; Italian Ministry for University and Research (FOE fund);
   Operational Program 'Competitiveness, Entrepreneurship and Innovation'
   (NSRF) [MIS 5002550]; European Union (European Regional Development
   Fund)European Union (EU); EU FP7 REGPOT [CT-2011-285950]
FX Work at BMRZ is supported by the state of Hesse. Work in COVID19-NMR was
   supported by the Goethe Corona Funds and the DFG in CRC902: "Molecular
   Principles of RNA-based regulation." Work at CERM is supported by the
   Italian Ministry for University and Research (FOE funding) to the
   Italian Center (CERM, University of Florence) of Instruct-ERIC, a
   European Research Infrastructure, ESFRI Landmark. This work was also
   supported by the INSPIRED (MIS 5002550) which is implemented under the
   Action 'Reinforcement of the Research and Innovation Infrastructure,'
   funded by the Operational Program 'Competitiveness, Entrepreneurship and
   Innovation' (NSRF 2014-2020) and co-financed by Greece and the European
   Union (European Regional Development Fund). EU FP7 REGPOT
   CT-2011-285950-"SEE-DRUG" project is acknowledged for the purchase of
   UPAT's 700 MHz NMR equipment.
CR Alhammad Yousef M O, 2020, J Virol, DOI 10.1128/JVI.01969-20
   Alhammad YMO, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040384
   Burrell Christopher J., 2017, CORONAVIRUSES FENNER, Vfifth, P437
   Cantini F, 2020, BIOMOL NMR ASSIGN, V14, P339, DOI 10.1007/s12104-020-09973-4
   Chatterjee A, 2009, J VIROL, V83, P1823, DOI 10.1128/JVI.01781-08
   Frick DN, 2020, BIOCHEMISTRY-US, V59, P2608, DOI 10.1021/acs.biochem.0c00309
   Johnson MA, 2010, J MOL BIOL, V400, P724, DOI 10.1016/j.jmb.2010.05.027
   Keller R, 2004, COMPUTER AIDED RESON
   Kusov Y, 2015, VIROLOGY, V484, P313, DOI 10.1016/j.virol.2015.06.016
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Lei J, 2017, FEBS LETT, V591, P3190, DOI 10.1002/1873-3468.12827
   Michalska K, 2020, CRYSTAL STRUCTURES S, DOI [10.1101/2020.05.14.096081, DOI 10.1101/2020.05.14.096081]
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Serrano P, 2009, J VIROL, V83, P12998, DOI 10.1128/JVI.01253-09
   Shen Y, 2009, J BIOMOL NMR, V44, P213, DOI 10.1007/s10858-009-9333-z
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Tan J, 2007, BIOCHEM BIOPH RES CO, V364, P877, DOI 10.1016/j.bbrc.2007.10.081
   Tan JZ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000428
   V'kovski P, 2020, NAT REV MICROBIOL, DOI 10.1038/s41579-020-00468-6
   WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777
NR 20
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1874-2718
EI 1874-270X
J9 BIOMOL NMR ASSIGN
JI Biomol. NMR Assign.
DI 10.1007/s12104-020-09987-y
EA NOV 2020
PG 5
WC Biophysics; Spectroscopy
SC Biophysics; Spectroscopy
GA OU4YB
UT WOS:000591534600001
PM 33225414
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Nakamura, S
   Kanemasa, Y
   Atsuta, Y
   Fujiwara, S
   Tanaka, M
   Fukushima, K
   Kobayashi, T
   Shimoyama, T
   Omuro, Y
   Sekiya, N
   Imamura, A
AF Nakamura, Shohei
   Kanemasa, Yusuke
   Atsuta, Yuya
   Fujiwara, Sho
   Tanaka, Masaru
   Fukushima, Kazuaki
   Kobayashi, Taiichiro
   Shimoyama, Tatsu
   Omuro, Yasushi
   Sekiya, Noritaka
   Imamura, Akifumi
TI Characteristics and outcomes of coronavirus disease 2019 (COVID-19)
   patients with cancer: a single-center retrospective observational study
   in Tokyo, Japan
SO INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Early Access
DE COVID-19; Cancer; Chemotherapy; Lymphocytopenia; Japan
ID 1ST-LINE TREATMENT; RITUXIMAB; INDOLENT
AB Background Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an international outbreak of coronavirus disease 2019 (COVID-19), data on the clinical characteristics of COVID-19 patients with cancer are limited. This study aimed to evaluate the clinical characteristics and outcomes including mortality and viral shedding period in COVID-19 patients with cancer in Japan. Methods We retrospectively analyzed 32 patients with a history of cancer who were referred to our hospital between January 31, 2020 and May 25, 2020. We evaluated the association between clinical outcomes and potential prognostic factors using univariate analyses. Results The median age was 74.5 (range 24-90) years and 22 patients (69%) were men. A total of 11 patients (34%) died. Our analyses demonstrated that the mortality was significantly associated with lymphocyte count, albumin, lactate dehydrogenase, serum ferritin, and C-reactive protein on admission. The median period between illness onset and the first effective negative SARS-CoV-2 PCR result was 22 days (interquartile range 18-25) in survivors. Of four patients with hematological malignancy who developed COVID-19 within the rest period of chemotherapy, three died and the other patient, who received bendamustine plus rituximab therapy, had the longest duration of viral shedding (56 days). Conclusion Our study suggested that the risk factors for mortality previously reported in general COVID-19 patients, including lymphocytopenia, were also effective in cancer patients. Patients who received cytotoxic chemotherapy recently or were treated with chemotherapy, which can lead to lymphocyte reduction, had poor prognosis and prolonged periods of viral shedding.
C1 [Nakamura, Shohei; Kanemasa, Yusuke; Shimoyama, Tatsu; Omuro, Yasushi] Komagome Hosp, Dept Med Oncol, Tokyo Metropolitan Canc & Infect Dis Ctr, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo, Japan.
   [Atsuta, Yuya] Komagome Hosp, Div Hematol, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan.
   [Fujiwara, Sho; Tanaka, Masaru; Fukushima, Kazuaki; Kobayashi, Taiichiro; Imamura, Akifumi] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Infect Dis, Tokyo, Japan.
   [Sekiya, Noritaka] Komagome Hosp, Dept Infect Prevent & Control, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan.
   [Sekiya, Noritaka] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Clin Lab, Tokyo, Japan.
RP Kanemasa, Y (corresponding author), Komagome Hosp, Dept Med Oncol, Tokyo Metropolitan Canc & Infect Dis Ctr, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo, Japan.
EM y-kanemasa@cick.jp
OI KOBAYASHI, TAIICHIRO/0000-0002-1239-0275
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Flinn IW, 2014, BLOOD, V123, P2944, DOI 10.1182/blood-2013-11-531327
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang M, 2020, J INFECT DIS, V222, P198, DOI 10.1093/infdis/jiaa252
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Khorana AA, 2008, BLOOD, V111, P4902, DOI 10.1182/blood-2007-10-116327
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET ONCOL, V21, P1309, DOI 10.1016/S1470-2045(20)30442-3
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Martin-Moro F, 2020, BRIT J HAEMATOL, V190, pE16, DOI 10.1111/bjh.16801
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   ROBILOTTI EV, 2020, NAT MED 0624, DOI DOI 10.1101/2020.05.04.20086322
   Rotz SJ, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26642
   Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2
   Walker AJ, 2013, EUR J CANCER, V49, P1404, DOI 10.1016/j.ejca.2012.10.021
   WAN S, 2020, BRIT J HAEMATOL 0420, DOI DOI 10.1101/2020.02.10.20021832
   WHO, 2020, REP WHO CHIN JOINT M
   World Health Organization, 2020, 1 WHO
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Xiao AT, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104346
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang H-Y, 2020, MULTICENTRE STUDY 20, DOI [10.1101/2020.03.21.20037127, DOI 10.1101/2020.03.21.20037127]
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 35
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 1341-9625
EI 1437-7772
J9 INT J CLIN ONCOL
JI Int. J. Clin. Oncol.
DI 10.1007/s10147-020-01837-0
EA NOV 2020
PG 9
WC Oncology
SC Oncology
GA OU5XW
UT WOS:000591602600001
PM 33225396
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yamaki, J
   Peled, H
   Mathews, S
   Park, D
   Firoozi, M
   Smith, K
   Nguyen, L
AF Yamaki, Jason
   Peled, Harry
   Mathews, Sajen
   Park, David
   Firoozi, Mina
   Smith, Kim
   Nguyen, Lee
TI Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital
   Emergency Department and Outpatient Laboratory in Northern Orange
   County, California
SO JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Immunoglobulin G
ID COVID-19
AB Introduction The severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) has infected more than 20 million people worldwide, and the spread is most prevalent in the USA, where California had accounted over 240,000 cases in the initial 5 months of the pandemic. To estimate the number of infected persons in our community, we conducted a cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection. Methods This cross-sectional study evaluated the presence of immunoglobulin G, antibody for SARS-CoV-2 during the time period of July 15, 2020, to July 27, 2020. Testing was done on serum samples from patients who had visited affiliated outpatient clinics or our emergency department. Additionally, we collected age, gender, ethnicity, race, and location of testing. Results Eight hundred sixty-five tests were included in the study. The outpatient clinics cohort accounted for 56% of results and emergency department (ED) contributed 44%. The positive percentage of SARS-CoV-2 test was 9.4% (95% CI: 0.08-0.12). The positivity rates of the outpatient (5.6%) and ED (14.2%) setting differed. The prevalence of SARS-CoV-2 IgG was greatest in those that identified as Hispanic/Latino, 18.1% versus 13.4% in other groups. Specifically compared to the non-Hispanic/Latino population, the prevalence was significantly higher, with a relative risk of 2.73 (95% CI: 1.8-4.1), p < 0.0001. Conclusion The low antibody positivity rate in the community indicates the need for a vaccine. The Hispanic/Latino patient population should be considered for increased education on preventing transmission and acquisition of COVID-19 as well as being considered as a priority for vaccination once a vaccine is available.
C1 [Yamaki, Jason] Chapman Univ, Sch Pharm, Dept Pharm Practice, Irvine, CA USA.
   [Yamaki, Jason] Hoag Mem Hosp, Dept Pharm, Newport Beach, CA USA.
   [Peled, Harry; Mathews, Sajen; Park, David; Firoozi, Mina; Smith, Kim; Nguyen, Lee] St Jude Med Ctr, Providence St Joseph Hlth Syst, Fullerton, CA 92835 USA.
   [Nguyen, Lee] Univ Calif Irvine, Dept Clin Pharm Practice, Sch Pharm & Pharmaceut Sci, Irvine, CA 92617 USA.
RP Nguyen, L (corresponding author), St Jude Med Ctr, Providence St Joseph Hlth Syst, Fullerton, CA 92835 USA.; Nguyen, L (corresponding author), Univ Calif Irvine, Dept Clin Pharm Practice, Sch Pharm & Pharmaceut Sci, Irvine, CA 92617 USA.
EM l.nguyen@uci.edu
CR Alobuia WM, 2020, J PUBLIC HEALTH-UK, V42, P470, DOI 10.1093/pubmed/fdaa069
   Bryan A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00941-20
   Bureau USC, QUICKFACTS
   California Department of Public Health, COVID 19 RAC ETHN DA
   Centers-for-Disease-Control-and-Prevention, IMPL MIT STRAT COMM
   Dong EDH, COVID 19 DASHBOARD C
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dyal JW, 2020, MMWR MORB MORTAL WKL, V69
   Kim TH, 2011, SCAND J INFECT DIS, V43, P683, DOI 10.3109/00365548.2011.582247
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Mahajan UV, 2020, J PUBLIC HEALTH-UK, V42, P445, DOI [10.1093/pubmed/fdaa070, 10.3171/2020.6.JNS20902]
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Moore JT, 2020, MMWR-MORBID MORTAL W, V69, P1122, DOI 10.15585/mmwr.mm6933e1
   Paakkari L, 2020, LANCET PUBLIC HEALTH, V5, pE249, DOI 10.1016/S2468-2667(20)30086-4
   QuickFacts, QUICKFACTS
   van Holm Eric Joseph, 2020, J Public Health (Oxf), DOI 10.1093/pubmed/fdaa147
   World Health Organization, 2020, CLIN MAN COVID 19 IN
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2197-3792
EI 2196-8837
J9 J RACIAL ETHN HEALTH
JI J. Racial Ethn. Health Disparities
DI 10.1007/s40615-020-00918-0
EA NOV 2020
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OV3FO
UT WOS:000592100500001
PM 33230735
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gallagher, ME
   Sieben, AJ
   Nelson, KN
   Kraay, ANM
   Orenstein, WA
   Lopman, B
   Handel, A
   Koelle, K
AF Gallagher, Molly E.
   Sieben, Andrew J.
   Nelson, Kristin N.
   Kraay, Alicia N. M.
   Orenstein, Walter A.
   Lopman, Ben
   Handel, Andreas
   Koelle, Katia
TI Indirect benefits are a crucial consideration when evaluating SARS-CoV-2
   vaccine candidates
SO NATURE MEDICINE
LA English
DT Letter; Early Access
C1 [Gallagher, Molly E.; Koelle, Katia] Emory Univ, Dept Biol, Atlanta, GA 30322 USA.
   [Sieben, Andrew J.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Nelson, Kristin N.; Kraay, Alicia N. M.; Lopman, Ben] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Orenstein, Walter A.] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA.
   [Orenstein, Walter A.; Koelle, Katia] Emory UGA Ctr Excellence Influenza Res & Surveill, Atlanta, GA USA.
   [Handel, Andreas] Univ Georgia, Dept Epidemiol & Biostat, Coll Publ Hlth, Athens, GA 30602 USA.
RP Gallagher, ME (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.
EM mgallagher@emory.edu
OI Gallagher, Molly/0000-0003-4451-0822
FU US National Institutes of Health National Institute of General Medical
   Sciences grant [1R01 GM124280-03S1]; National Science FoundationNational
   Science Foundation (NSF) [2032084]; National Institute of Allergy and
   Infectious Diseases Centers of Excellence for Influenza Research and
   Surveillance (CEIRS) grant [HHSN272201400004C]
FX The research reported in this paper was supported by US National
   Institutes of Health National Institute of General Medical Sciences
   grant 1R01 GM124280-03S1 (supplement); National Science Foundation grant
   2032084; and National Institute of Allergy and Infectious Diseases
   Centers of Excellence for Influenza Research and Surveillance (CEIRS)
   grant HHSN272201400004C.
CR Eichner M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2399-4
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Gallagher Molly E, 2020, medRxiv, DOI 10.1101/2020.08.07.20170456
   HALLORAN ME, 1991, EPIDEMIOLOGY, V2, P331, DOI 10.1097/00001648-199109000-00004
   Medlock J, 2009, SCIENCE, V325, P1705, DOI 10.1126/science.1175570
   ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
NR 8
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
DI 10.1038/s41591-020-01172-x
EA NOV 2020
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA OV1LP
UT WOS:000591980700004
PM 33230343
OA Bronze
DA 2021-01-01
ER

PT J
AU Chiroma, H
   Ezugwu, AE
   Jauro, F
   Al-Garadi, MA
   Abdullahi, IN
   Shuib, L
AF Chiroma, Haruna
   Ezugwu, Absalom E.
   Jauro, Fatsuma
   Al-Garadi, Mohammed A.
   Abdullahi, Idris N.
   Shuib, Liyana
TI Early survey with bibliometric analysis on machine learning approaches
   in controlling COVID-19 outbreaks
SO PEERJ COMPUTER SCIENCE
LA English
DT Article
DE Bibliometric analysis; Convolutional neural network; COVID-19 pandemic;
   COVID-19 diagnosis tool; Machine learning
ID CORONAVIRUS OUTBREAK; HEALTH; PREDICTION; NETWORKS; DISEASE
AB Background and Objective: The COVID-19 pandemic has caused severe mortality across the globe, with the USA as the current epicenter of the COVID-19 epidemic even though the initial outbreak was in Wuhan, China. Many studies successfully applied machine learning to fight COVID-19 pandemic from a different perspective. To the best of the authors' knowledge, no comprehensive survey with bibliometric analysis has been conducted yet on the adoption of machine learning to fight COVID-19. Therefore, the main goal of this study is to bridge this gap by carrying out an in-depth survey with bibliometric analysis on the adoption of machine learning-based technologies to fight COVID-19 pandemic from a different perspective, including an extensive systematic literature review and bibliometric analysis.
   Methods: We applied a literature survey methodology to retrieved data from academic databases and subsequently employed a bibliometric technique to analyze the accessed records. Besides, the concise summary, sources of COVID-19 datasets, taxonomy, synthesis and analysis are presented in this study. It was found that the Convolutional Neural Network (CNN) is mainly utilized in developing COVID-19 diagnosis and prognosis tools, mostly from chest X-ray and chest CT scan images. Similarly, in this study, we performed a bibliometric analysis of machine learning-based COVID-19 related publications in the Scopus and Web of Science citation indexes. Finally, we propose a new perspective for solving the challenges identified as direction for future research. We believe the survey with bibliometric analysis can help researchers easily detect areas that require further development and identify potential collaborators.
   Results: The findings of the analysis presented in this article reveal that machine learning-based COVID-19 diagnose tools received the most considerable attention from researchers. Specifically, the analyses of results show that energy and resources are more dispenses towards COVID-19 automated diagnose tools while COVID-19 drugs and vaccine development remains grossly underexploited. Besides, the machine learning-based algorithm that is predominantly utilized by researchers in developing the diagnostic tool is CNN mainly from X-rays and CT scan images.
   Conclusions: The challenges hindering practical work on the application of machine learning-based technologies to fight COVID-19 and new perspective to solve the identified problems are presented in this article. Furthermore, we believed that the presented survey with bibliometric analysis could make it easier for researchers to identify areas that need further development and possibly identify potential collaborators at author, country and institutional level, with the overall aim of furthering research in the focused area of machine learning application to disease control.
C1 [Chiroma, Haruna] Natl Yunlin Univ Sci & Technol, Future Technol Res Ctr, Yuanlin, Taiwan.
   [Ezugwu, Absalom E.] Univ KwaZulu Natal, Sch Math Stat & Comp Sci, Kwa Zulu, South Africa.
   [Jauro, Fatsuma] Ahmadu Bello Univ, Fac Sci, Dept Comp Sci, Zaria, Nigeria.
   [Al-Garadi, Mohammed A.] Emory Univ, Dept Biomed Informat, Atlanta, GA 30322 USA.
   [Abdullahi, Idris N.] Ahmadu Bello Univ, Coll Med Sci, Dept Med Lab Sci, Zaria, Nigeria.
   [Shuib, Liyana] Univ Malaya, Dept Informat Syst, Kuala Lumpur, Malaysia.
RP Ezugwu, AE (corresponding author), Univ KwaZulu Natal, Sch Math Stat & Comp Sci, Kwa Zulu, South Africa.
EM ezugwua@ukzn.ac.za
RI Shuib, Nor Liyana Mohd/M-8698-2013
OI Shuib, Nor Liyana Mohd/0000-0002-7907-0671; Abdullahi, Idris
   Nasir/0000-0002-5511-1272
CR Ahuja AS, 2020, INTEGR MED RES, V9, DOI 10.1016/j.imr.2020.100434
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Alimadadi A, 2020, PHYSIOL GENOMICS, V52, P200, DOI 10.1152/physiolgenomics.00029.2020
   Apostolopoulos ID, 2020, PHYS ENG SCI MED, V43, P635, DOI 10.1007/s13246-020-00865-4
   Ardakani AA, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103795
   Asif S, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103792.
   Ayyoubzadeh SM, 2020, JMIR PUBLIC HLTH SUR, V6, P192, DOI 10.2196/18828
   Barbosa RD, 2020, DATA BRIEF, V30, DOI 10.1016/j.dib.2020.105618
   Basheer IA, 2000, J MICROBIOL METH, V43, P3, DOI 10.1016/S0167-7012(00)00201-3
   Belfiore MP, 2020, RADIOL MED, V125, P500, DOI 10.1007/s11547-020-01195-x
   Bellazzi R, 1998, 5 INT WORKSH INT DAT
   Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Butt C, 2020, APPL INTELL, DOI 10.1007/s10489-020-01714-3
   Casey B, 2020, GOOD IS RADIOGRAPHY
   Chahrour M, 2020, CUREUS, V12, DOI 10.7759/cureus.7357
   Chimmula VKR, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109864
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Ribeiro MHD, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109853
   Dananjayan S, 2020, INT J HEALTH PLAN M, V35, P1260, DOI 10.1002/hpm.2987
   Das Karuna M, 2017, Indian J Radiol Imaging, V27, P342, DOI 10.4103/ijri.IJRI_469_16
   Deng L, 2014, APSIPA TRANS SIGNAL, V3, DOI 10.1017/atsip.2013.9
   Dong Di, 2020, IEEE Rev Biomed Eng, VPP, DOI 10.1109/RBME.2020.2990959
   Duan YN, 2020, RADIOLOGY, V295, P21, DOI 10.1148/radiol.2020200323
   Elavarasan RM, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138858
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Farhat H, 2020, MACH VISION APPL, V31, DOI 10.1007/s00138-020-01101-5
   Fong SJ, 2020, APPL SOFT COMPUT, V93, DOI 10.1016/j.asoc.2020.106282
   Gonzalez-Dias P, 2020, HUM VACC IMMUNOTHER, V16, P269, DOI 10.1080/21645515.2019.1697110
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Greff K, 2017, IEEE T NEUR NET LEAR, V28, P2222, DOI 10.1109/TNNLS.2016.2582924
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haque IRI, 2020, INFORM MED UNLOCKED, V18, P100297, DOI 10.1016/j.imu.2020.100297
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hossain M.M., 2020, F1000RESEARCH, V9, P374, DOI [10.12688/f1000research.23690.1, DOI 10.12688/F1000RESEARCH.23690.1]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang L, 2020, RADIOLOGY CARDIOTHOR, V2, P2, DOI DOI 10.1148/RYCT.2020200075
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Hurt B, 2020, J THORAC IMAG, V35, pW87, DOI 10.1097/RTI.0000000000000512
   Imai N, 2020, 2 IMP COLL LOND, DOI [10.25561/77150, DOI 10.25561/77150]
   Inui S, 2020, RADIOL CARDIOTHORAC, V2, DOI [10.1148/ryct.2020200110, DOI 10.1148/RYCT.2020200110]
   Jaiswal A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1788642
   Jiang XG, 2020, CMC-COMPUT MATER CON, V63, P537, DOI 10.32604/cmc.2020.010691
   Karim F, 2018, IEEE ACCESS, V6, P1662, DOI 10.1109/ACCESS.2017.2779939
   Ke YY, 2020, BIOMED J, V43, P355, DOI 10.1016/j.bj.2020.05.001
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Kooraki S, 2020, J AM COLL RADIOL, V17, P447, DOI 10.1016/j.jacr.2020.02.008
   Kumar A, 2020, SYNDROME CLIN RES RE, V14, P569, DOI DOI 10.1016/J.DSX.2020.05.008
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Li DS, 2020, KOREAN J RADIOL, V21, P505, DOI 10.3348/kjr.2020.0146
   Li L, 2020, RADIOLOGY, V296, pE65, DOI 10.1148/radiol.2020200905
   Li Z, 2020, EUR RADIOL, V30, P6828, DOI 10.1007/s00330-020-07042-x
   Lin PF, 2020, IEEE ACCESS, V8, P66139, DOI 10.1109/ACCESS.2020.2985329
   Liu FJ, 2020, THERANOSTICS, V10, P5613, DOI 10.7150/thno.45985
   Liu GQ, 2019, IEEE ACCESS, V7, DOI 10.1109/ACCESS.2019.2935463
   Liu Z, 2020, GLOBAL HLTH RES POLI, V5, P1, DOI DOI 10.1186/S41256-019-0129-8
   Livingstone DJ, 2008, ARTIFICIAL NEURAL NE
   Loey M, 2020, SYMMETRY-BASEL, V12, DOI 10.3390/sym12040651
   Lou J, 2020, EUR REV MED PHARMACO, V24, P3411, DOI 10.26355/eurrev_202003_20712
   Mei XY, 2020, NAT MED, V26, P1224, DOI 10.1038/s41591-020-0931-3
   Mohammadi M, 2018, IEEE COMMUN SURV TUT, V20, P2923, DOI 10.1109/COMST.2018.2844341
   Oh Y, 2020, IEEE T MED IMAGING, V39, P2688, DOI 10.1109/TMI.2020.2993291
   Ozturk T, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103792
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Park Y, 2020, TRENDS MOL MED, V26, P627, DOI 10.1016/j.molmed.2020.04.007
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   PIROUZ B, 2020, SUSTAINABILITY-BASEL, V12, DOI DOI 10.3390/SU12062427
   Pouyanfar S, 2018, ACM COMPUT SURV, V51, DOI 10.1145/3150226
   Qiang XL, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00649-8
   Rahaman MM, 2020, J X-RAY SCI TECHNOL, V28, P1
   Randhawa GS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232391
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.23.20018549, DOI 10.1101/2020.01.23.20018549]
   Rodrigues JCL, 2020, CLIN RADIOL, V75, P323, DOI 10.1016/j.crad.2020.03.003
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Sak H., 2014, 15 ANN C INT SPEECH
   Salman F.M., 2020, INT J ACAD ENG RES, V4, P18
   Santosh KC, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01562-1
   Shi Feng, 2020, IEEE Rev Biomed Eng, VPP, DOI 10.1109/RBME.2020.2987975
   Singh D, 2020, INT J PATTERN RECOGN, V4, DOI 10.1142/S0218001421510046.
   Singh D, 2020, EUR J CLIN MICROBIOL, V39, P1379, DOI 10.1007/s10096-020-03901-z
   Rao ASRS, 2020, INFECT CONT HOSP EP, V41, P826, DOI 10.1017/ice.2020.61
   Stewart Kelsey A, 2020, Int J MCH AIDS, V9, P103, DOI 10.21106/ijma.294
   TIWARI S, 2020, INTERNET OF THINGS, V18, DOI DOI 10.1016/J.IOT.2020.100222
   Tiwari Sunita, 2020, Disaster Med Public Health Prep, V14, pe33, DOI 10.1017/dmp.2020.115
   Togacar M, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103805
   Tummers J, 2020, J INTELL DISABIL RES, V64, P475, DOI 10.1111/jir.12730
   Ucar F, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109761
   Vaid S, 2020, J BONE JOINT SURG AM, V102, DOI 10.2106/JBJS.20.00715
   Vaishya R, 2020, DIABETES METAB SYND, V14, P337, DOI 10.1016/j.dsx.2020.04.012
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang YH, 2020, RADIOLOGY, V296, pE55, DOI 10.1148/radiol.2020200843
   Weidt F, 2016, SYSTEMATIC LIT REV C, V1, DOI [10.13140/RG.2.2.35453.87524, DOI 10.13140/RG.2.2.35453.87524]
   Wong HYF, 2020, RADIOLOGY, V296, pE72, DOI 10.1148/radiol.2020201160
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Wu XJ, 2020, EUR J RADIOL, V128, DOI 10.1016/j.ejrad.2020.109041
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Xu X, 2020, EUR J NUCL MED MOL I, V47, P1275, DOI 10.1007/s00259-020-04735-9
   XUE ZJ, 2020, RADIOL-CARDIOTHORACI, V2
   Yang SY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.132
   Yang ZF, 2020, J THORAC DIS, V12, P165, DOI 10.21037/jtd.2020.02.64
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zhao R, 2019, MECH SYST SIGNAL PR, V115, P213, DOI 10.1016/j.ymssp.2018.05.050
   Zhao Z, 2017, IET INTELL TRANSP SY, V11, P68, DOI 10.1049/iet-its.2016.0208
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 105
TC 0
Z9 0
U1 3
U2 3
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2376-5992
J9 PEERJ COMPUT SCI
JI PeerJ Comput. Sci.
PD NOV 23
PY 2020
AR e313
DI 10.7717/peerj-cs.313
PG 45
WC Computer Science, Artificial Intelligence; Computer Science, Information
   Systems; Computer Science, Theory & Methods
SC Computer Science
GA OV0UI
UT WOS:000591935700001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Manna, S
   Chowdhury, T
   Chakraborty, R
   Mandal, SM
AF Manna, Sounik
   Chowdhury, Trinath
   Chakraborty, Ranadhir
   Mandal, Santi M.
TI Probiotics-Derived Peptides and Their Immunomodulatory Molecules Can
   Play a Preventive Role Against Viral Diseases Including COVID-19
SO PROBIOTICS AND ANTIMICROBIAL PROTEINS
LA English
DT Article; Early Access
DE Probiotics; Immunomodulatory; Peptides; SARS-CoV-2; COVID-19
ID ANTIVIRAL ACTIVITY; ROTAVIRUS INFECTION; VIRUS-INFECTION; LACTOBACILLUS;
   ACTIVATION; MODEL
AB As of recent, the pandemic episode of COVID-19, a severe acute respiratory syndrome brought about by a novel coronavirus (SARS-CoV-2) expanding the pace of mortality, has affected the disease rate profoundly. Invulnerability is the fundamental choice to prevent the ruining event of COVID-19, as the drugs and antibodies are in the phase of preliminary clinical trials. Within this brief period, a few strains of SARS-CoV-2 have been recognized by the vaccine manufacturers, which could be an incorrect guess about the strain that will end up spreading. Since the circulating SARS-CoV-2 strains continue to mutate, immunizations, if at all works, might be for a restricted time. We have not put sufficient time in research to understand the immune responses that correlate with protection as this could help refine vaccines. Here, we have summed up the adequacy of the immunomodulatory component of probiotics for the prevention against viral infections. Furthermore, an in silico data have been provided in support of the "probiotics-derived lipopeptides" role in inactivating spike (S) glycoprotein of SARS-CoV-2 and its host receptor molecule, ACE2. Among well characterized lipopeptides derived from different probiotic strains, subtilisin (Bacillus amyloliquefaciens), curvacin A (Lactobacillus curvatus), sakacin P (Lactobacillus sakei), lactococcin Gb (Lactococcus lactis) was utilized in this study to demonstrate a higher binding proclivity to S-protein of SARS-CoV-2 and human ACE2. The outcome revealed noteworthy capabilities of the lipopeptides, due to their amphiphilic nature, to bind spike protein and receptor molecule, which may act to competitively inhibit the mandatory interaction of SARS-CoV-2 with the host epithelial cell expressing ACE2 for its entry into the cell for reproduction. In the current situation, probiotic treatment alongside chemotherapy may assist in bringing about substantial improvement of the health of COVID-19 patients. At the same time, probiotics may aid towards building up the immune defenses in people to evade COVID-19.
C1 [Manna, Sounik] Midnapore Coll Autonomous, Dept Microbiol, Paschim Medinipur, India.
   [Chowdhury, Trinath; Mandal, Santi M.] Indian Inst Technol Kharagpur, Cent Res Facil, Kharagpur 721302, W Bengal, India.
   [Chakraborty, Ranadhir] North Bengal Univ, Dept Biotechnol, Darjeeling, India.
RP Mandal, SM (corresponding author), Indian Inst Technol Kharagpur, Cent Res Facil, Kharagpur 721302, W Bengal, India.
EM mandalsm@gmail.com
OI Mandal, Santi M/0000-0002-0119-7138
FU Central Research Facility, IIT-Kharagpur, India
FX Authors are grateful to Central Research Facility, IIT-Kharagpur, India,
   for providing the necessary facilities and support.
CR Al Kassaa I, 2014, PROBIOTICS ANTIMICRO, V6, P177, DOI 10.1007/s12602-014-9162-6
   Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X
   Bahadoran A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01841
   Berggren A, 2011, EUR J NUTR, V50, P203, DOI 10.1007/s00394-010-0127-6
   Bermudez-Brito M, 2012, ANN NUTR METAB, V61, P160, DOI 10.1159/000342079
   Bodera P, 2009, RECENT PATENTS INFLA, V3, P58, DOI 10.2174/187221309787158461
   Botic T, 2007, INT J FOOD MICROBIOL, V115, P227, DOI 10.1016/j.ijfoodmicro.2006.10.044
   Chowdhury Trinath, 2020, Infect Disord Drug Targets, DOI 10.2174/1871526520666200727153643
   Rigo-Adrover MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01318
   Delcenserie V, 2008, CURR ISSUES MOL BIOL, V10, P37
   Eguchi K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39602-7
   Foligne B, 2010, INT J FOOD MICROBIOL, V140, P136, DOI 10.1016/j.ijfoodmicro.2010.04.007
   Gabryszewski SJ, 2011, J IMMUNOL, V186, P1151, DOI 10.4049/jimmunol.1001751
   Galdeano CM, 2006, CLIN VACCINE IMMUNOL, V13, P219, DOI 10.1128/CVI.13.2.219-226.2006
   Garcia-Crespo KE, 2013, ANTIVIR RES, V97, P270, DOI 10.1016/j.antiviral.2012.12.022
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026
   Goto H, 2013, BRIT J NUTR, V110, P1810, DOI 10.1017/S0007114513001104
   Guarino A, 2009, CURR OPIN GASTROEN, V25, P18, DOI 10.1097/MOG.0b013e32831b4455
   Iwabuchi N, 2011, BIOL PHARM BULL, V34, P1352, DOI 10.1248/bpb.34.1352
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Kanauchi O, 2018, CURR PHARM DESIGN, V24, P710, DOI 10.2174/1381612824666180116163411
   Kim MJ, 2014, BIOTECHNOL BIOTEC EQ, V28, P681, DOI 10.1080/13102818.2014.945237
   Kourelis A, 2010, J APPL MICROBIOL, V108, P274, DOI 10.1111/j.1365-2672.2009.04421.x
   Lee DK, 2013, ARCH PHARM RES, V36, P1525, DOI 10.1007/s12272-013-0141-3
   Lehtoranta L, 2014, EUR J CLIN MICROBIOL, V33, P1289, DOI 10.1007/s10096-014-2086-y
   MacDonald TT, 2011, GASTROENTEROLOGY, V140, P1768, DOI 10.1053/j.gastro.2011.02.047
   Mandal SM, 2018, BIOL CHEM, V399, P1277, DOI 10.1515/hsz-2018-0182
   Markland FS, 1971, ENZYMES, P561
   Moll G, 1996, J BACTERIOL, V178, P600, DOI 10.1128/jb.178.3.600-605.1996
   Monedero V, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020096
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Paul D, 2018, CURR PHARM DESIGN, V24, P821, DOI 10.2174/1381612824666171227221731
   Pimentel-Nunes P, 2010, EXPERT OPIN THER TAR, V14, P347, DOI 10.1517/14728221003642027
   Rather IA, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01417
   Rodriguez-Diaz J, 2013, BIOACT FOOD CHRON, P271, DOI 10.1016/B978-0-12-397154-8.00031-2
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Salminen S, 2010, CURR OPIN BIOTECH, V21, P157, DOI 10.1016/j.copbio.2010.03.016
   Savan R, 2006, COMP BIOCHEM PHYS D, V1, P89, DOI 10.1016/j.cbd.2005.08.005
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406
   Servin AL, 2004, FEMS MICROBIOL REV, V28, P405, DOI 10.1016/j.femsre.2004.01.003
   TICHACZEK PS, 1992, SYST APPL MICROBIOL, V15, P460, DOI 10.1016/S0723-2020(11)80223-7
   Varyukhina S, 2012, MICROBES INFECT, V14, P273, DOI 10.1016/j.micinf.2011.10.007
   Vijayanand P, 2004, CLIN MED, V4, P152, DOI 10.7861/clinmedicine.4-2-152
   Wan LYM, 2016, CRIT REV FOOD SCI, V56, P2628, DOI 10.1080/10408398.2014.905450
   Weiss G, 2010, IMMUNOLOGY, V131, P268, DOI 10.1111/j.1365-2567.2010.03301.x
   Wu S, 2013, CURR MICROBIOL, V67, P414, DOI 10.1007/s00284-013-0380-z
   Zabihollahi R, 2012, DARU, V20, DOI 10.1186/2008-2231-20-53
   Zhang BY, 2014, SCIENCE, V346, P861, DOI 10.1126/science.1256999
NR 49
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1867-1306
EI 1867-1314
J9 PROBIOTICS ANTIMICRO
JI Probiotics Antimicrob. Proteins
DI 10.1007/s12602-020-09727-7
EA NOV 2020
PG 13
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA OV1BO
UT WOS:000591954500001
PM 33226581
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rizzetto, G
   Diotallevi, F
   Campanati, A
   Radi, G
   Bianchelli, T
   Molinelli, E
   Mazzanti, S
   Offidani, A
AF Rizzetto, Giulio
   Diotallevi, Federico
   Campanati, Anna
   Radi, Giulia
   Bianchelli, Tommaso
   Molinelli, Elisa
   Mazzanti, Sara
   Offidani, Annamaria
TI Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical
   aspects and our management experience
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE alopecia; hair disorders; infection-bacterial/fungal/viral;
   therapy-systemic
ID ALOPECIA
AB Telogen effluvium (TE) is one of the most common form of hair loss in women. Many triggers have been identified, as stress, drugs, trauma, endocrine disease, nutritional deficiencies, and febrile states. We report three cases of TE occurred after severe Sars-Cov-2 infection and provide our clinical management, according to Sars-Cov-2 hygiene measures. Only one case report has been found in the literature associating anagen effluvium during severe Sars-Cov-2 infection. Other studies reported the exacerbation of a preexisting TE, correlated to the stress of lockdown. In our cases, patients never had a TE diagnosis before and did not report previous evident hair loss. TE can be associated with post severe Sars-Cov-2 infection. From our revision of the literature, this is the first case-series describing TE in post severe Sars-Cov-2 patients. Further studies are needed to evaluate the relationship between TE and Sars-Cov-2 infection.
C1 [Rizzetto, Giulio; Diotallevi, Federico; Campanati, Anna; Radi, Giulia; Bianchelli, Tommaso; Molinelli, Elisa; Offidani, Annamaria] Univ Politecn Marche, Dept Clin & Mol Sci, Dermatol Clin, Ancona, Italy.
   [Mazzanti, Sara] Univ Politecn Marche, Clin Malattie Infett, Dipartimento Sci Biomed & Sanita Pubbl, Ancona, Italy.
RP Campanati, A (corresponding author), Polytech Marche Univ, Dept Clin & Mol Sci, Dermatol Unit, Ancona, Italy.
EM anna.campanati@gmail.com
OI CAMPANATI, ANNA/0000-0002-3740-0839; DIOTALLEVI,
   FEDERICO/0000-0003-2274-1742; Rizzetto, Giulio/0000-0003-0091-4067
CR BERNSTEIN GM, 1988, CRIT CARE MED, V16, P98, DOI 10.1097/00003246-198801000-00020
   Bomhof G, 2020, BRIT J HAEMATOL, V190, pE61, DOI 10.1111/bjh.16850
   Borras-Blasco J, 2007, PHARMACOTHERAPY, V27, P1215, DOI 10.1592/phco.27.8.1215
   Campanati A, 2020, J EUR ACAD DERMATOL, V34, P1626, DOI 10.1111/jdv.16646
   Chrysos George, 2007, J Drugs Dermatol, V6, P742
   Chu CB, 2017, DERMATOL SIN, V35, P124, DOI 10.1016/j.dsi.2017.03.005
   Daoussis D, 2014, JOINT BONE SPINE, V81, P100, DOI 10.1016/j.jbspin.2013.07.002
   Dinh QQ, 2007, CLIN INTERV AGING, V2, P189
   Diotallevi F, INT J DERMATOL
   Diotallevi F, 2020, J MED VIROL, V92, P2332, DOI 10.1002/jmv.26012
   Garg S, 2020, DERMATOL THER, DOI 10.1111/dth.13859
   Guarrera M, 2011, GIORN ITAL DERMAT V, V146, P289
   Guo Emily L, 2017, Dermatol Pract Concept, V7, P1, DOI 10.5826/dpc.0701a01
   Hazen HH, 1919, J AMER MED ASSOC, V72, P1452, DOI 10.1001/jama.1919.02610200024010
   HEADINGTON JT, 1993, ARCH DERMATOL, V129, P356, DOI 10.1001/archderm.129.3.356
   Malkud S, 2015, J CLIN DIAGN RES, V9, pWE1, DOI 10.7860/JCDR/2015/15219.6492
   Messenger AG, 2004, BRIT J DERMATOL, V150, P186, DOI 10.1111/j.1365-2133.2004.05785.x
   Mysore Venkataram, 2019, Int J Trichology, V11, P107, DOI 10.4103/ijt.ijt_23_19
   OLSEN EA, 1989, J AM ACAD DERMATOL, V20, P395, DOI 10.1016/S0190-9622(89)70049-9
   Radi G, 2020, J EUR ACAD DERMATOL, V34, pE213, DOI 10.1111/jdv.16386
   Radi G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13740
   Rivetti N, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13648
   Savil A, 1952, HAIR SCALP CLIN STUD, P85
   Shanshal M, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1792400
   Torres F, 2015, SEMIN CUTAN MED SURG, V34, P67, DOI 10.12788/j.sder.2015.0142
   Trueb RM, 2008, HAIR GROWTH DISORDER, P259
   Turkmen D, 2020, DERMATOL THER, DOI 10.1111/dth.13923
   Wang YY, 2006, J CLIN PHARM THER, V31, P513, DOI 10.1111/j.1365-2710.2006.00769.x
   Watras M.M., 2016, DRUGS REAL WORLD OUT, V3, P1
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
NR 30
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14547
DI 10.1111/dth.14547
EA NOV 2020
PG 6
WC Dermatology
SC Dermatology
GA OU4NE
UT WOS:000591505200001
PM 33190397
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Oughtred, R
   Rust, J
   Chang, C
   Breitkreutz, BJ
   Stark, C
   Willems, A
   Boucher, L
   Leung, G
   Kolas, N
   Zhang, F
   Dolma, S
   Coulombe-Huntington, J
   Chatr-aryamontri, A
   Dolinski, K
   Tyers, M
AF Oughtred, Rose
   Rust, Jennifer
   Chang, Christie
   Breitkreutz, Bobby-Joe
   Stark, Chris
   Willems, Andrew
   Boucher, Lorrie
   Leung, Genie
   Kolas, Nadine
   Zhang, Frederick
   Dolma, Sonam
   Coulombe-Huntington, Jasmin
   Chatr-aryamontri, Andrew
   Dolinski, Kara
   Tyers, Mike
TI The BioGRID database: A comprehensive biomedical resource of curated
   protein, genetic, and chemical interactions
SO PROTEIN SCIENCE
LA English
DT Article
DE biological network; chemical interaction; COVID-19; CRISPR screen; drug
   target; genetic interaction; phenotype; post-translational modification;
   protein interaction; ubiquitin-proteasome system
ID NETWORK; DOMAIN
AB The BioGRID (Biological General Repository for Interaction Datasets, ) is an open-access database resource that houses manually curated protein and genetic interactions from multiple species including yeast, worm, fly, mouse, and human. The similar to 1.93 million curated interactions in BioGRID can be used to build complex networks to facilitate biomedical discoveries, particularly as related to human health and disease. All BioGRID content is curated from primary experimental evidence in the biomedical literature, and includes both focused low-throughput studies and large high-throughput datasets. BioGRID also captures protein post-translational modifications and protein or gene interactions with bioactive small molecules including many known drugs. A built-in network visualization tool combines all annotations and allows users to generate network graphs of protein, genetic and chemical interactions. In addition to general curation across species, BioGRID undertakes themed curation projects in specific aspects of cellular regulation, for example the ubiquitin-proteasome system, as well as specific disease areas, such as for the SARS-CoV-2 virus that causes COVID-19 severe acute respiratory syndrome. A recent extension of BioGRID, named the Open Repository of CRISPR Screens (ORCS, ), captures single mutant phenotypes and genetic interactions from published high throughput genome-wide CRISPR/Cas9-based genetic screens. BioGRID-ORCS contains datasets for over 1,042 CRISPR screens carried out to date in human, mouse and fly cell lines. The biomedical research community can freely access all BioGRID data through the web interface, standardized file downloads, or via model organism databases and partner meta-databases.
C1 [Oughtred, Rose; Rust, Jennifer; Chang, Christie; Dolinski, Kara] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA.
   [Breitkreutz, Bobby-Joe; Stark, Chris; Willems, Andrew; Boucher, Lorrie; Leung, Genie; Kolas, Nadine; Tyers, Mike] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
   [Zhang, Frederick; Dolma, Sonam] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr & Dev &, Toronto, ON, Canada.
   [Coulombe-Huntington, Jasmin; Chatr-aryamontri, Andrew; Tyers, Mike] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada.
RP Dolinski, K (corresponding author), Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA.; Tyers, M (corresponding author), Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada.
EM dolinski@princeton.edu
FU Canada Research Chair in Systems and Synthetic Biology; Stand Up To
   Cancer Canada; Genomics Technology Platform Award; Rapid Response
   Initiative Award; Genome Quebec; Genome CanadaGenome Canada; Canadian
   Institutes of Health ResearchCanadian Institutes of Health Research
   (CIHR) [FDN-167277]; National Center For Advancing Translational
   Sciences of the National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [OT3TR002026]; National Institutes of Health Office of Research
   Infrastructure Programs [R01OD010929]
FX Canada Research Chair in Systems and Synthetic Biology; Stand Up To
   Cancer Canada; Genomics Technology Platform Award; Rapid Response
   Initiative Award; Genome Canada and Genome Quebec; Canadian Institutes
   of Health Research, Grant/Award Number: FDN-167277; National Center For
   Advancing Translational Sciences of the National Institutes of Health,
   Grant/Award Number: OT3TR002026; National Institutes of Health Office of
   Research Infrastructure Programs, Grant/Award Number: R01OD010929
CR Aranda B, 2011, NAT METHODS, V8, P528, DOI 10.1038/nmeth.1637
   Banik SM, 2020, NATURE, V584, P291, DOI 10.1038/s41586-020-2545-9
   Bean DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106035
   Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256
   Bell DSH, 2007, DRUGS, V67, P1813, DOI 10.2165/00003495-200767130-00002
   Botstein D, 2011, GENETICS, V189, P695, DOI 10.1534/genetics.111.130765
   Bouhaddou M, 2020, CELL, V182, P685, DOI 10.1016/j.cell.2020.06.034
   Breitkreutz A, 2010, SCIENCE, V328, P1043, DOI 10.1126/science.1176495
   Burgess DJ, 2020, NAT REV GENET, V21, P273, DOI 10.1038/s41576-020-0232-1
   Burley Stephen K, 2017, Methods Mol Biol, V1607, P627, DOI 10.1007/978-1-4939-7000-1_26
   Cherry JM, 2012, NUCLEIC ACIDS RES, V40, pD700, DOI 10.1093/nar/gkr1029
   Costanzo M, 2016, SCIENCE, V353, DOI 10.1126/science.aaf1420
   Cromm PM, 2017, CELL CHEM BIOL, V24, P1181, DOI 10.1016/j.chembiol.2017.05.024
   Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Deans RM, 2016, NAT CHEM BIOL, V12, P361, DOI [10.1038/NCHEMBIO.2050, 10.1038/nchembio.2050]
   Dong SW, 2019, PLANT PHYSIOL, V179, P1893, DOI 10.1104/pp.18.01216
   Erard N, 2017, MOL CELL, V67, P348, DOI 10.1016/j.molcel.2017.06.030
   Gilson MK, 2016, NUCLEIC ACIDS RES, V44, pD1045, DOI 10.1093/nar/gkv1072
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Greenwald RJ, 2004, BLOOD, V103, P1475, DOI 10.1182/blood-2003-06-2116
   Haney MS, 2018, NAT GENET, V50, P1716, DOI 10.1038/s41588-018-0254-1
   Harris TW, 2020, NUCLEIC ACIDS RES, V48, pD762, DOI 10.1093/nar/gkz920
   Hnilicova J, 2013, MOL BIOL CELL, V24, P3557, DOI 10.1091/mbc.E13-06-0303
   Huang XD, 2016, CELL RES, V26, P484, DOI 10.1038/cr.2016.31
   Hynes NE, 2013, NAT REV MOL CELL BIO, V14, P393, DOI 10.1038/nrm3581
   Islamaj Dogan R, 2019, DATABASE, V2019
   Jacques S, 2020, GENETICS, V214, P1103, DOI 10.1534/genetics.119.302851
   Jain IH, 2020, CELL, V181, P716, DOI 10.1016/j.cell.2020.03.029
   Jin J, 2012, PHILOS T R SOC B, V367, P2540, DOI 10.1098/rstb.2012.0106
   Kim S, 2012, BIOINFORMATICS, V28, P597, DOI 10.1093/bioinformatics/btr702
   Koma T, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02016
   Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328
   Krallinger M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S8-S3
   Labeau A, 2020, J VIROL, V94, DOI 10.1128/JVI.01751-19
   Laurent EMN SY, 2020, GLOBAL BIOID BASED S, DOI [10.1101/2020.08.28.272955, DOI 10.1101/2020.08.28.272955]
   Lee HS, 2020, CELL, V182, P345, DOI 10.1016/j.cell.2020.06.005
   Li YY, 2012, GENOME MED, V4, DOI 10.1186/gm326
   Li ZY, 2020, AUTOPHAGY, V16, P185, DOI 10.1080/15548627.2019.1688556
   Lin A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw8412
   Lin DL, 2017, MBIO, V8, DOI [10.1128/mBio.00939-17, 10.1128/mbio.00939-17]
   Lock A, 2019, NUCLEIC ACIDS RES, V47, pD821, DOI 10.1093/nar/gky961
   Loganathan SK, 2020, SCIENCE, V367, P1264, DOI 10.1126/science.aax0902
   Ma JZ, 2018, NAT METHODS, V15, P290, DOI [10.1038/NMETH.4627, 10.1038/nmeth.4627]
   National Genomics Data Center M Partners, 2020, NUCLEIC ACIDS RES, V48, pD24, DOI DOI 10.1093/nar/gkz813.
   Oberfeld B, 2020, CELL, V181, P954, DOI 10.1016/j.cell.2020.04.013
   Olivieri M, 2020, CELL, V182, P481, DOI 10.1016/j.cell.2020.05.040
   Oughtred R, 2019, NUCLEIC ACIDS RES, V47, pD529, DOI 10.1093/nar/gky1079
   Pausch P, 2020, SCIENCE, V369, P333, DOI 10.1126/science.abb1400
   Pektas SD, 2017, CASE REP ENDOCRINOL, V2017, DOI 10.1155/2017/8320254
   Pratt D, 2015, CELL SYST, V1, P302, DOI 10.1016/j.cels.2015.10.001
   Reguly Teresa, 2006, J Biol, V5, P11, DOI 10.1186/jbiol36
   Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1
   Roussarie JP, 2020, NEURON, V107, P821, DOI 10.1016/j.neuron.2020.06.010
   Roux PP, 2013, MOL CELL PROTEOMICS, V12, P3453, DOI 10.1074/mcp.R113.032862
   Sadowski I, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat026
   Samavarchi-Tehrani P, 2020, SARS COV 2 HOST PROX, DOI [10.1101/2020.09.03.282103, DOI 10.1101/2020.09.03.282103]
   Sanjana NE, 2017, ANAL BIOCHEM, V532, P95, DOI 10.1016/j.ab.2016.05.014
   Shalem O, 2015, NAT REV GENET, V16, P299, DOI 10.1038/nrg3899
   Shi Y, 2020, J ZHEJIANG UNIV-SC B, V21, P343, DOI 10.1631/jzus.B2000083
   Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109
   Su Gang, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi0813s47
   Takahashi D, 2019, MOL CELL, V76, P797, DOI 10.1016/j.molcel.2019.09.009
   Thurmond J, 2019, NUCLEIC ACIDS RES, V47, pD759, DOI 10.1093/nar/gky1003
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Tse LV, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00658
   Waese J, 2017, METHODS MOL BIOL, V1533, P119, DOI 10.1007/978-1-4939-6658-5_6
   Wang Ruofan, 2020, bioRxiv, DOI 10.1101/2020.09.24.312298
   Wei Jin, 2020, bioRxiv, DOI 10.1101/2020.06.16.155101
   Wessels HH, 2020, NAT BIOTECHNOL, V38, P722, DOI 10.1038/s41587-020-0456-9
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
NR 71
TC 1
Z9 1
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-8368
EI 1469-896X
J9 PROTEIN SCI
JI Protein Sci.
PD JAN
PY 2021
VL 30
IS 1
SI SI
BP 187
EP 200
DI 10.1002/pro.3978
EA NOV 2020
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA PE9FV
UT WOS:000591375000001
PM 33070389
OA Other Gold
DA 2021-01-01
ER

PT J
AU Rossi, L
   Malagoli, A
   Biagi, A
   Zanni, A
   Sticozzi, C
   Comastri, G
   Pannone, L
   Gandolfi, S
   Vergara, P
   Villani, GQ
AF Rossi, Luca
   Malagoli, Alessandro
   Biagi, Andrea
   Zanni, Alessia
   Sticozzi, Concetta
   Comastri, Greta
   Pannone, Luigi
   Gandolfi, Stefano
   Vergara, Pasquale
   Villani, Giovanni Quinto
TI Renin-angiotensin system inhibitors and mortality in patients with
   COVID-19
SO INFECTION
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Renin&#8211; angiotensin system (RAS) inhibitors;
   Mortality; Hypertension
ID CONVERTING ENZYME-INHIBITORS; RECEPTOR BLOCKERS; HYPERTENSION; ACE2
AB Association of renin-angiotensin system inhibitors with risk of death in patients with hypertension (HTN) and coronavirus disease 2019 (COVID-19) is not well characterized. The aim of this study was to evaluate the outcomes of patients with HTN and COVID-19 with respect to different chronic antihypertensive drug intake. We performed a retrospective, observational study from a large cohort of patients with HTN and with a laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection admitted to the Emergency Rooms (ER) of the Piacenza Hospital network from February 21, 2020 to March 20, 2020. There were 1050 patients admitted to the ERs of the Piacenza Hospital network with COVID-19. HTN was present in 590 patients [median age, 76.2 years (IQR 68.2-82.6)]; 399 (66.1%) patients were male. Of them, 248 patients were chronically treated with ACEi, 181 with ARBs, and 161 with other drugs (O-drugs) including beta blockers, diuretics and calcium-channel inhibitors. With respect to the antihypertensive use, there was no difference between comorbid conditions. During a follow-up of 38 days (IQR 7.0-46.0), 256 patients (43.4%) died, without any difference stratifying for antihypertensive drugs. Of them, 107 (43.1%) were in ACEi group vs 67 (37%) in ARBs group vs 82 (50.7%) in O-drugs group, (log-rank test: p = 0.066). In patients with HTN and COVID-19, neither ACEi nor ARBs were independently associated with mortality. After adjusting for potential confounders in risk prediction, the rate of death was similar. Our data confirm Specialty Societal recommendations, suggesting that treatment with ACEIs or ARBs should not be discontinued because of COVID-19.
C1 [Rossi, Luca; Biagi, Andrea; Zanni, Alessia; Sticozzi, Concetta; Comastri, Greta; Villani, Giovanni Quinto] Guglielmo da Saliceto Hosp, Cardiovasc & Emergency Dept, Div Cardiol, Piacenza, Italy.
   [Malagoli, Alessandro] Univ Modena & Reggio Emilia, S Agostino Estense Publ Hosp, Nephrocardiovasc Dept, Div Cardiol, 1355 Via Pietro Giardini, I-41126 Modena, Italy.
   [Pannone, Luigi; Vergara, Pasquale] Osped San Raffaele, Arrhythmia Unit, Milan, Italy.
   [Pannone, Luigi; Vergara, Pasquale] Osped San Raffaele, Electrophysiol Labs, Milan, Italy.
   [Gandolfi, Stefano] ASL Piacenza, Guglielmo Saliceto Hosp, Hlth Management, Piacenza, Italy.
RP Malagoli, A (corresponding author), Univ Modena & Reggio Emilia, S Agostino Estense Publ Hosp, Nephrocardiovasc Dept, Div Cardiol, 1355 Via Pietro Giardini, I-41126 Modena, Italy.
EM ale.malagoli@gmail.com
OI Malagoli, Alessandro/0000-0001-9119-4311
CR Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lopes RD, 2020, AM HEART J, V226, P49, DOI 10.1016/j.ahj.2020.05.002
   Lu JP, 2017, LANCET, V390, P2549, DOI [10.1016/S0140-6736(17)32478-9, 10.1016/s0140-6736(17)32478-9]
   Messerli FH, 2018, J AM COLL CARDIOL, V71, P1474, DOI 10.1016/j.jacc.2018.01.058
   Potier L, 2017, HEART, V103, P1339, DOI 10.1136/heartjnl-2016-310705
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Williams B, 2018, J HYPERTENS, V36, P1953, DOI 10.1097/HJH.0000000000001940
   World Health Organization (WHO), 2020, NOV COR CHIN
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
NR 18
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
DI 10.1007/s15010-020-01550-0
EA NOV 2020
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA OU5BF
UT WOS:000591542900001
PM 33222020
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jones, B
AF Jones, Ben
TI Eating meat and not vaccinating: In defense of the analogy
SO BIOETHICS
LA English
DT Article; Early Access
DE COVID&#8208; 19; farming; infectious disease; meat; vaccine; vegetarian;
   zoonotic
ID GLOBAL TRENDS; ORIGINS
AB The devastating impact of the COVID-19 (coronavirus disease 2019) pandemic is prompting renewed scrutiny of practices that heighten the risk of infectious disease. One such practice is refusing available vaccines known to be effective at preventing dangerous communicable diseases. For reasons of preventing individual harm, avoiding complicity in collective harm, and fairness, there is a growing consensus among ethicists that individuals have a duty to get vaccinated. I argue that these same grounds establish an analogous duty to avoid buying and eating most meat sold today, based solely on a concern for human welfare. Meat consumption is a leading driver of infectious disease. Wildlife sales at wet markets, bushmeat hunting, and concentrated animal feeding operations (CAFOs) are all exceptionally risky activities that facilitate disease spread and impose immense harms on human populations. If there is a moral duty to vaccinate, we also should recognize a moral duty to avoid most meat. The paper concludes by considering the implications of this duty for policy.
C1 [Jones, Ben] Penn State Univ, Rock Eth Inst, 131 Sparks Bldg, University Pk, PA 16802 USA.
RP Jones, B (corresponding author), Penn State Univ, Rock Eth Inst, 131 Sparks Bldg, University Pk, PA 16802 USA.
EM btj7@psu.edu
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Anthis K., 2019, GLOBAL FARMED FACTOR
   Brennan J, 2018, J MED ETHICS, V44, P37, DOI 10.1136/medethics-2016-103486
   Chaber AL, 2010, CONSERV LETT, V3, P317, DOI 10.1111/j.1755-263X.2010.00121.x
   Clarke S, 2017, BIOETHICS, V31, P155, DOI 10.1111/bioe.12326
   Compton R., 2015, DRUG ALCOHOL CRASH R, P5
   Daly N, 2020, NATL GEOGRAPHIC
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   Flanigan J, 2014, HEC FORUM, V26, P5, DOI 10.1007/s10730-013-9221-5
   Flynn MM, 2015, J HUNGER ENVIRON NUT, V10, P467, DOI 10.1080/19320248.2015.1045675
   Giubilini A, 2019, PALGRAVE ST ETHICS P, P1, DOI 10.1007/978-3-030-02068-2
   Giubilini A, 2020, J APPL PHILOS, V37, P446, DOI 10.1111/japp.12400
   Giubilini A, 2018, MED HEALTH CARE PHIL, V21, P547, DOI 10.1007/s11019-018-9829-y
   Giubilini A, 2017, J AGR ENVIRON ETHIC, V30, P179, DOI 10.1007/s10806-017-9660-0
   Greger M, 2007, CRIT REV MICROBIOL, V33, P243, DOI 10.1080/10408410701647594
   Howard PH, 2019, FOOD HEALTH ENVIRON, P31
   Huemer M., 2019, DIALOGUES ETHICAL VE, P19
   Ilea RC, 2009, J AGR ENVIRON ETHIC, V22, P153, DOI 10.1007/s10806-008-9136-3
   Kingston E, 2018, ETHICAL THEORY MORAL, V21, P169, DOI 10.1007/s10677-017-9859-1
   Kocich R, 2010, METAL 2010: 19TH INTERNATIONAL METALLURGICAL AND MATERIALS CONFERENCE, P166
   Melina V, 2016, J ACAD NUTR DIET, V116, P1970, DOI 10.1016/j.jand.2016.09.025
   Morse SS, 2012, LANCET, V380, P1956, DOI 10.1016/S0140-6736(12)61684-5
   Navin Mark, 2013, PUBLIC AFFAIRS Q, V27, P69
   O'Neill J., 2016, TACKLING DRUG RESIST, P10
   Olive JK, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002578
   Ordaz-Nemeth I, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005450
   Patel MK, 2019, MMWR-MORBID MORTAL W, V68, P1105, DOI 10.15585/mmwr.mm6848a1
   Pierik R, 2018, J APPL PHILOS, V35, P381, DOI 10.1111/japp.12215
   Samuel S., 2020, VOX             0422
   Seither R, 2019, MMWR-MORBID MORTAL W, V68, P905, DOI 10.15585/mmwr.mm6841e1
   Shah S., 2016, PANDEMIC TRACKING CO
   Silbergeld EK, 2008, ANNU REV PUBL HEALTH, V29, P151, DOI 10.1146/annurev.publhealth.29.020907.090904
   Simonsen L, 2016, J INFECT DIS, V214, pS380, DOI 10.1093/infdis/jiw376
   Smith KF, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0950
   Smith KE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051219
   Van Boeckel TP, 2015, P NATL ACAD SCI USA, V112, P5649, DOI 10.1073/pnas.1503141112
   Verweij M, 2005, BIOETHICS, V19, P323, DOI 10.1111/j.1467-8519.2005.00446.x
   Winders B, 2019, FOOD HEALTH ENVIRON, P1
   Wolfe ND, 2007, NATURE, V447, P279, DOI 10.1038/nature05775
   Woo PCY, 2006, CURR OPIN INFECT DIS, V19, P401, DOI 10.1097/01.qco.0000244043.08264.fc
   Woolhouse M, 2007, CRIT REV MICROBIOL, V33, P231, DOI 10.1080/10408410701647560
   Woolhouse MEJ, 2005, EMERG INFECT DIS, V11, P1842, DOI 10.3201/eid1112.050997
NR 42
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-9702
EI 1467-8519
J9 BIOETHICS
JI Bioethics
DI 10.1111/bioe.12834
EA NOV 2020
PG 8
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA OT9NU
UT WOS:000591164800001
PM 33222212
OA Bronze
DA 2021-01-01
ER

PT J
AU Stevenson, JM
   Alexander, GC
   Palamuttam, N
   Mehta, HB
AF Stevenson, James M.
   Alexander, G. Caleb
   Palamuttam, Natasha
   Mehta, Hemalkumar B.
TI Projected Utility of Pharmacogenomic Testing Among Individuals
   Hospitalized With COVID-19: A Retrospective Multicenter Study in the
   United States
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article; Early Access
ID CONSORTIUM CPIC GUIDELINES; IMPLEMENTATION; CYP2D6; GENOTYPE; CYP2C19;
   POLYMORPHISMS; KNOWLEDGE; THERAPY
AB Many academic institutions are collecting blood samples from patients seeking treatment for coronavirus disease 2019 (COVID-19) to build research biorepositories. It may be feasible to extract pharmacogenomic (PGx) information from biorepositories for clinical use. We sought to characterize the potential value of multigene PGx testing among individuals hospitalized with COVID-19 in the United States. We performed a cross-sectional analysis of electronic health records from consecutive individuals hospitalized with COVID-19 at a large, urban academic health system. We characterized medication orders, focusing on medications with actionable PGx guidance related to 14 commonly assayed genes (CYP2C19, CYP2C9, CYP2D6, CYP3A5, DPYD, G6PD, HLA-A, HLA-B, IFNL3, NUDT15, SLCO1B1, TPMT, UGT1A1, and VKORC1). A simulation analysis combined medication data with population phenotype frequencies to estimate how many treatment modifications would be enabled if multigene PGx results were available. Sixty-four unique medications with PGx guidance were ordered at least once in the cohort (n = 1,852, mean age 60.1 years). Nearly nine in 10 individuals (89.7%) had at least one order for a medication with PGx guidance and 427 patients (23.1%) had orders for 4 or more actionable medications. Using a simulation, we estimated that 17 treatment modifications per 100 patients would be enabled if PGx results were available. The genes CYP2D6 and CYP2C19 were responsible for the majority of treatment modifications, and the medications most often affected were ondansetron, oxycodone, and clopidogrel. PGx results would be relevant for nearly all individuals hospitalized with COVID-19 and would provide the opportunity to improve clinical care.
C1 [Stevenson, James M.] Johns Hopkins Univ, Sch Med, Div Clin Pharmacol, Baltimore, MD 21218 USA.
   [Alexander, G. Caleb; Mehta, Hemalkumar B.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effect, Baltimore, MD USA.
   [Alexander, G. Caleb; Mehta, Hemalkumar B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Alexander, G. Caleb] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA.
   [Palamuttam, Natasha] Johns Hopkins Univ, Sch Med, Div Hlth Sci Informat, Baltimore, MD USA.
RP Stevenson, JM (corresponding author), Johns Hopkins Univ, Sch Med, Div Clin Pharmacol, Baltimore, MD 21218 USA.
EM stevenson@jhmi.edu
FU Hopkins inHealth, the Johns Hopkins Precision Medicine Program
FX The data utilized for this publication were part of the JH-CROWN: COVID
   PMAP Registry, which is based on the contribution of many patients and
   clinicians. JH-CROWN received funding from Hopkins inHealth, the Johns
   Hopkins Precision Medicine Program. The authors gratefully acknowledge
   Diana Gumas, Jacob Fiksel, Stuart Ray, and Bonnie Woods for their
   contributions to the JH-CROWN and our analytic approach.
CR Aquilante CL, 2020, PHARMACOGENOMICS, V21, P375, DOI 10.2217/pgs-2020-0007
   Beitelshees AL, 2020, GENET MED, V22, P1898, DOI 10.1038/s41436-020-0894-2
   Bell GC, 2017, CLIN PHARMACOL THER, V102, P213, DOI 10.1002/cpt.598
   Birdwell KA, 2015, CLIN PHARMACOL THER, V98, P19, DOI 10.1002/cpt.113
   Black RM, 2020, PHARMACOGENOMICS, V21, P431, DOI 10.2217/pgs-2019-0185
   Brown JT, 2019, CLIN PHARMACOL THER, V106, P94, DOI 10.1002/cpt.1409
   Candiotti KA, 2005, ANESTHESIOLOGY, V102, P543, DOI 10.1097/00000542-200503000-00011
   Caudle KE, 2014, CLIN PHARMACOL THER, V96, P542, DOI 10.1038/clpt.2014.159
   Caudle KE, 2016, AM J HEALTH-SYST PH, V73, P1977, DOI 10.2146/ajhp150977
   Cavallari LH, 2019, GENET MED, V21, P2255, DOI 10.1038/s41436-019-0484-3
   Cavallari LH, 2011, BLOOD CELL MOL DIS, V46, P147, DOI 10.1016/j.bcmd.2010.11.005
   Centers for Disease Control and Prevention, 2020, COVIDVIEW WEEKL SURV
   Chanfreau-Coffinier C, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.5345
   Clinical Pharmacogenetics Implementation Consortium, GEN DRUGS CPIC
   COVID-19 Treatment Guidelines Panel, 2020, COR DIS 2019 COVID 1
   Crews KR, 2012, CLIN PHARMACOL THER, V91, P321, DOI 10.1038/clpt.2011.287
   Dong OM, 2020, VALUE HEALTH, V23, P61, DOI 10.1016/j.jval.2019.08.002
   Dunnenberger HM, 2015, ANNU REV PHARMACOL, V55, P89, DOI 10.1146/annurev-pharmtox-010814-124835
   El Rouby N, 2020, CTS-CLIN TRANSL SCI, V13, P473, DOI 10.1111/cts.12729
   Empey PE, 2018, CLIN PHARMACOL THER, V104, P664, DOI 10.1002/cpt.1006
   Endo S, 2012, J HUM GENET, V57, P531, DOI 10.1038/jhg.2012.63
   Figueiras A, 2016, PHARMACOGENET GENOM, V26, P66, DOI 10.1097/FPC.0000000000000186
   Gammal RS, 2016, CLIN PHARMACOL THER, V99, P363, DOI 10.1002/cpt.269
   Goetz MP, 2018, CLIN PHARMACOL THER, V103, P770, DOI 10.1002/cpt.1007
   Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029
   Grice GR, 2006, PHARMACOGENOMICS, V7, P61, DOI 10.2217/14622416.7.1.61
   Haga SB, 2018, HEALTH AFFAIR, V37, P717, DOI 10.1377/hlthaff.2017.1564
   Hicks JK, 2017, CLIN PHARMACOL THER, V102, P37, DOI 10.1002/cpt.597
   Hicks JK, 2015, CLIN PHARMACOL THER, V98, P127, DOI 10.1002/cpt.147
   Kaiser R, 2002, J CLIN ONCOL, V20, P2805, DOI 10.1200/JCO.2002.09.064
   Lee Jangwoo, 2019, MSMR, V26, P14
   Lima JJ, 2020, CLIN PHARMACOL THER, DOI 10.1002/cpt.2015
   Macias Y, 2020, EXPERT OPIN DRUG MET, V16, P319, DOI 10.1080/17425255.2020.1744563
   Manickam K, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.2140
   Moriyama B, 2017, CLIN PHARMACOL THER, V102, P45, DOI 10.1002/cpt.583
   Murray MF, 2020, GENET MED, V22, P1175, DOI 10.1038/s41436-020-0832-3
   PharmGKB, 2020, ANN DPWG GUID RISP C
   Phillips EJ, 2018, CLIN PHARMACOL THER, V103, P574, DOI 10.1002/cpt.1004
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Relling MV, 2019, CLIN PHARMACOL THER, V105, P1095, DOI 10.1002/cpt.1304
   Saito Y, 2016, CLIN PHARMACOL THER, V99, P36, DOI 10.1002/cpt.161
   Scott SA, 2013, CLIN PHARMACOL THER, V94, P317, DOI 10.1038/clpt.2013.105
   Smith DM, 2020, CTS-CLIN TRANSL SCI, V13, P618, DOI 10.1111/cts.12748
   Stergachis AB, 2020, NAT MED, V26, P991, DOI 10.1038/s41591-020-0953-x
   Theken KN, 2020, CLIN PHARMACOL THER, V108, P191, DOI 10.1002/cpt.1830
   U.S. National Library of Medicine, 2020, DAILYMED COUMADIN WA
   United States Food and Drug Administration, 2020, TABL PHARM ASS
   United States Food and Drug Administration, 2020, TABL PHARM BIOM DRUG
   Vandell AG, 2017, HEART, V103, P1800, DOI 10.1136/heartjnl-2016-310901
   Whirl-Carrillo M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/clpt.2012.96
NR 50
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
DI 10.1111/cts.12919
EA NOV 2020
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OT9PX
UT WOS:000591170300001
PM 33085221
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Ibernon, M
   Bueno, I
   Rodriguez-Farre, N
   Ruiz, P
   Sanchez, A
   Masso, E
   Rap, O
   Gimenez, I
   Cabrera, C
AF Ibernon, Meritxell
   Bueno, Isabel
   Rodriguez-Farre, Neus
   Ruiz, Pilar
   Sanchez, Ana
   Masso, Elisabet
   Rap, Oana
   Gimenez, Isabel
   Cabrera, Cristina
TI The impact of COVID-19 in hemodialysis patients: Experience in a
   hospital dialysis unit
SO HEMODIALYSIS INTERNATIONAL
LA English
DT Article; Early Access
DE dialysis; COVID-19; SARS-CoV-2
ID OUTBREAK
AB IntroductionCOVID-19 is a very high transmission disease with a variable prognosis in the general population. Patients in hemodialysis therapy are particularly vulnerable to developing an infectious disease, but the incidence and prognosis of hemodialysis patients with COVID-19 is still unclear. The main objective is to describe the experience of our dialysis unit in preventing and controlling the spread of SARS-CoV-2 infection.
   MethodsPreventive structural and organizational changes were applied to all patients and health care personnel in order to limit the risk of local transmission of SARS-CoV-2 infection.
   FindingsThe Nephrology department at Sant Joan Despi Moises Broggi Hospital-Consorci Sanitari Integral is a reference for two satellite hemodialysis centers caring for 156 patients. We combine our own hemodialysis maintenance program for 87 patients with hospitalized patients from peripheral hemodialysis centers. In this area, the reported incident rate of COVID-19 in these peripherical hemodialysis centers was 9.5% to 19.9% and the death rate 25% to 30.5%. In our hemodialysis program, the incidence rate was 5.7%. Three out of five required hospitalization (60%) and nobody died.
   DiscussionAlthough the risk of local transmission of the disease was very high due to the increase in hemodialysis patients from peripheral centers admitted to hospital, the incidence rate of COVID-19 was very low in our own hemodialysis patients. We believe that the structural and organizational changes adopted early on and the diagnosis algorithm played an important role in minimizing the spread of the disease.
C1 [Ibernon, Meritxell; Bueno, Isabel; Rodriguez-Farre, Neus; Ruiz, Pilar; Sanchez, Ana; Masso, Elisabet; Rap, Oana; Gimenez, Isabel; Cabrera, Cristina] Hosp St Joan Despi Moises Broggi, Consorci Sanitari Integral, Nephrol Dept, Barcelona, Spain.
RP Ibernon, M (corresponding author), Hosp St Joan Despi Moises Broggi, Nephrol Dept, C Jacint Verdaguer 90, Barcelona 08970, Spain.
EM meritxell.ibernonvilaro@sanitatintegral.org
CR Alberici F, 2020, KIDNEY INT, V98, P20, DOI 10.1016/j.kint.2020.04.030
   Basile C, 2020, NEPHROL DIAL TRANSPL, V35, P737, DOI 10.1093/ndt/gfaa069
   Sanchez-Alvarez JE, 2020, NEFROLOGIA, V40, P272, DOI 10.1016/j.nefro.2020.04.002
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   La Milia V, 2020, KIDNEY INT REP, V5, P1095, DOI 10.1016/j.ekir.2020.05.019
   Ma YQ, 2020, KIDNEY INT REP, V5, P1333, DOI 10.1016/j.ekir.2020.06.003
   Rincon A, 2020, CLIN KIDNEY J, V13, P542, DOI 10.1093/ckj/sfaa119
   Vaziri ND, 2012, J RENAL NUTR, V22, P149, DOI 10.1053/j.jrn.2011.10.020
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
NR 12
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1492-7535
EI 1542-4758
J9 HEMODIAL INT
JI Hemodial. Int.
DI 10.1111/hdi.12905
EA NOV 2020
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA OU0JE
UT WOS:000591222100001
PM 33225565
OA Bronze
DA 2021-01-01
ER

PT J
AU Lentine, KL
   Lam, NN
   Caliskan, Y
   Alhamad, T
   Xiao, HL
   Schnitzler, MA
   Chang, SH
   Axelrod, D
   Segev, DL
   McAdams-DeMarco, M
   Kasiske, BL
   Hess, GP
   Brennan, DC
AF Lentine, Krista L.
   Lam, Ngan N.
   Caliskan, Yasar
   Alhamad, Tarek
   Xiao, Huiling
   Schnitzler, Mark A.
   Chang, Su-Hsin
   Axelrod, David
   Segev, Dorry L.
   McAdams-DeMarco, Mara
   Kasiske, Bertram L.
   Hess, Gregory P.
   Brennan, Daniel C.
TI Hydroxychloroquine and maintenance immunosuppression use in kidney
   transplant recipients: Analysis of linked US registry and claims data
SO CLINICAL TRANSPLANTATION
LA English
DT Article; Early Access
DE hydroxychloroquine; immunosuppression; kidney transplantation; outcomes;
   pharmacy claims; registries; scleroderma; systemic lupus erythematosus
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; LONG-TERM; CHLOROQUINE; NEPHRITIS;
   INDUCTION; SURVIVAL; DAMAGE; DRUGS; RISK; TOLL
AB Hydroxychloroquine (HCQ) is an antimalarial drug with immunomodulatory effects used to treat systemic lupus erythematosus (SLE) and scleroderma. The antiviral effects of HCQ have raised attention in the context of the COVID-19 pandemic, although safety is controversial. We examined linkages of national transplant registry data with pharmaceutical claims and Medicare billing claims to study HCQ use among Medicare-insured kidney transplant recipients with SLE or scleroderma (2008-2017; N = 1820). We compared three groups based on immunosuppression regimen 7 months-to-1 year post transplant: (a) tacrolimus (Tac) + mycophenolic acid (MPA) + prednisone (Pred) (referent group, 77.7%); (b) Tac + MPA + Pred + HCQ (16.5%); or (c) other immunosuppression + HCQ (5.7%). Compared to the referent group, recipients treated with other immunosuppression + HCQ had a 2-fold increased risk of abnormal ECG or QT prolongation (18.9% vs. 10.7%; aHR,(1.12)1.96(3.42), p = .02) and ventricular arrhythmias (15.2% vs. 11.4%; aHR,(1.00)1.81(3.29), p = .05) in the >1-to-3 years post-transplant. Tac + MPA + Pred + HCQ was associated with increased risk of ventricular arrhythmias (13.5% vs. 11.4%; aHR,(1.02)1.54(2.31), p = .04) and pancytopenia (35.9% vs. 31.4%; aHR,(1.03)1.31(1.68), p = .03) compared to triple immunosuppression without HCQ. However, HCQ-containing regimens were not associated with an increased risk of death or graft failure. HCQ may be used safely in selected kidney transplant recipients in addition to their maintenance immunosuppression, although attention to arrhythmias is warranted.
C1 [Lentine, Krista L.; Caliskan, Yasar; Xiao, Huiling; Schnitzler, Mark A.] St Louis Univ, Ctr Abdominal Transplantat, St Louis, MO 63103 USA.
   [Lam, Ngan N.] Univ Calgary, Calgary, AB, Canada.
   [Alhamad, Tarek; Chang, Su-Hsin] Washington Univ St Louis, St Louis, MO USA.
   [Axelrod, David] Univ Iowa, Iowa City, IA USA.
   [Segev, Dorry L.; McAdams-DeMarco, Mara; Brennan, Daniel C.] Johns Hopkins Univ, Baltimore, MD USA.
   [Kasiske, Bertram L.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
   [Hess, Gregory P.] Drexel Univ, Philadelphia, PA 19104 USA.
RP Lentine, KL (corresponding author), St Louis Univ, Transplant Ctr, 1402 S Grand Blvd, St Louis, MO 63104 USA.
EM krista.lentine@health.slu.edu
RI Lam, Ngan/AAX-3472-2020; Lentine, Krista/AAQ-6549-2020
OI Lam, Ngan/0000-0002-0129-7091; Lentine, Krista/0000-0002-9423-4849;
   Chang, Su-Hsin/0000-0001-5872-9556
FU National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [R01-DK120518]; Health Resources and Services
   AdministrationUnited States Department of Health & Human ServicesUnited
   States Health Resources & Service Administration (HRSA)
   [HHSH250201000018C]
FX National Institute of Diabetes and Digestive and Kidney Diseases,
   Grant/Award Number: R01-DK120518; Health Resources and Services
   Administration, Grant/Award Number: HHSH250201000018C
CR Alarcon GS, 2007, ANN RHEUM DIS, V66, P1168, DOI 10.1136/ard.2006.068676
   Alhamad T, 2019, TRANSPLANTATION, V103, P2373, DOI 10.1097/TP.0000000000002599
   Alhamad T, 2016, TRANSPLANTATION, V100, P1086, DOI 10.1097/TP.0000000000001113
   Axelrod DA, 2020, CLIN TRANSPLANT, V34, DOI 10.1111/ctr.13813
   Baccala R, 2007, NAT MED, V13, P543, DOI 10.1038/nm1590
   Bruni C, 2017, JOINT BONE SPINE, V84, P747, DOI 10.1016/j.jbspin.2016.10.002
   Dharnidharka VR, 2018, TRANSPL INT, V31, P198, DOI 10.1111/tri.13079
   Eckardt KU, 2009, AM J TRANSPLANT, V9, pS1, DOI 10.1111/j.1600-6143.2009.02834.x
   ESDAILE J, 1991, NEW ENGL J MED, V324, P150
   Fanouriakis A, 2020, ANN RHEUM DIS, V79, P713, DOI [10.1136/annrheumdis-2020-216924, 10.1136/annrheumdis-2020-217804]
   Fernandez-Codina A, 2018, ARTHRITIS RHEUMATOL, V70, P1820, DOI 10.1002/art.40560
   Fessler BJ, 2005, ARTHRITIS RHEUM, V52, P1473, DOI 10.1002/art.21039
   Halloran PF, 2004, NEW ENGL J MED, V351, P2715, DOI 10.1056/NEJMra033540
   Ikitimur B, 2015, ANN NONINVAS ELECTRO, V20, P426, DOI 10.1111/anec.12225
   Karres I, 1998, AM J PHYSIOL-REG I, V274, pR1058
   Lafyatis R, 2006, ARTHRITIS RHEUM, V54, P3068, DOI 10.1002/art.22157
   Lentine KL, 2018, AM J TRANSPLANT, V18, P2987, DOI 10.1111/ajt.14714
   Lentine KL, 2013, AM J NEPHROL, V38, P420, DOI 10.1159/000356092
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Newton-Cheh C, 2011, NEW ENGL J MED, V364, P1450, DOI 10.1056/NEJMcpc1011319
   Pons-Estel GJ, 2009, ARTHRIT RHEUM-ARTHR, V61, P830, DOI 10.1002/art.24538
   Ruiz-Irastorza G, 2006, LUPUS, V15, P577, DOI 10.1177/0961203306071872
   Smith KD, 2006, J AM SOC NEPHROL, V17, P3273, DOI 10.1681/ASN.2006101138
   Tang TT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0378-3
   Tonnesmann E, 2013, IMMUNOPHARM IMMUNOT, V35, P434, DOI 10.3109/08923973.2013.780078
   Tsakonas E, 1998, LUPUS, V7, P80
   Vest LS, 2018, CLIN TRANSPLANT, V32, DOI 10.1111/ctr.13302
NR 28
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
EI 1399-0012
J9 CLIN TRANSPLANT
JI Clin. Transplant.
AR e14118
DI 10.1111/ctr.14118
EA NOV 2020
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OT9QG
UT WOS:000591171200001
PM 33048372
DA 2021-01-01
ER

PT J
AU Malekahmadi, O
   Zarei, A
   Esfahani, MBB
   Hekmatifar, M
   Sabetvand, R
   Marjani, A
   Bach, QV
AF Malekahmadi, Omid
   Zarei, Akbar
   Botlani Esfahani, Mohammad Behzad
   Hekmatifar, Maboud
   Sabetvand, Roozbeh
   Marjani, Azam
   Bach, Quang-Vu
TI Thermal and hydrodynamic properties of coronavirus at various
   temperature and pressure via molecular dynamics approach
SO JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY
LA English
DT Article; Early Access
DE Coronavirus; Molecular dynamic simulation; Temperature effect;
   Thermodynamic properties
ID INITIAL CONFIGURATIONS
AB COVID-19 is an epidemic virus arising from a freshly discovered coronavirus. Most people involved with the coronavirus will experience slight to moderate respiratory disease and recover without needing particular therapy. In this work, the atomic stability of the coronavirus at different thermodynamic properties such as temperature and pressure, was studied. For this purpose, the manner of this virus by atomic precession was described with a molecular dynamics approach. For the atomic stability of coronavirus description, physical properties such as temperature, total energy, volume variation, and atomic force of this structure were reported. In molecular dynamics approach, coronavirus is precisely simulated via S, O, N, and C atoms and performed Dreiding force field to describe these atoms interaction in the virus. Simulation results show that coronavirus stability has reciprocal relation with atomic temperature and pressure. Numerically, after 2.5 ns simulation, the potential energy varies from - 31,163 to - 26,041 eV by temperature changes from 300 to 400 K. Furthermore, this physical parameter decreases to - 28,045 eV rate at 300 K and 2 bar pressure. The volume of coronavirus is another crucial parameter to the stability description of this structure. The simulation shows that coronavirus volume 92% and 14% increases by 100 K and 2 bar variation of simulation temperature and pressure, respectively.
C1 [Malekahmadi, Omid] Yazd Univ, Dept Min & Met Engn, Yazd, Iran.
   [Zarei, Akbar; Botlani Esfahani, Mohammad Behzad] Islamic Azad Univ, Najafabad Branch, Dept Mech Engn, Najafabad, Iran.
   [Hekmatifar, Maboud; Marjani, Azam] Islamic Azad Univ, Khomeinishahr Branch, Dept Mech Engn, Khomeinishahr, Iran.
   [Sabetvand, Roozbeh] Amirkabir Univ Technol, Fac Condensed Matter Phys, Dept Energy Engn & Phys, Tehran, Iran.
   [Bach, Quang-Vu] Duy Tan Univ, Inst Res & Dev, Danang 550000, Vietnam.
RP Bach, QV (corresponding author), Duy Tan Univ, Inst Res & Dev, Danang 550000, Vietnam.
EM bachquangvu@duytan.edu.vn
RI Malekahmadi, Omid/Q-6497-2017
OI Malekahmadi, Omid/0000-0002-1200-4039
CR Alamri SZ, 2019, J MOL LIQ, V273, P292, DOI 10.1016/j.molliq.2018.10.038
   ALDER BJ, 1959, J CHEM PHYS, V31, P459, DOI 10.1063/1.1730376
   Almeida JD, 1968, NATURE, V220, P650
   Ashkezari AZ, 2020, COMPUT METH PROG BIO, V188, DOI 10.1016/j.cmpb.2019.105256
   Berendsen H.J.C., 1981, INTERMOLECULAR FORCE
   Brown WM, 2012, COMPUT PHYS COMMUN, V183, P449, DOI 10.1016/j.cpc.2011.10.012
   Brown WM, 2011, COMPUT PHYS COMMUN, V182, P898, DOI 10.1016/j.cpc.2010.12.021
   Cavanagh D, 2001, AVIAN PATHOL, V30, P355, DOI 10.1080/03079450120066368
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ghanbari A, 2019, COATINGS, V9, DOI 10.3390/coatings9090584
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695
   Jolfaei NA, 2020, COMPUT METH PROG BIO, V185, DOI 10.1016/j.cmpb.2019.105169
   Jones JE, 1924, P R SOC LOND A-CONTA, V106, P463, DOI 10.1098/rspa.1924.0082
   King AMQ, 2012, 9 INT COMM TAX VIR, P806, DOI [10.1016/B978-0-12-384684-6.00068-9, DOI 10.1016/B978-0-12-384684-6.00068-9, 10.1016/B978-0-12-384684-6.00068-9.3.]
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Martinez JM, 2003, J COMPUT CHEM, V24, P819, DOI 10.1002/jcc.10216
   Martinez L, 2009, J COMPUT CHEM, V30, P2157, DOI 10.1002/jcc.21224
   Masters PS, 2019, VIROLOGY, V537, P198, DOI 10.1016/j.virol.2019.08.031
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   Neuman BW, 2006, J VIROL, V80, P7918, DOI 10.1128/JVI.00645-06
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334
   Qi C, 2020, J THERM ANAL CALORIM, V141, P277, DOI 10.1007/s10973-020-09519-9
   Qi C, 2017, INT J HEAT MASS TRAN, V105, P664, DOI 10.1016/j.ijheatmasstransfer.2016.10.043
   RAHMAN A, 1964, PHYS REV, V136, pA405, DOI 10.1103/PhysRev.136.A405
   Rapaport D. C., 2004, ART MOL DYNAMICS SIM
   Riaz A, 2020, PHYSICA A, V545, DOI 10.1016/j.physa.2019.123788
   Sabetvand R, 2020, J COMPUT ELECTRON, V19, P70, DOI 10.1007/s10825-020-01443-3
   Saif RS, 2020, PHYSICA A, V551, DOI 10.1016/j.physa.2019.124060
   Stukowski A, 2010, MODEL SIMUL MATER SC, V18, DOI 10.1088/0965-0393/18/1/015012
NR 35
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-6150
EI 1588-2926
J9 J THERM ANAL CALORIM
JI J. Therm. Anal. Calorim.
DI 10.1007/s10973-020-10353-2
EA NOV 2020
PG 10
WC Thermodynamics; Chemistry, Analytical; Chemistry, Physical
SC Thermodynamics; Chemistry
GA OU0WF
UT WOS:000591256400006
PM 33250660
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Paolucci, M
   Biguzzi, S
   Cordici, F
   Lotti, EM
   Morresi, S
   Romoli, M
   Strumia, S
   Terlizzi, R
   Vidale, S
   Menarini, M
   Ruggiero, M
   Valentino, A
   Longoni, M
AF Paolucci, Matteo
   Biguzzi, Sara
   Cordici, Francesco
   Lotti, Enrico Maria
   Morresi, Simonetta
   Romoli, Michele
   Strumia, Silvia
   Terlizzi, Rossana
   Vidale, Simone
   Menarini, Maurizio
   Ruggiero, Maria
   Valentino, Alessandro
   Longoni, Marco
TI Impact of COVID-19 pandemic on acute stroke care: facing an
   epidemiological paradox with a paradigm shift
SO NEUROLOGICAL SCIENCES
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Stroke incidence; Thrombolysis; Thrombectomy
AB Background During the coronavirus disease 2019 (COVID-19) outbreak, a decrease of stroke's hospital admissions and reperfusion therapy has been reported worldwide. This retrospective observational study assessed the volume of stroke cases managed in the Emergency Department (ED) and reperfusion therapies in an Italian stroke network with a high incidence of COVID-19, particularly to evaluate if the in-hospital rerouting and the switch from a drip-and-ship to a mothership model could assure an adequate volume of acute treatments. Methods We compared data from March 2020 with those from previous years and formulated five PICO questions regarding (1) incidence of stroke cases in the ED; (2) relation between stroke cases and COVID-19; (3) differences in the number of reperfusion therapies, (4) in the call-to-needle and door-to-needle times for intravenous thrombolysis, and (5) in the call-to-groin and door-to-groin times for thrombectomy. Results We found (1) a 28% decreased of confirmed stroke cases managed in the ED, (2) a negative correlation between stroke cases in ED and COVID-19 progression (r(s) = - .390, p = .030), and (3) a similar number of treatments in March 2020 and March 2019. The adoption of the mothership model (4) did not delay alteplase infusion (median call-to-needle p = .126, median door-to-needle p = .142) but led to (5) a significant reduction in median call-to-groin (p = .018) and door-to-groin times (p = .010). Conclusion The "hospital avoidance" of stroke patients during the "stay-at-home" appeals needs to be considered for future public health campaigns. A prompt reorganization of the stroke network can guarantee optimal performances at times of crisis.
C1 [Paolucci, Matteo; Biguzzi, Sara; Cordici, Francesco; Morresi, Simonetta; Romoli, Michele; Terlizzi, Rossana; Longoni, Marco] AUSL Romagna, Neurol Unit, M Bufalini Hosp, Viale Giovanni Ghirotti 286, I-47521 Cesena, FC, Italy.
   [Paolucci, Matteo] Campus Biomed Univ, Headache & Neurosonol Unit, Rome, Italy.
   [Lotti, Enrico Maria; Romoli, Michele; Vidale, Simone] AUSL Romagna, Neurol Unit, Infermi Hosp, Rimini, RN, Italy.
   [Strumia, Silvia; Longoni, Marco] AUSL Romagna, Neurol Unit, Morgagni Pierantoni Hosp, Forli, FC, Italy.
   [Menarini, Maurizio] AUSL Romagna, Cent Operat Romagna & Emergenza Terr Prov Ravenna, Ravenna, Italy.
   [Ruggiero, Maria] AUSL Romagna, Neuroradiol Unit, M Bufalini Hosp, Cesena, FC, Italy.
   [Valentino, Alessandro] AUSL Romagna, M Bufalini Hosp, Pronto Soccorso & Med Urgenza, Cesena, FC, Italy.
RP Paolucci, M (corresponding author), AUSL Romagna, Neurol Unit, M Bufalini Hosp, Viale Giovanni Ghirotti 286, I-47521 Cesena, FC, Italy.; Paolucci, M (corresponding author), Campus Biomed Univ, Headache & Neurosonol Unit, Rome, Italy.
EM matteo.paolucci@auslromagna.it
RI Paolucci, Matteo/AAE-2722-2019
OI Paolucci, Matteo/0000-0002-5347-378X
CR Aggarwal G, 2020, INT J STROKE, V15, P385, DOI 10.1177/1747493020921664
   de Sousa DA, 2020, STROKE, V51, P1921, DOI 10.1161/STROKEAHA.120.030792
   Baracchini C, 2020, NEUROL SCI, V41, P1003, DOI 10.1007/s10072-020-04375-9
   ISTAT-Istituto Nazionale di Statistica, 2020, POPOLAZIONE RESIDENT
   Kerleroux B, 2020, STROKE, V51, P2012, DOI 10.1161/STROKEAHA.120.030373
   Larson AS, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016793
   Montaner J, 2020, STROKE, V51, P2307, DOI 10.1161/STROKEAHA.120.030106
   Naccarato M, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116889
   Qin C, 2020, STROKE, V51, P2219, DOI 10.1161/STROKEAHA.120.030365
   Rudilosso S, 2020, STROKE, V51, P1991, DOI 10.1161/STROKEAHA.120.030329
   Siegler J E, 2020, J Stroke Cerebrovasc Dis, P104953, DOI 10.1016/j.jstrokecerebrovasdis.2020.104953
   Tsivgoulis G, 2020, STROKE, V51, P1924, DOI 10.1161/STROKEAHA.120.030791
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Yaghi S, 2020, STROKE, V51, P2002, DOI 10.1161/STROKEAHA.120.030335
   Zhao J, 2020, STROKE, V51, P1996, DOI 10.1161/STROKEAHA.120.030225
NR 15
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
DI 10.1007/s10072-020-04914-4
EA NOV 2020
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OU0UQ
UT WOS:000591252200003
PM 33222101
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Camilleri, M
   Sive, J
   Wilson, W
   Pang, G
   Jenner, R
   Phillips, E
   Popat, R
   Ramasamy, K
   Bygrave, C
   Dadaga, T
   Streetly, M
   Cavenagh, J
   Chapman, M
   Barrington, S
   Pike, L
   Owen, R
   Clifton-Hadley, L
   Yong, K
AF Camilleri, Marquita
   Sive, Jonathan
   Wilson, William
   Pang, Gavin
   Jenner, Richard
   Phillips, Elizabeth
   Popat, Rakesh
   Ramasamy, Karthik
   Bygrave, Ceri
   Dadaga, Tushhar
   Streetly, Matthew
   Cavenagh, James
   Chapman, Mike
   Barrington, Sally
   Pike, Lucy
   Owen, Roger
   Clifton-Hadley, Laura
   Yong, Kwee
TI COVID-19 and myeloma clinical research - experience from the CARDAMON
   clinical trial
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Letter; Early Access
DE myeloma; COVID-19; clinical trials
C1 [Camilleri, Marquita; Sive, Jonathan; Popat, Rakesh; Yong, Kwee] Univ Coll Hosp, Haematol Dept, London, England.
   [Wilson, William; Pang, Gavin; Jenner, Richard; Dadaga, Tushhar; Clifton-Hadley, Laura] UCL, Canc Res UK & UCL Canc Trials Ctr, London, England.
   [Phillips, Elizabeth] Univ Manchester, Manchester Canc Res Ctr, Div Canc Sci, Manchester, Lancs, England.
   [Camilleri, Marquita; Yong, Kwee] UCL, Canc Inst, London, England.
   [Ramasamy, Karthik] Oxford Univ Hosp NHS Trust, Haematol Dept, Oxford, England.
   [Ramasamy, Karthik] Univ Oxford, Radcliffe Dept Med, Oxford, England.
   [Bygrave, Ceri] Univ Hosp Wales, Haematol Dept, Cardiff, Wales.
   [Streetly, Matthew] Guys & St Thomas NHS Trust, Haematol Dept, London, England.
   [Cavenagh, James] Barts Hlth NHS Trust, Haematol Dept, London, England.
   [Chapman, Mike] Cambridge Inst Med Res, Haematol Dept, Cambridge, England.
   [Barrington, Sally; Pike, Lucy] Kings Coll London, Sch Biomed Engn & Imaging Sci, London, England.
   [Owen, Roger] St James Inst Oncol, HMDS Lab, Leeds, W Yorkshire, England.
RP Camilleri, M (corresponding author), Univ Coll Hosp, Haematol Dept, London, England.; Camilleri, M (corresponding author), UCL, Canc Inst, London, England.
EM marquita.camilleri@nhs.net
OI , Marquita/0000-0002-4161-8275; Bygrave, Ceri/0000-0002-1571-0692
FU Amgen LtdAmgen; Cancer Research UKCancer Research UK [C9203/A17750];
   UCL/UCLH National Institute for Health Research and Social Care (NIHR)
   Biomedical Research; NIHRNational Institute for Health Research (NIHR)
   [RP-2-16-07-001]; CRUKCancer Research UK; EPSRCEngineering & Physical
   Sciences Research Council (EPSRC); Department of Health and Social Care
   (England); Wellcome/EPSRC Centre for Medical Engineering at King's
   College London [WT 203148/Z/16/Z]; MRCMedical Research Council UK (MRC)
FX CARDAMON is coordinated by the CRUK & UCL CTC, funded by Amgen Ltd and
   endorsed by Cancer Research UK (C9203/A17750). The authors would like to
   thank CARDAMON participating sites, local investigators and research
   teams for their ongoing participation in the study, together with
   patients and their families.; Professor Kwee Yong and Dr Rakesh Popat
   acknowledge support and funding from the UCL/UCLH National Institute for
   Health Research and Social Care (NIHR) Biomedical Research.; Professor
   Barrington also acknowledges support from the NIHR (RP-2-16-07-001).
   King's College London and UCL Comprehensive Cancer Imaging Centre is
   funded by the CRUK and EPSRC in association with the MRC and Department
   of Health and Social Care (England). This work was also supported by the
   Wellcome/EPSRC Centre for Medical Engineering at King's College London
   (WT 203148/Z/16/Z). The views expressed are those of the author(s) and
   not necessarily those of the NHS, the NIHR or the Department of Health
   and Social Care.
CR British Society of Blood and Marrow Transplantation and Cellular Therapy, BSBMTCT REC MAN AD P
   Camilleri M, 2020, THROMBOTIC MICROANGI
   Doherty Gary J, 2020, Nat Cancer, P1, DOI 10.1038/s43018-020-0083-x
   European Medicines Agency, EMA1583302020
   European Medicines Agency and Heads of Medicines Agency, GUID MAN CLIN TRIALS
   European Society for Medical Oncology - ESMO, ESMO MAN TREATM AD R
   Fox TA, 2020, BRIT J HAEMATOL, V191, P194, DOI 10.1111/bjh.17027
   Medicines and Healthcare products Regulatory Agency, MAN CLIN TRIALS COR
   Public Health England, COR COVID 19 UK
   Terpos E, 2020, LEUKEMIA, V34, P2000, DOI 10.1038/s41375-020-0876-z
   UK Myeloma Forum, COV 19 GUID
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   World Health Organization, WHO COR DIS COVID 19
   Yong K, 2019, BLOOD, V134, DOI 10.1182/blood-2019-127992
NR 14
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
DI 10.1111/bjh.17168
EA NOV 2020
PG 3
WC Hematology
SC Hematology
GA OT8FA
UT WOS:000591074400001
PM 33222153
OA Bronze
DA 2021-01-01
ER

PT J
AU Padrao, EMH
   Valente, FS
   Besen, BAMP
   Rahhal, H
   Mesquita, PS
   deAlencar, JCG
   daCosta, MGP
   Wanderley, APB
   Emerenciano, DL
   Bortoleto, FM
   Fortes, JCL
   Marques, B
   deSouza, SFB
   Marchini, JFM
   Neto, RAB
   deSouza, HP
AF Padrao, Eduardo M. H.
   Valente, Fernando S.
   Besen, Bruno A. M. P.
   Rahhal, Hassan
   Mesquita, Paula S.
   deAlencar, Julio C. G.
   daCosta, Millena G. P.
   Wanderley, Annelise P. B.
   Emerenciano, Debora L.
   Bortoleto, Felipe M.
   Fortes, Julio C. L.
   Marques, Bruno
   deSouza, Stefany F. B.
   Marchini, Julio F. M.
   Neto, Rodrigo A. B.
   deSouza, Heraldo P.
CA COVIDTEAM
TI Awake Prone Positioning in COVID-19 Hypoxemic Respiratory Failure:
   Exploratory Findings in a Single-center Retrospective Cohort Study
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
ID DISTRESS-SYNDROME; VENTILATION
AB Background Awake prone positioning has been widely used in patients with COVID-19 respiratory failure to avoid intubation despite limited evidence. Our objective was to evaluate if prone positioning is associated with a reduced intubation rate when compared to usual care.
   Methods This was a retrospective cohort study in the emergency department of a large quaternary hospital in Sao Paulo. We retrieved data from all admitted patients in need of oxygen supplementation (>3 L/min) and tachypnea (>24 ipm) from March 1 to April 30, 2020, excluding those who had any contraindication to the prone position or who had an immediate need for intubation. The primary endpoint was endotracheal intubation up to 15 days. Secondary outcomes included a 6-point clinical outcome ordinal scale, mechanical ventilation-free days, admission to the intensive care unit, and need of hemodialysis and of vasoactive drugs, all assessed at or up to 15 days. We analyzed unadjusted and adjusted effect estimates with Cox proportional hazards models, logistic regression, quantile regression, and sensitivity analyses using propensity score models.
   Results Of 925 suspected COVID-19 patients admitted off mechanical ventilation, 166 patients fulfilled inclusion and exclusion criteria: 57 were exposed to prone positioning and 109 to usual care. In the intervention group, 33 (58%) were intubated versus 53 (49%) in the control group. We observed no difference in intubation rates in the univariate analysis (hazard ratio = 1.21, 95% confidence interval [CI] = 0.78 to 1.88, p = 0.39) nor in the adjusted analysis (hazard ratio = 0.90, 95% CI = 0.55 to 1.49, p = 0.69). Results were robust to the sensitivity analyses. Secondary outcomes did not differ between groups.
   Conclusions Awake prone positioning was not associated with lower intubation rates. Caution is necessary before widespread adoption of this technique, pending results of clinical trials.
C1 [Padrao, Eduardo M. H.] Univ Connecticut, Dept Internal Med, Farmington, CT 06032 USA.
   [Valente, Fernando S.; Rahhal, Hassan; Mesquita, Paula S.; deAlencar, Julio C. G.; daCosta, Millena G. P.; Wanderley, Annelise P. B.; Emerenciano, Debora L.; Bortoleto, Felipe M.; Fortes, Julio C. L.; Marques, Bruno; deSouza, Stefany F. B.; Marchini, Julio F. M.; Neto, Rodrigo A. B.] Hosp Clin HCFMUSP SP, Fac Med, Internal Med Dept, Emergency Dept,Med Emergencies Discipline, Sao Paulo, SP, Brazil.
   [Besen, Bruno A. M. P.] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Med ICU,Disciplina Emergencias Clin,Dept Clin Med, Sao Paulo, SP, Brazil.
   [deSouza, Heraldo P.] Univ Sao Paulo, Fac Med FMUSP, Sao Paulo, SP, Brazil.
RP Padrao, EMH (corresponding author), Univ Connecticut, Dept Internal Med, Farmington, CT 06032 USA.
EM padraoedu@gmail.com
OI Messias Hirano Padrao, Eduardo/0000-0001-5323-7579; Alencar,
   Julio/0000-0001-5859-6060
CR Albert RK, 2014, AM J RESP CRIT CARE, V189, P494, DOI 10.1164/rccm.201311-2056LE
   Bauer PR, 2017, J CRIT CARE, V42, P1, DOI 10.1016/j.jcrc.2017.06.010
   Caputo ND, 2020, ACAD EMERG MED, V27, P375, DOI 10.1111/acem.13994
   Coudroy R, 2020, THORAX, V75, P805, DOI 10.1136/thoraxjnl-2020-214863
   Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5
   Elharrar X, 2020, JAMA-J AM MED ASSOC, V323, P2336, DOI 10.1001/jama.2020.8255
   Feltracco P, 2009, CLIN TRANSPLANT, V23, P748, DOI 10.1111/j.1399-0012.2009.01050.x
   Ferreyro BL, 2020, JAMA-J AM MED ASSOC, V324, P57, DOI 10.1001/jama.2020.9524
   Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Jozwiak M, 2013, AM J RESP CRIT CARE, V188, P1428, DOI 10.1164/rccm.201303-0593OC
   Kangelaris KN, 2016, CRIT CARE MED, V44, P120, DOI 10.1097/CCM.0000000000001359
   Knight SR, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3339
   Lederer DJ, 2019, ANN AM THORAC SOC, V16, P22, DOI 10.1513/AnnalsATS.201808-564PS
   Mancebo J, 2006, AM J RESP CRIT CARE, V173, P1233, DOI 10.1164/rccm.200503-353OC
   Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT
   Ng Z, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01198-2020
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roca O, 2019, AM J RESP CRIT CARE, V199, P1368, DOI 10.1164/rccm.201803-0589OC
   Sartini C, 2020, JAMA-J AM MED ASSOC, V323, P2338, DOI 10.1001/jama.2020.7861
   Scaravilli V, 2015, J CRIT CARE, V30, P1390, DOI 10.1016/j.jcrc.2015.07.008
   Staffa SJ, 2020, ANESTH ANALG, V130, P542, DOI 10.1213/ANE.0000000000004535
   Sun Q, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00650-2
   Taccone P, 2009, JAMA-J AM MED ASSOC, V302, P1977, DOI 10.1001/jama.2009.1614
   Telias I, 2020, JAMA-J AM MED ASSOC, V323, P2265, DOI 10.1001/jama.2020.8539
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu QH, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02991-7
NR 30
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1069-6563
EI 1553-2712
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD DEC
PY 2020
VL 27
IS 12
BP 1249
EP 1259
DI 10.1111/acem.14160
EA NOV 2020
PG 11
WC Emergency Medicine
SC Emergency Medicine
GA PG9AD
UT WOS:000591035300001
PM 33107664
OA Bronze
DA 2021-01-01
ER

PT J
AU Siddiqui, S
   Upadhyay, S
   Ahmad, R
   Gupta, A
   Srivastava, A
   Trivedi, A
   Husain, I
   Ahmad, B
   Ahamed, M
   Khan, MA
AF Siddiqui, Sahabjada
   Upadhyay, Shivbrat
   Ahmad, Rumana
   Gupta, Anamika
   Srivastava, Aditi
   Trivedi, Anchal
   Husain, Ishrat
   Ahmad, Bilal
   Ahamed, Maqusood
   Khan, Mohsin Ali
TI Virtual screening of phytoconstituents from miracle herb nigella sativa
   targeting nucleocapsid protein and papain-like protease of SARS-CoV-2
   for COVID-19 treatment
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Nigella sativa; phytocomponents; SARS-CoV-2; nucleocapsid protein;
   papain-like protease; molecular chemoinformatics
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel etiological agent of coronavirus disease 2019 (COVID-19). Nigella sativa, commonly known as black seed or black cumin, has been a historical and traditional plant since thousands of years. Based on their therapeutic efficacy, the chief components of terpenoids and flavonoids were selected from N. sativa seeds and seed oil. This study was designed to check the antiviral efficacy of N. sativa main phytoconstituents against five potential targets of SARS-CoV-2 using in silico structure-based virtual screening approach. Out of twenty five phytocomponents, ten components showed best binding affinity against two viral proteins viz. N-terminal RNA binding domain (NRBD; PDB ID: 6M3M) of nucleocapsid protein and papain-like protease (PL-(PRO); PDB ID: 6W9C) of SARS-CoV-2 using AutoDock 4.2.6, AutoDock Vina and iGEMDOCK. PASS analyses of all ten phytocomponents using Lipinski's Rule of five showed promising results. Further, druglikeness and toxicity assessment using OSIRIS Data Warrior v5.2.1 software exhibited the feasibility of phytocomponents as drug candidates with no predicted toxicity. Molecular dynamics simulation study of NRBD of SARS-CoV-2 nucleocapsid protein-alpha-spinasterol complex and PL-(PRO)-cycloeucalenol complex displayed strong stability at 300 K. Both these complexes exhibited constant root mean square deviation (RMSDs) of protein side chains and C alpha atoms throughout the simulation run time. Interestingly, PL-(PRO) and NRBD are key proteins in viral replication, host cell immune evasion and viral assembly. Thus, NRBD and PL-(PRO) have the potential to serve as therapeutic targets for N. sativa phytoconstituents in drug discovery process against COVID-19.
   [GRAPHICS]
   .
C1 [Siddiqui, Sahabjada; Upadhyay, Shivbrat] Era Univ, Eras Lucknow Med Coll & Hosp, Dept Biotechnol, Lucknow, Uttar Pradesh, India.
   [Ahmad, Rumana; Gupta, Anamika; Srivastava, Aditi; Trivedi, Anchal; Husain, Ishrat] Era Univ, Eras Lucknow Med Coll & Hosp, Dept Biochem, Lucknow 226003, Uttar Pradesh, India.
   [Ahmad, Bilal] Era Univ, Eras Lucknow Med Coll & Hosp, Res Cell, Lucknow, Uttar Pradesh, India.
   [Ahamed, Maqusood] King Saud Univ, King Abdullah Inst Nanotechnol, Riyadh, Saudi Arabia.
   [Khan, Mohsin Ali] Era Univ, Eras Lucknow Med Coll & Hosp, Lucknow, Uttar Pradesh, India.
RP Ahmad, R (corresponding author), Era Univ, Eras Lucknow Med Coll & Hosp, Dept Biochem, Lucknow 226003, Uttar Pradesh, India.
EM rumana_ahmad@yahoo.co.in
RI Siddiqui, Sahabjada/E-8383-2015; Ahamed, Maqusood/R-8619-2017
OI Siddiqui, Sahabjada/0000-0003-0982-1465; Ahamed,
   Maqusood/0000-0001-6025-1950; Khan, Mohsin Ali/0000-0003-0748-3298
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University [RSP-
   2020/129]
FX The authors gratefully acknowledge Dr. Meraj Ahmad, Professor, Dept. of
   Sociology, University of Lucknow, Lucknow, India, for being the
   inspiration and motivation behind the present work in view of his
   exceptional work and contribution in the area of social sciences,
   humanities and public health. Maqusood Ahamed is also grateful to the
   Researchers Supporting Project number (RSP- 2020/129), King Saud
   University, Riyadh, Saudi Arabia.
CR Ahmad Aftab, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P337, DOI 10.1016/S2221-1691(13)60075-1
   Ahmad R, 2020, ANTI-CANCER AGENT ME, V20, P122, DOI 10.2174/1871520619666191015103712
   Ahmad R, 2019, PEERJ, V7, DOI 10.7717/peerj.6012
   Ahmad S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1775129
   Ahmad Z., 2004, NIGELLA SATIVA POTEN, V2, P6
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bahar I, 2010, CHEM REV, V110, P1463, DOI 10.1021/cr900095e
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chang CK, 2016, DRUG DISCOV TODAY, V21, P562, DOI 10.1016/j.drudis.2015.11.015
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Choudhary R, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100684
   de Oliveira M.D., 2020, CEP, V11981, P7
   Delaney JS, 2004, J CHEM INF COMP SCI, V44, P1000, DOI 10.1021/ci034243x
   Forouzanfar F, 2014, IRAN J BASIC MED SCI, V17, P929
   Ghildiyal R., 2020, PLANT DERIVED BIOACT, P279, DOI [10.1007/978-981-15-1761- 7_12, DOI 10.1007/978-981-15-1761-7_12]
   Heidary F, 2020, J ANTIBIOT, V73, P593, DOI 10.1038/s41429-020-0336-z
   Hospital Adam, 2015, Adv Appl Bioinform Chem, V8, P37, DOI 10.2147/AABC.S70333
   Khan T, 2018, COMPUT BIOL CHEM, V75, P178, DOI 10.1016/j.compbiolchem.2018.05.008
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   MENOUNOS P, 1986, PHYTOCHEMISTRY, V25, P761, DOI 10.1016/0031-9422(86)88046-3
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Naithani R, 2010, NUTR HEALTH SER, P421, DOI 10.1007/978-1-60761-061-8_24
   Oprea TI, 2001, J CHEM INF COMP SCI, V41, P1308, DOI 10.1021/ci010366a
   Pal M, 2020, CUREUS, V12, DOI 10.7759/cureus.7423
   Parasuraman S, 2011, J PHARMACOL PHARMACO, V2, P74, DOI 10.4103/0976-500X.81895
   Patil S., 2020, DRUG REPURPOSING COV, DOI [10.26434/chemrxiv.12482435.v1, DOI 10.26434/CHEMRXIV.12482435.V1]
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722
   Rebeaud ME, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00184
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Salem ML, 2000, INT J IMMUNOPHARMACO, V22, P729, DOI 10.1016/S0192-0561(00)00036-9
   Tian S, 2015, ADV DRUG DELIVER REV, V86, P2, DOI 10.1016/j.addr.2015.01.009
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Yang Jing-Fang, 2020, Brief Bioinform, V21, P2206, DOI 10.1093/bib/bbz141
   Yang JM, 2004, PROTEINS, V55, P288, DOI 10.1002/prot.20035
   Yang WQ, 2020, NAT PROD COMMUN, V15, DOI 10.1177/1934578X20903555
   Yarnell E., 2011, ALTERN COMPLEMENT TH, V17, P99, DOI [/10.1089/act.2011.17203, DOI 10.1089/act.2011.17203]
   Yimer EM, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/1528635
NR 42
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1852117
EA NOV 2020
PG 21
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA PC5CX
UT WOS:000597020100001
PM 33289456
OA Bronze
DA 2021-01-01
ER

PT J
AU Mir, JM
   Maurya, RC
AF Mir, Jan Mohammad
   Maurya, Ram Charitra
TI Nitric oxide boosters as defensive agents against COVID-19 infection: an
   opinion
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE NO; Immunity; NO-release; food; synthetic moieties
AB In the prevailing covid times, scientific community is busy in developing vaccine against COVID-19. Under such fascination this article describes the possible role of nitric oxide (NO) releasers in aiding the immune system of a human body against this dreadful pandemic disease. Despite some prodrug antiviral compounds are in practice to recover the patients suffering from covid-19, however, co-morbidity deaths are highest among the total deaths happened so far. This concurrence of a number of diseases in a patient along with this viral infection is indicative of the poor immunity. Literature background supports the use of NO as immunity boosting agent and hence, the nitric oxide releasing compounds could act as lucrative in this context. Some dietary suggestions of NO-containing food items have also been introduced in this article. Also, the profound effect of NO in relieving symptomatic severity of covid-19 has been opined in this work.
   Communicated by Ramaswamy H. Sarma
C1 [Mir, Jan Mohammad] Islamic Univ Sci & Technol Awantipora, Dept Chem, Pulwama, India.
   [Mir, Jan Mohammad; Maurya, Ram Charitra] RD Univ, Dept PG Studies & Res Chem & Pharm, Coordinat Metallopharmaceut & Computat Chem Lab, Jabalpur, MP, India.
RP Mir, JM (corresponding author), Islamic Univ Sci & Technol, Dept Chem, Awantipora 192122, India.
EM mirjanmohammad@gmail.com
OI Mir, Jan Mohammad/0000-0003-3231-0014
CR Akaike T, 2000, IMMUNOLOGY, V101, P300, DOI 10.1046/j.1365-2567.2000.00142.x
   AKARID K, 1995, J VIROL, V69, P7001, DOI 10.1128/JVI.69.11.7001-7005.1995
   Akerstrom S, 2005, J VIROL, V79, P1966, DOI 10.1128/JVI.79.3.1966-1969.2005
   [Anonymous], 2020, BRIEF BEYOND AIR REC
   ARNOLD WP, 1984, ANESTHESIOLOGY, V61, P254, DOI 10.1097/00000542-198409000-00004
   BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U
   Boe AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116504
   BUTLER AR, 1987, CHEM SOC REV, V16, P361, DOI 10.1039/cs9871600361
   CEDERQVIST B, 1994, BIOCHEM PHARMACOL, V47, P1047, DOI 10.1016/0006-2952(94)90416-2
   Cheng J, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00530
   CHUNG SJ, 1990, J PHARMACOL EXP THER, V253, P614
   CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479
   Deniz E, 2012, CHEM-EUR J, V18, P15782, DOI 10.1002/chem.201202845
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Doel JJ, 2000, BIOCHEM BIOPH RES CO, V270, P880, DOI 10.1006/bbrc.2000.2534
   Dong RJ, 2015, ADV MATER, V27, P498, DOI 10.1002/adma.201402975
   FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006
   Fiorucci S, 2004, J IMMUNOL, V173, P874, DOI 10.4049/jimmunol.173.2.874
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   HARRIS N, 1995, J VIROL, V69, P910, DOI 10.1128/JVI.69.2.910-915.1995
   HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665
   Hinz B, 1998, BIOCHEM BIOPH RES CO, V253, P658, DOI 10.1006/bbrc.1998.9845
   Ji YB, 1996, BIOCHEM J, V313, P377, DOI 10.1042/bj3130377
   Jin HB, 2018, J AM CHEM SOC, V140, P14178, DOI 10.1021/jacs.8b07661
   Jugdutt B.I, 2004, ROLE NITRIC OXIDE HE, DOI [10.1007/1-4020-7960-5_20, DOI 10.1007/1-4020-7960-5_20]
   Jung K, 2010, VET IMMUNOL IMMUNOP, V136, P335, DOI 10.1016/j.vetimm.2010.03.022
   Kaul P, 1999, AM J RESP CRIT CARE, V159, P1193, DOI 10.1164/ajrccm.159.4.9808043
   Keyaerts E, 2004, INT J INFECT DIS, V8, P223, DOI 10.1016/j.ijid.2004.04.012
   Klingstrom J, 2006, EUR J IMMUNOL, V36, P2649, DOI 10.1002/eji.200535587
   KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249
   KOWALUK EA, 1991, J PHARMACOL EXP THER, V259, P519
   KOWALUK EA, 1992, J PHARMACOL EXP THER, V262, P916
   LAMARQUE D, 1995, EUR J PHARMACOL, V277, P187, DOI 10.1016/0014-2999(95)00075-V
   LEIER CV, 1981, AM J CARDIOL, V48, P1115, DOI 10.1016/0002-9149(81)90329-5
   Lin YL, 1997, J VIROL, V71, P5227, DOI 10.1128/JVI.71.7.5227-5235.1997
   Lowe A, 2013, MICROPOR MESOPOR MAT, V181, P17, DOI 10.1016/j.micromeso.2013.07.017
   LSU Health, 2020, SHREV TRAILBL RES US
   MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323
   MARKS GS, 1995, DRUG METAB DISPOS, V23, P1248
   Martel J, 2020, MICROBES INFECT, V22, P168, DOI 10.1016/j.micinf.2020.05.002
   Maurya R.C., 2014, INT J SCI ENG RES, V5, P305
   MELOCHE BA, 1993, XENOBIOTICA, V23, P863, DOI 10.3109/00498259309059414
   MEYER DJ, 1994, FEBS LETT, V351, P427, DOI 10.1016/0014-5793(94)00904-X
   Mir JM, 2017, INORG CHIM ACTA, V467, P80, DOI 10.1016/j.ica.2017.07.051
   Mir J.M., 2018, ANN OPHTHALMOLOGY VI, V1003, P1
   Mir J.M., 2018, J CHINESE ADV MAT SO, V6, P434, DOI [10.1080/22243682.2018.1493951, DOI 10.1080/22243682.2018.1493951]
   Mir J.M., 2018, J CHINESE ADV MAT SO, V36, P156
   Mir JM, 2019, REV INORG CHEM, V39, P91, DOI 10.1515/revic-2018-0017
   Mir JM, 2018, REV INORG CHEM, V38, P193, DOI 10.1515/revic-2018-0011
   Mir JM, 2018, RSC ADV, V8, P35102, DOI 10.1039/c8ra05956j
   Mir JM, 2019, J KING SAUD UNIV SCI, V31, P89, DOI 10.1016/j.jksus.2017.06.006
   Mir JM, 2017, PHOTODIAGN PHOTODYN, V19, P363, DOI 10.1016/j.pdpdt.2017.07.006
   Mohazzab-H K.M., 1992, CIRCULATION, V86, P1
   PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0
   Park D, 2016, ADV HEALTHC MATER, V5, P2019, DOI 10.1002/adhm.201600150
   PATEL HMS, 1990, J CHEM SOC PERK T 2, P37, DOI 10.1039/p29900000037
   Piras L, 2013, CHEM-ASIAN J, V8, P2768, DOI 10.1002/asia.201300543
   RAO DNR, 1991, ARCH BIOCHEM BIOPHYS, V286, P30, DOI 10.1016/0003-9861(91)90005-4
   Resh Marilyn D, 2006, Sci STKE, V2006, pre14, DOI 10.1126/stke.3592006re14
   Ricciardolo FLM, 2003, THORAX, V58, P175, DOI 10.1136/thorax.58.2.175
   Riccio DA, 2012, CHEM SOC REV, V41, P3731, DOI 10.1039/c2cs15272j
   Ritz T, 2018, BIOL PSYCHOL, V132, P116, DOI 10.1016/j.biopsycho.2017.11.006
   Saadi S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0690hyp
   Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5
   Tan YJ, 2006, ANTIVIR RES, V72, P78, DOI 10.1016/j.antiviral.2006.05.010
   Thatcher RGJ, 1998, CHEM SOC REV, V27, P331
   TORFGARD KE, 1994, CARDIOVASC DRUG THER, V8, P701, DOI 10.1007/BF00877117
   Troncy E, 1997, CAN J ANAESTH, V44, P973, DOI 10.1007/BF03011970
   Uehara EU, 2015, INFLAMM RES, V64, P845, DOI 10.1007/s00011-015-0857-2
   Wink DA, 1996, ARCH BIOCHEM BIOPHYS, V331, P241, DOI 10.1006/abbi.1996.0304
   Zaragoza C, 1997, J CLIN INVEST, V100, P1760, DOI 10.1172/JCI119702
   Zaragoza C, 1998, P NATL ACAD SCI USA, V95, P2469, DOI 10.1073/pnas.95.5.2469
   Zhang HP, 2003, J AM CHEM SOC, V125, P5015, DOI 10.1021/ja0291538
   Zhelyaskov VR, 1999, NITRIC OXIDE-BIOL CH, V3, P419, DOI 10.1006/niox.1999.0253
NR 74
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1852969
EA NOV 2020
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA PB4GJ
UT WOS:000596280900001
PM 33251965
OA Bronze
DA 2021-01-01
ER

PT J
AU Van Damme, KFA
   Tavernier, S
   Van Roy, N
   De Leeuw, E
   Declercq, J
   Bosteels, C
   Maes, B
   De Bruyne, M
   Bogaert, D
   Bosteels, V
   Hoste, L
   Naesens, L
   Maes, P
   Grifoni, A
   Weiskopf, D
   Sette, A
   Depuydt, P
   Van Braeckel, E
   Haerynck, F
   Lambrecht, BN
AF Van Damme, Karel F. A.
   Tavernier, Simon
   Van Roy, Nele
   De Leeuw, Elisabeth
   Declercq, Jozefien
   Bosteels, Cedric
   Maes, Bastiaan
   De Bruyne, Marieke
   Bogaert, Delfien
   Bosteels, Victor
   Hoste, Levi
   Naesens, Leslie
   Maes, Piet
   Grifoni, Alba
   Weiskopf, Daniela
   Sette, Alessandro
   Depuydt, Pieter
   Van Braeckel, Eva
   Haerynck, Filomeen
   Lambrecht, Bart N.
TI Case Report: Convalescent Plasma, a Targeted Therapy for Patients with
   CVID and Severe COVID-19
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE convalescent plasma; COVID-19; common variable immunodeficiency
   disorders; immunodeficiencies; case report
AB The disease course of COVID-19 in patients with immunodeficiencies is unclear, as well as the optimal therapeutic strategy. We report a case of a 37-year old male with common variable immunodeficiency disorder and a severe SARS-CoV-2 infection. After administration of convalescent plasma, the patient's condition improved rapidly. Despite clinical recovery, viral RNA remained detectable up to 60 days after onset of symptoms. We propose that convalescent plasma might be considered as a treatment option in patients with CVID and severe COVID-19. In addition, in patients with immunodeficiencies, a different clinical course is possible, with prolonged viral shedding.
C1 [Van Damme, Karel F. A.; Tavernier, Simon; Van Roy, Nele; De Leeuw, Elisabeth; Declercq, Jozefien; Bosteels, Cedric; Maes, Bastiaan; Bogaert, Delfien; Bosteels, Victor; Hoste, Levi; Naesens, Leslie; Depuydt, Pieter; Van Braeckel, Eva; Haerynck, Filomeen; Lambrecht, Bart N.] Univ Ghent, Dept Internal Med & Pediat, Ghent, Belgium.
   [Van Damme, Karel F. A.; De Leeuw, Elisabeth; Declercq, Jozefien; Bosteels, Cedric; Maes, Bastiaan; Lambrecht, Bart N.] VIB UGent Ctr Inflammat Res, Lab Immunoregulat & Mucosal Immunol, Ghent, Belgium.
   [Tavernier, Simon] VIB UGent Ctr Inflammat Res, Unit Mol Signal Transduct Inflammat, Ghent, Belgium.
   [De Bruyne, Marieke] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium.
   [Bogaert, Delfien; Hoste, Levi; Naesens, Leslie; Haerynck, Filomeen] Ghent Univ Hosp, Primary Immunodeficiency Res Lab, Jeffrey Modell Diag & Res Ctr, Ghent, Belgium.
   [Bosteels, Victor] VIB UGent Ctr Inflammat Res, Lab ER Stress & Inflammat, Ghent, Belgium.
   [Maes, Piet] Katholieke Univ Leuven, Div Clin & Epidemiol Virol, Rega Inst Med Res, Dept Microbiol Immunol & Transplantat, Leuven, Belgium.
   [Grifoni, Alba; Weiskopf, Daniela; Sette, Alessandro] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA USA.
   [Sette, Alessandro] Univ Calif San Diego UCSD, Dept Med, Div Infect Dis & Global Publ Hlth, San Diego, CA USA.
   [Depuydt, Pieter] Ghent Univ Hosp, Dept Intens Care, Ghent, Belgium.
   [Van Braeckel, Eva; Lambrecht, Bart N.] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium.
   [Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands.
RP Lambrecht, BN (corresponding author), Univ Ghent, Dept Internal Med & Pediat, Ghent, Belgium.; Lambrecht, BN (corresponding author), VIB UGent Ctr Inflammat Res, Lab Immunoregulat & Mucosal Immunol, Ghent, Belgium.; Lambrecht, BN (corresponding author), Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium.; Lambrecht, BN (corresponding author), Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands.
EM bart.lambrecht@ugent.be
FU European Research Council advanced grant (ERC-2017-ADG); Grand
   Challenges Programs of VIB [M901BALA-GCP-COVID-19-SARPAC TRIAL,
   M902BALAGCP-COVID-19-IL6-IL1 TRIAL]; Ghent UniversityGhent University
   [BOF/GOA/028]; Excellence of Science (EOS) research grant [G0G2318N];
   FWOFWO; university research grant (BOF-UGent); Jeffrey Modell
   Foundation; University Hospital Ghent Spearhead Initiative for
   Immunology Research; Grand Challenges Program of VIB
FX BNL is supported by a European Research Council advanced grant
   (ERC-2017-ADG), Grand Challenges Programs of VIB
   (M901BALA-GCP-COVID-19-SARPAC TRIAL, M902BALAGCP-COVID-19-IL6-IL1
   TRIAL), a concerted research initiative grant from Ghent University
   (BOF/GOA/028) and an Excellence of Science (EOS) research grant
   (G0G2318N). JD, CB, BM, VB, and ST are supported by grants from FWO. ST
   is supported by a university research grant (BOF-UGent). FH is supported
   by the Jeffrey Modell Foundation, University Hospital Ghent Spearhead
   Initiative for Immunology Research and a Grand Challenges Program of
   VIB.
CR Bogaert DJA, 2016, J MED GENET, V53, P575, DOI 10.1136/jmedgenet-2015-103690
   Bosteels C, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04520-x
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Fill L, 2020, ANN ALLERG ASTHMA IM, V125, P113
   Fung Monica, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa863
   Gharbharan A, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.07.01.20139857, DOI 10.1101/2020.07.01.20139857, 10.1101/2020.07.01.20139857.]
   Hoepel W, 2020, ANTI SARS COV 2 IGG, V4, pe123158, DOI 10.1101/2020.07.01.20139857
   Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Minotti C, 2020, J INFECTION, V81, pE61, DOI 10.1016/j.jinf.2020.04.026
   Piechotta V, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600.pub2
   Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Roschewski M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd0110
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263
NR 18
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 20
PY 2020
VL 11
AR 596761
DI 10.3389/fimmu.2020.596761
PG 6
WC Immunology
SC Immunology
GA PB0GE
UT WOS:000596005400001
PM 33329586
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Harrell, CR
   Jovicic, BP
   Djonov, V
   Volarevic, V
AF Harrell, Carl Randall
   Jovicic, Biljana Popovska
   Djonov, Valentin
   Volarevic, Vladislav
TI Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in
   the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
SO ANALYTICAL CELLULAR PATHOLOGY
LA English
DT Article
ID STROMAL CELLS; COVID-19; TRANSPLANTATION
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, aerosols containing SARS-CoV-2 penetrate to the depths of the lungs and cause severe pneumonia, alveolar injury, and life-threatening acute respiratory distress syndrome (ARDS). Since there are no specific drugs or vaccines available to cure or prevent COVID-19 infection and COVID-19-related ARDS, a new therapeutic agent which will support oxygen supply and, at the same time, efficiently alleviate SARS-CoV-2-induced lung inflammation is urgently needed. Due to their potent immuno- and angiomodulatory characteristics, mesenchymal stem cells (MSCs) may increase oxygen supply in the lungs and may efficiently alleviate ongoing lung inflammation, including SARS-CoV-2-induced ARDS. In this review article, we described molecular mechanisms that are responsible for MSC-based modulation of immune cells which play a pathogenic role in the development of SARS-CoV-2-induced ARDS and we provided a brief outline of already conducted and ongoing clinical studies that increase our understanding about the therapeutic potential of MSCs and their secretome in the therapy of COVID-19-related ARDS.
C1 [Harrell, Carl Randall] Regenerat Proc Plant LLC, 34176 US Highway 19 N Palm Harbor, Palm Harbor, FL USA.
   [Jovicic, Biljana Popovska] Univ Kragujevac, Fac Med Sci, Dept Infect Dis, Svetozara Markovica 69, Kragujevac 34000, Serbia.
   [Djonov, Valentin] Univ Bern, Inst Anat, 2 Baltzerstr, CH-3012 Bern, Switzerland.
   [Volarevic, Vladislav] Univ Kragujevac, Fac Med Sci, Ctr Mol Med & Stem Cell Res, Dept Microbiol & Immunol, 69 Svetozar Markov St, Kragujevac, Serbia.
RP Volarevic, V (corresponding author), Univ Kragujevac, Fac Med Sci, Ctr Mol Med & Stem Cell Res, Dept Microbiol & Immunol, 69 Svetozar Markov St, Kragujevac, Serbia.
EM drvolarevic@yahoo.com
OI Djonov, Valentin/0000-0002-5062-1169
FU European Crohn's and Colitis Organization (ECCO) (grant "The role of
   galectin 3 in acute colitis"); ECLAT, spin off of the University of
   Catania (Replica grant); Swiss National Science FoundationSwiss National
   Science Foundation (SNSF) [IZSEZ0 185546]; Serbian Ministry of
   ScienceMinistry of Science, Serbia [ON175069, ON175103]; Faculty of
   Medical Sciences University of Kragujevac [MP01/18]
FX This work was supported by the European Crohn's and Colitis Organization
   (ECCO) (grant "The role of galectin 3 in acute colitis"), ECLAT, spin
   off of the University of Catania (Replica grant), Swiss National Science
   Foundation (IZSEZ0 185546), Serbian Ministry of Science (ON175069 and
   ON175103), and Faculty of Medical Sciences University of Kragujevac
   (MP01/18).
CR Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Fang XH, 2015, J IMMUNOL, V195, P875, DOI 10.4049/jimmunol.1500244
   Gazdic M, 2015, STEM CELL REV REP, V11, P280, DOI 10.1007/s12015-014-9583-3
   Han JB, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5432134
   Harrell CR, 2019, ADV EXP MED BIOL, V1084, P187, DOI 10.1007/5584_2018_306
   Harrell CR, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4236973
   Harrell CR, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12050474
   Harrell CR, 2020, ANAL CELL PATHOL, V2020, DOI 10.1155/2020/3153891
   Harrell CR, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121605
   Harrell CR, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050467
   Hu SL, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0320-5
   Laine M, 2020, LANCET RHEUMATOL, V2, pE586, DOI 10.1016/S2665-9913(20)30272-1
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   Li X, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02911-9
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Lindsay JO, 2017, LANCET GASTROENTEROL, V2, P399, DOI 10.1016/S2468-1253(17)30056-0
   Liu JS, 2019, J CHIN MED ASSOC, V82, P895, DOI 10.1097/JCMA.0000000000000189
   Maacha S, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/4356359
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Mohanty S, 2020, DIABETES METAB SYND, V14, P1027, DOI 10.1016/j.dsx.2020.06.068
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Prete M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093377
   Provenzani A, 2020, INT J CLIN PHARM-NET, V42, P833, DOI 10.1007/s11096-020-01049-6
   Sayad B, 2020, ARCH MED RES, V51, P577, DOI 10.1016/j.arcmed.2020.04.018
   Sengupta V, 2020, STEM CELLS DEV, V29, P747, DOI 10.1089/scd.2020.0080
   Sly LM, 2020, INT J CLIN PHARM TH, V58, P678, DOI 10.5414/CP203890
   Song Y, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106080
   Tang YJ, 2020, EMERG MICROBES INFEC, V9, P827, DOI 10.1080/22221751.2020.1760146
   Tong S, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106114
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Volarevic V, 2018, INT J MED SCI, V15, P36, DOI 10.7150/ijms.21666
   Volarevic V, 2017, BIOFACTORS, V43, P633, DOI 10.1002/biof.1374
   Volarevic V, 2011, BRIT MED BULL, V99, P155, DOI 10.1093/bmb/ldr027
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Yang Y, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/2347938
   Zhou YD, 2020, LANCET DIGIT HEALTH, V2, pE667, DOI 10.1016/S2589-7500(20)30192-8
NR 38
TC 0
Z9 0
U1 2
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2210-7177
EI 2210-7185
J9 ANAL CELL PATHOL
JI Anal. Cell. Pathol.
PD NOV 20
PY 2020
VL 2020
AR 1939768
DI 10.1155/2020/1939768
PG 11
WC Oncology; Cell Biology; Pathology
SC Oncology; Cell Biology; Pathology
GA PA7PB
UT WOS:000595821500001
PM 33274176
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brar, G
   Pinheiro, LC
   Shusterman, M
   Swed, B
   Reshetnyak, E
   Soroka, O
   Chen, F
   Yamshon, S
   Vaughn, J
   Martin, P
   Paul, D
   Hidalgo, M
   Shah, MA
AF Brar, Gagandeep
   Pinheiro, Laura C.
   Shusterman, Michael
   Swed, Brandon
   Reshetnyak, Evgeniya
   Soroka, Orysya
   Chen, Frank
   Yamshon, Samuel
   Vaughn, John
   Martin, Peter
   Paul, Doru
   Hidalgo, Manuel
   Shah, Manish A.
TI COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort
   Study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID ONCOLOGY
AB PURPOSESARS-CoV-2 (COVID-19) is a systemic infection. Patients with cancer are immunocompromised and may be vulnerable to COVID-related morbidity and mortality. The objectives of this study were to determine if patients with cancer have worse outcomes compared with patients without cancer and to identify demographic and clinical predictors of morbidity and mortality among patients with cancer.METHODSWe used data from adult patients who tested positive for COVID-19 and were admitted to two New York-Presbyterian hospitals between March 3 and May 15, 2020. Patients with cancer were matched 1:4 to controls without cancer in terms of age, sex, and number of comorbidities. Using Kaplan-Meier curves and the log-rank test, we compared morbidity (intensive care unit admission and intubation) and mortality outcomes between patients with cancer and controls. Among those with cancer, we identified demographic and clinical predictors of worse outcomes using Cox proportional hazard models.RESULTSWe included 585 patients who were COVID-19 positive, of whom 117 had active malignancy, defined as those receiving cancer-directed therapy or under active surveillance within 6 months of admission. Presenting symptoms and in-hospital complications were similar between the cancer and noncancer groups. Nearly one half of patients with cancer were receiving therapy, and 45% of patients received cytotoxic or immunosuppressive treatment within 90 days of admission. There were no statistically significant differences in morbidity or mortality (P = .894) between patients with and without cancer.CONCLUSIONWe observed that patients with COVID-19 and cancer had similar outcomes compared with matched patients without cancer. This finding suggests that a diagnosis of active cancer alone and recent anticancer therapy do not predict worse COVID-19 outcomes and therefore, recommendations to limit cancer-directed therapy must be considered carefully in relation to cancer-specific outcomes and death.
C1 [Brar, Gagandeep; Shusterman, Michael; Swed, Brandon; Yamshon, Samuel; Vaughn, John; Martin, Peter; Paul, Doru; Hidalgo, Manuel; Shah, Manish A.] Weill Cornell Med New York Presbyterian, Dept Med, Div Hematol & Med Oncol, New York, NY USA.
   [Pinheiro, Laura C.; Reshetnyak, Evgeniya; Soroka, Orysya; Chen, Frank] Weill Cornell Med New York Presbyterian, Dept Med, Div Gen Internal Med, New York, NY USA.
RP Shah, MA (corresponding author), Weill Cornell Med, Sandra & Edward Meyer Canc Ctr, Div Hematol & Med Oncol, 1305 York Ave,Room Y1247, New York, NY 10021 USA.
EM mas9313@med.cornell.edu
OI Reshetnyak, Evgeniya/0000-0001-9478-4405; Shusterman,
   Michael/0000-0003-2899-7714; Vaughn, John/0000-0001-8122-3852; soroka,
   orysya/0000-0003-3282-2378
FU New York-Presbyterian Hospital; Weill Cornell Medical College; Clinical
   and Translational Science Center [UL1 TR000457]; Joint Clinical Trials
   Office
FX Supported by New York-Presbyterian Hospital and Weill Cornell Medical
   College, including the Clinical and Translational Science Center (UL1
   TR000457) and the Joint Clinical Trials Office.
CR Caer C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02660-w
   Cannistra SA, 2020, J CLIN ONCOL, V38, P2206, DOI 10.1200/JCO.20.00858
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Deng GT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02902-w
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Jazieh AR, 2020, JCO GLOB ONCOL, V6, P471, DOI 10.1200/GO.20.00064
   LEE EW, 1992, NATO ADV SCI I E-APP, V211, P237
   Lewis MA, 2020, NEW ENGL J MED, V382, P2285, DOI 10.1056/NEJMp2006588
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   LIN DY, 1994, STAT MED, V13, P2233, DOI 10.1002/sim.4780132105
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Lou E, 2020, JCO ONCOL PRACT, V16, P383, DOI 10.1200/OP.20.00239
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Robinson AG, 2020, NAT REV CLIN ONCOL, V17, P386, DOI 10.1038/s41571-020-0394-y
   Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659
   Schmidt FM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121971
   Shah MA, 2020, CA-CANCER J CLIN, V70, P349, DOI 10.3322/caac.21627
   Sholle ET, 2018, AMIA ANN S P, V2017, P1581
   Sidaway P, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0366-2
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Treon SP, 2020, BLOOD, V135, P1912, DOI 10.1182/blood.2020006288
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 34
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD NOV 20
PY 2020
VL 38
IS 33
DI 10.1200/JCO.20.01580
PG 17
WC Oncology
SC Oncology
GA PA5XS
UT WOS:000595708800011
PM 32986528
DA 2021-01-01
ER

PT J
AU Tchesnokov, EP
   Gordon, CJ
   Woolner, E
   Kocinkova, D
   Perry, JK
   Feng, JY
   Porter, DP
   Gotte, M
AF Tchesnokov, Egor P.
   Gordon, Calvin J.
   Woolner, Emma
   Kocinkova, Dana
   Perry, Jason K.
   Feng, Joy Y.
   Porter, Danielle P.
   Gotte, Matthias
TI Template-dependent inhibition of coronavirus RNA-dependent RNA
   polymerase by remdesivir reveals a second mechanism of action
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE COVID-19; coronavirus; CoV; SARS-CoV-2; RNA-dependent RNA polymerase;
   RdRp; replication; remdesivir; delayed chain termination; viral
   polymerase; drug development; drug resistance; RNA polymerase; RNA
   virus; SARS-2
ID REVERSE-TRANSCRIPTASE; VIRUS; EXCISION; GS-5734; EXORIBONUCLEASE;
   DISCOVERY; EBOLA
AB Remdesivir (RDV) is a direct-acting antiviral agent that is used to treat patients with severe coronavirus disease 2019 (COVID-19). RDV targets the viral RNA-dependent RNA polymerase (RdRp) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have previously shown that incorporation of the active triphosphate form of RDV (RDV-TP) at position i causes delayed chain termination at position i + 3. Here we demonstrate that the S861G mutation in RdRp eliminates chain termination, which confirms the existence of a steric clash between Ser-861 and the incorporated RDV-TP. With WT RdRp, increasing concentrations of NTP pools cause a gradual decrease in termination and the resulting read-through increases full-length product formation. Hence, RDV residues could be embedded in copies of the first RNA strand that is later used as a template. We show that the efficiency of incorporation of the complementary UTP opposite template RDV is compromised, providing a second opportunity to inhibit replication. A structural model suggests that RDV, when serving as the template for the incoming UTP, is not properly positioned because of a significant clash with Ala-558. The adjacent Val-557 is in direct contact with the template base, and the V557L mutation is implicated in low-level resistance to RDV. We further show that the V557L mutation in RdRp lowers the nucleotide concentration required to bypass this template-dependent inhibition. The collective data provide strong evidence to show that template-dependent inhibition of SARS-CoV-2 RdRp by RDV is biologically relevant.
C1 [Tchesnokov, Egor P.; Gordon, Calvin J.; Woolner, Emma; Kocinkova, Dana; Gotte, Matthias] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada.
   [Perry, Jason K.; Feng, Joy Y.; Porter, Danielle P.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.
   [Gotte, Matthias] Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB, Canada.
RP Gotte, M (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada.; Gotte, M (corresponding author), Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB, Canada.
EM gotte@ualberta.ca
OI Perry, Jason/0000-0001-5492-0652; Woolner, Emma/0000-0002-8697-7802;
   Tchesnokov, Egor/0000-0003-1698-2961
FU Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR) [170343]; Gilead Sciences GrantGilead Sciences;
   Alberta Ministry of Economic Development, Trade and Tourism by the Major
   Innovation Fund Program for the AMR-One Health Consortium
FX This study was supported by Canadian Institutes of Health Research
   (CIHR) Grant 170343 (to M. G.); Gilead Sciences Grant (to M. G.); and
   Alberta Ministry of Economic Development, Trade and Tourism by the Major
   Innovation Fund Program for the AMR-One Health Consortium.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dulin D, 2017, CELL REP, V21, P1063, DOI 10.1016/j.celrep.2017.10.005
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Kennedy EM, 2010, J BIOL CHEM, V285, P39380, DOI 10.1074/jbc.M110.178582
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Maag D, 2001, J BIOL CHEM, V276, P46094, DOI 10.1074/jbc.C100349200
   Magee WC, 2008, ANTIMICROB AGENTS CH, V52, P586, DOI 10.1128/AAC.01172-07
   Marchand B, 2003, J BIOL CHEM, V278, P35362, DOI 10.1074/jbc.M304262200
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Peng Q, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107774
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Seifert M., 2020, BIORXIV
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Tchesnokov EP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22328-3
   Tchesnokov EP, 2008, J BIOL CHEM, V283, P34218, DOI 10.1074/jbc.M806797200
   TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361
   U.S. Food and Drug Administration, 2020, FACT SHEET HLTH CAR, P1
   Wang Q, 2020, CELL, V182, P417, DOI 10.1016/j.cell.2020.05.034
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
NR 33
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 20
PY 2020
VL 295
IS 47
BP 16156
EP 16165
DI 10.1074/jbc.AC120.015720
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA PA5ED
UT WOS:000595657900028
PM 32967965
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lim, JH
   Cho, JH
   Jeon, Y
   Kim, JH
   Lee, GY
   Jeon, S
   Noh, HW
   Lee, YH
   Lee, J
   Chang, HH
   Jung, HY
   Choi, JY
   Park, SH
   Kim, CD
   Kim, YL
   Kim, SW
AF Lim, Jeong-Hoon
   Cho, Jang-Hee
   Jeon, Yena
   Kim, Ji Hye
   Lee, Ga Young
   Jeon, Soojee
   Noh, Hee Won
   Lee, Yong-Hoon
   Lee, Jaehee
   Chang, Hyun-Ha
   Jung, Hee-Yeon
   Choi, Ji-Young
   Park, Sun-Hee
   Kim, Chan-Duck
   Kim, Yong-Lim
   Kim, Shin-Woo
TI Adverse impact of renin-angiotensin system blockade on the clinical
   course in hospitalized patients with severe COVID-19: a retrospective
   cohort study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CORONAVIRUS DISEASE 2019; CONVERTING ENZYME-2; ACE2; MORTALITY;
   LOSARTAN; RECEPTOR; OUTCOMES; RISK
AB The association between angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) and the risk of mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19) was investigated. This retrospective cohort study was performed in all hospitalized patients with COVID-19 in tertiary hospitals in Daegu, Korea. Patients were classified based on whether they received ACE-I or ARB before COVID-19 diagnosis. The analysis of the primary outcome, in-hospital mortality, was performed using the Cox proportional hazards regression model. Of 130 patients with COVID-19, 30 (23.1%) who received ACE-I or ARB exhibited an increased risk of in-hospital mortality (adjusted hazard ratio, 2.20; 95% confidence interval [CI], 1.10-4.38; P=0.025). ACE-I or ARB was also associated with severe complications, such as acute respiratory distress syndrome (ARDS) (adjusted odds ratio [aOR], 2.58; 95% CI, 1.02-6.51; P=0.045) and acute kidney injury (AKI) (aOR, 3.06; 95% CI, 1.15-8.15; P=0.026). Among the patients with ACE-I or ARB therapy, 8 patients (26.7%) used high equivalent doses of ACE-I or ARB and they had higher in-hospital mortality and an increased risk of ARDS and AKI (all, P<0.05). ACE-I or ARB therapy in patients with severe COVID-19 was associated with the occurrence of severe complications and increased in-hospital mortality. The potentially harmful effect of ACE-I or ARB therapy may be higher in patients who received high doses.
C1 [Lim, Jeong-Hoon; Cho, Jang-Hee; Kim, Ji Hye; Lee, Ga Young; Jeon, Soojee; Noh, Hee Won; Jung, Hee-Yeon; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med,Div Nephrol, Dongdeok Ro 130, Daegu 41944, South Korea.
   [Jeon, Yena] Kyungpook Natl Univ, Dept Stat, Daegu, South Korea.
   [Lee, Yong-Hoon; Lee, Jaehee] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Div Pulmonol & Crit Care Med, Dept Internal Med,Sch Med, Daegu, South Korea.
   [Chang, Hyun-Ha; Kim, Shin-Woo] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Div Infect Dis, Dept Internal Med,Sch Med, Daegu, South Korea.
RP Kim, SW (corresponding author), Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Div Infect Dis, Dept Internal Med,Sch Med, Daegu, South Korea.
EM ksw2kms@knu.ac.kr
RI Cho, Jang-hee/ABD-3534-2020; Lim, Jeong-Hoon/ABE-6003-2020
OI Cho, Jang-hee/0000-0002-7031-5214; Lim, Jeong-Hoon/0000-0001-5517-9886;
   Chang, Hyun-Ha/0000-0002-9405-2121
FU Daegu Medical Association COVID19 scientific committee; Korea Centers
   for Disease Control and Prevention [2020-ER5308-00]
FX We thank all the medical staff for their effort in the COVID-19 patient
   care. This work was supported by a research grant from Daegu Medical
   Association COVID19 scientific committee; and this work was supported by
   the Research Program funded by the Korea Centers for Disease Control and
   Prevention (2020-ER5308-00).
CR [Anonymous], 2020, WUH COR 2019 NCOV GL
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chung SM, 2020, DIABETES METAB J, V44, P405, DOI 10.4093/dmj.2020.0105
   Fisher M, 2020, J AM SOC NEPHROL, V31, P2145, DOI 10.1681/ASN.2020040509
   Fominskiy Evgeny V, 2020, Blood Purif, P1, DOI 10.1159/000508657
   Gao C, 2020, EUR HEART J, V41, P2058, DOI 10.1093/eurheartj/ehaa433
   Greco A, 2020, EUR HEART J-CARD PHA, V6, P335, DOI 10.1093/ehjcvp/pvaa074
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo XM, 2020, HYPERTENSION, V76, pE13, DOI 10.1161/HYPERTENSIONAHA.120.15572
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Jung Sun-Young, 2020, Clin Infect Dis, V71, P2121, DOI 10.1093/cid/ciaa624
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Kim S.-W., 2020, J KOREAN MED SCI, P35
   Klimas J, 2015, J CELL MOL MED, V19, P1965, DOI 10.1111/jcmm.12573
   Kormann R, 2020, CLIN KIDNEY J, V13, P362, DOI 10.1093/ckj/sfaa109
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lee YJ, 2011, POSTGRAD MED J, V87, P664, DOI 10.1136/pgmj.2011.118059
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Liabeuf Sophie, 2020, Eur Heart J Cardiovasc Pharmacother, DOI 10.1093/ehjcvp/pvaa062
   Lim JH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061718
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mizuiri Sonoo, 2015, World J Nephrol, V4, P74, DOI 10.5527/wjn.v4.i1.74
   Oussalah Abderrahim, 2020, Clin Infect Dis, V71, P2447, DOI 10.1093/cid/ciaa677
   Pirola CJ, 2020, J INFECTION, V81, P276, DOI 10.1016/j.jinf.2020.05.052
   Pranata R, 2020, DIABETES METAB SYND, V14, P983, DOI 10.1016/j.dsx.2020.06.047
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Senni M, 2016, EUR J HEART FAIL, V18, P1193, DOI 10.1002/ejhf.548
   Smith GB, 2013, RESUSCITATION, V84, P465, DOI 10.1016/j.resuscitation.2012.12.016
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wilson RF, 1996, MANAGEMENT TRAUMA PI
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 45
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 20
PY 2020
VL 10
IS 1
AR 20250
DI 10.1038/s41598-020-76915-4
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OZ0WK
UT WOS:000594656800010
PM 33219294
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sng, CCT
   Wong, YNS
   Wu, AJ
   Ottaviani, D
   Chopra, N
   Galazi, M
   Benafif, S
   Soosaipillai, G
   Roylance, R
   Lee, AJX
   Shaw, H
AF Sng, Christopher C. T.
   Wong, Yien Ning Sophia
   Wu, Anjui
   Ottaviani, Diego
   Chopra, Neha
   Galazi, Myria
   Benafif, Sarah
   Soosaipillai, Gehan
   Roylance, Rebecca
   Lee, Alvin J. X.
   Shaw, Heather
TI Cancer History and Systemic Anti-Cancer Therapy Independently Predict
   COVID-19 Mortality: A UK Tertiary Hospital Experience
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2 infection; solid cancers; risk factors; systemic
   anti-cancer therapy; co-morbidity
AB Background
   The COVID-19 pandemic remains a pressing concern to patients with cancer as countries enter the second peak of the pandemic and beyond. It remains unclear whether cancer and its treatment contribute an independent risk for mortality in COVID-19.
   Methods
   We included patients at a London tertiary hospital with laboratory confirmed SARS-CoV-2 infection. All patients with a history of solid cancer were included. Age- and sex-matched patients without cancer were randomly selected. Patients with hematological malignancies were excluded.
   Results
   We identified 94 patients with cancer, matched to 226 patients without cancer. After adjusting for age, ethnicity, and co-morbidities, patients with cancer had increased mortality following COVID-19 (HR 1.57, 95% CI:1.04-2.4, p = 0.03). Increasing age (HR 1.49 every 10 years, 95% CI:1.25-1.8, p < 0.001), South Asian ethnicity (HR 2.92, 95% CI:1.73-4.9, p < 0.001), and cerebrovascular disease (HR 1.93, 95% CI:1.18-3.2, p = 0.008) also predicted mortality. Within the cancer cohort, systemic anti-cancer therapy (SACT) within 60 days of COVID-19 diagnosis was an independent risk factor for mortality (HR 2.30, 95% CI: 1.16-4.6, p = 0.02).
   Conclusions
   Along with known risk factors, cancer and SACT confer an independent risk for mortality following COVID-19. Further studies are needed to understand the socio-economic influences and pathophysiology of these associations.
C1 [Sng, Christopher C. T.; Wong, Yien Ning Sophia; Wu, Anjui; Ottaviani, Diego; Chopra, Neha; Galazi, Myria; Benafif, Sarah; Soosaipillai, Gehan; Roylance, Rebecca; Lee, Alvin J. X.; Shaw, Heather] Univ Coll London Hosp NHS Fdn Trust, Canc Div, London, England.
   [Wong, Yien Ning Sophia; Lee, Alvin J. X.] UCL, UCL Canc Inst, London, England.
   [Roylance, Rebecca] NIHR Univ Coll London Hosp, Biomed Res Ctr, London, England.
RP Lee, AJX (corresponding author), Univ Coll London Hosp NHS Fdn Trust, Canc Div, London, England.; Lee, AJX (corresponding author), UCL, UCL Canc Inst, London, England.
EM a.j.lee@ucl.ac.uk
RI Lee, Alvin Jun Xing/A-1047-2017
OI Lee, Alvin Jun Xing/0000-0002-7427-9142
CR Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Flint TR, 2017, TRENDS MOL MED, V23, P451, DOI 10.1016/j.molmed.2017.03.001
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Harrison EM, 2020, ETHNICITY OUTCOMES C, DOI [10.2139/ssrn.3618215, DOI 10.2139/SSRN.3618215]
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   NICE, 2020, INT TREATM CHANG OPT
   Public Health England, 2020, GUID SHIELD PROT PEO
   Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 20
PY 2020
VL 10
AR 595804
DI 10.3389/fonc.2020.595804
PG 8
WC Oncology
SC Oncology
GA PA1SC
UT WOS:000595406400001
PM 33330085
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yang, JL
   Guo, ZY
   Liu, X
   Liu, Q
   Wu, M
   Yao, XT
   Liu, Y
   Cui, C
   Li, HY
   Song, CL
   Liu, DY
   Xue, LX
AF Yang, Jianling
   Guo, Zhengyang
   Liu, Xu
   Liu, Qi
   Wu, Meng
   Yao, Xueting
   Liu, Yang
   Cui, Cheng
   Li, Haiyan
   Song, Chunli
   Liu, Dongyang
   Xue, Lixiang
TI Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in
   Multiple Cell Lines and Tissues by Dynamic Imaging System and
   Physiologically Based Pharmacokinetic Model
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE ratio of tissue trough concentrations; dynamic imaging system;
   cytotoxicity; chloroquine and hydroxychloroquine; physiologically based
   pharmacokinetic model
ID LUPUS-ERYTHEMATOSUS
AB Chloroquine (CQ) and hydroxychloroquine (HCQ) have been challenged in treating COVID-19 patients and still under debate due to the uncertainty regarding the effectiveness and safety, and there is still lack of the systematic study on the toxicity of these two drugs. To further uncover the toxicity profile of CQ and HCQ in different tissues, we evaluated the cytotoxicity of them in eight cell lines and further adopted the physiologically based pharmacokinetic models to predict the tissue risk, respectively. Retina, myocardium, lung, liver, kidney, vascular endothelium, and intestinal epithelium originated cells were included in the toxicity evaluation of CQ and HCQ, respectively. The proliferation pattern was monitored in 0-72 h by IncuCyte S3. CC50 and the ratio of tissue trough concentrations to CC50 (R-TTCC) were brought into predicted toxicity profiles. Compared to CQ, HCQ was found to be less toxic in six cell types except Hep3B and Vero cells. In addition, R-TTCC was significantly higher in CQ treatment group compared to HCQ group, which indicates relative safety of HCQ. To further simulate the situation of the COVID-19 patients who suffered the dyspnea and hypoxemia, we also tested the cytotoxicity upon hypoxia and normoxia (1, 5 vs. 21% O-2). It was found that the cytotoxicity of CQ was more sensitive to hypoxia compared with that of HCQ, particularly in liver originated cells. Both CQ and HCQ showed cytotoxicity in time-dependent manner which indicates the necessity of short period administration clinically.
C1 [Yang, Jianling; Guo, Zhengyang; Wu, Meng; Liu, Yang; Xue, Lixiang] Peking Univ Third Hosp, Ctr Basic Med Res CBMR, Beijing, Peoples R China.
   [Liu, Xu; Liu, Qi; Yao, Xueting; Cui, Cheng; Li, Haiyan; Liu, Dongyang] Peking Univ Third Hosp, Drug Clin Trial Ctr, Beijing, Peoples R China.
   [Song, Chunli] Peking Univ Third Hosp, Dept Orthoped, Beijing, Peoples R China.
   [Liu, Xu] Univ Chinese Acad Sci, Savaid Med Sch, Beijing, Peoples R China.
RP Xue, LX (corresponding author), Peking Univ Third Hosp, Ctr Basic Med Res CBMR, Beijing, Peoples R China.; Liu, DY (corresponding author), Peking Univ Third Hosp, Drug Clin Trial Ctr, Beijing, Peoples R China.
EM liudongyang@vip.sina.com; lixiangxue@bjmu.edu.cn
FU MOST (Ministry of Science and Technology of the People's Republic of
   China) Foundation for SARSnCov-02 Research [2020YFC0844500]; Bill &
   Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR
   [INV-015694]
FX This work was supported by the MOST (Ministry of Science and Technology
   of the People's Republic of China) Foundation for SARSnCov-02 Research
   (grant No. 2020YFC0844500) and Bill & Melinda Gates Foundation
   [INV-015694].
CR ADELUSI SA, 1982, GEN PHARMACOL, V13, P433, DOI 10.1016/0306-3623(82)90110-0
   Bahloul E, 2017, LUPUS, V26, P1304, DOI 10.1177/0961203317700486
   Bonow RO, 2020, JAMA CARDIOL, V5, P986, DOI 10.1001/jamacardio.2020.1782
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chhonker YS, 2018, J CHROMATOGR B, V1072, P320, DOI 10.1016/j.jchromb.2017.11.026
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Concha JSS, 2019, J INVEST DERMATOL, V139, P270, DOI 10.1016/j.jid.2018.08.017
   Ezra N, 2012, CLIN EXP DERMATOL, V37, P327, DOI 10.1111/j.1365-2230.2011.04266.x
   Fernandez AP, 2017, J AM ACAD DERMATOL, V76, P1176, DOI 10.1016/j.jaad.2017.01.012
   Fihn SD, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.9035
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Jallouli M, 2013, JAMA DERMATOL, V149, P935, DOI 10.1001/jamadermatol.2013.709
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Min Qiong, 2019, Shengli Xuebao, V71, P336, DOI 10.13294/j.aps.2018.0082
   OLANSKY AJ, 1982, J AM ACAD DERMATOL, V6, P19, DOI 10.1016/S0190-9622(82)70002-7
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Schultz HY, 2015, J INVEST DERMATOL, V135, P7, DOI 10.1038/jid.2014.316
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 28
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 20
PY 2020
VL 11
AR 574720
DI 10.3389/fphar.2020.574720
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PA2FC
UT WOS:000595447800001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU London, J
   Boutboul, D
   Lacombe, K
   Pirenne, F
   Heym, B
   Zeller, V
   Baudet, A
   Ouedrani, A
   Berezne, A
AF London, Jonathan
   Boutboul, David
   Lacombe, Karine
   Pirenne, France
   Heym, Beate
   Zeller, Valerie
   Baudet, Antoine
   Ouedrani, Amani
   Berezne, Alice
TI Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to
   Convalescent Plasma Therapy
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Letter; Early Access
C1 [London, Jonathan; Zeller, Valerie] Hop Diaconesses Croix St Simon, Dept Internal Med & Infect Dis, 125 Rue Avron, F-75020 Paris, France.
   [Boutboul, David] Univ Paris, Dept Clin Immunol, Hop St Louis, AP HP, Paris, France.
   [Boutboul, David] Univ Paris, Hop St Louis, Insight Team, U976 HIPI, Paris, France.
   [Lacombe, Karine] Univ Paris, Dept Infect Dis, Hop St Louis, AP HP, Paris, France.
   [Pirenne, France] Univ Paris, Etab Francais Sang, INSERM U955, Creteil, France.
   [Heym, Beate] Hop Diaconesses Croix St Simon, Dept Microbiol, Paris, France.
   [Baudet, Antoine; Berezne, Alice] CHR Annecy Genevois, Dept Internal Med, Annecy, France.
   [Ouedrani, Amani] Univ Paris, Inst Necker Enfants Malad, CNRS UMR8253, INSERM UMR1151, Paris, France.
   [Ouedrani, Amani] Hop Necker Enfants Malad, AP HP, Immunol Lab, Paris, France.
RP London, J (corresponding author), Hop Diaconesses Croix St Simon, Dept Internal Med & Infect Dis, 125 Rue Avron, F-75020 Paris, France.; Boutboul, D (corresponding author), Univ Paris, Dept Clin Immunol, Hop St Louis, AP HP, Paris, France.; Boutboul, D (corresponding author), Univ Paris, Hop St Louis, Insight Team, U976 HIPI, Paris, France.
EM jlondon@hopital-dcss.org; david.boutboul@aphp.fr
CR Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585
   Bearden D, 2016, J ALLER CL IMM-PRACT, V4, P1059, DOI 10.1016/j.jaip.2015.12.015
   Browne SK, 2012, BLOOD, V119, P3933, DOI 10.1182/blood-2011-12-395707
   Burbelo PD, 2010, BLOOD, V116, P4848, DOI 10.1182/blood-2010-05-286161
   Fill L, 2020, ANN ALLERG ASTHMA IM, V125, P113
   Hueso T, 2020, BLOOD
   Jongco AM, 2014, ANN ALLERG ASTHMA IM, V112, P74, DOI 10.1016/j.anai.2013.10.008
   Malphettes M, 2015, CLIN INFECT DIS, V61, pE13, DOI 10.1093/cid/civ269
   Malphettes M, 2009, CLIN INFECT DIS, V49, P1329, DOI 10.1086/606059
   Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013
   Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263
   Williamson E., 2020, OPENSAFELY FACTORS A, DOI [10.1101/2020.05.06.20092999, DOI 10.1101/2020.05.06.20092999]
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
DI 10.1007/s10875-020-00904-5
EA NOV 2020
PG 6
WC Immunology
SC Immunology
GA OT9BV
UT WOS:000591133700002
PM 33219491
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rannard, SP
   McDonald, TO
   Owen, A
AF Rannard, Steven P.
   McDonald, Tom O.
   Owen, Andrew
TI Chasing COVID-19 chemotherapeutics without putting the cart before the
   horse
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Letter; Early Access
DE coronavirus; drug development; equitable access; repurposing; SARS-CoV-2
C1 [Rannard, Steven P.; McDonald, Tom O.] Univ Liverpool, Dept Chem, Liverpool, Merseyside, England.
   [Owen, Andrew] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool, Merseyside, England.
   [Rannard, Steven P.; McDonald, Tom O.] Univ Liverpool, Ctr Excellence Long acting Therapeut CELT, Liverpool, Merseyside, England.
RP Owen, A (corresponding author), Univ Liverpool, Mat Innovat Factory, Dept Pharmacol & Therapeut, 51 Oxford St, Liverpool L7 3NY, Merseyside, England.
EM aowen@liverpool.ac.uk
RI Owen, Andrew/M-7509-2017
OI Owen, Andrew/0000-0002-9819-7651
CR Arshad U, 2020, CLIN PHARMACOL THER, V108, P775, DOI 10.1002/cpt.1909
   Baker EH, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14416
   Bakshi RP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02603-z
   Beigel J. H., 2020, N ENGL J MED
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen C, 2020, FAVIPIRAVIR VERSUS A
   Dodds MG, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14486
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Markowitz M, 2017, LANCET HIV, V4, pE331, DOI 10.1016/S2352-3018(17)30068-1
   Mitchell JP, 2020, J AEROSOL MED PULM D, V33, P235, DOI 10.1089/jamp.2020.1622
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
NR 12
TC 0
Z9 0
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
DI 10.1111/bcp.14575
EA NOV 2020
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OT2GT
UT WOS:000590671100001
PM 33217038
OA Bronze
DA 2021-01-01
ER

PT J
AU Li, HK
AF Li, Hoiyan Karen
TI Keeping the alcohol and other drug workforce resilient after the
   COVID-19 emergency
SO DRUG AND ALCOHOL REVIEW
LA English
DT Letter; Early Access
C1 [Li, Hoiyan Karen] Queensland Hlth, Insight Ctr Alcohol & Other Drug Training & Workf, Brisbane, Qld, Australia.
RP Li, HK (corresponding author), Queensland Hlth, Insight Ctr Alcohol & Other Drug Training & Workf, Brisbane, Qld, Australia.
EM hoiyan.li@health.qld.gov.au
CR Armitage R, 2020, PUBLIC HEALTH, V183, P63, DOI 10.1016/j.puhe.2020.05.010
   Australian Institute of Health and Welfare, IMP COVID 19 ALC OTH
   Barello S, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113129
   Blake H, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17092997
   Chodkiewicz J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17134677
   Faux SG, 2020, MED J AUSTRALIA, V213, P60, DOI 10.5694/mja2.50685
   Fukuti P, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1963
   Galea-Singer S, 2020, NEW ZEAL MED J, V133, P104
   Giusti EM, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01684
   Heath C, 2020, ANAESTHESIA, V75, P1364, DOI 10.1111/anae.15180
   Khatri Utsha G, 2020, J Addict Med, V14, pe6, DOI 10.1097/ADM.0000000000000684
   Kinman Gail, 2020, Occup Med (Lond), V70, P294, DOI 10.1093/occmed/kqaa096
   Luceno-Moreno L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155514
   Lynch L, 2020, PRISONERS BE PAROLED
   Morgantini LA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238217
   Mota P, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113142
   Pineo MM, 2020, PSYCHOL TRAUMA-US, V12, pS108, DOI 10.1037/tra0000622
   Poonian J, 2020, EMERG MED AUSTRALAS, V32, P700, DOI 10.1111/1742-6723.13547
   Ren CY, 2020, PLASMA SCI TECHNOL, V22, DOI 10.1088/2058-6272/ab580d
   Ripp J, 2020, ACAD MED, V95, P1136, DOI 10.1097/ACM.0000000000003414
   Samuels Elizabeth A, 2020, J Addict Med, V14, pe8, DOI 10.1097/ADM.0000000000000685
   Shepherd S, 2020, MED J AUSTRALIA, V213, P58, DOI 10.5694/mja2.50672
   Skinner N, 2020, AUSTR ALCOHOL OTHER
   Sun Y, 2020, AM J ADDICTION, V29, P268, DOI 10.1111/ajad.13066
   Tracy DK, 2020, BRIT J PSYCHIAT, V217, P537, DOI [10.1192/bjp.2020.109, 10.1192/bjb.2020.61]
   Vindegaard N, 2020, BRAIN BEHAV IMMUN, V89, P531, DOI 10.1016/j.bbi.2020.05.048
   Walton M, 2020, EUR HEART J-ACUTE CA, V9, P241, DOI 10.1177/2048872620922795
   Whitbourn M, 2020, NSW PREPARES EARLY R
   World Health Organization, 2020, MENT HLTH PSYCH CONS
NR 29
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0959-5236
EI 1465-3362
J9 DRUG ALCOHOL REV
JI Drug Alcohol Rev.
DI 10.1111/dar.13218
EA NOV 2020
PG 2
WC Substance Abuse
SC Substance Abuse
GA OT0PC
UT WOS:000590556000001
PM 33215791
OA Bronze
DA 2021-01-01
ER

PT J
AU Kelly, S
   Jeremie-Brink, G
   Chambers, AL
   Smith-Bynum, MA
AF Kelly, Shalonda
   Jeremie-Brink, Gihane
   Chambers, Anthony L.
   Smith-Bynum, Mia A.
TI The Black Lives Matter Movement: A Call to Action for Couple and Family
   Therapists
SO FAMILY PROCESS
LA English
DT Article
DE Black Lives Matter; Structural racism; Couples therapy; Family therapy;
   Racial socialization; Clinical training
ID AFRICAN-AMERICAN; RACIAL SOCIALIZATION; LOW-INCOME; RACE; YOUTH;
   ADJUSTMENT; PARENTS; SCIENCE; STRESS
AB The frequent police killings during the COVID-19 pandemic forced a reckoning among Americans from all backgrounds and propelled the Black Lives Matter movement into a global force. This manuscript addresses major issues to aid practitioners in the effective treatment of African Americans via the lens of Critical Race Theory and the Bioecological Model. We place the impacts of racism on Black families in historical context and outline the sources of Black family resilience. We critique structural racism embedded in all aspects of psychology and allied fields. We provide an overview of racial socialization and related issues affecting the parenting decisions in Black families, as well as a detailed overview of impacts of structural racism on couple dynamics. Recommendations are made for engaging racial issues in therapy, providing emotional support and validation to couples and families experiencing discrimination and racial trauma, and using Black cultural strengths as therapeutic resources.
C1 [Kelly, Shalonda] Rutgers State Univ, New Brunswick, NJ USA.
   [Jeremie-Brink, Gihane] William Paterson Univ New Jersey, Wayne, NJ USA.
   [Chambers, Anthony L.] Northwestern Univ, Family Inst, Evanston, IL USA.
   [Smith-Bynum, Mia A.] Univ Maryland Coll Pk, Silver Spring, MD USA.
RP Kelly, S (corresponding author), Rutgers New Brunswick, Grad Sch Appl & Profess Psychol, Psych Bldg Room A207,152 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM shalonda.kelly@gsapp.rutgers.edu
RI Smith Bynum, Mia/C-2922-2008
OI Smith Bynum, Mia/0000-0002-3930-9414
CR Alexander M., 2010, NEW JIM CROW MASS IN
   Anderson Carol, 2016, WHITE RAGE UNSPOKEN
   Anderson RE, 2019, AM PSYCHOL, V74, P63, DOI 10.1037/amp0000392
   Anderson RE, 2018, J BLACK PSYCHOL, V44, P25, DOI 10.1177/0095798417732930
   [Anonymous], 2007, J BLACKS HIGH EDUC, V54, P58
   Aspen Institute Roundtable on Community Change, 2005, STRUCT RAC YOUTH DEV
   Banales J, 2020, J RES ADOLESCENCE, V30, P403, DOI 10.1111/jora.12485
   Berrey S. A., 2009, BLACK WOMEN GENDER F, V3, P65
   Boyd-Franklin N., 2013, BLACK FAMILIES THERA
   Boyd-Franklin N., 2001, BOYS MEN RAISING OUR
   Bronfenbrenner U, 2000, SOC DEV, V9, P115, DOI 10.1111/1467-9507.00114
   Brown TL, 2011, J BLACK PSYCHOL, V37, P311, DOI 10.1177/0095798410390688
   Brown TN, 2003, J HEALTH SOC BEHAV, V44, P292, DOI 10.2307/1519780
   Callahan JL, 2018, TRAIN EDUC PROF PSYC, V12, P273, DOI 10.1037/tep0000203
   Cedeno LA, 2010, AM J ORTHOPSYCHIAT, V80, P213, DOI 10.1111/j.1939-0025.2010.01025.x
   Chambers AL, 2019, FAM PROCESS, V58, P595, DOI 10.1111/famp.12478
   Chambers AL, 2012, COUPLE FAM PSYCHOL, V1, P31, DOI 10.1037/a0027505
   Chambers AL, 2011, FAM RELAT, V60, P648, DOI 10.1111/j.1741-3729.2011.00673.x
   Clark R, 1999, AM PSYCHOL, V54, P805, DOI 10.1037/0003-066X.54.10.805
   Coard SI, 2007, COUNS PSYCHOL, V35, P797, DOI 10.1177/0011000007304592
   Coates T., 2015, ATLANTIC MONTHLY
   Coates T-N, 2015, WORLD ME
   Crenshaw K, 1995, CRITICAL RACE THEORY
   Davis BL, 2017, J CHILD FAM STUD, V26, P709, DOI 10.1007/s10826-016-0601-8
   Diaquoi R, 2017, HARVARD EDUC REV, V87, P512
   Edsall T. B., 1991, CHAIN REACTION IMPAC
   Elmore CA, 2013, J CHILD FAM STUD, V22, P63, DOI 10.1007/s10826-012-9653-6
   Embrick DG, 2015, CRIT SOCIOL, V41, P835, DOI 10.1177/0896920515591950
   Furdyna HE, 2008, J MARRIAGE FAM, V70, P332, DOI 10.1111/j.1741-3737.2008.00485.x
   Ginther DK, 2011, SCIENCE, V333, P1015, DOI 10.1126/science.1196783
   Goff PA, 2008, J PERS SOC PSYCHOL, V94, P292, DOI 10.1037/0022-3514.94.2.292
   Gregory A, 2008, J SCHOOL PSYCHOL, V46, P455, DOI 10.1016/j.jsp.2007.09.001
   Higgins GE, 2013, AM J CRIM JUSTICE, V38, P1, DOI 10.1007/s12103-012-9162-6
   Hughes D, 2006, DEV PSYCHOL, V42, P747, DOI 10.1037/0012-1649.42.5.747
   Jeremie-Brink G., 2019, INTEGRATIVE COUPLE F, P237
   Jernigan M. M., 2017, RACE ETHNICITY PSYCH, P363
   Kelly S, 2001, J FAM PSYCHOL, V15, P110, DOI 10.1037/0893-3200.15.1.110
   Kelly S., 2017, DIVERSITY COUPLE FAM, P3
   Kelly S., 2019, CULTURALLY RESPONSIV, P105, DOI [10.1037/0000119-005, DOI 10.1037/0000119-005]
   Kelly S., 2003, CULTURALLY DIVERSE M, P141
   Kelly S., 2014, APA HDB MULTICULTURA, V2, P479, DOI [10.1037/14187-027, DOI 10.1037/14187-027]
   Kelly S, 2013, COUPLE FAM PSYCHOL, V2, P264, DOI 10.1037/cfp0000014
   Kwate Naa Oyo A., 2012, J URBAN HEALTH, V90, P632
   Lee JRS, 2019, J BLACK PSYCHOL, V45, P143, DOI 10.1177/0095798419865152
   Leong FTL, 2012, HANDBOOK OF RACE AND DEVELOPMENT IN MENTAL HEALTH, P11, DOI 10.1007/978-1-4614-0424-8_2
   Lesane-Brown CL, 2006, DEV REV, V26, P400, DOI 10.1016/j.dr.2006.02.001
   Maxie AC, 2006, PSYCHOTHERAPY, V43, P85, DOI 10.1037/0033-3204.43.1.85
   McCardle T., 2020, ED CONSIDERATIONS, V45, P1, DOI [10.4148/0146-9282.2186, DOI 10.4148/0146-9282.2186]
   Mistry RS, 2002, CHILD DEV, V73, P935, DOI 10.1111/1467-8624.00448
   Neblett EW, 2012, CHILD DEV PERSPECT, V6, P295, DOI 10.1111/j.1750-8606.2012.00239.x
   Nelson JC, 2013, PSYCHOL SCI, V24, P213, DOI 10.1177/0956797612451466
   New York Civil Liberties Union, 2019, STOP AND FRISK BLAS
   Pew Forum on Religion and Public Life, 2009, REL PORTR AFR AM
   Roberts SO, 2020, PERSPECT PSYCHOL SCI, V15, P1295, DOI 10.1177/1745691620927709
   Sampson RJ, 2004, SOC PSYCHOL QUART, V67, P319, DOI 10.1177/019027250406700401
   Seaton EK, 2020, J RACIAL ETHN HEALTH, V7, P1241, DOI 10.1007/s40615-020-00749-z
   Smith-Bynum MA, 2016, CHILD DEV, V87, P1926, DOI 10.1111/cdev.12562
   Stanton M., 2011, SPECIALTY COMPETENCI
   Stevenson H., 2002, J BLACK PSYCHOL, V28, P84, DOI DOI 10.1177/0095798402028002002
   Sue DW, 2007, AM PSYCHOL, V62, P271, DOI 10.1037/0003-066X.62.4.271
   Sue DW, 2011, CULT DIVERS ETHN MIN, V17, P331, DOI 10.1037/a0024190
   Tabak LA, 2011, SCIENCE, V333, P940, DOI 10.1126/science.1211704
   Thomas AJ, 2014, J RES ADOLESCENCE, V24, P485, DOI 10.1111/jora.12132
   Tucker M. B., 1995, DECLINE MARRIAGE AFR, P3
   Tudge J. R., 2009, J FAMILY THEORY REV, V1, P198, DOI [10.1111/j.1756-2589.2009.00026.x, DOI 10.1111/J.1756-2589.2009.00026.X]
   United States Federal Bureau of Investigation, 2015, UN CRIM REP HAT CRIM
   Wesley K., 2017, DIVERSITY COUPLE FAM, P393
   Williams DR, 2019, HEALTH SERV RES, V54, P1374, DOI 10.1111/1475-6773.13222
NR 68
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD DEC
PY 2020
VL 59
IS 4
SI SI
BP 1374
EP 1388
DI 10.1111/famp.12614
EA NOV 2020
PG 15
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA PD1AT
UT WOS:000590682600001
PM 33217004
DA 2021-01-01
ER

PT J
AU Pipe, SW
   Kaczmarek, R
   Srivastava, A
   Pierce, GF
   Makris, M
   Hermans, C
AF Pipe, Steven W.
   Kaczmarek, Radoslaw
   Srivastava, Alok
   Pierce, Glenn F.
   Makris, Mike
   Hermans, Cedric
CA Interim Guidance
   CPSSA Comm World Feder
TI Management of COVID-19-associated coagulopathy in persons with
   haemophilia
SO HAEMOPHILIA
LA English
DT Article; Early Access
DE clotting factor concentrates; coagulopathy; COVID&#8208; 19; emicizumab;
   haemophilia; thromboprophylaxis
AB Introduction The SARS-CoV-2 coronavirus-induced infection (COVID-19) can be associated with a coagulopathy mainly responsible for pulmonary microvasculature thrombosis and systemic thromboembolic manifestations. The pathophysiology and management of the COVID-19 coagulopathy are likely more complex in patients with inherited bleeding diseases such as haemophilia. These individuals might indeed present with both bleeding and thrombotic complications and require simultaneous antithrombotic and haemostatic treatments.
   Objective We propose practical guidance for the diagnosis and management of COVID-19 coagulopathy in persons with haemophilia.
   Results Continuation of regular haemostatic treatment is recommended for ambulatory patients. For patients requiring hospital admission and on replacement therapy with factors VIII or IX concentrates, prophylaxis with concentrates should be intensified according to the risk of bleeding complications and associated with prophylactic doses of LMWH. For patients on nonreplacement therapy, emicizumab should be continued and possibly combined with factor VIII and prophylactic doses of LMWH depending on the risk of bleeding and thrombosis. Dose escalation of LMWH tailored to the risk of thrombosis can be employed but not supported by evidence.
   Conclusions These practical recommendations are based on the current literature on COVID-19 with its impact on haemostasis, indications and modalities for thromboprophylaxis mainly in nonhaemophilic patients and how that is likely to affect persons with haemophilia in different circumstances. They will need to be tailored to each patient's clinical status and validated in future studies.
C1 [Pipe, Steven W.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA.
   [Pipe, Steven W.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Kaczmarek, Radoslaw] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.
   [Kaczmarek, Radoslaw] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland.
   [Srivastava, Alok] Christian Med Coll & Hosp, Dept Haematol, Vellore, Tamil Nadu, India.
   [Pierce, Glenn F.] World Federat Hemophilia, Montreal, PQ, Canada.
   [Makris, Mike] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England.
   [Makris, Mike] Royal Hallamshire Hosp, Sheffield Haemophilia & Thrombosis Ctr, Sheffield, S Yorkshire, England.
   [Hermans, Cedric] Univ Catholique Louvain UCLouvain, Hemostasis & Thrombosis Unit, Div Hematol, Clin Univ St Luc, Brussels, Belgium.
   [CPSSA Comm World Feder] World Federat Hemophilia, Coagulat Prod Safety Supply & Access Comm, Montreal, PQ, Canada.
RP Hermans, C (corresponding author), Univ Catholique Louvain UCLouvain, Hemostasis & Thrombosis Unit, Div Hematol, Clin Univ St Luc, Brussels, Belgium.
EM cedric.hermans@uclouvain.be
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Adamkewicz JI, 2019, THROMB HAEMOSTASIS, V119, P1084, DOI 10.1055/s-0039-1688687
   Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bowles L, 2020, NEW ENGL J MED, V383, P288, DOI 10.1056/NEJMc2013656
   Butterfield JSS, 2020, MOL THER, V28, P997, DOI 10.1016/j.ymthe.2019.11.006
   Chowdary P, 2018, DRUGS, V78, P881, DOI 10.1007/s40265-018-0922-6
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Coppola A, 2020, SEMIN THROMB HEMOST, V46, P819, DOI 10.1055/s-0040-1712961
   Cui DY, 2020, HAEMOPHILIA, V26, pE214, DOI 10.1111/hae.14000
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Harzallah I, 2020, J THROMB HAEMOST, V18, P2778, DOI 10.1111/jth.14937
   Hermans C, 2020, HAEMOPHILIA, V26, P768, DOI 10.1111/hae.14045
   Hermans C, 2020, HAEMOPHILIA, V26, P371, DOI 10.1111/hae.14001
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lang M, 2020, LANCET INFECT DIS
   Leisman DE, 2020, INTENS CARE MED, V46, P1105, DOI 10.1007/s00134-020-06059-6
   Levi M, 2020, RES PRACT THROMB HAE, V4, P744, DOI 10.1002/rth2.12400
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Libby P, 2020, EUR HEART J, V41, P3038, DOI 10.1093/eurheartj/ehaa623
   Miesbach Wolfgang, 2020, TH Open, V4, pe138, DOI 10.1055/s-0040-1713678
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Pasi KJ, 2017, NEW ENGL J MED, V377, P819, DOI [10.1056/NEJMoa1616569, 10.1056/NEJMoa1708483]
   Rivas-Pollmar MI, 2020, J THROMB HAEMOST, V18, P2202, DOI 10.1111/jth.14954
   Schneiderman J, 2007, HAEMOPHILIA, V13, P244, DOI 10.1111/j.1365-2516.2007.01451.x
   Schulman S, 2020, SEMIN THROMB HEMOST, V46, P772, DOI 10.1055/s-0040-1710337
   Shapiro AD, 2019, BLOOD, V134, P1973, DOI 10.1182/blood.2019001542
   Shi C, 2020, CTS-CLIN TRANSL SCI, V13, P1087, DOI 10.1111/cts.12880
   Thachil J, 2020, J THROMB HAEMOST, V18, P2138, DOI 10.1111/jth.15004
   Thachil J, 2020, SEMIN THROMB HEMOST, V46, P777, DOI 10.1055/s-0040-1712155
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Weyand AC, 2019, HAEMOPHILIA, V25, pE203, DOI 10.1111/hae.13721
   Xu HJ, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029619892683
   ZHANG A, 2020, HAEMOPHILIA 0906, DOI DOI 10.1111/HAE.14108
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 38
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-8216
EI 1365-2516
J9 HAEMOPHILIA
JI Haemophilia
DI 10.1111/hae.14191
EA NOV 2020
PG 8
WC Hematology
SC Hematology
GA OT1EI
UT WOS:000590596100001
PM 33216448
OA Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Nguyen, FT
   van den Akker, T
   Lally, K
   Lam, H
   Lenskaya, V
   Liu, STH
   Bouvier, NM
   Aberg, JA
   Rodriguez, D
   Krammer, F
   Strauss, D
   Shaz, BH
   Rudon, L
   Galdon, P
   Jhang, JS
   Arinsburg, SA
   Baine, I
AF Nguyen, Freddy T.
   van den Akker, Tayler
   Lally, Kimberly
   Lam, Hansen
   Lenskaya, Volha
   Liu, Sean T. H.
   Bouvier, Nicole M.
   Aberg, Judith A.
   Rodriguez, Denise
   Krammer, Florian
   Strauss, Donna
   Shaz, Beth H.
   Rudon, Louella
   Galdon, Patricia
   Jhang, Jeffrey S.
   Arinsburg, Suzanne A.
   Baine, Ian
CA Mt Sinai Hlth Syst Convalescent Pl
TI Transfusion reactions associated with COVID-19 convalescent plasma
   therapy for SARS-CoV-2
SO TRANSFUSION
LA English
DT Article; Early Access
DE FFP transfusion; immunology (other than RBC serology); transfusion
   practices (adult)
ID BLOOD-CELL ALLOIMMUNIZATION; ACUTE RESPIRATORY SYNDROME; LONG-TERM
   MORTALITY; CIRCULATORY OVERLOAD; VIRUS; SURVEILLANCE; RECEPTOR; DISEASE;
   IMPACT; SCORE
AB Background Convalescent plasma (CP) for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shown preliminary signs of effectiveness in moderate to severely ill patients in reducing mortality. While studies have demonstrated a low risk of serious adverse events, the comprehensive incidence and nature of the spectrum of transfusion reactions to CP is unknown. We retrospectively examined 427 adult inpatient CP transfusions to determine incidence and types of reactions, as well as clinical parameters and risk factors associated with transfusion reactions.
   Study Design and Methods Retrospective analysis was performed for 427 transfusions to 215 adult patients with coronavirus 2019 (COVID-19) within the Mount Sinai Health System, through the US Food and Drug Administration emergency investigational new drug and the Mayo Clinic Expanded Access Protocol to Convalescent Plasma approval pathways. Transfusions were blindly evaluated by two reviewers and adjudicated by a third reviewer in discordant cases. Patient demographics and clinical and laboratory parameters were compared and analyzed.
   Results Fifty-five reactions from 427 transfusions were identified (12.9% incidence), and 13 were attributed to transfusion (3.1% incidence). Reactions were classified as underlying COVID-19 (76%), febrile nonhemolytic (10.9%), transfusion-associated circulatory overload (9.1%), and allergic (1.8%) and hypotensive (1.8%) reactions. Statistical analysis identified increased transfusion reaction risk for ABO blood group B or Sequential Organ Failure Assessment scores of 12 to 13, and decreased risk within the age group of 80 to 89 years.
   Conclusion Our findings support the use of CP as a safe, therapeutic option from a transfusion reaction perspective, in the setting of COVID-19. Further studies are needed to confirm the clinical significance of ABO group B, age, and predisposing disease severity in the incidence of transfusion reaction events.
C1 [Nguyen, Freddy T.; Lally, Kimberly; Lam, Hansen; Lenskaya, Volha; Rudon, Louella; Galdon, Patricia; Jhang, Jeffrey S.; Arinsburg, Suzanne A.; Baine, Ian] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based Med, One Gustave L Levy Pl,Box 1024, New York, NY 10029 USA.
   [Nguyen, Freddy T.] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [van den Akker, Tayler] Icahn Sch Med Mt Sinai West, Dept Pathol, New York, NY USA.
   [Liu, Sean T. H.; Bouvier, Nicole M.; Aberg, Judith A.] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA.
   [Bouvier, Nicole M.; Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [Rodriguez, Denise] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA.
   [Strauss, Donna; Shaz, Beth H.] New York Blood Ctr Enterprises, New York, NY USA.
RP Baine, I (corresponding author), Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based Med, One Gustave L Levy Pl,Box 1024, New York, NY 10029 USA.
EM ian.baine@mountsinai.org
RI Nguyen, Freddy/X-2742-2019
OI Nguyen, Freddy/0000-0003-0106-8114; Shaz, Beth/0000-0002-2270-4821
FU Arnold and Mabel Beckman Foundation
FX The authors thank Joshua Wong for assistance with patient database
   management, and Thomas Schneider for automated calculation of SOFA
   scoring. The authors are grateful to Irene Protasio-Deslandes and
   Susette Celiz-Josue for convalescent plasma sample tracking. F.T.N. is
   supported by a postdoctoral fellowship from the Arnold and Mabel Beckman
   Foundation. The authors also thank the Mount Sinai Health System
   Convalescent Plasma Team for patient recruitment, donor recruitment,
   administration of the convalescent plasma treatments, and data
   collection.
CR Administration U.S.F.D., 2020, REC INV COVID 19 CON
   Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   [Anonymous], BIOV COMP HEM MOD SU
   [Anonymous], 2020, RECOMMENDATIONS INVE
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Bjursten H, 2013, INTENS CARE MED, V39, P437, DOI 10.1007/s00134-012-2723-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Chun S, 2016, ANN LAB MED, V36, P393, DOI 10.3343/alm.2016.36.4.393
   Clinic M., 2020, COVID 19 EXP ACC PRO
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Fasano RM, 2015, BRIT J HAEMATOL, V168, P291, DOI 10.1111/bjh.13123
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Geisen C, 2016, VOX SANG, V110, P329, DOI 10.1111/vox.12376
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guillon P, 2008, GLYCOBIOLOGY, V18, P1085, DOI 10.1093/glycob/cwn093
   Hendrickson JE, 2016, TRANSFUSION, V56, P2587, DOI 10.1111/trf.13730
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hong H, 2016, BLOOD, V127, P496, DOI 10.1182/blood-2015-07-655944
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Joyner M, 2020, EFFECT CONVALESCENT, DOI 10.1101/2020.08.12.20169359
   Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Lambden S, 2019, CRITICAL CARE, V23, P1
   Latz CA, 2020, ANN HEMATOL, V99, P2113, DOI 10.1007/s00277-020-04169-1
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu STH, 2020, NAT MED, V26, P1708, DOI 10.1038/s41591-020-1088-9
   Liu XQ, 2020, ANN HEMATOL, V99, P1421, DOI 10.1007/s00277-020-04103-5
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Minne L, 2008, CRIT CARE, V12, DOI 10.1186/cc7160
   Nakaseko Y, 2018, J SURG RES, V226, P157, DOI 10.1016/j.jss.2017.09.030
   Narick C, 2012, TRANSFUSION, V52, P160, DOI 10.1111/j.1537-2995.2011.03247.x
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Pandey S, 2012, TRANSFUSION, V52, p65S, DOI 10.1111/j.1537-2995.2012.03663.x
   Politis C, 2016, VOX SANG, V111, P409, DOI 10.1111/vox.12447
   Raval JS, 2015, VOX SANG, V108, P387, DOI 10.1111/vox.12234
   Ritchie G, 2010, VIROLOGY, V399, P257, DOI 10.1016/j.virol.2009.12.020
   Ryder AB, 2016, BRIT J HAEMATOL, V174, P483, DOI 10.1111/bjh.13781
   Saadah NH, 2017, TRANSFUSION, V57, P2104, DOI 10.1111/trf.14245
   Sahu A, 2020, HEMATOL TRANSF CELL, V42, P326, DOI 10.1016/j.htct.2019.09.006
   Shah S, 2018, J TRAUMA ACUTE CARE, V84, pS47, DOI 10.1097/TA.0000000000001820
   Shelton J. F, 2020, TRANS ETHNIC ANAL RE, DOI [10.1101/2020.09.04.20188318, DOI 10.1101/2020.09.04.20188318]
   Shen C, 2020, JAMA-J AM MED ASSOC, V323, P15829
   Shishehbor MH, 2009, JACC-CARDIOVASC INTE, V2, P46, DOI 10.1016/j.jcin.2008.09.011
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   StataCorp, 2019, STAT STAT SOFTW REL
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Vlaar APJ, 2019, TRANSFUSION, V59, P2465, DOI 10.1111/trf.15311
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang YM, 2020, J INFECT DIS, V221, P1688, DOI 10.1093/infdis/jiz656
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yazdanbakhsh K, 2016, HEMATOL-AM SOC HEMAT, P457, DOI 10.1182/asheducation-2016.1.457
   Yazdanbakhsh K, 2012, BLOOD, V120, P528, DOI 10.1182/blood-2011-11-327361
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 66
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
DI 10.1111/trf.16177
EA NOV 2020
PG 16
WC Hematology
SC Hematology
GA OT2FW
UT WOS:000590668800001
PM 33125158
OA Bronze
DA 2021-01-01
ER

PT J
AU Batool, F
   Mughal, EU
   Zia, K
   Sadiq, A
   Naeem, N
   Javid, A
   Ul-Haq, Z
   Saeed, M
AF Batool, Farwa
   Mughal, Ehsan Ullah
   Zia, Komal
   Sadiq, Amina
   Naeem, Nafeesa
   Javid, Asif
   Ul-Haq, Zaheer
   Saeed, Muhammad
TI Synthetic flavonoids as potential antiviral agents against SARS-CoV-2
   main protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; flavonoids; flavonols; thioflavonols; oxoaurones;
   thioaurones; 3-benzyloxyflavones; 3-O-flavonol glycosides;
   benzisothiazolinones; molecular docking
AB The COVID-19 pandemic has claimed more than a million lives worldwide within a short time span. Due to the unavailability of specific antiviral drugs or vaccine, the infections are causing panic both in general public and among healthcare providers. Therefore, an urgent discovery and development of effective antiviral drug for the treatment of COVID-19 is highly desired. Targeting the main protease (M-pro) of the causative agent, SARS-CoV-2 has great potential for drug discovery and drug repurposing efforts. Published crystal structures of SARS-CoV-2 M-pro further facilitated in silico investigations for discovering new inhibitors against M-pro. The present study aimed to screen several libraries of synthetic flavonoids and benzisothiazolinones as potential SARS-CoV-2 M-pro inhibitors using in silico methods. The short-listed compounds after virtual screening were filtered through SwissADME modeling tool to remove molecules with unfavorable pharmacokinetics and medicinal properties. The drug-like molecules were further subjected to iterative docking for the identification of top binders of SARS-CoV-2 M-pro. Finally, molecular dynamic (MD) simulations and binding free energy calculations were performed for the evaluation of the dynamic behavior, stability of protein-ligand complex, and binding affinity, resulting in the identification of thioflavonol, TF-9 as a potential inhibitor of M-pro. The computational studies further revealed the binding of TF-9 close to catalytic dyad and interactions with conserved residues in the S1 subsite of the substrate binding site. Our in-silico study demonstrated that synthetic analogs of flavonoids, particularly thioflavonols, have a strong tendency to inhibit the main protease M-pro, and thereby inhibit the reproduction of SARS-CoV-2.
   Communicated by Ramaswamy H. Sarma
C1 [Batool, Farwa; Saeed, Muhammad] Lahore Univ Management Sci, Syed Babar Ali Sch Sci & Engn, Dept Chem & Chem Engn, Lahore 54192, Pakistan.
   [Mughal, Ehsan Ullah; Naeem, Nafeesa; Javid, Asif] Univ Gujrat, Dept Chem, Gujrat, Pakistan.
   [Zia, Komal; Ul-Haq, Zaheer] Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, Int Ctr Chem & Biol Sci, Karachi 75210, Pakistan.
   [Sadiq, Amina] Govt Coll Women Univ, Dept Chem, Sialkot, Pakistan.
RP Saeed, M (corresponding author), Lahore Univ Management Sci, Syed Babar Ali Sch Sci & Engn, Dept Chem & Chem Engn, Lahore 54192, Pakistan.; Ul-Haq, Z (corresponding author), Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, Int Ctr Chem & Biol Sci, Karachi 75210, Pakistan.
EM zaheer.qasmi@iccs.edu; muhammad.saeed@lums.edu.pk
RI Ul-Haq, Zaheer/AAE-1628-2020
OI Ul-Haq, Zaheer/0000-0002-8530-8711; Mughal, Ehsan
   Ullah/0000-0001-9463-9398; Naeem, Nafeesa/0000-0002-6647-9697
FU Faculty Initiative Funding [FIF-642]; Faculty Initiative Funding from
   Lahore University of Management Sciences [FIF-642]
FX The study was supported by Faculty Initiative Funding (FIF-642) from
   Lahore University of Management Sciences
CR Ancy I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1786459
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Chae SC, 2013, EXCLI J, V12, P226
   Ciliberto G, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01590-2
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Ghosh R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779818
   Gupta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1776157
   Gurung AB, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117831
   Hage-Melim LID, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117963
   Holmes JA, 2020, LANCET GASTROENTEROL, V5, P626, DOI 10.1016/S2468-1253(20)30154-0
   Ibrahim MAA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1790037
   Jimenez-Alberto A, 2020, COMPUT BIOL CHEM, V88, DOI 10.1016/j.compbiolchem.2020.107325
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi T, 2020, EUR REV MED PHARMACO, V24, P4529, DOI 10.26355/eurrev_202004_21036
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   King AR, 2009, BRIT J PHARMACOL, V157, P974, DOI 10.1111/j.1476-5381.2009.00276.x
   Kumar Y, 2020, J INFECT PUBLIC HEAL, V13, P1210, DOI 10.1016/j.jiph.2020.06.016
   Lalani S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020184
   Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1036
   Marinho EM, 2020, MICROB PATHOGENESIS, V148, DOI 10.1016/j.micpath.2020.104365
   Mengist HM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0178-y
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mughal EU, 2019, BIOORG CHEM, V91, DOI 10.1016/j.bioorg.2019.103124
   Mughal EU, 2018, BIOORGAN MED CHEM, V26, P3696, DOI 10.1016/j.bmc.2018.05.050
   Mughal EU, 2017, BIOORGAN MED CHEM, V25, P100, DOI 10.1016/j.bmc.2016.10.016
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Narkhede RR, 2020, NAT PRODUCT BIOPROSP, V10, P297, DOI 10.1007/s13659-020-00253-1
   Niu C, 2008, BIOORGAN MED CHEM, V16, P293, DOI 10.1016/j.bmc.2007.09.034
   Panche AN, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.41
   Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509
   Ertekin SS, 2020, JAMA DERMATOL, V156, P471, DOI 10.1001/jamadermatol.2020.0013
   Sepay N, 2020, STRUCT CHEM, V31, P1831, DOI 10.1007/s11224-020-01537-5
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Sies H, 2020, FREE RADICAL BIO MED, V156, P107, DOI 10.1016/j.freeradbiomed.2020.06.032
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   Standing JF, 2020, CLIN PHARMACOL THER, V108, P187, DOI 10.1002/cpt.1872
   Tripathi MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1790425
   Viani F, 2017, TETRAHEDRON, V73, P1745, DOI 10.1016/j.tet.2017.02.025
   Villoutreix BO, 2020, DRUG DISCOV TODAY, V25, P1287, DOI 10.1016/j.drudis.2020.06.022
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang L, 2017, EUR J MED CHEM, V137, P450, DOI 10.1016/j.ejmech.2017.05.045
   Wang YL, 2015, Q REV BIOPHYS, V48, P488, DOI 10.1017/S0033583515000190
   Whitworth J, 2020, T ROY SOC TROP MED H, V114, P227, DOI 10.1093/trstmh/traa025
   World Health Organization, 2020, COR DIS COVID 19
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 51
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1850359
EA NOV 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA PC4JG
UT WOS:000596969000001
PM 33251983
OA Bronze
DA 2021-01-01
ER

PT J
AU Maurya, DK
   Sharma, D
AF Maurya, Dharmendra Kumar
   Sharma, Deepak
TI Evaluation of traditional ayurvedic Kadha for prevention and management
   of the novel Coronavirus (SARS-CoV-2) using in silico approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Ayurvedic Kadha; Coronavirus; COVID-19; molecular docking;
   phytochemicals
AB Since the emergence of novel Coronavirus (SARS-CoV-2) infection in Wuhan, China in December 2019, it has now spread to over 205 countries. The ever-growing list of globally spread corona virus-19 disease (COVID-19) patients has demonstrated the high transmission rate among the human population. Currently, there are no FDA approved drugs or vaccines to prevent and treat the infection of the SARS-CoV-2. Considering the current state of affairs, there is an urgent unmet medical need to identify novel and effective approaches for the prevention and treatment of COVID-19 by re-evaluating the knowledge of traditional medicines and repurposing of drugs. Here, we used molecular docking and molecular dynamics simulation approach to explore the beneficial roles of phytochemicals and active pharmacological agents present in the Indian herbs which are widely used in the preparation of Ayurvedic medicines in the form of Kadha to control various respiratory disorders such as cough, cold and flu. Our study has identified an array of phytochemicals present in these herbs which have significant docking scores and potential to inhibit different stages of SARS-CoV-2 infection as well as other Coronavirus target proteins. The phytochemicals present in these herbs possess significant anti-inflammatory property. Apart from this, based on their pharmaceutical characteristics, we have also performed in-silico drug-likeness and predicted pharmacokinetics of the selected phytochemicals found in the Kadha. Overall our study provides scientific justification in terms of binding of active ingredients present in different plants used in Kadha preparation with viral proteins and target proteins for prevention and treatment of the COVID-19.
   Communicated by Ramaswamy H. Sarma
C1 [Maurya, Dharmendra Kumar; Sharma, Deepak] Bhabha Atom Res Ctr, Radiat Biol & Hlth Sci Div, Mumbai, Maharashtra, India.
   [Maurya, Dharmendra Kumar; Sharma, Deepak] Homi Bhabha Natl Inst, Anushaktinagar, India.
RP Maurya, DK (corresponding author), Bhabha Atom Res Ctr, Radiat Biol & Hlth Sci Div, Free Rad Biol Sect, Mumbai 400085, Maharashtra, India.
EM dkmaurya@barc.gov.in
FU Department of Atomic Energy, Government of IndiaDepartment of Atomic
   Energy (DAE)
FX This work was supported by Department of Atomic Energy, Government of
   India.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Alamgeer Younis W., 2018, CHIN MED-UK, V13, P48, DOI [https://doi.org/10.1186/s13020-018-0204-y, 10.1186/s13020-018-0204-y, DOI 10.1186/s13020-018-0204-y]
   Alcantara J., 2010, VIRUS ADAPTATION TRE, V2, DOI [https://doi.org/10.2147/VAAT.S12733, DOI 10.2147/VAAT.S12733]
   Alleva LM, 2010, EVID-BASED COMPL ALT, V7, P501, DOI 10.1093/ecam/nep152
   Arora R, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/586506
   Barnes J., 2004, COMPLEMENTARY ALTERN
   Bhattarai K., 2018, J NUTR DIETETICS PRO, V1
   Chowdhury P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1803968
   Cortes-Rojas Diego Francisco, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P90, DOI 10.1016/S2221-1691(14)60215-X
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Damanhouri Z., 2014, MED AROMAT PLANT, V3, DOI [DOI 10.4172/2167-0412.1000161, https://doi.org/10.4172/2167-0412.1000161]
   Emirik M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1835719
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   He RT, 2004, VIRUS RES, V105, P121, DOI 10.1016/j.virusres.2004.05.002
   He RT, 2004, BIOCHEM BIOPH RES CO, V316, P476, DOI 10.1016/j.bbrc.2004.02.074
   Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Kumar A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772112
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li S, 2011, PHARM CROPS, V2, P28, DOI DOI 10.2174/2210290601102010028
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812
   Maurya D.K., 2020, COMBINATION IVERMECT, DOI [https://doi.org/10.26434/chemrxiv.12630539, 10.26434/chemrxiv.12630539, DOI 10.26434/CHEMRXIV.12630539]
   Noumi E, 2018, MOLECULES, V23, DOI 10.3390/molecules23112818
   Pan Min-Hsiung, 2011, J Tradit Complement Med, V1, P8
   Pattanayak Priyabrata, 2010, Pharmacogn Rev, V4, P95, DOI 10.4103/0973-7847.65323
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pinn G, 2001, Aust Fam Physician, V30, P775
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Prasad S, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/142979
   Raal A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058642
   Rangel CN, 2011, CIENCIA TECNOL ALIME, V31, P918, DOI 10.1590/S0101-20612011000400014
   Sachan A., 2018, J MED PLANTS STUDIES, V6, P116
   Saini Anu, 2016, J Family Med Prim Care, V5, P254
   Salata C, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftaa006
   Sangwan RS, 2004, CURR SCI INDIA, V86, P461
   Santana FPR, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/2348968
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   Sen D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1819883
   Sharma P, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02437
   Shingadiya R.K., 2016, J INDIAN SYSTEM MED, V4, P230
   Shree P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1810778
   Swargiary A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1835729
   Takeuchi O, 2007, IMMUNOL REV, V220, P214, DOI 10.1111/j.1600-065X.2007.00562.x
   The Ministry of AYUSH, 2020, AYURV IMM BOO MEAS S
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Tripathi MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1790425
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047
   VANDERCOOK CE, 1966, J AGR FOOD CHEM, V14, P450, DOI 10.1021/jf60147a003
   Vasanthi HR, 2010, CURR CARDIOL REV, V6, P274, DOI 10.2174/157340310793566172
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wang Q, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-99
   Weiss R.F., 2000, HERBAL MED
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 63
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1852119
EA NOV 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA PC4JQ
UT WOS:000596970000001
PM 33251972
OA Bronze
DA 2021-01-01
ER

PT J
AU Gopinath, K
   Jokinen, EM
   Kurkinen, ST
   Pentikainen, OT
AF Gopinath, Krishnasamy
   Jokinen, Elmeri M.
   Kurkinen, Sami T.
   Pentikainen, Olli T.
TI Screening of Natural Products Targeting SARS-CoV-2-ACE2 Receptor
   Interface - A MixMD Based HTVS Pipeline
SO FRONTIERS IN CHEMISTRY
LA English
DT Article
DE COVID-19; mixed solvent molecular dynamics simulation; natural product;
   spike protein; ACE2
ID MOLECULAR-DYNAMICS SIMULATIONS; TRADITIONAL CHINESE MEDICINE; PARTICLE
   MESH EWALD; AMBER; PARAMETERS; DOCKING; ENTRY
AB The COVID-19 pandemic, caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a severe global health crisis now. SARS-CoV-2 utilizes its Spike protein receptor-binding domain (S-protein) to invade human cell through binding to Angiotensin-Converting Enzyme 2 receptor (ACE2). S-protein is the key target for many therapeutics and vaccines. Potential S-protein-ACE2 fusion inhibitor is expected to block the virus entry into the host cell. In many countries, traditional practices, based on natural products (NPs) have been in use to slow down COVID-19 infection. In this study, a protocol was applied that combines mixed solvent molecular dynamics simulations (MixMD) with high-throughput virtual screening (HTVS) to search NPs to block SARS-CoV-2 entry into the human cell. MixMD simulations were employed to discover the most promising stable binding conformations of drug-like probes in the S-protein-ACE2 interface. Detected stable sites were used for HTVs of 612093 NPs to identify molecules that could interfere with the S-protein-ACE2 interaction. In total, 19 NPs were selected with rescoring model. These top-ranked NP-S-protein complexes were subjected to classical MD simulations for 300 ns (3 replicates of 100 ns) to estimate the stability and affinity of binding. Three compounds, ZINC000002128789, ZINC000002159944 and SN00059335, showed better stability in all MD runs, of which ZINC000002128789 was predicted to have the highest binding affinity, suggesting that it could be effective modulator in RBD-ACE2 interface to prevent SARS-CoV-2 infection. Our results support that NPs may provide tools to fight COVID-19.
C1 [Gopinath, Krishnasamy; Jokinen, Elmeri M.; Kurkinen, Sami T.; Pentikainen, Olli T.] Univ Turku, Inst Biomed, Fac Med Integrat Physiol & Pharmacol, Turku, Finland.
RP Pentikainen, OT (corresponding author), Univ Turku, Inst Biomed, Fac Med Integrat Physiol & Pharmacol, Turku, Finland.
EM olli.pentikainen@utu.fi
OI Kurkinen, Sami/0000-0003-2515-7429
FU CSC-IT Center for Science [2002823]; Academy of FinlandAcademy of
   Finland [323413]; Instrumentarium Science Foundation
FX We acknowledge the CSC-IT Center for Science (Project 2002823) for
   offering prioritized computational resources for this project. This
   study was financially supported by the Academy of Finland (OP; Grant No.
   323413), and by The Instrumentarium Science Foundation (EJ).
CR Ali Amanat, 2020, Sci Rep, V10, P14214, DOI 10.1038/s41598-020-71188-3
   Amaro RE, 2008, J COMPUT AID MOL DES, V22, P693, DOI 10.1007/s10822-007-9159-2
   Amaro RE, 2018, BIOPHYS J, V114, P2271, DOI 10.1016/j.bpj.2018.02.038
   ANDERSEN HC, 1980, J CHEM PHYS, V72, P2384, DOI 10.1063/1.439486
   Antonio AD, 2020, RSC ADV, V10, P23379, DOI 10.1039/d0ra03774e
   Banerjee P, 2015, NUCLEIC ACIDS RES, V43, pD935, DOI 10.1093/nar/gku886
   Bhutani I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119771
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497
   Case D., 2020, AMBER 2020
   Chen YH, 2020, ITAL J PURE APPL MAT, P14
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Galindo-Murillo R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6152
   Ghanakota P, 2016, J PHYS CHEM B, V120, P8685, DOI 10.1021/acs.jpcb.6b03515
   Gotz AW, 2012, J CHEM THEORY COMPUT, V8, P1542, DOI 10.1021/ct200909j
   Gopinath K, 2020, NAT PROD J, V10, P168, DOI 10.2174/2210315508666180622113414
   Haider S, 2008, BIOPHYS J, V95, P296, DOI 10.1529/biophysj.107.120501
   Jani V., 2020, CHEMRXIV PREPRINT, P1, DOI [10.26434/chemrxiv.12652832, DOI 10.26434/CHEMRXIV.12652832]
   Jokinen EM, 2019, CHEM BIOL DRUG DES, V94, P1799, DOI 10.1111/cbdd.13584
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kar P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1780947
   Kirschner KN, 2008, J COMPUT CHEM, V29, P622, DOI 10.1002/jcc.20820
   Koe T., 2020, NEWS ANAL SUPPLEMENT
   Korb O, 2009, J CHEM INF MODEL, V49, P84, DOI 10.1021/ci800298z
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kurkinen ST, 2019, J CHEM INF MODEL, V59, P3584, DOI 10.1021/acs.jcim.9b00383
   Kurkinen ST, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00260
   Laha S, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104445
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lexa KW, 2014, J CHEM INF MODEL, V54, P2190, DOI 10.1021/ci400741u
   Li L, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198082
   Lim G. Y., 2020, NEWS ANAL SUPPLEMENT
   Ling CQ, 2020, J INTEGR MED-JIM, V18, P87, DOI 10.1016/j.joim.2020.02.004
   Mahmoud IS, 2020, BIOCHIMIE, V175, P93, DOI 10.1016/j.biochi.2020.05.012
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Mittal A, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008762
   Niinivehmas SP, 2015, J COMPUT AID MOL DES, V29, P989, DOI 10.1007/s10822-015-9870-3
   Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Salmaso V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00923
   Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Steele J., 2020, LAB FINDS 125 NATURA
   Sun C, 2020, BIORXIV PREPRINT, DOI [10.1101/2020.02.16.951723., DOI 10.1101/2020.02.16.951723, 10.1101/2020.02.16.951723]
   Ung PMU, 2016, BIOPOLYMERS, V105, P21, DOI 10.1002/bip.22742
   Vainio MJ, 2009, J CHEM INF MODEL, V49, P492, DOI 10.1021/ci800315d
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   World Health Organization, 2020, WHO SUPPORTS SCIENTI
   Xiu SY, 2020, J MED CHEM, V63, P12256, DOI 10.1021/acs.jmedchem.0c00502
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
NR 58
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD NOV 19
PY 2020
VL 8
AR 589769
DI 10.3389/fchem.2020.589769
PG 13
WC Chemistry, Multidisciplinary
SC Chemistry
GA PA8SP
UT WOS:000595899500001
PM 33330376
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dar, HA
   Waheed, Y
   Najmi, MH
   Ismail, S
   Hetta, HF
   Ali, A
   Muhammad, K
AF Dar, Hamza Arshad
   Waheed, Yasir
   Najmi, Muzammil Hasan
   Ismail, Saba
   Hetta, Helal F.
   Ali, Amjad
   Muhammad, Khalid
TI Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike
   Protein of SARS-CoV-2: An In Silico Analysis
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID NORMAL-MODE ANALYSIS; WEB SERVER; REVERSE VACCINOLOGY; CODON USAGE;
   PREDICTION; GENOME; GENE; INFECTION; IMMUNITY; TARGET
AB The global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of COVID-19, has resulted in a negative impact on human health and on social and economic activities worldwide. Researchers around the globe need to design and develop successful therapeutics as well as vaccines against the novel COVID-19 disease. In the present study, we conducted comprehensive computer-assisted analysis on the spike glycoprotein of SARS-CoV-2 in order to design a safe and potent multiepitope vaccine. In silico epitope prioritization shortlisted six HLA I epitopes and six B-cell-derived HLA II epitopes. These high-ranked epitopes were all connected to each other via flexible GPGPG linkers, and at the N-terminus side, the sequence of Cholera Toxin beta subunit was attached via an EAAAK linker. Structural modeling of the vaccine was performed, and molecular docking analysis strongly suggested a positive association of a multiepitope vaccine with Toll-like Receptor 3. The structural investigations of the vaccine-TLR3 complex revealed the formation of fifteen interchain hydrogen bonds, thus validating its integrity and stability. Moreover, it was found that this interaction was thermodynamically feasible. In conclusion, our data supports the proposition that a multiepitope vaccine will provide protective immunity against COVID-19. However, further in vivo and in vitro experiments are needed to validate the immunogenicity and safety of the candidate vaccine.
C1 [Dar, Hamza Arshad; Waheed, Yasir; Najmi, Muzammil Hasan; Ismail, Saba] Fdn Univ Islamabad, Fdn Univ Med Coll, Islamabad 44000, Pakistan.
   [Hetta, Helal F.] Univ Cincinnati, Dept Internal Med, Coll Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.
   [Hetta, Helal F.] Assiut Univ, Fac Med, Dept Med Microbiol & Immunol, Assiut 71515, Egypt.
   [Ali, Amjad] Natl Univ Sci & Technol, Atta ur Rahman Sch Appl Biosci, Islamabad 44000, Pakistan.
   [Muhammad, Khalid] United Arab Emirates Univ, Coll Sci, Dept Biol, Al Ain 15551, U Arab Emirates.
RP Waheed, Y (corresponding author), Fdn Univ Islamabad, Fdn Univ Med Coll, Islamabad 44000, Pakistan.
EM yasir_waheed_199@hotmail.com
RI ; Waheed, Yasir/F-6390-2015; Ali, Amjad/F-6436-2015
OI Muhammad, Khalid/0000-0001-6488-1722; Waheed, Yasir/0000-0002-5789-4215;
   Dar, Hamza Arshad/0000-0002-0667-5653; Hetta, Helal/0000-0001-8541-7304;
   Ali, Amjad/0000-0002-0486-4661
FU Foundation University Internal Research grant; UAEU start up grant
   [31S411]
FX The authors acknowledge the administrative support provided by the
   Foundation University Medical College, Islamabad, Pakistan. BioRender
   was used to make the flow chart diagram. Y.W.'s research is supported by
   a Foundation University Internal Research grant. K.M.'s research is
   funded from the UAEU start up grant 31S411.
CR Agostini F, 2012, J MOL BIOL, V421, P237, DOI 10.1016/j.jmb.2011.12.005
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w
   Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906
   Andreatta M, 2018, BIOINFORMATICS, V34, P1522, DOI 10.1093/bioinformatics/btx820
   [Anonymous], 2020, SINOVAC COVID 19 VAC
   [Anonymous], 2020, AUSTR RESEARCHERS TR
   Antonio-Herrera L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02212
   Awan FM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010139
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Baseer S, 2017, BIOLOGICALS, V50, P87, DOI 10.1016/j.biologicals.2017.08.004
   Birra D, 2020, IMMUNOL RES, V68, P161, DOI 10.1007/s12026-020-09137-5
   Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266
   Capecchi B, 2004, CURR ISSUES MOL BIOL, V6, P17
   Chen HZ, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00713-3
   Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Corum J., 2020, NY TIMES, P5
   Dar HA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030088
   De Vries SJ, 2010, NAT PROTOC, V5, P883, DOI 10.1038/nprot.2010.32
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Funk CD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00937
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Guan PP, 2003, NUCLEIC ACIDS RES, V31, P3621, DOI 10.1093/nar/gkg510
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Ka T., 2020, SCI REPORTS, V10
   Keech Cheryl, 2020, N Engl J Med, V383, P2320, DOI 10.1056/NEJMoa2026920
   Khan M I, 2019, SCI REP, V9, P1, DOI DOI 10.1038/s41598-018-37186-2
   Kovacs JA, 2004, PROTEINS, V56, P661, DOI 10.1002/prot.20151
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Kruiswijk C, 2020, HUM VACC IMMUNOTHER, V16, P277, DOI 10.1080/21645515.2019.1703453
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221
   Lee GR, 2019, NUCLEIC ACIDS RES, V47, pW451, DOI 10.1093/nar/gkz288
   Li L, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198082
   Liang SD, 2006, NUCLEIC ACIDS RES, V34, P3698, DOI 10.1093/nar/gkl454
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551
   Magnan CN, 2009, BIOINFORMATICS, V25, P2200, DOI 10.1093/bioinformatics/btp386
   Manavalan B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01695
   Mazaleuskaya L, 2012, VIRUSES-BASEL, V4, P901, DOI 10.3390/v4050901
   Mckee M, 2020, NAT MED, V26, P640, DOI 10.1038/s41591-020-0863-y
   Meroueh S., 2007, NORMAL MODE ANAL THE
   MINCH MJ, 1999, J CHEM EDUC, V76, P759, DOI DOI 10.1021/ed076p759.1
   mondiale de la Sante Organisation World Health Organization, 2017, WEEKLY EPIDEMIOLOGIC, V92, P477
   Morla S, 2016, GENE, V584, P1, DOI 10.1016/j.gene.2016.02.047
   Muhammad A, 2020, ANAESTH PAIN INTENSI, V24, P94, DOI 10.35975/apic.v24i1.1231
   Mukonyora M., 2015, J CLIN CELL IMMUNOL, V6, P358
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Oyarzun P., 2013, BMC BIOINFORMATICS, V14, P1
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Prabhakar PK, 2016, J BIOMOL STRUCT DYN, V34, P778, DOI 10.1080/07391102.2015.1054430
   Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224
   Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339
   Lopez-Blanco JR, 2011, BIOINFORMATICS, V27, P2843, DOI 10.1093/bioinformatics/btr497
   Raoult D, 2020, CELL STRESS, V4, P66, DOI 10.15698/cst2020.04.216
   Rappuoli R, 2001, VACCINE, V19, P2688, DOI 10.1016/S0264-410X(00)00554-5
   Ren WL, 2020, VACCINE, V38, P5653, DOI 10.1016/j.vaccine.2020.06.066
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Singh H, 2003, BIOINFORMATICS, V19, P1009, DOI 10.1093/bioinformatics/btg108
   Stratmann T, 2015, VACCINES-BASEL, V3, P579, DOI 10.3390/vaccines3030579
   Tabish SA, 2020, J PUBLIC HEALTH RES, V9, P19, DOI 10.4081/jphr.2020.1786
   Tama F, 2006, ANNU REV BIOPH BIOM, V35, P115, DOI 10.1146/annurev.biophys.35.040405.102010
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   VanAalten DMF, 1997, J COMPUT CHEM, V18, P169
   Vercammen E, 2008, CLIN MICROBIOL REV, V21, P13, DOI 10.1128/CMR.00022-07
   Wang FZ, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.924700
   WHO, 2020, TRANSM SARS COV 2 IM
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Worldometer, 2020, COVID 19 COR PAND
   WUTHRICH K, 1980, BIOPHYS J, V32, P549
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Yu XX, 2020, INFLUENZA OTHER RESP, V14, P474, DOI 10.1111/irv.12743
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
NR 88
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PD NOV 19
PY 2020
VL 2020
AR 8893483
DI 10.1155/2020/8893483
PG 15
WC Immunology
SC Immunology
GA PA7PO
UT WOS:000595822800003
PM 33274246
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Borazjani, R
   Seraj, SR
   Fallahi, MJ
   Rahmanian, Z
AF Borazjani, Roham
   Seraj, Seyed Reza
   Fallahi, Mohammad Javad
   Rahmanian, Zhila
TI Acute portal vein thrombosis secondary to COVID-19: a case report
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE COVID-19; Pneumonia; Portal vein; Thrombosis
ID INFECTION
AB BackgroundCOVID-19 pneumonia exhibits several extra-pulmonary complications. Case presentationA 23-year old, asthmatic male with coronavirus pneumonia developed with generalized, acute abdominal pain. Further evaluations revealed a mild ascites and portal vein thrombosis although the patient received proper anticoagulation therapy. Routine lab data regarding the secondary causes of portal vein thrombosis were normal.ConclusionWe speculated that the underlying cause of portal vein thrombosis in our case was coronaviruses. Therefore, clinicians should always consider thrombosis and other hypercoagulable diseases in patients with COVID-19.
C1 [Borazjani, Roham] Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran.
   [Seraj, Seyed Reza] Shiraz Univ Med Sci, Dept Internal Med, Shiraz, Iran.
   [Fallahi, Mohammad Javad] Shiraz Univ Med Sci, Thorac & Vasc Surg Res Ctr, Shiraz, Iran.
   [Rahmanian, Zhila] Jahrom Univ Med Sci, Dept Internal Med, Jahrom, Iran.
RP Fallahi, MJ (corresponding author), Shiraz Univ Med Sci, Thorac & Vasc Surg Res Ctr, Shiraz, Iran.
EM fallahimj@sums.ac.ir
CR Barco S, 2020, RES PRACT THROMB HAE, V4, P741, DOI 10.1002/rth2.12364
   Basta M, 2014, CLIN EXP IMMUNOL, V178, P153, DOI 10.1111/cei.12551
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Bozzani A, 2020, ANN VASC SURG, V66, P11, DOI 10.1016/j.avsg.2020.04.037
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   de Barry Olivier, 2020, Radiol Case Rep, V15, P1054, DOI 10.1016/j.radcr.2020.04.055
   Efendizade A, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.573356
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   La Mura V, 2020, AM J GASTROENTEROL, V115, P1140, DOI 10.14309/ajg.0000000000000711
   Sharma Arun, 2020, Cell Rep Med, V1, P100052, DOI 10.1016/j.xcrm.2020.100052
   Vardavas CI, 2020, TOB INDUC DIS, V18, P20, DOI DOI 10.18332/TID/119324.EC0LLECTI0N
   Zhou B, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00296
   Zhou B, 2020, J THROMB THROMBOLYS, V50, P229, DOI 10.1007/s11239-020-02084-w
NR 16
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD NOV 19
PY 2020
VL 20
IS 1
AR 386
DI 10.1186/s12876-020-01518-2
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OZ5EI
UT WOS:000594948600001
PM 33213374
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vomero, M
   Barbati, C
   Colasanti, T
   Celia, AI
   Speziali, M
   Ucci, FM
   Ciancarella, C
   Conti, F
   Alessandri, C
AF Vomero, Marta
   Barbati, Cristiana
   Colasanti, Tania
   Celia, Alessandra Ida
   Speziali, Mariangela
   Ucci, Federica Maria
   Ciancarella, Claudia
   Conti, Fabrizio
   Alessandri, Cristiano
TI Autophagy Modulation in Lymphocytes From COVID-19 Patients: New
   Therapeutic Target in SARS-COV-2 Infection
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE SARS-CoV-2; CoViD-19; autophagy; lymphocytes; cytokines
ID TUMOR-NECROSIS-FACTOR; IN-VITRO; INTERLEUKIN-6; INFLAMMATION;
   CHLOROQUINE; RECEPTOR; STAT3; HYDROXYCHLOROQUINE; CELLS; IL-1
AB Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the novel coronavirus, causing coronavirus disease 2019 (COVID-19). During virus infection, several pro-inflammatory cytokines are produced, leading to the "cytokine storm." Among these, interleukin (IL)-6, tumor necrosis factor-alpha (TNF-alpha), and IL-1 beta seem to have a central role in the progression and exacerbation of the disease, leading to the recruitment of immune cells to infection sites. Autophagy is an evolutionarily conserved lysosomal degradation pathway involved in different aspects of lymphocytes functionality. The involvement of IL-6, TNF-alpha, and IL-1 beta in autophagy modulation has recently been demonstrated. Moreover, preliminary studies showed that SARS-CoV-2 could infect lymphocytes, playing a role in the modulation of autophagy. Several anti-rheumatic drugs, now proposed for the treatment of COVID-19, could modulate autophagy in lymphocytes, highlighting the therapeutic potential of targeting autophagy in SARS-CoV-2 infection.
C1 [Vomero, Marta; Barbati, Cristiana; Colasanti, Tania; Celia, Alessandra Ida; Speziali, Mariangela; Ucci, Federica Maria; Ciancarella, Claudia; Conti, Fabrizio; Alessandri, Cristiano] Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Rheumatol Unit, Rome, Italy.
RP Alessandri, C (corresponding author), Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Rheumatol Unit, Rome, Italy.
EM cristiano.alessandri@uniroma1.it
CR Alessandri C, 2012, FASEB J, V26, P4722, DOI 10.1096/fj.12-206060
   An Z, 2017, HEART VESSELS, V32, P1523, DOI 10.1007/s00380-017-1054-8
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Ballabio A, 2020, NAT REV MOL CELL BIO, V21, P101, DOI 10.1038/s41580-019-0185-4
   Barbati C, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1768-8
   Ben-Sasson SZ, 2009, P NATL ACAD SCI USA, V106, P7119, DOI 10.1073/pnas.0902745106
   Billah M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051692
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Colasanti T, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.211
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Dayer JM, 2010, RHEUMATOLOGY, V49, P15, DOI 10.1093/rheumatology/kep329
   de Luca A, 2014, P NATL ACAD SCI USA, V111, P3526, DOI 10.1073/pnas.1322831111
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Girija ASS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01206
   GOTLIEB WH, 1991, J IMMUNOL, V146, P2262
   Harris J, 2010, CLIN EXP IMMUNOL, V161, P1, DOI 10.1111/j.1365-2249.2010.04146.x
   INGLOT AD, 1969, J GEN VIROL, V4, P203, DOI 10.1099/0022-1317-4-2-203
   Jackson WT, 2015, VIROLOGY, V479, P450, DOI 10.1016/j.virol.2015.03.042
   Jiang L, 2015, CANCER BIOL THER, V16, P466, DOI 10.1080/15384047.2015.1016658
   Joosten LAB, 2013, SEMIN IMMUNOL, V25, P416, DOI 10.1016/j.smim.2013.10.018
   Kanayama M, 2015, J IMMUNOL, V194, P5465, DOI 10.4049/jimmunol.1403249
   Kane A, 2014, CURR OPIN IMMUNOL, V28, P49, DOI 10.1016/j.coi.2014.01.015
   Kang R, 2012, P NATL ACAD SCI USA, V109, P7031, DOI 10.1073/pnas.1113865109
   KATTWINK.J, 1966, ENDOCRINOLOGY, V79, P387, DOI 10.1210/endo-79-2-387
   Kimura A, 2010, AM J PATHOL, V176, P40, DOI 10.2353/ajpath.2010.090146
   Kruglov AA, 2008, CYTOKINE GROWTH F R, V19, P231, DOI 10.1016/j.cytogfr.2008.04.010
   Linnemann AK, 2017, FASEB J, V31, P4140, DOI 10.1096/fj.201700061RR
   Matrosovich M, 2015, TOP CURR CHEM, V367, P1, DOI 10.1007/128_2013_466
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Michalakis K, 2020, DIABETES METAB SYND, V14, P469, DOI 10.1016/j.dsx.2020.04.033
   Molitoris JK, 2011, J BIOL CHEM, V286, P30181, DOI 10.1074/jbc.M111.245423
   Monforte AD, 2020, INT J INFECT DIS, V99, P75, DOI 10.1016/j.ijid.2020.07.056
   Naghipour S, 2020, EXPERT REV ANTI-INFE, V18, P1119, DOI 10.1080/14787210.2020.1792291
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Ortona E, 2014, ANTIOXID REDOX SIGN, V21, P103, DOI 10.1089/ars.2013.5752
   Pierdominici M, 2014, FASEB J, V28, P524, DOI 10.1096/fj.13-235655
   Pinto AP, 2020, CYTOKINE, V130, DOI 10.1016/j.cyto.2020.155085
   Racanelli AC, 2018, AUTOPHAGY, V14, P221, DOI 10.1080/15548627.2017.1389823
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shen JL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41067
   Shen SS, 2012, MOL CELL, V48, P667, DOI 10.1016/j.molcel.2012.09.013
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Swerdlow S, 2008, AUTOPHAGY, V4, P612, DOI 10.4161/auto.5920
   Torene R, 2017, ANN RHEUM DIS, V76, P303, DOI 10.1136/annrheumdis-2016-209335
   Totino PRR, 2006, CELL BIOL INT, V30, P133, DOI 10.1016/j.cellbi.2005.09.002
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Veronese N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00170
   Vomero M, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1818-x
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Wang YX, 2013, P NATL ACAD SCI USA, V110, P16975, DOI 10.1073/pnas.1315862110
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446
   Yamada E, 2012, CELL REP, V1, P557, DOI 10.1016/j.celrep.2012.03.014
   Yamasaki S, 2001, ANN RHEUM DIS, V60, P678, DOI 10.1136/ard.60.7.678
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yokoyama T, 2007, AUTOPHAGY, V3, P496, DOI 10.4161/auto.4602
   Zhang M, 2015, ELIFE, V4, DOI 10.7554/eLife.11205
NR 69
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 19
PY 2020
VL 11
AR 569849
DI 10.3389/fphar.2020.569849
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ8MF
UT WOS:000595172800001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Metastasio, A
   Prevete, E
   Singh, D
   Grundmann, O
   Prozialeck, WC
   Veltri, C
   Bersani, G
   Corazza, O
AF Metastasio, Antonio
   Prevete, Elisabeth
   Singh, Darshan
   Grundmann, Oliver
   Prozialeck, Walter C.
   Veltri, Charles
   Bersani, Giuseppe
   Corazza, Ornella
TI Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE COVID-19; kratom; opioid; stimulants; new psychoactive substances; new
   treatments; long covid
ID LIVER-INJURY; WITHDRAWAL; 7-HYDROXYMITRAGYNINE; DEPENDENCE; ADDICTION;
   ALKALOIDS; CHEMISTRY; STATES; MICE
AB Among the symptoms of COVID-19 fever, general malaise, pain and aches, myalgia, fatigue, and headache can affect the quality of life of patients, even after the end of the acute phase of the infection and can be long lasting. The current treatment of these symptoms, also because COVID-19 patients have been asked not to use non-steroidal anti-inflammatory drugs (NSAIDs), in particular ibuprofen are often unsatisfactory. Among the above mentioned symptoms malaise and fatigue seem the most difficult to treat. In this case report we describe the use of kratom (Mitragyna speciosa) by a patient with confirmed COVID-19 infection. What we observed was a fast and sustained relieve of the above mentioned symptoms.
C1 [Metastasio, Antonio; Corazza, Ornella] Univ Hertfordshire, Sch Life & Med Sci, Hatfield, Herts, England.
   [Metastasio, Antonio] NHS Camden & Islington Trust, London, England.
   [Prevete, Elisabeth; Bersani, Giuseppe; Corazza, Ornella] Sapienza Univ Rome, Dept Medicosurg Sci & Biotechnol, Rome, Italy.
   [Singh, Darshan] Univ Sains Malaysia, Ctr Drug Res, Minden, Malaysia.
   [Grundmann, Oliver] Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL USA.
   [Prozialeck, Walter C.] Midwestern Univ, Dept Pharmacol, Downers Grove, IL 60515 USA.
   [Veltri, Charles] Midwestern Univ, Dept Pharmaceut Sci, Glendale, AZ USA.
RP Metastasio, A (corresponding author), Univ Hertfordshire, Sch Life & Med Sci, Hatfield, Herts, England.; Metastasio, A (corresponding author), NHS Camden & Islington Trust, London, England.
EM antonio.metastasio@gmail.com
CR Afzal H, 2020, CUREUS, V12, DOI 10.7759/cureus.6588
   Aggarwal Geeta, 2018, J Intensive Care Soc, V19, P61, DOI 10.1177/1751143717712652
   Ahmad K, 2012, J ETHNOPHARMACOL, V141, P446, DOI 10.1016/j.jep.2012.03.009
   Aldyab M, 2019, GASTROENTEROL RES, V12, P211, DOI 10.14740/gr1204
   Alsarraf E, 2019, CURR EMERG HOSP ME R, V7, P141, DOI 10.1007/s40138-019-00194-1
   Anwar M, 2016, MMWR-MORBID MORTAL W, V65, P748, DOI 10.15585/mmwr.mm6529a4
   Arndt T, 2011, FORENSIC SCI INT, V208, P47, DOI 10.1016/j.forsciint.2010.10.025
   Bath R, 2020, J ADDICT MED, V14, P244, DOI 10.1097/ADM.0000000000000570
   Bertisch S, 2020, CORONAVIRUS RESOURCE
   Bin Abdullah MFIL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234639
   Bowe A, 2020, J PSYCHOACTIVE DRUGS, V52, P447, DOI 10.1080/02791072.2020.1773586
   Boyer EW, 2008, ADDICTION, V103, P1048, DOI 10.1111/j.1360-0443.2008.02209.x
   Castillo Austin, 2017, Proc (Bayl Univ Med Cent), V30, P355
   Chin KY, 2018, CURR DRUG TARGETS, V19, P1359, DOI 10.2174/1389450118666170925154025
   Chittrakarn S, 2010, J ETHNOPHARMACOL, V129, P344, DOI 10.1016/j.jep.2010.03.035
   Coe MA, 2019, DRUG ALCOHOL DEPEN, V202, P24, DOI 10.1016/j.drugalcdep.2019.05.005
   Corkery JM, 2019, J PSYCHOPHARMACOL, V33, P1102, DOI 10.1177/0269881119862530
   Davidson L, 2019, J Neonatal Perinatal Med, V12, P109, DOI 10.3233/NPM-1863
   Domingo O, 2017, FORENSIC SCI INT, V271, pE1, DOI 10.1016/j.forsciint.2016.12.020
   Eastlack SC, 2020, PAIN THER, V9, P55, DOI 10.1007/s40122-020-00151-x
   Fernandes CT, 2019, J INVEST MED HIGH IM, V7, DOI 10.1177/2324709619836138
   Galbis-Reig David, 2016, WMJ, V115, P49
   Gallen T, 2020, COVID 19 IBUPROFEN F
   Garcia-Romeu A, 2020, DRUG ALCOHOL DEPEN, V208, DOI 10.1016/j.drugalcdep.2020.107849
   Gershman K, 2019, NEW ENGL J MED, V380, P97, DOI 10.1056/NEJMc1811055
   Grundmann O, 2017, DRUG ALCOHOL DEPEN, V176, P63, DOI 10.1016/j.drugalcdep.2017.03.007
   Henningfield JE, 2019, PREV MED, V128, DOI 10.1016/j.ypmed.2019.105851
   Huang XY, 2020, ARCH IRAN MED, V23, P268, DOI 10.34172/aim.2020.09
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Kakodkar P, 2020, CUREUS, V12, DOI 10.7759/cureus.7560
   Khazaeli A, 2018, J ADDICT MED, V12, P493, DOI 10.1097/ADM.0000000000000435
   Kruegel AC, 2018, NEUROPHARMACOLOGY, V134, P108, DOI 10.1016/j.neuropharm.2017.08.026
   LaBryer L, 2018, J INVEST MED HIGH IM, V6, DOI 10.1177/2324709618765022
   Lenkens M, 2020, NED TIJDSCHR GENEES, V164, pD4995
   Mackay L, 2018, CAN FAM PHYSICIAN, V64, P121
   Matson M, 2019, J FORENSIC SCI, V64, P1933, DOI 10.1111/1556-4029.14082
   Matsumoto K, 1996, EUR J PHARMACOL, V317, P75, DOI 10.1016/S0014-2999(96)00714-5
   Matsumoto K, 2004, LIFE SCI, V74, P2143, DOI 10.1016/j.lfs.2003.09.054
   Matsumoto K, 2006, EUR J PHARMACOL, V549, P63, DOI 10.1016/j.ejphar.2006.08.013
   Matsumoto K, 2015, KRATOM AND OTHER MITRAGYNINES: THE CHEMISTRY AND PHARMACOLOGY OF OPIOIDS FROM A NON-OPIUM SOURCE, P177
   Micallef J, 2020, THERAPIE, V75, P355, DOI 10.1016/j.therap.2020.05.003
   Moore N, 2020, DRUG SAFETY, V43, P611, DOI 10.1007/s40264-020-00953-0
   Mossadeq WMS, 2009, MED PRIN PRACT, V18, P378, DOI 10.1159/000226292
   Muller E, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04507
   Neerman MF, 2013, J FORENSIC SCI, V58, pS278, DOI 10.1111/1556-4029.12009
   Nelsen JL, 2010, J MED TOXICOL, V6, P424, DOI 10.1007/s13181-010-0079-5
   Osborne CS, 2019, J INVEST MED HIGH IM, V7, DOI 10.1177/2324709619826167
   Overbeek Daniel L, 2019, Clin Pract Cases Emerg Med, V3, P24, DOI 10.5811/cpcem.2018.11.40588
   Pergolizzi JV, 2020, PAIN THER, V9, P353, DOI 10.1007/s40122-020-00173-5
   Prozialeck WC, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155512
   Raja Aziddin RE, 2005, MJS, V24, P191
   Saingam D, 2013, INT J DRUG POLICY, V24, P351, DOI 10.1016/j.drugpo.2012.09.004
   Saref A, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111876
   Schimmel J, 2020, DRUGS, V80, P263, DOI 10.1007/s40265-019-01242-6
   Sheleg SV, 2011, J ADDICT MED, V5, P300, DOI 10.1097/ADM.0b013e318221fbfa
   SHELLARD EJ, 1974, B NARCOTICS, V26, P41
   Singh D, 2019, J ETHNOPHARMACOL, V233, P34, DOI 10.1016/j.jep.2018.12.038
   Singh D, 2018, J PSYCHOACTIVE DRUGS, V50, P445, DOI 10.1080/02791072.2018.1511879
   Singh D, 2018, J PSYCHOACTIVE DRUGS, V50, P266, DOI 10.1080/02791072.2018.1443234
   Singh D, 2018, J ETHNOPHARMACOL, V214, P197, DOI 10.1016/j.jep.2017.12.017
   Singh D, 2014, DRUG ALCOHOL DEPEN, V139, P132, DOI 10.1016/j.drugalcdep.2014.03.017
   Sridharan GK, 2020, AM J THER, V27, pE400, DOI 10.1097/MJT.0000000000001196
   Takayama H, 2004, CHEM PHARM BULL, V52, P916, DOI 10.1248/cpb.52.916
   Utar Z, 2011, J ETHNOPHARMACOL, V136, P75, DOI 10.1016/j.jep.2011.04.011
   Vicknasingam B, 2020, YALE J BIOL MED, V93, P229
   Wilson LL, 2020, DRUG ALCOHOL DEPEN, V216, DOI 10.1016/j.drugalcdep.2020.108310
   Wong Andrew, 2020, Case Rep Psychiatry, V2020, P8818095, DOI 10.1155/2020/8818095
   Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046
NR 69
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD NOV 19
PY 2020
VL 11
AR 594816
DI 10.3389/fpsyt.2020.594816
PG 6
WC Psychiatry
SC Psychiatry
GA OZ7XU
UT WOS:000595135000001
PM 33329145
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Melidou, A
   Pereyaslov, D
   Hungness, O
   Prosenck, K
   Alm, E
   Adlhoch, C
   Fielding, J
   Sneiderman, M
   Martinuka, O
   Celentano, LP
   Pebody, R
AF Melidou, Angeliki
   Pereyaslov, Dmitriy
   Hungness, Olav
   Prosenck, Katarina
   Alm, Erik
   Adlhoch, Cornelia
   Fielding, James
   Sneiderman, Miriam
   Martinuka, Oksana
   Celentano, Lucia Pastore
   Pebody, Richard
CA WHO European Region Influenza
TI Virological surveillance of influenza viruses in the WHO European Region
   in 2019/20-impact of the COVID-19 pandemic
SO EUROSURVEILLANCE
LA English
DT Article
AB The COVID-19 pandemic negatively impacted the 2019/20 WHO European Region influenza surveillance. Compared with previous 4-year averages, antigenic and genetic characterisations decreased by 17% (3,140 vs 2,601) and 24% (4,474 vs 3,403). Of sub typed influenza A viruses, 56% (26,477/47,357) were A(H-1)pdm09, 44% (20,880/47,357) A(H3). Of characterised B viruses, 98% (4,585/4,679) were B/Victoria. Considerable numbers of viruses antigenically differed from northern hemisphere vaccine components. In 2020/21, maintaining influenza virological surveillance, while supporting SARS-CoV-2 surveillance is crucial.
C1 [Melidou, Angeliki; Alm, Erik; Adlhoch, Cornelia; Martinuka, Oksana; Celentano, Lucia Pastore] European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden.
   [Pereyaslov, Dmitriy; Fielding, James; Sneiderman, Miriam; Pebody, Richard] World Hlth Org WHO Reg Off Europe, Copenhagen, Denmark.
   [Hungness, Olav] Norwegian Inst Publ Hlth, Oslo, Norway.
   [Prosenck, Katarina] Natl Influenza Ctr Slovenia, Lab Publ Hlth Virol, Natl Lab Hlth Environm & Food, Ljubljana, Slovenia.
RP Melidou, A (corresponding author), European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden.
EM angeliki.melidou@ecdc.europa.eu
RI Mossong, Joel/D-4998-2009
OI Mossong, Joel/0000-0003-0717-9835; Gioula, Georgia/0000-0002-9344-3956
FU World Health OrganizationWorld Health Organization [001] Funding Source:
   Medline
CR ECDC, 2020, ANN EP REP 2019
   European Centre for Disease Prevention and Control (ECDC), 2019, INFL VIR CHAR SUMM E
   European Centre for Disease Prevention and Control (ECDC), 2020, INFL VIR CHAR SUMM E
   European Centre for Disease Prevention and Control (ECDC) and WHO Regional Office for Europe, 2019, EUR EXT QUAL ASS PRO
   European Centre for Disease Prevention and Control (ECDC) and WHO Regional Office for Europe ( WHO/Euro), 2020, OP CONS INFL SURV WH
   European Centre for Disease Prevention and Control (ECDC) and World Health Organization. (WHO), FLUNEWSEUROPE JOINT
   European Food Safety Authority (EFSA) and European Centre for Disease Prevention and Control. ( ECDC) European Union Reference Laboratory for Avian Influenza (EURL), 2020, AV INFL OV MAY AUG 2
   Mook P, 2020, INFLUENZA OTHER RESP, V14, P150, DOI 10.1111/irv.12703
   Olsen SJ, 2020, MMWR-MORBID MORTAL W, V69, P1305, DOI 10.15585/mmwr.mm6937a6
   Rose A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.10.2000153
   Woldwide Influenza Centre ( WIC), 2019, REP PREP WHO ANN CON
   World Health Organisation Western Pacific (WHO Western Pacific), 2020, 760 WHO W PAC
   World Health Organization ( WHO), 2020, REC COMP INFL VIR US
   Worldwide Influenza Centre ( WIC), 2020, REP PREP WHO ANN CON
NR 14
TC 0
Z9 0
U1 0
U2 0
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1025-496X
EI 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD NOV 19
PY 2020
VL 25
IS 46
AR 2001822
DI 10.2807/1560-7917.ES.2020.25.46.2001822
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA OY0FC
UT WOS:000593929100003
PM 33213683
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bazoni, RF
   Moura, TA
   Rocha, MS
AF Bazoni, R. F.
   Moura, T. A.
   Rocha, M. S.
TI Hydroxychloroquine Exhibits a Strong Complex Interaction with DNA:
   Unraveling the Mechanism of Action
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
AB In the past months, the use of the drug hydroxychloroquine has considerably increased in many countries, associated with a proposed treatment for the COVID-19 disease. Although there is no conclusive evidence about the efficacy of the drug for this purpose, surprisingly there are no conclusive studies in the literature concerning its mechanism of action inside cells, which is related to its interaction with nucleic acids. Here, we performed a robust characterization of the interaction between hydroxychloroquine and double-stranded DNA using single-molecule force spectroscopy and gel electrophoresis. Two different binding modes were identified, namely, minor groove binding for low drug concentrations and intercalation for high drug concentrations, and the sets of binding parameters were determined for each of these modes. Such results have unraveled in detail the molecular mechanism of action of the drug as a DNA ligand.
C1 [Bazoni, R. F.] Univ Fed Espirito Santo, Dept Ciencias Nat, BR-29932540 Sao Mateus, ES, Brazil.
   [Moura, T. A.; Rocha, M. S.] Univ Fed Vicosa, Dept Fis, BR-36570900 Vicosa, MG, Brazil.
RP Rocha, MS (corresponding author), Univ Fed Vicosa, Dept Fis, BR-36570900 Vicosa, MG, Brazil.
EM marcios.rocha@ufv.br
RI Rocha, Marcio/F-9880-2012
OI Rocha, Marcio/0000-0003-0323-3718
FU Conselho Nacional de Desenvolvimento Cientifi co e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [403229/2016-2, 400412/2014-4]; Fundacao de Amparo a Pesquisa do
   Estado de Minas Gerais (FAPEMIG)Minas Gerais State Research Foundation
   (FAPEMIG) [01927-16, 01446-14]; Fundacao de Amparo a Pesquisa e Inovaca
   o do Espirito Santo (FAPES) [166/2019]; Coordenacao de Aperfeico amento
   de Pessoal de Nivel Superior (CAPES)CAPES [001]
FX This research was funded by Conselho Nacional de Desenvolvimento
   Cientifi co e Tecnologico (CNPq) grant numbers 403229/2016-2 and
   400412/2014-4; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG) grant numbers 01927-16 and 01446-14; Fundacao de Amparo a
   Pesquisa e Inovaca o do Espirito Santo (FAPES), Edital Universal number
   166/2019; and Coordenacao de Aperfeico amento de Pessoal de Nivel
   Superior (CAPES) Finance Code 001.
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Alves PS, 2020, J PHYS CHEM B, V124, P1020, DOI 10.1021/acs.jpcb.0c00155
   An J, 2015, J IMMUNOL, V194, P4089, DOI 10.4049/jimmunol.1402793
   Bazoni RF, 2015, SOFT MATTER, V11, P4306, DOI 10.1039/c5sm00706b
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Cesconetto EC, 2013, PHYS CHEM CHEM PHYS, V15, P11070, DOI 10.1039/c3cp50898f
   Chaurasiya KR, 2010, PHYS LIFE REV, V7, P299, DOI 10.1016/j.plrev.2010.06.001
   COHEN SN, 1965, J BIOL CHEM, V240, P3123
   Crisafuli FAP, 2015, EUR BIOPHYS J BIOPHY, V44, P1, DOI 10.1007/s00249-014-0995-4
   FRITZSCHE H, 1982, BIOCHEMISTRY-US, V21, P3940, DOI 10.1021/bi00260a006
   Goodman J., BBC REALITY CHECK
   IRVIN JL, 1949, SCIENCE, V110, P426, DOI 10.1126/science.110.2860.426
   Kapoor K. M., 2020, ROLE CHLOROQUINE HYD, DOI [10.1101/ 2020.03.24.20042366, DOI 10.1101/2020.03.24.20042366, 10.1101/2020.03.24.20042366]
   Kellett A, 2019, CHEM SOC REV, V48, P971, DOI 10.1039/c8cs00157j
   KWAKYEBERKO F, 1989, MOL BIOCHEM PARASIT, V35, P51, DOI 10.1016/0166-6851(89)90141-2
   Li SD, 2006, GENE THER, V13, P1313, DOI 10.1038/sj.gt.3302838
   Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008
   Mascolo A, 2018, INFLAMMOPHARMACOLOGY, V26, P1141, DOI 10.1007/s10787-018-0498-5
   MESHNICK SR, 1990, PARASITOL TODAY, V6, P77, DOI 10.1016/0169-4758(90)90215-P
   Morens DM, 2020, NEW ENGL J MED, V382, P1293, DOI 10.1056/NEJMp2002106
   Moura TA, 2019, INT J BIOL MACROMOL, V130, P1018, DOI 10.1016/j.ijbiomac.2019.02.125
   Olsen GL, 2003, NUCLEIC ACIDS RES, V31, P5084, DOI 10.1093/nar/gkg720
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Publio BC, 2018, INT J BIOL MACROMOL, V112, P175, DOI 10.1016/j.ijbiomac.2018.01.142
   Rocha MS, 2015, INTEGR BIOL-UK, V7, P967, DOI 10.1039/c5ib00127g
   Rocha MS, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3276555
   Rocha MS, 2009, PHYS BIOL, V6, DOI 10.1088/1478-3975/6/3/036013
   Sarma P, 2020, J MED VIROL, V92, P776, DOI 10.1002/jmv.25898
   Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Silva EF, 2017, BIOPOLYMERS, V107, DOI 10.1002/bip.22998
   Siman L, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.248103
   Sischka A, 2005, BIOPHYS J, V88, P404, DOI 10.1529/biophysj.103.036293
   Thomas K., NEW YORK TIMES
   Vladescu ID, 2007, NAT METHODS, V4, P517, DOI 10.1038/nmeth1044
   Yam J. C. S., 2006, Hong Kong Medical Journal, V12, P294
   Yielding K. L., 1971, P R S COMPL BIOL ACT, V2
NR 37
TC 0
Z9 0
U1 2
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD NOV 19
PY 2020
VL 11
IS 22
BP 9528
EP 9534
DI 10.1021/acs.jpclett.0c02590
PG 7
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA OW5XM
UT WOS:000592959100002
PM 33115235
DA 2021-01-01
ER

PT J
AU Vankadari, N
   Jeyasankar, NN
   Lopes, WJ
AF Vankadari, Naveen
   Jeyasankar, Nandhini Nisha
   Lopes, Wilma Jerom
TI Structure of the SARS-CoV-2 Nsp1/5 '-Untranslated Region Complex and
   Implications for Potential Therapeutic Targets, a Vaccine, and Virulence
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
AB SARS-CoV-2 is the cause of the ongoing Coronavirus disease 19 (COVID-19) pandemic around the world causing pneumonia and lower respiratory tract infections. In understanding the SARS-CoV-2 pathogenicity and mechanism of action, it is essential to depict the full repertoire of expressed viral proteins. The recent biological studies have highlighted the leader protein Nsp1 of SARS-CoV-2 importance in shutting down the host protein production. Besides, it still enigmatic how Nsp1 regulates for translation. Here we report the novel structure of Nsp1 from SARS-CoV-2 in complex with the SL1 region of 5'UTR of SARS-CoV-2, and its factual interaction is corroborated with enzyme kinetics and experimental binding affinity studies. The studies also address how leader protein Nsp1 of SARS-CoV-2 recognizes its self RNA toward translational regulation by further recruitment of the 40S ribosome. With the aid of molecular dynamics and simulations, we also demonstrated the real-time stability and functional dynamics of the Nsp1/SL1 complex. The studies also report the potential inhibitors and their mode of action to block viral protein/RNA complex formation. This enhance our understanding of the mechanism of the first viral protein Nsp1 synthesized in the human cell to regulate the translation of self and host. Understanding the structure and mechanism of SARS-CoV-2 Nsp1 and its interplay with the viral RNA and ribosome will open the arena for exploring the development of live attenuated vaccines and effective therapeutic targets for this disease.
C1 [Vankadari, Naveen; Jeyasankar, Nandhini Nisha; Lopes, Wilma Jerom] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic 3800, Australia.
   [Vankadari, Naveen] Monash Univ, Monash Biomed Discovery Inst, Clayton, Vic 3800, Australia.
   [Vankadari, Naveen] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
RP Vankadari, N (corresponding author), Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic 3800, Australia.; Vankadari, N (corresponding author), Monash Univ, Monash Biomed Discovery Inst, Clayton, Vic 3800, Australia.; Vankadari, N (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
EM Naveen.vankadari@monash.edu
OI Vankadari, Naveen/0000-0001-9363-080X
CR Amawi H, 2020, THER DELIV, V11, P245, DOI 10.4155/tde-2020-0035
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Bianchi M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4389089
   Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596
   Calligari P, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040445
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chaw SM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00665-8
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Menezes GD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1792992
   Diaz J, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00870
   Feibelman KM, 2018, ANTIVIR RES, V154, P124, DOI 10.1016/j.antiviral.2018.03.013
   Ferreira-Ramos AS, 2019, ANTIVIR RES, V163, P59, DOI 10.1016/j.antiviral.2019.01.003
   Gutierrez AL, 1997, J VIROL, V71, P3826
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Huang C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002433
   Huston Nicholas C, 2020, bioRxiv, DOI 10.1101/2020.07.10.197079
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Lokugamage KG, 2012, J VIROL, V86, P13598, DOI 10.1128/JVI.01958-12
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Shaffer Leah, 2020, Nat Med, DOI 10.1038/d41591-020-00019-9
   Sharma A, 2020, J BIOSCIENCES, V45, DOI 10.1007/s12038-020-00069-8
   Tanaka T, 2012, J VIROL, V86, P11128, DOI 10.1128/JVI.01700-12
   Terada Y, 2017, VIROLOGY, V511, P95, DOI 10.1016/j.virol.2017.08.026
   Thoms M, 2020, SCIENCE, V369, P1249, DOI 10.1126/science.abc8665
   Tohya Y, 2009, J VIROL, V83, P5282, DOI 10.1128/JVI.02485-08
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Vankadari N, 2020, J PHYS CHEM LETT, V11, P6655, DOI 10.1021/acs.jpclett.0c01698
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Vankadari N, 2020, GENE, V752, DOI 10.1016/j.gene.2020.144792
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4
   Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4
   Zhang Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16779-4
   Zust R, 2007, PLOS PATHOG, V3, P1062, DOI 10.1371/journal.ppat.0030109
NR 37
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD NOV 19
PY 2020
VL 11
IS 22
BP 9659
EP 9668
DI 10.1021/acs.jpclett.0c02818
PG 10
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA OW5XM
UT WOS:000592959100020
PM 33135884
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Luan, BQ
   Huynh, T
AF Luan, Binquan
   Huynh, Tien
TI In Silico Antibody Mutagenesis for Optimizing Its Binding to Spike
   Protein of Severe Acute Respiratory Syndrome Coronavirus 2
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
AB Coronavirus disease 2019 (COVID-19) is an on-going global pandemic, and there are currently no FDA-approved medicines for treatment or prevention. Inspired by promising outcomes for convalescent plasma treatment, the development of antibody drugs (biologics) to block SARS-CoV-2 infection has been the focus of drug discovery, along with tremendous efforts in repurposing small-molecule drugs. In the past several months, experimentally, many human neutralizing monoclonal antibodies (mAbs) were successfully extracted from plasma of recovered COVID-19 patients. Currently, several mAbs targeting the SARS-CoV-2's spike glycoprotein (S-protein) are in clinical trials. With known atomic structures of the mAb and S-protein complex, it becomes possible to investigate in silico the molecular mechanism of mAb's binding with S-protein and to design more potent mAbs through protein mutagenesis studies, complementary to existing experimental efforts. Leveraging today's superb computing power, we propose a fully automated in silico protocol for quickly identifying possible mutations in a mAb (e.g., CB6) to enhance its binding affinity for S-protein for the design of more efficacious therapeutic mAbs.
C1 [Luan, Binquan; Huynh, Tien] IBM Thomas J Watson Res, Computat Biol Ctr, Yorktown Hts, NY 10598 USA.
RP Luan, BQ (corresponding author), IBM Thomas J Watson Res, Computat Biol Ctr, Yorktown Hts, NY 10598 USA.
EM bluan@us.ibm.com
FU IBM Cognitive Computing Program
FX T.H. and B.L. gratefully acknowledge the help from Wendy Cornell and the
   computing resource from the IBM Cognitive Computing Program.
CR Allen M. P., 1987, COMPUTER SIMULATION
   Arvin AM, 2020, NATURE, DOI 10.1038/s41586-020-2538-8
   BEGLOV D, 1994, J CHEM PHYS, V100, P9050, DOI 10.1063/1.466711
   Beigel JH, 2020, NEW ENGL J MED, V383, P994, DOI 10.1056/NEJMc2022236
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Casalino L, 2020, ACS CENTRAL SCI, V6, P1722, DOI 10.1021/acscentsci.0c01056
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Chipot C., 2007, FREE ENERGY CALCULAT
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Freddolino PL, 2010, NAT PHYS, V6, P751, DOI 10.1038/NPHYS1713
   Gur M, 2020, J CHEM PHYS, V153, DOI 10.1063/5.0011141
   Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646
   Liu LH, 2020, NATURE, DOI 10.1038/s41586-020-2571-7
   Luan BQ, 2019, J AM CHEM SOC, V141, P6545, DOI 10.1021/jacs.8b13144
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   MARTINETZ T, 1994, NEURAL NETWORKS, V7, P507, DOI 10.1016/0893-6080(94)90109-0
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Taka E., 2020, CRITICAL INTERACTION, DOI [10.1101/2020.09.21.305490, DOI 10.1101/2020.09.21.305490]
   Huynh T, 2020, J PHYS CHEM LETT, V11, P4413, DOI 10.1021/acs.jpclett.0c00994
   TUCKERMAN M, 1992, J CHEM PHYS, V97, P1990, DOI 10.1063/1.463137
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang YJ, 2020, P NATL ACAD SCI USA, V117, P13967, DOI 10.1073/pnas.2008209117
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 42
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD NOV 19
PY 2020
VL 11
IS 22
BP 9781
EP 9787
DI 10.1021/acs.jpclett.0c02706
PG 7
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA OW5XM
UT WOS:000592959100036
PM 33147968
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Das, BK
   Chakraborty, D
AF Das, Bratin Kumar
   Chakraborty, Debashree
TI Epitope-Based Potential Vaccine Candidate for Humoral and Cell-Mediated
   Immunity to Combat Severe Acute Respiratory Syndrome Coronavirus 2
   Pandemic
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
ID MOLECULAR-DYNAMICS; INHIBITORS
AB The emergence of severe acute respiratory syndrome from novel Coronavirus (SARS-CoV-2) has put an immense pressure worldwide where vaccination is believed to be an efficient way for developing hard immunity. Herein, we employ immunoinformatic tools to identify B-cell, T-cell epitopes associated with the spike protein of SARS-CoV-2, which is important for genome release. The results showed that the highly immunogenic epitopes located at the stalk part are mostly conserved compared to the receptor binding domain (RDB). Further, two vaccine candidates were computationally modeled from the linear B-cell, T-cell epitopes. Molecular docking reveals the crucial interactions of the vaccines with immune-receptors, and their stability is assessed by MD simulation studies. The chimeric vaccines showed remarkable binding affinity toward the immune cell receptors computed by the MM/PBSA method. van der Waals and electrostatic interactions are found to be the dominant factors for the stability of the complexes. The molecular-level interaction obtained from this study may provide deeper insight into the process of vaccine development against the pandemic of COVID-19.
C1 [Das, Bratin Kumar; Chakraborty, Debashree] Natl Inst Technol Karnataka, Biophys & Computat Lab, Dept Chem, Mangalore 575025, India.
RP Chakraborty, D (corresponding author), Natl Inst Technol Karnataka, Biophys & Computat Lab, Dept Chem, Mangalore 575025, India.
EM debashree@nitk.edu.in
FU DST, SERBDepartment of Science & Technology (India)Science Engineering
   Research Board (SERB), India [CRG/2019/000578]; NIT K
FX Funding from DST, SERB (CRG/2019/000578) is highly acknowledged. BKD
   acknowledges NIT K for SRF. The authors would like to thank Mr. Omkar
   Singh for his timely help and contribution in manuscript preparation. We
   would also like to thank Department of Chemistry, NITK Surathkal for
   their constant support.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Agudelo WA, 2010, MINI-REV MED CHEM, V10, P746, DOI 10.2174/138955710791572488
   Alderete JF, 2013, IMMUNOTARGETS THER, V2, P91, DOI 10.2147/ITT.S46694
   Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906
   AVERILL FW, 1992, PHYS REV B, V46, P2498, DOI 10.1103/PhysRevB.46.2498
   Azmi F, 2014, HUM VACC IMMUNOTHER, V10, P778, DOI 10.4161/hv.27332
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Best RB, 2008, BIOPHYS J, V95, pL7, DOI 10.1529/biophysj.108.132696
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Chamachi NG, 2016, J PHYS CHEM B, V120, P7332, DOI 10.1021/acs.jpcb.6b03690
   Charles A, 2001, HUMORAL IMMUNE RESPO, V5th
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   CHOU PY, 1977, TRENDS BIOCHEM SCI, V2, P128, DOI 10.1016/0968-0004(77)90440-6
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Elcock AH, 2001, J PHYS CHEM B, V105, P1504, DOI 10.1021/jp003602d
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998
   Ghosh R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1802347
   Ghosh R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779818
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Kar T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67749-1
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lam TT-Y, 2020, IDENTIFICATION 2019, DOI [10.1101/2020.02.13.945485, 10.1101/2020.02.13.945485., DOI 10.1101/2020.02.13.945485]
   Lemkul JA, 2010, J PHYS CHEM B, V114, P1652, DOI 10.1021/jp9110794
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lin L., 2020, VIRUS RES, V288
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Lizbeth RSG, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1780944
   Gutierrez-Villagomez JM, 2020, J PHYS CHEM LETT, V11, P8008, DOI 10.1021/acs.jpclett.0c01685
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   Meza JC, 2010, WIRES COMPUT STAT, V2, P719, DOI 10.1002/wics.117
   Mishra SS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1791957
   Nazar A, 2020, J CHEM INF MODEL, V60, P3812, DOI 10.1021/acs.jcim.9b01134
   Nelapati AK, 2020, PROCESS BIOCHEM, V92, P288, DOI 10.1016/j.procbio.2020.01.022
   PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Punt J., 2019, KUBY IMMUNOLOGY
   Sanche S, 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.02.07.20021154, DOI 10.1101/2020.02.07.20021154]
   Schindewolf C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010074
   Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249-011-0700-9
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Man VH, 2019, J CHEM THEORY COMPUT, V15, P1440, DOI 10.1021/acs.jctc.8b01107
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zawawi A, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008243
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
NR 69
TC 0
Z9 0
U1 4
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD NOV 19
PY 2020
VL 11
IS 22
BP 9920
EP 9930
DI 10.1021/acs.jpclett.0c02846
PG 11
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA OW5XM
UT WOS:000592959100056
PM 33174418
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wahlund, T
   Mataix-Cols, D
   Lauri, KO
   de Schipper, E
   Ljotsson, B
   Aspvall, K
   Andersson, E
AF Wahlund, Tove
   Mataix-Cols, David
   Olofsdotter Lauri, Klara
   de Schipper, Elles
   Ljotsson, Brjann
   Aspvall, Kristina
   Andersson, Erik
TI Brief Online Cognitive Behavioural Intervention for Dysfunctional Worry
   Related to the COVID-19 Pandemic: A Randomised Controlled Trial
SO PSYCHOTHERAPY AND PSYCHOSOMATICS
LA English
DT Article; Early Access
DE Dysfunctional worry; COVID-19; Internet-based treatment; Cognitive
   behaviour therapy; Digital therapy
ID GENERALIZED ANXIETY DISORDER; SAFETY BEHAVIORS; HEALTH; VERSION; SCALE
AB Introduction: Worries about the immediate and long-term consequences of the COVID-19 pandemic may for some individuals develop into pervasive worry that is disproportionate in its intensity or duration and significantly interferes with everyday life. Objective: The aim of this study was to investigate if a brief self-guided, online psychological intervention can reduce the degree of dysfunctional worry related to the COVID-19 pandemic and associated symptoms. Methods: 670 adults from the Swedish general population reporting daily uncontrollable worry about CO-VID-19 and its possible consequences (e.g., illness, death, the economy, one's family) were randomised (1:1 ratio) to a 3-week self-guided, online cognitive behavioural intervention targeting dysfunctional COVID-19 worry and associated symptoms, or a waiting list of equal duration. The primary outcome measure was a COVID-19 adapted version of the Generalised Anxiety Disorder 7-item scale administered at baseline and weeks 1-3 (primary endpoint). Follow-up assessments were conducted 1 month after treatment completion. The trial was registered on ClinicalTrials.gov (NCT04341922) before inclusion of the first participant. Results: The main pre-specified intention-to-treat analysis indicated significant reductions in COVID-19-related worry for the intervention group compared to the waiting list (beta = 1.14, Z = 9.27, p < 0.001), corresponding to a medium effect size (bootstrapped d = 0.74 [95% CI: 0.58-0.90]). Improvements were also seen on all secondary measures, including mood, daily functioning, insomnia, and intolerance of uncertainty. Participant satisfaction was high. No serious adverse events were recorded. Conclusions: A brief digital and easily scalable self-guided psychological intervention can significantly reduce dysfunctional worry and associated behavioural symptoms related to the COVID-19 pandemic.
C1 [Wahlund, Tove; Olofsdotter Lauri, Klara; Ljotsson, Brjann; Andersson, Erik] Karolinska Inst, Div Psychol, Dept Clin Neurosci, Stockholm, Sweden.
   [Mataix-Cols, David; de Schipper, Elles; Aspvall, Kristina] Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden.
   [Mataix-Cols, David; de Schipper, Elles; Aspvall, Kristina] Reg Stockholm, Stockholm Hlth Care Serv, Stockholm, Sweden.
RP Wahlund, T (corresponding author), Karolinska Inst, Dept Clin Neurosci, Nobels Vag 9, SE-17165 Solna, Sweden.
EM tove.wahlund@ki.se
OI Wahlund, Tove/0000-0002-5123-2392
FU Swedish Innovation Agency (VINNOVA)Vinnova [2020-02196]; Strategic
   Research Area Healthcare Science (SFO-V)
FX This study was funded by the Swedish Innovation Agency (VINNOVA), grant
   number 2020-02196. This work used the BASS platform from the eHealth
   Core Facility at Karolinska Institutet, which is supported by the
   Strategic Research Area Healthcare Science (SFO-V). We want to express
   our gratitude to Mia Backlin and Mari Bentzer for helpful comments and
   revisions on the treatment outline. We also want to thank our
   collaborators at Region Stockholm: Eva Mannerstrale, Marten Skogman, and
   Linda Ahlqvist.
CR Adhanom Ghebreyesus T, 2020, COMMUNICATION
   Andersson Erik, 2020, Psychol Med, P1, DOI 10.1017/S0033291720000781
   Andersson E, 2017, BEHAV THER, V48, P391, DOI 10.1016/j.beth.2016.07.003
   Asmundson GJG, 2020, J ANXIETY DISORD, V70, DOI 10.1016/j.janxdis.2020.102196
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Behar E, 2009, J ANXIETY DISORD, V23, P1011, DOI 10.1016/j.janxdis.2009.07.006
   Carleton RN, 2007, J ANXIETY DISORD, V21, P105, DOI 10.1016/j.janxdis.2006.03.014
   Cuijpers P, 2014, CLIN PSYCHOL REV, V34, P130, DOI 10.1016/j.cpr.2014.01.002
   Deacon B, 2008, BEHAV RES THER, V46, P537, DOI 10.1016/j.brat.2008.01.010
   Farvolden Peter, 2005, J Med Internet Res, V7, pe7, DOI 10.2196/jmir.7.1.e7
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Gold SM, 2017, LANCET PSYCHIAT, V4, P725, DOI 10.1016/S2215-0366(17)30153-0
   Gonzalez-Sanguino C, 2020, BRAIN BEHAV IMMUN, V87, P172, DOI 10.1016/j.bbi.2020.05.040
   Hollis C, 2015, BRIT J PSYCHIAT, V206, P263, DOI 10.1192/bjp.bp.113.142612
   Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6
   Melville KM, 2010, BRIT J CLIN PSYCHOL, V49, P455, DOI 10.1348/014466509X472138
   Merikangas KR, 2020, CORONAVIRUS HLTH IMP
   Mundt JC, 2002, BRIT J PSYCHIAT, V180, P461, DOI 10.1192/bjp.180.5.461
   Olatunji BO, 2011, BEHAV RES THER, V49, P719, DOI 10.1016/j.brat.2011.07.008
   POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191
   Rachman S, 2003, TREATMENT OBSESSIONS, DOI [10.1093/med:psych/9780198515371.001.0001, DOI 10.1093/MED:PSYCH/9780198515371.001.0001]
   Richards Derek, 2015, Internet Interventions, V2, P272, DOI 10.1016/j.invent.2015.07.003
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Svanborg P, 2001, J AFFECT DISORDERS, V64, P203, DOI 10.1016/S0165-0327(00)00242-1
   Twomey C, 2014, BRIT J CLIN PSYCHOL, V53, P433, DOI 10.1111/bjc.12055
   Voitsidis P, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113076
   Wahlund T, 2020, PSYARXIV
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
NR 28
TC 0
Z9 0
U1 4
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0033-3190
EI 1423-0348
J9 PSYCHOTHER PSYCHOSOM
JI Psychother. Psychosom.
DI 10.1159/000512843
EA NOV 2020
PG 9
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA OV9JJ
UT WOS:000592516700001
PM 33212440
DA 2021-01-01
ER

PT J
AU De Wals, P
   Menzies, D
   Divangahi, M
AF De Wals, Philippe
   Menzies, Dick
   Divangahi, Maziar
TI Can BCG be useful to mitigate the COVID-19 pandemic? A Canadian
   perspective
SO CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE
LA English
DT Article; Early Access
DE BCG; COVID-19; SARS-CoV-2; Coronavirus; Trained immunity; Innate
   immunity
ID INNATE IMMUNITY; VACCINATION; HOSPITALIZATION; IMMUNIZATION;
   TUBERCULOSIS; PROTECTION; INFECTION; MORTALITY; VACCINES; QUEBEC
AB There is ample evidence from in vitro, animal and human studies that the Bacillus Calmette-Guerin (BCG) vaccine epigenetically reprograms innate immunity to provide "off target" protection against pathogens other than mycobacteria. This process has been termed "trained immunity". Although recent ecological studies suggested an association between BCG policies and the frequency or severity of COVID-19 in different countries, the interpretation of these results is challenging. For this reason, a case-control study aiming to test this hypothesis has been initiated in Quebec. Several phase III clinical trials are underway, including one in Canada, to assess the efficacy of BCG against SARS-CoV-2 infection (results expected in 2021). In the past, BCG has been widely used in Canada but current indications are restricted to high-risk individuals and communities experiencing TB outbreaks as well as for the treatment of bladder cancer. The potential implication of BCG as an interim measure to mitigate COVID-19 is the subject of widespread discussion in the scientific community and can be considered for the vulnerable population in Canada. To conclude, BCG vaccination should be placed on the agenda of research funding agencies, scientific advisory committees on immunization and federal/provincial/territorial public health authorities.
C1 [De Wals, Philippe] Univ Laval, Dept Med Sociale & Prevent, CRIUCPQ, 2725 Chemin St Foy, Quebec City, PQ G1G 4G5, Canada.
   [De Wals, Philippe] Inst Natl Sante Publ Quebec, Direct Risques Biol & Sante Travail, Quebec City, PQ, Canada.
   [De Wals, Philippe] Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada.
   [Menzies, Dick] McGill Univ, Montreal Chest Inst, Montreal, PQ, Canada.
   [Menzies, Dick] McGill Univ, Resp Epidemiol Unit, Montreal, PQ, Canada.
   [Divangahi, Maziar] McGill Univ, Hlth Ctr, Dept Med, Meakins Christie Labs, Montreal, PQ, Canada.
   [Divangahi, Maziar] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.
   [Divangahi, Maziar] McGill Univ, Hlth Ctr, McGill Int TB Ctr, Montreal, PQ, Canada.
RP De Wals, P (corresponding author), Univ Laval, Dept Med Sociale & Prevent, CRIUCPQ, 2725 Chemin St Foy, Quebec City, PQ G1G 4G5, Canada.; De Wals, P (corresponding author), Inst Natl Sante Publ Quebec, Direct Risques Biol & Sante Travail, Quebec City, PQ, Canada.; De Wals, P (corresponding author), Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada.
EM philippe.dewals@criucpq.ulaval.ca
CR Aaby P., 2020, NATURE REV IMMUNOL
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Canadian Institute for Health Information, 2020, HLTH WORKF 2018
   Cernuschi T, 2018, VACCINE, V36, P498, DOI 10.1016/j.vaccine.2017.12.010
   CIQ-Comite sur l'immunisation du Quebec, 2016, AV PERT REINTR VACC
   Curtis N, 2019, PEDIATR INFECT DIS J, V38, P195, DOI 10.1097/INF.0000000000002230
   De Wals P., 2020, VACCIN BCG POURRAIT
   De Wals P, 2020, FARDEAU INFECT RESP
   De Wals P, 2011, EXPERT REV VACCINES, V10, P55, DOI [10.1586/erv.10.151, 10.1586/ERV.10.151]
   Divangahi M, 2018, NAT REV IMMUNOL, V18, P661, DOI 10.1038/s41577-018-0070-y
   Giamarellos-Bourboulis EJ, 2020, CELL, V183, P315, DOI 10.1016/j.cell.2020.08.051
   Grzybowski S, 1999, CAN MED ASSOC J, V160, P1025
   Haahr S, 2016, INT J EPIDEMIOL, V45, P2122, DOI 10.1093/ije/dyw244
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Ismail SJ, 2010, VACCINE, V28, pA58, DOI 10.1016/j.vaccine.2010.02.035
   Jayaraman K, 2019, PEDIATR INFECT DIS J, V38, P198, DOI 10.1097/INF.0000000000002198
   de Castro MJ, 2015, CLIN INFECT DIS, V60, P1611, DOI 10.1093/cid/civ144
   Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031
   Khader SA, 2019, J CLIN INVEST, V129, P3482, DOI 10.1172/JCI128877
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Leentjens J, 2015, J INFECT DIS, V212, P1930, DOI 10.1093/infdis/jiv332
   Miyazaki J, 2018, INT J UROL, V25, P405, DOI 10.1111/iju.13538
   Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038
   Muthumbi E, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0041-2
   Nankabirwa V, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1497-8
   Naslund C, 1932, RESULTATS EXPERIENCE
   Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   Nieuwenhuizen NE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01147
   Nuovo G, 2020, ANN DIAGN PATHOL, V48, DOI 10.1016/j.anndiagpath.2020.151600
   Public Health Agency of Canada, 2020, CAN IMM GUID
   Redelman-Sidi G, 2014, NAT REV UROL, V11, P153, DOI 10.1038/nrurol.2014.15
   Ricco Matteo, 2020, Acta Biomed, V91, P207, DOI 10.23750/abm.v91i2.9700
   Rieckmann A, 2017, INT J EPIDEMIOL, V46, P695, DOI 10.1093/ije/dyw120
   Rousseau MC, 2017, VACCINE, V35, P4777, DOI 10.1016/j.vaccine.2017.06.064
   SAGE Working Group on BCG Vaccines and WHO Secretariat, 2017, REP BCG VACC US PROT
   Shann F, 2013, CLIN THER, V35, P109, DOI 10.1016/j.clinthera.2013.01.007
   Speiser DE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030404
   StatCan, 2020, STAT IND PEOPL
   Stensballe LG, 2017, ARCH DIS CHILD, V102, P224, DOI 10.1136/archdischild-2016-310760
   Storgaard L, 2015, CLIN INFECT DIS, V61, P950, DOI 10.1093/cid/civ452
   Wakefield J, 2008, ANNU REV PUBL HEALTH, V29, P75, DOI 10.1146/annurev.publhealth.29.020907.090821
   Walk J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08659-3
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427
NR 45
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0008-4263
EI 1920-7476
J9 CAN J PUBLIC HEALTH
JI Can. J. Public Health-Rev. Can. Sante Publ.
DI 10.17269/s41997-020-00439-7
EA NOV 2020
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OT6SB
UT WOS:000590972700001
PM 33211246
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cremer, S
   Jakob, C
   Berkowitsch, A
   Borgmann, S
   Pilgram, L
   Tometten, L
   Classen, A
   Wille, K
   Weidlich, S
   Gruener, B
   Dimmeler, S
   Massberg, S
   Rieg, S
   Zeiher, AM
AF Cremer, Sebastian
   Jakob, Carolin
   Berkowitsch, Alexander
   Borgmann, Stefan
   Pilgram, Lisa
   Tometten, Lukas
   Classen, Annika
   Wille, Kai
   Weidlich, Simon
   Gruener, Beate
   Dimmeler, Stefanie
   Massberg, Steffen
   Rieg, Siegbert
   Zeiher, Andreas M.
CA LEOSS Study Grp
TI Elevated markers of thrombo-inflammatory activation predict outcome in
   patients with cardiovascular comorbidities and COVID-19 disease:
   insights from the LEOSS registry
SO CLINICAL RESEARCH IN CARDIOLOGY
LA English
DT Article; Early Access
DE Inflammation; COVID-19; Myocardial injury; Coagulation; Mortality
AB Aims: SARS-CoV-2 infection is associated with adverse outcomes in patients with cardiovascular disease. Here, we analyzed whether specific biomarkers predict the clinical course of COVID-19 in patients with cardiovascular comorbidities.
   Methods and results: We enrolled 2147 patients with SARS-CoV-2 infection which were included in the Lean European Open Survey on SARS-CoV-2 (LEOSS)-registry from March to June 2020. Clinical data and laboratory values were collected and compared between patients with and without cardiovascular comorbidities in different clinical stages of the disease. Predictors for mortality were calculated using multivariate regression analysis. We show that patients with cardiovascular comorbidities display significantly higher markers of myocardial injury and thrombo-inflammatory activation already in the uncomplicated phase of COVID-19. In multivariate analysis, elevated levels of troponin [OR 1.54; (95% CI 1.22-1.96), p < 0.001)], IL-6 [OR 1.69 (95% CI 1.26-2.27), p < 0.013)], and CRP [OR 1.32; (95% CI 1.1-1.58), p < 0.003)] were predictors of mortality in patients with COVID-19.
   Conclusion: Patients with cardiovascular comorbidities show elevated markers of thrombo-inflammatory activation and myocardial injury, which predict mortality, already in the uncomplicated phase of COVID-19. Starting targeted anti-inflammatory therapy and aggressive anticoagulation already in the uncomplicated phase of the disease might improve outcomes after SARS-CoV-2 infection in patients with cardiovascular comorbidities.
   Graphic abstract: Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry
   [GRAPHICS]
   .
C1 [Cremer, Sebastian; Berkowitsch, Alexander; Zeiher, Andreas M.] Goethe Univ Frankfurt, Dept Med 3, Cardiol Angiol Nephrol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
   [Cremer, Sebastian; Dimmeler, Stefanie; Zeiher, Andreas M.] German Ctr Cardiovasc Res DZHK, Partner Site Rhine Main, Berlin, Germany.
   [Cremer, Sebastian; Dimmeler, Stefanie; Zeiher, Andreas M.] Goethe Univ Frankfurt, Cardiopulm Inst, Frankfurt, Germany.
   [Jakob, Carolin; Classen, Annika] Univ Cologne, Fac Med, Cologne, Germany.
   [Jakob, Carolin; Classen, Annika] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany.
   [Borgmann, Stefan] Ingolstadt Hosp, Dept Infect Dis & Infect Control, Ingolstadt, Germany.
   [Tometten, Lukas] Hosp Ernst Von Bergmann, Potsdam, Germany.
   [Wille, Kai] Johannes Wesling Hosp, Dept Hematol Oncol, Minden, Germany.
   [Weidlich, Simon] Tech Univ Munich, Univ Hosp Rechts Isar, Dept Internal Med 2, Munich, Germany.
   [Gruener, Beate] Dept Infect Dis, Internal Med 3, Ulm, Germany.
   [Dimmeler, Stefanie] Goethe Univ Frankfurt, Inst Cardiovasc Regenerat, Frankfurt, Germany.
   [Massberg, Steffen] Klinikum Univ Munchen, Dept Med 1, Munich, Germany.
   [Pilgram, Lisa] Goethe Univ Frankfurt, Dept Internal Med, Hematol Oncol, Frankfurt, Germany.
   [Rieg, Siegbert] Freiburg Univ Hosp, Dept Infect Dis, Internal Med 2, Freiburg, Germany.
RP Zeiher, AM (corresponding author), Goethe Univ Frankfurt, Dept Med 3, Cardiol Angiol Nephrol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.; Zeiher, AM (corresponding author), German Ctr Cardiovasc Res DZHK, Partner Site Rhine Main, Berlin, Germany.; Zeiher, AM (corresponding author), Goethe Univ Frankfurt, Cardiopulm Inst, Frankfurt, Germany.
EM zeiher@em.uni-frankfurt.de
FU Projekt DEAL; German Center for Infection Research; Pitzer Foundation;
   German Center for Cardiovascular Research DZHK, Berlin, Germany
FX Open Access funding enabled and organized by Projekt DEAL. The study was
   supported by the German Center for Infection Research, the Pitzer
   Foundation to J.V., and the German Center for Cardiovascular Research
   DZHK, Berlin, Germany to A.B.
CR Abplanalp WT, 2020, JAMA CARDIOL, V5, P1170, DOI 10.1001/jamacardio.2020.2468
   Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Bohm M, 2020, CLIN RES CARDIOL, V109, P1446, DOI 10.1007/s00392-020-01656-3
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106
   Hijazi Z, 2013, EUR HEART J, V34, P1475, DOI 10.1093/eurheartj/eht024
   Inciardi RM, 2020, EUR HEART J, V41, P1821, DOI 10.1093/eurheartj/ehaa388
   Jakob CEM, 2020, INFECTION, DOI 10.1007/s15010-020-01499-0
   Lala A, 2020, J AM COLL CARDIOL, V76, P533, DOI 10.1016/j.jacc.2020.06.007
   Libby P, 2019, J AM COLL CARDIOL, V74, P567, DOI 10.1016/j.jacc.2019.06.007
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Nahrendorf M, 2018, NAT MED, V24, P711, DOI 10.1038/s41591-018-0064-0
   Nicolai L, 2020, CIRCULATION, V142, P1176, DOI 10.1161/CIRCULATIONAHA.120.048488
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Patel K, 2020, J INTERN MED, DOI 10.1111/joim.13163
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ridker PM, 2014, EUR HEART J, V35, P1782, DOI 10.1093/eurheartj/ehu203
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Shi SB, 2020, EUR HEART J, V41, P2070, DOI 10.1093/eurheartj/ehaa408
   Strohbehn Garth W, 2020, medRxiv, DOI 10.1101/2020.07.20.20157503
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 24
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1861-0684
EI 1861-0692
J9 CLIN RES CARDIOL
JI Clin. Res. Cardiol.
DI 10.1007/s00392-020-01769-9
EA NOV 2020
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OT6ZO
UT WOS:000590992200002
PM 33211155
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Du, XH
   Zuo, XY
   Meng, F
   Han, CF
   Ouyang, W
   Han, Y
   Gu, YY
   Zhao, X
   Xu, F
   Qin, FX
AF Du, Xiaohong
   Zuo, Xiangyang
   Meng, Fang
   Han, Chenfeng
   Ouyang, Wei
   Han, Yu
   Gu, Yayun
   Zhao, Xin
   Xu, Feng
   Qin, Frank Xiaofeng
TI Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2
   viruses by azithromycin
SO CELL PROLIFERATION
LA English
DT Article; Early Access
DE alkalinization; azithromycin; influenza A virus; SARS&#8208; CoV&#8208;
   2
ID BRONCHIAL EPITHELIAL-CELLS; RHINOVIRUS INFECTION; CATHEPSIN-L;
   CORONAVIRUS; ERYTHROMYCIN; PH; EXPRESSION; IL-8
AB Objectives Using strategy of drug repurposing, antiviral agents against influenza A virus (IAV) and newly emerging SARS-coronavirus 2 (SARS-CoV-2, also as 2019-nCoV) could be quickly screened out.
   Materials and Methods A previously reported engineered replication-competent PR8 strain carrying luciferase reporter gene (IAV-luc) and multiple pseudotyped IAV and SARS-CoV-2 virus was used. To specifically evaluate the pH change of vesicles containing IAV, we constructed an A549 cell line with endosomal and lysosomal expression of pHluorin2.
   Results Here, we identified azithromycin (AZ) as an effective inhibitor against multiple IAV and SARS-CoV-2 strains. We found that AZ treatment could potently inhibit IAV infection in vitro. Moreover, using pseudotyped virus model, AZ could also markedly block the entry of SARS-CoV-2 in HEK293T-ACE2 and Caco2 cells. Mechanistic studies further revealed that such effect was independent of interferon signalling. AZ treatment neither impaired the binding and internalization of IAV virions, nor the viral replication, but rather inhibited the fusion between viral and vacuolar membranes. Using a NPC1-pHluorin2 reporter cell line, we confirmed that AZ treatment could alkalize the vesicles containing IAV virions, thereby preventing pH-dependent membrane fusion.
   Conclusions Overall, our findings demonstrate that AZ can exert broad-spectrum antiviral effects against IAV and SARS-CoV-2, and could be served as a potential clinical anti-SARS-CoV-2 drug in emergency as well as a promising lead compound for the development of next-generation anti-IAV drugs.
C1 [Du, Xiaohong; Zuo, Xiangyang; Meng, Fang; Han, Chenfeng; Gu, Yayun; Zhao, Xin; Qin, Frank Xiaofeng] Chinese Acad Med Sci & Peking Union Med Coll, Inst Basic Med Sci, Ctr Syst Med, Beijing 100005, Peoples R China.
   [Du, Xiaohong; Zuo, Xiangyang; Meng, Fang; Han, Chenfeng; Gu, Yayun; Zhao, Xin; Qin, Frank Xiaofeng] Suzhou Inst Syst Med, Suzhou, Peoples R China.
   [Du, Xiaohong] Nanjing Med Univ, Suzhou Sci & Technol Town Hosp, Affiliated Suzhou Hosp, Inst Clin Med Res, Suzhou, Peoples R China.
   [Ouyang, Wei; Han, Yu; Xu, Feng] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Infect Dis, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.
RP Qin, FX (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Basic Med Sci, Ctr Syst Med, Beijing 100005, Peoples R China.; Xu, F (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Infect Dis, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.
EM xufeng99@zju.edu.cn; fqin1@foxmail.com
FU Key Program for Innovative Drug Development of China [2015ZX09102023];
   Jiangsu Provincial Natural Science FoundationNatural Science Foundation
   of Jiangsu Province [BK20171232]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81701567,
   81773058, 31800726, 81970004]; Chinese Academy of Medical Sciences
   Initiative for Innovative Medicine (Grant CAMS-I2M) [2016-I2M-1-005];
   National grand Foreign Experts projects (culture and education)
   [GDW20181100054]; National grand Foreign Experts projects [G20190001633,
   G20190001639]
FX This work was supported by: The Key Program for Innovative Drug
   Development of China (Grant 2015ZX09102023); Jiangsu Provincial Natural
   Science Foundation (Grant BK20171232); The National Natural Science
   Foundation of China (Grant 81701567, 81773058, 31800726 and 81970004);
   The Chinese Academy of Medical Sciences Initiative for Innovative
   Medicine (Grant CAMS-I2M, 2016-I2M-1-005); National grand Foreign
   Experts projects (culture and education) (Grant GDW20181100054);
   National grand Foreign Experts projects (G20190001633 and G20190001639).
CR Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Asha K, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020192
   Bortz E, 2011, MBIO, V2, DOI 10.1128/mBio.00151-11
   CHINALI G, 1988, BIOCHIM BIOPHYS ACTA, V949, P71, DOI 10.1016/0167-4781(88)90056-5
   CRIDER BP, 1994, J BIOL CHEM, V269, P17379
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Edinger TO, 2014, J GEN VIROL, V95, P263, DOI 10.1099/vir.0.059477-0
   Fan HL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41226
   Funk RS, 2012, MOL PHARMACEUT, V9, P1384, DOI 10.1021/mp200641e
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Giroglou T, 2004, J VIROL, V78, P9007, DOI 10.1128/JVI.78.17.9007-9015.2004
   Han J, 2018, CURR MED CHEM, V25, P5115, DOI 10.2174/0929867324666170920165926
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200
   Jang YJ, 2006, EUR RESPIR J, V27, P12, DOI 10.1183/09031936.06.00008005
   Kakeya H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091293
   KHAIR OA, 1995, EUR RESPIR J, V8, P1451
   Kim H, 2018, VIRAL IMMUNOL, V31, P174, DOI 10.1089/vim.2017.0141
   Lambert LC, 2010, NEW ENGL J MED, V363, P2036, DOI 10.1056/NEJMra1002842
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li CF, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00394-19
   Loregian A, 2014, CELL MOL LIFE SCI, V71, P3659, DOI 10.1007/s00018-014-1615-2
   Lou XH, 2011, AM J PHYSIOL-CELL PH, V301, pC1431, DOI 10.1152/ajpcell.00154.2011
   Ma L, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00071
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Mahon Matthew J, 2011, Adv Biosci Biotechnol, V2, P132
   Menzel M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28698
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Ouyang Q, 2013, NEURON, V80, P97, DOI 10.1016/j.neuron.2013.07.043
   Pan WQ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3369
   Park JE, 2018, INFECT GENET EVOL, V65, P288, DOI 10.1016/j.meegid.2018.08.007
   Pleschka S, 2013, CURR TOP MICROBIOL, V370, P1, DOI 10.1007/82_2012_272
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sakai T, 2006, J VIROL, V80, P2013, DOI 10.1128/JVI.80.4.2013-2018.2006
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Schogler A, 2015, EUR RESPIR J, V45, P428, DOI 10.1183/09031936.00102014
   SCHOLTISSEK C, 1985, VACCINE, V3, P215, DOI 10.1016/0264-410X(85)90109-4
   Sekhavati E, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106143
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Suzuki T, 2002, AM J RESP CRIT CARE, V165, P1113, DOI 10.1164/ajrccm.165.8.2103094
   Suzuki T, 2001, AM J PHYSIOL-LUNG C, V280, pL1115
   SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645
   Takizawa H, 1997, AM J RESP CRIT CARE, V156, P266, DOI 10.1164/ajrccm.156.1.9612065
   TAKIZAWA H, 1995, BIOCHEM BIOPH RES CO, V210, P781, DOI 10.1006/bbrc.1995.1727
   TAMAOKI J, 1994, ANTIMICROB AGENTS CH, V38, P1641, DOI 10.1128/AAC.38.7.1641
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12
   Yeganeh B, 2015, AM J PHYSIOL-LUNG C, V308, pL270, DOI 10.1152/ajplung.00011.2014
   Yen HL, 2016, CURR OPIN VIROL, V18, P126, DOI 10.1016/j.coviro.2016.05.004
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 59
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
AR e12953
DI 10.1111/cpr.12953
EA NOV 2020
PG 13
WC Cell Biology
SC Cell Biology
GA OS7ID
UT WOS:000590332300001
PM 33211371
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Cismaru, CA
   Cismaru, GL
   Nabavi, SF
   Ghanei, M
   Burz, CC
   Nabavi, SM
   Neagoe, IB
AF Cismaru, Cosmin Andrei
   Cismaru, Gabriel Laurentiu
   Nabavi, Seyed Fazel
   Ghanei, Mostafa
   Burz, Claudia Cristina
   Nabavi, Seyed Mohammad
   Berindan Neagoe, Ioana
TI Multiple potential targets of opioids in the treatment of acute
   respiratory distress syndrome from COVID-19
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article; Early Access
DE ARDS; COVID&#8208; 19; cytokine storm; dyspnoea; immunomodulation;
   opioids
ID PALLIATIVE CARE PATIENTS; VENTILATORY RESPONSE; SYMPTOMATIC THERAPY;
   CANCER-PATIENTS; DYSPNEA; MORPHINE; RECEPTORS; PAIN; RECOMMENDATIONS;
   BREATHLESSNESS
AB COVID-19 can present with a variety of clinical features, ranging from asymptomatic or mild respiratory symptoms to fulminant acute respiratory distress syndrome (ARDS) depending on the host's immune responses and the extent of the associated pathologies. This implies that several measures need to be taken to limit severely impairing symptoms caused by viral-induced pathology in vital organs. Opioids are most exploited for their analgesic effects but their usage in the palliation of dyspnoea, immunomodulation and lysosomotropism may represent potential usages of opioids in COVID-19. Here, we describe the mechanisms involved in each of these potential usages, highlighting the benefits of using opioids in the treatment of ARDS from SARS-CoV-2 infection.
C1 [Cismaru, Cosmin Andrei; Berindan Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, Str Gh Marinescu 23, Cluj Napoca 400337, Romania.
   [Cismaru, Cosmin Andrei; Burz, Claudia Cristina] Iuliu Hatieganu Univ Med & Pharm, Dept Funct Sci Immunol & Allergol, Cluj Napoca, Romania.
   [Cismaru, Gabriel Laurentiu] Iuliu Hatieganu Univ Med & Pharm, Dept Internal Med Cardiol Rehabilitat, Cluj Napoca, Romania.
   [Nabavi, Seyed Fazel; Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran, Iran.
   [Ghanei, Mostafa] Baqiyatallah Univ Med Sci, Syst Biol & Poisoning Inst, Chem Injuries Res Ctr, Tehran, Iran.
   [Berindan Neagoe, Ioana] Oncol Inst Prof Dr Ion Chiricuta, Funct Genom Dept, Cluj Napoca, Romania.
RP Neagoe, IB (corresponding author), Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, Str Gh Marinescu 23, Cluj Napoca 400337, Romania.
EM ioana.neagoe@umfcluj.ro
RI Cismaru, Cosmin Andrei/AAD-1810-2020
OI Cismaru, Cosmin Andrei/0000-0001-5716-8101
FU Funding Agency-Ministry of Research and Innovation
FX This research was funded by the Funding Agency-Ministry of Research and
   Innovation, through the project PNCDI III 2015-2020 "Increasing the
   performance of scientific research and technology transfer in
   translational medicine through the formation of a new generation of
   young researchers"; ECHITAS.
CR Allard P, 1999, J PAIN SYMPTOM MANAG, V17, P256, DOI 10.1016/S0885-3924(98)00157-2
   [Anonymous], 2018, GLOBAL INITIATIVE CH
   [Anonymous], MORPH US DOS SID EFF
   Boom M, 2012, CURR PHARM DESIGN, V18, P5994, DOI 10.2174/138161212803582469
   Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Cismaru AC, 2020, ARCH MED SCI, V16
   Clemens KE, 2008, J PALLIAT MED, V11, P204, DOI 10.1089/jpm.2007.0131
   Clemens KE, 2008, SUPPORT CARE CANCER, V16, P93, DOI 10.1007/s00520-007-0310-3
   Clemens KE, 2007, J PAIN SYMPTOM MANAG, V33, P473, DOI 10.1016/j.jpainsymman.2006.09.015
   Currow DC, 2011, J PAIN SYMPTOM MANAG, V42, P388, DOI 10.1016/j.jpainsymman.2010.11.021
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9
   Diao B., 2020, REDUCTION FUNCTIONAL, DOI [10.1101/2020.02.18.20024364, DOI 10.1101/2020.02.18.20024364]
   Dinda Amit, 2005, Expert Opin Drug Saf, V4, P669, DOI 10.1517/14740338.4.4.669
   ECKENHOFF J E, 1955, Surg Forum, V5, P681
   El-Hage N, 2015, J VIROL, V89, P1024, DOI 10.1128/JVI.02022-14
   Garoff H, 1998, MICROBIOL MOL BIOL R, V62, P1171, DOI 10.1128/MMBR.62.4.1171-1190.1998
   Gastaminza P, 2010, P NATL ACAD SCI USA, V107, P291, DOI 10.1073/pnas.0912966107
   Ghiassi-Nejad Zahra, 2008, Expert Rev Gastroenterol Hepatol, V2, P803, DOI 10.1586/17474124.2.6.803
   Gibson PG, 2020, MED J AUSTRALIA, V213, P54, DOI 10.5694/mja2.50674
   Gklinos P, 2020, J NEUROL, V267, P2485, DOI 10.1007/s00415-020-09939-5
   Hoagland DA, MODULATING TRANSCRIP, DOI [10.1101/2020.07.12.199687, DOI 10.1101/2020.07.12.199687]
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Johnson MJ, 2016, AM J HOSP PALLIAT ME, V33, P194, DOI 10.1177/1049909114552692
   Kannan P, 2011, P NATL ACAD SCI USA, V108, P2593, DOI 10.1073/pnas.1014641108
   Kaufmann AM, 2007, J PHARM SCI-US, V96, P729, DOI 10.1002/jps.20792
   King S, 2011, PALLIATIVE MED, V25, P525, DOI 10.1177/0269216311406313
   Kloke M, 2015, ANN ONCOL, V26, pV169, DOI 10.1093/annonc/mdv306
   KRYGER MH, 1976, AM REV RESPIR DIS, V114, P333
   Lal RK, 2014, ACTA HORTIC, V1036, P71
   Levy MH, CONTINUE NCCN GUIDEL, DOI [10.6004/jnccn.2014.0136, DOI 10.6004/JNCCN.2014.0136]
   LIESSE M, 1976, ARCH INT PHYSIOL BIO, V84, P638
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   McCarthy L, 2001, DRUG ALCOHOL DEPEN, V62, P111, DOI 10.1016/S0376-8716(00)00181-2
   McCrory DC, 2013, ASSESSMENT MANAGEMEN
   Murtagh Fliss E M, 2007, J Pain Palliat Care Pharmacother, V21, P5
   OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327
   Page GG, 2005, J PAIN SYMPTOM MANAG, V29, pS25, DOI 10.1016/j.jpainsymman.2005.01.006
   Pang GS, 2016, AM J HOSP PALLIAT ME, V33, P222, DOI 10.1177/1049909114559769
   Pattinson KTS, 2009, J NEUROSCI, V29, P8177, DOI 10.1523/JNEUROSCI.1375-09.2009
   Prommer Eric, 2011, J Opioid Manag, V7, P401
   Rocker G, 2009, THORAX, V64, P910, DOI 10.1136/thx.2009.116699
   Salimi V, 2013, CRIT CARE MED, V41, P205, DOI 10.1097/CCM.0b013e31826767a8
   SANTIAGO TV, 1979, J APPL PHYSIOL, V47, P112
   Sharp BM, 1998, J NEUROIMMUNOL, V83, P45, DOI 10.1016/S0165-5728(97)00220-8
   Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019
   SIMONS K, 1982, SCI AM, V246, P58, DOI 10.1038/scientificamerican0282-58
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Tahamtan A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00970
   Twycross RG, 2011, PCF4 PALLIATIVE CARE
   Valentino RJ, 2018, NEUROPSYCHOPHARMACOL, V43, P2514, DOI 10.1038/s41386-018-0225-3
   von Leupoldt A, 2008, AM J RESP CRIT CARE, V177, P1026, DOI 10.1164/rccm.200712-1821OC
   von Leupoldt A, 2009, NEUROIMAGE, V48, P200, DOI 10.1016/j.neuroimage.2009.06.015
   WEIL JV, 1975, NEW ENGL J MED, V292, P1103, DOI 10.1056/NEJM197505222922106
   Whittaker A, 2020, ACTA NEUROL SCAND, V142, P14, DOI 10.1111/ane.13266
   WOODCOCK AA, 1981, NEW ENGL J MED, V305, P1611, DOI 10.1056/NEJM198112313052703
   Worsham CM, 2020, ANN AM THORAC SOC, V17, P926, DOI 10.1513/AnnalsATS.202004-322VP
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Young J, 2012, CAN FAM PHYSICIAN, V58, pE401
   Zhang HL, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015799
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 62
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
DI 10.1111/jcmm.15927
EA NOV 2020
PG 5
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA OS7ST
UT WOS:000590359900001
PM 33211389
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Roshdy, WH
   Rashed, HA
   Kandeil, A
   Mostafa, A
   Moatasim, Y
   Kutkat, O
   Shama, NMA
   Gomaa, MR
   El-Sayed, IH
   El Guindy, NM
   Naguib, A
   Kayali, G
   Ali, MA
AF Roshdy, Wael H.
   Rashed, Helmy A.
   Kandeil, Ahmed
   Mostafa, Ahmed
   Moatasim, Yassmin
   Kutkat, Omnia
   Abo Shama, Noura M.
   Gomaa, Mokhtar R.
   El-Sayed, Ibrahim H.
   El Guindy, Nancy M.
   Naguib, Amal
   Kayali, Ghazi
   Ali, Mohamed A.
TI EGYVIR: An immunomodulatory herbal extract with potent antiviral
   activity against SARS-CoV-2
SO PLOS ONE
LA English
DT Article
ID FACTOR-KAPPA-B; INFLUENZA-VIRUS INFECTION; BETA-SITOSTEROL; CYTOKINE
   STORM; NECK-CANCER; CURCUMIN; KINASE; INHIBITION; CELLS; PROLIFERATION
AB Due to the challenges for developing vaccines in devastating pandemic situations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing and screening of novel antiviral agents are peremptorily demanded. Herein, we developed EGYVIR as a potent immunomodulatory herbal extract with promising antiviral activity against SARS-CoV-2. It constitutes of a combination of black pepper extract with curcumin extract. The antiviral effect of EGYVIR extract is attributed to the two key phases of the disease in severe cases. First, the inhibition of the nuclear translocation of NF-k beta p50, attenuating the SARS-CoV-2 infection-associated cytokine storm. Additionally, the EGYVIR extract has an in vitro virucidal effect for SARS-CoV-2. The in vitro study of EGYVIR extract against SARS-CoV-2 on Huh-7 cell lines, revealed the potential role of NF-k beta/TNF alpha/IL-6 during the infection process. EGYVIR antagonizes the NF-k beta pathway in-silico and in-vitro studies. Consequently, it has the potential to hinder the release of IL-6 and TNF alpha, decreasing the production of essential cytokines storm elements.
C1 [Roshdy, Wael H.; Rashed, Helmy A.; El Guindy, Nancy M.; Naguib, Amal] Minist Hlth & Populat, Cent Publ Hlth Lab, Cairo, Egypt.
   [Kandeil, Ahmed; Mostafa, Ahmed; Moatasim, Yassmin; Kutkat, Omnia; Abo Shama, Noura M.; Gomaa, Mokhtar R.; Ali, Mohamed A.] Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Giza, Egypt.
   [El-Sayed, Ibrahim H.] Kafr El Sheikh Univ, Fac Sci, Biochem Dept, Kafr El Shaikh, Egypt.
   [Kayali, Ghazi] Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.
   [Kayali, Ghazi] Human Link, Baabda, Lebanon.
RP Roshdy, WH (corresponding author), Minist Hlth & Populat, Cent Publ Hlth Lab, Cairo, Egypt.; Ali, MA (corresponding author), Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Giza, Egypt.; Kayali, G (corresponding author), Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.; Kayali, G (corresponding author), Human Link, Baabda, Lebanon.
EM waelhamedroshdy@yahoo.com; ghazi@human-link.org;
   mohamedahmedali2004@yahoo.com
RI ; Elsayed, Ahmed Moustafa Mohamed/S-7462-2016
OI Moatasim, Yassmin/0000-0003-2159-2511; Elsayed, Ahmed Moustafa
   Mohamed/0000-0002-2878-5714
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, US Department of Health and Human ServicesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID)NIH National Institute of Neurological Disorders &
   Stroke (NINDS) [HHSN272201400006C]
FX This work was funded by the National Institute of Allergy and Infectious
   Diseases, National Institutes of Health, US Department of Health and
   Human Services (under contract HHSN272201400006C). Also this work was
   funded by pure diagnostic company.
CR [Anonymous], 2018, EUR J PHYS REHAB MED, V54, P177
   Arbab AH, 2016, FOOD NUTR RES, V60, DOI 10.3402/fnr.v60.30864
   Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071
   Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320
   Bouic PJD, 1996, INT J IMMUNOPHARMACO, V18, P693, DOI 10.1016/S0192-0561(97)85551-8
   Cao J, 2006, TOXICOL SCI, V91, P476, DOI 10.1093/toxsci/kfj153
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen TY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062482
   Chen XB, 2020, BMC PUBLIC HEALTH, V20, DOI [10.1186/s12889-020-08517-8, 10.1186/s12872-020-01640-9, 10.1186/s12879-020-05354-3]
   Cohen AN, 2009, ARCH OTOLARYNGOL, V135, P190, DOI 10.1001/archotol.135.2.190
   Derosa G, 2016, PHARMACOL RES, V111, P394, DOI 10.1016/j.phrs.2016.07.004
   Ferreira VH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124903
   Fiehn Oliver, 2016, Curr Protoc Mol Biol, V114, DOI 10.1002/0471142727.mb3004s114
   Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8
   Han SG, 2018, CLIN EXP PHARMACOL P, V45, P84, DOI 10.1111/1440-1681.12848
   HAYDEN FG, 1980, ANTIMICROB AGENTS CH, V18, P536, DOI 10.1128/AAC.18.4.536
   IVORRA MD, 1988, ARCH INT PHARMACOD T, V296, P224
   Kasinski AL, 2008, MOL PHARMACOL, V74, P654, DOI 10.1124/mol.108.046201
   Kim SG, 2011, CLIN CANCER RES, V17, P5953, DOI 10.1158/1078-0432.CCR-11-1272
   Kong LB, 2013, ANTIVIR RES, V98, P44, DOI 10.1016/j.antiviral.2013.02.003
   Kuo YC, 2002, ANTIMICROB AGENTS CH, V46, P2854, DOI 10.1128/AAC.46.9.2854-2864.2002
   Lee EC, 2016, NANOSCALE, V8, P16192, DOI 10.1039/c6nr03878f
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li YH, 2016, ACS APPL MATER INTER, V8, P24385, DOI 10.1021/acsami.6b06613
   LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857
   Mayadevi M, 2012, BIOORGAN MED CHEM, V20, P6040, DOI 10.1016/j.bmc.2012.08.029
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mostafa A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8070991
   Mounce BC, 2017, ANTIVIR RES, V142, P148, DOI 10.1016/j.antiviral.2017.03.014
   Obata K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070225
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Perrone D, 2015, EXP THER MED, V10, P1615, DOI 10.3892/etm.2015.2749
   Pradeep CR, 2004, INT IMMUNOPHARMACOL, V4, P1795, DOI 10.1016/j.intimp.2004.08.005
   Prasad S, 2014, CANCER RES TREAT, V46, P2, DOI 10.4143/crt.2014.46.1.2
   RAO GS, 1974, J PHARM SCI-US, V63, P471, DOI 10.1002/jps.2600630341
   Rao Xiayu, 2013, Biostat Bioinforma Biomath, V3, P71
   Reuter S, 2009, ANN NY ACAD SCI, V1171, P436, DOI 10.1111/j.1749-6632.2009.04731.x
   Schuhmacher A, 2003, PHYTOMEDICINE, V10, P504, DOI 10.1078/094471103322331467
   Siddique HR, 2011, LIFE SCI, V88, P285, DOI 10.1016/j.lfs.2010.11.020
   Tanaka T, 2004, CHEM PHARM BULL, V52, P1242, DOI 10.1248/cpb.52.1242
   Toden Shusuke, 2017, J Restor Med, V6, P27, DOI 10.14200/jrm.2017.6.0101
   Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu YM, 2017, INFLUENZA OTHER RESP, V11, P457, DOI 10.1111/irv.12459
   Yang M, 2016, MOLECULES, V21, DOI 10.3390/molecules21101401
   Yang XX, 2017, NANOSCALE, V9, P16086, DOI 10.1039/c7nr06520e
   Yang XX, 2016, NANOSCALE, V8, P3040, DOI 10.1039/c5nr07918g
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhang BY, 2019, FASEB J, V33, P13294, DOI 10.1096/fj.201901047RR
   Zhang J, 1995, Zhongguo Zhong Yao Za Zhi, V20, P556
   Zhang L, 2009, CANCER INVEST, V27, P163, DOI 10.1080/07357900802210745
   Zhang YL, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0199-1
   Zhao L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117496
NR 55
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2020
VL 15
IS 11
AR e0241739
DI 10.1371/journal.pone.0241739
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OZ9VG
UT WOS:000595265900052
PM 33206688
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sacco, V
   Rauch, B
   Gar, C
   Haschka, S
   Potzel, AL
   Kern-Matschilles, S
   Banning, F
   Benz, I
   Meisel, M
   Seissler, J
   Lechner, A
AF Sacco, Vanessa
   Rauch, Barbara
   Gar, Christina
   Haschka, Stefanie
   Potzel, Anne L.
   Kern-Matschilles, Stefanie
   Banning, Friederike
   Benz, Irina
   Meisel, Mandy
   Seissler, Jochen
   Lechner, Andreas
TI Overweight/obesity as the potentially most important lifestyle factor
   associated with signs of pneumonia in COVID-19
SO PLOS ONE
LA English
DT Article
ID INFLUENZA; ADULTS
AB Objective
   The occurrence of pneumonia separates severe cases of COVID-19 from the majority of cases with mild disease. However, the factors determining whether or not pneumonia develops remain to be fully uncovered. We therefore explored the associations of several lifestyle factors with signs of pneumonia in COVID-19.
   Methods
   Between May and July 2020, we conducted an online survey of 201 adults in Germany who had recently gone through COVID-19, predominantly as outpatients. Of these, 165 had a PCR-based diagnosis and 36 had a retrospective diagnosis by antibody testing. The survey covered demographic information, eight lifestyle factors, comorbidities and medication use. We defined the main outcome as the presence vs. the absence of signs of pneumonia, represented by dyspnea, the requirement for oxygen therapy or intubation.
   Results
   Signs of pneumonia occurred in 39 of the 165 individuals with a PCR-based diagnosis of COVID-19 (23.6%). Among the lifestyle factors examined, only overweight/obesity was associated with signs of pneumonia (odds ratio 2.68 (1.29-5.59) p = 0.008). The observed association remained significant after multivariate adjustment, with BMI as a metric variable, and also after including the antibody-positive individuals into the analysis.
   Conclusions
   This exploratory study finds an association of overweight/obesity with signs of pneumonia in COVID-19. This finding suggests that a signal proportional to body fat mass, such as the hormone leptin, impairs the body's ability to clear SARS-CoV-2 before pneumonia develops. This hypothesis concurs with previous work and should be investigated further to possibly reduce the proportion of severe cases of COVID-19.
C1 [Sacco, Vanessa; Rauch, Barbara; Gar, Christina; Haschka, Stefanie; Potzel, Anne L.; Kern-Matschilles, Stefanie; Banning, Friederike; Benz, Irina; Meisel, Mandy; Seissler, Jochen; Lechner, Andreas] LMU Klinikum, Med Klin & Poliklin 4, Diabet Res Grp, Munich, Germany.
   [Sacco, Vanessa; Rauch, Barbara; Gar, Christina; Haschka, Stefanie; Potzel, Anne L.; Kern-Matschilles, Stefanie; Banning, Friederike; Benz, Irina; Meisel, Mandy; Seissler, Jochen; Lechner, Andreas] Helmholtz Zentrum Munchen, Clin Cooperat Grp Type 2 Diabet, Neuherberg, Germany.
   [Sacco, Vanessa; Rauch, Barbara; Gar, Christina; Haschka, Stefanie; Potzel, Anne L.; Kern-Matschilles, Stefanie; Banning, Friederike; Benz, Irina; Meisel, Mandy; Seissler, Jochen; Lechner, Andreas] German Ctr Diabet Res DZD, Neuherberg, Germany.
RP Sacco, V; Seissler, J; Lechner, A (corresponding author), LMU Klinikum, Med Klin & Poliklin 4, Diabet Res Grp, Munich, Germany.; Sacco, V; Seissler, J; Lechner, A (corresponding author), Helmholtz Zentrum Munchen, Clin Cooperat Grp Type 2 Diabet, Neuherberg, Germany.; Sacco, V; Seissler, J; Lechner, A (corresponding author), German Ctr Diabet Res DZD, Neuherberg, Germany.
EM vanessa.sacco@med.uni-muenchen.de; jochen.seissler@med.uni-muenchen.de;
   andreas.lechner@med.uni-muenchen.de
FU LMU Klinikum; Helmholtz Zentrum MunchenHelmholtz Association; German
   Center for Diabetes Research
FX This work was funded by LMU Klinikum, Helmholtz Zentrum Munchen, and the
   German Center for Diabetes Research (all to AL). The funders had no role
   in the study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Davison G, 2016, AM J LIFESTYLE MED, V10, P152, DOI 10.1177/1559827614557773
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   McArthur L, 2020, AM J TROP MED HYG
   Neidich SD, 2017, INT J OBESITY, V41, P1324, DOI 10.1038/ijo.2017.131
   Nieman DC, 2019, J SPORT HEALTH SCI, V8, P201, DOI 10.1016/j.jshs.2018.09.009
   Teran-Cabanillas E, 2017, INFLAMMATION, V40, P58, DOI 10.1007/s10753-016-0452-x
   Wang X, 2020, CLIN MICROBIOL INFEC
   Weyh C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030622
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Woods JA, 2009, J AM GERIATR SOC, V57, P2183, DOI 10.1111/j.1532-5415.2009.02563.x
NR 10
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2020
VL 15
IS 11
AR e0237799
DI 10.1371/journal.pone.0237799
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OZ9VG
UT WOS:000595265900035
PM 33206653
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kuo, TY
   Lin, MY
   Coffman, RL
   Campbell, JD
   Traquina, P
   Lin, YJ
   Liu, LTC
   Cheng, JY
   Wu, YC
   Wu, CC
   Tang, WH
   Huang, CG
   Tsao, KC
   Chen, C
AF Kuo, Tsun-Yung
   Lin, Meei-Yun
   Coffman, Robert L.
   Campbell, John D.
   Traquina, Paula
   Lin, Yi-Jiun
   Liu, Luke Tzu-Chi
   Cheng, Jinyi
   Wu, Yu-Chi
   Wu, Chung-Chin
   Tang, Wei-Hsuan
   Huang, Chung-Guei
   Tsao, Kuo-Chien
   Chen, Charles
TI Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen
   as a subunit vaccine against COVID-19
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IMMUNOGENICITY; CORONAVIRUS
AB The COVID-19 pandemic is a worldwide health emergency which calls for an unprecedented race for vaccines and treatment. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein, S-2P. To enhance immunogenicity and mitigate the potential vaccine-induced immunopathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an adjuvant candidate. S-2P in combination with CpG 1018 and aluminum hydroxide (alum) was found to be the most potent immunogen and induced high titer of neutralizing antibodies in sera of immunized mice against pseudotyped lentivirus reporter or live wild-type SARS-CoV-2. In addition, the antibodies elicited were able to cross-neutralize pseudovirus containing the spike protein of the D614G variant, indicating the potential for broad spectrum protection. A marked Th1 dominant response was noted from cytokines secreted by splenocytes of mice immunized with CpG 1018 and alum. No vaccine-related serious adverse effects were found in the dose-ranging study in rats administered single- or two-dose regimens of S-2P combined with CpG 1018 alone or CpG 1018 with alum. These data support continued development of CHO-derived S-2P formulated with CpG 1018 and alum as a candidate vaccine to prevent COVID-19 disease.
C1 [Kuo, Tsun-Yung; Lin, Meei-Yun; Lin, Yi-Jiun; Liu, Luke Tzu-Chi; Cheng, Jinyi; Wu, Yu-Chi; Wu, Chung-Chin; Tang, Wei-Hsuan; Chen, Charles] Medigen Vaccine Biol Corp, Taipei, Taiwan.
   [Kuo, Tsun-Yung] Natl Ilan Univ, Dept Biotechnol & Anim Sci, Yilan, Yilan County, Taiwan.
   [Coffman, Robert L.; Campbell, John D.; Traquina, Paula] Dynavax Technol, Emeryville, CA 94608 USA.
   [Huang, Chung-Guei; Tsao, Kuo-Chien] Linkou Chang Gung Mem Hosp, Dept Lab Med, Taoyuan, Taiwan.
   [Huang, Chung-Guei; Tsao, Kuo-Chien] Chang Gung Univ, Coll Med, Res Ctr Emerging Viral Infect, Taoyuan, Taiwan.
   [Chen, Charles] Temple Univ, Coll Sci & Technol, Philadelphia, PA 19122 USA.
RP Chen, C (corresponding author), Medigen Vaccine Biol Corp, Taipei, Taiwan.; Chen, C (corresponding author), Temple Univ, Coll Sci & Technol, Philadelphia, PA 19122 USA.
EM charles@medigenvac.com
CR Campbell JD, 2017, METHODS MOL BIOL, V1494, P15, DOI 10.1007/978-1-4939-6445-1_2
   Council N.R., 2010, GUIDE CARE USE LAB A
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Huang CG, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01068-20
   Hyer RN, 2019, VACCINE, V37, P5854, DOI 10.1016/j.vaccine.2019.08.005
   Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Li Wei, 2020, bioRxiv, DOI 10.1101/2020.05.13.093088
   LOPEZ AF, 1986, J EXP MED, V163, P1085, DOI 10.1084/jem.163.5.1085
   Lu BJ, 2010, IMMUNOLOGY, V130, P254, DOI 10.1111/j.1365-2567.2010.03231.x
   O'Flaherty R, 2020, BIOTECHNOL ADV, V43, DOI 10.1016/j.biotechadv.2020.107552
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Perazzo P, 2015, INT J VACCINES VACCI, V1, P7
   Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055
   Thomas LJ, 2009, HUM VACCINES, V5, P79, DOI 10.4161/hv.5.2.6521
   Tian Jing-Hui, 2020, PREPRINT, DOI [10.1101/2020.06.29.178509., DOI 10.1101/2020.06.29.178509, 10.1101/2020.06.29.178509]
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 23
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 18
PY 2020
VL 10
IS 1
AR 20085
DI 10.1038/s41598-020-77077-z
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PA6CT
UT WOS:000595721900005
PM 33208827
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sun, R
   Ammari, S
   Bockel, S
   Achkar, S
   Merad, M
   Dercle, L
   Rivera, S
   Chargari, C
   Deutsch, E
AF Sun, Roger
   Ammari, Samy
   Bockel, Sophie
   Achkar, Samir
   Merad, Mansouria
   Dercle, Laurent
   Rivera, Sofia
   Chargari, Cyrus
   Deutsch, Eric
TI Optimization of Patient Management During the COVID-19 Pandemic: Chest
   CT Scan and PCR as Gatekeepers of the Radiation Therapy Workflow
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE coronavirus disease; radiotherapy; chest CT; workflow; PCR
C1 [Sun, Roger; Bockel, Sophie; Achkar, Samir; Rivera, Sofia; Chargari, Cyrus; Deutsch, Eric] Univ Paris Saclay, Dept Radolnerapie, Gustave Roussy, INSERM 1030, Villejuif, France.
   [Ammari, Samy] Univ Paris Saclay, Dept Imagerie Med, Gustave Roussy, Villejuif, France.
   [Merad, Mansouria] Univ Paris Saclay, Dept Oncol Med, Gustave Roussy, Villejuif, France.
   [Dercle, Laurent] Columbia Univ, Dept Radiol, Irving Med Ctr, New York, NY USA.
RP Sun, R; Deutsch, E (corresponding author), Univ Paris Saclay, Dept Radolnerapie, Gustave Roussy, INSERM 1030, Villejuif, France.
EM roger.sun@gustaveroussy.fr; eric.deutsch@gustaveroussy.fr
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Backer JA, 2020, CHINA EURO SURVEILL, V25, P5, DOI DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Benadjaoud MA, 2012, PHYS MED BIOL, V57, P7725, DOI 10.1088/0031-9155/57/22/7725
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Caraiani Cosmin, 2018, Clujul Med, V91, P293, DOI 10.15386/cjmed-931
   Chargari C, 2020, ADV RADIAT ONCOL, V5, P640, DOI 10.1016/j.adro.2020.04.034
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hermans JJR, 2020, EMERG RADIOL, V27, P641, DOI 10.1007/s10140-020-01821-1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim H, 2020, RADIOLOGY, V296, pE145, DOI 10.1148/radiol.2020201343
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Lepelletier D, 2020, J HOSP INFECT, V105, P414, DOI 10.1016/j.jhin.2020.04.036
   LI QB, 2020, LEUKEMIA 0720, DOI DOI 10.1038/S41375-020-0986-7
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Madariaga A, 2020, CLIN CANCER RES, V26, P4737, DOI 10.1158/1078-0432.CCR-20-2224
   Mettler FA, 2008, RADIOLOGY, V248, P254, DOI 10.1148/radiol.2481071451
   Minaya Flores P, 2020, PLACE TESTS SEROLOGI, P34
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Peeling RW, 2020, LANCET INFECT DIS, V20, pE245, DOI 10.1016/S1473-3099(20)30517-X
   Pereira GC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/231090
   Rubin GD, 2020, RADIOLOGY, V296, P172, DOI 10.1148/radiol.2020201365
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Smith-Bindman R, 2015, RADIOLOGY, V277, P134, DOI 10.1148/radiol.2015142728
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   Tian YH, 2021, INT J CANCER, V148, P363, DOI 10.1002/ijc.33213
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, ADV US POINT CAR IMM
   World Health Organization, 2020, NOV COR 2019 NCOV SI, P183
   Yang Yang M, 2020, EVALUATING ACCURACY, DOI [10.1101/2020.02.11.20021493, DOI 10.1101/2020.02.11.20021493]
   Zaorsky NG, 2020, ADV RADIAT ONCOL, V5, P659, DOI 10.1016/j.adro.2020.03.010
   Zhang B, 2020, IMMUNE PHENOTYPING B, V7, P157, DOI [10.1101/2020.03.12.20035048, DOI 10.1101/2020.03.12.20035048]
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 43
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 18
PY 2020
VL 10
AR 556334
DI 10.3389/fonc.2020.556334
PG 6
WC Oncology
SC Oncology
GA OZ2JJ
UT WOS:000594758500001
PM 33312944
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Lee, J
   Worrall, LJ
   Vuckovic, M
   Rosell, FI
   Gentile, F
   Ton, AT
   Caveney, NA
   Ban, F
   Cherkasov, A
   Paetzel, M
   Strynadka, NCJ
AF Lee, Jaeyong
   Worrall, Liam J.
   Vuckovic, Marija
   Rosell, Federico I.
   Gentile, Francesco
   Ton, Anh-Tien
   Caveney, Nathanael A.
   Ban, Fuqiang
   Cherkasov, Artem
   Paetzel, Mark
   Strynadka, Natalie C. J.
TI Crystallographic structure of wild-type SARS-CoV-2 main protease
   acyl-enzyme intermediate with physiological C-terminal autoprocessing
   site
SO NATURE COMMUNICATIONS
LA English
DT Article
ID X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; SUBSTRATE-BINDING; VP4 PROTEASE;
   M-PRO; SARS; COMPLEX; SCATTERING; SYSTEM; VALIDATION
AB Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the pathogen that causes the disease COVID-19, produces replicase polyproteins 1a and 1ab that contain, respectively, 11 or 16 nonstructural proteins (nsp). Nsp5 is the main protease (M-pro) responsible for cleavage at eleven positions along these polyproteins, including at its own N- and C-terminal boundaries, representing essential processing events for subsequent viral assembly and maturation. We have determined X-ray crystallographic structures of this cysteine protease in its wild-type free active site state at 1.8 angstrom resolution, in its acyl-enzyme intermediate state with the native C-terminal autocleavage sequence at 1.95 angstrom resolution and in its product bound state at 2.0 angstrom resolution by employing an active site mutation (C145A). We characterize the stereochemical features of the acyl-enzyme intermediate including critical hydrogen bonding distances underlying catalysis in the Cys/His dyad and oxyanion hole. We also identify a highly ordered water molecule in a position compatible for a role as the deacylating nucleophile in the catalytic mechanism and characterize the binding groove conformational changes and dimerization interface that occur upon formation of the acyl-enzyme. Collectively, these crystallographic snapshots provide valuable mechanistic and structural insights for future antiviral therapeutic development including revised molecular docking strategies based on M-pro inhibition. The SARS-CoV-2 main protease (M-pro) is one of two cysteine proteases essential for viral replication. Here, the authors determine the crystal structure of an M-pro acyl intermediate with its native C-terminal autocleavage sequence and the structure of a product bound active site mutant (C145A), which are of interest for antiviral drug development.
C1 [Lee, Jaeyong; Worrall, Liam J.; Vuckovic, Marija; Rosell, Federico I.; Caveney, Nathanael A.; Strynadka, Natalie C. J.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada.
   [Lee, Jaeyong; Worrall, Liam J.; Vuckovic, Marija; Rosell, Federico I.; Caveney, Nathanael A.; Strynadka, Natalie C. J.] Univ British Columbia, Ctr Blood Res, Vancouver, BC, Canada.
   [Lee, Jaeyong; Paetzel, Mark] Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC, Canada.
   [Gentile, Francesco; Ton, Anh-Tien; Ban, Fuqiang; Cherkasov, Artem] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada.
RP Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada.; Strynadka, NCJ (corresponding author), Univ British Columbia, Ctr Blood Res, Vancouver, BC, Canada.; Paetzel, M (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC, Canada.
EM mpaetzel@sfu.ca; ncjs@mail.ubc.ca
OI Caveney, Nathanael/0000-0003-4828-3479
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [ACB-12002]; National Institute of General Medical
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [AGM-12006]; DOE Office of Science by Argonne
   National LaboratoryUnited States Department of Energy (DOE)
   [DE-AC02-06CH11357]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [S10 OD012289];
   Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR)
FX We thank GM/CA beamline staff at beamline 23-ID-B at the APS for access
   and support. GM/CA@APS has been funded in whole or in part with Federal
   funds from the National Cancer Institute (ACB-12002) and the National
   Institute of General Medical Sciences (AGM-12006). This research used
   resources of the Advanced Photon Source, a U.S. Department of Energy
   (DOE) Office of Science User Facility operated for the DOE Office of
   Science by Argonne National Laboratory under Contract No.
   DE-AC02-06CH11357. The Eiger 16M detector at GM/CA-XSD was funded by NIH
   grant S10 OD012289. We thank Martin Walsh, Diamond Light Source, for
   sharing of earlier reagents and protocols. This work was funded by
   operating grants from the Canadian Institutes of Health Research to
   N.C.J.S., M.P., and A.C. N.C.J.S. is a Tier I Canada Research Chair in
   Antibiotic Discovery.
CR ALBER T, 1976, NATURE, V263, P297, DOI 10.1038/263297a0
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Bricogne G., 2017, BUSTER VERSION 2 10
   BURGI HB, 1974, TETRAHEDRON, V30, P1563, DOI 10.1016/S0040-4020(01)90678-7
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chung IYW, 2013, J BIOL CHEM, V288, P13068, DOI 10.1074/jbc.M112.386953
   Chung IYW, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.198812
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Ding XC, 2006, BIOORG CHEM, V34, P410, DOI 10.1016/j.bioorg.2006.10.002
   Douangamath A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18709-w
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Fodor K, 2006, BIOCHEMISTRY-US, V45, P2114, DOI 10.1021/bi0517133
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Goyal B, 2020, ACS COMB SCI, V22, P297, DOI 10.1021/acscombsci.0c00058
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Heinig M, 2004, NUCLEIC ACIDS RES, V32, pW500, DOI 10.1093/nar/gkh429
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Katona G, 2002, J BIOL CHEM, V277, P21962, DOI 10.1074/jbc.M200676200
   Kneller DW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16954-7
   Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779
   Lee JY, 2007, J BIOL CHEM, V282, P24928, DOI 10.1074/jbc.M701551200
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Mabonga Lloyd, 2019, Biophys Rev, V11, P559, DOI 10.1007/s12551-019-00570-x
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Paasche A, 2014, BIOCHEMISTRY-US, V53, P5930, DOI 10.1021/bi400604t
   Petoukhov MV, 2012, J APPL CRYSTALLOGR, V45, P342, DOI 10.1107/S0021889812007662
   Petoukhov MV, 2005, BIOPHYS J, V89, P1237, DOI 10.1529/biophysj.105.064154
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Strong M, 2006, P NATL ACAD SCI USA, V103, P8060, DOI 10.1073/pnas.0602606103
   Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047
   Swiderek K, 2020, CHEM SCI, V11, P10626, DOI 10.1039/d0sc02823a
   Tan JZ, 2005, J MOL BIOL, V354, P25, DOI 10.1016/j.jmb.2005.09.012
   Turlington M., DISCOVERY N BENZO 1
   Vivares D, 2005, P NATL ACAD SCI USA, V102, P18848, DOI 10.1073/pnas.0505833102
   Vuong W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18096-2
   Wilmouth RC, 1997, NAT STRUCT BIOL, V4, P456, DOI 10.1038/nsb0697-456
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Winter G, 2010, J APPL CRYSTALLOGR, V43, P186, DOI 10.1107/S0021889809045701
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 53
TC 0
Z9 0
U1 3
U2 3
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV 18
PY 2020
VL 11
IS 1
AR 5877
DI 10.1038/s41467-020-19662-4
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PA5PD
UT WOS:000595686500004
PM 33208735
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rack, JGM
   Zorzini, V
   Zhu, ZH
   Schuller, M
   Ahel, D
   Ahel, I
AF Rack, Johannes Gregor Matthias
   Zorzini, Valentina
   Zhu, Zihan
   Schuller, Marion
   Ahel, Dragana
   Ahel, Ivan
TI Viral macrodomains: a structural and evolutionary assessment of the
   pharmacological potential
SO OPEN BIOLOGY
LA English
DT Article
DE (ADP-ribosyl)hydrolase; alphavirus; antiviral
   poly(ADP-ribosyl)polymerases; coronavirus; non-structural protein 3; X
   domain
ID RESPIRATORY SYNDROME CORONAVIRUS; REVERSIBLE ADP-RIBOSYLATION;
   CHIKUNGUNYA VIRUS; MACRO DOMAIN; HOST-RANGE; REPLICATION; ALPHAVIRUS;
   RNA; NSP3; INHIBITION
AB Viral macrodomains possess the ability to counteract host ADP-ribosylation, a post-translational modification implicated in the creation of an antiviral environment via immune response regulation. This brought them into focus as promising therapeutic targets, albeit the close homology to some of the human macrodomains raised concerns regarding potential cross-reactivity and adverse effects for the host. Here, we evaluate the structure and function of the macrodomain of SARS-CoV-2, the causative agent of COVID-19. We show that it can antagonize ADP-ribosylation by PARP14, a cellular (ADP-ribosyl)transferase necessary for the restriction of coronaviral infections. Furthermore, our structural studies together with ligand modelling revealed the structural basis for poly(ADP-ribose) binding and hydrolysis, an emerging new aspect of viral macrodomain biology. These new insights were used in an extensive evolutionary analysis aimed at evaluating the druggability of viral macrodomains not only from the Coronaviridae but also Togaviridae and Iridoviridae genera (causing diseases such as Chikungunya and infectious spleen and kidney necrosis virus disease, respectively). We found that they contain conserved features, distinct from their human counterparts, which may be exploited during drug design.
C1 [Rack, Johannes Gregor Matthias; Zorzini, Valentina; Zhu, Zihan; Schuller, Marion; Ahel, Dragana; Ahel, Ivan] Univ Oxford, Sir William Dunn Sch Pathol, South Pk Rd, Oxford OX1 3RE, England.
RP Rack, JGM; Ahel, I (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, South Pk Rd, Oxford OX1 3RE, England.
EM johannes.rack@path.ox.ac.uk; ivan.ahel@path.ox.ac.uk
OI Rack, Johannes/0000-0001-8341-6439; Zorzini,
   Valentina/0000-0002-8727-309X
FU Wellcome TrustWellcome Trust [101794, 210634]; Biotechnology and
   Biological Sciences Research CouncilBiotechnology and Biological
   Sciences Research Council (BBSRC) [BB/R007195/1]; Cancer Research United
   KingdomCancer Research UK [C35050/A22284]; Edward Penley Abraham
   Research Fund
FX Work in I.A.'s laboratory was supported by Wellcome Trust (101794,
   210634); Biotechnology and Biological Sciences Research Council
   (BB/R007195/1); and Cancer Research United Kingdom (C35050/A22284). Work
   in D.A. laboratory has been funded for this work by the Edward Penley
   Abraham Research Fund. Funding for open access charge: Wellcome Trust.
CR Abraham R, 2018, P NATL ACAD SCI USA, V115, pE10457, DOI 10.1073/pnas.1812130115
   Adachi S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00811
   Alhammad YMO, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040384
   Atasheva S, 2014, J VIROL, V88, P2116, DOI 10.1128/JVI.03443-13
   Atasheva S, 2012, J VIROL, V86, P8147, DOI 10.1128/JVI.00733-12
   Barkauskaite E, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3164
   Batovska J, 2020, MICROBIOL RESOUR ANN, V9, DOI 10.1128/MRA.01476-19
   Bick MJ, 2003, J VIROL, V77, P11555, DOI 10.1128/JVI.77.21.11555-11562.2003
   Bock FJ, 2016, FEBS J, V283, P4017, DOI 10.1111/febs.13737
   Buch-Larsen SC, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108176
   Caprara G, 2018, J IMMUNOL, V200, P2439, DOI 10.4049/jimmunol.1701117
   Catara G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14156-8
   Chen D, 2011, J BIOL CHEM, V286, P13261, DOI 10.1074/jbc.M110.206771
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Crawford K, 2018, CRIT REV BIOCHEM MOL, V53, P64, DOI 10.1080/10409238.2017.1394265
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Cunningham AA, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0167
   D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249
   Daugherty MD, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004403
   Daugherty MD, 2012, ANNU REV GENET, V46, P677, DOI 10.1146/annurev-genet-110711-155522
   David KK, 2009, FRONT BIOSCI-LANDMRK, V14, P1116, DOI 10.2741/3297
   Eckei L, 2017, SCI REP-UK, V7, DOI 10.1038/srep41746
   Egloff MP, 2006, J VIROL, V80, P8493, DOI 10.1128/JVI.00713-06
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Eriksson KK, 2008, J VIROL, V82, P12325, DOI 10.1128/JVI.02082-08
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Fehr AR, 2020, GENE DEV, V34, P341, DOI 10.1101/gad.334425.119
   Fehr AR, 2018, TRENDS MICROBIOL, V26, P598, DOI 10.1016/j.tim.2017.11.011
   Fehr AR, 2016, MBIO, V7, DOI 10.1128/mBio.01721-16
   Fehr AR, 2015, J VIROL, V89, P1523, DOI 10.1128/JVI.02596-14
   Ferreira-Ramos Ana Sofia, 2020, Sci Rep, V10, P14422, DOI 10.1038/s41598-020-70870-w
   Forrester NL, 2012, J VIROL, V86, P2729, DOI 10.1128/JVI.05591-11
   Forst AH, 2013, STRUCTURE, V21, P462, DOI 10.1016/j.str.2012.12.019
   Frick DN, 2020, BIOCHEMISTRY-US, V59, P2608, DOI 10.1021/acs.biochem.0c00309
   Gaken JA, 1996, J VIROL, V70, P3992
   Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276
   Gossmann TI, 2014, DNA REPAIR, V23, P39, DOI 10.1016/j.dnarep.2014.07.005
   Gotte B, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10030105
   Grunewald ME, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007756
   Hermanns K, 2020, J GEN VIROL, V101, P96, DOI 10.1099/jgv.0.001344
   Hermanns K, 2017, J GEN VIROL, V98, P43, DOI 10.1099/jgv.0.000694
   Jankevicius G, 2013, NAT STRUCT MOL BIOL, V20, P508, DOI 10.1038/nsmb.2523
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Katoh K, 2010, BIOINFORMATICS, V26, P1899, DOI 10.1093/bioinformatics/btq224
   Keep S, 2018, J GEN VIROL, V99, P1097, DOI 10.1099/jgv.0.001098
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Kuri T, 2011, J GEN VIROL, V92, P1899, DOI 10.1099/vir.0.031856-0
   Lambrecht MJ, 2015, J AM CHEM SOC, V137, P3558, DOI 10.1021/ja512528p
   Le Sage V, 2017, VIROLOGY, V502, P73, DOI 10.1016/j.virol.2016.12.012
   Le SQ, 2008, MOL BIOL EVOL, V25, P1307, DOI 10.1093/molbev/msn067
   Lehtio L, 2013, FEBS J, V280, P3576, DOI 10.1111/febs.12320
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li CQ, 2016, J VIROL, V90, P8478, DOI 10.1128/JVI.00705-16
   Li LL, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aas9332
   Li Z, 2012, J VIROL, V86, P492, DOI 10.1128/JVI.05897-11
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Lin Meng-Hsuan, 2020, ACS Infect Dis, V6, P2970, DOI 10.1021/acsinfecdis.0c00441
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P14048, DOI 10.1073/pnas.1509745112
   LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745
   Ljungberg JK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02521
   Luscher B, 2018, CHEM REV, V118, P216, DOI 10.1021/acs.chemrev.7b00122
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Malet H, 2009, J VIROL, V83, P6534, DOI 10.1128/JVI.00189-09
   Mariotti L, 2017, BRIT J PHARMACOL, V174, P4611, DOI 10.1111/bph.14038
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McPherson RL, 2017, P NATL ACAD SCI USA, V114, P1666, DOI 10.1073/pnas.1621485114
   Michalska K, 2020, IUCRJ, V7, P814, DOI 10.1107/S2052252520009653
   Mitchell AL, 2020, NUCLEIC ACIDS RES, V48, pD570, DOI 10.1093/nar/gkz1035
   Muller S, 2007, J VIROL, V81, P2391, DOI 10.1128/JVI.01601-06
   Munnur D, 2019, NUCLEIC ACIDS RES, V47, P5658, DOI 10.1093/nar/gkz305
   Nasar F, 2012, P NATL ACAD SCI USA, V109, P14622, DOI 10.1073/pnas.1204787109
   Nei M., 2000, MOL EVOLUTION PHYLOG
   Palazzo L, 2017, FEBS J, V284, P2932, DOI 10.1111/febs.14078
   Parent M, 2005, J BIOL CHEM, V280, P448, DOI 10.1074/jbc.M408435200
   Park E, 2009, VIROLOGY, V388, P305, DOI 10.1016/j.virol.2009.03.031
   Parvez MK, 2015, GENE, V566, P47, DOI 10.1016/j.gene.2015.04.026
   Perina D, 2014, DNA REPAIR, V23, P4, DOI 10.1016/j.dnarep.2014.05.003
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Potterton L, 2018, ACTA CRYSTALLOGR D, V74, P68, DOI 10.1107/S2059798317016035
   Putics A, 2005, J VIROL, V79, P12721, DOI 10.1128/JVI.79.20.12721-12731.2005
   Rack JGM, 2020, GENE DEV, V34, P263, DOI 10.1101/gad.334631.119
   Rack JGM, 2018, CELL CHEM BIOL, V25, P1533, DOI 10.1016/j.chembiol.2018.11.001
   Rack JGM, 2016, ANNU REV BIOCHEM, V85, P431, DOI 10.1146/annurev-biochem-060815-014935
   Rehman SU, 2020, PATHOGENS, V9, DOI [10.3390/pathogens9030240, 10.19045/bspab.2020.90001]
   Robinson M, 2018, CELL MOL LIFE SCI, V75, P3693, DOI 10.1007/s00018-018-2882-0
   Roy S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8010008
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Sharifi R, 2013, EMBO J, V32, P1225, DOI 10.1038/emboj.2013.51
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Slade D, 2011, NATURE, V477, P616, DOI 10.1038/nature10404
   Tang QN, 2017, J VIROL, V91, DOI 10.1128/JVI.01909-16
   Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888
   Torii S, 2018, VIRUS RES, V250, P31, DOI 10.1016/j.virusres.2018.04.005
   Vyas S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5426
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wild R, 2017, PROTEIN SCI, V26, P365, DOI 10.1002/pro.3073
   Winter G, 2013, ACTA CRYSTALLOGR D, V69, P1260, DOI 10.1107/S0907444913015308
   Wong ACP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020174
   Woolhouse MEJ, 2001, SCIENCE, V292, P1109, DOI 10.1126/science.1059026
   Woolhouse MEJ, 2005, EMERG INFECT DIS, V11, P1842, DOI 10.3201/eid1112.050997
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Zapata-Perez R, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.160327
   Zhang Y, 2015, NAT IMMUNOL, V16, P1215, DOI 10.1038/ni.3279
NR 104
TC 0
Z9 0
U1 3
U2 3
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
EI 2046-2441
J9 OPEN BIOL
JI Open Biol
PD NOV 18
PY 2020
VL 10
IS 11
AR 200237
DI 10.1098/rsob.200237
PG 21
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OZ9WO
UT WOS:000595269300001
PM 33202171
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gill, D
   Arvanitis, M
   Carter, P
   Cordero, AIH
   Jo, B
   Karhunen, V
   Larsson, SC
   Li, X
   Lockhart, SM
   Mason, A
   Pashos, E
   Saha, A
   Tan, VY
   Zuber, V
   Bosse, Y
   Fahle, S
   Hao, K
   Jiang, T
   Joubert, P
   Lunt, AC
   Ouwehand, WH
   Roberts, DJ
   Timens, W
   van den Berge, M
   Watkins, NA
   Battle, A
   Butterworth, AS
   Danesh, J
   Di Angelantonio, E
   Engelhardt, BE
   Peters, JE
   Sin, DD
   Burgess, S
AF Gill, Dipender
   Arvanitis, Marios
   Carter, Paul
   Cordero, Ana I. Hernandez
   Jo, Brian
   Karhunen, Ville
   Larsson, Susanna C.
   Li, Xuan
   Lockhart, Sam M.
   Mason, Amy
   Pashos, Evanthia
   Saha, Ashis
   Tan, Vanessa Y.
   Zuber, Verena
   Bosse, Yohan
   Fahle, Sarah
   Hao, Ke
   Jiang, Tao
   Joubert, Philippe
   Lunt, Alan C.
   Ouwehand, Willem Hendrik
   Roberts, David J.
   Timens, Wim
   van den Berge, Maarten
   Watkins, Nicholas A.
   Battle, Alexis
   Butterworth, Adam S.
   Danesh, John
   Di Angelantonio, Emanuele
   Engelhardt, Barbara E.
   Peters, James E.
   Sin, Don D.
   Burgess, Stephen
TI ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2
   gene expression, and plasma ACE2 levels: a Mendelian randomization study
SO ROYAL SOCIETY OPEN SCIENCE
LA English
DT Article
DE COVID-19; Mendelian randomization; angiotensin-converting enzyme
   inhibitors; genetic epidemiology
ID CONVERTING ENZYME 2; HYPERTENSIVE PATIENTS; SARS CORONAVIRUS;
   HEART-FAILURE; RECEPTOR; MODULATION; CARDIOMYOPATHY; OLMESARTAN;
   OUTCOMES
AB Angiotensin-converting enzyme 2 (ACE2) and serine protease TMPRSS2 have been implicated in cell entry for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). The expression of ACE2 and TMPRSS2 in the lung epithelium might have implications for the risk of SARS-CoV-2 infection and severity of COVID-19. We use human genetic variants that proxy angiotensin-converting enzyme (ACE) inhibitor drug effects and cardiovascular risk factors to investigate whether these exposures affect lung ACE2 and TMPRSS2 gene expression and circulating ACE2 levels. We observed no consistent evidence of an association of genetically predicted serum ACE levels with any of our outcomes. There was weak evidence for an association of genetically predicted serum ACE levels with ACE2 gene expression in the Lung eQTL Consortium (p = 0.014), but this finding did not replicate. There was evidence of a positive association of genetic liability to type 2 diabetes mellitus with lung ACE2 gene expression in the Gene-Tissue Expression (GTEx) study (p = 4 x 10(-4)) and with circulating plasma ACE2 levels in the INTERVAL study (p = 0.03), but not with lung ACE2 expression in the Lung eQTL Consortium study (p = 0.68). There were no associations of genetically proxied liability to the other cardiometabolic traits with any outcome. This study does not provide consistent evidence to support an effect of serum ACE levels (as a proxy for ACE inhibitors) or cardiometabolic risk factors on lung ACE2 and TMPRSS2 expression or plasma ACE2 levels.
C1 [Gill, Dipender; Karhunen, Ville; Zuber, Verena; Lunt, Alan C.] Imperial Coll London, St Marys Hosp, Dept Epidemiol & Biostatist, Med Sch Bldg, London, England.
   [Arvanitis, Marios] Johns Hopkins Univ, Div Cardiol, Dept Med, Baltimore, MD USA.
   [Saha, Ashis] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD USA.
   [Battle, Alexis] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA.
   [Battle, Alexis] Johns Hopkins Univ, Ctr Computat Biol, Baltimore, MD USA.
   [Carter, Paul] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
   [Lockhart, Sam M.; Burgess, Stephen] Univ Cambridge, Med Res Council, Wellcome Trust Med Res Council Inst Metab Sci, Metab Dis Unit, Cambridge, England.
   [Mason, Amy; Fahle, Sarah; Jiang, Tao; Butterworth, Adam S.; Danesh, John; Di Angelantonio, Emanuele; Burgess, Stephen] Univ Cambridge, Dept Publ Hlth & Primary Care, British Heart Fdn, Cardiovasc Epidemiol Unit, Cambridge, England.
   [Zuber, Verena; Burgess, Stephen] Univ Cambridge, Cambridge Inst Publ Hlth, Med Res Council, Biostat Unit, Cambridge, England.
   [Fahle, Sarah; Roberts, David J.; Watkins, Nicholas A.; Butterworth, Adam S.; Danesh, John; Di Angelantonio, Emanuele] Univ Cambridge, Natl Inst Hlth Res, Blood & Transplant Res Unit Donor Hlth & Genom, Cambridge, England.
   [Butterworth, Adam S.; Danesh, John; Di Angelantonio, Emanuele; Burgess, Stephen] Univ Cambridge, British Heart Fdn Ctr Res Excellence, Cambridge, England.
   [Burgess, Stephen] Univ Cambridge, Homerton Coll, Cambridge, England.
   [Cordero, Ana I. Hernandez; Li, Xuan; Sin, Don D.] Univ British Columbia, St Pauls Hosp, Ctr Heart Lung Innovat, Vancouver, BC, Canada.
   [Jo, Brian] Lewis Sigler Inst Integrat Biol, Program Quantitat & Computat Biol, Princeton, NJ USA.
   [Larsson, Susanna C.] Karolinska Inst, Unit Cardiovasc & Nutr Epidemiol, Inst Environm Med, Stockholm, Sweden.
   [Larsson, Susanna C.] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden.
   [Mason, Amy; Fahle, Sarah; Butterworth, Adam S.; Danesh, John; Di Angelantonio, Emanuele; Burgess, Stephen] Uppsala Univ, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England.
   [Mason, Amy; Fahle, Sarah; Butterworth, Adam S.; Danesh, John; Di Angelantonio, Emanuele; Burgess, Stephen] Cambridge Univ Hosp, Cambridge, England.
   [Pashos, Evanthia] Pfizer Worldwide Res Dev & Med, Internal Med Res Unit, Cambridge, MA USA.
   [Tan, Vanessa Y.] Univ Bristol, Med Res Council Integrat Epidemiol Unit, Bristol, Avon, England.
   [Tan, Vanessa Y.] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England.
   [Bosse, Yohan; Joubert, Philippe] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Laval, PQ, Canada.
   [Hao, Ke] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Icahn Inst Data Sci & Genom Technol, New York, NY 10029 USA.
   [Ouwehand, Willem Hendrik] Univ Cambridge, Dept Haematol, Cambridge Biomed Campus, Cambridge, England.
   NHS Blood & Transplant, Biomed Campus, Cambridge, England.
   Wellcome Sanger Inst, Cambridge, England.
   [Roberts, David J.] NHS Blood & Transplant Oxford Ctr, John Radcliffe Hosp, Level 2, Oxford, England.
   [Roberts, David J.] Univ Oxford, John Radcliffe Hosp, Radcliffe Dept Med, Oxford, England.
   [Timens, Wim] Univ Groningen, Dept Pathol & Med Biol, Groningen, Netherlands.
   [van den Berge, Maarten] Univ Groningen, Groningen Res Inst Asthma, Groningen, Netherlands.
   [van den Berge, Maarten] Univ Groningen, COPD, Groningen, Netherlands.
   [van den Berge, Maarten] Univ Groningen, Dept Pulmonol, Groningen, Netherlands.
   [van den Berge, Maarten] Univ Groningen, Groningen Res Inst Asthma, Groningen, Netherlands.
   [van den Berge, Maarten] Univ Groningen, COPD, Groningen, Netherlands.
   [Butterworth, Adam S.; Danesh, John; Di Angelantonio, Emanuele; Peters, James E.] Wellcome Genome Campus, Hlth Data Res UK Cambridge, Cambridge, England.
   [Butterworth, Adam S.; Danesh, John; Di Angelantonio, Emanuele; Peters, James E.] Univ Cambridge, Cambridge, England.
   [Engelhardt, Barbara E.] Princeton Univ, Comp Sci Dept, Princeton, NJ 08544 USA.
   [Engelhardt, Barbara E.] Princeton Univ, Ctr Stat & Machine Learning, Princeton, NJ 08544 USA.
   [Peters, James E.] Imperial Coll London, Dept Immunol & Inflammat, Fac Med, London, England.
   [Lunt, Alan C.] Cambridge Inst Publ Hlth, MRC Biostat Unit, Robinson Way, Cambridge CB2 0SR, England.
RP Burgess, S (corresponding author), Univ Cambridge, Med Res Council, Wellcome Trust Med Res Council Inst Metab Sci, Metab Dis Unit, Cambridge, England.; Burgess, S (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, British Heart Fdn, Cardiovasc Epidemiol Unit, Cambridge, England.; Burgess, S (corresponding author), Univ Cambridge, Cambridge Inst Publ Hlth, Med Res Council, Biostat Unit, Cambridge, England.; Burgess, S (corresponding author), Univ Cambridge, British Heart Fdn Ctr Res Excellence, Cambridge, England.; Burgess, S (corresponding author), Univ Cambridge, Homerton Coll, Cambridge, England.; Burgess, S (corresponding author), Uppsala Univ, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England.
EM sb452@medschl.cam.ac.uk
FU British Heart FoundationCentre of Research ExcellenceBritish Heart
   Foundation [203928/Z/16/Z]; Wellcome TrustWellcome Trust
   [RE/18/4/34215]; Royal SocietyRoyal Society of London [204623/Z/16/Z];
   NIHR Blood and Transplant Research Unit in Donor Health and Genomics; UK
   Medical Research CouncilMedical Research Council UK (MRC) [NIHR
   BTRU-2014-10024]; British Heart FoundationBritish Heart Foundation; NIHR
   (Cambridge Biomedical Research Centre at the Cambridge University
   Hospitals NHS Foundation Trust), and Health Data Research UK - NIHR
   Blood and Transplant Research Unit in Donor Health and Genomics
   [SP/09/002, RG/13/13/30194, RG/18/13/33946]; British Heart Foundation
   Professorship [NIHR BTRU-2014-10024]; National Institute for Health
   Research Senior Investigator Award - Swedish Heart-Lung Foundation;
   Swedish Research CouncilSwedish Research Council; Swedish Research
   Council for Health, Working Life and Welfare - European Union's Horizon
   2020 research and innovation programme under the Marie Sklodowska-Curie
   grant [721567]; Cancer Research UK (CRUK) Integrative Cancer
   Epidemiology Programme; Academic Clinical Fellowship from the NIHR
   [C18281/A19169]; Canada Research Chair in Genomics of Heart and Lung
   Diseases; UKRI Innovation Fellowship at Health Data Research UK
   [MR/S004068/1]; National Institute for Health Research [Cambridge
   Biomedical Research Centre at the Cambridge University Hospitals NHS
   Foundation Trust] - European Council Innovative Medicines Initiative
   (BigData@Heart); Health Data Research UK - UK Medical Research Council,
   Engineering and Physical Sciences Research Council; Economic and Social
   Research Council, Department of Health and Social Care (England), Chief
   Scientist Office of the Scottish Government Health and Social Care
   Directorates, Health and Social Care Research and Development Division
   (Welsh Government); Public Health Agency (Northern Ireland); Wellcome
   Trust - National Institute for Health Research (NIHR); NIHR (Cambridge
   Biomedical Research Centre at the Cambridge University Hospitals NHS
   Foundation Trust) - Leidos Biomedical, Inc. (Leidos) [10XS170]; Roswell
   Park Cancer Institute; Leidos [10XS171, HHSN268201000029C, 10ST1035]; 
   [HHSN261200800001E]
FX D.G. is supported by theWellcome Trust 4i Programme (203928/Z/16/Z) and
   British Heart FoundationCentre of Research Excellence (RE/18/4/34215) at
   Imperial College London. S.B. is supported by a Sir Henry Dale
   Fellowship jointly funded by the Wellcome Trust and the Royal Society
   (award no. 204623/Z/16/Z). The academic coordinating centre for INTERVAL
   at Cambridge University was supported by core funding from: NIHR Blood
   and Transplant Research Unit in Donor Health and Genomics (NIHR
   BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British
   Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and the
   NIHR (Cambridge Biomedical Research Centre at the Cambridge University
   Hospitals NHS Foundation Trust), and Health Data Research UK. S.F. is
   funded by the NIHR Blood and Transplant Research Unit in Donor Health
   and Genomics (NIHR BTRU-2014-10024). J.D. holds a British Heart
   Foundation Professorship and a National Institute for Health Research
   Senior Investigator Award. S.C.L. is funded by the Swedish Heart-Lung
   Foundation, the Swedish Research Council and the Swedish Research
   Council for Health, Working Life and Welfare. V.K. is funded by a
   European Union's Horizon 2020 research and innovation programme under
   the Marie Sklodowska-Curie grant no. 721567. V.Y.T. is supported by the
   Cancer Research UK (CRUK) Integrative Cancer Epidemiology Programme
   (C18281/A19169). S.M.L. is supported by an Academic Clinical Fellowship
   from the NIHR. Y.B. holds a Canada Research Chair in Genomics of Heart
   and Lung Diseases. J.E.P. is supported by a UKRI Innovation Fellowship
   at Health Data Research UK (MR/S004068/1). T.J. is funded by the
   National Institute for Health Research [Cambridge Biomedical Research
   Centre at the Cambridge University Hospitals NHS Foundation Trust].
   A.M.M. is funded by the European Council Innovative Medicines Initiative
   (BigData@Heart).This work was supported by Health Data Research UK,
   which is funded by the UK Medical Research Council, Engineering and
   Physical Sciences Research Council, Economic and Social Research
   Council, Department of Health and Social Care (England), Chief Scientist
   Office of the Scottish Government Health and Social Care Directorates,
   Health and Social Care Research and Development Division (Welsh
   Government), Public Health Agency (Northern Ireland), British Heart
   Foundation and the Wellcome Trust. DNA extraction and genotyping was
   co-funded by the National Institute for Health Research (NIHR), the NIHR
   BioResource (http://bioresource.nihr.ac.uk) and the NIHR (Cambridge
   Biomedical Research Centre at the Cambridge University Hospitals NHS
   Foundation Trust). Donors were enrolled at Biospecimen Source Sites
   funded by Leidos Biomedical, Inc. (Leidos) subcontracts to the National
   Disease Research Interchange (10XS170) and Roswell Park Cancer Institute
   (10XS171). The Laboratory, Data Analysis and Coordinating Center (LDACC)
   was funded through a contract (HHSN268201000029C) to The Broad
   Institute, Inc. Biorepository operations were funded through a Leidos
   subcontract to Van Andel Institute (10ST1035). Additional data
   repository and project management provided by Leidos
   (HHSN261200800001E).
CR Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   [Anonymous], 1998, Circulation, V97, P2202
   Bavishi C, 2020, JAMA CARDIOL, V5, P745, DOI 10.1001/jamacardio.2020.1282
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Burgess S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14156-4
   Burgess S, 2016, STAT MED, V35, P1880, DOI 10.1002/sim.6835
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Burgess S, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7325
   Carter AR, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1855
   Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6
   Davey Smith G, 2019, PEERJ PREPR, V7, P1
   Del Greco MF, 2015, STAT MED, V34, P2926, DOI 10.1002/sim.6522
   Di Angelantonio E, 2017, LANCET, V390, P2360, DOI 10.1016/S0140-6736(17)31928-1
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Evangelou E, 2018, NAT GENET, V50, P1412, DOI 10.1038/s41588-018-0205-x
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Gill D, 2019, CIRCULATION, V140, P270, DOI 10.1161/CIRCULATIONAHA.118.038814
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Halliday BP, 2019, LANCET, V393, P61, DOI 10.1016/S0140-6736(18)32484-X
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9
   Klimas J, 2015, J CELL MOL MED, V19, P1965, DOI 10.1111/jcmm.12573
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Leung JM, 2020, 2020031820038455 MED, DOI [10.1101/2020.03.18.20038455, DOI 10.1101/2020.03.18.20038455]
   Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6
   Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Nielsen SF, 2016, EUR HEART J, V37, P908, DOI 10.1093/eurheartj/ehv641
   Ocaranza MP, 2006, HYPERTENSION, V48, P572, DOI 10.1161/01.HYP.0000237862.94083.45
   PFLUGFELDER PW, 1993, J AM COLL CARDIOL, V22, P1557, DOI 10.1016/0735-1097(93)90578-O
   Pigeyre M, 2020, DIABETES CARE, V43, P835, DOI 10.2337/dc19-1973
   Pinto Bruna G G, 2020, medRxiv, DOI 10.1101/2020.03.21.20040261
   Ponsford MJ, 2020, CIRCULATION, V142, P1791, DOI 10.1161/CIRCULATIONAHA.120.050753
   Pulit SL, 2019, HUM MOL GENET, V28, P166, DOI 10.1093/hmg/ddy327
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sakornsakolpat P, 2019, NAT GENET, V51, P494, DOI 10.1038/s41588-018-0342-2
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Soler MJ, 2009, AM J PHYSIOL-RENAL, V296, pF398, DOI 10.1152/ajprenal.90488.2008
   Sommerstein R, 2020, BMJ
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Soro-Paavonen A, 2012, J HYPERTENS, V30, P375, DOI 10.1097/HJH.0b013e32834f04b6
   Stegle O, 2012, NAT PROTOC, V7, P500, DOI 10.1038/nprot.2011.457
   Sukumaran V, 2017, BIOCHEM PHARMACOL, V144, P90, DOI 10.1016/j.bcp.2017.07.022
   Sukumaran V, 2012, FREE RADICAL RES, V46, P850, DOI 10.3109/10715762.2012.684878
   Sukumaran V, 2011, INT J BIOL SCI, V7, P1077, DOI 10.7150/ijbs.7.1077
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797
   Wootton RE, 2020, PSYCHOL MED, V50, P2435, DOI 10.1017/S0033291719002678
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang G, 2020, ANGIOTENSIN 2 RECEPT, DOI [10.1101/2020.03.31.20038935, DOI 10.1101/2020.03.31.20038935]
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhong JC, 2011, REGUL PEPTIDES, V166, P90, DOI 10.1016/j.regpep.2010.09.005
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 72
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 2054-5703
J9 ROY SOC OPEN SCI
JI R. Soc. Open Sci.
PD NOV 18
PY 2020
VL 7
IS 11
AR 200958
DI 10.1098/rsos.200958
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PA2LW
UT WOS:000595466300001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Kocas, BB
   Cetinkal, G
   Ser, OS
   Kilci, H
   Keskin, K
   Ozcan, SN
   Verdi, Y
   Zeren, MI
   Kilickesmez, K
AF Balaban Kocas, Betul
   Cetinkal, Gokhan
   Ser, Ozgur Selim
   Kilci, Hakan
   Keskin, Kudret
   Ozcan, Safiye Nur
   Verdi, Yildiz
   Zeren, Mustafa Ismet
   Kilickesmez, Kadriye
TI The relation between left ventricular global longitudinal strain and
   troponin levels in patients hospitalized with COVID-19 pneumonia
SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING
LA English
DT Article; Early Access
DE COVID-19; 2D speckle tracking echocardiography; Left ventricular global
   longitudinal strain; High sensitive troponin
ID ECHOCARDIOGRAPHY
AB Left ventricular global longitudinal strain (LVGLS) from two-dimensional speckle-tracking echocardiography (2D-STE) provides a more accurate estimation of subclinical myocardial dysfunction. In patients with COVID-19, elevated high sensitive troponin (hs-TnI) levels are frequent independent from the underlying cardiovascular disease. However, the relationship between high troponin levels and LVGLS in such patients remains unknown. We aimed to investigate the relation between troponin levels and LVGLS values in patients with COVID-19. A total of thirty-eight patients diagnosed with COVID-19 pneumonia who underwent echocardiography examination within the first week of hospital admission were enrolled in our study. Patients were divided into two groups according to their hs-TnI levels. Conventional left venticular (LV) function parameters, including ejection fraction, LV diastolic and systolic volumes were obtained and LVGLS was determined using 2D-STE. Frequency of hypertension, diabetes mellitus and current smoking were similar among groups. Compared with the patients in the negative troponin group, those in the positive troponin group were more likely to have a higher age; higher levels of D-dimer, C-reactive protein and ferritin; higher need for high-flow oxygen, invasive mechanical ventilation therapy or both; and a higher number of intensive care unit admissions. There was no statistically significant difference in LVGLS and ejection fraction values between the two groups.(- 18.5 +/- 2.9, - 19.8 +/- 2.8, p = 0.19; 55.2 +/- 9.9, 59.5 +/- 5.9, p = 0.11 respectively). Despite troponin increase is highly related to in-hospital adverse events; no relevance was found between troponin increase and LVGLS values of COVID-19 patients.
C1 [Balaban Kocas, Betul; Cetinkal, Gokhan; Ser, Ozgur Selim; Kilci, Hakan; Keskin, Kudret; Kilickesmez, Kadriye] Sisli Hamidiye Etfal Educ & Res Hosp, Dept Cardiol, TR-34360 Istanbul, Turkey.
   [Ozcan, Safiye Nur; Verdi, Yildiz; Zeren, Mustafa Ismet] Sisli Hamidiye Etfal Educ & Res Hosp, Dept Infect Dis & Microbiol, Istanbul, Turkey.
RP Kocas, BB (corresponding author), Sisli Hamidiye Etfal Educ & Res Hosp, Dept Cardiol, TR-34360 Istanbul, Turkey.
EM betulbalaban@yahoo.com
RI Cetinkal, Gokhan/AAC-4263-2020
OI Cetinkal, Gokhan/0000-0001-5291-0645
CR Azizi MS, 2020, ACTA MED INDONES, V52, P47
   Deng Q, 2020, INT J CARDIOL, V311, P116, DOI 10.1016/j.ijcard.2020.03.087
   Feihl F, 2009, CURR HYPERTENS REP, V11, P182, DOI 10.1007/s11906-009-0033-6
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jia GH, 2016, NAT REV ENDOCRINOL, V12, P144, DOI 10.1038/nrendo.2015.216
   Jung In Hyun, 2020, J Cardiovasc Imaging, V28, P137, DOI 10.4250/jcvi.2019.0111
   Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003
   Li YM, 2020, JACC-CARDIOVASC IMAG, V13, P2287, DOI 10.1016/j.jcmg.2020.04.014
   Lyngbakken MN, 2020, CLIN CHEM, V66, P567, DOI 10.1093/clinchem/hvaa023
   Marwick TH, 2009, JACC-CARDIOVASC IMAG, V2, P80, DOI 10.1016/j.jcmg.2007.12.007
   Mu YM, 2010, ECHOCARDIOGR-J CARD, V27, P146, DOI 10.1111/j.1540-8175.2009.00984.x
   Potter E, 2018, JACC-CARDIOVASC IMAG, V11, P260, DOI 10.1016/j.jcmg.2017.11.017
   Roos CJ, 2014, EUR HEART J-CARD IMG, V15, P41, DOI 10.1093/ehjci/jet075
   Sanfilippo F, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2113-y
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhou B, 2020, J INFECTION, V81, P168, DOI 10.1016/j.jinf.2020.03.021
   Zoroufian A, 2014, ECHOCARDIOGR-J CARD, V31, P456, DOI 10.1111/echo.12389
NR 19
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1569-5794
EI 1573-0743
J9 INT J CARDIOVAS IMAG
JI Int. J. Cardiovasc. Imaging
DI 10.1007/s10554-020-02102-1
EA NOV 2020
PG 9
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
   Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
   Medical Imaging
GA OS9XM
UT WOS:000590509500001
PM 33206248
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Fu, WY
   Chen, YJA
   Wang, KD
   Hettinghouse, A
   Hu, WH
   Wang, JQ
   Lei, ZN
   Chen, ZS
   Stapleford, KA
   Liu, CJ
AF Fu, Wenyu
   Chen, Yujianan
   Wang, Kaidi
   Hettinghouse, Aubryanna
   Hu, Wenhuo
   Wang, Jing-Quan
   Lei, Zi-Ning
   Chen, Zhe-Sheng
   Stapleford, Kenneth A.
   Liu, Chuan-ju
TI Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based
   screening for the inhibition of RBD/ACE2 interaction
SO PROTEIN & CELL
LA English
DT Letter; Early Access
ID N-ACETYLCYSTEINE; VITAMIN-D; COVID-19
C1 [Fu, Wenyu; Chen, Yujianan; Wang, Kaidi; Hettinghouse, Aubryanna; Liu, Chuan-ju] NYU, Med Ctr, Dept Orthopaed Surg, 301 East 17th St, New York, NY 10003 USA.
   [Hu, Wenhuo] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
   [Wang, Jing-Quan; Lei, Zi-Ning; Chen, Zhe-Sheng] St Johns Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, New York, NY 11439 USA.
   [Stapleford, Kenneth A.] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.
   [Liu, Chuan-ju] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.
RP Liu, CJ (corresponding author), NYU, Med Ctr, Dept Orthopaed Surg, 301 East 17th St, New York, NY 10003 USA.; Stapleford, KA (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.; Liu, CJ (corresponding author), NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.
EM Kenneth.Stapleford@nyulangone.org; chuanju.liu@nyumc.org
OI Stapleford, Kenneth/0000-0002-7796-2254; liu,
   chuanju/0000-0002-7181-8032
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01AR062207, R01AR061484, R01NS103931,
   R01AR076900]
FX This work was supported partly by NIH research grants R01AR062207,
   R01AR061484, R01NS103931, and R01AR076900 (CJ Liu).
CR Castaneda-Arriaga R, 2018, ACS OMEGA, V3, P18582, DOI 10.1021/acsomega.8b02943
   DeFlora S, 1997, EUR RESPIR J, V10, P1535, DOI 10.1183/09031936.97.10071535
   Geiler J, 2010, BIOCHEM PHARMACOL, V79, P413, DOI 10.1016/j.bcp.2009.08.025
   Ghezzi P, 2004, INT J IMMUNOPATH PH, V17, P99, DOI 10.1177/039463200401700114
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Gu C, 2020, POTENT ANTIVIRAL EFF
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Mitchell F, 2020, LANCET DIABETES ENDO, V8, P570, DOI 10.1016/S2213-8587(20)30183-2
   Nolin TD, 2010, CLIN J AM SOC NEPHRO, V5, P1588, DOI 10.2215/CJN.00210110
   Poe FL, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109862
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Zemb P, 2020, J GLOB ANTIMICROB RE, V22, P133, DOI 10.1016/j.jgar.2020.05.006
   Zhang C, 2019, JOVE-J VIS EXP, DOI 10.3791/59656
NR 15
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1674-800X
EI 1674-8018
J9 PROTEIN CELL
JI Protein Cell
DI 10.1007/s13238-020-00803-w
EA NOV 2020
PG 6
WC Cell Biology
SC Cell Biology
GA OS9XW
UT WOS:000590510500001
PM 33210243
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liang, Y
   Li, H
   Li, J
   Yang, ZN
   Li, JL
   Zheng, HW
   Chen, YL
   Shi, HJ
   Guo, L
   Liu, LD
AF Liang, Yan
   Li, Heng
   Li, Jing
   Yang, Ze-Ning
   Li, Jia-Li
   Zheng, Hui-Wen
   Chen, Yan-Li
   Shi, Hai-Jing
   Guo, Lei
   Liu, Long-Ding
TI Role of neutrophil chemoattractant CXCL5 in SARS-CoV-2 infection-induced
   lung inflammatory innate immune response in an in vivo hACE2
   transfection mouse model
SO ZOOLOGICAL RESEARCH
LA English
DT Article
DE SARS-CoV-2; Mouse model; Lung infection; ACE2; Neutrophil; CXCL5
ID PULMONARY HOST-DEFENSE; FUNCTIONAL-CHARACTERIZATION; CORONAVIRUS; SARS;
   PATHOGENESIS; RECRUITMENT; EXPRESSION
AB Understanding the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clarifying antiviral immunity in hosts are critical aspects for the development of vaccines and antivirals. Mice are frequently used to generate animal models of infectious diseases due to their convenience and ability to undergo genetic manipulation. However, normal adult mice are not susceptible to SARS-CoV-2. Here, we developed a viral receptor (human angiotensin-converting enzyme 2, hACE2) pulmonary transfection mouse model to establish SARS-CoV-2 infection rapidly in the mouse lung. Based on the model, the virus successfully infected the mouse lung 2 days after transfection. Viral RNA/protein, innate immune cell infiltration, inflammatory cytokine expression, and pathological changes in the infected lungs were observed after infection. Further studies indicated that neutrophils were the first and most abundant leukocytes to infiltrate the infected lungs after viral infection. In addition, using infected CXCL5-knockout mice, chemokine CXCL5 was responsible for neutrophil recruitment. CXCL5 knockout decreased lung inflammation without diminishing viral clearance, suggesting a potential target for controlling pneumonia.
C1 [Liang, Yan; Li, Heng; Li, Jing; Yang, Ze-Ning; Li, Jia-Li; Zheng, Hui-Wen; Chen, Yan-Li; Shi, Hai-Jing; Guo, Lei; Liu, Long-Ding] Chinese Acad Med Sci, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China.
RP Guo, L; Liu, LD (corresponding author), Chinese Acad Med Sci, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China.
EM shried@163.com; longdingl@gmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82041017]; Chinese Academy of Medical
   Sciences (CAMS) Innovation Fund for Medical Sciences [2016-I2M-1-014]
FX This work was supported by the National Natural Science Foundation of
   China (82041017) and Chinese Academy of Medical Sciences (CAMS)
   Innovation Fund for Medical Sciences (2016-I2M-1-014)
CR BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
   Balamayooran G, 2012, AM J RESP CELL MOL, V47, P104, DOI 10.1165/rcmb.2011-0260OC
   Balamayooran G, 2010, AM J RESP CELL MOL, V43, P5, DOI 10.1165/rcmb.2009-0047TR
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chen SC, 2001, J IMMUNOL, V166, P3362, DOI 10.4049/jimmunol.166.5.3362
   Das S, 2013, JOVE-J VIS EXP, DOI 10.3791/50318
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   DRISCOLL KE, 1995, J LEUKOCYTE BIOL, V58, P359
   FREVERT CW, 1995, J IMMUNOL, V154, P335
   Guo L, 2017, MUCOSAL IMMUNOL, V10, P1529, DOI 10.1038/mi.2017.1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu SY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00269-6
   Lukacs N W, 1999, Chem Immunol, V72, P102, DOI 10.1159/000058729
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Mei JJ, 2010, IMMUNITY, V33, P106, DOI 10.1016/j.immuni.2010.07.009
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Puneet P, 2005, AM J PHYSIOL-LUNG C, V288, pL3, DOI 10.1152/ajplung.00405.2003
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Shan C, 2020, CELL RES, V30, P670, DOI 10.1038/s41422-020-0364-z
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Song TZ, 2020, ZOOL RES, V41, P503, DOI 10.24272/j.issn.2095-8137.2020.202
   Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010
   Tate MD, 2009, J IMMUNOL, V183, P7441, DOI 10.4049/jimmunol.0902497
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   Xu L, 2020, ZOOL RES, V41, P517, DOI 10.24272/j.issn.2095-8137.2020.053
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Zhang YN, 2020, CELL RES, V30, P1046, DOI 10.1038/s41422-020-00405-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 35
TC 0
Z9 0
U1 1
U2 1
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 2095-8137
J9 ZOOL RES
JI Zool. Res.
PD NOV 18
PY 2020
VL 41
IS 6
BP 621
EP +
DI 10.24272/j.issn.2095-8137.2020.118
PG 14
WC Zoology
SC Zoology
GA OR4FV
UT WOS:000589429200003
PM 33045777
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU de Andrade, J
   Goncalves, PFB
   Netz, PA
AF de Andrade, Jones
   Goncalves, Paulo Fernando Bruno
   Netz, Paulo Augusto
TI Why Does the Novel Coronavirus Spike Protein Interact so Strongly with
   the Human ACE2? A Thermodynamic Answer
SO CHEMBIOCHEM
LA English
DT Article; Early Access
DE COVID-19; free energy of binding; molecular docking; molecular dynamics;
   spike protein
ID GENERALIZED BORN; RECEPTOR-BINDING; FORCE-FIELD; SARS-COV-2; DYNAMICS
AB The SARS-CoV-2 pandemic is the biggest health concern today, but until now there is no treatment. One possible drug target is the receptor binding domain (RBD) of the coronavirus' spike protein, which recognizes the human angiotensin-converting enzyme 2 (hACE2). Our in silico study discusses crucial structural and thermodynamic aspects of the interactions involving RBDs from the SARS-CoV and SARS-CoV-2 with the hACE2. Molecular docking and molecular dynamics simulations explain why the chemical affinity of the new SARS-CoV-2 for hACE2 is much higher than in the case of SARS-CoV, revealing an intricate pattern of hydrogen bonds and hydrophobic interactions and estimating a free energy of binding, which is consistently much more negative in the case of SARS-CoV-2. This work presents a chemical reason for the difficulty in treating the SARS-CoV-2 virus with drugs targeting its spike protein and helps to explain its infectiousness.
C1 [de Andrade, Jones] Univ Fed Rio Grande do Sul, Inst Chem, Dept Phys Chem, Theoret Chem Grp, Ave Bento Goncalves 9-500, BR-91501970 Porto Alegre, RS, Brazil.
   [Goncalves, Paulo Fernando Bruno] Univ Fed Rio Grande do Sul, Dept Phys Chem, Theoret Chem Grp, Inst Chem, Ave Bento Goncalves 9-500, BR-91501970 Porto Alegre, RS, Brazil.
   [Netz, Paulo Augusto] Univ Fed Rio Grande do Sul, Dept Phys Chem, Inst Chem, Theoret Chem Grp, Ave Bento Goncalves 9-500, BR-91501970 Porto Alegre, RS, Brazil.
RP de Andrade, J (corresponding author), Univ Fed Rio Grande do Sul, Inst Chem, Dept Phys Chem, Theoret Chem Grp, Ave Bento Goncalves 9-500, BR-91501970 Porto Alegre, RS, Brazil.; Goncalves, PFB (corresponding author), Univ Fed Rio Grande do Sul, Dept Phys Chem, Theoret Chem Grp, Inst Chem, Ave Bento Goncalves 9-500, BR-91501970 Porto Alegre, RS, Brazil.; Netz, PA (corresponding author), Univ Fed Rio Grande do Sul, Dept Phys Chem, Inst Chem, Theoret Chem Grp, Ave Bento Goncalves 9-500, BR-91501970 Porto Alegre, RS, Brazil.
EM jdandrade@iq.ufrgs.br; paulo@iq.ufrgs.br; netz@iq.ufrgs.br
RI Goncalves, Paulo/C-2702-2015
OI Goncalves, Paulo/0000-0002-5348-9028; de Andrade,
   Jones/0000-0003-3429-8119
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -
   Brasil (CAPES)CAPES [001]
FX The authors would like to acknowledge CNPq and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance
   Code 001 for the financial support, and the High-Performance Computing
   Center (NPAD) at UFRN for the computational resources provided. We would
   also like to express our deepest gratitude towards Engr. Danilo Chaves
   de Sousa Ichihara and Engr. Haroldo Watson Teodosio da Silva, whose hard
   and dedicated work, even in the midst of a pandemic, to put the NPAD
   supercomputer back online was absolutely fundamental for the completion
   of the present study in time. We thank also Livia Streit and Hermes L.
   N. de Amorim for careful reading of the manuscript and valuable
   suggestions
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   COVID-19 Clinical Res Coalition, 2020, LANCET, V395, P1322, DOI 10.1016/S0140-6736(20)30798-4
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   David L, 2000, J COMPUT CHEM, V21, P295, DOI 10.1002/(SICI)1096-987X(200003)21:4<295::AID-JCC5>3.0.CO;2-8
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Gibney E, 2020, NATURE, V581, P15, DOI 10.1038/d41586-020-01248-1
   Hansson T, 1998, J COMPUT AID MOL DES, V12, P27, DOI 10.1023/A:1007930623000
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Mori M, 2020, EXPERT OPIN THER PAT, V30, P481, DOI 10.1080/13543776.2020.1760838
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Onufriev A, 2000, J PHYS CHEM B, V104, P3712, DOI 10.1021/jp994072s
   Onufriev A, 2004, PROTEINS, V55, P383, DOI 10.1002/prot.20033
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Rifai EA, 2019, J CHEM INF MODEL, V59, P4018, DOI [10.1021/acs.jcim.9b00609, 10.1021/acsicim.9b00609]
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Spinello A, 2020, J PHYS CHEM LETT, V11, P4785, DOI 10.1021/acs.jpclett.0c01148
   Sun ZX, 2017, J CHEM PHYS, V146, DOI 10.1063/1.4978893
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   TIRONI IG, 1995, J CHEM PHYS, V102, P5451, DOI 10.1063/1.469273
   Vosmeer CR, 2016, J MOL MODEL, V22, DOI 10.1007/s00894-015-2883-y
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang YJ, 2020, P NATL ACAD SCI USA, V117, P13967, DOI 10.1073/pnas.2008209117
   Weiser J, 1999, J COMPUT CHEM, V20, P217, DOI 10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 35
TC 0
Z9 0
U1 2
U2 2
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1439-4227
EI 1439-7633
J9 CHEMBIOCHEM
JI ChemBioChem
DI 10.1002/cbic.202000455
EA NOV 2020
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA OS3QO
UT WOS:000590080000001
PM 33084150
DA 2021-01-01
ER

PT J
AU Michaud, V
   Dow, P
   Al Rihani, SB
   Deodhar, M
   Arwood, M
   Cicali, B
   Turgeon, J
AF Michaud, Veronique
   Dow, Pamela
   Al Rihani, Sweilem B.
   Deodhar, Malavika
   Arwood, Meghan
   Cicali, Brian
   Turgeon, Jacques
TI Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19
   Repurposed Drugs
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article; Early Access
ID IN-VITRO; INTERVAL PROLONGATION; PHARMACOKINETICS; AZITHROMYCIN;
   CHLOROQUINE; METABOLISM; DESETHYLCHLOROQUINE; RITONAVIR; HIV
AB The risk-benefit ratio associated with the use of repurposed drugs to treat severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)-related infectious coronavirus disease 2019 (COVID-19) is complicated because benefits are awaited, not proven. A thorough literature search was conducted to source information on the pharmacological properties of 5 drugs and 1 combination (azithromycin, chloroquine, favipiravir, hydroxychloroquine, remdesivir, and lopinavir/ritonavir) repurposed to treat COVID-19. A risk assessment of drug-induced long QT syndrome (LQTS) associated with COVID-19 repurposed drugs was performed and compared with 23 well-known torsadogenic and 10 low torsadogenic risk compounds. Computer calculations were performed using pharmacokinetic and pharmacodynamic data, including affinity to block the rapid component of the delayed rectifier cardiac potassium current (I-Kr) encoded by the human ether-a-go-go gene (hERG), propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP). Seven different LQTS indices were calculated and compared. The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried with specific key words relating to arrhythmogenic events. Estimators of LQTS risk levels indicated a very high or moderate risk for all COVID-19 repurposed drugs with the exception for azithromycin, although cases of TdP have been reported with this drug. There was excellent agreement among the various indices used to assess risk of drug-induced LQTS for the 6 repurposed medications and 23 torsadogenic compounds. Based on our results, monitoring of the QT interval shall be performed when some COVID-19 repurposed drugs are used, as such monitoring is possible for hospitalized patients or with the use of biodevices for outpatients.
C1 [Michaud, Veronique; Dow, Pamela; Al Rihani, Sweilem B.; Deodhar, Malavika; Arwood, Meghan; Turgeon, Jacques] Tabula Rasa HealthCare Precis Pharmacotherapy Res, Orlando, FL 32827 USA.
   [Michaud, Veronique; Turgeon, Jacques] Univ Montreal, Fac Pharm, Montreal, PQ, Canada.
   [Cicali, Brian] Univ Florida, Coll Pharm, Lake Nona Campus, Orlando, FL USA.
RP Turgeon, J (corresponding author), Tabula Rasa HealthCare Precis Pharmacotherapy Res, Orlando, FL 32827 USA.; Turgeon, J (corresponding author), Univ Montreal, Fac Pharm, Montreal, PQ, Canada.
EM jturgeon@trhc.com
FU Tabula Rasa HealthCare
FX Funding for this research was made possible by Tabula Rasa HealthCare.
CR Ademowo OG, 2000, CLIN PHARMACOL THER, V67, P237, DOI 10.1067/mcp.2000.104257
   Agency (EMA), 2020, SUMMARY ON COMPASSIO
   Al Rihani S.B., POTENTIAL COVID 19 T
   Al Rihani SB, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082591
   Amirian ES, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100128
   Anson BD, 2005, LANCET, V365, P682, DOI 10.1016/S0140-6736(05)70936-3
   Bouvy JC, 2012, CLIN PHARMACOL THER, V91, P281, DOI 10.1038/clpt.2011.224
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chorin E, 2020, QT INTERVAL PATIENTS, V2020, DOI [10.1101/2020.04.02.20047050, DOI 10.1101/2020.04.02.20047050]
   Colatsky T, 2016, J PHARMACOL TOX MET, V81, P15, DOI 10.1016/j.vascn.2016.06.002
   CredibleMeds.org, SEARCH FOR DRUGS THA
   de Maat MMR, 2003, CLIN PHARMACOKINET, V42, P223, DOI 10.2165/00003088-200342030-00002
   DREW RH, 1992, PHARMACOTHERAPY, V12, P161
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Foisy MM, 2008, ANN PHARMACOTHER, V42, P1048, DOI 10.1345/aph.1K615
   Food and Drug Administration HHS, 2005, FED REGISTER, V70, P61133
   FOULDS G, 1990, J ANTIMICROB CHEMOTH, V25, P73, DOI 10.1093/jac/25.suppl_A.73
   Furuta Y, 2002, ANTIMICROB AGENTS CH, V46, P977, DOI 10.1128/AAC.46.4.977-981.2002
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geelen, 1999, J Cardiovasc Pharmacol Ther, V4, P143, DOI 10.1177/107424849900400303
   Hreiche R, 2011, J PHARM SCI-US, V100, P2469, DOI 10.1002/jps.22437
   Huang BH, 2007, PACE, V30, P1579, DOI 10.1111/j.1540-8159.2007.00912.x
   ICH. International Conference on Harmonisation, 2005, FED REGISTER, V70, P61134
   Japanese Pharmaceuticals and Medical Devices Agency, 2011, REPORT ON THE DELIBE
   Kiso M, 2010, P NATL ACAD SCI USA, V107, P882, DOI 10.1073/pnas.0909603107
   Kramer J, 2013, SCI REP-UK, V3, DOI 10.1038/srep02100
   Lee W, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00934
   Milberg P, 2002, J PHARMACOL EXP THER, V303, P218, DOI 10.1124/jpet.102.037911
   O'Hara T, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002061
   Ouedraogo HG, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-0345-6
   Patel N, 2018, AAPS J, V20, DOI 10.1208/s12248-018-0244-3
   Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078
   Piscitelli SC, 2001, NEW ENGL J MED, V344, P984, DOI 10.1056/NEJM200103293441307
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   Redfern WS, 2003, CARDIOVASC RES, V58, P32, DOI 10.1016/S0008-6363(02)00846-5
   Romero L, 2018, J CHEM INF MODEL, V58, P867, DOI 10.1021/acs.jcim.7b00440
   Sager PT, 2014, AM HEART J, V167, P292, DOI 10.1016/j.ahj.2013.11.004
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Simpson T., 2020, VENTRICULAR ARRHYTHM
   Stas P, 2008, INT J CARDIOL, V127, pE80, DOI 10.1016/j.ijcard.2007.04.055
   Tabula Rasa HealthCare, SIMULATION OF RISK O
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   Traebert M, 2004, EUR J PHARMACOL, V484, P41, DOI 10.1016/j.ejphar.2003.11.003
   Turgeon J., Treatment Methods Having Reduced Drug-Related Toxicity and Methods of Identifying the Likelihood of Patient Harm from Prescribed Medications, Patent No. [WO2017213825, 2017213825]
   US Food and Drug Administration, QUESTIONS AND ANSWER
   US National Library of Medicine, CLINICALTRIALS GOV C
   Woosley A., QTDRUGS LISTS
   Wu CI, 2020, HEART RHYTHM, V17, P1456, DOI 10.1016/j.hrthm.2020.03.024
   Yap YG, 2003, HEART, V89, P1363, DOI 10.1136/heart.89.11.1363
NR 49
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
DI 10.1111/cts.12882
EA NOV 2020
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OS4QU
UT WOS:000590150300001
PM 32888379
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Di Altobrando, A
   La Placa, M
   Neri, I
   Piraccini, BM
   Vincenzi, C
AF Di Altobrando, Ambra
   La Placa, Michelangelo
   Neri, Iria
   Piraccini, Bianca Maria
   Vincenzi, Colombina
TI Contact dermatitis due to masks and respirators during COVID-19
   pandemic: What we should know and what we should do
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE allergy; contact dermatitis; COVID&#8208; 19; mask; pandemic; respirator
AB Given the current lack of a therapeutic vaccine for coronavirus disease 2019 (COVID-19), preventive measures including mask wearing are crucial in slowing the transmission of cases. However, prolonged wearing of protective respirators, medical and fabric masks can easily generate excessive sweating, moisture and friction. Closed and warm environments heighten the skin's permeability and sensitivity to physical or chemical irritants, leading to chronic cumulative irritant contact dermatitis or, rarely, even allergic contact dermatitis. Although not representing a life-threatening condition, contact dermatitis can have a significant impact on emergency management, as it is potentially able to reduce work performance and create emotional discomfort due to the involvement of evident body areas. To minimize the skin breakdown, adherence to standards on wearing protective and safe equipments and avoidance of overprotection should be performed. At the same time, some measures of skin care are recommended. Here, we offer some tips on how to prevent and manage contact dermatitis due to masks not only in health care workers, but also in the general population during this COVID-19 outbreak.
C1 [Di Altobrando, Ambra; La Placa, Michelangelo; Neri, Iria; Piraccini, Bianca Maria; Vincenzi, Colombina] Univ Bologna, Div Dermatol, Dept Expt Diagnost & Specialty Med, Via Massarenti,1, I-40138 Bologna, Italy.
RP Di Altobrando, A (corresponding author), Univ Bologna, Div Dermatol, Dept Expt Diagnost & Specialty Med, Via Massarenti,1, I-40138 Bologna, Italy.
EM ambra.dialtobrando@studio.unibo.it
OI Di Altobrando, Ambra/0000-0003-3236-8822
CR Abtahi-Naeini Bahareh, 2020, Health Sci Rep, V3, pe163, DOI 10.1002/hsr2.163
   Aerts O, 2020, CONTACT DERMATITIS, V83, P172, DOI 10.1111/cod.13626
   Al Badri FM, 2017, CURR ALLERGY CLIN IM, V30, P183
   Auler AC, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.139090
   Balato A, 2020, J EUR ACAD DERMATOL, V34, pE353, DOI 10.1111/jdv.16557
   Beiu C, 2020, CUREUS, V12, DOI 10.7759/cureus.7506
   Cavanagh G, 2020, J AM ACAD DERMATOL, V82, pE211, DOI 10.1016/j.jaad.2020.03.090
   Cook TM, 2020, ANAESTHESIA, V75, P920, DOI 10.1111/anae.15071
   Di Altobrando A, 2020, BRIT J DERMATOL, V182, P495, DOI 10.1111/bjd.18453
   Donovan J, 2007, DERMATITIS, V18, P40, DOI 10.2310/6620.2007.05003
   Elston DM, 2020, J AM ACAD DERMATOL, V82, P1085, DOI 10.1016/j.jaad.2020.03.012
   Gheisari M, 2020, J EUR ACAD DERMATOL, V34, pE297, DOI 10.1111/jdv.16492
   Iwata M, 2015, ACTA DERM-VENEREOL, V95, P628, DOI 10.2340/00015555-1962
   Komericki P, 2000, BRIT J DERMATOL, V142, P163, DOI 10.1046/j.1365-2133.2000.03261.x
   Lan JJ, 2020, J AM ACAD DERMATOL, V82, P1215, DOI 10.1016/j.jaad.2020.03.014
   Liao L, 2020, ACS NANO, V14, P6348, DOI 10.1021/acsnano.0c03597
   Lin P, 2020, BRIT J DERMATOL, V183, P190, DOI 10.1111/bjd.19089
   Lipozencic J, 2014, CLIN DERMATOL, V32, P125, DOI 10.1016/j.clindermatol.2013.05.034
   Navarro-Trivino FJ, 2020, CONTACT DERMATITIS, V83, P168, DOI 10.1111/cod.13600
   O'Dowd K, 2020, MATERIALS, V13, DOI 10.3390/ma13153363
   Oberg T, 2008, AM J INFECT CONTROL, V36, P276, DOI 10.1016/j.ajic.2007.07.008
   Patruno C, 2020, CONTACT DERMATITIS, V83, P174, DOI 10.1111/cod.13568
   Placucci F, 1996, CONTACT DERMATITIS, V34, P76, DOI 10.1111/j.1600-0536.1996.tb02131.x
   State Council China, 2020, GUID SEL US DIFF TYP
   Tirupathi Raghavendra, 2020, Infez Med, V28, P57
   Wigger-Alberti W, 1997, Am J Contact Dermat, V8, P106, DOI 10.1016/S1046-199X(97)90002-6
   Wilkinson M, 2019, CONTACT DERMATITIS, V80, P1, DOI 10.1111/cod.13155
   Xie Z, 2020, CONTACT DERMATITIS, V83, P166, DOI 10.1111/cod.13599
   Yan YC, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13310
   Zuo Y, 2020, CONTACT DERMATITIS, DOI 10.1111/cod.13555
NR 30
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14528
DI 10.1111/dth.14528
EA NOV 2020
PG 4
WC Dermatology
SC Dermatology
GA OS4QS
UT WOS:000590150100001
PM 33174266
OA Bronze
DA 2021-01-01
ER

PT J
AU Berlivet, L
   Lowy, I
AF Berlivet, Luc
   Lowy, Ilana
TI Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the
   Democratization of Science
SO MEDICAL ANTHROPOLOGY QUARTERLY
LA English
DT Article; Early Access
DE COVID&#8208; 19; chloroquine; hydroxychloroquine; randomized clinical
   trials; AIDS activism
AB The claim that anti-malaria drugs, chloroquine and hydroxychloroquine, can cure COVID-19 became a focus of fierce political battles that pitted promoters of these pharmaceuticals, Presidents Bolsonaro and Trump among them, against "medical elites." At the center of these battles are different meanings of effectiveness in medicine, the complex role of randomized clinical trials (RCTs) in proving such effectiveness, the task of medical experts and the state in regulating pharmaceuticals, patients' activism, and the collective production of medical knowledge. This article follows the trajectory of chloroquine and hydroxychloroquine as anti-COVID-19 drugs, focusing on the reception of views of their main scientific promoter, the French infectious disease specialist, Didier Raoult. The surprising career of these drugs, our text proposes, is fundamentally a political event, not in the narrow sense of engaging specific political fractions, but in the much broader sense of the politics of public participation in science.
C1 [Berlivet, Luc] EHESS, CNRS, CERMES3, Paris, France.
   [Lowy, Ilana] EHESS, INSERM, CERMES3, Paris, France.
RP Berlivet, L (corresponding author), EHESS, CNRS, CERMES3, Paris, France.
EM luc.berlivet@cnrs.fr
OI Lowy, Ilana/0000-0001-6963-0578
CR Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209
   [Anonymous], 1948, Br Med J, V2, P769
   [Anonymous], 2020, FRANCE 24 NEWS  0409
   [Anonymous], 2020, REUTERS
   [Anonymous], 2018, BREAK PATENT
   [Anonymous], 2020, BBC NEWS
   [Anonymous], 2020, NY TIMES
   Armitage P, 2003, INT J EPIDEMIOL, V32, P925, DOI 10.1093/ije/dyg286
   Baker Peter, 2020, NY TIMES
   Barbot J., 2002, MALADES MOUVEMENTS M
   Bastos C, 2008, POLITICS OF AIDS: GLOBALIZATION, THE STATE AND CIVIL SOCIETY, P225
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bendix T., 2020, NY TIMES
   Berlivet L., 2020, MONDE
   Biehl J, 2007, ANTHROPOL QUART, V80, P1083, DOI 10.1353/anq.2007.0056
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boseley S., 2020, GUARDIAN
   Briggs C. L., 2016, MAKING HLTH PUBLIC N
   Briggs CL, 2007, SOC TEXT, V25, P43, DOI 10.1215/01642472-2007-011
   Briggs CL, 2011, BLACKW COMPANION ANT, P459
   Cascella M, 2020, FEATURES EVALUATION
   Chalmers I, 2004, INT J EPIDEMIOL, V33, P253, DOI 10.1093/ije/dyh162
   Cowie C, 2020, COMPANIONS IN GUILT ARGUMENTS IN METAETHICS, P1
   DOLL R, 1992, BMJ-BRIT MED J, V305, P1521, DOI 10.1136/bmj.305.6868.1521
   Eboko F., 2020, MONDE
   Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709
   EPSTEIN S, 1995, SCI TECHNOL HUM VAL, V20, P408, DOI 10.1177/016224399502000402
   Epstein S, 1996, IMPURE SCI AIDS ACTI
   Fauci A., 1995, AIDS PUBLIC DEBATE, P67
   FDA, 2020, FDA CAUT US HYDR CHL
   France David, 2016, SURVIVE PLAGUE
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gonsalves G., 2020, NATION
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guilherme H., 2020, NEXO            0409
   Heise L., 2005, MAPPING STANDARDS CA
   Heise L., 2005, RETHINKING ETHICAL R
   Ioannidis JPA, 2016, J CLIN EPIDEMIOL, V73, P82, DOI 10.1016/j.jclinepi.2016.02.012
   ISAC, 2020, OFF STAT INT SOC ANT
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karni Annie, 2020, NY TIMES
   Kolata G, 2020, NY TIMES
   Krakower Douglas, 2011, Curr HIV/AIDS Rep, V8, P241, DOI 10.1007/s11904-011-0094-4
   LAWRENCE C, 1985, J CONTEMP HIST, V20, P503, DOI 10.1177/002200948502000402
   Lowy I., 2000, LIVING WORKING NEW M, P49
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Marks HM, 2003, INT J EPIDEMIOL, V32, P932, DOI 10.1093/ije/dyg288
   Norrie JD, 2020, LANCET, V395, P1525, DOI 10.1016/S0140-6736(20)31023-0
   Oreskes N., 2015, MERCHANTS DOUBT HAND
   Payet M., 2020, COVID 19 PLUS 80 000
   Petryna A., 2009, EXPT TRAVEL CLIN TRI
   Phillips D, 2020, GUARDIAN
   Raoult D., 2020, RADIO CLASSIQUE 0417
   Raoult D., 2020, RADIO CLASSIQUE 0519
   Raoult D., 2020, MONDE
   Raoult D., 2020, COMMUNICATION   0422
   Raoult D., 2020, RADIO CLASSIQUE 0401
   Roussel Y., 2020, LA PROVENCE     0420
   Sayare S., 2020, NY TIMES
   Sciama Y., 2020, SCIENCE
   Shapin S, 2010, NEVER PURE HIST STUD
   Shapiro HT, 2001, NEW ENGL J MED, V345, P139, DOI 10.1056/NEJM200107123450212
   Shulman S., 2003, COMMUNICATION   0308
   TAG and PrEP4All, 2020, TREATM ACT GROUP PRE
   Terry M., 2019, BIOSPACE
   TRT5, 2020, INFORMATIONS
   Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411
   Viktorovitch C., 2020, VIDEO RAOULTS RHETOR
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wasunna M., 2020, GUARDIAN
   Wong J.C., 2020, GUARDIAN
   1951, BMJ-BRIT MED J, V1, P1463
NR 72
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0745-5194
EI 1548-1387
J9 MED ANTHROPOL Q
JI Med. Anthropol. Q.
DI 10.1111/maq.12622
EA NOV 2020
PG 17
WC Anthropology; Public, Environmental & Occupational Health; Social
   Sciences, Biomedical
SC Anthropology; Public, Environmental & Occupational Health; Biomedical
   Social Sciences
GA OS4US
UT WOS:000590160500001
PM 33210338
OA Other Gold
DA 2021-01-01
ER

PT J
AU Rafi, MO
   Bhattacharje, G
   Al-Khafaji, K
   Taskin-Tok, T
   Alfasane, MA
   Das, AK
   Parvez, MAK
   Rahman, MS
AF Rafi, Md. Oliullah
   Bhattacharje, Gourab
   Al-Khafaji, Khattab
   Taskin-Tok, Tugba
   Alfasane, Md. Almujaddade
   Das, Amit Kumar
   Parvez, Md. Anowar Khasru
   Rahman, Md. Shahedur
TI Combination of QSAR, molecular docking, molecular dynamic simulation and
   MM-PBSA: analogues of lopinavir and favipiravir as potential drug
   candidates against COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; protease; RNA polymerase; lopinavir; favipiravir; molecular
   docking; QSAR; novel drug; molecular dynamic simulations
AB Pandemic COVID-19 infections have spread throughout the world. There is no effective treatment against this disease. Viral RNA-dependent RNA polymerase (RdRp) catalyzes the replication of RNA from RNA and the main protease (M-pro) has a role in the processing of polyproteins that are translated from the RNA of SARS-CoV-2, and thus these two enzymes are strong candidates for targeting by anti-viral drugs. Small molecules such as lopinavir and favipiravir significantly inhibit the activity of M-pro and RdRp in vitro. Studies have shown that structurally modified lopinavir, favipiravir, and other similar compounds can inhibit COVID-19 main protease (M-pro) and RNA-dependent RNA polymerase (RdRp). In this study, lopinavir and its structurally similar compounds were chosen to bind the main protease, and favipiravir was chosen to target RNA-dependent RNA polymerase. Molecular docking and the quantitative structure-activity relationships (QSAR) study revealed that the selected candidates have favorable binding affinity but less druggable properties. To improve the druggability, four structural analogues of lopinavir and one structural analogue of favipiravir was designed by structural modification. Molecular interaction analyses have displayed that lopinavir and favipiravir analogues interact with the active site residues of M-pro and RdRp, respectively. Absorption, distribution, metabolism, excretion and toxicity (ADMET) properties, medicinal chemistry profile, and physicochemical features were shown that all structurally modified analogues are less toxic and contain high druggable properties than the selected candidates. Subsequently, 50 ns molecular dynamics simulation of the top four docked complexes demonstrated that CID44271905, a lopinavir analogue, forms the most stable complex with the M-pro. Further MMPBSA analyses using the MD trajectories also confirmed the higher binding affinity of CID44271905 towards M-pro. In summary, this study demonstrates a new way to identify leads for novel anti-viral drugs against COVID-19.
   Communicated by Ramaswamy H. Sarma
C1 [Rafi, Md. Oliullah; Rahman, Md. Shahedur] Jashore Univ Sci & Technol, Dept Genet Engn & Biotechnol, Jashore 7408, Bangladesh.
   [Bhattacharje, Gourab; Das, Amit Kumar] Indian Inst Technol Kharagpur, Dept Biotechnol, Kharagpur, W Bengal, India.
   [Al-Khafaji, Khattab; Taskin-Tok, Tugba] Gaziantep Univ, Fac Arts & Sci, Dept Chem, TR-27310 Gaziantep, Turkey.
   [Taskin-Tok, Tugba] Gaziantep Univ, Inst Hlth Sci, Dept Bioinformat & Computat Biol, Gaziantep, Turkey.
   [Alfasane, Md. Almujaddade] Univ Dhaka, Dept Bot, Dhaka, Bangladesh.
   [Parvez, Md. Anowar Khasru] Jahangirnagar Univ, Dept Microbiol, Dhaka, Bangladesh.
   [Parvez, Md. Anowar Khasru] Pabna Univ Sci & Technol, Treasurer Off, Pabna, Bangladesh.
RP Rahman, MS (corresponding author), Jashore Univ Sci & Technol, Dept Genet Engn & Biotechnol, Jashore 7408, Bangladesh.; Taskin-Tok, T (corresponding author), Gaziantep Univ, Fac Arts & Sci, Dept Chem, TR-27310 Gaziantep, Turkey.
EM taskin.tugba@gmail.com; ms.rahman@just.edu.bd
RI Al-Khafaji, Khattab/AAU-4146-2020; Taskin Tok, Tugba/A-8885-2016
OI Al-Khafaji, Khattab/0000-0002-2165-9256; Taskin Tok,
   Tugba/0000-0002-0064-8400; Rafi, Md. Oliullah/0000-0002-1707-655X
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   [Anonymous], 2013, DISCOVERY STUDIO 3 5
   Bajorath F, 2002, NAT REV DRUG DISCOV, V1, P882, DOI 10.1038/nrd941
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Balani SK, 2005, CURR TOP MED CHEM, V5, P1033, DOI 10.2174/156802605774297038
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cheng FX, 2019, J CHEM INF MODEL, V59, P4959, DOI 10.1021/acs.jcim.9b00969
   Cheng TJ, 2014, DRUG DISCOV TODAY, V19, P1751, DOI 10.1016/j.drudis.2014.08.008
   Chien A, 2002, DRUG DISCOV TODAY, V7, pS176, DOI 10.1016/S1359-6446(02)02369-3
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   de Leuw Philipp, 2017, GMS Infect Dis, V5, pDoc08, DOI 10.3205/id000034
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Ezat Ahmed A., 2019, VirusDisease, V30, P207, DOI 10.1007/s13337-019-00516-7
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Kalia M, 2017, MICROB PATHOGENESIS, V107, P136, DOI 10.1016/j.micpath.2017.03.026
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kumar GN, 1999, DRUG METAB DISPOS, V27, P86
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Z, 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212, DOI 10.1101/2020.02.08.20021212]
   Lill MA, 2011, J COMPUT AID MOL DES, V25, P13, DOI 10.1007/s10822-010-9395-8
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Martinez L, 2009, J COMPUT CHEM, V30, P2157, DOI 10.1002/jcc.21224
   Park DS, 2008, J COMPUT AID MOL DES, V22, P873, DOI 10.1007/s10822-008-9219-2
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Samadi A, 2020, J MACROMOL SCI B, V59, P376, DOI [10.1080/00222348.2020.1730573, 10.1080/07391102.2020.1792347]
   Sander T., 2001, OSIRIS PROPERTY EXPL
   Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249-011-0700-9
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218
   Suh ME, 2002, B KOR CHEM SOC, V23, P417
   Tozser J, 2010, VIRUSES-BASEL, V2, P147, DOI 10.3390/v2010147
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang ZJ, 2020, J INTEGR MED-JIM, V18, P229, DOI 10.1016/j.joim.2020.03.004
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 43
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1850355
EA NOV 2020
PG 20
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA PB9FM
UT WOS:000596618100001
PM 33251975
OA Bronze
DA 2021-01-01
ER

PT J
AU Ao, S
   Han, D
   Sun, L
   Wu, YH
   Liu, S
   Huang, YJ
AF Ao, Shuang
   Han, Dan
   Sun, Lei
   Wu, Yanhong
   Liu, Shuang
   Huang, Yaojiang
TI Identification of Potential Key Agents for Targeting RNA-Dependent RNA
   Polymerase of SARS-CoV-2 by Integrated Analysis and Virtual Drug
   Screening
SO FRONTIERS IN GENETICS
LA English
DT Article
DE SARS-CoV-2; COVID-19; family analysis; molecular docking; virtual drug
   screening
ID SARS-COV; INHIBITORS; DISCOVERY; DOCKING; DESIGN
AB Background RNA-dependent RNA polymerase (RdRp) is the key enzyme responsible for the SARS-CoV-2 replication process and catalyzes the synthesis of complementary minus strand RNA and genomic plus strand RNA, often recognized as good targets for antiviral drugs. Materials and Methods A systematic screening of existing antiviral compounds, family analysis, conserved domain analysis, three-dimensional structure modeling, drug virtual screening, and bioassays were performed to identify agents that potentially targeted RNA-dependent RNA polymerase of SARS-CoV-2. Results Four thousand nine hundred and forty seven antiviral lead compounds were selected and evaluated by systematic screening. Of these, 359 agents were screened by family analysis and conserved domain analysis. They were further analyzed by three-dimensional structure modeling, virtual drug screening, and bioassays. The results identified 102 agents with potential for repurposing to target the RNA-dependent RNA polymerase of SARS-CoV-2. Conclusion This study identified 102 key agents with potential anti-SARS-CoV-2 RNA-dependent RNA polymerase function and prospects of rapid clinical application for the treatment of COVID-19.
C1 [Ao, Shuang; Wu, Yanhong; Liu, Shuang; Huang, Yaojiang] Minzu Univ China, Beijing Engn Res Ctr Food Environm & Publ Hlth, Beijing, Peoples R China.
   [Han, Dan] Minzu Univ China, Coll Med, Beijing, Peoples R China.
   [Sun, Lei] Beijing Gardening & Greening Bur, Beijing Wildlife Conservat & Nat Reserve Manageme, Beijing, Peoples R China.
   [Wu, Yanhong; Liu, Shuang] Minzu Univ China, Coll Life & Environm Sci, Beijing, Peoples R China.
   [Huang, Yaojiang] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
RP Huang, YJ (corresponding author), Minzu Univ China, Beijing Engn Res Ctr Food Environm & Publ Hlth, Beijing, Peoples R China.; Huang, YJ (corresponding author), Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
EM yaojiang@muc.edu.cn
FU Double First Class University Plan (MOE, China Ministry of Education);
   Beijing Municipal Science and Technology CommissionBeijing Municipal
   Science & Technology Commission; Department of Environmental Health,
   Harvard School of Public Health; China Ministry of EducationMinistry of
   Education, China; Minzu University 985 Academic Team-building Fund
   [2018MDTD25C]
FX This work was supported by the Double First Class University Plan (MOE,
   China Ministry of Education) and Beijing Municipal Science and
   Technology Commission. This work was also supported in part by the
   Department of Environmental Health, Harvard School of Public Health, and
   the Double Top University Plan from China Ministry of Education; grants
   2018MDTD25C from the Minzu University 985 Academic Team-building Fund.
CR Aliper A, 2016, MOL PHARMACEUT, V13, P2524, DOI 10.1021/acs.molpharmaceut.6b00248
   Bedford J, 2019, NATURE, V575, P130, DOI 10.1038/s41586-019-1717-y
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Biovia Dicovery Studio, 2015, DASS SYST DASS SYST
   Cohen J, 2020, SCIENCE, V370
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Farha MA, 2019, NAT MICROBIOL, V4, P565, DOI 10.1038/s41564-019-0357-1
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Heidebrecht RW, 2009, BIOORG MED CHEM LETT, V19, P2053, DOI 10.1016/j.bmcl.2009.02.009
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Klambauer G. N., 2019, MACHINE LEARNING DRU
   Kumar V, 2016, BIOORGAN MED CHEM, V24, P3035, DOI 10.1016/j.bmc.2016.05.013
   Lee C, 2009, BIOORG MED CHEM LETT, V19, P4538, DOI 10.1016/j.bmcl.2009.07.009
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lu IL, 2006, J MED CHEM, V49, P5154, DOI 10.1021/jm060207o
   Macalino SJY, 2015, ARCH PHARM RES, V38, P1686, DOI 10.1007/s12272-015-0640-5
   RStudio Team, 2015, NTEGRATED DEV R
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsai KC, 2006, J MED CHEM, V49, P3485, DOI 10.1021/jm050852f
   World Health Organization [WHO], 2020, 103 WHO
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 25
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD NOV 17
PY 2020
VL 11
AR 581668
DI 10.3389/fgene.2020.581668
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA OY7FR
UT WOS:000594409600001
PM 33281876
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fan, YZ
   Guo, T
   Yan, FF
   Gong, M
   Zhang, XA
   Li, CZ
   He, T
   Luo, HM
   Zhang, L
   Chen, M
   Wu, XY
   Wang, HR
   Deng, KQ
   Bai, J
   Cai, L
   Lu, ZB
AF Fan, Yongzhen
   Guo, Tao
   Yan, Feifei
   Gong, Ming
   Zhang, Xin A.
   Li, Chenze
   He, Tao
   Luo, Huimin
   Zhang, Lin
   Chen, Ming
   Wu, Xiaoyan
   Wang, Hairong
   Deng, Ke-Qiong
   Bai, Jiao
   Cai, Lin
   Lu, Zhibing
TI Association of Statin Use With the In-Hospital Outcomes of
   2019-Coronavirus Disease Patients: A Retrospective Study
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; statin; outcome; mortality; ARDS
ID CHOLESTEROL; MORTALITY; THERAPY; INFECTION; PNEUMONIA
AB Background: Statins have multiple protective effects on inflammation, immunity and coagulation, and may help alleviate pneumonia. However, there was no report focusing on the association of statin use with in-hospital outcomes of patients with coronavirus disease 2019 (COVID-19). We investigated the association between the use of statins and in-hospital outcomes of patients with COVID-19.
   Methods: In this retrospective case series, consecutive COVID-19 patients admitted at 2 hospitals in Wuhan, China, from March 12, 2020 to April 14, 2020 were analyzed. A 1:1 matched cohort was created by propensity score-matched analysis. Demographic data, laboratory findings, comorbidities, treatments and in-hospital outcomes were collected and compared between COVID-19 patients taking and not taking statins.
   Result: A total of 2,147 patients with COVID-19 were enrolled in this study. Of which, 250 patients were on statin therapy. The mortality was 2.4% (6/250) for patients taking statins while 3.7% (70/1,897) for those not taking statins. In the multivariate Cox model, after adjusting for age, gender, admitted hospital, comorbidities, in-hospital medications and blood lipids, the risk was lower for mortality (adjusted HR, 0.428; 95% CI, 0.169-0.907; P = 0.029), acute respiratory distress syndrome (ARDS) (adjusted HR, 0.371; 95% CI, 0.180-0.772; P = 0.008) or intensive care unit (ICU) care (adjusted HR, 0.319; 95% CI, 0.270-0.945; P = 0.032) in the statin group vs. the non-statin group. After propensity score-matched analysis based on 18 potential confounders, a 1:1 matched cohort (206:206) was created. In the matched cohort, the Kaplan-Meier survival curves showed that the use of statins was associated with better survival (P = 0.025). In a Cox regression model, the use of statins was associated with lower risk of mortality (unadjusted HR, 0.254; 95% CI, 0.070-0.926; P = 0.038), development of ARDS (unadjusted HR, 0.240; 95% CI, 0.087-0.657; P = 0.006), and admission of ICU (unadjusted HR, 0.349; 95% CI, 0.150-0.813; P = 0.015). The results remained consistent when being adjusted for age, gender, total cholesterol, triglyceride, low density lipoprotein cholesterol, procalcitonin, and brain natriuretic peptide. The favorable outcomes in statin users remained statistically significant in the first sensitivity analysis with comorbid diabetes being excluded in matching and in the second sensitivity analysis with chronic obstructive pulmonary disease being added in matching.
   Conclusion: In this retrospective analysis, the use of statins in COVID-19 patients was associated with better clinical outcomes and is recommended to be continued in patients with COVID-19.
C1 [Fan, Yongzhen; Guo, Tao; Li, Chenze; He, Tao; Luo, Huimin; Zhang, Lin; Chen, Ming; Wu, Xiaoyan; Wang, Hairong; Deng, Ke-Qiong; Lu, Zhibing] Wuhan Univ, Zhongnan Hosp, Dept Cardiol, Wuhan, Peoples R China.
   [Yan, Feifei; Gong, Ming; Cai, Lin] Wuhan Univ, Zhongnan Hosp, Dept Orthoped, Wuhan, Peoples R China.
   [Yan, Feifei; Gong, Ming; Cai, Lin] Leishenshan Hosp, Dept Med Qual Control, Wuhan, Peoples R China.
   [Zhang, Xin A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
   [Bai, Jiao] Wuhan Univ, Dept Ultrasonog, Zhongnan Hosp, Wuhan, Peoples R China.
RP Lu, ZB (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Cardiol, Wuhan, Peoples R China.; Cai, L (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Orthoped, Wuhan, Peoples R China.; Cai, L (corresponding author), Leishenshan Hosp, Dept Med Qual Control, Wuhan, Peoples R China.; Bai, J (corresponding author), Wuhan Univ, Dept Ultrasonog, Zhongnan Hosp, Wuhan, Peoples R China.
EM baijiao2013@163.com; orthopedics@whu.edu.cn; luzhibing222@163.com
CR Argenziano MG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1996
   Bjorkhem-Bergman L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010702
   Blamoun AI, 2008, INT J CLIN PRACT, V62, P1373, DOI 10.1111/j.1742-1241.2008.01731.x
   Chalmers JD, 2010, RESP MED, V104, P1081, DOI 10.1016/j.rmed.2010.04.005
   China L, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00508
   Chopra V, 2012, AM J MED, V125, P1111, DOI 10.1016/j.amjmed.2012.04.011
   Crea F, 2017, CIRCULATION, V136, P1155, DOI 10.1161/CIRCULATIONAHA.117.029870
   De Spiegeleer A, 2020, J AM MED DIR ASSOC, V21, P909, DOI 10.1016/j.jamda.2020.06.018
   Dreher M, 2020, DTSCH ARZTEBL INT, V117, P271, DOI 10.3238/arztebl.2020.0271
   Fedson DS, 2015, J INFECT DIS, V211, P661, DOI 10.1093/infdis/jiu474
   Fernandez R, 2006, INTENS CARE MED, V32, P160, DOI 10.1007/s00134-005-2743-9
   Gowdy KM, 2013, PULM PHARMACOL THER, V26, P430, DOI 10.1016/j.pupt.2012.06.002
   Hariyanto Timotius Ivan, 2020, Diabetes Metab Syndr, V14, P1613, DOI 10.1016/j.dsx.2020.08.023
   Henry Christopher, 2018, Proc (Bayl Univ Med Cent), V31, P419, DOI 10.1080/08998280.2018.1499293
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hothersall E, 2006, THORAX, V61, P729, DOI 10.1136/thx.2005.057976
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Janda S, 2010, J CRIT CARE, V25
   Karalis DG, 2020, J CLIN LIPIDOL, V14, P396, DOI 10.1016/j.jacl.2020.06.009
   Liappis AP, 2001, CLIN INFECT DIS, V33, P1352, DOI 10.1086/323334
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Massachusetts General Hospital, 2020, MASS GEN HOSP COVID
   Mortensen EM, 2008, EUR RESPIR J, V31, P611, DOI 10.1183/09031936.00162006
   Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000
   Schuster H, 2004, AM HEART J, V147, P705, DOI 10.1016/j.ahj.2003.10.004
   Subir R, 2020, DIABETES METAB SYND, V14, P1225, DOI 10.1016/j.dsx.2020.07.011
   Tikoo K, 2015, BIOCHEM PHARMACOL, V93, P343, DOI 10.1016/j.bcp.2014.11.013
   Tleyjeh IM, 2009, ARCH INTERN MED, V169, P1658, DOI 10.1001/archinternmed.2009.286
   Viasus D, 2010, EUR J CLIN MICROBIOL, V29, P143, DOI 10.1007/s10096-009-0835-0
   WHO, 2020, CLIN MAN SEV AC RESP
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
NR 33
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 17
PY 2020
VL 7
AR 584870
DI 10.3389/fmed.2020.584870
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA OY6CH
UT WOS:000594332100001
PM 33330541
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Rashid, M
   Gale, CP
   Curzen, N
   Ludman, P
   De Belder, M
   Timmis, A
   Mohamed, MO
   Luscher, TF
   Hains, J
   Wu, JH
   Shoaib, A
   Kontopantelis, E
   Roebuck, C
   Denwood, T
   Deanfield, J
   Mamas, MA
AF Rashid (Hons), Muhammad
   Gale (Hons), Chris P.
   Curzen (Hons), Nick
   Ludman (Hons), Peter
   De Belder (Hons), Mark
   Timmis (Hons), Adam
   Mohamed (Hons), Mohamed O.
   Luescher (Hons), Thomas F.
   Hains (Hons), Julian
   Wu, Jianhua
   Shoaib, Ahmad
   Kontopantelis, Evangelos
   Roebuck, Chris
   Denwood, Tom
   Deanfield, John
   Mamas, Mamas A.
TI Impact of Coronavirus Disease 2019 Pandemic on the Incidence and
   Management of Out-of-Hospital Cardiac Arrest in Patients Presenting With
   Acute Myocardial Infarction in England
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE acute myocardial infarction; coronavirus disease 2019; incidence;
   mortality; out&#8208; of&#8208; hospital cardiac arrest
ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE ST-ELEVATION; MULTIPLE
   IMPUTATION; FRENCH REGISTRY; COVID-19; OUTCOMES; MORTALITY; SURVIVAL;
   INSIGHTS; THERAPY
AB Background
   Studies have reported significant reduction in acute myocardial infarction-related hospitalizations during the coronavirus disease 2019 (COVID-19) pandemic. However, whether these trends are associated with increased incidence of out-of-hospital cardiac arrest (OHCA) in this population is unknown.
   Methods and Results
   Acute myocardial infarction hospitalizations with OHCA during the COVID-19 period (February 1-May 14, 2020) from the Myocardial Ischaemia National Audit Project and British Cardiovascular Intervention Society data sets were analyzed. Temporal trends were assessed using Poisson models with equivalent pre-COVID-19 period (February 1-May 14, 2019) as reference. Acute myocardial infarction hospitalizations during COVID-19 period were reduced by >50% (n=20 310 versus n=9325). OHCA was more prevalent during the COVID-19 period compared with the pre-COVID-19 period (5.6% versus 3.6%), with a 56% increase in the incidence of OHCA (incidence rate ratio, 1.56; 95% CI, 1.39-1.74). Patients experiencing OHCA during COVID-19 period were likely to be older, likely to be women, likely to be of Asian ethnicity, and more likely to present with ST-segment-elevation myocardial infarction. The overall rates of invasive coronary angiography (58.4% versus 71.6%; P<0.001) were significantly lower among the OHCA group during COVID-19 period with increased time to reperfusion (mean, 2.1 versus 1.1 hours; P=0.05) in those with ST-segment-elevation myocardial infarction. The adjusted in-hospital mortality probability increased from 27.7% in February 2020 to 35.8% in May 2020 in the COVID-19 group (P<.001).
   Conclusions
   In this national cohort of hospitalized patients with acute myocardial infarction, we observed a significant increase in incidence of OHCA during COVID-19 period paralleled with reduced access to guideline-recommended care and increased in-hospital mortality.
C1 [Rashid (Hons), Muhammad; Mohamed (Hons), Mohamed O.; Shoaib, Ahmad; Mamas, Mamas A.] Keele Univ, Keele Cardiovasc Res Grp, Inst Prognosis Res, Sch Primary Care, Newcastle Upon Tyne, Tyne & Wear, England.
   [Rashid (Hons), Muhammad; Mohamed (Hons), Mohamed O.; Shoaib, Ahmad; Mamas, Mamas A.] Royal Stoke Hosp, Dept Cardiol, Stoke On Trent, Staffs, England.
   [Gale (Hons), Chris P.; Wu, Jianhua] Univ Leeds, Leeds Inst Data Analyt, Leeds, W Yorkshire, England.
   [Gale (Hons), Chris P.; Wu, Jianhua] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England.
   [Gale (Hons), Chris P.; Wu, Jianhua] Univ Leeds, Leeds Inst Cardiovasc & Metab Med, Leeds, W Yorkshire, England.
   [Curzen (Hons), Nick] Univ Southampton, Univ Hosp Southampton, Coronary Res Grp, Southampton, Hants, England.
   [Curzen (Hons), Nick] Univ Southampton, Fac Med, Southampton, Hants, England.
   [Ludman (Hons), Peter] Queen Elizabeth Hosp Birmingham, Dept Cardiol, Birmingham, W Midlands, England.
   [De Belder (Hons), Mark; Hains (Hons), Julian] Barts Hlth NHS Trust, Natl Inst Cardiovasc Outcomes Res, London, England.
   [Timmis (Hons), Adam] Queen Mary Univ London, Barts Heart Centre, London, England.
   [Luescher (Hons), Thomas F.] Royal Brompton Hosp, London, England.
   [Luescher (Hons), Thomas F.] Harefield Hosp, London, England.
   [Luescher (Hons), Thomas F.] Imperial Coll, London, England.
   [Luescher (Hons), Thomas F.] Univ Zurich, Ctr Mol Cardiol, Zurich, Switzerland.
   [Kontopantelis, Evangelos] Univ Manchester, Div Populat Hlth, Hlth Serv Res & Primary Care, Manchester, Lancs, England.
   [Roebuck, Chris; Denwood, Tom] NHS Digital, Leeds, W Yorkshire, England.
   [Deanfield, John] UCL, Inst Cardiovasc Sci, London, England.
   [Mamas, Mamas A.] Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA.
RP Rashid, M (corresponding author), Keele Univ, Sch Primary Social & Community Care, Ctr Prognosis, Keele Cardiovasc Res Grp, Stoke On Trent, Staffs, England.; Rashid, M (corresponding author), Royal Stoke Hosp, Dept Cardiol, Stoke On Trent, Staffs, England.
EM m.rashid@keele.ac.uk
OI Mamas, Mamas/0000-0001-9241-8890; Wu, Jianhua/0000-0001-6093-599X;
   Mohamed, Mohamed/0000-0002-9678-5222; Luescher,
   Thomas/0000-0002-5259-538X
FU University of Leeds; University of Keele; National Institute of Health
   ResearchNational Institute for Health Research (NIHR)
FX Dr Wu and Dr Gale are funded by the University of Leeds. Dr Mamas is
   funded by the University of Keele. Dr Rashid is funded by the National
   Institute of Health Research. The Myocardial Ischaemia National Audit
   Project is commissioned by the Health Quality Improvement Partnership as
   part of the National Clinical Audit and Patient Outcomes Programme. The
   funding organizations for this study had no involvement in the design
   and conduct of the study; collection, management, analysis, and
   interpretation of the data; preparation, review, or approval of the
   manuscript; or the decision to submit the manuscript for publication.
CR a R-M, 2020, J CLIN MED, V9
   Abdelaziz HK, 2020, AM HEART J, V226, P45, DOI 10.1016/j.ahj.2020.04.022
   Aldridge Robert W, 2020, Wellcome Open Res, V5, P88, DOI 10.12688/wellcomeopenres.15922.2
   Baldi E, 2020, NEW ENGL J MED, V383, P496, DOI 10.1056/NEJMc2010418
   Bebb O, 2017, EUR HEART J, V38, P974, DOI 10.1093/eurheartj/ehx008
   Borgia F, 2010, EUR HEART J, V31, P2156, DOI 10.1093/eurheartj/ehq204
   Cattle BA, 2011, STAT MED, V30, P2736, DOI 10.1002/sim.4314
   Chieffo A, 2020, EUROINTERVENTION, V16, P233, DOI 10.4244/EIJY20M05_01
   Danchin N, 2014, CIRCULATION, V129, P1629, DOI 10.1161/CIRCULATIONAHA.113.005874
   De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166
   De Rosa S, 2020, EUR HEART J, V41, P2083, DOI 10.1093/eurheartj/ehaa409
   DeFilippis EM, 2020, CIRCULATION, V141, P1833, DOI 10.1161/CIRCULATIONAHA.120.047260
   Edelson DP, 2020, CIRCULATION, V141, pE933, DOI 10.1161/CIRCULATIONAHA.120.047463
   Gale CP, 2012, HEART, V98, P1040, DOI 10.1136/heartjnl-2012-302469
   Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Hall M, 2016, JAMA-J AM MED ASSOC, V316, P1073, DOI 10.1001/jama.2016.10766
   Herrett E, 2010, HEART, V96, P1264, DOI 10.1136/hrt.2009.192328
   Huet F, 2020, ARCH CARDIOVASC DIS, V113, P303, DOI 10.1016/j.acvd.2020.04.002
   Khera R, 2018, OPEN HEART, V5, DOI 10.1136/openhrt-2018-000809
   Kwok CS, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.117.005866
   Lai PH, 2020, JAMA CARDIOL, V5, P1154, DOI 10.1001/jamacardio.2020.2488
   Mafham MM, 2020, LANCET, V396, P381, DOI 10.1016/S0140-6736(20)31356-8
   Mahmud E, 2020, J AM COLL CARDIOL, V76, P1375, DOI 10.1016/j.jacc.2020.04.039
   Metzler B, 2020, EUR HEART J, V41, P1852, DOI 10.1093/eurheartj/ehaa314
   Mohamed MO, 2019, INT J CARDIOL, V290, P7, DOI 10.1016/j.ijcard.2019.05.035
   Noman A, 2017, CATHETER CARDIO INTE, V89, P1195, DOI 10.1002/ccd.26882
   Pareek M, 2020, LANCET, V395, P1421, DOI 10.1016/S0140-6736(20)30922-3
   Puymirat E, 2017, CIRCULATION, V136, P1908, DOI 10.1161/CIRCULATIONAHA.117.030798
   Rashid M, 2020, CAN J CARDIOL, V36, P868, DOI 10.1016/j.cjca.2019.10.010
   Rashid M, 2020, INT J CARDIOL, V301, P7, DOI 10.1016/j.ijcard.2019.11.146
   Rashid M, 2019, EUR HEART J-QUAL CAR, V5, P292, DOI 10.1093/ehjqcco/qcz023
   Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908
   Solomon MD, 2020, NEW ENGL J MED, V383, P691, DOI 10.1056/NEJMc2015630
   Taxiarchi P, 2019, JACC-CARDIOVASC INTE, V12, P1479, DOI 10.1016/j.jcin.2019.03.030
   Wilkinson C, 2020, EUR HEART J-QUAL CAR, V6, P19, DOI 10.1093/ehjqcco/qcz052
NR 35
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD NOV 17
PY 2020
VL 9
IS 22
AR e018379
DI 10.1161/JAHA.120.018379
PG 20
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OY4KG
UT WOS:000594216700030
PM 33023348
OA DOAJ Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Shmakov, RG
   Prikhodko, A
   Polushkina, E
   Shmakova, E
   Pyregov, A
   Bychenko, V
   Priputnevich, TV
   Dolgushin, GO
   Yarotskaya, E
   Pekarev, O
   Bolibok, N
   Degtyarev, D
   Sukhikh, GT
AF Shmakov, Roman G.
   Prikhodko, Andrey
   Polushkina, Evgeniya
   Shmakova, Elena
   Pyregov, Aleksey
   Bychenko, Vladimir
   Priputnevich, Tatyana V.
   Dolgushin, Grigory O.
   Yarotskaya, Ekaterina
   Pekarev, Oleg
   Bolibok, Nikolai
   Degtyarev, Dmitriy
   Sukhikh, Gennady T.
TI Clinical course of novel COVID-19 infection in pregnant women
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article; Early Access
DE Pregnancy; maternal and perinatal outcomes; COVID-19; coronavirus;
   SARS-CoV-2
AB Objectives
   Evaluation of clinical course of COVID-19 during pregnancy and maternal and perinatal outcomes of this pregnancy.
   Methods
   66 women with polymerase chain reaction (PCR) - confirmed SARS-CoV-2 and their 42 neonates were included in the prospective observational study. Demographic, epidemiological, clinical, laboratory and instrumental data of pregnancy, delivery, postpartum period, including pharmacotherapy and neonatal outcomes were analyzed.
   Results
   15 (22.7%) women were asymptomatic, 25 (38%) had mild disease, while moderate and severe forms were detected in 20 (30.2%) and 6 (9.1%) cases, respectively. Additional oxygenation was required in 6 (9%) cases: 4 (6%) received CPAP therapy and 2 (3%) - mechanical ventilation. Main clinical symptoms were cough (51.5%), anosmia (34.9%), and hyperthermia (33.3%). Laboratory changes included increased levels of lactate dehydrogenase (LDH), creatinine, d-dimer, and C-reactive protein (CRP), anemia, and leukopenia. All pregnant women received low molecular weight heparin and interferon alfa-2b according to the National clinical recommendations. Antimicrobial drugs included Amoxicillin/Clavulanic acid (46%) and macrolides (28%) or carbapenems in severe cases of disease. Spontaneous abortion was reported in 6.1% of cases. Eight preterm (19%) and 34 term deliveries (81%) occurred. The mean weight of neonates was (3283 +/- 477) g, 1- and 5-min Apgar score was (7.8 +/- 0.6) and (8.7 +/- 0.5), respectively. No cases of neonatal COVID-19 infection were reported.
   Conclusions
   Mostly, the manifestations of COVID-19 were mild. However, 9% of cases were severe, and could contribute to preterm delivery or maternal morbidity. Main predictors of severe COVID-19 course in pregnant women were a decrease in the levels of erythrocytes and lymphocytes and increase in the levels of alanine aminotransferase and CRP. Elimination of the virus in pregnant women required more time due to altered immunity. No evidence of vertical transmission during pregnancy and delivery was found. However, the possibility of this cannot be excluded.
C1 [Shmakov, Roman G.; Pekarev, Oleg] Minist Healthcare Russian Federat, Inst Obstet, Natl Med Res Ctr Obstet Gynecol & Perinatol, Moscow, Russia.
   [Prikhodko, Andrey; Polushkina, Evgeniya] Minist Healthcare Russian Federat, Inst Obstet, Natl Med Res Ctr Obstet Gynecol & Perinatol, Dept Matern, Moscow, Russia.
   [Shmakova, Elena; Dolgushin, Grigory O.; Bolibok, Nikolai; Degtyarev, Dmitriy; Sukhikh, Gennady T.] Minist Healthcare Russian Federat, Natl Med Res Ctr Obstet Gynecol & Perinatol, Ac Oparina Str 4, Moscow 117997, Russia.
   [Pyregov, Aleksey] Minist Healthcare Russian Federat, Inst Anesthesiol, Moscow, Russia.
   [Pyregov, Aleksey] Minist Healthcare Russian Federat, Intens Care Natl Med Res Ctr Obstet Gynecol & Per, Moscow, Russia.
   [Bychenko, Vladimir] Minist Healthcare Russian Federat, Dept Radiol, Natl Med Res Ctr Obstet Gynecol & Perinatol, Moscow, Russia.
   [Priputnevich, Tatyana V.] Minist Healthcare Russian Federat, Dept Microbiol & Clin Pharmacol & Epidemiol, Natl Med Res Ctr Obstet Gynecol & Perinatol, Moscow, Russia.
   [Yarotskaya, Ekaterina] Minist Healthcare Russian Federat, Dept Int Cooperat, Natl Med Res Ctr Obstet Gynecol & Perinatol, Moscow, Russia.
RP Polushkina, E (corresponding author), Minist Healthcare Russian Federat, Natl Med Res Ctr Obstet Gynecol & Perinatol, Ac Oparina Str 4, Moscow 117997, Russia.
EM epolushkina@mail.ru
OI Shmakova, Elena/0000-0002-6228-725X
CR Alfaraj SH, 2019, J MICROBIOL IMMUNOL, V52, P501, DOI 10.1016/j.jmii.2018.04.005
   Allotey J, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3320
   [Anonymous], 2020, CORONAVIRUS DIS COVI
   [Anonymous], 2020, 2020 CTD
   Breslin N., 2020, AM J OBSTET GYNECOL, V2, P194
   Capanna F, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1749258
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1165
   Di Renzo GC, 2020, AM J OBSTET GYNECOL, V223, P135, DOI 10.1016/j.ajog.2020.04.017
   Forestieri S, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1771692
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacob CM, 2020, LANCET PUBLIC HEALTH, V5, pE624, DOI 10.1016/S2468-2667(20)30200-0
   Karimi-Zarchi M, 2020, FETAL PEDIATR PATHOL, V39, P246, DOI 10.1080/15513815.2020.1747120
   Liu DH, 2020, AM J ROENTGENOL, V215, P127, DOI [10.2214/AJR.20.23072, 10.1080/13813455.2020.1799018]
   Liu HH, 2020, J INFECTION, V80, pE7, DOI 10.1016/j.jinf.2020.03.007
   Maleki Dana Parisa, 2020, Infez Med, V28, P46
   Methodological recommendations, 2020, ORG MED CARE PREGNAN
   Mimouni F, 2020, J PERINATOL, V40, P820, DOI 10.1038/s41372-020-0665-6
   Muhidin S, 2020, ARCH ACAD EMERG MED, V8
   ODay MP, 1997, SEMIN PERINATOL, V21, P268, DOI 10.1016/S0146-0005(97)80069-9
   Parazzini F, 2020, INT J GYNECOL OBSTET, V150, P41, DOI 10.1002/ijgo.13166
   Poon LC, 2020, ULTRASOUND OBST GYN, V55, P700, DOI 10.1002/uog.22013
   [Приходько Андрей Михайлович Prikhod'ko Andrey M.], 2020, [Акушерство и гинекология, Akusherstvo i ginekologiya], P87, DOI 10.18565/aig.2020.7.87-92
   Savelyeva GM., 2000, MEDICINE, P481
   Schwartz DA, 2020, ARCH PATHOL LAB MED, V144, P799, DOI 10.5858/arpa.2020-0901-SA
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   Simpson S, 2020, J THORAC IMAG, V35, P219, DOI 10.1097/RTI.0000000000000524
   Westgren M, 2020, ACTA OBSTET GYN SCAN, V99, P815, DOI 10.1111/aogs.13900
   Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019
   Wu Y, 2020, BJOG-INT J OBSTET GY, V127, P1109, DOI 10.1111/1471-0528.16276
   Yan J, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.014
   Zhang I., 2020, ZHONGHUA FU CHAN KE, V55, P66
NR 33
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
DI 10.1080/14767058.2020.1850683
EA NOV 2020
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA OY1TJ
UT WOS:000594035100001
PM 33249969
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Sahu, SN
   Mishra, B
   Sahu, R
   Pattanayak, SK
AF Sahu, Satya Narayan
   Mishra, Biswajit
   Sahu, Rojalin
   Pattanayak, Subrat Kumar
TI Molecular dynamics simulation perception study of the binding affinity
   performance for main protease of SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARC-CoV-2 virus; binding affinity; drug likeness properties; molecular
   dynamics simulations; Gibbs free energy landscape
ID CHLOROQUINE; DRUG; CHEMISTRY; DOCKING; GROMACS; SARS
AB Like common cold and flu, SARC-CoV-2 virus spreads by droplets of sneezes or coughs which virus affects people of various age groups. Today, this virus is almost distributed all over the world. Since binding process plays a crucial role between host and receptor, therefore, we studied the molecules intended toward inhibition process through molecular docking and molecular dynamics simulation process. From the molecular docking study, it is noteworthy that remdesivir shows better binding affinity toward the main protease of SARS-CoV2 compared to other studied drugs. Within studied phytochemicals, carnosic acid shows better binding poses toward main protease of SARS-CoV2 among studied phytochemicals. The amino acid residues GLN110 and PHE294 were almost found in all the studied interactions of drugs and phytochemicals with main protease of SARS-CoV-2. Furthermore, the results show a larger contribution of the Van der Waals energies as compared to others like electrostatic energies suggesting that ligands at the binding pocket are predominantly stabilized by hydrophobic interactions. The conformational change during ligand binding was predicted from Gibbs free energy landscape analysis through molecular dynamics simulation. We observed that, there were two main free energy basins for both docked carnosic acid complex and for docked remdesivir complex, only one main free energy basin was found in the global free energy minimum region.
   Communicated by Ramaswamy H. Sarma
C1 [Sahu, Satya Narayan; Mishra, Biswajit; Sahu, Rojalin] Deemed Be Univ, Sch Appl Sci, Kalinga Inst Ind Technol KIIT, Bhubaneswar 751024, India.
   [Pattanayak, Subrat Kumar] Natl Inst Technol, Dept Chem, Raipur 492010, Madhya Pradesh, India.
RP Sahu, R (corresponding author), Deemed Be Univ, Sch Appl Sci, Kalinga Inst Ind Technol KIIT, Bhubaneswar 751024, India.; Pattanayak, SK (corresponding author), Natl Inst Technol, Dept Chem, Raipur 492010, Madhya Pradesh, India.
EM rsahufch@kiit.ac.in; skpiitbbs@gmail.com
CR Al-Obaidi A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1774417
   ALASADI A, 2018, CELL DEATH DIS, V9, DOI DOI https://doi.org/10.1038/s41419-017-0092-6
   ANDREWS P, 1982, PHARMACOL THERAPEUT, V19, P245, DOI 10.1016/0163-7258(82)90064-X
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   Bissoyi A, 2017, VIRAL PROTEASES AND THEIR INHIBITORS, P77, DOI 10.1016/B978-0-12-809712-0.00004-6
   Boelaert JR, 2001, J CLIN VIROL, V20, P137, DOI 10.1016/S1386-6532(00)00140-2
   Bunyapraphatsara N, 2000, PHYTOMEDICINE, V6, P421, DOI 10.1016/S0944-7113(00)80069-0
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chand A., 2018, MOL BASIS EMERG STRA, DOI [10.1007/978-981-13-1699-9_12, DOI 10.1007/978-981-13-1699-9_12]
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Curini M, 2006, CURR MED CHEM, V13, P199, DOI 10.2174/092986706775197890
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Das P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1796799
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Ewald PP, 1921, ANN PHYS-BERLIN, V64, P253
   Gassen NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13659-4
   Ghosh R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779818
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Havranek B, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1776158, 10.1080/07391102.2020.1805018]
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hsieh PW, 2004, J NAT PROD, V67, P1175, DOI 10.1021/np0400196
   Keshtkar-Jahromi M, 2020, AM J TROP MED HYG, V102, P932, DOI 10.4269/ajtmh.20-0230
   Kumar Y, 2020, J INFECT PUBLIC HEAL, V13, P1210, DOI 10.1016/j.jiph.2020.06.016
   Leung E. L. H., 2020, ENGINEERING, DOI [https://doi.org/10.1016/j.eng.2020.08.009, 10.1016/j.eng.2020.08.009, DOI 10.1016/J.ENG.2020.08.009]
   Mahato DR, 2018, J BIOMOL STRUCT DYN, V36, P2618, DOI 10.1080/07391102.2017.1364671
   Mani JS, 2020, VIRUS RES, V284, DOI 10.1016/j.virusres.2020.197989
   Manoharan P, 2018, J BIOMOL STRUCT DYN, V36, P1878, DOI 10.1080/07391102.2017.1337590
   Martonak R, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.075503
   Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146
   Mizuiri Sonoo, 2015, World J Nephrol, V4, P74, DOI 10.5527/wjn.v4.i1.74
   Panda J, 2019, J MOL LIQ, V278, P536, DOI 10.1016/j.molliq.2019.01.033
   Plantone D, 2018, CLIN DRUG INVEST, V38, P653, DOI 10.1007/s40261-018-0656-y
   Rane JS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1794969
   Romanelli F, 2004, CURR PHARM DESIGN, V10, P2643, DOI 10.2174/1381612043383791
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Sahu SN, 2019, J MOL STRUCT, V1198, DOI 10.1016/j.molstruc.2019.126936
   Sahu SN, 2019, J MOL LIQ, V281, P549, DOI 10.1016/j.molliq.2019.02.120
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   SHIN HB, 2013, VIROL J, V10, DOI DOI https://doi.org/10.1186/1743-422X-10-303
   Shin MS, 2005, ANTIVIR RES, V67, P163, DOI 10.1016/j.antiviral.2005.06.005
   Farias KJS, 2014, MICROBIOL IMMUNOL, V58, P318, DOI 10.1111/1348-0421.12154
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Trapani A, 2005, INT J PHARMACEUT, V295, P163, DOI 10.1016/j.ijpharm.2005.02.013
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Visualizer D. S, 2013, VERSION 2 0 1 7347
   Vraka C, 2017, NUCL MED BIOL, V50, P1, DOI 10.1016/j.nucmedbio.2017.03.003
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yousefifard M, 2020, ARCH ACAD EMERG MED, V8
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Yuan J, 2020, INFLAMM RES, V69, P599, DOI 10.1007/s00011-020-01342-0
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110429
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhu S., 2020, DISCOVERIES, V8, P105, DOI DOI https://doi.org/10.15190/d.2020.2
   Zhu XJ, 2013, J THORAC DIS, V5, pS142, DOI 10.3978/j.issn.2072-1439.2013.06.06
NR 69
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1850362
EA NOV 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OU8DU
UT WOS:000591754400001
PM 33228481
OA Bronze
DA 2021-01-01
ER

PT J
AU Mayssam, N
   Silvia, S
   Idris, G
AF Mayssam, Nehme
   Silvia, Stringhini
   Idris, Guessous
CA SEROCoV-POP Study Team
TI Perceptions of immunity and vaccination certificates among the general
   population: a nested study within a serosurvey of anti-SARS-CoV-2
   antibodies (SEROCoV-POP)
SO SWISS MEDICAL WEEKLY
LA English
DT Article
DE vaccination certificate; immunity certificate; COVID-19; anti-SARS-CoV-2
   antibodies; travel
ID PASSPORTS
AB At a time when COVID-19 immunity certificates are debated and vaccination certificates might potentially be made available if an effective vaccine is established, we conducted a study to elucidate public opinion on this issue. Our objective was to determine social and individual perceptions of COVID-19 immunity certificates through a population-based study.
   A nested survey within the SEROCoV-POP study, a population-based serosurvey of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland, was conducted with a self-administered questionnaire. The questionnaire was proposed to 1520 SEROCoV-POP participants. Measures included percentage of participants agreeing or disagreeing with statements on immunity and vaccination certificates. Stratification by age, gender, education and work status was used to examine socio-demographic variations.
   Of the 1520 SEROCoV-POP participants, 1425 completed the questionnaire (response rate 93%; mean age +/- standard deviation 52 +/- 15.1 years; 51.9% women). About 80% of participants agreed that knowing one's serology status would lead to a change in one's behaviour. In the event that the presence of antibodies correlated with immunity, 60% of participants reported that certificates should be offered to the general population. The results showed variations in perceptions of certificates depending on the context (73% agreed on certificates' utility for travel, 72% for entering a country, and 32% for the right to work). Provided an effective vaccine was available, 55% of participants agreed that vaccination should be mandatory and 49% agreed that a vaccination certificate should be mandatory. About 68% reported a potential risk of discrimination and 28% a risk of deliberate infection. Differences were seen with age, gender and education level.
   This study shows that the general adult population in Geneva, Switzerland can envisage scenarios where COVID-19 immunity, and eventually vaccination, certificates would be useful. Seroprevalence estimates of anti-SARS-CoV-2 antibodies remain low to date, and the interpretability of serological testing and immunity remains undefined. However, the information from this study is important, especially the differences based on context and the socio-demographic variations, and should be taken into account if COVID-19-related certificates are to be implemented.
C1 [Mayssam, Nehme; Silvia, Stringhini; Idris, Guessous] Geneva Univ Hosp, Div Primary Care, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland.
   [Silvia, Stringhini; Idris, Guessous] Univ Geneva, Fac Med, Geneva, Switzerland.
   [Silvia, Stringhini; Idris, Guessous] Univ Geneva, Fac Med, Geneva, Switzerland.
   [Silvia, Stringhini] Univ Lausanne, Univ Ctr Gen Med & Publ Hlth, Lausanne, Switzerland.
RP Mayssam, N (corresponding author), Geneva Univ Hosp, Div Primary Care, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland.
EM Mayssam.nehme@hcuge.ch
CR Childress JF, 2002, J LAW MED ETHICS, V30, P170, DOI 10.1111/j.1748-720X.2002.tb00384.x
   de Mestral C, 2020, DIABETIC MED, V37, P1374, DOI 10.1111/dme.14206
   Goldstein Dana, 2020, NY TIMES
   Hall MA, 2020, JAMA-J AM MED ASSOC, V323, P2243, DOI 10.1001/jama.2020.7712
   Havers FP, 2020, JAMA INTERN MED, DOI [10.1001/jamaintern-, DOI 10.1001/JAMAINTERN]
   Kofler N, 2020, NATURE, V581, P379, DOI 10.1038/d41586-020-01451-0
   Laing A., 2020, REUTERS
   Miller J., 2020, REUTERS
   National COVID-19 Science Task Force (NCS-TF), 2020, ETH LEG SOC ISS ASS
   OECD, 2020, EV IN IMP COVID 19 C
   Persad G, 2020, JAMA-J AM MED ASSOC, V323, P2241, DOI 10.1001/jama.2020.8102
   Phelan AL, 2020, LANCET, V395, P1595, DOI 10.1016/S0140-6736(20)31034-5
   Proctor K., 2020, GUARDIAN
   Roberton T, 2020, LANCET GLOB HEALTH, V8, pE901, DOI 10.1016/S2214-109X(20)30229-1
   Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0
   World Health Organization, IMM PASSP CONT COVID
   Wright L, 2020, J EPIDEMIOL COMMUN H, V74, P764, DOI [10.1136/jech-2020-214227, 10.1136/jech-2020-214475]
NR 17
TC 0
Z9 0
U1 0
U2 0
PU E M H SWISS MEDICAL PUBLISHERS LTD
PI MUTTENZ
PA FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND
SN 1424-7860
EI 1424-3997
J9 SWISS MED WKLY
JI Swiss Med. Wkly.
PD NOV 17
PY 2020
VL 150
AR w20398
DI 10.4414/smw.2020.20398
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OW3PJ
UT WOS:000592802800001
PM 33202421
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Marshall, HD
AF Marshall, Henry D.
TI Covid-19 vaccine trials: we must preserve the ends when communicating
   the means
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Letter
C1 [Marshall, Henry D.] Royal London Hosp, London E1 1FR, England.
RP Marshall, HD (corresponding author), Royal London Hosp, London E1 1FR, England.
EM henryduncan.marshall@nhs.net
CR Ipsos, 2020, 3 4 AD GLOB SAY THEY
   MAHASE E, 2020, BMJ-BRIT MED J, V371, DOI DOI 10.1136/BMJ.M4042
NR 2
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD NOV 17
PY 2020
VL 371
AR m4392
DI 10.1136/bmj.m4392
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA OU4UU
UT WOS:000591526100014
OA Bronze
DA 2021-01-01
ER

PT J
AU Aishwarya, S
   Gunasekaran, K
   Margret, AA
AF Aishwarya, S.
   Gunasekaran, K.
   Margret, A. Anita
TI Computational gene expression profiling in the exploration of
   biomarkers, non-coding functional RNAs and drug perturbagens for
   COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; bioconductor; differential gene expression; miRNAs; lncRNAs;
   drug perturbations
ID ENRICHMENT
AB The coronavirus disease, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a global health crisis that is being endured with an increased alarm of transmission each day. Though the pandemic has activated innumerable research attention to decipher an antidote, fundamental understanding of the molecular mechanisms is necessary to halt the disease progression. The study focused on comparison of the COVID-19 infected lung tissue gene expression datasets -GSE155241 and GSE150316 with the GEO2R-limma package. The significant up- and downregulated genes were annotated. Further evaluation of the enriched pathways, transcription factors, kinases, noncoding RNAs and drug perturbations revealed the significant molecular mechanisms of the host response. The results revealed a surge in mitochondrial respiration, cytokines, neurodegenerative mechanisms and deprived oxygen, iron, copper, and glucose transport. Hijack of ubiquitination by SARS-CoV-2, hox gene differentiation, histone modification, and miRNA biogenesis were the notable molecular mechanisms inferred. Long non-coding RNAs such as C058791.1, TTTY15 and TPTEP1 were predicted to be efficient in regulating the disease mechanisms. Drugs-F-1566-0341, Digoxin, Proscillaridin and Linifanib that reverse the gene expression signatures were predicted from drug perturbations analysis. The binding efficiency and interaction of proscillaridin and digoxin as obtained from the molecular docking studies confirmed their therapeutic potential. Two overlapping upregulated genes MDH1, SGCE and one downregulated gene PFKFB3 were appraised as potential biomarkers candidates. The upregulation of PGM5, ISLR and ANK2 as measured from their expressions in normal lungs affirmed their possible prognostic biomarker competence. The study explored significant insights for better diagnosis, and therapeutic options for COVID-19.
   Communicated by Ramaswamy H. Sarma
C1 [Aishwarya, S.] Stella Maris Coll, Dept Bioinformat, Chennai, Tamil Nadu, India.
   [Aishwarya, S.; Gunasekaran, K.] Univ Madras, Ctr Adv Study Crystallog & Biophys, Chennai, Tamil Nadu, India.
   [Margret, A. Anita] Bishop Heber Coll, Dept Biotechnol, Tiruchirappalli, Tamil Nadu, India.
RP Aishwarya, S (corresponding author), Stella Maris Coll, Dept Bioinformat, Chennai, Tamil Nadu, India.
EM aishwarya@stellamariscollege.edu.in
RI A, Anita Margret/ABI-4579-2020
OI A, Anita Margret/0000-0002-0417-2462; Gunasekaran,
   Krishnasamy/0000-0001-9027-0108; S, Aishwarya/0000-0002-5112-9379
FU Department of Science and Technology (DST), New Delhi, India, through
   FIST ProgrammeDepartment of Science & Technology (India)Department of
   Science & Technology (DOST), Philippines [SR/FIST/College-252-C.Dy,
   3555/IFD/2016-2017]; DST-FIST grantDepartment of Science & Technology
   (India); CASChinese Academy of Sciences
FX The authors are obligated to the management of Stella Maris College
   Chennai, Tamil Nadu, India. The facility provided by seed research grant
   is immensely accredited. The Schrodinger software used in the study was
   procured from the grant of Department of Science and Technology (DST),
   New Delhi, India, through FIST Programme (Level -0, No:
   SR/FIST/College-252-C.Dy.No.3555/IFD/2016-2017), to Stella Maris
   College, Chennai, India. DST-FIST grant is greatly acknowledged. The
   support extended by the CAS in Crystallography and Biophysics,
   University of Madras, Chennai, India and Bishop Heber College,
   Tiruchirappalli is extensively gratified.
CR Ahmad SA, 2001, CANCER RES, V61, P1255
   Amarelle L, 2017, ARCH BRONCONEUMOL, V53, P19, DOI 10.1016/j.arbres.2016.07.004
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   BAKER N, 2020, PHARM RES DORDR, V37, DOI DOI https://doi.org/10.1007/s11095-020-02842-8
   Bedre R., 2020, RENESHBEDRE BIOINFOK, DOI [https://doi.org/10.5281/zenodo.3965241, DOI 10.5281/ZENODO.3965241]
   Bermudo-Soriano CR, 2009, PROG NEURO-PSYCHOPH, V33, P345, DOI 10.1016/j.pnpbp.2008.12.015
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Broeks MH, 2019, HUM GENET, V138, P1247, DOI 10.1007/s00439-019-02063-z
   Cagliani R, 2020, J VIROL, V94, DOI 10.1128/JVI.00411-20
   CANTINI L, 2017, NPJ SYST BIOL APPL, V3, DOI DOI https://doi.org/10.1038/s41540-017-0038-8
   Chang L, 2020, NUCLEIC ACIDS RES, V48, pW244, DOI 10.1093/nar/gkaa467
   Chen J., 2016, BIO PROTOC, V6, pe2079, DOI DOI https://doi.org/10.1038/srep29382
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Cogill SB, 2014, CANCER INFORM, V13, P49, DOI 10.4137/CIN.S14070
   Da Costa EM, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1242-8
   Davis CA, 2018, NUCLEIC ACIDS RES, V46, pD794, DOI 10.1093/nar/gkx1081
   Desai Niyati, 2020, medRxiv, DOI 10.1101/2020.07.30.20165241
   Ding HD, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1193-0
   DONG L, 2018, MEDICINE, V97, DOI DOI https://doi.org/10.1097/md.0000000000010362
   Dubitzky W., 2013, ENCY SYSTEMBIOL
   Emery A. E. H., 2001, MUSCULAR DYSTROPHIES
   ENOMOTO Y, 2017, SCI REP UK, V7, DOI DOI https://doi.org/10.1038/s41598-017-07853-x
   Fabregat A, 2018, BIOINFORMATICS, V34, P1208, DOI 10.1093/bioinformatics/btx752
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Ham O, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0134-x
   Han Yuling, 2020, bioRxiv, DOI 10.1101/2020.05.05.079095
   Hou T, 2019, INT J CLIN EXP PATHO, V12, P4002
   Hsu PWC, 2007, NUCLEIC ACIDS RES, V35, pD381, DOI 10.1093/nar/gkl1009
   HUANG H, 2018, BMC CANCER, V18, DOI DOI https://doi.org/10.1186/s12885-018-4714-x
   Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779131
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Lachmann A, 2009, BIOINFORMATICS, V25, P684, DOI 10.1093/bioinformatics/btp026
   LAI I, 2019, INT J MOL SCI, V20, DOI DOI https://doi.org/10.3390/ijms20143473
   LEI FC, 2019, PEERJ, V7, DOI DOI https://doi.org/10.7717/peerj.7135
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li SC, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-164
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Mackenzie EL, 2008, ANTIOXID REDOX SIGN, V10, P997, DOI 10.1089/ars.2007.1893
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   MOHLER PJ, 2007, PLOS ONE, V2, DOI DOI https://doi.org/10.1371/journal.pone.0001051
   MONROIGBOSQUE PD, 2018, SCI REP UK, V8, DOI DOI https://doi.org/10.1038/s41598-018-30989-3
   Nagasawa A, 1999, GENOMICS, V61, P37, DOI 10.1006/geno.1999.5934
   OGIDIGO JO, 2020, J BIOMOL STRUCT 1024, DOI DOI https://doi.org/10.1080/07391102.2020.1837681
   Papatheodorou I, 2020, NUCLEIC ACIDS RES, V48, pD77, DOI 10.1093/nar/gkz947
   Perez S, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008181
   Prohaska JR, 2008, AM J CLIN NUTR, V88, p826S
   Ravi Kumar A, 2000, Indian Heart J, V52, P315
   Redell MS, 2005, CURR PHARM DESIGN, V11, P2873, DOI 10.2174/1381612054546699
   Ritsner M. S., 2011, HDB SCHIZOPHRENIA SP
   Rivals I, 2007, BIOINFORMATICS, V23, P401, DOI 10.1093/bioinformatics/btl633
   Saddala MS, 2020, DATA BRIEF, V31, DOI 10.1016/j.dib.2020.105915
   SADDALA MS, 2020, BMC GENOMICS, V21, DOI DOI https://doi.org/10.1186/s12864-020-6550-z
   Sears A., 2009, HUMAN COMPUTER INTER
   SHIVANIKA C, 2020, J BIOMOL STRUCT 0903, DOI DOI https://doi.org/10.1080/07391102.2020.1815584
   STEPHENS KE, 2019, BMC GENOMICS, V20, DOI DOI https://doi.org/10.1186/s12864-019-5512-9
   SUN YF, 2019, CANCER CELL INT, V19, DOI DOI https://doi.org/10.1186/s12935-019-0967-y
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Vishvakarma V. K., PREPRINT, DOI [https://doi.org/10.26434/chemrxiv.12891656.v1, DOI 10.26434/CHEMRXIV.12891656.V1]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   WANG P, 2019, FRONT IMMUNOL, V9, DOI DOI https://doi.org/10.3389/fimmu.2018.03138
   Wang ZC, 2018, BIOINFORMATICS, V34, P2150, DOI 10.1093/bioinformatics/bty060
   WEN J, 2019, BMC MED GENOMICS S7, V12, DOI DOI https://doi.org/10.1186/s12920-019-0597-1
   Wong RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003241
   WU MN, 2019, SCI REP UK, V9, DOI DOI https://doi.org/10.1038/s41598-019-52883-2
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   YE CY, 2018, NAT COMMUN, V9, DOI DOI https://doi.org/10.1038/s41467-018-06500-x
   Yousefi H, 2020, ONCOGENE, V39, P953, DOI 10.1038/s41388-019-1040-y
   ZERR I, 2019, BIOMOLECULES, V9, DOI DOI https://doi.org/10.3390/biom9120800
   Zhao P, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/6069189
   Zhou HH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040610
   Zhou QQ, 2019, EXP THER MED, V18, P4011, DOI 10.3892/etm.2019.8035
   ZHU H, 2020, CURR CARDIOL REP, V22, DOI DOI https://doi.org/10.1007/s11886-020-01302-4
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 79
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1850360
EA NOV 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OV2DJ
UT WOS:000592026900001
PM 33228475
OA Bronze
DA 2021-01-01
ER

PT J
AU Elekofehinti, OO
   Iwaloye, O
   Josiah, SS
   Lawal, AO
   Akinjiyan, MO
   Ariyo, EO
AF Elekofehinti, Olusola Olalekan
   Iwaloye, Opeyemi
   Josiah, Sunday Solomon
   Lawal, Akeem Olalekan
   Akinjiyan, Moses Orimoloye
   Ariyo, Esther Opeyemi
TI Molecular docking studies, molecular dynamics and ADME/tox reveal
   therapeutic potentials of STOCK1N-69160 against papain-like protease of
   SARS-CoV-2
SO MOLECULAR DIVERSITY
LA English
DT Article; Early Access
DE Coronavirus; Drug design; Molecular dynamics; Natural compounds;
   STOCKIN-69160; SARS-CoV-2
ID DRUG DISCOVERY; CORONAVIRUS; PNEUMONIA; OUTBREAK; RECEPTOR; RULE
AB SARS-CoV-2 is a new strain of Coronavirus that caused the pneumonia outbreak in Wuhan, China and has spread to over 200 countries of the world. It has received worldwide attention due to its virulence and high rate of infection. So far, several drugs have experimented against SARS-CoV-2, but the failure of these drugs to specifically interact with the viral protease necessitates urgent measure to boost up researches for the development of effective therapeutics against SARS-CoV-2. Papain-like protease (PLpro) of the viral polyproteins is essential for maturation and infectivity of the virus, making it one of the prime targets explored for SARS-CoV-2 drug design. This study was conducted to evaluate the efficacy of similar to 50,000 natural compounds retrieved from IBS database against COVID-19 PLpro using computer-aided drug design. Based on molecular dock scores, molecular interaction with active catalytic residues and molecular dynamics (MD) simulations studies, STOCK1N-69160 [(S)-2-((R)-4-((R)-2-amino-3-methylbutanamido)-3-(4-chlorophenyl) butanamido) propanoic acid hydrochloride] has been proposed as a novel inhibitor against COVID-19 PLpro. It demonstrated favourable docking score, the free energy of binding, interacted with key amino acid residues necessary for PLpro inhibition and also showed significant moderation for parameters investigated for ADME/tox (Adsorption, distribution, metabolism, excretion and toxicological) properties. The edge of the compound was further established by its stability in MD simulation conducted for 30 ns employing GROMACS software. We propose that STOCK1N-69160 is worth further investigation for preventing SARS-CoV-2.
   [GRAPHICS]
   .
C1 [Elekofehinti, Olusola Olalekan; Iwaloye, Opeyemi; Lawal, Akeem Olalekan; Akinjiyan, Moses Orimoloye; Ariyo, Esther Opeyemi] Fed Univ Technol Akure, Dept Biochem, Bioinformat & Mol Biol Unit, Ondo, Nigeria.
   [Josiah, Sunday Solomon] Fed Univ Technol Akure, Dept Biochem, Phytomed Biochem Pharmacol & Toxicol Unit, Ondo, Nigeria.
RP Elekofehinti, OO (corresponding author), Fed Univ Technol Akure, Dept Biochem, Bioinformat & Mol Biol Unit, Ondo, Nigeria.
EM ooelekofehinti@futa.edu.ng
OI Elekofehinti, Olusola/0000-0002-7921-7047
CR [Anonymous], 2018, SCHROD REL 201 8 4 L
   [Anonymous], 2016, SCHROD REL 2020 2 IN
   [Anonymous], 2018, SCHROD REL 201 8 4 Q
   [Anonymous], 2020, SCHROD REL 2020 2 PR
   Baell J, 2013, FUTURE MED CHEM, V5, P745, DOI [10.4155/fmc.13.61, 10.4155/FMC.13.61]
   Baez-Santos YM, 2014, J VIROL, V88, P12511, DOI 10.1128/JVI.01294-14
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang KO, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020197
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cho JK, 2013, BIOORGAN MED CHEM, V21, P3051, DOI 10.1016/j.bmc.2013.03.027
   Congreve M, 2003, DRUG DISCOV TODAY, V8, P876, DOI 10.1016/S1359-6446(03)02831-9
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Elekofehinti Olusola O, 2020, Curr Drug Discov Technol, DOI 10.2174/1570163817999200918103705
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grant MC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234765
   Guedes Isabella A, 2014, Biophys Rev, V6, P75, DOI 10.1007/s12551-013-0130-2
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Iwaloye Opeyemi, 2020, In Silico Pharmacology, V8, P2, DOI 10.1007/s40203-020-00054-x
   Iwaloye O, 2020, NETW MODEL ANAL HLTH, V9, DOI 10.1007/s13721-020-00262-7
   John Hopkins University, 2020, COVID 19 DASHB CTR S
   Koster H, 2011, J MED CHEM, V54, P7784, DOI 10.1021/jm200642w
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lambel F, 2020, SOMALI MEDICS REPORT
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu X., 2020, POTENTIAL INHIBITORS, DOI [10.1101/2020.01.29.924100, DOI 10.1101/2020.01.29.924100]
   Lumber JL, 2020, AFRICAN COUNTRIES RE
   Maffucci I, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00043
   Mielech AM, 2014, VIRUS RES, V194, P184, DOI 10.1016/j.virusres.2014.01.025
   Park JY, 2012, BIOL PHARM BULL, V35, P2036, DOI 10.1248/bpb.b12-00623
   Park JY, 2012, BIOORGAN MED CHEM, V20, P5928, DOI 10.1016/j.bmc.2012.07.038
   Rampogu S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4050-1
   Sherman W, 2006, CHEM BIOL DRUG DES, V67, P83, DOI 10.1111/j.1747-0285.2005.00327.x
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P22035, DOI 10.1039/c4cp03179b
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wei XS, 2020, LANCET RESP MED, DOI [10.2139/ssrn.3546120, DOI 10.2139/SSRN.3546120]
   WHO, 2020, DIR GEN OP REM MED B
   World Health Organization, 2019, PRIOR DIS RES DEV EM
   World Health Organization, 2015, BLUEPR R D PREP RES
   World Health Organization, 2020, COR DIS
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yang HB, 2018, J CHEM INF MODEL, V58, P2051, DOI 10.1021/acs.jcim.8b00532
   Zhang MQ, 2007, CURR OPIN BIOTECH, V18, P478, DOI 10.1016/j.copbio.2007.10.005
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 54
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1381-1991
EI 1573-501X
J9 MOL DIVERS
JI Mol. Divers.
DI 10.1007/s11030-020-10151-w
EA NOV 2020
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry,
   Medicinal; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA OS9HT
UT WOS:000590468400001
PM 33201386
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pretorius, E
   Venter, C
   Laubscher, GJ
   Lourens, PJ
   Steenkamp, J
   Kell, DB
AF Pretorius, Etheresia
   Venter, Chantelle
   Laubscher, Gert Jacobus
   Lourens, Petrus Johannes
   Steenkamp, Janami
   Kell, Douglas B.
TI Prevalence of readily detected amyloid blood clots in 'unclotted' Type 2
   Diabetes Mellitus and COVID-19 plasma: a preliminary report
SO CARDIOVASCULAR DIABETOLOGY
LA English
DT Article
DE COVID-19; Coagulopathies; Amyloid; Pathologies
ID FIBRIL FORMATION; COAGULATION; IRON; FERRITIN; PRODUCT
AB Background Type 2 Diabetes Mellitus (T2DM) is a well-known comorbidity to COVID-19 and coagulopathies are a common accompaniment to both T2DM and COVID-19. In addition, patients with COVID-19 are known to develop micro-clots within the lungs. The rapid detection of COVID-19 uses genotypic testing for the presence of SARS-Cov-2 virus in nasopharyngeal swabs, but it can have a poor sensitivity. A rapid, host-based physiological test that indicated clotting severity and the extent of clotting pathologies in the individual who was infected or not would be highly desirable. Methods Platelet poor plasma (PPP) was collected and frozen. On the day of analysis, PPP samples were thawed and analysed. We show here that microclots can be detected in the native plasma of twenty COVID-19, as well as ten T2DM patients, without the addition of any clotting agent, and in particular that such clots are amyloid in nature as judged by a standard fluorogenic stain. Results were compared to ten healthy age-matched individuals. Results In COVID-19 plasma these microclots are significantly increased when compared to the levels in T2DM. Conclusions This fluorogenic test may provide a rapid and convenient test with 100% sensitivity (P < 0.0001) and is consistent with the recognition that the early detection and prevention of such clotting can have an important role in therapy.
C1 [Pretorius, Etheresia; Venter, Chantelle; Kell, Douglas B.] Stellenbosch Univ, Fac Sci, Dept Physiol Sci, Private Bag X1, ZA-7602 Stellenbosch, Matieland, South Africa.
   [Laubscher, Gert Jacobus; Lourens, Petrus Johannes] Mediclin Stellenbosch, Suite 104,1 Elsie Toit St, ZA-7600 Stellenbosch, South Africa.
   [Steenkamp, Janami] PathCare Business Ctr, PathCare Labs, Neels Bothma St,N1, ZA-7460 Cape Town, South Africa.
   [Kell, Douglas B.] Univ Liverpool, Fac Hlth & Life Sci, Inst Syst Mol & Integrat Biol, Dept Biochem & Syst Biol, Liverpool L69 7ZB, Merseyside, England.
   [Kell, Douglas B.] Tech Univ Denmark, Novo Nordisk Fdn, Ctr Biosustainabil, Bldg 220, DK-2800 Lyngby, Denmark.
RP Pretorius, E; Kell, DB (corresponding author), Stellenbosch Univ, Fac Sci, Dept Physiol Sci, Private Bag X1, ZA-7602 Stellenbosch, Matieland, South Africa.; Kell, DB (corresponding author), Univ Liverpool, Fac Hlth & Life Sci, Inst Syst Mol & Integrat Biol, Dept Biochem & Syst Biol, Liverpool L69 7ZB, Merseyside, England.
EM resiap@sun.ac.za; dbk@liv.ac.uk
RI Kell, Douglas/E-8318-2011
OI Kell, Douglas/0000-0001-5838-7963
FU Medical Research Council of South Africa (MRC) [A0X331]; Novo Nordisk
   FoundationNovo Nordisk Foundation [NNF10CC1016517]
FX We thank the Medical Research Council of South Africa (MRC)
   (Self-Initiated Research Program: A0X331) for supporting this
   collaboration. DBK thanks the Novo Nordisk Foundation for funding (Grant
   NNF10CC1016517). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520
   Bakchoul T, 2020, FIBRINOLYSIS SHUT CO, V1, DOI 10.1016/j.tru.2020.100008
   Buys AV, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-25
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   de Villiers S, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01262
   Dorgalaleh A, 2020, SEMIN THROMB HEMOST, V46, P815, DOI 10.1055/s-0040-1713434
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Francone M, 2020, EUR RADIOL
   Gomez-Pastora J, 2020, CLIN CHIM ACTA, V509, P249, DOI 10.1016/j.cca.2020.06.033
   Goshua G, 2020, LANCET HAEMATOL, V7, pE575, DOI 10.1016/S2352-3026(20)30216-7
   Grobler C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145168
   Iba T, 2020, J THROMB HAEMOST
   Iba T, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03077-0
   Jamal Alainna J, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa848
   Kander T, 2020, LANCET HAEMATOL
   Kell DB, 2018, BIOL REV, V93, P1518, DOI 10.1111/brv.12407
   Kell DB, 2018, SEMIN THROMB HEMOST, V44, P224, DOI 10.1055/s-0037-1604108
   Kell DB, 2017, PROG BIOPHYS MOL BIO, V123, P16, DOI 10.1016/j.pbiomolbio.2016.08.006
   Kell DB, 2014, METALLOMICS, V6, P748, DOI 10.1039/c3mt00347g
   Levi M, 2020, SEMIN THROMB HEMOST
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Liao D, 2020, LANCET HAEMATOL
   Malmos KG, 2017, AMYLOID, V24, P1, DOI 10.1080/13506129.2017.1304905
   Matacic C, 2020, SCIENCE, V368, P1039, DOI 10.1126/science.368.6495.1039
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meng H, 2020, J INFECTION, V81, pE33, DOI 10.1016/j.jinf.2020.04.004
   Nielsen VG, 2008, THROMB RES, V122, P145, DOI 10.1016/j.thromres.2007.09.003
   Nielsen VG, 2007, BLOOD COAGUL FIBRIN, V18, P145, DOI 10.1097/MBC.0b013e32802f7d91
   Nielsen VG, 2007, ANESTH ANALG, V104, P59, DOI 10.1213/01.ane.0000248223.05152.a1
   Nielsen VG, 2017, J THROMB THROMBOLYS, V44, P481, DOI 10.1007/s11239-017-1549-2
   Pretorius E, 2017, BIORXIV, V1, P143867
   Pretorius E, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00257
   Pretorius E, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0941
   Pretorius E, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0624-5
   Pretorius E, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0539
   Pretorius E, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0192-5
   Pretorius E, 2013, TOXICOL MECH METHOD, V23, P352, DOI 10.3109/15376516.2012.762082
   Pretorius E, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-63
   Pretorius E, 2013, CURR DRUG TARGETS, V14, P13, DOI 10.2174/138945013804806541
   Ruscitti P, 2020, ANN RHEUM DIS, V79, P1515, DOI [10.1136/annrheumdis-2020-217618, 10.1136/annrheumdis-2020-218048, 10.1136/annrheumdis-2020-218868, 10.1136/annrheumdis-2020-218909, 10.1136/annrheumdis-2020-218032]
   Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Vargas-Vargas M, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.72
   Wallace Collett L, 2020, AUST CRIT CARE
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Watson J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1808
   Willyard C, 2020, NATURE, V581, P250, DOI 10.1038/d41586-020-01403-8
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Woloshin S, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2015897
   Wright FL, 2020, J AM COLL SURGEONS, V231, P193, DOI 10.1016/j.jamcollsurg.2020.05.007
   Xiao AT, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104346
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Xu BY, 2020, EUR RADIOL, V30, P5720, DOI 10.1007/s00330-020-06934-2
   Yuriditsky E, 2020, CRIT CARE MED
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
NR 56
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2840
J9 CARDIOVASC DIABETOL
JI Cardiovasc. Diabetol.
PD NOV 17
PY 2020
VL 19
IS 1
AR 193
DI 10.1186/s12933-020-01165-7
PG 8
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism
GA OS5VW
UT WOS:000590232300001
PM 33203441
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Feng, Y
   Huang, JY
   Wu, JY
   Xu, Y
   Chen, B
   Jiang, LJ
   Xiang, H
   Peng, ZY
   Wang, XH
AF Feng, Ying
   Huang, Jianying
   Wu, Jianyuan
   Xu, Yan
   Chen, Bo
   Jiang, Lijun
   Xiang, Hui
   Peng, Zhiyong
   Wang, Xinghuan
TI Safety and feasibility of umbilical cord mesenchymal stem cells in
   patients with COVID-19 pneumonia: A pilot study
SO CELL PROLIFERATION
LA English
DT Article
DE coronavirus disease&#8208; 2019; cytokine storm; safety; umbilical cord
   mesenchymal stem cells
AB Objectives We aim to explore the safety and feasibility of umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in patients with severe and critically severe coronavirus disease-2019 (COVID-19).
   Methods We conducted a small sample, single arm, pilot trial. In addition to standard therapy, we performed four rounds of transplantation of UC-MSCs in sixteen patients with severe and critically severe COVID-19. We recorded adverse events from enrolment to Day 28. We evaluated the oxygenation index, inflammatory biomarkers, radiological presentations of the disease and lymphocyte subsets count on the 7th day (D7 +/- 1 day), the 14th day (D14 +/- 1 day) and the 28th day (D28 +/- 3 days).
   Results There were no infusion-related or allergic reactions. The oxygenation index was improved after transplantation. The mortality of enrolled patients was 6.25%, whereas the historical mortality rate was 45.4%. The level of cytokines estimated varied in the normal range, the radiological presentations (ground glass opacity) were improved and the lymphocyte count and lymphocyte subsets (CD4(+) T cells, CD8(+) T cells and NK cells) count showed recovery after transplantation.
   Conclusions Intravenous transplantation of UC-MSCs was safe and feasible for treatment of patients with severe and critically severe COVID-19 pneumonia.
C1 [Feng, Ying; Xiang, Hui; Peng, Zhiyong] Wuhan Univ, Zhongnan Hosp, Dept Crit Care Med, Wuhan 430071, Hubei, Peoples R China.
   [Feng, Ying; Huang, Jianying; Wu, Jianyuan; Chen, Bo; Xiang, Hui; Peng, Zhiyong; Wang, Xinghuan] Wuhan Leishenshan Hosp, Wuhan, Peoples R China.
   [Huang, Jianying; Wu, Jianyuan; Chen, Bo; Wang, Xinghuan] Wuhan Univ, Clin Trial Ctr, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Xu, Yan; Jiang, Lijun] Jilin Tuohua Biotechnol Co Ltd, Changchun, Jilin, Peoples R China.
RP Peng, ZY (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Crit Care Med, Wuhan 430071, Hubei, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Clin Trial Ctr, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
EM pengzy5@hotmail.com; wangxinghuan@whu.edu.cn
FU Development Center for Medical Science & Technology,National Health
   Commission of the People's Republic of China [2020ZX09201007]; Hubei
   Province Science Technology Department [2020FCA048]
FX Development Center for Medical Science & Technology,National Health
   Commission of the People's Republic of China, Grant/Award Number:
   2020ZX09201007; Hubei Province Science Technology Department,
   Grant/Award Number: 2020FCA048
CR Behnke J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030682
   Ben-Mordechai T, 2015, J CARDIOVASC PHARM T, V20, P36, DOI 10.1177/1074248414534916
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Mitra AR, 2020, CAN MED ASSOC J, V192, pE694, DOI 10.1503/cmaj.200794
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Sengupta V, 2020, STEM CELLS DEV, V29, P747, DOI 10.1089/scd.2020.0080
   Tropea KA, 2012, AM J PHYSIOL-LUNG C, V302, pL829, DOI 10.1152/ajplung.00347.2011
   Uccelli A, 2015, ANN NY ACAD SCI, V1351, P114, DOI 10.1111/nyas.12815
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Yang JB, 2014, REGEN MED RES, V2, DOI 10.1186/2050-490X-2-7
   Yu Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02939-x
   Zangrillo A, 2020, CRIT CARE RESUSC
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD DEC
PY 2020
VL 53
IS 12
SI SI
AR e12947
DI 10.1111/cpr.12947
EA NOV 2020
PG 8
WC Cell Biology
SC Cell Biology
GA PB0MV
UT WOS:000590300800001
PM 33205469
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Karimipour, A
   Amini, A
   Nouri, M
   D'Orazio, A
   Sabetvand, R
   Hekmatifar, M
   Marjani, A
   Bach, QV
AF Karimipour, Aliakbar
   Amini, Ali
   Nouri, Mohammad
   D'Orazio, Annunziata
   Sabetvand, Roozbeh
   Hekmatifar, Maboud
   Marjani, Azam
   Bach, Quang-vu
TI Molecular dynamics performance for coronavirus simulation by C, N, O,
   and S atoms implementation dreiding force field: drug delivery atomic
   interaction in contact with metallic Fe, Al, and steel
SO COMPUTATIONAL PARTICLE MECHANICS
LA English
DT Article; Early Access
DE Coronavirus; Molecular dynamic simulation; Atomic interaction; Metallic
   matrix
ID WATER/GRAPHENE OXIDE NANOFLUID; ARTIFICIAL NEURAL-NETWORK;
   HEAT-TRANSFER; THERMAL-CONDUCTIVITY; HYBRID NANOFLUID; FLOW;
   TEMPERATURE; ENHANCEMENT; CONVECTION; STABILITY
AB Coronavirus causes some illnesses to include cold, COVID-19, MERS, and SARS. This virus can be transmitted through contact with different atomic matrix between humans. So, this atomic is essential in medical cases. In this work, we describe the atomic manner of this virus in contact with various metallic matrix such as Fe, Al, and steel with equilibrium molecular dynamic method. For this purpose, we reported physical properties such as temperature, total energy, distance and angle of structures, mutual energy, and volume variation of coronavirus. In this approach, coronavirus is precisely simulated by O, C, S, and N atoms and they are implemented dreiding force field. Our simulation shows that virus interaction with steel matrix causes the maximum removing of the virus from the surfaces. After 1 ns, the atomic distance between these two structures increases from 45 to 75 angstrom. Furthermore, the volume of coronavirus 14.62% increases after interaction with steel matrix. This atomic manner shows that coronavirus removes and destroyed with steel surface, and this metallic structure can be a promising material for use in medical applications.
C1 [Karimipour, Aliakbar] Duy Tan Univ, Inst Res & Dev, Da Nang 550000, Vietnam.
   [Amini, Ali; Nouri, Mohammad] Najaf Abad Univ, Dept Mech Engn, Esfahan, Iran.
   [D'Orazio, Annunziata] Sapienza Univ Roma, Dipartimento Ingn Astronaut Elettr & Energet, Via Eudossiana 18, I-00184 Rome, Italy.
   [Sabetvand, Roozbeh] Amirkabir Univ Technol, Fac Condensed Matter Phys, Dept Energy Engn & Phys, Tehran, Iran.
   [Hekmatifar, Maboud] Khomeini Shahr Univ, Dept Mech Engn, Esfahan, Iran.
   [Marjani, Azam] Ton Duc Thang Univ, Dept Management Sci & Technol Dev, Ho Chi Minh City, Vietnam.
   [Marjani, Azam] Ton Duc Thang Univ, Fac Appl Sci, Ho Chi Minh City, Vietnam.
   [Bach, Quang-vu] Ton Duc Thang Univ, Fac Sci Appl, Ho Chi Minh City, Vietnam.
RP Marjani, A (corresponding author), Ton Duc Thang Univ, Dept Management Sci & Technol Dev, Ho Chi Minh City, Vietnam.; Marjani, A (corresponding author), Ton Duc Thang Univ, Fac Appl Sci, Ho Chi Minh City, Vietnam.; Bach, QV (corresponding author), Ton Duc Thang Univ, Fac Sci Appl, Ho Chi Minh City, Vietnam.
EM azam.marjani@tdtu.edu.vn; bachquangvu@tdtu.edu.vn
CR Akbari OA, 2016, ADV POWDER TECHNOL, V27, P2175, DOI 10.1016/j.apt.2016.08.002
   Akbari OA, 2016, APPL MATH COMPUT, V290, P135, DOI 10.1016/j.amc.2016.05.053
   Al-Rashed AAAA, 2019, PHYSICA A, V521, P724, DOI 10.1016/j.physa.2019.01.106
   ALDER BJ, 1959, J CHEM PHYS, V31, P459, DOI 10.1063/1.1730376
   Almeida JD, 1968, NATURE, V220, P650
   Arani AAA, 2017, INT J HEAT MASS TRAN, V113, P780, DOI 10.1016/j.ijheatmasstransfer.2017.05.089
   Ashkezari AZ, 2020, COMPUT METH PROG BIO, V188, DOI 10.1016/j.cmpb.2019.105256
   Bahiraei M, 2019, J MOL LIQ, V273, P88, DOI 10.1016/j.molliq.2018.10.003
   Bahiraei M, 2019, ENERG CONVERS MANAGE, V180, P72, DOI 10.1016/j.enconman.2018.10.098
   Behnampour A, 2017, PHYSICA E, V91, P15, DOI 10.1016/j.physe.2017.04.006
   Berchet AB, 2020, COMPUT PART MECH, DOI 10.1007/s40571-020-00350-5
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   Brown WM, 2012, COMPUT PHYS COMMUN, V183, P449, DOI 10.1016/j.cpc.2011.10.012
   Brown WM, 2011, COMPUT PHYS COMMUN, V182, P898, DOI 10.1016/j.cpc.2010.12.021
   Cherry J, 2017, FEIGIN CHERRYS TXB P
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   DAW MS, 1984, PHYS REV B, V29, P6443, DOI 10.1103/PhysRevB.29.6443
   Decaro N, 2011, GAMMACORONAVIRUS COR, P403
   ESTOLA T, 1970, AVIAN DIS, V14, P330, DOI 10.2307/1588476
   Fabricant J, 1998, AVIAN DIS, V42, P648, DOI 10.2307/1592697
   Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210
   Ghanbari A, 2019, COATINGS, V9, DOI 10.3390/coatings9090584
   Goodarzi M, 2014, ABSTR APPL ANAL, DOI 10.1155/2014/762184
   Haghighi SS, 2018, INT J HEAT MASS TRAN, V125, P640, DOI 10.1016/j.ijheatmasstransfer.2018.04.122
   Heydari A, 2018, J THERM ANAL CALORIM, V131, P2893, DOI 10.1007/s10973-017-6746-x
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695
   Imoto Y, 2019, COMPUT PART MECH, V6, P671, DOI 10.1007/s40571-019-00247-y
   Imoto Y, 2019, COMPUT PART MECH, V6, P297, DOI 10.1007/s40571-018-0214-7
   Jolfaei NA, 2020, COMPUT METH PROG BIO, V185, DOI 10.1016/j.cmpb.2019.105169
   Jones JE, 1924, P R SOC LOND A-CONTA, V106, P463, DOI 10.1098/rspa.1924.0082
   Khodabandeh E, 2018, RENEW ENERG, V122, P1, DOI 10.1016/j.renene.2018.01.023
   King AMQ, 2012, 9 INT COMM TAX VIR, P806, DOI [10.1016/B978-0-12-384684-6.00068-9, DOI 10.1016/B978-0-12-384684-6.00068-9, 10.1016/B978-0-12-384684-6.00068-9.3.]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maleki H, 2019, J THERM ANAL CALORIM, V135, P1655, DOI 10.1007/s10973-018-7277-9
   Maleki H, 2019, J THERM ANAL CALORIM, V135, P1643, DOI 10.1007/s10973-018-7559-2
   Malvandi A, 2015, J MAGN MAGN MATER, V382, P296, DOI 10.1016/j.jmmm.2015.01.060
   Martinez L, 2009, J COMPUT CHEM, V30, P2157, DOI 10.1002/jcc.21224
   Masters PS, 2019, VIROLOGY, V537, P198, DOI 10.1016/j.virol.2019.08.031
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   McIntosh K, 1974, CURR TOP MICROBIOL, P87, DOI DOI 10.1007/978-3-642-65775-7_3
   Moradikazerouni A, 2019, PHYSICA A, V521, P138, DOI 10.1016/j.physa.2019.01.051
   Morikawa D, 2020, COMPUT PART MECH, DOI 10.1007/s40571-020-00347-0
   Mukherjee RM, 2008, INT J NONLIN MECH, V43, P1040, DOI 10.1016/j.ijnonlinmec.2008.04.003
   Nasiri H, 2019, J THERM ANAL CALORIM, V135, P1733, DOI 10.1007/s10973-018-7022-4
   Nazari S, 2019, J THERM ANAL CALORIM, DOI 10.1007/s10973-019-08841-1
   NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   RAHMAN A, 1964, PHYS REV, V136, pA405, DOI 10.1103/PhysRev.136.A405
   Ranjbarzadeh R, 2019, J CLEAN PROD, V206, P1089, DOI 10.1016/j.jclepro.2018.09.205
   Ranjbarzadeh R, 2018, POWDER TECHNOL, V335, P375, DOI 10.1016/j.powtec.2018.05.036
   Ranjbarzadeh R, 2017, APPL THERM ENG, V126, P538, DOI 10.1016/j.applthermaleng.2017.07.189
   Ranjbarzadeh R, 2017, APPL THERM ENG, V125, P69, DOI 10.1016/j.applthermaleng.2017.06.110
   Rapaport D. C., 2004, ART MOL DYNAMICS SIM
   Sabetvand R, 2020, J COMPUT ELECTRON, V19, P70, DOI 10.1007/s10825-020-01443-3
   Safaei MR, 2019, PHYSICA A, V519, P209, DOI 10.1016/j.physa.2018.12.010
   Stukowski A, 2010, MODEL SIMUL MATER SC, V18, DOI 10.1088/0965-0393/18/1/015012
   Su YC, 2019, COMPUT PART MECH, V6, P177, DOI 10.1007/s40571-018-0205-8
   TOUKAN K, 1985, PHYS REV B, V31, P2643, DOI 10.1103/PhysRevB.31.2643
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
NR 59
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2196-4378
EI 2196-4386
J9 COMPUT PART MECH
JI Comput. Part. Mech.
DI 10.1007/s40571-020-00367-w
EA NOV 2020
PG 13
WC Mathematics, Interdisciplinary Applications; Mechanics
SC Mathematics; Mechanics
GA OS5SU
UT WOS:000590224300001
PM 33224712
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Brazzelli, V
   Isoletta, E
   Barak, O
   Barruscotti, S
   Vassallo, C
   Giorgini, C
   Michelerio, A
   Tomasini, CF
   Musella, V
   Klersy, C
AF Brazzelli, Valeria
   Isoletta, Eugenio
   Barak, Oren
   Barruscotti, Stefania
   Vassallo, Camilla
   Giorgini, Chiara
   Michelerio, Andrea
   Tomasini, Carlo Francesco
   Musella, Valeria
   Klersy, Catherine
TI Does therapy with biological drugs influence COVID-19 infection?
   Observational monocentric prevalence study on the clinical and
   epidemiological data of psoriatic patients treated with biological drugs
   or with topical drugs alone
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE biologics; COVID&#8208; 19; immunosuppressive treatment; psoriasis;
   topical therapy
AB Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, there has been an open debate on the impact of biological drugs used in the treatment of psoriasis. To define whether patients under treatment with biologics suffer from increased morbidity and mortality from COVID-19, compared to psoriatic patients treated only with topical drugs, we designed an observational monocentric prevalence study recording the personal and clinical data of psoriatic patients, with focus on the presentation of signs and symptoms related to COVID-19 in the period of time ranging from 1 January 2020 to 31 May 2020. A total of 180 patients were enrolled into two groups: 100 patients in the topical therapy group and 80 patients in the biological therapy group. No statistically significant difference was found between the groups regarding the prevalence of COVID-19 infection and symptoms at a bivariable analysis with adjustment for confounders. In conclusion, psoriatic patients under treatment with biologics do not seem to be more susceptible to COVID-19 compared to other psoriatic patients and we suggest not interrupting treatment with biological drugs, even in areas suffering from active outbreaks of the disease.
C1 [Brazzelli, Valeria; Isoletta, Eugenio; Barak, Oren; Barruscotti, Stefania; Vassallo, Camilla; Giorgini, Chiara; Michelerio, Andrea; Tomasini, Carlo Francesco] Policlin San Matteo Fdn, Inst Dermatol, IRCCS, Ple C Golgi 19, I-27100 Pavia, Italy.
   [Brazzelli, Valeria; Isoletta, Eugenio; Barak, Oren; Barruscotti, Stefania; Vassallo, Camilla; Giorgini, Chiara; Michelerio, Andrea; Tomasini, Carlo Francesco] Univ Pavia, Ple C Golgi 19, I-27100 Pavia, Italy.
   [Musella, Valeria; Klersy, Catherine] Policlin San Matteo Fdn, IRCCS, Unit Clin Epidemiol & Biometr, Sci Direct, Pavia, Italy.
RP Brazzelli, V (corresponding author), Policlin San Matteo Fdn, Inst Dermatol, IRCCS, Ple C Golgi 19, I-27100 Pavia, Italy.; Brazzelli, V (corresponding author), Univ Pavia, Ple C Golgi 19, I-27100 Pavia, Italy.
EM vbrazzelli@libero.it
CR Bashiri A, 2020, J MATERN-FETAL NEO M, DOI [10.1080/14767058.2020.1839877, 10.1080/09546634.2020.1742438]
   Capone A, 2020, INT J INFECT DIS, V99, P393, DOI 10.1016/j.ijid.2020.07.077
   Chernyshov PV, 2020, J EUR ACAD DERMATOL, V34, P1666, DOI 10.1111/jdv.16720
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13298
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   Friedman N, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100515
   Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Kim GU, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.04.040
   Magnano M, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13706
   Megna M, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13467
   Riccardo F, 2020, EPIDEMIA COVID 19 AG, P1
   Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588
NR 14
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14516
DI 10.1111/dth.14516
EA NOV 2020
PG 5
WC Dermatology
SC Dermatology
GA OS0VR
UT WOS:000589882500001
PM 33169500
OA Bronze
DA 2021-01-01
ER

PT J
AU Muraoka, D
   Situo, D
   Sawada, SI
   Akiyoshi, K
   Harada, N
   Ikeda, H
AF Muraoka, Daisuke
   Situo, Deng
   Sawada, Shin-ichi
   Akiyoshi, Kazunari
   Harada, Naozumi
   Ikeda, Hiroaki
TI Identification of a dominant CD8(+) CTL epitope in the SARS-associated
   coronavirus 2 spike protein
SO VACCINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Spike protein; CTL epitope
ID T-CELL RESPONSES
AB Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, has been spreading throughout the world. To date, there are still no approved human vaccines for this disease. To develop an effective vaccine, the establishment of animal models for evaluating post-vaccination immune responses is necessary. In this study, we have identified a CTL epitope in the SARS-CoV-2 spike (S) protein that could be used to measure the cellular immune response against this protein. Potential predicted CTL epitopes of the SARS-CoV-2 S protein were investigated by immunizing BALB/c mice with a recombinant of the receptor-binding domain (RBD) of the S protein. Then, CD8(+) T cells specific for S-RBD were detected by stimulating with potential epitope peptides and then measuring the interferon-gamma production. Truncation of this peptide revealed that S-RBD-specific CD8(+) T cells recognized a H2-D-d-restricted S526-533 peptide. In conclusion, this animal model is suitable for evaluating the immunogenicity of SARS-CoV-2 vaccines. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Muraoka, Daisuke; Situo, Deng; Ikeda, Hiroaki] Nagasaki Univ, Dept Oncol, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki, Nagasaki 8528523, Japan.
   [Sawada, Shin-ichi; Akiyoshi, Kazunari] Kyoto Univ, Dept Polymer Chem, Grad Sch Engn, Kyoto 6158510, Japan.
   [Harada, Naozumi] United Immun Co Ltd, Tsu, Mie 5148507, Japan.
RP Muraoka, D (corresponding author), Nagasaki Univ, Dept Oncol, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki, Nagasaki 8528523, Japan.
EM dmuraoka@nagasaki-u.ac.jp
CR Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Huang J, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-50
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Miyahara Y, 2005, CLIN CANCER RES, V11, P5581, DOI 10.1158/1078-0432.CCR-04-2585
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Swadling L, 2020, NAT IMMUNOL, V21, P1307, DOI 10.1038/s41590-020-0798-y
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhang F, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00263-y
   Zhi Y, 2005, VIROLOGY, V335, P34, DOI 10.1016/j.virol.2005.01.050
   Zhou YS, 2018, EXPERT REV VACCINES, V17, P677, DOI 10.1080/14760584.2018.1506702
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 0
Z9 0
U1 11
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 17
PY 2020
VL 38
IS 49
BP 7697
EP 7701
DI 10.1016/j.vaccine.2020.10.039
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OP5LS
UT WOS:000588128100001
PM 33164796
OA Green Published
DA 2021-01-01
ER

PT J
AU Bell, S
   Clarke, R
   Mounier-Jack, S
   Walker, JL
   Paterson, P
AF Bell, Sadie
   Clarke, Richard
   Mounier-Jack, Sandra
   Walker, Jemma L.
   Paterson, Pauline
TI Parents' and guardians' views on the acceptability of a future COVID-19
   vaccine: A multi-methods study in England
SO VACCINE
LA English
DT Article
DE COVID-19; Coronavirus; Vaccine; Acceptance; Child
AB Background: The availability of a COVID-19 vaccine has been heralded as key to controlling the COVID-19 pandemic. COVID-19 vaccination programme success will rely on public willingness to be vaccinated.
   Methods: We used a multi-methods approach - involving an online cross-sectional survey and semi-structured interviews - to investigate parents' and guardians' views on the acceptability of a future COVID-19 vaccine. 1252 parents and guardians (aged 16 + years) who reported living in England with a child aged 18 months or under completed the survey. Nineteen survey participants were interviewed.
   Findings: Most survey participants reported they would likely accept a COVID-19 vaccine for themselves (Definitely 55.8%; Unsure but leaning towards yes 34.3%) and their child/children (Definitely 48.2%; Unsure but leaning towards yes 40.9%). Less than 4% of survey participants reported that they would definitely not accept a COVID-19 vaccine. Survey participants were more likely to accept a COVID-19 vaccine for themselves than their child/children. Participants that self-reported as Black, Asian, Chinese, Mixed or Other ethnicity were almost 3 times more likely to reject a COVID-19 vaccine for themselves and their children than White British, White Irish and White Other participants. Survey participants from lower-income households were also more likely to reject a COVID-19 vaccine. In open-text survey responses and interviews, self-protection from COVID-19 was reported as the main reason for vaccine acceptance. Common concerns identified in open-text responses and interviews were around COVID-19 vaccine safety and effectiveness, mostly prompted by the newness and rapid development of the vaccine.
   Conclusion: Information on how COVID-19 vaccines are developed and tested, including their safety and efficacy, must be communicated clearly to the public. To prevent inequalities in uptake, it is crucial to understand and address factors that may affect COVID-19 vaccine acceptability in ethnic minority and lower-income groups who are disproportionately affected by COVID-19. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Bell, Sadie; Mounier-Jack, Sandra] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Global Hlth & Dev, 15-17 Tavistock Pl, London WC1H 9SH, England.
   [Clarke, Richard] Newcastle Univ London, Newcastle Univ Business Sch, 102 Middlesex St, London E1 7EZ, England.
   [Walker, Jemma L.; Paterson, Pauline] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.
   [Walker, Jemma L.] Publ Hlth England, Natl Infect Serv, Dept Stat Modelling & Econ, 61 Colindale Ave, London NW9 5EQ, England.
RP Bell, S (corresponding author), London Sch Hyg & Trop Med, 15-17 Tavistock Pl, London WC1H 9SH, England.
EM sadie.bell@lshtm.ac.uk
OI Bell, Sadie/0000-0003-4381-0030
FU National Institute for Health Research Health Protection Research Unit
   (NIHR HPRU) in Immunisation at the London School of Hygiene and Tropical
   Medicine (LSHTM); Public Health England (PHE)
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The
   research was funded by the National Institute for Health Research Health
   Protection Research Unit (NIHR HPRU)) in Immunisation at the London
   School of Hygiene and Tropical Medicine (LSHTM) in partnership with
   Public Health England (PHE). The views expressed are those of the
   author(s) and not necessarily those of the NHS, the NIHR, the Department
   of Health or Public Health England.
CR [Anonymous], 2020, COMMUNICATION   0323
   Bedford H, 2007, VACCINE, V25, P7818, DOI 10.1016/j.vaccine.2007.08.057
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]
   Coconel Group, 2020, LANCET INFECT DIS
   Dodd R.H., 2020, LANCET INFECT DIS
   European Centre for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR
   Gust DA, 2008, PEDIATRICS, V122, P718, DOI 10.1542/peds.2007-0538
   Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381
   Hungerford D, 2016, EPIDEMIOL INFECT, V144, P1201, DOI 10.1017/S0950268815002599
   Immunisation J.C.o.V.a, 2020, JCVI UPD INT ADV PRI
   Larson HJ, 2018, NAT HUM BEHAV, V2, P316, DOI 10.1038/s41562-018-0331-6
   Larson HJ, 2014, HUM VACC IMMUNOTHER, V10, P2543, DOI 10.4161/21645515.2014.969618
   Loiacono MM, 2020, VACCINE, V4
   Malik Amyn A., 2020, DETERMINANTS COVID 1
   Marlow LAV, 2009, J EPIDEMIOL COMMUN H, V63, P1010, DOI 10.1136/jech.2008.085886
   Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6
   Office for National Statistics, 2013, KS201UK ETHN GROUP L
   Paterson P, 2018, VACCINE, V36, P5397, DOI 10.1016/j.vaccine.2017.08.016
   Public Health England, DISP RISK OUTC COVID
   Schreyogg J.S., 2020, MANAGING COVID 19 PA
   Statistics O. f.N, 2020, AV HOUS INC UK FIN Y
   Tiley KS, 2018, VACCINE, V36, P6726, DOI 10.1016/j.vaccine.2018.09.032
   UK Government, 2020, COR COVID UK
   UK Government, 2020, MILL COULD BE VACC C
   UK Government, 2020, STAYING AL SAF SOC D
   UK Government, 2020, GOV LAUNCH VACC TASK
   Viner RM, 2020, SUSCEPTIBILITY TRANS
   Wagner KS, 2014, ARCH DIS CHILD, V99, P348, DOI 10.1136/archdischild-2013-304388
   World Health Organisation, 2020, PUSH COVID 19 VACC
   Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7
NR 30
TC 0
Z9 0
U1 11
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 17
PY 2020
VL 38
IS 49
BP 7789
EP 7798
DI 10.1016/j.vaccine.2020.10.027
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OP5LS
UT WOS:000588128100012
PM 33109389
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Matin, MM
   Uzzaman, M
   Chowdhury, SA
   Bhuiyan, MMH
AF Matin, Mohammed Mahbubul
   Uzzaman, Monir
   Chowdhury, Shagir Ahammad
   Bhuiyan, Md Mosharef Hossain
TI In vitro antimicrobial, physicochemical, pharmacokinetics and molecular
   docking studies of benzoyl uridine esters against SARS-CoV-2 main
   protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Uridine esters; density functional theory; thermodynamic and orbital
   properties; antimicrobial activities; PASS and ADMET predications;
   SARS-CoV-2 main protease
AB Different esters were found potential against microorganisms, and could be a better choice to solve the multidrug resistant (MDR) pathogenic global issue due to their improved biological and pharmacokinetic properties. In this view, several 4-t-butylbenzoyl uridine esters 4-15 with different aliphatic and aromatic groups were synthesized for antimicrobial, physicochemical and biological studies. In vitro antimicrobial tests against nine bacteria and three fungi along with prediction of activity spectra for substances (PASS) indicated promising antifungal functionality of these uridine esters compared to the antibacterial activities. In support of this observation their cytotoxicity and molecular docking studies have been performed against lanosterol 14 alpha-demethylase (CYP51A1) and Aspergillus flavus (1R51). Significant binding affinities were observed against SARS-CoV-2 main protease (7BQY) considering hydroxychloroquine (HCQ) as standard. ADMET predictions were investigated to evaluate their absorption, metabolism and toxic properties. Most of the uridine esters showed better results than that of the HCQ. Overall, the present study might be useful for the development of uridine-based novel MDR antimicrobial and COVID-19 drugs.
C1 [Matin, Mohammed Mahbubul; Uzzaman, Monir; Chowdhury, Shagir Ahammad; Bhuiyan, Md Mosharef Hossain] Univ Chittagong, Fac Sci, Dept Chem, Bioorgan & Med Chem Lab, Chattogram 4331, Bangladesh.
   [Uzzaman, Monir] Shizuoka Univ, Fac Engn, Dept Appl Chem & Biochem Engn, Hamamatsu, Shizuoka, Japan.
RP Matin, MM (corresponding author), Univ Chittagong, Fac Sci, Dept Chem, Bioorgan & Med Chem Lab, Chattogram 4331, Bangladesh.
EM mahbubchem@cu.ac.bd
OI Chowdhury, Shagir/0000-0001-6866-2922; Uzzaman,
   Monir/0000-0002-6887-9344
FU Research Cell, University of Chittagong, Bangladesh (2019-20); Ministry
   of Education, Bangladesh [PS 201660]; BANBEIS [PS 201660]
FX M. M. Matin acknowledges Research Cell, University of Chittagong,
   Bangladesh (2019-20) for providing partial financial support. Also, the
   financial contribution (grant no. PS 201660, 2016-17) from the Ministry
   of Education, Bangladesh and BANBEIS is appreciated.
CR Lakshmi SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1778537
   Awual MR, 2017, CHEM ENG J, V307, P85, DOI 10.1016/j.cej.2016.07.110
   Banasch M, 2006, AIDS, V20, P1554, DOI 10.1097/01.aids.0000237373.38939.14
   Escobar JFB, 2016, ARS PHARM, V57, P183, DOI [10.4321/S2340-98942016000300002, 10.4321/S2340-98942016000400005]
   Carlezon WA, 2005, BIOL PSYCHIAT, V57, P343, DOI 10.1016/j.biopsych.2004.11.038
   Chowdhury S.A., 2016, CURRENT CHEM LETT, V5, P83, DOI [10.5267/j.ccl.2015.12.001, DOI 10.5267/J.CCL.2015.12.001]
   Clayden J., 2012, ORGANIC CHEM, V2nd, P1234
   COHEN N, 1993, CHEM REV, V93, P2419, DOI 10.1021/cr00023a005
   De Clercq E, 2011, ANNU REV PHARMACOL, V51, P1, DOI 10.1146/annurev-pharmtox-010510-100228
   Dobolyi A, 2011, CURR TOP MED CHEM, V11, P1058, DOI 10.2174/156802611795347618
   Du LH, 2018, RSC ADV, V8, P12614, DOI 10.1039/c8ra01030g
   Ghosh R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779818
   Hostettmann K., 1991, METHODS PLANT BIOCH, V6, P1
   Kabir A. K. M. S., 1998, Chittagong University Journal of Science, V22, P41
   Kabir A.K.M.S., 1998, CHITTAGONG U J SCI, V22, P13
   Kabir A.K.M.S., 1998, CHITTAGONG U J SCI, V22, P37
   Kabir A.K.M.S., 1997, CHITTAGONG U STUDI 2, V21, P39
   Kabir A.K.M.S., 2003, J BANGL ACAD SCI, V27, P43
   Kabir A.K.M.S., 1998, CHITTAGONG U J SCI, V22, P97
   Kabir A.K.M.S., 2002, J BANGLADESH CHEM SO, V15, P13
   Kruse H, 2012, J ORG CHEM, V77, P10824, DOI 10.1021/jo302156p
   Laws Mark, 2020, Curr Med Chem, DOI 10.2174/0929867327666200721161840
   LIEN EJ, 1982, J PHARM SCI, V71, P641, DOI 10.1002/jps.2600710611
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lucido MJ, 2016, BIOCHEMISTRY-US, V55, P1226, DOI 10.1021/acs.biochem.5b01378
   Matin M. M., 2013, International Journal of Biosciences (IJB), V3, P279
   Matin M.M., 2020, J MOL STRUCT, V1222, DOI [10.1016/j.molstruc.2020.128821, DOI 10.1016/J.MOLSTRUC.2020.128821, https://doi.org/10.1016/j.molstruc.2020.128821]
   Matin M.M., 2015, J TURK CHEM SOC A, V2, P12, DOI 10.18596/jotcsa.83708
   Matin M.M., 2017, CURRENT CHEM LETT, V6, P31, DOI [10.5267/j.ccl.2016.10.001., DOI 10.5267/J.CCL.2016.10.001, 10.5267/j.ccl.2016.10.001]
   Matin M.M., 2008, J APPL SCI RES, V4, P1478
   Matin M.M., 2020, MED RES ARCH, V8, DOI [https://doi.org/10.18103/mra.v8i7.2165, DOI 10.18103/MRA.V8I7.2165, 10.18103/mra.v8i7.2165]
   Matin MM, 2020, CARBOHYD RES, V496, DOI 10.1016/j.carres.2020.108130
   Matin MM, 2019, CARBOHYD RES, V485, DOI 10.1016/j.carres.2019.107812
   Matin MM, 2019, J MOL STRUCT, V1195, P189, DOI 10.1016/j.molstruc.2019.05.102
   Matin MM, 2014, ORBITAL, V6, P20
   Matin MM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091412
   PEARSON RG, 1986, P NATL ACAD SCI USA, V83, P8440, DOI 10.1073/pnas.83.22.8440
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Sharavanan VJ, 2020, ENVIRON CHEM LETT, V18, P325, DOI 10.1007/s10311-019-00944-3
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Strasser S, 2006, DIFFERENTIATION, V74, P488, DOI 10.1111/j.1432-0436.2006.00082.x
   Susilo R, 2008, PHARM ACTIVE URIDINE
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Yamamoto T, 2011, CLIN CHIM ACTA, V412, P1712, DOI 10.1016/j.cca.2011.06.006
NR 44
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1850358
EA NOV 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA PC9RY
UT WOS:000597335800001
PM 33297848
OA Bronze
DA 2021-01-01
ER

PT J
AU Lombana, Y
AF Lombana, Yaneth
TI COVID en Espanol: Reflections of a trauma therapist serving
   Spanish-speaking Latinx survivors of violence
SO QUALITATIVE SOCIAL WORK
LA English
DT Article; Early Access
DE Latino; trauma; therapy; critical reflection; cultural competence;
   patients&#8217; experiences
AB In this reflexive essay I share my experiences as a trauma-focused psychotherapist serving Spanish-speaking Latinx survivors of violence in New York City during the COVID-19 pandemic. Successes and challenges of working with this population during the pandemic are highlighted and connected to broader realities in the mental health field. Vicarious trauma is presented from the lens of a practitioner who shares a similar background to the population served.
C1 [Lombana, Yaneth] CUNY, Grad Ctr, 365 Fifth Ave, New York, NY 10016 USA.
RP Lombana, Y (corresponding author), CUNY, Grad Ctr, 365 Fifth Ave, New York, NY 10016 USA.
EM yml2106@columbia.edu
CR Berrol CF, 2006, ART PSYCHOTHER, V33, P302, DOI 10.1016/j.aip.2006.04.001
   Lamm C, 2007, J COGNITIVE NEUROSCI, V19, P42, DOI 10.1162/jocn.2007.19.1.42
   LIN L, 2018, MONITOR PSYCHOL, V49, P19
   Van Der Kok B, 2014, BODY KEEPS SCORE BRA
   Van Dernoot Lipsky L, 2009, TRAUMA STEWARDSHIP E
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1473-3250
EI 1741-3117
J9 QUAL SOC WORK
JI Qual. Soc. Work
AR 1473325020973324
DI 10.1177/1473325020973324
EA NOV 2020
PG 5
WC Social Work
SC Social Work
GA PF2BV
UT WOS:000598866900001
DA 2021-01-01
ER

PT J
AU Asabere, NY
   Acakpovi, A
   Ofori, EK
   Torgby, W
   Kuuboore, M
   Lawson, G
   Adjaloko, E
AF Asabere, Nana Yaw
   Acakpovi, Amevi
   Ofori, Emmanuel Kwaku
   Torgby, Wisdom
   Kuuboore, Marcellinus
   Lawson, Gare
   Adjaloko, Edward
TI SARPPIC: Exploiting COVID-19 Contact Tracing Recommendation through
   Social Awareness
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
ID PEOPLE
AB Globally, the current coronavirus disease 2019 (COVID-19) pandemic is resulting in high fatality rates. Consequently, the prevention of further transmission is very vital. Until vaccines are widely available, the only available infection prevention methods include the following: contact tracing, case isolation and quarantine, social (physical) distancing, and hygiene measures (washing of hands with soap and water and using alcohol-based hand sanitizers). Contact tracing, which is key in preventing the spread of COVID-19, refers to the process of finding unreported people who maybe infected by using a verified case to trace back possible infections of contacts. Consequently, the wide and fast spread of COVID-19 requires computational approaches which utilize innovative algorithms that build a memory of proximity contacts of cases that are positive. In this paper, a recommender algorithm called socially aware recommendation of people probably infected with COVID-19 (SARPPIC) is proposed. SARPPIC initially utilizes betweenness centrality in a social network to measure the number of target contact points (nodes/users) who have come into contact with an infected contact point (COVID-19 patient). Then, using contact durations and contact frequencies, tie strengths of the same contact points above are also computed. Finally, the above algorithmic computations are hybridized through profile integration to generate results for effective contact tracing recommendations of possible COVID-19-infected patients who will require testing in a healthcare facility. Benchmarking experimental results in the paper demonstrate that, using two interconnected relevant real-world datasets, SARPPIC outperforms other relevant methods in terms of suitable evaluation metrics such as precision, recall, and F-measure.
C1 [Asabere, Nana Yaw; Torgby, Wisdom; Lawson, Gare; Adjaloko, Edward] Accra Tech Univ, Dept Comp Sci, Accra, Ghana.
   [Acakpovi, Amevi] Accra Tech Univ, Dept Elect Elect Engn, Accra, Ghana.
   [Ofori, Emmanuel Kwaku] Univ Ghana, Dept Chem Pathol, Accra, Ghana.
   [Kuuboore, Marcellinus] Univ Profess Studies, Dept Informat Technol Studies, Madina, Ghana.
RP Asabere, NY (corresponding author), Accra Tech Univ, Dept Comp Sci, Accra, Ghana.
EM yawasabere2005@yahoo.com; acakpovia@gmail.com; oforiman@yahoo.co.uk;
   torgby@gmail.com; marcellinus.kuuboore@upsamail.edu.gh;
   gare.lawson@gmail.com; adjalokoedward@gmail.com
RI Acakpovi, Amevi/M-5121-2018
OI Acakpovi, Amevi/0000-0003-1838-0155
CR Abeler J, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/19359
   Asabere N. Y., 2018, IEEE T EMERG TOP COM, DOI [10.1109/tetc.2018.2854718, DOI 10.1109/TETC.2018.2854718]
   Asabere NY, 2018, IEEE T AFFECT COMPUT, V9, P351, DOI 10.1109/TAFFC.2017.2695605
   Asabere NY, 2015, INT J PARALLEL EMERG, V30, P211, DOI 10.1080/17445760.2014.904859
   Asabere NY, 2014, IEEE T HUM-MACH SYST, V44, P689, DOI 10.1109/THMS.2014.2325837
   Baykan E, 2011, ACM T WEB, V5, DOI 10.1145/1993053.1993057
   Bobadilla J, 2013, KNOWL-BASED SYST, V46, P109, DOI 10.1016/j.knosys.2013.03.012
   Bourke S., 2011, P 5 ACM C REC SYST R, P337
   Cai XC, 2010, LECT NOTES ARTIF INT, V6464, P476, DOI 10.1007/978-3-642-17432-2_48
   Christensen IA, 2014, ONLINE INFORM REV, V38, P524, DOI 10.1108/OIR-08-2013-0187
   Drew DA, 2020, SCIENCE, V368, P1362, DOI 10.1126/science.abc0473
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Jang H., 2016, IEEE T HUMAN MACHINE, V47, P801
   Krzywicki A., 2012, P 24 ANN C INN APPL, P2305
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Mahyar H., 2017, P 26 INT C WORLD WID, P1187, DOI DOI 10.1145/3041021.3055363
   Neto FMM, 2016, ADV GAME BASE LEARN, P1, DOI 10.4018/978-1-5225-0125-1
   Oechslein O, 2014, P ANN HICSS, P1864, DOI 10.1109/HICSS.2014.235
   Pucci A., 2006, P INT WORKSH KNOWL D, P127
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Samad A., 2019, EAI ENDORSED T IND N, V6, P159121, DOI 10.4108/eai.13-6-2019.159121
   Sie R. L. L., 2014, RECOMMENDER SYSTEMS, DOI [10.1007/978-1-4939-0530-0_13, DOI 10.1007/978-1-4939-0530-0_13]
   Sulieman D., 2013, COMBINING SOCIAL SEM
   Tsai C., 2016, ICONFERENCE 2016 P P
   Unnithan S. K. R., 2014, INT J COMB, V2014, P12, DOI [10.1155/2014/241723, DOI 10.1155/2014/241723]
   Vastardis N, 2013, IEEE COMMUN SURV TUT, V15, P1355, DOI 10.1109/SURV.2012.060912.00108
   Wobcke W, 2015, AI MAG, V36, P5, DOI 10.1609/aimag.v36i3.2599
   Xia F, 2014, WWW'14 COMPANION: PROCEEDINGS OF THE 23RD INTERNATIONAL CONFERENCE ON WORLD WIDE WEB, P781, DOI 10.1145/2567948.2579239
   Xia F, 2015, IEEE SYST J, V9, P904, DOI 10.1109/JSYST.2013.2281262
   Xia F, 2017, IEEE SYST J, V11, P2255, DOI 10.1109/JSYST.2014.2342375
   Xia F, 2013, 2013 IEEE 10TH INTERNATIONAL CONFERENCE ON AND 10TH INTERNATIONAL CONFERENCE ON AUTONOMIC AND TRUSTED COMPUTING (UIC/ATC) UBIQUITOUS INTELLIGENCE AND COMPUTING, P134, DOI 10.1109/UIC-ATC.2013.81
   Yasaka TM, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/18936
NR 32
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD NOV 16
PY 2020
VL 2020
AR 3460130
DI 10.1155/2020/3460130
PG 14
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA PD7NC
UT WOS:000597866100001
PM 33224266
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chen, RM
AF Chen, Ray-Ming
TI Randomness for Nucleotide Sequences of SARS-CoV-2 and Its Related
   Subfamilies
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
ID EVOLUTION
AB The origin and evolution of SARS-CoV-2 has been an important issue in tackling COVID-19. Research on these topics would enhance our knowledge of this virus and help us develop vaccines or predict its paths of mutations. There are many theoretical and clinical researches in this area. In this article, we devise a structural metric which directly measures the structural differences between any two nucleotide sequences. In order to explore the mechanisms of how the evolution works, we associate the nucleotide sequences of SARS-CoV-2 and its related families with the degrees of randomness. Since the distances between randomly generated nucleotide sequences are very concentrated around a mean with low variance, they are qualified as good candidates for the fundamental reference. Such reference could then be applied to measure the randomness of other Coronaviridae sequences. Our findings show that the relative randomness ratios are very consistent and concentrated. This result indicates their randomness is very stable and predictable. The findings also reveal the evolutional behaviours between the Coronaviridae and all its subfamilies.
C1 [Chen, Ray-Ming] Baise Univ, Sch Math & Stat, 21,2 Rd, Zhongshan, Guangxi Provinc, Peoples R China.
RP Chen, RM (corresponding author), Baise Univ, Sch Math & Stat, 21,2 Rd, Zhongshan, Guangxi Provinc, Peoples R China.
EM baotaoxi@163.com
FU Humanities and Social Science Fund of Ministry of Education of
   ChinaMinistry of Education, China [20XJA-GAT001]
FX This work is supported by the Humanities and Social Science Fund of
   Ministry of Education of China (Grant No. 20XJA-GAT001).
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Chung YS, 2019, EMERG INFECT DIS, V25, P958, DOI 10.3201/eid2505.181534
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Danchin A, 2020, ENVIRON MICROBIOL, V22, P2001, DOI 10.1111/1462-2920.15053
   Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Holmes EC, 2004, PHILOS T R SOC B, V359, P1059, DOI 10.1098/rstb.2004.1478
   Kandpal M, 2020, STAT APPL, V18, P253
   Lazarus JV, 2020, NAT MED, DOI 10.1038/s41591-020-1124-9
   Mercatelli D., 2020, GEOGRAPHIC GENOMIC D
   Milne-Price S, 2014, PATHOG DIS, V71, P119, DOI 10.1111/2049-632X.12166
   National Library of Medicine, COR GEN NCBI DAT
   Payne S., 2017, VIRUSES, V149
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
NR 15
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD NOV 16
PY 2020
VL 2020
AR 8819942
DI 10.1155/2020/8819942
PG 8
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA PD7NC
UT WOS:000597866100003
PM 33273962
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ayyagari, VS
   Venkateswarulu, TC
   Peele, KA
   Srirama, K
AF Ayyagari, Vijaya Sai
   Venkateswarulu, T. C.
   Peele, Abraham K.
   Srirama, Krupanidhi
TI Design of a multi-epitope-based vaccine targeting M-protein of
   SARS-CoV2: an immunoinformatics approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV2; membrane glycoprotein; immunoinformatics;
   multi-epitope vaccine
AB In the present study, one of the targets present on the envelopes of coronaviruses, membrane glycoprotein (M) was chosen for the design of a multi-epitope vaccine by Immunoinformatics approach. The B-cell and T-cell epitopes used for the construction of vaccine were antigenic, nonallergic and nontoxic. An adjuvant, beta-defensin and PADRE sequence were included at the N-terminal end of the vaccine. All the epitopes were joined by linkers for decreasing the junctional immunogenicity. Various physicochemical parameters of the vaccine were evaluated. Secondary and tertiary structures were predicted for the vaccine construct. The tertiary structure was further refined, and various parameters related to the refinement of the protein structure were validated by using different tools. Humoral immunity induced by B-cells relies upon the identification of antigenic determinants on the surface of the vaccine construct. In this regard, the vaccine construct was found to consist of several B-cell epitopes in its three-dimensional conformation. Molecular docking of the vaccine was carried out with TLR-3 receptor to study their binding and its strength. Further, protein-protein interactions in the docked complex were visualized using LigPlot+. Population coverage analysis had shown that the multi-epitope vaccine covers 94.06% of the global population. The vaccine construct was successfully cloned in silico into pET-28a (+). Immune simulation studies showed the induction of primary, secondary and tertiary immune responses marked by the increased levels of antibodies, INF-gamma, IL-2, TGF-beta, B- cells, CD4+ and CD8+ cells. Finally, the vaccine construct was able to elicit immune response as desired.
   Communicated by Ramaswamy H. Sarma
C1 [Ayyagari, Vijaya Sai; Venkateswarulu, T. C.; Peele, Abraham K.; Srirama, Krupanidhi] Vignans Fdn Sci Technol & Res, Dept Biotechnol, Guntur, Andhra Pradesh, India.
RP Venkateswarulu, TC; Srirama, K (corresponding author), Vignans Fdn Sci Technol & Res Deemed Univ, Dept Biotechnol, Guntur 522213, Andhra Pradesh, India.
EM venki_biotech327@yahoo.com; krupanidhi.srirama@gmail.com
OI Ayyagari, Vijaya Sai/0000-0001-5438-2268
FU DSTFISTDepartment of Science & Technology (India) [LSI-576/2013]
FX The authors acknowledge to VFSTR (Deemed to be university) and DSTFIST
   (LSI-576/2013) networking facility to carry out this work.
CR Alexander J, 2000, J IMMUNOL, V164, P1625, DOI 10.4049/jimmunol.164.3.1625
   Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w
   Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495
   Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529
   Bhatnager R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1787227
   Bhattacharya Manojit, 2020, Inform Med Unlocked, V20, P100394, DOI 10.1016/j.imu.2020.100394
   Bianchi M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4389089
   Buchan DWA, 2019, NUCLEIC ACIDS RES, V47, pW402, DOI 10.1093/nar/gkz297
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Dagur H.S., 2020, EURASIAN J MED ONCOL, V4, P107
   Devi A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1804460
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Dong R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01784
   Duhovny D, 2002, LECT NOTES COMPUT SC, V2452, P185
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Ghaffari-Nazari H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142563
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Graham RL, 2008, VIRUS RES, V133, P88, DOI 10.1016/j.virusres.2007.02.017
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Gu Y, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01475
   Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957
   He YQ, 2010, J BIOMED BIOTECHNOL, P1, DOI 10.1155/2010/218590
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091
   Joshi Amit, 2020, Inform Med Unlocked, V19, P100338, DOI 10.1016/j.imu.2020.100338
   Kar T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67749-1
   Kazi A, 2018, PATHOG GLOB HEALTH, V112, P123, DOI 10.1080/20477724.2018.1446773
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kim J, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1035-2
   Kim YS, 2019, MICROB PATHOGENESIS, V127, P56, DOI 10.1016/j.micpath.2018.11.053
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Kumar S., 2020, CORONAVIRUS DIS 2019, V2020, P23, DOI [DOI 10.1007/978-981-15-4814-7_3, https://doi.org/10.1007/978-981-15-4814-7_3]
   Lee GR, 2019, NUCLEIC ACIDS RES, V47, pW451, DOI 10.1093/nar/gkz288
   Lei Y, 2019, PEERJ, V6, DOI 10.7717/peerj.6185
   Li XY, 2015, INTERVIROLOGY, V58, P403, DOI 10.1159/000445059
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Lizbeth RSG, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1780944
   Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186
   Meza B, 2017, INFECT GENET EVOL, V49, P309, DOI 10.1016/j.meegid.2017.02.007
   Mittal A, 2020, INT J PEPT RES THER, V26, P2231, DOI 10.1007/s10989-020-10020-y
   Modjarrad K, 2017, HUMAN VACCINES: EMERGING TECHNOLOGIES IN DESIGN AND DEVELOPMENT, P1
   Nain Z, 2020, J BIOMOL STRUCT DYN, V38, P4850, DOI 10.1080/07391102.2019.1692072
   Narula A, 2018, INFECT GENET EVOL, V61, P4, DOI 10.1016/j.meegid.2018.03.007
   Nezafat N, 2016, COMPUT BIOL CHEM, V62, P82, DOI 10.1016/j.compbiolchem.2016.04.006
   Oli AN, 2020, IMMUNOTARGETS THER, V9, P13, DOI 10.2147/ITT.S241064
   Pandey RK, 2018, VACCINE, V36, P2262, DOI 10.1016/j.vaccine.2018.03.042
   Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139
   Peele K.A., 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1770127, DOI 10.1080/07391102.2020.1770127]
   Prasad A, 2020, J GENET, V99, DOI 10.1007/s12041-020-01205-x
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Reynisson B, 2020, J PROTEOME RES, V19, P2304, DOI 10.1021/acs.jproteome.9b00874
   Rottier P.J.M., 1995, CORONAVIRIDAE VIRUSE, DOI [https://doi.org/10.1007/978-1-4899-1531-3_6, DOI 10.1007/978-1-4899-1531-3_6]
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Samadi A, 2020, J MACROMOL SCI B, V59, P376, DOI [10.1080/00222348.2020.1730573, 10.1080/07391102.2020.1792347]
   Sarkar B, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151955
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x
   SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404
   Stranzl T, 2010, IMMUNOGENETICS, V62, P357, DOI 10.1007/s00251-010-0441-4
   Tang XC, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-52
   Tau G, 1999, ALLERGY, V54, P1233, DOI 10.1034/j.1398-9995.1999.00099.x
   Thomas S, 2013, EXPERT REV VACCINES, V12, P1301, DOI 10.1586/14760584.2013.840092
   Walker J M, 2005, PROTEOMICS PROTOCOLS
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wu CY, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-88
   Yang Y, 2015, HUM VACC IMMUNOTHER, V11, P795, DOI 10.1080/21645515.2015.1012017
   Yano A, 2005, VACCINE, V23, P2322, DOI 10.1016/j.vaccine.2005.01.031
NR 70
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1850357
EA NOV 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA PC4JE
UT WOS:000596968800001
PM 33252008
OA Bronze
DA 2021-01-01
ER

PT J
AU Perez-Belmonte, LM
   Torres-Pena, JD
   Lopez-Carmona, MD
   Ayala-Gutierrez, MM
   Fuentes-Jimenez, F
   Huerta, LJ
   Munoz, JA
   Rubio-Rivas, M
   Madrazo, M
   Garcia, MG
   Montes, BV
   Sola, JF
   Ena, J
   Ferrer, RG
   Perez, CM
   Ripper, CJ
   Lecumberri, JJN
   Acedo, IE
   Canteli, SP
   Cosio, SF
   Martinez, FA
   Rodriguez, BC
   Perez-Martinez, P
   Ramos-Rincon, JM
   Gomez-Huelgas, R
AF Perez-Belmonte, Luis M.
   Torres-Pena, Jose David
   Lopez-Carmona, Maria D.
   Ayala-Gutierrez, M. Mar.
   Fuentes-Jimenez, Francisco
   Huerta, Lucia Jorge
   Munoz, Jaime Alonso
   Rubio-Rivas, Manuel
   Madrazo, Manel
   Garcia, Marcos Guzman
   Montes, Beatriz Vicente
   Sola, Joaquim Fernandez
   Ena, Javier
   Ferrer, Ruth Gonzalez
   Perez, Carmen Mella
   Ripper, Carlos Jorge
   Lecumberri, Jose Javier Napal
   Acedo, Iris El Attar
   Canteli, Susana Plaza
   Cosio, Sara Fuente
   Martinez, Francisco Amoros
   Rodriguez, Begona Cortes
   Perez-Martinez, Pablo
   Ramos-Rincon, Jose Manuel
   Gomez-Huelgas, Ricardo
CA SEMI-COVID-19 Network
TI Mortality and other adverse outcomes in patients with type 2 diabetes
   mellitus admitted for COVID-19 in association with glucose-lowering
   drugs: a nationwide cohort study
SO BMC MEDICINE
LA English
DT Article
DE Type 2 diabetes mellitus; Glucose-lowering drug; Coronavirus disease
   2019
AB BackgroundLimited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay.MethodsWe selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine's registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference >10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was >= 100.ResultsA total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays.ConclusionsIn patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed.
C1 [Perez-Belmonte, Luis M.; Lopez-Carmona, Maria D.; Ayala-Gutierrez, M. Mar.; Gomez-Huelgas, Ricardo] Univ Malaga UMA, Univ Hosp Malaga, Biomed Res Inst Malaga IBIMA, Internal Med Dept, Ave Carlos Haya S-N, Malaga 29010, Spain.
   [Torres-Pena, Jose David; Fuentes-Jimenez, Francisco; Perez-Martinez, Pablo] Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Lipids & Atherosclerosis Unit,Dept Internal Med, Cordoba, Spain.
   [Torres-Pena, Jose David; Fuentes-Jimenez, Francisco; Perez-Martinez, Pablo] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain.
   [Huerta, Lucia Jorge] Octubre Univ Hosp, Internal Med Dept, Madrid, Spain.
   [Munoz, Jaime Alonso] Gregorio Maranon Univ Hosp, Internal Med Dept, Madrid, Spain.
   [Rubio-Rivas, Manuel] Bellvitge Univ Hosp, Internal Med Dept, Barcelona, Spain.
   [Madrazo, Manel] Dr Peset Univ Hosp, Internal Med Dept, Valencia, Spain.
   [Garcia, Marcos Guzman] San Juan Cruz Hosp, Internal Med Dept, Ubeda, Jaen, Spain.
   [Montes, Beatriz Vicente] Leon Univ Hosp Complex, Internal Med Dept, Leon, Spain.
   [Sola, Joaquim Fernandez] Clin Barcelona Hosp, Internal Med Dept, Barcelona, Spain.
   [Ena, Javier] Marina Baixa Hosp, Internal Med Dept, Villajoyosa, Alicante, Spain.
   [Ferrer, Ruth Gonzalez] Tajo Hosp, Internal Med Dept, Aranjuez, Madrid, Spain.
   [Perez, Carmen Mella] Ferrol Univ Hosp Complex, Internal Med Dept, Ferrol, A Coruna, Spain.
   [Ripper, Carlos Jorge] Insular Gran Canaria Hosp, Internal Med Dept, Las Palmas Gran Canaria, Spain.
   [Lecumberri, Jose Javier Napal] Marques Valdecilla Univ Hosp, Internal Med Dept, Santander, Spain.
   [Acedo, Iris El Attar] Torrecardenas Hosp, Internal Med Dept, Almeria, Spain.
   [Canteli, Susana Plaza] Severo Ochoa Univ Hosp, Internal Med Dept, Leganes, Madrid, Spain.
   [Cosio, Sara Fuente] Valle Nalon Hosp, Internal Med Dept, Sama De Langreo, Asturias, Spain.
   [Martinez, Francisco Amoros] Vinalopo Univ Hosp, Internal Med Dept, Elche, Alicante, Spain.
   [Rodriguez, Begona Cortes] Alto Guadalquivir Hosp, Internal Med Dept, Andujar, Jaen, Spain.
   [Ramos-Rincon, Jose Manuel] Miguel Hernandez Univ Elche, Dept Clin Med, Alicante, Spain.
RP Perez-Belmonte, LM (corresponding author), Univ Malaga UMA, Univ Hosp Malaga, Biomed Res Inst Malaga IBIMA, Internal Med Dept, Ave Carlos Haya S-N, Malaga 29010, Spain.; Perez-Martinez, P (corresponding author), Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Lipids & Atherosclerosis Unit,Dept Internal Med, Cordoba, Spain.; Perez-Martinez, P (corresponding author), Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain.
EM luismiguelpb1984@gmail.com; pablopermar@yahoo.es
OI Torres Pena, Jose D./0000-0003-1366-5549
CR Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS14, DOI 10.2337/dc20-S002
   Apicella M, 2020, LANCET DIABETES ENDO, V8, P782, DOI 10.1016/S2213-8587(20)30238-2
   Austin PC, 2011, STAT MED, V30, P1292, DOI 10.1002/sim.4200
   Berlin DA, 2020, N ENGL J MED
   Bode Bruce, 2020, J Diabetes Sci Technol, V14, P813, DOI 10.1177/1932296820924469
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Bramante C, 2020, OBSERVATIONAL STUDY
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445
   Casas Rojo JM, 2020, REV CLIN ESP
   Ceriello A, 2020, DIABETES RES CLIN PR, V163, DOI 10.1016/j.diabres.2020.108151
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen YC, 2020, DIABETES CARE, V43, P1399, DOI 10.2337/dc20-0660
   Costela-Ruiz VJ, 2020, CYTOKINE GROWTH FACT
   Cure E, 2020, DIABETES METAB SYND, V14, P405, DOI 10.1016/j.dsx.2020.04.024
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Hussain A, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108142
   Iacobellis G, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108125
   Maddaloni E, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3321
   MAHONEY F I, 1965, Md State Med J, V14, P61
   Marfella R, 2020, DIABETES METAB
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pal R, 2020, DIABETES RES CLIN PR, V163, DOI 10.1016/j.diabres.2020.108146
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z
   Rhee S. Y., 2020, EFFECTS DPP 4 INHIBI
   Rodilla E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103136
   Sardu C, 2020, DIABETOLOGIA, V63, P2486, DOI 10.1007/s00125-020-05216-2
   Sardu C, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016948
   Sardu C, 2020, DIABETES CARE, V43, P1408, DOI 10.2337/dc20-0723
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Sharma S, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108183
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD NOV 16
PY 2020
VL 18
IS 1
AR 359
DI 10.1186/s12916-020-01832-2
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA PA5CY
UT WOS:000595654800001
PM 33190637
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Delre, P
   Caporuscio, F
   Saviano, M
   Mangiatordi, GF
AF Delre, Pietro
   Caporuscio, Fabiana
   Saviano, Michele
   Mangiatordi, Giuseppe Felice
TI Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the
   SARS-CoV-2 Papain-Like Protease
SO FRONTIERS IN CHEMISTRY
LA English
DT Article
DE drug repurposing; SARS&#8211; CoV&#8211; 2; papain-like cysteine
   protease; molecular docking; molecular interaction fingerprints
ID CORONAVIRUS; MANAGEMENT; DOCKING; GENERATION; VILAZODONE; OUTBREAK;
   CURCUMIN; EFFICACY; SAFETY; MODEL
AB In the absence of an approved vaccine, developing effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals is essential to tackle the current pandemic health crisis due to the coronavirus disease 2019 (COVID-19) spread. As any traditional drug discovery program is a time-consuming and costly process requiring more than one decade to be completed, in silico repurposing of existing drugs is the preferred way for rapidly selecting promising clinical candidates. We present a virtual screening campaign to identify covalent and non-covalent inhibitors of the SARS-CoV-2 papain-like protease (PLpro) showing potential multitarget activities (i.e., a desirable polypharmacology profile) for the COVID-19 treatment. A dataset including 688 phase III and 1,702 phase IV clinical trial drugs was downloaded from ChEMBL (version 27.1) and docked to the recently released crystal structure of PLpro in complex with a covalently bound peptide inhibitor. The obtained results were analyzed by combining protein-ligand interaction fingerprint similarities, conventional docking scores, and MM-GBSA-binding free energies and allowed the identification of some interesting candidates for further in vitro testing. To the best of our knowledge, this study represents the first attempt to repurpose drugs for a covalent inhibition of PLpro and could pave the way for new therapeutic strategies against COVID-19.
C1 [Delre, Pietro] Univ Bari Aldo Moro, Dept Chem, Bari, Italy.
   [Delre, Pietro; Saviano, Michele; Mangiatordi, Giuseppe Felice] Nat Res Council CNR, Inst Crystallog, Bari, Italy.
   [Caporuscio, Fabiana] Univ Modena & Reggio Emilia, Dept Life Sci, Modena, Italy.
RP Mangiatordi, GF (corresponding author), Nat Res Council CNR, Inst Crystallog, Bari, Italy.
EM giuseppe.mangiatordi@ic.cnr.it
CR Abruzzese E, 2020, MEDITERR J HEMATOL I, V12, DOI 10.4084/MJHID.2020.031
   Aguila EJT, 2020, DIGEST DIS SCI, V65, P2452, DOI 10.1007/s10620-020-06430-z
   Amin SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1780946
   [Anonymous], 2019, LIGPREP
   [Anonymous], 2019, PROT PREP WIZ
   [Anonymous], 2019, PRIM MM GBSA
   Armocida D, 2020, J CLIN NEUROSCI, V79, P231, DOI 10.1016/j.jocn.2020.07.007
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Benner B, 2020, DRUG DES DEV THER, V14, P1693, DOI 10.2147/DDDT.S253232
   Bhalla A., 2017, INT J BASIC CLIN PHA, V6, P1238, DOI [10.18203/2319-2003.ijbcp20172220, DOI 10.18203/2319-2003.IJBCP20172220]
   Braga CL, 2020, PHARMACOL RES PERSPE, V8, DOI 10.1002/prp2.623
   Bundgaard C, 2016, NEUROPHARMACOLOGY, V103, P104, DOI 10.1016/j.neuropharm.2015.12.009
   Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245
   Contreras-Puentes N., 2020, Biomedical & Pharmacology Journal, V13, P933, DOI 10.13005/bpj/1962
   Deeks Emma D, 2018, Drugs Ther Perspect, V34, P89, DOI 10.1007/s40267-018-0482-6
   DEGET F, 1991, DRUGS, V41, P799, DOI 10.2165/00003495-199141050-00008
   Deng Z, 2004, J MED CHEM, V47, P337, DOI 10.1021/jm030331x
   Deslee G., 2020, RESP MED RES, V78, P100764, DOI 10.1016/j.resmer.2020.100764
   Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Elfiky A., 2020, ANTI SARS ANTI HCV D, DOI [10.21203/rs.2.23280/v1, DOI 10.21203/RS.2.23280/V1]
   Fernandez-Fernandez B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072030
   Freedberg DE, 2020, GASTROENTEROLOGY, V159, P1129, DOI 10.1053/j.gastro.2020.05.053
   Freeman TL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01518
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Fung HB, 2000, CLIN THER, V22, P549, DOI 10.1016/S0149-2918(00)80044-2
   Gaulton A, 2017, NUCLEIC ACIDS RES, V45, pD945, DOI 10.1093/nar/gkw1074
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gradisar H, 2007, J LEUKOCYTE BIOL, V82, P968, DOI 10.1189/jlb.1206727
   Hahn YI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23840-2
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Hannoodee M., 2020, STATPEARLS
   Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007/s00018-008-7452-4
   Ho J, 2017, TRENDS MICROBIOL, V25, P942, DOI 10.1016/j.tim.2017.04.009
   Jakher H, 2019, DIABET METAB SYND OB, V12, P209, DOI 10.2147/DMSO.S184437
   Keskin D, 2016, DRUG DES DEV THER, V10, P3355, DOI 10.2147/DDDT.S85050
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   King Paul, 2008, Int J Chron Obstruct Pulmon Dis, V3, P385
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Liu ZT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00479
   Llanes A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124546
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Marcou G, 2007, J CHEM INF MODEL, V47, P195, DOI 10.1021/ci600342e
   Mirzaei Mohsen, 2019, Iran J Psychiatry, V14, P137
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Nakano M, 2011, EUR J PHARMACOL, V658, P236, DOI 10.1016/j.ejphar.2011.02.007
   Nishio S, 2015, DIABET METAB SYND OB, V8, P163, DOI 10.2147/DMSO.S54679
   Pinzi L., 2020, NAT COMMUN, DOI [10.21203/rs.3.rs-27222/v1, DOI 10.21203/RS.3.RS-27222/V1]
   Plosker GL, 1999, DRUGS, V58, P1165, DOI 10.2165/00003495-199958060-00011
   Praditya D, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00912
   Prezioso C, 2020, J NEUROVIROL, V26, P311, DOI 10.1007/s13365-020-00862-z
   Pryzdial ELG, 2020, RES PRACT THROMB HAE, V4, P774, DOI 10.1002/rth2.12406
   Quimque MTJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1776639
   Ramadan WH, 2019, CLIN RESPIR J, V13, P663, DOI 10.1111/crj.13073
   Rehman B., 2020, STATPEARLS
   Research CDE, 2019, FDA APPR DAR NONM CA
   Rut Wioletta, 2020, bioRxiv, DOI 10.1101/2020.04.29.068890
   Safavi F, 2020, J NEUROL SCI, V415, DOI 10.1016/j.jns.2020.116942
   Santos MMM, 2007, MINI-REV MED CHEM, V7, P1040, DOI 10.2174/138955707782110105
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Singh H, 2020, EXPERT REV ANTI-INFE, V18, P997, DOI 10.1080/14787210.2020.1782190
   Singh J, 2006, CHEM BIOL DRUG DES, V67, P5, DOI 10.1111/j.1747-0285.2005.00323.x
   Singh J, 2011, NAT REV DRUG DISCOV, V10, P307, DOI 10.1038/nrd3410
   Solerte SB, 2020, ACTA DIABETOL, V57, P779, DOI 10.1007/s00592-020-01539-z
   Song Y, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106080
   Stacy ZA, 2016, CARDIOL THER, V5, P1, DOI 10.1007/s40119-016-0058-2
   Stahl SM, 2014, CNS SPECTRUMS, V19, P105, DOI 10.1017/S1092852914000169
   STRATFORD BC, 1965, BMJ-BRIT MED J, V1, P922, DOI 10.1136/bmj.1.5439.922
   Sugawara T, 2019, INT J CANCER, V145, P1382, DOI 10.1002/ijc.32242
   Tack J, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13284
   Tarantelli C, 2020, BLOOD ADV, V4, P819, DOI 10.1182/bloodadvances.2019000844
   Testa S, 2020, INTERN EMERG MED, V15, P751, DOI 10.1007/s11739-020-02331-1
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Trujillo T, 2014, DRUGS, V74, P1587, DOI 10.1007/s40265-014-0278-5
   Tungol A, 2011, J MANAGE CARE PHARM, V17, P685, DOI 10.18553/jmcp.2011.17.9.685
   Vasanthakumar N, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109809
   Watts KS, 2010, J CHEM INF MODEL, V50, P534, DOI 10.1021/ci100015j
   WEIZMAN Z, 1985, GASTROENTEROLOGY, V89, P596, DOI 10.1016/0016-5085(85)90456-1
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Yu Cheng-Han, 2018, Oncotarget, V9, P21512, DOI 10.18632/oncotarget.25177
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu K, 2014, J CHEM INF MODEL, V54, P1932, DOI 10.1021/ci500118s
   Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065
NR 90
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD NOV 16
PY 2020
VL 8
AR 594009
DI 10.3389/fchem.2020.594009
PG 17
WC Chemistry, Multidisciplinary
SC Chemistry
GA OZ0WZ
UT WOS:000594658300001
PM 33304884
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lamazou, F
   Oger, P
   Dieli-crimi, R
   Guerin, A
   Letouzey, V
   Octernaud, S
   Place, V
   Cales, P
   Descamps, P
   Delaroche, L
AF Lamazou, F.
   Oger, P.
   Dieli-crimi, R.
   Guerin, A.
   Letouzey, V.
   Octernaud, S.
   Place, V.
   Cales, P.
   Descamps, P.
   Delaroche, L.
TI COVID-19 infection in first trimester of pregnancy marked by a liver
   cytolysis in a woman previously treated by hydroxychloroquine for
   repeated implantation failure: a case report
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; First trimester; Hepatic cytolysis; Liver; Case report;
   Hydroxychloroquine
AB Background In December 2019, a new disease (COVID-19) caused by a novel coronavirus called SARS-CoV-2 emerged in China and spread to many other countries. There is only limited data about the clinical features of COVID-19 during pregnancy, especially in first trimester. Case presentation We report a COVID-19 infection in a 35 years-old patient in first trimester of pregnancy and its consequent medical care. At 7 weeks of pregnancy, the patient, who did not have any pregestational comorbidities, complained of intense nausea and asthenia. An important liver cytolysis was discovered with biological perturbations of transaminases levels. No respiratory symptoms were recorded. Classical viral aetiologies and drug-related toxicity were discarded. Because of the aggravation of the symptoms and the occurrence of the breathlessness, the patient was tested for the COVID-19 in a nasopharyngeal swab. The RTq-PCR assay indicated the presence of SARS-CoV-2 RNA. In the absence of severe symptoms, the patient was monitored at home according to the French government guidelines. After a few days, the symptoms resolved without any complications. The pregnancy is still ongoing without any visible sequelae on the foetus so far. Conclusions This first case illustrated the difficulty of COVID-19 diagnosis in patients with isolated digestive symptoms in first trimester of pregnancy that could be confused with gravida hyperemesis. Monitoring of pregnancy after an episode of COVID-19 should be strengthened with bimonthly foetal growth ultrasounds and doppler assessments because of the risks for intrauterine growth restriction. Comprehensive data on larger numbers of first trimester gravid women with COVID-19 are required to better understanding the overall impact of SARS-CoV-2 on maternal and birth outcomes.
C1 [Lamazou, F.; Oger, P.; Delaroche, L.] Hop Prive Parly 2, Inst Fertilite Maternite Parly 2, Ramsay Gen Sante, 21 Rue Moxouris, F-78150 Le Chesnay, France.
   [Dieli-crimi, R.] Autonomous Univ Barcelona UAB, Immunol Div, Hosp Univ Vall Hebron HUVH, Vall Hebron Res Inst VHIR,Dept Cell Biol Physiol, Barcelona, Catalonia, Spain.
   [Dieli-crimi, R.] Jeffrey Model Fdn Excellence Ctr, Barcelona, Spain.
   [Guerin, A.] IVI, Ronda Gen Mitre 14, Barcelona 08017, Spain.
   [Letouzey, V.] Univ Hosp Caremeau, Dept Obstet & Gynecol, Nimes, France.
   [Octernaud, S.; Place, V.] Med Radiol Ctr Juras, Paris, France.
   [Cales, P.] Univ Hosp, Hepatogastroenterol Dept, Angers, France.
   [Cales, P.] Univ Angers, UPRES 3859, HIFIH Lab, Angers, France.
   [Descamps, P.] Angers Univ Hosp, Dept Ob Gyn, 4 Rue Larrey, F-49933 Angers 09, France.
   [Descamps, P.] Univ Montpellier, Inst Biomol Max Mousseron IBMM, UMR 5247, CNRS,ENSCM, F-34093 Montpellier, France.
   [Delaroche, L.] Hop Prive Parly 2, Ctr Biol Med, 21 Rue Moxouris, F-78150 Le Chesnay, France.
RP Lamazou, F (corresponding author), Hop Prive Parly 2, Inst Fertilite Maternite Parly 2, Ramsay Gen Sante, 21 Rue Moxouris, F-78150 Le Chesnay, France.
EM dr.lamazou@gmail.com
CR Asakura H, 2020, J THROMB HAEMOST, V18, P1521, DOI 10.1111/jth.14858
   Bangash MN, 2020, LANCET GASTROENTEROL, V5, P529, DOI 10.1016/S2468-1253(20)30084-4
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Ellington S, 2020, MMWR-MORBID MORTAL W, V69, P769, DOI 10.15585/mmwr.mm6925a1externalicon
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Feng G, 2020, J CLIN TRANSL HEPATO, V8, P18, DOI 10.14218/JCTH.2020.00018
   Galil SMA, 2015, LUPUS, V24, P638, DOI 10.1177/0961203314561667
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Karimi-Zarchi M, 2020, FETAL PEDIATR PATHOL, V39, P246, DOI 10.1080/15513815.2020.1747120
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Liu W, 2020, FRONT MED-PRC, V14, P193, DOI 10.1007/s11684-020-0772-y
   Luo SH, 2020, CLIN GASTROENTEROL H, V18, P1636, DOI 10.1016/j.cgh.2020.03.043
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   Qiao J, 2020, LANCET, V395, P760, DOI 10.1016/S0140-6736(20)30365-2
   Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017
   Schwartz David A, 2020, Arch Pathol Lab Med, DOI 10.5858/arpa.2020-0901-SA
   Sheikhansari G, 2020, J REPROD IMMUNOL, V139, DOI 10.1016/j.jri.2020.103121
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wang SS, 2020, CURR MED SCI, V40, P285, DOI 10.1007/s11596-020-2174-4
   Wong SH, 2020, J GASTROEN HEPATOL, V35, P744, DOI 10.1111/jgh.15047
   Xie HS, 2020, LIVER INT, V40, P1321, DOI 10.1111/liv.14449
   Yan J, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.014
   Yang P, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104356
   Zaigham M, 2020, ACTA OBSTET GYN SCAN, V99, P823, DOI 10.1111/aogs.13867
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 30
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD NOV 16
PY 2020
VL 20
IS 1
AR 845
DI 10.1186/s12879-020-05551-0
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA OY5RV
UT WOS:000594304800002
PM 33198681
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Arnold, F
   Westermann, L
   Rieg, S
   Neumann-Haefelin, E
   Biever, PM
   Walz, G
   Kalbhenn, J
   Tanriver, Y
AF Arnold, Frederic
   Westermann, Lukas
   Rieg, Siegbert
   Neumann-Haefelin, Elke
   Biever, Paul Marc
   Walz, Gerd
   Kalbhenn, Johannes
   Tanriver, Yakup
TI Comparison of different anticoagulation strategies for renal replacement
   therapy in critically ill patients with COVID-19: a cohort study
SO BMC NEPHROLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Acute kidney injury; Renal replacement therapy;
   Anticoagulation; Critical care; Emerging communicable diseases
ID ACUTE KIDNEY INJURY; REGIONAL CITRATE; HEPARIN ANTICOAGULATION; TRIAL;
   CVVH
AB Background Critically ill coronavirus disease 2019 (COVID-19) patients have a high risk of acute kidney injury (AKI) that requires renal replacement therapy (RRT). A state of hypercoagulability reduces circuit life spans. To maintain circuit patency and therapeutic efficiency, an optimized anticoagulation strategy is needed. This study investigates whether alternative anticoagulation strategies for RRT during COVID-19 are superior to administration of unfractionated heparin (UFH). Methods Retrospective cohort study on 71 critically ill COVID-19 patients (>= 18 years), admitted to intensive care units at a tertiary health care facility in the southwestern part of Germany between February 26 and May 21, 2020. We collected data on the disease course, AKI, RRT, and thromboembolic events. Four different anticoagulatory regimens were administered. Anticoagulation during continuous veno-venous hemodialysis (CVVHD) was performed with UFH or citrate. Anticoagulation during sustained low-efficiency daily dialysis (SLEDD) was performed with UFH, argatroban, or low molecular weight heparin (LMWH). Primary outcome is the effect of the anticoagulation regimen on mean treatment times of RRT. Results In patients receiving CVVHD, mean treatment time in the UFH group was 21.3 h (SEM: +/- 5.6 h), in the citrate group 45.6 h (SEM: +/- 2.7 h). Citrate anticoagulation significantly prolonged treatment times by 24.4 h (P = .001). In patients receiving SLEDD, mean treatment time with UFH was 8.1 h (SEM: +/- 1.3 h), with argatroban 8.0 h (SEM: +/- 0.9 h), and with LMWH 11.8 h (SEM: +/- 0.5 h). LMWH significantly prolonged treatment times by 3.7 h (P = .008) and 3.8 h (P = .002), respectively. Conclusions UFH fails to prevent early clotting events in the dialysis circuit during COVID-19. For patients, who do not require effective systemic anticoagulation, regional citrate dialysis is the most effective strategy. For patients, who require effective systemic anticoagulation, the usage of LMWH results in the longest circuit life spans. The proposed anticoagulatory strategies are safe, can easily be monitored, and allow an individualized treatment.
C1 [Arnold, Frederic; Westermann, Lukas; Neumann-Haefelin, Elke; Walz, Gerd; Tanriver, Yakup] Univ Freiburg, Fac Med, Med Ctr, Dept Med Nephrol & Primary Care 4, Freiburg, Germany.
   [Arnold, Frederic; Tanriver, Yakup] Univ Freiburg, Fac Med, Inst Med Microbiol & Hyg, Freiburg, Germany.
   [Arnold, Frederic] Univ Freiburg, Fac Med, Berta Ottenstein Programme Clinician Scientists, Freiburg, Germany.
   [Rieg, Siegbert] Univ Freiburg, Fac Med, Med Ctr, Div Infect Dis,Dept Med 3, Freiburg, Germany.
   [Biever, Paul Marc] Univ Freiburg, Fac Med, Med Ctr, Dept Med Interdisciplinary Med Intens Care 3, Freiburg, Germany.
   [Biever, Paul Marc] Univ Freiburg, Ctr Heart, Dept Cardiol & Angiol 1, Freiburg, Germany.
   [Kalbhenn, Johannes] Univ Freiburg, Fac Med, Med Ctr, Dept Anesthesiol & Crit Care, Freiburg, Germany.
RP Tanriver, Y (corresponding author), Univ Freiburg, Fac Med, Med Ctr, Dept Med Nephrol & Primary Care 4, Freiburg, Germany.; Tanriver, Y (corresponding author), Univ Freiburg, Fac Med, Inst Med Microbiol & Hyg, Freiburg, Germany.
EM yakup.tanriver@uniklinik-freiburg.de
FU Berta-Ottenstein-Programme for Clinician Scientists, Faculty of
   Medicine, University of Freiburg; Else Kroner-Fresenius-Stiftung, Bad
   Homburg, Germany [2016_Kolleg.03, 2017_EKES.34];
   Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of
   Medicine, University of Freiburg; Deutsche Forschungsgemeinschaft, Bonn,
   GermanyGerman Research Foundation (DFG) [SFB 1160 (P06/B08)]; Projekt
   DEAL
FX FA is supported by the Berta-Ottenstein-Programme for Clinician
   Scientists, Faculty of Medicine, University of Freiburg. LW is supported
   by the Else Kroner-Fresenius-Stiftung (2016_Kolleg.03), Bad Homburg,
   Germany. ENH is supported by the Berta-Ottenstein-Programme for Advanced
   Clinician Scientists, Faculty of Medicine, University of Freiburg. YT is
   supported by the Else Kroner-Fresenius-Stiftung (2017_EKES.34), Bad
   Homburg, Germany and the Deutsche Forschungsgemeinschaft (SFB 1160
   (P06/B08)), Bonn, Germany. Open Access funding enabled and organized by
   Projekt DEAL.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Batlle D, 2020, J AM SOC NEPHROL, V31, P1380, DOI 10.1681/ASN.2020040419
   Beumer MC, 2019, J CRIT CARE, V50, P59, DOI 10.1016/j.jcrc.2018.11.013
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Davenport A, 2004, CONTRIB NEPHROL, V144, P228
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Gao JP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42916-1
   Garcia DA, 2012, CHEST, V141, pE24S, DOI 10.1378/chest.11-2291
   Gattas DJ, 2015, CRIT CARE MED, V43, P1622, DOI 10.1097/CCM.0000000000001004
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Joannidis M, 2007, CRIT CARE, V11, DOI 10.1186/cc5937
   Karkar A, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-0648-y
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Levin A, 2013, KIDNEY INT, V83, P1001, DOI 10.1038/ki.2013.91
   Liu C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1299-0
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Neumann-Haefelin Elke, 2020, Crit Care Explor, V2, pe0155, DOI 10.1097/CCE.0000000000000155
   NHS-England, 2020, CLIN GUID REN REPL T
   O'Connor ME, 2015, CRIT CARE CLIN, V31, P803, DOI 10.1016/j.ccc.2015.06.013
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Ranucci M, 2002, PERFUSION-UK, V17, P199, DOI 10.1191/0267659102pf562oa
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Sandset PR, 2000, HAEMOSTASIS, V30, P48
   Scialpi M, 2020, INT J INFECT DIS, V95, P361, DOI 10.1016/j.ijid.2020.04.056
   Turpie AGG, 1998, AM HEART J, V135, pS329, DOI 10.1053/hj.1998.v135.90304
   van der Voort PHJ, 2005, BLOOD PURIFICAT, V23, P175, DOI 10.1159/000083938
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 31
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD NOV 16
PY 2020
VL 21
IS 1
AR 486
DI 10.1186/s12882-020-02150-8
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA OY7EI
UT WOS:000594406000005
PM 33198670
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pastor, DM
   Lee-Wisdom, K
   Arai, AE
   Sirajuddin, A
   Rosing, DR
   Korchin, B
   Gulley, JL
   Bilusic, M
AF Pastor, Danielle M.
   Lee-Wisdom, Katherine
   Arai, Andrew E.
   Sirajuddin, Arlene
   Rosing, Douglas R.
   Korchin, Borys
   Gulley, James L.
   Bilusic, Marijo
TI Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine
   Immunotherapy for Metastatic Chordoma: A Case Report
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE severe acute respiratory syndrome coronavirus 2; coronavirus disease
   2019; chordoma; modified vaccinia Ankara-brachyury vaccine;
   immunotherapy
ID TUMOR-INFILTRATING LYMPHOCYTES; PHASE-I; EXPRESSION; COVID-19; PD-L1
AB The emergence of the SARS-CoV-2 virus has been associated with perplexing clinical sequelae and phenomena that often have no clear link to the underlying infection. There is a wide spectrum of symptoms associated with infection, from minimal respiratory complaints to severe multi-organ failure, often resulting in death. Individuals with malignancies, particularly those whose treatments have left them immunocompromised or immunosuppressed, are among the patient populations thought to be at greater risk for more severe illness. A man with aggressive metastatic chordoma contracted the SARS-CoV-2 virus and was diagnosed with COVID-19 while undergoing intravenous brachyury vaccine immunotherapy. His disease course was remarkably mild, and the virus cleared rapidly. Despite a treatment delay of 3 months due to the COVID-19 pandemic, the patient's disease has been stable and tumor-related pain has significantly improved. This suggests not only an intact, functional immune system, but also one that appears to have been responsive to cancer treatment. It has been suggested that individuals undergoing treatment for metastatic cancer are at greater risk of severe SARS-CoV-2-related illnesses and complications. While immunosuppression may be a problem, particularly in those receiving conventional chemotherapeutic agents, it is possible that the non-specific effects of immune-enhancing therapies may confer some protection against SARS-CoV-2.
C1 [Pastor, Danielle M.; Lee-Wisdom, Katherine] NCI, Med Oncol Serv, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Arai, Andrew E.; Sirajuddin, Arlene; Rosing, Douglas R.] NHLBI, Cardiovasc Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Korchin, Borys] Bavarian Nord, Morrisville, NC USA.
   [Gulley, James L.; Bilusic, Marijo] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Pastor, DM (corresponding author), NCI, Med Oncol Serv, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM danielle.pastor@nih.gov
RI Bilusic, Marijo/AAZ-2056-2020; Bilusic, Marijo/A-2170-2019
OI Bilusic, Marijo/0000-0003-1020-689X
CR [Anonymous], 2018, ASCO POST
   CDC, 2019, CDC 2019 NOV COR NCO
   Donahue RN, 2014, J IMMUNOTHER CANC S3, V2, P148, DOI DOI 10.1186/2051-1426-2-S3-P148
   Feng Y, 2015, ONCOTARGET, V6, P11139, DOI 10.18632/oncotarget.3576
   Gursel M, 2020, ALLERGY, V75, P1815, DOI 10.1111/all.14345
   Heery CR, 2017, CLIN CANCER RES, V23, P6833, DOI 10.1158/1078-0432.CCR-17-1087
   Heery CR, 2015, CANCER IMMUNOL RES, V3, P1248, DOI 10.1158/2326-6066.CIR-15-0119
   Kattan J, 2020, IMMUNOTHERAPY-UK, V12, P351, DOI 10.2217/imt-2020-0077
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lauterbach H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009659
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mathios D, 2016, J NEURO-ONCOL, V128, P183, DOI 10.1007/s11060-016-2130-0
   Miettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462
   Migliorini D, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1338235
   Miller A, 2020, CORRELATION UNIVERSA, DOI 10.1101/2020.03.24.20042937
   Oda Y, 2000, JPN CIRC J, V64, P627, DOI 10.1253/jcj.64.627
   Shen XF, 2002, J IMMUNOL, V169, P4222, DOI 10.4049/jimmunol.169.8.4222
   Vivarelli S, 2020, CANCERS, V12, DOI 10.3390/cancers12082237
   Zou MX, 2016, AM J TRANSL RES, V8, P3274
NR 20
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 16
PY 2020
VL 10
AR 603248
DI 10.3389/fonc.2020.603248
PG 6
WC Oncology
SC Oncology
GA OY0JX
UT WOS:000593941600001
PM 33330104
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Porcari, DE
   Palmer, K
   Spalletta, G
   Ciullo, V
   Banaj, N
AF Porcari, Desiree E.
   Palmer, Katie
   Spalletta, Gianfranco
   Ciullo, Valentina
   Banaj, Nerisa
TI A Survey for Examining the Effects of COVID-19 and Infection Control
   Measures in Older Persons With Mild Cognitive Impairment and Dementia
   and Their Caregivers
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE COVID-19; SARS-CoV-2 coronavirus; neurocognitive disorders; mild
   cognitive impairment; MCI; dementia; caregivers; neuropsychiatric
   symptoms
ID ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC PREDICTORS; PROGRESSION;
   LONELINESS; DEPRESSION; SYMPTOMS; VERSION; BURDEN
AB Background: During the first wave of the COVID-19 pandemic, many non-urgent outpatient services in Italy were closed due to the Government-enforced lockdown period. So far, little is known about what effect the pandemic, quarantine measures, and reductions in medical services had on people with cognitive impairment and their caregivers.
   Objectives: To develop two versions (i.e., patients and informants/caregivers) of a survey designed to assess the impact of the COVID-19 pandemic during the first Italian lockdown period (11 March -4 May 2020) on Memory Clinic outpatients with Mild Cognitive Impairment (MCI) or dementia, and their caregivers.
   Design: Psychiatrists, neuropsychologists, and epidemiologists developed two versions: one for patients with Mild Cognitive Impairment and other cognitive disorders, the other for their relatives and/or caregivers. Each version of the survey includes five sections: (a) socio-demographic information and access to technology devices; (b) individual COVID-19 protection methods; (c) knowledge about COVID-19; (d) the effect of COVID-19 on daily life; and (e) the effect of COVID-19 on emotional state.
   Conclusion: Until an effective vaccine is developed it is likely that future waves of COVID-19 will result in shielding of vulnerable older adults. We believe that this instrument will be useful as a tool to collect information and help clinicians to promptly respond to changes in patients' cognitive, psychiatric, and somatic health needs, and to help for future planning in possible subsequent quarantine periods.
C1 [Porcari, Desiree E.; Spalletta, Gianfranco; Ciullo, Valentina; Banaj, Nerisa] IRCCS Santa Lucia Fdn, Lab Neuropsychiat, Dept Clin & Behav Neurol, Rome, Italy.
   [Porcari, Desiree E.] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy.
   [Palmer, Katie] Univ Cattolica Sacro Cuore, Dept Internal Med & Geriatr, Rome, Italy.
   [Spalletta, Gianfranco] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Banaj, N (corresponding author), IRCCS Santa Lucia Fdn, Lab Neuropsychiat, Dept Clin & Behav Neurol, Rome, Italy.
EM n.banaj@hsantalucia.it
OI Porcari, Desiree Estela/0000-0003-4338-1547
CR Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8
   Bedard M, 2001, GERONTOLOGIST, V41, P652, DOI 10.1093/geront/41.5.652
   Bersano A, 2020, NEUROLOGY, V94, P905, DOI 10.1212/WNL.0000000000009508
   Boutoleau-Bretonniere C, 2020, J ALZHEIMERS DIS, V76, P41, DOI 10.3233/JAD-200604
   Brodaty Henry, 2009, Dialogues Clin Neurosci, V11, P217
   Campbell NL, 2013, CLIN GERIATR MED, V29, P873, DOI 10.1016/j.cger.2013.07.009
   Casagrande M, 2020, SLEEP MED, V75, P12, DOI 10.1016/j.sleep.2020.05.011
   Choi EPH, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103740
   Colombo D, 2018, J WOMENS HEALTH, V27, P1368, DOI 10.1089/jwh.2017.6420
   Donovan NJ, 2016, JAMA PSYCHIAT, V73, P1230, DOI 10.1001/jamapsychiatry.2016.2657
   Favieri F, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3576804, DOI 10.2139/SSRN.3576804]
   Forte G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17114151
   Forte G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061802
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Isik AT, 2019, INT J GERIATR PSYCH, V34, P1326, DOI 10.1002/gps.4965
   Lara B, 2020, EUR J NEUROL, V27, P1744, DOI 10.1111/ene.14339
   Lara E, 2019, INT J GERIATR PSYCH, V34, P1613, DOI 10.1002/gps.5174
   Lee SA, 2020, DEATH STUD, DOI [10.1080/07481187.2020.1853885, 10.1080/07481187.2020.1748481]
   Lucas-Carrasco R, 2011, ALZ DIS ASSOC DIS, V25, P345, DOI 10.1097/WAD.0b013e31820bc98b
   Goodman-Casanov JM, 2020, J MED INTERNET RES, V22, DOI 10.2196/19434
   Mazza C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093165
   Musicco M, 2009, J NEUROL, V256, P1288, DOI 10.1007/s00415-009-5116-4
   Nicol GE, 2020, J AM GERIATR SOC, V68, P922, DOI 10.1111/jgs.16443
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Paital B, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138914
   Palmer K, 2020, AGING CLIN EXP RES, V32, P1189, DOI 10.1007/s40520-020-01601-4
   Palmer K, 2010, J ALZHEIMERS DIS, V20, P175, DOI 10.3233/JAD-2010-1352
   Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2
   Spalletta G, 2015, J ALZHEIMERS DIS, V48, P627, DOI 10.3233/JAD-150391
   Spalletta G, 2012, PSYCHIAT RES, V198, P263, DOI 10.1016/j.psychres.2011.11.018
   Spalletta G, 2010, AM J GERIAT PSYCHIAT, V18, P1026, DOI 10.1097/JGP.0b013e3181d6b68d
   Sussams R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60607-0
   Tuite AR, 2020, LANCET INFECT DIS, V20, P537, DOI 10.1016/S1473-3099(20)30227-9
   Victor CR, 2020, AGING MENT HEALTH, DOI 10.1080/13607863.2020.1753014
   Victor CR, 2020, INT J GERIATR PSYCH, V35, P851, DOI 10.1002/gps.5305
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Weinstein A, 2020, AM J GERIAT PSYCHIAT, V28, pS79
   World Health Organization (WHO), 2020, NOV COR CHIN
NR 38
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD NOV 16
PY 2020
VL 11
AR 599851
DI 10.3389/fpsyt.2020.599851
PG 5
WC Psychiatry
SC Psychiatry
GA OY0LI
UT WOS:000593945300001
PM 33304288
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mendes-Santos, C
   Andersson, G
   Weiderpass, E
   Santana, R
AF Mendes-Santos, Cristina
   Andersson, Gerhard
   Weiderpass, Elisabete
   Santana, Rui
TI Mitigating COVID-19 Impact on the Portuguese Population Mental Health:
   The Opportunity That Lies in Digital Mental Health
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE COVID-19; public mental health; digital mental health; internet
   interventions; Portugal; EU; eHealth and eMental-health
ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIOR THERAPY; GENERALIZED
   ANXIETY DISORDER; GUIDED SELF-HELP; PSYCHOLOGICAL IMPACT; HOSPITAL
   EMPLOYEES; INTERNET; SARS; INTERVENTIONS; DEPRESSION
AB COVID-19 mitigation measures present unprecedented challenges in mental healthcare delivery, posing high risk to the mental health of at-risk populations, namely patients diagnosed with COVID-19, frontline healthcare providers, and those submitted to quarantine or isolation measures, as well as the general population. Ensuring safe and equitable access to mental healthcare by these groups entails resorting to innovative psychosocial intervention strategies, such as digital mental health. In this perspective piece, we describe the impact of COVID-19 on the Portuguese population's mental health, present an overview on initiatives developed to address the challenges currently faced by the Portuguese mental healthcare system, and discuss how the timely implementation of a comprehensive digital mental health strategy, coupling research, education, implementation, and quality assessment initiatives, might buffer COVID-19's impact on the Portuguese society.
C1 [Mendes-Santos, Cristina] Linkoping Univ, Dept Culture & Soc, Linkoping, Sweden.
   [Mendes-Santos, Cristina; Santana, Rui] Univ NOVA Lisboa, NOVA Natl Sch Publ Hlth, Publ Hlth Res Ctr, Lisbon, Portugal.
   [Mendes-Santos, Cristina] Fraunhofer Ctr Assist Informat & Commun Solut, Porto, Portugal.
   [Andersson, Gerhard] Linkoping Univ, Dept Behav Sci & Learning, Linkoping, Sweden.
   [Andersson, Gerhard] Karolinska Inst, Psychiat Sect, Dept Clin Neurosci, Stockholm, Sweden.
   [Weiderpass, Elisabete] Int Agcy Res Canc, Lyon, France.
RP Mendes-Santos, C (corresponding author), Linkoping Univ, Dept Culture & Soc, Linkoping, Sweden.; Mendes-Santos, C (corresponding author), Univ NOVA Lisboa, NOVA Natl Sch Publ Hlth, Publ Hlth Res Ctr, Lisbon, Portugal.; Mendes-Santos, C (corresponding author), Fraunhofer Ctr Assist Informat & Commun Solut, Porto, Portugal.
EM cristina.mendes.santos@liu.se
FU Erasmus+ Program of the European Union: Phoenix JDP on Dynamics of
   Health and Welfare - Fraunhofer Portugal AICOS
FX CM-S was funded by the Erasmus+ Program of the European Union: Phoenix
   JDP on Dynamics of Health and Welfare until July 2020 being currently
   funded by Fraunhofer Portugal AICOS.
CR Agboola SO, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4009
   Andersson G, 2002, PSYCHOSOM MED, V64, P810, DOI 10.1097/01.PSY.0000031577.42041.F8
   Andersson G, 2018, INTERNET INTERV, V12, P181, DOI 10.1016/j.invent.2018.03.008
   Andersson G, 2014, WORLD PSYCHIATRY, V13, P4, DOI 10.1002/wps.20083
   Andersson G, 2013, J AFFECT DISORDERS, V151, P986, DOI 10.1016/j.jad.2013.08.022
   Andersson G, 2012, PSYCHOTHER PSYCHOSOM, V81, P344, DOI 10.1159/000339371
   Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P196, DOI 10.1080/16506070903318960
   Andersson G, 2008, J TECHNOL HUMAN SERV, V26, P161, DOI 10.1080/15228830802094627
   Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Bai Y, 2004, PSYCHIAT SERV, V55, P1055, DOI 10.1176/appi.ps.55.9.1055
   Balcombe L, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/21718
   Barak A, 2009, ANN BEHAV MED, V38, P4, DOI 10.1007/s12160-009-9130-7
   Barak A, 2008, J TECHNOL HUMAN SERV, V26, P109, DOI 10.1080/15228830802094429
   Barbisch D, 2015, DISASTER MED PUBLIC, V9, P547, DOI 10.1017/dmp.2015.38
   Ben-Zeev Dror, 2020, Psychiatr Serv, V71, P1212, DOI 10.1176/appi.ps.202000306
   Bento H, 2020, COVID 19 NAO SOFRA S
   Berryhill MB, 2019, TELEMED E-HEALTH, V25, P435, DOI 10.1089/tmj.2018.0058
   Blom K, 2015, BEHAV RES THER, V70, P47, DOI 10.1016/j.brat.2015.05.002
   Boulos C, 2017, GERIATR GERONTOL INT, V17, P286, DOI 10.1111/ggi.12711
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Buhrman M, 2004, PAIN, V111, P368, DOI 10.1016/j.pain.2004.07.021
   Caldas Almeida JM, 2013, NATL EPIDEMIOLOGICAL
   Carlbring P, 2011, BEHAV RES THER, V49, P18, DOI 10.1016/j.brat.2010.10.002
   Carvalho R, 2019, LINHAS ORIENTACAO PR
   CESOP, 2020, VID QUAR 14 PORT PAS
   CHANG BP, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/bmj.m2541
   Crawford A, 2020, J MED INTERNET RES, V22, DOI 10.2196/19361
   Deane FP, 2015, AUST PSYCHOL, V50, P241, DOI 10.1111/ap.12107
   DGS, 2020, 162 DGS
   Dias S, 2020, BAROMETRO COVID 19
   Dias S, 2020, OPINIAO SOCIAL PERCE
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Espinoza Juan, 2020, JMIR Public Health Surveill, V6, pe18808, DOI 10.2196/18808
   Fagherazzi G, 2020, J MED INTERNET RES, V22, DOI 10.2196/19284
   FCT, 2020, RESEARCH4COVID 19 CA
   FCT, 2020, IN EST AP INV COVID
   Ferguson N, 2020, IMPACT NONPHARMACEUT
   Fonseca A, 2018, COGN BEHAV PRACT, V25, P473, DOI 10.1016/j.cbpra.2018.02.002
   Gosling SD, 2015, ANNU REV PSYCHOL, V66, P877, DOI 10.1146/annurev-psych-010814-015321
   Goulia P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-322
   Hadjiconstantinou M, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5991
   Hedman E, 2013, ACTA PSYCHIAT SCAND, V128, P457, DOI 10.1111/acps.12079
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Hossain MM, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020038
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   ISPUP INESC-TEC, 2020, DIAR PAND RES PRIM S
   Ivarsson D, 2014, INTERNET INTERV, V1, P33, DOI [10.1016/j.invent.2014.03.002, DOI 10.1016/J.INVENT.2014.03.002]
   Kang LJ, 2020, LANCET PSYCHIAT, V7, pE14, DOI 10.1016/S2215-0366(20)30047-X
   Kim AR, 2015, STUD HEALTH TECHNOL, V216, P142, DOI 10.3233/978-1-61499-564-7-142
   Kitsiou S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173160
   Kuijpers W, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2281
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lavie CJ, 2019, CIRC RES, V124, P799, DOI 10.1161/CIRCRESAHA.118.312669
   Lee SM, 2018, COMPR PSYCHIAT, V87, P123, DOI 10.1016/j.comppsych.2018.10.003
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Liu XH, 2012, COMPR PSYCHIAT, V53, P15, DOI 10.1016/j.comppsych.2011.02.003
   Ljotsson B, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-110
   Lusa, 2020, MAIS MET POP MUND ES
   Mak IWC, 2009, GEN HOSP PSYCHIAT, V31, P318, DOI 10.1016/j.genhosppsych.2009.03.001
   McAlpine H, 2015, PATIENT EDUC COUNS, V98, P283, DOI 10.1016/j.pec.2014.11.002
   McGrath P, 2018, TOOLKIT MENTAL HLTH
   Mendes-Santo C, 2019, INTERNET INTERV, V17, DOI 10.1016/j.invent.2019.01.004
   Mendes-Santos C, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/16817
   Mohr DC, 2018, JAMA PSYCHIAT, V75, P113, DOI 10.1001/jamapsychiatry.2017.3838
   Mohr DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070086
   Mohr DC, 2013, GEN HOSP PSYCHIAT, V35, P332, DOI 10.1016/j.genhosppsych.2013.03.008
   O'Mahen HA, 2014, PSYCHOL MED, V44, P1675, DOI 10.1017/S0033291713002092
   Onnela JP, 2016, NEUROPSYCHOPHARMACOL, V41, P1691, DOI 10.1038/npp.2016.7
   OPP, 2020, VIA VERD AP OPP INV
   Paxling Bjorn, 2011, Cognitive Behaviour Therapy, V40, P159, DOI 10.1080/16506073.2011.576699
   PNSM, 2017, PROGR NAC SAUD MENT
   Proudfoot Judith, 2011, Cognitive Behaviour Therapy, V40, P82, DOI 10.1080/16506073.2011.573807
   Qi J, 2020, EVALUATION SLEEP DIS
   Reger MA, 2020, JAMA PSYCHIAT, V77, P1093, DOI 10.1001/jamapsychiatry.2020.1060
   Richards D, 2012, CLIN PSYCHOL REV, V32, P329, DOI 10.1016/j.cpr.2012.02.004
   Riper H, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1713
   Salgado J, 2016, 9 C INT 14 NAC PSIC
   Salgado J, 2020, WEBINAR OPP CONSULTA
   Santana R, 2020, MOMENTOS POLITICAS S
   Shah K, 2020, CUREUS, V12, DOI 10.7759/cureus.7405
   SNS, 2020, LINH CTR CONT SNS 24
   SNS, 2020, CONS TEL
   SNS24, 2020, AC PSIC SNS 24
   Sousa M, 2019, 35 ANN C SOC EXPL PS
   Sousa Uva A, 2020, SAUDE OCUPACIONAL RI
   Spence J, 2011, DEPRESS ANXIETY, V28, P541, DOI 10.1002/da.20835
   SPMS, 2019, PLAN ESTR NAC TEL 20
   Sprang G, 2013, DISASTER MED PUBLIC, V7, P105, DOI 10.1017/dmp.2013.22
   Tam CWC, 2004, PSYCHOL MED, V34, P1197, DOI 10.1017/S0033291704002247
   Taylor MR, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-347
   Torous J, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/18848
   Torous J, 2016, JMIR MENT HEALTH, V3, DOI 10.2196/mental.5165
   Wagner B, 2014, J AFFECT DISORDERS, V152, P113, DOI 10.1016/j.jad.2013.06.032
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   WHO, 2020, 206 WHO
   WHO, 2005, 2 M INT HLTH REG
   Wind TR, 2020, INTERNET INTERV, V20, DOI 10.1016/j.invent.2020.100317
   Wu P, 2008, ALCOHOL ALCOHOLISM, V43, P706, DOI 10.1093/alcalc/agn073
   Wu P, 2009, CAN J PSYCHIAT, V54, P302, DOI 10.1177/070674370905400504
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Xiao H, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923921
   Xu Z, 2020, LANCET, V395, P947, DOI 10.1016/S0140-6736(20)30308-1
   Yang SQ, 2019, CHEM RES CHINESE U, V35, P1052, DOI 10.1007/s40242-019-9169-3
   Zhang J, 2020, PRECISION CLIN MED, V3, P3, DOI [10.1093/pcmedi/pbaa006, DOI 10.1093/pcmedi/pbaa006]
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
   Zhu Z, 2020, COVID 19 WUHAN IMMED, DOI [10.1101/2020.02.20.20025338, 10.1101/2020.02.20.20025338.medRxiv2020.02.20, DOI 10.1101/2020.02.20.20025338]
NR 107
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD NOV 16
PY 2020
VL 8
AR 553345
DI 10.3389/fpubh.2020.553345
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OX9UW
UT WOS:000593902100001
PM 33313033
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sarkar, I
   Sen, A
AF Sarkar, Indrani
   Sen, Arnab
TI In silico screening predicts common cold drug Dextromethorphan along
   with Prednisolone and Dexamethasone can be effective against novel
   Coronavirus disease (COVID-19)
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Covid-19; Dextromethorphan; Prednisolone; Dexamethasone; Coronavirus
   main protease (M-pro)
AB The ongoing outbreak of Coronavirus disease 2019 (COVID-19) is a matter of great concern. Although the mortality rate caused by this virus is less than that of SARS and MERS, it is showing higher efficacy in terms of human-to-human transmission. Several strategies have been taken by scientists and researchers worldwide to combat this virus. Numerous phytochemicals and synthesized chemicals are under incessant inspection to obtain a potent anti-covid drug. Since, till now no precise therapy is available for covid patients, researchers are trying to categorize all possible anti-covid substances. Repurposing of drugs and combined drug therapy are becoming popular in treating such viral diseases. In this study, we are proposing the repurposing of three chemicals-Dextromethorphan, Prednisolone and Dexamethasone as anti-covid agents. We have used the tertiary structure of Coronavirus main protease (M-pro) with PDB ID 6LU7 as the target protein in this analysis. Molecular docking and dynamics study further revealed their synergistic effect against the COVID-19 protease protein.
   Communicated by Ramaswamy H. Sarma
C1 [Sarkar, Indrani; Sen, Arnab] Univ North Bengal, Dept Bot, Bioinformat Facil, Darjeeling, W Bengal, India.
RP Sen, A (corresponding author), Univ North Bengal, Dept Bot, Bioinformat Facil, Darjeeling, W Bengal, India.
EM senarnab_nbu@hotmail.com
FU Department of Biotechnology, Govt. of West Bengal
FX This work is partially funded by the Department of Biotechnology, Govt.
   of West Bengal.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelli I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763199
   Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   BEM JL, 1992, DRUG SAFETY, V7, P190, DOI 10.2165/00002018-199207030-00004
   Brown C, 2004, BRIT J PHARMACOL, V141, P233, DOI 10.1038/sj.bjp.0705605
   Dunkel J, 2014, NAT PHYS, V10, P67, DOI [10.1038/nphys2815, 10.1038/NPHYS2815]
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   KAR P, 2020, J BIOMOL STRUCT 0618, DOI DOI https://doi.org/10.1080/07391102.2020.1780947
   KHAN MT, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1769733
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Patel SK, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101844
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001
   Shabalin IG, 2020, IUCRJ, V7, P1048, DOI 10.1107/S2052252520012944
NR 20
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1850528
EA NOV 2020
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OU4KR
UT WOS:000591498700001
PM 33225870
OA Bronze
DA 2021-01-01
ER

PT J
AU Surucic, R
   Tubic, B
   Stojiljkovic, MP
   Djuric, DM
   Travar, M
   Grabez, M
   Savikin, K
   Skrbic, R
AF Surucic, Relja
   Tubic, Biljana
   Stojiljkovic, Milos P.
   Djuric, Dragan M.
   Travar, Maja
   Grabez, Milkica
   Savikin, Katarina
   Skrbic, Ranko
TI Computational study of pomegranate peel extract polyphenols as potential
   inhibitors of SARS-CoV-2 virus internalization
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Molecular docking; Pomegranate peel extract;
   Punicalagin; Punicalin
ID PROTEIN; INFLAMMATION; PUNICALAGIN; INFECTION; SPIKE; ACE2
AB The search for effective coronavirus disease (COVID-19) therapy has attracted a great deal of scientific interest due to its unprecedented health care system overload worldwide. We have carried out a study to investigate the in silico effects of the most abundant pomegranate peel extract constituents on the multi-step process of serious acute respiratory syndrome coronavirus 2 (SARS-CoV-2) internalization in the host cells. Binding affinities and interactions of ellagic acid, gallic acid, punicalagin and punicalin were studied on four selected protein targets with a significant and confirmed role in the process of the entry of virus into a host cell. The protein targets used in this study were: SARS-CoV-2 spike glycoprotein, angiotensin-converting enzyme 2, furin and transmembrane serine protease 2. The results showed that the constituents of pomegranate peel extracts, namely punicalagin and punicalin had very promising potential for significant interactions with the selected protein targets and were therefore deemed good candidates for further in vitro and in vivo evaluation.
C1 [Surucic, Relja] Univ Banja Luka, Dept Pharmacognosy, Fac Med, Banja Luka, Bosnia & Herceg.
   [Tubic, Biljana] Univ Banja Luka, Dept Pharmaceut Chem, Fac Med, Banja Luka, Bosnia & Herceg.
   [Stojiljkovic, Milos P.; Skrbic, Ranko] Univ Banja Luka, Fac Med, Dept Pharmacol Toxicol & Clin Pharmacol, Banja Luka, Bosnia & Herceg.
   [Djuric, Dragan M.] Univ Belgrade, Inst Med Physiol Richard Burian, Fac Med, Belgrade, Serbia.
   [Djuric, Dragan M.] Univ Banja Luka, Fac Med, Banja Luka, Bosnia & Herceg.
   [Travar, Maja] Univ Banja Luka, Dept Microbiol, Fac Med, Banja Luka, Bosnia & Herceg.
   [Grabez, Milkica] Publ Hlth Inst Republ Srpska, Dept Hyg, Banja Luka, Bosnia & Herceg.
   [Grabez, Milkica] Univ Banja Luka, Dept Prevent Med, Fac Med, Banja Luka, Bosnia & Herceg.
   [Savikin, Katarina] Inst Med Plant Res Dr Josif Pancic, Belgrade, Serbia.
RP Skrbic, R (corresponding author), Univ Banja Luka, Fac Med, Dept Pharmacol Toxicol & Clin Pharmacol, Banja Luka, Bosnia & Herceg.
EM ranko.skrbic@med.unibl.org
OI Djuric, Dragan M./0000-0003-2196-9438
CR Aimovi J, 2020, SCR MED, V51, P74, DOI [10.5937/scriptamed51-27298, DOI 10.5937/SCRIPTAMED51-27298]
   Akhtar S, 2015, FOOD CHEM, V174, P417, DOI 10.1016/j.foodchem.2014.11.035
   Al-Jarallah A, 2013, ATHEROSCLEROSIS, V228, P80, DOI 10.1016/j.atherosclerosis.2013.02.025
   Alhenc-Gelas F, 2020, KIDNEY INT, V97, P1091, DOI 10.1016/j.kint.2020.04.009
   Banihani S, 2013, NUTR RES, V33, P341, DOI 10.1016/j.nutres.2013.03.003
   BenSaad LA, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1555-0
   Cerda B, 2003, EUR J NUTR, V42, P18, DOI 10.1007/s00394-003-0396-4
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Danesi F, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090958
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Ekici OD, 2008, PROTEIN SCI, V17, P2023, DOI 10.1110/ps.035436.108
   Fathi SMS, 2014, BMC STRUCT BIOL, V14, DOI 10.1186/1472-6807-14-18
   Grabez M, 2020, J FUNCT FOODS, V64, DOI 10.1016/j.jff.2019.103692
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Haidari M, 2009, PHYTOMEDICINE, V16, P1127, DOI 10.1016/j.phymed.2009.06.002
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Hoffmann M, 2018, PRIMING TIME CELLULA, P71, DOI [10.1007/978-3-319-75474-1_4, DOI 10.1007/978-3-319-75474-1_4]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Howell AB, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/606212
   Jankovi S, 2020, SCR MED, V51, P101, DOI [10.5937/scriptamed51-27183, DOI 10.5937/SCRIPTAMED51-27183]
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Kleine-Weber H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34859-w
   Krieger E, 2004, PROTEINS, V54, P768, DOI 10.1002/prot.10590
   Lansky EP, 2007, J ETHNOPHARMACOL, V109, P177, DOI 10.1016/j.jep.2006.09.006
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Moradi MT, 2020, AVICENNA J PHYTOMEDI, V10, P143, DOI 10.22038/AJP.2019.13855
   Moradi Mohammad-Taghi, 2019, Avicenna Journal of Medical Biotechnology, V11, P285
   Nayal M, 2006, PROTEINS, V63, P892, DOI 10.1002/prot.20897
   Odhar HA, 2020, BIOINFORMATION, V16, P236, DOI 10.6026/97320630016236
   Orgil O, 2014, LWT-FOOD SCI TECHNOL, V58, P571, DOI 10.1016/j.lwt.2014.03.030
   Ozbil M, 2020, COMP CLIN APPROVED M, DOI [10.26434/chemrxiv.12090828.v1, DOI 10.26434/CHEMRXIV.12090828.V1]
   Pecheur EI, 2016, J VIROL, V90, P3086, DOI 10.1128/JVI.02077-15
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Reddy BU, 2014, SCI REP-UK, V4, DOI 10.1038/srep05411
   Roshanravan N, 2020, DIABETES METAB SYND, V14, P637, DOI 10.1016/j.dsx.2020.05.022
   Saeed M, 2018, RECENT PATENTS INFLA, V12, P24, DOI 10.2174/1872213X12666180221154713
   Sheybani Z, 2020, ROLE FOLIC ACID MANA, DOI [10.26434/chemrxiv.12034980.v1, DOI 10.26434/CHEMRXIV.12034980.V1]
   Sohrab G, 2019, CLIN NUTR ESPEN, V29, P30, DOI 10.1016/j.clnesp.2018.11.013
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Villoutreix BO, 2020, PHARMACODYNAMICS, DOI [10.21203/rs.3.rs-25856/v1, DOI 10.21203/RS.3.RS-25856/V1]
   Volkamer A, 2012, J CHEM INF MODEL, V52, P360, DOI 10.1021/ci200454v
   Volkamer A, 2010, J CHEM INF MODEL, V50, P2041, DOI 10.1021/ci100241y
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu XL, 2014, INFLAMMATION, V37, P956, DOI 10.1007/s10753-014-9816-2
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Young T, 2010, PROTEINS, V78, P1856, DOI 10.1002/prot.22699
NR 54
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
DI 10.1007/s11010-020-03981-7
EA NOV 2020
PG 15
WC Cell Biology
SC Cell Biology
GA OT3PV
UT WOS:000590763400005
PM 33200379
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Giannantoni, A
   Rubilotta, E
   Balzarro, M
   Gubbiotti, M
AF Giannantoni, Antonella
   Rubilotta, Emanuele
   Balzarro, Matteo
   Gubbiotti, Marilena
TI Continuing care for patients affected by urologic chronic pelvic pain in
   the era of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
   pandemic
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Article; Early Access
DE anxiety; catastrophizing; chronic pelvic pain; COVID&#8208; 19;
   depression; severe acute respiratory syndrome coronavirus&#8208; 2;
   stress
ID PSYCHOMETRIC PROPERTIES; DEPRESSION; CLASSIFICATION; MANAGEMENT;
   COMMUNITY; THERAPY
AB Aims Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic poses a challenge to treatment of patients with urologic chronic pelvic pain (UCPP), who are at risk to be postponed in the priority of care. We investigated pain, catastrophizing, and psychological status in UCPP patients during SARS-CoV-2 by means of Skype telephone calls.
   Methods A total of 28 UCPP patients underwent Skype video consultations. Pain intensity was assessed with Pain Numerical Rating Scale (PNRS). Pain Catastrophizing Scale (PCS) and Depression Anxiety Stress Scales (DASS-21) were used to assess catastrophizing and psychological status.
   Results During SARS-CoV-2, UCPP patients showed higher intensity of pain than before (mean +/- SD PNRS score: 7.25 +/- 0.9 vs. 5.4 +/- 0.7; p < .0001), with pain exacerbation in 75%; they showed higher PCS and DASS-21 scores as compared to before the pandemic (mean +/- SD PCS total score: 32.4 +/- 1.2 vs. 23.7 +/- 3.5; mean +/- SD DASS-21 total score: 42.03 +/- 4.5 vs. 34.4 +/- 2.2; p < .001 and p < .001, respectively).
   Conclusion During SARS-CoV-2 pandemic UCPP patients presented with high intensity of pain, marked catastrophizing thoughts and severe alteration of the psychological status. These observations impose the need not to postpone assessment and treatment of these patients during the pandemic. Remote visits with video telephone calls are a simple way of continuing care in UCPP patients.
C1 [Giannantoni, Antonella] Univ Siena, Dept Surg & Med Sci & Neurosci, Funct & Surg Urol Unit, Siena, Italy.
   [Rubilotta, Emanuele; Balzarro, Matteo] AOUI Verona Univ, Dept Urol, Verona, Italy.
   [Gubbiotti, Marilena] San Donato Hosp, Dept Urol, Pelv Unit, Arezzo, Italy.
RP Giannantoni, A (corresponding author), Univ Siena, S Maria Scotte Hosp, Dept Surg & Med Sci & Neurosci, Funct & Surg Urol Unit, Viale M Bracci, I-53100 Siena, Italy.
EM antonella.giannantoni@unisi.it
OI Gubbiotti, Marilena/0000-0002-3486-1226
CR [Anonymous], 2020, WHO DIRECTOR GENERAL
   Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176
   Bottesi G, 2015, COMPR PSYCHIAT, V60, P170, DOI 10.1016/j.comppsych.2015.04.005
   Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55
   Carter A, 2015, JMIR MHEALTH UHEALTH, V3, P99, DOI 10.2196/mhealth.4538
   COVID-19 Recommendations, EAU GUID OFF RAP REA
   de Heer EW, 2018, PAIN, V159, P712, DOI 10.1097/j.pain.0000000000001133
   Eccleston C, 2020, PAIN, V161, P889, DOI 10.1097/j.pain.0000000000001885
   Eccleston C, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010152.pub2
   El-Metwally A, 2015, J PUBLIC HLTH EPIDEM, V7, P170, DOI DOI 10.5897/JPHE2014.0702
   Goldfinger C, 2016, J SEX MED, V13, P88, DOI 10.1016/j.jsxm.2015.12.003
   Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147
   Huang XF, 2020, TRANSL ANDROL UROL, V9, P485, DOI 10.21037/tau.2020.01.25
   JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9
   Krieger JN, 1999, JAMA-J AM MED ASSOC, V282, P236, DOI 10.1001/jama.282.3.236
   Lindstrom S, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0265-3
   Liu LW, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/19417
   Lovibond SH, 1995, MANUAL DEPRESSION AN
   Monticone M, 2012, QUAL LIFE RES, V21, P1045, DOI 10.1007/s11136-011-0007-4
   Nolen-Hoeksema S, 2008, PERSPECT PSYCHOL SCI, V3, P400, DOI 10.1111/j.1745-6924.2008.00088.x
   Portnoy J, 2020, J ALLER CL IMM-PRACT, V8, P1489, DOI 10.1016/j.jaip.2020.03.008
   Rice ASC, 2016, PAIN, V157, P791, DOI 10.1097/j.pain.0000000000000454
   Shoskes DA, 2010, UROLOGY, V75, P1249, DOI 10.1016/j.urology.2010.01.021
   Slattery BW, 2019, J MED INTERNET RES, V21, DOI 10.2196/11086
   Stones RW, 2000, BEST PRACT RES CL OB, V14, P415, DOI 10.1053/beog.1999.0084
   Tripp DA, 2016, CUAJ-CAN UROL ASSOC, V10, P383, DOI 10.5489/cuaj.3892
   van de Merwe JP, 2008, EUR UROL, V53, P60, DOI 10.1016/j.eururo.2007.09.019
   Walsh S, 2019, IRISH J MED SCI, V188, P1379, DOI 10.1007/s11845-019-01999-5
   WHO Coronavirus Disease (COVID-19), 2020, HLTH EM DASHB COVID
NR 29
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
EI 1520-6777
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
DI 10.1002/nau.24574
EA NOV 2020
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA OS8ZM
UT WOS:000590446800001
PM 33197061
OA Bronze
DA 2021-01-01
ER

PT J
AU Bolzetta, F
   Maselli, M
   Formilan, M
   Busonera, F
   Albanese, P
   Chiaromanni, F
   Romano, A
   Veronese, N
AF Bolzetta, Francesco
   Maselli, Monica
   Formilan, Marino
   Busonera, Flavio
   Albanese, Paolo
   Chiaromanni, Federica
   Romano, Antonietta
   Veronese, Nicola
TI Prophylactic or therapeutic doses of heparins for COVID-19 infection? A
   retrospective study
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article; Early Access
DE COVID-19; Heparin; Mortality
AB Background Coronavirus disease 19 (COVID-19) is a global outbreak. COVID-19 patients seem to have relevant coagulative abnormalities, even if they are not typical of disseminated intravascular coagulopathy (DIC) of the kind seen in septicaemia. Therefore, anticoagulant therapy with heparins is increasing in interest for a clinical approach to these patients, particularly if older. Studies comparing if prophylactic doses are more effective than therapeutic ones are still missing. Methods Data were collected in the Geriatric Section of the Dolo Hospital, ULSS 3 "Serenissima", Venice from 31st March to 01st May 2020. Heparins (calciparin, fondaparinux, enoxaparine) were divided into prophylactic or therapeutic doses. People previously treated with oral anticoagulants were removed. Vital status was assessed using administrative data. Cox's regression analysis, adjusted for potential confounders, was used for assessing the strength of the association between heparins and mortality. The data were reported as hazard ratio (HR) with 95% confidence intervals (CIs). Results 81 older people (mean age 84.1 years; females = 61.9%) were included. No significant differences in terms of demographic and clinical characteristics emerged between people treated with prophylactic or therapeutic doses, including age, gender, X-rays findings or severity of disease. Therapeutic doses were not associated to a better survival rate (HR 1.06; 95% CI 0.47-2.60; p = 0.89), even after adjusting for 15 confounders related to mortality (HR 0.89; 95% CI 0.30-2.71; p = 0.84). Conclusions Our paper indicates that in older people affected by COVID-19 there is no justification for using therapeutic doses instead of prophylactic ones, having a similar impact on mortality risk.
C1 [Bolzetta, Francesco; Maselli, Monica; Formilan, Marino; Busonera, Flavio; Albanese, Paolo; Chiaromanni, Federica; Romano, Antonietta] Azienda ULSS 3 Serenissima, Dept Med, Geriatr Unit, Unita Locale Socio Sanit, Venice, Italy.
   [Veronese, Nicola] Azienda ULSS 3 Serenissima, Primary Care Dept, Unita Locale Socio Sanit, Via Murano 17, Venice, Italy.
RP Veronese, N (corresponding author), Azienda ULSS 3 Serenissima, Primary Care Dept, Unita Locale Socio Sanit, Via Murano 17, Venice, Italy.
EM ilmannato@gmail.com
OI Veronese, Nicola/0000-0002-9328-289X
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Atallah B, 2020, EUR HEART J-CARD PHA, V6, P260, DOI 10.1093/ehjcvp/pvaa036
   Gavioli EM, 2020, J CARDIOVASC PHARM, V76, P146, DOI 10.1097/FJC.0000000000000861
   Iba T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017046
   Kreuziger L, 2020, AM SOC HEMATOL
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Marietta M, 2020, BLOOD TRANSFUS-ITALY, V18, P167, DOI 10.2450/2020.0083-20
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Miesbach W, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620938149
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
NR 11
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1594-0667
EI 1720-8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
DI 10.1007/s40520-020-01750-6
EA NOV 2020
PG 5
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA OS2TQ
UT WOS:000590020300001
PM 33196991
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kasperkiewicz, M
AF Kasperkiewicz, Michael
TI Covid-19, heat shock proteins, and autoimmune bullous diseases: a
   potential link deserving further attention
SO CELL STRESS & CHAPERONES
LA English
DT Letter
DE Autoimmunity; Covid-19; Heat shock proteins; SARS-CoV-2
AB A link between Covid-19 and development of autoimmunity has been reported. A possible explanation could be molecular mimicry between SARS-CoV-2 and human proteins. Peptide sharing has been found between antigenic epitopes of this virus and heat shock proteins (Hsp) 60 and 90, both of which are associated with autoimmune diseases including those of the bullous type. In particular, there is evidence for the latter Hsp acting as a pathophysiological factor and treatment target in autoimmune blistering dermatoses. Considering multimodal anti-inflammatory mechanisms of action of anti-Hsp90 treatment and drug repositioning results, it may be hypothesized that Hsp90 inhibition could also be a treatment option for cytokine storm-mediated acute respiratory distress syndrome in Covid-19 patients. Hence, although Covid-19-induced autoimmune bullous diseases have not been described in the literature so far, the potential relationship between Covid-19, Hsp, and these autoimmune disorders deserves further attention with respect to both pathophysiology and treatment.
C1 [Kasperkiewicz, Michael] Univ Southern Calif, Dept Dermatol, Keck Sch Med, Los Angeles, CA 90007 USA.
RP Kasperkiewicz, M (corresponding author), Univ Southern Calif, Dept Dermatol, Keck Sch Med, Los Angeles, CA 90007 USA.
EM Michael.Kasperkiewicz@med.usc.edu
CR Cappello F, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072038
   Cugno M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01407
   Ehrenfeld M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102597
   Gammazza AM, 2020, CELL STRESS CHAPERON, V25, P737, DOI 10.1007/s12192-020-01148-3
   Kasperkiewicz Michael, 2020, J Am Acad Dermatol, DOI 10.1016/j.jaad.2020.08.012
   Kasperkiewicz M, 2014, CELL STRESS CHAPERON, V19, P837, DOI 10.1007/s12192-014-0507-6
   Lucchese G, 2020, CELL STRESS CHAPERON, V25, P731, DOI 10.1007/s12192-020-01145-6
   Sultan I., 2020, RES SQUARE, DOI DOI 10.21203/RS.3.RS-18714/V1
   Tukaj S, 2015, EXP DERMATOL, V24, P567, DOI 10.1111/exd.12760
NR 9
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1355-8145
EI 1466-1268
J9 CELL STRESS CHAPERON
JI Cell Stress Chaperones
PD JAN
PY 2021
VL 26
IS 1
BP 1
EP 2
DI 10.1007/s12192-020-01180-3
EA NOV 2020
PG 2
WC Cell Biology
SC Cell Biology
GA PF1MB
UT WOS:000590057600001
PM 33196989
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mendez-Echevarria, A
   Perez-Martinez, A
   del Valle, LG
   Ara, MF
   Melendo, S
   de Valbuena, MR
   Vazquez-Martinez, JL
   Morales-Martinez, A
   Remesal, A
   Sandor-Bajusz, KA
   Cabanas, F
   Calvo, C
AF Mendez-Echevarria, Ana
   Perez-Martinez, Antonio
   Gonzalez del Valle, Luis
   Ara, Maria Fatima
   Melendo, Susana
   Ruiz de Valbuena, Marta
   Vazquez-Martinez, Jose Luis
   Morales-Martinez, Antonio
   Remesal, Agustin
   Sandor-Bajusz, Kinga Amalia
   Cabanas, Fernando
   Calvo, Cristina
TI Compassionate use of remdesivir in children with COVID-19
SO EUROPEAN JOURNAL OF PEDIATRICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; Remdesivir; Children; Infant
AB Children represent a minority of total COVID-19 cases, but studies have reported severe disease and death in pediatric patients. Remdesivir (RDV) has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in children.
   A nationwide multicenter observational study was conducted on children with confirmed SARS-CoV-2 receiving compassionate treatment with RDV in Spain. Eight patients were included in the study, four infants and four older children [median age 5 years old; IQR 4 months-11.6 years old]. Half of them had complex underlying medical conditions, and the rest were mostly infants (3/4). Six out of eight children needed Pediatric Intensive Care Unit Admission. No RDV-related adverse outcomes were observed in our patients. Seven have reached successful clinical outcome, but one patient with serious clinical status died due to complications. However, she received RDV very late after the first COVID-19 symptom.
   Conclusions: In our cohort, most of the patients achieved successful clinical outcome, without observing adverse events. Clinical trials of RDV therapy for children with COVID-19 are urgently needed, to assess the safety, tolerability, efficacy, and pharmacokinetics of RDV in children, as this could be an effective treatment in severe cases.
C1 [Mendez-Echevarria, Ana; Calvo, Cristina] La Paz Univ Hosp, Paediat Infect Dis Dept, Translat Res Network Paediat Infect Dis RITIP, Paseo Castellana 261, Madrid 28046, Spain.
   [Perez-Martinez, Antonio] La Paz Univ Hosp, La Paz Inst Hlth Res IdiPAZ, Translat Res Pediat Oncol Hematopoiet Transplanta, Paediat Hematooncol Dept, Madrid, Spain.
   [Gonzalez del Valle, Luis] La Paz Univ Hosp, Dept Pharm, Madrid, Spain.
   [Ara, Maria Fatima] Quironsalud Madrid Univ Hosp, Dept Paediat & Neonatol, Madrid, Spain.
   [Melendo, Susana] Vall dHebron Res Inst VHIR, Hosp Univ Vall dHebron HUVH, Paediat Infect Dis & Immunodeficiencies Unit, Barcelona, Spain.
   [Ruiz de Valbuena, Marta] La Paz Univ Hosp, Pediat Pulmunol Unit, Madrid, Spain.
   [Vazquez-Martinez, Jose Luis] Ramon & Cajal Univ Hosp, Paediat Intens Care Unit, Madrid, Spain.
   [Morales-Martinez, Antonio] Univ Reg Malaga Hosp, Paediat Intens Care Unit, Malaga, Spain.
   [Remesal, Agustin] La Paz Univ Hosp, Paediat Rheumatol Unit, Madrid, Spain.
   [Sandor-Bajusz, Kinga Amalia] Univ Pecs, Med Sch, Dept Paediat, Pecs, Hungary.
   [Cabanas, Fernando] La Paz Univ Hosp, Quironsalud Madrid Univ Hosp, Dept Neonatol, Madrid, Spain.
   [Cabanas, Fernando] La Paz Univ Hosp, Biomed Res Fdn, Madrid, Spain.
RP Mendez-Echevarria, A (corresponding author), La Paz Univ Hosp, Paediat Infect Dis Dept, Translat Res Network Paediat Infect Dis RITIP, Paseo Castellana 261, Madrid 28046, Spain.
EM amendezes@yahoo.es; aperezmartinez@salud.madrid.org;
   lgvalle@salud.madrid.org; fatiaramon@gmail.com; susanamelendo@upiip.com;
   martaruizde@hotmail.com; jvazquezm@salud.madrid.org;
   moralesmartinezantonio@gmail.com; agusremesal@hotmail.com;
   sandor.kinga@pte.hu; fernando.cabanas@quironsalud.es;
   ccalvorey@gmail.com
OI ANA, MENDEZ ECHEVARRIA/0000-0002-7455-9080
CR Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Chiotos Kathleen, 2020, J Pediatric Infect Dis Soc, DOI 10.1093/jpids/piaa115
   Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2
   Kim L, 2020, MMWR-MORBID MORTAL W, V69, P1081, DOI 10.15585/mmwr.mm6932e3
   Maharaj AR, 2020, JAMA PEDIATR, V174, DOI 10.1001/jamapediatrics.2020.2422
   Perez-Martinez A, 2020, EUR J PEDIATR, DOI 10.1007/s00431-020-03793-3
   Quintana-Ortega Cristian, 2021, Mod Rheumatol Case Rep, V5, P101, DOI 10.1080/24725625.2020.1832755
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Tagarro Alfredo, 2020, JAMA Pediatr, DOI 10.1001/jamapediatrics.2020.1346
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Xiao AT, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104346
NR 11
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-6199
EI 1432-1076
J9 EUR J PEDIATR
JI Eur. J. Pediatr.
DI 10.1007/s00431-020-03876-1
EA NOV 2020
PG 6
WC Pediatrics
SC Pediatrics
GA OS3FL
UT WOS:000590051100001
PM 33200304
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Butters, D
   Whitehouse, M
AF Butters, Desley
   Whitehouse, Michael
TI COVID-19 and nutriceutical therapies, especially using zinc to
   supplement antimicrobials
SO INFLAMMOPHARMACOLOGY
LA English
DT Article; Early Access
DE SARS-2; Hydroxychloroquine; Ivermectin; Transdermal zinc supplements;
   Drug-nutrient synergy; Post-viral fatigue
AB The nutritional status of a patient can be critical for the efficacy of other pharmaceuticals, especially organic antibiotics, to treat viral pandemics. There may be political and scientific difficulties in achieving a constructive synergy of nutritional and prescribed allopathic remedies. For adequate treatment, timelines may need to extend well beyond eliminating viral proliferation, e.g., with vaccines, to include the goals of (a) reducing post-viral fatigue, (b) promoting earliest recovery, and (c) future resistance in often poorly nourished patients, e.g., obese (!). Many trace minerals (TM) and vitamins may need to be replenished. This review focusses only upon zinc to illustrate some problems in rectifying these TM deficiencies affecting the balance between continued ill-health ('illth') or regaining optimal physical and mental wellbeing. Ultimately, this is a matter of behaviour, lifestyle, and informed choice(s). See Hetzel and McMichael 1959.
C1 [Butters, Desley] Griffith Univ, Sch Med, Gold Coast, Qld, Australia.
   [Whitehouse, Michael] Griffith Univ Gold Coast Campus, POB 6168, Woolloongabba, Qld 4102, Australia.
RP Whitehouse, M (corresponding author), Griffith Univ Gold Coast Campus, POB 6168, Woolloongabba, Qld 4102, Australia.
EM whitehousemd@bigpond.com
CR BourBour F, 2020, ARCH PHYSIOL BIOCHEM, DOI 10.1080/13813455.2020.1791188
   Bramstedt Katrina A, 2020, J Med Ethics, V46, P803, DOI 10.1136/medethics-2020-106494
   Campbell WC, 1989, IVERMECTIN ABAMECTIN, P363
   Chaari A, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00476
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   CHANDRA RK, 1984, JAMA-J AM MED ASSOC, V252, P1443, DOI 10.1001/jama.252.11.1443
   Chasapis CT, 2012, ARCH TOXICOL, V86, P521, DOI 10.1007/s00204-011-0775-1
   Cribb J, 1996, WHITE DEATH DID USE, P239
   Derwand R, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109815
   Garner P, 2020, BMJ BLOGS
   Hetzel B, 1959, LS FACTOR LIFESTYLE, P324
   HOEKSTRA WG, 1969, AM J CLIN NUTR, V22, P1268
   Kaddoura M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01196
   Kambunga SN, 2019, ENVIRON GEOCHEM HLTH, V41, P2949, DOI 10.1007/s10653-019-00288-5
   Khorsandi H, 2019, DIABETOL METAB SYNDR, V11, DOI 10.1186/s13098-019-0497-8
   Lockhart Sam M, 2020, Med (N Y), V1, P33, DOI 10.1016/j.medj.2020.06.005
   Menzel M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28698
   Mindell E, 1985, VITAMIN BIBLE RIGHT, P91
   Naz S., 2016, WORLDS POULT SCI J, V1, P1
   PFEIFFER CC, 1982, BIOL PSYCHIAT, V17, P513
   Pfeiffer CC, 1982, TOTAL NUTR, P162
   Polamarasetti P, 2020, BIOACT COMPD HLTH DI, V3, P109
   Popkin BM, 2020, OBES REV, V21, DOI 10.1111/obr.13128
   Prasad A, 1978, TRACE ELEMENTS IRON, P108
   Prasad AS, 2011, NUTRITION, V27, P816, DOI 10.1016/j.nut.2010.08.010
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Razzaque MS, 2020, TOHOKU J EXP MED, V251, P175, DOI 10.1620/tjem.251.175
   Read SA, 2019, ADV NUTR, V10, P696, DOI 10.1093/advances/nmz013
   Rebello CJ, 2020, INT J OBESITY, V44, P1810, DOI 10.1038/s41366-020-0640-5
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Root-Bernstein RS, 1977, GEOPHARMACY HONEY MU, P59
   Sanchis-Gomar F, 2020, MAYO CLIN PROC, V95, P1445, DOI 10.1016/j.mayocp.2020.05.006
   Skalny AV, 2020, INT J MOL MED, V46, P17, DOI 10.3892/ijmm.2020.4575
   Swingle KF, 1974, ANTIINFLAMMATORY AGE, P91
   TNIV, 2005, HOL BIBL TOD NEW INT, V1
   Vaughan JG, 2003, OXFORD BOOK HLTH FOO, P165
   Wallach J, 1999, DEAD DOCTORS DONT LI, P270
   Whitehouse MW, 2020, INFLAMMOPHARMACOLOGY, V28, P1401, DOI 10.1007/s10787-019-00669-3
NR 38
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0925-4692
EI 1568-5608
J9 INFLAMMOPHARMACOLOGY
JI Inflammopharmacology
DI 10.1007/s10787-020-00774-8
EA NOV 2020
PG 5
WC Immunology; Pharmacology & Pharmacy; Toxicology
SC Immunology; Pharmacology & Pharmacy; Toxicology
GA OS2QP
UT WOS:000590012300002
PM 33196946
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Arruda, GV
   Weber, RRD
   Bruno, AC
   Pavoni, JF
AF Arruda, Gustavo Viani
   Weber, Raissa Renata dos Santos
   Bruno, Alexandre Colello
   Pavoni, Juliana Fernandes
TI The risk of induced cancer and ischemic heart disease following low dose
   lung irradiation for COVID-19: estimation based on a virtual case
SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
LA English
DT Article; Early Access
DE COVID-19; radiotherapy; cancer induction; whole lung irradiation
ID IONIZING-RADIATION; PNEUMONIA; THERAPY
AB Background
   Recently, low dose radiotherapy delivered to the whole lung has been proposed as treatment for the pneumonia due to COVID-19. Although there is biological plausibility for its use, the evidence supporting its effectiveness is scarce, and the risks associated with it may be significant. Thus, based on a virtual case simulation, we estimated the risks of radiation-induced cancer (RIC) and cardiac disease.
   Methods
   Lifetime attributable risks (LAR) of RIC were calculated for the lung, liver, esophagus, and breast of female patients. The cardiovascular risk of exposure-induced death (REID) due to ischemic heart disease was also calculated. The doses received by the organs involved in the treatment were obtained from a simulation of conformal radiotherapy (RT) treatment, delivering a dose of 0.5 Gy-1.5 Gy to the lungs. We considered a LAR and REID <1% as acceptable, 1-2% cautionary, and >2% unacceptable.
   Results
   The lung was at the highest risk for RIC (absolute LAR below 5200 cases/100,000 and 2250 cases/100,000 for women and men, respectively). For women, the breast had the second-highest LAR, especially for young women. The liver and esophagus had LARs below 700/100,000 for both sexes, with a higher incidence of esophageal cancer in women and liver cancer in men. Regarding the LAR cutoff, we observed an unacceptable or cautionary LAR for lung cancer in all women and men 1 Gy. LAR for lung cancer with an RT dose of 1 Gy was cautionary for women >60 years of age and men Conclusions
   A RT dose <= 0.5 Gy provides an acceptable LAR estimate (<= 1%) for RIC and REID, irrespective of sex and age. The current ongoing trials should initially use doses <= 0.5 Gy to maintain the risks at an acceptable level and include only patients who fail or do not have any other treatment option.
C1 [Arruda, Gustavo Viani; Bruno, Alexandre Colello; Pavoni, Juliana Fernandes] Univ Sao Paulo, Ribeirao Preto Med Sch Hosp & Clin, Radiotherapy Dept, Ave Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP, Brazil.
   [Weber, Raissa Renata dos Santos; Pavoni, Juliana Fernandes] Univ Sao Paulo, Fac Philosophy Sci & Letters Ribeirao Preto, Dept Phys, Sao Paulo, Brazil.
RP Pavoni, JF (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch Hosp & Clin, Radiotherapy Dept, Ave Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP, Brazil.
EM jfpavoni@ffclrp.usp.br
RI Pavoni, Juliana F/B-4865-2014; Bruno, Alexandre Colello/F-2648-2012
OI Pavoni, Juliana F/0000-0002-1647-8231; Bruno, Alexandre
   Colello/0000-0002-0299-8404; Viani, Gustavo/0000-0002-4337-7575; Renata
   dos Santos Weber, Raissa/0000-0001-8504-8422
CR Ameri A, 2020, INT J RAD ONCOL
   Cascella M, 2020, FEATURES EVALUATION
   Chen Y, 2020, LANCET INFECT DIS, V20, P515, DOI 10.1016/S1473-3099(20)30235-8
   Dhawan G, 2020, RADIOTHER ONCOL, V147, P212, DOI 10.1016/j.radonc.2020.05.002
   Furukawa K, 2010, RADIAT RES, V174, P72, DOI 10.1667/RR2083.1
   Hess CB, 2020, CANCER-AM CANCER SOC, V126, P5109, DOI 10.1002/cncr.33130
   Kirkby C, 2020, RADIOTHER ONCOL, V149, P72, DOI 10.1016/j.radonc.2020.04.050
   Kirsch DG, 2020, RADIOTHER ONCOL, V147, P217, DOI 10.1016/j.radonc.2020.04.060
   Little MP, 2012, ENVIRON HEALTH PERSP, V120, P1503, DOI 10.1289/ehp.1204982
   Little MP, 2020, INT J RAD ONCOL
   Rodel F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00120
   Salomaa S, 2020, INT J RADIAT BIOL, V96, P1228, DOI 10.1080/09553002.2020.1786609
   Salomaa S, 2020, INT J RADIAT BIOL, V96, P1224, DOI 10.1080/09553002.2020.1762020
   Yang GZ, 2014, CANCER BIOTHER RADIO, V29, P428, DOI 10.1089/cbr.2014.1702
   Zhang W, 2020, INT J RADIAT BIOL, V96, P596, DOI 10.1080/09553002.2020.1708499
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0955-3002
EI 1362-3095
J9 INT J RADIAT BIOL
JI Int. J. Radiat. Biol.
DI 10.1080/09553002.2021.1846818
EA NOV 2020
PG 6
WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
SC Life Sciences & Biomedicine - Other Topics; Nuclear Science &
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA OS3UB
UT WOS:000590089100001
PM 33164596
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Patel, D
   Athar, M
   Jha, PC
AF Patel, Dhaval
   Athar, Mohd
   Jha, P. C.
TI Computational investigation of binding of chloroquinone and
   hydroxychloroquinone against PLPro of SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-Cov2; PLpro; molecular dynamics; chloroquine;
   hydroxychloroquine
ID PAPAIN-LIKE PROTEASE; RESPIRATORY SYNDROME CORONAVIRUS; GLOBAL HEALTH;
   SARS; INHIBITORS; OUTBREAK; VIRUS; POTENTIALS; PNEUMONIA; GROMACS
AB Novel coronavirus SARS-CoV-2 has infected 18 million people with 700,000+ mortalities worldwide and this deadly numeric figure is rapidly rising. With very few success stories, the therapeutic targeting of this epidemic has been mainly attributed to main protease (Mpro), whilst Papain-like proteases (PLpro) also plays a vital role in the processing of replicase polyprotein. Multifunctional roles of PLpro such as viral polypeptide cleavage, de-ISGlyation and immune suppression have made it a promising drug target for therapeutic interventions. Whilst there have been a number of studies and others are on-going on repurposing and new-small molecule screening, albeit previously FDA approved drugs viz. Chloroquine (CQ) and Hydroxychloroquine (HCQ) have only been found effective against this pandemic. Inspired by this fact, we have carried out molecular docking and dynamics simulation studies of FDA approved CQ and HCQ against SARS-CoV-2 PLpro. The end aim is to characterise the binding mode of CQ and HCQ and identify the key amino acid residues involved in the mechanism of action. Further, molecular dynamics simulations (MDS) were carried out with the docked complex to search for the conformational space and for understanding the integrity of binding mode. We showed that the CQ and HCQ can bind with better binding affinity with PLpro as compared to reference known PLpro inhibitor. Based on the presented findings, it can be anticipated that the SARS-CoV-2 PLpro may act as molecular target of CQ and HCQ, and can be projected for further exploration to design potent inhibitors of SARS-CoV-2 PLpro in the near future.
C1 [Patel, Dhaval] Indian Inst Adv Res, Dept Biol Sci & Biotechnol, Gandhinagar 382426, Gujarat, India.
   [Athar, Mohd] InStem, Ctr Chem Biol & Therapeut, Bangalore, Karnataka, India.
   [Jha, P. C.] Cent Univ Gujarat, Sch Appl Mat Sci, Gandhinagar 382030, Gujarat, India.
RP Patel, D (corresponding author), Indian Inst Adv Res, Dept Biol Sci & Biotechnol, Gandhinagar 382426, Gujarat, India.; Jha, PC (corresponding author), Cent Univ Gujarat, Sch Appl Mat Sci, Gandhinagar 382030, Gujarat, India.
EM pateldhaval.in@gmail.com; prakash.jha@cug.ac.in
RI Patel, Dhaval/M-4265-2018; Jha, Prakash/I-5341-2017
OI Patel, Dhaval/0000-0002-1811-2057; Jha, Prakash/0000-0002-1709-511X
CR ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   AMIN M, 2020, J BIOMOL STRUCT 0703, DOI DOI https://doi.org/10.1080/07391102.2020.1775703
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Baildya N, 2020, J MOL STRUCT, V1219, DOI 10.1016/j.molstruc.2020.128595
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   BIOVIA. (, 2020, DASS SYST DISC STUD
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Daczkowski CM, 2017, J MOL BIOL, V429, P1661, DOI 10.1016/j.jmb.2017.04.011
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gay B, 2012, INFECT GENET EVOL, V12, P1275, DOI 10.1016/j.meegid.2012.02.003
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Ghosh AK, 2009, J MED CHEM, V52, P5228, DOI 10.1021/jm900611t
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lee H, 2015, ACS CHEM BIOL, V10, P1456, DOI 10.1021/cb500917m
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Lovell SC, 2002, PROTEIN-STRUCT FUNCT, V50, P437, DOI DOI 10.1002/PR0T.10286
   MUKHERJEE S, 2020, J BIOMOL STRUCT 0807, DOI DOI https://doi.org/10.1080/07391102.2020.1804458
   Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878
   NIMGAMPALLE M, 2020, J BIOMOL STRUCT 0623, DOI DOI https://doi.org/10.1080/07391102.2020.1782265
   PARRINELLO M, 1980, PHYS REV LETT, V45, P1196, DOI 10.1103/PhysRevLett.45.1196
   Patel B, 2018, BBA-PROTEINS PROTEOM, V1866, P426, DOI 10.1016/j.bbapap.2017.12.002
   Patel D., 2020, BIORXIV, DOI [10.1101/2020.03.31.017541, DOI 10.1101/2020.03.31.017541]
   Patel P, 2018, INT J BIOL MACROMOL, V114, P666, DOI 10.1016/j.ijbiomac.2018.03.152
   Patel P, 2017, J MOL GRAPH MODEL, V77, P295, DOI 10.1016/j.jmgm.2017.09.004
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shivakumar D, 2010, J CHEM THEORY COMPUT, V6, P1509, DOI 10.1021/ct900587b
   Sun HY, 2018, PHYS CHEM CHEM PHYS, V20, P14450, DOI 10.1039/c7cp07623a
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang CH, 2016, J COMPUT CHEM, V37, P2436, DOI 10.1002/jcc.24467
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Xu D, 2011, BIOPHYS J, V101, P2525, DOI 10.1016/j.bpj.2011.10.024
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 57
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1844804
EA NOV 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OS7DJ
UT WOS:000590319900001
PM 33200683
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Alsalme, A
   Pooventhiran, T
   Al-Zaqri, N
   Rao, DJ
   Rao, SS
   Thomas, R
AF Alsalme, Ali
   Pooventhiran, T.
   Al-Zaqri, Nabil
   Rao, D. Jagadeeswara
   Rao, Siriki Srinivasa
   Thomas, Renjith
TI Modelling the structural and reactivity landscapes of tucatinib with
   special reference to its wavefunction-dependent properties and screening
   for potential antiviral activity
SO JOURNAL OF MOLECULAR MODELING
LA English
DT Article
DE DFT; Tucatinib; Docking; NCI; LIE
ID LOCAL IONIZATION ENERGIES; ELECTRON LOCALIZATION FUNCTION; REDUCED
   DENSITY GRADIENT; COMPUTATIONAL CHEMISTRY; HARDNESS; AFFINITY;
   ELECTRONEGATIVITY; COCRYSTALS; COVID-19; HOMO
AB HER-2 type breast cancer is one of the most aggressive malignancies found in women. Tucatinib is recently developed and approved as a potential medicine to fight this disease. In this manuscript, we present the gross structural features of this compound and its reactivity and wave function properties using computational simulations. Density functional theory was used to optimise the ground state geometry of the molecule and molecular docking was used to predict biological activity. As the electrons interact with electromagnetic radiations, electronic excitations between different energy levels are analysed in detail using time-dependent density functional theory. Various intermolecular and intermolecular interactions are analysed and reaction sites for attacking electrophiles and nucleophiles identified. Information entropy calculations show that the compound is inherently stable. Docking with COVID-19 proteins show docking score of - 9.42, - 8.93, - 8.45 and - 8.32 kcal/mol respectively indicating high interaction between the drug and proteins. Hence, this is an ideal candidate to study repurposing of existing drugs to combat the pandemic.
C1 [Alsalme, Ali; Al-Zaqri, Nabil] King Saud Univ, Coll Sci, Dept Chem, POB 2455, Riyadh 11451, Saudi Arabia.
   [Pooventhiran, T.; Thomas, Renjith] St Berchmans Coll, Dept Chem, Changanassery, Kerala, India.
   [Rao, D. Jagadeeswara] Dr Lankapalli Bullayya Coll, Dept Phys, Visakhapatnam, Andhra Pradesh, India.
   [Rao, Siriki Srinivasa] Mrs AVN Coll, Dept Phys, Visakhapatnam, Andhra Pradesh, India.
RP Thomas, R (corresponding author), St Berchmans Coll, Dept Chem, Changanassery, Kerala, India.
EM renjith@sbcollege.ac.in
RI ; Thomas, Renjith/P-7028-2019
OI Thangaiyan, Pooventhiran/0000-0002-7470-7178; Thomas,
   Renjith/0000-0003-0011-633X
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP-2020/78]
FX This work was financially supported by Researchers Supporting Project
   number (RSP-2020/78), King Saud University, Riyadh, Saudi Arabia.
CR Al-Otaibi JS, 2020, POLYCYCL AROMAT COMP, DOI 10.1080/10406638.2020.1827270
   Al-Otaibi JS, 2020, J MOL STRUCT, V1202, DOI 10.1016/j.molstruc.2019.127316
   Al-Otaibi JS, 2019, J MOL STRUCT, V1197, P719, DOI 10.1016/j.molstruc.2019.07.110
   Al-Otaibi JS, 2019, J MOL STRUCT, V1175, P916, DOI 10.1016/j.molstruc.2018.08.055
   Andijani N, 2019, SOL ENERGY, V188, P898, DOI 10.1016/j.solener.2019.06.074
   Baltschukat S, 2019, CLIN CANCER RES, V25, P3164, DOI 10.1158/1078-0432.CCR-18-2814
   Bekaii-Saab T, 2019, CLIN COLORECTAL CANC, V18, pE117, DOI 10.1016/j.clcc.2018.11.002
   Boto RA, 2017, THEOR CHEM ACC, V136, DOI 10.1007/s00214-017-2169-9
   Braso-Maristany F, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14111-3
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Chattaraj PK, 2006, CHEM REV, V106, P2065, DOI 10.1021/cr040109f
   Chattaraj PK, 2009, ANNU REP PROG CHEM C, V105, P13, DOI 10.1039/b802832j
   Curutchet C, 2017, CHEM REV, V117, P294, DOI 10.1021/acs.chemrev.5b00700
   De Proft F, 2007, FARADAY DISCUSS, V135, P151, DOI 10.1039/b605302p
   de Silva P, 2014, J CHEM THEORY COMPUT, V10, P3745, DOI 10.1021/ct500490b
   Dekker TJA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2004854
   del Campo JM, 2012, INT J QUANTUM CHEM, V112, P3594, DOI 10.1002/qua.24241
   Domingo LR, 2016, MOLECULES, V21, DOI 10.3390/molecules21060748
   DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153
   Dunnington BD, 2012, J CHEM THEORY COMPUT, V8, P1902, DOI 10.1021/ct300002t
   Foresman J. B., 2015, EXPLORING CHEM ELECT, V3rd
   Frisch M.J., 2013, GAUSSIAN09 REVISION
   Frisch MJ, 2016, GAUSSIAN 16 REV C 01
   Fuentealba P, 2007, THEOR COMPU CHEM, V19, P57
   Fuster F, 2000, J PHYS CHEM A, V104, P852, DOI 10.1021/jp992783k
   Gibbs GV, 2003, PHYS CHEM MINER, V30, P305, DOI 10.1007/s00269-003-0318
   Gil-Gil MJ, 2014, CLIN TRANSL ONCOL, V16, P436, DOI 10.1007/s12094-013-1110-5
   Glendening ED, 2012, WIRES COMPUT MOL SCI, V2, P1, DOI 10.1002/wcms.51
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Grimme S, 2018, ANGEW CHEM INT EDIT, V57, P4170, DOI 10.1002/anie.201709943
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Hedley GJ, 2017, CHEM REV, V117, P796, DOI 10.1021/acs.chemrev.6b00215
   Hosna S, 2018, SPECTROCHIM ACTA A, V204, P328, DOI 10.1016/j.saa.2018.06.062
   Irfan A, 2020, OPTIK STUTTG, P165530, DOI 10.1016/j.ijleo.2020.165530
   Irfan A, 2020, J COMPUT ELECTRON, DOI 10.1007/s10825-020-01597-0
   Irfan A, 2020, J SULFUR CHEM, DOI 10.1080/17415993.2020.1830401
   Irfan A, 2020, MAT SCI SEMICON PROC, V107, DOI 10.1016/j.mssp.2019.104855
   Irfan A, 2018, ORG ELECTRON, V57, P211, DOI 10.1016/j.orgel.2018.03.022
   Jacobsen H, 2008, CAN J CHEM, V86, P695, DOI 10.1139/V08-052
   John AM, 2020, SPECTROCHIM ACTA A, V236, DOI 10.1016/j.saa.2020.118329
   Klamt A, 2015, J CHEM THEORY COMPUT, V11, P4220, DOI 10.1021/acs.jctc.5b00601
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kummel S, 2008, REV MOD PHYS, V80, P3, DOI 10.1103/RevModPhys.80.3
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Lefebvre C, 2017, PHYS CHEM CHEM PHYS, V19, P17928, DOI 10.1039/c7cp02110k
   Louis E, 2017, J PHYS CHEM LETT, V8, P2445, DOI 10.1021/acs.jpclett.7b00681
   Lu T, 2012, J COMPUT CHEM, V33, P580, DOI 10.1002/jcc.22885
   Majumdar D, 2020, APPL ORGANOMET CHEM, V34, DOI 10.1002/aoc.5269
   Majumdar D, 2019, INORG CHIM ACTA, V492, P221, DOI 10.1016/j.ica.2019.04.041
   Matondo A, 2019, J MOL GRAPH MODEL, V88, P237, DOI 10.1016/j.jmgm.2019.02.006
   Metzger Filho O, 2020, ANN ONCOL, DOI [10.1016/j.annonc.2020.05.014, DOI 10.1016/J.ANN0NC.2020.05.014]
   Mukherjee A, 2007, EXPERT OPIN PHARMACO, V8, P2189, DOI 10.1517/14656566.8.13.2189
   Murray J.S., 1996, THEORET COMPUT CHEM, P143
   Murray JS, 1998, THEORET COMPUT CHEM, V5, P189, DOI 10.1016/S1380-7323(98)80009-5
   Murthy RK, 2020, NEW ENGL J MED, V382, P597, DOI 10.1056/NEJMoa1914609
   O'Boyle NM, 2008, J COMPUT CHEM, V29, P839, DOI 10.1002/jcc.20823
   Okuno K, 2012, J PHOTOCH PHOTOBIO A, V235, P29, DOI 10.1016/j.jphotochem.2012.03.003
   Orio M, 2009, PHOTOSYNTH RES, V102, P443, DOI 10.1007/s11120-009-9404-8
   Orozco M, 1996, THEOR COMPU CHEM, V3, P181
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PEARSON RG, 1988, INORG CHEM, V27, P734, DOI 10.1021/ic00277a030
   Politzer P, 1998, INT J QUANTUM CHEM, V69, P607, DOI 10.1002/(SICI)1097-461X(1998)69:4<607::AID-QUA18>3.0.CO;2-W
   Politzer P, 2002, INT J QUANTUM CHEM, V90, P459, DOI 10.1002/qua.10105
   POLITZER P, 1985, ENVIRON HEALTH PERSP, V61, P191, DOI 10.2307/3430072
   POLITZER P, 1991, REV COMP CH, V2, P273
   Politzer P, 2018, J MOL MODEL, V24, DOI 10.1007/s00894-018-3864-8
   Politzer P, 2010, J MOL MODEL, V16, P1731, DOI 10.1007/s00894-010-0709-5
   Prat A, 2017, ONCOTARGET, V8, P73362, DOI 10.18632/oncotarget.20629
   Priya YS, 2020, J MOL STRUCT, V1203, DOI 10.1016/j.molstruc.2019.127461
   Rani PRK, 2019, COMPUT BIOL CHEM, V78, P153, DOI 10.1016/j.compbiolchem.2018.11.022
   Rao DJ, 2019, POLYCYCL AROMAT COMP, DOI 10.1080/10406638.2019.1709083
   REED AE, 1988, CHEM REV, V88, P899, DOI 10.1021/cr00088a005
   Rong CY, 2020, WIRES COMPUT MOL SCI, V10, DOI 10.1002/wcms.1461
   Schmider HL, 2000, J MOL STRUC-THEOCHEM, V527, P51, DOI 10.1016/S0166-1280(00)00477-2
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Scholes GD, 2017, CHEM REV, V117, P247, DOI 10.1021/acs.chemrev.6b00826
   SJOBERG P, 1990, CAN J CHEM, V68, P1440, DOI 10.1139/v90-220
   Srikanth KE, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04106
   STEPHENS PJ, 1994, J PHYS CHEM-US, V98, P11623, DOI 10.1021/j100096a001
   Tanaka Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18702-2
   Teale AM, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2961035
   Thadathil DA, 2019, J FLUORESC, V29, P1013, DOI 10.1007/s10895-019-02415-y
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Tsirelson V, 2002, ACTA CRYSTALLOGR B, V58, P780, DOI 10.1107/S0108768102012338
   Vydrov OA, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2409292
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wazzan N, 2020, MAT SCI SEMICON PROC, V120, DOI 10.1016/j.mssp.2020.105260
   Weinhold F, 2012, J COMPUT CHEM, V33, P2363, DOI 10.1002/jcc.23060
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Xu HF, 2017, ACS OMEGA, V2, P7185, DOI 10.1021/acsomega.7b01039
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zhan CG, 2003, J PHYS CHEM A, V107, P4184, DOI 10.1021/jp0225774
   Zhang G, 2007, J PHYS CHEM A, V111, P1554, DOI 10.1021/jp061633o
   Zhao H, 2017, J MOL MODEL, V23, DOI 10.1007/s00894-017-3298-8
   Zupan A, 1997, INT J QUANTUM CHEM, V61, P835
NR 97
TC 0
Z9 0
U1 6
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1610-2940
EI 0948-5023
J9 J MOL MODEL
JI J. Mol. Model.
PD NOV 16
PY 2020
VL 26
IS 12
AR 341
DI 10.1007/s00894-020-04603-1
PG 17
WC Biochemistry & Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer
   Science
GA OS3EF
UT WOS:000590047900001
PM 33200284
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, J
   Wu, Q
   Liu, ZY
   Wang, QJ
   Wu, JJ
   Hu, YB
   Bai, TT
   Xie, T
   Huang, MC
   Wu, TT
   Peng, DH
   Huang, WJ
   Jin, K
   Niu, L
   Guo, WY
   Luo, DX
   Lei, DZ
   Wu, ZJ
   Li, GC
   Huang, RB
   Lin, YB
   Xie, XP
   He, SY
   Deng, YF
   Liu, JH
   Li, WL
   Lu, ZY
   Chen, HF
   Zeng, T
   Luo, QT
   Li, YP
   Wang, YC
   Liu, WP
   Qu, XW
AF Zhang, Jian
   Wu, Qian
   Liu, Ziyan
   Wang, Qijie
   Wu, Jiajing
   Hu, Yabin
   Bai, Tingting
   Xie, Ting
   Huang, Mincheng
   Wu, Tiantian
   Peng, Danhong
   Huang, Weijin
   Jin, Kun
   Niu, Ling
   Guo, Wangyuan
   Luo, Dixian
   Lei, Dongzhu
   Wu, Zhijian
   Li, Guicheng
   Huang, Renbin
   Lin, Yingbiao
   Xie, Xiangping
   He, Shuangyan
   Deng, Yunfan
   Liu, Jianghua
   Li, Weilang
   Lu, Zhongyi
   Chen, Haifu
   Zeng, Ting
   Luo, Qingting
   Li, Yi-Ping
   Wang, Youchun
   Liu, Wenpei
   Qu, Xiaowang
TI Spike-specific circulating T follicular helper cell and
   cross-neutralizing antibody responses in COVID-19-convalescent
   individuals
SO NATURE MICROBIOLOGY
LA English
DT Article; Early Access
ID CXC CHEMOKINE RECEPTOR-5; CORONAVIRUS; INTERLEUKIN-21; OPTIMIZATION;
   QUANTITATION; GENERATION; ASSAY; SERA
AB Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(1-3) and individuals with COVID-19 have symptoms that can be asymptomatic, mild, moderate or severe(4,5). In the early phase of infection, T- and B-cell counts are substantially decreased(6,7); however, IgM(8-11) and IgG(12-14) are detectable within 14 d after symptom onset. In COVID-19-convalescent individuals, spike-specific neutralizing antibodies are variable(3,15,16). No specific drug or vaccine is available for COVID-19 at the time of writing; however, patients benefit from treatment with serum from COVID-19-convalescent individuals(17,18). Nevertheless, antibody responses and cross-reactivity with other coronaviruses in COVID-19-convalescent individuals are largely unknown. Here, we show that the majority of COVID-19-convalescent individuals maintained SARS-CoV-2 spike S1- and S2-specific antibodies with neutralizing activity against the SARS-CoV-2 pseudotyped virus, and that some of the antibodies cross-neutralized SARS-CoV, Middle East respiratory syndrome coronavirus or both pseudotyped viruses. Convalescent individuals who experienced severe COVID-19 showed higher neutralizing antibody titres, a faster increase in lymphocyte counts and a higher frequency of CXCR3(+) T follicular help (T-FH) cells compared with COVID-19-convalescent individuals who experienced non-severe disease. Circulating T-FH cells were spike specific and functional, and the frequencies of CXCR3(+) T-FH cells were positively associated with neutralizing antibody titres in COVID-19-convalescent individuals. No individuals had detectable autoantibodies. These findings provide insights into neutralizing antibody responses in COVID-19-convalescent individuals and facilitate the treatment and vaccine development for SARS-CoV-2 infection.
C1 [Zhang, Jian; Wu, Qian; Liu, Ziyan; Hu, Yabin; Jin, Kun; Niu, Ling; Guo, Wangyuan; Luo, Dixian; Lei, Dongzhu; Wu, Zhijian; Li, Guicheng; Huang, Renbin; Lin, Yingbiao; Liu, Wenpei; Qu, Xiaowang] Univ South China, Peoples Hosp Chenzhou 1, Translat Med Inst, Chenzhou, Peoples R China.
   [Wang, Qijie; Xie, Ting; Huang, Mincheng; Peng, Danhong; Xie, Xiangping; He, Shuangyan; Zeng, Ting] Cent Hosp Shaoyang, Shaoyang, Peoples R China.
   [Wu, Jiajing; Huang, Weijin; Wang, Youchun] Natl Inst Food & Drug Control, Minist Hlth Res Qual & Standardizat Biotech Prod, Key Lab Biol Prod Qual Res & Evaluat, Natl Med Prod Adm,Key Lab, Beijing, Peoples R China.
   [Wu, Jiajing] Wuhan Inst Biol Prod, Wuhan, Peoples R China.
   [Bai, Tingting; Liu, Wenpei] Southern Med Univ, Sch Clin Med 1, Guangzhou, Peoples R China.
   [Wu, Tiantian; Li, Yi-Ping] Sun Yat Sen Univ, Inst Human Virol, Zhongshan Sch Med, Minist Educ, Guangzhou, Peoples R China.
   [Wu, Tiantian; Li, Yi-Ping] Sun Yat Sen Univ, Key Lab Trop Dis Control, Minist Educ, Guangzhou, Peoples R China.
   [Deng, Yunfan] Longhui Peoples Hosp, Longhui, Peoples R China.
   [Liu, Jianghua] Xinshao Peoples Hosp, Xinshao, Peoples R China.
   [Li, Weilang] Dongkou Peoples Hosp, Dongkou, Peoples R China.
   [Lu, Zhongyi] Shaoyang Peoples Hosp, Shaoyang, Peoples R China.
   [Chen, Haifu] Suining Peoples Hosp, Suining, Peoples R China.
   [Luo, Qingting] Baoqing Psychiat Hosp, Shaoyang, Peoples R China.
   [Liu, Wenpei] Southern Med Univ, Sch Lab Med & Biotechnol, Guangzhou, Peoples R China.
   [Qu, Xiaowang] Southern Med Univ, Sch Publ Hlth, Guangzhou, Peoples R China.
RP Liu, WP; Qu, XW (corresponding author), Univ South China, Peoples Hosp Chenzhou 1, Translat Med Inst, Chenzhou, Peoples R China.; Wang, YC (corresponding author), Natl Inst Food & Drug Control, Minist Hlth Res Qual & Standardizat Biotech Prod, Key Lab Biol Prod Qual Res & Evaluat, Natl Med Prod Adm,Key Lab, Beijing, Peoples R China.; Liu, WP (corresponding author), Southern Med Univ, Sch Clin Med 1, Guangzhou, Peoples R China.; Li, YP (corresponding author), Sun Yat Sen Univ, Inst Human Virol, Zhongshan Sch Med, Minist Educ, Guangzhou, Peoples R China.; Li, YP (corresponding author), Sun Yat Sen Univ, Key Lab Trop Dis Control, Minist Educ, Guangzhou, Peoples R China.; Liu, WP (corresponding author), Southern Med Univ, Sch Lab Med & Biotechnol, Guangzhou, Peoples R China.; Qu, XW (corresponding author), Southern Med Univ, Sch Publ Hlth, Guangzhou, Peoples R China.
EM lyiping@mail.sysu.edu.cn; wangyc@nifdc.org.cn;
   wenpeiliu_2008@foxmail.com; quxiaowang@163.com
OI Zhang, Jian/0000-0002-5982-419X
FU COVID-19 Emergency Special Program of Hunan Province [2020SK3052]; Key
   Research and Development Project of Chenzhou City, Hunan Province
   [ZDYF2020010, ZDYF2020007]; European CommissionEuropean
   CommissionEuropean Commission Joint Research Centre [101003562]
FX We thank all of the participants. This work was supported by the
   COVID-19 Emergency Special Program of Hunan Province (no. 2020SK3052, to
   W. Liu), Key Research and Development Project of Chenzhou City, Hunan
   Province (no. ZDYF2020010 and ZDYF2020007) and by the
   SC1-PHE-CORONAVIRUS-2020: Advancing knowledge for the clinical and
   public health response to the 2019-nCoV epidemic' from the European
   Commission (CORONADX, no. 101003562, to Y.-P.L.).
CR Alshukairi AN, 2016, EMERG INFECT DIS, V22, P1113, DOI 10.3201/eid2206.160010
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Anderson DE, 2020, EMERG MICROBES INFEC, V9, P900, DOI 10.1080/22221751.2020.1761267
   Baiyegunhi O, 2018, J VIROL, V92, DOI 10.1128/JVI.00659-18
   Bentebibel SE, 2016, SCI REP-UK, V6, DOI 10.1038/srep26494
   Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191
   Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen QQ, 2018, HUM VACC IMMUNOTHER, V14, P199, DOI 10.1080/21645515.2017.1373922
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   Dan JM, 2016, J IMMUNOL, V197, P983, DOI 10.4049/jimmunol.1600318
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Gauduin MC, 2006, METHODS, V38, P263, DOI 10.1016/j.ymeth.2005.12.004
   Gauduin MC, 2004, J IMMUNOL METHODS, V288, P61, DOI 10.1016/j.jim.2004.02.007
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   [马建 Ma Jian], 2019, [病毒学报, Chinese Journal of Virology], V35, P189
   Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ray R, 2010, J INFECT DIS, V202, P862, DOI 10.1086/655902
   Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799
   Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI 10.1172/JCI138759
   Welten SPM, 2016, J VIROL, V90, P4402, DOI 10.1128/JVI.03177-15
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46533-w
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao JX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5393
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 46
TC 0
Z9 0
U1 6
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2058-5276
J9 NAT MICROBIOL
JI NAT. MICROBIOL
DI 10.1038/s41564-020-00824-5
EA NOV 2020
PG 24
WC Microbiology
SC Microbiology
GA OS2SD
UT WOS:000590016400001
PM 33199863
OA Bronze
DA 2021-01-01
ER

PT J
AU Badavath, VN
   Kumar, A
   Samanta, PK
   Maji, S
   Das, A
   Blum, G
   Jha, A
   Sen, A
AF Badavath, Vishnu Nayak
   Kumar, Akhil
   Samanta, Pralok K.
   Maji, Siddhartha
   Das, Anik
   Blum, Galia
   Jha, Anjali
   Sen, Anik
TI Determination of potential inhibitors based on isatin derivatives
   against SARS-CoV-2 main protease (m(pro)): a molecular docking,
   molecular dynamics and structure-activity relationship studies
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; heterocyclic inhibitors; density functional theory;
   molecular docking; molecular dynamics
ID CURCUMIN-BASED DESIGN; MICROWAVE-ASSISTED SYNTHESIS; PARTICLE MESH
   EWALD; PYRAZOLINE ANALOGS; ANTIVIRAL ACTIVITY; FORCE-FIELD; IN-VITRO;
   CORONAVIRUS; SARS; 1,3,4-OXADIAZOLE
AB SARS-COV-2, the novel coronavirus and root of global pandemic COVID-19 caused a severe health threat throughout the world. Lack of specific treatments raised an effort to find potential inhibitors for the viral proteins. The recently invented crystal structure of SARS-CoV-2 main protease (M-pro) and its key role in viral replication; non-resemblance to any human protease makes it a perfect target for inhibitor research. This article reports a computer-aided drug design (CADD) approach for the screening of 118 compounds with 16 distinct heterocyclic moieties in comparison with 5 natural products and 7 repurposed drugs. Molecular docking analysis against M-pro protein were performed finding isatin linked with a oxidiazoles (A2 and A4) derivatives to have the best docking scores of -11.22 kcal/mol and -11.15 kcal/mol respectively. Structure-activity relationship studies showed a good comparison with a known active M-pro inhibitor and repurposed drug ebselen with an IC50 value of -0.67 mu M. Molecular Dynamics (MD) simulations for 50 ns were performed for A2 and A4 supporting the stability of the two compounds within the binding pocket, largely at the S1, S2 and S4 domains with high binding energy suggesting their suitability as potential inhibitors of M-pro for SARS-CoV-2.
C1 [Badavath, Vishnu Nayak; Blum, Galia] Hebrew Univ Jerusalem, Inst Drug Res, IL-9112001 Jerusalem, Israel.
   [Kumar, Akhil] Cent Inst Med & Aromat Plants, CSIR, Biotechnol Div, Lucknow, Uttar Pradesh, India.
   [Samanta, Pralok K.] Univ Coll Dublin, Sch Chem & Bioproc Engn, Dublin, Ireland.
   [Maji, Siddhartha] Birla Inst Technol, Dept Pharmaceut Sci & Technol, Ranchi, Bihar, India.
   [Das, Anik; Jha, Anjali; Sen, Anik] GITAM Deemed Univ, Inst Sci, Dept Chem, Visakhapatnam, Andhra Pradesh, India.
   [Maji, Siddhartha] Ram Eesh Inst Vocat & Tech Educ, Inst Pharm, Greater Noida 201310, Uttar Pradesh, India.
RP Blum, G (corresponding author), Hebrew Univ Jerusalem, Inst Drug Res, IL-9112001 Jerusalem, Israel.; Sen, A (corresponding author), GITAM Deemed Univ, Inst Sci, Dept Chem, Visakhapatnam 530045, AP, India.
EM galiabl@ekmd.huji.ac.il; anikchem@gmail.com
RI sen, anik/G-5416-2011; Samanta, Pralok/O-5958-2017; Badavath, Dr. Vishnu
   Nayak/H-2671-2016
OI sen, anik/0000-0002-1336-5995; Samanta, Pralok/0000-0002-1926-7720;
   Badavath, Dr. Vishnu Nayak/0000-0002-6433-2691
FU Department of Science and Technology, India under DST-FIST
   ProgramDepartment of Science & Technology (India)Department of Science &
   Technology (DOST), Philippines [SR/FST/ETI-373/2016]; Hebrew University
   of Jerusalem, Israel
FX AD, AJ and AS also thank the Department of Science and Technology, India
   under DST-FIST Program 2014 with Grant No. SR/FST/ETI-373/2016. The
   Hebrew University of Jerusalem, Israel for Corona Fund to GB.
CR Afifi TH, 2017, EXCLI J, V16, P868, DOI 10.17179/excli2017-356
   Agarwal M, 2016, MED CHEM RES, V25, P2289, DOI 10.1007/s00044-016-1672-1
   Anand P. S., 2019, CHEM DATA COLLECT, V21
   Badavath V. N., 2015, ACS MED CHEM LETT
   Badavath VN, 2016, ARCH PHARM, V349, P9, DOI 10.1002/ardp.201500317
   Badavath VN, 2017, CHINESE CHEM LETT, V28, P1528, DOI 10.1016/j.cclet.2017.02.009
   Badavath VN, 2016, CHEMISTRYSELECT, V1, P5879, DOI 10.1002/slct.201600914
   Badavath VN, 2016, ACS MED CHEM LETT, V7, P56, DOI 10.1021/acsmedchemlett.5b00326
   BAUER DJ, 1960, BRIT J PHARM CHEMOTH, V15, P101, DOI 10.1111/j.1476-5381.1960.tb01216.x
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Beedie SL, 2015, MOL CANCER THER, V14, P2228, DOI 10.1158/1535-7163.MCT-15-0320
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Bhatt P, 2020, CHEMISTRYSELECT, V5, P3347, DOI 10.1002/slct.201904412
   Bhatt P, 2018, CHEMISTRYSELECT, V3, P7060, DOI 10.1002/slct.201800832
   Bhattacharjee M. K., 2016, CHEM ANTIBIOTICS REL, V219
   Blair JA, 2007, NAT CHEM BIOL, V3, P229, DOI 10.1038/nchembio866
   Burger A., 1979, BURGERS MED CHEM
   BZOWKA M, 2020, INT J MOL SCI, V21, DOI DOI https://doi.org/10.3390/ijms21093099
   Chen L, 2005, HERPETOL J, V15, p23l, DOI DOI https://doi.org/10.1016/j.bmcl.2005.04.027
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   De Clercq Erik, 2006, Expert Rev Anti Infect Ther, V4, P291, DOI 10.1586/14787210.4.2.291
   Dong LR, 2016, PHOSPHORUS SULFUR, V191, P904, DOI 10.1080/10426507.2015.1114944
   EINARSSON K, 1994, SCAND J GASTROENTERO, V29, P19, DOI 10.3109/00365529409103620
   Enogieru AB, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6241017
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fan H.-H., 2020, CHINESE MED J-PEKING
   FISCHER A, 2020, INT J MOL SCI, V21, DOI DOI https://doi.org/10.3390/ijms21103626
   Fischmann TO, 2008, BIOPOLYMERS, V89, P372, DOI 10.1002/bip.20868
   Forli W., 2012, AUTODOCK VERSION 4 2
   Gangireddy MR, 2019, CHEMISTRYSELECT, V4, P13622, DOI 10.1002/slct.201902955
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gerova MS, 2016, EUR J MED CHEM, V120, P121, DOI 10.1016/j.ejmech.2016.05.012
   Ghosh AK, 2016, J MED CHEM, V59, P5172, DOI 10.1021/acs.jmedchem.5b01697
   Gorbalenya A. E., 2020, SEVERE ACUTE RESP SY
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Ivanova Y, 2007, EUR J MED CHEM, V42, P1382, DOI 10.1016/j.ejmech.2007.02.019
   Jha A, 2018, RES CHEM INTERMEDIAT, V44, P585, DOI 10.1007/s11164-017-3121-2
   Jia WH, 2020, CARDIOVASC DRUG THER, V34, P525, DOI 10.1007/s10557-020-06965-3
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Keogh-Brown MR, 2008, HEALTH POLICY, V88, P110, DOI 10.1016/j.healthpol.2008.03.003
   Kharb R, 2011, MINI-REV MED CHEM, V11, P84, DOI 10.2174/138955711793564051
   Kok SHL, 2008, BIOORGAN MED CHEM, V16, P3626, DOI 10.1016/j.bmc.2008.02.005
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lakshmithendral K, 2019, EUR J MED CHEM, V168, P1, DOI 10.1016/j.ejmech.2019.02.033
   Lane ME, 2001, CANCER RES, V61, P6170
   Li Z, 2011, MINI-REV MED CHEM, V11, P1130, DOI 10.2174/138955711797655407
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   LIU K, 2020, CELL DISCOV, V6, DOI DOI https://doi.org/10.1038/s41421-019-0132-8
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   Martin F, 2005, J COMPUT CHEM, V26, P97, DOI 10.1002/jcc.20157
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Munusamy S., 2019, NEW J CHEM, V43
   Nath C, 2018, MEDCHEMCOMM, V9, P1164, DOI 10.1039/c8md00196k
   Nayak BV, 2015, BIOORG CHEM, V58, P72, DOI 10.1016/j.bioorg.2014.11.008
   Nimgampalle M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1782265
   Ogliaro F., 2016, GAUSSIAN 16 REVISION
   Pandeya SN, 2000, EUR J MED CHEM, V35, P249, DOI 10.1016/S0223-5234(00)00125-2
   PARK GL, 1988, PHYS REV B, V38, P13200, DOI 10.1103/PhysRevB.38.13200
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Pessoa C, 2010, CHEMMEDCHEM, V5, P523, DOI 10.1002/cmdc.200900525
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   POPP FD, 1969, J MED CHEM, V12, P182, DOI 10.1021/jm00301a054
   Rasul A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/379850
   Raugi DN, 2016, J VIROL, V90, P1062, DOI 10.1128/JVI.01772-15
   Rozas I, 1997, INT J QUANTUM CHEM, V62, P477, DOI 10.1002/(SICI)1097-461X(1997)62:5<477::AID-QUA4>3.0.CO;2-T
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Schelman WR, 2011, INVEST NEW DRUG, V29, P118, DOI 10.1007/s10637-009-9318-5
   Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249-011-0700-9
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Selvam P, 2008, INDIAN J PHARM SCI, V70, P91, DOI 10.4103/0250-474X.40339
   Serafim RAM, 2017, MED CHEM RES, V26, P760, DOI 10.1007/s00044-016-1776-7
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Shiraki K., 2020, PHARM THERAPEUTICS
   Sreekanth K, 2020, RUSS J GEN CHEM+, V90, P129, DOI 10.1134/S107036322001020X
   Tamokou J-de-D, 2016, PHARMACOLOGIA, V7, P182, DOI [10.5567/pharmacologia.2016.182.192, DOI 10.5567/PHARMACOLO-GIA.2016.182.192]
   TEITZ Y, 1994, ANTIVIR RES, V24, P305, DOI 10.1016/0166-3542(94)90077-9
   Huynh T, 2020, J PHYS CHEM LETT, V11, P4413, DOI 10.1021/acs.jpclett.0c00994
   Tsuzuki S, 1996, J MOL STRUC-THEOCHEM, V365, P81, DOI 10.1016/0166-1280(96)04500-9
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   VARMA RS, 1967, J MED CHEM, V10, P972, DOI 10.1021/jm00317a061
   Venkatarao V., 2019, CHEM DATA COLLECT, V22, DOI [10.1016/j.cdc.2019.100236, DOI 10.1016/J.CDC.2019.100236]
   Vishnu Nayak B, 2013, Eur J Med Chem, V69, P762, DOI 10.1016/j.ejmech.2013.09.010
   Wang F. H., 2016, SCI REP UK, V6, DOI DOI https://doi.org/10.1038/srep22677
   Wang JQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197563
   Wang M, 2020, CELL RES 0204, V30, P269, DOI [DOI 10.1038/S41422-020-0282-0, 10.1038/s41422-020-0282-0]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Xu Z., 2020, NELFINAVIR WAS PREDI
   Xu Z, 2019, EUR J MED CHEM, V183, DOI 10.1016/j.ejmech.2019.111700
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yadagiri B, 2015, BIOORG MED CHEM LETT, V25, P2220, DOI 10.1016/j.bmcl.2015.03.032
   Yang S, 2006, J MED CHEM, V49, P4971, DOI 10.1021/jm0603926
   Zhang HP, 2020, INTERDISCIP SCI, V12, P368, DOI 10.1007/s12539-020-00376-6
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhang XM, 2011, BIOORGAN MED CHEM, V19, P6518, DOI 10.1016/j.bmc.2011.08.013
   Zhou L, 2006, J MED CHEM, V49, P3440, DOI 10.1021/jm0602357
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 110
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1845800
EA NOV 2020
PG 19
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OS0MA
UT WOS:000589856800001
PM 33200681
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hashimoto, H
   Ito, T
   Ide, T
   Sasaki, N
   Hikichi, S
   Furue, M
AF Hashimoto, Hiroki
   Ito, Takamichi
   Ide, Taketoshi
   Sasaki, Natsuki
   Hikichi, Shiori
   Furue, Masutaka
TI Pyrexia by COVID-19 in a patient treated with dabrafenib/trametinib
   therapy
SO JOURNAL OF DERMATOLOGY
LA English
DT Letter; Early Access
C1 [Hashimoto, Hiroki; Ito, Takamichi; Ide, Taketoshi; Sasaki, Natsuki; Hikichi, Shiori; Furue, Masutaka] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka, Japan.
RP Hashimoto, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Higashi Ku, 3-1-1 Maida Shi, Fukuoka, Fukuoka 8128582, Japan.
EM h-hashi@dermatol.med.kyushu-u.ac.jp
OI Furue, Masutaka/0000-0002-2967-1073
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Heinzerling L, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000491
   Pascarella G, 2020, J INTERN MED, V288, P192, DOI 10.1111/joim.13091
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0385-2407
EI 1346-8138
J9 J DERMATOL
JI J. Dermatol.
DI 10.1111/1346-8138.15696
EA NOV 2020
PG 2
WC Dermatology
SC Dermatology
GA OR7EG
UT WOS:000589630100001
PM 33200424
OA Bronze
DA 2021-01-01
ER

PT J
AU Batool-Anwar, S
   Omobomi, OS
   Quan, SF
AF Batool-Anwar, Salma
   Omobomi, Olabimpe S.
   Quan, Stuart F.
TI Impact of the novel coronavirus disease on treatment adherence and sleep
   duration in patients with obstructive sleep apnea treated with positive
   airway pressure
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Article
DE obstructive sleep apnea; COVID-19; positive airway pressure; insomnia;
   sleep duration
ID INSOMNIA
AB Study Objectives: The study objective was to examine the effect of coronavirus disease on treatment adherence and self-reported sleep duration among patients with obstructive sleep apnea (OSA) treated with positive airway pressure therapy.
   Methods: This was a retrospective review of medical records of patients seen in the Sleep and Circadian Clinic at Brigham Health during the immediate period of 1 month after the national lockdown was announced on March 15, 2020. Patients with OSA were included only if positive airway pressure adherence data were available in the 12 months before and in the month after the lockdown. Patients with other sleep disorders and patients with OSA without adherence data were excluded.
   Results: The mean age of the patients was 63.5 +/- 13.9 years, 55% of the participants were men, and the mean body mass index was 31.8 +/- 7.9 kg/m(2). Severe OSA was noted among 59.5% compared with 29.3% with moderate OSA, and 11.2% with mild OSA. An increased number of patients reported insomnia after the lockdown (41% vs 48%, P=.02). Sex stratification showed worsening insomnia only among women. There was no significant difference in positive airway pressure adherence as measured by hours of use, self-reported sleep duration, or use of sleep medications.
   Conclusions: Post- coronavirus disease lockdown had a negative impact on sleep as evidenced by increased reporting of insomnia, particularly among women, but no impact on positive airway pressure adherence or self-reported sleep duration.
C1 [Batool-Anwar, Salma; Omobomi, Olabimpe S.; Quan, Stuart F.] Brigham Hlth, Div Sleep & Circadian Disorders, Boston, MA USA.
   [Batool-Anwar, Salma; Omobomi, Olabimpe S.; Quan, Stuart F.] Harvard Med Sch, Boston, MA 02115 USA.
   [Quan, Stuart F.] Univ Arizona, Asthma & Airways Res Ctr, Tucson, AZ USA.
RP Quan, SF (corresponding author), Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 221 Longwood Ave, Boston, MA 02115 USA.
EM Stuart_Quan@hms.harvard.edu
CR Askenasy JJH, 1996, SLEEP, V19, P47, DOI 10.1093/sleep/19.1.47
   Attias D, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01607-2020
   Belleville G, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091604
   Budhiraja R, 2016, J CLIN SLEEP MED, V12, P333, DOI 10.5664/jcsm.5578
   Glidewell RN, 2015, SLEEP MED CLIN, V10, P93, DOI 10.1016/j.jsmc.2014.11.008
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Khazaie H, 2019, DISASTER MED PUBLIC, V13, P745, DOI 10.1017/dmp.2018.156
   Kokou-Kpolou CK, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113128
   LAVIE P, 1991, ISRAEL J MED SCI, V27, P681
   Li Y, 2020, J CLIN SLEEP MED, V16, P1417, DOI 10.5664/jcsm.8524
   Lotsch F, 2017, TRAVEL MED INFECT DI, V18, P18, DOI 10.1016/j.tmaid.2017.05.001
   Morin CM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.26
   Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342
   Suda T, 2019, TOHOKU J EXP MED, V248, P73, DOI 10.1620/tjem.248.73
   Suh S, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0940-9
   Tsang HWH, 2004, EMERG INFECT DIS, V10, P1326
   Watson NF, 2015, J CLIN SLEEP MED, V11, P931, DOI 10.5664/jcsm.4950
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 0
Z9 0
U1 1
U2 1
PU AMER ACAD SLEEP MEDICINE
PI DARIEN
PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA
SN 1550-9389
EI 1550-9397
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PD NOV 15
PY 2020
VL 16
IS 11
BP 1917
EP 1920
DI 10.5664/jcsm.8746
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA PE0PK
UT WOS:000598075200012
PM 32780011
OA Bronze
DA 2021-01-01
ER

PT J
AU Sierro, C
   Leslie, W
   Putois, B
AF Sierro, Caroline
   Leslie, Wendy
   Putois, Benjamin
TI Long-term effects of treatment for chronic nightmares: is imagery
   rehearsal therapy robust in the COVID-19 pandemic?
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Letter
C1 [Sierro, Caroline; Putois, Benjamin] Swiss Distance Learning Univ, Brig, Switzerland.
   [Leslie, Wendy] Univ Ulster, Clin Hlth Psychol, Ulster, North Ireland.
   [Putois, Benjamin] Lyon 1 Univ, Lyon Neurosci Res Ctr, CNRS UMR 5292, INSERM U1028, Lyon, France.
RP Putois, B (corresponding author), Swiss Distance Learning Univ, Brig, Switzerland.; Putois, B (corresponding author), Lyon 1 Univ, Lyon Neurosci Res Ctr, CNRS UMR 5292, INSERM U1028, Lyon, France.
EM benjamin.putois@unidistance.ch
CR Gupta MA, 2020, J CLIN SLEEP MED, V16, P1419, DOI 10.5664/jcsm.8562
   Monfils MH, 2009, SCIENCE, V324, P951, DOI 10.1126/science.1167975
   Nielsen T, 2007, SLEEP MED REV, V11, P295, DOI 10.1016/j.smrv.2007.03.004
   Putois B, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00724
   Putois B, 2019, PSYCHOTHER PSYCHOSOM, V88, P315, DOI 10.1159/000501105
NR 5
TC 1
Z9 1
U1 0
U2 0
PU AMER ACAD SLEEP MEDICINE
PI DARIEN
PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA
SN 1550-9389
EI 1550-9397
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PD NOV 15
PY 2020
VL 16
IS 11
BP 1993
EP 1993
DI 10.5664/jcsm.8742
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA PE0PK
UT WOS:000598075200026
PM 32780012
OA Bronze
DA 2021-01-01
ER

PT J
AU Broom, A
   Kenny, K
   Page, A
   Cort, N
   Lipp, ES
   Tan, AC
   Ashley, DM
   Walsh, KM
   Khasraw, M
AF Broom, Alex
   Kenny, Katherine
   Page, Alexander
   Cort, Nicole
   Lipp, Eric S.
   Tan, Aaron C.
   Ashley, David M.
   Walsh, Kyle M.
   Khasraw, Mustafa
TI The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and
   Potential Lasting Impacts
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID UNEMPLOYMENT
AB Coronavirus disease 2019 (COVID-19) has fundamentally disrupted the practice of oncology, shifting care onto virtual platforms, rearranging the logistics and economics of running a successful clinical practice and research, and in some contexts, redefining what treatments patients with cancer should and can receive. Since the start of the pandemic in early 2020, there has been considerable emphasis placed on the implications for patients with cancer in terms of their vulnerability to the virus and potential exposure in healthcare settings. But little emphasis has been placed on the significant, and potentially enduring, consequences of COVID-19 for how cancer care is delivered. In this article, we outline the importance of a focus on the effects of COVID-19 for oncology practice during and potentially after the pandemic, focusing on key shifts that are already evident, including: the pivot to online consultations, shifts in access to clinical trial and definitions of "essential care," the changing economics of practice, and the potential legacy effects of rapidly implemented changes in cancer care. COVID-19 is reshaping oncology practice, clinical trials, and delivery of cancer care broadly, and these changes might endure well beyond the short- to mid-term of the active pandemic. Therefore, shifts in practice brought about by the pandemic must be accompanied by improved training and awareness, enhanced infrastructure, and evidence-based support if they are to harness the positives and offset the potential negative consequences of the impacts of COVID-19 on cancer care.
C1 [Broom, Alex; Kenny, Katherine; Page, Alexander; Khasraw, Mustafa] Univ Sydney, Sydney, NSW, Australia.
   [Cort, Nicole; Lipp, Eric S.; Ashley, David M.; Walsh, Kyle M.; Khasraw, Mustafa] Duke Univ, Med Ctr, Durham, NC USA.
   [Tan, Aaron C.] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore.
RP Khasraw, M (corresponding author), Duke Univ, Duke Canc Inst, Durham, NC 27708 USA.
EM mustafa.khasraw@duke.edu
OI Page, Alexander/0000-0001-5674-4517; Tan, Aaron/0000-0001-7292-1114;
   Walsh, Kyle/0000-0002-5879-9981; Lipp, Eric/0000-0002-4372-5533
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Alhalabi O, 2020, TRENDS CANCER, V6, P533, DOI 10.1016/j.trecan.2020.04.005
   Armfield NR, 2015, INT J MED INFORM, V84, P737, DOI 10.1016/j.ijmedinf.2015.06.006
   Bell SA, 2020, J GEN INTERN MED, V35, P380, DOI 10.1007/s11606-019-05465-x
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Catalano RA, 2003, ANN EPIDEMIOL, V13, P8, DOI 10.1016/S1047-2797(02)00273-9
   Catalano RA, 1998, AM J PUBLIC HEALTH, V88, P586, DOI 10.2105/AJPH.88.4.586
   Cinar P, 2020, J NATL COMPR CANC NE
   de Paula BHR, 2020, LANCET ONCOL, V21, P624, DOI 10.1016/S1470-2045(20)30226-6
   Dietz JR, 2020, BREAST CANCER RES TR, V181, P487, DOI 10.1007/s10549-020-05644-z
   Dingwall R, 2013, SOCIOL HLTH ILLN, V26, P665
   Donaghy E, 2019, BRIT J GEN PRACT, V69, pE586, DOI 10.3399/bjgp19X704141
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Gordon HS, 2020, J GEN INTERN MED, V35, P1751, DOI 10.1007/s11606-020-05673-w
   Gorji Hasan Abolghasem, 2018, Asian Pac J Cancer Prev, V19, P2695
   Greenhalgh T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m998
   Greenhalgh T, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9897
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Hollander JE, 2020, NEJM CATALY INNOVAT, DOI [10.1056/CAT.20.0093, DOI 10.1056/CAT.20.0093.]
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Irvine R, 2005, INTERN MED J, V35, P56, DOI 10.1111/j.1445-5994.2004.00731.x
   Kutikov A, 2020, ANN INTERN MED, V172, P756, DOI 10.7326/M20-1133
   Leite H, 2020, PUBLIC MONEY MANAGE, V40, P483, DOI 10.1080/09540962.2020.1748855
   Luker GD, 2020, RADIOLOGY IMAGING CA, P2
   Lurie N, 2018, JAMA INTERN MED, V178, P745, DOI 10.1001/jamainternmed.2018.1314
   Man RXG, 2018, LANCET ONCOL, V19, pE482, DOI 10.1016/S1470-2045(18)30412-1
   Mann Devin M, 2020, J Am Med Inform Assoc, V27, P1132, DOI 10.1093/jamia/ocaa072
   Marzorati C, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9812
   Mehrotra A, 2020, NEW ENGL J MED, DOI [10.1056/CAT.20.0091, DOI 10.1056/CAT.20.0091.]
   Mitchell A, 3 MONTHS MANY AM SEE
   Moujaess E, 2020, CRIT REV ONCOL HEMAT, V150, DOI 10.1016/j.critrevonc.2020.102972
   Richards Mike, 2020, Nat Cancer, P1, DOI 10.1038/s43018-020-0074-y
   Sahar L, 2020, CANCER-AM CANCER SOC, V126, P3388, DOI 10.1002/cncr.32920
   Schrag D, 2020, JAMA-J AM MED ASSOC, V323, P2005, DOI 10.1001/jama.2020.6236
   Shachar C, 2020, JAMA-J AM MED ASSOC, V323, P2375, DOI 10.1001/jama.2020.7943
   Shaw S, 2018, HLTH SERVICES DELIVE, V6, P1, DOI DOI 10.3310/HSDR06210
   Shaw SE, 2020, SOC SCI MED, V255, DOI 10.1016/j.socscimed.2020.112984
   Spicer J, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0370-6
   Sud A, 2020, ANN ONCOL, V31, P1065, DOI 10.1016/j.annonc.2020.05.009
   Tan AC, 2020, CLIN CANCER RES, V26, P3100, DOI 10.1158/1078-0432.CCR-20-1364
   Turck R, 2017, ANN ONCOL, V28, P427, DOI 10.1093/annonc/mdw548
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   Veinot TC, 2018, J AM MED INFORM ASSN, V25, P1080, DOI 10.1093/jamia/ocy052
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Wherton J, 2020, BMJ LEADER, DOI [10.1136/leader-2020-000262., DOI 10.1136/LEADER-2020-000262.]
   White DB, 2020, JAMA-J AM MED ASSOC, V323, P1773, DOI 10.1001/jama.2020.5046
   Wosik J, 2020, J AM MED INFORM ASSN, V27, P957, DOI 10.1093/jamia/ocaa067
   Zaorsky NG, 2020, ADV RADIAT ONCOL, V5, P659, DOI 10.1016/j.adro.2020.03.010
NR 49
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD NOV 15
PY 2020
VL 26
IS 22
BP 5809
EP 5813
DI 10.1158/1078-0432.CCR-20-2989
PG 5
WC Oncology
SC Oncology
GA OW3NP
UT WOS:000592798200006
PM 32816894
OA Bronze
DA 2021-01-01
ER

PT J
AU Prasad, K
   Khatoon, F
   Rashid, S
   Ali, N
   AlAsmari, AF
   Ahmed, MZ
   Alqahtani, AS
   Alqahtani, MS
   Kumar, V
AF Prasad, Kartikay
   Khatoon, Fatima
   Rashid, Summya
   Ali, Nemat
   AlAsmari, Abdullah F.
   Ahmed, Mohammad Z.
   Alqahtani, Ali S.
   Alqahtani, Mohammed S.
   Kumar, Vijay
TI Targeting hub genes and pathways of innate immune response in COVID-19:
   A network biology perspective
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE COVID-19; Network biology; Immune response; Interferon stimulating
   genes; Drug repurposing
ID ANTIVIRAL RESPONSE; MITOMYCIN-C; INTERFERON; INFLUENZA; VIRUS; SARS;
   IMMUNOMODULATORS; REPLICATION; INHIBITORS; PNEUMONIA
AB The current pandemic of 2019 novel coronavirus disease (COVID-19) caused by a novel virus strain, 2019-nCoV/SARS-CoV-2 have posed a serious threat to global public health and economy. It is largely unknown how the human immune system responds to this infection. A better understanding of the immune response to SARS-CoV-2 will be important to develop therapeutics against COVID-19. Here, we have used transcriptomic profile of human alveolar adenocarcinoma cells (A549) infected with SARS-CoV-2 and employed a network biology approach to generate human-virus interactome. Network topological analysis discovers 15 SARS-CoV-2 targets, which belongs to a subset of interferon (IFN) stimulated genes (ISGs). These ISGs (IFIT1, IFITM1, IRF7, ISG15, MX1, and OAS2) can be considered as potential candidates for drug targets in the treatments of COVID-19. We have identified significant interaction between ISGs and TLR3 agonists, like poly I: C, and imiquimod, and suggests that TLR3 agonists can be considered as a potential drug for drug repurposing in COVID-19. Our network centric analysis suggests that moderating the innate immune response is a valuable approach to target COVID-19. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Prasad, Kartikay; Khatoon, Fatima; Kumar, Vijay] Amity Univ, Amity Inst Neuropsychol & Neurosci, Noida 201303, UP, India.
   [Rashid, Summya] Prince Sattam Bin AbdulAziz Univ, Coll Pharm Girls Sect, Dept Pharmacol & Toxicol, Al Kharj 11942, Saudi Arabia.
   [Ali, Nemat; AlAsmari, Abdullah F.] King Saud Univ, Coll Pharm, Dept Pharmacol & Toxicol, Riyadh 11451, Saudi Arabia.
   [Ahmed, Mohammad Z.; Alqahtani, Ali S.] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh 11451, Saudi Arabia.
   [Alqahtani, Mohammed S.] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh 11451, Saudi Arabia.
RP Kumar, V (corresponding author), Amity Univ, Amity Inst Neuropsychol & Neurosci, Noida 201303, UP, India.
EM vkumar33@amity.edu
RI AlAsmari, Abdullah F./AAM-6548-2020; Prasad, Kartikay/AAS-1028-2020
OI Prasad, Kartikay/0000-0002-8730-0967; AlAsmari,
   Abdullah/0000-0001-7569-4287; Alqahtani, Mohammed/0000-0002-5027-6545
FU Department of Science and Technology, Government of IndiaDepartment of
   Science & Technology (India); Deanship of Scientific Research at King
   Saud UniversityKing Saud University [RG-1441-461]
FX Authors sincerely thank to the Department of Science and Technology,
   Government of India. The authors extend their appreciation to the
   Deanship of Scientific Research at King Saud University for funding this
   work through research group no. RG-1441-461.
CR Ackerman EE, 2018, MBIO, V9, DOI 10.1128/mBio.02002-18
   Arguel Marie-Jeanne, 2019, BIORXIV
   Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Blanco-Melo D., 2020, BIORXIV
   Blanco-Melo D., 2020, SARS COV 2 LAUNCHES
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bosl K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02186
   Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Ciancanelli MJ, 2016, CURR OPIN IMMUNOL, V38, P109, DOI 10.1016/j.coi.2015.12.002
   Ciliberto G, 2020, DRUG DISCOV TODAY, V25, P946, DOI 10.1016/j.drudis.2020.04.005
   Ciliberto G, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01590-2
   Daczkowski CM, 2017, J MOL BIOL, V429, P1661, DOI 10.1016/j.jmb.2017.04.011
   Dai JF, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-468
   Davis AP, 2019, NUCLEIC ACIDS RES, V47, pD948, DOI 10.1093/nar/gky868
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Dzimianski JV, 2019, J MOL BIOL, V431, P4203, DOI 10.1016/j.jmb.2019.03.013
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Garcia-Cremades M., 2020, CLIN PHARM THER
   GIBSON SJ, 1995, J INTERF CYTOK RES, V15, P537, DOI 10.1089/jir.1995.15.537
   Golonka RM, 2020, PHYSIOL GENOMICS, V52, P217, DOI 10.1152/physiolgenomics.00033.2020
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamano E, 2005, BIOCHEM BIOPH RES CO, V329, P1234, DOI 10.1016/j.bbrc.2005.02.101
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Johansen LM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005471
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kim YJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005850
   Kindler E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006195
   Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Kumaki Y, 2017, ANTIVIR RES, V139, P1, DOI 10.1016/j.antiviral.2016.12.007
   Kumar A, 2006, IMMUNOLOGY, V117, P11, DOI 10.1111/j.1365-2567.2005.02258.x
   Li C, 2020, ASIAN J PHARM SCI, V15, P1, DOI 10.1016/j.ajps.2018.12.006
   McKechnie JL, 2020, CELL HOST MICROBE, V27, P863, DOI 10.1016/j.chom.2020.05.009
   Melchjorsen J, 2009, J INTERF CYTOK RES, V29, P199, DOI 10.1089/jir.2008.0050
   Mielech AM, 2014, VIROLOGY, V450, P64, DOI 10.1016/j.virol.2013.11.040
   NAYAK DP, 1966, VIROLOGY, V30, P673, DOI 10.1016/0042-6822(66)90172-3
   Nerurkar L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16707-5
   Ngoi SM, 2008, J IMMUNOL, V181, P7670, DOI 10.4049/jimmunol.181.11.7670
   Okumura A, 2006, P NATL ACAD SCI USA, V103, P1440, DOI 10.1073/pnas.0510518103
   Padhi A.K., 2020, BIORXIV
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Pingale KD, 2019, J GEN VIROL, V100, P471, DOI 10.1099/jgv.0.001229
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shapira SD, 2009, CELL, V139, P1255, DOI 10.1016/j.cell.2009.12.018
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Snodgrass RG, 2010, J BIOL CHEM, V285, P19068, DOI 10.1074/jbc.M109.040477
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tsave O, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4013639
   Verhelst J, 2012, J VIROL, V86, P13445, DOI 10.1128/JVI.01682-12
   VERWEIJ J, 1990, Anti-Cancer Drugs, V1, P5, DOI 10.1097/00001813-199010000-00002
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wong MT, 2016, CELL MOL IMMUNOL, V13, P11, DOI 10.1038/cmi.2014.127
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Yang SP, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00303-18
   Yang Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep17554
   Zhao JC, 2012, J VIROL, V86, P11416, DOI 10.1128/JVI.01410-12
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zwolak I, 2014, TOXICOL MECH METHOD, V24, P1, DOI 10.3109/15376516.2013.843110
NR 74
TC 2
Z9 2
U1 13
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV 15
PY 2020
VL 163
BP 1
EP 8
DI 10.1016/j.ijbiomac.2020.06.228
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA OD4RK
UT WOS:000579839600001
PM 32599245
OA Green Published
DA 2021-01-01
ER

PT J
AU Ugurel, OM
   Mutlu, O
   Sariyer, E
   Kocer, S
   Ugurel, E
   Inci, TG
   Ata, O
   Turgut-Balik, D
AF Ugurel, Osman Mutluhan
   Mutlu, Ozal
   Sariyer, Emrah
   Kocer, Sinem
   Ugurel, Erennur
   Inci, Tugba Gul
   Ata, Oguz
   Turgut-Balik, Dilek
TI Evaluation of the potency of FDA-approved drugs on wild type and mutant
   SARS-CoV-2 helicase (Nsp13)
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE SARS-CoV-2; Helicase; Nsp13; Drug repositioning; Mutation analysis
ID MULTIPLE SEQUENCE ALIGNMENT; CELL LUNG-CANCER; MOLECULAR-DYNAMICS;
   PROTEIN MODELS; CORONAVIRUS; SARS; ACCURACY; VIRUS; INHIBITION;
   DISCOVERY
AB SARS-CoV-2 has caused COVID-19 outbreak with nearly 2 M infected people and over 100K death worldwide, until middle of April 2020. There is no confirmed drug for the treatment of COVID-19 yet. As the disease spread fast and threaten human life, repositioning of FDA approved drugs may provide fast options for treatment. In this aspect, structure-based drug design could be applied as a powerful approach in distinguishing the viral drug target regions from the host. Evaluation of variations in SARS-CoV-2 genome may ease finding specific drug targets in the viral genome. In this study, 3458 SARS-CoV-2 genome sequences isolated from all around the world were analyzed. Incidence of C17747T and A17858G mutations were observed to be much higher than others and they were on Nsp13, a vital enzyme of SARS-CoV-2. Effect of these mutations was evaluated on protein-drug interactions using in silico methods. The most potent drugs were found to interact with the key and neighbor residues of the active site responsible from ATP hydrolysis. As result, cangrelor, fludarabine, folic acid and polydatin were determined to be the most potent drugs which have potency to inhibit both the wild type and mutant SARS-CoV-2 helicase. Clinical data supporting these findings would be important towards overcoming COVID-19. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Ugurel, Osman Mutluhan; Ugurel, Erennur; Inci, Tugba Gul; Turgut-Balik, Dilek] Yildiz Tech Univ, Fac Chem & Met Engn, Dept Bioengn, Davutpasa Campus, TR-34210 Istanbul, Turkey.
   [Ugurel, Osman Mutluhan] Altinbas Univ, Sch Engn & Nat Sci, Dept Basic Sci, TR-34217 Istanbul, Turkey.
   [Mutlu, Ozal] Marmara Univ, Fac Arts & Sci, Dept Biol, Goztepe Campus, TR-34722 Istanbul, Turkey.
   [Sariyer, Emrah] Artvin Coruh Univ, Vocat Sch Hlth Serv, Med Lab Tech, Artvin, Turkey.
   [Kocer, Sinem] Istanbul Yeni Yuzyil Univ, Fac Pharm, Dept Pharmaceut Biotechnol, TR-34010 Istanbul, Turkey.
   [Ata, Oguz] Altinbas Univ, Sch Engn & Nat Sci, Dept Software Engn, TR-34217 Istanbul, Turkey.
RP Turgut-Balik, D (corresponding author), Yildiz Tech Univ, Fac Chem & Met Engn, Dept Bioengn, Davutpasa Campus, TR-34210 Istanbul, Turkey.
EM dilekbalik@gmail.com
OI SARIYER, Emrah/0000-0003-1721-0314
CR Ai JW, 2020, EMERG MICROBES INFEC, V9, P597, DOI 10.1080/22221751.2020.1738905
   Baker Danial E, 2015, Hosp Pharm, V50, P922
   Barnes M.R., 2003, BIOINFORMATICS GENET
   Beck S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040338
   Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Borowski P, 2001, ACTA BIOCHIM POL, V48, P739
   Borowski P, 2000, ACTA BIOCHIM POL, V47, P173, DOI 10.18388/abp.2000_4075
   Briguglio I, 2011, INT J MED CHEM, V2011, DOI 10.1155/2011/213135
   Case D.A., 2012, AMBER 12 REFERENCE M, P350
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Du QH, 2013, PHARM BIOL, V51, P1347, DOI 10.3109/13880209.2013.792849
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Fairman-Williams ME, 2010, CURR OPIN STRUC BIOL, V20, P313, DOI 10.1016/j.sbi.2010.03.011
   Fang SG, 2007, VIROLOGY, V358, P136, DOI 10.1016/j.virol.2006.08.020
   FLETCHER R, 1964, COMPUT J, V7, P149, DOI 10.1093/comjnl/7.2.149
   FLETCHER R, 1963, COMPUT J, V6, P163, DOI 10.1093/comjnl/6.2.163
   Fraternale A, 2000, J ACQ IMMUN DEF SYND, V23, P209
   Frick DN, 2006, CURR PHARM DESIGN, V12, P1315, DOI 10.2174/138161206776361147
   GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201
   GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2
   Gordon D.E., 2020, BIORXIV, DOI [10.1101/2020.03.22.002386 2020.03.22.002386, DOI 10.1101/2020.03.22.0023862020.03.22.002386.]
   Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163
   Hitchcock MJM, 1996, ANTIVIR CHEM CHEMOTH, V7, P115, DOI 10.1177/095632029600700301
   Huennekens F M, 1968, Vitam Horm, V26, P375
   Jang KJ, 2008, BIOCHEM BIOPH RES CO, V366, P738, DOI 10.1016/j.bbrc.2007.12.020
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   Keating MJ, 1998, BLOOD, V92, P1165, DOI 10.1182/blood.V92.4.1165.416k03_1165_1171
   Kuraku S, 2013, NUCLEIC ACIDS RES, V41, pW22, DOI 10.1093/nar/gkt389
   Kwong AD, 2005, NAT REV DRUG DISCOV, V4, P845, DOI 10.1038/nrd1853
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Lin SC, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2253-8
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Martin P, 2008, J GASTROEN HEPATOL, V23, P844, DOI 10.1111/j.1440-1746.2008.05398.x
   Mirza M.U., 2020, STRUCTURAL ELUCIDATI, DOI [10.20944/preprints202003.0085, DOI 10.20944/PREPRINTS202003.0085]
   Moinpour M., 2020, BIORXIV
   Morgan AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053785
   Moser A, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-5
   O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189
   Papich D., 2015, SAUNDERS HDB VET DRU
   Parvez MK, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5753804
   PASTOR RW, 1988, MOL PHYS, V65, P1409, DOI 10.1080/00268978800101881
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rusthoven JJ, 1999, J CLIN ONCOL, V17, P1194, DOI 10.1200/JCO.1999.17.4.1194
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Sanford M, 2009, DRUGS, V69, P461, DOI 10.2165/00003495-200969040-00006
   Saw WG, 2017, ANTIVIR RES, V141, P73, DOI 10.1016/j.antiviral.2017.02.005
   Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954
   Shum KT, 2008, CHEMBIOCHEM, V9, P3037, DOI 10.1002/cbic.200800491
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Stadler AM, 2016, PHYS CHEM CHEM PHYS, V18, P21527, DOI 10.1039/c6cp04146a
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Subissi L, 2014, ANTIVIR RES, V101, P122, DOI 10.1016/j.antiviral.2013.11.006
   Vyas VK, 2012, INDIAN J PHARM SCI, V74, P1, DOI 10.4103/0250-474X.102537
   Wallner B, 2003, PROTEIN SCI, V12, P1073, DOI 10.1110/ps.0236803
   Wang DM, 2020, PESTIC BIOCHEM PHYS, V166, DOI 10.1016/j.pestbp.2019.07.017
   Wang SM, 2009, EXPERT REV ANTI-INFE, V7, P735, DOI [10.1586/eri.09.45, 10.1586/ERI.09.45]
   Wang XY, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43254
   Wang Z, 2011, FEBS J, V278, P383, DOI 10.1111/j.1742-4658.2010.07961.x
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Waye MMY, 2010, PHARMACEUTICALS-BASE, V3, P3343, DOI 10.3390/ph3103343
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yano M, 2000, AM J PHYSIOL-HEART C, V279, pH1898
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122415
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 84
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV 15
PY 2020
VL 163
BP 1687
EP 1696
DI 10.1016/j.ijbiomac.2020.09.138
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA OD4RK
UT WOS:000579839600168
PM 32980406
OA Green Published
DA 2021-01-01
ER

PT J
AU Parvez, MSA
   Karim, MA
   Hasan, M
   Jaman, J
   Karim, Z
   Tahsin, T
   Hasan, MN
   Hosen, MJ
AF Parvez, Md Sorwer Alam
   Karim, Md Adnan
   Hasan, Mahmudul
   Jaman, Jomana
   Karim, Ziaul
   Tahsin, Tohura
   Hasan, Md Nazmul
   Hosen, Mohammad Jakir
TI Prediction of potential inhibitors for RNA-dependent RNA polymerase of
   SARS-CoV-2 using comprehensive drug repurposing and molecular docking
   approach
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE COVID-19; SARS-CoV-2; RNA-dependent RNA polymerase; Drug
ID PROTEIN; DISCOVERY; ZINC
AB The pandemic prevalence of COVID-19 has become a very serious global health issue. Scientists all over the world have been seriously attempting in the discovery of a drug to combat SARS-CoV-2. It has been found that RNA-dependent RNA polymerase (RdRp) plays a crucial role in SARS-CoV-2 replication, and thus could be a potential drug target. Here, comprehensive computational approaches including drug repurposing and molecular docking were employed to predict an effective drug candidate targeting RdRp of SARS-CoV-2. This study revealed that Rifabutin, Rifapentine, Fidaxomicin, 7-methyl-guanosine-5'-triphosphate-5'-guanosine and Ivermectin have a potential inhibitory interaction with RdRp of SARS-CoV-2 and could be effective drugs for COVID-19. In addition, virtual screening of the compounds from ZINC database also allowed the prediction of two compounds (ZINC09128258 and ZINC09883305) with pharmacophore features that interact effectively with RdRp of SARS-CoV-2, indicating their potentiality as effective inhibitors of the enzyme. Furthermore, ADME analysis along with analysis of toxicity was also undertaken to check the pharmacokinetics and drug-likeness properties of the two compounds. Comparative structural analysis of protein-inhibitor complexes revealed that the amino acids Y32, K47, Y122, Y129, H133, N138, D140, T141, S709 and N781 are crucial for drug surface hotspot in the RdRp of SARS-CoV-2. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Parvez, Md Sorwer Alam; Tahsin, Tohura; Hosen, Mohammad Jakir] Shahjalal Univ Sci & Technol, Dept Genet Engn & Biotechnol, Sylhet 3114, Bangladesh.
   [Karim, Md Adnan; Hasan, Md Nazmul] Jashore Univ Sci & Technol, Dept Genet Engn & Biotechnol, Jashore, Bangladesh.
   [Hasan, Mahmudul] Sylhet Agr Univ, Dept Pharmaceut & Ind Biotechnol, Sylhet 3100, Bangladesh.
   [Jaman, Jomana] Bangladesh Agr Univ, Dept Biotechnol, Mymensingh, Bangladesh.
   [Karim, Ziaul] Free Univ Berlin, Dept Biol Chem & Pharm, Berlin, Germany.
   [Karim, Md Adnan] Univ Saarland, Ctr Bioinformat, Saarbrucken, Germany.
RP Hosen, MJ (corresponding author), Shahjalal Univ Sci & Technol, Dept Genet Engn & Biotechnol, Sylhet 3114, Bangladesh.
EM sorwersust@yahoo.com; jakir-gen@sust.edu
OI Parvez, Md Sorwer Alam/0000-0002-9726-1009; Hosen, Mohammad
   Jakir/0000-0001-6444-0214; KARIM, MD ADNAN/0000-0002-7114-2095
FU Research Center, Shahjalal University of Science and Technology;
   Bangladesh Bureau of Educational Information and Statistics; Ministry of
   Education, Government of Bangladesh
FX No specific grant was received for this study. MH receives grant support
   from the (1) Research Center, Shahjalal University of Science and
   Technology, (2) Bangladesh Bureau of Educational Information and
   Statistics, and the (3) Ministry of Education, Government of Bangladesh.
CR Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095, 10.1093/nar/gks1189]
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Agrawal P., 2019, BENCHMARKING DIFFERE, V19
   Biovia D.S., 2016, DISCOVERY STUDIO MOD
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Daina A, 2016, CHEMMEDCHEM, V11, P1117, DOI 10.1002/cmdc.201600182
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Ekins S, 2007, BRIT J PHARMACOL, V152, P9, DOI 10.1038/sj.bjp.0707305
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Fang Y., 2020, RADIOLOGY, DOI [10.1148/radiol.2020200432, DOI 10.1148/RADIOL.2020200432.]
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Ganeshpurkar A, 2019, VIRAL POLYMERASES: STRUCTURES, FUNCTIONS, AND ROLES AS ANTIVIRAL DRUG TARGETS, P1, DOI 10.1016/B978-0-12-815422-9.00001-2
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hsu KC, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S33
   Hubbard RE, 2007, CURR OPIN DRUG DISC, V10, P289
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Koes DR, 2012, NUCLEIC ACIDS RES, V40, pW409, DOI 10.1093/nar/gks378
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Leach A. R., 2001, MOL MODELLING PRINCI
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li X., 2020, NETWORK BIOINFORMATI, DOI [10.20944/preprints202003.0286., DOI 10.20944/PREPRINTS202003.0286]
   Li X, 2015, MOL INFORM, V34, P228, DOI 10.1002/minf.201400127
   Li Z., 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212, DOI 10.1101/2020.02.08.200212122020.02.08.20021212]
   Lung JH, 2020, J MED VIROL, V92, P693, DOI 10.1002/jmv.25761
   Mercorelli B, 2018, TRENDS MICROBIOL, V26, P865, DOI 10.1016/j.tim.2018.04.004
   Mishra S., 2019, J DRUG DELIV THERAPE, V9, P366
   Pal M, 2020, CUREUS, V12, DOI 10.7759/cureus.7423
   Pizzorno A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00531
   Polsky B., 1989, REV INFECT DIS    S7, V11, pS1648, DOI /10.1093/CLINIDS/11.SUPPLEMENT_7
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Prichard Mark N., 2005, Current Drug Targets - Infectious Disorders, V5, P17, DOI 10.2174/1568005053174627
   Rose PW, 2017, NUCLEIC ACIDS RES, V45, pD271, DOI 10.1093/nar/gkw1000
   Sakano T, 2016, BIOPHYS PHYSICOBIOL, V13, P181, DOI 10.2142/biophysico.13.0_181
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Schneidman-Duhovny D, 2008, J COMPUT BIOL, V15, P737, DOI 10.1089/cmb.2007.0130
   Schneidman-Duhovny D, 2008, NUCLEIC ACIDS RES, V36, pW223, DOI 10.1093/nar/gkn187
   Shen J, 2010, J CHEM INF MODEL, V50, P1034, DOI 10.1021/ci100104j
   Tripathi P., 2019, WORLD SCI NEWS, V131, P147
   Trott O., 2009, J COMPUT CHEM, V31, DOI [10.1002/jcc.21334, DOI 10.1002/JCC.21334NA-NA.]
   Wang SJ, 2020, IET SIGNAL PROCESS, V14, P269, DOI 10.1049/iet-spr.2019.0365
   WHO, 2020, COR DIS COVID 19 SIT
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xu CY, 2012, J CHEM INF MODEL, V52, P2840, DOI 10.1021/ci300400a
   Xu HT, 2017, J ANTIMICROB CHEMOTH, V72, P727, DOI 10.1093/jac/dkw514
   Yang JF, 2020, IEEE T PATTERN ANAL, V42, P1537, DOI 10.1109/TPAMI.2019.2913863
   Yang Y., 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.02.10.20021675, DOI 10.1101/2020.02.10.200216752020.02.10.20021675]
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zhang L., 2020, RNA DEPENDENT RNA PO, DOI [10.20944/preprints202003.0267.v1., DOI 10.20944/PREPRINTS202003.0267.V1.]
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 58
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV 15
PY 2020
VL 163
BP 1787
EP 1797
DI 10.1016/j.ijbiomac.2020.09.098
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA OD4RK
UT WOS:000579839600178
PM 32950529
OA Green Published
DA 2021-01-01
ER

PT J
AU Al-Zaqri, N
   Pooventhiran, T
   Alsalme, A
   Warad, I
   John, AM
   Thomas, R
AF Al-Zaqri, Nabil
   Pooventhiran, T.
   Alsalme, Ali
   Warad, Ismail
   John, Athira M.
   Thomas, Renjith
TI Structural and physico-chemical evaluation of melatonin and its
   solution-state excited properties, with emphasis on its binding with
   novel coronavirus proteins
SO JOURNAL OF MOLECULAR LIQUIDS
LA English
DT Article
DE DFT; Melatonin; Coronavirus; NLO; NBO
ID 6-HYDROXYDOPAMINE MODEL; COCRYSTALS
AB Melatonin is a natural hormone from the pineal gland that regulates the sleep-wake cycle. We examined the structure and physico-chemical properties of melatonin using electronic structure methods and molecular-mechanics tools. Density functional theory (DFT) was used to optimise the ground-state geometry of the molecule from frontier molecular orbitals, which were analysed using the B3LYP functional. As its electrons interacted with electromagnetic radiation, electronic excitations between different energy levels were analysed in detail using time-dependent DFT with CAM-B3LYP orbitals. The results provide a wealth of information about melatonin's electronic properties, which will enable the prediction of its bioactivity. Molecular docking studies predict the biological activity of the molecules against the coronavirus2 protein. Excellent docking scores of -7.28, -7.20, and -7.06 kcal/mol indicate that melatonin can help to defend against the viral load in vulnerable populations. Hence it can be investigated as a candidate drug for the management of COVID. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Al-Zaqri, Nabil; Alsalme, Ali] King Saud Univ, Coll Sci, Dept Chem, POB 2455, Riyadh 11451, Saudi Arabia.
   [Al-Zaqri, Nabil] Ibb Univ, Coll Sci, Dept Chem, POB 70270, Ibb, Yemen.
   [Pooventhiran, T.; Thomas, Renjith] St Berchmans Coll Autonomous, Dept Chem, Changanassery, Kerala, India.
   [Warad, Ismail] An Najah Natl Univ, Sci Coll, Dept Chem, POB 7, Nablus, Palestine.
   [John, Athira M.] CHRIST Deemed Be Univ, Dept Chem, Bangalore, Karnataka, India.
RP Thomas, R (corresponding author), St Berchmans Coll Autonomous, Dept Chem, Changanassery, Kerala, India.
EM renjith@sbcollege.ac.in
RI Thomas, Renjith/P-7028-2019
OI Thomas, Renjith/0000-0003-0011-633X; Thangaiyan,
   Pooventhiran/0000-0002-7470-7178; Warad, Ismail/0000-0001-8853-8961
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP-2020/78]
FX Researchers Supporting Project number (RSP-2020/78), King Saud
   University, Riyadh, Saudi Arabia.
CR Al-Otaibi JS, 2020, J MOL LIQ, V310, DOI 10.1016/j.molliq.2020.112871
   Al-Otaibi JS, 2019, J MOL STRUCT, V1197, P719, DOI 10.1016/j.molstruc.2019.07.110
   Al-Otaibi JS, 2019, J MOL STRUCT, V1175, P916, DOI 10.1016/j.molstruc.2018.08.055
   Allouche AR, 2011, J COMPUT CHEM, V32, P174, DOI 10.1002/jcc.21600
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bagheri H, 2015, RSC ADV, V5, P21659, DOI 10.1039/c4ra16802j
   Barlow KM, 2019, J NEUROTRAUM, V36, P523, DOI 10.1089/neu.2018.5752
   Beegum S, 2020, SPECTROCHIM ACTA A, V224, DOI 10.1016/j.saa.2019.117414
   Bidabadi SS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63986-6
   Bonnet MH, 2007, J CLIN SLEEP MED, V3, P133
   Bulat FA, 2010, J MOL MODEL, V16, P1679, DOI 10.1007/s00894-010-0692-x
   DeAlmeida WB, 1995, STRUCT CHEM, V6, P383, DOI 10.1007/BF02310180
   Diss LB, 2013, ACS CHEM NEUROSCI, V4, P879, DOI 10.1021/cn4000617
   Dubey K., 2019, BIOMETRICAL J, V2020, P4
   Durdagi S., 2020, CHEMRXIV, P1
   Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155
   Frisch M. J., GAUSSIAN09 REVISION
   Gendy M.N.S., 2020, SCI REP, V10, P1
   Glendening E., 1998, NBO VERSION 3 1
   Golabchi A, 2018, BIOMATERIALS, V180, P225, DOI 10.1016/j.biomaterials.2018.07.026
   Gonzalez-Gonzalez A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61622-x
   Hardeland Rudiger, 2005, Nutr Metab (Lond), V2, P22, DOI 10.1186/1743-7075-2-22
   Haruna K, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01987
   Hatada R., 2020, J CHEM INF MODEL
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jinny C., 2020, SCI REP, V10, P1
   Johnson ER, 2010, J AM CHEM SOC, V132, P6498, DOI 10.1021/ja100936w
   Kim SW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59314-7
   Liu S., 2018, ONCOMEDICINE, V3, P37, DOI [10.7150/oncm.25566, DOI 10.7150/ONCM.25566]
   Lu T, 2012, J COMPUT CHEM, V33, P580, DOI 10.1002/jcc.22885
   Mary YS, 2019, POLYCYCL AROMAT COMP, DOI 10.1080/10406638.2019.1624974
   McCarter SJ, 2013, SLEEP MED, V14, P237, DOI 10.1016/j.sleep.2012.09.018
   Mesecar, 2020, RCSB PDB 6W63 STRUCT
   Osman E.E.A., 2020, ACS INFECT DIS
   Pappolla MA, 2000, J NEURAL TRANSM, V107, P203, DOI 10.1007/s007020050018
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   Peele K Abraham, 2020, Inform Med Unlocked, V19, P100345, DOI 10.1016/j.imu.2020.100345
   POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x
   Prater W. T., 2018, J BEHAV BRAIN SCI, V8, P117, DOI [10.4236/jbbs.2018.83007, DOI 10.4236/JBBS.2018.83007]
   Priya YS, 2020, J MOL STRUCT, V1203, DOI 10.1016/j.molstruc.2019.127461
   Reiter RJ, 2020, MELATONIN RES, V3, P43, DOI [10.32794/mr11250047, DOI 10.32794/MR11250047]
   Sharma R, 2006, BRAIN RES, V1068, P230, DOI 10.1016/j.brainres.2005.10.084
   Sharma R, 2007, J PINEAL RES, V43, P245, DOI 10.1111/j.1600-079X.2007.00469.x
   Srikanth KE, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04106
   Srinivasan V, 2005, NEUROTOX RES, V7, P293, DOI 10.1007/BF03033887
   Stehle JH, 2011, J PINEAL RES, V51, P17, DOI 10.1111/j.1600-079X.2011.00856.x
   SUGDEN D, 1994, NEUROCHEM INT, V24, P147, DOI 10.1016/0197-0186(94)90101-5
   Tan DX, 2011, OBES REV, V12, P167, DOI 10.1111/j.1467-789X.2010.00756.x
   Tan DX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122124
   Tan DX, 2016, J PINEAL RES, V61, P27, DOI 10.1111/jpi.12336
   Tan DX, 2010, CURR NEUROPHARMACOL, V8, P162, DOI [10.2174/157015910792246182, 10.2174/157015910792246263]
   Tan DX, 1999, BIOL SIGNAL RECEPT, V8, P70
   Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137
   Tan DX, 2020, MELATONIN RES, V3, P120, DOI DOI 10.32794/mr11250052
   Thadathil DA, 2019, J FLUORESC, V29, P1013, DOI 10.1007/s10895-019-02415-y
   Thomas R, 2019, J MOL STRUCT, V1181, P599, DOI 10.1016/j.molstruc.2019.01.014
   Thomas R, 2019, J MOL STRUCT, V1181, P455, DOI 10.1016/j.molstruc.2019.01.003
   Turjanski AG, 1999, J MOL MODEL, V5, P271, DOI 10.1007/s0089490050271
   VANECEK J, 1987, BRAIN RES, V435, P359, DOI 10.1016/0006-8993(87)91625-8
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zhang Z., 2020, RCSB PDB 6M03 CRYSTA
NR 61
TC 2
Z9 2
U1 15
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-7322
EI 1873-3166
J9 J MOL LIQ
JI J. Mol. Liq.
PD NOV 15
PY 2020
VL 318
AR 114082
DI 10.1016/j.molliq.2020.114082
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA OJ4HO
UT WOS:000583924900085
PM 32863490
OA Green Published
DA 2021-01-01
ER

PT J
AU El-hoshoudy, AN
AF El-hoshoudy, A. N.
TI Investigating the potential antiviral activity drugs against SARS-CoV-2
   by molecular docking simulation
SO JOURNAL OF MOLECULAR LIQUIDS
LA English
DT Article
DE COVID-19; Coronavirus; Molecular docking; SARS-CoV-2; Homology modeling
ID SPIKE
AB Recently, scary viral pneumonia is known as (COVID-19) has swept the whole world. The new virus strain designated as SARS-CoV-2 belonging to the coronavirus family. Although the current medical research directed towards the development or a novel therapeutic agent, no anti-viral drug approved until now. On the medical scale, the development of an approved drug is a time-consuming process, so research is directed towards screening of ligands and drugs multimodal structure-based-design and then docked to the main viral protease to Investigate the active binding sites. The bioinformatic approaches used to evaluate the competence of a comprehensive range of ligands and drugs before their clinical implementation. In this study, a computational approach through molecular docking simulation is conducted for screening the antiviral activity of drugs, natural sources, and inhibitory compounds against the SARS-CoV-2 genome. The main virus protease was collected from a Protein Data Bank (PDB# 6YB7) and docked with a sequence of 19 approved antiviral drugs, 10 natural inhibitory ligands against COVID-19 downloaded from PubChem, in addition to 10 natural sources optimized for Escherichia coli BL31 (DE3) to identify the antiviral activity of these candidates against COVID-19. The docking results were promised and indicated that the reported ligands can firmly bind to the SARS-CoV-2 main protease and leads to inhibition of its infectious impact. (C) 2020 Elsevier B.V. All rights reserved.
C1 [El-hoshoudy, A. N.] Egyptian Petr Res Inst, Computat Chem Grp, Cairo 11727, Egypt.
RP El-hoshoudy, AN (corresponding author), Egyptian Petr Res Inst, Computat Chem Grp, Cairo 11727, Egypt.
EM azizchemist@yahoo.com
CR Ahmed-Belkacem A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12777
   Batool M., 2017, SCI REP, V7, P1
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa008
   Chitrala KN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43232-4
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2019, LIFE SCI, V238, DOI 10.1016/j.lfs.2019.116958
   Elfiky AA, 2017, J MED VIROL, V89, P1040, DOI 10.1002/jmv.24736
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guo HX, 2005, ACTA PHARMACOL SIN, V26, P1201, DOI 10.1111/j.1745-7254.2005.00189.x
   Hopkins S, 2015, BBA-GEN SUBJECTS, V1850, P2103, DOI 10.1016/j.bbagen.2014.11.011
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kumar Suresh, 2015, BMC Res Notes, V8, P9, DOI 10.1186/s13104-015-0976-4
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Macchiagodena M, 2020, CHEM PHYS LETT, V750, DOI 10.1016/j.cplett.2020.137489
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Perlman S, 2020, J ULTRAS MED, V39, P1665, DOI 10.1002/jum.15251
   Perricone C, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102468
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Robson B., 2010, POSSIBLE IMPORTANCE
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Sarialioglu F., 2020, MED HYPOTHESES, V142
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Tobaiqy M, 2020, INFECT PREVENTION PR, V100061, DOI [10.1016/j.infpip.2020.100061, DOI 10.1016/J.INFPIP.2020.100061]
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xiong XL, 2018, J VIROL, V92
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 49
TC 0
Z9 0
U1 9
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-7322
EI 1873-3166
J9 J MOL LIQ
JI J. Mol. Liq.
PD NOV 15
PY 2020
VL 318
AR 113968
DI 10.1016/j.molliq.2020.113968
PG 19
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA OJ4HO
UT WOS:000583924900060
PM 32839634
OA Green Published
DA 2021-01-01
ER

PT J
AU Cacciapuoti, S
   De Rosa, A
   Gelzo, M
   Megna, M
   Raia, M
   Pinchera, B
   Pontarelli, A
   Scotto, R
   Scala, E
   Scarano, F
   Scalia, G
   Castaldo, G
   Fabbrocini, G
   Gentile, I
   Parrella, R
AF Cacciapuoti, Sara
   De Rosa, Annunziata
   Gelzo, Monica
   Megna, Matteo
   Raia, Maddalena
   Pinchera, Biagio
   Pontarelli, Agostina
   Scotto, Riccardo
   Scala, Emanuele
   Scarano, Francesco
   Scalia, Giulia
   Castaldo, Giuseppe
   Fabbrocini, Gabriella
   Gentile, Ivan
   Parrella, Roberto
TI Immunocytometric analysis of COVID patients: A contribution to
   personalized therapy?
SO LIFE SCIENCES
LA English
DT Article
DE SARS-CoV-2; COVID-19; Lymphocyte subpopulations; Serum cytokines
ID CELLS
AB Aims: This study aims to cast light on immunocytometric alterations in COVID-19, a potentially fatal viral infection with heterogeneous clinical expression and a not completely defined pathophysiology.
   Methods: We studied 35 COVID patients at hospital admission testing by cytofluorimetry a large panel of lymphocyte subpopulations and serum tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-17A and the soluble receptor of IL-17A (IL-17RA).
   Key findings: At hospital admission, total lymphocytes and most T and B subpopulations were reduced in 50-80% of patients, with close relationship to disease severity. While activated T helper 1 (TH1) and TH17 cells resulted normal or higher. Serum IL-6 was increased in all patients, while TNF-alpha and IL-17A were higher in advanced stages. A patient subset with low severity had very high IL-17RA levels. Tocilizumab treatment caused an increase of IL-17A in 3/6 patients and a reduction in 3 others, while the lymphocyte number increased in 3 patients and did not change in the others.
   Significance: Cytofluorimetry revealed a functional exhaustion of most lymphocyte populations in COVID patients not involving activated TH1 and TH17. Consequently, there was a relevant cytokines production that contributes to impair the respiratory inflammation. The increase of TH17 and IL-17 in a subset of cases and the evidence of a significant increase of IL-17RA (that prevents the interaction of IL-17 with the cell receptor) in patients with low severity suggest that some patients could benefit from monoclonal antibodies treatment targeting IL-17 pathway. Immunocytofluorimetric markers may contribute to a personalized therapy in COVID patients.
C1 [Cacciapuoti, Sara; Megna, Matteo; Pinchera, Biagio; Scotto, Riccardo; Scala, Emanuele; Fabbrocini, Gabriella; Gentile, Ivan] Univ Napoli Federico II, Dipartimento Med Clin & Chirurg, Naples, Italy.
   [De Rosa, Annunziata; Pontarelli, Agostina; Scarano, Francesco; Parrella, Roberto] AORN Colli, Div Malattie Infett Resp, Osped Cotugno, Dipartimento Malattie Infett & Emergenze Infett, Naples, Italy.
   [Gelzo, Monica; Raia, Maddalena; Scalia, Giulia; Castaldo, Giuseppe] CEINGE Biotecnol Avanzate, Scarl, Naples, Italy.
   [Gelzo, Monica; Castaldo, Giuseppe] Univ Napoli Federico II, Dipartimento Med Mol & Biotecnol Med, Naples, Italy.
RP Castaldo, G (corresponding author), CEINGE Biotecnol Avanzate, Via Gaetano Salvatore 486, I-80145 Naples, Italy.
EM giuseppe.castaldo@unina.it
OI PINCHERA, BIAGIO/0000-0002-8685-5434
FU Regione Campania (TASK-force COVID-19)Regione Campania
FX This work was supported by Regione Campania (TASK-force COVID-19).
CR Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   Adan A, 2017, CRIT REV BIOTECHNOL, V37, P163, DOI 10.3109/07388551.2015.1128876
   Arnaldez FI, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000930
   Brembilla NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01682
   Cascella M, 2020, STATPEARLS
   Chen X, 2020, CHINA PERSPECT-SER, P1
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Klopfenstein T, 2020, MED MALADIES INFECT, V50, P397, DOI 10.1016/j.medmal.2020.05.001
   Kurte M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00802
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Megna M, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109749
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Radbel J, 2020, CHEST, V158, pE15, DOI 10.1016/j.chest.2020.04.024
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9
   Song Y, 2017, BIOCHEM BIOPH RES CO, V493, P1, DOI 10.1016/j.bbrc.2017.08.109
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057
   von Cube M., 2020, HARMONIZING HETEROGE, DOI [10.1101/2020.03.31.20049007., DOI 10.1101/2020.03.31.20049007]
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang HL, 2008, AM J EMERG MED, V26, P711, DOI 10.1016/j.ajem.2007.10.031
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 35
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD NOV 15
PY 2020
VL 261
AR 118355
DI 10.1016/j.lfs.2020.118355
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OP7UA
UT WOS:000588290900024
PM 32871183
OA Green Published
DA 2021-01-01
ER

PT J
AU Quadros, CA
   Leal, MCBD
   Baptista-Sobrinho, CD
   Nonaka, CKV
   Souza, BSD
   Milan-Mattos, JC
   Catai, AM
   Di Lorenzo, VAP
   Ferreira, AG
AF Quadros, Claudio Almeida
   Leal, Maria Carolina Bezerra Di Medeiros
   Baptista-Sobrinho, Carlos de Almeida
   Nonaka, Carolina Kymie Vasques
   Souza, Bruno Solano De Freitas
   Milan-Mattos, Juliana Cristina
   Catai, Aparecida Maria
   Pires Di Lorenzo, Valeria Amorim
   Ferreira, Antonio Gilberto
TI Preclinical validation of occupational and environmental safety of an
   isolation system for noninvasive ventilation in COVID-19 and other
   aerosol-transmitted infections
SO EXPERT REVIEW OF MEDICAL DEVICES
LA English
DT Article; Early Access
DE Occupational respiratory infection; isolation devices respiratory
   infection; COVID-19; influenza; high-flow oxygen; continuous positive
   airway pressure
ID CORONAVIRUS
AB Background: The current SARS-CoV-2 pandemic has provoked the collapse of some health systems due to insufficient intensive care unit capacity. The use of continuous positive airway pressure (CPAP) and high-flow nasal oxygen (HFNO) therapies has been limited in consideration of the risk of occupational infection in health-care professionals.
   Aims: In preclinical experimental simulations, evaluate occupational and environmental safety of the newly developed isolation system for aerosol-transmitted infections (ISATI).
   Method: Simulations were conducted to test ISATI's capability to isolate aerosolized molecular (caffeine), and biological (SARS-CoV-2 synthetic RNA) markers. Caffeine deposition was analyzed on nitrocellulose sensor discs by proton nuclear magnetic resonance spectroscopy. Synthetic SARS-CoV-2 detection was performed by reverse transcription-polymerase chain reaction.
   Results: ISATI demonstrated efficacy in isolating molecular and biological markers within the enclosed environment in simulated conditions of CPAP, HFNO and mechanical ventilation therapy. Neither the molecular marker nor substantial amounts of synthetic SARS-CoV-2 RNA were detected in the surrounding environment, outside ISATI, indicating appropriate occupational safety for health-care professionals.
   Conclusion: Aerosolized markers were successfully contained within ISATI in all experimental simulations, offering occupational and environmental protection against the dissemination of aerosolized microparticles under CPAP or HFNO therapy conditions, which are indicated for patients with acute respiratory infections.
C1 [Quadros, Claudio Almeida] Bahia State Univ, Med Sch, Dept Life Sci, Salvador, BA, Brazil.
   [Leal, Maria Carolina Bezerra Di Medeiros; Ferreira, Antonio Gilberto] Univ Fed Sao Carlos, Dept Chem, Sao Carlos, SP, Brazil.
   [Baptista-Sobrinho, Carlos de Almeida] Univ Ctr Planalto Cent Aparecido Santos, Federal Dist, Brazil.
   [Nonaka, Carolina Kymie Vasques; Souza, Bruno Solano De Freitas] Sao Rafael Hosp, Ctr Biotechnol & Cell Therapy, Salvador, BA, Brazil.
   [Nonaka, Carolina Kymie Vasques; Souza, Bruno Solano De Freitas] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Souza, Bruno Solano De Freitas] Fiocruz MS, Goncalo Moniz Inst, Salvador, BA, Brazil.
   [Milan-Mattos, Juliana Cristina; Catai, Aparecida Maria; Pires Di Lorenzo, Valeria Amorim] Univ Fed Sao Carlos, Dept Physiotherapy, Sao Carlos, SP, Brazil.
RP Quadros, CA (corresponding author), Univ Estado Bahia, Colegiado Med, Dept Ciencias Vida, BR-41150000 Salvador, BA, Brazil.
EM caquadros@uneb.br
RI Di Lorenzo, Valeria Amorim Pires/D-8690-2012; Ferreira, Antonio
   Gilberto/D-8254-2013
OI Di Lorenzo, Valeria Amorim Pires/0000-0001-9804-7445; Quadros,
   Claudio/0000-0002-9266-2006; Catai, Aparecida Maria/0000-0002-4837-3936;
   Ferreira, Antonio Gilberto/0000-0003-2314-216X
FU Laboratory of Nuclear Magnetic Resonance, Department of Chemistry, Sao
   Carlos Federal University; Center for Biotechnology and Cell Therapy,
   Sao Rafael Hospital, D'Or Institute for Research and Education
FX This study was sponsored by the Laboratory of Nuclear Magnetic
   Resonance, Department of Chemistry, Sao Carlos Federal University and
   the Center for Biotechnology and Cell Therapy, Sao Rafael Hospital, D'Or
   Institute for Research and Education.
CR Agarwal R, 2006, RESP MED, V100, P2235, DOI 10.1016/j.rmed.2006.03.018
   Bischoff WE, 2013, J INFECT DIS, V207, P1037, DOI 10.1093/infdis/jis773
   Brewster DJ, 2020, MED J AUSTRALIA, V212, P472, DOI 10.5694/mja2.50598
   Burns GP, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000621
   Cherrie John W, 2020, Occup Med (Lond), V70, P335, DOI 10.1093/occmed/kqaa077
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du RH, 2020, ANN AM THORAC SOC, V17, P839, DOI 10.1513/AnnalsATS.202003-225OC
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Italian Thoracic Society Italian Respiratory Society, MAN RESP CAR PAT COV
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kopic J, 2014, DISASTER MED PUBLIC, V8, P310, DOI 10.1017/dmp.2014.71
   Kutter JS, 2018, CURR OPIN VIROL, V28, P142, DOI 10.1016/j.coviro.2018.01.001
   Lindsley WG, 2012, J OCCUP ENVIRON HYG, V9, P443, DOI 10.1080/15459624.2012.684582
   Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3
   Masclans JR, 2013, CLIN MICROBIOL INFEC, V19, P249, DOI 10.1111/j.1469-0691.2012.03797.x
   Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Nightingale R, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000639
   Oranger M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01692-2020
   Pan XF, 2020, LANCET INFECT DIS, V20, P410, DOI 10.1016/S1473-3099(20)30114-6
   Pfeifer M, 2020, PNEUMOLOGIE, V74, P337, DOI 10.1055/a-1157-9976
   Ramsey CD, 2010, CRIT CARE MED, V38, pE58, DOI 10.1097/CCM.0b013e3181cde600
   Santarpia JL, 2020, TRANSMISSION POTENTI, DOI [10.1101/2020.03.23.20039446, DOI 10.1101/2020.03.23.20039446]
   Siegel JD, 2007, AM J INFECT CONTR S2, V35
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang WK, 2004, EMERG INFECT DIS, V10, P1213, DOI 10.3201/eid1007.031113
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
NR 29
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1743-4440
EI 1745-2422
J9 EXPERT REV MED DEVIC
JI Expert Rev. Med. Devices
DI 10.1080/17434440.2020.1842190
EA NOV 2020
PG 10
WC Engineering, Biomedical
SC Engineering
GA OR6OQ
UT WOS:000589588500001
PM 33103939
OA Bronze
DA 2021-01-01
ER

PT J
AU Abo-zeid, Y
   Williams, GR
   Touabi, L
   McLean, GR
AF Abo-zeid, Yasmin
   Williams, Gareth R.
   Touabi, Lila
   McLean, Gary R.
TI An investigation of rhinovirus infection on cellular uptake of poly
   (glycerol-adipate) nanoparticles
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Polymer nanoparticles; Poly (glycerol-adipate); Virus infection;
   Nanoparticle uptake; HeLa and Beas-2B cells
ID HEPATITIS-C VIRUS; RECEPTOR; DELIVERY; CELLS; ADULTS; DRUGS;
   EXACERBATIONS; ASTHMA
AB Viral infections represent 44% of newly emerging infections, and as is shown by the COVID-19 outbreak constitute a major risk to human health and wellbeing. Although there are many efficient antiviral agents, they still have drawbacks such as development of virus resistance and accumulation within off-target organs. Encapsulation of antiviral agents into nanoparticles (NPs) has been shown to improve bioavailability, control release, and reduce side effects. However, there is little quantitative understanding of how the uptake of NPs into virally infected cells compares to uninfected cells. In this work, the uptake of fluorescently labeled polymer NPs was investigated in several models of rhinovirus (RV) infected cells. Different multiplicities of RV infections (MOI) and timings of NPs uptake were also investigated. In some cases, RV infection resulted in a significant increase of NPs uptake, but this was not universally noted. For HeLa cells, RV-A16 and RV-A01 infection elevated NPs uptake upon increasing the incubation time, whereas at later timepoints (6 h) a reduced uptake was noted with RV-A01 infection (owing to decreased cell viability). Beas-2B cells exhibited more complex trends: decreases in NPs uptake (cf. uninfected cells) were observed at short incubation times following RV-A01 and RVA16 infection. At later incubation times (4 h), we found a marked decrease of NPs uptake for RV-A01 infected cells but an increase in uptake with RV-A16 infected cells. Where increases in NPs uptake were found, they were very modest compared to results previously reported for a hepatitis C/ Huh7.5 cell line model. An increase in RV dose (MOI) was not associated with any notable change of NPs uptake. We argue that the diverse endocytic pathways among the different cell lines, together with changes in virus nature, size, and entry mechanism are responsible for these differences. These findings suggest that NPs entry into virally infected cells is a complex process, and further work is required to unravel the different factors which govern this. Undertaking this additional research will be crucial to develop potent nanomedicines for the delivery of antiviral agents.
C1 [Abo-zeid, Yasmin] Helwan Univ, Fac Pharm, Dept Pharmaceut, Cairo, Egypt.
   [Abo-zeid, Yasmin; Williams, Gareth R.] UCL, UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.
   [Abo-zeid, Yasmin; Touabi, Lila; McLean, Gary R.] London Metropolitan Univ, Cellular & Mol Immunol Res Ctr, 166-220 Holloway Rd, London N7 8DB, England.
   [McLean, Gary R.] Imperial Coll London, Natl Heart & Lung Inst, Norfolk Pl, London W2 1PG, England.
RP Abo-zeid, Y (corresponding author), Helwan Univ, Fac Pharm, Dept Pharmaceut, Cairo, Egypt.
EM yasmin.abozeid@pharm.helwan.edu.eg; g.williams@ucl.ac.uk;
   lit0208@my.londonmet.ac.uk; g.mclean@londonmet.ac.uk
RI Williams, Gareth/A-5980-2013
OI Williams, Gareth/0000-0002-3066-2860
FU British Council and Science and Technology Development Fund in Egypt
   [27654]
FX We would like to thank the British Council and Science and Technology
   Development Fund in Egypt for awarding a Newton Mosharafa Researcher
   Links Travel Grant to Dr. Yasmin Abo-zeid. Grant/Award Number is: Travel
   Grant - ID 27654.
CR Abo-zeid Y, 2020, EUR J PHARM SCI, V153, DOI 10.1016/j.ejps.2020.105465
   Abo-Zeid Y, 2020, J DRUG DELIV SCI TEC, V56, DOI 10.1016/j.jddst.2020.101552
   Abo-zeid Y, 2018, J DRUG DELIV SCI TEC, V46, P354, DOI 10.1016/j.jddst.2018.05.027
   Abo-zeid Y, 2018, INT J PHARMACEUT, V547, P572, DOI 10.1016/j.ijpharm.2018.06.027
   Adalja A, 2019, EXPERT REV ANTI-INFE, V17, P467, DOI 10.1080/14787210.2019.1635009
   Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997
   Arruda E, 1996, J CLIN MICROBIOL, V34, P1277, DOI 10.1128/JCM.34.5.1277-1279.1996
   Bartlett NW, 2012, EMBO MOL MED, V4, P1244, DOI 10.1002/emmm.201201650
   Calattini S, 2015, J BIOL CHEM, V290, P23173, DOI 10.1074/jbc.M115.662999
   Chawla A, 2018, INFECT DIS THER, V7, P183, DOI 10.1007/s40121-018-0201-6
   Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI DOI 10.1128/CMR.00102-15
   De Franceschi L, 2000, HEPATOLOGY, V31, P997, DOI 10.1053/he.2000.5789
   Dustin LB, 2016, CLIN MICROBIOL INFEC, V22, P826, DOI 10.1016/j.cmi.2016.08.025
   Fiandra L, 2015, NANOMED-NANOTECHNOL, V11, P1387, DOI 10.1016/j.nano.2015.03.009
   Foroozandeh P, 2018, NANOSCALE RES LETT, V13, DOI 10.1186/s11671-018-2728-6
   Fuchs R., 2009, REV MED VIROL, V19, P57, DOI [10.1002/rmv., DOI 10.1002/RMV]
   Fuchs R, 2012, ADV VIROL, V2012, DOI 10.1155/2012/826301
   GARNETT MC, 1986, EUR J CELL BIOL, V41, P214
   Gastaminza P, 2010, J VIROL, V84, P10999, DOI 10.1128/JVI.00526-10
   Gaur PK, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/363404
   GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0
   Grove J, 2011, J CELL BIOL, V195, P1071, DOI 10.1083/jcb.201108131
   Harvie P, 1996, ANTIMICROB AGENTS CH, V40, P225, DOI 10.1128/AAC.40.1.225
   Henquell C, 2012, J CLIN VIROL, V53, P280, DOI 10.1016/j.jcv.2011.10.009
   Hillaireau H, 2006, J CONTROL RELEASE, V116, P346, DOI 10.1016/j.jconrel.2006.09.016
   HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839
   Irwin KK, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew014
   Jia FJ, 2020, PROTEIN CELL, V11, P624, DOI 10.1007/s13238-020-00708-8
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Kallinteri P, 2005, BIOMACROMOLECULES, V6, P1885, DOI 10.1021/bm049200j
   Kiang D, 2007, J CLIN VIROL, V38, P227, DOI 10.1016/j.jcv.2006.12.016
   Lembo D, 2018, EXPERT OPIN DRUG DEL, V15, P93, DOI 10.1080/17425247.2017.1360863
   Lembo D, 2013, INT J PHARMACEUT, V443, P262, DOI 10.1016/j.ijpharm.2012.12.031
   Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Meng W, 2006, J CONTROL RELEASE, V116, P314, DOI 10.1016/j.jconrel.2006.09.014
   Moyle G, 2000, CLIN THER, V22, P911, DOI 10.1016/S0149-2918(00)80064-8
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   Nii-Trebi NI, 2017, BIOMED RES INT, V2017, P1, DOI 10.1155/2017/5245021
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/nnm.09.38
   Ochekpe NA, 2009, TROP J PHARM RES, V8, P265
   Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC
   Peters CJ, 1999, J INFECT DIS, V179, pIX
   Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938
   Pradhan P., 2020, UNCANNY SIMILARITY U, DOI [10.1101/2020.01.30.927871, DOI 10.1101/2020.01.30.927871]
   REDDEL RR, 1988, CANCER RES, V48, P1904
   Sayers EJ, 2019, MOL THER, V27, P1950, DOI 10.1016/j.ymthe.2019.07.018
   Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529
   Schober D, 1998, J VIROL, V72, P1354, DOI 10.1128/JVI.72.2.1354-1364.1998
   Schuler BA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093897
   Shanks GD, 2012, EMERG INFECT DIS, V18, P201, DOI 10.3201/eid1802.102042
   Soota K, 2014, WORLD J GASTROENTERO, V20, P16184, DOI 10.3748/wjg.v20.i43.16184
   Stobart CC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02412
   Szunerits S, 2015, MOLECULES, V20, P14051, DOI 10.3390/molecules200814051
   Winther Birgit, 2011, Proc Am Thorac Soc, V8, P79, DOI 10.1513/pats.201006-039RN
   Zhang T, 2014, POLYMER, V55, P5065, DOI 10.1016/j.polymer.2014.08.036
NR 56
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD NOV 15
PY 2020
VL 589
AR 119826
DI 10.1016/j.ijpharm.2020.119826
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OE6QY
UT WOS:000580654300034
PM 32871219
DA 2021-01-01
ER

PT J
AU Booz, GW
   Altara, R
   Eid, AH
   Wehbe, Z
   Fares, S
   Zaraket, H
   Habeichi, NJ
   Zouein, FA
AF Booz, George W.
   Altara, Raffaele
   Eid, Ali H.
   Wehbe, Zena
   Fares, Souha
   Zaraket, Hassan
   Habeichi, Nada J.
   Zouein, Fouad A.
TI Macrophage responses associated with COVID-19: A pharmacological
   perspective
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Immunopharmacology; Immunomodulation therapy; Pandemic; Cytokine storm;
   Macrophage activation syndrome; Biologicals
ID COLONY-STIMULATING FACTOR; CYTOKINE STORM; RECEPTOR; EXPRESSION;
   PNEUMONIA; IMMUNE; ACE2; PATHOGENESIS; INHIBITION; INTERFERON
AB COVID-19 has caused worldwide death and economic destruction. The pandemic is the result of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has demonstrated high rates of infectivity leading to great morbidity and mortality in vulnerable populations. At present, scientists are exploring various approaches to curb this pandemic and alleviate its health consequences, while racing to develop a vaccine. A particularly insidious aspect of COVID-19 is the delayed overactivation of the body's immune system that is manifested as the cytokine storm. This unbridled production of pro-inflammatory cytokines and chemokines can directly or indirectly cause massive organ damage and failure. Systemic vascular endothelial inflammation and thrombocytopenia are potential consequences as well. In the case of COVID-19, the cytokine storm often fits the pattern of the macrophage activation syndrome with lymphocytopenia. The basis for the imbalance between the innate and adaptive immune systems is not clearly defined, but highlights the effect of SARS-CoV-2 on macrophages. Here we discuss the potential underlying basis for the impact of SARS-CoV-2 on macrophages, both direct and indirect, and potential therapeutic targets. These include granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 6 (IL-6), interferons, and CXCL10 (IP-10). Various biopharmaceuticals are being repurposed to target the cytokine storm in COVID-19 patients. In addition, we discuss the rationale for activating the macrophage alpha 7 nicotinic receptors as a therapeutic target. A better understanding of the molecular consequences of SARS-CoV-2 infection of macrophages could lead to novel and more effective treatments for COVID-19.
C1 [Booz, George W.] Dept Pharmacol & Toxicol, Jackson, MS USA.
   [Altara, Raffaele] Univ Mississippi, Med Ctr, Sch Med, Dept Pathol, Jackson, MS 39216 USA.
   [Altara, Raffaele] Oslo Univ Hosp, Expt Med Res Inst, Oslo, Norway.
   [Altara, Raffaele] Univ Oslo, Oslo, Norway.
   [Altara, Raffaele] KG Jebsen Ctr Cardiac Res, Oslo, Norway.
   [Eid, Ali H.; Habeichi, Nada J.; Zouein, Fouad A.] Amer Univ Beirut, Dept Pharmacol & Toxicol, Fac Med, Beirut, Lebanon.
   [Wehbe, Zena] Amer Univ Beirut, Fac Med, Dept Biol, Beirut, Lebanon.
   [Fares, Souha] Amer Univ Beirut, Hariri Sch Nursing, Beirut, Lebanon.
   [Zaraket, Hassan] Amer Univ Beirut, Fac Med, Dept Expt Pathol Immunol & Microbiol, Beirut, Lebanon.
   [Zaraket, Hassan] Amer Univ Beirut, Fac Med, Ctr Infect Dis Res, Beirut, Lebanon.
   [Habeichi, Nada J.] Univ Paris Saclay, INSERM, UMR S1180, Dept Signaling & Cardiovasc Pathophysiol, Chatenay Malabry, France.
   [Eid, Ali H.] Qatar Univ, Coll Med, Doha, Qatar.
RP Zouein, FA (corresponding author), Amer Univ Beirut & Med Ctr, FAHA Dept Pharmacol & Toxicol, Beirut 11072020, Lebanon.
EM fz15@aub.edu.lb
OI Reis, AlessanRSS/0000-0001-8486-7469
FU American University of Beirut Faculty of Medicine [MPP - 320145/320095];
   Centre National de la Recherche Scientifique (CNRS)Centre National de la
   Recherche Scientifique (CNRS) [103507/103487/103941]; Collaborative
   Research Stimulus (CRS) [103556]; Institute of Experimental Medical
   Research (IEMR, OUS); Department of Pharmacology and Toxicology (UMMC);
   Seed grant [100410]
FX This work was supported by a grant to FAZ from the American University
   of Beirut Faculty of Medicine (MPP - 320145/320095) and by Centre
   National de la Recherche Scientifique (CNRS) #103507/103487/103941; Seed
   grant #100410; and Collaborative Research Stimulus (CRS) #103556. RA
   acknowledges the support of the Institute of Experimental Medical
   Research (IEMR, OUS). GWB acknowledges the support of the Department of
   Pharmacology and Toxicology (UMMC).
CR Abassi Z, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01312
   Abrial C., 2012, EUR RESP SOC S56, V40, p5094A
   Altara R, 2016, CLIN SCI, V130, P463, DOI 10.1042/CS20150666
   Baez-Pagan CA, 2015, J NEUROIMMUNE PHARM, V10, P468, DOI 10.1007/s11481-015-9601-5
   Baleeiro CEO, 2006, AM J PHYSIOL-LUNG C, V291, pL1246, DOI 10.1152/ajplung.00016.2006
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Bost P, 2020, CELL, V181, P1475, DOI 10.1016/j.cell.2020.05.006
   Buckley LF, 2020, J CARDIOVASC PHARM, V75, P526, DOI 10.1097/FJC.0000000000000840
   Cakarova L, 2009, AM J RESP CRIT CARE, V180, P521, DOI 10.1164/rccm.200812-1837OC
   Cao YH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8038
   Changeux JP, 2020, CR BIOL, V343, P33, DOI 10.5802/crbiol.8
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Cheemarla N.R., 2020, HOST RESPONSE BASED, DOI [10.1101/2020.06.04.20109306, DOI 10.1101/2020.06.04.20109306,2020.06.04.20109306]
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P1623, DOI 10.23812/20-34-4EDIT-65
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P339
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P333, DOI 10.23812/Editorial-Conti-2
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Egea L, 2010, EXPERT REV GASTROENT, V4, P723, DOI 10.1586/EGH.10.73
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Farsalinos K, 2020, EUR RESPIR J, V56, DOI [10.1183/13993003.01589-2020, 10.1183/13223003.01589-2020]
   Farsalinos K, 2020, INTERN EMERG MED, V15, P845, DOI 10.1007/s11739-020-02355-7
   Farsalinos Konstantinos, 2020, Toxicol Rep, V7, P658, DOI 10.1016/j.toxrep.2020.04.012
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fleetwood AJ, 2007, J IMMUNOL, V178, P5245, DOI 10.4049/jimmunol.178.8.5245
   Forrester SJ, 2018, PHYSIOL REV, V98, P1627, DOI 10.1152/physrev.00038.2017
   Furukawa Nathan W, 2020, Emerg Infect Dis, V26, DOI 10.3201/eid2607.201595
   GUO GQ, 2020, FRONT CELL DEV BIOL, V8, DOI DOI 10.3389/FCELL.2020.00410.
   Hamilton JA, 2020, J EXP MED, V217, DOI 10.1084/jem.20190945
   Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129
   Herold S, 2014, AM J RESP CRIT CARE, V189, P609, DOI 10.1164/rccm.201311-2041LE
   Horby P., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436.NEJMoa2021436., DOI 10.1056/NEJMOA2021436.NEJMOA2021436]
   Hu GC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02275
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huff Hanalise V, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa654
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600
   Igase M, 2008, HYPERTENS RES, V31, P553, DOI 10.1291/hypres.31.553
   Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC
   Kalamida D, 2007, FEBS J, V274, P3799, DOI 10.1111/j.1742-4658.2007.05935.x
   Kloc M, 2020, IMMUNOL LETT, V224, P28, DOI 10.1016/j.imlet.2020.06.002
   Komuczki J, 2019, IMMUNITY, V50, P1289, DOI 10.1016/j.immuni.2019.04.006
   Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lang FM, 2020, NAT REV IMMUNOL, V20, P507, DOI 10.1038/s41577-020-0357-7
   Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01261-2020
   Li CC, 2019, DRUG DISCOV TODAY, V24, P726, DOI 10.1016/j.drudis.2019.01.018
   Li JY, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198074
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu CL, 2013, J EPIDEMIOL, V23, P344, DOI 10.2188/jea.JE20120112
   Liu XQ, 2020, ANN HEMATOL, V99, P1421, DOI 10.1007/s00277-020-04103-5
   Liu Y.C., 2020, BIOMED J, DOI [10.1016/j.bj.2020.04.007, DOI 10.1016/J.BJ.2020.04.007.S2319-4170-5]
   Lokugamage K.G., 2020, BIORXIV, DOI [10.1101/2020.03.07.982264, DOI 10.1101/2020.03.07.982264,2020.03.07.982264]
   Lu B, 2014, MOL MED, V20, P350, DOI 10.2119/molmed.2013.00117
   Matute-Bello G, 2000, CRIT CARE MED, V28, P1, DOI 10.1097/00003246-200001000-00001
   McFadyen JD, 2020, CIRC RES, V127, P571, DOI 10.1161/CIRCRESAHA.120.317447
   Mehta P, 2020, LANCET RESP MED, V8, P822, DOI 10.1016/S2213-2600(20)30267-8
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Miyara M, 2020, QEIOS, DOI [10.32388/WPP19W.4, DOI 10.32388/WPP19W.4, 10.32388/WPP19W.4.]
   Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002
   Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012
   Paces J, 2020, PHYSIOL RES, V69, P379, DOI 10.33549/physiolres.934492
   Paine R, 2003, AM J PATHOL, V163, P2397, DOI 10.1016/S0002-9440(10)63594-8
   Petrilli C.M., 2020, FACTORS ASS HOSPITAL
   Prieto-Perez L, 2020, MODERN PATHOL, V33, P2139, DOI 10.1038/s41379-020-0613-1
   Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X
   Rosler Barbara, 2016, Mol Cell Pediatr, V3, P29, DOI 10.1186/s40348-016-0055-5
   Russo P, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01116-2020
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shinohara Y, 2012, ADV THER, V29, P900, DOI 10.1007/s12325-012-0049-1
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Smith JC, 2020, DEV CELL, V53, P514, DOI 10.1016/j.devcel.2020.05.012
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0
   Theoharides T.C., 2020, J BIOL REGUL HOMEOST, V34, DOI [10.23812/20-EDITORIAL_1-5, DOI 10.23812/20-EDITORIAL_1-5.]
   Tindle HA, 2020, NICOTINE TOB RES, V22, P1669, DOI 10.1093/ntr/ntaa077
   Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
   Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Wang C., 2020, AVEOLAR MACROPHAGE A, DOI [10.21203/rs.3.rs-19346/v1.PPR:PPR129332, DOI 10.21203/RS.3.RS-19346/V1.PPR:PPR129332]
   Wang J, 2020, J LEUKOCYTE BIOL, V108, P17, DOI 10.1002/JLB.3COVR0520-272R
   Wang Y, 2019, J CELL PHYSIOL, V234, P5507, DOI 10.1002/jcp.27347
   Watanabe K, 2020, SOC SCI COMPUT REV, DOI 10.1177/0894439320907027
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu PY, 2020, ANN HEMATOL, V99, P1205, DOI 10.1007/s00277-020-04019-0
   Yang D, 2020, J INFECT DIS, V222, P734, DOI 10.1093/infdis/jiaa356
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhang J, 2013, CELL DEATH DIFFER, V20, P1731, DOI 10.1038/cdd.2013.130
   Zhao Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139834
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 99
TC 0
Z9 0
U1 9
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 15
PY 2020
VL 887
AR 173547
DI 10.1016/j.ejphar.2020.173547
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OH6SG
UT WOS:000582725000021
PM 32919938
OA Green Published
DA 2021-01-01
ER

PT J
AU Islam, T
   Rahman, MR
   Aydin, B
   Beklen, H
   Arga, KY
   Shahjaman, M
AF Islam, Tania
   Rahman, Md Rezanur
   Aydin, Busra
   Beklen, Hande
   Arga, Kazim Yalcin
   Shahjaman, Md
TI Integrative transcriptomics analysis of lung epithelial cells and
   identification of repurposable drug candidates for COVID-19
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2, transcriptomics; Drug repositioning
ID IMMUNE-RESPONSE; INFLUENZA-VIRUS; PNEUMONIA; APOPTOSIS; CORONAVIRUS;
   DABRAFENIB; ACTIVATION; INHIBITOR; DASATINIB; RADICICOL
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease, more commonly COVID-19 has emerged as a world health pandemic. There are couples of treatment methods for COVID-19, however, well-established drugs and vaccines are urgently needed to treat the COVID-19. The new drug discovery is a tremendous challenge; repurposing of existing drugs could shorten the time and expense compared with de novo drug development. In this study, we aimed to decode molecular signatures and pathways of the host cells in response to SARS-CoV-2 and the rapid identification of repurposable drugs using bioinformatics and network biology strategies. We have analyzed available transcriptomic RNA-seq COVID-19 data to identify differentially expressed genes (DEGs). We detected 177 DEGs specific for COVID-19 where 122 were upregulated and 55 were downregulated compared to control (FDR<0.05 and logFC >= 1). The DEGs were significantly involved in the immune and inflammatory response. The pathway analysis revealed the DEGs were found in influenza A, measles, cytokine signaling in the immune system, interleukin-4, interleukin 13, interleukin 17 signaling, and TNF signaling pathways. Protein-protein interaction analysis showed 10 hub genes (BIRC3, ICAM1, IRAK2, MAP3K8, S100A8, SOCS3, STAT5A, TNF, TNFAIP3, TNIP1). The regulatory network analysis showed significant transcription factors (TFs) that target DEGs, namely FOXC1, GATA2, YY1, FOXL1, NFKB1. Finally, drug repositioning analysis was performed with these 10 hub genes and showed that in silico validated three drugs with molecular docking. The transcriptomics signatures, molecular pathways, and regulatory biomolecules shed light on candidate biomarkers and drug targets which have potential roles to manage COVID-19. ICAM1 and TNFAIP3 were the key hubs that have demonstrated good binding affinities with repurposed drug candidates. Dabrafenib, radicicol, and AT-7519 were the top-scored repurposed drugs that showed efficient docking results when they tested with hub genes. The identified drugs should be further evaluated in molecular level wet-lab experiments in prior to clinical studies in the treatment of COVID-19.
C1 [Islam, Tania; Rahman, Md Rezanur] Islamic Univ, Fac Biol Sci, Dept Biotechnol & Genet Engn, Kushtia, Bangladesh.
   [Rahman, Md Rezanur] Khwaja Yunus Ali Univ, Sch Biomed Sci, Dept Biochem & Biotechnol, Enayetpur, Sirajganj, Bangladesh.
   [Aydin, Busra; Beklen, Hande; Arga, Kazim Yalcin] Marmara Univ, Fac Engn, Dept Bioengn, Istanbul, Turkey.
   [Shahjaman, Md] Begum Rokeya Univ, Dept Stat, Rangpur, Bangladesh.
RP Rahman, MR (corresponding author), Khwaja Yunus Ali Univ, Sch Biomed Sci, Dept Biochem & Biotechnol, Enayetpur, Sirajganj, Bangladesh.
EM rezanur12@yahoo.com
CR Angell RM, 2007, BIOORG MED CHEM LETT, V17, P1296, DOI 10.1016/j.bmcl.2006.12.003
   Arleevskaya MI, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01725
   Basha O, 2018, NUCLEIC ACIDS RES, V46, pD522, DOI 10.1093/nar/gkx981
   Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451
   Blanco-Melo D., 2020, BIORXIV
   Bussel J, 2018, AM J HEMATOL, V93, P921, DOI 10.1002/ajh.25125
   Cainap C, 2015, J CLIN ONCOL, V33, P172, DOI 10.1200/JCO.2013.54.3298
   Campillos M, 2008, SCIENCE, V321, P263, DOI 10.1126/science.1158140
   Cavalli E, 2020, INT J MOL MED, V46, P1266, DOI 10.3892/ijmm.2020.4702
   Cavalli E, 2020, INT J MOL MED, V46, P903, DOI 10.3892/ijmm.2020.4659
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen JZ, 2016, ADV ENERGY MATER, V6, DOI 10.1002/aenm.201600160
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chuang J, 2019, CASE REP ONCOL MED, DOI 10.1155/2019/9246596
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Davis AP, 2017, NUCLEIC ACIDS RES, V45, pD972, DOI 10.1093/nar/gkw838
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Degtyarenko K, 2008, NUCLEIC ACIDS RES, V36, pD344, DOI 10.1093/nar/gkm791
   Duan QN, 2016, NPJ SYST BIOL APPL, V2, DOI 10.1038/npjsba.2016.15
   Fagone P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102571
   Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Franz M, 2018, NUCLEIC ACIDS RES, V46, pW60, DOI 10.1093/nar/gky311
   Ganaie SS, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006370
   Gong J., 2020, CORRELATION ANAL DIS, DOI [10.1101/2020.02.25.20025643, DOI 10.1101/2020.02.25.20025643]
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang TH, 2019, J CELL MOL MED, V23, P8184, DOI 10.1111/jcmm.14689
   Ju SY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.155
   Kakar SS, 2017, ONCOTARGET, V8, P74494, DOI 10.18632/oncotarget.20170
   Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kim YJ, 2012, MOL CELL BIOCHEM, V359, P33, DOI 10.1007/s11010-011-0997-9
   Kindler E, 2016, CELL HOST MICROBE, V19, P139, DOI 10.1016/j.chom.2016.01.012
   Laquerre S., 2009, AACR NCI EORTC INT C
   Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI [10.1038/nchembio.332, 10.1038/NCHEMBIO.332]
   Liu SS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01843
   Mamoor S., 2020, MAP3K8 COT TPL 2 IS
   Monaco G, 2019, CELL REP, V26, P1627, DOI 10.1016/j.celrep.2019.01.041
   Monteleone G, 2020, LANCET RHEUMATOL, V2, pE255, DOI 10.1016/S2665-9913(20)30092-8
   Nelemans T, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100961
   Newton AH, 2016, SEMIN IMMUNOPATHOL, V38, P471, DOI 10.1007/s00281-016-0558-0
   Othumpangat S, 2016, VIROLOGY, V487, P85, DOI 10.1016/j.virol.2015.10.005
   Perricone C, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102468
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25
   Roscioli E, 2017, J ASTHMA, V54, P116, DOI 10.1080/02770903.2016.1196371
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Santo L, 2010, ONCOGENE, V29, P2325, DOI 10.1038/onc.2009.510
   Scatena C, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0938-3
   Seong RK, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030163
   Shamilov R, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3491269
   Stan SD, 2008, CANCER RES, V68, P7661, DOI 10.1158/0008-5472.CAN-08-1510
   Subbiah V, 2018, J CLIN ONCOL, V36, P7, DOI 10.1200/JCO.2017.73.6785
   Teijaro JR, 2014, P NATL ACAD SCI USA, V111, P3799, DOI 10.1073/pnas.1400593111
   Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112
   Traub S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003520
   Turanli B, 2017, OMICS, V21, P584, DOI 10.1089/omi.2017.0127
   Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298
   Wilson JAC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006155
   Wu MS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/987612
   Xi CL, 2019, BIOCHEM BIOPH RES CO, V513, P589, DOI 10.1016/j.bbrc.2019.04.014
   Zhang L., 2020, PREPRINTS, DOI [10.20944/preprints202003.0307.v1., DOI 10.20944/PREPRINTS202003.0307.V1.]
   Zhang PP, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0268-6
   Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240
   Zhou H, 2010, J BIOL CHEM, V285, P41412, DOI 10.1074/jbc.M110.183574
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 68
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 15
PY 2020
VL 887
AR 173594
DI 10.1016/j.ejphar.2020.173594
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OH6SG
UT WOS:000582725000046
PM 32971089
OA Green Published
DA 2021-01-01
ER

PT J
AU Marcolino, VA
   Pimentel, TC
   Barao, CE
AF Marcolino, Vanessa Aparecida
   Pimentel, Tatiana Colombo
   Barao, Carlos Eduardo
TI What to expect from different drugs used in the treatment of COVID-19: A
   study on applications and in vivo and in vitro results
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Chloroquine; Antivirals; Dexamethasone; Ivermectin; Anticoagulants
ID CONVALESCENT PLASMA; VIRAL-INFECTIONS; CHLOROQUINE; SARS; CORONAVIRUS;
   EFFICACY; INHIBITORS; PNEUMONIA; THERAPY
AB The end of 2019 was marked by the emergence of a new type of coronavirus (SARS-CoV-2), which has killed more than 240,000 people around the world so far. Several clinical studies are being performed to test possible drugs in response to the COVID-19 outbreak; however, there is still no treatment that is completely effective. Our goal in this paper is to bring together the results of main studies carried out with different drugs in order to help spread the knowledge about possible treatments for COVID-19 that have been suggested so far.
C1 [Marcolino, Vanessa Aparecida; Pimentel, Tatiana Colombo; Barao, Carlos Eduardo] Inst Fed Parana IFPR, Campus Paranavai, BR-87703536 Paranavai, Parana, Brazil.
RP Barao, CE (corresponding author), Inst Fed Parana IFPR, Campus Paranavai, BR-87703536 Paranavai, Parana, Brazil.
EM carlos.barao@ifpr.edu.br
RI Barao, Carlos Eduardo/A-9968-2016; Pimentel, Tatiana Colombo/G-5025-2012
OI Barao, Carlos Eduardo/0000-0003-3343-0835; Pimentel, Tatiana
   Colombo/0000-0003-4600-8932
CR Accapezzato D, 2005, J EXP MED, V202, P817, DOI 10.1084/jem.20051106
   Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Ben-Nathan D, 2003, J INFECT DIS, V188, P5, DOI 10.1086/376870
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Caly L, 2012, ANTIVIR RES, V95, P202, DOI 10.1016/j.antiviral.2012.06.008
   Cao B., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2001282.NEJMoa2001282, DOI 10.1056/NEJMOA2001282.NEJMOA2001282]
   Chandwani Ashish, 2008, Ther Clin Risk Manag, V4, P1023
   Chen C., 2020, FAVIPIRAVIR VERSUS A, V17, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432,03.]
   Chen H., 2020, 1 CLIN STUDY USING H, DOI [10.1101/2020.03.22.20034041, DOI 10.1101/2020.03.22.20034041]
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   ClinicalTrials.gov, 2020, CAM MES COVID 19 OUT
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Fragkou PC, 2020, CLIN MICROBIOL INFEC, V26, P988, DOI 10.1016/j.cmi.2020.05.019
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jans DA, 2019, CURR OPIN CELL BIOL, V58, P50, DOI 10.1016/j.ceb.2019.01.001
   Karalis V, 2020, SAFETY SCI, V129, DOI 10.1016/j.ssci.2020.104842
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Kraft CS, 2015, CLIN INFECT DIS, V61, P496, DOI 10.1093/cid/civ334
   Kwon S, 2009, J MOL STRUCT, V938, P192, DOI 10.1016/j.molstruc.2009.09.025
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Lv CJ, 2018, ANTIVIR RES, V159, P55, DOI 10.1016/j.antiviral.2018.09.010
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Modrow S., 2013, MOL VIROLOGY, V185-349
   Momekov G., 2020, IVERMECTIN POTENTIAL, DOI [10.1101/2020.04.11.20061804., DOI 10.1101/2020.04.11.20061804]
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   RIBEIRO FA, 2001, REV BRAS OTORRINOLAR, V67, P755, DOI DOI 10.1590/S0034-72992001000600002
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Sai JK, 2010, J GASTROENTEROL, V45, P335, DOI 10.1007/s00535-009-0148-1
   Salvi R, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110267
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Savarino A, 2001, J CLIN VIROL, V20, P131, DOI 10.1016/S1386-6532(00)00139-6
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sisay M, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104779
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Su B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01472
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wei L, 2019, J CLIN TRANSL HEPATO, V7, P221, DOI 10.14218/JCTH.2019.00018
   WHO, 2020, TARG UPD SAF EFF HYD
   World Health Organization, 2020, 105 WHO
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 60
TC 1
Z9 1
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 15
PY 2020
VL 887
AR 173467
DI 10.1016/j.ejphar.2020.173467
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OH6SG
UT WOS:000582725000012
PM 32777212
OA Green Published
DA 2021-01-01
ER

PT J
AU Monji, F
   Siddiquee, AA
   Hashemian, F
AF Monji, Faezeh
   Siddiquee, Abrar Al-Mahmood
   Hashemian, Farshad
TI Can pentoxifylline and similar xanthine derivatives find a niche in
   COVID-19 therapeutic strategies? A ray of hope in the midst of the
   pandemic
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; Methylxanthines; Pentoxifylline and caffeine
ID CAFFEINE-POTENTIATED CHEMOTHERAPY; RESPIRATORY SYNDROME CORONAVIRUS;
   IMMUNODEFICIENCY-VIRUS TYPE-1; INDUCED LUNG INJURY; ALVEOLAR
   MACROPHAGES; NLRP3 INFLAMMASOME; OXIDATIVE STRESS; DOUBLE-BLIND;
   HEPATITIS-C; IN-VIVO
AB COVID-19 pandemic presents an unprecedented challenge to identify effective drugs for treatment. Despite multiple clinical trials using different agents, there is still a lack of specific treatment for COVID-19. Having the potential role in suppressing inflammation, immune modulation, antiviral and improving respiratory symptoms, this review discusses the potential role of methylxanthine drugs like pentoxifylline and caffeine in the management of COVID-19 patients. COVID-19 pathogenesis for clinical features like severe pneumonia, acute lung injury (ALI) / acute respiratory distress syndrome (ARDS), and multi-organ failures are excessive inflammation, oxidation, and cytokine storm by the exaggerated immune response. Drugs like pentoxifylline have already shown improvement of the symptoms of ARDS and caffeine has been in clinical use for decades to treat apnea of prematurity (AOP) in preterm infants and improve respiratory function. Pentoxifylline is well-known anti-inflammatory and anti-oxidative molecules that have already shown to suppress Tumor Necrosis Factor (TNF-alpha) as well as other inflammatory cytokines in pulmonary diseases, and this may be beneficial for better clinical outcomes in COVID-19 patients. Pentoxifylline enhances blood flow, improves microcirculation and tissue oxygenation, and caffeine also efficiently improves tissue oxygenation, asthma, decreases pulmonary hypertension and an effective analgesic. There are significant shreds of evidence that proved the properties of pentoxifylline and caffeine against virus-related diseases as well. Along with the aforementioned evidences and high safety profiles, both pentoxifylline and caffeine offer a glimpse of considerations for future use as a potential adjuvant to COVID-19 treatment. However, additional clinical studies are required to confirm this speculation.
C1 [Monji, Faezeh; Hashemian, Farshad] Islamic Azad Univ, Fac Pharm, Dept Clin Pharm, Tehran, Iran.
   [Siddiquee, Abrar Al-Mahmood] Agcy Sci, Inst Mol & Cell Biol IMCB, Singapore, Singapore.
RP Hashemian, F (corresponding author), Islamic Azad Univ, Fac Pharm, Dept Clin Pharm, Tehran Med Sci, 99 Yakhchal St,Shariati Ave, Tehran 1941933111, Iran.
EM Faezeh.monji@u.nus.edu; abrarams@imcb.a-star.edu.sg;
   Hashemian.f@iaups.ac.ir
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   ALI S, 1992, AGENTS ACTIONS, V37, P165, DOI 10.1007/BF02028098
   Almario B, 2012, PEDIATR RES, V71, P583, DOI 10.1038/pr.2012.14
   AMVROSIEVA TV, 1993, VOP VIRUSOL+, V38, P230
   Jimenez-Luevano MA, 2013, ANN HEPATOL, V12, P248, DOI 10.1016/S1665-2681(19)31363-8
   Barnes PJ, 2013, AM J RESP CRIT CARE, V188, P901, DOI 10.1164/rccm.201302-0388PP
   Batista MN, 2015, ARCH VIROL, V160, P399, DOI 10.1007/s00705-014-2302-1
   Bauer TT, 2006, CLIN INFECT DIS, V43, P748, DOI 10.1086/506430
   Bech BH, 2007, BMJ-BRIT MED J, V334, P409, DOI 10.1136/bmj.39062.520648.BE
   BECKER AB, 1984, NEW ENGL J MED, V310, P743, DOI 10.1056/NEJM198403223101202
   Bishop NC, 2005, EUR J APPL PHYSIOL, V93, P606, DOI 10.1007/s00421-004-1271-6
   Bohn SK, 2012, FOOD FUNCT, V3, P575, DOI 10.1039/c2fo10288a
   Brie D, 2016, J HYPERTENS, V34, P2318, DOI 10.1097/HJH.0000000000001086
   Browne ML, 2011, BIRTH DEFECTS RES A, V91, P93, DOI 10.1002/bdra.20752
   BRUCE M, 1992, ARCH GEN PSYCHIAT, V49, P867
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen L, 2012, BIRTH DEFECTS RES A, V94, P1033, DOI 10.1002/bdra.23050
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Childs E, 2008, EXP CLIN PSYCHOPHARM, V16, P13, DOI 10.1037/1064-1297.16.1.13
   Clark RH, 2006, PEDIATRICS, V117, P1979, DOI 10.1542/peds.2005-1707
   Clerici M, 1997, J INFECT DIS, V175, P1210, DOI 10.1086/593570
   Coccheri S, 2016, PHLEBOLOGY, V31, P366, DOI 10.1177/0268355515619562
   Cohen J, 2020, SCIENCE, V367, P234, DOI 10.1126/science.367.6475.234
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Corbel M, 2000, BRAZ J MED BIOL RES, V33, P749, DOI 10.1590/S0100-879X2000000700004
   Dahl J, 2005, J VIROL, V79, P13007, DOI 10.1128/JVI.79.20.13007-13017.2005
   Daniel R, 2005, J VIROL, V79, P2058, DOI 10.1128/JVI.79.4.2058-2065.2005
   Dekker J, 2017, PEDIATR RES, V82, P290, DOI 10.1038/pr.2017.45
   Deree J, 2007, J SURG RES, V143, P99, DOI 10.1016/j.jss.2007.03.083
   DETTELBACH HR, 1985, J CLIN PHARMACOL, V25, P8, DOI 10.1002/j.1552-4604.1985.tb02796.x
   Dobson NR, 2014, J PEDIATR-US, V164, P992, DOI 10.1016/j.jpeds.2013.12.025
   Doyen D, 2020, LANCET, V395, P1516, DOI 10.1016/S0140-6736(20)30912-0
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Duley L, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001449.pub3, 10.1002/14651858.CD001449.pub2]
   Dulson DK, 2016, APPL PHYSIOL NUTR ME, V41, P224, DOI 10.1139/apnm-2015-0456
   Evered J., 2018, BMJ CASE REP, P1, DOI [10.1136/bcr-2017-223102bcr-2017., DOI 10.1136/BCR-2017-223102BCR-2017]
   FAZELY F, 1991, BLOOD, V77, P1653
   Fernandes JL, 2008, ATHEROSCLEROSIS, V196, P434, DOI 10.1016/j.atherosclerosis.2006.11.032
   Fleming CM, 2001, J IMMUNOL, V167, P1703, DOI 10.4049/jimmunol.167.3.1703
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gonzalez-Amaro R, 1998, J IMMUNOL, V161, P65
   Gonzalez-Espinoza L, 2012, NEPHROL DIAL TRANSPL, V27, P2023, DOI 10.1093/ndt/gfr579
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Group C.S., 2008, BMJ, V337
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Gupta M, 1999, J IMMUNOL, V162, P689
   HAAS F, 1990, CHEST, V97, P621, DOI 10.1378/chest.97.3.621
   Hanania AN, 2019, CHEST, V156, P150, DOI 10.1016/j.chest.2019.03.033
   Harris S., 2017, HLTH SCI INT C HSIC
   Hayashi M, 2005, ANTICANCER RES, V25, P2399
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Horrigan LA, 2004, INT IMMUNOPHARMACOL, V4, P1409, DOI 10.1016/j.intimp.2004.06.005
   Horrigan LA, 2006, PHARMACOL THERAPEUT, V111, P877, DOI 10.1016/j.pharmthera.2006.02.002
   Hoyt AT, 2014, MATERN CHILD HLTH J, V18, P1540, DOI 10.1007/s10995-013-1397-4
   HSU CY, 1988, STROKE, V19, P716, DOI 10.1161/01.STR.19.6.716
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Jaruvongvanich V, 2017, CLIN RES HEPATOL GAS, V41, P46, DOI 10.1016/j.clinre.2016.05.012
   Jilani T.N., 2019, THEOPHYLLINE
   Jobe AH, 2017, AM J RESP CRIT CARE, V196, P1241, DOI 10.1164/rccm.201707-1402ED
   Joob B, 2020, J AM ACAD DERMATOL, V82, pE177, DOI 10.1016/j.jaad.2020.03.036
   Josset L, 2013, MBIO, V4, DOI 10.1128/mBio.00165-13
   Journey J.D., 2018, THEOPHYLLINE TOXICIT
   KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765
   Kempf K, 2015, EUR J NUTR, V54, P845, DOI 10.1007/s00394-014-0763-3
   Kempf K, 2010, AM J CLIN NUTR, V91, P950, DOI 10.3945/ajcn.2009.28548
   Kimura H, 2009, J ORTHOP SCI, V14, P556, DOI 10.1007/s00776-009-1372-5
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   LAM A, 1990, CHEST, V98, P44, DOI 10.1378/chest.98.1.44
   Lamkanfi M, 2012, ANNU REV CELL DEV BI, V28, P137, DOI 10.1146/annurev-cellbio-101011-155745
   Lara DR, 2010, J ALZHEIMERS DIS, V20, pS239, DOI 10.3233/JAD-2010-1378
   Li HL, 2016, AM J TRANSL RES, V8, P2210
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   LILLY CM, 1989, AM REV RESPIR DIS, V139, P1361, DOI 10.1164/ajrccm/139.6.1361
   Lipton RB, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0806-2
   Magnusson M, 2009, EUR J CANCER, V45, P2488, DOI 10.1016/j.ejca.2009.05.015
   MANZINI S, 1993, EUR J PHARMACOL, V249, P251, DOI 10.1016/0014-2999(93)90519-N
   Martin J.F.B., 2003, MED SCI MON INT MED, V9, pSR29
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   McCarty MF, 2016, OPEN HEART, V3, DOI 10.1136/openhrt-2015-000365
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mensah-Brown EPK, 2002, MOL IMMUNOL, V38, P941, DOI 10.1016/S0161-5890(02)00021-4
   Misirlioglu CH, 2007, MED ONCOL, V24, P308, DOI 10.1007/s12032-007-0006-z
   MONTRAVERS P, 1993, CHEST, V103, P1017, DOI 10.1378/chest.103.4.1017
   Moschino L, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00330-2019
   Murayama M, 2008, MOL MED REP, V1, P251
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Nawrot P, 2003, FOOD ADDIT CONTAM A, V20, P1, DOI 10.1080/0265203021000007840
   Okuno T, 2002, JPN J OPHTHALMOL, V46, P170, DOI 10.1016/S0021-5155(01)00498-1
   OLSON NJ, 1979, AM J VET RES, V40, P387
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pal R, 2016, INFLAMMOPHARMACOLOGY, V24, P221, DOI 10.1007/s10787-016-0281-4
   Park MK, 2009, SARCOIDOSIS VASC DIF, V26, P121
   PAUWELS R, 1987, CHEST, V92, pS32, DOI 10.1378/chest.92.1.32S
   Poulakis N, 1999, RESP MED, V93, P52, DOI 10.1016/S0954-6111(99)90077-X
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Rogers MC, 2018, ANNU REV VIROL, V5, P363, DOI 10.1146/annurev-virology-092917-043515
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sarma JV, 2011, COMPR PHYSIOL, V1, P1365, DOI 10.1002/cphy.c100068
   Sayed R, 2019, MED ONCOL, V37, DOI 10.1007/s12032-019-1334-5
   Sebastian L, 2009, INT J ANTIMICROB AG, V33, P168, DOI 10.1016/j.ijantimicag.2008.07.013
   Sharp C, 2015, RESPIRATION, V89, P420, DOI 10.1159/000381102
   Shaw SM, 2009, EUR J HEART FAIL, V11, P113, DOI 10.1093/eurjhf/hfn040
   Shen C., 2020, FRONT PHARMACOL
   SHIRAKI K, 1988, INTERVIROLOGY, V29, P235
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Steck RP, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.180
   SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9
   Sunil VR, 2014, EXP MOL PATHOL, V97, P89, DOI 10.1016/j.yexmp.2014.05.009
   Suresh R, 2002, J IMMUNOL, V169, P4262, DOI 10.4049/jimmunol.169.8.4262
   Talik P, 2012, SEP PURIF REV, V41, P1, DOI 10.1080/15422119.2011.569047
   Tate MD, 2016, SCI REP-UK, V6, DOI 10.1038/srep27912
   Tauler P, 2013, MED SCI SPORT EXER, V45, P1269, DOI 10.1249/MSS.0b013e3182857c8a
   Thebaud B, 2007, AM J RESP CRIT CARE, V175, P978, DOI 10.1164/rccm.200611-1660PP
   Tilley Stephen L, 2011, Handb Exp Pharmacol, P439, DOI 10.1007/978-3-642-13443-2_17
   Tong ZH, 2003, CHEST, V124, P1526, DOI 10.1378/chest.124.4.1526
   Torii K, 1997, AM J RESP CRIT CARE, V155, P43, DOI 10.1164/ajrccm.155.1.9001287
   Tynell J, 2016, J GEN VIROL, V97, P344, DOI 10.1099/jgv.0.000351
   Utsunomiya H, 2014, INT J MOL MED, V34, P1020, DOI 10.3892/ijmm.2014.1859
   van Koert RR, 2018, EPILEPSY BEHAV, V80, P37, DOI 10.1016/j.yebeh.2017.11.003
   Vyas-Read S, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0910-0
   Wallis RS, 1996, J INFECT DIS, V174, P727, DOI 10.1093/infdis/174.4.727
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wedick NM, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-93
   Welsh EJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001112.pub2
   Wen WX, 2017, ADV THER, V34, P1245, DOI 10.1007/s12325-017-0547-2
   Weng XP, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.10.803
   Whitfield K, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007339.pub2
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu JB, 2013, J IMMUNOL, V190, P3590, DOI 10.4049/jimmunol.1200860
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   YAMAZAKI Z, 1980, J GEN VIROL, V50, P429, DOI 10.1099/0022-1317-50-2-429
   Yang CY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020588
   Yang RZ, 2006, PLOS MED, V3, P884, DOI 10.1371/journal.pmed.0030287
   Ye MX, 2020, BRAIN BEHAV IMMUN, V88, P945, DOI 10.1016/j.bbi.2020.04.017
   Zhao WM, 2019, INT J BIOL SCI, V15, P1571, DOI 10.7150/ijbs.34211
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zito PM, 2018, J DERMAT NURSES ASSO, V10, P294, DOI 10.1097/JDN.0000000000000437
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 152
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 15
PY 2020
VL 887
AR 173561
DI 10.1016/j.ejphar.2020.173561
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OH6SG
UT WOS:000582725000028
PM 32946870
OA Green Published
DA 2021-01-01
ER

PT J
AU Sahebnasagh, A
   Saghafi, F
   Avan, R
   Khoshi, A
   Khataminia, M
   Safdari, M
   Habtemariam, S
   Ghaleno, HR
   Nabavi, SM
AF Sahebnasagh, Adeleh
   Saghafi, Fatemeh
   Avan, Razieh
   Khoshi, Amirhosein
   Khataminia, Masoud
   Safdari, Mohammadreza
   Habtemariam, Solomon
   Ghaleno, Hassan Rezai
   Nabavi, Seyed Mohammad
TI The prophylaxis and treatment potential of supplements for COVID-19
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; Coronavirus; Supplements; Vitamins; Adjuvant therapy
ID ENDOTHELIAL GROWTH-FACTOR; DISTRESS-SYNDROME ARDS; N-ACETYLCYSTEINE;
   VITAMIN-C; SUPEROXIDE-DISMUTASE; ADJUVANT THERAPY; SEPTIC SHOCK;
   MELATONIN; CORONAVIRUS; ZINC
AB The global impact of the new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infection that caused COVID-19 has been evident in the last few months from the unprecedented socioeconomic disruption to more than 600,000 deaths. The lack of vaccine and effective therapeutic agents for the disease prompted world-wide effort to test those antiviral therapeutics already in use for other diseases. Another interesting approach has been based on the pathological sequel of the disease that involve severe inflammatory reaction (or the cytokine storm) associated with pneumonia in critically ill patients. This article outlines the prophylaxis therapeutic potential of supplements vitamins and micronutrients in COVID-19. By ameliorating the inflammatory and oxidative stress associated with the disease and some direct antiviral effects, the application of these agents as adjuvants and other alternative approaches are discussed. Available clinical trials including those currently registered on these supplements are scrutinized.
C1 [Sahebnasagh, Adeleh] North Khorasan Univ Med Sci, Clin Res Ctr, Dept Internal Med, Bojnurd, Iran.
   [Saghafi, Fatemeh] Shahid Sadoughi Univ Med Sci, Fac Pharm, Dept Clin Pharm, Yazd, Iran.
   [Saghafi, Fatemeh] Shahid Sadoughi Univ Med Sci, Pharmaceut Sci Res Ctr, Yazd, Iran.
   [Avan, Razieh] Birjand Univ Med Sci, Dept Clin Pharm, Med Toxicol & Drug Abuse Res Ctr MTDRC, Fac Pharm, Birjand, Iran.
   [Khoshi, Amirhosein] North Khorasan Univ Med Sci, Dept Clin Biochem, Sch Med, Bojnurd, Iran.
   [Khataminia, Masoud] Univ Tehran Med Sci, Student Res Comm, Fac Pharm, Tehran, Iran.
   [Safdari, Mohammadreza] North Khorasan Univ Med Sci, Dept Orthoped Surg, Fac Med, Bojnurd, Iran.
   [Habtemariam, Solomon] Univ Greenwich, Pharmacognosy Res Labs, Cent Ave, Chatham ME4 4TB, Kent, England.
   [Habtemariam, Solomon] Univ Greenwich, Herbal Anal Serv UK, Cent Ave, Chatham ME4 4TB, Kent, England.
   [Ghaleno, Hassan Rezai] Lorestan Univ Med Sci, Dept Surg, Fac Med, Khorramabad, Iran.
   [Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran, Iran.
   [Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Div Translat Med, Baqiyatallah Hosp, POB 19945-546, Tehran, Iran.
RP Sahebnasagh, A (corresponding author), North Khorasan Univ Med Sci, Clin Res Ctr, Dept Internal Med, Bojnurd, Iran.; Nabavi, SM (corresponding author), Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran, Iran.; Nabavi, SM (corresponding author), Baqiyatallah Univ Med Sci, Div Translat Med, Baqiyatallah Hosp, POB 19945-546, Tehran, Iran.
EM masoomehsahebnasagh@gmail.com; saghafi.fa@gmail.com; avanr91@gmail.com;
   ahkh83@gmail.com; masoodkhataminia@yahoo.com; safdari57@yahoo.com;
   s.habtemariam@herbalanalysis.co.uk; Hassan_Rezai2020@yahoo.com;
   Nabavi208@gmail.com
OI Khoshi, Amirhosein/0000-0001-9520-1857
CR Adikwu E., 2019, J NEPHROPHARMACOL, V9
   Alan Rossetti C., 2020, ARS PHARM, V61, P145
   Alemdar E., 2020, CHRONOBIOLOGICAL TRE, DOI [10.13140/ RG.2.2.32942.46402, DOI 10.13140/RG.2.2.32942.46402.]
   Alipio M., 2020, DO LATITUDE OZONE CO, DOI [10.1101/2020.04.09.20060202, DOI 10.1101/2020.04.09.20060202]
   Alipio M., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3571484, DOI 10.2139/SSRN.3571484]
   Alvarez-Garcia V, 2013, J PINEAL RES, V54, P373, DOI 10.1111/jpi.12007
   Alvarez-Garcia V, 2013, MICROVASC RES, V87, P25, DOI 10.1016/j.mvr.2013.02.008
   Amini K., 2020, CRIT COMMENTS BIOMED
   Anderson G, 2019, MELATONIN RES, V2, P1, DOI [10.32794/mr11250037, DOI 10.32794/MR1125]
   Anderson G, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2109
   Bafaro E, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.29
   Banerjee S., 2020, EVALUATE SAFETY EFFI
   Barazzoni R, 2020, CLIN NUTR, V39, P1631, DOI 10.1016/j.clnu.2020.03.022
   BASE Medicine Task Force, 2020, SCI INSIGT, V33, P138
   Beck MA, 2001, FASEB J, V15, P1481, DOI 10.1096/fj.00-0721fje
   Cabrera-Ben -tez N.E., 2016, CRIT CARE MED, V40, P510
   Caccialanza R, 2020, NUTRITION, V74, DOI 10.1016/j.nut.2020.110835
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Carbajo-Pescador S, 2013, BRIT J CANCER, V109, P83, DOI 10.1038/bjc.2013.285
   Carr A.C., 2020, CRIT CARE, V24, P1, DOI DOI 10.1186/s13054-019-2683-3
   Celleno L, 2018, DERMATOL THER, V31, DOI 10.1111/dth.12690
   Chasapis CT, 2012, ARCH TOXICOL, V86, P521, DOI 10.1007/s00204-011-0775-1
   Cheng Y, 2020, COGN RES, V5, DOI 10.1186/s41235-020-00230-9
   Chilvers MA, 2001, EUR RESPIR J, V18, P965, DOI 10.1183/09031936.01.00093001
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cookson BT, 2001, TRENDS MICROBIOL, V9, P113, DOI 10.1016/S0966-842X(00)01936-3
   Costa C, 2019, INT J ONLINE PEDAGOG, V9, P1, DOI 10.4018/IJOPCD.2019040101
   Dabbagh-Bazarbachi H, 2014, J AGR FOOD CHEM, V62, P8085, DOI 10.1021/jf5014633
   DeFlora S, 1997, EUR RESPIR J, V10, P1535, DOI 10.1183/09031936.97.10071535
   Douedi Steven, 2020, Cureus, V12, pe7714, DOI 10.7759/cureus.7714
   Downing D., 2020, ORTHOMOLECULAR MED N
   Elfiky A.A., 2020, LIFE SCI
   Emerit I, 2004, PHOTOCHEM PHOTOBIOL, V80, P579, DOI 10.1562/0031-8655(2004)080<0579:PEOSDA>2.0.CO;2
   Erol A, 2020, HIGH DOSE INTRAVENOU, DOI [10.31219/osf.io/p7ex8, DOI 10.31219/OSF.IO/P7EX8]
   Monge MFE, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010150
   Fabbri A, 2020, EUR REV MED PHARMACO, V24, P4038
   Fairweather-Tait SJ, 2011, ANTIOXID REDOX SIGN, V14, P1337, DOI 10.1089/ars.2010.3275
   Forceville X, 2007, J TRACE ELEM MED BIO, V21, P62, DOI 10.1016/j.jtemb.2007.09.021
   Fowler AA, 2019, JAMA-J AM MED ASSOC, V322, P1261, DOI 10.1001/jama.2019.11825
   Gasmi A, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108409
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Ghavideldarestani M., 2020, ROLE VITAMIN D PATHO, DOI [10.20944/preprints202004.0355.v1, DOI 10.20944/PREPRINTS202004.0355.V1]
   Ghezzi P, 2004, INT J IMMUNOPATH PH, V17, P99, DOI 10.1177/039463200401700114
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Grant WB, 2009, DERM-ENDOCRINOL, V1, P215, DOI 10.4161/derm.1.4.9063
   Guastalegname M., 2020, CLIN INFEC DIS
   Haldar C, 2006, COMP BIOCHEM PHYS A, V144, P395, DOI 10.1016/j.cbpa.2006.02.041
   Hamidi Alamdari D., 2020, ARCH BONE JOINT SURG
   Han Z., 2007, CHINA PHARM, V10
   Heideman PD, 1996, J PINEAL RES, V20, P90
   Hemila H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040708
   Hernandez A, 2020, REV ESP ANEST REANIM, V67, P245, DOI 10.1016/j.redar.2020.03.004
   Hiffler L, 2020, FRONT NUTR, V7, DOI 10.3389/fnut.2020.00164
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann PR, 2008, MOL NUTR FOOD RES, V52, P1273, DOI 10.1002/mnfr.200700330
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Iranian Clinical Trial Register, 2020, IRANIAN CLIN TRIAL R
   Ishida T., 2019, AM J BIOMED SCI RES, V2, DOI [10.34297/AJBSR.2019.02.000566, DOI 10.34297/AJBSR.2019.02.000566.AJBSR.MS.ID.000566]
   Jamaati H, 2020, IRAN J PHARM RES, V19, P31, DOI 10.22037/ijpr.2020.113337.14239
   Kashiouris MG, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020292
   Khomich O.A., VIRUSES, V10, P392
   Kim WY, 2018, J CRIT CARE, V47, P211, DOI 10.1016/j.jcrc.2018.07.004
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Kouhpayeh S., 2020, MOL STORY COVID 19 N, DOI [10.20944/preprints202003.0346.v1, DOI 10.20944/PREPRINTS202003.0346.V1]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   LAW ML, 1986, P NATL ACAD SCI USA, V83, P6920, DOI 10.1073/pnas.83.18.6920
   Li AY, 2020, MULTIVARIATE ANAL FA
   Li H, 2020, LANCET
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lin FC, 2014, CYTOKINE GROWTH F R, V25, P369, DOI 10.1016/j.cytogfr.2014.07.015
   Lin Jincan, 2018, OPEN J INTERNAL MED, V08, P146, DOI [10.4236/ojim.2018.82015, DOI 10.4236/OJIM.2018.82015]
   Lin L., EMERG MICROB INFECT, P1
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Lionetti V, 2005, CURR OPIN CRIT CARE, V11, P82, DOI 10.1097/00075198-200502000-00013
   Luo W., 2020, PATHOLOGY PATHOBIOLO
   Malhotra S., 2004, MEDSC GEN MED, V6
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   Marik PE, 2017, CHEST, V151, P1229, DOI 10.1016/j.chest.2016.11.036
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   Maywald M., 2019, ZN SIGNALING, P243
   Medford ARL, 2006, THORAX, V61, P621, DOI 10.1136/thx.2005.040204
   MEDICI TC, 1979, J INT MED RES, V7, P434, DOI 10.1177/030006057900700518
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Michaelides M, 2011, ARCH OPHTHALMOL-CHIC, V129, P30, DOI 10.1001/archophthalmol.2010.321
   Millea PJ, 2009, AM FAM PHYSICIAN, V80, P265
   Mirza-Aghazadeh-Attari M, 2020, IUBMB LIFE, V72, P1560, DOI 10.1002/iub.2287
   Molina-Lopez J, 2016, INT J ELECTROCHEM SC, V11, P4470, DOI 10.20964/2016.06.38
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Myers S, 2017, CURR PHARM DESIGN, V23, P2328, DOI 10.2174/1381612823666170124115850
   Nagamine T, 2000, BIOL TRACE ELEM RES, V75, P53, DOI 10.1385/BTER:75:1-3:53
   Nnolim U., 2020, COMBINATION BASED AP, DOI 10.20944/preprints202003.0435.v1
   NORDLUND JJ, 1977, J CLIN ENDOCR METAB, V45, P768, DOI 10.1210/jcem-45-4-768
   Panarese A, 2020, ALIMENT PHARM THER, V51, P993, DOI 10.1111/apt.15752
   Panesar NS, 2003, LANCET, V361, P1985, DOI 10.1016/S0140-6736(03)13557-X
   PAPAVASILIOU PS, 1972, J AMER MED ASSOC, V221, P88, DOI 10.1001/jama.221.1.88
   Park SY, 2004, BIOL TRACE ELEM RES, V101, P147, DOI 10.1385/BTER:101:2:147
   Pascual A.S., 2012, MED INT REV INT MED, P55
   Peng K, 2020, OSTEOPOROSIS INT, V31, P1545, DOI 10.1007/s00198-020-05393-1
   Phillips JM, 2017, J VIROL, V91, DOI 10.1128/JVI.01564-16
   Pontes GN, 2007, J PINEAL RES, V43, P365, DOI 10.1111/j.1600-079X.2007.00487.x
   Puig-Domingo M, 2020, ENDOCRINE, V68, P2, DOI 10.1007/s12020-020-02294-5
   Qin YY, 2020, CHINESE MED J-PEKING, V133, P1080, DOI 10.1097/CM9.0000000000000791
   Ramanathan L, 2002, NEUROREPORT, V13, P1387, DOI 10.1097/00001756-200208070-00007
   Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1
   Reiter RJ, 2000, NEWS PHYSIOL SCI, V15, P246
   Reiter RJ, 1997, AGE, V20, P201, DOI 10.1007/s11357-997-0020-2
   REITER RJ, 1995, J PINEAL RES, V18, P1, DOI 10.1111/j.1600-079X.1995.tb00133.x
   REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749-6632.1994.tb56817.x
   REITER RJ, 2019, MELATONIN RES, V2, P105, DOI DOI 10.32794/MR11250033
   Reiter RJ, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00226
   Ren L.-L., 2020, CHINESE MED J
   REPPERT SM, 1979, PEDIATR RES, V13, P362
   Rhodes JM, 2020, ALIMENT PHARM THER
   Romero MP, 1998, FASEB J, V12, P1401
   Roscioli E, 2017, AM J PHYSIOL-LUNG C, V313, pL453, DOI 10.1152/ajplung.00083.2017
   Sanders J.M., 2019, JAMA-J AM MED ASSOC, V323, P1824, DOI DOI 10.1001/jama.2020.6019
   Scheer FAJL, 2004, HYPERTENSION, V43, P192, DOI 10.1161/01.HYP.0000113293.15186.3b
   Shi C.-S., CELL DEATH DISCOV, V5, P1
   Shneider MN, 2020, IOP SER PL PHYS, P1, DOI 10.1088/978-0-7503-2372-7
   Skalnuj A., 2003, BIOELEMENTS MED, P272
   Steinbrenner H, 2015, ADV NUTR, V6, P73, DOI 10.3945/an.114.007575
   Szakmany T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006616.pub2
   Takagi H, 2001, J VIRAL HEPATITIS, V8, P367, DOI 10.1046/j.1365-2893.2001.00311.x
   Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x
   Teskey G, 2018, ADV CLIN CHEM, V87, P141, DOI 10.1016/bs.acc.2018.07.004
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   Tian Y, 2020, ALIMENT PHARM THER, V51, P995, DOI 10.1111/apt.15764
   Van Hecke O., 2020, N ACETYLCYSTEINE RAP
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang H, 2020, Int J Nurs Sci, V7, P128, DOI 10.1016/j.ijnss.2020.03.010
   Wang LF, 2006, EMERG INFECT DIS, V12, P1834
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wessels I, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121286
   Wimalawansa S.J., 2020, EUR J BIOMED PHARM S, V7, P432
   Wong ACP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020174
   Xu Z, 2020, LANCET RESP MED
   Xue J., 2014, PLOS ONE, V9
   Yasuda H., 2017, BIOMED RES TRACE ELE, V27, P125
   Zahid A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02538
   Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046
   Zhang JS, 2020, AM J CLIN NUTR, V111, P1297, DOI 10.1093/ajcn/nqaa095
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang TQ, 2020, J MED VIROL, V92, P909, DOI 10.1002/jmv.25795
   Zisapel N, 2018, BRIT J PHARMACOL, V175, P3190, DOI 10.1111/bph.14116
NR 146
TC 1
Z9 1
U1 9
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 15
PY 2020
VL 887
AR 173530
DI 10.1016/j.ejphar.2020.173530
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OH6SG
UT WOS:000582725000018
PM 32882216
OA Green Published
DA 2021-01-01
ER

PT J
AU Liu, P
   Liu, HB
   Sun, Q
   Liang, H
   Li, CM
   Deng, XB
   Liu, Y
   Lai, LH
AF Liu, Pei
   Liu, Hongbo
   Sun, Qi
   Liang, Hao
   Li, Chunmei
   Deng, Xiaobing
   Liu, Ying
   Lai, Luhua
TI Potent inhibitors of SARS-CoV-2 3C-like protease derived from
   N-substituted isatin compounds
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE COVID-19; SARS-CoV-2 3C-like protease; N-substituted isatin compounds;
   In vitro assay; Structure-activity relationship
ID SARS; CORONAVIRUS; PROTEINASE
AB SARS-CoV-2 3C like protease is the main protease of SARS-CoV-2 and has been considered as one of the key targets for drug discovery against COVID-19. We identified several N-substituted isatin compounds as potent SARS-CoV-2 3C-like protease inhibitors. The three most potent compounds inhibit SARS-CoV-2 3C-like protease with IC50's of 45 nM, 47 nM and 53 nM, respectively. Our study indicates that N-substituted isatin compounds have the potential to be developed as broad-spectrum anti-coronavirus drugs. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Liu, Pei; Liu, Hongbo; Sun, Qi; Liang, Hao; Deng, Xiaobing; Liu, Ying; Lai, Luhua] Peking Univ, Coll Chem & Mol Engn, BNLMS, State Key Lab Struct Chem Unstable & Stable Speci, Beijing 100871, Peoples R China.
   [Li, Chunmei; Liu, Ying; Lai, Luhua] Peking Univ, Ctr Quantitat Biol, Beijing 100871, Peoples R China.
   [Lai, Luhua] Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China.
RP Liu, Y; Lai, LH (corresponding author), Peking Univ, Coll Chem & Mol Engn, BNLMS, State Key Lab Struct Chem Unstable & Stable Speci, Beijing 100871, Peoples R China.
EM liuying@pku.edu.cn; lhlai@pku.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21633001,21877003]; Ministry of Science and
   Technology of ChinaMinistry of Science and Technology, China
   [2016YFA0502303]
FX This work was supported in part by the National Natural Science
   Foundation of China (21633001,21877003), and the Ministry of Science and
   Technology of China (2016YFA0502303).
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Du QS, 2004, PEPTIDES, V25, P1857, DOI 10.1016/j.peptides.2004.06.018
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Konno H, 2017, BIOORG MED CHEM LETT, V27, P2746, DOI 10.1016/j.bmcl.2017.04.056
   Liu HY, 2020, BRIT J NUTR, V124, P1013, DOI 10.1017/S0007114520002263
   Ohnishi K, 2019, BIOORGAN MED CHEM, V27, P425, DOI 10.1016/j.bmc.2018.12.019
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Sandmeyer T, 1919, HELV CHIM ACTA, V2, P234, DOI 10.1002/hlca.19190020125
   Su H., 2020, BIORXIV, DOI [10.1101/2020.04.13.038687, DOI 10.1101/2020.04.13.038687]
   Yoshizawa S, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2019.115273
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou L, 2006, J MED CHEM, V49, P3440, DOI 10.1021/jm0602357
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 18
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD NOV 15
PY 2020
VL 206
AR 112702
DI 10.1016/j.ejmech.2020.112702
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA OC3ZJ
UT WOS:000579097000022
PM 32798789
OA Green Published
DA 2021-01-01
ER

PT J
AU Chaudhry, F
   Bulka, H
   Rathnam, AS
   Said, OM
   Lin, J
   Lorigan, H
   Bernitsas, E
   Rube, J
   Korzeniewski, SJ
   Memon, AB
   Levy, PD
   Schultz, L
   Javed, A
   Lisak, R
   Cerghet, M
AF Chaudhry, Farhan
   Bulka, Helena
   Rathnam, Anirudha S.
   Said, Omar M.
   Lin, Jia
   Lorigan, Holly
   Bernitsas, Eva
   Rube, Jacob
   Korzeniewski, Steven J.
   Memon, Anza B.
   Levy, Phillip D.
   Schultz, Lonni
   Javed, Adil
   Lisak, Robert
   Cerghet, Mirela
TI COVID-19 in multiple sclerosis patients and risk factors for severe
   infection
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Coronavirus; SARS-CoV-2019; Multiple sclerosis;
   Disease-modifying therapy
AB Multiple sclerosis (MS) patients have been considered a higher-risk population for COVID-19 due to the high prevalence of disability and disease-modifying therapy use; however, there is little data identifying clinical characteristics of MS associated with worse COVID-19 outcomes. Therefore, we conducted a multicenter prospective cohort study looking at the outcomes of 40 MS patients with confirmed COVID-19. Severity of COVID-19 infection was based on hospital course, where a mild course was defined as the patient not requiring hospital admission, moderate severity was defined as the patient requiring hospital admission to the general floor, and most severe was defined as requiring intensive care unit admission and/or death. 19/40(47.5%) had mild courses, 15/40(37.5%) had moderate courses, and 6/40(15%) had severe courses. Patients with moderate and severe courses were significantly older than those with a mild course (57[50-63] years old and 66[58.8-69.5] years old vs 48[40-51.5] years old, P = 0.0121, P = 0.0373). There was differing prevalence of progressive MS phenotype in those with more severe courses (severe:2/6[33.3%]primary-progressing and 0/6[0%]secondary-progressing, moderate:1/14[7.14%] and 5/14[35.7%] vs mild:0/19[0%] and 1/19[5.26%], P = 0.0075, 1 unknown). Significant disability was found in 1/19(5.26%) mild course-patients, but was in 9/15(60%, P = 0.00435) of moderate course-patients and 2/6(33.3%, P = 0.200) of severe course-patients. Disease-modifying therapy prevalence did not differ among courses (mild:17/19[89.5%], moderate:12/15[80%] and severe:3/6[50%], P = 0.123). MS patients with more severe COVID-19 courses tended to be older, were more likely to suffer from progressive phenotype, and had a higher degree of disability. However, disease-modifying therapy use was not different among courses.
C1 [Chaudhry, Farhan; Bulka, Helena; Rathnam, Anirudha S.; Lorigan, Holly; Memon, Anza B.; Schultz, Lonni; Cerghet, Mirela] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA.
   [Chaudhry, Farhan; Said, Omar M.; Lin, Jia; Bernitsas, Eva; Rube, Jacob; Korzeniewski, Steven J.; Memon, Anza B.; Levy, Phillip D.; Lisak, Robert; Cerghet, Mirela] Wayne State Univ, Sch Med, Detroit, MI USA.
   [Lin, Jia; Bernitsas, Eva; Rube, Jacob; Lisak, Robert] Detroit Med Ctr, Dept Neurol, Detroit, MI USA.
   [Javed, Adil] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA.
   [Schultz, Lonni] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI USA.
RP Chaudhry, F (corresponding author), Henry Ford Hosp, Dept Neurol, K11,2799 West Grand Blvd, Detroit, MI 48202 USA.
EM gf9603@wayne.edu
CR [Anonymous], 2020, DETROIT HLTH DEP COV
   [Anonymous], 2020, N AM COVID 19 MS CLI
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Berger JR, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000761
   Bowen JD, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000783
   Braveman PA, 2010, AM J PUBLIC HEALTH, V100, pS186, DOI 10.2105/AJPH.2009.166082
   Ferdinand KC, 2020, J AM COLL CARDIOL, V75, P2746, DOI 10.1016/j.jacc.2020.04.040
   Gholipour T, 2011, NEUROLOGY, V76, P1996, DOI 10.1212/WNL.0b013e31821e559d
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581
   Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560
   McKay KA, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/817238
   Montgomery S, 2013, EUR J NEUROL, V20, P1153, DOI 10.1111/ene.12130
   Novi G, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101430
   Patefield W.M., 1981, APPL STATIST, V30, P91, DOI DOI 10.2307/2346669
   RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Tremlett H, 2006, NEUROLOGY, V66, P172, DOI 10.1212/01.wnl.0000194259.90286.fe
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD NOV 15
PY 2020
VL 418
AR 117147
DI 10.1016/j.jns.2020.117147
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OH9TD
UT WOS:000582930900055
PM 32980780
OA Bronze
DA 2021-01-01
ER

PT J
AU Garnero, M
   Del Sette, M
   Assini, A
   Beronio, A
   Capello, E
   Cabona, C
   Reni, L
   Serrati, C
   Bandini, F
   Granata, A
   Pesce, G
   Mancardi, GL
   Uccelli, A
   Schenone, A
   Benedetti, L
AF Garnero, Martina
   Del Sette, Massimo
   Assini, Andrea
   Beronio, Alessandro
   Capello, Elisabetta
   Cabona, Corrado
   Reni, Lizia
   Serrati, Carlo
   Bandini, Fabio
   Granata, Alfredo
   Pesce, Giampaola
   Mancardi, Giovanni L.
   Uccelli, Antonio
   Schenone, Angelo
   Benedetti, Luana
TI COVID-19-related and not related Guillain-Barre syndromes share the same
   management pitfalls during lock down: The experience of Liguria region
   in Italy
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Guillain-Barre syndrome; AMAN; AIDP; COVID-19; Miller Fisher
ID INFECTION
AB Recently, during the pandemic infection of the novel SARS-CoV-2, some cases of Guillan-Barre Syndrome (GBS) have been reported.
   The aim of this work is to report the natural history of patients with GBS, both COVID and not-COVID related, hospitalized in Liguria region, during lock down period, in order to assess clinical features of both groups and possible managements pitfalls due to pandemic emergency.
   Fifteen GBS patients were admitted to the Hospitals of Liguria, from February 15th to May 3rd 2020, six with SARS-CoV-2 infection and nine without infection.
   In COVID-19 related GBS five patients presented with classical GBS and one with variant. Two patients presented neurologic symptoms during or shortly after the viral syndrome, suggesting the pattern of a para-infectious profile. Multi-organ involvement, delay in the diagnosis, incomplete work up and start of therapy, were registered in 50% of cases with a GBS-Disability scale >= 4 at follow-up evaluation.
   In not-COVID-19 related GBS, main problem was diagnostic delay. In three patients the first neurological observation took place after a mean of 33,6 days. Moreover, five patients went to emergency room after an average of 30 days since the onset of neurological symptoms because of fear of contagion.
   In conclusion, not only SARS-CoV-2 infection can cause GBS, but it can also, due to effects of pandemic on the health organization, affect the outcome of patients with not COVID-19 related GBS.
C1 [Garnero, Martina; Serrati, Carlo] Imperia Hosp, Dept Neurol, St Agata St 57, I-18100 Imperia, Italy.
   [Del Sette, Massimo; Assini, Andrea] Galliera Hosp Genova, Neurol Unit, Genoa, Italy.
   [Beronio, Alessandro] St Andrea Hosp, Dept Neurol, La Spessia, Italy.
   [Capello, Elisabetta; Mancardi, Giovanni L.; Uccelli, Antonio; Schenone, Angelo; Benedetti, Luana] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
   [Capello, Elisabetta; Pesce, Giampaola; Uccelli, Antonio; Schenone, Angelo; Benedetti, Luana] Osped Policlin San Martino, IRCCS, Genoa, Italy.
   [Cabona, Corrado; Reni, Lizia] IRCCS Osped Policlin San Martino, Div Clin Neurophysiol, Genoa, Italy.
   [Bandini, Fabio] S Paolo Hosp, Dept Neurol, Savona, Italy.
   [Granata, Alfredo] Santa Corona Hosp, Dept Neurol, Pietra Ligure, Savona, Italy.
   [Pesce, Giampaola] Univ Genoa, Dept Internal Med, Genoa, Italy.
   [Mancardi, Giovanni L.] IRCCS ICS Maugeri, Pavia, Italy.
RP Garnero, M (corresponding author), Imperia Hosp, Dept Neurol, St Agata St 57, I-18100 Imperia, Italy.
EM martina.garnero@hotmail.it
OI Assini, Andrea/0000-0003-1192-6899
CR ASBURY AK, 1990, ANN NEUROL, V27, pS2, DOI 10.1002/ana.410270703
   Assini A, 2020, NEUROL SCI, V41, P1657, DOI 10.1007/s10072-020-04484-5
   Chevret S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001798.pub3
   Fokke C, 2014, BRAIN, V137, P33, DOI 10.1093/brain/awt285
   Franciotta D, 2018, CLIN CHEM LAB MED, V56, P1921, DOI 10.1515/cclm-2018-0234
   Gutierrez-Ortiz C, 2020, NEUROLOGY, V95, pE601, DOI 10.1212/WNL.0000000000009619
   Hadden RDM, 1998, ANN NEUROL, V44, P780, DOI 10.1002/ana.410440512
   JUGUREANU A, 2014, COCHRANE DB SYST REV, V19, DOI DOI 10.5153/SRO.3240
   Kim JE, 2017, J CLIN NEUROL, V13, P227, DOI 10.3988/jcn.2017.13.3.227
   KLEYWEG RP, 1991, MUSCLE NERVE, V14, P1103, DOI 10.1002/mus.880141111
   Lawn ND, 1999, NEUROLOGY, V52, P635, DOI 10.1212/WNL.52.3.635
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Pieter A., 2013, MED DIAGNOSIS, V42, pe193, DOI 10.1016.
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P2368, DOI 10.1056/NEJMms2009984
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sedaghat Z., 2020, CLIN NEUROSCI, V15, DOI 10.1016)
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Tsai Li-Kai, 2005, Acta Neurol Taiwan, V14, P113
   Uncini A, 2010, J NEUROL NEUROSUR PS, V81, P1157, DOI 10.1136/jnnp.2010.208538
   van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121
   Virani A, 2020, IDCases, V20, DOI 10.1016/j.idcr.2020.e00771
   Wakerley BR, 2014, NAT REV NEUROL, V10, P537, DOI 10.1038/nrneurol.2014.138
   Witsch J, 2013, J NEUROL, V260, P1367, DOI 10.1007/s00415-012-6806-x
   Yuki N, 2000, J NEUROL NEUROSUR PS, V68, P398
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD NOV 15
PY 2020
VL 418
AR 117114
DI 10.1016/j.jns.2020.117114
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OH9TD
UT WOS:000582930900035
PM 32947089
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Venkateshan, M
   Muthu, M
   Suresh, J
   Kumar, RR
AF Venkateshan, M.
   Muthu, M.
   Suresh, J.
   Kumar, R. Ranjith
TI Azafluorene derivatives as inhibitors of SARS CoV-2 RdRp: Synthesis,
   physicochemical, quantum chemical, modeling and molecular docking
   analysis
SO JOURNAL OF MOLECULAR STRUCTURE
LA English
DT Article
DE SARS Coronavirus; Homology modeling; RdRp; Azafluorene; ADMET; MM-GBSA
ID RESPIRATORY SYNDROME CORONAVIRUS; DEPENDENT RNA-POLYMERASE; PROTEIN;
   CHAIN; VISUALIZATION; GENERATION; ALKALOIDS; ACCURACY; PROGRAM; QUALITY
AB The crystal structures of 2-(1H-indol-3-yl)-4-phenyl-5H-indeno [( Cheng et al., 2007; Lee et al., 2003) 1,21,2-b]pyridine-3-carbonitrile (la) and 2-(1H-indol-3-yl)-4-(4-methoxyphenyl)-5H-indeno [( Cheng et al., 2007; Lee et al., 2003) 1,21,2-b]pyridine-3-carbonitrile (Ib) were determined using single crystal Xray diffraction. Both the compounds belong to the triclinic system with the P-1 space group. The azafluorene ring system in both the compounds is effectively planar. The intermolecular interactions present in the compounds are discussed using Hirshfeld surface analysis, QTAIM and NCI. Compound Ib formed a strong interaction (-24.174 kJ/mol) with the solvent molecule. Both the compounds were geometry optimized using DET/B3LYP level of theory. The compound's drug-like behaviors were studied using HOMO-LUMO analysis. The homology modeling of SARS CoV-2 RdRp was done utilizing the PDB 6NUR_A as a template. The model showed above 99% similarity with its preceder SARS CoV. The molecular docking analysis of the synthesized compounds was carried out along with some suggested drugs for COVID-19 and some phytochemicals. The docking results were then analyzed. The binding free energy of the complexes were calculated using MM-PB(GB)SA and ADMET properties of Ia and Ib were also predicted. Some suggestions are given from this analysis. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Venkateshan, M.; Suresh, J.] Madura Coll, Dept Phys, Madurai 625011, Tamil Nadu, India.
   [Muthu, M.; Kumar, R. Ranjith] Madurai Kamaraj Univ, Dept Organ Chem, Madurai 625021, Tamil Nadu, India.
RP Venkateshan, M (corresponding author), Madura Coll, Dept Phys, Madurai 625011, Tamil Nadu, India.
EM venkateshan@maduracollege.edu.in
CR Ahn DG, 2012, ARCH VIROL, V157, P2095, DOI 10.1007/s00705-012-1404-x
   Almeida M.E.L., 1976, PHYTOCHEMISTRY, V15, P1186, DOI DOI 10.1016/0031-9422(76)85134-5
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Babu B, 2016, RSC ADV, V6, P110884, DOI 10.1039/c6ra15791b
   Beckers T, 2003, DRUG FUTURE, V28, P767, DOI 10.1358/dof.2003.028.08.744356
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Ciliberto G, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01590-2
   Cobo D, 2006, ACTA CRYSTALLOGR E, V62, pO5176, DOI 10.1107/S160053680604205X
   Contreras-Garcia J, 2011, J CHEM THEORY COMPUT, V7, P625, DOI 10.1021/ct100641a
   Cooper K., 1989, Eur. Pat. Appl., Patent No. [19890118., 0118]
   Cooper K., 1989, Eur. Pat. Appl., Patent No. [EP 299, 727 A1 19890118, 299727, EP 299727]
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Duflos Alain, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P55, DOI 10.2174/1568011023354452
   Earl RA, 1998, J MED CHEM, V41, P4615, DOI 10.1021/jm9803424
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Farrugia L.J., 1997, J APPL CRYSTALLOGR, V30, P565, DOI [DOI 10.1107/S0021889897003117, 10.1107/S0021889897003117]
   FRISCH MJ, 1984, J CHEM PHYS, V80, P3265, DOI 10.1063/1.447079
   Ganeshpurkar A, 2019, VIRAL POLYMERASES: STRUCTURES, FUNCTIONS, AND ROLES AS ANTIVIRAL DRUG TARGETS, P1, DOI 10.1016/B978-0-12-815422-9.00001-2
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Girgis AS, 2018, J CHEM RES, P90, DOI 10.3184/174751918X15183538282993
   Girgis AS, 2015, EUR J MED CHEM, V89, P835, DOI 10.1016/j.ejmech.2013.12.032
   GIRGIS AS, 2016, KRISTALLOGRAFIYA, V231, P179, DOI DOI 10.1515/ZKRI-2015-1892
   Gonzalez HF, 2012, ORGANOMETALLICS, V31, P6572, DOI 10.1021/om300570q
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Heintzelman G.R., 2004, Pat. Appl. Publ., Patent No. [A1 200400429, 00429]
   Heintzelman G.R., 2003, PCT Int. Appl., Patent No. [A1 20031030, 1030]
   Heintzelman G.R., 2004, Pat. Appl. Publ., Patent No. [US 20040082578, 0082578]
   Heintzelman G.R., 2002, PCT Int. Appl., Patent No. [WO 2002085894, 085894]
   Heintzelman G.R., 2003, PCT Int. Appl., Patent No. [WO 2003088963, 088963]
   Heintzelman G.R., 2002, PCT Int. Appl., Patent No. [WO 20021031, 1031]
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0
   HUFFORD CD, 1987, J NAT PROD, V50, P961, DOI 10.1021/np50053a037
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.3.CO;2-G
   Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kraus GA, 2010, J NAT PROD, V73, P1967, DOI 10.1021/np100536a
   KUNSTMANN R, 1984, J MED CHEM, V27, P1312, DOI 10.1021/jm00376a015
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Lemmerer A, 2012, NEW J CHEM, V36, P2242, DOI 10.1039/c2nj40186j
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu T, 2012, J COMPUT CHEM, V33, P580, DOI 10.1002/jcc.22885
   Macrae CF, 2008, J APPL CRYSTALLOGR, V41, P466, DOI 10.1107/S0021889807067908
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Miri R, 2004, BIOORGAN MED CHEM, V12, P2529, DOI 10.1016/j.bmc.2004.03.032
   Neese F, 2012, WIRES COMPUT MOL SCI, V2, P73, DOI 10.1002/wcms.81
   Padwa A, 2000, J ORG CHEM, V65, P2368, DOI 10.1021/jo9915729
   Pawar AY, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105984
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628
   Portilla J, 2011, ACTA CRYSTALLOGR C, V67, pO479, DOI 10.1107/S0108270111045082
   Prachayasittikul S, 2009, MOLECULES, V14, P4414, DOI 10.3390/molecules14114414
   Rajput C.S., 2011, INT J PHARM BIOSCI, V2, P200
   RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6
   Ramesh P., 2009, ACTA CRYSTALLOGR E, V65, po996
   Ramesh P., 2009, ACTA CRYSTALLOGR E, V65, po450
   Ramesh P., 2008, ACTA CRYSTALLOGR E, V64, po1891
   Rowland RS, 1996, J PHYS CHEM-US, V100, P7384, DOI 10.1021/jp953141+
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Salihovic M., 2014, B CHEM TECHNOL BOSNI, V42, P31
   Schneidman-Duhovny D, 2008, NUCLEIC ACIDS RES, V36, pW223, DOI 10.1093/nar/gkn187
   Seah I, 2020, EYE, V34, P1155, DOI 10.1038/s41433-020-0790-7
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218
   Spek AL, 2009, ACTA CRYSTALLOGR D, V65, P148, DOI 10.1107/S090744490804362X
   Suresh J., 2007, ACTA CRYSTALLOGR C, V63, po538
   Tchesnokov E.P., 2019, VIRUSES, V4, P11
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tu S.J., 2006, ACTA CRYSTALLOGR E, V62, po3928
   Tu S.J., 2006, ACTA CRYSTALLOGR E, V62, po3930
   Uhl W, 2003, Z ANORG ALLG CHEM, V629, P2157, DOI 10.1002/zaac.200300197
   Venkateshan M, 2019, J MOL STRUCT, V1180, P826, DOI 10.1016/j.molstruc.2018.12.071
   Vimala G., 2015, ACTA CRYSTALLOGR E, V71, po822
   Vishnupriya R., 2014, ACTA CRYSTALLOGR E, V70, po968
   Vishnupriya R., 2014, ACTA CRYSTALLOGR E, V70, po978
   Vrabel M, 2007, EUR J INORG CHEM, P1752, DOI 10.1002/ejic.200700030
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Z, 2019, BIOINFORMATICS, V35, P1777, DOI 10.1093/bioinformatics/bty879
   Wass MN, 2010, NUCLEIC ACIDS RES, V38, pW469, DOI 10.1093/nar/gkq406
   Wolff S., 2012, CRYSTALEXPLORER
   Xu HT, 2017, J ANTIMICROB CHEMOTH, V72, P727, DOI 10.1093/jac/dkw514
   Yang HB, 2019, BIOINFORMATICS, V35, P1067, DOI 10.1093/bioinformatics/bty707
   Yin W., 2020, STRUCTURAL BASIS INH, DOI [DOI 10.1101/2020.04.08.032763, 10.1101/2020.04.08.032763]
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu W., 2009, ACTA CRYSTALLOGR E, V65, po1187
NR 99
TC 0
Z9 0
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2860
EI 1872-8014
J9 J MOL STRUCT
JI J. Mol. Struct.
PD NOV 15
PY 2020
VL 1220
AR 128741
DI 10.1016/j.molstruc.2020.128741
PG 14
WC Chemistry, Physical
SC Chemistry
GA NU3UB
UT WOS:000573567000017
PM 32834110
OA Green Published
DA 2021-01-01
ER

PT J
AU Saavedra, D
   Ane-Kouri, AL
   Sanchez, N
   Filgueira, LM
   Betancourt, J
   Herrera, C
   Manso, L
   Chavez, E
   Caballero, A
   Hidalgo, C
   Lorenzo, G
   Cepeda, M
   Valenzuela, C
   Ramos, M
   Leon, K
   Mazorra, Z
   Crombet, T
AF Saavedra, Danay
   Ane-Kouri, Ana Laura
   Sanchez, Naivy
   Filgueira, Lazaro Manuel
   Betancourt, Julio
   Herrera, Carlos
   Manso, Leniel
   Chavez, Elibet
   Caballero, Armando
   Hidalgo, Carlos
   Lorenzo, Geydi
   Cepeda, Meylan
   Valenzuela, Carmen
   Ramos, Mayra
   Leon, Kalet
   Mazorra, Zaima
   Crombet, Tania
TI An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in
   severe COVID-19 elderly patients
SO IMMUNITY & AGEING
LA English
DT Article
DE COVID-19; IL-6; Itolizumab; Cytokine release syndrome
ID CYTOKINE STORM
AB Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around the world has been placed. In Cuba, the first case of COVID-19 was reported on March 11. Elderly with multiple comorbidities have been the most risky population. Although most patients present a mild to moderate disease, some have developed severe symptoms. One of the possible mechanisms underlying rapid disease progression is a cytokine storm, in which interleukin (IL) -6 seems to be a major mediator. Itolizumab is a humanized recombinant anti-CD6 monoclonal antibody (MAb), with the ability of reducing serum interferon gamma (INF-gamma), tumour necrosis factor alpha (TNF alpha) and IL-6. Based on these previous results in patients with psoriasis and rheumatoid arthritis, an expanded access clinical trial was approved by the Cuban regulatory agency for COVID-19 critically, severely and moderately ill patients.
   Results: We show here a short kinetic of IL-6 serum concentration in the first 24 COVID-19 patients treated with itolizumab. Most of patients were elderly with multiple comorbidities. We found that with one itolizumab dose, the circulating IL-6 decreased in critically and severely ill patients, whereas in moderately ill patients the values didn't rise as compared to their low baseline levels.
   Conclusion: These findings suggest that itolizumab could be an attractive therapeutic option to decrease the negative outcome of the cytokine storm in COVID-19 patients.
C1 [Saavedra, Danay; Lorenzo, Geydi; Cepeda, Meylan; Valenzuela, Carmen; Ramos, Mayra; Leon, Kalet; Mazorra, Zaima; Crombet, Tania] Ctr Mol Immunol, Dept Clin Immunol, 216 St,Corner 15,POB 16040, Havana, Atabey, Cuba.
   [Ane-Kouri, Ana Laura] ICBP Victoria de Giron, Biochem Dept, Calle 146 3102, Havana, Playa, Cuba.
   [Sanchez, Naivy; Hidalgo, Carlos] Manuel Piti Fajardo Univ Hosp, Ciudad Escolar Abel Santamaria U-M 9958, Santa Clara, Villa Clara, Cuba.
   [Filgueira, Lazaro Manuel; Betancourt, Julio; Herrera, Carlos; Manso, Leniel; Caballero, Armando] Arnaldo Milian Castro Univ Hosp, Arnaldo Milian Castro St, Santa Clara, Villa Clara, Cuba.
   [Chavez, Elibet] Cardioctr Ernesto Che Guevara, Cuba St 610, Santa Clara, Villa Clara, Cuba.
RP Saavedra, D (corresponding author), Ctr Mol Immunol, Dept Clin Immunol, 216 St,Corner 15,POB 16040, Havana, Atabey, Cuba.
EM danays@cim.sld.cu
CR Aira LE, 2016, MABS-AUSTIN, V8, P187, DOI 10.1080/19420862.2015.1105416
   Aira LE, 2014, MABS-AUSTIN, V6, P782, DOI 10.4161/mabs.28376
   Arnaldez FI, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000930
   Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948
   Babaha Fateme, 2020, Am J Med Sci, V360, P740, DOI 10.1016/j.amjms.2020.07.027
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen X, 2020, CHINA PERSPECT-SER, P1
   Choy EH, 2020, NAT REV RHEUMATOL, V16, P335, DOI 10.1038/s41584-020-0419-z
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Dogra S, 2017, EXPERT OPIN BIOL TH, V17, P395, DOI 10.1080/14712598.2017.1279601
   Fulop T, 2018, SEMIN IMMUNOL, V40, P17, DOI 10.1016/j.smim.2018.09.003
   Har-Noy M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02363-3
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Kirkwood KL, 2018, IMMUNOL INVEST, V47, P770, DOI 10.1080/08820139.2018.1552392
   Krupashankar DS, 2014, J AM ACAD DERMATOL, V71, P484, DOI 10.1016/j.jaad.2014.01.897
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Marfella R, 2020, DIABETES METAB, V46, P403, DOI 10.1016/j.diabet.2020.05.005
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Nair P, 2010, CLIN EXP IMMUNOL, V162, P116, DOI 10.1111/j.1365-2249.2010.04235.x
   Pawelec G, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00180-2
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Rodriguez PC, 2018, CLIN EXP IMMUNOL, V191, P229, DOI 10.1111/cei.13061
   Shahid Z, 2020, J AM GERIATR SOC, V68, P926, DOI 10.1111/jgs.16472
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang H, 2020, PREPRINT, DOI [10.2139/ssrn.3544837, DOI 10.2139/SSRN.3544837]
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang P, 2020, PREPRINT, DOI [10.1101/2020.02.28.20028068, DOI 10.1101/2020.02.28.20028068]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang J, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104392
   Zhou YFB, 2020, PREPRINT, DOI 10.1101/2020.02.12.945576.
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 35
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4933
J9 IMMUN AGEING
JI Immun. Ageing
PD NOV 14
PY 2020
VL 17
IS 1
AR 34
DI 10.1186/s12979-020-00207-8
PG 8
WC Geriatrics & Gerontology; Immunology
SC Geriatrics & Gerontology; Immunology
GA OY3QO
UT WOS:000594164500001
PM 33292350
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Verma, AK
AF Verma, Akalesh Kumar
TI Cordycepin: a bioactive metabolite of Cordyceps militaris and
   polyadenylation inhibitor with therapeutic potential against COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronavirus; main proteases; 2019nCov; SARS-CoV-2; spike protein
ID CORONAVIRUS; SPIKE; ACE2
AB Spike protein and main proteases of SARS-CoV-2 have been identified as potential therapeutic targets and their inhibition may lead to the reticence of viral entry and replication in the host body. Despite several efforts; till now no specific drugs are available to treat SARS-CoV-2. Considering all these challenges, the main objective of the present study was to establish therapeutic potential of cordycepin against COVID-19 as a conventional therapeutic strategy. In the present study; molecular interaction study was performed to assess potential binding affinity of cordycepin with SARS-CoV-2 target proteins using computational approach. Additionally, network pharmacology was used to understand cordycepin-protein interactions and their associated pathways in human body. Cordycepin is under clinical trial (NCT00709215) and possesses structural similarity with adenosine except that, it lacks a 3 ' hydroxyl group in its ribose moiety and hence it served as a poly(A) polymerase inhibitor and terminate premature protein synthesis. Additionally, it is known that functional RNAs of SARS-CoV-2 genome are highly 3'-plyadenylated and leading to synthesis of all viral proteins and if cordycepin can destabilize SARS-CoV-2 RNAs by inhibiting polyadenylation process then it may step forward in terms of inhibition of viral replication and multiplication in the host. Moreover, cordycepin showed strong binding affinity with SARS-CoV-2 spike protein (-145.3) and main proteases (-180.5) that further corroborate therapeutic potential against COVID-19. Since cordycepin has both pre-clinical and clinical information about antiviral activities, therefore; it is suggested to the world community to undertake repurposing cordycepin to test efficacy and safety for the treatment of COVID-19.
C1 [Verma, Akalesh Kumar] Cotton Univ, Dept Zool, Cell & Biochem Technol Lab, Gauhati, India.
RP Verma, AK (corresponding author), Cotton Univ, Dept Zool, Cell & Biochem Technol Lab, Gauhati, India.
EM akhilesh@cottonuniversity.ac.in
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Biovia D.S., 2017, DISCOVERY STUDIO VIS
   Bitencourt-Ferreira G, 2019, METHODS MOL BIOL, V2053, P149, DOI 10.1007/978-1-4939-9752-7_10
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chanda S.D., 2015, J VIROL ANTIVIR RES, V04, P1, DOI [10.4172/2324-8955, DOI 10.4172/2324-8955]
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010
   Gollapalli P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1841681
   Hawas UW, 2012, EGYPT PHARM J, V11, P124
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holbein S, 2009, RNA, V15, P837, DOI 10.1261/rna.1458909
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kusumaningrum S, 2014, J APP SCI, V4, P47, DOI [DOI 10.7324/JAPS.2014.4119, 10.7324/JAPS.2014.4119]
   Lambeir AM, 2003, CRIT REV CL LAB SCI, V40, P209, DOI 10.1080/713609354
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Liu Y, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/575063
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Ohta Y, 2007, J AGR FOOD CHEM, V55, P10194, DOI 10.1021/jf0721287
   Oti M, 2006, J MED GENET, V43, DOI 10.1136/jmg.2006.041376
   OVERGAARDHANSEN K, 1964, BIOCHIM BIOPHYS ACTA, V80, P504, DOI 10.1016/0926-6550(64)90154-9
   Panda Ashok Kumar, 2011, J Ayurveda Integr Med, V2, P9, DOI 10.4103/0975-9476.78183
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   PRIDGEN CL, 1976, J VIROL, V18, P356, DOI 10.1128/JVI.18.1.356-360.1976
   Ryu Eunhyun, 2014, Oncoscience, V1, P866
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sharan R, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100129
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Sugrue Richard J, 2007, Methods Mol Biol, V379, P1
   Suwannarach N, 2020, MOLECULES, V25, DOI 10.3390/molecules25081800
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e
   Tuli HS, 2014, 3 BIOTECH, V4, P1, DOI 10.1007/s13205-013-0121-9
   Ustyantsev IG, 2020, MOL BIOL+, V54, P67, DOI 10.1134/S0026893319040150
   Wang Q, 2020, VIROL SIN, V35, P337, DOI 10.1007/s12250-020-00212-7
   Watanabe Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16567-0
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Watanabe Y, 2019, BBA-GEN SUBJECTS, V1863, P1480, DOI 10.1016/j.bbagen.2019.05.012
   WHO, 2020, COR DIS COVID 19 PAN
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xi J., 2020, EMERG MICROBES INFEC, V9
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao P, 2020, CELL HOST MICROBE, V28, P586, DOI 10.1016/j.chom.2020.08.004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 48
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1850352
EA NOV 2020
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OU4KF
UT WOS:000591497500001
PM 33225826
OA Bronze
DA 2021-01-01
ER

PT J
AU Bialer, M
   Johannessen, SI
   Koepp, MJ
   Levy, RH
   Perucca, E
   Perucca, P
   Tomson, T
   White, HS
AF Bialer, Meir
   Johannessen, Svein I.
   Koepp, Matthias J.
   Levy, Rene H.
   Perucca, Emilio
   Perucca, Piero
   Tomson, Torbjorn
   White, H. Steve
TI Progress report on new antiepileptic drugs: A summary of the Fifteenth
   Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I.
   Drugs in preclinical and early clinical development
SO EPILEPSIA
LA English
DT Article
DE 2&#8208; deoxy&#8208; D&#8208; glucose; antiepileptic drugs; drugs
   development; epilepsy; GAO&#8208; 3&#8208; 02; JNJ&#8208; 40411813;
   NBI&#8208; 921352; NTX&#8208; 001; sec&#8208; butylpropylacetamide;
   XEN1101; XEN496
ID SEC-BUTYL-PROPYLACETAMIDE; METABOTROPIC GLUTAMATE-RECEPTOR; MOUSE MODEL;
   BUTYLPROPYLACETAMIDE SPD; GABAERGIC INTERNEURONS; ALLOSTERIC MODULATOR;
   SPONTANEOUS SEIZURES; STATUS EPILEPTICUS; UNIQUE ACTIVITY;
   NERVOUS-SYSTEM
AB Since 1992, the Eilat Conferences have provided a forum for all stakeholders in the epilepsy community to appraise the latest data on new antiepileptic drugs and emergency seizure treatments, including, in recent years, updates on progress with the development of novel monitoring and therapeutic devices. Because of the COVID-19 pandemic, the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV) was held as a fully virtual conference on July 27-30, 2020 for the sessions on drugs and on August 3, 2020 for the sessions on devices, and was attended during the 5 days by >500 participants from 63 countries. This progress report summarizes key preclinical and initial (phase 1) clinical data on eight investigational treatments that are currently in early development, including 2-deoxy-D-glucose, GAO-3-02, JNJ-40411813, NBI-921352, NTX-001, sec-butylpropylacetamide, XEN1101, and XEN496. This report provides an overview of current scenarios in the area of treatment discovery and development. The information presented illustrates a variety of innovative strategies, including exploration of compounds with novel mechanisms of action, transplantation of interneurons into epileptogenic brain regions, and the targeting of rare, previously neglected syndromes.
C1 [Bialer, Meir] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, IL-91120 Jerusalem, Israel.
   [Bialer, Meir] Hebrew Univ Jerusalem, Inst Drug Res, David R Bloom Ctr Pharm, IL-91120 Jerusalem, Israel.
   [Johannessen, Svein I.] Natl Ctr Epilepsy, Sandvika, Norway.
   [Johannessen, Svein I.] Oslo Univ Hosp, Dept Pharmacol, Oslo, Norway.
   [Koepp, Matthias J.] UCL Inst Neurol, Dept Clin & Expt Epilepsy, London, England.
   [Levy, Rene H.] Univ Washington, Dept Pharmaceut & Neurol Surg, Seattle, WA 98195 USA.
   [Perucca, Emilio] Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
   [Perucca, Emilio] ERN EpiCARE, RCCS Mondino Fdn, Pavia, Italy.
   [Perucca, Piero] Monash Univ, Dept Neurosci, Cent Clin Sch, Melbourne, Vic, Australia.
   [Perucca, Piero] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic, Australia.
   [Perucca, Piero] Univ Melbourne, Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia.
   [Perucca, Piero] Alfred Hlth, Dept Neurol, Melbourne, Vic, Australia.
   [Tomson, Torbjorn] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
   [White, H. Steve] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA.
RP Bialer, M (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, IL-91120 Jerusalem, Israel.; Bialer, M (corresponding author), Hebrew Univ Jerusalem, Inst Drug Res, David R Bloom Ctr Pharm, IL-91120 Jerusalem, Israel.
EM bialer@md.huji.ac.il
OI Tomson, torbjorn/0000-0003-0554-5352; Perucca,
   emilio/0000-0001-8703-223X; Perucca, Piero/0000-0002-7855-7066
FU technology transfer office PULSALYS
FX We wish to thank the authors of the summary sections for their patience
   in addressing the queries raised during the review process, and for
   their collaboration with the final editing of the manuscript. The work
   described in the GAO-3-02 section, to which all summary authors
   contributed equally, was supported by a grant from the technology
   transfer office PULSALYS. The authors of the same summary also wish to
   thank Victor Blot, Melodie Borel, and Beatrice Georges for their
   technical support.
CR Agranat I, 2002, NAT REV DRUG DISCOV, V1, P753, DOI 10.1038/nrd915
   Australian Government . Department of Health, 2013, AUSTR PUBL ASS REP R
   Bar-Klein G, 2014, EPILEPSIA, V55, P1953, DOI 10.1111/epi.12838
   Baraban SC, 2009, P NATL ACAD SCI USA, V106, P15472, DOI 10.1073/pnas.0900141106
   Bialer M, EPILEPSIA
   Bialer M, 2018, EPILEPSIA, V59, P1842, DOI 10.1111/epi.14555
   Bialer M, 2017, EPILEPSIA, V58, P181, DOI [10.1111/epi.14557, 10.1111/epi.13634]
   Bibi D, 2020, EPILEPSIA, V61, P149, DOI 10.1111/epi.16411
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   Boada CM, 2020, EPILEPSY BEHAV, V111, DOI 10.1016/j.yebeh.2020.107189
   Brickel N, 2020, EPILEPSY BEHAV, V102, DOI 10.1016/j.yebeh.2019.106580
   Broeer S, 2019, NEUROSCIENCE M PLANN
   Casalia ML, 2017, ANN NEUROL, V82, P530, DOI 10.1002/ana.25021
   Center for Drug Evaluation and Research, 2011, PHARM REV
   Chohan MO, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00064
   Cunningham M, 2014, CELL STEM CELL, V15, P559, DOI 10.1016/j.stem.2014.10.006
   Ding Y, 2010, NEUROSCI LETT, V477, P33, DOI 10.1016/j.neulet.2010.04.030
   Dmytriyeva O, 2019, NEUROBIOL AGING, V81, P88, DOI 10.1016/j.neurobiolaging.2019.05.003
   Duveau V, 2016, CNS NEUROSCI THER, V22, P497, DOI 10.1111/cns.12523
   Fares RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053888
   French JA, 2020, EPILEPSY CURR, V20, P69, DOI 10.1177/1535759720905516
   Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791
   Gataullina S, 2017, SEIZURE-EUR J EPILEP, V44, P58, DOI 10.1016/j.seizure.2016.10.014
   GlaxoSmithKline, 2016, HIGHL PRESCR INF POT
   Haines KM, 2019, EPILEPSIA, V60, P315, DOI 10.1111/epi.14630
   Hen N, 2013, J MED CHEM, V56, P6467, DOI 10.1021/jm4007565
   Henderson KW, 2014, J NEUROSCI, V34, P13492, DOI 10.1523/JNEUROSCI.0005-14.2014
   Hofmann G, 2016, EPILEPSIA, V57, P977, DOI 10.1111/epi.13376
   Hu WQ, 2009, NAT NEUROSCI, V12, P996, DOI 10.1038/nn.2359
   Huang BX, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0831-6
   Hunt RF, 2013, NAT NEUROSCI, V16, P692, DOI 10.1038/nn.3392
   Ihara Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150095
   Kent JM, 2016, PROG NEURO-PSYCHOPH, V67, P66, DOI 10.1016/j.pnpbp.2016.01.009
   Kim HY, 2018, MOL ASPECTS MED, V64, P34, DOI 10.1016/j.mam.2018.03.004
   Kobayashi E, 2012, TRANSPLANT RES, V1, DOI 10.1186/2047-1440-1-8
   Krook-Magnuson E, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2376
   Kuersten M, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2019.02.001
   Langberg T, 2016, NEUROBIOL DIS, V85, P122, DOI 10.1016/j.nbd.2015.10.008
   Leclercq K, 2015, EPILEPSIA, V56, P310, DOI 10.1111/epi.12893
   Lian XY, 2007, J NEUROSCI, V27, P12007, DOI 10.1523/JNEUROSCI.3163-07.2007
   Loscher W, 2008, TRENDS NEUROSCI, V31, P62, DOI 10.1016/j.tins.2007.11.012
   Loscher W, 2016, EPILEPSY RES, V126, P157, DOI 10.1016/j.eplepsyres.2016.05.016
   LOSCHER W, 1991, EPILEPSY RES, V8, P79, DOI 10.1016/0920-1211(91)90075-Q
   Maljevic S, 2008, J PHYSIOL-LONDON, V586, P1791, DOI 10.1113/jphysiol.2008.150656
   Meisler MH, 2016, EPILEPSIA, V57, P1027, DOI 10.1111/epi.13422
   Metcalf CS, 2018, EPILEPSIA, V59, P724, DOI 10.1111/epi.14005
   Metcalf CS, 2017, EPILEPSIA, V58, P484, DOI 10.1111/epi.13659
   Millichap JJ, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000096
   Molosh AI, 2020, MOL PSYCHIATR, V25, P442, DOI 10.1038/s41380-018-0119-0
   OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X
   Olson H, 2017, AM EP SOC ANN M 2017
   Pan YZ, 2019, J NEUROPHYSIOL, V121, P1092, DOI 10.1152/jn.00723.2018
   Park T, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1621-2
   Perucca E, 2020, LANCET NEUROL, V19, P544, DOI 10.1016/S1474-4422(20)30035-1
   Porter RJ, 2012, EPILEPSY RES, V101, P103, DOI 10.1016/j.eplepsyres.2012.03.010
   Pouliot W, 2013, NEUROSCIENCE, V231, P145, DOI 10.1016/j.neuroscience.2012.11.005
   Premoli I, 2019, ANN CLIN TRANSL NEUR, V6, P2164, DOI 10.1002/acn3.50896
   Shekh-Ahmad T, 2015, EPILEPSY BEHAV, V49, P298, DOI 10.1016/j.yebeh.2015.04.012
   Shekh-Ahmad T, 2013, EPILEPSIA, V54, P99, DOI 10.1111/epi.12290
   Sonti S, 2018, CHEM PHYS LIPIDS, V210, P90, DOI 10.1016/j.chemphyslip.2017.11.002
   Stafstrom CE, 2009, ANN NEUROL, V65, P435, DOI 10.1002/ana.21603
   Stein M, 2010, PROSTATE, V70, P1388, DOI 10.1002/pros.21172
   Sutula T, 2019, NEUROSCIENCE M PLANN
   Tompson DJ, 2013, CURR CLIN PHARMACOL, V8, P319, DOI 10.2174/15748847113089990053
   Upadhya D, 2019, P NATL ACAD SCI USA, V116, P287, DOI 10.1073/pnas.1814185115
   Waldau B, 2010, STEM CELLS, V28, P1153, DOI 10.1002/stem.446
   Watanabe H, 2000, J NEUROCHEM, V75, P28, DOI 10.1046/j.1471-4159.2000.0750028.x
   White HS, 2012, EPILEPSIA, V53, P134, DOI 10.1111/j.1528-1167.2011.03338.x
   Yang H, 2013, NEUROCHEM RES, V38, P677, DOI 10.1007/s11064-012-0958-z
   Yu FH, 2006, NAT NEUROSCI, V9, P1142, DOI 10.1038/nn1754
   Zolkowska D, 2017, ANN M AM EP SOC DEC
NR 71
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD NOV
PY 2020
VL 61
IS 11
BP 2340
EP 2364
DI 10.1111/epi.16725
EA NOV 2020
PG 25
WC Clinical Neurology
SC Neurosciences & Neurology
GA OZ4HX
UT WOS:000589433200001
PM 33190243
DA 2021-01-01
ER

PT J
AU Roumier, M
   Paule, R
   Vallee, A
   Rohmer, J
   Ballester, M
   Brun, AL
   Cerf, C
   Chabi, ML
   Chinet, T
   Colombier, MA
   Farfour, E
   Fourn, E
   Geri, G
   Khau, D
   Marroun, I
   Ponsoye, M
   Roux, A
   Salvator, H
   Schoindre, Y
   Larbi, AGS
   Tcherakian, C
   Vasse, M
   Verrat, A
   Zuber, B
   Couderc, LJ
   Kahn, JE
   Groh, M
   Ackermann, F
AF Roumier, Mathilde
   Paule, Romain
   Vallee, Alexandre
   Rohmer, Julien
   Ballester, Marie
   Brun, Anne-Laure
   Cerf, Charles
   Chabi, Marie-Laure
   Chinet, Thierry
   Colombier, Marie-Alice
   Farfour, Eric
   Fourn, Erwan
   Geri, Guillaume
   Khau, David
   Marroun, Ibrahim
   Ponsoye, Matthieu
   Roux, Antoine
   Salvator, Helene
   Schoindre, Yoland
   Si Larbi, Anne-Gaelle
   Tcherakian, Colas
   Vasse, Marc
   Verrat, Anne
   Zuber, Benjamin
   Couderc, Louis-Jean
   Kahn, Jean-Emmanuel
   Groh, Matthieu
   Ackermann, Felix
CA Foch COVID-19 Study Grp
TI Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score
   Analysis
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Article; Early Access
DE COVID-19; tocilizumab; interleukin-6; cytokine storm; intensive care
   unit
ID MULTICENTER; SAFETY
AB Background High levels of serum interleukin-6 (IL-6) correlate with disease severity in COVID-19. We hypothesized that tocilizumab (a recombinant humanized anti-IL-6 receptor) could improve outcomes in selected patients with severe worsening COVID-19 pneumonia and high inflammatory parameters. Methods The TOCICOVID study included a prospective cohort of patients aged 16-80 years with severe (requiring > 6 L/min of oxygen therapy to obtain Sp02 > 94%) rapidly deteriorating (increase by >= 3 L/min of oxygen flow within the previous 12 h) COVID-19 pneumonia with >= 5 days of symptoms and C-reactive protein levels > 40 mg/L. They entered a compassionate use program of treatment with intravenous tocilizumab (8 mg/kg with a maximum of 800 mg per infusion; and if needed a second infusion 24 to 72 h later). A control group was retrospectively selected with the same inclusion criteria. Outcomes were assessed at D28 using inverse probability of treatment weighted (IPTW) methodology. Results Among the 96 patients included (81% male, mean (SD) age: 60 (12.5) years), underlying conditions, baseline disease severity, and concomitant medications were broadly similar between the tocilizumab (n = 49) and the control (n = 47) groups. In the IPTW analysis, treatment with tocilizumab was associated with a reduced need for overall ventilatory support (49 vs. 89%, wHR: 0.39 [0.25-0.56]; p < 0.001). Albeit lacking statistical significance, there was a substantial trend towards a reduction of mechanical ventilation (31% vs. 45%; wHR: 0.58 [0.36-0.94]; p = 0.026). However, tocilizumab did not improve overall survival (wHR = 0.68 [0.31-1.748], p = 0.338). Among the 85 (89%) patients still alive at D28, patients treated with tocilizumab had a higher rate of oxygen withdrawal (82% vs. 73.5%, wHR = 1.66 [1.17-2.37], p = 0.005), with a shorter delay before being weaned of oxygen therapy (mean 11 vs. 16 days; p < 0.001). At D28, the rate of patients discharged from hospital was higher in the tocilizumab group (70% vs. 40%, wHR = 1.82 [1.22-2.75]; p = 0.003). The levels of CRP and fibrinogen post therapy (p < 0.001 for both variables) were significantly lower in the tocilizumab group (interaction test, mixed model). Rates of neutropenia (35% vs. 0%; p < 0.001) were higher in the tocilizumab group, yet rates of infections (22% vs. 38%, p = 0.089) including ventilator-acquired pneumonia (8% vs. 26%, p = 0.022) were higher in the control group. Conclusion These data could be helpful for the design of future trials aiming to counter COVID-19-induced inflammation, especially before patients require admission to the intensive care unit.
C1 [Roumier, Mathilde; Paule, Romain; Rohmer, Julien; Colombier, Marie-Alice; Fourn, Erwan; Khau, David; Marroun, Ibrahim; Ponsoye, Matthieu; Schoindre, Yoland; Groh, Matthieu; Ackermann, Felix] Foch Hosp, Dept Internal Med, F-92151 Suresnes, France.
   [Vallee, Alexandre] Paris Descartes Univ, Hotel Dieu Hosp, AP HP, Diag & Therapeut Ctr,Hypertens & Cardiovasc Preve, Paris, France.
   [Ballester, Marie; Verrat, Anne] Foch Hosp, Emergency Dept, F-92151 Suresnes, France.
   [Brun, Anne-Laure; Chabi, Marie-Laure] Foch Hosp, Dept Radiol, F-92151 Suresnes, France.
   [Cerf, Charles; Si Larbi, Anne-Gaelle; Zuber, Benjamin] Foch Hosp, Dept Anesthesiol & Intens Care, F-92151 Suresnes, France.
   [Chinet, Thierry] Ambroise Pare Hosp, AP HP, Dept Resp Med, F-92100 Boulogne, France.
   [Chinet, Thierry; Geri, Guillaume; Roux, Antoine; Salvator, Helene; Couderc, Louis-Jean; Kahn, Jean-Emmanuel] Univ Paris Saclay, Simone Veil Med Fac, Montigny Le Bretonneux, France.
   [Farfour, Eric; Vasse, Marc] Foch Hosp, Dept Clin Biol, F-92151 Suresnes, France.
   [Farfour, Eric; Vasse, Marc] Foch Hosp, INSERM, UMRS 1176, F-92151 Suresnes, France.
   [Geri, Guillaume] Ambroise Pare Hosp, AP HP, Med Intens Care Unit, F-92100 Boulogne, France.
   [Geri, Guillaume] INSERM, UMR 1018, Villejuif, France.
   [Roux, Antoine; Salvator, Helene; Tcherakian, Colas; Couderc, Louis-Jean] Foch Hosp, Dept Resp Med, F-92151 Suresnes, France.
   [Kahn, Jean-Emmanuel] Ambroise Pare Hosp, AP HP, Dept Internal Med, F-92100 Boulogne, France.
RP Ackermann, F (corresponding author), Foch Hosp, Dept Internal Med, F-92151 Suresnes, France.
EM f.ackermann@hopital-foch.com
FU Foch Hospital
FX All costs (including funding for tocilizumab) were borne by Foch
   Hospital.
CR Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022
   [Anonymous], 2020, SANOFI PROVIDES UPDA
   [Anonymous], 2020, ROCHE PROVIDES UPDAT
   Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Biran N, 2020, LANCET RHEUMATOL, V2, pE603, DOI 10.1016/S2665-9913(20)30277-0
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Canete JD, 2017, EXPERT OPIN BIOL TH, V17, P1089, DOI 10.1080/14712598.2017.1346078
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao Y, 2020, J ALLERGY CLIN IMMUN, V146, P137, DOI 10.1016/j.jaci.2020.05.019
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   De Luca G, 2020, LANCET RHEUMATOL, V2, pE465, DOI 10.1016/S2665-9913(20)30170-3
   Dequin PF, 2020, JAMA-J AM MED ASSOC, V324, P1298, DOI 10.1001/jama.2020.16761
   Figuero-Perez Luis, 2020, Reumatol Clin, DOI 10.1016/j.reuma.2020.06.003
   Galvan-Roman Jose Maria, 2020, J Allergy Clin Immunol, DOI 10.1016/j.jaci.2020.09.018
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Haukoos JS, 2015, JAMA-J AM MED ASSOC, V314, P1637, DOI 10.1001/jama.2015.13480
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, DOI 10.1056/NEJM0A2021436]
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Innes AJ, 2020, BRIT J HAEMATOL, V190, pE198, DOI 10.1111/bjh.16979
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pan H., 2020, REPURPOSED ANTIVIRAL
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Radbel J, 2020, CHEST, V158, pE15, DOI 10.1016/j.chest.2020.04.024
   Somers Emily C, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa954
   SRLF-SFAR-SFMU-GFRUP-SPILF-SPLF, 2020, REC EXP PORT PRIS CH
   Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023
   Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
   Zhao X, 2020, INCIDENCE CLIN CHARA
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 43
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
DI 10.1007/s10875-020-00911-6
EA NOV 2020
PG 12
WC Immunology
SC Immunology
GA OR5HU
UT WOS:000589502000001
PM 33188624
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Saad-Roy, CM
   Wagner, CE
   Baker, RE
   Morris, SE
   Farrar, J
   Graham, AL
   Levin, SA
   Mina, MJ
   Metcalf, CJE
   Grenfell, BT
AF Saad-Roy, Chadi M.
   Wagner, Caroline E.
   Baker, Rachel E.
   Morris, Sinead E.
   Farrar, Jeremy
   Graham, Andrea L.
   Levin, Simon A.
   Mina, Michael J.
   Metcalf, C. Jessica E.
   Grenfell, Bryan T.
TI Immune life history, vaccination, and the dynamics of SARS-CoV-2 over
   the next 5 years
SO SCIENCE
LA English
DT Article
ID CORONAVIRUS; MODELS
AB The future trajectory of the coronavirus disease 2019 (COVID-19) pandemic hinges on the dynamics of adaptive immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, salient features of the immune response elicited by natural infection or vaccination are still uncertain. We use simple epidemiological models to explore estimates for the magnitude and timing of future COVID-19 cases, given different assumptions regarding the protective efficacy and duration of the adaptive immune response to SARS-CoV-2, as well as its interaction with vaccines and nonpharmaceutical interventions. We find that variations in the immune response to primary SARS-CoV-2 infections and a potential vaccine can lead to markedly different immune landscapes and burdens of critically severe cases, ranging from sustained epidemics to near elimination. Our findings illustrate likely complexities in future COVID-19 dynamics and highlight the importance of immunological characterization beyond the measurement of active infections for adequately projecting the immune landscape generated by SARS-CoV-2 infections.
C1 [Saad-Roy, Chadi M.] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08540 USA.
   [Wagner, Caroline E.; Baker, Rachel E.; Graham, Andrea L.; Levin, Simon A.; Metcalf, C. Jessica E.; Grenfell, Bryan T.] Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA.
   [Wagner, Caroline E.; Baker, Rachel E.] Princeton Univ, Princeton Environm Inst, Princeton, NJ 08544 USA.
   [Wagner, Caroline E.] McGill Univ, Dept Bioengn, Montreal, PQ H3A 0C3, Canada.
   [Morris, Sinead E.] Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY 10032 USA.
   [Farrar, Jeremy] Wellcome Trust Res Labs, London, England.
   [Mina, Michael J.] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Mina, Michael J.] Harvard Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Metcalf, C. Jessica E.; Grenfell, Bryan T.] Princeton Univ, Princeton Sch Publ & Int Affairs, Princeton, NJ 08544 USA.
   [Grenfell, Bryan T.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
RP Grenfell, BT (corresponding author), Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA.; Grenfell, BT (corresponding author), Princeton Univ, Princeton Sch Publ & Int Affairs, Princeton, NJ 08544 USA.; Grenfell, BT (corresponding author), NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
EM grenfell@princeton.edu
RI Levin, Simon A/J-1218-2014
OI Levin, Simon A/0000-0002-8216-5639; Mina, Michael/0000-0002-0674-5762;
   Morris, Sinead/0000-0001-8626-1698; Grenfell, Bryan/0000-0003-3227-5909;
   Reis, AlessanRSS/0000-0001-8486-7469; Wagner,
   Caroline/0000-0001-5193-2797; Baker, Rachel/0000-0002-2661-8103
FU Natural Sciences and Engineering Research Council of Canada through a
   Postgraduate-Doctoral ScholarshipNatural Sciences and Engineering
   Research Council of Canada; Cooperative Institute for Modelling the
   Earth System (CIMES); James S. McDonnell Foundation 21st Century Science
   Initiative Collaborative Award in Understanding Dynamic and Multi-scale
   Systems; C3.ai Digital Transformation Institute; National Science
   FoundationNational Science Foundation (NSF) [CNS-2027908]; National
   Science Foundation Expeditions Grant [CCF1917819]; U.S. CDCUnited States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA; Flu Lab
FX C.M.S.-R. acknowledges support from the Natural Sciences and Engineering
   Research Council of Canada through a Postgraduate-Doctoral Scholarship.
   C.E.W. is an Open Philanthropy Project fellow of the Life Sciences
   Research Foundation. R.E.B. is supported by the Cooperative Institute
   for Modelling the Earth System (CIMES). S.A.L. and C.M.S.-R. acknowledge
   support from the James S. McDonnell Foundation 21st Century Science
   Initiative Collaborative Award in Understanding Dynamic and Multi-scale
   Systems. S.A.L. acknowledges support from the C3.ai Digital
   Transformation Institute, the National Science Foundation under grant
   CNS-2027908, and the National Science Foundation Expeditions Grant
   CCF1917819. B.T.G. acknowledges support from the U.S. CDC and Flu Lab.
CR Aguas R., 2020, 20160762 MEDRXIV
   AGUAS R., 2020, HERD IMMUNITY THRESH, DOI 10.1101/2020.07.23.20160762
   Althouse BM, 2020, ARXIV2020200513689, V2005, P13689
   ANDERSON R M, 1991
   Anichini G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010066
   [Anonymous], 2013, R LANG ENV STAT COMP
   Arinaminpathy N, 2017, AM J EPIDEMIOL, V186, P92, DOI 10.1093/aje/kwx037
   Baker MG, 2020, MED J AUSTRALIA, V213, P198, DOI 10.5694/mja2.50735
   Baker RE, 2020, SCIENCE, V369, P315, DOI 10.1126/science.abc2535
   Becker AD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185528
   Bedford J., 2020, LANCET, DOI [10.2139/ssrn.3678593, DOI 10.2139/SSRN.3678593]
   Braun J., 2020, 20061440 MEDRXIV
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Dushoff J, 2004, P NATL ACAD SCI USA, V101, P16915, DOI 10.1073/pnas.0407293101
   Ellner PD, 1998, INFECTION, V26, P263, DOI 10.1007/BF02962244
   Ferguson N, 1999, P NATL ACAD SCI USA, V96, P790, DOI 10.1073/pnas.96.2.790
   Frank K., 2020, CANADIANS WILLINGNES
   Frank K., CANADIANS WILLINGNES
   From the Chinese Center for Disease Control and Prevention, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Gandon S, 2001, NATURE, V414, P751, DOI 10.1038/414751a
   Gaunt ER, 2010, J CLIN MICROBIOL, V48, P2940, DOI 10.1128/JCM.00636-10
   Gelaro R, 2017, J CLIMATE, V30, P5419, DOI 10.1175/JCLI-D-16-0758.1
   Gilmour H., 2015, H1N1 VACCINATION
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116
   Halloran M. E., 2010, DESIGN ANAL VACCINE
   Huang J., 2020, 20071258 MEDRXIV
   Huang J, 2020, LONG PERIOD DYNAMICS, DOI [10.1101/2020.04.22.20071258, DOI 10.1101/2020.04.22.20071258]
   Jaume M, 2012, Hong Kong Med J, V18 Suppl 2, P31
   Jaume M., HONG KONG MED J S2, V18, P31
   King AA, 2009, AM NAT, V173, P446, DOI 10.1086/597217
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Laksono BM, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8080210
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   MACNAUGHTON MR, 1982, INFECT IMMUN, V38, P419, DOI 10.1128/IAI.38.2.419-423.1982
   Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511
   Metcalf CJE, 2017, LANCET, V389, P252, DOI 10.1016/S0140-6736(17)30054-5
   Metcalf CJE, 2016, LANCET, V388, P728, DOI 10.1016/S0140-6736(16)30164-7
   Mina MJ, 2020, ELIFE, V9, DOI 10.7554/eLife.58989
   Morris SE, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.1245
   Mulligan M. J., 2020, PHASE 1 2 STUDY DESC, DOI [10.1101/2020.06.30.20142570, DOI 10.1101/2020.06.30.20142570]
   Ng K., 2020, PREEXISTING NOVO HUM, V15, DOI [10.1101/2020.05.14.095414, DOI 10.1101/2020.05.14.095414]
   Ng K. W., 2020, BIORXIV
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   OKeefe S. M., 2020, ONE 3 AM WOULD NOT G
   OKeefe S. M., ONE 3 AM WOULD NOT G
   Park SW, 2020, J R SOC INTERFACE, V17, DOI 10.1098/rsif.2020.0144
   Perkins TA, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006710
   Pitzer VE, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004591
   Pitzer VE, 2009, SCIENCE, V325, P290, DOI 10.1126/science.1172330
   Puntmann V, 2020, JAMA CARDIOL, DOI 10.1001/jamacardio.2020.5285
   Puntmann Valentina O, 2020, JAMA Cardiol, V5, P1265, DOI 10.1001/jamacardio.2020.3557
   Salathe M, 2008, J R SOC INTERFACE, V5, P1505, DOI 10.1098/rsif.2008.0271
   Tan W, 2020, VIRAL KINETICS ANTIB, DOI [10.1101/2020.03.24.20042382, DOI 10.1101/2020.03.24.20042382]
   Tan W., 2020, 20042382 MEDRXIV
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   U.S. Centers for Disease Control and Prevention, 2011, FIN EST 2009 10 SEAS
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Viboud C, 2018, EPIDEMICS-NETH, V22, P13, DOI 10.1016/j.epidem.2017.08.002
   Wang YC, 2020, EUR J CLIN INVEST, DOI 10.1111/eci.13408
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Yip M. S., HONG KONG MED J S4, V22, P25
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Zhang JJ, 2020, SCIENCE, V368, P1481, DOI 10.1126/science.abb8001
   Zhang JJ, 2020, LANCET INFECT DIS, V20, P793, DOI 10.1016/S1473-3099(20)30230-9
NR 77
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD NOV 13
PY 2020
VL 370
IS 6518
SI SI
BP 811
EP +
DI 10.1126/science.abd7343
PG 48
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OT0CO
UT WOS:000590522900056
PM 32958581
OA Other Gold
DA 2021-01-01
ER

PT J
AU Hong, L
   Ye, EL
   Sun, GQ
   Wang, XY
   Zhang, SG
   Wu, YH
   Xie, XG
   Xia, SC
   Zheng, XD
   Dong, L
   Cai, FJ
   Lou, XX
   Zhao, RG
   Hu, YQ
   Ruan, ZW
   Ding, JG
   Sun, QF
AF Hong, Liang
   Ye, Enling
   Sun, Gangqiang
   Wang, Xiaoyang
   Zhang, Shengguo
   Wu, Yanghe
   Xie, Xiangao
   Xia, Shichun
   Zheng, Xudong
   Dong, Ling
   Cai, Fujing
   Lou, Xixian
   Zhao, Renguo
   Hu, Yongqi
   Ruan, Zhanwei
   Ding, Jiguang
   Sun, Qingfeng
TI Clinical and radiographic characteristics, management and short-term
   outcomes of patients with COVID-19 in Wenzhou, China
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; Clinical; Radiographic characteristics; SARS-cov-2;
   Epidemiology
ID CORONAVIRUS PNEUMONIA; FEATURES
AB Background Coronavirus disease 2019 (COVID-19) is an emerging viral disease. Here, we report the clinical features, management, and short-term outcomes of COVID-19 patients in Wenzhou, China, an area outside Wuhan. Methods Patients admitted to the Infectious Diseases Department of Ruian People's Hospital in Wenzhou, from January 21 to February 7, 2020, were recruited. Medical data on epidemiological history, demographics, clinical characteristics, laboratory tests, chest computerized tomography (CT) examination, treatment, and short-term outcomes were retrospectively reviewed. Blood biochemistry and routine tests were examined using standard methods and automatic machines. CT examination was performed several times during hospitalization as necessary. Results A total of 67 confirmed COVID-19 cases were diagnosed; 64 (95.4%) were common cases and three (4.5%) were severe cases. The most common symptoms at admission were fever (86.6%), cough (77.6%), productive cough (52.2%), chest distress (17.9%), and sore throat (11.9%), followed by diarrhea (7.4%), headache (7.4%), shortness of breath (6.0%), dizziness (4.5%), muscular soreness (4.5%), and running nose (4.5%). Thirty patients (47.8%) had increased C-reactive protein levels. The CT radiographs at admission showed abnormal findings in 54 (80.6%) patients. The patients were treated mainly by oxygen therapy and antiviral drugs. By March 3, 2020, all 67 patients completely recovered and had negative nucleic acid tests. The patients were discharged from the hospital and transferred to a medical observation isolation center for further observation. Conclusion Cases of COVID-19 in Wenzhou are milder and have a better prognosis, compared to those in Wuhan. Timely and appropriate screening, diagnosis, and treatment are the key to achieve good outcomes.
C1 [Hong, Liang; Zhang, Shengguo; Wu, Yanghe; Cai, Fujing; Ding, Jiguang; Sun, Qingfeng] Wenzhou Med Univ, Dept Infect Dis, Affiliated Hosp 3, Ruian Peoples Hosp, 108 Wansong Rd, Wenzhou 325200, Zhejiang, Peoples R China.
   [Ye, Enling] Wenzhou Med Univ, Endocrinol Dept, Affiliated Hosp 3, Ruian Peoples Hosp, Ruian City 325200, Zhejiang, Peoples R China.
   [Sun, Gangqiang] Gordon Coll, Dept Biol, Wenham, MA 01984 USA.
   [Wang, Xiaoyang] Wenzhou Med Univ, Radiog Dept, Affiliated Hosp 3, Ruian Peoples Hosp, Ruian City 325200, Zhejiang, Peoples R China.
   [Xie, Xiangao] Hlth Bur Ruian City, 333 Ruihu Rd, Wenzhou 325200, Zhejiang, Peoples R China.
   [Xia, Shichun] Wenzhou Med Univ, Hosp Off, Affiliated Hosp 3, Ruian Peoples Hosp, Ruian City 325200, Zhejiang, Peoples R China.
   [Zheng, Xudong; Hu, Yongqi; Ruan, Zhanwei] Wenzhou Med Univ, Emergency Dept, Affiliated Hosp 3, Ruian Peoples Hosp, Ruian City 325200, Zhejiang, Peoples R China.
   [Dong, Ling; Lou, Xixian; Zhao, Renguo] Wenzhou Med Univ, Pneumol Dept, Affiliated Hosp 3, Ruian Peoples Hosp, Ruian City 325200, Zhejiang, Peoples R China.
RP Ding, JG; Sun, QF (corresponding author), Wenzhou Med Univ, Dept Infect Dis, Affiliated Hosp 3, Ruian Peoples Hosp, 108 Wansong Rd, Wenzhou 325200, Zhejiang, Peoples R China.
EM djg5011@163.com; sunxue0806@126.com
OI sun, qingfeng/0000-0001-8562-5189
FU Ruian Science and Technology Bureau [MS2020023, MS2020025]
FX This work was supported by a fund of Ruian Science and Technology
   Bureau: MS2020023 and MS2020025. The funding bodies had no role in the
   design of the study, the collection, analysis, or interpretation of the
   data, or writing the manuscript.
CR Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
   Bastola A, 2020, LANCET INFECT DIS, V20, P279, DOI 10.1016/S1473-3099(20)30067-0
   Baud D., 2020, LANCET INFECT DIS
   Beatty GW, 2010, EMERG MED CLIN N AM, V28, P299, DOI 10.1016/j.emc.2010.01.003
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Bray Christopher, 2016, WMJ, V115, P317
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen TL, 2020, J GERONTOL A-BIOL, V75, P1788, DOI 10.1093/gerona/glaa089
   Ding JG, 2020, EUR REV MED PHARMACO, V24, P5788, DOI 10.26355/eurrev_202005_21373
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lei JQ, 2020, RADIOLOGY, V295, P18, DOI 10.1148/radiol.2020200236
   Li J, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001491
   Lin XQ, 2020, KOREAN J RADIOL, V21, P365, DOI 10.3348/kjr.2020.0078
   Liu Chun-Yu, 2005, J Chin Med Assoc, V68, P110, DOI 10.1016/S1726-4901(09)70231-X
   Mahase E., 2020, JOURNAL
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Pongpirul WA, 2020, NEW ENGL J MED, V382, P1067, DOI 10.1056/NEJMc2001621
   Shen YZ, 2015, BIOSCI TRENDS, V9, P91, DOI 10.5582/bst.2015.01024
   Shi HS, 2020, RADIOLOGY, V295, P20, DOI 10.1148/radiol.2020200269
   Team TNCPERE, 2020, CHIN CDC WEEKL 2020
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang XY, 2020, BMC MED IMAGING, V20, DOI 10.1186/s12880-020-00471-6
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Yu ZJ, 2011, INT J INFECT DIS, V15, pE845, DOI 10.1016/j.ijid.2011.08.006
   Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   Zhang Y H, 2020, Zhonghua Er Ke Za Zhi, V58, pE006, DOI 10.3760/cma.j.issn.0578-1310.2020.0006
NR 33
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD NOV 13
PY 2020
VL 20
IS 1
AR 841
DI 10.1186/s12879-020-05528-z
PG 13
WC Infectious Diseases
SC Infectious Diseases
GA OZ0SQ
UT WOS:000594647000001
PM 33187475
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rivera-Izquierdo, M
   Valero-Ubierna, MD
   R-delAmo, JL
   Fernandez-Garcia, MA
   Martinez-Diz, S
   Tahery-Mahmoud, A
   Rodriguez-Camacho, M
   Gamiz-Molina, AB
   Barba-Gyengo, N
   Gamez-Baeza, P
   Cabrero-Rodriguez, C
   Guirado-Ruiz, PA
   Martin-Romero, DT
   Lainez-Ramos-Bossini, AJ
   Sanchez-Perez, MR
   Mancera-Romero, J
   Garcia-Martin, M
   Martin-delosReyes, LM
   Martinez-Ruiz, V
   Jimenez-Mejias, E
AF Rivera-Izquierdo, Mario
   Valero-Ubierna, Maria del Carmen
   R-delAmo, Juan Luis
   Fernandez-Garcia, Miguel Angel
   Martinez-Diz, Silvia
   Tahery-Mahmoud, Arezu
   Rodriguez-Camacho, Marta
   Gamiz-Molina, Ana Belen
   Barba-Gyengo, Nicolas
   Gamez-Baeza, Pablo
   Cabrero-Rodriguez, Celia
   Guirado-Ruiz, Pedro Antonio
   Martin-Romero, Divina Tatiana
   Lainez-Ramos-Bossini, Antonio Jesus
   Sanchez-Perez, Maria Rosa
   Mancera-Romero, Jose
   Garcia-Martin, Miguel
   Miguel Martin-delosReyes, Luis
   Martinez-Ruiz, Virginia
   Jimenez-Mejias, Eladio
TI Therapeutic agents tested in 238 COVID-19 hospitalized patients and
   their relationship with mortality
SO MEDICINA CLINICA
LA Spanish
DT Article
DE COVID; SARS-CoV-2; Treatments; Mortality; Hospitalized
AB Background and objectives: In the last months great efforts have been developed to evaluate the more efficient therapeutic agents in the management of patients with COVID-19. Currently, no specific drug combination has consistently demonstrated an association with mortality. The aim of this study was to assess the pattern of associations observed between the different in-hospital treatments administered to a series of 238 patients admitted for COVID-19 and their relationship with mortality.
   Methods: The electronic medical records of patients that discharged or died from COVID-19 in the Hospital Universitario San Cecilio (Granada, Spain) between March 16 and April 10, 2020 were analysed. From these records, information was obtained on sex, age, comorbidities at admission, clinical information, analytical parameters, imaging tests and empirical treatments used. The outcome variable was the inhospital mortality. To estimate the associations between the different therapeutic alternatives and the risk of mortality, hazard ratios adjusted for age, sex, previous pathologies and severity at discharge were estimated using Cox regression models.
   Results: The most frequently used combination of drugs was low molecular weight heparins, hydroxychloroquine, and ritonavir/lopinavir. None of the analysed treatments showed independent association with mortality. The drugs that showed a greater inverse association with mortality were tocilizumab and corticoids.
   Conclusions: The observed association patterns are consistentwith previous literature. It seems necessary to design randomized controlled clinical trials that evaluate the possible protector effect of tocilizumab and corticoids in the risk of mortality for some subgroups of COVID-19 hospitalized patients. (c) 2020 Elsevier Espan similar to a, S.L.U. All rights reserved.
C1 [Rivera-Izquierdo, Mario; Valero-Ubierna, Maria del Carmen; Fernandez-Garcia, Miguel Angel; Martinez-Diz, Silvia; Martin-Romero, Divina Tatiana] Hosp Univ Clin San Cecilio, Serv Med Prevent & Salud Publ, Granada, Spain.
   [Rivera-Izquierdo, Mario; Garcia-Martin, Miguel; Miguel Martin-delosReyes, Luis; Martinez-Ruiz, Virginia; Jimenez-Mejias, Eladio] Univ Granada, Dept Med Prevent & Salud Publ, Granada, Spain.
   [Rivera-Izquierdo, Mario; Garcia-Martin, Miguel; Martinez-Ruiz, Virginia; Jimenez-Mejias, Eladio] Inst Biosanitario Granada, Granada, Spain.
   [R-delAmo, Juan Luis; Rodriguez-Camacho, Marta; Guirado-Ruiz, Pedro Antonio] Hosp Univ Clin San Cecilio, Serv Neurol, Granada, Spain.
   [Tahery-Mahmoud, Arezu] Hosp Univ Clin San Cecilio, Serv Psiquiatria, Granada, Spain.
   [Gamiz-Molina, Ana Belen; Barba-Gyengo, Nicolas; Gamez-Baeza, Pablo; Cabrero-Rodriguez, Celia] Hosp Univ Clin San Cecilio, Serv Neumol, Granada, Spain.
   [Lainez-Ramos-Bossini, Antonio Jesus; Miguel Martin-delosReyes, Luis] Univ Granada, Programa Doctorado Med Clin & Salud Publ, Granada, Spain.
   [Sanchez-Perez, Maria Rosa; Mancera-Romero, Jose; Jimenez-Mejias, Eladio] Univ Granada, Catedra Docencia & Invest Med Familia SEMERGEN UG, Granada, Spain.
   [Garcia-Martin, Miguel; Miguel Martin-delosReyes, Luis; Martinez-Ruiz, Virginia; Jimenez-Mejias, Eladio] CIBER Epidemiol & Salud Publ Espana, Madrid, Spain.
RP Martin-delosReyes, LM (corresponding author), Univ Granada, Dept Med Prevent & Salud Publ, Granada, Spain.; Martin-delosReyes, LM (corresponding author), Univ Granada, Programa Doctorado Med Clin & Salud Publ, Granada, Spain.; Martin-delosReyes, LM (corresponding author), CIBER Epidemiol & Salud Publ Espana, Madrid, Spain.
EM luismiguelmr@ugr.es
OI Martin-delosReyes, Luis Miguel/0000-0002-2163-354X; Lainez
   Ramos-Bossini, Antonio Jesus/0000-0002-0663-2856
CR Abd El-Aziz TM, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104327
   Ahsan W, 2020, DRUG DISCOV THER, V14, P67, DOI 10.5582/ddt.2020.03008
   Beigel JH, 2020, NEW ENGL J MED, DOI DOI 10.1056/NEJMOA2007764.34.
   Callejas Rubio JL, 2020, MED CLIN-BARCELONA, p[S0025, 30283], DOI [10.1016/j.medcli.2020.04.018.32, DOI 10.1016/J.MEDCLI.2020.04.018.32]
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du Y-X, 2020, CLIN PHARM THER
   Esposito Silvano, 2020, Infez Med, V28, P198
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   National Health Commission and State Administration of Traditional Chinese Medicine, 2020, DIAGN TREATM PROT NO
   Nicola M, 2020, INT J SURG, V77, P206, DOI 10.1016/j.ijsu.2020.04.001
   Rabby MII, 2020, J PHARM PHARM SCI, V23, P58, DOI 10.18433/jpps31002
   Red Nacional de Vigilancia Epidemiologica, 2020, INFORM COVID 19
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Saghazadeh A, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106560
   Sanders JM, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.6019.8., DOI 10.1001/JAMA.2020.6019.8]
   Simsek Yavuz S, 2020, TURK J MED SCI, V50, P611, DOI 10.3906/sag-2004-145
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yao X, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa237.11, DOI 10.1093/CID/CIAA237.11]
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0025-7753
EI 1578-8989
J9 MED CLIN-BARCELONA
JI Med. Clin.
PD NOV 13
PY 2020
VL 155
IS 9
BP 375
EP 381
DI 10.1016/j.medcli.2020.06.025
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA ON9PF
UT WOS:000587022400001
PM 32773165
OA Green Published
DA 2021-01-01
ER

PT J
AU Pedrioli, G
   Patani, R
   Paganetti, P
AF Pedrioli, Giona
   Patani, Rickie
   Paganetti, Paolo
TI Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A
   Perspective
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE chloroquine; COVID-19; coronavirus; neurodegeneration; clinical trials
ID AMYOTROPHIC-LATERAL-SCLEROSIS; ALLEVIATES MEMORY DEFICITS; MOUSE MODEL;
   ALZHEIMERS-DISEASE; AMYLOID-BETA; AUTOPHAGY; INHIBITION; TREHALOSE;
   BRAIN; PATHOLOGY
AB On the verge of the ongoing coronavirus pandemic, in vitro data suggested that chloroquine, and its analog hydroxychloroquine, may be useful in controlling SARS-CoV-2 infection. Efforts are ongoing in order to test this hypothesis in clinical trials. Some studies demonstrated no evidence of efficacy, whereas in some cases results were retracted after reporting. Despite the lack of scientific validation, support for the use of these compounds continues from various influencers. At the cellular level, the lysosomotropic drug chloroquine accumulates in acidic organelles where it acts as an alkalizing agent with possible downstream effects on several cellular pathways. In this perspective, we discuss a possible modulatory role of these drugs in two shared features of neurodegenerative diseases, the cellular accumulation of aberrantly folded proteins and the contribution of neuroinflammation in this pathogenic process. Certainly, the decision on the use of chloroquine must be determined by its efficacy in the specific clinical situation. However, at an unprecedented time of a potential widespread use of chloroquine, we seek to raise awareness of its potential impact in ongoing clinical trials evaluating disease-modifying therapies in neurodegeneration.
C1 [Pedrioli, Giona; Paganetti, Paolo] Ente Osped Cantonale, Neuroctr Southern Switzerland, Lab Biomed Neurosci, Neurodegenerat Res Grp, Torricella Taverne, Switzerland.
   [Pedrioli, Giona] Univ Basel, Int PhD Program, Biozentrum, Basel, Switzerland.
   [Patani, Rickie] UCL, Queen Sq Inst Neurol, Dept Neuromuscular Dis, London, England.
   [Patani, Rickie] Francis Crick Inst, London, England.
   [Paganetti, Paolo] Univ Svizzera Italiana, Fac Biomed Sci, Lugano, Switzerland.
RP Paganetti, P (corresponding author), Ente Osped Cantonale, Neuroctr Southern Switzerland, Lab Biomed Neurosci, Neurodegenerat Res Grp, Torricella Taverne, Switzerland.; Paganetti, P (corresponding author), Univ Svizzera Italiana, Fac Biomed Sci, Lugano, Switzerland.
EM paolo.paganetti@eoc.ch
RI Patani, Rickie/J-3107-2018
OI Patani, Rickie/0000-0002-3825-7675
FU Synapsis Foundation; Gelu Foundation; Mecri Foundation; MRC Senior
   Clinical FellowshipMedical Research Council UK (MRC) [MR/S006591/1]
FX PP was funded by the Synapsis Foundation, the Gelu Foundation, and the
   Mecri Foundation. RP holds an MRC Senior Clinical Fellowship
   [MR/S006591/1].
CR ADELUSI SA, 1982, J PHARM PHARMACOL, V34, P733, DOI 10.1111/j.2042-7158.1982.tb06211.x
   Administration U,.S.F.a.D, 2020, COR COVID 19 UPD DAI
   Administration U,.S.F.a.D, 2020, COR COVID 19 UPD FDA
   Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Ali SS, 2018, RHEUMATOLOGY ADV S1, V2, prky033, DOI [10.1093/rap/rky033.014., DOI 10.1093/RAP/RKY033.014, 10.1093/rap/rky033.014]
   Andersen PM, 2011, NAT REV NEUROL, V7, P603, DOI 10.1038/nrneurol.2011.150
   Angelova DM, 2019, J NEUROCHEM, V151, P676, DOI 10.1111/jnc.14860
   BAHR BA, 1994, EXP NEUROL, V129, P81, DOI 10.1006/exnr.1994.1149
   Baudry S, 1997, J PHARM PHARMACOL, V49, P1086, DOI 10.1111/j.2042-7158.1997.tb06047.x
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Bussian TJ, 2018, NATURE, V562, P578, DOI 10.1038/s41586-018-0543-y
   Caccamo A, 2010, J BIOL CHEM, V285, P13107, DOI 10.1074/jbc.M110.100420
   CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252
   Castillo K, 2013, AUTOPHAGY, V9, P1308, DOI 10.4161/auto.25188
   Chen C, 2015, J NEUROSCI, V35, P2674, DOI 10.1523/JNEUROSCI.4389-14.2015
   Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Ciechanover A, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.117
   Crews L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009313
   Cui CM, 2015, MOL MED REP, V12, P2323, DOI 10.3892/mmr.2015.3611
   Cui DR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.318
   Daniyan MO, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9070295
   Du J, 2013, J PHARM PHARMACOL, V65, P1753, DOI 10.1111/jphp.12108
   Fornai F, 2008, P NATL ACAD SCI USA, V105, P2052, DOI 10.1073/pnas.0708022105
   Frautschy SA, 1998, AM J PATHOL, V152, P307
   Hickman S, 2018, NAT NEUROSCI, V21, P1359, DOI 10.1038/s41593-018-0242-x
   Klinger G, 2001, LANCET, V358, P813, DOI 10.1016/S0140-6736(01)06004-4
   LANDEWE RBM, 1995, CLIN EXP IMMUNOL, V102, P144
   Letiembre M, 2007, NEUROSCIENCE, V146, P248, DOI 10.1016/j.neuroscience.2007.01.004
   Li LX, 2013, CURR ALZHEIMER RES, V10, P433, DOI 10.2174/1567205011310040008
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   Manzo Ciro, 2017, Drug Saf Case Rep, V4, P6, DOI 10.1007/s40800-017-0048-x
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Menzies FM, 2015, CELL DEATH DIFFER, V22, P433, DOI 10.1038/cdd.2014.151
   Menzies FM, 2017, NEURON, V93, P1015, DOI 10.1016/j.neuron.2017.01.022
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Myeku N, 2011, J BIOL CHEM, V286, P22426, DOI 10.1074/jbc.M110.149252
   Neznanov N, 2009, CELL CYCLE, V8, P3960, DOI 10.4161/cc.8.23.10179
   OSIFO NG, 1979, TOXICOL APPL PHARM, V50, P109, DOI 10.1016/0041-008X(79)90498-8
   Pedrioli G, 2020, BIORXIV PREPRINT, DOI [10.1101/2020.05.27.118323, DOI 10.1101/2020.05.27.118323]
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   Popert A J, 1976, Rheumatol Rehabil, V15, P235, DOI 10.1093/rheumatology/15.3.235
   PULLMAN TN, 1948, J CLIN INVEST, V27, P46, DOI 10.1172/JCI101970
   Qiao LY, 2009, NEUROSCI LETT, V456, P15, DOI 10.1016/j.neulet.2009.03.085
   Quinn Jane C, 2015, J Parasitol Res, V2015, P368064, DOI 10.1155/2015/368064
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Redmann M, 2017, REDOX BIOL, V11, P73, DOI 10.1016/j.redox.2016.11.004
   Redmann M, 2017, REDOX BIOL, V11, P429, DOI 10.1016/j.redox.2016.12.032
   Ross CA, 2011, LANCET NEUROL, V10, P83, DOI 10.1016/S1474-4422(10)70245-3
   Schaeffer V, 2012, BRAIN, V135, P2169, DOI 10.1093/brain/aws143
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Selkoe DJ, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004457
   Siddiqi FH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09494-2
   Son JH, 2012, EXP MOL MED, V44, P89, DOI 10.3858/emm.2012.44.2.031
   Spencer B, 2009, J NEUROSCI, V29, P13578, DOI 10.1523/JNEUROSCI.4390-09.2009
   Sprangers R, 2008, BIOCHEMISTRY-US, V47, P6727, DOI 10.1021/bi8005913
   Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626
   Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985
   TISCHNER K, 1974, ACTA NEUROPATHOL, V28, P233, DOI 10.1007/BF00719028
   Vodicka P, 2014, J HUNTINGTONS DIS, V3, P159, DOI 10.3233/JHD-130081
   Walter S, 2007, CELL PHYSIOL BIOCHEM, V20, P947, DOI 10.1159/000110455
   Wang IF, 2012, P NATL ACAD SCI USA, V109, P15024, DOI 10.1073/pnas.1206362109
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xilouri M, 2013, BRAIN, V136, P2130, DOI 10.1093/brain/awt131
   Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937
   Zhang PS, 2019, NAT NEUROSCI, V22, P719, DOI 10.1038/s41593-019-0372-9
   Zhang XJ, 2019, AGING DIS, V10, P1159, DOI 10.14336/AD.2019.0228
   Zhang X, 2011, J ALZHEIMERS DIS, V24, P739, DOI 10.3233/JAD-2011-101875
   Zhang Z, 2006, CELL MOL LIFE SCI, V63, P2901, DOI 10.1007/s00018-006-6189-1
NR 71
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD NOV 13
PY 2020
VL 11
AR 596528
DI 10.3389/fneur.2020.596528
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OV8HN
UT WOS:000592443800001
PM 33281734
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Al-Sehemi, AG
   Olotu, FA
   Dev, S
   Pannipara, M
   Soliman, ME
   Carradori, S
   Mathew, B
AF Al-Sehemi, Abdullah G.
   Olotu, Fisayo A.
   Dev, Sanal
   Pannipara, Mehboobali
   Soliman, Mahmoud E.
   Carradori, Simone
   Mathew, Bijo
TI Natural Products Database Screening for the Discovery of Naturally
   Occurring SARS-Cov-2 Spike Glycoprotein Blockers
SO CHEMISTRYSELECT
LA English
DT Article
DE Castanospermine; coronavirus; COVID-19; karuquinone B; library
   screening; spike glycoprotein
AB SARS-CoV-2 coronavirus has been recognized the causative agent of the recent and ongoing pandemic. Effective and specific antiviral agents or vaccines are still missing, despite a large plethora of compounds have been proposed and tested worldwide. New compounds are requested urgently and virtual screening can offer fast and robust predictions to investigate. Moreover, natural compounds were shown to exert antiviral effects and can be endowed with limited side effects and wide availability. Our approach consisted in the validation of a docking protocol able to refine the most suitable candidates, within the 31000 natural compounds of the natural product activity and species source (NPASS) library, interacting with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein. After the refinement process two natural compounds, castanospermine and karuquinone B, were shown to be the best-in-class derivatives in silico able to target an essential structure of the virus and to act in the early stage of infection.
C1 [Al-Sehemi, Abdullah G.; Pannipara, Mehboobali] King Khalid Univ, Res Ctr Adv Mat Sci, Abha 61413, Saudi Arabia.
   [Al-Sehemi, Abdullah G.; Pannipara, Mehboobali] King Khalid Univ, Dept Chem, Abha 61413, Saudi Arabia.
   [Olotu, Fisayo A.; Soliman, Mahmoud E.] Univ KwaZulu Natal, Sch Hlth Sci, Mol Biocomputat & Drug Design Lab, Westville Campus, ZA-4001 Durban, South Africa.
   [Dev, Sanal] Al Shifa Coll Pharm, Dept Pharmaceut Chem, Perinthalmanna, Kerala, India.
   [Carradori, Simone] G dAnnunzio Univ Chieti Pescara, Dept Pharm, I-66100 Chieti, Italy.
   [Mathew, Bijo] Amrita Vishwa Vidyapeetham, Amrita Sch Pharm, Dept Pharmaceut Chem, AIMS Hlth Sci Campus, Kochi 682041, Kerala, India.
RP Carradori, S (corresponding author), G dAnnunzio Univ Chieti Pescara, Dept Pharm, I-66100 Chieti, Italy.; Mathew, B (corresponding author), Amrita Vishwa Vidyapeetham, Amrita Sch Pharm, Dept Pharmaceut Chem, AIMS Hlth Sci Campus, Kochi 682041, Kerala, India.
EM simone.carradori@unich.it; bijovilaventgu@gmail.com
RI Carradori, Simone/S-4776-2019
OI Carradori, Simone/0000-0002-8698-9440
FU King Khalid University [3-N-20/21]; research centre for advanced
   material science
FX The authors are thankful to institute of research and consulting studies
   at King Khalid University for funding this research through grant no
   3-N-20/21 and the support of research centre for advanced material
   science is highly acknowledged.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Bhushan G, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00531
   Carradori Simone, 2020, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V19, P85, DOI 10.2174/1871523019999200228100917
   Chang JH, 2013, ANTIVIR RES, V99, P251, DOI 10.1016/j.antiviral.2013.06.011
   Choi HG, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010091
   Daina A, 2016, CHEMMEDCHEM, V11, P1117, DOI 10.1002/cmdc.201600182
   Dowall SD, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8110277
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Kumar Rajesh, 2020, Curr Med Chem, DOI 10.2174/0929867327666200702151018
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Messina F, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02405-w
   Naik B, 2020, INT J BIOL MACROMOL, V160, P1, DOI 10.1016/j.ijbiomac.2020.05.184
   Norton PA, 2010, HEPATOLOGY, V52, P1242, DOI 10.1002/hep.23806
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Ozkan H, 2020, CHEMISTRYSELECT, V5, P5422, DOI 10.1002/slct.202001123
   Prasanth DSNBK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779129
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Takemoto K, 2014, J NAT PROD, V77, P1992, DOI 10.1021/np500175j
   Tanaka Y, 2006, ANTIVIR RES, V72, P1, DOI 10.1016/j.antiviral.2006.03.016
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Watanabe S, 2012, ANTIVIR RES, V96, P32, DOI 10.1016/j.antiviral.2012.07.008
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhou Dapeng, 2020, Glycobiology, DOI 10.1093/glycob/cwaa052
NR 27
TC 0
Z9 0
U1 1
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2365-6549
J9 CHEMISTRYSELECT
JI ChemistrySelect
PD NOV 13
PY 2020
VL 5
IS 42
BP 13309
EP 13317
DI 10.1002/slct.202003349
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA OU1DT
UT WOS:000591276200049
PM 33363254
OA Bronze
DA 2021-01-01
ER

PT J
AU Singh, J
   Malik, D
   Raina, A
AF Singh, Jitender
   Malik, Deepti
   Raina, Ashvinder
TI Computational investigation for identification of potential
   phytochemicals and antiviral drugs as potential inhibitors for
   RNA-dependent RNA polymerase of COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Phytochemicals; antiviral drugs; pharmacokinetics; binding pocket;
   molecular docking; structural activity relationship
ID MULTIPLE SEQUENCE ALIGNMENT; CORONAVIRUS; FLAVONOIDS; PREDICTION
AB Since the SARS/MERS epidemic, scientists across the world have been racing to identify the novel-CoVs as it has been predicted that next epidemic can very well be a result from a new mutation of CoV, for which hundred mutations have already been discovered, and the same fear has come true with world facing a raging pandemic due to COVID-19, an infectious disease caused by a newly discovered coronavirus. COVID-19 or Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), is a single stranded RNA virus. COVID -19 is highly contagious and has resulted in current global pandemic with almost no country of the world unaffected by this virus. Owing to the lack of effective therapeutics or vaccines, the best measures to control human coronaviruses remain a strong public health surveillance system coupled with rapid diagnostic testing and quarantine/social; distancing/lockdowns as and when necessary. In the present study, we have used the insilico approach for the prediction of novel drug molecules from available antiviral drugs and also from natural compounds that can be best target against RNA-dependent RNA-polymerase (Pol/RdRp) protein of SARS-CoV-2 which can be suitable drugs for the treatment of COVID-19 virus. From the current study we observed that three antiviral and three phyto-chemicals have minimum binding energy with the target protein which were further evaluated in molecular dynamics studies and could specifically bind to RdRp protein of COVID-19. Based on results we suggest that these drugs may act as best or novel inhibitor that may be used for the treatment of SARS-CoV-2.
   Communicated by Ramaswamy H. Sarma
C1 [Singh, Jitender; Malik, Deepti; Raina, Ashvinder] Post Grad Inst Med Educ & Res, Chandigarh 160012, India.
RP Raina, A (corresponding author), Post Grad Inst Med Educ & Res, Chandigarh 160012, India.
EM drashvinder@gmail.com
CR Ahlquist P, 2003, J VIROL, V77, P8181, DOI 10.1128/JVI.77.15.8181-8186.2003
   Ahmed S, 2019, HLTH SCI REPORTS, V2, pe140
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Andres A, 2009, J NUTR BIOCHEM, V20, P563, DOI 10.1016/j.jnutbio.2009.04.004
   Badam Lalita, 1999, Journal of Communicable Diseases, V31, P79
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Carugo O, 2001, PROTEIN SCI, V10, P1470, DOI 10.1110/ps.690101
   Chatterjee S., 2020, ENVELOPE MEMBRANE NU
   Chen Li, 2020, Cardiovasc Res, V116, P1932, DOI 10.1093/cvr/cvaa093
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Cyranoski D, 2020, NATURE, V579, P18, DOI 10.1038/d41586-020-00548-w
   Dalip K., 2010, BMC BIOINFORMATICS, V20, P3916, DOI DOI 10.1186/1471-2105-9-396
   Drwal MN, 2014, NUCLEIC ACIDS RES, V42, pW53, DOI 10.1093/nar/gku401
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Garozzo A, 2011, ANTIVIR RES, V89, P83, DOI 10.1016/j.antiviral.2010.11.010
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Huang FF, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104929
   Jendele L, 2019, NUCLEIC ACIDS RES, V47, pW345, DOI 10.1093/nar/gkz424
   Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091
   KAUL TN, 1985, J MED VIROL, V15, P71, DOI 10.1002/jmv.1890150110
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   KRIEGER E, 2009, PROTEINS S9, V77
   Kufareva Irina, 2012, Methods Mol Biol, V857, P231, DOI 10.1007/978-1-61779-588-6_10
   LAGORCE D, 2015, NUCL ACIDS RES, V43
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lam AM, 2012, ANTIMICROB AGENTS CH, V56, P3359, DOI 10.1128/AAC.00054-12
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Mair C. E., 2016, PLANTA MED, V81
   Miller WA, 2000, VIROLOGY, V273, P1, DOI 10.1006/viro.2000.0421
   Moghadamtousi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/186864
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pandit M., 2020, BIOINFORMATICS, DOI [10.21203/rs.3.rs-22687/v1, DOI 10.21203/RS.3.RS-22687/V1]
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Sudhanshu Agrawal, 2016, National Journal of Physiology, Pharmacy and Pharmacology, V6, P1
   Tatar G., 2020, SCIENCEOPEN, DOI [10.14293/S2199-1006.1.SOR-.PPPT99I.v1, DOI 10.14293/S2199-1006.1.SOR-.PPPT99I.V1]
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Ubani A., 2020, BIORXIV, DOI 10.1101/2020.03.31.017657
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Ye YZ, 2004, NUCLEIC ACIDS RES, V32, pW582, DOI 10.1093/nar/gkh430
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 54
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1847688
EA NOV 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OS6PF
UT WOS:000590282600001
PM 33200678
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, Y
   Zhang, M
   Yu, Y
   Han, T
   Zhou, J
   Bi, LQ
AF Wang, Yu
   Zhang, Meng
   Yu, Yan
   Han, Tao
   Zhou, Ji
   Bi, Liqing
TI Sputum characteristics and airway clearance methods in patients with
   severe COVID-19
SO MEDICINE
LA English
DT Article
DE COVID-19; expectorant drugs; prone-position drainage; severity; sputum
   characteristics
AB Critically ill patients with coronavirus disease 2019 (COVID-19) have a high case fatality rate. Hence, controlling the disease progression of severely ill COVID-19 patients to avoid the development of severe-to-critical COVID-19 is the most important target of COVID-19 treatment. The latest autopsy results of COVID-19 patients have shown the presence of viscous secretions in the airways. However, no studies are available that specifically describe and analyze the sputum characteristics and the effects of various sputum drainage methods on the prognosis of COVID-19 patients. In our study, we found that elderly COVID-19 patients were more susceptible to progression to critical illness (P = .024) and were likely to have accompanying lymphopenia (P = .035) or increased neutrophil counts (P = .019). We observed that there was a higher proportion of patients with Grade 3 sticky sputum in the critically ill group than in the noncritically ill group (P = .026), suggesting that changes in sputum characteristics may be one of the early warning signs of critical COVID-19. In addition, we found that the application rates of large doses of ambroxol (P = .043) and prone-position drainage (P = .037) were relatively high in COVID-19 patients with good prognoses, suggesting that the early application of large doses of expectorant drugs and prone-position drainage in COVID-19 patients may avoid progression to critical illness and improve the prognosis.
C1 [Wang, Yu; Bi, Liqing] Nanjing Med Univ, Affiliated Hosp 1, Intens Care Unit, Dept Neurosurg, Nanjing, Peoples R China.
   [Zhang, Meng; Yu, Yan; Han, Tao] Nanjing Med Univ, Affiliated Hosp 1, Dept Crit Care Med, Nanjing, Peoples R China.
   [Zhou, Ji] Nanjing Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Nanjing, Peoples R China.
RP Bi, LQ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Nanjing 210029, Jiangsu, Peoples R China.
EM biliqing@163.com
FU Cadre Healthcare Research Fund from Jiangsu Province Commission of
   Health [BJ14001]
FX This study was funded by the Cadre Healthcare Research Fund from Jiangsu
   Province Commission of Health (BJ14001).
CR Arentz M, 2020, JAMA
   Chinese Association of Rehabilitation Medicine, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P308, DOI 10.3760/cma.j.cn112147-20200228-00206
   COVID-19 Treatment Cooperation Group in Tongji Hospital Wuhan, 2020, J INTERN INTENS MED, V26, P1
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   LI HQ, 2020, CHIN J TUBERC RESP D, V43, DOI DOI 10.1016/J.MSARD.2020.102167
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Liu Q, 2020, Fa Yi Xue Za Zhi, V36, P21, DOI 10.12116/j.issn.1004-5619.2020.01.005
   National Health Commission of the People's Republic of China, 2020, J CARDIOVASC PULMON, V39, P103
   National Health Commission of the People's Republic of China, NOV COR CHIN
   Pan C, 2020, AM J RESP CRIT CARE, V201, P1294, DOI 10.1164/rccm.202003-0527LE
   [沈梅芬 SHEN Mei-fen], 2009, [中华护理杂志, Chinese Journal of Nursing], V44, P694
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zanasi A, 2014, PULM PHARMACOL THER, V27, P102, DOI 10.1016/j.pupt.2013.05.007
   Zhong LH, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00130-2019
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV 13
PY 2020
VL 99
IS 46
DI 10.1097/MD.0000000000023257
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS0ED
UT WOS:000589836300086
PM 33181718
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rygalski, CJ
   Zhao, SZ
   Eskander, A
   Zhan, KY
   Mroz, EA
   Brock, G
   Silverman, DA
   Blakaj, D
   Bonomi, MR
   Carrau, RL
   Old, MO
   Rocco, JW
   Seim, NB
   Puram, SV
   Kang, SY
AF Rygalski, Chandler J.
   Zhao, Songzhu
   Eskander, Antoine
   Zhan, Kevin Y.
   Mroz, Edmund A.
   Brock, Guy
   Silverman, Dustin A.
   Blakaj, Dukagjin
   Bonomi, Marcelo R.
   Carrau, Ricardo L.
   Old, Matthew O.
   Rocco, James W.
   Seim, Nolan B.
   Puram, Sidharth V.
   Kang, Stephen Y.
TI Time to Surgery and Survival in Head and Neck Cancer
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article; Early Access
ID POSTOPERATIVE RADIATION-THERAPY; SURGICALLY MANAGED HEAD; TREATMENT
   PACKAGE TIME; TREATMENT INITIATION; HOSPITAL VOLUME; INCREASING TIME;
   CARCINOMA; MORTALITY; IMPACT; CARE
AB Background The COVID-19 pandemic has required triage and delays in surgical care throughout the world. The impact of these surgical delays on survival for patients with head and neck squamous cell carcinoma (HNSCC) remains unknown. Methods A retrospective cohort study of 37 730 patients in the National Cancer Database with HNSCC who underwent primary surgical management from 2004 to 2016 was performed. Uni- and multivariate analyses were used to identify predictors of overall survival. Bootstrapping methods were used to identify optimal time-to-surgery (TTS) thresholds at which overall survival differences were greatest. Cox proportional hazard models with or without restricted cubic splines were used to determine the association between TTS and survival. Results The study identified TTS as an independent predictor of overall survival (OS). Bootstrapping the data to dichotomize the cohort identified the largest rise in hazard ratio (HR) at day 67, which was used as the optimal TTS cut-point in survival analysis. The patients who underwent surgical treatment longer than 67 days after diagnosis had a significantly increased risk of death (HR, 1.189; 95% confidence interval [CI], 1.122-1.261; P < 0.0001). For every 30-day delay in TTS, the hazard of death increased by 4.6%. Subsite analysis showed that the oropharynx subsite was most affected by surgical delays, followed by the oral cavity. Conclusions Increasing TTS is an independent predictor of survival for patients with HNSCC and should be performed within 67 days after diagnosis to achieve optimal survival outcomes.
C1 [Rygalski, Chandler J.; Zhan, Kevin Y.; Mroz, Edmund A.; Silverman, Dustin A.; Carrau, Ricardo L.; Old, Matthew O.; Rocco, James W.; Seim, Nolan B.; Kang, Stephen Y.] Ohio State Univ, Dept Otolaryngol Head & Neck Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Zhao, Songzhu; Brock, Guy] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA.
   [Zhao, Songzhu; Brock, Guy] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA.
   [Eskander, Antoine] Sunnybrook Hlth Sci Ctr, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada.
   [Blakaj, Dukagjin] Ohio State Univ, Dept Radiat Oncol, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Bonomi, Marcelo R.] Ohio State Univ, Dept Internal Med, Div Med Oncol, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Puram, Sidharth V.] Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Ear Nose & Throat Ctr, St Louis, MO 63110 USA.
RP Kang, SY (corresponding author), Ohio State Univ, Dept Otolaryngol Head & Neck Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Stephen.kang@osumc.edu
CR Bilimoria KY, 2008, ANN SURG ONCOL, V15, P683, DOI 10.1245/s10434-007-9747-3
   Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337
   Cheraghlou S, 2017, LARYNGOSCOPE, V127, P616, DOI 10.1002/lary.26259
   Cracchiolo JR, 2016, CANCER-AM CANCER SOC, V122, P1523, DOI 10.1002/cncr.29938
   Eskander A, 2014, LARYNGOSCOPE, V124, P2081, DOI 10.1002/lary.24704
   Finlayson EVA, 2003, ARCH SURG-CHICAGO, V138, P721, DOI 10.1001/archsurg.138.7.721
   Fujiwara RJT, 2017, HEAD NECK-J SCI SPEC, V39, P639, DOI 10.1002/hed.24608
   Goel AN, 2019, ORAL ONCOL, V88, P39, DOI 10.1016/j.oraloncology.2018.11.021
   Graboyes EM, 2019, JAMA OTOLARYNGOL, V145, P166, DOI 10.1001/jamaoto.2018.2716
   Graboyes EM, 2017, CANCER-AM CANCER SOC, V123, P4841, DOI 10.1002/cncr.30939
   Harris JP, 2018, JAMA OTOLARYNGOL, V144, P349, DOI 10.1001/jamaoto.2017.3406
   Ho AS, 2018, CANCER-AM CANCER SOC, V124, P3154, DOI 10.1002/cncr.31533
   Hollenbeck BK, 2007, J CLIN ONCOL, V25, P91, DOI 10.1200/JCO.2006.07.2454
   McCahill LE, 2009, ARCH SURG-CHICAGO, V144, P455, DOI 10.1001/archsurg.2009.56
   Murphy CT, 2016, J CLIN ONCOL, V34, P169, DOI 10.1200/JCO.2015.61.5906
   Murphy CT, 2015, CANCER-AM CANCER SOC, V121, P1204, DOI 10.1002/cncr.29191
   Rosenthal DI, 2002, HEAD NECK-J SCI SPEC, V24, P115, DOI 10.1002/hed.10038
   Wuthrick EJ, 2015, J CLIN ONCOL, V33, P156, DOI 10.1200/JCO.2014.56.5218
   Xiao R, 2018, CANCER-AM CANCER SOC, V124, P1400, DOI 10.1002/cncr.31213
   Zhan KY, 2018, HEAD NECK-J SCI SPEC, V40, P1967, DOI 10.1002/hed.25178
   Zhan KY, CANCER, DOI [10.1002/cncr.32654.%3caq3, DOI 10.1002/CNCR.32654.%3CAQ3&GT;]
NR 21
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
DI 10.1245/s10434-020-09326-4
EA NOV 2020
PG 9
WC Oncology; Surgery
SC Oncology; Surgery
GA OR4XY
UT WOS:000589476400003
PM 33188461
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rajendran, M
   Roy, S
   Ravichandran, K
   Mishra, B
   Gupta, DK
   Nagarajan, S
   Selvaraj, RCA
   Provaznik, I
AF Rajendran, Mala
   Roy, Sudeep
   Ravichandran, Keerthana
   Mishra, Bagdevi
   Gupta, Deepak K.
   Nagarajan, Subash
   Arul Selvaraj, Ruby Celsia
   Provaznik, Ivo
TI In silico screening and molecular dynamics of phytochemicals from Indian
   cuisine against SARS-CoV-2 M-Pro
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE cinnamon; cinnamtannin; cyanin; hydroxychloroquine diphosphate;
   remdesivir and spices
ID CORONAVIRUS 3C-LIKE PROTEASE; ANTIVIRAL ACTIVITY; DIMER INTERFACE;
   VIRUS; FLAVONOIDS; PROANTHOCYANIDINS; INHIBITION; PROTEINASE; MUTATION;
   EXTRACT
AB SARS-CoV-2 cause fatal infection in 213 countries accounting for the death of millions of people globally. In the present study, phytochemicals from spices were assessed for their ability to interact with SARS-CoV-2 M-Pro. Structure based virtual screening was performed with 146 phytochemicals from spices using Autodock Vina. Phytochemicals with binding energy >= -8.0 kcal/mol were selected to understand their interaction with M-Pro. Virtual screening was further validated by performing molecular docking to generate favorable docked poses and the participation of important amino acid residues. Molecular dynamics simulation for the docked poses was performed to study thermodynamic properties of the protein, ligand and protein-ligand complexes. The finding shows that cinnamtannin B2 and cyanin showed favorable binding affinity values with SARS-CoV-2 M-Pro. The results are comparable in terms of docked poses, important amino acid participation and thermodynamic properties with the standard control drugs remdesivir, benazepril and hydroxychloroquine diphosphate. Prime MM-GBSA was employed for end-point binding energy calculation. Binding to domain I and II of M-Pro were mediated through the OH, SH, NH2 and non-polar side chain of amino acids. Cinnamtannin B2 and cyanin binds to M-Pro with many sub sites within the active site with RMSD and RMSF within 4 angstrom. The results computed using Prime MM-GBSA show that cinnamtannin B2 (-68.54940214 kcal/mol) and cyanin (-62.1902835 kcal/mol) have better binding affinity in comparison to hydroxychloroquine diphosphate (-54.00912412 kcal/mol) and benazepril (-53.70242369 kcal/mol). The results provide a basis for exploiting cinnamtannin B2 and cyanin as a starting point potential candidate for the development of drug against SARS-CoV-2.
   Communicated by Ramaswamy H. Sarma
C1 [Rajendran, Mala; Ravichandran, Keerthana; Nagarajan, Subash; Arul Selvaraj, Ruby Celsia] Mepco Schlenk Engn Coll, Dept Biotechnol, Sivakasi 626005, Tamil Nadu, India.
   [Roy, Sudeep; Provaznik, Ivo] Brno Univ Technol, Fac Elect Engn & Commun, Dept Biomed Engn, Brno, Czech Republic.
   [Mishra, Bagdevi; Gupta, Deepak K.] Neogen Informat, A121 Vikas Marg, New Delhi, India.
RP Rajendran, M (corresponding author), Mepco Schlenk Engn Coll, Dept Biotechnol, Sivakasi 626005, Tamil Nadu, India.
EM maalsindia@mepcoeng.ac.in
CR Abdelrheem DA, 2020, J ENVIRON SCI HEAL A, V55, P1373, DOI 10.1080/10934529.2020.1826192
   Al-Bari M. A. A., 2017, PHARMACOL RES PERSPE, V23, DOI 10.1002/prp2.29310.1002/prp2.293
   Amin Faiz Ul, 2017, J Nanobiotechnology, V15, P12, DOI 10.1186/s12951-016-0227-4
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Arkin MR, 2014, CHEM BIOL, V21, P1102, DOI 10.1016/j.chembiol.2014.09.001
   Ballabio A, 2020, NAT REV MOL CELL BIO, V21, P101, DOI 10.1038/s41580-019-0185-4
   Beard H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082849
   Borrelli KW, 2010, J COMPUT CHEM, V31, P1224, DOI 10.1002/jcc.21409
   Campagna M, 2010, BIOCHEM SOC T, V38, P50, DOI 10.1042/BST0380050
   Carmo ES, 2008, BRAZ J MICROBIOL, V39, P91, DOI 10.1590/S1517-838220080001000021
   Chen J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2603-0
   Chen S, 2008, J BIOL CHEM, V283, P554, DOI 10.1074/jbc.M705240200
   Cheng SC, 2010, BIOPHYS J, V98, P1327, DOI 10.1016/j.bpj.2009.12.4272
   Chiang LC, 2003, PLANTA MED, V69, P600, DOI 10.1055/s-2003-41113
   Doak B, 2017, EXPERT OPIN DRUG DIS, V12, P115, DOI 10.1080/17460441.2017.1264385
   Evers DL, 2005, ANTIVIR RES, V68, P124, DOI 10.1016/j.antiviral.2005.08.002
   Forni C, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8748253
   Ganesan A, 2017, EXPERT OPIN DRUG DIS, V12, P407, DOI 10.1080/17460441.2017.1291628
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Ghosh D., 2005, Current Topics in Nutraceutical Research, V3, P113
   Gimeno A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061375
   Gohlke H, 2002, ANGEW CHEM INT EDIT, V41, P2645
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695
   Hu TC, 2009, VIROLOGY, V388, P324, DOI 10.1016/j.virol.2009.03.034
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jayaprakasha GK, 2007, J FOOD COMPOS ANAL, V20, P330, DOI 10.1016/j.jfca.2006.07.006
   Jimenez Avalos G. M., 2020, HIGH THROUGHPUT VIRT
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kimmel EM, 2011, ANTIVIR RES, V90, P80, DOI 10.1016/j.antiviral.2011.02.011
   Krueger CG, 2013, ANAL BIOANAL CHEM, V405, P4385, DOI 10.1007/s00216-013-6750-3
   Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750
   Kwon HJ, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-307
   Lai KF, 2018, J THORAC DIS, V10, P6314, DOI 10.21037/jtd.2018.09.153
   Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335
   Li CM, 2010, J BIOL CHEM, V285, P28134, DOI 10.1074/jbc.M109.095851
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   LIETTI A, 1976, ARZNEIMITTEL-FORSCH, V26, P829
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Lin LT, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-187
   Liu JY, 2020, EMERG INFECT DIS, V26, P1320, DOI 10.3201/eid2606.200239
   Luganini A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01826
   Luo Y, 2019, PHARMACOGN MAG, V15, P124, DOI 10.4103/pm.pm_162_18
   Lyu SY, 2005, ARCH PHARM RES, V28, P1293, DOI 10.1007/BF02978215
   Maciorowski D, 2020, SLAS DISCOV, V25, P1108, DOI 10.1177/2472555220958385
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Orhan DD, 2010, MICROBIOL RES, V165, P496, DOI 10.1016/j.micres.2009.09.002
   Patri A, 2020, J AM ACAD DERMATOL, V82, pe221, DOI 10.1016/j.jaad.2020.04.017
   Peele K Abraham, 2020, Inform Med Unlocked, V19, P100345, DOI 10.1016/j.imu.2020.100345
   Peng QX, 2015, DRUG RES, V65, P587, DOI 10.1055/s-0034-1395564
   Pour PM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01207
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Prasanth DSNBK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779129
   Qiu XG, 2016, ANTIMICROB AGENTS CH, V60, P5182, DOI 10.1128/AAC.00307-16
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shivanika C, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1815584
   Shojai TM, 2016, AVICENNA J PHYTOMEDI, V6, P458
   Singh TU, 2020, PHARMACOL REP, V72, P1479, DOI 10.1007/s43440-020-00155-6
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Su XW, 2010, FOOD MICROBIOL, V27, P535, DOI 10.1016/j.fm.2010.01.001
   Takeshita M, 2009, J BIOL CHEM, V284, P21165, DOI 10.1074/jbc.M109.004945
   Terlizzi ME, 2016, ANTIVIR RES, V132, P154, DOI 10.1016/j.antiviral.2016.06.006
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Townsend EA, 2013, AM J RESP CELL MOL, V48, P157, DOI 10.1165/rcmb.2012-0231OC
   TSUDA T, 1994, J AGR FOOD CHEM, V42, P2407, DOI 10.1021/jf00047a009
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Unlu M, 2010, FOOD CHEM TOXICOL, V48, P3274, DOI 10.1016/j.fct.2010.09.001
   van der Spoel D, 1998, J CHEM PHYS, V108, P10220, DOI 10.1063/1.476482
   Villar EA, 2014, NAT CHEM BIOL, V10, P723, DOI [10.1038/NCHEMBIO.1584, 10.1038/nchembio.1584]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang TF, 2016, HEMATOL-AM SOC HEMAT, P714, DOI 10.1182/asheducation-2016.1.714
   Wevers BA, 2009, CLIN LAB MED, V29, P715, DOI 10.1016/j.cll.2009.07.007
   Wongwichai T, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108610
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xu YN, 2000, FEBS LETT, V487, P185, DOI 10.1016/S0014-5793(00)02336-X
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yasuhara-Bell J, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-182
   Zandi K, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-560
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhuang M, 2009, ANTIVIR RES, V82, P73, DOI 10.1016/j.antiviral.2009.02.001
NR 90
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1845980
EA NOV 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OS0PH
UT WOS:000589865300001
PM 33200680
OA Bronze
DA 2021-01-01
ER

PT J
AU Tegeler, C
   Beyer, AK
   Hoppmann, F
   Ludwig, V
   Kessler, E
AF Tegeler, Christina
   Beyer, Ann-Kristin
   Hoppmann, Fee
   Ludwig, Valentina
   Kessler, Eva-Marie
TI Current state of research on psychotherapy for home-living vulnerable
   older adults with depression
SO ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE
LA English
DT Article
DE State of the art review; Frailty; Homebound individuals; Psychosocial
   interventions; Collaborative care
ID LATE-LIFE DEPRESSION; PRIMARY-CARE; THERAPY; METAANALYSIS
AB Older home-living vulnerable adults often suffer from chronic conditions accompanied by restrictions in mobility, social participation and reduced independence. Among this rapidly growing population depression is a common and serious health problem; however, there are shortcomings in the diagnosis of depression and provision of psychotherapy. Despite growing evidence in treating depression among the group of nursing home residents or the "young-old", there is a research gap regarding needs-oriented healthcare strategies for very old, frail or care-dependent older adults living at home. The present article provides an overview of different outpatient psychotherapeutic treatment approaches for vulnerable older adults with depression, in particular adaptations tailored to those who are homebound or in need of care. Based on the current state of research, this article derives recommendations for psychotherapy in this special setting to consider the physical and psychosocial resources of this patient group. Furthermore, healthcare strategies for embedding psychotherapy in collaborative, telehealth or home-delivered healthcare services are described and their applicability as psychosocial support for older adults during the coronavirus disease 2019 (COVID-19) pandemic is discussed. Psychotherapy is an efficacious treatment for depression in home-living vulnerable older adults. Further implementing telehealth or home delivered settings, individually tailored psychotherapeutic approaches as well as collaborative and stepped care approaches can increase utilization and medical supply of this patient group. More research and innovative programs are needed to improve access to and provision of psychotherapeutic care as well as their social inclusion.
C1 [Tegeler, Christina; Hoppmann, Fee; Ludwig, Valentina; Kessler, Eva-Marie] MSB Med Sch Berlin, Dept Psychol, Rudesheimer Str 50, D-14197 Berlin, Germany.
   [Beyer, Ann-Kristin] Charite Univ Med Berlin, Inst Med Sociol & Rehabil Sci, Charitepl 1, D-10117 Berlin, Germany.
RP Tegeler, C; Kessler, E (corresponding author), MSB Med Sch Berlin, Dept Psychol, Rudesheimer Str 50, D-14197 Berlin, Germany.
EM christina.tegeler@medicalschool-berlin.de;
   eva-marie.kessler@medicalschool-berlin.de
CR Aguirre E, 2013, AGEING RES REV, V12, P253, DOI 10.1016/j.arr.2012.07.001
   Atiq Rafay, 2006, Psychiatry (Edgmont), V3, P53
   Banerjee D, 2020, INT J GERIATR PSYCH, V35, P1466, DOI 10.1002/gps.5320
   Bharucha AJ, 2006, J AM MED DIR ASSOC, V7, P568, DOI 10.1016/j.jamda.2006.08.003
   Bjerregaard F, 2018, GESUNDHEITSWESEN, V80, P34, DOI 10.1055/s-0042-107344
   Blackburn P, 2017, B C MED J, V59, P171
   Brooks J, 2020, J MATERN-FETAL NEO M, DOI [10.1080/14767058.2020.1827384, 10.1111/jocn.15274]
   Carpenter B, 2002, CLIN GERONTOLOGIST, P25
   Choi NG, 2013, CURR GERIATR REP, V2, P16, DOI 10.1007/s13670-012-0032-3
   Choi NG, 2013, BEHAV THER, V44, P489, DOI 10.1016/j.beth.2013.04.002
   DGPPN BKA, 2015, S3 LEITLINIE NATIONA, DOI [10.6101/AZQ/000364, DOI 10.6101/AZQ/000364]
   Frost R, 2019, BRIT J GEN PRACT, V69, pE171, DOI 10.3399/bjgp19X701297
   Gellert P, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01661-1
   Harerimana B, 2019, INT J MENT HEALTH NU, V28, P657, DOI 10.1111/inm.12571
   Hinrichsen GA, 2014, AM PSYCHOL, V69, P34, DOI [10.1037/a0035063, 10.1037/0003-066X.59.4.236]
   Holzel LP, 2018, DTSCH ARZTEBL INT, V115, P741, DOI 10.3238/arztebl.2018.0741
   Huang AX, 2015, AM J GERIAT PSYCHIAT, V23, P261, DOI 10.1016/j.jagp.2014.04.003
   Huang CQ, 2009, J INVEST MED, V57, P446, DOI 10.2310/JIM.0b013e3181954c2f
   Humanitarian UN, 2020, COVID 19 OLDER PEOPL
   Hunsaker A, 2018, NEW MEDIA SOC, V20, P3937, DOI 10.1177/1461444818787348
   Kessler EM, 2018, PSYCHOTHERAPEUT, V63, P501, DOI 10.1007/s00278-018-0315-z
   Kessler EM, 2020, AGING MENT HEALTH, V24, P193, DOI 10.1080/13607863.2018.1515889
   Kessler EM, 2015, GEROPSYCH, V28, P47, DOI 10.1024/1662-9647/a000129
   Kiosses DN, 2015, JAMA PSYCHIAT, V72, P22, DOI 10.1001/jamapsychiatry.2014.1305
   Kirkham J, 2015, AM J GERIAT PSYCHIAT, V23, pS129, DOI 10.1016/j.jagp.2014.12.131
   Koder DA, 2006, AUST PSYCHOL, V41, P179, DOI 10.1080/00050060600730876
   Konnert C, 2014, OXFORD HDB CLIN GERO, P949
   Laidlaw K, 2015, GEROPSYCH, V28, P57, DOI 10.1024/1662-9647/a000128
   Luck-Sikorski C, 2017, INT PSYCHOGERIATR, V29, P389, DOI 10.1017/S1041610216001885
   Luppa M, 2012, J AFFECT DISORDERS, V136, P212, DOI 10.1016/j.jad.2010.11.033
   McGovern AR, 2014, PSYCHIAT ANN, V44, P147, DOI 10.3928/00485713-20140306-07
   Meeks S, 2008, GERONTOLOGIST, V48, P105, DOI 10.1093/geront/48.1.105
   Office EE, 2020, J AM MED DIR ASSOC, V21, P948, DOI 10.1016/j.jamda.2020.06.003
   Orgeta V, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009125.pub2
   Raue PJ, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0812-8
   Read JR, 2017, J AFFECT DISORDERS, V221, P36, DOI 10.1016/j.jad.2017.06.009
   Soysal P, 2017, AGEING RES REV, V36, P78, DOI 10.1016/j.arr.2017.03.005
   Tedeschini E, 2011, J CLIN PSYCHIAT, V72, P1660, DOI 10.4088/JCP.10r06531
   Titov N, 2015, BEHAV THER, V46, P193, DOI 10.1016/j.beth.2014.09.008
   Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836
   Wernher I, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-351
   Wilson KCM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004853.pub2
   Woods B, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005562.pub2
   World Health Organization, 2020, HLTH CAR CONS OLD PE
   Yates LA, 2015, CLIN INTERV AGING, V10, P95, DOI 10.2147/CIA.S73844
   Zivin K, 2013, PSYCHIAT CLIN N AM, V36, P631, DOI 10.1016/j.psc.2013.08.008
NR 46
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0948-6704
EI 1435-1269
J9 Z GERONTOL GERIATR
JI Z. Gerontol. Geriatr.
PD DEC
PY 2020
VL 53
IS 8
SI SI
BP 721
EP 727
DI 10.1007/s00391-020-01805-3
EA NOV 2020
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA PA8MH
UT WOS:000589467700002
PM 33185718
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yao, XT
   Yan, XY
   Wang, XH
   Cai, T
   Zhang, S
   Cui, C
   Wang, XX
   Hou, Z
   Liu, Q
   Li, HY
   Lin, J
   Xiong, Z
   Liu, DY
AF Yao, Xueting
   Yan, Xiaoyu
   Wang, Xiaohan
   Cai, Ting
   Zhang, Shun
   Cui, Cheng
   Wang, Xiaoxu
   Hou, Zhe
   Liu, Qi
   Li, Haiyan
   Lin, Jing
   Xiong, Zi
   Liu, Dongyang
TI Population-based meta-analysis of chloroquine: informing chloroquine
   pharmacokinetics in COVID-19 patients
SO EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Early Access
DE Chloroquine; Population pharmacokinetics; Coronavirus disease 2019
ID METABOLISM; PHOSPHATE; MALARIA; MODEL; DRUG
AB Aims Chloroquine (CQ) has been repurposed to treat coronavirus disease 2019 (COVID-19). Understanding the pharmacokinetics (PK) in COVID-19 patients is essential to study its exposure-efficacy/safety relationship and provide a basis for a possible dosing regimen optimization. Subject and methods In this study, we used a population-based meta-analysis approach to develop a population PK model to characterize the CQ PK in COVID-19 patients. An open-label, single-center study (ethical review approval number: PJ-NBEY-KY-2020-063-01) was conducted to assess the safety, efficacy, and pharmacokinetics of CQ in patients with COVID-19. The sparse PK data from 50 COVID-19 patients, receiving 500 mg CQ phosphate twice daily for 7 days, were combined with additional CQ PK data from 18 publications. Results A two-compartment model with first-order oral absorption and first-order elimination and an absorption lag best described the data. Absorption rate (ka) was estimated to be 0.559 h(-1), and a lag time of absorption (ALAG) was estimated to be 0.149 h. Apparent clearance (CL/F) and apparent central volume of distribution (V2/F) was 33.3 l/h and 3630 l. Apparent distribution clearance (Q/F) and volume of distribution of peripheral compartment (Q3/F) were 58.7 l/h and 5120 l. The simulated CQ concentration under five dosing regimens of CQ phosphate were within the safety margin (400 ng/ml). Conclusion Model-based simulation using PK parameters from the COVID-19 patients shows that the concentrations under the currently recommended dosing regimen are below the safety margin for side-effects, which suggests that these dosing regimens are generally safe. The derived population PK model should allow for the assessment of pharmacokinetics-pharmacodynamics (PK-PD) relationships for CQ when given alone or in combination with other agents to treat COVID-19.
C1 [Yao, Xueting; Wang, Xiaohan; Cui, Cheng; Wang, Xiaoxu; Hou, Zhe; Liu, Qi; Li, Haiyan; Liu, Dongyang] Peking Univ Third Hosp, Drug Clin Trial Ctr, Beijing 100191, Peoples R China.
   [Yan, Xiaoyu] Chinese Univ Hong Kong, Sch Pharm, Fac Med, Shatin, Hong Kong 999077, Peoples R China.
   [Wang, Xiaohan; Wang, Xiaoxu; Hou, Zhe] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing 211198, Peoples R China.
   [Cai, Ting; Zhang, Shun; Lin, Jing; Xiong, Zi] Univ Chinese Acad Sci, HwaMei Hosp, Key Lab Diag & Treatment Digest Syst Tumors Zheji, Ningbo Hosp 2, Ningbo 315010, Peoples R China.
   [Liu, Qi] Peking Univ Third Hosp, Dept Orthoped, Beijing 100191, Peoples R China.
   [Li, Haiyan] Peking Univ Third Hosp, Dept Cardiol, Beijing 100191, Peoples R China.
   [Li, Haiyan] Peking Univ Third Hosp, Inst Vasc Med, Beijing 100191, Peoples R China.
RP Liu, DY (corresponding author), Peking Univ Third Hosp, Drug Clin Trial Ctr, Beijing 100191, Peoples R China.
EM liudongyang@vip.sina.com
FU Ministry of Science and Technology (MOST) of the People's Republic of
   China foundation for SARS-nCov-2 Research [2020YFC0844500]; Bill &
   Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR
   [INV-015694]
FX This study was supported by the Ministry of Science and Technology
   (MOST) of the People's Republic of China foundation for SARS-nCov-2
   Research (grant No. 2020YFC0844500) and the Bill & Melinda Gates
   Foundation (grant No. INV-015694).
CR ADELUSI SA, 1982, GEN PHARMACOL, V13, P433, DOI 10.1016/0306-3623(82)90110-0
   Administration TUSFaD, 2020, FACT SHEET HLTH CAR
   Ahn JE, 2010, J PHARMACOKINET PHAR, V37, P179, DOI 10.1007/s10928-010-9152-6
   Anderson BJ, 2000, BRIT J CLIN PHARMACO, V50, P125, DOI 10.1046/j.1365-2125.2000.00231.x
   [Anonymous], 2020, CHINESE CLIN GUIDANC
   Bergstrand M, 2011, AAPS J, V13, P143, DOI 10.1208/s12248-011-9255-z
   Kwong AHXPC, 2020, J PHARMACOKINET PHAR, V47, P431, DOI 10.1007/s10928-020-09695-z
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Cui C, 2020, ACTA PHARMACOL SIN B, V10, P1216, DOI 10.1016/j.apsb.2020.04.007
   Dolton MJ, 2017, J ANTIMICROB CHEMOTH, V72, P1129, DOI 10.1093/jac/dkw553
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   FRISKHOLMBERG M, 1983, BRIT J CLIN PHARMACO, V15, P502, DOI 10.1111/j.1365-2125.1983.tb01540.x
   FRISKHOLMBERG M, 1979, CLIN PHARMACOL THER, V25, P345
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Hoglund R, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1181-1
   Lindbom L, 2004, COMPUT METH PROG BIO, V75, P85, DOI 10.1016/j.cmpb.2003.11.003
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Milosheska D, 2016, BRIT J CLIN PHARMACO, V82, P399, DOI 10.1111/bcp.12984
   Obua C, 2008, BRIT J CLIN PHARMACO, V65, P493, DOI 10.1111/j.1365-2125.2007.03050.x
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101
   Salman S, 2017, INT J ANTIMICROB AG, V50, P542, DOI 10.1016/j.ijantimicag.2017.05.011
   Sanchez-Chapula JA, 2002, J BIOL CHEM, V277, P23587, DOI 10.1074/jbc.M200448200
   Sanofi-Aventis U.S. LLC, 2017, ARALEN CHLOR PHOSPH
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Van Wart SA, 2013, BIOPHARM DRUG DISPOS, V34, P527, DOI 10.1002/bdd.1863
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhao QY, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-36
NR 30
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0031-6970
EI 1432-1041
J9 EUR J CLIN PHARMACOL
JI Eur. J. Clin. Pharmacol.
DI 10.1007/s00228-020-03032-6
EA NOV 2020
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OR4NN
UT WOS:000589449200001
PM 33188451
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Jung, LS
   Gund, TM
   Narayan, M
AF Jung, Lindsey S.
   Gund, Tamara M.
   Narayan, Mahesh
TI Comparison of Binding Site of Remdesivir and Its Metabolites with
   NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential
   Drugs for COVID-19 Treatment
SO PROTEIN JOURNAL
LA English
DT Article
DE Remdesivir; Non-structural protein 3 (NSP3) of SARS CoV-2 virus; Virtual
   screening
ID HEPATITIS-B VACCINATION; MOLECULAR DOCKING; SEARCH
AB Remdesivir was approved by the U.S.A. Food and Drug administration for emergency use to interfere with the replication of SARS CoV-2 virus (the agent that causes COVID-19) in adults and children hospitalized with severe disease. The crystal structure of the metabolite of remdesivir (Monophosphate of GS-441524) and NSP12-NSP8-NSP7 of SARS CoV-2 virus was recently reported. The crystal structures of ADP-Ribose or AMP and NSP3 of SARS CoV-2 virus were also released, recently. This study compared their binding sites and suggests the crystal structure of NSP3 of SARS CoV-2 virus as an alternative binding site of AMP or ADP-ribose to treat COVID-19. We virtually screened 682 FDA-approved compounds, and the top 10 compounds were selected by analysis of docking scores, (G-score, D-score, and Chemscore) and visual analysis using a structure-based docking approach of NSP3 of SARS CoV-2 virus. All immunization approaches are based on the SARS-CoV-2 virus spike protein. A recent study reported that the D614G mutation in the SARS-CoV-2 virus spike protein reduces S1 shedding and increases infectivity of SARS COV-2 virus. Therefore, if there is a severe change in the spike protein of a modified Coronavirus, all developed vaccines can lose their efficacy, necessitating the need for an alternative treatment method. The top 10 compounds (FDA-approved) in this study are selected based on NSP 3 binding site, and therefore are a potential viable treatment because they will show potential activity for all mutations in the SARS-CoV-2 virus spike protein.
C1 [Jung, Lindsey S.] Tenafly High Sch, Tenafly, NJ 07670 USA.
   [Gund, Tamara M.] New Jersey Inst Technol, Dept Chem & Environm Sci, Newark, NJ 07102 USA.
   [Narayan, Mahesh] Univ Texas El Paso, Dept Chem & Biochem, 500 W Univ Ave, El Paso, TX 79968 USA.
RP Narayan, M (corresponding author), Univ Texas El Paso, Dept Chem & Biochem, 500 W Univ Ave, El Paso, TX 79968 USA.
EM lindseyjung@gmail.com; gund@njit.edu; mnarayan@utep.edu
CR Baxter CA, 1998, PROTEINS, V33, P367, DOI 10.1002/(SICI)1097-0134(19981115)33:3<367::AID-PROT6>3.0.CO;2-W
   Catov JM, 2011, AM J CLIN NUTR, V94, P906, DOI 10.3945/ajcn.111.012393
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Egloff MP, 2006, J VIROL, V80, P8493, DOI 10.1128/JVI.00713-06
   Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450
   Fernandez A, 2020, ACS MED CHEM LETT, V11, P1667, DOI 10.1021/acsmedchemlett.0c00410
   Forino M, 2005, J MED CHEM, V48, P2278, DOI 10.1021/jm048962u
   Frick DN, 2020, BIOCHEMISTRY-US, V59, P2608, DOI 10.1021/acs.biochem.0c00309
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Guedes IA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01089
   Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Li Y, 2014, J CHEM INF MODEL, V54, P1717, DOI 10.1021/ci500081m
   Michalska K, 2020, IUCRJ, V7, P814, DOI 10.1107/S2052252520009653
   Mooij WTM, 2005, PROTEINS, V61, P272, DOI 10.1002/prot.20588
   Muegge I, 2006, J MED CHEM, V49, P5895, DOI 10.1021/jm050038s
   Saccone G, 2016, J MATERN-FETAL NEO M, V29, P916, DOI 10.3109/14767058.2015.1023189
   Schonberger K, 2013, PEDIATR INFECT DIS J, V32, P307, DOI 10.1097/INF.0b013e31827bd1b0
   Serseg Talia, 2020, Curr Comput Aided Drug Des, DOI 10.2174/1573409916666200422075440
   Shakoor Hira, 2021, Maturitas, V144, P108, DOI 10.1016/j.maturitas.2020.08.007
   Stephens B, 2020, NY TIMES
   Tchesnokov EP, 2020, J BIOL CHEM, V295, P16156, DOI 10.1074/jbc.AC120.015720
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhao XY, 2018, HUM VACC IMMUNOTHER, V14, P2478, DOI 10.1080/21645515.2018.1482168
NR 26
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1572-3887
EI 1573-4943
J9 PROTEIN J
JI Protein J.
PD DEC
PY 2020
VL 39
IS 6
SI SI
BP 619
EP 630
DI 10.1007/s10930-020-09942-9
EA NOV 2020
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA PC9FZ
UT WOS:000589470500001
PM 33185784
DA 2021-01-01
ER

PT J
AU Billett, HH
   Reyes-Gil, M
   Szymanski, J
   Ikemura, K
   Stahl, LR
   Lo, YT
   Rahman, S
   Gonzalez-Lugo, JD
   Kushnir, M
   Barouqa, M
   Golestaneh, L
   Bellin, E
AF Billett, Henny H.
   Reyes-Gil, Morayma
   Szymanski, James
   Ikemura, Kenji
   Stahl, Lindsay R.
   Lo, Yungtai
   Rahman, Shafia
   Gonzalez-Lugo, Jesus D.
   Kushnir, Margarita
   Barouqa, Mohammad
   Golestaneh, Ladan
   Bellin, Eran
TI Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban
   on Mortality
SO THROMBOSIS AND HAEMOSTASIS
LA English
DT Article; Early Access
DE anticoagulation; apixaban; COVID-19; D-dimer; enoxaparin; mortality
AB Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has been proposed as therapy to decrease mortality, often adjusted for illness severity.
   Objective We wanted to investigate whether anticoagulation improves survival in COVID-19 and if this improvement in survival is associated with disease severity.
   Methods This is a cohort study simulating an intention-to-treat clinical trial, by analyzing the effect on mortality of anticoagulation therapy chosen in the first 48hours of hospitalization. We analyzed 3,625 COVID-19+ inpatients, controlling for age, gender, glomerular filtration rate, oxygen saturation, ventilation requirement, intensive care unit admission, and time period, all determined during the first 48hours.
   Results Adjusted logistic regression analyses demonstrated a significant decrease in mortality with prophylactic use of apixaban (odds ratio [OR] 0.46, p =0.001) and enoxaparin (OR=0.49, p =0.001). Therapeutic apixaban was also associated with decreased mortality (OR 0.57, p =0.006) but was not more beneficial than prophylactic use when analyzed over the entire cohort or within D-dimer stratified categories. Higher D-dimer levels were associated with increased mortality ( p <0.0001). When adjusted for these same comorbidities within D-dimer strata, patients with D-dimer levels<1 mu g/mL did not appear to benefit from anticoagulation while patients with D-dimer levels>10 mu g/mL derived the most benefit. There was no increase in transfusion requirement with any of the anticoagulants used.
   Conclusion We conclude that COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in this disease.
C1 [Billett, Henny H.; Rahman, Shafia; Gonzalez-Lugo, Jesus D.; Kushnir, Margarita] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol, Div Hematol, Bronx, NY 10467 USA.
   [Billett, Henny H.; Rahman, Shafia; Gonzalez-Lugo, Jesus D.; Kushnir, Margarita] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Med, Div Hematol, Bronx, NY 10467 USA.
   [Reyes-Gil, Morayma; Szymanski, James; Ikemura, Kenji; Barouqa, Mohammad] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Pathol, Bronx, NY 10467 USA.
   [Stahl, Lindsay R.] Albert Einstein Coll Med, Montefiore Med Ctr, Montefiore Informat Technol, Bronx, NY 10467 USA.
   [Lo, Yungtai; Bellin, Eran] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Epidemiol & Populat Hlth & Med, Bronx, NY 10467 USA.
   [Golestaneh, Ladan] Albert Einstein Coll Med, Montefiore Med Ctr, Div Nephrol, Bronx, NY 10467 USA.
RP Billett, HH (corresponding author), Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol Med, Div Hematol, 3411 Wayne Ave, Bronx, NY 10467 USA.
EM hbillett@montefiore.org
OI Golestaneh, Ladan/0000-0003-1848-582X
CR Al-Harbi NO, 2020, J THROMB THROMBOLYS, V50, P361, DOI 10.1007/s11239-020-02123-6
   Bellin E, 2019, MISSING MANAGEMENT H
   Bellin E, 2010, ACAD MED, V85, P1362, DOI 10.1097/ACM.0b013e3181df0f3b
   Carrier M, 2019, NEW ENGL J MED, V380, P711, DOI 10.1056/NEJMoa1814468
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cohoon KP, 2018, J THROMB HAEMOST, V16, P1278, DOI 10.1111/jth.14146
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Hanif A, 2020, ANN HEMATOL, V99, P2323, DOI 10.1007/s00277-020-04216-x
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Khorana AA, 2019, NEW ENGL J MED, V380, P720, DOI 10.1056/NEJMoa1814630
   Liu XL, 2014, EXP THER MED, V7, P604, DOI 10.3892/etm.2013.1466
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Papadaki S, 2019, ANGIOLOGY, V70, P896, DOI 10.1177/0003319719840861
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Thachil J, 2020, J THROMB HAEMOST, V18, P2138, DOI 10.1111/jth.15004
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Wang ML, 2020, CLIN CHIM ACTA, V510, P220, DOI 10.1016/j.cca.2020.06.051
   Yoshida RD, 2013, ANN VASC SURG, V27, P355, DOI 10.1016/j.avsg.2012.06.010
NR 22
TC 0
Z9 0
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0340-6245
EI 2567-689X
J9 THROMB HAEMOSTASIS
JI Thromb. Haemost.
DI 10.1055/s-0040-1720978
EA NOV 2020
PG 9
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OQ8RZ
UT WOS:000589044600002
PM 33186991
OA Bronze
DA 2021-01-01
ER

PT J
AU Ghorbani, M
   Brooks, BR
   Klauda, JB
AF Ghorbani, Mahdi
   Brooks, Bernard R.
   Klauda, Jeffery B.
TI Critical Sequence Hotspots for Binding of Novel Coronavirus to
   Angiotensin Converter Enzyme as Evaluated by Molecular Simulations
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
AB The novel coronavirus (nCOV-2019) outbreak has put the world on edge, causing millions of cases and hundreds of thousands of deaths all around the world, as of June 2020, let alone the societal and economic impacts of the crisis. The spike protein of nCOV-2019 resides on the virion's surface mediating coronavirus entry into host cells by binding its receptor binding domain (RBD) to the host cell surface receptor protein, angiotensin converter enzyme (ACE2). Our goal is to provide a detailed structural mechanism of how nCOV-2019 recognizes and establishes contacts with ACE2 and its difference with an earlier severe acute respiratory syndrome coronavirus (SARS-COV) in 2002 via extensive molecular dynamics (MD) simulations. Numerous mutations have been identified in the RBD of nCOV-2019 strains isolated from humans in different parts of the world. In this study, we investigated the effect of these mutations as well as other Ala-scanning mutations on the stability of the RBD/ACE2 complex. It is found that most of the naturally occurring mutations to the RBD either slightly strengthen or have the same binding affinity to ACE2 as the wild-type nCOV-2019. This means that the virus had sufficient binding affinity to its receptor at the beginning of the crisis. This also has implications for any vaccine design endeavors since these mutations could act as antibody escape mutants. Furthermore, in silico Ala-scanning and long-timescale MD simulations highlight the crucial role of the residues at the interface of RBD and ACE2 that may be used as potential pharmacophores for any drug development endeavors. From an evolutional perspective, this study also identifies how the virus has evolved from its predecessor SARS-COV and how it could further evolve to become even more infectious.
C1 [Ghorbani, Mahdi; Klauda, Jeffery B.] Univ Maryland, Dept Chem & Biomol Engn, College Pk, MD 20742 USA.
   [Ghorbani, Mahdi; Brooks, Bernard R.] NHLBI, Lab Computat Biol, NIH, Bethesda, MD 20824 USA.
   [Klauda, Jeffery B.] Univ Maryland, Biophys Grad Program, College Pk, MD 20742 USA.
RP Klauda, JB (corresponding author), Univ Maryland, Dept Chem & Biomol Engn, College Pk, MD 20742 USA.; Klauda, JB (corresponding author), Univ Maryland, Biophys Grad Program, College Pk, MD 20742 USA.
EM jbklauda@umd.edu
FU Intramural Research Program of the National Heart, Lung, and Blood
   Institute (NHLBI) at the National Institutes of Health (NIH)
FX This work was supported by the Intramural Research Program of the
   National Heart, Lung, and Blood Institute (NHLBI) at the National
   Institutes of Health (NIH). The authors acknowledge the Biowulf high
   performance Linux cluster at the NIH for providing computational
   resources for this project. The authors would like to dedicate this
   article to the doctors and nurses who sacrificed their time, health, and
   even their lives to fight COVID-19, particularly those in Iran and the
   United States. J.B.K. would also like to dedicate this work to family
   friend Joe Kaplan (Silver Spring, MD) who passed away because of
   COVID-19 on April 22, 2020.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Batool M., 2017, SCI REP, V7, P1
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   Boorla V. S., 2020, BIORXIV2020034866
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497
   BROOKS BR, 1995, J COMPUT CHEM, V16, P1522, DOI 10.1002/jcc.540161209
   Brown DK, 2017, BIOINFORMATICS, V33, P2768, DOI 10.1093/bioinformatics/btx349
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Chakraborti S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-73
   Chan PKS, 2004, EMERG INFECT DIS, V10, P825, DOI 10.3201/eid1005.030682
   Coughlin MM, 2012, REV MED VIROL, V22, P2, DOI 10.1002/rmv.706
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   David CC, 2014, METHODS MOL BIOL, V1084, P193, DOI 10.1007/978-1-62703-658-0_11
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Greenough TC, 2005, J INFECT DIS, V191, P507, DOI 10.1086/427242
   Guan SS, 2016, J BIOMOL STRUCT DYN, V34, P15, DOI 10.1080/07391102.2015.1007167
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li F, 2013, ANTIVIR RES, V100, P246, DOI 10.1016/j.antiviral.2013.08.014
   Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004
   Li Y., 2020, BIORXIV2020077842, DOI [10.1101/2020.05.04.077842, DOI 10.1101/2020.05.04.077842]
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Liu H., 2020, COMPUTATIONAL SIMULA, DOI [10.1101/2020.03.24.005561, DOI 10.1101/2020.03.24.005561]
   Malik A., 2020, BIORXIV2020152892, DOI [10.1101/2020.06.15.152892, DOI 10.1101/2020.06.15.152892]
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Ren JY, 2020, J CHIN CHEM SOC-TAIP, V67, P46, DOI 10.1002/jccs.201900148
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Rodrigues CHM, 2019, NUCLEIC ACIDS RES, V47, pW338, DOI 10.1093/nar/gkz383
   Shang J., 2020, STRUCTURAL BASIS REC
   Sharma S., 2020, BIORXIV2020050534
   Spinello A, 2020, J PHYS CHEM LETT, V11, P4785, DOI 10.1021/acs.jpclett.0c01148
   Starr T. N., 2020, BIORXIV2020157982
   Sui JH, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000197
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang CH, 2018, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00087
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang Y., P NATL ACAD SCI
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803
   Yang TY, 2011, PROTEINS, V79, P1940, DOI 10.1002/prot.23018
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 57
TC 0
Z9 0
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
EI 1520-5207
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD NOV 12
PY 2020
VL 124
IS 45
BP 10034
EP 10047
DI 10.1021/acs.jpcb.0c05994
PG 14
WC Chemistry, Physical
SC Chemistry
GA OW2OK
UT WOS:000592732700008
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hueso, T
   Pouderoux, C
   Pere, H
   Beaumont, AL
   Raillon, LA
   Ader, F
   Chatenoud, L
   Eshagh, D
   Szwebel, TA
   Martinot, M
   Camou, F
   Crickx, E
   Michel, M
   Mahevas, M
   Boutboul, D
   Azoulay, E
   Joseph, A
   Hermine, O
   Rouzaud, C
   Faguer, S
   Petua, P
   Pommeret, F
   Clerc, S
   Planquette, B
   Merabet, F
   London, J
   Zeller, V
   Ghez, D
   Veyer, D
   Ouedrani, A
   Gallian, P
   Pacanowski, J
   Mekinian, A
   Garnier, M
   Pirenne, F
   Tiberghien, P
   Lacombe, K
AF Hueso, Thomas
   Pouderoux, Cecile
   Pere, Helene
   Beaumont, Anne-Lise
   Raillon, Laure-Anne
   Ader, Florence
   Chatenoud, Lucienne
   Eshagh, Deborah
   Szwebel, Tali-Anne
   Martinot, Martin
   Camou, Fabrice
   Crickx, Etienne
   Michel, Marc
   Mahevas, Matthieu
   Boutboul, David
   Azoulay, Elie
   Joseph, Adrien
   Hermine, Olivier
   Rouzaud, Claire
   Faguer, Stanislas
   Petua, Philippe
   Pommeret, Fanny
   Clerc, Sebastien
   Planquette, Benjamin
   Merabet, Fatiha
   London, Jonathan
   Zeller, Valerie
   Ghez, David
   Veyer, David
   Ouedrani, Amani
   Gallian, Pierre
   Pacanowski, Jerome
   Mekinian, Arsene
   Garnier, Marc
   Pirenne, France
   Tiberghien, Pierre
   Lacombe, Karine
TI Convalescent plasma therapy for B-cell-depleted patients with protracted
   COVID-19
SO BLOOD
LA English
DT Article
ID RITUXIMAB
AB Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies or autoimmune disease but may be responsible for a secondary humoral deficiency. In the context of COVID-19 infection, this may prevent the elicitation of a specific SARS-CoV-2 antibody response. We report a series of 17 consecutive patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms, negative immunoglobulin G (IgG)-IgM SARS-CoV-2 serology, and positive RNAemia measured by digital polymerase chain reaction who were treated with 4 units of COVID-19 convalescent plasma. Within 48 hours of transfusion, all but 1 patient experienced an improvement of clinical symptoms. The inflammatory syndrome abated within a week. Only 1 patient who needed mechanical ventilation for severe COVID-19 disease died of bacterial pneumonia. SARS-CoV2 RNAemia decreased to below the sensitivity threshold in all 9 evaluated patients. In 3 patients, virus-specific T-cell responses were analyzed using T-cell enzyme-linked immuno spot assay before convalescent plasma transfusion. All showed a maintained SARS-CoV2 T-cell response and poor cross-response to other coronaviruses. No adverse event was reported. Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2. (Blood. 2020;136(20):2290-2295)
C1 [Hueso, Thomas; Ghez, David] Gustave Roussy, Hematol Dept, Villejuif, France.
   [Hueso, Thomas] Paris Saclay Univ, Paris Sud Univ, Le Kremlin Bicetre, France.
   [Pouderoux, Cecile; Raillon, Laure-Anne; Ader, Florence] Hosp Civils Lyon, Croix Rousse Hosp, Infect Dis Dept, Lyon, France.
   [Pere, Helene] Hop Europeen Georges Pompidou, AP HP, Lab Virol, Paris, France.
   [Pere, Helene] Univ Paris, Paris Cardiovasc Res Ctr, INSERM, U970, Paris, France.
   [Beaumont, Anne-Lise; Veyer, David; Pacanowski, Jerome; Lacombe, Karine] St Antoine Hosp, AP HP, Infect Dis Dept, Paris, France.
   [Ader, Florence] Univ Claude Bernard Lyon 1, Ctr Int Rech Infectiol UCBL1, INSERM 1111, Lyon, France.
   [Chatenoud, Lucienne; Ouedrani, Amani] Paris Univ, CNRS, Inst Necker Enfants Malades, UMR 8253, Paris, France.
   [Chatenoud, Lucienne; Ouedrani, Amani] Hop Necker Enfants Malad, INSERM, UMR1151, Paris, France.
   [Chatenoud, Lucienne; Ouedrani, Amani] Hop Necker Enfants Malad, Lab Immunol Biol, Paris, France.
   [Eshagh, Deborah; Szwebel, Tali-Anne] Cochin Hosp, AP HP, Internal Med Dept, Paris, France.
   [Martinot, Martin] Hop Civils Colmar, Infect Dis Dept, Colmar, France.
   [Camou, Fabrice] St Andre Hosp, Intens Care & Infect Dis Dept, Bordeaux, France.
   [Crickx, Etienne; Michel, Marc; Mahevas, Matthieu] Univ Paris Est Creteil, CHU Henri Mondor, Ctr Natl Reference Cytopenies Autoimmunes Adulte, Internal Med Dept ,AP HP, Creteil, France.
   [Boutboul, David] Hop St Louis Hosp, AP HP, Dept Clin Immunol, Paris, France.
   [Boutboul, David] INSERM, Imagine Inst, Lab Lymphocyte Activat & Susceptibil EBV Infect, Paris, France.
   [Azoulay, Elie; Joseph, Adrien] Paris Diderot Sorbonne Univ, Hop St Louis, AP HP, Intens Care Unit, Paris, France.
   [Hermine, Olivier] Imagine Inst, Lab Mol Mech Hematol Disorders & Therapeut Implic, Paris, France.
   [Hermine, Olivier] Hop Necker Enfants Malad, Dept Clin Hematol, Paris, France.
   [Rouzaud, Claire] Necker Enfants Malades Hosp, AP HP, Infect Dis Dept, Paris, France.
   [Faguer, Stanislas] CHU Toulouse, Ctr Reference Malad Renales Rares, Dept Nephrol & Transplantat Organes, Toulouse, France.
   [Petua, Philippe] Tarbes Hosp, Intens Care Unit, Tarbes, France.
   [Pommeret, Fanny] Gustave Roussy, Oncol Dept, Villejuif, France.
   [Clerc, Sebastien; Planquette, Benjamin] Hop Europeen Georges Pompidou, AP HP, Resp Dis Intens Care Unit, Paris, France.
   [Merabet, Fatiha] Versailles Hosp, Hematol Dept, Versailles, France.
   [London, Jonathan; Zeller, Valerie] Hop Diaconesses Croix St Simon, Dept Internal Med & Infect Dis, Paris, France.
   [Veyer, David] Univ Paris, Paris, France.
   [Veyer, David] Sorbonne Univ, Ctr Rech Cordeliers, INSERM, Funct Genom Solid Tumors FunGeST, Paris, France.
   [Gallian, Pierre] Aix Marseille Univ, Inst Rech Dev 190, Unite Virus Emergents UVE, INSERM 1207,IHU Mediterranee Infect, Marseille, France.
   [Gallian, Pierre; Pirenne, France; Tiberghien, Pierre] Etab Francais Sang, La Plaine St Denis, France.
   [Mekinian, Arsene] Sorbonne Univ, St Antoine Hosp, Inflammat Immunopathol Biotherapy Dept DMU i3D, Internal Med Dept,AP HP, Paris, France.
   [Garnier, Marc] Sorbonne Univ, St Antoine Hosp, AP HP, DMU DREAM,Anesthesiol & Intens Care Dept,GRC 29, Paris, France.
   [Pirenne, France] Univ Paris Est Creteil, Equipe 2 Transfus & Malad Globule Rouge, Inst Mondor Rech Biomed, INSERM,Etab Francais Sang,Unite 955, Creteil, France.
   [Tiberghien, Pierre] Univ Franche Comte, Etab Francais Sang, INSERM, RIGHT,UMR 1098, Besancon, France.
   [Lacombe, Karine] Sorbonne Univ, AP HP, INSERM, IPLESP, Paris, France.
RP Hueso, T (corresponding author), Paris Saclay Univ, Gustave Roussy Canc Ctr, 114 Rue Paul Vaillant, F-94805 Villejuif, France.
EM hueso.th@gmail.com
OI Reis, AlessanRSS/0000-0001-8486-7469
FU Fonds Groupe Hospitalier Universitaire de l'Assistance Publique des
   Hopitaux de Paris, Commission Recherche, Innovation et Universite
FX This work was supported by Fonds Groupe Hospitalier Universitaire de
   l'Assistance Publique des Hopitaux de Paris, Commission Recherche,
   Innovation et Universite.
CR ANSM, COVID 19 ANSM ENC RE
   Avouac J, 2020, ANN RHEUM DIS, V79, P597, DOI 10.1136/annrheumdis-2020-eular.5408
   Candon S, 2009, AM J TRANSPLANT, V9, P2346, DOI 10.1111/j.1600-6143.2009.02787.x
   Clark E, 2020, BRIT J HAEMATOL, V190, pE154, DOI 10.1111/bjh.16981
   Gallian P, 2020, ANTIVIR RES, V181, DOI 10.1016/j.antiviral.2020.104880
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383
   Hawker K, 2009, ANN NEUROL, V66, P460, DOI 10.1002/ana.21867
   Lazareth H, 2020, AM J KIDNEY DIS, V76, P590, DOI 10.1053/j.ajkd.2020.06.009
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7
   Perotti C, 2020, INTERN EMERG MED, V15, P819, DOI 10.1007/s11739-020-02384-2
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Sacco KA, 2018, IMMUNOTHERAPY-UK, V10, P713, DOI 10.2217/imt-2017-0178
   Salles G, 2017, ADV THER, V34, P2232, DOI 10.1007/s12325-017-0612-x
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Suo Tao, 2020, Emerg Microbes Infect, V9, P1259, DOI 10.1080/22221751.2020.1772678
   Taly V, 2012, TRENDS MOL MED, V18, P405, DOI 10.1016/j.molmed.2012.05.001
   Tepasse PR, 2020, BRIT J HAEMATOL, V190, P185, DOI 10.1111/bjh.16896
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   Woyach JA, 2014, BLOOD, V123, P1810, DOI 10.1182/blood-2013-09-527853
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
NR 25
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD NOV 12
PY 2020
VL 136
IS 20
BP 2290
EP 2295
DI 10.1182/blood.2020008423
PG 6
WC Hematology
SC Hematology
GA OT0SW
UT WOS:000590565800007
PM 32959052
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mohapatra, S
   Nath, P
   Chatterjee, M
   Das, N
   Kalita, D
   Roy, P
   Satapathi, S
AF Mohapatra, Sovesh
   Nath, Prathul
   Chatterjee, Manisha
   Das, Neeladrisingha
   Kalita, Deepjyoti
   Roy, Partha
   Satapathi, Soumitra
TI Repurposing therapeutics for COVID-19: Rapid prediction of commercially
   available drugs through machine learning and docking
SO PLOS ONE
LA English
DT Article
AB Background
   The outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus has spread rapidly around the globe during the past 3 months. As the virus infected cases and mortality rate of this disease is increasing exponentially, scientists and researchers all over the world are relentlessly working to understand this new virus along with possible treatment regimens by discovering active therapeutic agents and vaccines. So, there is an urgent requirement of new and effective medications that can treat the disease caused by SARS-CoV-2.
   Methods and findings
   We perform the study of drugs that are already available in the market and being used for other diseases to accelerate clinical recovery, in other words repurposing of existing drugs. The vast complexity in drug design and protocols regarding clinical trials often prohibit developing various new drug combinations for this epidemic disease in a limited time. Recently, remarkable improvements in computational power coupled with advancements in Machine Learning (ML) technology have been utilized to revolutionize the drug development process. Consequently, a detailed study using ML for the repurposing of therapeutic agents is urgently required. Here, we report the ML model based on the Naive Bayes algorithm, which has an accuracy of around 73% to predict the drugs that could be used for the treatment of COVID-19. Our study predicts around ten FDA approved commercial drugs that can be used for repurposing. Among all, we found that 3 of the drugs fulfils the criterions well among which the antiretroviral drug Amprenavir (DrugBank ID-DB00701) would probably be the most effective drug based on the selected criterions.
   Conclusions
   Our study can help clinical scientists in being more selective in identifying and testing the therapeutic agents for COVID-19 treatment. The ML based approach for drug discovery as reported here can be a futuristic smart drug designing strategy for community applications.
C1 [Mohapatra, Sovesh; Nath, Prathul; Satapathi, Soumitra] Indian Inst Technol, Dept Phys, Haridwar, Uttarakhand, India.
   [Chatterjee, Manisha] Subharti Med Coll, Dept Pharmacol, Meerut, Uttar Pradesh, India.
   [Das, Neeladrisingha; Roy, Partha] Indian Inst Technol, Dept Biotechnol, Roorkee, Uttarakhand, India.
   [Kalita, Deepjyoti] All India Inst Med Sci, Dept Microbiol, Rishikesh, Uttarakhand, India.
   [Satapathi, Soumitra] Indian Inst Technol, Ctr Nanotechnol, Roorkee, Uttarakhand, India.
RP Satapathi, S (corresponding author), Indian Inst Technol, Dept Phys, Haridwar, Uttarakhand, India.; Chatterjee, M (corresponding author), Subharti Med Coll, Dept Pharmacol, Meerut, Uttar Pradesh, India.; Satapathi, S (corresponding author), Indian Inst Technol, Ctr Nanotechnol, Roorkee, Uttarakhand, India.
EM ssphf.fph@iitr.ac.in; manishachaterjee1988@gmail.com
OI Satapathi, Soumitra/0000-0001-9218-3796
FU Ministry of Information Science and Technology, Government of India
FX Ministry of Information Science and Technology, Government of India.
CR [Anonymous], 2013, EUR J MED CHEM, DOI 10.1016%2Fj.ejmech.2012.10.053&atitle=Design%2C+synthesis+and+crystallographic+analysis+of+nitrile-based+broad-spectrum+peptidomimetic+inhibitors+for+coronavirus+3C-like+proteases&stitle=Eur.+J.+Med.+Chem.&title=European+Journal+of+Medicinal+Chemistry&volume=59&issue=&spage=1&epage=6&aulast=Chuck&aufirst=Chi-Pang&auinit=C.-P.&aufull=Chuck+C.-P.&coden
   Armstrong GL, 2019, NEW ENGL J MED, V381, P2569, DOI 10.1056/NEJMsr1813907
   Arshad U, 2020, PRIORITISATION POTEN, DOI [10.1101/2020.04.16.20068379, DOI 10.1101/2020.04.16.20068379]
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Browne MW, 2000, J MATH PSYCHOL, V44, P108, DOI 10.1006/jmps.1999.1279
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Cheng TJ, 2012, AAPS J, V14, P133, DOI 10.1208/s12248-012-9322-0
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Ekins S, 2020, DRUG DISCOV TODAY, V25, P928, DOI 10.1016/j.drudis.2020.03.019
   Ezat Ahmed A., 2019, VirusDisease, V30, P207, DOI 10.1007/s13337-019-00516-7
   Fintelman-Rodrigues N., 2020, BIORXIV, DOI [10.1101/2020.04.04.020925, DOI 10.1101/2020.04.04.020925]
   Friedman N, 1997, MACH LEARN, V29, P131, DOI 10.1023/A:1007465528199
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hop P, 2018, MOL PHARMACEUT, V15, P4371, DOI 10.1021/acs.molpharmaceut.7b01144
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang R, 2020, LANCET INFECT DIS, V20, P534, DOI 10.1016/S1473-3099(20)30147-X
   Liu GS, 2019, BIOMED ENVIRON SCI, V32, P438, DOI 10.3967/bes2019.058
   Liu L., 2009, ENCY DATABASE SYSTEM, P532, DOI [DOI 10.1007/978-0-387-39940-9_565, 10.1007/978-0-387-39940-9_565]
   Lowe R, 2010, MOL PHARMACEUT, V7, P1708, DOI 10.1021/mp100103e
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Markland W, 2000, ANTIMICROB AGENTS CH, V44, P859, DOI 10.1128/AAC.44.4.859-866.2000
   Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186
   Masnadi-Shirazi H, 2011, IEEE T PATTERN ANAL, V33, P294, DOI 10.1109/TPAMI.2010.71
   Melville JL, 2009, COMB CHEM HIGH T SCR, V12, P332, DOI 10.2174/138620709788167980
   Mitchell TM, 1997, ANN REV COMPUTER SCI, DOI DOI 10.1016/S0933-3657(96)00367-3
   Ng A., 2012, MACH LEARN, DOI [10.1111/j.1466-8238.2009.00506.x, DOI 10.1111/J.1466-8238.2009.00506.X]
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Schierz AC, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-21
   Sen P, 2008, DATA MIN KNOWL DISC, V17, P136, DOI 10.1007/s10618-008-0090-5
   She J, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-00271-z
   Sun YM, 2007, PATTERN RECOGN, V40, P3358, DOI 10.1016/j.patcog.2007.04.009
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Thai-Nghe N., 2010, 2010 INT JOINT C NEU, P1, DOI [10.1109/IJCNN.2010.5596486, DOI 10.1109/IJCNN.2010.5596486]
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Wang JL, 2014, IEEE T KNOWL DATA EN, V26, P2425, DOI 10.1109/TKDE.2013.157
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang PL, 2011, CURR OPIN VIROL, V1, P607, DOI 10.1016/j.coviro.2011.10.019
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 47
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 12
PY 2020
VL 15
IS 11
AR e0241543
DI 10.1371/journal.pone.0241543
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OY0MJ
UT WOS:000593948000086
PM 33180803
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Arcanjo, A
   Logullo, J
   Menezes, CCB
   Giangiarulo, TCDC
   dos Reis, MC
   de Castro, GMM
   Fontes, YD
   Todeschini, AR
   Freire-de-Lima, L
   Decote-Ricardo, D
   Ferreira-Pereira, A
   Freire-de-Lima, CG
   Barroso, SPC
   Takiya, C
   Conceicao-Silva, F
   Savino, W
   Morrot, A
AF Arcanjo, Angelica
   Logullo, Jorgete
   Barreto Menezes, Camilla Cristie
   de Souza Carvalho Giangiarulo, Thais Chrispim
   dos Reis, Mirella Carneiro
   Migliani de Castro, Gabriellen Menezes
   Fontes, Yasmin da Silva
   Todeschini, Adriane Regina
   Freire-de-Lima, Leonardo
   Decote-Ricardo, Debora
   Ferreira-Pereira, Antonio
   Freire-de-Lima, Celio Geraldo
   Coutinho Barroso, Shana Priscila
   Takiya, Christina
   Conceicao-Silva, Fatima
   Savino, Wilson
   Morrot, Alexandre
TI The emerging role of neutrophil extracellular traps in severe acute
   respiratory syndrome coronavirus 2 (COVID-19)
SO SCIENTIFIC REPORTS
LA English
DT Article
AB The novel coronavirus SARS-CoV-2 causes COVID-19, a highly pathogenic viral infection threatening millions. The majority of the individuals infected are asymptomatic or mildly symptomatic showing typical clinical signs of common cold. However, approximately 20% of the patients can progress to acute respiratory distress syndrome (ARDS), evolving to death in about 5% of cases. Recently, angiotensin-converting enzyme 2 (ACE2) has been shown to be a functional receptor for virus entry into host target cells. The upregulation of ACE2 in patients with comorbidities may represent a propensity for increased viral load and spreading of infection to extrapulmonary tissues. This systemic infection is associated with higher neutrophil to lymphocyte ratio in infected tissues and high levels of pro-inflammatory cytokines leading to an extensive microthrombus formation with multiorgan failure. Herein we investigated whether SARS-CoV-2 can stimulate extracellular neutrophils traps (NETs) in a process called NETosis. We demonstrated for the first time that SARS-CoV-2 in fact is able to activate NETosis in human neutrophils. Our findings indicated that this process is associated with increased levels of intracellular Reactive Oxygen Species (ROS) in neutrophils. The ROS-NET pathway plays a role in thrombosis formation and our study suggest the importance of this target for therapy approaches against disease.
C1 [Arcanjo, Angelica] Univ Fed Rio de Janeiro, Med Biochem Inst, Rio De Janeiro, Brazil.
   [Logullo, Jorgete; Todeschini, Adriane Regina; Freire-de-Lima, Leonardo; Freire-de-Lima, Celio Geraldo; Takiya, Christina] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Rio De Janeiro, Brazil.
   [Barreto Menezes, Camilla Cristie; Morrot, Alexandre] Univ Fed Rio de Janeiro, Fac Med, TB Res Lab, Rio De Janeiro, Brazil.
   [de Souza Carvalho Giangiarulo, Thais Chrispim; Coutinho Barroso, Shana Priscila] Navy Brazil, Marcilio Dias Naval Hosp, Mol Biol Lab, Inst Biomed Res, Rio De Janeiro, Brazil.
   [dos Reis, Mirella Carneiro] Navy Brazil, Marcilio Dias Naval Hosp, Parasit Dis Div, Rio De Janeiro, Brazil.
   [Migliani de Castro, Gabriellen Menezes; Fontes, Yasmin da Silva; Ferreira-Pereira, Antonio] Univ Fed Rio de Janeiro, Microbiol Inst, Rio De Janeiro, Brazil.
   [Decote-Ricardo, Debora] Univ Fed Rural Rio de Janeiro, Vet Inst, Rio De Janeiro, Brazil.
   [Conceicao-Silva, Fatima; Morrot, Alexandre] Fundacao Oswaldo Cruz, Immunoparasitol Lab, Oswaldo Cruz Inst, FIOCRUZ, Bld Leonidas & Maria Deane Room 406C, Rio De Janeiro, RJ, Brazil.
   [Savino, Wilson] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Thymus Res, Rio De Janeiro, RJ, Brazil.
   [Savino, Wilson] Fundacao Oswaldo Cruz, Natl Inst Sci & Technol Neuroimmunomodulat INCT N, Oswaldo Cruz Inst, Rio De Janeiro, RJ, Brazil.
   [Savino, Wilson] Fundacao Oswaldo Cruz, Rio de Janeiro Res Network Neuroinflammat, Oswaldo Cruz Inst, Rio De Janeiro, RJ, Brazil.
RP Morrot, A (corresponding author), Univ Fed Rio de Janeiro, Fac Med, TB Res Lab, Rio De Janeiro, Brazil.; Morrot, A (corresponding author), Fundacao Oswaldo Cruz, Immunoparasitol Lab, Oswaldo Cruz Inst, FIOCRUZ, Bld Leonidas & Maria Deane Room 406C, Rio De Janeiro, RJ, Brazil.
EM alexandre.morrot@ioc.fiocruz.br
OI Barroso, Shana/0000-0001-7890-9255
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico do Brasil
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES)CAPES; MercoSur Fund for Structural Convergence
   (Focem/Mercosur)
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico do Brasil (CNPq), Fundacao de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and the MercoSur
   Fund for Structural Convergence (Focem/Mercosur).
CR Alba G, 2020, CELL, V20, P3
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Bourgonje AR, 2020, J PATHOL, V251, P228, DOI 10.1002/path.5471
   Brechard S, 2005, CELL CALCIUM, V37, P531, DOI 10.1016/j.ceca.2005.01.019
   Chen X, 2020, CHINA PERSPECT-SER, P1
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   D'Ardes D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21083003
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   Gutmann C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061918
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Kalkeri R, 2020, AM J TROP MED HYG, V103, P18, DOI 10.4269/ajtmh.20-0279
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Konopka KE, 2020, CHEST, VS0012-3692, P30775
   Kubes P, 2018, CELL TISSUE RES, V371, P399, DOI 10.1007/s00441-018-2790-5
   Li JY, 2020, BRIT J HAEMATOL, V190, P24, DOI 10.1111/bjh.16797
   Lima TFA, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/752923
   Liu Y, 2020, J INFECTION, V81, P6
   Masuda S, 2016, CLIN CHIM ACTA, V459, P89, DOI 10.1016/j.cca.2016.05.029
   Nguyen GT, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00373
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Qi RC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1157-x
   Reshi Mohammad Latif, 2014, Int J Cell Biol, V2014, P467452, DOI 10.1155/2014/467452
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Shi FJ, 2020, VIROLOGY, V546, P122, DOI 10.1016/j.virol.2020.04.011
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 31
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 12
PY 2020
VL 10
IS 1
AR 19630
DI 10.1038/s41598-020-76781-0
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OZ9RI
UT WOS:000595255700023
PM 33184506
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kyrychko, YN
   Blyuss, KB
   Brovchenko, I
AF Kyrychko, Yuliya N.
   Blyuss, Konstantin B.
   Brovchenko, Igor
TI Mathematical modelling of the dynamics and containment of COVID-19 in
   Ukraine
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TRANSMISSION; POPULATION; STRATEGIES; PATTERNS
AB COVID-19 disease caused by the novel SARS-CoV-2 coronavirus has already brought unprecedented challenges for public health and resulted in huge numbers of cases and deaths worldwide. In the absence of effective vaccine, different countries have employed various other types of non-pharmaceutical interventions to contain the spread of this disease, including quarantines and lockdowns, tracking, tracing and isolation of infected individuals, and social distancing measures. Effectiveness of these and other measures of disease containment and prevention to a large degree depends on good understanding of disease dynamics, and robust mathematical models play an important role in forecasting its future dynamics. In this paper we focus on Ukraine, one of Europe's largest countries, and develop a mathematical model of COVID-19 dynamics, using latest data on parameters characterising clinical features of disease. For improved accuracy, our model includes age-stratified disease parameters, as well as age- and location-specific contact matrices to represent contacts. We show that the model is able to provide an accurate short-term forecast for the numbers and age distribution of cases and deaths. We also simulated different lockdown scenarios, and the results suggest that reducing work contacts is more efficient at reducing the disease burden than reducing school contacts, or implementing shielding for people over 60.
C1 [Kyrychko, Yuliya N.; Blyuss, Konstantin B.] Univ Sussex, Dept Math, Brighton BN1 9QH, E Sussex, England.
   [Brovchenko, Igor] Inst Math Machines & Syst Problems, Glushkov Av 42, UA-03187 Kiev, Ukraine.
RP Kyrychko, YN (corresponding author), Univ Sussex, Dept Math, Brighton BN1 9QH, E Sussex, England.
EM y.kyrychko@sussex.ac.uk
CR Agaba GO, 2017, MATH BIOSCI, V286, P22, DOI 10.1016/j.mbs.2017.01.009
   Aguiar M, 2020, ENCYCLOP MATH APPL, P19
   Anastassopoulou C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230405
   [Anonymous], 2020, Nature, DOI 10.1038/d41586-020-01409-2
   [Anonymous], 2020, FOR 23 WORK GROUP MA
   [Anonymous], 2020, COVID 19 BCG PERSPEC
   [Anonymous], 2020, FOR 9 WORK GROUP MAT
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   Blyuss K. B., 2020, EFFECTS LATENCY AGE, DOI [10.1101/2020.04.25.20079848v1, DOI 10.1101/2020.04.25.20079848V1]
   Boldog P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020571
   Brovchenko I, 2020, SVITOGLYAD, V82, P2
   BYRNE AW, 2020, BMJ OPEN, V10, DOI DOI 10.1136/bmjopen-2020-039856
   Caulfield Timothy, 2020, Nature, DOI 10.1038/d41586-020-01266-z
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Davies NG, 2020, LANCET PUBLIC HEALTH, V5, pE375, DOI 10.1016/S2468-2667(20)30133-X
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1165
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Dreher N, 2020, IMPACT POLICY INTERV, DOI [10.1101/2020.05.01.20088179v1, DOI 10.1101/2020.05.01.20088179V1]
   Giordano G, 2020, NAT MED, V26, P855, DOI 10.1038/s41591-020-0883-7
   Hahn GJ, 1994, STAT MODELS ENG
   Jarvis CI, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01597-8
   Klepac P, 2020, CONTACTS CONTEXT LAR, DOI [10.1101/2020.02.16.20023754, DOI 10.1101/2020.02.16.20023754]
   Klepac P, 2018, EPIDEMICS-NETH, V24, P49, DOI 10.1016/j.epidem.2018.03.003
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P1151, DOI 10.1016/S1473-3099(20)30457-6
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Lloyd AL, 2001, THEOR POPUL BIOL, V60, P59, DOI 10.1006/tpbi.2001.1525
   McAloon C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039652
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Moghadas SM, 2020, P NATL ACAD SCI USA, V117, P9122, DOI 10.1073/pnas.2004064117
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   National Statistical Service of Ukraine, 2019, DISTR PERM POP UKR A
   Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Prem K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005697
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0
   Towers S, 2012, MATH BIOSCI, V240, P241, DOI 10.1016/j.mbs.2012.07.007
   Tsay C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67459-8
   Tuite AR, 2020, CAN MED ASSOC J, V192, pE1276, DOI 10.1503/cmaj.200476-f
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wallinga J, 2006, AM J EPIDEMIOL, V164, P936, DOI 10.1093/aje/kwj317
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   World Bank, 2018, LIF EXP BIRTH UKR
   Wu P., 2020, SUPPRESSING COVID 19
   Zhou WK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213898
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 48
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 12
PY 2020
VL 10
IS 1
AR 19662
DI 10.1038/s41598-020-76710-1
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OZ9RI
UT WOS:000595255700055
PM 33184338
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Nelson, KM
   Bisson, J
   Singh, G
   Graham, JG
   Chen, SN
   Friesen, JB
   Dahlin, JL
   Niemitz, M
   Walters, MA
   Pauli, GF
AF Nelson, Kathryn M.
   Bisson, Jonathan
   Singh, Gurpreet
   Graham, James G.
   Chen, Shao-Nong
   Friesen, J. Brent
   Dahlin, Jayme L.
   Niemitz, Matthias
   Walters, Michael A.
   Pauli, Guido F.
TI The Essential Medicinal Chemistry of Cannabidiol (CBD)
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID DRUG-METABOLIZING-ENZYMES; CANNABINOID RECEPTOR; MOLECULAR TARGETS; ORAL
   CANNABIDIOL; PLASMA-PROTEIN; NMR DATA; PHASE-I; IDENTIFICATION; BINDING;
   SINGLE
AB This Perspective of the published essential medicinal chemistry of cannabidiol (CBD) provides evidence that the popularization of CBD-fortified or CBD-labeled health products and CBD-associated health claims lacks a rigorous scientific foundation. CBD's reputation as a cure-all puts it in the same class as other "natural" panaceas, where valid ethnobotanicals are reduced to single, purportedly active ingredients. Such reductionist approaches oversimplify useful, chemically complex mixtures in an attempt to rationalize the commercial utility of natural compounds and exploit the "natural" label. Literature evidence associates CBD with certain semiubiquitous, broadly screened, primarily plantbased substances of undocumented purity that interfere with bioassays and have a low likelihood of becoming therapeutic agents. Widespread health challenges and pandemic crises such as SARS-CoV-2 create circumstances under which scientists must be particularly vigilant about healing claims that lack solid foundational data. Herein, we offer a critical review of the published medicinal chemistry properties of CBD, as well as precise definitions of CBD-containing substances and products, distilled to reveal the essential factors that impact its development as a therapeutic agent.
C1 [Nelson, Kathryn M.; Singh, Gurpreet; Walters, Michael A.] Univ Minnesota, Dept Med Chem, Inst Therapeut Discovery & Dev, Minneapolis, MN 55414 USA.
   [Bisson, Jonathan; Graham, James G.; Chen, Shao-Nong; Friesen, J. Brent; Pauli, Guido F.] Univ Illinois, Ctr Nat Prod Technol, Program Collaborat Res Pharmaceut Sci PCRPS, Chicago, IL 60612 USA.
   [Bisson, Jonathan; Graham, James G.; Chen, Shao-Nong; Pauli, Guido F.] Univ Illinois, Dept Pharmaceut Sci, Coll Pharm, Chicago, IL 60612 USA.
   [Bisson, Jonathan; Graham, James G.; Chen, Shao-Nong; Pauli, Guido F.] Univ Illinois, Coll Pharm, Inst TB Res, Chicago, IL 60612 USA.
   [Dahlin, Jayme L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Dahlin, Jayme L.] Harvard Med Sch, Boston, MA 02115 USA.
   [Niemitz, Matthias] NMR Solut Ltd, Kuopio 70110, Finland.
RP Pauli, GF (corresponding author), Univ Illinois, Ctr Nat Prod Technol, Program Collaborat Res Pharmaceut Sci PCRPS, Chicago, IL 60612 USA.; Pauli, GF (corresponding author), Univ Illinois, Dept Pharmaceut Sci, Coll Pharm, Chicago, IL 60612 USA.; Pauli, GF (corresponding author), Univ Illinois, Coll Pharm, Inst TB Res, Chicago, IL 60612 USA.
EM gfp@uic.edu
OI BISSON, Jonathan/0000-0003-1640-9989; Friesen, John
   Brent/0000-0002-0739-9224; Graham, James/0000-0002-7114-8921; Niemitz,
   Matthias/0000-0002-5452-5203; Chen, Shao-Nong/0000-0003-0748-0863;
   Dahlin, Jayme/0000-0003-4151-9944; Walters, Michael/0000-0001-5650-9277
FU National Institute of Mental Health's Psychoactive Drug Screening
   Program (NIMH PDSP)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [HHSN-271-2018-00023-C]; NHLBI/NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [T32 HL007627];
   ODS/NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U41 AT008706, P50 AT000155]; NCCIH/NIH
   [U41 AT008706, P50 AT000155]; Research Open Access Publishing (ROAAP)
   Fund of the University of Illinois at Chicago
FX The Ki determinations, receptor binding profiles, agonist and/or
   antagonist functional data, HERG data, MDR1 data, etc. as appropriate
   were generously provided by the National Institute of Mental Health's
   Psychoactive Drug Screening Program, Contract HHSN-271-2018-00023-C
   (NIMH PDSP), directed by Dr. Bryan L. Roth at the University of North
   Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH,
   Bethesda, MD, U.S. The authors acknowledge the following financial
   support: J.L.D. through Grant T32 HL007627 from NHLBI/NIH; J.B., J.G.G.,
   S.-N.C., and G.F.P. through Grants U41 AT008706 and P50 AT000155 jointly
   from ODS/NIH and NCCIH/NIH. Furthermore, the authors acknowledge the
   collegial spirit of Drs. Young-Hae Choi and Rob Verpoorte, University of
   Leiden, for kindly sharing their historic raw NMR data. J.L.D.
   gratefully acknowledges Drs. Parnian Lak and Brian Shoichet for
   performing DLS experiments. We kindly acknowledge the Research Open
   Access Publishing (ROAAP) Fund of the University of Illinois at Chicago
   for financial support towards the open access publishing fee for this
   article. Finally, the authors thank M. Backmann for help in creating the
   figure for the graphical abstract. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The opinions or assertions contained
   herein belong to the authors and are not necessarily the official views
   of the funders.
CR Adams R, 1940, J AM CHEM SOC, V62, P2204, DOI 10.1021/ja01865a083
   Aizpurua-Olaizola O, 2016, J NAT PROD, V79, P324, DOI 10.1021/acs.jnatprod.5b00949
   American Epilepsy Foundation, 2019, AES POS STAT CANN TR
   [Anonymous], WHO CBD REP MAY 2018
   Atsmon J, 2018, J PHARM SCI-US, V107, P1423, DOI 10.1016/j.xphs.2017.12.020
   Basas-Jaumandreu J, 2020, PLANTA MED, V86, P338, DOI 10.1055/a-1110-1045
   Ben-Shabat S, 2006, J MED CHEM, V49, P1113, DOI 10.1021/jm050709m
   Benedetti F, 2014, NEURON, V84, P623, DOI 10.1016/j.neuron.2014.10.023
   Bergmann KR, 2020, BRIT J CLIN PHARMACO, V86, P380, DOI 10.1111/bcp.14158
   Biosciences G, EP CANN OR SOL PRESC
   BioSpace. Kannalife Inc, FURTH EL MECH ACT KL
   Bisogno T, 2001, BRIT J PHARMACOL, V134, P845, DOI 10.1038/sj.bjp.0704327
   Bisson J, 2016, NAT PROD REP, V33, P1028, DOI 10.1039/c6np00022c
   Bonaccorso S, 2019, NEUROTOXICOLOGY, V74, P282, DOI 10.1016/j.neuro.2019.08.002
   Brown Joshua D, 2021, Res Social Adm Pharm, V17, P2053, DOI 10.1016/j.sapharm.2020.03.020
   Brzozowska N, 2016, PEERJ, V4, DOI 10.7717/peerj.2081
   Caesar LK, 2019, NAT PROD REP, V36, P869, DOI 10.1039/c9np00011a
   Carvalho RK, 2018, J APPL TOXICOL, V38, P1215, DOI 10.1002/jat.3631
   Chen GF, 2012, SCI CHINA LIFE SCI, V55, P527, DOI 10.1007/s11427-012-4317-8
   Choules MP, 2020, J PHARMACEUT BIOMED, V178, DOI 10.1016/j.jpba.2019.112915
   Choules MP, 2018, J ORG CHEM, V83, P6664, DOI 10.1021/acs.joc.8b00988
   Citti C, 2019, J PHARMACEUT BIOMED, V175, DOI 10.1016/j.jpba.2019.06.049
   Console-Bram L, 2014, BRIT J PHARMACOL, V171, P3908, DOI 10.1111/bph.12746
   CONSROE P, 1991, PHARMACOL BIOCHEM BE, V40, P517, DOI 10.1016/0091-3057(91)90357-8
   Degenhardt F, 2017, HANDBOOK OF CANNABIS AND RELATED PATHOLOGIES: BIOLOGY, PHARMACOLOGY, DIAGNOSIS, AND TREATMENT, P13, DOI 10.1016/B978-0-12-800756-3.00002-8
   Deiana S, 2012, PSYCHOPHARMACOLOGY, V219, P859, DOI 10.1007/s00213-011-2415-0
   Devinsky O, 2018, NEW ENGL J MED, V378, P1888, DOI 10.1056/NEJMoa1714631
   Dietz BM, 2017, J NAT PROD, V80, P2284, DOI 10.1021/acs.jnatprod.7b00284
   Elbaz M, 2015, MOL ONCOL, V9, P906, DOI 10.1016/j.molonc.2014.12.010
   Ewing LE, 2019, MOLECULES, V24, DOI 10.3390/molecules24091694
   Freeman J., RHEUMATOID ARTHRITIS
   Freeman TP, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1141
   Friesen JB, 2019, J NAT PROD, V82, P621, DOI 10.1021/acs.jnatprod.9b00020
   GAONI Y, 1966, TETRAHEDRON, V22, P1481, DOI 10.1016/S0040-4020(01)99446-3
   Gaston TE, 2017, EPILEPSIA, V58, P1586, DOI 10.1111/epi.13852
   Geffrey AL, 2015, EPILEPSIA, V56, P1246, DOI 10.1111/epi.13060
   Geller SE, 2009, MENOPAUSE, V16, P1156, DOI 10.1097/gme.0b013e3181ace49b
   Gertsch J., 2018, MED CANNABIS CANNABI, V1, P60
   Ghovanloo MR, 2018, J BIOL CHEM, V293, P16546, DOI 10.1074/jbc.RA118.004929
   Groeneveld GJ, 2020, BRIT J CLIN PHARMACO, V86, P189, DOI 10.1111/bcp.14028
   Grotenhermen F, 2017, CANNABIS CANNABINOID, V2, P1, DOI 10.1089/can.2016.0036
   Gutman A. L., 2006, U.S. Patent, Patent No. 8383842
   Guy G.W., 2004, J CANNABIS THER, V3, P35, DOI DOI 10.1300/J175V03N03_
   Hanus LO, 2005, ORG BIOMOL CHEM, V3, P1116, DOI 10.1039/b416943c
   HARVEY DJ, 1991, J CHROMATOGR-BIOMED, V562, P299, DOI 10.1016/0378-4347(91)80587-3
   HARVEY DJ, 1990, XENOBIOTICA, V20, P303, DOI 10.3109/00498259009046849
   Hazekamp A, 2004, CHEM PHARM BULL, V52, P718, DOI 10.1248/cpb.52.718
   Hiemstra B, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0879-5
   Hopp C, 2015, HERBALGRAM, V107, P44
   Huestis MA, 2005, HANDB EXP PHARMACOL, V168, P657
   Ingolfsson HI, 2014, ACS CHEM BIOL, V9, P1788, DOI 10.1021/cb500086e
   Jacob A, 1940, J CHEM SOC, P649, DOI 10.1039/jr9400000649
   Jiang RR, 2011, LIFE SCI, V89, P165, DOI 10.1016/j.lfs.2011.05.018
   Johns DG, 2007, BRIT J PHARMACOL, V152, P825, DOI 10.1038/sj.bjp.0707419
   Johnson J., CBD WEIGHT LOSS DOES
   JONES PG, 1977, ACTA CRYSTALLOGR B, V33, P3211, DOI 10.1107/S0567740877010577
   Kathmann M, 2006, N-S ARCH PHARMACOL, V372, P354, DOI 10.1007/s00210-006-0033-x
   Kinney WA, 2016, ACS MED CHEM LETT, V7, P424, DOI 10.1021/acsmedchemlett.6b00009
   Kubala J., 7 BENEFITS USES CBD
   Kumari S, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau120
   Lachenmeier Dirk W, 2019, F1000Res, V8, P1394, DOI 10.12688/f1000research.19931.2
   LITTLE PJ, 1988, J PHARMACOL EXP THER, V247, P1046
   Luo XZ, 2019, NATURE, V567, P123, DOI 10.1038/s41586-019-0978-9
   MacKeen D., 2019, NY TIMES
   Martin Emanuele R., 2019, Patent No. [WO 2019118360 A1, 2019118360]
   Mascal M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44056-y
   McAlpine JB, 2019, NAT PROD REP, V36, P35, DOI 10.1039/c7np00064b
   Mechoulam R, 2002, CHEM PHYS LIPIDS, V121, P35, DOI 10.1016/S0009-3084(02)00144-5
   Merrick J, 2016, CANNABIS CANNABINOID, V1, P102, DOI 10.1089/can.2015.0004
   Millar SA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01365
   Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011
   Mogil JS, 2017, LAB ANIMAL, V46, P136, DOI 10.1038/laban.1223
   Morales P, 2019, ACS MED CHEM LETT, V10, P694, DOI 10.1021/acsmedchemlett.9b00127
   Morales P, 2017, PROG CHEM ORG NAT PR, V103, P103, DOI 10.1007/978-3-319-45541-9_4
   Morrison G, 2019, CLIN PHARM DRUG DEV, V8, P1009, DOI 10.1002/cpdd.665
   Murphy SK, 2018, EPIGENETICS-US, V13, P1208, DOI 10.1080/15592294.2018.1554521
   Nahler G, 2017, CANNABIS CANNABINOID, V2, P81, DOI 10.1089/can.2017.0009
   Nelson KM, 2017, J MED CHEM, V60, P1620, DOI 10.1021/acs.jmedchem.6b00975
   Office of the Commissioner, WARNN LETT TEST RES
   Office of the Commissioner, FDA REG CANN CANN DE
   Office of the Commissioner, FDA CANN RES DRUG AP
   OHLSSON A, 1986, BIOMED ENVIRON MASS, V13, P77, DOI 10.1002/bms.1200130206
   ONeil M. J., 2013, MERCK INDEX ENCY CHE, P2707
   Pacifici R, 2017, CLIN CHEM LAB MED, V55, P1555, DOI 10.1515/cclm-2016-1060
   Palazzoli F, 2018, J PHARMACEUT BIOMED, V150, P25, DOI 10.1016/j.jpba.2017.11.054
   Pauli GF, 2014, J MED CHEM, V57, P9220, DOI 10.1021/jm500734a
   Pauli GF, 2012, J NAT PROD, V75, P1243, DOI 10.1021/np300066q
   Pauli GF, 2012, J NAT PROD, V75, P834, DOI 10.1021/np200993k
   Pertwee RG, 2004, EUPHYTICA, V140, P73, DOI 10.1007/s10681-004-4756-9
   Popejoy S., CBGENIUS
   Popovic A, 2019, FORENSIC SCI INT, V302, DOI 10.1016/j.forsciint.2019.109911
   Reece AS, 2019, EPIGENETICS-US, V14, P1041, DOI 10.1080/15592294.2019.1633868
   Russo C, 2019, ARCH TOXICOL, V93, P179, DOI 10.1007/s00204-018-2322-9
   Russo EB, 2005, NEUROCHEM RES, V30, P1037, DOI 10.1007/s11064-005-6978-1
   Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460
   SAMARA E, 1988, DRUG METAB DISPOS, V16, P469
   Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989
   Siciliano C., 2019, IOP Conference Series: Materials Science and Engineering, V572, DOI 10.1088/1757-899X/572/1/012010
   Skrobin N., 2019, CHICAGO TRIBUNE
   Solinas M, 2012, BRIT J PHARMACOL, V167, P1218, DOI 10.1111/j.1476-5381.2012.02050.x
   Sorkin BC, 2020, FASEB J, V34, P41, DOI 10.1096/fj.201902143R
   Stott CG, 2013, EUR J CLIN PHARMACOL, V69, P1135, DOI 10.1007/s00228-012-1441-0
   Stott CG, 2013, EUR J CLIN PHARMACOL, V69, P825, DOI 10.1007/s00228-012-1393-4
   Stout SM, 2014, DRUG METAB REV, V46, P86, DOI 10.3109/03602532.2013.849268
   Taylor L, 2018, CNS DRUGS, V32, P1053, DOI 10.1007/s40263-018-0578-5
   Tayo B, 2020, CLIN PHARMACOKINET, V59, P747, DOI 10.1007/s40262-019-00841-6
   The Skyline Agency, CBD OIL CANN TINCT P
   Thorne N, 2010, CURR OPIN CHEM BIOL, V14, P315, DOI 10.1016/j.cbpa.2010.03.020
   Trainor GL, 2007, ANNU REP MED CHEM, V42, P489, DOI 10.1016/S0065-7743(07)42031-0
   Ujvary I, 2016, CANNABIS CANNABINOID, V1, P90, DOI 10.1089/can.2015.0012
   Wall M. E., 1976, PHARM MARIHUANA, P113
   WATANABE K, 1991, J PHARMACOBIO-DYNAM, V14, P421, DOI 10.1248/bpb1978.14.421
   Watanabe K, 2007, FORENSICTOXICOL, V25, P16, DOI DOI 10.1007/s11419-007-0021-y
   Watanabe K, 2019, FORENSIC TOXICOL, V37, P449, DOI 10.1007/s11419-019-00467-0
   Watkins AR, 2019, CHANNELS, V13, P162, DOI 10.1080/19336950.2019.1615824
   Watkinson A, 2017, J PAIN, V18, P908, DOI 10.1016/j.jpain.2017.02.435
   Webster G. R. B., 2004, United States Patent, Patent No. [2004/ 0143126 A1, 20040143126]
   Wheless JW, 2019, CNS DRUGS, V33, P593, DOI 10.1007/s40263-019-00624-4
   Wray Louise, 2017, Cannabis Cannabinoid Res, V2, P282, DOI 10.1089/can.2017.0032
   Yang Y, 2014, FITOTERAPIA, V92, P133, DOI 10.1016/j.fitote.2013.10.010
   Zendulka O, 2016, CURR DRUG METAB, V17, P206, DOI 10.2174/1389200217666151210142051
   Zuardi AW, 2006, BRAZ J MED BIOL RES, V39, P421, DOI 10.1590/S0100-879X2006000400001
NR 122
TC 0
Z9 0
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 12
PY 2020
VL 63
IS 21
BP 12137
EP 12155
DI 10.1021/acs.jmedchem.0c00724
PG 19
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA OW2PA
UT WOS:000592734300003
PM 32804502
OA Bronze
DA 2021-01-01
ER

PT J
AU Xiu, SY
   Dick, A
   Ju, H
   Mirzaie, S
   Abdi, F
   Cocklin, S
   Zhan, P
   Liu, XY
AF Xiu, Siyu
   Dick, Alexej
   Ju, Han
   Mirzaie, Sako
   Abdi, Fatemeh
   Cocklin, Simon
   Zhan, Peng
   Liu, Xinyong
TI Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
AB Recently, a novel coronavirus initially designated 2019-nCoV but now termed SARS-CoV-2 has emerged and raised global concerns due to its virulence. SARS-CoV-2 is the etiological agent of "coronavirus disease 2019", abbreviated to COVID-19, which despite only being identified at the very end of 2019, has now been classified as a pandemic by the World Health Organization (WHO). At this time, no specific prophylactic or postexposure therapy for COVID-19 are currently available. Viral entry is the first step in the SARS-CoV-2 lifecycle and is mediated by the trimeric spike protein. Being the first stage in infection, entry of SARS-CoV-2 into host cells is an extremely attractive therapeutic intervention point. Within this review, we highlight therapeutic intervention strategies for anti-SARS-CoV, MERS-CoV, and other coronaviruses and speculate upon future directions for SARS-CoV-2 entry inhibitor designs.
C1 [Xiu, Siyu; Ju, Han; Zhan, Peng; Liu, Xinyong] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Jinan 250012, Peoples R China.
   [Dick, Alexej; Cocklin, Simon] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
   [Mirzaie, Sako] Islamic Azad Univ, Sanandaj Branch, Dept Biochem, Sanandaj 6616935391, Iran.
   [Abdi, Fatemeh] Islamic Azad Univ, Dept Cellular & Mol Biol, Tehran 1651153311, Iran.
RP Zhan, P; Liu, XY (corresponding author), Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Jinan 250012, Peoples R China.; Cocklin, S (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
EM sc349@drexel.edu; zhanpeng1982@sdu.edu.cn; xinyongl@sdu.edu.cn
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [81973181, 81773574]; Key Project of
   NSFC for International Cooperation [81420108027]; Key Research and
   Development Project of Shandong Province [2017CXGC1401, 2019JZZY021011,
   2020SFXGFY08]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01AI150491]; 
   [NS089435]
FX Financial support from the National Natural Science Foundation of China
   (NSFC nos. 81973181, 81773574), Key Project of NSFC for International
   Cooperation (no. 81420108027), Key Research and Development Project of
   Shandong Province (nos. 2017CXGC1401, 2019JZZY021011, 2020SFXGFY08), and
   NIH grant R01AI150491 (Cocklin, PI) are gratefully acknowledged. A.D. is
   partially funded by NS089435 (Cocklin, Co-I [Nonnemacher, PI]). We thank
   Megan Meuser for comments that greatly improved the manuscript.
CR Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   [Anonymous], 2020, COR DIS COVID 2019 S
   [Anonymous], 2020, MIDDL E RESP SYNDR C
   [Anonymous], 2020, COR DIS 2019 COVID 1
   [Anonymous], 2020, SEV AC RESP SYNDR CO
   Arabi Y, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1490-9
   Bestle D., 2020, 042085 BIORXIV
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Blanchard E, 2006, J VIROL, V80, P6964, DOI 10.1128/JVI.00024-06
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Cao JZ, 2015, ANTIVIR RES, V114, P1, DOI 10.1016/j.antiviral.2014.11.010
   Channappanavar R, 2015, J INFECT DIS, V212, P1894, DOI 10.1093/infdis/jiv325
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005
   Cherian Sarah S, 2020, Indian J Med Res, V151, P160, DOI 10.4103/ijmr.IJMR_585_20
   Chu LHM, 2008, J CELL BIOCHEM, V104, P2335, DOI 10.1002/jcb.21790
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Coughlin M, 2007, VIROLOGY, V361, P93, DOI 10.1016/j.virol.2006.09.029
   Coughlin MM, 2009, VIROLOGY, V394, P39, DOI 10.1016/j.virol.2009.07.028
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dana D, 2020, MOLECULES, V25, DOI 10.3390/molecules25030698
   de Wit E, 2018, ANTIVIR RES, V156, P64, DOI 10.1016/j.antiviral.2018.06.006
   Deng YQ, 2006, STRUCTURE, V14, P889, DOI 10.1016/j.str.2006.03.007
   Dibo M, 2019, CURR PHARM BIOTECHNO, V20, P1108, DOI 10.2174/1389201020666190809112704
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Du J., 2020, CHINESE CHEM LETT, DOI j.cclet.2020.03.028
   Dyall J, 2017, DRUGS, V77, P1935, DOI 10.1007/s40265-017-0830-1
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Frey G, 2006, P NATL ACAD SCI USA, V103, P13938, DOI 10.1073/pnas.0601036103
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   GLUPCZYNSKI Y, 1986, ANTIMICROB AGENTS CH, V29, P52, DOI 10.1128/AAC.29.1.52
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Greenough TC, 2005, J INFECT DIS, V191, P507, DOI 10.1086/427242
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Gurevich Eugenia V, 2014, Handb Exp Pharmacol, V219, P1, DOI 10.1007/978-3-642-41199-1_1
   Haga S, 2010, ANTIVIR RES, V85, P551, DOI 10.1016/j.antiviral.2009.12.001
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   Ho TY, 2007, ANTIVIR RES, V74, P92, DOI 10.1016/j.antiviral.2006.04.014
   Ho TY, 2006, ANTIVIR RES, V69, P70, DOI 10.1016/j.antiviral.2005.10.005
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hu HB, 2005, J COMB CHEM, V7, P648, DOI 10.1021/cc0500607
   Huang LL, 2003, J BIOL CHEM, V278, P15532, DOI 10.1074/jbc.M212934200
   Huentelman MJ, 2004, HYPERTENSION, V44, P903, DOI 10.1161/01.HYP.0000146120.29648.36
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048
   Inoue Y, 2007, J VIROL, V81, P8722, DOI 10.1128/JVI.00253-07
   Islam MT, 2020, PHYTOTHER RES, V34, P2471, DOI 10.1002/ptr.6700
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kilianski A, 2014, ANTIVIR RES, V101, P105, DOI 10.1016/j.antiviral.2013.11.004
   Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200
   Lei C. H., 929976 BIORXIV, V2020
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li W., 2020, 093088 BIORXIV
   Ling RS, 2020, PEPTIDES, V130, DOI 10.1016/j.peptides.2020.170328
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu Q, 2015, ANTIMICROB AGENTS CH, V59, P742, DOI 10.1128/AAC.03977-14
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Lundin A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004166
   Madu IG, 2009, J VIROL, V83, P7411, DOI 10.1128/JVI.00079-09
   Milewska A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156552
   Milewska A, 2013, ANTIVIR RES, V97, P112, DOI 10.1016/j.antiviral.2012.11.006
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Mingo RM, 2015, J VIROL, V89, P2931, DOI 10.1128/JVI.03398-14
   Mitsuki YY, 2008, MICROBES INFECT, V10, P908, DOI 10.1016/j.micinf.2008.05.009
   Miyoshi-Akiyama T, 2011, J INFECT DIS, V203, P1574, DOI 10.1093/infdis/jir084
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Ng OW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102415
   Ngo HX, 2018, MEDCHEMCOMM, V9, P757, DOI 10.1039/c8md90019a
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Pascal KE, 2015, P NATL ACAD SCI USA, V112, P8738, DOI 10.1073/pnas.1510830112
   Petit CM, 2005, VIROLOGY, V341, P215, DOI 10.1016/j.virol.2005.06.046
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Pohjala L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028923
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Pu YH, 2008, J VIROL, V82, P8112, DOI 10.1128/JVI.00837-08
   Pyrc K, 2006, ANTIMICROB AGENTS CH, V50, P2000, DOI 10.1128/AAC.01598-05
   Raab CP, 2011, PRIMARY CARE, V38, P681, DOI 10.1016/j.pop.2011.07.006
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Robertson NS, 2018, MOLECULES, V23, DOI 10.3390/molecules23040959
   Sainz B, 2005, J VIROL, V79, P7195, DOI 10.1128/JVI.79.11.7195-7206.2005
   Shah PP, 2010, MOL PHARMACOL, V78, P319, DOI 10.1124/mol.110.064261
   Shin JS, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060283
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Skowronski DA, 2005, ANNU REV MED, V56, P357, DOI 10.1146/annurev.med.56.091103.134135
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Sosnowski P, 2016, FEBS LETT, V590, P1253, DOI 10.1002/1873-3468.12140
   Stas P, 2008, INT J CARDIOL, V127, pE80, DOI 10.1016/j.ijcard.2007.04.055
   Struck AW, 2012, ANTIVIR RES, V94, P288, DOI 10.1016/j.antiviral.2011.12.012
   Sun YP, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9090255
   Swinney DC, 2013, CLIN PHARMACOL THER, V93, P299, DOI 10.1038/clpt.2012.236
   ter Meulen J, 2007, EXPERT OPIN EMERG DR, V12, P525, DOI 10.1517/14728214.12.4.525
   Tong TR, 2009, EXPERT OPIN THER PAT, V19, P357, DOI 10.1517/13543770802609384
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Turner AJ, 2008, HYPERTENSION, V52, P816, DOI 10.1161/HYPERTENSIONAHA.108.116137
   van Dongen MJP, 2019, SCIENCE, V363, P1056, DOI 10.1126/science.aar6221
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Verma S, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00107
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang K, 2020, 988345 BIORXIV
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang X, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0169-8
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Woo PCY, 2005, VACCINE, V23, P4959, DOI 10.1016/j.vaccine.2005.05.023
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu GC, 2019, J MED CHEM, V62, P9375, DOI 10.1021/acs.jmedchem.9b00359
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xia S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020487
   Xiao Xiaodong, 2007, Recent Pat Antiinfect Drug Discov, V2, P171, DOI 10.2174/157489107782497272
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yaylali SA, 2013, INT OPHTHALMOL, V33, P627, DOI 10.1007/s10792-013-9748-0
   Yi L, 2004, J VIROL, V78, P11334, DOI 10.1128/JVI.78.20.11334-11339.2004
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang J. S., 2020, 935387 BIORXIV
   Zhao GY, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-266
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhou YS, 2018, EXPERT REV VACCINES, V17, P677, DOI 10.1080/14760584.2018.1506702
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 139
TC 2
Z9 2
U1 4
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 12
PY 2020
VL 63
IS 21
BP 12256
EP 12274
DI 10.1021/acs.jmedchem.0c00502
PG 19
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA OW2PA
UT WOS:000592734300009
PM 32539378
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gil, C
   Ginex, T
   Maestro, I
   Nozal, V
   Barrado-Gil, L
   Cuesta-Geijo, MA
   Urquiza, J
   Ramirez, D
   Alonso, C
   Campillo, NE
   Martinez, A
AF Gil, Carmen
   Ginex, Tiziana
   Maestro, Ines
   Nozal, Vanesa
   Barrado-Gil, Lucia
   Angel Cuesta-Geijo, Miguel
   Urquiza, Jesus
   Ramirez, David
   Alonso, Covadonga
   Campillo, Nuria E.
   Martinez, Ana
TI COVID-19: Drug Targets and Potential Treatments
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID RESPIRATORY-SYNDROME-CORONAVIRUS; PAPAIN-LIKE PROTEASE; SARS-ASSOCIATED
   CORONAVIRUS; HOST-CELL ENTRY; ANGIOTENSIN-CONVERTING ENZYME; X-RAY
   STRUCTURES; SPIKE PROTEIN; CYTOKINE STORM; REPLICATION INHIBITOR;
   CRYSTAL-STRUCTURE
AB Currently, humans are immersed in a pandemic caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health worldwide. To date, no drug or vaccine has been approved to treat the severe disease caused by this coronavirus, COVID-19. In this paper, we will focus on the main virus-based and host-based targets that can guide efforts in medicinal chemistry to discover new drugs for this devastating disease. In principle, all CoV enzymes and proteins involved in viral replication and the control of host cellular machineries are potentially druggable targets in the search for therapeutic options for SARS-CoV-2. This Perspective provides an overview of the main targets from a structural point of view, together with reported therapeutic compounds with activity against SARS-CoV-2 and/or other CoVs. Also, the role of innate immune response to coronavirus infection and the related therapeutic options will be presented.
C1 [Gil, Carmen; Ginex, Tiziana; Maestro, Ines; Nozal, Vanesa; Barrado-Gil, Lucia; Angel Cuesta-Geijo, Miguel; Campillo, Nuria E.; Martinez, Ana] CSIC, Ctr Invest Biol Margarita Salas, Madrid 28040, Spain.
   [Urquiza, Jesus; Alonso, Covadonga] Inst Nacl Invest & Tecnol Agr & Alimentari INIA, Dept Biotechnol, Madrid 28040, Spain.
   [Ramirez, David] Univ Autonoma Chile, Inst Ciencias Biomed, Santiago 7500912, Chile.
RP Gil, C; Martinez, A (corresponding author), CSIC, Ctr Invest Biol Margarita Salas, Madrid 28040, Spain.
EM carmen.gil@csic.es; ana.martinez@csic.es
RI Barrado-Gil, Lucia/H-4691-2015; Gil, Carmen/J-8932-2014; Ramirez,
   David/Q-9537-2018
OI Barrado-Gil, Lucia/0000-0002-1053-2997; urquiza,
   jesus/0000-0002-7870-4580; NOZAL GARCIA, VANESA/0000-0001-5260-5683;
   Gil, Carmen/0000-0002-3882-6081; Ramirez, David/0000-0003-0002-1189;
   Alonso, Covadonga/0000-0002-0862-6177
FU CSICConsejo Superior de Investigaciones Cientificas (CSIC) [201980E024,
   202020E103]; "la Caixa" Banking FoundationLa Caixa Foundation
   [HR18-00469]; Instituto de Salud Carlos IIIInstituto de Salud Carlos III
   [ISCIII-COV20/01007]; Spanish Ministry of Science and InnovationSpanish
   Government [RTI2018-097305-R-I00]; CONICYT-PCI [REDES190074];
   FONDECYTComision Nacional de Investigacion Cientifica y Tecnologica
   (CONICYT)CONICYT FONDECYT [11180604]; H2020-MSCAITN-2017 [765912];
   predoctoral FPU grant [FPU16/04466];  [FPISGIT2018-04]
FX Funding from CSIC (201980E024 and 202020E103) is acknowledged. This
   research was partially supported through "la Caixa" Banking Foundation
   (HR18-00469), Instituto de Salud Carlos III (ISCIII-COV20/01007),
   Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00),
   CONICYT-PCI (REDES190074 to D.R. and A.M.), and FONDECYT (11180604 to
   D.R.). I.M. was funded by H2020-MSCAITN-2017 (grant no. 765912), V.N.
   holds a predoctoral FPU grant (FPU16/04466), and J.U. was financed by
   FPISGIT2018-04.
CR Adedeji AO, 2014, ANTIMICROB AGENTS CH, V58, P4894, DOI 10.1128/AAC.02994-14
   Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Adedeji AO, 2012, ANTIMICROB AGENTS CH, V56, P4718, DOI 10.1128/AAC.00957-12
   Afsar CU, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109770
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362
   Barton C, 2014, ANTIMICROB AGENTS CH, V58, P120, DOI 10.1128/AAC.01407-13
   Batra R, 2020, SCREENING THERAPEUTI
   Becares M, 2016, J VIROL, V90, P5399, DOI 10.1128/JVI.03259-15
   Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bertram S, 2013, J VIROL, V87, P6150, DOI 10.1128/JVI.03372-12
   Bertram S, 2011, J VIROL, V85, P13363, DOI 10.1128/JVI.05300-11
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Cai WT, 2015, ANTIVIR RES, V118, P82, DOI 10.1016/j.antiviral.2015.03.008
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao LW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06121-4
   Chaikuad A, 2014, BIOCHEM J, V459, P59, DOI 10.1042/BJ20131399
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chang CK, 2016, DRUG DISCOV TODAY, V21, P562, DOI 10.1016/j.drudis.2015.11.015
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Chen Y, 2020, LANCET INFECT DIS, V20, P515, DOI 10.1016/S1473-3099(20)30235-8
   Chen ZN, 2005, J INFECT DIS, V191, P755, DOI 10.1086/427811
   Cheng A, 2005, VIROLOGY, V335, P165, DOI 10.1016/j.virol.2005.02.017
   Cheng JL, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100972
   Cheng WJ, 2015, VIROL SIN, V30, P153, DOI 10.1007/s12250-015-3581-8
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Couture F, 2015, EXPERT OPIN THER PAT, V25, P379, DOI 10.1517/13543776.2014.1000303
   Cuesta-Geijo MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048853
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dahms SO, 2018, BIOCHEMISTRY-US, V57, P925, DOI 10.1021/acs.biochem.7b01124
   Dahms SO, 2017, ACS CHEM BIOL, V12, P2474, DOI 10.1021/acschembio.7b00633
   Dahms SO, 2016, P NATL ACAD SCI USA, V113, P11196, DOI 10.1073/pnas.1613630113
   Dahms SO, 2014, ACS CHEM BIOL, V9, P1113, DOI 10.1021/cb500087x
   De Clercq Erik, 2006, Expert Rev Anti Infect Ther, V4, P291, DOI 10.1586/14787210.4.2.291
   de Lartigue J, 2009, TRAFFIC, V10, P883, DOI 10.1111/j.1600-0854.2009.00915.x
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Dong SJ, 2020, J MED VIROL, V92, P1542, DOI 10.1002/jmv.25768
   Dosch SF, 2009, VIRUS RES, V142, P19, DOI 10.1016/j.virusres.2009.01.005
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Ehmke V, 2013, CHEMMEDCHEM, V8, P967, DOI 10.1002/cmdc.201300112
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grimm C, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00045
   Guo C., 2020, BIORXIV PREPRINT
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0
   Hardegger LA, 2011, CHEMMEDCHEM, V6, P2048, DOI 10.1002/cmdc.201100353
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Hasan A., 2020, J BIOMOL STRUCT DYN
   Haschke M, 2013, CLIN PHARMACOKINET, V52, P783, DOI 10.1007/s40262-013-0072-7
   He KM, 2017, NATURE, V552, P410, DOI 10.1038/nature25146
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu XP, 2016, J ETHNOPHARMACOL, V179, P128, DOI 10.1016/j.jep.2015.07.019
   Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang SH, 2017, J MICROBIOL IMMUNOL, V50, P277, DOI 10.1016/j.jmii.2015.07.002
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Ikonomov OC, 2009, BIOCHEM BIOPH RES CO, V382, P566, DOI 10.1016/j.bbrc.2009.03.063
   Ivanova T, 2017, CHEMMEDCHEM, V12, P1953, DOI 10.1002/cmdc.201700596
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jauregui AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062416
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jin X., 2020, EMERGING MICROBES IN
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Kang Y.-L., 2020, BIORXIV PREPRINT
   Kim MK, 2011, EUR J MED CHEM, V46, P5698, DOI 10.1016/j.ejmech.2011.09.005
   Kindler E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006195
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Kintzer AF, 2018, FEBS J, V285, P233, DOI 10.1111/febs.14154
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kobayashi Y, 2012, J VIROL, V86, P3446, DOI 10.1128/JVI.06147-11
   Konno Y., 2020, BIORXIV PREPRINT
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuba K, 2010, PHARMACOL THERAPEUT, V128, P119, DOI 10.1016/j.pharmthera.2010.06.003
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Kuri T, 2011, J GEN VIROL, V92, P1899, DOI 10.1099/vir.0.031856-0
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Leber A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00178
   Lee H, 2013, CHEMMEDCHEM, V8, P1361, DOI 10.1002/cmdc.201300134
   Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004
   Lehmann KC, 2015, VIRUS RES, V202, P12, DOI 10.1016/j.virusres.2014.12.001
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li NN, 2008, P NATL ACAD SCI USA, V105, P4796, DOI 10.1073/pnas.0712051105
   Li SW, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050678
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Lin SM, 2020, J MED CHEM, V63, P3131, DOI 10.1021/acs.jmedchem.9b01913
   Lin SC, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2253-8
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu DX, 2014, ANTIVIR RES, V109, P97, DOI 10.1016/j.antiviral.2014.06.013
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Liu WB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00461-20
   Lokugamage K. G., 2020, BIORXIV PREPRINT
   Lu XL, 2011, VIRUS GENES, V42, P37, DOI 10.1007/s11262-010-0544-x
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Ma-Lauer Y, 2016, P NATL ACAD SCI USA, V113, pE5192, DOI 10.1073/pnas.1603435113
   Maggio R, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104837
   Mahlakoiv T, 2012, J GEN VIROL, V93, P2601, DOI 10.1099/vir.0.046284-0
   McBride CE, 2007, J VIROL, V81, P2418, DOI 10.1128/JVI.02146-06
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   McDonald SM, 2013, WIRES RNA, V4, P351, DOI 10.1002/wrna.1164
   Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705
   Mielech AM, 2014, VIROLOGY, V450, P64, DOI 10.1016/j.virol.2013.11.040
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Miyazaki M, 2006, J PHARMACOL SCI, V100, P391, DOI 10.1254/jphs.CPJ06008X
   Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Nelson EA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005540
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Ng ML, 2003, J MED VIROL, V71, P323, DOI 10.1002/jmv.10499
   Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010
   Nutho B, 2020, BIOCHEMISTRY-US, V59, P1769, DOI 10.1021/acs.biochem.0c00160
   Ohbayashi N, 2018, CHEMISTRYOPEN, V7, P713, DOI 10.1002/open.201800177
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Padmanabhan P., 2020, TARGETING TMPRSS2 CA
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Penny CJ, 2019, BBA-MOL CELL RES, V1866, P1151, DOI 10.1016/j.bbamcr.2018.10.022
   Piao YJ, 2020, PROCEEDINGS OF THE 2020 14TH INTERNATIONAL CONFERENCE ON UBIQUITOUS INFORMATION MANAGEMENT AND COMMUNICATION (IMCOM)
   Pradhan A, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-8
   Praveen D, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105967
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Pu SY, 2018, ANTIVIR RES, V155, P67, DOI 10.1016/j.antiviral.2018.05.001
   Qiu S, 2018, VIROLOGY, V513, P17, DOI 10.1016/j.virol.2017.09.028
   Rabouw HH, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005982
   Ramasamy S, 2016, P NATL ACAD SCI USA, V113, P1871, DOI 10.1073/pnas.1511380113
   Ran H, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9091143
   Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0
   Rao S, 2019, CELL CHEM BIOL, V26, P818, DOI 10.1016/j.chembiol.2019.02.021
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rossignol JF, 2008, ALIMENT PHARM THER, V28, P574, DOI 10.1111/j.1365-2036.2008.03781.x
   Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014
   Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001
   Rothlin RP, 2020, DRUG DEVELOP RES, V81, P768, DOI 10.1002/ddr.21679
   Sartori GR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222055
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   She J., 2019, ELIFE, V8
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Shirogane Y, 2008, J VIROL, V82, P8942, DOI 10.1128/JVI.00676-08
   Shisheva A, 2008, CELL BIOL INT, V32, P591, DOI 10.1016/j.cellbi.2008.01.006
   Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R
   Siu KL, 2009, J BIOL CHEM, V284, P16202, DOI 10.1074/jbc.M109.008227
   Smith M., 2020, REPURPOSING THERAPEU
   Sorrell FJ, 2016, STRUCTURE, V24, P401, DOI 10.1016/j.str.2015.12.015
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Tanner JA, 2005, CHEM BIOL, V12, P303, DOI 10.1016/j.chembiol.2005.01.006
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   US Food and Drug Administration, 2020, COR COVID 19 UPD FDA
   V'kovski P, 2019, ELIFE, V8, DOI 10.7554/eLife.42037
   Vaarala MH, 2001, J PATHOL, V193, P134, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH743>3.0.CO;2-T
   van Ooij C, 2012, NAT REV MICROBIOL, V10, DOI 10.1038/nrmicro2715
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Verdonck S, 2019, J MED CHEM, V62, P5810, DOI 10.1021/acs.jmedchem.9b00136
   Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang B, 2017, J BIOL CHEM, V292, P5860, DOI [10.1074/jbc.M116.768168, 10.1074/jbc.m116.768168]
   Wang C, 2009, NAT IMMUNOL, V10, P744, DOI 10.1038/ni.1742
   Wang C, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010045
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang X., 2020, TMPRSS2 Transcriptional Inhibition as a Therapeutic Strategy for COVID-19, DOI 10.20944/PREPRINTS202003.0360.V2
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang YS, 2015, ACTA CRYSTALLOGR F, V71, P977, DOI 10.1107/S2053230X15010146
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   Watanabe Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16567-0
   Watanabe Y, 2019, BBA-GEN SUBJECTS, V1863, P1480, DOI 10.1016/j.bbagen.2019.05.012
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Wolkerstorfer A, 2009, ANTIVIR RES, V83, P171, DOI 10.1016/j.antiviral.2009.04.012
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao L, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050491
   Xu PF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1448-9
   Yang ML, 2020, CONTEMP NURSE, V56, P90, DOI [10.1080/10376178.2020.1742178, 10.1080/02713683.2020.1857781]
   Yang WP, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2178-9
   Yang XX, 2014, J GEN VIROL, V95, P614, DOI 10.1099/vir.0.059014-0
   Yang Y, 2013, PROTEIN CELL, V4, P951, DOI 10.1007/s13238-013-3096-8
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yu IM, 2006, J BIOL CHEM, V281, P17134, DOI 10.1074/jbc.M602107200
   Yuan L, 2020, BIOORG CHEM, V94, DOI 10.1016/j.bioorg.2019.103417
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhang QF, 2004, J MED VIROL, V73, P332, DOI 10.1002/jmv.20095
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhou YS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010060
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 237
TC 11
Z9 11
U1 7
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 12
PY 2020
VL 63
IS 21
BP 12359
EP 12386
DI 10.1021/acs.jmedchem.0c00606
PG 28
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA OW2PA
UT WOS:000592734300012
PM 32511912
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Sirohi, PR
   Gupta, J
   Somvanshi, P
   Prajapati, VK
   Grover, A
AF Sirohi, Preeti Rana
   Gupta, Jyoti
   Somvanshi, Pallavi
   Prajapati, Vijay Kumar
   Grover, Abhinav
TI Multiple epitope-based vaccine prediction against SARS-CoV-2 spike
   glycoprotein
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Spike glycoprotein; receptor binding domain; subunit vaccine; COVID-19;
   immunoinformatics
AB The global emergence of novel coronavirus disease and its rapid global expansion over a short span of time require effective countermeasures to combat it. Development of a specific vaccine can induce an optimal antibody response, thus providing immunity against it. Our study proposes a detailed and comprehensive immunoinformatic approach that can be applied to the currently available coronavirus protein data in the online server for vaccine candidate development. We have identified the receptor binding domain (RBD) of structural spike protein (S1) as a potential target for immunity against COVID- 19 infection. Epitope prediction illustrated cytotoxic T-cell epitopes, helper T-cell epitopes, and B-cell epitopes associated with the target protein. These were joined through specific linkers along with adjuvant beta-defensin located at the N-terminal to create a multi epitope subunit vaccine (MESV). The specificity in the binding of the devised vaccine candidate to the TLR-3 immune cell receptor was evaluated via molecular docking interaction studies. Good docking score combined with robust interactions in the binding cavity certified the stringency of the engineered vaccine. Molecular dynamics simulation data showed minimal variation of the root-mean square deviations (RMSDs) and root-mean-square fluctuations (RMSFs) which confirmed the interaction stability. These results obtained from various in-silico experiments indicate the potency of this vaccine candidate as a probable therapeutic agent against COVID-19. Vaccination strategies targeting conserved epitope-based immune response would be beneficial in providing cross protection across beta-coronaviruses, and such vaccines would be resistant to the ever-evolving viruses.
   Communicated by Ramaswamy H. Sarma
C1 [Sirohi, Preeti Rana; Gupta, Jyoti; Grover, Abhinav] Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India.
   [Sirohi, Preeti Rana; Somvanshi, Pallavi] TERI Sch Adv Studies, Dept Biotechnol, New Delhi, India.
   [Prajapati, Vijay Kumar] Cent Univ Rajasthan, Sch Life Sci, Dept Biochem, Ajmer, Rajasthan, India.
RP Grover, A (corresponding author), Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India.
EM agrover@jnu.ac.in
OI Prajapati, Vijay/0000-0001-6510-0596; Somvanshi,
   Pallavi/0000-0003-1214-9374; Sirohi, Preeti Rana/0000-0002-7679-6557
FU Indian Council of Medical Research (ICMR), IndiaIndian Council of
   Medical Research (ICMR); DBTDepartment of Biotechnology (DBT) India
FX PRS is thankful to Indian Council of Medical Research (ICMR), India for
   the senior research fellowship. JG is contended to DBT for fellowship.
   PS is grateful to TERI School of Advanced Studies for research and
   management. AG is thankful to the University Grant Commission, India for
   the faculty recharge position.
CR Alberts B, 2002, MOL BIOL CELL
   [Anonymous], 2020, COR DIS COVID 19 WEE
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Enjuanes L, 2006, ANNU REV MICROBIOL, V60, P211, DOI 10.1146/annurev.micro.60.080805.142157
   Fauquet C. M., 2008, ENCY VIROLOGY, V3rd, DOI [https://doi.org/10.1016/B978-012374410-4.00509-4, DOI 10.1016/B978-012374410-4.00509-4]
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Gupta N, 2020, INT J BIOL MACROMOL, V152, P535, DOI 10.1016/j.ijbiomac.2020.02.297
   Gupta S, 2015, METHODS MOL BIOL, V1268, P143, DOI 10.1007/978-1-4939-2285-7_7
   Janeway C. A., 2001, IMMUNOBIOLOGY IMMUNE
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lee C, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0421-2
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Mackenzie JS, 2020, MICROBIOL AUST, V41, P45, DOI 10.1071/MA20013
   Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Mohan T, 2013, VACCINE, V31, P1707, DOI 10.1016/j.vaccine.2013.01.041
   Neurath A. R., 2008, ENCY VIROLOGY, V3rd, P56, DOI [https://doi.org/10.1016/B978-012374410-4.00591-4, 10.1016/B978-012374410-4.00591-4, DOI 10.1016/B978-012374410-4.00591-4]
   Ojha R, 2019, ACS OMEGA, V4, P13069, DOI 10.1021/acsomega.9b00944
   Owusu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099782
   Palatnik-de-Sousa CB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00826
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Song PP, 2020, CLIN CHIM ACTA, V509, P280, DOI 10.1016/j.cca.2020.06.017
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Yano A, 2005, VACCINE, V23, P2322, DOI 10.1016/j.vaccine.2005.01.031
   Ye R, 2004, J VIROL, V78, P9904, DOI 10.1128/JVI.78.18.9904-9917.2004
NR 35
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1846626
EA NOV 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OW7VY
UT WOS:000593090600001
PM 33246394
OA Bronze
DA 2021-01-01
ER

PT J
AU Ghorbani, M
   Brooks, BR
   Klauda, JB
AF Ghorbani, Mahdi
   Brooks, Bernard R.
   Klauda, Jeffery B.
TI Critical Sequence Hotspots for Binding of Novel Coronavirus to
   Angiotensin Converter Enzyme as Evaluated by Molecular Simulations
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
AB The novel coronavirus (nCOV-2019) outbreak has put the world on edge, causing millions of cases and hundreds of thousands of deaths all around the world, as of June 2020, let alone the societal and economic impacts of the crisis. The spike protein of nCOV-2019 resides on the virion's surface mediating coronavirus entry into host cells by binding its receptor binding domain (RBD) to the host cell surface receptor protein, angiotensin converter enzyme (ACE2). Our goal is to provide a detailed structural mechanism of how nCOV-2019 recognizes and establishes contacts with ACE2 and its difference with an earlier severe acute respiratory syndrome coronavirus (SARS-COV) in 2002 via extensive molecular dynamics (MD) simulations. Numerous mutations have been identified in the RBD of nCOV-2019 strains isolated from humans in different parts of the world. In this study, we investigated the effect of these mutations as well as other Ala-scanning mutations on the stability of the RBD/ACE2 complex. It is found that most of the naturally occurring mutations to the RBD either slightly strengthen or have the same binding affinity to ACE2 as the wild-type nCOV-2019. This means that the virus had sufficient binding affinity to its receptor at the beginning of the crisis. This also has implications for any vaccine design endeavors since these mutations could act as antibody escape mutants. Furthermore, in silico Ala-scanning and long-timescale MD simulations highlight the crucial role of the residues at the interface of RBD and ACE2 that may be used as potential pharmacophores for any drug development endeavors. From an evolutional perspective, this study also identifies how the virus has evolved from its predecessor SARS-COV and how it could further evolve to become even more infectious.
C1 [Ghorbani, Mahdi; Klauda, Jeffery B.] Univ Maryland, Dept Chem & Biomol Engn, College Pk, MD 20742 USA.
   [Ghorbani, Mahdi; Brooks, Bernard R.] NHLBI, Lab Computat Biol, NIH, Bethesda, MD 20824 USA.
   [Klauda, Jeffery B.] Univ Maryland, Biophys Grad Program, College Pk, MD 20742 USA.
RP Klauda, JB (corresponding author), Univ Maryland, Biophys Grad Program, College Pk, MD 20742 USA.
EM jbklauda@umd.edu
FU Intramural Research Program of the National Heart, Lung, and Blood
   Institute (NHLBI) at National Institutes of Health (NIH)
FX This work was supported by the Intramural Research Program of the
   National Heart, Lung, and Blood Institute (NHLBI) at the National
   Institutes of Health (NIH). The authors acknowledge the Biowulf high
   performance Linux cluster at the NIH for providing computational
   resources for this project. The authors would like to dedicate this
   article to the doctors and nurses who sacrificed their time, health, and
   even their lives to fight COVID-19, particularly those in Iran and the
   United States. J.B.K. would also like to dedicate this work to family
   friend Joe Kaplan (Silver Spring, MD) who passed away because of
   COVID-19 on April 22, 2020.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Batool M., 2017, SCI REP, V7, P1
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   Boorla V. S., 2020, BIORXIV2020034866
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497
   BROOKS BR, 1995, J COMPUT CHEM, V16, P1522, DOI 10.1002/jcc.540161209
   Brown DK, 2017, BIOINFORMATICS, V33, P2768, DOI 10.1093/bioinformatics/btx349
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Chakraborti S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-73
   Chan PKS, 2004, EMERG INFECT DIS, V10, P825, DOI 10.3201/eid1005.030682
   Coughlin MM, 2012, REV MED VIROL, V22, P2, DOI 10.1002/rmv.706
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   David CC, 2014, METHODS MOL BIOL, V1084, P193, DOI 10.1007/978-1-62703-658-0_11
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Greenough TC, 2005, J INFECT DIS, V191, P507, DOI 10.1086/427242
   Guan SS, 2016, J BIOMOL STRUCT DYN, V34, P15, DOI 10.1080/07391102.2015.1007167
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li F, 2013, ANTIVIR RES, V100, P246, DOI 10.1016/j.antiviral.2013.08.014
   Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004
   Li Y., 2020, BIORXIV2020077842, DOI [10.1101/2020.05.04.077842, DOI 10.1101/2020.05.04.077842]
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Liu H., 2020, COMPUTATIONAL SIMULA, DOI [10.1101/2020.03.24.005561, DOI 10.1101/2020.03.24.005561]
   Malik A., 2020, BIORXIV2020152892, DOI [10.1101/2020.06.15.152892, DOI 10.1101/2020.06.15.152892]
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Ren JY, 2020, J CHIN CHEM SOC-TAIP, V67, P46, DOI 10.1002/jccs.201900148
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Rodrigues CHM, 2019, NUCLEIC ACIDS RES, V47, pW338, DOI 10.1093/nar/gkz383
   Shang J., 2020, STRUCTURAL BASIS REC
   Sharma S., 2020, BIORXIV2020050534
   Spinello A, 2020, J PHYS CHEM LETT, V11, P4785, DOI 10.1021/acs.jpclett.0c01148
   Starr T. N., 2020, DEEP MUTATIONAL SCAN, P157982
   Sui JH, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000197
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang CH, 2018, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00087
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang Y., P NATL ACAD SCI
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803
   Yang TY, 2011, PROTEINS, V79, P1940, DOI 10.1002/prot.23018
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 57
TC 0
Z9 0
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
EI 1520-5207
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD NOV 12
PY 2020
VL 124
IS 45
BP 10034
EP 10047
DI 10.1021/acs.jpcb.0c05994
PG 14
WC Chemistry, Physical
SC Chemistry
GA OW2QH
UT WOS:000592737600008
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jackson, LA
   Anderson, EJ
   Rouphael, NG
   Roberts, PC
   Makhene, M
   Coler, RN
   McCullough, MP
   Chappell, JD
   Denison, MR
   Stevens, LJ
   Pruijssers, AJ
   McDermott, A
   Flach, B
   Doria-Rose, NA
   Corbett, KS
   Morabito, KM
   O'Dell, S
   Schmidt, SD
   Swanson, PA
   Padilla, M
   Mascola, JR
   Neuzil, KM
   Bennett, H
   Sun, W
   Peters, E
   Makowski, M
   Albert, J
   Cross, K
   Buchanan, W
   Pikaart-Tautges, R
   Ledgerwood, JE
   Graham, BS
   Beigel, JH
AF Jackson, L. A.
   Anderson, E. J.
   Rouphael, N. G.
   Roberts, P. C.
   Makhene, M.
   Coler, R. N.
   McCullough, M. P.
   Chappell, J. D.
   Denison, M. R.
   Stevens, L. J.
   Pruijssers, A. J.
   McDermott, A.
   Flach, B.
   Doria-Rose, N. A.
   Corbett, K. S.
   Morabito, K. M.
   O'Dell, S.
   Schmidt, S. D.
   Swanson, P. A.
   Padilla, M.
   Mascola, J. R.
   Neuzil, K. M.
   Bennett, H.
   Sun, W.
   Peters, E.
   Makowski, M.
   Albert, J.
   Cross, K.
   Buchanan, W.
   Pikaart-Tautges, R.
   Ledgerwood, J. E.
   Graham, B. S.
   Beigel, J. H.
CA mRNA-1273 Study Grp
TI An mRNA Vaccine against SARS-CoV-2-Preliminary Report
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ANTIBODY-RESPONSES; CORONAVIRUS; SPIKE
AB BACKGROUND
   The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein.
   METHODS
   We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 mu g, 100 mu g, or 250 mu g. There were 15 participants in each dose group.
   RESULTS
   After the first vaccination, antibody responses were higher with higher dose (day 29 enzyme-linked immunosorbent assay anti-S-2P antibody geometric mean titer [GMT], 40,227 in the 25-mu g group, 109,209 in the 100-mu g group, and 213,526 in the 250-mu g group). After the second vaccination, the titers increased (day 57 GMT, 299,751, 782,719, and 1,192,154, respectively). After the second vaccination, serum-neutralizing activity was detected by two methods in all participants evaluated, with values generally similar to those in the upper half of the distribution of a panel of control convalescent serum specimens. Solicited adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site. Systemic adverse events were more common after the second vaccination, particularly with the highest dose, and three participants (21%) in the 250-mu g dose group reported one or more severe adverse events.
   CONCLUSIONS
   The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine.
C1 [Jackson, L. A.] Kaiser Permanente Washington Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.
   [Coler, R. N.] Seattle Childrens Res Inst, Ctr Global Infect Dis Res CGIDR, Seattle, WA USA.
   [Anderson, E. J.; Peters, E.] Childrens Healthcare Atlanta, Ctr Childhood Infect & Vaccines CCIV, Dept Med, Atlanta, GA USA.
   [Anderson, E. J.; Peters, E.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA.
   [Rouphael, N. G.; McCullough, M. P.] Emory Univ, Sch Med, Dept Med, Lope Clin, Decatur, GA 30033 USA.
   [Roberts, P. C.; Makhene, M.; Buchanan, W.; Pikaart-Tautges, R.; Beigel, J. H.] NIAID, Div Microbiol & Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [McDermott, A.; Flach, B.; Doria-Rose, N. A.; Corbett, K. S.; Morabito, K. M.; O'Dell, S.; Schmidt, S. D.; Swanson, P. A.; Padilla, M.; Mascola, J. R.; Ledgerwood, J. E.; Graham, B. S.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Neuzil, K. M.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Makowski, M.; Albert, J.; Cross, K.] Emmes Co, Rockville, MD USA.
   [Chappell, J. D.; Denison, M. R.; Stevens, L. J.; Pruijssers, A. J.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN USA.
   [Denison, M. R.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA.
   [Chappell, J. D.; Denison, M. R.; Pruijssers, A. J.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Infect Immunol & Inflammat, Nashville, TN USA.
   [Bennett, H.; Sun, W.] Moderna, Cambridge, MA USA.
RP Jackson, LA (corresponding author), Kaiser Permanente Washington Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.
EM lisa.a.jachson@kp.org
OI Kao, Carol/0000-0002-0295-0785; Rostad, Christina/0000-0001-8439-0592
FU NIAID, National Institutes of Health (NIH), Bethesda [UM1AI148373,
   UM1AI148576, UM1AI148684, UM1Al148684-01S1, HHSN272201500002C]; National
   Center for Advancing Translational Sciences, NIH [UL1 TR002243]; Dolly
   Parton COVID-19 Research Fund (Vanderbilt University Medical Center)
FX Supported by the NIAID, National Institutes of Health (NIH), Bethesda,
   under award numbers UM1AI148373 (Kaiser Washington), UM1AI148576 (Emory
   University), UM1AI148684 (Emory University), UM1Al148684-01S1
   (Vanderbilt University Medical Center), and HHSN272201500002C (Emmes);
   by the National Center for Advancing Translational Sciences, NIH, under
   award number UL1 TR002243 (Vanderbilt University Medical Center); and by
   the Dolly Parton COVID-19 Research Fund (Vanderbilt University Medical
   Center). Funding for the manufacture of mRNA-1273 phase 1 material was
   provided by the Coalition for Epidemic Preparedness Innovation (CEPI).
CR Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Chandrashekar A, 2020, SCIENCE
   Choe PG, 2017, EMERG INFECT DIS, V23, P1079, DOI 10.3201/eid2307.170310
   Corbett KS, 2020, PREPRINT, DOI [10.1101/2020.06.11.145920v1, DOI 10.1101/2020.06.11.145920V1]
   Crank MC, 2019, SCIENCE, V365, P505, DOI 10.1126/science.aav9033
   Food and Drug Administration, 2007, TOX GRAD SCAL HLTH A
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Graham BS, 2019, ANNU REV MED, V70, P91, DOI 10.1146/annurev-med-121217-094234
   Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kulkarni PS, 2018, VIRAL IMMUNOL, V31, P195, DOI 10.1089/vim.2017.0147
   Mulligan MJ, 2020, PHASE 1 2 STUDY DESC, DOI [10.1101/2020.06.30.20142570v1, DOI 10.1101/2020.06.30.20142570V1]
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450
   Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   van Doremalen N, 2020, CHADOX1 NCOV 19 VACC, DOI [10.1101/2020.05.13.093195v1, DOI 10.1101/2020.05.13.093195V1]
   Verschoor CP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131531
   Wang N, 2019, CELL REP, V28
   Wang X, 2020, CLIN INFECT DIS
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wrapp D, 2020, CELL, V181
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365v2, DOI 10.1101/2020.03.30.20047365V2]
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Yu J, 2020, SCIENCE
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 32
TC 99
Z9 99
U1 26
U2 26
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 12
PY 2020
VL 383
IS 20
BP 1920
EP 1931
DI 10.1056/NEJMoa2022483
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OQ4VG
UT WOS:000588782400009
PM 32663912
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Vaidya, NA
   Vyas, R
AF Vaidya, Niteen A.
   Vyas, Renu
TI Computational Studies of Hydroxychloroquine and Chloroquine Metabolites
   as Possible Candidates for Coronavirus (COVID-19) Treatment
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE coronavirus (COVID-19); chloroquine; hydroxychloroquine; drug design;
   computational toxicity; molecular docking; metabolites; ViridisChem;
   SARS-CoV-2; reaction mechanism; cheminformatics
ID ANTIPLASMODIAL ACTIVITY; DESIGN; HYBRID
AB The coronavirus disease 2019 or COVID-19 pandemic is claiming many lives, impacting the health and livelihoods of billions of people worldwide and causing global economic havoc. As a novel disease with protean manifestations, it has pushed the scientific community into a frenzy to find a cure. The chloroquine class of compounds, used for decades for their antimalarial activity, have been well characterized. Hydroxychloroquine (HCQ), a less toxic metabolite of chloroquine, is used to treat rheumatic diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and Sjogren's syndrome. Preliminary studies in non-randomized clinical trials point to the possible use of chloroquine and its derivatives in the treatment of coronavirus. However, more robust clinical studies carried out in the United States, Italy, Australia, and China have shown mixed and inconclusive results and indicate the need for additional research. Cardiac, neurological, and retinal toxicity as well as increasing parasite resistance to these drugs is a major hindrance for their use in a world that is already dealing with antimicrobial resistance (AMR). In this context, we chose to study the monoquinoline analogs of 4-aminoquinoline as well as their metabolites which have the same mechanism of action albeit with lower toxicity. All the compounds were extensively studied computationally using docking, cheminformatics, and toxicity prediction tools. Based on the docking scores against ACE (angiotensin-converting enzyme) receptors and the toxicity data computed by employing the chemical analyzer module by ViridisChem((TM)) Inc., the work reveals significant findings that can help in the process of use of these metabolites against coronavirus.
C1 [Vaidya, Niteen A.] ChiroSolve, San Jose, CA 95129 USA.
   [Vyas, Renu] MIT Sch Bioengn Sci & Res, Pune, Maharashtra, India.
RP Vaidya, NA (corresponding author), ChiroSolve, San Jose, CA 95129 USA.
EM niteenv@chirosolve.com
CR Bodor N, 2000, MED RES REV, V20, P58, DOI 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.3.CO;2-O
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Aguiar ACC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037259
   Casagrande M, 2012, BIOORGAN MED CHEM, V20, P5965, DOI 10.1016/j.bmc.2012.07.040
   Clarke NE, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/307315
   Cozier GE, 2018, FEBS J, V285, P1477, DOI 10.1111/febs.14421
   Guantai EM, 2011, J MED CHEM, V54, P3637, DOI 10.1021/jm200149e
   Kaur K, 2010, EUR J MED CHEM, V45, P3245, DOI 10.1016/j.ejmech.2010.04.011
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Penna-Coutinho J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021237
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Riordan JF, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-225
   RUDRAPAL M, 2010, INT J CHEMTECH RES, V2, P1606, DOI DOI 10.1007/s00044-012-0371-9
   Sahu NK, 2014, ARAB J CHEM, V7, P701, DOI 10.1016/j.arabjc.2010.12.005
   Sharma R, 2014, BIOORG MED CHEM LETT, V24, P298, DOI 10.1016/j.bmcl.2013.11.018
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
NR 18
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 12
PY 2020
VL 11
AR 569665
DI 10.3389/fphar.2020.569665
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OW6QB
UT WOS:000593007700001
PM 33364944
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Husain-Syed, F
   Birk, HW
   Wilhelm, J
   Ronco, C
   Ranieri, VM
   Karle, B
   Kuhnert, S
   Tello, K
   Hecker, M
   Morty, RE
   Herold, S
   Kehl, O
   Walmrath, HD
   Seeger, W
   Vadasz, I
AF Husain-Syed, Faeq
   Birk, Horst-Walter
   Wilhelm, Jochen
   Ronco, Claudio
   Ranieri, V. Marco
   Karle, Bianka
   Kuhnert, Stefan
   Tello, Khodr
   Hecker, Matthias
   Morty, Rory E.
   Herold, Susanne
   Kehl, Oliver
   Walmrath, Hans-Dieter
   Seeger, Werner
   Vadasz, Istvan
TI Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy
   Platform to Enhance Lung-Protective Ventilation in Hypercapnic Patients
   With Coronavirus Disease 2019-Associated Acute Respiratory Distress
   Syndrome
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE continuous renal replacement therapy; respiratory acidosis; SARS-CoV-2;
   extracorporeal organ support; respiratory dialysis
AB Coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS) is associated with high mortality. Lung-protective ventilation is the current standard of care in patients with ARDS, but it might lead to hypercapnia, which is independently associated with worse outcomes. Extracorporeal carbon dioxide removal (ECCO2R) has been proposed as an adjuvant therapy to avoid progression of clinical severity and limit further ventilator-induced lung injury, but its use in COVID-19 has not been described yet. Acute kidney injury requiring renal replacement therapy (RRT) is common among critically ill COVID-19 patients. In centers with available dialysis, low-flow ECCO2R (<500 mL/min) using RRT platforms could be carried out by dialysis specialists and might be an option to efficiently allocate resources during the COVID-19 pandemic for patients with hypercapnia as the main indication. Here, we report the feasibility, safety, and efficacy of ECCO2R using an RRT platform to provide either standalone ECCO2R or ECCO2R combined with RRT in four hypercapnic patients with moderate ARDS. A randomized clinical trial is required to assess the overall benefit and harm.
C1 [Husain-Syed, Faeq; Birk, Horst-Walter; Karle, Bianka; Kehl, Oliver; Walmrath, Hans-Dieter; Seeger, Werner] Justus Liebig Univ Giessen, Univ Hosp Giessen & Marburg, Dept Internal Med 2, Div Nephrol, Giessen, Germany.
   [Husain-Syed, Faeq; Wilhelm, Jochen; Kuhnert, Stefan; Tello, Khodr; Hecker, Matthias; Morty, Rory E.; Herold, Susanne; Walmrath, Hans-Dieter; Seeger, Werner; Vadasz, Istvan] Justus Liebig Univ Giessen, Univ Hosp Giessen & Marburg, Dept Internal Med 2, Div Pulm & Crit Care Med, Giessen, Germany.
   [Husain-Syed, Faeq; Ronco, Claudio] San Bortolo Hosp, Int Renal Res Inst Vicenza, Vicenza, Italy.
   [Wilhelm, Jochen; Tello, Khodr; Hecker, Matthias; Morty, Rory E.; Herold, Susanne; Seeger, Werner; Vadasz, Istvan] Justus Liebig Univ Giessen, Univ Giessen & Marburg Lung Ctr, Giessen, Germany.
   [Wilhelm, Jochen; Tello, Khodr; Morty, Rory E.; Herold, Susanne; Seeger, Werner; Vadasz, Istvan] Cardiopulm Inst, Giessen, Germany.
   [Wilhelm, Jochen; Seeger, Werner] Justus Liebig Univ Giessen, Inst Lung Hlth, Giessen, Germany.
   [Ronco, Claudio] Univ Padua, Dept Med DIMED, Padua, Italy.
   [Ranieri, V. Marco] Univ Bologna, Alma Mater Studiorum, St Orsola Malpighi Hosp, Dept Med & Surg Sci DIMEC,Anaesthesia & Intens Ca, Bologna, Italy.
   [Morty, Rory E.; Seeger, Werner] Max Planck Inst Heart & Lung Res, Dept Lung Dev & Remodelling, Bad Nauheim, Germany.
RP Husain-Syed, F (corresponding author), Justus Liebig Univ Giessen, Univ Hosp Giessen & Marburg, Dept Internal Med 2, Div Nephrol, Giessen, Germany.; Husain-Syed, F; Vadasz, I (corresponding author), Justus Liebig Univ Giessen, Univ Hosp Giessen & Marburg, Dept Internal Med 2, Div Pulm & Crit Care Med, Giessen, Germany.; Husain-Syed, F (corresponding author), San Bortolo Hosp, Int Renal Res Inst Vicenza, Vicenza, Italy.; Vadasz, I (corresponding author), Justus Liebig Univ Giessen, Univ Giessen & Marburg Lung Ctr, Giessen, Germany.; Vadasz, I (corresponding author), Cardiopulm Inst, Giessen, Germany.
EM faeq.husain-syed@innere.med.uni-giessen.de;
   istvan.vadasz@innere.med.uni-giessen.de
OI Vadasz, Istvan/0000-0003-1370-9783
FU Federal Ministry of Education and Research [German Centre for Lung
   Research (DZL/ALI)]; German Research FoundationGerman Research
   Foundation (DFG) [DFG/KFO309]; Cardio-Pulmonary Institute [390649896];
   von Behring Rontgen Foundation [66-LV07]
FX This work was supported by grants from the Federal Ministry of Education
   and Research [German Centre for Lung Research (DZL/ALI); to SH, WS, and
   IV], the German Research Foundation (DFG/KFO309; to JW, RM, SH, WS, and
   IV), The Cardio-Pulmonary Institute (EXC 2026; Project ID: 390649896; to
   JW, KT, RM, SH, WS, and IV), and the von Behring Rontgen Foundation
   (Project 66-LV07; to IV).
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bowen DJ, 2009, AM J PREV MED, V36, P452, DOI 10.1016/j.amepre.2009.02.002
   Combes A, 2019, INTENS CARE MED, V45, P592, DOI 10.1007/s00134-019-05567-4
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST
   Fanelli V, 2018, AM J RESP CRIT CARE, V198, P687, DOI 10.1164/rccm.201712-2575LE
   Forster C, 2013, CRIT CARE, V17, DOI 10.1186/cc12833
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iba T, 2020, CRIT CARE MED, V48, P1358, DOI 10.1097/CCM.0000000000004458
   Joannidis M, 2007, CRIT CARE, V11, DOI 10.1186/cc5937
   Nin N, 2017, INTENS CARE MED, V43, P200, DOI 10.1007/s00134-016-4611-1
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schmidt M, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2038-5
   Villa G, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1456-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, CORT COVID 19 LIV GU
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 21
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 12
PY 2020
VL 7
AR 598379
DI 10.3389/fmed.2020.598379
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA OV4WA
UT WOS:000592211000001
PM 33304914
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhu, S
   Huang, YX
   Tang, W
   Nussler, AK
   Zheng, F
AF Zhu, Sheng
   Huang, Yaxiong
   Tang, Wei
   Nussler, Andreas K.
   Zheng, Fang
TI Increasing Age, the Existence of Comorbidities, and Corticosteroid
   Treatment in Combination With Antiviral Therapy Prolongs the Recovery of
   SARS-COV-2-Infected Patients, Measured as the Conversion From Positive
   to Negative rtPCR: A 239 Patients' Retrospective Study
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID19; SARS-CoV-2; RTPCR; age; comorbidity; corticosteroid
ID CORONAVIRUS PNEUMONIA; COVID-19; DIAGNOSIS; PROTEIN
AB Background: Severe acute respiratory syndrome (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), has become a global pandemic in the past months. An overall defined treatment has not yet been established. Therefore, it is important to summarize and report treatment experiences and identify patient groups that have a significantly higher risk of an adverse clinical outcome.
   Methods: Two hundred thirty-nine COVID-19 patients were recruited from January 25 to February 15, 2020. Demographic, clinical, laboratory, treatment management, and outcome data obtained from patients' medical records were evaluated.
   Results: Patients who recovered from PCR positive to negative within 2 weeks had significantly lower erythrocyte sedimentation rate (ESR) and higher C-reactive protein (CRP) levels than those recovered post 2 weeks. During antiviral treatment, COVID-19 patients with older age, comorbidities, and corticosteroid treatment required a significantly longer time to turn from PCR positive to negative COVID-19 result.
   Conclusion: PCR tests are of great importance to evaluate the recovery of COVID-19-positive patients, and ESR could be an indirect indicator to monitor SARS-COV-2 activity. Furthermore, our data suggest that older age, the existence of comorbidities, and corticosteroid treatment of COVID-19 patients during antiviral treatment could prolong the duration of conversion from SARS-COV-2 positive to negative.
C1 [Zhu, Sheng; Nussler, Andreas K.] Eberhard Karls Univ Tuebingen, Siegfried Weller Inst Trauma Res, Dept Trauma & Reconstruct Surg, BG Trauma Ctr Tuebingen, Tubingen, Germany.
   [Huang, Yaxiong; Tang, Wei; Zheng, Fang] First Hosp Changsha, Changsha, Peoples R China.
RP Zheng, F (corresponding author), First Hosp Changsha, Changsha, Peoples R China.
EM zhengfang578@gmail.com
OI Zhu, Sheng/0000-0001-7078-4371
FU Special Subject of the Science and Technology Department of Hunan
   Province [2020SK 3013]; Special Science and Technology Program for
   Emergency Response of New Coronary Pneumonia in Changsha [kq2001006]
FX This work was supported by a Special Subject of the Science and
   Technology Department of Hunan Province (2020SK 3013) and Special
   Science and Technology Program for Emergency Response of New Coronary
   Pneumonia in Changsha (kq2001006).
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Cacciapaglia G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72611-5
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cevik M, 2020, CLIN MICROBIOL INFEC, V26, P842, DOI 10.1016/j.cmi.2020.04.023
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Corsonello A, 2011, ARCH GERONTOL GERIAT, V53, P190, DOI 10.1016/j.archger.2010.10.015
   Dai WC, 2020, CAN ASSOC RADIOL J, V71, P195, DOI 10.1177/0846537120913033
   Dong X, 2020, ALLERGY, V75, P1699, DOI 10.1111/all.14289
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussain A, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108142
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li M, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-8
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Litao MKS, 2014, PEDIATR ANN, V43, P417, DOI 10.3928/00904481-20140924-10
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Malik YA, 2020, MALAYS J PATHOL, V42, P3
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Nie XQ, 2020, J INFECT DIS, V222, P26, DOI 10.1093/infdis/jiaa211
   Osama T, 2020, J ROY SOC MED, V113, P169, DOI 10.1177/0141076820921107
   Pacheco-Barrios K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239175
   Pal M, 2020, CUREUS, V12, DOI 10.7759/cureus.7423
   Pal R, 2020, DIABETES METAB SYND, V14, P513, DOI 10.1016/j.dsx.2020.04.049
   Peck KR, 2020, CLIN MICROBIOL INFEC, V26, P805, DOI 10.1016/j.cmi.2020.04.025
   Rabaan Ali A, 2020, Infez Med, V28, P174
   Rabaan AA, 2017, J MED MICROBIOL, V66, P1261, DOI 10.1099/jmm.0.000565
   Sarma P, 2020, INDIAN J PHARMACOL, V52, P1, DOI 10.4103/ijp.IJP_119_20
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tamas V, 2020, ORVOSI HETILAP, V161, P678, DOI 10.1556/650.2020.31810
   Tenda ED, 2020, ACTA MED INDONES, V52, P68
   Theoharides T C, 2020, J Biol Regul Homeost Agents, V34, P1241, DOI 10.23812/20-EDITORIAL_1-5
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang JJ, 2020, LANCET INFECT DIS, V20, P793, DOI 10.1016/S1473-3099(20)30230-9
   Zhao JY, 2020, CHINESE MED J-PEKING, V133, P1347, DOI 10.1097/CM9.0000000000000866
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 43
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 12
PY 2020
VL 7
AR 575439
DI 10.3389/fmed.2020.575439
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OV5EM
UT WOS:000592233000001
PM 33282889
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gonzalez-Paz, LA
   Lossada, CA
   Fernandez-Materan, FV
   Paz, JL
   Vera-Villalobos, J
   Alvarado, YJ
AF Gonzalez-Paz, Lenin A.
   Lossada, Carla A.
   Fernandez-Materan, Francelys V.
   Paz, J. L.
   Vera-Villalobos, Joan
   Alvarado, Ysaias J.
TI Can Non-steroidal Anti-inflammatory Drugs Affect the Interaction Between
   Receptor Binding Domain of SARS-COV-2 Spike and the Human ACE2 Receptor?
   A Computational Biophysical Study
SO FRONTIERS IN PHYSICS
LA English
DT Article
DE SARS-COV-2; NSAIDs; molecular docking; molecular dynamics; COVID-19
ID SERUM HEME-ALBUMIN; VIRUS-INFECTION; 3-DIMENSIONAL STRUCTURES; WEB
   SERVER; IBUPROFEN; PROTEIN; CYCLOOXYGENASE-2; INDOMETHACIN; RECOGNITION;
   DERIVATIVES
AB SARS-CoV-2 has caused millions of infections and more than 600,000 deaths worldwide. Despite the large number of studies to date, there is no specifically effective treatment available for SARS-CoV-2. However, it has been proposed to target reused drugs with potential antiviral activity to the interface between the angiotensin-converting enzymes 2 (ACE2) and the receptor binding domain (RBD) of SARS-CoV-2 to avoid cell recognition. Some non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to have some type of activity against a wide variety of viruses including SARS-CoV-2. Therefore, we carried out an exhaustive computational biophysical study of various NSAIDs targeting the RBD-ACE2 complex using multiple comparative analysis of docking and molecular dynamics. Only the Ibuprofen (Propionic acid derivative), Aspirin (Salicylate), and the Acetaminophen (p-aminophenol derivative) had a thermodynamically favorable docking with the interface of the RBD-ACE2 complex under the conditions of this study. Although, Ibuprofen was the NSAIDs with the most thermodynamically favorable docking in the shortest simulation time, and was the major inducer of structural changes, conformational changes, and overall changes in the complex throughout the simulation, including disturbances in composition and distribution of cavities at the interface. Results that point to Ibuprofen as an NSAID that, under the conditions outlined in this investigation, may have the highest probability of generating a disturbance in the stability of the RBD-ACE2 complex. This statement, although it could contribute information for the empirical treatment and prevention of COVID-19, represents only a theoretical orientation and approach, and requires its experimental demonstration because our predictions cannot secure a pharmacologically and clinically relevant interaction. However, these results are relevant due that suggest a possible mechanism of action of Ibuprofen against COVID-19 in addition to its anti-inflammatory properties, of which there are no reports in the literature.
C1 [Gonzalez-Paz, Lenin A.] Univ Zulia LUZ, FEC, LGBM, Dept Biol, Maracaibo, Venezuela.
   [Lossada, Carla A.; Fernandez-Materan, Francelys V.; Alvarado, Ysaias J.] Ctr Invest & Tecnol Mat CITeMA, Lab Caracterizac Mol & Biomol, IVIC, Maracaibo, Venezuela.
   [Paz, J. L.] Escuela Politec Nacl, Dept Fis, Quito, Ecuador.
   [Vera-Villalobos, Joan] Escuela Super Politecn Litoral, Fac Ciencias Nat & Matemat, Lab Anal Quim Instrumental LAQUINS, Dept Quim & Ciencias Ambientales, Guayaquil, Ecuador.
RP Gonzalez-Paz, LA (corresponding author), Univ Zulia LUZ, FEC, LGBM, Dept Biol, Maracaibo, Venezuela.; Paz, JL (corresponding author), Escuela Politec Nacl, Dept Fis, Quito, Ecuador.
EM lgonzalezpaz@gmail.com; jose.pazr@epn.edu.ec.com
FU IVIC-VEN; L.G.B.M-F.E.C-LUZ-VEN; Vice-Rectorado de Investigacion,
   Innovacion y Vinculacion of Escuela Politecnica Nacional of Ecuador
   [PII-DFIS-2020-04]
FX This research was supported by IVIC-VEN and L.G.B.M-F.E.C-LUZ-VEN. JLP
   acknowledges the financial support provided by the Vice-Rectorado de
   Investigacion, Innovacion y Vinculacion of Escuela Politecnica Nacional
   of Ecuador (Grant PII-DFIS-2020-04).
CR Amici C, 2015, CELL MICROBIOL, V17, P1391, DOI 10.1111/cmi.12446
   [Anonymous], 2020, 20 MINUTES
   [Anonymous], 2020, MONDA
   Ardra P, 2020, POTENTIAL PHYTOCHEMI
   Ascenzi P, 2011, BIOCHEM BIOPH RES CO, V411, P185, DOI 10.1016/j.bbrc.2011.06.130
   Ascenzi P, 2009, BIOCHEM BIOPH RES CO, V387, P83, DOI 10.1016/j.bbrc.2009.06.117
   Azam F, 2018, J BIOMOL STRUCT DYN, V36, P2099, DOI 10.1080/07391102.2017.1338164
   Baez-Santos YM, 2014, J VIROL, V88, P12511, DOI 10.1128/JVI.01294-14
   Bally M, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1909
   Baroni S, 2001, EUR J BIOCHEM, V268, P6214, DOI 10.1046/j.0014-2956.2001.02569.x
   Bhal S, 2007, DATA LOGP MAKING SEN
   BOURINBAIAR AS, 1995, FEBS LETT, V360, P85, DOI 10.1016/0014-5793(95)00057-G
   Cer RZ, 2009, NUCLEIC ACIDS RES, V37, pW441, DOI 10.1093/nar/gkp253
   Chan PKS, 2006, CLIN SCI, V110, P193, DOI 10.1042/CS20050188
   Chen CJ, 2002, J GEN VIROL, V83, P1897, DOI 10.1099/0022-1317-83-8-1897
   Chen N, 2000, VIROLOGY, V276, P44, DOI 10.1006/viro.2000.0562
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   CHERRICK HM, 1992, ORAL SURG ORAL MED O, V73, P321, DOI 10.1016/0030-4220(92)90129-E
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DGS-urgent, 2020, ACT REC COV 19
   di Masi A, 2011, FEBS J, V278, P654, DOI 10.1111/j.1742-4658.2010.07986.x
   Eyal E, 2015, BIOINFORMATICS, V31, P1487, DOI 10.1093/bioinformatics/btu847
   Eze FU, 2019, BIOORG CHEM, V92, DOI 10.1016/j.bioorg.2019.103265
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Garcia Nestor H, 2020, Med Hypotheses, V144, P110079, DOI 10.1016/j.mehy.2020.110079
   Gimeno A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113793
   Giollo Alessandro, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-218830, 10.1136/annrheumdis-2020-218845, 10.1136/annrheumdis-2020-217598]
   Gomez D, 2019, J PHYS CHEM LETT, V10, P7650, DOI 10.1021/acs.jpclett.9b02642
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Hinz B, 2008, FASEB J, V22, P383, DOI 10.1096/fj.07-8506com
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang WK, 2013, BIOINFORMATICS, V29, P2357, DOI 10.1093/bioinformatics/btt399
   Husain MA, 2015, PHYS CHEM CHEM PHYS, V17, P13837, DOI 10.1039/c5cp00272a
   Hussain Bash S, 2020, J PEERSCI, V2, P1, DOI [10.5281/zenodo.3747641, DOI 10.5281/ZENODO.3747641]
   Hussein HA, 2015, NUCLEIC ACIDS RES, V43, pW436, DOI 10.1093/nar/gkv462
   Kasahara K, 2016, BIOPHYS PHYSICOBIOL, V13, P209, DOI 10.2142/biophysico.13.0_209
   Kumar Y, 2020, SILICO IDENTIFICATIO, DOI [10.26434/chemrxiv.12049590.v1, DOI 10.26434/CHEMRXIV.12049590.V1]
   Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0
   Lagzian M, 2020, REPURPOSING NAPROXEN
   Lanas A, 2017, LANCET, V390, P613, DOI 10.1016/S0140-6736(16)32404-7
   Lands LC, 2010, PHARMACEUTICALS, V3, P2213, DOI 10.3390/ph3072213
   Little P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1185
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Martins PR, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13576
   Marzolini C, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01177-20
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   Mikra C, 2017, LETT DRUG DES DISCOV, V14, P949, DOI 10.2174/1570180814666161207143231
   Moore N, 2020, DRUG SAFETY, V43, P611, DOI 10.1007/s40264-020-00953-0
   Olotu Fisayo A, 2020, Inform Med Unlocked, V21, P100451, DOI 10.1016/j.imu.2020.100451
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Paessler S, 2018, FRONT BIOSCI-LANDMRK, V23, P947, DOI 10.2741/4627
   Patel A, 2020, VIRTUAL SCREENING CU, DOI [10.26434/chemrxiv.12142383.v2, DOI 10.26434/CHEMRXIV.12142383.V2]
   Popov ME, 2013, MOL BIOL+, V47, P592, DOI 10.1134/S0026893313040122
   Rajic Z, 2009, CHEM BIOL DRUG DES, V73, P328, DOI 10.1111/j.1747-0285.2009.00774.x
   Rinott E, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.06.003
   Robb CT, 2020, BRIT J PHARMACOL, V177, P4899, DOI 10.1111/bph.15206
   Rothan HA, 2016, ANTIVIR RES, V127, P50, DOI 10.1016/j.antiviral.2016.01.006
   Santos KB, 2020, J CHEM INF MODEL, V60, P667, DOI 10.1021/acs.jcim.9b00905
   Saxena A, 2013, EUR J PHARMACOL, V721, P215, DOI 10.1016/j.ejphar.2013.09.032
   Shahera U, 2020, AM J BIOMED LIFE SCI, V8, P76, DOI [10.11648/j.ajbls.20200804.13, DOI 10.11648/J.AJBLS.20200804.13]
   Shin HS, 2020, INFECT CHEMOTHER, V52, P142, DOI 10.3947/ic.2020.52.2.142
   Siddiqui AJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1802345
   SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404
   Sodhi M, 2020, CHEST, V158, P55, DOI 10.1016/j.chest.2020.03.040
   Sridharan GK, 2020, AM J THER, V27, pE400, DOI 10.1097/MJT.0000000000001196
   Subramanian S, 2020, SOME NEEM LEAVES EXT
   Subramanian S, 2020, SOME FDA APPROVED DR
   Terrier O, 2020, BROAD SPECTRUM ANTIV, DOI 10.1101/2020.04.30.069922
   Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e
   Tong Tommy R., 2009, Infectious Disorders - Drug Targets, V9, P223
   TORJESEN I, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1555
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Vanden Eynde JJ, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13040065
   Veljkovic Veljko, 2015, F1000Res, V4, P104, DOI 10.12688/f1000research.6436.1
   Velraj M, 2019, INT J RES PHARM SCI, V10, P303, DOI [10.26452/ijrps.v10i1.1824, DOI 10.26452/IJRPS.V10I1.1824]
   Wada M, 2011, J CHEM INF MODEL, V51, P2398, DOI 10.1021/ci200236x
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang Z, 2020, BIOPHARM DRUG DISPOS, V41, P231, DOI 10.1002/bdd.2241
   Warden SJ, 2010, PHYSICIAN SPORTSMED, V38, P132, DOI 10.3810/psm.2010.04.1770
   Wei P, 2010, ACTA PHYS-CHIM SIN, V26, P1093, DOI 10.3866/PKU.WHXB20100449
   WHO, 2020, US NONST ANT DRUGS N
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Winther Birgit, 2003, Inflammopharmacology, V11, P445, DOI 10.1163/156856003322699627
   Wittine K, 2009, EUR J MED CHEM, V44, P143, DOI 10.1016/j.ejmech.2008.03.037
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Xia B, 2011, PROTEIN CELL, V2, P282, DOI 10.1007/s13238-011-1034-1
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang Y., 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.02.10.20021675, DOI 10.1101/2020.02.10.20021675]
   Yonezawa Y, 2013, CHEM PHYS LETT, V556, P308, DOI 10.1016/j.cplett.2012.12.028
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zoete V, 2016, J CHEM INF MODEL, V56, P1399, DOI 10.1021/acs.jcim.6b00174
NR 94
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-424X
J9 FRONT PHYS-LAUSANNE
JI Front. Physics
PD NOV 12
PY 2020
VL 8
AR 587606
DI 10.3389/fphy.2020.587606
PG 17
WC Physics, Multidisciplinary
SC Physics
GA OV6WE
UT WOS:000592346700001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Khade, SM
   Yabaji, SM
   Srivastava, J
AF Khade, Shankar M.
   Yabaji, Shivraj M.
   Srivastava, Jyoti
TI An update on COVID-19: SARS-CoV-2 life cycle, immunopathology, and BCG
   vaccination
SO PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; hydroxychloroquine; BCG vaccination;
   immunopathological response
ID ACUTE-RESPIRATORY-SYNDROME; SYNDROME-CORONAVIRUS; GUERIN VACCINATION;
   SARS CORONAVIRUS; YOUNG-CHILDREN; INFECTION; VIRUS; IDENTIFICATION;
   BATS; RECEPTOR
AB The causative agent of novel coronavirus disease (COVID-19) is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 possesses RNA as a genetic material with 79% of the match with the bat SARS-CoV genome, which became epidemic in 2002. The SARS-CoV-2 peripheral Spike-Fc protein binds specifically to the ACE2 receptors present on bronchial epithelial cells and alveolar pneumocytes to downmodulates its expression which leads to severe acute respiratory failure. The disease is super infectious from human to human and the symptoms are similar to flu. The old aged and immunocompromised population are severely affected, and healthcare providers globally applied various strategies for treatment including the repurposing of drugs including antimalarial drug, hydroxychloroquine and anti-viral drugs.
   Herein, we described the SARS-CoV-2 pandemic, immune responses, possible drug targets, vaccines under the trials and correlated the possibility of trained immunity induced by BCG vaccination over control of SARS-CoV-2 infection. The countries with constraint BCG vaccination policy are struggling badly compared to countries with BCG vaccination policy. The BCG vaccination policy supports either lowering the total number of COVID-19 cases or the increasing recovery rate.
C1 [Khade, Shankar M.; Srivastava, Jyoti] Sri Sathya Sai Univ Human Excellence, Dept Biosci, Kalaburgi 585313, Karnataka, India.
   [Yabaji, Shivraj M.] Boston Univ, Sch Med, Dept Med, Pulm Ctr,Natl Emerging Infect Dis Labs NEIDL, Boston, MA 02118 USA.
RP Khade, SM (corresponding author), Sri Sathya Sai Univ Human Excellence, Dept Biosci, Kalaburgi 585313, Karnataka, India.
EM khadeshankar007@gmail.com
CR ANDRIES K, 1980, AM J VET RES, V41, P1372
   [Anonymous], 1996, DIABETES, V45, p235A
   Asai A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082839
   BASS EP, 1975, LANCET, V2, P822
   Brown MA, 2009, EMERG INFECT DIS, V15, P1445, DOI 10.3201/eid1509.081573
   Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Davids V, 2006, J INFECT DIS, V193, P531, DOI 10.1086/499825
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   GERDES JC, 1981, J VIROL, V38, P231, DOI 10.1128/JVI.38.1.231-238.1981
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hawn TR, 2014, MICROBIOL MOL BIOL R, V78, P650, DOI 10.1128/MMBR.00021-14
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Hirve S, 2012, VACCINE, V30, P7300, DOI 10.1016/j.vaccine.2012.09.035
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iqbal HMN, 2020, J PURE APPL MICROBIO, V14, P13, DOI 10.22207/JPAM.14.1.03
   Khalili JS, 2020, J MED VIROL, V92, P740, DOI 10.1002/jmv.25798
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   LAVI E, 1987, MICROB PATHOGENESIS, V3, P79, DOI 10.1016/0882-4010(87)90066-0
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Lim XF, 2019, J GEN VIROL, V100, P1363, DOI 10.1099/jgv.0.001307
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Maldonado L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007323
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Murray RA, 2006, J IMMUNOL, V177, P5647, DOI 10.4049/jimmunol.177.8.5647
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   PARKER JC, 1970, ARCH GES VIRUSFORSCH, V31, P293, DOI 10.1007/BF01253764
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Raj VS, 2014, EMERG INFECT DIS, V20, P1339, DOI 10.3201/eid2008.140663
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   RESTA S, 1985, SCIENCE, V229, P978, DOI 10.1126/science.2992091
   REYNOLDS DJ, 1985, ARCH VIROL, V85, P71, DOI 10.1007/BF01317007
   RIMMELZWAAN GF, 1991, VET MICROBIOL, V26, P25, DOI 10.1016/0378-1135(91)90039-I
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Shah P. S., 2020, NEWS VIEWS, V26, DOI [10.1038/s41591-020-0784-9, DOI 10.1038/S41591-020-0784-9]
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Sisay M, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104779
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Suryaman GK, 2019, VET WORLD, V12, P1797, DOI 10.14202/vetworld.2019.1797-1805
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   TRAAVIK T, 1977, ARCH VIROL, V55, P25, DOI 10.1007/BF01314476
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wang LF, 2006, EMERG INFECT DIS, V12, P1834
   Weir RE, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-9
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou GF, 2003, EMERG INFECT DIS, V9, P1608
NR 67
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6068
EI 1532-2297
J9 PREP BIOCHEM BIOTECH
JI Prep. Biochem. Biotechnol.
DI 10.1080/10826068.2020.1848869
EA NOV 2020
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA OU7ZP
UT WOS:000591743500001
PM 33226885
OA Bronze
DA 2021-01-01
ER

PT J
AU Piccoli, L
   Park, YJ
   Tortorici, MA
   Czudnochowski, N
   Walls, AC
   Beltramello, M
   Silacci-Fregni, C
   Pinto, D
   Rosen, LE
   Bowen, JE
   Acton, OJ
   Jaconi, S
   Guarino, B
   Minola, A
   Zatta, F
   Sprugasci, N
   Bassi, J
   Peter, A
   De Marco, A
   Nix, JC
   Mele, F
   Jovic, S
   Rodriguez, BF
   Gupta, SV
   Jin, F
   Piumatti, G
   Lo Presti, G
   Pellanda, AF
   Biggiogero, M
   Tarkowski, M
   Pizzuto, MS
   Cameroni, E
   Havenar-Daughton, C
   Smithey, M
   Hong, D
   Lepori, V
   Albanese, E
   Ceschi, A
   Bernasconi, E
   Elzi, L
   Ferrari, P
   Garzoni, C
   Riva, A
   Snell, G
   Sallusto, F
   Fink, K
   Virgin, HW
   Lanzavecchia, A
   Corti, D
   Veesler, D
AF Piccoli, Luca
   Park, Young-Jun
   Tortorici, M. Alejandra
   Czudnochowski, Nadine
   Walls, Alexandra C.
   Beltramello, Martina
   Silacci-Fregni, Chiara
   Pinto, Dora
   Rosen, Laura E.
   Bowen, John E.
   Acton, Oliver J.
   Jaconi, Stefano
   Guarino, Barbara
   Minola, Andrea
   Zatta, Fabrizia
   Sprugasci, Nicole
   Bassi, Jessica
   Peter, Alessia
   De Marco, Anna
   Nix, Jay C.
   Mele, Federico
   Jovic, Sandra
   Rodriguez, Blanca Fernandez
   Gupta, Sneha, V
   Jin, Feng
   Piumatti, Giovanni
   Lo Presti, Giorgia
   Pellanda, Alessandra Franzetti
   Biggiogero, Maira
   Tarkowski, Maciej
   Pizzuto, Matteo S.
   Cameroni, Elisabetta
   Havenar-Daughton, Colin
   Smithey, Megan
   Hong, David
   Lepori, Valentino
   Albanese, Emiliano
   Ceschi, Alessandro
   Bernasconi, Enos
   Elzi, Luigia
   Ferrari, Paolo
   Garzoni, Christian
   Riva, Agostino
   Snell, Gyorgy
   Sallusto, Federica
   Fink, Katja
   Virgin, Herbert W.
   Lanzavecchia, Antonio
   Corti, Davide
   Veesler, David
TI Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike
   Receptor-Binding Domain by Structure-Guided High-Resolution Serology
SO CELL
LA English
DT Article
ID CRYO-EM STRUCTURE; HUMAN MONOCLONAL-ANTIBODY; FC-RECEPTOR;
   BAYESIAN-APPROACH; MERS-COV; B-CELLS; CORONAVIRUS; VIRUS; VALIDATION;
   PROTECTION
AB Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2 infection is crucial for understanding immune protection and identifying targets for vaccine design. In a cohort of 647SARS-CoV-2-infected subjects, we found that both the magnitude of Ab responses to SARS-CoV-2 spike (S) and nucleoprotein and nAb titers correlate with clinical scores. The receptor-binding domain (RBD) is immunodominant and the target of 90% of the neutralizing activity present in SARS-CoV-2 immune sera. Whereas overall RBD-specific serum IgG titers waned with a half-life of 49 days, nAb titers and avidity increased overtime for some individuals, consistent with affinity maturation. We structurally defined an RBD antigenic map and serologically quantified serumAbs specific for distinct RBD epitopes leading to the identification of two major receptor-binding motif antigenic sites. Our results explain the immunodominance of the receptor-binding motif and will guide the design of COVID-19 vaccines and therapeutics.
C1 [Piccoli, Luca; Beltramello, Martina; Silacci-Fregni, Chiara; Pinto, Dora; Jaconi, Stefano; Guarino, Barbara; Minola, Andrea; Zatta, Fabrizia; Sprugasci, Nicole; Bassi, Jessica; Peter, Alessia; De Marco, Anna; Pizzuto, Matteo S.; Cameroni, Elisabetta; Fink, Katja; Lanzavecchia, Antonio; Corti, Davide] Humabs BioMed SA, Vir Biotechnol, CH-6500 Bellinzona, Switzerland.
   [Park, Young-Jun; Tortorici, M. Alejandra; Walls, Alexandra C.; Bowen, John E.; Acton, Oliver J.; Veesler, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Tortorici, M. Alejandra] Inst Pasteur, F-75015 Paris, France.
   [Tortorici, M. Alejandra] CNRS UMR 3569, Unite Virol Structurale, F-75015 Paris, France.
   [Czudnochowski, Nadine; Rosen, Laura E.; Gupta, Sneha, V; Jin, Feng; Havenar-Daughton, Colin; Smithey, Megan; Hong, David; Snell, Gyorgy; Virgin, Herbert W.] Vir Biotechnol, San Francisco, CA 94158 USA.
   [Nix, Jay C.] Lawrence Berkeley Natl Lab, Adv Light Source, Mol Biol Consortium, Berkeley, CA 94720 USA.
   [Mele, Federico; Jovic, Sandra; Rodriguez, Blanca Fernandez; Sallusto, Federica] Univ Svizzera Italiana, Inst Res Biomed, CH-6500 Bellinzona, Switzerland.
   [Piumatti, Giovanni] Geneva Univ Hosp, Div Primary Care, CH-1205 Geneva, Switzerland.
   [Piumatti, Giovanni; Ceschi, Alessandro] Univ Svizzera Italiana, Fac Biomed Sci, CH-6900 Lugano, Switzerland.
   [Lo Presti, Giorgia; Pellanda, Alessandra Franzetti; Biggiogero, Maira; Garzoni, Christian] Clin Luganese Moncucco, Clin Internal Med & Infect Dis, CH-6900 Lugano, Switzerland.
   [Tarkowski, Maciej; Riva, Agostino] Luigi Sacco Hosp, Div Infect Dis 3, ASST Fatebenefratelli Sacco, I-20157 Milan, Italy.
   [Albanese, Emiliano] Univ Svizzera Italiana, Inst Publ Hlth, CH-6900 Lugano, Switzerland.
   [Ceschi, Alessandro] Ente Osped Cantonale, Div Clin Pharmacol & Toxicol, Inst Pharmacol Sci Southern Switzerland, CH-6900 Lugano, Switzerland.
   [Ceschi, Alessandro] Univ Hosp Zurich, Dept Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland.
   [Bernasconi, Enos] Ente Osped Cantonale, Osped Civ, Div Infect Dis, CH-6900 Lugano, Switzerland.
   [Bernasconi, Enos] Osped Italiano, CH-6900 Lugano, Switzerland.
   [Elzi, Luigia] Osped Reg Bellinzona & Valli, Div Infect Dis, Ente Osped Cantonale, CH-6600 Locarno, Switzerland.
   [Elzi, Luigia] Osped Reg, CH-6600 Locarno, Switzerland.
   [Ferrari, Paolo] Ente Osped Cantonale, Osped Civ Lugano, Dept Nephrol, CH-6900 Lugano, Switzerland.
   [Ferrari, Paolo] Univ New South Wales, Prince Wales Hosp, Clin Sch, Sydney, NSW 2052, Australia.
RP Corti, D (corresponding author), Humabs BioMed SA, Vir Biotechnol, CH-6500 Bellinzona, Switzerland.; Veesler, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
EM dcorti@vir.bio; dveesler@uw.edu
OI Virgin, Herbert/0000-0001-8580-7628; Rosen, Laura/0000-0002-8030-0219;
   Zatta, Fabrizia/0000-0003-4945-8058; Riva, Agostino/0000-0003-3171-3049
FU National Institute of General Medical SciencesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM120553];
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [DP1AI158186, HHSN272201700059C]; Pew Biomedical Scholars Award;
   Burroughs Wellcome FundBurroughs Wellcome Fund; Fast Grants; University
   of Washington Arnold and Mabel Beckman cryo-EM center, the Pasteur
   Institute; National Institutes of Health, National Institute of General
   Medical SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [P30 GM124169-01]; Henry Krenter
   Foundation;  [DE-AC02-05CH11231]
FX This study was supported by the National Institute of General Medical
   Sciences (R01GM120553, D.V.), the National Institute of Allergy and
   Infectious Diseases (DP1AI158186 and HHSN272201700059C, D.V.), a Pew
   Biomedical Scholars Award (D.V.), an Investigators in the Pathogenesis
   of Infectious Disease Award from the Burroughs Wellcome Fund (D.V.),
   Fast Grants (D.V.), the University of Washington Arnold and Mabel
   Beckman cryo-EM center, the Pasteur Institute (M.A.T.), and beamline
   4.2.2 and 5.0.2 at the Advanced Light Source at Lawrence Berkeley
   National Laboratory. Both beamlines are supported in part by the
   National Institutes of Health, National Institute of General Medical
   Sciences (grant P30 GM124169-01). The Advanced Light Source is a US
   Department of Energy Office of Science User Facility under Contract No.
   DE-AC02-05CH11231. F.S. is supported by the Henry Krenter Foundation. We
   would like to thank Isaac Hoffman for his help with refinement of the
   S304-S309-S2H14-RBD crystal structure. We would like to thank Marcel
   Meury for assistance with protein production and Josh Dillen and Cindy
   Ng for assistance with protein production and crystallization. We
   acknowledge Tatiana Terrot (Ente Ospedaliero Cantonale, Lugano,
   Switzerland) as well as Marco Schiuma and Alice Covizzi (Luigi Sacco
   Hospital) for filling the database of the Ticino healthcare workers and
   Luigi Sacco Hospital cohorts, respectively. We are grateful to Joel
   Quispe and Quinton Beedle for assistance with data collection. We thank
   Dr. Alice Covizzi, Dr. Marco Schiuma, and Prof. Massimo Galli, Director
   of the Unit for their help with patient sample collection.
CR Agirre J, 2015, NAT STRUCT MOL BIOL, V22, P833, DOI 10.1038/nsmb.3115
   Alshukairi AN, 2016, EMERG INFECT DIS, V22, P1113, DOI 10.3201/eid2206.160010
   Alsoussi WB, 2020, J IMMUNOL, V205, P915, DOI 10.4049/jimmunol.2000583
   Barad BA, 2015, NAT METHODS, V12, P943, DOI [10.1038/nmeth.3541, 10.1038/NMETH.3541]
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Battye TGG, 2011, ACTA CRYSTALLOGR D, V67, P271, DOI 10.1107/S0907444910048675
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   CALLOW KA, 1985, J HYG-CAMBRIDGE, V95, P173, DOI 10.1017/S0022172400062410
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Cardone G, 2013, J STRUCT BIOL, V184, P226, DOI 10.1016/j.jsb.2013.08.002
   Chen SX, 2013, ULTRAMICROSCOPY, V135, P24, DOI 10.1016/j.ultramic.2013.06.004
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   de Wit E, 2019, ANTIVIR RES, V163, P70, DOI 10.1016/j.antiviral.2019.01.016
   DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428
   DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016
   DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443
   Drosten C, 2014, NEW ENGL J MED, V371, P828, DOI 10.1056/NEJMoa1405858
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Edridge AWD, 2020, CORONAVIRUS PROTECTI, DOI [10.1101/2020.05.11.20086439, DOI 10.1101/2020.05.11.20086439]
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Frenz B, 2019, STRUCTURE, V27, P134, DOI 10.1016/j.str.2018.09.006
   GIMSON AES, 1983, GUT, V24, P615, DOI 10.1136/gut.24.7.615
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guo X., 2020, LONG TERM PERSISTENC, DOI [10.1101/2020.02.12.20021386, DOI 10.1101/2020.02.12.20021386]
   He WQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00928-3
   Hensley SE, 2009, SCIENCE, V326, P734, DOI 10.1126/science.1178258
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Johnson RF, 2016, VIROLOGY, V490, P49, DOI 10.1016/j.virol.2016.01.004
   Joyce M Gordon, 2020, bioRxiv, DOI 10.1101/2020.03.15.992883
   Ju B, 2020, POTENT HUMAN NEUTRAL, DOI [10.1101/2020.03.21.990770, DOI 10.1101/2020.03.21.990770, 10.1101/2020.03.21.990770.]
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   Ke ZL, 2020, NATURE, DOI 10.1038/s41586-020-2665-2
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lau SY, 2020, EMERG MICROBES INFEC, V9, P837, DOI 10.1080/22221751.2020.1756700
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   LINDHARDT BO, 1989, EUR J CLIN MICROBIOL, V8, P614
   Liu Lihong, 2020, bioRxiv, DOI 10.1101/2020.06.17.153486
   Liu STH, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.05.20.20102236, DOI 10.1101/2020.05.20.20102236]
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Luchsinger Larry L, 2020, medRxiv, DOI 10.1101/2020.06.08.20124792
   Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4
   Ng K., 2020, PREEXISTING NOVO HUM, V15, DOI [10.1101/2020.05.14.095414, DOI 10.1101/2020.05.14.095414]
   Ortiz DF, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9418
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Prevost Jeremie, 2020, bioRxiv, DOI 10.1101/2020.06.08.140244
   Punjani A., 2019, NONUNIFORM REFINEMEN, DOI [10.1101/2019.12.15.877092, DOI 10.1101/2019.12.15.877092]
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006
   Scheres SHW, 2012, J MOL BIOL, V415, P406, DOI 10.1016/j.jmb.2011.11.010
   Seow G., 2020, LONGITUDINAL EVALUAT, DOI [10.1101/2020.07.09.20148429., 10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   Seydoux Emilie, 2020, bioRxiv, DOI 10.1101/2020.05.12.091298
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   Tan YZ, 2017, NAT METHODS, V14, P793, DOI [10.1038/NMETH.4347, 10.1038/nmeth.4347]
   Tang AM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12137-1
   Tegunov D, 2019, NAT METHODS, V16, P1146, DOI 10.1038/s41592-019-0580-y
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Turonova B, 2020, SCIENCE, V370, P203, DOI 10.1126/science.abd5223
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang RYR, 2016, ELIFE, V5, DOI 10.7554/eLife.17219
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Ying TL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9223
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Tongqing, 2020, bioRxiv, DOI 10.1101/2020.07.04.187989
   Zivanov J, 2019, IUCRJ, V6, P5, DOI 10.1107/S205225251801463X
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 113
TC 2
Z9 2
U1 5
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD NOV 12
PY 2020
VL 183
IS 4
BP 1024
EP +
DI 10.1016/j.cell.2020.09.037
PG 40
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA OQ2TD
UT WOS:000588640900017
PM 32991844
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Leist, SR
   Dinnon, KH
   Schafer, A
   Tse, LV
   Okuda, K
   Hou, YXJ
   West, A
   Edwards, CE
   Sanders, W
   Fritch, EJ
   Gully, KL
   Scobey, T
   Brown, AJ
   Sheahan, TP
   Moorman, NJ
   Boucher, RC
   Gralinski, LE
   Montgomery, SA
   Baric, RS
AF Leist, Sarah R.
   Dinnon, Kenneth H.
   Schafer, Alexandra
   Tse, Longping, V
   Okuda, Kenichi
   Hou, Yixuan J.
   West, Ande
   Edwards, Caitlin E.
   Sanders, Wes
   Fritch, Ethan J.
   Gully, Kendra L.
   Scobey, Trevor
   Brown, Ariane J.
   Sheahan, Timothy P.
   Moorman, Nathaniel J.
   Boucher, Richard C.
   Gralinski, Lisa E.
   Montgomery, Stephanie A.
   Baric, Ralph S.
TI A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in
   Standard Laboratory Mice
SO CELL
LA English
DT Article
ID HUMAN CORONAVIRUS; PATHOGENESIS; SARS; PNEUMONIA; INFECTION; RESPONSES;
   COVID-19
AB The SARS-CoV-2 pandemic has caused extreme human suffering and economic harm. We generated and characterized a new mouse-adapted SARS-CoV-2 virus that captures multiple aspects of severe COVID-19 disease in standard laboratory mice. This SARS-CoV-2 model exhibits the spectrum of morbidity and mortality of COVID-19 disease as well as aspects of host genetics, age, cellular tropisms, elevated Th1 cytokines, and loss of surfactant expression and pulmonary function linked to pathological features of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). This model can rapidly access existing mouse resources to elucidate the role of host genetics, underlying molecular mechanisms governing SARS-CoV-2 pathogenesis, and the protective or pathogenic immune responses related to disease severity. The model promises to provide a robust platform for studies of ALI and ARDS to evaluate vaccine and antiviral drug performance, including in the most vulnerable populations (i.e., the aged) using standard laboratory mice.
C1 [Leist, Sarah R.; Schafer, Alexandra; Tse, Longping, V; Hou, Yixuan J.; West, Ande; Edwards, Caitlin E.; Gully, Kendra L.; Scobey, Trevor; Brown, Ariane J.; Sheahan, Timothy P.; Gralinski, Lisa E.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Dinnon, Kenneth H.; Sanders, Wes; Fritch, Ethan J.; Moorman, Nathaniel J.; Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA.
   [Okuda, Kenichi; Sanders, Wes; Boucher, Richard C.] Univ N Carolina, Mars Lung Inst, Chapel Hill, NC 27515 USA.
   [Moorman, Nathaniel J.; Montgomery, Stephanie A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.
   [Montgomery, Stephanie A.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA.
   [Moorman, Nathaniel J.; Baric, Ralph S.] Univ N Carolina, Rapidly Emerging Antiviral Drug Discovery Initiat, Chapel Hill, NC 27515 USA.
RP Baric, RS (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.; Baric, RS (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA.; Baric, RS (corresponding author), Univ N Carolina, Rapidly Emerging Antiviral Drug Discovery Initiat, Chapel Hill, NC 27515 USA.
EM rbaric@email.unc.edu
RI Hou, Yixuan/P-6443-2019
OI Hou, Yixuan/0000-0002-8323-7243
FU North Carolina Policy Collaboratory at the University of North Carolina
   at Chapel Hill; North Carolina Coronavirus Relief Fund; NCI Center Core
   Support Grant [5P30CA016086-41]; National Institute of Allergy and
   Infectious Diseases, NIH, U.S. Department of Health and Human Services
   [1U19 AI142759, 5R01AI132178, AI100625, AI108197]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [HHSN272201700036I75N93020F00001]; NCIUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [U54CA260543]
FX This project was supported by the North Carolina Policy Collaboratory at
   the University of North Carolina at Chapel Hill with funding from the
   North Carolina Coronavirus Relief Fund established and appropriated by
   the North Carolina General Assembly. Animal histopathology service was
   performed by Dawud Hilliard, Lily Wai, Ling Wang, and Mia Evangelista in
   the Animal Histopathology and Laboratory Medicine Core at the University
   of North Carolina, which is supported in part by an NCI Center Core
   Support Grant (5P30CA016086-41) to the UNC Lineberger Comprehensive
   Cancer Center. This project was funded in part by the National Institute
   of Allergy and Infectious Diseases, NIH, U.S. Department of Health and
   Human Services award 1U19 AI142759 (Antiviral Drug Discovery and
   Development Center awarded to R.S.B), 5R01AI132178 (partnership grant
   awarded to T.P.S. and R.S.B), AI100625, and AI108197 to R.S.B. as well
   as an animal models contract from the NIH
   (HHSN272201700036I75N93020F00001) and U54CA260543 sponsored by NCI.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Agnihothram S, 2018, J VIROL, V92, DOI [10.1128/JVI.00027-18, 10.1128/jvi.00027-18]
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Bradley BT, 2020, LANCET, V396, P320, DOI 10.1016/S0140-6736(20)31305-2
   Bryant CD, 2011, ANN NY ACAD SCI, V1245, P31, DOI 10.1111/j.1749-6632.2011.06325.x
   Butler N, 2006, VIROLOGY, V347, P410, DOI 10.1016/j.virol.2005.11.044
   Chamanza R, 2015, J COMP PATHOL, V153, P287, DOI 10.1016/j.jcpa.2015.08.009
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Cheung EW, 2020, JAMA-J AM MED ASSOC, V324, P294, DOI 10.1001/jama.2020.10374
   Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Costela-Ruiz VJ, 2020, CYTOKINE GROWTH F R, V54, P62, DOI 10.1016/j.cytogfr.2020.06.001
   Dinnon KH, 2020, NATURE, DOI 10.1038/s41586-020-2708-8
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Felgenhauer U, 2020, J BIOL CHEM, V295, P13958, DOI 10.1074/jbc.AC120.013788
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Frieman M, 2012, J VIROL, V86, P884, DOI 10.1128/JVI.05957-11
   Fulcher M Leslie, 2005, Methods Mol Med, V107, P183
   Graham JB, 2015, MBIO, V6, DOI 10.1128/mBio.00493-15
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Gralinski LE, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005504
   Gralinski LE, 2013, MBIO, V4, DOI 10.1128/mBio.00271-13
   Gu HJ, 2020, SCIENCE, V369, P1603, DOI 10.1126/science.abc4730
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta Krishan, 2020, Brief Bioinform, DOI 10.1093/bib/bbaa168
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Israelow Benjamin, 2020, J Exp Med, V217, DOI 10.1084/jem.20201241
   Jacomy H, 2006, VIROLOGY, V349, P335, DOI 10.1016/j.virol.2006.01.049
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Koumbourlis AC, 2020, AM J RESP CRIT CARE, V202, P624, DOI 10.1164/rccm.202004-1471LE
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li X, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02911-9
   Manet C, 2020, J VIROL, V94, DOI 10.1128/JVI.01034-19
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131451
   Mesev EV, 2019, NAT MICROBIOL, V4, P914, DOI 10.1038/s41564-019-0421-x
   Noll KE, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107587
   Okuda K, 2019, AM J RESP CRIT CARE, V199, P715, DOI 10.1164/rccm.201804-0734OC
   QUIDINGJARBRINK M, 1995, INFECT IMMUN, V63, P853
   Rasmussen AL, 2014, SCIENCE, V346, P987, DOI 10.1126/science.1259595
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Schmidt ME, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006810
   Sheahan T, 2011, J VIROL, V85, P217, DOI 10.1128/JVI.01805-10
   Sheahan T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000240
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Sims AC, 2013, J VIROL, V87, P3885, DOI 10.1128/JVI.02520-12
   Sinha P, 2020, JAMA INTERN MED, V180, P1152, DOI 10.1001/jamainternmed.2020.3313
   Song PP, 2020, CLIN CHIM ACTA, V509, P280, DOI 10.1016/j.cca.2020.06.017
   Spinato G, 2020, JAMA-J AM MED ASSOC, V323, P2089, DOI 10.1001/jama.2020.6771
   Stevens TP, 2007, CHEST, V131, P1577, DOI 10.1378/chest.06-2371
   Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Vanderheiden A, 2020, J VIROL, V94, DOI 10.1128/JVI.00985-20
   Wang JL, 2020, PROTEIN CELL, V11, P776, DOI 10.1007/s13238-020-00767-x
   Weaver TE, 2001, ANNU REV PHYSIOL, V63, P555, DOI 10.1146/annurev.physiol.63.1.555
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Zhang Anna Jinxia, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa995
   Zhang HJ, 2020, AM J RESP CRIT CARE, V202, P219, DOI 10.1164/rccm.202003-0541OC
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 76
TC 1
Z9 1
U1 5
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD NOV 12
PY 2020
VL 183
IS 4
BP 1070
EP +
DI 10.1016/j.cell.2020.09.050
PG 28
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA OQ2TD
UT WOS:000588640900020
PM 33031744
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lenze, EJ
   Mattar, C
   Zorumski, CF
   Stevens, A
   Schweiger, J
   Nicol, GE
   Miller, JP
   Yang, L
   Yingling, M
   Avidan, MS
   Reiersen, AM
AF Lenze, Eric J.
   Mattar, Caline
   Zorumski, Charles F.
   Stevens, Angela
   Schweiger, Julie
   Nicol, Ginger E.
   Miller, J. Philip
   Yang, Lei
   Yingling, Michael
   Avidan, Michael S.
   Reiersen, Angela M.
TI Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With
   Symptomatic COVID-19 A Randomized Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID SIGMA-1 RECEPTOR CHAPERONE; BRAIN
AB Importance Coronavirus disease 2019 (COVID-19) may lead to serious illness as a result of an excessive immune response. Fluvoxamine may prevent clinical deterioration by stimulating the sigma-1 receptor, which regulates cytokine production. Objective To determine whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and decreases the severity of disease. Design, Setting, and Participants Double-blind, randomized, fully remote (contactless) clinical trial of fluvoxamine vs placebo. Participants were community-living, nonhospitalized adults with confirmed severe acute respiratory syndrome coronavirus 2 infection, with COVID-19 symptom onset within 7 days and oxygen saturation of 92% or greater. One hundred fifty-two participants were enrolled from the St Louis metropolitan area (Missouri and Illinois) from April 10, 2020, to August 5, 2020. The final date of follow-up was September 19, 2020. Interventions Participants were randomly assigned to receive 100 mg of fluvoxamine (n = 80) or placebo (n = 72) 3 times daily for 15 days. Main Outcomes and Measures The primary outcome was clinical deterioration within 15 days of randomization defined by meeting both criteria of (1) shortness of breath or hospitalization for shortness of breath or pneumonia and (2) oxygen saturation less than 92% on room air or need for supplemental oxygen to achieve oxygen saturation of 92% or greater. Results Of 152 patients who were randomized (mean [SD] age, 46 [13] years; 109 [72%] women), 115 (76%) completed the trial. Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events. Conclusions and Relevance In this preliminary study of adult outpatients with symptomatic COVID-19, patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days. However, the study is limited by a small sample size and short follow-up duration, and determination of clinical efficacy would require larger randomized trials with more definitive outcome measures.
   This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects vs placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild coronavirus disease 2019 (COVID-19) illness.
C1 [Lenze, Eric J.; Zorumski, Charles F.; Stevens, Angela; Schweiger, Julie; Nicol, Ginger E.; Yang, Lei; Yingling, Michael; Reiersen, Angela M.] Washington Univ, Dept Psychiat, Sch Med, 660 S Euclid Ave,POB 8134, St Louis, MO 63110 USA.
   [Mattar, Caline] Washington Univ, Dept Internal Med, Div Infect Dis, Sch Med, St Louis, MO 63110 USA.
   [Miller, J. Philip] Washington Univ, Informat Inst, Div Biostat, Sch Med, St Louis, MO 63110 USA.
   [Avidan, Michael S.] Washington Univ, Dept Anesthesiol, Sch Med, St Louis, MO 63110 USA.
RP Lenze, EJ (corresponding author), Washington Univ, Dept Psychiat, Sch Med, 660 S Euclid Ave,POB 8134, St Louis, MO 63110 USA.
EM lenzee@wustl.edu
FU Taylor Family Institute for Innovative Psychiatric Treatment
   atWashington University; COVID-19 Early Treatment Fund; Center for Brain
   Research in Mood Disorders atWashington University; Bantly Foundation;
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [UL1TR002345]
FX This study was supported by the Taylor Family Institute for Innovative
   Psychiatric Treatment atWashington University and the COVID-19 Early
   Treatment Fund. Additional support came from the Center for Brain
   Research in Mood Disorders atWashington University, the Bantly
   Foundation, and grant UL1TR002345 from the National Institutes of
   Health.
CR Assimon MM, 2019, J AM SOC NEPHROL, V30, P611, DOI 10.1681/ASN.2018101032
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chastain DB, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2021971
   Christensen M, 2002, CLIN PHARMACOL THER, V71, P141, DOI 10.1067/mcp.2002.121788
   Cobos EJ, 2008, CURR NEUROPHARMACOL, V6, P344, DOI 10.2174/157015908787386113
   Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136
   Fung OS, 2019, VIROLOGY, V533, P34, DOI 10.1016/j.virol.2019.05.002
   Gillings D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hallifax D, 2007, DRUG METAB DISPOS, V35, P1325, DOI 10.1124/dmd.107.015131
   Hashimoto K, 2015, J PHARMACOL SCI, V127, P6, DOI 10.1016/j.jphs.2014.11.010
   Hashimoto K, 2013, PROG NEUROBIOL, V100, P15, DOI 10.1016/j.pneurobio.2012.09.001
   Homolak J, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106044
   Hosszu A, 2017, J AM SOC NEPHROL, V28, P152, DOI 10.1681/ASN.2015070772
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ishikawa M, 2007, BIOL PSYCHIAT, V62, P878, DOI 10.1016/j.biopsych.2007.04.001
   Ishima T, 2014, EUR J PHARMACOL, V727, P167, DOI 10.1016/j.ejphar.2014.01.064
   Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Lippi G, 2020, PROG CARDIOVASC DIS, V63, P390, DOI 10.1016/j.pcad.2020.03.001
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mofsen AM, 2019, JMIR MENT HEALTH, V6, DOI 10.2196/11845
   Nicol GE, J CLIN PSYCHIAT, DOI [10.4088/JCP.20com13373, DOI 10.4088/JCP.20C0M13373]
   Nicol GE, 2020, J AM GERIATR SOC, V68, P922, DOI 10.1111/jgs.16443
   Omori IM, 2009, J PSYCHOPHARMACOL, V23, P539, DOI 10.1177/0269881108089876
   Prasad A, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00370
   Puntmann Valentina O, 2020, JAMA Cardiol, V5, P1265, DOI 10.1001/jamacardio.2020.3557
   ROSEN DA, 2019, SCI TRANSL MED, V11, P478
   Schlienger Raymond G, 2003, Am J Cardiovasc Drugs, V3, P149, DOI 10.2165/00129784-200303030-00001
   Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   World Health Organization, NOV COR
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053
NR 33
TC 1
Z9 1
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 8
PY 2020
VL 324
IS 22
BP 2292
EP 2300
DI 10.1001/jama.2020.22760
EA NOV 2020
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA PD9VK
UT WOS:000592281900001
PM 33180097
OA Bronze
DA 2021-01-01
ER

PT J
AU Tripathi, N
   Goel, B
   Bhardwaj, N
   Sahu, B
   Kumar, H
   Jain, SK
AF Tripathi, Nancy
   Goel, Bharat
   Bhardwaj, Nivedita
   Sahu, Bharat
   Kumar, Hemant
   Jain, Shreyans K.
TI Virtual screening and molecular simulation study of natural products
   database for lead identification of novel coronavirus main protease
   inhibitors
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; natural products; virtual screening; molecular docking;
   protease inhibitors
ID RESPIRATORY SYNDROME CORONAVIRUS
AB 3CL like protease (3CLpro or Mpro) is one of the main proteases of 2019-nCoV. The 3CLpro is a nonstructural protein of SARS-CoV and has an essential role in viral replication and transcription, thus, could be a potential target for anti-SARS drug development. The present study employed ligand- and structure-based approaches to identify the potent inhibitors of 2019-nCoV protease. The e-pharmacophore developed from 3CLpro-1 yielded virtual hits, that were subjected through drug likeliness and PAINS filters to remove interfering compounds. Further comprehensive docking studies, free energy calculations and ADMET studies resulted in two virtual leads- MolPort-000-410-348 and MolPort-002-530-156. The compounds MolPort-000-410-348 and MolPort-002-530-156 displayed good docking score of -12.09 and -13.38 Kcal/mol and free binding energy of -63.34 +/- 2.03 and -61.52 +/- 2.24 Kcal/mol, respectively. The compounds also exhibited satisfactory predicted ADMET profile and were subjected to molecular dynamic (MD) studies. The MD simulation produced stable complexes of these ligands with 3CLpro protein and ligand RMSD in acceptable limits.
   Communicated by Ramaswamy H. Sarma
C1 [Tripathi, Nancy; Goel, Bharat; Bhardwaj, Nivedita; Sahu, Bharat; Jain, Shreyans K.] Banaras Hindu Univ, Indian Inst Technol, Dept Pharmaceut Engn & Technol, Varanasi 221005, Uttar Pradesh, India.
   [Kumar, Hemant] Banaras Hindu Univ, Inst Med Sci, Mol Biol Unit, Varanasi, Uttar Pradesh, India.
RP Jain, SK (corresponding author), Banaras Hindu Univ, Indian Inst Technol, Dept Pharmaceut Engn & Technol, Varanasi 221005, Uttar Pradesh, India.
EM sjain.phe@itbhu.ac.in
OI GOEL, BHARAT/0000-0002-6297-0067
FU IIT (BHU)
FX The authors acknowledge financial support of Seed Research Grant from
   the IIT (BHU).
CR Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bhuyan MSI, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S14-S10
   Camp D, 2015, J NAT PROD, V78, P1370, DOI 10.1021/acs.jnatprod.5b00255
   Cheng KW, 2015, ANTIVIR RES, V115, P9, DOI 10.1016/j.antiviral.2014.12.011
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Danker T, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00203
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Ganeshpurkar A, 2020, MOL SIMULAT, V46, P169, DOI 10.1080/08927022.2019.1682572
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kumar V, 2017, ANTIVIR RES, V141, P101, DOI 10.1016/j.antiviral.2017.02.007
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Singh R, 2020, J BIOMOL STRUCT DYN, V38, P2533, DOI 10.1080/07391102.2019.1635530
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768149
   Sunseri J, 2016, NUCLEIC ACIDS RES, V44, pW442, DOI 10.1093/nar/gkw287
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Wang EC, 2019, CHEM REV, V119, P9478, DOI 10.1021/acs.chemrev.9b00055
   World Health Organization, 2020, COVID 19 SIT REP
   Yan AX, 2008, INT J MOL SCI, V9, P1961, DOI 10.3390/ijms9101961
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 27
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1848630
EA NOV 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OT1UZ
UT WOS:000590639800001
PM 33213294
OA Bronze
DA 2021-01-01
ER

PT J
AU Rampino, T
   Gregorini, M
   Perotti, L
   Ferrari, F
   Pattonieri, EF
   Grignano, MA
   Valente, M
   Garrone, A
   Islam, T
   Libetta, C
   Sepe, V
   Albertini, R
   Bruno, R
   Belliato, M
AF Rampino, Teresa
   Gregorini, Marilena
   Perotti, Luciano
   Ferrari, Fiorenza
   Pattonieri, Eleonora Francesca
   Grignano, Maria Antonietta
   Valente, Mauro
   Garrone, Alberto
   Islam, Tefik
   Libetta, Carmelo
   Sepe, Vincenzo
   Albertini, Riccardo
   Bruno, Raffaele
   Belliato, Mirko
TI Hemoperfusion with CytoSorb as Adjuvant Therapy in Critically Ill
   Patients with SARS-CoV2 Pneumonia
SO BLOOD PURIFICATION
LA English
DT Article; Early Access
DE Blood purification; COVID-19; Critical illness cytokines; Hemoperfusion;
   Case report
AB We report a preliminary experience of adjuvant therapy with Hemoperfusion (HP) in patients with Severe Acute Respiratory Syndrome-CoronaVirus 2 (SARS-CoV2) pneumonia. Currently, there are no approved treatments for CoronaVirus Disease 19 (COVID-19); however, therapeutic strategies based on the preclinical evidence include supportive measures, such as oxygen supplementation, antiviral, and anticoagulant agents. Despite these treatments, 10% of patients worsen and develop severe acute respiratory distress syndrome (ARDS). Since the pathogenic mechanism of ARDS is an uncontrolled inflammatory state, we speculate that removing inflammation effectors from blood may contrast tissue injury and improve clinical outcome. In a scenario of dramatic medical emergency, we conducted an observational study on 9 consecutive patients hospitalized in COVID Intensive Care Unit, where 5 of 9 consecutive patients were treated with HP, due to the emergency overload made it impossible to deliver blood purification in the other 4 patients. COVID-19 was diagnosed through the identification of virus sequences by reverse transcription-PCR on respiratory specimens. All patients had severe pneumonia requiring continuous positive airway pressure. HP was started in all patients 6-7 days after hospital admission. The treated patients (T) received 2 consecutive sessions of HP using CytoSorb cartridge. Our results show a better clinical course of T compared to control patients (C), in fact all T except 1 survived, and only 2 of them were intubated, while all C required intubation and died. Lymphocytopenia worsened in C but not in T. C-reactive protein decreased in both patients, but to a greater extent in T. IL-6, IL-8, and TNF-alpha decreased after HP, IL-10 did not change. Respiratory function remained stable and did not worsen in T compared to C. The limited sample size and observational study design preclude a sound statement about the potential effectiveness of HP in COVID-19 patients, but our experience suggests a potential therapeutic role of adjuvant CytoSorb HP in the early course of CO-VID-19 pneumonia. A randomized clinical trial is ongoing.
C1 [Rampino, Teresa; Gregorini, Marilena; Pattonieri, Eleonora Francesca; Grignano, Maria Antonietta; Valente, Mauro; Garrone, Alberto; Islam, Tefik; Libetta, Carmelo; Sepe, Vincenzo; Albertini, Riccardo] Fdn IRCCS Policlin San Matteo, Unit Nephrol Dialysis & Transplantat, Pavia, Italy.
   [Gregorini, Marilena; Valente, Mauro; Garrone, Alberto; Islam, Tefik; Libetta, Carmelo] Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
   [Perotti, Luciano; Ferrari, Fiorenza; Belliato, Mirko] Fdn IRCCS Policlin San Matteo, Dept Anaesthesia, Pavia, Italy.
   [Perotti, Luciano; Ferrari, Fiorenza; Belliato, Mirko] Fdn IRCCS Policlin San Matteo, Intens Care Unit, Pavia, Italy.
   [Ferrari, Fiorenza] San Bortolo Hosp, Int Renal Res Inst Vicenza IRRIV, Vicenza, Italy.
   [Albertini, Riccardo] Fdn IRCCS Policlin San Matteo, Clin Chem Lab, Pavia, Italy.
   [Bruno, Raffaele] Fdn IRCCS Policlin San Matteo, Div Infect Dis 1, Pavia, Italy.
   [Bruno, Raffaele] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy.
RP Gregorini, M (corresponding author), IRCCS San Matteo Hosp, Nephrol Dialysis & Transplant Unit, Ple Golgi 2, IT-27100 Pavia, Italy.; Gregorini, M (corresponding author), IRCCS San Matteo Hosp, Internal Med ad Therapeut, Ple Golgi 2, IT-27100 Pavia, Italy.; Gregorini, M (corresponding author), Univ Pavia, Ple Golgi 2, IT-27100 Pavia, Italy.
EM mgregorini@hotmail.com
RI Grignano, Maria Antonietta/AAA-9194-2019
OI Grignano, Maria Antonietta/0000-0003-1439-7662
CR Brouwer WP, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2588-1
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Harm S, 2020, BLOOD PURIFICAT, V49, P33, DOI 10.1159/000502680
   Hotchkiss RS, 2009, NAT MED, V15, P496, DOI 10.1038/nm0509-496
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Li L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00661-z
   Rimmele T, 2011, CRIT CARE, V15, DOI 10.1186/cc9411
   Ronco C, 2003, ARTIF ORGANS, V27, P792, DOI 10.1046/j.1525-1594.2003.07289.x
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
NR 10
TC 0
Z9 0
U1 2
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0253-5068
EI 1421-9735
J9 BLOOD PURIFICAT
JI Blood Purif.
DI 10.1159/000511725
EA NOV 2020
PG 6
WC Hematology; Urology & Nephrology
SC Hematology; Urology & Nephrology
GA OT0ZP
UT WOS:000590583800001
PM 33181508
OA Green Published
DA 2021-01-01
ER

PT J
AU Clarfield, AM
   Jotkowitz, A
AF Clarfield, A. Mark
   Jotkowitz, Alan
TI Age, ageing, ageism and "age-itation" in the Age of COVID-19: rights and
   obligations relating to older persons in Israel as observed through the
   lens of medical ethics
SO ISRAEL JOURNAL OF HEALTH POLICY RESEARCH
LA English
DT Article
AB COVID-19, the illness caused by the SARS-CoV-2 virus, has reached pandemic proportions. Although the virus can cause disease in anyone, it is particularly dangerous for those with various "co-morbidities" such as heart disease, hypertension, diabetes, obesity and others. Furthermore, advancing age (from about 60 on), even in those older persons without any accompanying illnesses, is a strong and independent risk factor for pneumonia, need for an ICU bed and death from the virus. It is therefore essential to find ways to protect all at-risk persons (old or young) from the virus but at the same time not harming, more than absolutely necessary their essential freedoms as well as taking into account their social/psychological needs. Compared with other OECD countries, Israel's population is still relatively young, with only 11.5% being over 65+ with a smaller proportion of older persons in long-term institutions than that found in most other comparable jurisdictions. These factors might explain a part of the country's (so far) relatively low rates of serious disease and mortality compared to those seen in other developed countries. However there are still over a million older citizens at risk and the numbers of infected, hospitalized and seriously ill persons are rising once again. This is no time for complacency. An analysis of the effect of age on the disease as seen through the principles of medical ethics is followed by a proposal as to how best to balance these sometimes conflicting goals. This paper relates mainly to older persons in the community since the Ministry of Health early on in the pandemic initiated an effective program (Magen Avot) meant to protect those older persons in long-term care institutions. Recommendations include the Ministry of Health publishing clear guidelines as to risk factors and offering sensible advice on how to practice physical (not "social") distancing without exacerbating an older person's sense of social isolation. In order to reduce the incidence of influenza (which can clinically be confused with COVID-19) and the potentially disastrous consequences of a "double pandemic" this coming winter, a robust flu vaccination program needs immediate implementation. Persons at all ages (but especially those 60+) should be encouraged and assisted to sign advance directives, especially those who do not wish to undergo invasive therapy. An individual older person's wish to "make way" for younger people should be respected as an expression of his/her autonomy. As we enter the second wave, triage mechanisms and protocols need to be circulated in readiness for and well before a situation in which an acute imbalance develops between the availability for acute resources and the population's need for them. The Ministry of Health, in cooperation with other relevant ministries and NGOs, should take the lead in developing plans, ensuring that they are carried out in an orderly, timely and transparent manner. The blanket is indeed not large enough but we must place it as judiciously as possible in order as much as possible to protect, cover and keep warm the body politic.
C1 [Clarfield, A. Mark] Ben Gurion Univ Negev, MSIH Bet Caroline, Ctr Global Hlth, Geriatr Med, POB 653, IL-8410501 Beer Sheva, Israel.
   [Clarfield, A. Mark] Ben Gurion Univ Negev, MSIH Bet Caroline, Med Sch Int Hlth, Fac Hlth Sci, POB 653, IL-8410501 Beer Sheva, Israel.
   [Clarfield, A. Mark] McGill Univ, Montreal, PQ, Canada.
   [Jotkowitz, Alan] Ben Gurion Univ Negev, Med Sch Int Hlth, Beer Sheva, Israel.
   [Jotkowitz, Alan] Ben Gurion Univ Negev, Fac Hlth Sci, Jakobovits Ctr Jewish Med Eth, Beer Sheva, Israel.
RP Clarfield, AM (corresponding author), Ben Gurion Univ Negev, MSIH Bet Caroline, Ctr Global Hlth, Geriatr Med, POB 653, IL-8410501 Beer Sheva, Israel.; Clarfield, AM (corresponding author), Ben Gurion Univ Negev, MSIH Bet Caroline, Med Sch Int Hlth, Fac Hlth Sci, POB 653, IL-8410501 Beer Sheva, Israel.; Clarfield, AM (corresponding author), McGill Univ, Montreal, PQ, Canada.
EM markclar@bgu.ac.il
OI Clarfield, A Mark/0000-0002-0388-5663
CR Aleman A, 2020, PSYCHOSOCIAL MED
   Antommaria AHM, 2020, ANN INTERN MED, V173, P188, DOI 10.7326/M20-1738
   Aronson L, 2020, NEW ENGL J MED, V383, P4, DOI 10.1056/NEJMp2006115
   Banerjee A, 2020, LANCET, V395, P1715, DOI 10.1016/S0140-6736(20)30854-0
   Barker-Davies RM, 2020, BRIT J SPORT MED, V54, P949, DOI 10.1136/bjsports-2020-102596
   Begno Y, 2020, PRICE CONTINUED ISOL
   Churchill LR., 2020, BEING ELDER PANDEMIC
   Clarfield AM, 2006, J GERONTOL A-BIOL, V61, P621, DOI 10.1093/gerona/61.6.621
   Clarfield AM, 2020, J AM GERIATR SOC, V68, P1370, DOI 10.1111/jgs.16554
   Clarfield AM, 2003, J AM GERIATR SOC, V51, P1149, DOI 10.1046/j.1532-5415.2003.51364.x
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Hanlon P, 2020, WELLCOME OPEN RES
   Miller FG, 2020, WHY I SUPPORT AGE RE
   OLIVER D, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/bmj.m1545
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492
   Scharf T, 2020, BSG STATEMENT COVID
   Shaulov A, 2019, ISR J HEALTH POLICY, V8, DOI 10.1186/s13584-019-0348-y
   Steinberg A, 2020, RAMBAM MAIMONIDES ME, V11, DOI 10.5041/RMMJ.10411
   Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689
   Walensky RP, 2020, JAMA-J AM MED ASSOC, V323, P1889, DOI 10.1001/jama.2020.6572
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Wurgaft N., 2020, HAARETZ         0404
   Yehoshua AB, 2020, YNET HEBREW     0414
NR 24
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-4015
J9 ISR J HEALTH POLICY
JI Isr. J. Health Policy Res.
PD NOV 12
PY 2020
VL 9
IS 1
AR 64
DI 10.1186/s13584-020-00416-y
PG 13
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA OQ8TB
UT WOS:000589047400001
PM 33183358
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hwang, J
AF Hwang, Juwon
TI Health Information Sources and the Influenza Vaccination: The Mediating
   Roles of Perceived Vaccine Efficacy and Safety
SO JOURNAL OF HEALTH COMMUNICATION
LA English
DT Article; Early Access
DE influenza vaccination; health information sources; medical
   professionals; social media; perceived vaccine efficacy; perceived
   vaccine safety
ID HUMAN-PAPILLOMAVIRUS; NATIONAL-SURVEY; UNITED-STATES; SOCIAL MEDIA;
   ATTITUDES; ADULTS; KNOWLEDGE; BELIEFS; RISK
AB Although the influenza vaccine is widely recognized as an effective preventive measure, influenza vaccination rates among U.S. adults remain low. Moreover, influenza-related respiratory illnesses may increase the risk of adverse outcomes of COVID-19. Thus, this study examines the mechanisms involved in influenza vaccination uptake. Specifically, this study investigates how health information sources are associated with perceived vaccine efficacy and safety, which, in turn, associated with influenza vaccine uptake. Analyzing cross-sectional survey data from a national U.S. adult sample (N = 19,420), mediation analyses were conducted. Results revealed that considering vaccine efficacy, health information seekers who assigned more value to medical professionals, medical journals, and newspaper articles were more likely to perceive a vaccine as effective, thus being more likely to receive the influenza vaccine. By contrast, individuals who placed more value in social media were less likely to perceive vaccine efficacy, and, in turn, were less likely to get the influenza vaccine. Turning to vaccine safety, the value ascribed to medical professionals was positively associated with vaccine safety, which, in turn, related to influenza vaccine uptake. By contrast, social media, family or friends, and promotions were negatively associated with vaccine safety, and then influenza vaccine uptake.
C1 [Hwang, Juwon] Univ Wisconsin, Sch Journalism & Mass Commun, 821 Univ Ave, Madison, WI 53706 USA.
RP Hwang, J (corresponding author), Univ Wisconsin, Sch Journalism & Mass Commun, 821 Univ Ave, Madison, WI 53706 USA.
EM jhwang79@wisc.edu
OI Hwang, Juwon/0000-0002-5155-1000
CR Ahmed N, 2018, VACCINE, V36, P7556, DOI 10.1016/j.vaccine.2018.10.049
   Almeida CM, 2012, VACCINE, V30, P3003, DOI 10.1016/j.vaccine.2012.01.079
   Andreassen S, 2005, EUR J CANCER CARE, V14, P426, DOI 10.1111/j.1365-2354.2005.00602.x
   Bean SJ, 2011, VACCINE, V29, P1874, DOI 10.1016/j.vaccine.2011.01.003
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Bults M, 2011, VACCINE, V29, P6226, DOI 10.1016/j.vaccine.2011.06.075
   Centers for Disease Control and Prevention, 2019, FLU VACC COV US 2018
   Centers for Disease Control and Prevention, 2019, INFL ACT US 2018 19
   Centers for Disease Control and Prevention, 2016, TOP OBJ IMM INF DIS
   Chen WW, 2020, VACCINE, V38, P271, DOI 10.1016/j.vaccine.2019.10.019
   Dawood FS, 2020, MMWR-MORBID MORTAL W, V69, P177, DOI 10.15585/mmwr.mm6907a1
   Doyle JD, 2019, MMWR-MORBID MORTAL W, V68, P135, DOI 10.15585/mmwr.mm6806a2
   Dunn AG, 2017, VACCINE, V35, P3033, DOI 10.1016/j.vaccine.2017.04.060
   Dutta-Bergman MJ, 2004, HEALTH COMMUN, V16, P273, DOI 10.1207/S15327027HC1603_1
   Featherstone JD, 2019, VACCINE, V37, P2993, DOI 10.1016/j.vaccine.2019.04.063
   Freed GL, 2010, PEDIATRICS, V125, P654, DOI 10.1542/peds.2009-1962
   Fridman D, 2011, AM J OBSTET GYNECOL, V204, pS124, DOI 10.1016/j.ajog.2011.04.011
   Gargano LM, 2015, HUM VACC IMMUNOTHER, V11, P1641, DOI 10.1080/21645515.2015.1038445
   Harper Scott A., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Hwang J, 2019, HEALTH COMMUN, V34, P1279, DOI 10.1080/10410236.2018.1481707
   Im H, 2017, J HEALTH COMMUN, V22, P214, DOI [10.7838/jsebs.2017.22.1.001, 10.1080/10810730.2016.1261970]
   Jones Abbey M, 2012, Adv Prev Med, V2012, P932741, DOI 10.1155/2012/932741
   KAPLAN AM, 2010, BUS HORIZONS, V53, P59, DOI [10.1016/j.bushor.2009.09.003, DOI 10.1016/J.BUSH0R.2009.09.003]
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Katz ML, 2011, J MENS HEALTH, V8, P175, DOI 10.1016/j.jomh.2011.04.002
   Kim S, 2019, HEALTH COMMUN, V34, P21, DOI 10.1080/10410236.2017.1384353
   Lehmann BA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-547
   Liao Q, 2013, VACCINE, V31, P4084, DOI 10.1016/j.vaccine.2013.07.009
   Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016
   Maurer J, 2010, PREV MED, V51, P185, DOI 10.1016/j.ypmed.2010.05.008
   Nan XL, 2012, HEALTH COMMUN, V27, P559, DOI 10.1080/10410236.2011.617243
   Petrovic M, 2003, Commun Dis Public Health, V6, P325
   Polgreen PM, 2008, CLIN INFECT DIS, V47, P1443, DOI 10.1086/593098
   Quinn SC, 2017, VACCINE, V35, P1167, DOI 10.1016/j.vaccine.2016.12.046
   Renner B, 2012, VACCINE, V30, P7019, DOI 10.1016/j.vaccine.2012.09.064
   Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Sharma M, 2017, AM J INFECT CONTROL, V45, P301, DOI 10.1016/j.ajic.2016.08.022
   Skrondal A, 2014, J R STAT SOC C-APPL, V63, P211, DOI 10.1111/rssc.12023
   Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046
   Smith LE, 2017, VACCINE, V35, P1936, DOI 10.1016/j.vaccine.2017.02.031
   Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923
   Teo LM, 2019, VACCINE, V37, P6665, DOI 10.1016/j.vaccine.2019.09.037
   Tingley D, 2014, J STAT SOFTW, V59
   Viswanath K, 2008, J HEALTH COMMUN, V13, P759, DOI 10.1080/10810730802487430
   Walsh S, 2015, EPIDEMIOL INFECT, V143, P550, DOI 10.1017/S0950268814000752
   Wheeler M, 2013, HUM VACC IMMUNOTHER, V9, P1782, DOI 10.4161/hv.25959
   Wilson K, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2409
   Witteman HO, 2012, VACCINE, V30, P3734, DOI 10.1016/j.vaccine.2011.12.039
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 50
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1081-0730
EI 1087-0415
J9 J HEALTH COMMUN
JI J. Health Commun.
DI 10.1080/10810730.2020.1840675
EA NOV 2020
PG 9
WC Communication; Information Science & Library Science
SC Communication; Information Science & Library Science
GA OQ9PG
UT WOS:000589107100001
PM 33186091
OA Bronze
DA 2021-01-01
ER

PT J
AU Bello, M
   Martinez-Munoz, A
   Balbuena-Rebolledo, I
AF Bello, Martiniano
   Martinez-Munoz, Alberto
   Balbuena-Rebolledo, Irving
TI Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2
   main protease through MM/GBSA
SO JOURNAL OF MOLECULAR MODELING
LA English
DT Article
DE Protease; SARS-CoV2; Docking; MD simulations
ID SIMULATIONS; PROTEINASE; DYNAMICS; BINDING
AB Among targets selected for studies aimed at identifying potential inhibitors against COVID-19, SARS-CoV2 main proteinase (M-pro) is highlighted. M-pro is indispensable for virus replication and is a promising target of potential inhibitors of COVID-19. Recently, monomeric SARS-CoV2 M-pro, drug repurposing, and docking methods have facilitated the identification of several potential inhibitors. Results were refined through the assessment of dimeric SARS-CoV2 M-pro, which represents the functional state of enzyme. Docking and molecular dynamics (MD) simulations combined with molecular mechanics/generalized Born surface area (MM/GBSA) studies indicated that dimeric M-pro most significantly impacts binding affinity tendency compared with the monomeric state, which suggests that dimeric state is most useful when performing studies aimed at identifying drugs targeting M-pro. In this study, we extend previous research by performing docking and MD simulation studies coupled with an MM/GBSA approach to assess binding of dimeric SARS-CoV2 M-pro to 12 FDA-approved drugs (darunavir, indinavir, saquinavir, tipranavir, diosmin, hesperidin, rutin, raltegravir, velpatasvir, ledipasvir, rosuvastatin, and bortezomib), which were identified as the best candidates for the treatment of COVID-19 in some previous dockings studies involving monomeric SARS-CoV2 M-pro. This analysis identified saquinavir as a potent inhibitor of dimeric SARS-CoV2 M-pro; therefore, the compound may have clinical utility against COVID-19.
C1 [Bello, Martiniano; Martinez-Munoz, Alberto; Balbuena-Rebolledo, Irving] Inst Politecn Nacl, Escuela Super Med, Lab Modelado Mol Bioinformat & Diseno Farm, Plan San Luis & Diaz Miron S-N, Mexico City 11340, DF, Mexico.
RP Bello, M (corresponding author), Inst Politecn Nacl, Escuela Super Med, Lab Modelado Mol Bioinformat & Diseno Farm, Plan San Luis & Diaz Miron S-N, Mexico City 11340, DF, Mexico.
EM bellomartini@gmail.com
OI Bello Ramirez, Martiniano/0000-0002-9686-0755
FU CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT)
   [CB-A1-S-21278]; SIP/IPN [20201015]
FX The work was supported by grants from CONACYT (CB-A1-S-21278) and
   SIP/IPN (20201015).
CR Adem S., 2020, IDENTIFICATION POTEN, V46, P1, DOI [10.20944/preprints202003.0333.v1., 10.20944/preprints202003.0333.v1, DOI 10.20944/PREPRINTS202003.0333.V1]
   Andrianov AM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1792989
   Bello M, 2020, PREDICTION POTENTIAL, DOI [10.21203/rs.3.rs-21205/v1, DOI 10.21203/RS.3.RS-21205/V1]
   Bello M, 2018, CURR PHARM DESIGN, V24, P3466, DOI 10.2174/1381612824666181102142432
   Bello M, 2014, BIOCHEM PHARMACOL, V90, P145, DOI 10.1016/j.bcp.2014.04.016
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Case DA, 2010, AMBER 12
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Dierynck I, 2007, J VIROL, V81, P13845, DOI 10.1128/JVI.01184-07
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Farag A, 2020, IDENTIFICATION FDA A, DOI [10.26434/chemrxiv.12003930.v3, DOI 10.26434/CHEMRXIV.12003930.V3]
   Frisch M., 2009, GAUSSIAN
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Graziano V, 2006, BIOCHEMISTRY-US, V45, P14632, DOI 10.1021/bi061746y
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Jimenez-Alberto A, 2020, COMPUT BIOL CHEM, V88, DOI 10.1016/j.compbiolchem.2020.107325
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kumar Y, 2020, SILICO IDENTIFICATIO, DOI [10.26434/chemrxiv.12049590.v1, DOI 10.26434/CHEMRXIV.12049590.V1]
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Richardson Paul G, 2003, Cancer Control, V10, P361
   Sang P, 2020, INSIGHT DERIVED MOL, DOI [10.26434/chemrxiv.11932995.v1, DOI 10.26434/CHEMRXIV.11932995.V1]
   Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003
   VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571
   Vastag B, 2003, JAMA-J AM MED ASSOC, V290, P1695, DOI 10.1001/jama.290.13.1695
   Vega Valdez IR, 2020, THEORETICAL EVALUATI, DOI [10.26434/chemrxiv.12047346.v1, DOI 10.26434/CHEMRXIV.12047346.V1]
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Xu Z, 2020, NELFINAVIR IS ACTIVE, DOI [10.26434/chemrxiv.12039888.v1, DOI 10.26434/CHEMRXIV.12039888.V1]
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 38
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1610-2940
EI 0948-5023
J9 J MOL MODEL
JI J. Mol. Model.
PD NOV 12
PY 2020
VL 26
IS 12
AR 340
DI 10.1007/s00894-020-04600-4
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer
   Science
GA OQ9JS
UT WOS:000589092700001
PM 33184722
OA Bronze, Green Published
DA 2021-01-01
ER

EF